<SEC-DOCUMENT>0000927653-23-000062.txt : 20230802
<SEC-HEADER>0000927653-23-000062.hdr.sgml : 20230802
<ACCEPTANCE-DATETIME>20230802173023
ACCESSION NUMBER:		0000927653-23-000062
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		85
CONFORMED PERIOD OF REPORT:	20230630
FILED AS OF DATE:		20230802
DATE AS OF CHANGE:		20230802

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MCKESSON CORP
		CENTRAL INDEX KEY:			0000927653
		STANDARD INDUSTRIAL CLASSIFICATION:	WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES [5122]
		IRS NUMBER:				943207296
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-13252
		FILM NUMBER:		231137166

	BUSINESS ADDRESS:	
		STREET 1:		6555 STATE HIGHWAY 161
		CITY:			IRVING
		STATE:			TX
		ZIP:			75039
		BUSINESS PHONE:		972-446-4800

	MAIL ADDRESS:	
		STREET 1:		6555 STATE HIGHWAY 161
		CITY:			IRVING
		STATE:			TX
		ZIP:			75039

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MCKESSON HBOC INC
		DATE OF NAME CHANGE:	19990115

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MCKESSON CORP
		DATE OF NAME CHANGE:	19950209

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SP VENTURES INC
		DATE OF NAME CHANGE:	19940728
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>mck-20230630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with the Workiva Platform--><!--Copyright 2023 Workiva--><!--r:65f23265-c924-40c8-9b40-7c0acd48a82a,g:b9e463ca-a0e1-4231-8e93-a7255a3f4103,d:f4d8dc006b964583a173e59149947157--><html xmlns:srt="http://fasb.org/srt/2023" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mck="http://mckesson123.com/20230630" xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>mck-20230630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-34">0000927653</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="f-35">03/31</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-36">2024</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-37">Q1</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-38">false</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="mck-20230630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mck:A1500NotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mck:A1625NotesDue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mck:A3125NotesDue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>mck:segment</xbrli:measure></xbrli:unit><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:RxTsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mck:RxSavingsSolutionsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:RxTsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mck:RxSavingsSolutionsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:RxTsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mck:RxSavingsSolutionsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:RxTsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mck:RxSavingsSolutionsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:RxTsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mck:RxSavingsSolutionsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:USPharmaceuticalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mck:SCRIOncologyLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:USPharmaceuticalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mck:SCRIOncologyLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-31</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">mck:SarahCannonResearchInstituteMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:USPharmaceuticalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mck:SCRIOncologyLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">mck:McKessonUSOncologyResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:USPharmaceuticalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mck:SCRIOncologyLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mck:EUBusinessesDisposalGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mck:UKBusinessesDisposalGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="gbp"><xbrli:measure>iso4217:GBP</xbrli:measure></xbrli:unit><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mck:AureliusElephantLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mck:InternationalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-06</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mck:AureliusElephantLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mck:InternationalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-06</xbrli:startDate><xbrli:endDate>2022-04-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mck:UKBusinessesDisposalGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-06</xbrli:startDate><xbrli:endDate>2022-04-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">mck:StrategicGrowthInitiativePlanOperationalEfficienciesAndCostOptimizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">mck:StrategicGrowthInitiativePlanOperationalEfficienciesAndCostOptimizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">mck:StrategicGrowthInitiativePlanOperationalEfficienciesAndCostOptimizationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:USPharmaceuticalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:PrescriptionTechnologySolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:MedicalSurgicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:InternationalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:USPharmaceuticalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:PrescriptionTechnologySolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:MedicalSurgicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:InternationalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:USPharmaceuticalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:PrescriptionTechnologySolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:MedicalSurgicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:InternationalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:USPharmaceuticalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:PrescriptionTechnologySolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:MedicalSurgicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:InternationalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:USPharmaceuticalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:PrescriptionTechnologySolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:MedicalSurgicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:InternationalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:USPharmaceuticalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:PrescriptionTechnologySolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:MedicalSurgicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:InternationalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:USPharmaceuticalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:PrescriptionTechnologySolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:MedicalSurgicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:InternationalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ServiceAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ServiceAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:A380NotesDueMarch152024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:A380NotesDueMarch152024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:A090NotesDueDecember32025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:A090NotesDueDecember32025Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:A525NotesDueFebruary152026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:A525NotesDueFebruary152026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:A130NotesDueAugust152026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:A130NotesDueAugust152026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:A765DebenturesDueMarch12027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:A765DebenturesDueMarch12027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:A395NotesDueFebruary162028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:A395NotesDueFebruary162028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:A490NotesDueJuly152028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:A490NotesDueJuly152028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:A475NotesDueMay302029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:A475NotesDueMay302029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:A510NotesDueJuly152033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:A510NotesDueJuly152033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:A600NotesDueMarch12041Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:A600NotesDueMarch12041Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:A488NotesDueMarch152044Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:A488NotesDueMarch152044Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:A150EuroNotesDueNovember172025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:A150EuroNotesDueNovember172025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:A163EuroNotesDueOctober302026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:A163EuroNotesDueOctober302026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:A313SterlingNotesDueFebruary172029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:A313SterlingNotesDueFebruary172029Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mck:LeaseAndOtherObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mck:LeaseAndOtherObligationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:A490NotesDueJuly152028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:A510NotesDueJuly152033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:A490NotesDueJuly152028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-15</xbrli:startDate><xbrli:endDate>2023-06-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:A510NotesDueJuly152033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-15</xbrli:startDate><xbrli:endDate>2023-06-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:A380NotesDueMarch152024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:A380NotesDueMarch152024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-16</xbrli:startDate><xbrli:endDate>2023-06-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:A380NotesDueMarch152024Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:SeniorUnsecuredCreditFacilityThe2022CreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:SeniorUnsecuredCreditFacilityThe2022CreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-07</xbrli:startDate><xbrli:endDate>2022-11-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:SeniorUnsecuredCreditFacilityThe2022CreditFacilityCanadianDollarBritishPoundSterlingAndEurosSublimitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:SeniorUnsecuredCreditFacilitythe2020CreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:SeniorUnsecuredCreditFacilitythe2020CreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-25</xbrli:startDate><xbrli:endDate>2019-09-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:SeniorUnsecuredCreditFacilitythe2020CreditFacilityCanadianDollarBritishPoundSterlingandEurosSublimitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:SeniorUnsecuredCreditFacilitythe2020CreditFacilityCanadianDollarBritishPoundSterlingandEurosSublimitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:SeniorUnsecuredCreditFacilityThe2022CreditFacilityCanadianDollarBritishPoundSterlingAndEurosSublimitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:SeniorUnsecuredCreditFacilityThe2022CreditFacilityCanadianDollarBritishPoundSterlingAndEurosSublimitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mck:UKBusinessesDisposalGroupMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:BritishPoundSterlingDenominatedNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:EuroDenominatedNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:EuroDenominatedNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="cad"><xbrli:measure>iso4217:CAD</xbrli:measure></xbrli:unit><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mck:FixedInterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mck:FixedInterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mck:FixedInterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mck:FixedInterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mck:CurrentAssetLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mck:CurrentAssetLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mck:OtherNonCurrentAssetsAndLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mck:OtherNonCurrentAssetsAndLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mck:OtherNonCurrentAssetsAndLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mck:OtherNonCurrentAssetsAndLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mck:NationalPrescriptionOpiateLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="distributor"><xbrli:measure>mck:distributor</xbrli:measure></xbrli:unit><xbrli:unit id="state"><xbrli:measure>mck:state</xbrli:measure></xbrli:unit><xbrli:unit id="case"><xbrli:measure>mck:case</xbrli:measure></xbrli:unit><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mck:NationalPrescriptionOpiateLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mck:ThreeLargestUSPharmaceuticalDistributorsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mck:NationalPrescriptionOpiateLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mck:StateOfAlabamaAndSubdivisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mck:NationalPrescriptionOpiateLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mck:ThreeNationalPharmaceuticalDistributorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mck:StateOfWestVirginiaAndSubdivisionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="jurisdiction"><xbrli:measure>mck:jurisdiction</xbrli:measure></xbrli:unit><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mck:NationalPrescriptionOpiateLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mck:ThreeNationalPharmaceuticalDistributorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mck:CherokeeNationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mck:NationalPrescriptionOpiateLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">mck:ThreeNationalPharmaceuticalDistributorsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mck:NativeAmericanTribesOtherThanCherokeeNationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mck:NationalPrescriptionOpiateLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mck:NativeAmericanTribesOtherThanCherokeeNationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mck:NationalPrescriptionOpiateLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mck:NationalPrescriptionOpiateLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mck:NationalPrescriptionOpiateLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mck:NationalPrescriptionOpiateLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mck:NationalPrescriptionOpiateLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mck:NationalPrescriptionOpiateLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mck:IndividualClaimantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mck:NationalPrescriptionOpiateLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2018-12-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="officer"><xbrli:measure>mck:officer</xbrli:measure></xbrli:unit><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mck:EvanstonPolicePensionFundVMcKessonCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mck:EvanstonPolicePensionFundVMcKessonCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mck:UnitedStatesExRelHartVMcKessonCorporationEtAl15CV00903RAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="vote"><xbrli:measure>mck:vote</xbrli:measure></xbrli:unit><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">mck:AcceleratedShareRepurchaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">mck:AcceleratedShareRepurchaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">mck:AcceleratedShareRepurchaseInitialShareSettlementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">mck:AcceleratedShareRepurchaseCompletionOfProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">mck:AcceleratedShareRepurchaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-01</xbrli:startDate><xbrli:endDate>2022-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">mck:AcceleratedShareRepurchaseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-02-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">mck:AcceleratedShareRepurchaseInitialShareSettlementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">mck:AcceleratedShareRepurchaseCompletionOfProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-05-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">mck:OpenMarketShareRepurchaseTransactionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">mck:OpenMarketShareRepurchaseTransactionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">mck:OpenMarketShareRepurchaseTransactionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mck:AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mck:AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mck:AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-253"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-254"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mck:AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mck:AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-265"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mck:AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-266"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-268"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:USPharmaceuticalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-271"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:PrescriptionTechnologySolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-272"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:MedicalSurgicalSolutionsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-273"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:InternationalSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-274"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-275"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-276"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-277"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:InternationalSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mck:EUBusinessesDisposalGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-278"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000927653</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mck:EUBusinessesDisposalGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="if4d8dc006b964583a173e59149947157_1"></div><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160;&#160;&#160;           &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="f-2">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3">June&#160;30, 2023</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="f-4">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:9pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">1-13252</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-align:center"><img src="mck-20230630_g1.jpg" alt="mckessonlogoa01.jpg" style="height:29px;margin-bottom:5pt;vertical-align:text-bottom;width:196px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-6">McKESSON CORPORATION</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:40.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.759%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.338%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-7">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-8">94-3207296</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction<br/>of incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-9">6555 State Hwy 161</ix:nonNumeric>, </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-10">Irving</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-11">TX</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-12">75039</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address of principal executive offices, including zip code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-13">972</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-14">446-4800</ix:nonNumeric> </span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act: </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:40.603%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.759%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.338%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(Title of each class)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(Trading Symbol)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(Name of each exchange on which registered)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-2" name="dei:Security12bTitle" id="f-15">Common stock, $0.01 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-2" name="dei:TradingSymbol" id="f-16">MCK</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-2" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-17">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-3" name="dei:Security12bTitle" id="f-18">1.500% Notes due 2025</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-3" name="dei:TradingSymbol" id="f-19">MCK25</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-3" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-20">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-4" name="dei:Security12bTitle" id="f-21">1.625% Notes due 2026</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-4" name="dei:TradingSymbol" id="f-22">MCK26</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-4" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-23">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-5" name="dei:Security12bTitle" id="f-24">3.125% Notes due 2029</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-5" name="dei:TradingSymbol" id="f-25">MCK29</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-5" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-26">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.75pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-27">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.75pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.75pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.75pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.75pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-28">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.75pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.75pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.75pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.75pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="text-align:justify;text-indent:24.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.929%"><tr><td style="width:1.0%"></td><td style="width:29.065%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.067%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.501%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.553%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.916%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.920%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-29">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="f-30">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-31">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.75pt;font-weight:400;line-height:120%">f</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.75pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).&#160; Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.75pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="f-32">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9.75pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9.75pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="text-align:justify;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate the number of shares outstanding of each of the issuer&#8217;s classes of common stock, as of the latest practicable date. <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-33">134,902,380</ix:nonFraction> shares of the issuer&#8217;s common stock were outstanding as of June 30, 2023.</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:24.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="if4d8dc006b964583a173e59149947157_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">McKESSON CORPORATION</span></div><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.031%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:88.636%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.033%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Item</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Page</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_10">PART I&#8212;FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_10">Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_13">Condensed Consolidated Statements of Operations for the three months ended </a></span><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">June 30, 2023</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_13"> and </a></span><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_13">3</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_16">Condensed Consolidated Statements of Comprehensive Income for the three months ended </a></span><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">June 30, 2023</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_16"> and </a></span><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_16">4</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_19">Condensed Consolidated Balance Sheets as of </a></span><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">June 30, 2023</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_19"> and </a></span><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">March 31, 2023</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_19">5</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_22">Condensed Consolidated Statements of Stockholders&#8217; </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_22">Deficit</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_22"> for the three months ended </a></span><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">June 30, 2023</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_22"> and </a></span><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_22">6</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_28">Condensed Consolidated Statements of Cash Flows for the three months ended </a></span><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">June 30, 2023</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_28"> and </a></span><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">2022</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_28">7</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_31">Financial Notes</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_31">8</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_34">Note 1 - Significant Accounting Policies</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_34">8</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_37">Note 2 - Business Acquisitions and Divestitures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_37">9</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_40">Note 3 - Restructuring, Impairment, and Related Charges, Net</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_40">12</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_43">Note 4 - Income Taxes</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_43">13</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_49">Note 5 - Earnings </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_49">P</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_49">er Common Share</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_49">14</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_52">Note 6 - Goodwill and Intangible Assets, Net</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_52">15</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_55">Note 7 - Debt and Financing Activities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_55">17</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_61">Note 8 - Hedging Activities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_61">19</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_64">Note 9 - Fair Value Measurements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_64">22</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_67">Note 10 - Commitments and Contingent Liabilities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_67">24</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_70">Note 11 - Stockholders&#8217; Deficit</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_70">26</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_73">Note 12 - Segments of Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_73">29</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_79">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_79">31</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_124">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_124">44</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_127">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_127">45</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_130">PART II&#8212;OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_133">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_133">46</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1A</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_136">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_136">46</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_139">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_139">46</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_142">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_142">47</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_145">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_145">47</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_148">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_148">47</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_151">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_151">48</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_154">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_154">49</a></span></div></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="height:33.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="if4d8dc006b964583a173e59149947157_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">McKESSON CORPORATION</span></div><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I&#8212;FINANCIAL INFORMATION</span></div><div style="padding-left:54pt;text-indent:-54pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Consolidated Financial Statements.</span></div><div style="padding-left:54pt;text-indent:-54pt"><span><br/></span></div><div id="if4d8dc006b964583a173e59149947157_13"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In millions, except per share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.574%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-39">74,483</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-40">67,154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="f-41">71,461</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="f-42">64,131</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="f-43">3,022</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="f-44">3,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, distribution, general, and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-45">1,870</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-46">1,959</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims and litigation charges, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:GainLossRelatedToLitigationSettlement" format="ixt:fixed-zero" scale="6" id="f-47">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" sign="-" name="us-gaap:GainLossRelatedToLitigationSettlement" scale="6" id="f-48">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, impairment, and related charges, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="mck:RestructuringImpairmentAndOtherRelatedCharges" scale="6" id="f-49">52</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="mck:RestructuringImpairmentAndOtherRelatedCharges" scale="6" id="f-50">23</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="6" id="f-51">1,922</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="6" id="f-52">1,987</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-53">1,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-54">1,036</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-55">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-56">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="f-57">47</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="f-58">45</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations before income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-59">1,091</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-60">1,006</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-61">94</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-62">199</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-63">997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-64">807</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:fixed-zero" scale="6" id="f-65">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="f-66">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="f-67">997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="f-68">809</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="f-69">39</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="f-70">41</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to McKesson Corporation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="f-71">958</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="f-72">768</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per common share attributable to McKesson Corporation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="f-73">7.02</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="f-74">5.25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="f-75">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="f-76">0.01</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-77">7.02</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-78">5.26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="f-79">7.07</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="f-80">5.31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:31.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="f-81">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="f-82">0.01</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-83">7.07</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-84">5.32</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-85">136.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-86">145.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-87">135.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-88">144.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See Financial Notes</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="if4d8dc006b964583a173e59149947157_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">McKESSON CORPORATION</span></div><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In millions)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.574%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="f-89">997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="f-90">809</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="f-91">52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="f-92">582</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains on cash flow and other hedges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="f-93">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="f-94">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in retirement-related benefit plans</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="f-95">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="f-96">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-97">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-98">636</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-99">1,054</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-100">1,445</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="f-101">39</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="f-102">91</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income attributable to McKesson Corporation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-103">1,015</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-104">1,354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See Financial Notes</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="if4d8dc006b964583a173e59149947157_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">McKESSON CORPORATION</span></div><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In millions, except per share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited) </span></div><div style="margin-top:2pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:68.592%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.543%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-105">2,636</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-106">4,678</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="f-107">21,860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="f-108">19,410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="f-109">20,510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="f-110">19,691</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="f-111">533</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="f-112">513</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="f-113">45,539</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="f-114">44,292</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant, and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="f-115">2,172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="f-116">2,177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="f-117">1,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="f-118">1,635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-119">9,971</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-120">9,947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="f-121">2,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="f-122">2,277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-123">2,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-124">1,992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-125">64,096</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-126">62,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="12" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND DEFICIT</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Drafts and accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="f-127">43,982</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="f-128">42,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="6" id="f-129">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="6" id="f-130">968</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="f-131">300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="f-132">299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-133">4,090</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-134">4,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-135">48,422</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-136">47,957</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="f-137">5,611</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="f-138">4,626</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="f-139">1,139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="f-140">1,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-141">1,462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-142">1,402</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term litigation liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:LitigationReserveNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-143">6,628</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:LitigationReserveNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-144">6,625</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-145">2,074</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-146">1,813</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation stockholders&#8217; deficit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-8" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-147"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-148">0.01</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-6" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="f-149"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="-6" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="f-150">100</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="6" id="f-151"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="6" id="f-152"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="f-153"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="f-154">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued or   outstanding</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="f-155">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="f-156">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-8" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-157"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-158">0.01</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-6" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="f-159"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="-6" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="f-160">800</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="f-161">278</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-8" decimals="-6" name="us-gaap:CommonStockSharesIssued" scale="6" id="f-162">277</ix:nonFraction> shares issued at June 30, 2023 and March 31, 2023, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:CommonStockValue" scale="6" id="f-163">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:CommonStockValue" scale="6" id="f-164">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="f-165">7,824</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="f-166">7,747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="f-167">13,182</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="f-168">12,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-169">848</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-170">905</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury shares, at cost, <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-6" name="us-gaap:TreasuryStockCommonShares" scale="6" id="f-171">143</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-8" decimals="-6" name="us-gaap:TreasuryStockCommonShares" scale="6" id="f-172">141</ix:nonFraction> shares at June 30, 2023 and March 31, 2023, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:TreasuryStockCommonValue" format="ixt:num-dot-decimal" scale="6" id="f-173">21,763</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:TreasuryStockCommonValue" format="ixt:num-dot-decimal" scale="6" id="f-174">20,997</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total McKesson Corporation stockholders&#8217; deficit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-175">1,602</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-176">1,857</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="f-177">362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:MinorityInterest" scale="6" id="f-178">367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deficit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-179">1,240</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-180">1,490</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and deficit</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-181">64,096</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-182">62,320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See Financial Notes</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="if4d8dc006b964583a173e59149947157_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">McKESSON CORPORATION</span></div><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; DEFICIT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In millions, except per share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.454%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:4.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.558%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.558%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.642%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="51" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid-in Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained Earnings</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Noncontrolling<br/>Interests</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Deficit</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, March 31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="-6" name="us-gaap:SharesOutstanding" scale="6" id="f-183">277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-184">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-185">7,747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-186">12,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-187">905</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-13" decimals="-6" name="us-gaap:TreasuryStockCommonShares" scale="6" id="f-188">141</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-189">20,997</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-190">367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-191">1,490</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of shares under employee plans, net of forfeitures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-6" name="mck:StockIssuedDuringPeriodSharesEmployeeStockPlansNetOfForfeitures" scale="6" id="f-192">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-6" name="mck:StockIssuedDuringPeriodValueEmployeeStockPlansNetOfForfeitures" scale="6" id="f-193">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-6" sign="-" name="mck:StockIssuedDuringPeriodValueEmployeeStockPlansNetOfForfeitures" scale="6" id="f-194">93</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="mck:StockIssuedDuringPeriodValueEmployeeStockPlansNetOfForfeitures" scale="6" id="f-195">66</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-196">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-197">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-17" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="f-198">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="f-199">673</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="f-200">673</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-6" name="mck:NetIncomeLossIncludingPortionAttributabletoNoncontrollingInterestExcludingRedeemableNoncontrollingInterest" scale="6" id="f-201">958</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-6" name="mck:NetIncomeLossIncludingPortionAttributabletoNoncontrollingInterestExcludingRedeemableNoncontrollingInterest" scale="6" id="f-202">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="mck:NetIncomeLossIncludingPortionAttributabletoNoncontrollingInterestExcludingRedeemableNoncontrollingInterest" scale="6" id="f-203">997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-204">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-205">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends declared, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="f-206">0.54</ix:nonFraction> per common share</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-6" name="us-gaap:DividendsCommonStockCash" scale="6" id="f-207">73</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:DividendsCommonStockCash" scale="6" id="f-208">73</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="f-209">39</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="f-210">39</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="f-211">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="f-212">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="f-213">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="f-214">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, June 30, 2023</span></div></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="-6" name="us-gaap:SharesOutstanding" scale="6" id="f-215">278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-216">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-217">7,824</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-218">13,182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-219">848</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-25" decimals="-6" name="us-gaap:TreasuryStockCommonShares" scale="6" id="f-220">143</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-221">21,763</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-222">362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-223">1,240</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.454%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:4.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.558%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.635%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.558%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.642%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="51" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid-in Capital</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained Earnings</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Noncontrolling<br/>Interests</span></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>&#160;Deficit</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, March 31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="-6" name="us-gaap:SharesOutstanding" scale="6" id="f-224">275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-225">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-226">7,275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-227">9,030</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-228">1,534</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-31" decimals="-6" name="us-gaap:TreasuryStockCommonShares" scale="6" id="f-229">130</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-230">17,045</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-231">480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-232">1,792</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of shares under employee plans, net of forfeitures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-34" decimals="-6" name="mck:StockIssuedDuringPeriodSharesEmployeeStockPlansNetOfForfeitures" scale="6" id="f-233">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-6" name="mck:StockIssuedDuringPeriodValueEmployeeStockPlansNetOfForfeitures" scale="6" id="f-234">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-6" name="mck:StockIssuedDuringPeriodValueEmployeeStockPlansNetOfForfeitures" scale="6" id="f-235">91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-6" sign="-" name="mck:StockIssuedDuringPeriodValueEmployeeStockPlansNetOfForfeitures" scale="6" id="f-236">152</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" sign="-" name="mck:StockIssuedDuringPeriodValueEmployeeStockPlansNetOfForfeitures" scale="6" id="f-237">60</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-238">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-239">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-35" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="f-240">56</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-36" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="f-241">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="f-242">944</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="f-243">1,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-6" name="mck:NetIncomeLossIncludingPortionAttributabletoNoncontrollingInterestExcludingRedeemableNoncontrollingInterest" scale="6" id="f-244">768</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-6" name="mck:NetIncomeLossIncludingPortionAttributabletoNoncontrollingInterestExcludingRedeemableNoncontrollingInterest" scale="6" id="f-245">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="mck:NetIncomeLossIncludingPortionAttributabletoNoncontrollingInterestExcludingRedeemableNoncontrollingInterest" scale="6" id="f-246">809</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-247">586</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-248">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-249">636</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash dividends declared, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="f-250">0.47</ix:nonFraction> per common share</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-6" name="us-gaap:DividendsCommonStockCash" scale="6" id="f-251">67</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:DividendsCommonStockCash" scale="6" id="f-252">67</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="f-253">36</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="f-254">36</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reclassification of recurring compensation to other accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-6" name="mck:NoncontrollingInterestDecreaseFromReclassificationToLiability" scale="6" id="f-255">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="mck:NoncontrollingInterestDecreaseFromReclassificationToLiability" scale="6" id="f-256">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-6" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="f-257">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="f-258">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:StockholdersEquityOther" format="ixt:fixed-zero" scale="6" id="f-259">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, June 30, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-40" decimals="-6" name="us-gaap:SharesOutstanding" scale="6" id="f-260">277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-261">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-262">7,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-263">9,732</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-264">948</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-44" decimals="-6" name="us-gaap:TreasuryStockCommonShares" scale="6" id="f-265">133</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-266">18,141</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-267">532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-268">1,472</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See Financial Notes</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="if4d8dc006b964583a173e59149947157_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">McKESSON CORPORATION</span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In millions)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:76.498%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.590%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OPERATING ACTIVITIES</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="f-269">997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:ProfitLoss" scale="6" id="f-270">809</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:Depreciation" scale="6" id="f-271">64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:Depreciation" scale="6" id="f-272">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:AdjustmentForAmortization" scale="6" id="f-273">95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:AdjustmentForAmortization" scale="6" id="f-274">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-lived asset impairment charges</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OtherAssetImpairmentCharges" scale="6" id="f-275">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:OtherAssetImpairmentCharges" format="ixt:fixed-zero" scale="6" id="f-276">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="6" id="f-277">235</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="6" id="f-278">109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credits associated with last-in, first-out inventory method</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:InventoryLIFOReservePeriodCharge" scale="6" id="f-279">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" sign="-" name="us-gaap:InventoryLIFOReservePeriodCharge" scale="6" id="f-280">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash operating lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:OperatingLeaseExpense" scale="6" id="f-281">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:OperatingLeaseExpense" scale="6" id="f-282">63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain from sales of businesses and investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:GainLossOnSaleOfOtherAssets" scale="6" id="f-283">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:GainLossOnSaleOfOtherAssets" scale="6" id="f-284">33</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">European businesses held for sale</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" format="ixt:fixed-zero" scale="6" id="f-285">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" scale="6" id="f-286">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-cash items</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="f-287">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="f-288">102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in assets and liabilities, net of acquisitions:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncreaseDecreaseInReceivables" format="ixt:num-dot-decimal" scale="6" id="f-289">2,380</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:IncreaseDecreaseInReceivables" format="ixt:num-dot-decimal" scale="6" id="f-290">1,584</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="f-291">826</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="f-292">955</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Drafts and accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="6" id="f-293">1,473</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="6" id="f-294">1,006</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="6" id="f-295">80</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="6" id="f-296">94</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncreaseDecreaseInAccruedTaxesPayable" scale="6" id="f-297">236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:IncreaseDecreaseInAccruedTaxesPayable" scale="6" id="f-298">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="mck:IncreaseDecreaseInLitigationReserve" format="ixt:fixed-zero" scale="6" id="f-299">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" sign="-" name="mck:IncreaseDecreaseInLitigationReserve" scale="6" id="f-300">370</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="f-301">536</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="f-302">186</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-303">1,052</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="f-304">941</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">INVESTING ACTIVITIES</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments for property, plant, and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="f-305">78</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="f-306">71</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized software expenditures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PaymentsToAcquireSoftware" scale="6" id="f-307">46</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:PaymentsToAcquireSoftware" scale="6" id="f-308">29</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisitions, net of cash, cash equivalents, and restricted cash acquired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="f-309">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="f-310">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sales of businesses and investments, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates" scale="6" id="f-311">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates" scale="6" id="f-312">240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="f-313">64</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="f-314">100</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="f-315">149</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="f-316">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FINANCING ACTIVITIES</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from short-term borrowings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProceedsFromShortTermDebt" scale="6" id="f-317">65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:ProceedsFromShortTermDebt" format="ixt:fixed-zero" scale="6" id="f-318">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayments of short-term borrowings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:RepaymentsOfShortTermDebt" scale="6" id="f-319">65</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:RepaymentsOfShortTermDebt" format="ixt:fixed-zero" scale="6" id="f-320">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuances of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="f-321">991</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:fixed-zero" scale="6" id="f-322">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repayments of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="f-323">268</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="f-324">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchase of U.S. government obligations for the satisfaction and discharge of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="mck:PaymentsForPurchaseOfGovernmentObligationsForSatisfactionAndDischargeOfLongTermDebt" scale="6" id="f-325">647</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="mck:PaymentsForPurchaseOfGovernmentObligationsForSatisfactionAndDischargeOfLongTermDebt" format="ixt:fixed-zero" scale="6" id="f-326">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock transactions:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="6" id="f-327">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="6" id="f-328">91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share repurchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="f-329">696</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-330">1,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividends paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" scale="6" id="f-331">74</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:PaymentsOfDividendsCommonStock" scale="6" id="f-332">71</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="f-333">176</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="f-334">199</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="f-335">843</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="f-336">1,181</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-337">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-338">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in cash, cash equivalents, and restricted cash classified as Assets held for sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="mck:CashCashEquivalentsRestrictedCashClassifiedWithinAssetsHeldForSalePeriodIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="f-339">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="mck:CashCashEquivalentsRestrictedCashClassifiedWithinAssetsHeldForSalePeriodIncreaseDecrease" scale="6" id="f-340">470</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net decrease in cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="f-341">2,042</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="f-342">1,595</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash at beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-343">4,679</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-344">3,935</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash at end of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-345">2,637</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-346">2,340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Restricted cash at end of period included in Prepaid expenses and other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:RestrictedCashCurrent" scale="6" id="f-347">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-6" name="us-gaap:RestrictedCashCurrent" scale="6" id="f-348">107</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-349">2,636</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-350">2,233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See Financial Notes</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="if4d8dc006b964583a173e59149947157_31"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">McKESSON CORPORATION</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL NOTES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div></div><div style="text-align:center"><span><br/></span></div><div id="if4d8dc006b964583a173e59149947157_34"></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="f-351" continuedAt="i59a93d08ccb14704a0a95e3c42e29809" escape="true">Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i59a93d08ccb14704a0a95e3c42e29809" continuedAt="i92b132cd954d4a948d092311988343ac"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nature of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: McKesson Corporation (&#8220;McKesson,&#8221; or the &#8220;Company,&#8221;) is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. McKesson partners with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products, and services to help make quality care more accessible and affordable. The Company reports its financial results in <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-352">four</ix:nonFraction> reportable segments: U.S. Pharmaceutical, Prescription Technology Solutions (&#8220;RxTS&#8221;), Medical-Surgical Solutions, and International. Refer to Financial Note 12, &#8220;Segments of Business,&#8221; for additional information.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationPolicyTextBlock" id="f-353" continuedAt="i9a4c57801525469b990de95b3844cdb4" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements and accompanying notes are prepared in accordance with United States (&#8220;U.S.&#8221;) generally accepted accounting principles (&#8220;GAAP&#8221;) for interim financial reporting and the rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) and therefore do not include all information and disclosures normally included in the annual consolidated financial statements.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements of McKesson include the financial statements of all wholly-owned subsidiaries and majority-owned or controlled companies. For those consolidated subsidiaries where the Company&#8217;s ownership is less than 100%, the portion of the net income or loss allocable to the noncontrolling interests is reported as &#8220;Net income attributable to noncontrolling interests&#8221; in the Condensed Consolidated Statements of Operations. All significant intercompany balances and transactions have been eliminated in consolidation, including the intercompany portion of transactions with equity method investees. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income attributable to noncontrolling interests includes third-party equity interests in the Company&#8217;s consolidated entities, including ClarusONE Sourcing Services LLP, Vantage Oncology Holdings, LLC, and SCRI Oncology, LLC. Net income attributable to noncontrolling interests also included recurring compensation that the Company was obligated to pay to the noncontrolling shareholders of McKesson Europe AG (&#8220;McKesson Europe&#8221;). The Company&#8217;s noncontrolling interest in McKesson Europe was included in the divestiture of certain of the Company&#8217;s businesses in the European Union (&#8220;E.U.&#8221;) in October 2022, which is discussed further in Financial Note 2, &#8220;Business Acquisitions and Divestitures.&#8221; </span></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9a4c57801525469b990de95b3844cdb4">The Company considers itself to control an entity if it is the majority owner of or has voting control over such entity. The Company also assesses control through means other than voting rights and determines which business entity is the primary beneficiary of the variable interest entity (&#8220;VIE&#8221;). The Company consolidates VIEs when it is determined that it is the primary beneficiary of the VIE. Investments in business entities in which the Company does not have control, but instead has the ability to exercise significant influence over operating and financial policies, are accounted for using the equity method.</ix:continuation> </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><ix:nonNumeric contextRef="c-1" name="us-gaap:FiscalPeriod" id="f-354" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fiscal Period:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company&#8217;s fiscal year begins on April 1 and ends on March 31. Unless otherwise noted, all references to a particular year shall mean the Company&#8217;s fiscal year.</span></ix:nonNumeric></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><ix:nonNumeric contextRef="c-1" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="f-355" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reclassifications:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Certain prior period amounts have been reclassified to conform to the current year presentation.</span></ix:nonNumeric></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-356" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of these financial statements and income and expenses during the reporting period. Actual amounts could differ from those estimated amounts. In the opinion of management, the unaudited condensed consolidated financial statements include all normal recurring adjustments necessary for a fair presentation of the results of operations, financial position, and cash flows of McKesson for the interim periods presented.</span></ix:nonNumeric></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:ComparabilityOfPriorYearFinancialData" id="f-357" escape="true">The results of operations for the three months ended June 30, 2023 are not necessarily indicative of the results that may be anticipated for the entire year. These interim financial statements should be read in conjunction with the annual audited financial statements, accounting policies, and financial notes included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended March 31, 2023, previously filed with the SEC on May&#160;9, 2023 (the &#8220;2023 Annual Report&#8221;).</ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">McKESSON CORPORATION</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL NOTES (CONTINUED)</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div></div><ix:continuation id="i92b132cd954d4a948d092311988343ac"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 16, 2022, the U.S. government enacted the Inflation Reduction Act of 2022 (the &#8220;IRA&#8221;). Among other provisions, the IRA includes a 15% corporate minimum tax, a 1% excise tax on certain repurchases of an entity&#8217;s own common stock after December 31, 2022, and various drug pricing reforms. The Company does not anticipate that this guidance will have a material impact on its consolidated financial statements or related disclosures. The Company will continue to evaluate the full impact of these legislative changes as they are announced and implemented. Refer to Financial Note 11, &#8220;Stockholders' Deficit,&#8221; for further details regarding excise taxes incurred on the Company&#8217;s share repurchases during the three months ended June 30, 2023.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-358" continuedAt="i99127eb443e64d5693b60ad2ac5de49d" escape="true"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Pronouncements </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no accounting standards adopted by the Company during the three months ended June 30, 2023.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Issued Accounting Pronouncements Not Yet Adopted</span></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><ix:continuation id="i99127eb443e64d5693b60ad2ac5de49d" continuedAt="i0c1d9f5edde247d09afc4abe57a27c27"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Financial Accounting Standards Board issued Accounting Standards Update (&#8220;ASU&#8221;) 2022-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0c1d9f5edde247d09afc4abe57a27c27">, which clarifies the guidance when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of such equity security, and requires additional disclosure requirements. ASU 2022-03 is effective for the Company on a prospective basis for fiscal years beginning after December 15, 2023, with early adoption permitted. The Company does not anticipate that this guidance will have a material impact on its consolidated financial statements or related disclosures</ix:continuation>.</span></div></ix:continuation><div id="if4d8dc006b964583a173e59149947157_37"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock" id="f-359" continuedAt="ie08cb7a34f5b46118aa468073744f5c4" escape="true">Business Acquisitions and Divestitures</ix:nonNumeric></span></div><div id="if4d8dc006b964583a173e59149947157_1099511629162"></div><ix:continuation id="ie08cb7a34f5b46118aa468073744f5c4" continuedAt="ic5057f29f89543d8b8e3dbb5535b291c"><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rx Savings Solutions, LLC</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 1, 2022, the Company completed its acquisition of <ix:nonFraction unitRef="number" contextRef="c-47" decimals="2" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="f-360">100</ix:nonFraction>% of the shares of Rx Savings Solutions, LLC (&#8220;RxSS&#8221;), a privately-owned company headquartered in Overland Park, Kansas, to further connect biopharma and payer services to patients. RxSS is a prescription price transparency and benefit insight company that offers affordability and adherence solutions to health plans and employers. The purchase consideration included a payment of $<ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="f-361">600</ix:nonFraction>&#160;million in cash made upon closing and a maximum of $<ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="f-362">275</ix:nonFraction>&#160;million of contingent consideration based on RxSS&#8217; operational and financial performance through calendar year 2025. The payment made upon closing was funded from cash on hand. The financial results of RxSS are included in the Company&#8217;s RxTS segment as of the acquisition date. The transaction was accounted for as a business combination.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded a liability for the contingent consideration at its fair value of $<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="f-363">92</ix:nonFraction>&#160;million as of the acquisition date. The fair value of the contingent consideration liability was estimated using a Monte Carlo simulation model, utilizing internal cash flow projections which are Level 3 inputs under Accounting Standards Codification (&#8220;ASC&#8221;) Topic 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The contingent liability will be remeasured to fair value at each reporting date until the liability is settled with changes in fair value being recognized within &#8220;Selling, distribution, general, and administrative expenses&#8221; in the Company&#8217;s Condensed Consolidated Statements of Operations. During the three months ended June 30, 2023, the Company recognized a fair value adjustment gain of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="6" id="f-364">28</ix:nonFraction>&#160;million, which reduced its contingent consideration liability, based on the estimated amount and timing of projected operational and financial information and the probability of achievement of certain performance milestones. As of June 30, 2023 and March 31, 2023, the current portion of $<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-365">45</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-366">83</ix:nonFraction>&#160;million, respectively, is included within &#8220;Other accrued liabilities&#8221; and the long-term portion of $<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-367">19</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-368">9</ix:nonFraction>&#160;million, respectively, is included within &#8220;Other non-current liabilities&#8221; in the Company&#8217;s Condensed Consolidated Balance Sheets. Recognition of the initial fair value of this contingent consideration was a non-cash investing activity. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price allocation included acquired identifiable intangible assets of $<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="6" id="f-369">229</ix:nonFraction>&#160;million, primarily representing customer relationships and technology with a weighted average amortization period of <ix:nonNumeric contextRef="c-48" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="f-370">12</ix:nonNumeric> years, and goodwill of $<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-371">463</ix:nonFraction>&#160;million. Goodwill has been allocated to the Company&#8217;s RxTS segment, which reflects the expected future benefits from certain synergies and intangible assets that do not qualify for separate recognition. Goodwill attributable to the acquisition is deductible for tax purposes.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">McKESSON CORPORATION</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL NOTES (CONTINUED)</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div></div><ix:continuation id="ic5057f29f89543d8b8e3dbb5535b291c" continuedAt="if6c5c999f1c74658a42bc6fc22f50fa3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="f-372" continuedAt="i4636710944cd46d5a48c4d84d4510999" escape="true"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the preliminary purchase price allocation for this acquisition:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.368%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts Recognized as of Acquisition Date (As Adjusted)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchase consideration:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="f-373">600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="f-374">92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total purchase consideration</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-6" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="6" id="f-375">692</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identifiable assets acquired and liabilities assumed:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" scale="6" id="f-376">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="f-377">229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" scale="6" id="f-378">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" scale="6" id="f-379">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total identifiable net assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" scale="6" id="f-380">229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-6" name="us-gaap:Goodwill" scale="6" id="f-381">463</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net assets acquired</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest" scale="6" id="f-382">692</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SCRI Oncology, LLC</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 31, 2022, the Company completed a transaction with HCA Healthcare, Inc. (&#8220;HCA&#8221;) to form SCRI Oncology, LLC (&#8220;SCRI Oncology&#8221;), an oncology research business combining McKesson&#8217;s U.S. Oncology Research (&#8220;USOR&#8221;) and HCA&#8217;s Sarah Cannon Research Institute (&#8220;SCRI&#8221;) based in Nashville, Tennessee, to advance cancer care and increase access to oncology clinical research. Upon consummation of the transaction, McKesson owns a <ix:nonFraction unitRef="number" contextRef="c-52" decimals="2" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="f-383">51</ix:nonFraction>% controlling interest in the combined business, and the financial results are consolidated by the Company and reported within its U.S. Pharmaceutical segment as of the acquisition date. Transaction consideration included the transfer of full ownership interest in USOR to the combined business and $<ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="f-384">166</ix:nonFraction>&#160;million of net cash paid to HCA, which was funded from cash on hand. The transaction was accounted for as a business combination.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price allocation included acquired identifiable intangible assets of $<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="6" id="f-385">177</ix:nonFraction>&#160;million, primarily representing customer relationships as well as trademarks and trade names with a weighted average amortization period of <ix:nonNumeric contextRef="c-53" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="f-386">17</ix:nonNumeric> years, and goodwill of $<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-387">113</ix:nonFraction>&#160;million. Goodwill has been allocated to the Company&#8217;s U.S. Pharmaceutical segment, which reflects the expected future benefits from certain synergies and intangible assets that do not qualify for separate recognition. Goodwill attributable to the acquisition of $<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-6" name="us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" format="ixt:num-dot-decimal" scale="6" id="f-388">46</ix:nonFraction>&#160;million is deductible for tax purposes. The Company recorded noncontrolling interest of $<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-6" name="us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" format="ixt:num-dot-decimal" scale="6" id="f-389">222</ix:nonFraction>&#160;million as a component of equity, which includes HCA&#8217;s proportionate interest in the identifiable net assets of SCRI at fair value of $<ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-6" name="us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" format="ixt:num-dot-decimal" scale="6" id="f-390">202</ix:nonFraction>&#160;million and its proportionate interest in the contributed net assets of USOR at carrying value of $<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-6" name="us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" format="ixt:num-dot-decimal" scale="6" id="f-391">20</ix:nonFraction>&#160;million. The difference between the fair value of the Company&#8217;s acquired interest in SCRI net assets and the $<ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="f-392">166</ix:nonFraction>&#160;million of net cash paid to HCA was recognized as additional paid in capital, as well as the Company&#8217;s reduction in ownership interest in USOR net assets. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">McKESSON CORPORATION</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL NOTES (CONTINUED)</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div></div><ix:continuation id="if6c5c999f1c74658a42bc6fc22f50fa3" continuedAt="i74cd8cf85de84c3888792074469f5463"><ix:continuation id="i4636710944cd46d5a48c4d84d4510999"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the preliminary purchase price allocation for this acquisition:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.368%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts Recognized as of Acquisition Date (As Adjusted)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchase consideration:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="f-393">166</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contribution of USOR</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-6" name="mck:BusinessCombinationConsiderationTransferredOwnershipInterest" scale="6" id="f-394">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total purchase consideration</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-6" name="us-gaap:BusinessCombinationConsiderationTransferred1" scale="6" id="f-395">206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identifiable assets acquired and liabilities assumed:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" scale="6" id="f-396">224</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant, and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" scale="6" id="f-397">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-6" name="mck:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" scale="6" id="f-398">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="f-399">177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" scale="6" id="f-400">42</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-6" name="mck:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermOperatingLeaseLiabilities" scale="6" id="f-401">29</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" scale="6" id="f-402">43</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total identifiable net assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" scale="6" id="f-403">340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-6" name="us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" scale="6" id="f-404">222</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-6" name="mck:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdditionalPaidInCapital" scale="6" id="f-405">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-6" name="us-gaap:Goodwill" scale="6" id="f-406">113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net assets acquired</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest" scale="6" id="f-407">206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the acquired identifiable intangible assets from the acquisitions discussed above were determined by applying the income approach, using a discounted cash flow model in which cash flows anticipated over several periods are discounted to their present value using an appropriate rate that is commensurate with the risk inherent with the transaction. These inputs are considered Level 3 inputs under the fair value measurements and disclosure guidance. The amounts presented above are subject to change as the Company&#8217;s fair value assessments are finalized. There have been no material changes to the purchase price allocation of these acquisitions since the acquisition date. Pro forma financial information has not been provided as these acquisitions did not have a material impact, individually, or in the aggregate, to the Company&#8217;s consolidated results of operations.</span></div></ix:continuation><div id="if4d8dc006b964583a173e59149947157_1437"></div><ix:continuation id="i74cd8cf85de84c3888792074469f5463" continuedAt="iad4909795cea4d13be3fd508485a5256"><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Divestitures</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">European Divestiture Activities</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, the Company announced its intention to exit its businesses in Europe. On October 31, 2022, the Company completed its previously announced transaction to sell certain of its businesses in the European Union (&#8220;E.U.&#8221;) located in France, Italy, Ireland, Portugal, Belgium, and Slovenia, along with its German headquarters and wound-care business, part of a shared services center in Lithuania, and its ownership stake in a joint venture in the Netherlands (&#8220;E.U. disposal group&#8221;) to the PHOENIX Group. During the three months ended June 30, 2022, the Company recorded a gain of $<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-6" sign="-" name="us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" format="ixt:num-dot-decimal" scale="6" id="f-408">12</ix:nonFraction>&#160;million to remeasure the E.U. disposal group to fair value less costs to sell which was recorded within &#8220;Selling, distribution, general, and administrative expenses&#8221; in the Condensed Consolidated Statement of Operations. The Company&#8217;s measurement of the fair value of the E.U. disposal group was based on the total consideration expected to be received by the Company as outlined in the transaction agreement. Certain components of the total consideration included fair value measurements that fall within Level 3 of the fair value hierarchy.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 6, 2022, the Company completed the previously announced sale of its retail and distribution businesses in the United Kingdom (&#8220;U.K. disposal group&#8221;) to Aurelius Elephant Limited for a purchase price of &#163;<ix:nonFraction unitRef="gbp" contextRef="c-57" decimals="-6" name="mck:DisposalGroupIncludingDiscontinuedOperationConsiderationExpected" format="ixt:num-dot-decimal" scale="6" id="f-409">110</ix:nonFraction>&#160;million (or, approximately $<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-6" name="mck:DisposalGroupIncludingDiscontinuedOperationConsiderationExpected" format="ixt:num-dot-decimal" scale="6" id="f-410">144</ix:nonFraction>&#160;million), including certain adjustments. As part of the transaction, the Company divested net assets of $<ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-6" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation" format="ixt:num-dot-decimal" scale="6" id="f-411">615</ix:nonFraction>&#160;million and released $<ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodTax" format="ixt:num-dot-decimal" scale="6" id="f-412">731</ix:nonFraction>&#160;million of accumulated other comprehensive loss, within the International segment, and the buyer assumed and repaid a note payable to the Company of $<ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-6" name="us-gaap:ProceedsFromCollectionOfNotesReceivable" format="ixt:num-dot-decimal" scale="6" id="f-413">118</ix:nonFraction>&#160;million.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">McKESSON CORPORATION</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL NOTES (CONTINUED)</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iad4909795cea4d13be3fd508485a5256" continuedAt="ib4f16c484cb24b44b7cf23960d3dfc0f">At June 30, 2023 and March 31, 2023, the Company had no assets or liabilities related to these European divestiture activities that met the criteria for classification as held for sale. Subsequent to the divestiture activities discussed above, the Company&#8217;s European operations primarily consist of its retail and distribution businesses in Norway.</ix:continuation></span></div><div id="if4d8dc006b964583a173e59149947157_1455"></div><ix:continuation id="ib4f16c484cb24b44b7cf23960d3dfc0f"><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the periods presented, the Company also completed de minimis acquisitions and divestitures within its operating segments. Financial results for the Company&#8217;s business acquisitions have been included in its consolidated financial statements as of their respective acquisition dates. Purchase prices for business acquisitions have been allocated based on estimated fair values at the respective acquisition dates.</span></div></ix:continuation><div id="if4d8dc006b964583a173e59149947157_40"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="f-414" continuedAt="idbfbf73052204216bc289e14f22dda30" escape="true">Restructuring, Impairment, and Related Charges, Net</ix:nonNumeric></span></div><ix:continuation id="idbfbf73052204216bc289e14f22dda30" continuedAt="i87c1db10b35d45a895b2c304bc33727f"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded restructuring, impairment, and related charges, net of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="mck:RestructuringImpairmentAndOtherRelatedCharges" format="ixt:num-dot-decimal" scale="6" id="f-415">52</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="mck:RestructuringImpairmentAndOtherRelatedCharges" format="ixt:num-dot-decimal" scale="6" id="f-416">23</ix:nonFraction> million for the three months ended June 30, 2023 and 2022, respectively. These charges were included in &#8220;Restructuring, impairment, and related charges, net&#8221; in the Condensed Consolidated Statements of Operations. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring Initiatives</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of fiscal 2023, the Company approved a broad set of initiatives to drive operational efficiencies and increase cost optimization efforts, with the intent of simplifying its infrastructure and realizing long-term sustainable growth. These initiatives include headcount reductions and the exit or downsizing of certain facilities. The Company anticipates total charges of approximately $<ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-6" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="6" id="f-417">125</ix:nonFraction> million across its RxTS and U.S. Pharmaceutical segments as well as Corporate, consisting primarily of employee severance and other employee-related costs, facility and other exit-related costs, as well as long-lived asset impairments. Of this amount, $<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" format="ixt:num-dot-decimal" scale="6" id="f-418">96</ix:nonFraction> million of charges were recorded to date. For the three months ended June 30, 2023, the Company recorded charges of $<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="f-419">36</ix:nonFraction> million related to this program, which primarily includes real estate and other related asset impairments and facility costs within Corporate. This restructuring program is anticipated to be substantially complete by the end of fiscal 2024. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="f-420" continuedAt="i810ee7c207574c55ad7f22f4ac12db59" escape="true"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring, impairment, and related charges, net for the three months ended June 30, 2023 and 2022 consisted of the following: </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:20.861%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.102%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.173%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.784%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. Pharmaceutical</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Prescription Technology Solutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical-Surgical Solutions</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">International</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance and employee-related costs, net </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-6" name="us-gaap:SeveranceCosts1" scale="6" id="f-421">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-6" name="us-gaap:SeveranceCosts1" format="ixt:fixed-zero" scale="6" id="f-422">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-6" name="us-gaap:SeveranceCosts1" format="ixt:fixed-zero" scale="6" id="f-423">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-6" name="us-gaap:SeveranceCosts1" format="ixt:fixed-zero" scale="6" id="f-424">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-6" name="us-gaap:SeveranceCosts1" scale="6" id="f-425">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:SeveranceCosts1" scale="6" id="f-426">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exit and other-related costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-6" name="us-gaap:BusinessExitCosts1" scale="6" id="f-427">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-6" name="us-gaap:BusinessExitCosts1" scale="6" id="f-428">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-6" name="us-gaap:BusinessExitCosts1" scale="6" id="f-429">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-6" name="us-gaap:BusinessExitCosts1" scale="6" id="f-430">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-6" name="us-gaap:BusinessExitCosts1" scale="6" id="f-431">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:BusinessExitCosts1" scale="6" id="f-432">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairments and accelerated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-6" name="mck:AssetImpairmentChargesIncludingAcceleratedDepreciation" format="ixt:fixed-zero" scale="6" id="f-433">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-6" name="mck:AssetImpairmentChargesIncludingAcceleratedDepreciation" format="ixt:fixed-zero" scale="6" id="f-434">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-6" name="mck:AssetImpairmentChargesIncludingAcceleratedDepreciation" format="ixt:fixed-zero" scale="6" id="f-435">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-6" name="mck:AssetImpairmentChargesIncludingAcceleratedDepreciation" scale="6" id="f-436">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-6" name="mck:AssetImpairmentChargesIncludingAcceleratedDepreciation" scale="6" id="f-437">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="mck:AssetImpairmentChargesIncludingAcceleratedDepreciation" scale="6" id="f-438">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-439">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-440">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-441">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-442">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-443">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-444">52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company&#8217;s technology solutions. </span></div><div style="margin-bottom:12pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred. </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">McKESSON CORPORATION</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL NOTES (CONTINUED)</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div></div><ix:continuation id="i87c1db10b35d45a895b2c304bc33727f"><ix:continuation id="i810ee7c207574c55ad7f22f4ac12db59"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:21.008%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.102%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.173%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.784%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.737%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. Pharmaceutical</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Prescription Technology Solutions</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical-Surgical Solutions</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance and employee-related costs, net </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-6" name="us-gaap:SeveranceCosts1" scale="6" id="f-445">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-6" name="us-gaap:SeveranceCosts1" format="ixt:fixed-zero" scale="6" id="f-446">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-6" name="us-gaap:SeveranceCosts1" format="ixt:fixed-zero" scale="6" id="f-447">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-6" name="us-gaap:SeveranceCosts1" format="ixt:fixed-zero" scale="6" id="f-448">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-6" sign="-" name="us-gaap:SeveranceCosts1" scale="6" id="f-449">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:SeveranceCosts1" scale="6" id="f-450">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exit and other-related costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-6" name="us-gaap:BusinessExitCosts1" scale="6" id="f-451">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-6" name="us-gaap:BusinessExitCosts1" scale="6" id="f-452">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-6" name="us-gaap:BusinessExitCosts1" scale="6" id="f-453">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-6" name="us-gaap:BusinessExitCosts1" scale="6" id="f-454">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-6" name="us-gaap:BusinessExitCosts1" scale="6" id="f-455">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:BusinessExitCosts1" scale="6" id="f-456">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairments and accelerated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-6" name="mck:AssetImpairmentChargesIncludingAcceleratedDepreciation" format="ixt:fixed-zero" scale="6" id="f-457">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-6" name="mck:AssetImpairmentChargesIncludingAcceleratedDepreciation" scale="6" id="f-458">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-6" name="mck:AssetImpairmentChargesIncludingAcceleratedDepreciation" format="ixt:fixed-zero" scale="6" id="f-459">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-6" name="mck:AssetImpairmentChargesIncludingAcceleratedDepreciation" format="ixt:fixed-zero" scale="6" id="f-460">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-6" sign="-" name="mck:AssetImpairmentChargesIncludingAcceleratedDepreciation" scale="6" id="f-461">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="mck:AssetImpairmentChargesIncludingAcceleratedDepreciation" format="ixt:fixed-zero" scale="6" id="f-462">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-463">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-464">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-465">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-466">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-467">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-468">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="f-469" escape="true"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to the liabilities associated with the Company&#8217;s restructuring initiatives for the three months ended June 30, 2023:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.946%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.263%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Prescription Technology Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical-Surgical Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, March 31, 2023 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="f-470">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="f-471">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="f-472">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="f-473">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="f-474">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="f-475">92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, impairment, and related charges, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-476">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-477">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-478">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-479">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-480">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="f-481">52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-6" name="us-gaap:RestructuringReserveSettledWithoutCash2" format="ixt:fixed-zero" scale="6" id="f-482">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-6" name="us-gaap:RestructuringReserveSettledWithoutCash2" format="ixt:fixed-zero" scale="6" id="f-483">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-6" name="us-gaap:RestructuringReserveSettledWithoutCash2" format="ixt:fixed-zero" scale="6" id="f-484">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-6" name="us-gaap:RestructuringReserveSettledWithoutCash2" scale="6" id="f-485">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-6" name="us-gaap:RestructuringReserveSettledWithoutCash2" scale="6" id="f-486">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:RestructuringReserveSettledWithoutCash2" scale="6" id="f-487">28</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-488">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-489">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-490">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-491">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-492">15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-493">37</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-6" name="us-gaap:RestructuringReserveTranslationAndOtherAdjustment" format="ixt:fixed-zero" scale="6" id="f-494">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-6" name="us-gaap:RestructuringReserveTranslationAndOtherAdjustment" format="ixt:fixed-zero" scale="6" id="f-495">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-6" name="us-gaap:RestructuringReserveTranslationAndOtherAdjustment" format="ixt:fixed-zero" scale="6" id="f-496">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-6" sign="-" name="us-gaap:RestructuringReserveTranslationAndOtherAdjustment" scale="6" id="f-497">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-6" name="us-gaap:RestructuringReserveTranslationAndOtherAdjustment" format="ixt:fixed-zero" scale="6" id="f-498">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:RestructuringReserveTranslationAndOtherAdjustment" scale="6" id="f-499">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, June 30, 2023 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="f-500">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="f-501">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="f-502">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="f-503">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="f-504">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="f-505">74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">As of March 31, 2023, the total reserve balance was $<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="6" id="f-506">92</ix:nonFraction> million, of which $<ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="6" id="f-507">66</ix:nonFraction> million was recorded in &#8220;Other accrued liabilities&#8221; and $<ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="6" id="f-508">26</ix:nonFraction> million was recorded in &#8220;Other non-current liabilities&#8221; in the Company&#8217;s Condensed Consolidated Balance Sheet.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Other primarily includes cumulative translation adjustments and transfers to certain other liabilities. </span></div><div style="margin-bottom:12pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">As of June 30, 2023, the total reserve balance was $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="6" id="f-509">74</ix:nonFraction> million, of which $<ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="6" id="f-510">44</ix:nonFraction> million was recorded in &#8220;Other accrued liabilities&#8221; and $<ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="6" id="f-511">30</ix:nonFraction> million was recorded in &#8220;Other non-current liabilities&#8221; in the Company&#8217;s Condensed Consolidated Balance Sheet.</span></div></ix:nonNumeric></ix:continuation><div id="if4d8dc006b964583a173e59149947157_43"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-512" continuedAt="ic7c498ccd3c84204a25f5901822371a1" escape="true">Income Taxes </ix:nonNumeric></span></div><ix:continuation id="ic7c498ccd3c84204a25f5901822371a1" continuedAt="i3fb5900be9244fe59c5afae82958db0e"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="f-513" escape="true"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense related to continuing operations was as follows:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.574%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(Dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-514">94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-515">199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported income tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-516">8.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-7" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-517">19.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fluctuations in the Company&#8217;s reported income tax rates were primarily due to changes in the mix of earnings between various taxing jurisdictions and discrete items recognized in the quarters.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June 30, 2023, the Company repatriated certain intellectual property between McKesson wholly-owned legal entities that are based in different tax jurisdictions. The transferor entity of the intellectual property was not subject to income tax on this transaction. The recipient entity of the intellectual property is entitled to amortize the fair value of the assets for tax purposes. As a result of this repatriation, and in accordance with ASU 2016-16, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intra-Entity Transfers of Assets Other Than Inventory</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a net discrete tax benefit of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="mck:EffectiveIncomeTaxReconciliationTaxExpenseBenefitIntraEntityTransfersOfAssetsOtherThanInventoryAmount" format="ixt:num-dot-decimal" scale="6" id="f-518">147</ix:nonFraction>&#160;million was recognized in the first quarter of fiscal 2024. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">McKESSON CORPORATION</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL NOTES (CONTINUED)</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div></div><ix:continuation id="i3fb5900be9244fe59c5afae82958db0e" continuedAt="ie67288b281e3451aad1d6db80677da44"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June 30, 2022, the Company recognized a net discrete tax benefit of $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" format="ixt:num-dot-decimal" scale="6" id="f-519">45</ix:nonFraction>&#160;million primarily related to the tax impact of share-based compensation.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2023, the Company had $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-8" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="9" id="f-520">1.4</ix:nonFraction> billion of unrecognized tax benefits, of which $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-8" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="9" id="f-521">1.3</ix:nonFraction> billion would reduce income tax expense and the effective tax rate if recognized. During the next twelve months, the Company does not anticipate any material reduction in its unrecognized tax benefits based on the information currently available. However, this may change as the Company continues to have ongoing discussions with various taxing authorities throughout the year. &#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company files income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions, and various foreign jurisdictions. The Company is generally subject to audit by taxing authorities in various U.S. states and in foreign jurisdictions for fiscal years 2016 through the current fiscal year. </span></div></ix:continuation><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie67288b281e3451aad1d6db80677da44">During the fourth quarter of fiscal 2023, the Internal Revenue Service (&#8220;IRS&#8221;) communicated proposed adjustments to taxable income reported in the Company&#8217;s fiscal 2018 and fiscal 2019 U.S. Federal Corporate Income Tax returns. The adjustments would increase the Company&#8217;s federal income tax liability in the range of $<ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-6" name="mck:IncomeTaxExaminationEstimateOfPossibleLiabilityAdjustment" format="ixt:num-dot-decimal" scale="6" id="f-522">600</ix:nonFraction>&#160;million to $<ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-6" name="mck:IncomeTaxExaminationEstimateOfPossibleLiabilityAdjustment" format="ixt:num-dot-decimal" scale="6" id="f-523">700</ix:nonFraction>&#160;million. The Company disagrees with the proposed adjustments and intends to pursue resolution through the administrative process with the IRS Independent Office of Appeals and, if necessary, through judicial remedies. During the first quarter of fiscal 2024, the Company filed a formal protest with the IRS. The Company does not anticipate a final resolution of these matters until fiscal 2026 or after. Although the final resolution of these matters is uncertain, the Company believes in the merits of its tax positions and believes that it has adequately reserved for any adjustments to the provision of income taxes that may ultimately result. However, if the IRS prevails in these matters, the assessed tax and interest could have a material adverse effect on the Company&#8217;s financial position, results of operations, and cash flows in future periods.</ix:continuation> </span></div><div id="if4d8dc006b964583a173e59149947157_49"></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-524" continuedAt="i4df463c63cdd4f0a9477f6aacba756cb" escape="true">Earnings Per Common Share</ix:nonNumeric></span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4df463c63cdd4f0a9477f6aacba756cb" continuedAt="i38b7929b133e489ab44accf59fc9e989">Basic earnings per common share is computed by dividing net income by the weighted-average number of common shares outstanding during the reporting period. The computation of diluted earnings per common share is similar to that of basic earnings per common share, except that the former reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock. Potentially dilutive securities include outstanding stock options, restricted stock units, and performance-based restricted stock units. Less than <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="f-525"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="f-526">1.0</ix:nonFraction></ix:nonFraction> million of potentially dilutive securities for the three months ended June 30, 2023 and 2022 were excluded from the computation of diluted earnings per common share as they were anti-dilutive.</ix:continuation></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">McKESSON CORPORATION</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL NOTES (CONTINUED)</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div></div><ix:continuation id="i38b7929b133e489ab44accf59fc9e989"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-527" escape="true"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The computations for basic and diluted earnings per common share were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.574%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions, except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-528">997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-529">807</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="f-530">39</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="f-531">41</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations attributable to McKesson Corporation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperations" scale="6" id="f-532">958</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperations" scale="6" id="f-533">766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" format="ixt:fixed-zero" scale="6" id="f-534">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" scale="6" id="f-535">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to McKesson Corporation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="f-536">958</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="f-537">768</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-538">135.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-539">144.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-90" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="f-540">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-91" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="f-541">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-92" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="f-542">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-93" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="f-543">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-544">136.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-545">145.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per common share attributable to McKesson Corporation: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="f-546">7.02</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" scale="0" id="f-547">5.25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" format="ixt:fixed-zero" scale="0" id="f-548">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" scale="0" id="f-549">0.01</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-550">7.02</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-551">5.26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="f-552">7.07</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" scale="0" id="f-553">5.31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" format="ixt:fixed-zero" scale="0" id="f-554">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" scale="0" id="f-555">0.01</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-556">7.07</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-557">5.32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes dilutive effect from restricted stock units and performance-based stock units.</span></div><div style="margin-bottom:12pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Certain computations may reflect rounding adjustments.</span></div></ix:nonNumeric></ix:continuation><div id="if4d8dc006b964583a173e59149947157_52"></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="f-558" continuedAt="if9d13996c99b4f908c24dee02941bdba" escape="true">Goodwill and Intangible Assets, Net </ix:nonNumeric></span></div><div id="if4d8dc006b964583a173e59149947157_1650"></div><ix:continuation id="if9d13996c99b4f908c24dee02941bdba" continuedAt="i6ba734de11fe4a2e9bb9416602fb200e"><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates goodwill for impairment on an annual basis in the first fiscal quarter, and more frequently if indicators for potential impairment exist. Goodwill impairment testing is conducted at the reporting unit level, which is generally defined as an operating segment or one level below an operating segment (also known as a component), for which discrete financial information is available and segment management regularly reviews the operating results of that reporting unit. The annual impairment testing performed in fiscal 2024 and fiscal 2023 did not indicate any impairment of goodwill. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">McKESSON CORPORATION</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL NOTES (CONTINUED)</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div></div><ix:continuation id="i6ba734de11fe4a2e9bb9416602fb200e" continuedAt="i771349452c9348f2bd8d6411d31e9103"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfGoodwillTextBlock" id="f-559" escape="true"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the carrying amount of goodwill were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:26.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.652%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. Pharmaceutical </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Prescription Technology Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical-Surgical Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">International</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, March 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-560">4,050</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-561">2,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-562">2,453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-563">1,439</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-564">9,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="f-565">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="f-566">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="f-567">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="f-568">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" scale="6" id="f-569">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other adjustments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-6" sign="-" name="us-gaap:GoodwillPurchaseAccountingAdjustments" scale="6" id="f-570">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-6" name="us-gaap:GoodwillPurchaseAccountingAdjustments" format="ixt:fixed-zero" scale="6" id="f-571">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-6" name="us-gaap:GoodwillPurchaseAccountingAdjustments" format="ixt:fixed-zero" scale="6" id="f-572">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-6" name="us-gaap:GoodwillPurchaseAccountingAdjustments" format="ixt:fixed-zero" scale="6" id="f-573">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:GoodwillPurchaseAccountingAdjustments" scale="6" id="f-574">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, June 30, 2023</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-575">4,045</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-576">2,005</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-577">2,453</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-578">1,468</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-579">9,971</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The goodwill balance allocated to the U.S. Pharmaceutical segment related to McKesson Europe&#8217;s Celesio AG acquisition no longer reflects foreign currency translation adjustments as its functional currency was changed from Euros to U.S. dollars with the completion of the sale of the E.U. disposal group.</span></div><div style="margin-bottom:12pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes purchase price allocation adjustments related to the formation of SCRI Oncology, which is discussed in Financial Note 2, &#8220;Business Acquisitions and Divestitures.&#8221;</span></div></ix:nonNumeric></ix:continuation><div id="if4d8dc006b964583a173e59149947157_1677"></div><ix:continuation id="i771349452c9348f2bd8d6411d31e9103" continuedAt="i426639e158b9421a9f2800faefd09088"><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="f-580" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding intangible assets was as follows: </span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:23.716%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.032%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.032%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.156%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(Dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Amortization<br/>Period<br/>(Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-106" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" id="f-581">12</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="f-582">2,984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-583">1,801</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="f-584">1,183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="f-585">2,971</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-586">1,765</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="f-587">1,206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service agreements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-108" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" id="f-588">10</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="f-589">1,141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="f-590">641</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="f-591">500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="f-592">1,137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="f-593">623</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="f-594">514</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks and trade names</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-110" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" id="f-595">12</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="f-596">843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="f-597">446</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="f-598">397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="f-599">833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="f-600">430</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="f-601">403</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-112" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" id="f-602">11</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="f-603">264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="f-604">133</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="f-605">131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="f-606">264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="f-607">129</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="f-608">135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-114" name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" format="ixt-sec:duryear" id="f-609">6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="f-610">184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="f-611">174</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="f-612">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="f-613">193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="f-614">174</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="f-615">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="f-616">5,416</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-617">3,195</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="f-618">2,221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="f-619">5,398</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-620">3,121</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="f-621">2,277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i426639e158b9421a9f2800faefd09088">All intangible assets were subject to amortization as of June 30, 2023 and March 31, 2023. Amortization expense of intangible assets was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-622">62</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-623">56</ix:nonFraction> million for the three months ended June 30, 2023 and 2022, respectively. Estimated amortization expense of the assets listed in the table above is as follows: $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="6" id="f-624">185</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="f-625">240</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="6" id="f-626">208</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="6" id="f-627">202</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="6" id="f-628">198</ix:nonFraction> million for the remainder of fiscal 2024 and each of the succeeding years through fiscal 2028, respectively, and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-8" name="mck:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" format="ixt:num-dot-decimal" scale="9" id="f-629">1.2</ix:nonFraction> billion thereafter.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><div id="if4d8dc006b964583a173e59149947157_55"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">McKESSON CORPORATION</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL NOTES (CONTINUED)</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-630" continuedAt="i1c92728dbe7647ca9dcd6a2b3ee30374" escape="true">Debt and Financing Activities</ix:nonNumeric></span></div><ix:continuation id="i1c92728dbe7647ca9dcd6a2b3ee30374" continuedAt="iedeba5750d0640eebe36d8b01e611a15"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDebtTableTextBlock" id="f-631" escape="true"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.636%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">U.S. Dollar notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1) (2)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-116" decimals="4" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-632">3.80</ix:nonFraction>% Notes due March 15, 2024</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="f-633">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-634">918</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-118" decimals="4" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-635">0.90</ix:nonFraction>% Notes due December 3, 2025</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-636">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-637">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-120" decimals="4" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-638">5.25</ix:nonFraction>% Notes due February 15, 2026</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-639">499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-640">499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-122" decimals="4" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-641">1.30</ix:nonFraction>% Notes due August 15, 2026</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-642">499</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-643">498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-124" decimals="4" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-644">7.65</ix:nonFraction>% Debentures due March 1, 2027</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-645">150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-646">150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-126" decimals="4" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-647">3.95</ix:nonFraction>% Notes due February 16, 2028</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-648">343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-649">343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-128" decimals="4" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-650">4.90</ix:nonFraction>% Notes due July 15, 2028</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-651">399</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="f-652">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-130" decimals="4" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-653">4.75</ix:nonFraction>% Notes due May 30, 2029</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-654">196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-655">196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-132" decimals="4" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-656">5.10</ix:nonFraction>% Notes due July 15, 2033</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-657">596</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="f-658">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-134" decimals="4" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-659">6.00</ix:nonFraction>% Notes due March 1, 2041</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-660">218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-661">218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-136" decimals="4" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-662">4.88</ix:nonFraction>% Notes due March 15, 2044</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-663">255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-664">255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Foreign currency notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1) (3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-138" decimals="4" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-665">1.50</ix:nonFraction>% Euro Notes due November 17, 2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-666">653</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-667">649</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-140" decimals="4" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-668">1.63</ix:nonFraction>% Euro Notes due October 30, 2026 </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-669">545</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-670">542</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-142" decimals="4" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-671">3.13</ix:nonFraction>% Sterling Notes due February 17, 2029</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-672">571</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-673">555</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease and other obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-674">237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="f-675">271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-676">5,661</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-677">5,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="6" id="f-678">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" scale="6" id="f-679">968</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="f-680">5,611</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="6" id="f-681">4,626</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">These notes are unsecured and unsubordinated obligations of the Company.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Interest on these U.S. dollar notes is payable semi-annually.</span></div><div style="margin-bottom:12pt;margin-top:3pt;padding-left:18pt;padding-right:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Interest on these foreign currency notes is payable annually.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-Term Debt</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s long-term debt includes both U.S. dollar and foreign currency-denominated borrowings. At June 30, 2023 and March 31, 2023, $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-8" name="us-gaap:DebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="9" id="f-682">5.7</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-8" name="us-gaap:DebtAndCapitalLeaseObligations" format="ixt:num-dot-decimal" scale="9" id="f-683">5.6</ix:nonFraction> billion, respectively, of total debt was outstanding, of which $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" format="ixt:num-dot-decimal" scale="6" id="f-684">50</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent" format="ixt:num-dot-decimal" scale="6" id="f-685">968</ix:nonFraction> million, respectively, was included under the caption &#8220;Current portion of long-term debt&#8221; in the Company&#8217;s Condensed Consolidated Balance Sheets. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Notes Offerings</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 15, 2023, the Company completed a public offering of <ix:nonFraction unitRef="number" contextRef="c-146" decimals="4" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-686">4.90</ix:nonFraction>% Notes due July 15, 2028 in a principal amount of $<ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-687">400</ix:nonFraction> million (the &#8220;2028 Notes&#8221;) and a public offering of <ix:nonFraction unitRef="number" contextRef="c-147" decimals="4" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-688">5.10</ix:nonFraction>% Notes due July 15, 2033 in a principal amount of $<ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-689">600</ix:nonFraction> million (the &#8220;2033 Notes&#8221; and, together with the 2028 Notes, the &#8220;Notes&#8221;). Interest on the Notes is payable semi-annually on January 15th and July 15th of each year, commencing on January 15, 2024. Proceeds received from the issuance of the Notes, net of discounts and offering expenses, were $<ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-6" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="f-690">397</ix:nonFraction> million for the 2028 Notes and $<ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-6" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="f-691">592</ix:nonFraction> million for the 2033 Notes. The Company utilized a portion of the net proceeds from the offerings of the Notes to fund the purchase price payable with respect to the  portion of the Company&#8217;s then outstanding <ix:nonFraction unitRef="number" contextRef="c-150" decimals="4" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-692">3.80</ix:nonFraction>% Notes due March 15, 2024 (the &#8220;2024 Notes&#8221;) that was validly tendered and accepted for purchase pursuant to the Concurrent Tender Offer (as defined below) and to effect the satisfaction and discharge of the remaining portion of the 2024 Notes, all of which is described further below. The remaining net proceeds from the offerings of the Notes is available for general corporate purposes.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">McKESSON CORPORATION</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL NOTES (CONTINUED)</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div></div><ix:continuation id="iedeba5750d0640eebe36d8b01e611a15"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each series of the Notes is an unsecured and unsubordinated obligation of the Company and ranks equally with all of the Company&#8217;s existing, and future unsecured and unsubordinated indebtedness that may be outstanding from time-to-time. The Notes are governed by an indenture and officers&#8217; certificate that are materially similar to those of other series of notes issued by the Company. Upon at least <ix:nonNumeric contextRef="c-151" name="mck:DebtInstrumentRedemptionPeriod" format="ixt-sec:durday" id="f-693">10</ix:nonNumeric> days&#8217; and not more than <ix:nonNumeric contextRef="c-152" name="mck:DebtInstrumentRedemptionPeriod" format="ixt-sec:durday" id="f-694">60</ix:nonNumeric> days&#8217; notice to holders of the applicable series of the Notes, the Company may redeem either series of the Notes for cash in whole, at any time, or in part, from time to time, at redemption prices that include accrued and unpaid interest and a make-whole premium before a specified date, and at par plus accrued and unpaid interest thereafter until maturity, each as specified in the indenture and the officers&#8217; certificate. If there were to occur both (1) a change of control of the Company and (2) a downgrade of the applicable series of the Notes below an investment grade rating by each of the Ratings Agencies (as defined in the officers&#8217; certificate) within a specified period, then the Company would be required to make an offer to purchase those Notes at a price equal to <ix:nonFraction unitRef="number" contextRef="c-153" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="f-695">101</ix:nonFraction>% of the then outstanding principal amount of such Notes, plus accrued and unpaid interest to, but not including, the date of repurchase. The indenture and the related officers&#8217; certificate for the Notes, subject to the exceptions and in compliance with the conditions as applicable, specify that the Company may not consolidate, merge or sell all or substantially all of its assets, incur liens, or enter into sale-leaseback transactions exceeding specific terms, without the lenders&#8217; consent. The indenture also contains customary events of default provisions.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concurrent Tender Offer </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 16, 2023, the Company completed a cash tender offer for any and all of its then outstanding 2024 Notes, which was made concurrently with the offerings of the Notes (the &#8220;Concurrent Tender Offer&#8221;). The Company paid an aggregate consideration of $<ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-696">268</ix:nonFraction> million in the Concurrent Tender Offer to repurchase $<ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-6" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-697">271</ix:nonFraction> million principal amount of the 2024 Notes at a repurchase price equal to <ix:nonFraction unitRef="number" contextRef="c-154" decimals="4" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="f-698">98.75</ix:nonFraction>% of the principal amount plus accrued and unpaid interest. The repurchase of the 2024 Notes accepted for purchase in the Concurrent Tender Offer was accounted for as a debt extinguishment. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Satisfaction and Discharge of the 2024 Notes</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 16, 2023, after completing the Concurrent Tender Offer, the Company irrevocably deposited with the trustee under the indenture governing the 2024 Notes (the &#8220;2024 Notes Indenture&#8221;) U.S. government obligations in an amount sufficient to fund the payment of accrued and unpaid interest of the remaining $<ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-6" name="mck:PaymentsForPurchaseOfGovernmentObligationsForSatisfactionAndDischargeOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-699">647</ix:nonFraction>&#160;million principal amount of the 2024 Notes as it becomes due, and of the principal amount of those 2024 Notes on their March 15, 2024 maturity date. The U.S. government obligations were purchased using a portion of the net proceeds from the offerings of the Notes. After the deposit of such funds with the trustee, the Company&#8217;s obligations under the 2024 Notes Indenture with respect to the 2024 Notes were satisfied and discharged and the transaction was accounted for as a debt extinguishment. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total gain recognized on the debt extinguishments described above for the three months ended June 30, 2023 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="f-700">9</ix:nonFraction> million and included within &#8220;Interest expense&#8221; in the Company&#8217;s Condensed Consolidated Statement of Operations.  </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revolving Credit Facilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 7, 2022, the Company entered into a Credit Agreement (the &#8220;2022 Credit Facility&#8221;), that provides a syndicated $<ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-8" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="f-701">4.0</ix:nonFraction> billion <ix:nonNumeric contextRef="c-157" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="f-702">five-year</ix:nonNumeric> senior unsecured credit facility with a $<ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-8" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="f-703">3.6</ix:nonFraction> billion aggregate sublimit of availability in Canadian dollars, British pound sterling, and Euro. The 2022 Credit Facility is scheduled to mature in November 2027. The 2022 Credit Facility replaced the Company&#8217;s previous syndicated $<ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-8" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="f-704">4.0</ix:nonFraction> billion <ix:nonNumeric contextRef="c-160" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="f-705">five-year</ix:nonNumeric> senior unsecured credit facility, dated as of September 25, 2019, as amended (the &#8220;2020 Credit Facility&#8221;), which was scheduled to mature in September 2024. The 2020 Credit Facility was terminated in connection with the execution of the 2022 Credit Facility. There were <ix:nonFraction unitRef="usd" contextRef="c-161" decimals="INF" name="us-gaap:ProceedsFromLinesOfCredit" format="ixt:fixed-zero" scale="0" id="f-706">no</ix:nonFraction> borrowings under the 2020 Credit Facility during the three months ended June 30, 2022, and <ix:nonFraction unitRef="usd" contextRef="c-162" decimals="INF" name="us-gaap:LineOfCredit" format="ixt:fixed-zero" scale="0" id="f-707">no</ix:nonFraction> amounts outstanding at the time of its termination. There were <ix:nonFraction unitRef="usd" contextRef="c-163" decimals="INF" name="us-gaap:ProceedsFromLinesOfCredit" format="ixt:fixed-zero" scale="0" id="f-708">no</ix:nonFraction> borrowings under the 2022 Credit Facility during the three months ended June 30, 2023 and <ix:nonFraction unitRef="usd" contextRef="c-164" decimals="INF" name="us-gaap:LineOfCredit" format="ixt:fixed-zero" scale="0" id="f-709">no</ix:nonFraction> amounts outstanding at June 30, 2023. At June 30, 2023, the Company was in compliance with all covenants under the 2022 Credit Facility. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commercial Paper</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a commercial paper program to support its working capital requirements and for other general corporate purposes. Under the program, the Company can issue up to $<ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-8" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="f-710">4.0</ix:nonFraction> billion in outstanding commercial paper notes. During the three months ended June 30, 2023, the Company borrowed and repaid $<ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-6" name="us-gaap:RepaymentsOfCommercialPaper" format="ixt:num-dot-decimal" scale="6" id="f-711"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfCommercialPaper" format="ixt:num-dot-decimal" scale="6" id="f-712">65</ix:nonFraction></ix:nonFraction> million under the program. During the three months ended June 30, 2022, there were <ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfCommercialPaper" format="ixt:fixed-zero" scale="9" id="f-713">no</ix:nonFraction> material borrowings under the program. At June 30, 2023 and March 31, 2023, there were <ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-6" name="us-gaap:LongTermCommercialPaperCurrent" format="ixt:fixed-zero" scale="0" id="f-714"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-6" name="us-gaap:LongTermCommercialPaperCurrent" format="ixt:fixed-zero" scale="0" id="f-715">no</ix:nonFraction></ix:nonFraction> commercial paper notes outstanding.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><div id="if4d8dc006b964583a173e59149947157_61"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">McKESSON CORPORATION</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL NOTES (CONTINUED)</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="f-716" continuedAt="iab720a8f191d477ba4cee388fdd5d28b" escape="true">Hedging Activities </ix:nonNumeric></span></div><ix:continuation id="iab720a8f191d477ba4cee388fdd5d28b" continuedAt="ic41a388219cb4835b91bdb49f7cc159a"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company is exposed to interest rate and foreign currency exchange rate fluctuations. At times, the Company limits these risks through the use of derivatives as described below. In accordance with the Company&#8217;s policy, derivatives are only used for hedging purposes. It does not use derivatives for trading or speculative purposes. The Company uses different counterparties for its derivative contracts to minimize the exposure to credit risk but does not anticipate non-performance by these parties.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Exchange Risk</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company conducts its business worldwide in U.S. dollars and the functional currencies of its foreign subsidiaries, including Canadian dollars, Euro, and British pounds sterling. Changes in foreign currency exchange rates could have a material adverse impact on the Company&#8217;s financial results that are reported in U.S. dollars. The Company is also exposed to foreign currency exchange rate risk related to its foreign subsidiaries, including intercompany loans denominated in non-functional currencies. The Company has certain foreign currency exchange rate risk programs that use cross-currency swaps. These forward contracts and cross-currency swaps are generally used to offset the potential income statement effects from intercompany loans and other obligations denominated in non-functional currencies. These programs reduce but do not entirely eliminate foreign currency exchange rate risk. </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Derivative Instruments Designated as Hedges</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the divestiture of the E.U. disposal group, the Company had &#8364;<ix:nonFraction unitRef="eur" contextRef="c-169" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="f-717">1.1</ix:nonFraction> billion of Euro-denominated notes designated as non-derivative net investment hedges. These hedges were utilized to hedge portions of the Company&#8217;s net investments in non-U.S. subsidiaries against the effect of exchange rate fluctuations on the translation of foreign currency balances to the U.S. dollar. For all notes that were designated as net investment hedges and met effectiveness requirements, the changes in carrying value of the notes attributable to the change in spot rates were recorded as foreign currency translation adjustments in &#8220;Accumulated other comprehensive loss&#8221; where they offset foreign currency translation gains and losses recorded on the Company&#8217;s net investments.&#160;To the extent foreign currency denominated notes designated as net investment hedges were ineffective, changes in carrying value attributable to the change in spot rates were recorded in earnings. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In connection with the divestiture of the E.U. disposal group in October 2022, the Euro-denominated notes described above were de-designated as net investment hedges.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the sale of the U.K. disposal group in April 2022, the Company reclassified $<ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-6" name="us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" format="ixt:num-dot-decimal" scale="6" id="f-718">26</ix:nonFraction>&#160;million of gains from accumulated other comprehensive loss to &#8220;Selling, distribution, general, and administrative expenses&#8221; in the Condensed Consolidated Statement of Operations for the three months ended June 30, 2022. This amount related to the Company&#8217;s &#163;<ix:nonFraction unitRef="gbp" contextRef="c-171" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-719">450</ix:nonFraction> million of British pound sterling-denominated notes, which were previously accounted for as net investment hedges until de-designated in fiscal 2020, and was included in the fiscal 2022 calculation of charges to remeasure the assets and liabilities of the disposal group to fair value less costs to sell.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="f-720" escape="true"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency gains (losses) from non-derivative instruments included in other comprehensive income in the Condensed Consolidated Statements of Comprehensive Income were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.531%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.574%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-derivatives designated as net investment hedges: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Euro-denominated notes </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" format="ixt:fixed-zero" scale="6" id="f-721">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" scale="6" id="f-722">64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">There was no ineffectiveness in these hedges for the three months ended June 30, 2022.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">McKESSON CORPORATION</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL NOTES (CONTINUED)</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div></div><ix:continuation id="ic41a388219cb4835b91bdb49f7cc159a" continuedAt="ia6010959579b4b87885665931313b451"><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Instruments</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" id="f-723" escape="true"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June 30, 2023 and March 31, 2023, the notional amounts of the Company&#8217;s outstanding derivatives were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:42.640%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.178%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.658%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.480%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.336%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Currency</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity Date</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notional</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as net investment hedges: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swaps </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CAD</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-24 to Mar-25</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-174" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-724">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-175" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-725">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as fair value hedges: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swaps </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GBP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-28</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#163;</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="gbp" contextRef="c-176" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="f-726">450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#163;</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="gbp" contextRef="c-177" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="f-727">450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swaps </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EUR</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aug-25 to Jul-26</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8364;</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-178" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-728">1,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8364;</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="eur" contextRef="c-179" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-729">1,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Floating interest rate swaps </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">USD</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Feb-26 to Sep-29</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-730">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-731">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as cash flow hedges: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swaps </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CAD</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jan-24</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-182" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="f-732">400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="cad" contextRef="c-183" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="f-733">400</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed interest rate swaps </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">USD</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jun-23</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:fixed-zero" scale="6" id="f-734">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-6" name="us-gaap:DerivativeNotionalAmount" scale="6" id="f-735">450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The maturity date reflected is for outstanding derivatives as of June 30, 2023.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">There was no ineffectiveness in these hedges for the three months ended June 30, 2023 and 2022.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The Company agreed with third parties to exchange fixed interest payments in one currency for fixed interest payments in another currency at specified intervals and to exchange principal in one currency for principal in another currency, calculated by reference to agreed-upon notional amounts.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Represents cross-currency fixed-to-fixed interest rate swaps to mitigate the foreign currency exchange fluctuations on its foreign currency-denominated notes. </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Represents fixed-to-floating interest rate swaps to hedge the changes in fair value caused by fluctuations in the benchmark interest rates. </span></div><div style="margin-bottom:12pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The Company entered into agreements with financial institutions to lock into the fixed benchmark interest rates for future bond issuance, which were terminated during the first quarter of fiscal 2024 as discussed further below.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Investment Hedges</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses cross-currency swaps to hedge portions of the Company&#8217;s net investments denominated in Canadian dollars against the effect of exchange rate fluctuations on the translation of foreign currency balances to the U.S. dollar. The changes in the fair value of these derivatives attributable to the changes in spot currency exchange rates and differences between spot and forward interest rates are recorded in accumulated other comprehensive loss and offset foreign currency translation gains and losses recorded on the Company&#8217;s net investments denominated in Canadian dollars. To the extent cross-currency swaps designated as hedges are ineffective, changes in carrying value attributable to the change in spot rates are recorded in earnings.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Hedges</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses cross-currency swaps to hedge the changes in the fair value of its foreign currency notes resulting from changes in benchmark interest rates and foreign currency exchange rates. The changes in the fair value of these derivatives and the offsetting changes in the fair value of the hedged notes are recorded in earnings. Gains from the changes in the Company&#8217;s fair value hedges recorded in earnings were largely offset by the losses recorded in earnings on the hedged item. For components excluded from the assessment of hedge effectiveness, the initial value of the excluded component is recognized in accumulated other comprehensive loss and then released into earnings over the life of the hedging instrument. The difference between the change in the fair value of the excluded component and the amount amortized into earnings during the period is recorded in other comprehensive income (loss).</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">McKESSON CORPORATION</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL NOTES (CONTINUED)</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div></div><ix:continuation id="ia6010959579b4b87885665931313b451" continuedAt="i891eeb28a678405a8f7d37235d7f2f4a"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flow Hedges</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company enters into cross-currency swaps to hedge intercompany loans denominated in non-functional currencies to reduce the income statement effects arising from fluctuations in foreign currency rates and also enters into forward contracts to hedge the variability of future benchmark interest rates on planned bond issuances. The effective portion of changes in the fair value&#160;of these hedges is recorded in accumulated other comprehensive loss and reclassified into earnings in the same period in which the hedged transaction affects earnings. Changes in fair values representing hedge ineffectiveness are recognized in current earnings. Gains or losses reclassified from accumulated other comprehensive loss and recorded in &#8220;Selling, distribution, general, and administrative expenses&#8221; in the Condensed Consolidated Statements of Operations were not material for the three months ended June 30, 2023 and 2022.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into forward-starting fixed interest rate swaps designated as cash flow hedges in fiscal 2023 with a notional amount of $<ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-6" name="mck:DerivativeNotionalAmountEnteredIntoDuringPeriod" format="ixt:num-dot-decimal" scale="6" id="f-736">450</ix:nonFraction>&#160;million, and in the first quarter of fiscal 2024 with a notional amount of $<ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-6" name="mck:DerivativeNotionalAmountEnteredIntoDuringPeriod" format="ixt:num-dot-decimal" scale="6" id="f-737">50</ix:nonFraction>&#160;million, to hedge the variability of future benchmark interest rates on a planned bond issuance. On June 15, 2023, the Company completed a public offering of the 2033 Notes, at which point the $<ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-6" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-738">500</ix:nonFraction>&#160;million cash flow hedges were terminated and the proceeds are amortized to interest expense over the life of the 2033 Notes, or <ix:nonNumeric contextRef="c-187" name="mck:DerivativeTerminationProceedsAmortizationPeriod" format="ixt-sec:duryear" id="f-739">10</ix:nonNumeric> years. Refer to Financial Note 7, &#8220;Debt and Financing Activities,&#8221; for additional information on the public offering of the 2033 Notes.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives Not Designated as Hedges</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derivative instruments not designated as hedges are marked-to-market at the end of each accounting period with the change in fair value included in earnings. Changes in the fair values for contracts not designated as hedges are recorded directly into earnings in &#8220;Selling, distribution, general, and administrative expenses&#8221; in the Condensed Consolidated Statements of Operations. The Company did not have any outstanding derivative instruments not designated as hedges during the periods presented. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Information on Derivative Instruments</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="f-740" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="f-741" escape="true"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains (losses) from derivatives included in other comprehensive income in the Condensed Consolidated Statements of Comprehensive Income were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.531%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.574%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as net investment hedges:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swaps</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="f-742">20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="f-743">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as cash flow and other hedges:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swaps </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="f-744">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="f-745">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed interest rate swaps</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="f-746">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="f-747">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes other comprehensive income (loss) related to the excluded component of certain fair value hedges.</span></div></ix:nonNumeric></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">McKESSON CORPORATION</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL NOTES (CONTINUED)</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div></div><ix:continuation id="i891eeb28a678405a8f7d37235d7f2f4a"><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueByBalanceSheetGroupingTextBlock" id="f-748" escape="true"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding the fair value of derivatives on a gross basis were as follows:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.263%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet <br/>Caption</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value of <br/>Derivative</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. Dollar Notional</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value of <br/>Derivative</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. Dollar Notional</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Asset</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liability</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Asset</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liability</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="39" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated for hedge accounting:</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swaps (current)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other/Other accrued liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:fixed-zero" scale="6" id="f-749">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="f-750">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-6" name="us-gaap:DerivativeAssetNotionalAmount" scale="6" id="f-751">301</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="f-752">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:fixed-zero" scale="6" id="f-753">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-6" name="us-gaap:DerivativeAssetNotionalAmount" scale="6" id="f-754">301</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swaps (non-current)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets/liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="f-755">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="f-756">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-6" name="us-gaap:DerivativeAssetNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-757">2,760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-198" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="f-758">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-198" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="f-759">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-198" decimals="-6" name="us-gaap:DerivativeAssetNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-760">2,760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps (non-current)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets/liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:fixed-zero" scale="6" id="f-761">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="f-762">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-6" name="us-gaap:DerivativeLiabilityNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-763">1,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="f-764">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="f-765">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-6" name="us-gaap:DerivativeLiabilityNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-766">1,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="f-767">84</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="f-768">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="f-769">80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="f-770">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Financial Note 9, "Fair Value Measurements," for more information on these recurring fair value measurements.</span></div></ix:continuation><div id="if4d8dc006b964583a173e59149947157_64"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-771" continuedAt="i3551742b0c39474da4c31a850090167b" escape="true">Fair Value Measurements </ix:nonNumeric></span></div><ix:continuation id="i3551742b0c39474da4c31a850090167b" continuedAt="i309a079274fb40ff88ea2fddadf7b8ef"><div style="margin-bottom:12pt;text-align:justify;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures certain assets and liabilities at fair value in accordance with ASC Topic 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The fair value hierarchy consists of three levels of inputs that may be used to measure fair value as follows:</span></div><div style="margin-bottom:6pt;padding-left:58.5pt;text-align:justify;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 - quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:6pt;padding-left:58.5pt;text-align:justify;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 - significant other observable market-based inputs.</span></div><div style="margin-bottom:12pt;padding-left:58.5pt;text-align:justify;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 - significant unobservable inputs for which little or no market data exists and requires considerable assumptions that are significant to the fair value measurement.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents at June 30, 2023 and March 31, 2023 included investments in money market funds of $<ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-6" name="us-gaap:MoneyMarketFundsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-772">806</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-8" name="us-gaap:MoneyMarketFundsAtCarryingValue" format="ixt:num-dot-decimal" scale="9" id="f-773">1.4</ix:nonFraction> billion, respectively, which are reported at fair value. The fair value of money market funds was determined using quoted prices for identical investments in active markets, which are considered to be Level 1 inputs under the fair value measurements and disclosure guidance. The carrying value of all other cash equivalents approximates their fair value due to their relatively short-term nature.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair values of the Company&#8217;s interest rate swaps and cross-currency swaps were determined using observable inputs from available market information, including quoted interest rates, foreign currency exchange rates, and other observable inputs from available market information.&#160;These inputs are considered Level 2 under the fair value measurements and disclosure guidance, and may not be representative of actual values that could have been realized or that will be realized in the future. Refer to Financial Note 8, &#8220;Hedging Activities,&#8221; for fair values and other information on the Company&#8217;s derivatives.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company holds investments in equity securities of U.S. growth stage companies that address both current and emerging business challenges in the healthcare industry and which had a carrying value of $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="f-774"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="f-775">237</ix:nonFraction></ix:nonFraction>&#160;million at June 30, 2023 and March 31, 2023. These investments primarily consist of equity securities without readily determinable fair values and are included in &#8220;Other non-current assets&#8221; in the Condensed Consolidated Balance Sheets. The carrying value of publicly-traded investments, which was not material for the periods presented, was determined using quoted prices for identical investments in active markets and are considered to be Level 1 inputs. The net realized and unrealized gains as well as impairment charges related to these investments are included within &#8220;Other income, net&#8221; in the Condensed Consolidated Statements of Operations and were not material for the three months ended June 30, 2023 and 2022.  </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">McKESSON CORPORATION</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL NOTES (CONTINUED)</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div></div><ix:continuation id="i309a079274fb40ff88ea2fddadf7b8ef" continuedAt="i27da179ae61244c2bc2e9f8a56950fe3"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to assets and liabilities that are measured at fair value on a recurring basis, the Company&#8217;s assets and liabilities are also subject to nonrecurring fair value measurements. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges or as a result of charges to remeasure assets classified as held for sale to fair value less costs to sell.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June 30, 2023 and  March 31, 2023, the contingent consideration liability related to the Company&#8217;s acquisition of RxSS in November 2022 was measured at fair value on a nonrecurring basis. Refer to Financial Note 2, &#8220;Business Acquisitions and Divestitures," for more information on this transaction. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aforementioned investments in equity securities of U.S. growth stage companies include the carrying value of investments without readily determinable fair values, which were determined using a measurement alternative and are recorded at cost less impairment, plus or minus any changes in observable price from orderly transactions of the same or similar security of the same issuer. These inputs related to changes in observable price are considered Level 2 under the fair value measurements and disclosure guidance and may not be representative of actual values that could have been realized or that will be realized in the future. Inputs related to impairments of investments are generally considered Level 3 fair value measurements due to their inherently unobservable nature based on significant assumptions by management and use of company-specific information.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no other material assets or liabilities measured at fair value on a nonrecurring basis at June 30, 2023 and March 31, 2023.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Fair Value Disclosures</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June 30, 2023 and March 31, 2023, the carrying amounts of cash, certain cash equivalents, restricted cash, receivables, drafts and accounts payable, short-term borrowings, and other current assets and liabilities approximated their estimated fair values because of the short-term maturity of these financial instruments.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the fair value of commercial paper using quoted prices in active markets for identical instruments, which are considered Level 1 inputs under the fair value measurements and disclosure guidance.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" id="f-776" escape="true"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s long-term debt is recorded at amortized cost. The carrying value and fair value of the Company&#8217;s long-term debt was as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.698%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, including current maturities</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-777">5,661</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-6" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="f-778">5,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-206" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-779">5,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-206" decimals="-6" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="f-780">5,386</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the Company&#8217;s long-term debt was determined using quoted market prices in a less active market and other observable inputs from available market information, which are considered to be Level 2 inputs, and may not be representative of actual values that could have been realized or that will be realized in the future.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value assessments of the reporting unit and the reporting unit's net assets, which are performed for goodwill impairment tests, are considered a Level 3 measurement due to the significance of unobservable inputs developed using company-specific information. The Company considered a market approach as well as an income approach using a discounted cash flow (&#8220;DCF&#8221;) model to determine the fair value of each reporting unit.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-lived Assets</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes multiple approaches, including the DCF model and market approaches, for estimating the fair value of intangible assets. The future cash flows used in the analysis are based on internal cash flow projections from its long-range plans and include significant assumptions by management. Accordingly, the fair value assessment of long-lived assets is considered a Level 3 fair value measurement.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">McKESSON CORPORATION</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL NOTES (CONTINUED)</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i27da179ae61244c2bc2e9f8a56950fe3">The Company measures certain long-lived and intangible assets at fair value on a nonrecurring basis when events occur that indicate an asset group may not be recoverable. If the carrying amount of an asset group is not recoverable, an impairment charge is recorded to reduce the carrying amount by the excess over its fair value.</ix:continuation></span></div><div id="if4d8dc006b964583a173e59149947157_67"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-781" continuedAt="i334af7351f5c49ba9114b0f6863fca3f" escape="true">Commitments and Contingent Liabilities</ix:nonNumeric></span></div><ix:continuation id="i334af7351f5c49ba9114b0f6863fca3f" continuedAt="i0c131df5f0234a6eafae91df337c0ac1"><ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="f-782" escape="true"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to commitments and obligations incurred in the ordinary course of business, the Company is subject to a variety of claims and legal proceedings, including claims from customers and vendors, pending and potential legal actions for damages, governmental investigations, and other matters. The Company and its affiliates are parties to the legal claims and proceedings described below and in </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/927653/000092765323000038/mck-20230331.htm#i04335d018da94076b0acf21e81ac886b_172">Financial Note 1</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/927653/000092765323000038/mck-20230331.htm#i04335d018da94076b0acf21e81ac886b_172">7</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/927653/000092765323000038/mck-20230331.htm#i04335d018da94076b0acf21e81ac886b_172"> to the Company&#8217;s 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/927653/000092765323000038/mck-20230331.htm#i04335d018da94076b0acf21e81ac886b_172">3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/927653/000092765323000038/mck-20230331.htm#i04335d018da94076b0acf21e81ac886b_172"> Annual Report</a></span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which disclosure is incorporated in this footnote by this reference. The Company is vigorously defending itself against those claims and in those proceedings. Significant developments in those matters are described below. If the Company is unsuccessful in defending, or if it determines to settle, any of these matters, it may be required to pay substantial sums, be subject to injunction and/or be forced to change how it operates its business, which could have a material adverse impact on its financial position or results of operations.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise stated, the Company is unable to reasonably estimate the loss or a range of possible loss for the matters described below. Often, the Company is unable to determine that a loss is probable, or to reasonably estimate the amount of loss or a range of loss, for a claim because of the limited information available and the potential effects of future events and decisions by third parties, such as courts and regulators, that will determine the ultimate resolution of the claim. Many of the matters described are at preliminary stages, raise novel theories of liability, or seek an indeterminate amount of damages. It is not uncommon for claims to remain unresolved over many years. The Company reviews loss contingencies at least quarterly to determine whether the likelihood of loss has changed and whether it can make a reasonable estimate of the loss or range of loss. When the Company determines that a loss from a claim is probable and reasonably estimable, it records a liability for an estimated amount. The Company also provides disclosure when it is reasonably possible that a loss may be incurred or when it is reasonably possible that the amount of a loss will exceed its recorded liability. Amounts included within &#8220;Claims and litigation charges, net&#8221; in the Condensed Consolidated Statements of Operations consist of estimated loss contingencies related to opioid-related litigation matters.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">I. Litigation and Claims Involving Distribution of Controlled Substances</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its affiliates have been sued as defendants in many cases asserting claims related to distribution of controlled substances. They have been named as defendants along with other pharmaceutical wholesale distributors, pharmaceutical manufacturers, and retail pharmacies. The plaintiffs in these actions have included state attorneys general, county and municipal governments, school districts, tribal nations, hospitals, health and welfare funds, third-party payors, and individuals. These actions have been filed in state and federal courts throughout the U.S., and in Puerto Rico and Canada. They have sought monetary damages and other forms of relief based on a variety of causes of action, including negligence, public nuisance, unjust enrichment, and civil conspiracy, as well as alleging violations of the Racketeer Influenced and Corrupt Organizations Act (&#8220;RICO&#8221;), state and federal controlled substances laws, and other statutes. Because of the many uncertainties associated with opioid-related litigation matters, the Company is not able to conclude that a liability is probable or provide a reasonable estimate for the range of ultimate possible loss for opioid-related litigation matters other than those for which an accrual is described below. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">McKESSON CORPORATION</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL NOTES (CONTINUED)</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div></div><ix:continuation id="i0c131df5f0234a6eafae91df337c0ac1" continuedAt="i04f55a3dfe1c425e9ef0efe147bce727"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">State and Local Government Claims</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and <ix:nonFraction unitRef="distributor" contextRef="c-207" decimals="INF" name="mck:LossContingencyNumberOfOtherDefendants" format="ixt-sec:numwordsen" scale="0" id="f-783">two</ix:nonFraction> other national pharmaceutical distributors (collectively &#8220;Distributors&#8221;) entered into a settlement agreement (the &#8220;Settlement&#8221;) and consent judgment with <ix:nonFraction unitRef="state" contextRef="c-207" decimals="INF" name="mck:LossContingencyNumberofStates" scale="0" id="f-784">48</ix:nonFraction> states and their participating subdivisions, as well as the District of Columbia and all eligible territories (the &#8220;Settling Governmental Entities&#8221;). Approximately <ix:nonFraction unitRef="case" contextRef="c-207" decimals="INF" name="mck:LossContingencyNumberOfCasesDismissed" format="ixt:num-dot-decimal" scale="0" id="f-785">2,300</ix:nonFraction> cases have been dismissed. The Distributors did not admit liability or wrongdoing and do not waive any defenses pursuant to the Settlement. Under the Settlement, the Company has paid the Settling Governmental Entities approximately $<ix:nonFraction unitRef="usd" contextRef="c-208" decimals="-8" name="us-gaap:PaymentsForLegalSettlements" format="ixt:num-dot-decimal" scale="9" id="f-786">1.0</ix:nonFraction>&#160;billion as of June 30, 2023, and additionally will pay the Settling Governmental Entities up to approximately $<ix:nonFraction unitRef="usd" contextRef="c-208" decimals="-8" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="9" id="f-787">6.8</ix:nonFraction>&#160;billion through 2038. A minimum of <ix:nonFraction unitRef="number" contextRef="c-207" decimals="2" name="mck:LitigationSettlementAwardAmountToBeUsedByStateAndLocalGovernment" scale="-2" id="f-788">85</ix:nonFraction>% of the Settlement payments must be used by state and local governmental entities to remediate the opioid epidemic, while the remainder relates to plaintiffs&#8217; attorneys&#8217; fees and costs and will be paid out through 2030. Under the Settlement, the Distributors will establish a clearinghouse to consolidate their controlled-substance distribution data, which will be available to the settling U.S. states to use as part of their anti-diversion efforts. Alabama and West Virginia did not participate in the Settlement. Under a separate settlement agreement with Alabama and its subdivisions, the Company has paid approximately $<ix:nonFraction unitRef="usd" contextRef="c-209" decimals="-6" name="us-gaap:PaymentsForLegalSettlements" format="ixt:num-dot-decimal" scale="6" id="f-789">42</ix:nonFraction>&#160;million as of June 30, 2023, and additionally will pay approximately $<ix:nonFraction unitRef="usd" contextRef="c-209" decimals="-6" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="f-790">132</ix:nonFraction>&#160;million through 2031. The Company previously settled with the state of West Virginia in 2018, so West Virginia and its subdivisions were not eligible to participate in the Settlement. Under a separate settlement agreement, the Company has paid certain West Virginia subdivisions approximately $<ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-6" name="us-gaap:PaymentsForLegalSettlements" format="ixt:num-dot-decimal" scale="6" id="f-791">38</ix:nonFraction>&#160;million as of June 30, 2023, and additionally will pay approximately $<ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-6" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="f-792">114</ix:nonFraction>&#160;million through 2033. That agreement does not include school districts or the claims of Cabell County and the City of Huntington. After a trial, the claims of Cabell County and the City of Huntington, were decided in the Company&#8217;s favor on July 4, 2022. Those subdivisions appealed that decision. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some other state and local governmental subdivisions did not participate in the Settlement, including certain municipal governments, government hospitals, school districts, and government-affiliated third-party payors. The Company contends that those subdivisions&#8217; claims are foreclosed by the Settlement or other dispositive defenses, but the subdivisions contend that their claims are not foreclosed. The City of Baltimore, Maryland, is <ix:nonFraction unitRef="jurisdiction" contextRef="c-207" decimals="INF" name="mck:LossContingencyClaimsSettledNumberOfJurisdictionsNotParticipatingInSettlement" format="ixt-sec:numwordsen" scale="0" id="f-793">one</ix:nonFraction> such subdivision, and a trial of its claims is scheduled to begin September 26, 2024. An accrual for the remaining governmental subdivision claims is reflected in the total estimated liability for opioid-related claims in a manner consistent with how Settlement amounts were allocated to Settling Governmental Entities.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Native American Tribe Claims</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also entered into settlement agreements for opioid-related claims of federally recognized Native American tribes. Under those agreements, the Company has paid the settling Native American tribes approximately $<ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-6" name="us-gaap:PaymentsForLegalSettlements" format="ixt:num-dot-decimal" scale="6" id="f-794">56</ix:nonFraction>&#160;million as of June 30, 2023, and additionally will pay approximately $<ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-6" name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" format="ixt:num-dot-decimal" scale="6" id="f-795">140</ix:nonFraction>&#160;million through 2027. A minimum of <ix:nonFraction unitRef="number" contextRef="c-213" decimals="2" name="mck:LitigationSettlementAmountAwardedToOtherPartyPercentageOfTotalSettlementToBeUsedToRemediateDamages" scale="-2" id="f-796">85</ix:nonFraction>% of the total settlement payments must be used by the settling Native American tribes to remediate the opioid epidemic.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock" id="f-797" escape="true"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s estimated accrued liability for the opioid-related claims of U.S. governmental entities, including Native American tribes, was as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:68.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.564%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current litigation liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-214" decimals="-6" name="us-gaap:LossContingencyAccrualCarryingValueCurrent" scale="6" id="f-798">545</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-215" decimals="-6" name="us-gaap:LossContingencyAccrualCarryingValueCurrent" scale="6" id="f-799">548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term litigation liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-214" decimals="-6" name="us-gaap:LossContingencyAccrualCarryingValueNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-800">6,628</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-215" decimals="-6" name="us-gaap:LossContingencyAccrualCarryingValueNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-801">6,625</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total litigation liabilities</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-214" decimals="-6" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-802">7,173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-215" decimals="-6" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-803">7,173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">These amounts, recorded in &#8220;Other accrued liabilities&#8221; in the Condensed Consolidated Balance Sheets, are the amounts estimated to be paid within the next twelve months following each respective period end date.</span></div></ix:nonNumeric><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June 30, 2023, the Company made <ix:nonFraction unitRef="usd" contextRef="c-216" decimals="-6" name="us-gaap:PaymentsForLegalSettlements" format="ixt:fixed-zero" scale="0" id="f-804">no</ix:nonFraction> payments associated with the Settlement and the separate settlement agreements for opioid-related claims discussed above. In July 2023, the Company made payments totaling $<ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-6" name="us-gaap:PaymentsForLegalSettlements" format="ixt:num-dot-decimal" scale="6" id="f-805">529</ix:nonFraction>&#160;million associated with the Settlement and separate settlement agreements.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-Governmental Plaintiff Claims</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also a defendant in approximately <ix:nonFraction unitRef="case" contextRef="c-218" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="f-806">400</ix:nonFraction> opioid-related cases brought in the U.S. by private plaintiffs, such as hospitals, health and welfare funds, third-party payors, and individuals. These claims, and those of private entities generally, are not included in the settlement agreements described above or in the charges recorded by the Company. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">McKESSON CORPORATION</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL NOTES (CONTINUED)</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div></div><ix:continuation id="i04f55a3dfe1c425e9ef0efe147bce727"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Canadian Plaintiff Claims</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its Canadian affiliate are also defendants in <ix:nonFraction unitRef="case" contextRef="c-219" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="f-807">four</ix:nonFraction> opioid-related cases pending in Canada. These cases involve the claims of the provincial governments, a group representing indigenous people, as well as <ix:nonFraction unitRef="case" contextRef="c-220" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt-sec:numwordsen" scale="0" id="f-808">one</ix:nonFraction> case brought by an individual.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Defense of Opioids Claims</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes it has valid legal defenses in all opioid-related matters, including claims not covered by settlement agreements, and it intends to mount a vigorous defense in such matters. Other than the settlement agreements and the U.S. governmental subdivision claims described above, the Company has not concluded a loss is probable in any of the matters; nor is any possible loss or range of loss reasonably estimable. An adverse judgment or negotiated resolution in any of these matters could have a material adverse impact on the Company&#8217;s financial position, cash flows or liquidity, or results of operations.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">II. Other Litigation and Claims</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 12, 2018, the Company received a purported class action complaint in the United States District Court for the Northern District of California, alleging that McKesson and <ix:nonFraction unitRef="officer" contextRef="c-221" decimals="0" name="mck:LossContingencyNumberOfFormerOfficers" format="ixt-sec:numwordsen" scale="0" id="f-809">two</ix:nonFraction> of its former officers, CEO John Hammergren and CFO James Beer, violated the Securities Exchange Act of 1934 by reporting profits and revenues from 2013 until early 2017 that were false and misleading, due to an alleged undisclosed conspiracy to fix the prices of generic drugs. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Evanston Police Pension Fund v. McKesson Corporation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 3:18-06525. In October 2022, the parties reached an agreement in principle to settle this class action lawsuit for an amount covered in full by the Company&#8217;s insurance policy. This settlement does not include any admission of liability, and defendants expressly deny wrongdoing. The Company&#8217;s estimated probable loss, entirely offset by probable loss recovery from the Company&#8217;s insurers, was $<ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-6" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="6" id="f-810"><ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-6" name="us-gaap:EstimatedInsuranceRecoveries" format="ixt:num-dot-decimal" scale="6" id="f-811">141</ix:nonFraction></ix:nonFraction>&#160;million, both of which were recognized in the Condensed Consolidated Balance Sheet as of September 30, 2022 within &#8220;Other accrued liabilities&#8221; and &#8220;Prepaid expenses and other.&#8221; In February 2023, the insurance carriers funded the settlement, and the probable loss and loss recovery of $<ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-6" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="6" id="f-812"><ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-6" name="us-gaap:EstimatedInsuranceRecoveries" format="ixt:num-dot-decimal" scale="6" id="f-813">141</ix:nonFraction></ix:nonFraction>&#160;million have been reversed in the Consolidated Balance Sheet as of March 31, 2023. On July 14, 2023, the court granted the motion for final approval of the settlement. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, the Company was served with a first amended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> complaint filed in the United States District Court for the Southern District of New York by a relator on behalf of the U.S., <ix:nonFraction unitRef="state" contextRef="c-224" decimals="0" name="mck:LossContingencyNumberOfStatesFiledOnBehalfOf" scale="0" id="f-814">27</ix:nonFraction> states and the District of Columbia against McKesson Corporation, McKesson Specialty Distribution LLC, and McKesson Specialty Care Distribution Corporation, alleging that defendants violated the Anti-Kickback Statute, federal False Claims Act, and various state false claims statutes by providing certain business analytical tools to oncology practice customers, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United States ex rel. Hart v. McKesson Corporation, et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 15-cv-00903-RA. The U.S. and the named states have declined to intervene in the case. The complaint seeks relief including damages, treble damages, civil penalties, attorney fees, and costs of suit, all in unspecified amounts. On May 5, 2022, the district court granted the Company&#8217;s motion to dismiss the complaint, but granted the plaintiff leave to amend the complaint. The relator filed the second amended complaint on June 7, 2022, which was dismissed on March 28, 2023. On April 26, 2023, the relator filed a notice of appeal to the United States Court of Appeals for the Second Circuit.  </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">III.&#160;Government Subpoenas and Investigations</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company receives subpoenas or requests for information from various government agencies. The Company generally responds to such subpoenas and requests in a cooperative, thorough, and timely manner. These responses sometimes require time and effort and can result in considerable costs being incurred by the Company. Such subpoenas and requests can lead to the assertion of claims or the commencement of civil or criminal legal proceedings against the Company and other members of the health care industry, as well as to settlements of claims against the Company. The Company responds to these requests in the ordinary course of business.</span></div></ix:continuation><div id="if4d8dc006b964583a173e59149947157_70"></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-815" continuedAt="i67d9caf953de45bf9d30b53d19d661c5" escape="true">Stockholders' Deficit </ix:nonNumeric></span></div><ix:continuation id="i67d9caf953de45bf9d30b53d19d661c5" continuedAt="iaef70fa0b8a64d6caf6a59ddf0afb55c"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each share of the Company&#8217;s outstanding common stock is permitted <ix:nonFraction unitRef="vote" contextRef="c-6" decimals="INF" name="mck:CommonStockVotingRightsNumberofVotesPerCommonShare" format="ixt-sec:numwordsen" scale="0" id="f-816">one</ix:nonFraction> vote on proposals presented to stockholders and is entitled to participate equally in any dividends declared by the Company&#8217;s Board of Directors (the &#8220;Board&#8221;). </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2023, the quarterly dividend was raised from $<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="f-817">0.54</ix:nonFraction> to $<ix:nonFraction unitRef="usdPerShare" contextRef="c-225" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="f-818">0.62</ix:nonFraction> per share of common stock for dividends declared on or after such date by the Board. The Company anticipates that it will continue to pay quarterly cash dividends in the future.&#160;However, the payment and amount of future dividends remain within the discretion of the Board and will depend upon the Company's future earnings, financial condition, capital requirements, legal requirements, and other factors. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><div id="if4d8dc006b964583a173e59149947157_1316"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">McKESSON CORPORATION</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL NOTES (CONTINUED)</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div></div><ix:continuation id="iaef70fa0b8a64d6caf6a59ddf0afb55c" continuedAt="i5d8a861b0d5f43b6b88a0c13b641b9aa"><div style="margin-bottom:6pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share Repurchase Plans </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board has authorized the repurchase of McKesson&#8217;s common stock. The Company may effect stock repurchases from time-to-time through open market transactions, privately negotiated transactions, accelerated share repurchase (&#8220;ASR&#8221;) programs, or by combinations of such methods, any of which may use pre-arranged trading plans that are designed to meet the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. The timing of any repurchases and the actual number of shares repurchased will depend on a variety of factors, including the Company&#8217;s stock price, corporate and regulatory requirements, tax implications, restrictions under the Company&#8217;s debt obligations, other uses for capital, impacts on the value of remaining shares, and market and economic conditions. The ASR programs discussed below were designed to comply with Rule 10b5-1(c).</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2023, the Company&#8217;s repurchase of McKesson&#8217;s common stock, adjusted for allowable items, are subject to a 1% excise tax as a result of the IRA. Excise taxes incurred on share repurchases of an entity&#8217;s own common stock are direct and incremental costs to purchase treasury stock, and accordingly are included in the total cost basis of the common stock acquired and reflected as a reduction of stockholders&#8217; equity within &#8220;Treasury shares&#8221; in the Company&#8217;s Condensed Consolidated Balance Sheets and Condensed Consolidated Statements of Stockholders&#8217; Deficit. Excise taxes are not reflected in the Company&#8217;s remaining authorization for the repurchase of McKesson&#8217;s common stock.  </span></div><div style="margin-bottom:12pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, the Company entered into an ASR program with a third-party financial institution to repurchase $<ix:nonFraction unitRef="usd" contextRef="c-226" decimals="-8" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="9" id="f-819">1.0</ix:nonFraction>&#160;billion of the Company&#8217;s common stock. The total number of shares repurchased under this ASR program was <ix:nonFraction unitRef="shares" contextRef="c-227" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" scale="6" id="f-820">3.1</ix:nonFraction> million shares at an average price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-227" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="f-821">321.05</ix:nonFraction>. The Company received <ix:nonFraction unitRef="shares" contextRef="c-228" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="f-822">2.6</ix:nonFraction> million shares as the initial share settlement, and in August 2022, the Company received an additional <ix:nonFraction unitRef="shares" contextRef="c-229" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="f-823">0.5</ix:nonFraction> million shares upon the completion of this ASR program.</span></div><div style="margin-bottom:12pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, the Company entered into an ASR program with a third-party financial institution to repurchase $<ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-8" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="9" id="f-824">1.5</ix:nonFraction> billion of the Company&#8217;s common stock. The total number of shares repurchased under this ASR program was <ix:nonFraction unitRef="shares" contextRef="c-231" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" scale="6" id="f-825">5.1</ix:nonFraction> million shares at an average price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-231" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="f-826">295.16</ix:nonFraction>. The Company received <ix:nonFraction unitRef="shares" contextRef="c-232" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="f-827">4.8</ix:nonFraction> million shares as the initial share settlement in the fourth quarter of fiscal 2022, and in May 2022, the Company received an additional <ix:nonFraction unitRef="shares" contextRef="c-233" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="f-828">0.3</ix:nonFraction> million shares upon the completion of this ASR program.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June 30, 2023, the Company repurchased <ix:nonFraction unitRef="shares" contextRef="c-234" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="f-829">1.8</ix:nonFraction>&#160;million of the Company&#8217;s shares of common stock for $<ix:nonFraction unitRef="usd" contextRef="c-234" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredParValueMethod" format="ixt:num-dot-decimal" scale="6" id="f-830">673</ix:nonFraction>&#160;million through open market transactions at an average price per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-234" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="f-831">379.14</ix:nonFraction>. Of the total dollar value, $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-6" name="mck:ExciseTaxPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="f-832">4</ix:nonFraction> million was accrued within &#8220;Other non-current liabilities&#8221; in the Company&#8217;s Condensed Consolidated Balance Sheet for excise taxes incurred during the three months ended June 30, 2023. As of March 31, 2023, the Company had $<ix:nonFraction unitRef="usd" contextRef="c-235" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-833">27</ix:nonFraction>&#160;million accrued within &#8220;Other accrued liabilities&#8221; for share repurchases that were executed in late March 2023, which settled in early April 2023. There were <ix:nonFraction unitRef="shares" contextRef="c-236" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:fixed-zero" scale="0" id="f-834">no</ix:nonFraction> open market share repurchases during the three months ended June 30, 2022.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total remaining authorization outstanding for repurchases of the Company&#8217;s common stock at June 30, 2023 was $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-8" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" format="ixt:num-dot-decimal" scale="9" id="f-835">2.9</ix:nonFraction> billion. In July 2023, the Board approved an increase of $<ix:nonFraction unitRef="usd" contextRef="c-237" decimals="-8" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="9" id="f-836">6.0</ix:nonFraction> billion in the authorization for repurchase of McKesson&#8217;s common stock. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><div id="if4d8dc006b964583a173e59149947157_1343"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">McKESSON CORPORATION</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL NOTES (CONTINUED)</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div></div><ix:continuation id="i5d8a861b0d5f43b6b88a0c13b641b9aa" continuedAt="i38e400a9bc794e648767202f46127482"><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated Other Comprehensive Loss </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="f-837" continuedAt="i2ed6cdd320ef479a89b3a4e8a2b574b2" escape="true"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding changes in accumulated other comprehensive loss, including noncontrolling interests, by components for the three months ended June 30, 2023 and 2022 were as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.657%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.228%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.657%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.333%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustments, Net of Tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Losses on Net Investment Hedges, <br/>Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized  Gains (Losses) on Cash Flow and Other Hedges, <br/>Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Losses and Other Components of Benefit Plans, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Accumulated Other Comprehensive Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, March 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-238" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-838">847</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-239" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-839">14</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-240" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-840">36</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-241" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-841">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-842">905</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-843">67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-844">15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8317;&#178;&#8318;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-845">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-846">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-847">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified to earnings and other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="f-848">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="f-849">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="f-850">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="f-851">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="f-852">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-853">67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-854">15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-855">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-856">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-857">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: amounts attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="f-858">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="f-859">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="f-860">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="f-861">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="f-862">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) attributable to McKesson</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-863">67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-864">15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-865">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-866">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-867">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, June 30, 2023</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-248" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-868">780</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-249" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-869">29</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-250" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-870">29</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-251" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-871">10</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-252" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-872">848</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Primarily results from the conversion of non-U.S. dollar financial statements of the Company&#8217;s operations in Canada and Europe into the Company&#8217;s reporting currency, U.S. dollars.</span></div><div style="margin-bottom:12pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Amounts recorded for the three months ended June 30, 2023 includ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e l</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">osses of $<ix:nonFraction unitRef="usd" contextRef="c-253" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" format="ixt:num-dot-decimal" scale="6" id="f-873">20</ix:nonFraction> million related to net investment hedges from cross-currency swaps, which are net of income tax benefit of $<ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" format="ixt:num-dot-decimal" scale="6" id="f-874">5</ix:nonFraction> million.</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.711%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.025%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.655%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.025%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.025%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.798%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.025%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.798%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.313%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustments, Net of Tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Net Investment Hedges, <br/>Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Gains on Cash Flow and Other  Hedges, <br/>Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) and Other Components of Benefit Plans, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Accumulated Other Comprehensive Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, March 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-875">1,504</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-876">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-877">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-878">67</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-879">1,534</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-259" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-880">176</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-260" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-881">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8317;&#178;&#8318;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-882">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-883">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-263" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="f-884">101</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified to earnings and other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-259" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-885">730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-260" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-886">17</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-6" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="f-887">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-888">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-263" decimals="-6" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="f-889">737</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-259" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-890">554</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-260" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-891">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-892">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-893">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-263" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-894">636</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: amounts attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-259" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" scale="6" id="f-895">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-260" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="f-896">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="f-897">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" scale="6" id="f-898">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-263" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" scale="6" id="f-899">50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income attributable to McKesson</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-259" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-900">507</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-260" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-901">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-902">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-903">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-263" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-904">586</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, June 30, 2022</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-264" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-905">997</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-906">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-266" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-907">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-908">34</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-268" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-909">948</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Primarily results from the conversion of non-U.S. dollar financial statements of the Company&#8217;s operations in Canada and Europe into the Company&#8217;s reporting currency, U.S. dollars.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Amounts recorded for the three months ended June 30, 2022 include gains of $<ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" format="ixt:num-dot-decimal" scale="6" id="f-910">64</ix:nonFraction> million related to net investment hedges from Euro-denominated notes and gains of $<ix:nonFraction unitRef="usd" contextRef="c-269" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" format="ixt:num-dot-decimal" scale="6" id="f-911">12</ix:nonFraction> million related to net investment hedges from cross-currency swaps. These amounts are net of income tax expense of $<ix:nonFraction unitRef="usd" contextRef="c-260" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax" format="ixt:num-dot-decimal" scale="6" id="f-912">31</ix:nonFraction> million.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">McKESSON CORPORATION</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL NOTES (CONTINUED)</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div></div><div style="margin-bottom:12pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><ix:continuation id="i38e400a9bc794e648767202f46127482"><ix:continuation id="i2ed6cdd320ef479a89b3a4e8a2b574b2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Primarily included adjustments for amounts related to the sale of the U.K. disposal group, as discussed in more detail in Financial Note 2, &#8220;Business Acquisitions and Divestitures.&#8221; These amounts were included in the fiscal 2022 calculation of charges to remeasure the assets and liabilities held for sale to fair value less costs to sell recorded within &#8220;Selling, distribution, general, and administrative expenses&#8221; in the Consolidated Statements of Operations.</span></ix:continuation></ix:continuation></div><div id="if4d8dc006b964583a173e59149947157_73"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingDisclosureTextBlock" id="f-913" continuedAt="ie51e30a4cc65428ba0b594f92a524cd3" escape="true">Segments of Business</ix:nonNumeric></span></div><ix:continuation id="ie51e30a4cc65428ba0b594f92a524cd3" continuedAt="i0d8bdd992b25498d80d210d22ad53d98"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reports its financial results in <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-914">four</ix:nonFraction> reportable segments: U.S. Pharmaceutical, RxTS, Medical-Surgical Solutions, and International. The organizational structure also includes Corporate, which consists of income and expenses associated with administrative functions and projects, and the results of certain investments. The factors for determining the reportable segments include the manner in which management evaluates the performance of the Company combined with the nature of the individual business activities. The Company evaluates the performance of its operating segments on a number of measures, including revenues and operating profit (loss) before interest expense and income taxes. Assets by operating segment are not reviewed by management for the purpose of assessing performance or allocating resources.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products in the U.S. This segment provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices. In addition, the segment sells financial, operational, and clinical solutions to pharmacies (retail, hospital, alternate sites) and provides consulting, outsourcing, technological, and other services.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The RxTS segment helps solve medication access, affordability, and adherence challenges for patients by working across healthcare to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies. RxTS serves our biopharma and life sciences partners, delivering innovative solutions that help people get the medicine they need to live healthier lives. RxTS also offers prescription price transparency, benefit insight, dispensing support services, third-party logistics, and wholesale distribution support across various therapeutic categories and temperature ranges to biopharma customers throughout the product lifecycle.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home health care agencies. This segment offers national brand medical-surgical products as well as McKesson&#8217;s own line of high-quality products through a network of distribution centers in the U.S.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The International segment includes the Company&#8217;s operations in Canada and Europe, bringing together non-U.S.-based drug distribution services, specialty pharmacy, retail, and infusion care services. The Company&#8217;s Canadian operations deliver medicines, supplies, and information technology solutions throughout Canada and includes Rexall Health retail pharmacies. The Company completed the divestitures of the U.K. disposal group in April 2022 and the E.U. disposal group in October 2022, as discussed in Financial Note 2, &#8220;Business Acquisitions and Divestitures.&#8221; The Company&#8217;s remaining operations in Europe provide distribution and services to wholesale, institutional, and retail customers in Norway where it owns, partners, or franchises with retail pharmacies. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">McKESSON CORPORATION</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL NOTES (CONCLUDED)</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div></div><ix:continuation id="i0d8bdd992b25498d80d210d22ad53d98"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="f-915" escape="true"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial information relating to the Company&#8217;s reportable operating segments and reconciliations to the condensed consolidated totals was as follows: </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.531%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.574%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment revenues </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Pharmaceutical</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-916">67,160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-917">56,947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prescription Technology Solutions</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-918">1,244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-271" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-919">1,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical-Surgical Solutions</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-920">2,611</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-272" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-921">2,592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-922">3,468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-273" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-923">6,549</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-924">74,483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-925">67,154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment operating profit (loss) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Pharmaceutical </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3) </span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="f-926">827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="f-927">696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prescription Technology Solutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="f-928">231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="f-929">144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical-Surgical Solutions</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="f-930">227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="f-931">256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5) </span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="f-932">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="f-933">6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-274" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-934">1,342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-275" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-935">1,090</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate expenses, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6) </span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="mck:CorporateOperatingExpenseandOtherIncomeNet" scale="6" id="f-936">204</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="mck:CorporateOperatingExpenseandOtherIncomeNet" scale="6" id="f-937">39</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="f-938">47</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="f-939">45</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations before income taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-940">1,091</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-941">1,006</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Revenues from services on a disaggregated basis represent approximately <ix:nonFraction unitRef="number" contextRef="c-64" decimals="2" name="mck:RevenueDerivedFromServicesPercentage" scale="-2" id="f-942">1</ix:nonFraction>% of the U.S. Pharmaceutical segment&#8217;s total revenues, less than <ix:nonFraction unitRef="number" contextRef="c-65" decimals="2" name="mck:RevenueDerivedFromServicesPercentage" scale="-2" id="f-943">37</ix:nonFraction>% of the RxTS segment&#8217;s total revenues, less than <ix:nonFraction unitRef="number" contextRef="c-66" decimals="2" name="mck:RevenueDerivedFromServicesPercentage" scale="-2" id="f-944">1</ix:nonFraction>% of the Medical-Surgical Solutions segment&#8217;s total revenues, and less than <ix:nonFraction unitRef="number" contextRef="c-67" decimals="2" name="mck:RevenueDerivedFromServicesPercentage" scale="-2" id="f-945">1</ix:nonFraction>% of the International segment&#8217;s total revenues. The International segment reflects foreign revenues. Revenues for the remaining <ix:nonFraction unitRef="segment" contextRef="c-276" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-946">three</ix:nonFraction> reportable segments are derived in the U.S.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Segment operating profit (loss) includes gross profit, net of total operating expenses, as well as other income, net, for the Company&#8217;s reportable segments.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The Company&#8217;s U.S. Pharmaceutical segment&#8217;s operating profit includes the following:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">cash receipts for the Company&#8217;s share of antitrust legal settlements of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" name="us-gaap:ProceedsFromLegalSettlements" format="ixt:num-dot-decimal" scale="6" id="f-947">118</ix:nonFraction> million for the three months ended June 30, 2023; and</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">a charge of $<ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-6" name="us-gaap:InventoryLIFOReservePeriodCharge" format="ixt:num-dot-decimal" scale="6" id="f-948">32</ix:nonFraction> million and a credit of $<ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-6" sign="-" name="us-gaap:InventoryLIFOReservePeriodCharge" format="ixt:num-dot-decimal" scale="6" id="f-949">13</ix:nonFraction> million related to the last-in, first-out (&#8220;LIFO&#8221;) method of accounting for inventories for the three months ended June 30, 2023 and 2022, respectively.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The Company&#8217;s RxTS segment&#8217;s operating profit for the three months ended June 30, 2023 includes a fair value adjustment gain of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-6" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="6" id="f-950">28</ix:nonFraction>&#160;million, which reduced the Company&#8217;s contingent consideration liability related to the RxSS acquisition, as discussed in more detail in Financial Note 2, &#8220;Business Acquisitions and Divestitures.&#8221;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The Company&#8217;s International segment&#8217;s operating loss for the three months ended June 30, 2022 includes charges of $<ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-6" name="us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" format="ixt:num-dot-decimal" scale="6" id="f-951">94</ix:nonFraction> million to remeasure the assets and liabilities of the E.U. disposal group to fair value less costs to sell, as discussed in more detail in Financial Note 2, &#8220;Business Acquisitions and Divestitures.&#8221;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Corporate expenses, net includes the following:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">restructuring charges of $<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="f-952">40</ix:nonFraction> million for the three months ended June 30, 2023 for restructuring initiatives as discussed in more detail in Financial Note 3, &#8220;Restructuring, Impairment, and Related Charges, Net;&#8221; and</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">a gain of $<ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-6" sign="-" name="us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" format="ixt:num-dot-decimal" scale="6" id="f-953">106</ix:nonFraction> million for the three months ended June 30, 2022 primarily related to the effect of accumulated other comprehensive loss components from the E.U. disposal group, as discussed in more detail in Financial Note 2, &#8220;Business Acquisitions and Divestitures.&#8221;</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><div id="if4d8dc006b964583a173e59149947157_76"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_76">MD&amp;A Index</a></span></div></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">McKESSON CORPORATION</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL REVIEW </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div></div><div style="text-align:center"><span><br/></span></div><div id="if4d8dc006b964583a173e59149947157_79"></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="margin-bottom:12pt;padding-left:27pt;padding-right:27pt;text-align:center;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:92.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.187%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Section</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Page</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_82">General</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_82">31</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_85">Overview of our Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_85">31</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_88">Executive Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_88">32</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_91">Trends and Uncertainties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_91">33</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_94">Overview of Consolidated Results</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_94">34</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_97">Overview of Segment Results</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_97">38</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_106">Business Combinations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_106">40</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_109">New Accounting Pronouncements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_109">40</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_112">Financial Condition, Liquidity, and Capital Resources</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_112">41</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_121">Cautionary Notice About Forward-Looking Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_121">44</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_1582">Available Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_1582">44</a></span></div></td></tr></table></div><div id="if4d8dc006b964583a173e59149947157_82"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GENERAL</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management&#8217;s discussion and analysis of financial condition and results of operations, referred to as the &#8220;Financial Review,&#8221; is intended to assist the reader in the understanding and assessment of significant changes and trends related to the results of operations and financial position of McKesson Corporation together with its subsidiaries (collectively, the &#8220;Company,&#8221; &#8220;McKesson,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; or &#8220;us,&#8221; and other similar pronouns). This discussion and analysis should be read in conjunction with the condensed consolidated financial statements and accompanying financial notes in Item 1 of Part I of this Quarterly Report on Form 10-Q (&#8220;Quarterly Report&#8221;) and in Item 8 of Part II of our Annual Report on Form 10-K for the fiscal year ended March 31, 2023 previously filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on May&#160;9, 2023 (&#8220;2023 Annual Report&#8221;).</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our fiscal year begins on April 1 and ends on March 31. Unless otherwise noted, all references to a particular year shall mean our fiscal year. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain statements in this report constitute forward-looking statements. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Cautionary Notice About Forward-Looking Statements&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> included in this Quarterly Report.</span></div><div id="if4d8dc006b964583a173e59149947157_85"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview of our Business:</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products, and services to help make quality care more accessible and affordable.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We report our financial results in four reportable segments: U.S. Pharmaceutical, Prescription Technology Solutions (&#8220;RxTS&#8221;), Medical-Surgical Solutions, and International. Our organizational structure also includes Corporate, which consists of income and expenses associated with administrative functions and projects as well as the results of certain investments. The factors for determining the reportable segments include the manner in which management evaluates the performance of the Company combined with the nature of individual business activities. We evaluate the performance of our operating segments on a number of measures, including revenues and operating profit (loss) before interest expense and income taxes. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_76">MD&amp;A Index</a></span></div></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">McKESSON CORPORATION</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL REVIEW (CONTINUED) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes our four reportable segments. Refer to Financial Note 12, &#8220;Segments of Business,&#8221; to the accompanying condensed consolidated financial statements included in this Quarterly Report for further information regarding our reportable segments. </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">U.S. Pharmaceutical</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a reportable segment that distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs, and other healthcare-related products in the United States (&#8220;U.S.&#8221;). This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices. In addition, the segment sells financial, operational, and clinical solutions to pharmacies (retail, hospital, alternate sites) and provides consulting, outsourcing, technological, and other services.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Prescription Technology Solutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is a reportable segment that combines automation and our ability to navigate the healthcare ecosystems to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies to address patients&#8217; medication access, affordability, and adherence challenges. RxTS also offers prescription price transparency, benefit insight, dispensing support services, third-party logistics, and wholesale distribution support across various therapeutic categories and temperature ranges to biopharma customers throughout the product lifecycle.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Medical-Surgical Solutions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a reportable segment that provides medical-surgical supply distribution, logistics, and other services to healthcare providers in the U.S., including physician offices, surgery centers, nursing homes, hospital reference labs, and home health care agencies. This segment offers national brand medical-surgical products as well as McKesson&#8217;s own line of high-quality products through a network of distribution centers within the U.S.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">International</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is a reportable segment that includes our operations in Canada and Europe, bringing together non-U.S.-based drug distribution services, specialty pharmacy, retail, and infusion care services. Our operations in Canada deliver medicines, supplies, and information technology solutions throughout Canada and includes Rexall Health pharmacies. During fiscal 2023, we completed transactions to sell certain of our businesses in the European Union (&#8220;E.U. disposal group&#8221;), and our retail and distribution businesses in the United Kingdom (&#8220;U.K. disposal group&#8221;). Our remaining operations in Europe provide distribution and services to wholesale, institutional, and retail customers in Norway where we own, partner, or franchise with retail pharmacies. Refer to Financial Note 2, &#8220;Business Acquisitions and Divestitures,&#8221; to the accompanying condensed consolidated financial statements included in this Quarterly Report for more information regarding these divestiture transactions.</span></div><div id="if4d8dc006b964583a173e59149947157_88"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Executive Summary: </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summary provides highlights and key factors that impacted our business, operating results, financial condition, and liquidity for the three months ended June 30, 2023:</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">For the three months ended June 30, 2023 compared to the prior year, revenues increased by 11%, gross profit was flat, total operating expenses decreased by 3%, and other income, net increased by $23 million. Refer to the &#8220;Overview of Consolidated Results&#8221; section below for an analysis of these changes;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Diluted earnings per common share from continuing operations attributable to McKesson Corporation increased to $7.02 from $5.25 in the three months ended June 30, 2023 compared to the prior year period; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">For the three months ended June 30, 2023, we recognized a net discrete tax benefit of $147&#160;million related to the repatriation of certain intellectual property between McKesson wholly-owned legal entities that are based in different tax jurisdictions; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">For the three months ended June 30, 2023, we received $118&#160;million related to our share of antitrust settlements. This amount was recorded as a gain within "Cost of sales" in the Condensed Consolidated Statement of Operations within our U.S. Pharmaceutical segment;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On June 15, 2023, we completed a public offering of 4.90% Notes due June 15, 2028 in a principal amount of $400 million and 5.10% Notes due July 15, 2033 in a principal amount of $600 million, for proceeds received, net of discounts and offering expenses, of $397 million and $592 million, respectively. A portion of the net proceeds from these offerings was utilized to fund the repurchase of our 3.80% Notes due March 15, 2024 (the &#8220;2024 Notes&#8221;) discussed below, while the remaining net proceeds is available for general corporate purposes;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_76">MD&amp;A Index</a></span></div></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">McKESSON CORPORATION</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL REVIEW (CONTINUED) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On June 16, 2023, we completed a cash tender offer for any and all of our 2024 Notes with a principal amount of $918 million. Using a portion of the net proceeds from the June 15, 2023 notes offering described above, we paid an aggregate consideration of $268 million to repurchase $271 million of principal amount of the 2024 Notes plus any accrued and unpaid interest;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Following the consummation of the cash tender offer discussed above, on June 16, 2023, we irrevocably deposited U.S. government obligations with the trustee under the indenture governing the 2024 Notes sufficient to fund the payment of accrued and unpaid interest of the remaining $647&#160;million principal amount of the 2024 Notes as it becomes due, and of the principal amount of those 2024 Notes on their March 15, 2024 maturity date. Refer to Financial Note 7, &#8220;Debt and Financing Activities,&#8221; to the accompanying condensed consolidated financial statements included in this Quarterly Report for more information; </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We returned $770 million of cash to shareholders during the three months ended June 30, 2023 through $696 million of common stock repurchases through open market transactions and $74 million of dividend payments. The total remaining authorization outstanding for repurchases of the Company&#8217;s common stock at June 30, 2023 was $2.9 billion; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In July 2023, our Board of Directors (the &#8220;Board&#8221;) approved an increase of $6.0 billion in the authorization for repurchase of the Company&#8217;s common stock and raised our quarterly dividend from $0.54 to $0.62 per share of common stock.</span></div><div id="if4d8dc006b964583a173e59149947157_91"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Trends and Uncertainties:</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legislative Developments</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 16, 2022, the U.S. government enacted the Inflation Reduction Act of 2022 (the &#8220;IRA&#8221;). Among other provisions, the IRA includes a 15% corporate minimum tax, a 1% excise tax on certain repurchases of an entity&#8217;s own common stock after December 31, 2022, and various drug pricing reforms. Based on our ongoing assessment, we do not anticipate that this guidance will have a material impact on our consolidated financial statements or related disclosures; however, we will continue to evaluate the full impact of these legislative changes as they are announced and implemented. Refer to Financial Note 11, &#8220;Stockholders' Deficit,&#8221; to the accompanying condensed consolidated financial statements included in this Quarterly Report for further details regarding excise taxes incurred on our share repurchases during the three months ended June 30, 2023.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVID-19</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. federal government and World Health Organization suspended their respective public health emergencies in regards to the SARS-CoV-2 coronavirus (&#8220;COVID-19&#8221;) in May 2023. We have experienced a decrease in revenues and operating profit within our U.S. Pharmaceutical segment from COVID-19 vaccine distribution, and within our Medical-Surgical Solutions segment from COVID-19 tests and the assembly and distribution of ancillary supply kits needed to administer COVID-19 vaccines. These decreases were driven by a decline in demand and we anticipate these decreases to persist throughout fiscal 2024. The impacts of these programs and COVID-19 tests were not material to revenues and operating profit for the three months ended June 30, 2023. For additional disclosure of trends and uncertainties due to COVID-19, refer to Item 7 - Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations in Part II of our 2023 Annual Report.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_76">MD&amp;A Index</a></span></div></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">McKESSON CORPORATION</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL REVIEW (CONTINUED) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Opioid-Related Litigation and Claims</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in the discussion of opioid-related matters in Financial Note 10, &#8220;Commitments and Contingent Liabilities,&#8221; to the financial statements accompanying this Quarterly Report, we are a defendant in many legal proceedings asserting claims related to the distribution of controlled substances (opioids) in federal and state courts throughout the U.S., and in Puerto Rico and Canada. The plaintiffs in these actions have included state attorneys general, county and municipal governments, tribal nations, hospitals, health and welfare funds, third-party payors, and individuals. The Company believes it has valid legal defenses in all opioid-related matters, including claims not covered by settlement agreements, and it intends to mount a vigorous defense. Other than as to the settlement agreements and the U.S. governmental subdivision claims described in Financial Note 10, the Company has not concluded a loss is probable in any of the matters; nor is any possible loss or range of loss reasonably estimable. An adverse judgment or negotiated resolution in any of these matters could have a material adverse impact on the Company&#8217;s financial position, cash flows or liquidity, or results of operations. Our total estimated liability for opioid-related claims was $7.2 billion as of June 30, 2023, of which $545 million was included in &#8220;Other accrued liabilities&#8221; for the amount estimated to be paid within the next twelve months, and the remaining liability was included in &#8220;Long-term litigation liabilities&#8221; in our Condensed Consolidated Balance Sheet. In July 2023, the Company made payments totaling $529&#160;million associated with various settlement agreements for opioid-related claims of states, subdivisions, and Native American tribes.</span></div><div id="if4d8dc006b964583a173e59149947157_94"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview of Consolidated Results:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.590%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.973%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:23pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(Dollars in millions, except per share data)</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,483&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,154&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,022&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,023&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Gross profit margin</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">4.06&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">4.50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(44)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">bp</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,922)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,987)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Total operating expenses as a percentage of revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">2.58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">2.96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">bp</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,006&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(199)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Reported income tax rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">19.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(1,120)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">bp</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">997&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">807&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">997&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">809&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to McKesson Corporation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">958&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">768&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted earnings per common share attributable to McKesson Corporation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.02&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.02&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.26&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average diluted common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">bp - basis points</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_76">MD&amp;A Index</a></span></div></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">McKESSON CORPORATION</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL REVIEW (CONTINUED) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues increased for the three months ended June 30, 2023 compared to the same prior year period largely due to market growth in our U.S. Pharmaceutical segment, including higher volumes from retail national account customers and growth in specialty pharmaceuticals. Market growth includes growing drug utilization, price increases, and newly launched products, partially offset by price deflation associated with branded to generic drug conversion. This revenue growth was partially offset by lower revenues in our International segment driven by the completed divestiture of our E.U. disposal group and unfavorable effects of foreign currency exchange fluctuations.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gross Profit </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross profit was flat for the three months ended June 30, 2023 compared to the same prior year period primarily driven by the completed divestiture of our E.U. disposal group and unfavorable effects of foreign currency exchange fluctuations in our International segment, partially offset by our share of antitrust settlements received in the first quarter of fiscal 2024, growth of specialty pharmaceuticals and increased contributions from our generics programs in our U.S. Pharmaceutical segment, and increased volumes with new and existing customers in our RxTS segment.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended June 30, 2023, we recognized a gain of $118&#160;million related to our share of antitrust settlements. We recognized this amount within "Cost of sales" in the Condensed Consolidated Statement of Operations within our U.S. Pharmaceutical segment.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A last-in, first-out (&#8220;LIFO&#8221;) inventory charge of $32 million and a credit of $13 million were recognized during the three months ended June 30, 2023 and 2022, respectively. A LIFO charge in the first quarter of fiscal 2024 compared a LIFO credit in the same prior year period was primarily due to higher estimated brand inflation and higher brand inventory levels as well as lower estimated generics deflation, partially offset by higher estimated off patent launch activity. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our U.S. Pharmaceutical business uses the LIFO method of accounting for the majority of its inventories, which results in cost of sales that more closely reflects replacement cost than under other accounting methods. The business&#8217; practice is to pass on to customers published price changes from suppliers. Manufacturers generally provide us with price protection, which limits price related inventory losses. A LIFO charge is recognized when the net effect of price increases on pharmaceutical and non-pharmaceutical products held in inventory exceeds the impact of price declines, including the effect of branded pharmaceutical products that have lost market exclusivity. A LIFO credit is recognized when the net effect of price declines exceeds the impact of price increases on pharmaceutical and non-pharmaceutical products held in inventory. Our quarterly LIFO adjustment is based on our estimates of the annual LIFO credit which is impacted by expected changes in year-end inventory quantities, product mix, and manufacturer pricing practices, which may be influenced by market and other external factors. Changes to any of the above factors could have a material impact to our annual LIFO adjustment. The actual valuation of inventory under the LIFO method is calculated at the end of the fiscal year. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Total Operating Expenses</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the components of our total operating expenses for the three months ended June 30, 2023 and 2022 is as follows: </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Selling, distribution, general, and administrative expenses (&#8220;SDG&amp;A&#8221;):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> SDG&amp;A consists of personnel costs, transportation costs, depreciation and amortization, lease costs, professional fee expenses, administrative expenses, remeasurement charges to the lower of carrying value or fair value less costs to sell, and other general charges.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Claims and litigation charges, net:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> These charges include adjustments for estimated probable settlements related to our controlled substance monitoring and reporting, and opioid-related claims, as well as any applicable income items or credit adjustments due to subsequent changes in estimates. Legal fees to defend claims, which are expensed as incurred, are included within SDG&amp;A.</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Restructuring, impairment, and related charges, net:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Charges recorded under this component include those incurred for programs in which we change our operations, the scope of a business undertaken by our business units, or the manner in which that business is conducted, as well as long-lived asset impairments.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_76">MD&amp;A Index</a></span></div></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">McKESSON CORPORATION</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL REVIEW (CONTINUED) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:64.346%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.289%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.927%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.978%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(Dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, distribution, general, and administrative expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,870&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,959&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Claims and litigation charges, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, impairment, and related charges, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,922&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,987&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Percent of revenues</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">2.58&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">2.96&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">bp</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">bp - basis points</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended June 30, 2023, total operating expenses and total operating expenses as a percentage of revenues decreased compared to the same prior year period. Total operating expenses were impacted by the following significant items:</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">SDG&amp;A for the three months ended June 30, 2023 reflects lower operating expenses due to the completed divestiture of our E.U. disposal group in fiscal 2023;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Claims and litigation charges, net was not material. Refer to the Opioid-Related Litigation and Claims section of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">"Trends and Uncertainties" </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for further discussion;</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Restructuring, impairment, and related charges, net for three months ended June 30, 2023 and 2022 were $52 million and $23 million, respectively, as discussed in more detail below under &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring Initiatives</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;&#8221; and </span></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Total operating expenses were favorably impacted by foreign currency exchange fluctuations for the three months ended June 30, 2023 and 2022.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill Impairment</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate goodwill for impairment on an annual basis in the first fiscal quarter, and at an interim date if indicators of potential impairment exist. The annual impairment testing performed in fiscal 2024 and fiscal 2023 did not indicate any impairment of goodwill and no goodwill impairment charges were recorded during the three months ended June 30, 2023 and 2022. However, other risks, expenses, and future developments, such as additional government actions, increased regulatory uncertainty, and material changes in key market assumptions limit our ability to estimate projected cash flows, which could adversely affect the fair value of various reporting units in future periods, including our McKesson Canada reporting unit within our International segment, where the risk of a material goodwill impairment is higher than other reporting units.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring Initiatives</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recorded restructuring, impairment, and related charges of $52 million and $23 million for the three months ended June 30, 2023 and 2022, respectively. These charges were included in &#8220;Restructuring, impairment, and related charges, net&#8221; in the Condensed Consolidated Statements of Operations.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of fiscal 2023, we approved a broad set of initiatives to drive operational efficiencies and increase cost optimization efforts, with the intent of simplifying our infrastructure and realizing long-term sustainable growth. These initiatives include headcount reductions and the exit or downsizing of certain facilities. We anticipate total charges of approximately $125 million across our RxTS and U.S. Pharmaceutical segments as well as Corporate, consisting primarily of employee severance and other employee-related costs, facility and other exit-related costs, as well as long-lived asset impairments. Of this amount, $96 million of charges were recorded to date. For the three months ended June 30, 2023, we recorded charges of $36 million related to this program, which primarily includes real estate and other related asset impairments and facility costs within Corporate. This restructuring program is anticipated to be substantially complete by the end of fiscal 2024.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Financial Note 3, &#8220;Restructuring, Impairment, and Related Charges, Net,&#8221; to the accompanying condensed consolidated financial statements included in this Quarterly Report for further information on our restructuring initiatives.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_76">MD&amp;A Index</a></span></div></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">McKESSON CORPORATION</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL REVIEW (CONTINUED) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income, Net</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net increased for the three months ended June 30, 2023 compared to the same prior year period primarily due to a favorable impact to interest income from higher interest rates on certain of our cash balances compared to the prior year period.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Expense</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense increased for the three months ended June 30, 2023 compared to the same prior year period primarily due to the impact of higher interest rates on our derivative portfolio, partially offset by a $9 million gain on debt extinguishment in the first quarter of fiscal 2024, as discussed in more detail in Financial Note 7, &#8220;Debt and Financing Activities,&#8221; to the accompanying condensed consolidated financial statements included in this Quarterly Report. Interest expense may fluctuate based on timing, amounts, and interest rates of term debt repaid and new term debt issued, as well as amounts incurred associated with financing fees.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Tax Expense</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended June 30, 2023 and 2022, we recorded income tax expense of $94 million and $199 million, respectively. Our reported income tax rates were 8.6% and 19.8% for the three months ended June 30, 2023 and 2022, respectively. Fluctuations in our reported income tax rates are primarily due to changes in our business mix of earnings between various taxing jurisdictions, and discrete tax benefits recognized in the quarters, including a net discrete tax benefit of $147&#160;million recognized in the first quarter of fiscal 2024 related to the repatriation of certain intellectual property between McKesson wholly-owned legal entities that are based in different tax jurisdictions. Refer to Financial Note 4, &#8220;Income Taxes,&#8221; to the accompanying condensed consolidated financial statements included in this Quarterly Report for more information.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income from Discontinued Operations, Net of Tax </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income from discontinued operations, net of tax, was $2 million for the three months ended June 30, 2022. Subsequent to our divestiture of the E.U. disposal group in October 2022, we no longer have discontinued operations.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Income Attributable to Noncontrolling Interests</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income attributable to noncontrolling interests for the three months ended June 30, 2023 and 2022 primarily represents the proportionate results of third-party equity interests in the Company&#8217;s consolidated entities of ClarusONE Sourcing Services LLP and Vantage Oncology Holdings, LLC. For the three months ended June 30, 2023, net income attributable to noncontrolling interests also includes the proportionate results of third-party equity interest in SCRI Oncology, LLC.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Income Attributable to McKesson Corporation</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income attributable to McKesson Corporation was $958 million and $768 million for the three months ended June 30, 2023 and 2022, respectively. Diluted earnings per common share attributable to McKesson Corporation was $7.02 and $5.26 for the three months ended June 30, 2023 and 2022, respectively. Our diluted earnings per share reflects the cumulative effects of share repurchases during each period.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Weighted-Average Diluted Common Shares Outstanding</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted earnings per common share was calculated based on a weighted-average number of shares outstanding of 136.6 million and 145.9 million for the three months ended June 30, 2023 and 2022, respectively. Weighted-average diluted shares outstanding for the three months ended June 30, 2023 decreased from the same prior year period primarily due to the cumulative effect of share repurchases.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><div id="if4d8dc006b964583a173e59149947157_97"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_76">MD&amp;A Index</a></span></div></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">McKESSON CORPORATION</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL REVIEW (CONTINUED) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview of Segment Results:</span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Revenues:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.590%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.973%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(Dollars in millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Pharmaceutical</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,947&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prescription Technology Solutions</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,066&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical-Surgical Solutions</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,611&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,468&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,549&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,483&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,154&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. Pharmaceutical </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Three Months Ended June 30, 2023 vs. 2022</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Pharmaceutical revenues for the three months ended June 30, 2023 increased $10.2 billion or</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18% compared to the same prior year period. Within the segment, sales to pharmacies and institutional healthcare providers increased $9.6 billion and sales to specialty practices and other increased $613 million. Overall, these increases were primarily due to market growth, including higher volumes from retail national account customers, growth in specialty pharmaceuticals, and branded pharmaceutical price increases, partially offset by branded to generic drug conversions.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prescription Technology Solutions</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Three Months Ended June 30, 2023 vs. 2022</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RxTS revenues for the three months ended June 30, 2023 increased $178 million or 17% compared to the same prior year period due to increased volume with new and existing customers primarily in our third-party logistics and wholesale distribution services, as well as higher technology service revenues.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medical-Surgical Solutions</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Three Months Ended June 30, 2023 vs. 2022</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical-Surgical Solutions revenues for the three months ended June 30, 2023 increased $19 million or 1% compared to the same prior year period. Within the segment, sales to extended care customers increased $76 million, and sales to primary care customers decreased $4 million. The decrease in our primary care business was driven by lower sales of COVID-19 tests, largely offset by underlying core business growth. Other sales declined $53 million driven by lower contribution from the kitting and distribution of ancillary supplies used to administer COVID-19 vaccines.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">International</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Three Months Ended June 30, 2023 vs. 2022</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">International revenues for the three months ended June 30, 2023 decreased $3.1 billion or 47% compared to the same prior year period which included unfavorable effects of foreign currency exchange fluctuations of $199 million. Within the segment, sales in Europe declined by $3.1 billion largely due to the completed divestiture of our E.U. disposal group in the third quarter of fiscal 2023, partially offset by increased sales in Canada of $238 million primarily driven by higher pharmaceutical distribution volumes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><div id="if4d8dc006b964583a173e59149947157_103"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_76">MD&amp;A Index</a></span></div></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">McKESSON CORPORATION</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL REVIEW (CONTINUED) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Operating Profit (Loss) and Corporate Expenses, Net:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:64.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.152%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.152%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.991%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(Dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment operating profit (loss) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Pharmaceutical </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prescription Technology Solutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical-Surgical Solutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,342&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,090&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate expenses, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(204)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">423&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations before income taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,006&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment operating profit (loss) margin</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Pharmaceutical </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">bp</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prescription Technology Solutions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.51&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical-Surgical Solutions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.64&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.09)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">All percentage changes displayed above which are not meaningful are displayed as zero percent.</span></div><div style="margin-bottom:6pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">bp - basis points</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Segment operating profit (loss) includes gross profit, net of total operating expenses, as well as other income, net, for our reportable segments.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Operating profit for our U.S. Pharmaceutical segment includes the following:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">cash receipts for our share of antitrust legal settlements of $118 million for the three months ended June 30, 2023; and</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">a charge of $32 million and a credit of $13 million related to the LIFO method of accounting for inventories for the three months ended June 30, 2023 and 2022, respectively.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Operating profit for our RxTS segment for the three months ended June 30, 2023 includes a fair value adjustment gain of $28&#160;million which reduced our contingent consideration liability related to the RxSS acquisition, as discussed in more detail in Financial Note 2, &#8220;Business Acquisitions and Divestitures,&#8221; to the accompanying condensed consolidated financial statements included in this Quarterly Report.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Operating loss for our International segment includes charges of $94 million for the three months ended June 30, 2022 to remeasure the assets and liabilities of our E.U. disposal group to fair value less costs to sell, as discussed in more detail in Financial Note 2, &#8220;Business Acquisitions and Divestitures,&#8221; to the accompanying condensed consolidated financial statements included in this Quarterly Report.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Corporate expenses, net includes the following:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">restructuring charges of $40 million for the three months ended June 30, 2023 for restructuring initiatives as discussed in more detail in Financial Note 3, &#8220;Restructuring, Impairment, and Related Charges, Net,&#8221; to the accompanying condensed consolidated financial statements included in this Quarterly Report; and</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">a gain of $106 million for the three months ended June 30, 2022 primarily related to the effect of accumulated other comprehensive loss components from our E.U. disposal group.</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_76">MD&amp;A Index</a></span></div></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">McKESSON CORPORATION</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL REVIEW (CONTINUED) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. Pharmaceutical</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Three Months Ended June 30, 2023 vs. 2022</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating profit for this segment increased for the three months ended June 30, 2023 compared to the same prior year period primarily due to an increase from net cash proceeds received of $118 million representing our share of antitrust legal settlements and growth in specialty pharmaceuticals, partially offset by a LIFO charge in the first quarter of fiscal 2024 compared to a credit in the same prior year period.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prescription Technology Solutions</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Three Months Ended June 30, 2023 vs. 2022</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating profit for this segment increased for the three months ended June 30, 2023 compared to the same prior year period driven by increased volumes with new and existing customers due to growth in our access solutions, primarily related to electronic prior authorization services.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medical-Surgical Solutions</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Three Months Ended June 30, 2023 vs. 2022</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating profit for this segment decreased for the three months ended June 30, 2023 compared to the same prior year period due to a lower contribution from kitting and distribution of ancillary supplies for COVID-19 vaccines and higher employee-related expenses to support core business growth, partially offset by growth in extended care and our core primary care businesses.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">International</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Three Months Ended June 30, 2023 vs. 2022</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating profit for this segment for the three months ended June 30, 2023 compared to an operating loss in the same prior year period was primarily as a result of remeasurement charges recorded in the prior year related to the E.U. disposal group, partially offset by lower contributions from the European operations divested in fiscal 2023.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Corporate Expenses, Net</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Three Months Ended June 30, 2023 vs. 2022</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Corporate expenses, net increased for the three months ended June 30, 2023 compared to the same prior year period primarily as a result of remeasurement gains recorded in the prior year related to the E.U. disposal group, and higher restructuring charges recorded in fiscal 2024. This was partially offset by a favorable impact to interest income from higher interest rates on certain of our cash balances compared to the prior year period.</span></div><div id="if4d8dc006b964583a173e59149947157_106"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Combinations </span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Financial Note 2, &#8220;Business Acquisitions and Divestitures,&#8221; to the accompanying condensed consolidated financial statements included in this Quarterly Report for our disclosures on business combinations.</span></div><div id="if4d8dc006b964583a173e59149947157_109"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Accounting Pronouncements</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New accounting pronouncements that we have recently adopted as well as those that have been recently issued but not yet adopted by us are included in Financial Note 1, &#8220;Significant Accounting Policies,&#8221; to the accompanying condensed consolidated financial statements included in this Quarterly Report.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><div id="if4d8dc006b964583a173e59149947157_112"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_76">MD&amp;A Index</a></span></div></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">McKESSON CORPORATION</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL REVIEW (CONTINUED) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL CONDITION, LIQUIDITY, AND CAPITAL RESOURCES </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our available cash generated from operations and our short-term investment portfolio, together with our existing sources of liquidity from our credit facilities, commercial paper program, and other borrowings will be sufficient to fund our short-term and long-term capital expenditures, working capital, and other cash requirements. We remain adequately capitalized, including access to liquidity from our $4.0 billion revolving credit facility. At June 30, 2023, we were in compliance with all debt covenants, and believe we have the ability to continue to meet our debt covenants in the future.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the net change in cash, cash equivalents, and restricted cash for the periods shown: </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(Dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,052)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(941)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(188)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(843)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,181)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash, cash equivalents, and restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in cash, cash equivalents, and restricted cash classified as Assets held for sale </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">470&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(470)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash, cash equivalents, and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,042)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,595)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(447)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The fiscal 2023 change reflects a reversal of cash, cash equivalents, and restricted cash previously classified as assets held for sale at March 31, 2022 as part of the U.K. disposal group and is offset by cash outflows primarily related to the settlement of liabilities which is reflected in operating activities.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Activities</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating activities used cash of $1.1 billion and $941 million during the three months ended June 30, 2023 and 2022, respectively. Cash flows from operations can be significantly impacted by factors such as the timing of receipts from customers, inventory receipts, and payments to vendors. Additionally, working capital is primarily a function of sales and purchase volumes, inventory requirements, and vendor payment terms.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating activities for the three months ended June 30, 2023 were affected by net income of $1.0 billion, adjusted for non-cash items, as well as increases in receivables of $2.4 billion, drafts and accounts payable of $1.5 billion, and inventories of $826 million, all primarily driven by higher revenues and timing.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating activities for the three months ended June 30, 2022 were affected by net income of $809 million, adjusted for non-cash items, as well as increases in receivables of $1.6 billion, drafts and accounts payable of $1.0 billion, and inventory of $955 million, all primarily driven by higher revenues and timing. Our litigation liabilities also decreased by $370 million primarily driven by payments made during the first quarter of fiscal 2023 associated with various settlement agreements for opioid-related claims of states, subdivisions, and Native American tribes, as discussed in more detail in Financial Note 10, &#8220;Commitments and Contingent Liabilities,&#8221; to the accompanying condensed consolidated financial statements included in this Quarterly Report .</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investing Activities</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing activities used cash of $149 million and provided cash of $39 million during the three months ended June 30, 2023 and 2022, respectively. Investing activities for the three months ended June 30, 2023 and 2022 includes $124 million and $100 million, respectively, in capital expenditures for property, plant, and equipment and capitalized software. Investing activities for the three months ended June 30, 2022 also includes proceeds from sales of businesses and investments of $240 million, primarily due to the completed divestiture of our U.K. disposal group in April 2022. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_76">MD&amp;A Index</a></span></div></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">McKESSON CORPORATION</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL REVIEW (CONTINUED) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing Activities</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing activities used cash of $843 million and $1.2 billion during the three months ended June 30, 2023 and 2022, respectively. On June 15, 2023, we completed a public offering of 4.90% Notes due June 15, 2028 in a principal amount of $400 million and 5.10% Notes due July 15, 2033 in a principal amount of $600 million, for proceeds received, net of discounts and offering expenses, of $397 million and $592 million, respectively. A portion of the net proceeds from these notes was utilized to fund the repurchase of our 2024 Notes discussed below, while the remaining net proceeds is available for general corporate purposes.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 16, 2023, we completed a cash tender offer for any and all of our 2024 Notes with a principal amount of $918&#160;million. Using a portion of the proceeds from the June 15, 2023 notes offering described above, we paid an aggregate consideration of $268 million to repurchase $271 million principal amount of the 2024 Notes. Following the consummation of this tender offer, on June 16, 2023, we irrevocably deposited U.S. government obligations with the trustee under the indenture governing the 2024 Notes sufficient to fund the payment of accrued and unpaid interest of the remaining $647&#160;million principal amount of the 2024 Notes as it becomes due, and of the principal amount of those 2024 Notes on their March 15, 2024 maturity date.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing activities for the three months ended June 30, 2023 and 2022 includes $696 million and $1.0 billion of cash paid for share repurchases, respectively, as well as $74 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and $71 million of cash paid for dividends, respectively.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used for other financing activities generally includes the cash value of shares surrendered for tax withholding and payments to noncontrolling interests.</span></div><div id="if4d8dc006b964583a173e59149947157_115"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchase Plans</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board has authorized the repurchase of McKesson&#8217;s common stock. We may effect stock repurchases from time-to-time through open market transactions, privately negotiated transactions, accelerated share repurchase (&#8220;ASR&#8221;) programs, or by combinations of such methods, any of which may use pre-arranged trading plans that are designed to meet the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended (&#8220;Exchange Act&#8221;). The timing of any repurchases and the actual number of shares repurchased will depend on a variety of factors, including our stock price, corporate and regulatory requirements, tax implications, restrictions under our debt obligations, other uses for capital, impacts on the value of remaining shares, and market and economic conditions. The ASR programs discussed below were designed to comply with Rule 10b5-1(c).</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2023, the Company&#8217;s repurchase of McKesson&#8217;s common stock, adjusted for allowable items, are subject to a 1% excise tax as a result of the IRA. Excise taxes incurred on share repurchases of an entity&#8217;s own common stock are direct and incremental costs to purchase treasury stock, and accordingly are included in the total cost basis of the common stock acquired and reflected as a reduction of stockholders&#8217; equity within &#8220;Treasury shares&#8221; in the Company&#8217;s Condensed Consolidated Balance Sheets and Condensed Consolidated Statements of Stockholders&#8217; Deficit. Excise taxes are not reflected in the Company&#8217;s remaining authorization for the repurchase of McKesson&#8217;s common stock. </span><span style="color:#008080;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, we entered into an ASR program with a third-party financial institution to repurchase $1.0&#160;billion of the Company&#8217;s common stock. The total number of shares repurchased under this ASR program was 3.1 million shares at an average price per share of $321.05. We received 2.6 million shares as the initial share settlement, and in August 2022, we received an additional 0.5 million shares upon the completion of this ASR program.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, we entered into an ASR program with a third-party financial institution to repurchase $1.5 billion of the Company&#8217;s common stock. The total number of shares repurchased under this ASR program was 5.1 million shares at an average price per share of $295.16. We received 4.8 million shares as the initial share settlement in the fourth quarter of fiscal 2022, and in May 2022, we received an additional 0.3 million shares upon the completion of this ASR program. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June 30, 2023, we repurchased 1.8&#160;million of the Company&#8217;s shares of common stock for $673&#160;million through open market transactions at an average price per share of $379.14. Of the total dollar value, $4&#160;million was accrued within &#8220;Other non-current liabilities&#8221; in our Condensed Consolidated Balance Sheet for excise taxes incurred during the three months ended June 30, 2023. As of March 31, 2023, we had $27&#160;million accrued within &#8220;Other accrued liabilities&#8221; for share repurchases that were executed in late March 2023, which settled in early April 2023. There were no open market share repurchases during the three months ended June 30, 2022.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_7">Table of Contents</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_76">MD&amp;A Index</a></span></div></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">McKESSON CORPORATION</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL REVIEW (CONTINUED) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The total remaining authorization outstanding for repurchases of the Company&#8217;s common stock at June 30, 2023 was $2.9 billion. In July 2023, the Board approved an increase of $6.0 billion in the authorization for repurchase of McKesson&#8217;s common stock.</span></div><div id="if4d8dc006b964583a173e59149947157_118"></div><div style="margin-bottom:6pt;margin-top:12pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selected Measures of Liquidity and Capital Resources </span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:55.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.640%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.974%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.640%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.978%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(Dollars in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,637&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,679&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,883)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,665)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt to capital ratio </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">This ratio describes the relationship and changes within our capital resources, and is computed as total debt divided by the sum of total debt and McKesson stockholders&#8217; deficit, which excludes noncontrolling interests and accumulated other comprehensive loss.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents, which are readily convertible to known amounts of cash, are carried at fair value. Cash equivalents are primarily invested in AAA-rated U.S. government money market funds, short-term deposits with financial institutions, and short-term commercial papers issued by non-financial institutions. Deposits with financial institutions are primarily denominated in U.S. dollars and the functional currencies of our foreign subsidiaries, including Canadian dollars, Euro, and British pounds sterling. Deposits could exceed the amounts insured by the Federal Deposit Insurance Corporation in the U.S. and similar deposit insurance programs in other jurisdictions. We mitigate the risk of our short-term investment portfolio by depositing funds with reputable financial institutions and monitoring risk profiles and investment strategies of money market funds.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash and cash equivalents balance as of June 30, 2023 and March 31, 2023 included approximately</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$616 million and $1.3 billion of cash held by our subsidiaries outside of the U.S., respectively. Our primary intent is to utilize this cash for foreign operations for an indefinite period of time. Although the vast majority of cash held outside the U.S. is available for repatriation, doing so could subject us to foreign withholding taxes and state income taxes.&#160;We may remit foreign earnings to the U.S. to the extent it is tax efficient to do so. We do not anticipate the tax impact from remitting these earnings to be material. Following enactment of the 2017 Tax Cuts and Jobs Act, the repatriation of cash to the U.S. is generally no longer taxable for federal income tax purposes.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Working capital primarily includes cash and cash equivalents, receivables, inventories, and prepaid expenses, net of drafts and accounts payable, current portion of long-term debt, current portion of operating lease liabilities, and other accrued liabilities. Our businesses require substantial investments in working capital that are susceptible to large variations during the year as a result of inventory purchase patterns and seasonal demands. Inventory purchase activity is a function of sales activity and other requirements. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated working capital increased at June 30, 2023 compared to March 31, 2023 primarily due to an increase in receivables, net and inventories, driven by higher revenues and timing, and a decrease in the current portion of long-term debt largely funded by an issuance of long-term debt in the first quarter of 2024. These were partially offset by a decrease in cash and cash equivalents and increase in drafts and accounts payable driven by the aforementioned increased revenues and timing.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our debt to capital ratio decreased for the three months ended June 30, 2023 due to net income attributable to McKesson for the quarter and issuance of new long-term debt, partially offset by share repurchases and dividend payments as well as repayments of long-term debt.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2023, we raised our quarterly dividend from $0.54 to $0.62 per share of common stock for dividends declared on or after such date by the Board. We anticipate that we will continue to pay quarterly cash dividends in the future. However, the payment and amount of future dividends remain within the discretion of the Board and will depend upon our future earnings, financial condition, capital requirements, legal requirements, and other factors.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">McKESSON CORPORATION</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL REVIEW (CONCLUDED)</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(UNAUDITED)</span></div></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Capital Resources</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We fund our working capital requirements primarily with cash and cash equivalents, proceeds from short-term borrowings from our commercial paper issuances, and longer-term credit agreements and debt offerings. Funds necessary for future debt maturities and our other cash requirements, including any future payments that may be made related to our total estimated litigation liability of $7.2 billion as of June 30, 2023 payable under the terms of various settlement agreements for opioid-related claims, are expected to be met by existing cash balances, cash flow from operations, existing credit sources, and future borrowings. Long-term debt markets and commercial paper markets, our primary sources of capital after cash flow from operations, are open and accessible to us should we decide to access those markets. Detailed information regarding our debt and financing activities is included in Financial Note 7, &#8220;Debt and Financing Activities,&#8221; to the accompanying condensed consolidated financial statements included in this Quarterly Report.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our future operating cash flow, financial assets, and access to capital and credit markets, including our credit facilities, give us the ability to meet our financing needs for the foreseeable future. However, there can be no assurance that an increase in volatility or disruption in the global capital and credit markets will not impair our liquidity or increase our costs of borrowing.</span></div><div id="if4d8dc006b964583a173e59149947157_121"></div><div style="margin-bottom:12pt;margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY NOTICE ABOUT FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q, including &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in Item 2 of Part I of this report, contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Exchange Act. Forward-looking statements may be identified by their use of terminology such as &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;seeks,&#8221; &#8220;approximately,&#8221; &#8220;intends,&#8221; &#8220;projects,&#8221; &#8220;plans,&#8221; &#8220;estimates,&#8221; &#8220;targets,&#8221; or the negative of these words or other comparable terminology. The discussion of financial trends, strategy, plans, assumptions, or intentions may also include forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected, anticipated, or implied. Although it is not possible to predict or identify all such risks and uncertainties, they include, but are not limited to, the factors discussed in the &#8220;Risk Factors&#8221; section in Item 1A of Part I of the 2023 Annual Report and in our publicly available SEC filings and press releases. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date such statements were first made. Except to the extent required by federal securities laws, we undertake no obligation to publicly release the result of any revisions to any forward-looking statements to reflect events or circumstances after the date the statements are made, or to reflect the occurrence of unanticipated events.</span></div><div id="if4d8dc006b964583a173e59149947157_1582"></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AVAILABLE INFORMATION</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We routinely post on our company website, and via our social media channels, information that may be material to investors, including details and updates to information disclosed elsewhere, which may include business developments, earnings and financial performance, sustainability matters, and materials for presentations to investors and financial analysts. Investors are encouraged to monitor our website </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">www.mckesson.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Interested parties can sign up on our website, including our Investor Relations site, to receive automated e-mail alerts, such as via RSS newsfeed, when we post certain information. Interested parties can also follow our social media feed @McKesson on Twitter. The content on any website or social media channel is not incorporated by reference into this report, unless expressly noted otherwise.</span></div><div id="if4d8dc006b964583a173e59149947157_124"></div><div style="padding-left:18pt;text-indent:-36pt"><span><br/></span></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">McKESSON CORPORATION</span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:54pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:24.02pt">Quantitative and Qualitative Disclosures about Market Risk.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe there has been no material change in our exposure to risks associated with fluctuations in interest and foreign currency exchange rates as disclosed in our Annual Report on Form 10-K for the fiscal year ended March 31, 2023. </span></div><div id="if4d8dc006b964583a173e59149947157_127"></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:24.02pt">Controls and Procedures.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Chief Executive Officer and our Chief Financial Officer, with the participation of other members of the Company&#8217;s management, have evaluated the effectiveness of the Company&#8217;s &#8220;disclosure controls and procedures&#8221; (as such term is defined in Exchange Act Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (&#8220;Exchange Act&#8221;)) as of the end of the period covered by this quarterly report, and our Chief Executive Officer and our Chief Financial Officer have concluded that our disclosure controls and procedures are effective based on their evaluation of these controls and procedures as required by paragraph (b) of Exchange Act Rules 13a-15 or 15d-15.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our &#8220;internal control over financial reporting&#8221; (as such term is defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) identified in connection with the evaluation required by paragraph (d) of Exchange Act Rules 13a-15 and 15d-15 that occurred during the three months ended June 30, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div id="if4d8dc006b964583a173e59149947157_130"></div><div style="margin-bottom:12pt;text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">McKESSON CORPORATION</span></div></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II&#8212;OTHER INFORMATION</span></div><div id="if4d8dc006b964583a173e59149947157_133"></div><div><span><br/></span></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:24.02pt">Legal Proceedings. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information set forth in Financial Note 10, &#8220;Commitments and Contingent Liabilities,&#8221; to the accompanying condensed consolidated financial statements included in this Quarterly Report on Form 10-Q, and in Financial Note 17, &#8220;Commitments and Contingent Liabilities,&#8221; to the consolidated financial statements included in our Annual Report on Form 10-K for the fiscal year ended March 31, 2023, is incorporated herein by reference. Disclosure of an environmental proceeding with a governmental agency generally is included only if we expect monetary sanctions in the proceeding to exceed $1 million, unless otherwise material.</span></div><div id="if4d8dc006b964583a173e59149947157_136"></div><div style="padding-left:18pt;text-indent:-36pt"><span><br/></span></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16.8pt">Risk Factors.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than factual updates discussed in this Quarterly Report on Form 10-Q, there have been no material changes for the period covered by this Quarterly Report on Form 10-Q to the risk factors disclosed in Part I of Item 1A of our Annual Report on Form 10-K for the fiscal year ended March 31, 2023.</span></div><div id="if4d8dc006b964583a173e59149947157_139"></div><div><span><br/></span></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:24.02pt">Unregistered Sales of Equity Securities and Use of Proceeds.</span></div><div style="margin-bottom:12pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board of Directors has authorized the repurchase of McKesson&#8217;s common stock. We may effect stock repurchases from time-to-time through open market transactions, privately negotiated transactions, accelerated share repurchase programs, or by combinations of such methods, any of which may use pre-arranged trading plans that are designed to meet the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. The timing of any repurchases and the actual number of shares repurchased will depend on a variety of factors, including our stock price, corporate and regulatory requirements, tax implications, restrictions under our debt obligations, other uses for capital, impacts on the value of remaining shares, and market and economic conditions.</span></div><div style="margin-bottom:12pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Financial Note 11, &#8220;Stockholders' Deficit,&#8221; to the accompanying condensed consolidated financial statements included in this Quarterly Report on Form 10-Q for a full discussion of the Company&#8217;s share repurchases for the three months ended June 30, 2023 and 2022.</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information on the Company&#8217;s share repurchases during the three months ended June 30, 2023:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.666%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Share Repurchases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions, except price per share)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Number<br/>of Shares<br/>Purchased</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average&#160;Price</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Paid&#160;Per&#160;Share </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Number&#160;of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Purchased</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">as Part of Publicly</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Announced</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Program</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"> (3)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approximate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Dollar&#160;Value&#160;of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares&#160;that&#160;May</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Yet Be Purchased Under the Programs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 1, 2023 &#8211; April 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363.11&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,361&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 1, 2023 &#8211; May 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378.52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,158&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 1, 2023 &#8211; June 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">393.22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,944&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">This table does not include the value of equity awards surrendered to satisfy tax withholding obligations or forfeitures of equity awards.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The average price paid per share and the remaining authorization outstanding for repurchases of the Company&#8217;s common stock excludes $4 million of excise taxes incurred on share repurchases for the three months ended June 30, 2023.</span></div><div style="margin-bottom:12pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">In July 2022, the Board authorized the Company to repurchase up to an additional $4.0 billion of its shares of common stock. The authorization has no expiration date.</span></div><div style="margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2023, the Board approved an increase of $6.0 billion in the authorization for repurchase of McKesson&#8217;s common   stock.</span></div><div style="margin-bottom:12pt;margin-top:3pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><div id="if4d8dc006b964583a173e59149947157_142"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">McKESSON CORPORATION</span></div><div style="text-align:center"><span><br/></span></div></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:24.02pt">Defaults Upon Senior Securities.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="if4d8dc006b964583a173e59149947157_145"></div><div style="padding-left:18pt;text-indent:-36pt"><span><br/></span></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:24.02pt">Mine Safety Disclosures.</span></div><div style="margin-bottom:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="if4d8dc006b964583a173e59149947157_148"></div><div style="padding-left:18pt;text-indent:-36pt"><span><br/></span></div><div style="margin-bottom:12pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:24.02pt">Other Information.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-954"><ix:nonNumeric contextRef="c-1" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-955"><ix:nonNumeric contextRef="c-1" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-956"><ix:nonNumeric contextRef="c-1" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-957">None.</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></span></div><div style="margin-bottom:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><div id="if4d8dc006b964583a173e59149947157_151"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">McKESSON CORPORATION</span></div><div style="text-align:center"><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:12pt;margin-top:12pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:24.02pt">Exhibits.</span></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibits identified in parentheses below are on file with the SEC and are incorporated by reference as exhibits hereto. </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:6.042%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.002%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Number</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/927653/000119312523168978/d481928dex41.htm">Officer&#8217;s Certificate, dated as of June 15, 2023, and related Form of 2028 Note and Form of 2033 Note (Exhibit 4.1, 4.2</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/927653/000119312523168978/d481928dex41.htm">,</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/927653/000119312523168978/d481928dex41.htm"> and 4.3 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on June 16, 2023, File No. 1-13252).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#8224;*</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mck_ex101x2022stockplanstcs.htm">Forms of Statement of Terms and Conditions and Grant Notices Applicable to Awards Pursuant to the McKesson Corporation 2022 Stock Plan.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#8224;*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mck_ex102xmipstcsmay2023.htm">Form of Statement of Terms and Conditions Applicable to Awards Pursuant to the McKesson Corporation Management Incentive Plan, effective May 23, 202</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mck_ex102xmipstcsmay2023.htm">3</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mck_ex102xmipstcsmay2023.htm">.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1&#8224;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mck_exhibit311x630202310-q.htm">Certification of the Chief Executive Officer Pursuant to Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2&#8224;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mck_exhibit312x630202310-q.htm">Certification of the Chief Financial Officer Pursuant to Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#8224;&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="mck_exhibit32x630202310-q.htm">Certification Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following materials from the McKesson Corporation Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, formatted in Inline Extensible Business Reporting Language (iXBRL): (i) Condensed Consolidated Statements of Operations, (ii) Condensed Consolidated Statements of Comprehensive Income, (iii) Condensed Consolidated Balance Sheets, (iv) Condensed Consolidated Statements of Stockholders&#8217; Equity (Deficit), (v) Condensed Consolidated Statements of Cash Flows, and (vi) related Financial Notes.</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as iXBRL and contained in Exhibit 101).</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt;padding-left:22.5pt;text-align:justify;text-indent:-20.25pt"><span><br/></span></div><div style="margin-bottom:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Management contract or compensation plan or arrangement in which directors and/or executive officers are eligible to participate.</span></div><div style="margin-bottom:3pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;&#160;&#160;&#160;&#160;Filed herewith.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;&#8224;&#160;&#160;&#160;&#160;Furnished herewith.</span></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><div id="if4d8dc006b964583a173e59149947157_154"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if4d8dc006b964583a173e59149947157_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">McKESSON CORPORATION</span></div><div style="text-align:center"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:25.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:207.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:10.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:261.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ESSON</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ORPORATION</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 2, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/  Britt J. Vitalone</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Britt J. Vitalone</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:25.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:207.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:10.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:261.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">M</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ESSON</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> C</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ORPORATION</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 2, 2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/  Napoleon B. Rutledge Jr.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Napoleon B. Rutledge Jr.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and Controller</span></td></tr></table></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>mck_ex101x2022stockplanstcs.htm
<DESCRIPTION>EX-10.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i9909940b100446f4adf3c825eaf11602_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.1</font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OUTSIDE DIRECTOR<br>Div Equiv Cash</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">McKESSON CORPORATION<br>STATEMENT OF TERMS AND CONDITIONS APPLICABLE TO<br>RESTRICTED STOCK UNITS GRANTED TO<br>OUTSIDE DIRECTORS PURSUANT TO THE 2022 STOCK PLAN</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">I.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:29.61pt">INTRODUCTION</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following terms and conditions shall apply to Restricted Stock Unit Awards granted under the Plan and are subject to the terms and conditions of the Plan. This Statement of Terms and Conditions is intended to meet the requirements of Code Section 409A and any regulations and rules promulgated thereunder. In the event of any inconsistency between this Statement of Terms and Conditions and the Plan, the Plan shall govern. Capitalized terms not otherwise defined in this Statement of Terms and Conditions shall have the meaning set forth in the Plan. </font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">II.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:25.72pt">RESTRICTED STOCK UNITS</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Award Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  A Restricted Stock Unit Award granted to an Outside Director under the Plan shall be evidenced by a Restricted Stock Unit Agreement to be executed by the Outside Director and the Corporation setting forth the terms and conditions of the Restricted Stock Unit Award. Each Restricted Stock Unit Grant Notice shall incorporate by reference and be subject to this Statement of Terms and Conditions, including the special terms and conditions in the Appendix for the Outside Director&#8217;s country (if any) which forms part of this Statement of Terms and Conditions, and together both documents shall constitute the Restricted Stock Unit Agreement. The Restricted Stock Units are also subject to the terms and conditions of the Plan. </font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Terms and Conditions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Administrator administering the Plan has authority to determine the Outside Directors to whom, and the time or times at which, grants of Restricted Stock Units will be made, the number of Units to be awarded, and all other terms and conditions of such awards. With respect to annual Restricted Stock Unit Awards granted to Outside Directors under the Plan, such awards shall be subject to the following terms, conditions and restrictions. </font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt;text-decoration:underline">Grant Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Each Outside Director may be granted a Restricted Stock Unit Award on the date of each annual meeting of stockholders. An Outside Director that is elected to the Board between annual meetings of stockholders may also be granted a Restricted Stock Unit Award on the date that the Board determines in its sole discretion.  </font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt;text-decoration:underline">Number of Restricted Stock Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Unless otherwise determined by the Board or the Governance Committee of the Board (the &#8220;Governance Committee&#8221;), the number of Restricted Stock Units (&#8220;Units&#8221;) granted for the annual meeting grant will be determined by dividing the Fair Market Value of a Share on the date of grant into $200,000 (with any fractional Unit rounded up to the nearest whole Unit).  In addition to such grant, unless otherwise determined by the Board or the Governance Committee, the Independent Chair shall be granted an annual meeting grant determined by dividing the Fair Market Value of a Share on the date of grant into $120,000 (with any fractional Unit rounded up to the nearest whole Unit).  Notwithstanding the foregoing, in no event shall the aggregate number of Units granted to any Outside Director pursuant to such annual meeting grant or grants exceed 5,000.  A newly elected Outside Director may receive a prorated annual meeting grant effective upon the date of the Outside Director&#8217;s election to the Board.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(C)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt;text-decoration:underline">No Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Each Restricted Stock Unit Award granted to an Outside Director will be fully vested on the date of grant.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Dividend Equivalents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Dividend equivalents in respect of Restricted Stock Units, if granted in tandem with such Units, will be credited on behalf of an Outside Director to a deferred cash account until such time as the underlying Shares are issued. </font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Assignability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. An Outside Director shall not be permitted to sell, transfer, pledge, assign or encumber Restricted Stock Units, other than pursuant to a qualified domestic relations order as defined in the Code or Title I of the U.S. Employee Retirement Income Security Act.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2022 Stock Plan STC (Outside Director)</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">No Stockholder Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Neither an Outside Director nor any person entitled to exercise an Outside Director&#8217;s rights in the event of the Outside Director&#8217;s death shall have any of the rights of a stockholder with respect to a Restricted Stock Unit Award except to the extent that a book entry has been entered in the records of the Corporation&#8217;s transfer agent with respect to the underlying Shares paid upon the settlement of any Restricted Stock Unit Award as described in Section II.6 below. </font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Time of Payment of Restricted Stock Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Except as noted in Section II.7 below, Restricted Stock Units granted to Outside Directors shall not be paid until after the Outside Director&#8217;s separation of service with the Corporation (&#8220;Automatic Deferral Requirement&#8221;). &#8220;Separation from service&#8221; shall have the meaning provided under the McKesson Corporation Deferred Compensation Administration Plan III (&#8220;DCAP&#160;III&#8221;). Payment shall be made in Shares in the form of an appropriate book entry entered in the records of the Corporation&#8217;s transfer agent recording the Outside Director&#8217;s unrestricted interest in the number of Shares subject to the Restricted Stock Unit Award. </font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Satisfaction of Director Stock Ownership Guidelines</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  For those Outside Directors who have met the Director Stock Ownership Guidelines in effect at the time, Restricted Stock Unit grants shall not be subject to the Automatic Deferral Requirement and such grants will be immediately converted into Shares and distributed to the Outside Director&#59; provided, however, that the Outside Director may elect to defer receipt of the Shares underlying the Restricted Stock Units.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Deferrals of Restricted Stock Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Deferrals of Restricted Stock Units, whether elective or pursuant to the Automatic Deferral Requirement, shall be subject to the terms and conditions of DCAP III.</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">III.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:21.83pt">MISCELLANEOUS</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">No Effect on Terms of Service with the Corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Nothing contained in this Statement of Terms and Conditions, the Plan or a Restricted Stock Unit Agreement shall affect the Corporation&#8217;s right to terminate the service of any Outside Director.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Grants to Outside Directors in Foreign Countries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. If an Outside Director is not a United States citizen or resident, the Board has the full discretion to deviate from this Statement of Terms and Conditions in order to adjust a Restricted Stock Unit Award to prevailing local conditions, including custom and legal and tax requirements. Furthermore, the Corporation reserves the right to impose other requirements on the Outside Director&#8217;s participation in the Plan, on the Award and on any Shares acquired under the Plan, to the extent the Corporation determines it is necessary or advisable in order to comply with local law or facilitate the administration of the Plan, and to require the Outside Director to sign any additional agreements or undertaking that may be necessary to accomplish the foregoing.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Information Notification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Any information required to be given under the terms of a Restricted Stock Unit Award shall be addressed to the Corporation in care of its Corporate Secretary at McKesson Corporation, 6555 North State Highway 161, Irving, Texas 75039, and any notice to be given to an Outside Director shall be addressed to the Outside Director at the address indicated beneath the Outside Director&#8217;s name on the Restricted Stock Unit Agreement or such other address as either party may designate in writing to the other. Any such notice shall be deemed to have been duly given when enclosed in a properly sealed envelope or wrapper addressed as aforesaid, registered or certified and deposited (postage or registration or certification fee prepaid) in a post office or branch post office. The parties may use email delivery, so long as the message is clearly marked, sent to the email address(es) set forth herein. Email delivery will be deemed to occur when the sender receives confirmation that such message has been received and read by the recipient. Emails to the Corporation shall be delivered to CorpSecretary&#64;McKesson.com.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Electronic Delivery</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Corporation may, in its sole discretion, decide to deliver any documents related to current or future participation in the Plan by electronic means. The Participant hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by the Corporation or a third party designated by the Corporation.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Administrator Decisions Conclusive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. All decisions of the Administrator administering the Plan upon any questions arising under the Plan, under this Statement of Terms and Conditions, or under a Restricted Stock Unit Agreement, shall be conclusive and binding on all persons.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">No Effect on Other Benefit Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Nothing herein contained shall affect an Outside Director&#8217;s right, if any, to participate in and receive benefits from and in accordance with the then current provisions of any benefit plan or program offered by the Corporation.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Each Outside Director shall agree to make appropriate arrangements with the Corporation for satisfaction of any applicable federal, state or local income tax withholding requirements or payroll tax requirements, if any is required.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:28.5pt">Data Privacy Information and Consent.  </font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:22.68pt">Data Collection and Usage.  The Corporation may collect, process and use certain personal information about the Outside Director, including, but not limited to, the Outside Director&#8217;s name, home address and telephone number, email address, date of birth, social insurance number, passport or other identification number, salary, nationality, job title, any Shares held in the Corporation, details of all Restricted Stock Units or any other entitlement to Shares awarded, canceled, exercised, vested, unvested or outstanding in the Outside Director&#8217;s favor (&#8220;Data&#8221;), for the purposes of implementing, administering and managing the Plan. The legal basis, where required, for the processing of Data is the Outside Director&#8217;s consent.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:22.68pt">Stock Plan Administration Service Providers.  The Corporation transfers Data to Fidelity Stock Plan Services LLC and its affiliated companies, an independent service provider based in the United States, which is assisting the Corporation with the implementation, administration and management of the Plan. The Corporation may select a different service provider or additional service providers and share Data with such other provider serving in a similar manner. The Outside Director may be asked to agree on separate terms and data processing practices with the service provider, with such agreement being a condition to the ability to participate in the Plan.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(C)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:22.68pt">International Data Transfers.  The Corporation and its service providers are based in the United States.  The Outside Director&#8217;s country or jurisdiction may have different data privacy laws and protections than the United States. The Corporation&#8217;s legal basis, where required, for the transfer of Data is</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">the Outside Director&#8217;s consent.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(D)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:22.12pt">Data Retention.  The Corporation will hold and use the Data only as long as is necessary to implement, administer and manage the Outside Director&#8217;s participation in the Plan, or as required to comply with legal or regulatory obligations, including under tax and security laws. In the latter case, the Outside Director understands and acknowledges that the Corporation&#8217;s legal basis for the processing of the Outside Director&#8217;s Data would be compliance with the relevant laws or regulations or the pursuit by the Corporation of respective legitimate interests not outweighed by the Outside Director&#8217;s interests, rights or freedoms. When the Corporation no longer needs the Outside Director&#8217;s Data for any of the above purposes, the Outside Director understands the Corporation will remove it from its systems.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(E)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:22.68pt">Voluntariness and Consequences of Consent Denial or Withdrawal.  Participation in the Plan is voluntary and the Outside Director is providing the consents herein on a purely voluntary basis. If the Outside Director does not consent, or if the Outside Director later seeks to revoke the Outside Director&#8217;s consent, the Outside Director&#8217;s retainer and fees from or services with the Corporation will not be affected&#59; the only consequence of refusing or withdrawing the Outside Director&#8217;s consent is that the Corporation would not be able to grant Awards to the Outside Director or administer or maintain such Awards.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(F)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:22.68pt">Data Subject Rights.  The Outside Director may have a number of rights under data privacy laws in the Outside Director&#8217;s jurisdiction. Depending on where the Outside Director is based, such rights may include the right to (i) inquire whether and what kind of Data the Corporation holds about the Outside Director and how it is processed, and to request access or copies of Data the Corporation processes, (ii) request the correction or supplementation of Data about the Outside Director that is inaccurate, incomplete or out-of-date in light of the purposes underlying the processing, (iii) obtain the erasure of Data no longer necessary for the purposes underlying the processing, processed based on withdrawn consent, processed for legitimate interests that, in the context of the Outside Director&#8217;s objection, do not prove to be compelling, or processed in non-compliance with applicable legal requirements, (iv) request restrictions on processing of Data in certain situations where the Outside Director feels its processing is inappropriate, (v) request portability of the Outside Director&#8217;s Data that the Outside Director has actively or passively provided to the Corporation (which does not include data derived or inferred from the collected data), where the processing of such Data is based on consent or the Outside Director&#8217;s service on the Board and is carried out by automated means, (vi) object, in certain circumstances, to the processing of Data for legitimate interests, (vii) lodge complaints with competent authorities in the Outside Director&#8217;s jurisdiction, and&#47;or (viii) receive a list with the names and addresses of any potential recipients of Data. To receive clarification regarding these rights or to exercise these rights, the Outside Director can contact the Corporate Secretary.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">By accepting the Award and indicating consent via the Corporation&#8217;s acceptance procedure, the Outside Director is declaring that he or she agrees with the data processing practices described herein and consents to the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">collection, processing and use of Data by the Corporation and the transfer of Data to the recipients mentioned above, including recipients located in countries which do not adduce an adequate level of protection from a European (or other non-U.S.) data protection law perspective, for the purposes described above.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The provisions in this Statement of Terms and Conditions are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.5pt;text-decoration:underline">Successors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  This Statement of Terms and Conditions and the Restricted Stock Unit Agreements shall be binding upon and inure to the benefit of any successor or successors of the Corporation. &#8220;Outside Director&#8221; as used herein shall include the Outside Director&#8217;s Beneficiary.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.5pt;text-decoration:underline">Delaware Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The interpretation, performance, and enforcement of this Statement of Terms and Conditions and all Restricted Stock Unit Agreements shall be governed by the laws of the State of Delaware.  </font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div><div><font><br></font></div></div></div><div id="i9909940b100446f4adf3c825eaf11602_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OUTSIDE DIRECTOR<br>Div Equiv Units</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">McKESSON CORPORATION<br>STATEMENT OF TERMS AND CONDITIONS APPLICABLE TO<br>RESTRICTED STOCK UNITS GRANTED TO<br>OUTSIDE DIRECTORS PURSUANT TO THE 2022 STOCK PLAN</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:center"><font><br></font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">I.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:29.61pt">INTRODUCTION</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following terms and conditions shall apply to Restricted Stock Unit Awards granted under the Plan and are subject to the terms and conditions of the Plan. This Statement of Terms and Conditions is intended to meet the requirements of Code Section 409A and any regulations and rules promulgated thereunder. In the event of any inconsistency between this Statement of Terms and Conditions and the Plan, the Plan shall govern. Capitalized terms not otherwise defined in this Statement of Terms and Conditions shall have the meaning set forth in the Plan. </font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">II.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:25.72pt">RESTRICTED STOCK UNITS</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Award Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  A Restricted Stock Unit Award granted to an Outside Director under the Plan shall be evidenced by a Restricted Stock Unit Agreement to be executed by the Outside Director and the Corporation setting forth the terms and conditions of the Restricted Stock Unit Award. Each Restricted Stock Unit Grant Notice shall incorporate by reference and be subject to this Statement of Terms and Conditions, including the special terms and conditions in the Appendix for the Outside Director&#8217;s country (if any) which forms part of this Statement of Terms and Conditions, and together both documents shall constitute the Restricted Stock Unit Agreement. The Restricted Stock Units are also subject to the terms and conditions of the Plan. </font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Terms and Conditions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Administrator administering the Plan has authority to determine the Outside Directors to whom, and the time or times at which, grants of Restricted Stock Units will be made, the number of Units to be awarded, and all other terms and conditions of such awards. With respect to annual Restricted Stock Unit Awards granted to Outside Directors under the Plan, such awards shall be subject to the following terms, conditions and restrictions. </font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt;text-decoration:underline">Grant Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Each Outside Director may be granted a Restricted Stock Unit Award on the date of each annual meeting of stockholders. An Outside Director that is elected to the Board between annual meetings of stockholders may also be granted a Restricted Stock Unit Award on the date that the Board determines in its sole discretion.  </font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt;text-decoration:underline">Number of Restricted Stock Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Unless otherwise determined by the Board or the Governance Committee of the Board (the &#8220;Governance Committee&#8221;), the number of Restricted Stock Units (&#8220;Units&#8221;) granted for the annual meeting grant will be determined by dividing the Fair Market Value of a Share on the date of grant into $200,000 (with any fractional </font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unit rounded up to the nearest whole Unit).  In addition to such grant, unless otherwise determined by the Board or the Governance Committee, the Independent Chair shall be granted an annual meeting grant determined by dividing the Fair Market Value of a Share on the date of grant into $120,000 (with any fractional Unit rounded up to the nearest whole Unit).  Notwithstanding the foregoing, in no event shall the aggregate number of Units granted to any Outside Director pursuant to such annual meeting grant or grants exceed 5,000.  A newly elected Outside Director may receive a prorated annual meeting grant effective upon the date of the Outside Director&#8217;s election to the Board.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(C)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt;text-decoration:underline">No Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Each Restricted Stock Unit Award granted to an Outside Director will be fully vested on the date of grant.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Dividend Equivalents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Dividend equivalents in respect of Restricted Stock Units, if granted in tandem with such Units, will be converted into additional Restricted Stock Units, which will be subject to all of the terms and conditions of the underlying Restricted Stock Unit Award. The number of such additional Restricted Stock Units shall be calculated by dividing (a)&#160;the aggregate amount or value of the dividends paid with respect to that number of Shares equal to the number of Restricted Stock Units credited as of the record date for such dividend by (b)&#160;the Fair Market Value per Share on the payment date for such dividend. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2022 Stock Plan STC (Outside Director)</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Assignability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. An Outside Director shall not be permitted to sell, transfer, pledge, assign or encumber Restricted Stock Units, other than pursuant to a qualified domestic relations order as defined in the Code or Title I of the U.S. Employee Retirement Income Security Act.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">No Stockholder Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Neither an Outside Director nor any person entitled to exercise an Outside Director&#8217;s rights in the event of the Outside Director&#8217;s death shall have any of the rights of a stockholder with respect to a Restricted Stock Unit Award except to the extent that a book entry has been entered in the records of the Corporation&#8217;s transfer agent with respect to the underlying Shares paid upon the settlement of any Restricted Stock Unit Award as described in Section II.6 below. </font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Time of Payment of Restricted Stock Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Except as noted in Section II.7 below, Restricted Stock Units granted to Outside Directors shall not be paid until after the Outside Director&#8217;s separation of service with the Corporation (&#8220;Automatic Deferral Requirement&#8221;). &#8220;Separation from service&#8221; shall have the meaning provided under the McKesson Corporation Deferred Compensation Administration Plan III (&#8220;DCAP&#160;III&#8221;). Payment shall be made in Shares in the form of an appropriate book entry entered in the records of the Corporation&#8217;s transfer agent recording the Outside Director&#8217;s unrestricted interest in the number of Shares subject to the Restricted Stock Unit Award. Any fractional Shares resulting from the accumulation of dividend equivalents shall be paid in cash. </font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Satisfaction of Director Stock Ownership Guidelines</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  For those Outside Directors who have met the Director Stock Ownership Guidelines in effect at the time, Restricted Stock Unit grants shall not be subject to the Automatic Deferral Requirement and such grants will be immediately converted into Shares and distributed to the Outside Director&#59; provided, however, that the Outside Director may elect to defer receipt of the Shares underlying the Restricted Stock Units.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Deferrals of Restricted Stock Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Deferrals of Restricted Stock Units, whether elective or pursuant to the Automatic Deferral Requirement, shall be subject to the terms and conditions of DCAP III.</font></div><div style="margin-bottom:12pt;margin-top:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">III.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:21.83pt">MISCELLANEOUS</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">No Effect on Terms of Service with the Corporation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Nothing contained in this Statement of Terms and Conditions, the Plan or a Restricted Stock Unit Agreement shall affect the Corporation&#8217;s right to terminate the service of any Outside Director.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Grants to Outside Directors in Foreign Countries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. If an Outside Director is not a United States citizen or resident, the Board has the full discretion to deviate from this Statement of Terms and Conditions in order to adjust a Restricted Stock Unit Award to prevailing local conditions, including custom and legal and tax requirements. Furthermore, the Corporation reserves the right to impose other requirements on the Outside Director&#8217;s participation in the Plan, on the Award and on any Shares acquired under the Plan, to the extent the Corporation determines it is necessary or advisable in order to comply with local law or facilitate the administration of the Plan, and to require the Outside Director to sign any additional agreements or undertaking that may be necessary to accomplish the foregoing.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Information Notification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Any information required to be given under the terms of a Restricted Stock Unit Award shall be addressed to the Corporation in care of its Corporate Secretary at McKesson Corporation, 6555 North State Highway 161, Irving, Texas 75039, and any notice to be given to an Outside Director shall be addressed to the Outside Director at the address indicated beneath the Outside Director&#8217;s name on the Restricted Stock Unit Agreement or such other address as either party may designate in writing to the other. Any such notice shall be deemed to have been duly given when enclosed in a properly sealed envelope or wrapper addressed as aforesaid, registered or certified and deposited (postage or registration or certification fee prepaid) in a post office or branch post office. The parties may use email delivery, so long as the message is clearly marked, sent to the email address(es) set forth herein. Email delivery will be deemed to occur when the sender receives confirmation that such message has been received and read by the recipient. Emails to the Corporation shall be delivered to CorpSecretary&#64;McKesson.com.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Electronic Delivery</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Corporation may, in its sole discretion, decide to deliver any documents related to current or future participation in the Plan by electronic means. The Participant hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by the Corporation or a third party designated by the Corporation.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Administrator Decisions Conclusive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. All decisions of the Administrator administering the Plan upon any questions arising under the Plan, under this Statement of Terms and Conditions, or under a Restricted Stock Unit Agreement, shall be conclusive and binding on all persons.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">No Effect on Other Benefit Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Nothing herein contained shall affect an Outside Director&#8217;s right, if any, to participate in and receive benefits from and in accordance with the then current provisions of any benefit plan or program offered by the Corporation.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Each Outside Director shall agree to make appropriate arrangements with the Corporation for satisfaction of any applicable federal, state or local income tax withholding requirements or payroll tax requirements, if any is required.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:28.5pt">Data Privacy Information and Consent.  </font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:22.68pt">Data Collection and Usage.  The Corporation may collect, process and use certain personal information about the Outside Director, including, but not limited to, the Outside Director&#8217;s name, home address and telephone number, email address, date of birth, social insurance number, passport or other identification number, salary, nationality, job title, any Shares held in the Corporation, details of all Restricted Stock Units or any other entitlement to Shares awarded, canceled, exercised, vested, unvested or outstanding in the Outside Director&#8217;s favor (&#8220;Data&#8221;), for the purposes of implementing, administering and managing the Plan. The legal basis, where required, for the processing of Data is the Outside Director&#8217;s consent.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:22.68pt">Stock Plan Administration Service Providers.  The Corporation transfers Data to Fidelity Stock Plan Services LLC and its affiliated companies, an independent service provider based in the United States, which is assisting the Corporation with the implementation, administration and management of the Plan. The Corporation may select a different service provider or additional service providers and share Data with such other provider serving in a similar manner. The Outside Director may be asked to agree on separate terms and data processing practices with the service provider, with such agreement being a condition to the ability to participate in the Plan.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(C)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:22.68pt">International Data Transfers.  The Corporation and its service providers are based in the United States.  The Outside Director&#8217;s country or jurisdiction may have different data privacy laws and protections than the United States. The Corporation&#8217;s legal basis, where required, for the transfer of Data is</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">the Outside Director&#8217;s consent.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(D)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:22.12pt">Data Retention.  The Corporation will hold and use the Data only as long as is necessary to implement, administer and manage the Outside Director&#8217;s participation in the Plan, or as required to comply with legal or regulatory obligations, including under tax and security laws. In the latter case, the Outside Director understands and acknowledges that the Corporation&#8217;s legal basis for the processing of the Outside Director&#8217;s Data would be compliance with the relevant laws or regulations or the pursuit by the Corporation of respective legitimate interests not outweighed by the Outside Director&#8217;s interests, rights or freedoms. When the Corporation no longer needs the Outside Director&#8217;s Data for any of the above purposes, the Outside Director understands the Corporation will remove it from its systems.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(E)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:22.68pt">Voluntariness and Consequences of Consent Denial or Withdrawal.  Participation in the Plan is voluntary and the Outside Director is providing the consents herein on a purely voluntary basis. If the Outside Director does not consent, or if the Outside Director later seeks to revoke the Outside Director&#8217;s consent, the Outside Director&#8217;s retainer and fees from or services with the Corporation will not be affected&#59; the only consequence of refusing or withdrawing the Outside Director&#8217;s consent is that the Corporation would not be able to grant Awards to the Outside Director or administer or maintain such Awards.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">(F)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:22.68pt">Data Subject Rights.  The Outside Director may have a number of rights under data privacy laws in the Outside Director&#8217;s jurisdiction. Depending on where the Outside Director is based, such rights may include the right to (i) inquire whether and what kind of Data the Corporation holds about the Outside Director and how it is processed, and to request access or copies of Data the Corporation processes, (ii) request the correction or supplementation of Data about the Outside Director that is inaccurate, incomplete or out-of-date in light of the purposes underlying the processing, (iii) obtain the erasure of Data no longer necessary for the purposes underlying the processing, processed based on withdrawn consent, processed for legitimate interests that, in the context of the Outside Director&#8217;s objection, do not prove to be compelling, or processed in non-compliance with applicable legal requirements, (iv) request restrictions on processing of Data in certain situations where the Outside Director feels its processing is inappropriate, (v) request portability of the Outside Director&#8217;s Data that the Outside Director has actively or passively provided to the Corporation (which does not include data derived or inferred from the collected data), where the processing of such Data is based on consent or the Outside Director&#8217;s service on the Board and is carried out by automated means, (vi) object, in certain circumstances, to the processing of Data for legitimate interests, (vii) lodge complaints with competent authorities in the Outside Director&#8217;s jurisdiction, and&#47;or (viii) receive a list with the names and addresses of any potential </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">recipients of Data. To receive clarification regarding these rights or to exercise these rights, the Outside Director can contact the Corporate Secretary.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">By accepting the Award and indicating consent via the Corporation&#8217;s acceptance procedure, the Outside Director is declaring that he or she agrees with the data processing practices described herein and consents to the collection, processing and use of Data by the Corporation and the transfer of Data to the recipients mentioned above, including recipients located in countries which do not adduce an adequate level of protection from a European (or other non-U.S.) data protection law perspective, for the purposes described above.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The provisions in this Statement of Terms and Conditions are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.5pt;text-decoration:underline">Successors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  This Statement of Terms and Conditions and the Restricted Stock Unit Agreements shall be binding upon and inure to the benefit of any successor or successors of the Corporation. &#8220;Outside Director&#8221; as used herein shall include the Outside Director&#8217;s Beneficiary.</font></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.5pt;text-decoration:underline">Delaware Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. The interpretation, performance, and enforcement of this Statement of Terms and Conditions and all Restricted Stock Unit Agreements shall be governed by the laws of the State of Delaware</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div><div><font><br></font></div></div></div><div id="i9909940b100446f4adf3c825eaf11602_7"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EXECUTIVE OFFICERS</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">McKESSON CORPORATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">STATEMENT OF TERMS AND CONDITIONS APPLICABLE TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OPTIONS, RESTRICTED STOCK, RESTRICTED STOCK UNITS</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AND PERFORMANCE STOCK UNITS GRANTED TO EXECUTIVE OFFICERS<br>PURSUANT TO THE 2022 STOCK PLAN</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For Grants Beginning May 23, 2023</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">I.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:29.61pt">INTRODUCTION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following terms and conditions shall apply to an Award granted under the Plan and are subject to the terms and conditions of the Plan. This Statement of Terms and Conditions is intended to meet the requirements of Code Section&#160;409A and any rules promulgated thereunder.  In the event of any inconsistency between this Statement of Terms and Conditions and the Plan, the Plan shall govern. Capitalized terms not otherwise defined in this Statement of Terms and Conditions shall have the meaning set forth in the Plan.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">II.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:25.72pt">OPTIONS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Option Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  An Option granted under the Plan shall be evidenced by an Option Agreement setting forth the terms and conditions of the Option, including whether the Option is an Incentive Stock Option or a Nonstatutory Stock Option and the number of Shares subject to the Option. Each Option Grant Notice shall incorporate by reference and be subject to this Statement of Terms and Conditions, including the special terms and conditions in the Appendix for the Participant&#8217;s country (if any) which forms part of this Statement of Terms and Conditions, and together both documents shall constitute the Option Agreement. The Option is also subject to the terms and conditions of the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Exercise Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Exercise Price of an Option, as specified in the Option Agreement, shall be equal to or greater than the Fair Market Value of the Shares underlying the Option on the Grant Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Option Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  An Option shall be exercisable only during the applicable Option Period, and during such Option Period the exercisability of the Option shall be subject to the vesting provisions of Section&#160;II.4 as modified by the rules set forth in Sections&#160;II.5 and VI. The Option Period shall be not more than seven years from the Grant Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Vesting of Right to Exercise Options</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">Subject to Sections&#160;II.5 and VI, an Option shall be exercisable during the Option Period in accordance with the vesting terms and conditions established on the Grant Date and specified in the Option Grant Notice.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">Any vested portion of an Option not exercised hereunder shall accumulate and be exercisable at any time on or before the Expiration Date, subject to the rules set forth in Sections&#160;II.5 and VI. No Option may be exercised for less than 5% of the total number of Shares then available for exercise under such Option.  In no event shall the Corporation be required to issue fractional Shares.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Limits on Option Period and Acceleration of Vesting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Option Period may end before the Expiration Date, and in certain circumstances the vesting schedule of an Option may be accelerated (subject to the provisions of Section&#160;VI), as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">If a Participant ceases to be a bona fide employee of the Corporation or of its Affiliates during the Option Period for reasons other than for Cause, Long-Term Disability, Normal Retirement, Early Retirement, Severance under the circumstances provided in Section II.5(F)(ii), or death, the Option Period shall end on the earlier of (i)&#160;90 days after the date of the Participant&#8217;s termination of employment and (ii)&#160;the Expiration Date, and in all cases the Option shall be exercisable only to the extent that it was exercisable at the time of such termination of employment. If a Participant is absent from work with the Corporation or an Affiliate because of the Participant's Short-Term Disability or because the Participant is on an approved leave of absence, the Participant shall not be deemed during the period of any such absence, by virtue of such absence alone, to have terminated employment with the Corporation or an Affiliate except as the Administrator may otherwise expressly determine.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2022 Stock Plan STC (EO)</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">Notwithstanding any other provision in this Section II.5, if a Participant&#8217;s employment is terminated for Cause during the Option Period, the Option Period shall end on the date of such termination of employment and the Option shall thereupon not be exercisable to any extent whatsoever.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(C)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">If a Participant ceases to be a bona fide employee of the Corporation or of its Affiliates during the Option Period by reason of Long-Term Disability, the vesting schedule of the Participant&#8217;s Option shall be accelerated, the Option shall become fully exercisable and the Option Period shall end on the earlier of (i) three years after the date of the Participant&#8217;s termination of employment and (ii) the Expiration Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(D)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">If a Participant ceases to be a bona fide employee of the Corporation or of its Affiliates during the Option Period by reason of Early Retirement, (i)&#160;the Option shall be exercisable only to the extent that it was exercisable at the time of such retirement and (ii)&#160;the Option Period for that portion of the Option designated as a Nonstatutory Stock Option shall end on the earlier of (a) three years after the date of such retirement and (b) the Expiration Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(E)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.24pt">If a Participant ceases to be a bona fide employee of the Corporation or of its Affiliates during the Option Period by reason of Normal Retirement&#58; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.57pt">If such Normal Retirement occurs prior to the first anniversary of the Grant Date of the Option, such Option shall be subject to the provisions of Section II.5(D) as though the Participant were eligible for Early Retirement&#59; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.8pt">If such Normal Retirement occurs on or after the first anniversary of the Grant Date of an Option, (a)&#160;that portion of the Option designated as a Nonstatutory Stock Option shall continue to vest as though the Participant had continued to be employed by the Corporation or one of its Affiliates during such vesting period, and (b)&#160;the Option Period for such portion of the Option designated as a Nonstatutory Stock Option shall end on the Expiration Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(F)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">If a Participant ceases to be a bona fide employee of the Corporation or of its Affiliates during the Option Period by reason of Severance, and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.57pt">The Participant has attained the requirements for Normal Retirement on or prior to the Participant&#8217;s termination date, then such Option shall be subject to the Normal Retirement provisions of Section II.5(E)&#59; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.8pt">The Participant has not attained the requirements for Normal Retirement on or prior to the Participant&#8217;s termination date, but would have attained the requirements for Normal Retirement within six months after the termination date, and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:121.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:11.21pt">The first anniversary of the Grant Date of the applicable Award has not occurred on or prior to the termination date, then such Option shall be subject to the Early Retirement provision in Section II.5(D)&#59; or</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:121.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.64pt">The first anniversary of the Grant Date of the applicable Award has occurred on or prior to the termination date, then (x) that portion of the Option designated as a Nonstatutory Stock Option shall continue to vest as though the Participant had continued to be employed by the Corporation or one of its Affiliates during such vesting period, and (y) the Option Period for such portion of the Option designated as a Nonstatutory Stock Option shall end on the Expiration Date&#59; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:21.03pt">The Participant has not attained the requirements for Normal Retirement on or prior to the Participant&#8217;s termination date, and would not have attained the requirements for Normal Retirement within six months after the termination date, then (a) the vesting schedule of the Participant&#8217;s Option shall be accelerated as to the portion of the Option that would have vested in accordance with the original vesting schedule as though the Participant had continued to be employed by the Corporation or one of its Affiliates six months after the termination date, and (b) the expiration of the Option Period provided in Section II.5(A) shall apply&#59; provided that if the Participant is also eligible for Early Retirement at the time of the termination of employment, then the expiration of the Option Period provided in Section II.5(D) shall apply.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(G)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">If a Participant should die (i) while in the employ of the Corporation or an Affiliate and (ii) during the Option Period, the vesting schedule of the Participant&#8217;s Option shall be accelerated and the Option shall become fully exercisable, the Option Period shall end on the earlier of (a) three years after the date of death and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) the Expiration Date, and the Participant&#8217;s Beneficiary may exercise the entire unexercised portion of the then exercisable Shares covered by such Option (or any lesser amount)&#160;remaining on the date of death.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(H)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">If a Participant who ceases to be a bona fide employee of the Corporation or an Affiliate is subsequently rehired prior to the expiration of the Participant's Option, then the Option shall continue to remain outstanding until the earlier of (i) such time as the Participant subsequently terminates employment and (ii) the Expiration Date. Upon the Participant&#8217;s subsequent termination of employment, the post-termination exercise period calculated pursuant to the terms and conditions of this Section II.5 shall be reduced by the number of days between the date of the Participant&#8217;s initial termination of employment and the Participant's re-hire date&#59; provided, however, that if the rehired Participant continues to be employed by the Corporation or an Affiliate for at least one year from the Participant's rehire date, then the post termination exercise period for the Option shall be determined in accordance with Sections II.5(A) through (G) and shall not be adjusted as described in this Section II.5(H).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Method of Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  A Participant may exercise an Option with respect to all or any part of the exercisable Shares as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">By giving the Corporation, or its authorized representative designated for this purpose, written notice of such exercise specifying the number of Shares as to which the Option is so exercised. Such notice shall be accompanied by an amount equal to the Exercise Price multiplied by the number of Shares exercised, in the form of any one or combination of the following&#58;&#160;&#160;cash or a certified check, bank draft, postal or express money order payable to the order of the Corporation in lawful money of the United States. Unless otherwise determined by the Administrator in its sole discretion, the Participant may pay the Exercise Price, in whole or in part, by tendering to the Corporation or its authorized representative Shares, which have been owned by the Participant for at least six months prior to said tender, and having a fair market value, as determined by the Corporation, equal to the Exercise Price, or in lieu of the delivery of actual Shares in such tender, the Corporation may accept an attestation by the Participant, in a form prescribed by the Corporation or its authorized representative, that the Participant owns sufficient Shares of record or in an account in street name to satisfy the Exercise Price, and such attestation will be deemed a tender of Shares for purposes of this method of exercise.  The Corporation or its authorized representative may accept payment of the amount due upon the exercise of the Option in the form of a Participant&#8217;s personal check.  Payment may also be made by delivery (including by FAX transmission)&#160;to the Corporation or its authorized representative of an executed irrevocable Option exercise form together with irrevocable instructions to an approved registered investment broker to sell Shares in an amount sufficient to pay the Exercise Price plus any applicable Tax-Related Items (as defined in Section VIII.6) and to transfer the proceeds of such sale to the Corporation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">If required by the Corporation, by giving satisfactory assurance in writing, signed by the Participant, the Participant shall give the Participant's assurance that the Shares subject to the Option are being purchased for investment and not with a view to the distribution thereof&#59; provided that such assurance shall be deemed inapplicable to (i)&#160;any sale of the Shares by such Participant made in accordance with the terms of a registration statement covering such sale, which has heretofore been (or may hereafter be)&#160;filed and become effective under the U.S. Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;)&#160;and with respect to which no stop order suspending the effectiveness thereof has been issued, and (ii)&#160;any other sale of the Shares with respect to which, in the opinion of counsel for the Corporation, such assurance is not required to be given in order to comply with the provisions of the Securities Act.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(C)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">As soon as practicable after receipt of the notice and the assurance described in Sections&#160;II.6(A)&#160;and (B), the Corporation shall, without transfer or issue tax (except for withholding tax arrangements contemplated in Section&#160;VIII.6)&#160;and without other incidental expense to the Participant, credit the purchased Shares to the Participant&#8217;s brokerage account of record.  If the Participant does not have a brokerage account of record, then the Corporation shall cause an appropriate book entry to be entered in the records of the Corporation&#8217;s transfer agent recording the Participant&#8217;s unrestricted interest in the purchased Shares&#59; provided, however, that the time of such delivery may be postponed by the Corporation for such period as may be required for it with reasonable diligence to comply with applicable registration requirements under the Securities Act, the Exchange Act, any applicable listing requirements of any national securities exchange and requirements under any other law or regulation applicable to the issuance or transfer of the Shares.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Limitations on Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  An Option shall, during a Participant&#8217;s lifetime, be exercisable only by the Participant. No Option or any right granted thereunder shall be transferable by the Participant by operation of law or otherwise, other than by will or the laws of descent and distribution. Notwithstanding the foregoing&#58; (A)&#160;unless otherwise determined by the Administrator in its sole discretion, a Participant may designate a beneficiary to succeed, after the Participant&#8217;s death, to all of the Participant&#8217;s Options outstanding on the date of death&#59; (B)&#160;a Nonstatutory Stock Option may be transferable pursuant to a qualified domestic relations order as defined in the Code or Title I of the U.S. Employee Retirement Income Security Act&#59; and (C)&#160;any Participant, who is a senior executive officer recommended by the Chief Executive Officer of the Corporation and approved by the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Administrator may voluntarily transfer any Nonstatutory Stock Option to a Family Member as a gift or through a transfer to an entity in which more than 50% of the voting interests are owned by Family Members (or the Participant)&#160;in exchange for an interest in that entity. In the event of any attempt by a Participant to alienate, assign, pledge, hypothecate, or otherwise dispose of an Option or of any right thereunder, except as provided herein, or in the event of the levy of any attachment, execution, or similar process upon the rights or interest hereby conferred, the Corporation at its election may terminate the affected Option by notice to the Participant and the Option shall thereupon become null and void.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">No Stockholder Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Neither a Participant nor any person entitled to exercise a Participant&#8217;s rights in the event of the Participant&#8217;s death shall have any of the rights of a stockholder with respect to the Shares subject to an Option except to the extent that a book entry has been entered in the records of the Corporation&#8217;s transfer agent with respect to such Shares upon the exercise of an Option.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">III.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:21.83pt">RESTRICTED STOCK</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Restricted Stock Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  A Restricted Stock Award granted under the Plan shall be evidenced by a Restricted Stock Agreement to be executed by the Participant and the Corporation setting forth the terms and conditions of the Restricted Stock Award. Each Restricted Stock Grant Notice shall incorporate by reference and be subject to this Statement of Terms and Conditions, including the special terms and conditions in the Appendix for the Participant&#8217;s country (if any) which forms part of this Statement of Terms and Conditions, and together both documents shall constitute the Restricted Stock Agreement.  The Restricted Stock Award is also subject to the terms and conditions of the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Rights with Respect to Shares of Restricted Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Upon written acceptance of a Restricted Stock Award by a Participant, including the restrictions and other terms and conditions described in the Plan and the Restricted Stock Agreement, the Corporation shall cause an appropriate book entry to be entered in the records of the Corporation&#8217;s transfer agent recording the Participant&#8217;s interest in the Restricted Stock. From and after the Grant Date, the Participant shall have the rights of Common Stock ownership, including the right to vote and to receive dividends on Shares of Restricted Stock, subject to the terms, conditions and restrictions described in the Plan and the Restricted Stock Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Special Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Each Restricted Stock Award made under the Plan shall be subject to the following terms, conditions and restrictions and such additional terms, conditions and restrictions as may be determined by the Administrator&#59; provided, however, that no Restricted Stock grant shall be subject to additional terms, conditions and restrictions which are more favorable to a Participant than the terms, conditions and restrictions set forth elsewhere in the Plan or the Restricted Stock Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt;text-decoration:underline">Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Until the restrictions imposed on any Restricted Stock grant shall lapse (the &#8220;Restriction Period&#8221;), Shares of Restricted Stock granted to a Participant&#160;(i)&#160;shall not be sold, assigned, transferred, pledged, hypothecated, or otherwise disposed of, other than pursuant to a qualified domestic relations order as defined in the Code or Title I of the U.S. Employee Retirement Income Security Act and (ii)&#160;shall, if the Participant&#8217;s continuous employment with the Corporation or any of its Affiliates shall terminate for any reason (except as otherwise provided in the Plan, or in Section&#160;III.3(B) or Section III.3(C))&#160;be returned to the Corporation forthwith, and all the rights of the Participant to such Shares shall immediately terminate. If a Participant is absent from work with the Corporation or an Affiliate because of the Participant's Short-Term Disability or because the Participant is on an approved leave of absence, the Participant shall not be deemed during the period of any such absence, by virtue of such absence alone, to have terminated employment with the Corporation or an Affiliate except as the Administrator may otherwise expressly determine.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt;text-decoration:underline">Termination of Employment by Reason of Death, Long-Term Disability or Normal Retirement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Notwithstanding any provision to the contrary contained in the Restricted Stock Grant Notice, if a Participant who has been in the continuous employment of the Corporation or any of its Affiliates since the Grant Date of a Restricted Stock Award ceases to be a bona fide employee of the Corporation or an Affiliate as a result of&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.57pt">Death or Long-Term Disability, then the restrictions imposed on any Restricted Stock Award shall lapse as to all Shares granted to such Participant pursuant to such Restricted Stock Award on the date of such termination&#59; or </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.8pt">Normal Retirement on or after the first anniversary of the Grant Date of any time-vesting Restricted Stock Award, the restrictions applicable to such Restricted Stock Award shall continue to lapse at such time(s) as are set forth in the applicable Grant Notice, as though the Participant had continued to be employed by the Corporation or one of its Affiliates during such restricted period&#59; provided, that notwithstanding any other provision of the Plan or this Statement of Terms and Conditions, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">this Section III.3(B)(ii) shall not apply to any Restricted Stock Award the vesting of which is based, in whole or in part, on attainment of performance objectives.  The procedures set forth in Section VIII.6 will be applied for any taxes due upon the lapse of restrictions imposed on a Restricted Stock Award due to a Participant&#8217;s Normal Retirement eligibility.</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(C)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt;text-decoration:underline">Termination of Employment by Reason of Severance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Notwithstanding any provision to the contrary contained in the Restricted Stock Grant Notice, if a Participant who has been in the continuous employment of the Corporation or any of its Affiliates since the Grant Date of a Restricted Stock Award ceases to be a bona fide employee of the Corporation or an Affiliate as a result of Severance, and&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.57pt">The Participant either (a) has attained the requirements for Normal Retirement on or prior to the Participant&#8217;s termination date or (b)&#160;would have attained the requirements for Normal Retirement within six months after the Participant&#8217;s termination date, then any time-vesting Restricted Stock Award shall be subject to the Normal Retirement provisions of Section&#160;III.3(B)(ii)&#59; or</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.8pt">The Participant has not attained the requirements for Normal Retirement on or prior to the Participant&#8217;s termination date, and would not have attained the requirements for Normal Retirement within six months after the Participant&#8217;s termination date, then the restrictions applicable to any time-vesting Restricted Stock Award shall lapse upon the Participant&#8217;s termination date, as to such Shares of Restricted Stock that would have vested at such time(s) as are set forth in the applicable Grant Notice as if the Participant had continued to be employed by the Corporation or one of its Affiliates during the six-month period after the Participant&#8217;s termination date.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, this Section III.3(C) shall not apply to any Restricted Stock Award the vesting of which is based, in whole or in part, on attainment of performance objectives. The procedures set forth in Section VIII.6 will be applied for any taxes due upon the lapse of restrictions imposed on a Restricted Stock Award due to a Participant&#8217;s Normal Retirement eligibility.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(D)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt;text-decoration:underline">Restriction on Sale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Administrator reserves the right to impose a restriction on the sale of Shares that the Participant receives upon the vesting and settlement of a Restricted Stock Award, unless the Participant has satisfied the ownership targets applicable to the Participant as provided in the Stock Ownership Policy.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Dividends</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Cash dividends paid with respect to Restricted Stock during the Restriction Period shall be credited on behalf of the Participant to a deferred cash account (in a manner designed to comply with Code Section 409A) and the restrictions on such cash dividends shall lapse at the same time that the restrictions lapse on the associated Restricted Stock Award.  Stock dividends paid with respect to Restricted Stock during the Restriction Period shall be treated as Restricted Stock which shall be subject to the same restrictions as the original award for the duration of the Restriction Period.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Election to Recognize Gross Income in the Year of Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  If any Participant who is a U.S. taxpayer validly elects within 30 days of the Grant Date, to include in gross income for federal income tax purposes an amount equal to the fair market value of the Shares of Restricted Stock granted on the Grant Date, such Participant shall (at the same time or prior to the date that the Participant files the Participant's election with the Internal Revenue Service) (A) pay to the Corporation, or make arrangements satisfactory to the Administrator to pay to the Corporation in the year of such grant, any federal, state or local taxes required to be withheld with respect to such Shares in accordance with Section&#160;VIII.6, and (B) provide the Administrator with a copy of the election filed with the Internal Revenue Service.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Restrictive Legend</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Each book entry in the records of the Corporation&#8217;s transfer agent evidencing Shares granted pursuant to a Restricted Stock grant may bear an appropriate legend referring to the terms, conditions and restrictions described in the Plan and&#47;or the Restricted Stock Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Expiration of Restriction Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  If and when the Restriction Period applicable to the Restricted Stock expires without a prior forfeiture, Shares shall be credited to the Participant&#8217;s brokerage account of record. If the Participant does not have a brokerage account of record, then an appropriate book entry recording the Participant&#8217;s interest in the unrestricted Shares shall be entered on the records of the Corporation&#8217;s transfer agent.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">IV.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.39pt">RESTRICTED STOCK UNITS </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Restricted Stock Unit Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Restricted Stock Units granted under the Plan shall be evidenced by a Restricted Stock Unit Agreement to be executed by the Participant and the Corporation setting forth the terms and conditions of the Restricted Stock Units.  Each Restricted Stock Unit Grant Notice shall incorporate </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">by reference and be subject to this Statement of Terms and Conditions, including the special terms and conditions in the Appendix for the Participant&#8217;s country (if any) which forms part of this Statement of Terms and Conditions, and together both documents shall constitute the Restricted Stock Unit Agreement.  The Restricted Stock Units are also subject to the terms and conditions of the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Special Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Restricted Stock Units granted under the Plan shall be subject to the following terms, conditions and restrictions and such additional terms, conditions and restrictions as may be determined by the Administrator, consistent with the terms of the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt;text-decoration:underline">Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  If a Participant ceases to be a bona fide employee of the Corporation or any Affiliate (except as otherwise provided in the Plan, or in Section IV.2(B) or Section IV.2(C)) prior to the lapse of the restrictions imposed on the Award, the unvested Restricted Stock Units shall be canceled, and all the rights of the Participant to such Awards shall immediately terminate. If a Participant is absent from work with the Corporation or an Affiliate because of the Participant's Short-Term Disability or because the Participant is on an approved leave of absence, the Participant shall not be deemed during the period of any such absence, by virtue of such absence alone, to have terminated employment with the Corporation or an Affiliate except as the Administrator may otherwise expressly determine.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt;text-decoration:underline">Termination of Employment by Reason of Death, Long-Term Disability or Normal Retirement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Notwithstanding any provision contained to the contrary in the Restricted Stock Unit Grant Notice, if a Participant who has been in the continuous employment of the Corporation or any of its Affiliates since the Grant Date of such Award ceases to be a bona fide employee of the Corporation or an Affiliate as a result of&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.57pt">Death or Long-Term Disability, then the restrictions imposed on any Award of Restricted Stock Units shall lapse on the date of such termination&#59; or</font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.8pt">Normal Retirement on or after the first anniversary of the Grant Date of any time-vesting Restricted Stock Units, the restrictions applicable to such Restricted Stock Units shall continue to lapse at such time(s) as are set forth in the applicable Grant Notice, as though the Participant had continued to be employed by the Corporation or one of its Affiliates during such restricted period.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(C)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt;text-decoration:underline">Termination of Employment by Reason of Severance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Notwithstanding any provision to the contrary contained in the Restricted Stock Unit Grant Notice, if a Participant who has been in the continuous employment of the Corporation or any of its Affiliates since the Grant Date of a Restricted Stock Unit Award ceases to be a bona fide employee of the Corporation or an Affiliate as a result of Severance, and&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.57pt">The Participant either (a) has attained the requirements for Normal Retirement on or prior to the Participant&#8217;s termination date or (b)&#160;would have attained the requirements for Normal Retirement within six months after the Participant&#8217;s termination date, then any time-vesting Restricted Stock Unit Award shall be subject to the Normal Retirement provisions of Section IV.2(B)(ii)&#59; or</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.8pt">The Participant has not attained the requirements for Normal Retirement on or prior to the Participant&#8217;s termination date, and would not have attained the requirements for Normal Retirement within six months after the Participant&#8217;s termination date, then the restrictions applicable to any time-vesting Restricted Stock Unit Award shall lapse upon the termination date, as to such Restricted Stock Units that would have vested at such time(s) as are set forth in the applicable Grant Notice as if the Participant had continued to be employed by the Corporation or one of its Affiliates during the six-month period after the termination date.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(D)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt;text-decoration:underline">Restriction on Sale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Administrator reserves the right to impose a restriction on the sale of Shares that the Participant receives upon the settlement of Restricted Stock Units, unless the Participant has satisfied the ownership targets applicable to the Participant as provided in the Stock Ownership Policy.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Dividend Equivalents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Subject to the discretion of the Compensation Committee, dividend equivalents shall be credited in respect of Restricted Stock Units. Cash dividends shall be credited on behalf of the Participant to a deferred cash account (in a manner designed to comply with Code Section 409A) and the restrictions on such cash dividends shall lapse at the same time that the restrictions lapse on the associated Award of Restricted Stock Units, and cash dividends shall be paid in a lump sum at the same time that the Shares underlying the Restricted Stock Unit Award, and to which the cash dividends relate, are distributed. Stock dividends shall be converted into additional Restricted Stock Units, which will be subject to all of the terms and conditions of the underlying Restricted Stock Units, including the same vesting restrictions as the underlying Award. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Assignability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  A Participant shall not be permitted to sell, transfer, pledge, assign or encumber Restricted Stock Units, other than pursuant to a qualified domestic relations order as defined in the Code or Title I of the U.S. Employee Retirement Income Security Act.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">No Stockholder Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Neither a Participant nor any person entitled to exercise a Participant&#8217;s rights in the event of the Participant&#8217;s death shall have any of the rights of a stockholder with respect to an Award of Restricted Stock Units except to the extent that a book entry has been entered in the records of the Corporation&#8217;s transfer agent with respect to the Shares paid upon the settlement of any vested Restricted Stock Units.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Time of Payment of Restricted Stock Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Upon the lapse of the restriction imposed on Restricted Stock Units, all Restricted Stock Units that were not forfeited pursuant to Section&#160;IV.2(A), Section IV.2(B)(i), Section IV.2(C)(i),&#160;or Section VI shall be paid to the Participant as soon as reasonably practicable after the restrictions lapse. Payment shall be made in Shares to the Participant&#8217;s brokerage account of record.  If the Participant does not have a brokerage account of record, then in the form of an appropriate book entry entered in the records of the Corporation&#8217;s transfer agent recording the Participant&#8217;s unrestricted interest in the number of Shares subject to the Restricted Stock Units.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, if a Participant becomes eligible for Normal Retirement, or is eligible for additional vesting under Section IV.2(C)(ii), prior to the date of the lapse of restrictions imposed on Restricted Stock Units and the vesting provisions of Section IV.2(B)(ii) or Section IV.2(C)(ii) apply, then such Restricted Stock Units shall be paid to the Participant&#8217;s brokerage account of record as soon as reasonably practicable after the earlier of the Participant&#8217;s Separation from Service or the originally scheduled vesting date (in any event before the end of the calendar year in which such date occurs), subject to the delay of payment (if applicable) provided in Section VIII.14. The procedures set forth in Section VIII.6 will be applied for any taxes due upon the lapse of restrictions imposed on a Restricted Stock Unit Award due to a Participant&#8217;s Normal Retirement eligibility or additional vesting as provided in Section IV.2(C)(ii).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">V.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:26.28pt">PERFORMANCE STOCK UNITS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Award Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Performance Stock Unit Awards shall be evidenced by a Performance Stock Unit Agreement to be executed by the Participant and the Corporation setting forth the terms and conditions of the Performance Stock Unit Award.  Performance Stock Unit Awards are &#8220;Performance Awards&#8221; as provided under Section 10 of the Plan.  Each Performance Stock Unit Agreement shall incorporate by reference and be subject to this Statement of Terms and Conditions, including the special terms and conditions in the Appendix for the Participant&#8217;s country (if any) which forms part of this Statement of Terms and Conditions, and together both documents shall constitute the Performance Stock Unit Agreement. Performance Stock Unit Awards are also subject to the terms and conditions of the Plan.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Number of Shares Granted Based on Performance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The performance period of a Performance Stock Unit Award shall be greater than one year, and performance shall be based on such criteria as the Compensation Committee shall determine in its discretion at the beginning of the performance period. Following the end of the performance period, the Compensation Committee shall determine the extent to which the criteria have been achieved, and shall authorize the grant and issuance of Shares in respect of the Performance Stock Unit Award.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Special Conditions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Performance Stock Unit Awards shall be subject to the following terms, conditions and restrictions and such additional terms, conditions and restrictions as may be determined by the Compensation Committee, consistent with the terms of the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt;text-decoration:underline">Forfeiture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  If a Participant ceases to be a bona fide employee of the Corporation or any Affiliate (except as otherwise provided in the Plan or in Section V.3(B) or Section V.3(C)) prior to the end of the performance period, any then-outstanding Performance Stock Units shall be canceled, and all the rights of the Participant to such Award shall immediately terminate.  If a Participant is absent from work with the Corporation or an Affiliate because of the Participant's Short-Term Disability or because the Participant is on an approved leave of absence, the Participant shall not be deemed during the period of any such absence, by virtue of such absence alone, to have terminated employment with the Corporation or an Affiliate except as the Compensation Committee may otherwise expressly determine.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt;text-decoration:underline">Termination of Employment by Reason of Death, Long-Term Disability or Normal Retirement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Notwithstanding any provision contained herein or in the Plan or the Award Agreement to the contrary, if a Participant who has been in the continuous employment of the Corporation or any of its Affiliates since the Grant Date of such Award ceases to be a bona fide employee of the Corporation or an Affiliate as a result of&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.57pt">Death or Long-Term Disability, the Participant shall be eligible to receive, following completion of the applicable performance period, a prorated portion of each such Performance Stock Unit Award, equal to (1)&#160;the target number of Performance Stock Units subject to such Award, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">multiplied by</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (2)&#160;the performance criteria determined by the Compensation Committee to apply to such Award, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">multiplied by</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (3)&#160;a fraction, the numerator of which is the number of whole calendar months, rounded down to the nearest whole month, during which the Participant provided Service to the Corporation or an Affiliate during the performance period applicable to such Award, and the denominator of which is the number of calendar months in such performance period&#59; provided, that for purposes of this clause&#160;(3), &#8220;whole calendar months&#8221; shall be calculated commencing on the applicable Grant Date&#59; provided, however, that in no event shall such amount exceed any applicable cap or limitation set forth in the Performance Stock Unit Grant Notice&#59; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.8pt">Normal Retirement on or after the first anniversary of the Grant Date, the Participant shall be eligible to vest in such Performance Stock Unit Award following completion of the applicable performance period, as though the Participant had continued to be employed by the Corporation or one of its Affiliates through the date on which the Compensation Committee determines performance against the applicable performance goals.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts, if any, to be paid under this Section V.3(B) shall be paid in accordance with Section&#160;V.7 and, if applicable, Section&#160;VIII.14.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(C)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt;text-decoration:underline">Termination of Employment by Reason of Severance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Notwithstanding any provision to the contrary, if the Participant has been in the continuous employment of the Corporation or any of its Affiliates since the Grant Date and ceases to be a bona fide employee of the Corporation or an Affiliate as a result of Severance, and&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.57pt">The Participant either (a) has attained the requirements for Normal Retirement on or prior to the Participant&#8217;s termination date or (b)&#160;would have attained the requirements for Normal Retirement within six months after the Participant&#8217;s termination date, then any Performance Stock Unit Award shall be subject to the Normal Retirement provisions of Section&#160;V.3(B)(ii)&#59; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.8pt">The Participant has not attained the requirements for Normal Retirement on or prior to the Participant&#8217;s termination date, and would not have attained the requirements for Normal Retirement within six months after the Participant&#8217;s termination date, then if such Participant&#8217;s termination date is no greater than six months prior to the date on which the Compensation Committee determines performance against the applicable performance goals, such Participant shall be eligible to vest in such Performance Stock Unit Award following completion of the applicable performance period, as though the Participant had continued to be employed by the Corporation or one of its Affiliates through such performance determination date.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts, if any, to be paid under this Section V.3(C) shall be paid in accordance with Section&#160;V.7 and, if applicable, Section&#160;VIII.14.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(D)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt;text-decoration:underline">Restriction on Sale of Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Administrator reserves the right to impose a restriction on the sale of Shares that the Participant receives with respect to the settlement of a Performance Stock Unit Award, unless the Participant has satisfied the ownership targets applicable to the Participant as provided in the Stock Ownership Policy.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Dividend Equivalents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Unless otherwise determined by the Compensation Committee in its sole discretion, Dividend Equivalents shall not be accrued with respect to Performance Stock Unit Awards during the performance period. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Assignability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  A Participant shall not be permitted to sell, transfer, pledge, assign or encumber all or any portion of a Performance Stock Unit Award.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">No Stockholder Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Neither a Participant nor any person entitled to exercise a Participant&#8217;s rights in the event of the Participant&#8217;s death shall have any of the rights of a stockholder with respect to a Performance Stock Unit Award, except to the extent that a book entry has been entered in the records of the Corporation&#8217;s transfer agent with respect to the Shares paid upon the settlement of any Performance Stock Unit Award.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Time of Payment of Performance Stock Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Compensation Committee shall determine the extent to which Shares are payable pursuant to a Performance Stock Unit Award as soon as practicable following the end of the performance period, and such Shares shall be paid as soon as practicable thereafter and in any event no later than the end of the period under which payment would be deemed to be a &#8220;short-term deferral&#8221; as defined in the regulations under Code Section 409A. Payment shall be made in the form of Shares to the Participant&#8217;s brokerage account of record. If the Participant does not have a brokerage account of record, then in the form of an appropriate book entry entered in the records of the Corporation&#8217;s transfer agent recording the Participant&#8217;s unrestricted interest in the number of Shares earned pursuant to the Performance Stock Unit Award.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">VI.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.39pt">SPECIAL FORFEITURE AND REPAYMENT RULES</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Any other provision of this Statement of Terms and Conditions to the contrary notwithstanding, if the Administrator determines that a Participant has engaged in any of the actions described in 3 below, the consequences set forth in 1 and 2 below shall result&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt">Any outstanding Option shall immediately and automatically terminate, be forfeited and shall cease to be exercisable, without limitation.  In addition, any Award of Restricted Stock or Restricted Stock Units as to which the restrictions have not lapsed shall immediately and automatically be forfeited, Performance Stock Unit Awards shall immediately and automatically be forfeited and any such Shares of Restricted Stock shall be returned to the Corporation and all of the rights of the Participant to such Awards and the underlying Shares shall immediately terminate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt">If the Participant exercised an Option within 12 months prior to the date upon which the Corporation discovered that the Participant engaged in any actions described in 3 below, the Participant, upon written notice from the Corporation, shall immediately pay to the Corporation the economic value realized or obtained by the exercise of such Option measured at the date of exercise.  In addition, if the restrictions imposed on any Award of Restricted Stock or Restricted Stock Units (including any unpaid dividends or Dividend Equivalents) lapsed, or any Performance Stock Unit Award was settled, within 12 months prior to the date the Corporation discovered that the Participant engaged in any action described in 3 below, the Participant, upon written notice from the Corporation, shall immediately pay to the Corporation the economic value realized or obtained with respect to such Award, measured at the date such Award vested. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt">The consequences described in 1 and 2 above shall apply if the Participant, either before or after termination of employment with the Corporation or its Affiliates&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">Discloses to others, or takes or uses for the Participant&#8217;s own purpose or the purpose of others, any trade secrets, confidential information, knowledge, data or know-how or any other proprietary information or intellectual property belonging to the Corporation or its Affiliates and obtained by the Participant during the term of the Participant&#8217;s employment, whether or not they are the Participant&#8217;s work product. Examples of such confidential information or trade secrets include, without limitation, customer lists, supplier lists, pricing and cost data, computer programs, delivery routes, advertising plans, wage and salary data, financial information, research and development plans, processes, equipment, product information and all other types and categories of information as to which the Participant knows or has reason to know that the Corporation or its Affiliates intends or expects secrecy to be maintained&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">Fails to promptly return all documents and other tangible items belonging to the Corporation or its Affiliates in the Participant&#8217;s possession or control, including all complete or partial copies, recordings, abstracts, notes or reproductions of any kind made from or about such documents or information contained therein, upon termination of employment, whether pursuant to retirement or otherwise&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(C)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">Fails to provide the Corporation with at least 30&#160;days&#8217; written notice prior to directly or indirectly engaging in, becoming employed by, or rendering services, advice or assistance to any business in competition with the Corporation or its Affiliates. As used herein, &#8220;business in competition&#8221; means any person, organization or enterprise which is engaged in or is about to become engaged in any line of business engaged in by the Corporation or its Affiliates at the time of the termination of the Participant&#8217;s employment with the Corporation or its Affiliates&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(D)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">Fails to inform any new employer, before accepting employment, of the terms of this paragraph and of the Participant&#8217;s continuing obligation to maintain the confidentiality of the trade secrets and other confidential information belonging to the Corporation or its Affiliates and obtained by the Participant during the term of the Participant&#8217;s employment with the Corporation or any of its Affiliates&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(E)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.24pt">Induces or attempts to induce, directly or indirectly, any of the customers of the Corporation or its Affiliates, employees, representatives or consultants to terminate, discontinue or cease working with or for the Corporation or its Affiliates, or to breach any contract with the Corporation or any of its Affiliates, in order to work with or for, or enter into a contract with, the Participant or any third party&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(F)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">Engages in conduct which is not in good faith and which disrupts, damages, impairs or interferes with the business, reputation or employees of the Corporation or its Affiliates&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(G)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">Fails to meet the Participant&#8217;s continuing obligations with respect to non-disclosure, non-competition and&#47;or non-solicitation under the Participant&#8217;s agreement with the Corporation or any Affiliate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Administrator shall determine in its sole discretion whether the Participant has engaged in any of the acts set forth in (A) through (G) above, and its determination shall be conclusive and binding on all interested persons.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Any provision of this Section&#160;VI which is determined by a court of competent jurisdiction to be invalid or unenforceable should be construed or limited in a manner that is valid and enforceable and that comes closest to the business objectives intended by such invalid or unenforceable provision, without invalidating or rendering unenforceable the remaining provisions of this Section&#160;VI.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">VII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:18.5pt">CHANGE IN CONTROL  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If as a result of a Change in Control, the Common Stock ceases to be listed for trading on a national securities exchange (an &#8220;Exchange&#8221;), any Option, Restricted Stock Award, Restricted Stock Unit Award or Performance Stock Unit Award that is unvested on the effective date of the Change in Control shall continue to vest according to the terms and conditions of such Award, provided that such Award is replaced with an award for voting securities of the resulting corporation or the acquiring corporation, as the case may be, (including without limitation, the voting securities of any corporation which as a result of the Change in Control owns the Corporation or all or substantially all of the Corporation&#8217;s assets either directly or through one or more subsidiaries) (the &#8220;Surviving Company&#8221;) which are traded on an Exchange (a &#8220;Replacement Award&#8221;), which Replacement Award, (i) in the case of an Option, shall consist of an option with the number of underlying shares and exercise price determined in a manner consistent with Code Section 424(a) with vesting and any other terms continuing in the same manner as the replaced Option&#59; (ii) in the case of a Performance Stock Unit Award, shall consist of restricted stock or restricted stock units with a value (determined using the Surviving Company&#8217;s stock price as of the effective date of the Change in Control) equal to the value of the Performance Stock Unit Award (determined using the Corporation&#8217;s stock price and assuming attainment of target performance or actual performance achieved, if greater, as of the effective date of the Change in Control), with any restrictions on such Replacement Award lapsing at the end of the measuring period over which performance for the replaced Performance Stock Unit Award was to be measured prior to the granting of the Replacement Award&#59; and (iii) in the case of a Restricted Stock Award or Restricted Stock Unit Award, shall consist of restricted stock or restricted stock units with a value (determined using the Surviving Company&#8217;s stock price as of the effective date of the Change in Control) equal to the value of the Restricted Stock Award or Restricted Stock Unit Award (determined using the Corporation&#8217;s stock price as of the effective date of the Change in Control), with any restrictions on such restricted stock or restricted stock units lapsing at the same time and manner as the replaced Award&#59; provided, however, that in the event of the Participant&#8217;s involuntary Separation from Service by the Corporation without Cause or Separation from Service by the Participant for Good Reason during the vesting period of any Replacement Award, the Replacement Award shall immediately vest and be paid as soon as practicable following such Separation from Service (subject to Section VIII.14), based on the fair market value of the underlying shares on the vesting date, or in the case of options, based on the excess of the fair market value of the underlying shares over the option exercise price on the vesting date. If any Option, Restricted Stock Award, Restricted Stock Unit Award or Performance Stock Unit Award that is unvested at the effective time of the Change in Control is not replaced with a Replacement Award, such Award shall immediately vest and, in the case of a Performance Stock Unit Award, shall vest based upon deemed attainment of target performance or actual performance achieved, if greater.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If as a result of a Change in Control, the Common Stock continues to be listed for trading on an Exchange, any unvested Option, Restricted Stock Award, or Restricted Stock Unit Award shall continue to vest according to the terms and conditions of such Award and any Performance Stock Unit Award shall be replaced with a Restricted Stock Unit Award where the number of shares subject to such Restricted Stock Unit Award shall be equal to the number of Shares assuming attainment of target performance or actual performance achieved, if greater, as of the effective date of the Change in Control with any restrictions on such Restricted Stock Unit Award lapsing at the end of the measuring period over which performance for the replaced Performance Stock Unit Award was to be measured prior to the granting of the Replacement Award&#59; provided however, that, in the event of the Participant&#8217;s involuntary Separation from Service by the Corporation without Cause or Separation from Service by the Participant </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">for Good Reason during the vesting period of an Award, such Award shall immediately vest and be paid as soon as practicable following such Separation from Service (subject to Section VIII.14).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">VIII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:14.61pt">MISCELLANEOUS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">No Effect on Terms of Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Participation in the Plan shall not create a right to further employment with the Participant&#8217;s employer (the &#8220;Employer&#8221;) and shall not interfere with the ability of the Employer to terminate, with or without cause, or change the terms of employment of a Participant at any time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Grants to Participants in Foreign Countries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  In making grants to Participants in foreign countries, the Administrator has the full discretion to deviate from this Statement of Terms and Conditions in order to adjust grants under the Plan to prevailing local conditions, including custom and legal and tax requirements.  Furthermore, the Corporation reserves the right to impose other requirements on the Participant&#8217;s participation in the Plan on the Award and on any Shares acquired under the Plan, to the extent the Corporation determines it is necessary or advisable in order to comply with local law or facilitate the administration of the Plan, and to require the Participant to sign any additional agreements or undertaking that may be necessary to accomplish the foregoing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Information Notification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Any information required to be given under the terms of an Award shall be addressed to the Corporation in care of its Corporate Secretary at McKesson Corporation, 6555 North State Highway 161, Irving, Texas 75039, and any notice to be given to a Participant shall be addressed to such Participant at the address indicated beneath the Participant's name on the Award Agreement or such other address as either party may designate in writing to the other. Any such notice shall be deemed to have been duly given when enclosed in a properly sealed envelope or wrapper addressed as aforesaid, registered or certified and deposited (postage or registration or certification fee prepaid)&#160;in a post office or branch post office. The parties may use email delivery, so long as the message is clearly marked, sent to the email address(es) set forth herein, and a delivery receipt and a read receipt are made part of the message.&#160; Email delivery will be deemed to occur when the sender receives confirmation that such message has been received and read by the recipient. Emails to the Corporation shall be delivered to CorpSecretary&#64;McKesson.com.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Administrator Decisions Conclusive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  All decisions of the Administrator administering the Plan upon any questions arising under the Plan or under an Award Agreement, shall be conclusive and binding on all interested persons.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">No Effect on Other Benefit Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Nothing herein contained shall affect a Participant&#8217;s right to participate in and receive benefits from and in accordance with the then current provisions of any pensions, insurance or other employment welfare plan or program offered by the Corporation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Regardless of any action the Corporation or the Employer takes with respect to any federal, state or local income tax, social insurance contributions, payroll tax, payment on account or other tax-related items related to the Participant&#8217;s participation in the Plan and legally applicable to the Participant (&#8220;Tax-Related Items&#8221;), the Participant acknowledges that the ultimate liability for all Tax-Related Items is and remains the Participant's responsibility and may exceed the amount actually withheld by the Corporation or the Employer. The Participant further acknowledges that the Corporation and&#47;or the Employer (1) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Award, including the grant, vesting, settlement or exercise of the Award, as applicable, the subsequent sale of Shares acquired pursuant to the Plan and the receipt of any dividends and&#47;or dividend equivalents&#59; and (2) do not commit and are under no obligation to structure the terms of the grant or any aspect of the Award to reduce or eliminate the Participant&#8217;s liability for Tax-Related Items or achieve any particular tax result. Further, if the Participant has become subject to tax in more than one jurisdiction between the Grant Date and the date of any relevant taxable event, the Participant acknowledges that the Corporation and&#47;or the Employer (or former employer, as applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior to any relevant taxable or tax withholding event, as applicable, the Participant will pay or make adequate arrangements satisfactory to the Corporation and&#47;or the Employer, or their respective agents, at their discretion, to satisfy the obligations with regard to all Tax-Related Items by one or a combination of the following&#58; (1) withholding from the Participant&#8217;s wages or other cash compensation paid to the Participant by the Corporation and&#47;or the Employer&#59; (2)&#160;withholding from proceeds of the sale of Shares acquired under the Plan either through a voluntary sale or through a mandatory sale arranged by the Corporation (on the Participant&#8217;s behalf pursuant to this authorization and any other authorization the Corporation and&#47;or the broker designated by the Corporation may require the Participant to sign in connection with the sale of Shares)&#59; (3) withholding Shares to be issued upon grant, vesting&#47;settlement or exercise, as applicable&#59; or (4) any other method of withholding determined by the Corporation and to the extent required by applicable law or the Plan, approved by the Compensation Committee. Calculation of the number of Shares to be withheld shall be made based on the closing price of the Common Stock on the New </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">York Stock Exchange on the date that the amount of tax to be withheld is determined.  In no event, however, shall the Corporation be required to issue fractional Shares.  With respect to an Award other than an Option, if adequate arrangements to satisfy the obligations with regard to all Tax-Related Items are not made by the Participant with the Corporation and&#47;or the Employer prior to the relevant taxable event, the Corporation will satisfy such obligations as provided above in clause (3) of this paragraph.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Corporation or the Employer may withhold or account for Tax-Related Items by considering applicable minimum statutory withholding amounts or other applicable withholding rates, including maximum applicable rates in the Participant&#8217;s jurisdictions(s). If the obligation for Tax-Related Items is satisfied by withholding in Shares, for tax purposes, the Participant will be deemed to have been issued the full number of Shares subject to the Award, notwithstanding that a number of the Shares are held back solely for the purpose of paying the Tax-Related Items due as a result of any aspect of the Participant&#8217;s participation in the Plan. In the event any excess amounts are withheld to satisfy the obligation for Tax-Related Items, the Participant may be entitled to receive a refund of any over-withheld amount (with no entitlement to the Share equivalent), or if not refunded by the Corporation or the Employer, the Participant must seek a refund from the local tax authorities to the extent the Participant wishes to recover the over-withheld amount in the form of a refund. In the event of under-withholding, the Participant may be required to pay any additional Tax-Related Items directly to the applicable tax authority or to the Corporation and&#47;or the Employer.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finally, the Participant shall pay to the Corporation or the Employer any amount of Tax-Related Items that the Corporation or the Employer may be required to withhold or account for as a result of the Participant&#8217;s participation in the Plan that cannot be satisfied by the means previously described. The Corporation may refuse to issue or deliver the Shares or the proceeds of the sale of Shares if the Participant fails to comply with the Participant's obligations in connection with the Tax-Related Items.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Administrator shall be authorized to establish such rules, forms and procedures as it deems necessary to implement the foregoing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Successors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Award Agreements shall be binding upon and inure to the benefit of any successor or successors of the Corporation. &#8220;Participant&#8221; as used herein shall include the Participant&#8217;s Beneficiary.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Delaware Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The interpretation, performance, and enforcement of all Award Agreements shall be governed by the laws of the State of Delaware.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Nature of Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  In accepting the grant, the Participant acknowledges that&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">the Plan is established voluntarily by the Corporation, it is discretionary in nature and it may be modified, amended, suspended or terminated by the Corporation at any time&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">the grant of the Award is exceptional, voluntary and occasional and does not create any contractual or other right to receive future Award grants, or benefits in lieu of Awards, even if Awards have been granted repeatedly in the past&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(C)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">all decisions with respect to future Awards, if any, will be at the sole discretion of the Corporation&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(D)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">the Participant is voluntarily participating in the Plan&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(E)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.24pt">the Award and the Shares subject to the Award, and the income from and value of same, are not part of normal or expected compensation for any purpose, including, but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, long-service awards, pension or retirement benefits or similar payments&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(F)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the Award will not be interpreted to form an employment contract or relationship with the Corporation&#59; and furthermore, the Award will not be interpreted to form an employment contract with any subsidiary or Affiliate of the Corporation&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(G)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">the future value of the underlying Shares is unknown, indeterminable and cannot be predicted with certainty&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(H)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">if the underlying Shares do not increase in value, the Options will have no value&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.01pt">in consideration of the grant of the Award, no claim or entitlement to compensation or damages shall arise from forfeiture of the Award which results from termination of the Participant&#8217;s employment with the Employer or the Corporation or one of its Affiliates (for any reason whatsoever, and whether or not such forfeiture is later found to be invalid or in breach of employment laws in the jurisdiction where the Participant is employed or the terms of the Participant&#8217;s employment agreement, if any) and the Participant irrevocably releases the Corporation or its Affiliates from any such claim that may arise&#59; provided that, notwithstanding the foregoing, in the event any such claim is found by a court of competent jurisdiction to have arisen, then, by accepting the Award, the Participant shall be deemed irrevocably to have waived the Participant's entitlement to pursue such claim&#59;  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(J)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:25.45pt">for purposes of an Award, the Participant&#8217;s employment relationship will be considered terminated as of the date the Participant is no longer a bona fide employee of the Corporation, the Employer or one of the Corporation&#8217;s other Affiliates (regardless of the reason for such termination and whether or not later found to be invalid or in breach of the employment laws in the jurisdiction where the Participant is employed or the terms of the Participant&#8217;s employment agreement, if any), and unless otherwise expressly provided in this Award Agreement or determined by the Corporation in its sole discretion, the Participant&#8217;s right to receive Awards and vest in Awards under the Plan, if any, will terminate effective as of such date and will not be extended by any notice period mandated under local law (for example, the Participant&#8217;s period of service would not include any contractual notice period or any period of &#8220;garden leave&#8221; or similar period mandated under employment laws in the jurisdiction where the Participant is employed or the terms of the Participant&#8217;s employment agreement, if any)&#59; similarly, any right to exercise Options under the Plan after termination of employment will be measured as of the date the Participant is no longer a bona fide employee of the Corporation, the Employer or one of the Corporation&#8217;s other Affiliates and will not be extended by any notice period mandated under local law&#59; the Administrator shall have the sole discretion to determine when the Participant is no longer a bona fide employee for purposes of an Award (including whether the Participant may still be considered to be providing services while on a leave of absence)&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(K)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">the Corporation is not providing any tax, legal or financial advice, nor is the Corporation making any recommendations regarding participation in the Plan or the Participant&#8217;s acquisition or sale of Shares&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(L)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.24pt">the Participant is hereby advised to consult with the Participant's own personal tax, legal and financial advisors regarding Participant&#8217;s participation in the Plan before taking any action related to the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:23.5pt;text-decoration:underline">Data Privacy Information and Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:22.12pt">Data Collection and Usage.  The Corporation and the Employer may collect, process and use certain personal information about the Participant, including, but not limited to, the Participant&#8217;s name, home address and telephone number, email address, date of birth, social insurance number, passport or other identification number, salary, nationality, job title, any Shares or directorships held in the Corporation, details of all Options, Restricted Stock, Restricted Stock Units, Performance Stock Units, Other Share-Based Awards, or any other entitlement to Shares awarded, canceled, exercised, vested, unvested or outstanding in the Employee&#8217;s favor (&#8220;Data&#8221;), for the purposes of implementing, administering and managing the Plan. The legal basis, where required, for the processing of Data is the Participant&#8217;s consent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:22.68pt">Stock Plan Administration Service Providers.  The Corporation transfers Data to Fidelity Stock Plan Services LLC and its affiliated companies, an independent service provider based in the United States, which is assisting the Corporation with the implementation, administration and management of the Plan. The Corporation may select a different service provider or additional service providers and share Data with such other provider serving in a similar manner. The Participant may be asked to agree on separate terms and data processing practices with the service provider, with such agreement being a condition to the ability to participate in the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(C)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:22.68pt">International Data Transfers.  The Corporation and its service providers are based in the United States.  The Participant&#8217;s country or jurisdiction may have different data privacy laws and protections than the United States. The Corporation&#8217;s legal basis, where required, for the transfer of Data is</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">the Participant&#8217;s consent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(D)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:22.12pt">Data Retention.  The Corporation will hold and use the Data only as long as is necessary to implement, administer and manage the Participant&#8217;s participation in the Plan, or as required to comply with legal or regulatory obligations, including under tax and security laws.  In the latter case, the Participant understands and acknowledges that the Corporation&#8217;s legal basis for the processing of the Participant&#8217;s Data would be compliance with the relevant laws or regulations or the pursuit by the Corporation of respective legitimate interests not outweighed by the Participant&#8217;s interests, rights or freedoms.  When the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Corporation no longer needs the Participant&#8217;s Data for any of the above purposes, the Participant understands the Corporation will remove it from its systems.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(E)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:23.24pt">Voluntariness and Consequences of Consent Denial or Withdrawal.  Participation in the Plan is voluntary and the Participant is providing the consents herein on a purely voluntary basis.  If the Participant does not consent, or if the Participant later seeks to revoke the Participant&#8217;s consent, the Participant&#8217;s salary from or employment with the Employer will not be affected&#59; the only consequence of refusing or withdrawing the Participant&#8217;s consent is that the Corporation would not be able to grant Awards to the Participant or administer or maintain such Awards.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(F)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:23.78pt">Data Subject Rights.  The Participant may have a number of rights under data privacy laws in the Participant&#8217;s jurisdiction.  Depending on where the Participant is based, such rights may include the right to (i) inquire whether and what kind of Data the Corporation holds about the Participant and how it is processed, and to request access or copies of Data the Corporation processes, (ii) request the correction or supplementation of Data about the Participant that is inaccurate, incomplete or out-of-date in light of the purposes underlying the processing, (iii) obtain the erasure of Data no longer necessary for the purposes underlying the processing, processed based on withdrawn consent, processed for legitimate interests that, in the context of the Participant&#8217;s objection, do not prove to be compelling, or processed in non-compliance with applicable legal requirements, (iv) request restrictions on processing of Data in certain situations where the Participant feels its processing is inappropriate, (v) request portability of the Participant&#8217;s Data that the Participant has actively or passively provided to the Corporation (which does not include data derived or inferred from the collected data), where the processing of such Data is based on consent or the Participant&#8217;s employment and is carried out by automated means, (vi) object, in certain circumstances, to the processing of Data for legitimate interests, (vii) lodge complaints with competent authorities in the Participant&#8217;s jurisdiction, and&#47;or (viii) receive a list with the names and addresses of any potential recipients of Data.  To receive clarification regarding these rights or to exercise these rights, the Participant can contact his or her local human resources representative.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">By accepting the Award and indicating consent via the Corporation&#8217;s acceptance procedure, the Participant is declaring that he or she agrees with the data processing practices described herein and consents to the collection, processing and use of Data by the Corporation and the transfer of Data to the recipients mentioned above, including recipients located in countries which do not adduce an adequate level of protection from a European (or other non-U.S.) data protection law perspective, for the purposes described above.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.5pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The provisions in this Statement of Terms and Conditions are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.5pt;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Participant acknowledges that the Participant is proficient in the English language, or has consulted with an advisor who is sufficiently proficient in the English language, and, accordingly, understands the provisions of the Plan and this Statement of Terms and Conditions. If the Participant has received this Statement of Terms and Conditions or any other document related to the Plan translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control unless otherwise required by local law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.5pt;text-decoration:underline">Electronic Delivery</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Corporation may, in its sole discretion, decide to deliver any documents related to current or future participation in the Plan by electronic means. The Participant hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by the Corporation or a third party designated by the Corporation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.5pt;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  If (A) the Participant is a Specified Employee at the time of the Participant&#8217;s Separation from Service, and (B) some or any portion of the amounts payable to the Participant, if any, when considered together with any other payments or benefits which may be considered deferred compensation under section 409A of the Internal Revenue Code of 1986, as amended (&#8220;Section 409A&#8221;) and subject to the plan aggregation rules under Treasury Regulation section 1.409A-1(c)(3)(viii) (together, the &#8220;Deferred Compensation Benefits&#8221;) would result in the imposition of additional tax under Section 409A if paid to the Participant on or within the six month period following the Separation from Service, then to the extent such portion of the Deferred Compensation Benefits resulting in the imposition of additional tax would otherwise have been payable on or within the first six months following the Separation from Service, it will instead become payable on the first payroll date that occurs in the seventh month following the Separation from Service (or such longer period as is required to avoid the imposition of additional tax under Section 409A). All subsequent Deferred Compensation Separation Benefits, if any, will be payable in accordance with the payment schedule applicable to each payment or benefit.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">IX.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.39pt">DEFINITIONS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">When capitalized in this Statement of Terms and Conditions, the following terms shall have the meaning set forth below&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Award Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means an agreement between the Participant and the Corporation evidencing the grant of an Option, Restricted Stock Award, Restricted Stock Unit Award, Performance Stock Unit Award or Other Share-Based Award, as applicable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means termination of the Participant&#8217;s employment with the Corporation or an Affiliate upon the Participant&#8217;s negligent or willful engagement in misconduct which, in the sole determination of the Chief Executive Officer of the Corporation (or the Chief Executive Officer&#8217;s designee), is injurious to the Corporation, its employees, or its customers.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Early Retirement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means a termination of employment (other than due to death, Long-Term Disability or for Cause) which occurs prior to Normal Retirement but on or after the date on which the Participant&#8217;s age (expressed in terms of years and completed months) plus service with the Corporation or an Affiliate equals 65. For purposes of determining eligibility for Early Retirement, the term &#8220;service&#8221; shall include years and completed whole months of service.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Family Member</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any person identified as an &#8220;immediate family&#8221; member in Rule 16(a)-1(e) of the Exchange Act, as such Rule may be amended from time to time.  Notwithstanding the foregoing, the Administrator may designate any other person(s)&#160;or entity(ies) as a &#8220;family member.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any of the following actions, if taken without the express written consent of the Participant&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(A)&#160;&#160;&#160;&#160;Any material change by the Corporation in the Participant&#8217;s functions, duties, or responsibilities, which change would cause the Participant&#8217;s position with the Corporation to become of less dignity, responsibility, importance, or scope from the position and attributes that applied to the Participant immediately prior to the Change in Control&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(B)&#160;&#160;&#160;&#160;Any significant reduction in the Participant&#8217;s aggregate base annual salary and target incentive opportunity, as in effect immediately prior to the Change in Control&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(C)&#160;&#160;&#160;&#160;Any material failure by the Corporation to comply with any of the provisions of an Award subsequent to a Change in Control&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(D)&#160;&#160;&#160;&#160;The Corporation&#8217;s requiring the Participant to be based at any location which would increase the Participant&#8217;s regular one-way commute by more than 25 miles from that in effect immediately preceding the Change in Control, except for travel reasonably required in the performance of the Participant&#8217;s responsibilities&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(E)&#160;&#160;&#160;&#160;Any change in the person to whom the Participant reports, as this relationship existed immediately prior to a Change in Control&#59;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provided that the Participant gives notice to the Corporation of the existence of the Good Reason condition within 30 days of the initial existence of the Good Reason condition and the Corporation is provided 30 days after receipt of the Participant&#8217;s notice to remedy the Good Reason condition&#59; provided further that the Participant&#8217;s Separation from Service must occur within six months from the initial existence of the Good Reason condition if the Corporation does not remedy such condition for such separation to be considered to be for Good Reason.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Expiration Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the date that an Option expires as set forth in the Option Grant Notice as the &#8220;Expiration Date.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Grant Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the date the Administrator grants the Award.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Grant Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the notice of an Award granted to the Participant, which sets forth certain terms of such Award.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Long-Term Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means a physical or mental condition in respect of which the administrator of the Corporation&#8217;s long-term disability plan has determined that the Participant is eligible to receive income replacement benefits&#59; or, if the Participant is not then a participant in the Corporation&#8217;s long-term disability plan, a physical or mental condition that the administrator of the Corporation&#8217;s long-term disability plan determines would have rendered the Participant eligible to receive income replacement benefits, had the Participant been enrolled in such plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Normal Retirement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means termination of employment (other than due to death, Long-Term Disability or for Cause) at or after age 60 with at least 10 years of service with the Corporation or an Affiliate. For purposes of determining eligibility for Normal Retirement, &#8220;service&#8221; shall mean completed whole years of service (12 consecutive months).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Option Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the period commencing on the Grant Date of an Option and, except at otherwise provided in Section&#160;II.5, ending on the Expiration Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Separation from Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means termination of employment with the Corporation or an affiliate. A Participant shall be deemed to have had a Separation from Service if the Participant&#8217;s service with the Corporation or an affiliate is reduced to an annual rate that is equal to or less than 20% of the services rendered, on average, during the immediately preceding three years of service with the Corporation or an affiliate (or, if providing service to the Corporation or an affiliate for less than three years, such lesser period).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Severance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means termination of employment with the Corporation or an Affiliate, and qualified for participation in and entitlement to benefits under the McKesson Corporation Severance Pay Plan or the McKesson Corporation Severance Policy for Executive Employees, as applicable, in accordance with the terms and conditions of such plans. A Participant outside the United States who is not qualified for participation in and entitlement to the benefits under such plans will nonetheless be treated for the limited purposes of his or her Awards, and subject to the provisions of Section VIII.9 of this Statement of Terms and Conditions, as terminated by reason of Severance to the extent his or her employment with the Corporation or an Affiliate is terminated and he or she would satisfy the conditions for termination for reason of Severance but for the fact that such plan is only applicable to employees of the Corporation or an Affiliate in the United States who qualify for participation in that plan. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.&#160;&#160;&#160;&#160; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Short-Term Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means short-term disability as defined in the Corporation&#8217;s short-term disability plan. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Specified Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means those employees identified by the Corporation as &#34;Specified Employees&#34; for purposes of Code Section 409A.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Stock Ownership Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the Corporation&#8217;s Stock Ownership Policy, as amended from time to time, which can be found on McKNet. A Participant or a Participant&#8217;s beneficiary may also request a copy of the Stock Ownership Policy by writing to the Corporate Secretary at McKesson Corporation, 6555 North State Highway 161, Irving, Texas 75039 or emailing CorpSecretary&#64;McKesson.com.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16</font></div><div><font><br></font></div></div></div><div id="i9909940b100446f4adf3c825eaf11602_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EMPLOYEES SUBJECT TO STOCK OWNERSHIP POLICY</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">McKESSON CORPORATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">STATEMENT OF TERMS AND CONDITIONS APPLICABLE TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OPTIONS, RESTRICTED STOCK, RESTRICTED STOCK UNITS</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AND PERFORMANCE STOCK UNITS GRANTED TO EMPLOYEES SUBJECT TO STOCK OWNERSHIP POLICY PURSUANT TO THE 2022 STOCK PLAN</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For Grants beginning May 23, 2023</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">I.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:29.61pt">INTRODUCTION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following terms and conditions shall apply to an Award granted under the Plan and are subject to the terms and conditions of the Plan. This Statement of Terms and Conditions is intended to meet the requirements of Code Section&#160;409A and any rules promulgated thereunder.  In the event of any inconsistency between this Statement of Terms and Conditions and the Plan, the Plan shall govern. Capitalized terms not otherwise defined in this Statement of Terms and Conditions shall have the meaning set forth in the Plan.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">II.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:25.72pt">OPTIONS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Option Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  An Option granted under the Plan shall be evidenced by an Option Agreement setting forth the terms and conditions of the Option, including whether the Option is an Incentive Stock Option or a Nonstatutory Stock Option and the number of Shares subject to the Option. Each Option Grant Notice shall incorporate by reference and be subject to this Statement of Terms and Conditions, including the special terms and conditions in the Appendix for the Participant&#8217;s country (if any) which forms part of this Statement of Terms and Conditions, and together both documents shall constitute the Option Agreement. The Option is also subject to the terms and conditions of the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Exercise Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Exercise Price of an Option, as specified in the Option Agreement, shall be equal to or greater than the Fair Market Value of the Shares underlying the Option on the Grant Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Option Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  An Option shall be exercisable only during the applicable Option Period, and during such Option Period the exercisability of the Option shall be subject to the vesting provisions of Section&#160;II.4 as modified by the rules set forth in Sections&#160;II.5 and VI. The Option Period shall be not more than seven years from the Grant Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Vesting of Right to Exercise Options</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">Subject to Sections&#160;II.5 and VI, an Option shall be exercisable during the Option Period in accordance with the vesting terms and conditions established on the Grant Date and specified in the Option Grant Notice.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">Any vested portion of an Option not exercised hereunder shall accumulate and be exercisable at any time on or before the Expiration Date, subject to the rules set forth in Sections&#160;II.5 and VI. No Option may be exercised for less than 5% of the total number of Shares then available for exercise under such Option.  In no event shall the Corporation be required to issue fractional Shares.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Limits on Option Period and Acceleration of Vesting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Option Period may end before the Expiration Date, and in certain circumstances the vesting schedule of an Option may be accelerated (subject to the provisions of Section&#160;VI), as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">If a Participant ceases to be a bona fide employee of the Corporation or of its Affiliates during the Option Period for reasons other than for Cause, Long-Term Disability, Normal Retirement, Early Retirement, Severance under the circumstances provided in Section II.5(F)(ii), or death, the Option Period shall end on the earlier of (i)&#160;90 days after the date of the Participant&#8217;s termination of employment and (ii)&#160;the Expiration Date, and in all cases the Option shall be exercisable only to the extent that it was exercisable at the time of such termination of employment. If a Participant is absent from work with the Corporation or an Affiliate because of the Participant's Short-Term Disability or because the Participant is on an approved leave of absence, the Participant shall not be deemed during the period of any such absence, by virtue of such absence alone, to have terminated employment with the Corporation or an Affiliate except as the Administrator may otherwise expressly determine.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2022 Stock Plan STC (Emp Subj to SOP)</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">Notwithstanding any other provision in this Section II.5, if a Participant&#8217;s employment is terminated for Cause during the Option Period, the Option Period shall end on the date of such termination of employment and the Option shall thereupon not be exercisable to any extent whatsoever.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(C)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">If a Participant ceases to be a bona fide employee of the Corporation or of its Affiliates during the Option Period by reason of Long-Term Disability, the vesting schedule of the Participant&#8217;s Option shall be accelerated, the Option shall become fully exercisable and the Option Period shall end on the earlier of (i) three years after the date of the Participant&#8217;s termination of employment and (ii) the Expiration Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(D)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">If a Participant ceases to be a bona fide employee of the Corporation or of its Affiliates during the Option Period by reason of Early Retirement, (i)&#160;the Option shall be exercisable only to the extent that it was exercisable at the time of such retirement and (ii)&#160;the Option Period for that portion of the Option designated as a Nonstatutory Stock Option shall end on the earlier of (a) three years after the date of such retirement and (b) the Expiration Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(E)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.24pt">If a Participant ceases to be a bona fide employee of the Corporation or of its Affiliates during the Option Period by reason of Normal Retirement&#58; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.57pt">If such Normal Retirement occurs prior to the first anniversary of the Grant Date of the Option, such Option shall be subject to the provisions of Section II.5(D) as though the Participant were eligible for Early Retirement&#59; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.8pt">If such Normal Retirement occurs on or after the first anniversary of the Grant Date of an Option, (a)&#160;that portion of the Option designated as a Nonstatutory Stock Option shall continue to vest as though the Participant had continued to be employed by the Corporation or one of its Affiliates during such vesting period, and (b)&#160;the Option Period for such portion of the Option designated as a Nonstatutory Stock Option shall end on the Expiration Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(F)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">If a Participant ceases to be a bona fide employee of the Corporation or of its Affiliates during the Option Period by reason of Severance, and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.57pt">The Participant has attained the requirements for Normal Retirement on or prior to the Participant&#8217;s termination date, then such Option shall be subject to the Normal Retirement provisions of Section II.5(E)&#59; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.8pt">The Participant has not attained the requirements for Normal Retirement on or prior to the Participant&#8217;s termination date, but would have attained the requirements for Normal Retirement within six months after the termination date, and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:121.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:11.21pt">The first anniversary of the Grant Date of the applicable Award has not occurred on or prior to the termination date, then such Option shall be subject to the Early Retirement provision in Section II.5(D)&#59; or</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:121.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.64pt">The first anniversary of the Grant Date of the applicable Award has occurred on or prior to the termination date, then (x) that portion of the Option designated as a Nonstatutory Stock Option shall continue to vest as though the Participant had continued to be employed by the Corporation or one of its Affiliates during such vesting period, and (y) the Option Period for such portion of the Option designated as a Nonstatutory Stock Option shall end on the Expiration Date&#59; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:21.03pt">The Participant has not attained the requirements for Normal Retirement on or prior to the Participant&#8217;s termination date, and would not have attained the requirements for Normal Retirement within six months after the termination date, then (a) the vesting schedule of the Participant&#8217;s Option shall be accelerated as to the portion of the Option that would have vested in accordance with the original vesting schedule as though the Participant had continued to be employed by the Corporation or one of its Affiliates six months after the termination date, and (b) the expiration of the Option Period provided in Section II.5(A) shall apply&#59; provided that if the Participant is also eligible for Early Retirement at the time of the termination of employment, then the expiration of the Option Period provided in Section II.5(D) shall apply.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(G)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">If a Participant should die (i) while in the employ of the Corporation or an Affiliate and (ii) during the Option Period, the vesting schedule of the Participant&#8217;s Option shall be accelerated and the Option shall become fully exercisable, the Option Period shall end on the earlier of (a) three years after the date of death and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) the Expiration Date, and the Participant&#8217;s Beneficiary may exercise the entire unexercised portion of the then exercisable Shares covered by such Option (or any lesser amount)&#160;remaining on the date of death.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(H)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">If a Participant who ceases to be a bona fide employee of the Corporation or an Affiliate is subsequently rehired prior to the expiration of the Participant's Option, then the Option shall continue to remain outstanding until the earlier of (i) such time as the Participant subsequently terminates employment and (ii) the Expiration Date. Upon the Participant&#8217;s subsequent termination of employment, the post-termination exercise period calculated pursuant to the terms and conditions of this Section II.5 shall be reduced by the number of days between the date of the Participant&#8217;s initial termination of employment and the Participant's re-hire date&#59; provided, however, that if the rehired Participant continues to be employed by the Corporation or an Affiliate for at least one year from the Participant's rehire date, then the post termination exercise period for the Option shall be determined in accordance with Sections II.5(A) through (G) and shall not be adjusted as described in this Section II.5(H).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Method of Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  A Participant may exercise an Option with respect to all or any part of the exercisable Shares as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">By giving the Corporation, or its authorized representative designated for this purpose, written notice of such exercise specifying the number of Shares as to which the Option is so exercised.  Such notice shall be accompanied by an amount equal to the Exercise Price multiplied by the number of Shares exercised, in the form of any one or combination of the following&#58;&#160;&#160;cash or a certified check, bank draft, postal or express money order payable to the order of the Corporation in lawful money of the United States. Unless otherwise determined by the Administrator in its sole discretion, the Participant may pay the Exercise Price, in whole or in part, by tendering to the Corporation or its authorized representative Shares, which have been owned by the Participant for at least six months prior to said tender, and having a fair market value, as determined by the Corporation, equal to the Exercise Price, or in lieu of the delivery of actual Shares in such tender, the Corporation may accept an attestation by the Participant, in a form prescribed by the Corporation or its authorized representative, that the Participant owns sufficient Shares of record or in an account in street name to satisfy the Exercise Price, and such attestation will be deemed a tender of Shares for purposes of this method of exercise. The Corporation or its authorized representative may accept payment of the amount due upon the exercise of the Option in the form of a Participant&#8217;s personal check. Payment may also be made by delivery (including by FAX transmission)&#160;to the Corporation or its authorized representative of an executed irrevocable Option exercise form together with irrevocable instructions to an approved registered investment broker to sell Shares in an amount sufficient to pay the Exercise Price plus any applicable Tax-Related Items (as defined in Section VIII.6) and to transfer the proceeds of such sale to the Corporation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">If required by the Corporation, by giving satisfactory assurance in writing, signed by the Participant, the Participant shall give the Participant's assurance that the Shares subject to the Option are being purchased for investment and not with a view to the distribution thereof&#59; provided that such assurance shall be deemed inapplicable to (i)&#160;any sale of the Shares by such Participant made in accordance with the terms of a registration statement covering such sale, which has heretofore been (or may hereafter be)&#160;filed and become effective under the U.S. Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;)&#160;and with respect to which no stop order suspending the effectiveness thereof has been issued, and (ii)&#160;any other sale of the Shares with respect to which, in the opinion of counsel for the Corporation, such assurance is not required to be given in order to comply with the provisions of the Securities Act.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(C)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">As soon as practicable after receipt of the notice and the assurance described in Sections&#160;II.6(A)&#160;and (B), the Corporation shall, without transfer or issue tax (except for withholding tax arrangements contemplated in Section&#160;VIII.6)&#160;and without other incidental expense to the Participant, credit the purchased Shares to the Participant&#8217;s brokerage account of record.  If the Participant does not have a brokerage account of record, then the Corporation shall cause an appropriate book entry to be entered in the records of the Corporation&#8217;s transfer agent recording the Participant&#8217;s unrestricted interest in the purchased Shares&#59; provided, however, that the time of such delivery may be postponed by the Corporation for such period as may be required for it with reasonable diligence to comply with applicable registration requirements under the Securities Act, the Exchange Act, any applicable listing requirements of any national securities exchange and requirements under any other law or regulation applicable to the issuance or transfer of the Shares.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Limitations on Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  An Option shall, during a Participant&#8217;s lifetime, be exercisable only by the Participant.  No Option or any right granted thereunder shall be transferable by the Participant by operation of law or otherwise, other than by will or the laws of descent and distribution. Notwithstanding the foregoing&#58; (A)&#160;unless otherwise determined by the Administrator in its sole discretion, a Participant may designate a beneficiary to succeed, after the Participant&#8217;s death, to all of the Participant&#8217;s Options outstanding on the date of death&#59; (B)&#160;a Nonstatutory Stock Option may be transferable pursuant to a qualified domestic relations order as defined in the Code or Title I of the U.S. Employee Retirement Income Security Act&#59; and (C)&#160;any Participant, who is a senior executive officer recommended by the Chief Executive Officer of the Corporation and approved by the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Administrator may voluntarily transfer any Nonstatutory Stock Option to a Family Member as a gift or through a transfer to an entity in which more than 50% of the voting interests are owned by Family Members (or the Participant)&#160;in exchange for an interest in that entity.  In the event of any attempt by a Participant to alienate, assign, pledge, hypothecate, or otherwise dispose of an Option or of any right thereunder, except as provided herein, or in the event of the levy of any attachment, execution, or similar process upon the rights or interest hereby conferred, the Corporation at its election may terminate the affected Option by notice to the Participant and the Option shall thereupon become null and void.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">No Stockholder Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Neither a Participant nor any person entitled to exercise a Participant&#8217;s rights in the event of the Participant&#8217;s death shall have any of the rights of a stockholder with respect to the Shares subject to an Option except to the extent that a book entry has been entered in the records of the Corporation&#8217;s transfer agent with respect to such Shares upon the exercise of an Option.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">III.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:21.83pt">RESTRICTED STOCK</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Restricted Stock Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  A Restricted Stock Award granted under the Plan shall be evidenced by a Restricted Stock Agreement to be executed by the Participant and the Corporation setting forth the terms and conditions of the Restricted Stock Award. Each Restricted Stock Grant Notice shall incorporate by reference and be subject to this Statement of Terms and Conditions, including the special terms and conditions in the Appendix for the Participant&#8217;s country (if any) which forms part of this Statement of Terms and Conditions, and together both documents shall constitute the Restricted Stock Agreement. The Restricted Stock Award is also subject to the terms and conditions of the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Rights with Respect to Shares of Restricted Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Upon written acceptance of a Restricted Stock Award by a Participant, including the restrictions and other terms and conditions described in the Plan and the Restricted Stock Agreement, the Corporation shall cause an appropriate book entry to be entered in the records of the Corporation&#8217;s transfer agent recording the Participant&#8217;s interest in the Restricted Stock. From and after the Grant Date, the Participant shall have the rights of Common Stock ownership, including the right to vote and to receive dividends on Shares of Restricted Stock, subject to the terms, conditions and restrictions described in the Plan and the Restricted Stock Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Special Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Each Restricted Stock Award made under the Plan shall be subject to the following terms, conditions and restrictions and such additional terms, conditions and restrictions as may be determined by the Administrator&#59; provided, however, that no Restricted Stock grant shall be subject to additional terms, conditions and restrictions which are more favorable to a Participant than the terms, conditions and restrictions set forth elsewhere in the Plan or the Restricted Stock Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt;text-decoration:underline">Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Until the restrictions imposed on any Restricted Stock grant shall lapse (the &#8220;Restriction Period&#8221;), Shares of Restricted Stock granted to a Participant&#160;(i)&#160;shall not be sold, assigned, transferred, pledged, hypothecated, or otherwise disposed of, other than pursuant to a qualified domestic relations order as defined in the Code or Title I of the U.S. Employee Retirement Income Security Act and (ii)&#160;shall, if the Participant&#8217;s continuous employment with the Corporation or any of its Affiliates shall terminate for any reason (except as otherwise provided in the Plan, or in Section&#160;III.3(B) or Section III.3(C))&#160;be returned to the Corporation forthwith, and all the rights of the Participant to such Shares shall immediately terminate. If a Participant is absent from work with the Corporation or an Affiliate because of the Participant's Short-Term Disability or because the Participant is on an approved leave of absence, the Participant shall not be deemed during the period of any such absence, by virtue of such absence alone, to have terminated employment with the Corporation or an Affiliate except as the Administrator may otherwise expressly determine.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt;text-decoration:underline">Termination of Employment by Reason of Death, Long-Term Disability or Normal Retirement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Notwithstanding any provision to the contrary contained in the Restricted Stock Grant Notice, if a Participant who has been in the continuous employment of the Corporation or any of its Affiliates since the Grant Date of a Restricted Stock Award ceases to be a bona fide employee of the Corporation or an Affiliate as a result of&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.57pt">Death or Long-Term Disability, then the restrictions imposed on any Restricted Stock Award shall lapse as to all Shares granted to such Participant pursuant to such Restricted Stock Award on the date of such termination&#59; or </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.8pt">Normal Retirement on or after the first anniversary of the Grant Date of any time-vesting Restricted Stock Award, the restrictions applicable to such Restricted Stock Award shall continue to lapse at such time(s) as are set forth in the applicable Grant Notice, as though the Participant had continued to be employed by the Corporation or one of its Affiliates during such restricted period&#59; provided, that notwithstanding any other provision of the Plan or this Statement of Terms and Conditions, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">this Section III.3(B)(ii) shall not apply to any Restricted Stock Award the vesting of which is based, in whole or in part, on attainment of performance objectives.  The procedures set forth in Section VIII.6 will be applied for any taxes due upon the lapse of restrictions imposed on a Restricted Stock Award due to a Participant&#8217;s Normal Retirement eligibility.</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(C)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt;text-decoration:underline">Termination of Employment by Reason of Severance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Notwithstanding any provision to the contrary contained in the Restricted Stock Grant Notice, if a Participant who has been in the continuous employment of the Corporation or any of its Affiliates since the Grant Date of a Restricted Stock Award ceases to be a bona fide employee of the Corporation or an Affiliate as a result of Severance, and&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.57pt">The Participant either (a) has attained the requirements for Normal Retirement on or prior to the Participant&#8217;s termination date or (b)&#160;would have attained the requirements for Normal Retirement within six months after the Participant&#8217;s termination date, then any time-vesting Restricted Stock Award shall be subject to the Normal Retirement provisions of Section&#160;III.3(B)(ii)&#59; or</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.8pt">The Participant has not attained the requirements for Normal Retirement on or prior to the Participant&#8217;s termination date, and would not have attained the requirements for Normal Retirement within six months after the Participant&#8217;s termination date, then the restrictions applicable to any time-vesting Restricted Stock Award shall lapse upon the Participant&#8217;s termination date, as to such Shares of Restricted Stock that would have vested at such time(s) as are set forth in the applicable Grant Notice as if the Participant had continued to be employed by the Corporation or one of its Affiliates during the six-month period after the Participant&#8217;s termination date.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, this Section III.3(C) shall not apply to any Restricted Stock Award the vesting of which is based, in whole or in part, on attainment of performance objectives. The procedures set forth in Section VIII.6 will be applied for any taxes due upon the lapse of restrictions imposed on a Restricted Stock Award due to a Participant&#8217;s Normal Retirement eligibility.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(D)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt;text-decoration:underline">Restriction on Sale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Administrator reserves the right to impose a restriction on the sale of Shares that the Participant receives upon the vesting and settlement of a Restricted Stock Award, unless the Participant has satisfied the ownership targets applicable to the Participant as provided in the Stock Ownership Policy.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Dividends</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Cash dividends paid with respect to Restricted Stock during the Restriction Period shall be credited on behalf of the Participant to a deferred cash account (in a manner designed to comply with Code Section 409A) and the restrictions on such cash dividends shall lapse at the same time that the restrictions lapse on the associated Restricted Stock Award.  Stock dividends paid with respect to Restricted Stock during the Restriction Period shall be treated as Restricted Stock which shall be subject to the same restrictions as the original award for the duration of the Restriction Period.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Election to Recognize Gross Income in the Year of Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  If any Participant who is a U.S. taxpayer validly elects within 30 days of the Grant Date, to include in gross income for federal income tax purposes an amount equal to the fair market value of the Shares of Restricted Stock granted on the Grant Date, such Participant shall (at the same time or prior to the date that the Participant files the Participant's election with the Internal Revenue Service) (A) pay to the Corporation, or make arrangements satisfactory to the Administrator to pay to the Corporation in the year of such grant, any federal, state or local taxes required to be withheld with respect to such Shares in accordance with Section&#160;VIII.6, and (B) provide the Administrator with a copy of the election filed with the Internal Revenue Service.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Restrictive Legend</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Each book entry in the records of the Corporation&#8217;s transfer agent evidencing Shares granted pursuant to a Restricted Stock grant may bear an appropriate legend referring to the terms, conditions and restrictions described in the Plan and&#47;or the Restricted Stock Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Expiration of Restriction Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  If and when the Restriction Period applicable to the Restricted Stock expires without a prior forfeiture, Shares shall be credited to the Participant&#8217;s brokerage account of record. If the Participant does not have a brokerage account of record, then an appropriate book entry recording the Participant&#8217;s interest in the unrestricted Shares shall be entered on the records of the Corporation&#8217;s transfer agent.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">IV.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.39pt">RESTRICTED STOCK UNITS </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Restricted Stock Unit Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Restricted Stock Units granted under the Plan shall be evidenced by a Restricted Stock Unit Agreement to be executed by the Participant and the Corporation setting forth the terms and conditions of the Restricted Stock Units. Each Restricted Stock Unit Grant Notice shall incorporate by </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">reference and be subject to this Statement of Terms and Conditions, including the special terms and conditions in the Appendix for the Participant&#8217;s country (if any) which forms part of this Statement of Terms and Conditions, and together both documents shall constitute the Restricted Stock Unit Agreement.  The Restricted Stock Units are also subject to the terms and conditions of the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Special Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Restricted Stock Units granted under the Plan shall be subject to the following terms, conditions and restrictions and such additional terms, conditions and restrictions as may be determined by the Administrator, consistent with the terms of the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt;text-decoration:underline">Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  If a Participant ceases to be a bona fide employee of the Corporation or any Affiliate (except as otherwise provided in the Plan, or in Section IV.2(B) or Section IV.2(C)) prior to the lapse of the restrictions imposed on the Award, the unvested Restricted Stock Units shall be canceled, and all the rights of the Participant to such Awards shall immediately terminate. If a Participant is absent from work with the Corporation or an Affiliate because of the Participant's Short-Term Disability or because the Participant is on an approved leave of absence, the Participant shall not be deemed during the period of any such absence, by virtue of such absence alone, to have terminated employment with the Corporation or an Affiliate except as the Administrator may otherwise expressly determine.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt;text-decoration:underline">Termination of Employment by Reason of Death, Long-Term Disability or Normal Retirement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Notwithstanding any provision contained to the contrary in the Restricted Stock Unit Grant Notice, if a Participant who has been in the continuous employment of the Corporation or any of its Affiliates since the Grant Date of such Award ceases to be a bona fide employee of the Corporation or an Affiliate as a result of&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.57pt">Death or Long-Term Disability, then the restrictions imposed on any Award of Restricted Stock Units shall lapse on the date of such termination&#59; or</font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.8pt">Normal Retirement on or after the first anniversary of the Grant Date of any time-vesting Restricted Stock Units, the restrictions applicable to such Restricted Stock Units shall continue to lapse at such time(s) as are set forth in the applicable Grant Notice, as though the Participant had continued to be employed by the Corporation or one of its Affiliates during such restricted period.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(C)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt;text-decoration:underline">Termination of Employment by Reason of Severance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Notwithstanding any provision to the contrary contained in the Restricted Stock Unit Grant Notice, if a Participant who has been in the continuous employment of the Corporation or any of its Affiliates since the Grant Date of a Restricted Stock Unit Award ceases to be a bona fide employee of the Corporation or an Affiliate as a result of Severance, and&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.57pt">The Participant either (a) has attained the requirements for Normal Retirement on or prior to the Participant&#8217;s termination date or (b)&#160;would have attained the requirements for Normal Retirement within six months after the Participant&#8217;s termination date, then any time-vesting Restricted Stock Unit Award shall be subject to the Normal Retirement provisions of Section IV.2(B)(ii)&#59; or</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.8pt">The Participant has not attained the requirements for Normal Retirement on or prior to the Participant&#8217;s termination date, and would not have attained the requirements for Normal Retirement within six months after the Participant&#8217;s termination date, then the restrictions applicable to any time-vesting Restricted Stock Unit Award shall lapse upon the termination date, as to such Restricted Stock Units that would have vested at such time(s) as are set forth in the applicable Grant Notice as if the Participant had continued to be employed by the Corporation or one of its Affiliates during the six-month period after the termination date.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(D)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt;text-decoration:underline">Restriction on Sale</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Administrator reserves the right to impose a restriction on the sale of Shares that the Participant receives upon the settlement of Restricted Stock Units, unless the Participant has satisfied the ownership targets applicable to the Participant as provided in the Stock Ownership Policy.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Dividend Equivalents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Subject to the discretion of the Compensation Committee, dividend equivalents shall be credited in respect of Restricted Stock Units. Cash dividends shall be credited on behalf of the Participant to a deferred cash account (in a manner designed to comply with Code Section 409A) and the restrictions on such cash dividends shall lapse at the same time that the restrictions lapse on the associated Award of Restricted Stock Units, and cash dividends shall be paid in a lump sum at the same time that the Shares underlying the Restricted Stock Unit Award, and to which the cash dividends relate, are distributed. Stock dividends shall be converted into additional Restricted Stock Units, which will be subject to all of the terms and conditions of the underlying Restricted Stock Units, including the same vesting restrictions as the underlying Award. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Assignability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  A Participant shall not be permitted to sell, transfer, pledge, assign or encumber Restricted Stock Units, other than pursuant to a qualified domestic relations order as defined in the Code or Title I of the U.S. Employee Retirement Income Security Act.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">No Stockholder Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Neither a Participant nor any person entitled to exercise a Participant&#8217;s rights in the event of the Participant&#8217;s death shall have any of the rights of a stockholder with respect to an Award of Restricted Stock Units except to the extent that a book entry has been entered in the records of the Corporation&#8217;s transfer agent with respect to the Shares paid upon the settlement of any vested Restricted Stock Units.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Time of Payment of Restricted Stock Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Upon the lapse of the restriction imposed on Restricted Stock Units, all Restricted Stock Units that were not forfeited pursuant to Section&#160;IV.2(A), Section IV.2(B)(i), Section IV.2(C)(i),&#160;or Section VI shall be paid to the Participant as soon as reasonably practicable after the restrictions lapse. Payment shall be made in Shares to the Participant&#8217;s brokerage account of record. If the Participant does not have a brokerage account of record, then in the form of an appropriate book entry entered in the records of the Corporation&#8217;s transfer agent recording the Participant&#8217;s unrestricted interest in the number of Shares subject to the Restricted Stock Units.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, if a Participant becomes eligible for Normal Retirement, or is eligible for additional vesting under Section IV.2(C)(ii), prior to the date of the lapse of restrictions imposed on Restricted Stock Units and the vesting provisions of Section IV.2(B)(ii) or Section IV.2(C)(ii) apply, then such Restricted Stock Units shall be paid to the Participant&#8217;s brokerage account of record as soon as reasonably practicable after the earlier of the Participant&#8217;s Separation from Service or the originally scheduled vesting date (in any event before the end of the calendar year in which such date occurs), subject to the delay of payment (if applicable) provided in Section VIII.14. The procedures set forth in Section VIII.6 will be applied for any taxes due upon the lapse of restrictions imposed on a Restricted Stock Unit Award due to a Participant&#8217;s Normal Retirement eligibility or additional vesting as provided in Section IV.2(C)(ii).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">V.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:26.28pt">PERFORMANCE STOCK UNITS </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Award Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Performance Stock Unit Awards shall be evidenced by a Performance Stock Unit Agreement to be executed by the Participant and the Corporation setting forth the terms and conditions of the Performance Stock Unit Award.  Performance Stock Unit Awards are &#8220;Performance Awards&#8221; as provided under Section 10 of the Plan. Each Performance Stock Unit Agreement shall incorporate by reference and be subject to this Statement of Terms and Conditions, including the special terms and conditions in the Appendix for the Participant&#8217;s country (if any) which forms part of this Statement of Terms and Conditions, and together both documents shall constitute the Performance Stock Unit Agreement. Performance Stock Unit Awards are also subject to the terms and conditions of the Plan.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Number of Shares Granted Based on Performance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The performance period of a Performance Stock Unit Award shall be greater than one year, and performance shall be based on such criteria as the Compensation Committee shall determine in its discretion at the beginning of the performance period. Following the end of the performance period, the Compensation Committee shall determine the extent to which the criteria have been achieved, and shall authorize the grant and issuance of Shares in respect of the Performance Stock Unit Award.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Special Conditions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Performance Stock Unit Awards shall be subject to the following terms, conditions and restrictions and such additional terms, conditions and restrictions as may be determined by the Compensation Committee, consistent with the terms of the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt;text-decoration:underline">Forfeiture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  If a Participant ceases to be a bona fide employee of the Corporation or any Affiliate (except as otherwise provided in the Plan or in Section V.3(B) or Section V.3(C)) prior to the end of the performance period, any then-outstanding Performance Stock Units shall be canceled, and all the rights of the Participant to such Award shall immediately terminate. If a Participant is absent from work with the Corporation or an Affiliate because of the Participant's Short-Term Disability or because the Participant is on an approved leave of absence, the Participant shall not be deemed during the period of any such absence, by virtue of such absence alone, to have terminated employment with the Corporation or an Affiliate except as the Compensation Committee may otherwise expressly determine.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt;text-decoration:underline">Termination of Employment by Reason of Death, Long-Term Disability or Normal Retirement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Notwithstanding any provision contained herein or in the Plan or the Award Agreement to the contrary, if a Participant who has been in the continuous employment of the Corporation or any of its Affiliates since the Grant Date of such Award ceases to be a bona fide employee of the Corporation or an Affiliate as a result of&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.57pt">Death or Long-Term Disability, the Participant shall be eligible to receive, following completion of the applicable performance period, a prorated portion of each such Performance Stock Unit Award, equal to (1)&#160;the target number of Performance Stock Units subject to such Award, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">multiplied by</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (2)&#160;the performance criteria determined by the Compensation Committee to apply to such Award, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">multiplied by</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (3)&#160;a fraction, the numerator of which is the number of whole calendar months, rounded down to the nearest whole month, during which the Participant provided Service to the Corporation or an Affiliate during the performance period applicable to such Award, and the denominator of which is the number of calendar months in such performance period&#59; provided, that for purposes of this clause&#160;(3), &#8220;whole calendar months&#8221; shall be calculated commencing on the applicable Grant Date&#59; provided, however, that in no event shall such amount exceed any applicable cap or limitation set forth in the Performance Stock Unit Grant Notice&#59; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.8pt">Normal Retirement on or after the first anniversary of the Grant Date, the Participant shall be eligible to vest in such Performance Stock Unit Award following completion of the applicable performance period, as though the Participant had continued to be employed by the Corporation or one of its Affiliates through the date on which the Compensation Committee determines performance against the applicable performance goals.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts, if any, to be paid under this Section V.3(B) shall be paid in accordance with Section&#160;V.7 and, if applicable, Section&#160;VIII.14.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(C)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt;text-decoration:underline">Termination of Employment by Reason of Severance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Notwithstanding any provision to the contrary, if the Participant has been in the continuous employment of the Corporation or any of its Affiliates since the Grant Date and ceases to be a bona fide employee of the Corporation or an Affiliate as a result of Severance, and&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.57pt">The Participant either (a) has attained the requirements for Normal Retirement on or prior to the Participant&#8217;s termination date or (b)&#160;would have attained the requirements for Normal Retirement within six months after the Participant&#8217;s termination date, then any Performance Stock Unit Award shall be subject to the Normal Retirement provisions of Section V.3(B)(ii)&#59; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.8pt">The Participant has not attained the requirements for Normal Retirement on or prior to the Participant&#8217;s termination date, and would not have attained the requirements for Normal Retirement within six months after the Participant&#8217;s termination date, then if such Participant&#8217;s termination date is no greater than six months prior to the date on which the Compensation Committee determines performance against the applicable performance goals, such Participant shall be eligible to vest in such Performance Stock Unit Award following completion of the applicable performance period, as though the Participant had continued to be employed by the Corporation or one of its Affiliates through such performance determination date. </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts, if any, to be paid under this Section V.3(C) shall be paid in accordance with Section&#160;V.7 and, if applicable, Section&#160;VIII.14.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(D)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt;text-decoration:underline">Restriction on Sale of Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Administrator reserves the right to impose a restriction on the sale of Shares that the Participant receives with respect to the settlement of a Performance Stock Unit Award, unless the Participant has satisfied the ownership targets applicable to the Participant as provided in the Stock Ownership Policy.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Dividend Equivalents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Unless otherwise determined by the Compensation Committee in its sole discretion, Dividend Equivalents shall not be accrued with respect to Performance Stock Unit Awards during the performance period. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Assignability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  A Participant shall not be permitted to sell, transfer, pledge, assign or encumber all or any portion of a Performance Stock Unit Award.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">No Stockholder Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Neither a Participant nor any person entitled to exercise a Participant&#8217;s rights in the event of the Participant&#8217;s death shall have any of the rights of a stockholder with respect to a Performance Stock Unit Award, except to the extent that a book entry has been entered in the records of the Corporation&#8217;s transfer agent with respect to the Shares paid upon the settlement of any Performance Stock Unit Award.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Time of Payment of Performance Stock Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Compensation Committee shall determine the extent to which Shares are payable pursuant to a Performance Stock Unit Award as soon as practicable following the end of the performance period, and such Shares shall be paid as soon as practicable thereafter and in any event no later than the end of the period under which payment would be deemed to be a &#8220;short-term deferral&#8221; as defined in the regulations under Code Section 409A. Payment shall be made in the form of Shares to the Participant&#8217;s brokerage account of record. If the Participant does not have a brokerage account of record, then in the form of an appropriate book entry entered in the records of the Corporation&#8217;s transfer agent recording the Participant&#8217;s unrestricted interest in the number of Shares earned pursuant to the Performance Stock Unit Award.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">VI.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.39pt">SPECIAL FORFEITURE AND REPAYMENT RULES</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Any other provision of this Statement of Terms and Conditions to the contrary notwithstanding, if the Administrator determines that a Participant has engaged in any of the actions described in 3 below, the consequences set forth in 1 and 2 below shall result&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt">Any outstanding Option shall immediately and automatically terminate, be forfeited and shall cease to be exercisable, without limitation. In addition, any Award of Restricted Stock or Restricted Stock Units as to which the restrictions have not lapsed shall immediately and automatically be forfeited, Performance Stock Unit Awards shall immediately and automatically be forfeited and any such Shares of Restricted Stock shall be returned to the Corporation and all of the rights of the Participant to such Awards and the underlying Shares shall immediately terminate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt">If the Participant exercised an Option within 12 months prior to the date upon which the Corporation discovered that the Participant engaged in any actions described in 3 below, the Participant, upon written notice from the Corporation, shall immediately pay to the Corporation the economic value realized or obtained by the exercise of such Option measured at the date of exercise. In addition, if the restrictions imposed on any Award of Restricted Stock or Restricted Stock Units (including any unpaid dividends or Dividend Equivalents) lapsed, or any Performance Stock Unit Award was settled, within 12 months prior to the date the Corporation discovered that the Participant engaged in any action described in 3 below, the Participant, upon written notice from the Corporation, shall immediately pay to the Corporation the economic value realized or obtained with respect to such Award, measured at the date such Award vested. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt">The consequences described in 1 and 2 above shall apply if the Participant, either before or after termination of employment with the Corporation or its Affiliates&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">Discloses to others, or takes or uses for the Participant&#8217;s own purpose or the purpose of others, any trade secrets, confidential information, knowledge, data or know-how or any other proprietary information or intellectual property belonging to the Corporation or its Affiliates and obtained by the Participant during the term of the Participant&#8217;s employment, whether or not they are the Participant&#8217;s work product. Examples of such confidential information or trade secrets include, without limitation, customer lists, supplier lists, pricing and cost data, computer programs, delivery routes, advertising plans, wage and salary data, financial information, research and development plans, processes, equipment, product information and all other types and categories of information as to which the Participant knows or has reason to know that the Corporation or its Affiliates intends or expects secrecy to be maintained&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">Fails to promptly return all documents and other tangible items belonging to the Corporation or its Affiliates in the Participant&#8217;s possession or control, including all complete or partial copies, recordings, abstracts, notes or reproductions of any kind made from or about such documents or information contained therein, upon termination of employment, whether pursuant to retirement or otherwise&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(C)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">Fails to provide the Corporation with at least 30&#160;days&#8217; written notice prior to directly or indirectly engaging in, becoming employed by, or rendering services, advice or assistance to any business in competition with the Corporation or its Affiliates. As used herein, &#8220;business in competition&#8221; means any person, organization or enterprise which is engaged in or is about to become engaged in any line of business engaged in by the Corporation or its Affiliates at the time of the termination of the Participant&#8217;s employment with the Corporation or its Affiliates&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(D)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">Fails to inform any new employer, before accepting employment, of the terms of this paragraph and of the Participant&#8217;s continuing obligation to maintain the confidentiality of the trade secrets and other confidential information belonging to the Corporation or its Affiliates and obtained by the Participant during the term of the Participant&#8217;s employment with the Corporation or any of its Affiliates&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(E)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.24pt">Induces or attempts to induce, directly or indirectly, any of the customers of the Corporation or its Affiliates, employees, representatives or consultants to terminate, discontinue or cease working with or for the Corporation or its Affiliates, or to breach any contract with the Corporation or any of its Affiliates, in order to work with or for, or enter into a contract with, the Participant or any third party&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(F)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">Engages in conduct which is not in good faith and which disrupts, damages, impairs or interferes with the business, reputation or employees of the Corporation or its Affiliates&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(G)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">Fails to meet the Participant&#8217;s continuing obligations with respect to non-disclosure, non-competition and&#47;or non-solicitation under the Participant&#8217;s agreement with the Corporation or any Affiliate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Administrator shall determine in its sole discretion whether the Participant has engaged in any of the acts set forth in (A) through (G) above, and its determination shall be conclusive and binding on all interested persons.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Any provision of this Section&#160;VI which is determined by a court of competent jurisdiction to be invalid or unenforceable should be construed or limited in a manner that is valid and enforceable and that comes closest to the business objectives intended by such invalid or unenforceable provision, without invalidating or rendering unenforceable the remaining provisions of this Section&#160;VI.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">VII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:18.5pt">CHANGE IN CONTROL  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If as a result of a Change in Control, the Common Stock ceases to be listed for trading on a national securities exchange (an &#8220;Exchange&#8221;), any Option, Restricted Stock Award, Restricted Stock Unit Award or Performance Stock Unit Award that is unvested on the effective date of the Change in Control shall continue to vest according to the terms and conditions of such Award, provided that such Award is replaced with an award for voting securities of the resulting corporation or the acquiring corporation, as the case may be, (including without limitation, the voting securities of any corporation which as a result of the Change in Control owns the Corporation or all or substantially all of the Corporation&#8217;s assets either directly or through one or more subsidiaries) (the &#8220;Surviving Company&#8221;) which are traded on an Exchange (a &#8220;Replacement Award&#8221;), which Replacement Award, (i) in the case of an Option, shall consist of an option with the number of underlying shares and exercise price determined in a manner consistent with Code Section 424(a) with vesting and any other terms continuing in the same manner as the replaced Option&#59; (ii) in the case of a Performance Stock Unit Award, shall consist of restricted stock or restricted stock units with a value (determined using the Surviving Company&#8217;s stock price as of the effective date of the Change in Control) equal to the value of the Performance Stock Unit Award (determined using the Corporation&#8217;s stock price and assuming attainment of target performance or actual performance achieved, if greater, as of the effective date of the Change in Control), with any restrictions on such Replacement Award lapsing at the end of the measuring period over which performance for the replaced Performance Stock Unit Award was to be measured prior to the granting of the Replacement Award&#59; and (iii) in the case of a Restricted Stock Award or Restricted Stock Unit Award, shall consist of restricted stock or restricted stock units with a value (determined using the Surviving Company&#8217;s stock price as of the effective date of the Change in Control) equal to the value of the Restricted Stock Award or Restricted Stock Unit Award (determined using the Corporation&#8217;s stock price as of the effective date of the Change in Control), with any restrictions on such restricted stock or restricted stock units lapsing at the same time and manner as the replaced Award&#59; provided, however, that in the event of the Participant&#8217;s involuntary Separation from Service by the Corporation without Cause or Separation from Service by the Participant for Good Reason during the vesting period of any Replacement Award, the Replacement Award shall immediately vest and be paid as soon as practicable following such Separation from Service (subject to Section VIII.14), based on the fair market value of the underlying shares on the vesting date, or in the case of options, based on the excess of the fair market value of the underlying shares over the option exercise price on the vesting date. If any Option, Restricted Stock Award, Restricted Stock Unit Award or Performance Stock Unit Award that is unvested at the effective time of the Change in Control is not replaced with a Replacement Award, such Award shall immediately vest and, in the case of a Performance Stock Unit Award, shall vest based upon deemed attainment of target performance or actual performance achieved, if greater.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If as a result of a Change in Control, the Common Stock continues to be listed for trading on an Exchange, any unvested Option, Restricted Stock Award, or Restricted Stock Unit Award shall continue to vest according to the terms and conditions of such Award and any Performance Stock Unit Award shall be replaced with a Restricted Stock Unit Award where the number of shares subject to such Restricted Stock Unit Award shall be equal to the number of Shares assuming attainment of target performance or actual performance achieved, if greater, as of the effective date of the Change in Control with any restrictions on such Restricted Stock Unit Award lapsing at the end of the measuring period over which performance for the replaced Performance Stock Unit Award was to be measured prior to the granting of the Replacement Award&#59; provided however, that, in the event of the Participant&#8217;s involuntary Separation from Service by the Corporation without Cause or Separation from Service by the Participant </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">for Good Reason during the vesting period of an Award, such Award shall immediately vest and be paid as soon as practicable following such Separation from Service (subject to Section VIII.14).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">VIII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:14.61pt">MISCELLANEOUS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">No Effect on Terms of Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Participation in the Plan shall not create a right to further employment with the Participant&#8217;s employer (the &#8220;Employer&#8221;) and shall not interfere with the ability of the Employer to terminate, with or without cause, or change the terms of employment of a Participant at any time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Grants to Participants in Foreign Countries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  In making grants to Participants in foreign countries, the Administrator has the full discretion to deviate from this Statement of Terms and Conditions in order to adjust grants under the Plan to prevailing local conditions, including custom and legal and tax requirements. Furthermore, the Corporation reserves the right to impose other requirements on the Participant&#8217;s participation in the Plan on the Award and on any Shares acquired under the Plan, to the extent the Corporation determines it is necessary or advisable in order to comply with local law or facilitate the administration of the Plan, and to require the Participant to sign any additional agreements or undertaking that may be necessary to accomplish the foregoing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Information Notification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Any information required to be given under the terms of an Award shall be addressed to the Corporation in care of its Corporate Secretary at McKesson Corporation, 6555 North State Highway 161, Irving, Texas 75039, and any notice to be given to a Participant shall be addressed to such Participant at the address indicated beneath the Participant's name on the Award Agreement or such other address as either party may designate in writing to the other.  Any such notice shall be deemed to have been duly given when enclosed in a properly sealed envelope or wrapper addressed as aforesaid, registered or certified and deposited (postage or registration or certification fee prepaid)&#160;in a post office or branch post office. The parties may use email delivery, so long as the message is clearly marked, sent to the email address(es) set forth herein, and a delivery receipt and a read receipt are made part of the message.&#160; Email delivery will be deemed to occur when the sender receives confirmation that such message has been received and read by the recipient. Emails to the Corporation shall be delivered to CorpSecretary&#64;McKesson.com.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Administrator Decisions Conclusive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  All decisions of the Administrator administering the Plan upon any questions arising under the Plan or under an Award Agreement, shall be conclusive and binding on all interested persons.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">No Effect on Other Benefit Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Nothing herein contained shall affect a Participant&#8217;s right to participate in and receive benefits from and in accordance with the then current provisions of any pensions, insurance or other employment welfare plan or program offered by the Corporation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Regardless of any action the Corporation or the Employer takes with respect to any federal, state or local income tax, social insurance contributions, payroll tax, payment on account or other tax-related items related to the Participant&#8217;s participation in the Plan and legally applicable to the Participant (&#8220;Tax-Related Items&#8221;), the Participant acknowledges that the ultimate liability for all Tax-Related Items is and remains the Participant's responsibility and may exceed the amount actually withheld by the Corporation or the Employer. The Participant further acknowledges that the Corporation and&#47;or the Employer (1) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Award, including the grant, vesting, settlement or exercise of the Award, as applicable, the subsequent sale of Shares acquired pursuant to the Plan and the receipt of any dividends and&#47;or dividend equivalents&#59; and (2) do not commit and are under no obligation to structure the terms of the grant or any aspect of the Award to reduce or eliminate the Participant&#8217;s liability for Tax-Related Items or achieve any particular tax result. Further, if the Participant has become subject to tax in more than one jurisdiction between the Grant Date and the date of any relevant taxable event, the Participant acknowledges that the Corporation and&#47;or the Employer (or former employer, as applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior to any relevant taxable or tax withholding event, as applicable, the Participant will pay or make adequate arrangements satisfactory to the Corporation and&#47;or the Employer, or their respective agents, at their discretion, to satisfy the obligations with regard to all Tax-Related Items by one or a combination of the following&#58; (1) withholding from the Participant&#8217;s wages or other cash compensation paid to the Participant by the Corporation and&#47;or the Employer&#59; (2)&#160;withholding from proceeds of the sale of Shares acquired under the Plan either through a voluntary sale or through a mandatory sale arranged by the Corporation (on the Participant&#8217;s behalf pursuant to this authorization and any other authorization the Corporation and&#47;or the broker designated by the Corporation may require the Participant to sign in connection with the sale of Shares)&#59; (3) withholding Shares to be issued upon grant, vesting&#47;settlement or exercise, as applicable&#59; or (4) any other method of withholding determined by the Corporation and to the extent required by applicable law or the Plan, approved by the Compensation Committee. Calculation of the number of Shares to be withheld shall be made based on the closing price of the Common Stock on the New </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">York Stock Exchange on the date that the amount of tax to be withheld is determined. In no event, however, shall the Corporation be required to issue fractional Shares. With respect to an Award other than an Option, if adequate arrangements to satisfy the obligations with regard to all Tax-Related Items are not made by the Participant with the Corporation and&#47;or the Employer prior to the relevant taxable event, the Corporation will satisfy such obligations as provided above in clause (3) of this paragraph.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Corporation or the Employer may withhold or account for Tax-Related Items by considering applicable minimum statutory withholding amounts or other applicable withholding rates, including maximum applicable rates in the Participant&#8217;s jurisdiction(s). If the obligation for Tax-Related Items is satisfied by withholding in Shares, for tax purposes, the Participant will be deemed to have been issued the full number of Shares subject to the Award, notwithstanding that a number of the Shares are held back solely for the purpose of paying the Tax-Related Items due as a result of any aspect of the Participant&#8217;s participation in the Plan. In the event any excess amounts are withheld to satisfy the obligation for Tax-Related Items, the Participant may be entitled to receive a refund of any over-withheld amount (with no entitlement to the Share equivalent), or if not refunded by the Corporation or the Employer, the Participant must seek a refund from the local tax authorities to the extent the Participant wishes to recover the over-withheld amount in the form of a refund. In the event of under-withholding, the Participant may be required to pay any additional Tax-Related Items directly to the applicable tax authority or to the Corporation and&#47;or the Employer.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finally, the Participant shall pay to the Corporation or the Employer any amount of Tax-Related Items that the Corporation or the Employer may be required to withhold or account for as a result of the Participant&#8217;s participation in the Plan that cannot be satisfied by the means previously described. The Corporation may refuse to issue or deliver the Shares or the proceeds of the sale of Shares if the Participant fails to comply with the Participant's obligations in connection with the Tax-Related Items.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Administrator shall be authorized to establish such rules, forms and procedures as it deems necessary to implement the foregoing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Successors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Award Agreements shall be binding upon and inure to the benefit of any successor or successors of the Corporation. &#8220;Participant&#8221; as used herein shall include the Participant&#8217;s Beneficiary.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Delaware Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The interpretation, performance, and enforcement of all Award Agreements shall be governed by the laws of the State of Delaware.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Nature of Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  In accepting the grant, the Participant acknowledges that&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">the Plan is established voluntarily by the Corporation, it is discretionary in nature and it may be modified, amended, suspended or terminated by the Corporation at any time&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">the grant of the Award is exceptional, voluntary and occasional and does not create any contractual or other right to receive future Award grants, or benefits in lieu of Awards, even if Awards have been granted repeatedly in the past&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(C)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">all decisions with respect to future Awards, if any, will be at the sole discretion of the Corporation&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(D)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">the Participant is voluntarily participating in the Plan&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(E)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.24pt">the Award and the Shares subject to the Award, and the income from and value of same, are not part of normal or expected compensation for any purpose, including, but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, long-service awards, pension or retirement benefits or similar payments&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(F)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the Award will not be interpreted to form an employment contract or relationship with the Corporation&#59; and furthermore, the Award will not be interpreted to form an employment contract with any subsidiary or Affiliate of the Corporation&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(G)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">the future value of the underlying Shares is unknown, indeterminable and cannot be predicted with certainty&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(H)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">if the underlying Shares do not increase in value, the Options will have no value&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.01pt">in consideration of the grant of the Award, no claim or entitlement to compensation or damages shall arise from forfeiture of the Award which results from termination of the Participant&#8217;s employment with the Employer or the Corporation or one of its Affiliates (for any reason whatsoever, and whether or not such forfeiture is later found to be invalid or in breach of employment laws in the jurisdiction where the Participant is employed or the terms of the Participant&#8217;s employment agreement, if any) and the Participant irrevocably releases the Corporation or its Affiliates from any such claim that may arise&#59; provided that, notwithstanding the foregoing, in the event any such claim is found by a court of competent jurisdiction to have arisen, then, by accepting the Award, the Participant shall be deemed irrevocably to have waived the Participant's entitlement to pursue such claim&#59;  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(J)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:25.45pt">for purposes of an Award, the Participant&#8217;s employment relationship will be considered terminated as of the date the Participant is no longer a bona fide employee of the Corporation, the Employer or one of the Corporation&#8217;s other Affiliates (regardless of the reason for such termination and whether or not later found to be invalid or in breach of the employment laws in the jurisdiction where the Participant is employed or the terms of the Participant&#8217;s employment agreement, if any), and unless otherwise expressly provided in this Award Agreement or determined by the Corporation in its sole discretion, the Participant&#8217;s right to receive Awards and vest in Awards under the Plan, if any, will terminate effective as of such date and will not be extended by any notice period mandated under local law (for example, the Participant&#8217;s period of service would not include any contractual notice period or any period of &#8220;garden leave&#8221; or similar period mandated under employment laws in the jurisdiction where the Participant is employed or the terms of the Participant&#8217;s employment agreement, if any)&#59; similarly, any right to exercise Options under the Plan after termination of employment will be measured as of the date the Participant is no longer a bona fide employee of the Corporation, the Employer or one of the Corporation&#8217;s other Affiliates and will not be extended by any notice period mandated under local law&#59; the Administrator shall have the sole discretion to determine when the Participant is no longer a bona fide employee for purposes of an Award (including whether the Participant may still be considered to be providing services while on a leave of absence)&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(K)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">the Corporation is not providing any tax, legal or financial advice, nor is the Corporation making any recommendations regarding participation in the Plan or the Participant&#8217;s acquisition or sale of Shares&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(L)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.24pt">the Participant is hereby advised to consult with the Participant's own personal tax, legal and financial advisors regarding Participant&#8217;s participation in the Plan before taking any action related to the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:23.5pt;text-decoration:underline">Data Privacy Information and Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:22.12pt">Data Collection and Usage.  The Corporation and the Employer may collect, process and use certain personal information about the Participant, including, but not limited to, the Participant&#8217;s name, home address and telephone number, email address, date of birth, social insurance number, passport or other identification number, salary, nationality, job title, any Shares or directorships held in the Corporation, details of all Options, Restricted Stock, Restricted Stock Units, Performance Stock Units, Other Share-Based Awards, or any other entitlement to Shares awarded, canceled, exercised, vested, unvested or outstanding in the Employee&#8217;s favor (&#8220;Data&#8221;), for the purposes of implementing, administering and managing the Plan. The legal basis, where required, for the processing of Data is the Participant&#8217;s consent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:22.68pt">Stock Plan Administration Service Providers.  The Corporation transfers Data to Fidelity Stock Plan Services LLC and its affiliated companies, an independent service provider based in the United States, which is assisting the Corporation with the implementation, administration and management of the Plan. The Corporation may select a different service provider or additional service providers and share Data with such other provider serving in a similar manner. The Participant may be asked to agree on separate terms and data processing practices with the service provider, with such agreement being a condition to the ability to participate in the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(C)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:22.68pt">International Data Transfers.  The Corporation and its service providers are based in the United States.  The Participant&#8217;s country or jurisdiction may have different data privacy laws and protections than the United States. The Corporation&#8217;s legal basis, where required, for the transfer of Data is</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">the Participant&#8217;s consent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(D)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:22.12pt">Data Retention.  The Corporation will hold and use the Data only as long as is necessary to implement, administer and manage the Participant&#8217;s participation in the Plan, or as required to comply with legal or regulatory obligations, including under tax and security laws.  In the latter case, the Participant understands and acknowledges that the Corporation&#8217;s legal basis for the processing of the Participant&#8217;s Data would be compliance with the relevant laws or regulations or the pursuit by the Corporation of respective legitimate interests not outweighed by the Participant&#8217;s interests, rights or freedoms. When the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Corporation no longer needs the Participant&#8217;s Data for any of the above purposes, the Participant understands the Corporation will remove it from its systems.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(E)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:23.24pt">Voluntariness and Consequences of Consent Denial or Withdrawal.  Participation in the Plan is voluntary and the Participant is providing the consents herein on a purely voluntary basis.  If the Participant does not consent, or if the Participant later seeks to revoke the Participant&#8217;s consent, the Participant&#8217;s salary from or employment with the Employer will not be affected&#59; the only consequence of refusing or withdrawing the Participant&#8217;s consent is that the Corporation would not be able to grant Awards to the Participant or administer or maintain such Awards.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(F)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:23.78pt">Data Subject Rights.  The Participant may have a number of rights under data privacy laws in the Participant&#8217;s jurisdiction.  Depending on where the Participant is based, such rights may include the right to (i) inquire whether and what kind of Data the Corporation holds about the Participant and how it is processed, and to request access or copies of Data the Corporation processes, (ii) request the correction or supplementation of Data about the Participant that is inaccurate, incomplete or out-of-date in light of the purposes underlying the processing, (iii) obtain the erasure of Data no longer necessary for the purposes underlying the processing, processed based on withdrawn consent, processed for legitimate interests that, in the context of the Participant&#8217;s objection, do not prove to be compelling, or processed in non-compliance with applicable legal requirements, (iv) request restrictions on processing of Data in certain situations where the Participant feels its processing is inappropriate, (v) request portability of the Participant&#8217;s Data that the Participant has actively or passively provided to the Corporation (which does not include data derived or inferred from the collected data), where the processing of such Data is based on consent or the Participant&#8217;s employment and is carried out by automated means, (vi) object, in certain circumstances, to the processing of Data for legitimate interests, (vii) lodge complaints with competent authorities in the Participant&#8217;s jurisdiction, and&#47;or (viii) receive a list with the names and addresses of any potential recipients of Data.  To receive clarification regarding these rights or to exercise these rights, the Participant can contact his or her local human resources representative.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">By accepting the Award and indicating consent via the Corporation&#8217;s acceptance procedure, the Participant is declaring that he or she agrees with the data processing practices described herein and consents to the collection, processing and use of Data by the Corporation and the transfer of Data to the recipients mentioned above, including recipients located in countries which do not adduce an adequate level of protection from a European (or other non-U.S.) data protection law perspective, for the purposes described above.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.5pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The provisions in this Statement of Terms and Conditions are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.5pt;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Participant acknowledges that the Participant is proficient in the English language, or has consulted with an advisor who is sufficiently proficient in the English language, and, accordingly, understands the provisions of the Plan and this Statement of Terms and Conditions.  If the Participant has received this Statement of Terms and Conditions or any other document related to the Plan translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control unless otherwise required by local law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.5pt;text-decoration:underline">Electronic Delivery</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Corporation may, in its sole discretion, decide to deliver any documents related to current or future participation in the Plan by electronic means.  The Participant hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by the Corporation or a third party designated by the Corporation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.5pt;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  If (A) the Participant is a Specified Employee at the time of the Participant&#8217;s Separation from Service, and (B) some or any portion of the amounts payable to the Participant, if any, when considered together with any other payments or benefits which may be considered deferred compensation under section 409A of the Internal Revenue Code of 1986, as amended (&#8220;Section 409A&#8221;) and subject to the plan aggregation rules under Treasury Regulation section 1.409A-1(c)(3)(viii) (together, the &#8220;Deferred Compensation Benefits&#8221;) would result in the imposition of additional tax under Section 409A if paid to the Participant on or within the six month period following the Separation from Service, then to the extent such portion of the Deferred Compensation Benefits resulting in the imposition of additional tax would otherwise have been payable on or within the first six months following the Separation from Service, it will instead become payable on the first payroll date that occurs in the seventh month following the Separation from Service (or such longer period as is required to avoid the imposition of additional tax under Section 409A). All subsequent Deferred Compensation Separation Benefits, if any, will be payable in accordance with the payment schedule applicable to each payment or benefit.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">IX.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.39pt">DEFINITIONS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">When capitalized in this Statement of Terms and Conditions, the following terms shall have the meaning set forth below&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Award Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means an agreement between the Participant and the Corporation evidencing the grant of an Option, Restricted Stock Award, Restricted Stock Unit Award, Performance Stock Unit Award or Other Share-Based Award, as applicable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means termination of the Participant&#8217;s employment with the Corporation or an Affiliate upon the Participant&#8217;s negligent or willful engagement in misconduct which, in the sole determination of the Chief Executive Officer of the Corporation (or the Chief Executive Officer&#8217;s designee), is injurious to the Corporation, its employees, or its customers.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Early Retirement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means a termination of employment (other than due to death, Long-Term Disability or for Cause) which occurs prior to Normal Retirement but on or after the date on which the Participant&#8217;s age (expressed in terms of years and completed months) plus service with the Corporation or an Affiliate equals 65. For purposes of determining eligibility for Early Retirement, the term &#8220;service&#8221; shall include years and completed whole months of service.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Family Member</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any person identified as an &#8220;immediate family&#8221; member in Rule 16(a)-1(e) of the Exchange Act, as such Rule may be amended from time to time.  Notwithstanding the foregoing, the Administrator may designate any other person(s)&#160;or entity(ies) as a &#8220;family member.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any of the following actions, if taken without the express written consent of the Participant&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(A)&#160;&#160;&#160;&#160;Any material change by the Corporation in the Participant&#8217;s functions, duties, or responsibilities, which change would cause the Participant&#8217;s position with the Corporation to become of less dignity, responsibility, importance, or scope from the position and attributes that applied to the Participant immediately prior to the Change in Control&#59; provided, however, that, any such change attributable to the Corporation&#8217;s no longer being a company with publicly traded common stock shall not constitute Good Reason&#59; and provided, further, that a reduction in the Participant&#8217;s functions, duties or responsibilities solely by virtue of the Corporation being acquired and made part of a larger entity (for example, if following a Change in Control the Participant retains the Participant&#8217;s position, or has a comparable position, with respect to a division or subsidiary of the acquirer that contains the Corporation&#8217;s business) shall not constitute Good Reason&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(B)&#160;&#160;&#160;&#160;Any significant reduction in the Participant&#8217;s aggregate base annual salary and target incentive opportunity, as in effect immediately prior to the Change in Control&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(C)&#160;&#160;&#160;&#160;Any material failure by the Corporation to comply with any of the provisions of an Award subsequent to a Change in Control&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(D)&#160;&#160;&#160;&#160;The Corporation&#8217;s requiring the Participant to be based at any location which would increase the Participant&#8217;s regular one-way commute by more than 25 miles from that in effect immediately preceding the Change in Control, except for travel reasonably required in the performance of the Participant&#8217;s responsibilities&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provided that the Participant gives notice to the Corporation of the existence of the Good Reason condition within 30 days of the initial existence of the Good Reason condition and the Corporation is provided 30 days after receipt of the Participant&#8217;s notice to remedy the Good Reason condition&#59; provided further that the Participant&#8217;s Separation from Service must occur within six months from the initial existence of the Good Reason condition if the Corporation does not remedy such condition for such separation to be considered to be for Good Reason. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Expiration Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the date that an Option expires as set forth in the Option Grant Notice as the &#8220;Expiration Date.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Grant Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the date the Administrator grants the Award.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Grant Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the notice of an Award granted to the Participant, which sets forth certain terms of such Award.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Long-Term Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means a physical or mental condition in respect of which the administrator of the Corporation&#8217;s long-term disability plan has determined that the Participant is eligible to receive income replacement benefits&#59; or, if the Participant is not then a participant in the Corporation&#8217;s long-term disability plan, a physical or mental condition that the administrator of the Corporation&#8217;s long-term disability plan determines would have rendered the Participant eligible to receive income replacement benefits, had the Participant been enrolled in such plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Normal Retirement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means termination of employment (other than due to death, Long-Term Disability or for Cause) at or after age 60 with at least 10 years of service with the Corporation or an Affiliate. For purposes of determining eligibility for Normal Retirement, &#8220;service&#8221; shall mean completed whole years of service (12 consecutive months).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Option Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the period commencing on the Grant Date of an Option and, except at otherwise provided in Section&#160;II.5, ending on the Expiration Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Separation from Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means termination of employment with the Corporation or an affiliate. A Participant shall be deemed to have had a Separation from Service if the Participant&#8217;s service with the Corporation or an affiliate is reduced to an annual rate that is equal to or less than 20% of the services rendered, on average, during the immediately preceding three years of service with the Corporation or an affiliate (or, if providing service to the Corporation or an affiliate for less than three years, such lesser period).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Severance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means termination of employment with the Corporation or an Affiliate, and qualified for participation in and entitlement to benefits under the McKesson Corporation Severance Pay Plan or the McKesson Corporation Severance Policy for Executive Employees, as applicable, in accordance with the terms and conditions of such plans. A Participant outside the United States who is not qualified for participation in and entitlement to the benefits under such plans will nonetheless be treated for the limited purposes of his or her Awards, and subject to the provisions of Section VIII.9 of this Statement of Terms and Conditions, as terminated by reason of Severance to the extent his or her employment with the Corporation or an Affiliate is terminated and he or she would satisfy the conditions for termination for reason of Severance but for the fact that such plan is only applicable to employees of the Corporation or an Affiliate in the United States who qualify for participation in that plan. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.&#160;&#160;&#160;&#160; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Short-Term Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means short-term disability as defined in the Corporation&#8217;s short-term disability plan. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Specified Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means those employees identified by the Corporation as &#34;Specified Employees&#34; for purposes of Code Section 409A.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Stock Ownership Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the Corporation&#8217;s Stock Ownership Policy, as amended from time to time, which can be found on McKNet. A Participant or a Participant&#8217;s beneficiary may also request a copy of the Stock Ownership Policy by writing to the Corporate Secretary at McKesson Corporation, 6555 North State Highway 161, Irving, Texas 75039 or emailing CorpSecretary&#64;McKesson.com.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16</font></div><div><font><br></font></div></div></div><div id="i9909940b100446f4adf3c825eaf11602_13"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EMPLOYEES</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">McKESSON CORPORATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">STATEMENT OF TERMS AND CONDITIONS APPLICABLE TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OPTIONS, RESTRICTED STOCK, RESTRICTED STOCK UNITS</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">AND PERFORMANCE STOCK UNITS GRANTED TO EMPLOYEES<br>PURSUANT TO THE 2022 STOCK PLAN</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For Grants Beginning May 23, 2023</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">I.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:29.61pt">INTRODUCTION</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following terms and conditions shall apply to an Award granted under the Plan and are subject to the terms and conditions of the Plan.  This Statement of Terms and Conditions is intended to meet the requirements of Code Section&#160;409A and any rules promulgated thereunder.  In the event of any inconsistency between this Statement of Terms and Conditions and the Plan, the Plan shall govern.  Capitalized terms not otherwise defined in this Statement of Terms and Conditions shall have the meaning set forth in the Plan.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">II.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:25.72pt">OPTIONS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Option Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  An Option granted under the Plan shall be evidenced by an Option Agreement setting forth the terms and conditions of the Option, including whether the Option is an Incentive Stock Option or a Nonstatutory Stock Option and the number of Shares subject to the Option.  Each Option Grant Notice shall incorporate by reference and be subject to this Statement of Terms and Conditions, including the special terms and conditions in the Appendix for the Participant&#8217;s country (if any) which forms part of this Statement of Terms and Conditions, and together both documents shall constitute the Option Agreement.  The Option is also subject to the terms and conditions of the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Exercise Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Exercise Price of an Option, as specified in the Option Agreement, shall be equal to or greater than the Fair Market Value of the Shares underlying the Option on the Grant Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Option Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  An Option shall be exercisable only during the applicable Option Period, and during such Option Period the exercisability of the Option shall be subject to the vesting provisions of Section&#160;II.4 as modified by the rules set forth in Sections&#160;II.5 and VI.  The Option Period shall be not more than seven years from the Grant Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Vesting of Right to Exercise Options</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">Subject to Sections&#160;II.5 and VI, an Option shall be exercisable during the Option Period in accordance with the vesting terms and conditions established on the Grant Date and specified in the Option Grant Notice.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">Any vested portion of an Option not exercised hereunder shall accumulate and be exercisable at any time on or before the Expiration Date, subject to the rules set forth in Sections&#160;II.5 and VI.  No Option may be exercised for less than 5% of the total number of Shares then available for exercise under such Option.  In no event shall the Corporation be required to issue fractional Shares.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Limits on Option Period and Acceleration of Vesting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Option Period may end before the Expiration Date, and in certain circumstances the vesting schedule of an Option may be accelerated (subject to the provisions of Section&#160;VI), as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">If a Participant ceases to be a bona fide employee of the Corporation or of its Affiliates during the Option Period for reasons other than for Cause, Long-Term Disability, Normal Retirement, Early Retirement, Severance under the circumstances provided in Section II.5(F)(ii), or death, the Option Period shall end on the earlier of (i)&#160;90 days after the date of the Participant&#8217;s termination of employment and (ii)&#160;the Expiration Date, and in all cases the Option shall be exercisable only to the extent that it was exercisable at the time of such termination of employment.  If a Participant is absent from work with the Corporation or an Affiliate because of the Participant's Short-Term Disability or because the Participant is on an approved leave of absence, the Participant shall not be deemed during the period of any such absence, by virtue of such absence alone, to have terminated employment with the Corporation or an Affiliate except as the Administrator may otherwise expressly determine.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">Notwithstanding any other provision in this Section II.5, if a Participant&#8217;s employment is terminated for Cause during the Option Period, the Option Period shall end on the date of such termination of employment and the Option shall thereupon not be exercisable to any extent whatsoever.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(C)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">If a Participant ceases to be a bona fide employee of the Corporation or of its Affiliates during the Option Period by reason of Long-Term Disability, the vesting schedule of the Participant&#8217;s Option shall be accelerated, the Option shall become fully exercisable and the Option Period shall end on the earlier of (i) three years after the date of the Participant&#8217;s termination of employment and (ii) the Expiration Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(D)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">If a Participant ceases to be a bona fide employee of the Corporation or of its Affiliates during the Option Period by reason of Early Retirement, (i)&#160;the Option shall be exercisable only to the extent that it was exercisable at the time of such retirement and (ii)&#160;the Option Period for that portion of the Option designated as a Nonstatutory Stock Option shall end on the earlier of (a) three years after the date of such retirement and (b) the Expiration Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(E)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.24pt">If a Participant ceases to be a bona fide employee of the Corporation or of its Affiliates during the Option Period by reason of Normal Retirement&#58; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.57pt">If such Normal Retirement occurs prior to the first anniversary of the Grant Date of the Option, such Option shall be subject to the provisions of Section II.5(D) as though the Participant were eligible for Early Retirement&#59; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.8pt">If such Normal Retirement occurs on or after the first anniversary of the Grant Date of an Option, (a)&#160;that portion of the Option designated as a Nonstatutory Stock Option shall continue to vest as though the Participant had continued to be employed by the Corporation or one of its Affiliates during such vesting period, and (b)&#160;the Option Period for such portion of the Option designated as a Nonstatutory Stock Option shall end on the Expiration Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(F)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">If a Participant ceases to be a bona fide employee of the Corporation or of its Affiliates during the Option Period by reason of Severance, and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.57pt">The Participant has attained the requirements for Normal Retirement on or prior to the Participant&#8217;s termination date, then such Option shall be subject to the Normal Retirement provisions of Section II.5(E)&#59; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.8pt">The Participant has not attained the requirements for Normal Retirement on or prior to the Participant&#8217;s termination date, but would have attained the requirements for Normal Retirement within six months after the termination date, and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:121.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:11.21pt">The first anniversary of the Grant Date of the applicable Award has not occurred on or prior to the termination date, then such Option shall be subject to the Early Retirement provision in Section II.5(D)&#59; or</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:121.7pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.64pt">The first anniversary of the Grant Date of the applicable Award has occurred on or prior to the termination date, then (x) that portion of the Option designated as a Nonstatutory Stock Option shall continue to vest as though the Participant had continued to be employed by the Corporation or one of its Affiliates during such vesting period, and (y) the Option Period for such portion of the Option designated as a Nonstatutory Stock Option shall end on the Expiration Date&#59; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:21.03pt">The Participant has not attained the requirements for Normal Retirement on or prior to the Participant&#8217;s termination date, and would not have attained the requirements for Normal Retirement within six months after the termination date, then (a) the vesting schedule of the Participant&#8217;s Option shall be accelerated as to the portion of the Option that would have vested in accordance with the original vesting schedule as though the Participant had continued to be employed by the Corporation or one of its Affiliates six months after the termination date, and (b) the expiration of the Option Period provided in Section II.5(A) shall apply&#59; provided that if the Participant is also eligible for Early Retirement at the time of the termination of employment, then the expiration of the Option Period provided in Section II.5(D) shall apply.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(G)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">If a Participant should die (i) while in the employ of the Corporation or an Affiliate and (ii) during the Option Period, the vesting schedule of the Participant&#8217;s Option shall be accelerated and the Option shall become fully exercisable, the Option Period shall end on the earlier of (a) three years after the date of death and </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b) the Expiration Date, and the Participant&#8217;s Beneficiary may exercise the entire unexercised portion of the then exercisable Shares covered by such Option (or any lesser amount)&#160;remaining on the date of death.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(H)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">If a Participant who ceases to be a bona fide employee of the Corporation or an Affiliate is subsequently rehired prior to the expiration of the Participant's Option, then the Option shall continue to remain outstanding until the earlier of (i) such time as the Participant subsequently terminates employment and (ii) the Expiration Date.  Upon the Participant&#8217;s subsequent termination of employment, the post-termination exercise period calculated pursuant to the terms and conditions of this Section II.5 shall be reduced by the number of days between the date of the Participant&#8217;s initial termination of employment and the Participant's re-hire date&#59; provided, however, that if the rehired Participant continues to be employed by the Corporation or an Affiliate for at least one year from the Participant's rehire date, then the post termination exercise period for the Option shall be determined in accordance with Sections II.5(A) through (G) and shall not be adjusted as described in this Section II.5(H).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Method of Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  A Participant may exercise an Option with respect to all or any part of the exercisable Shares as follows&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">By giving the Corporation, or its authorized representative designated for this purpose, written notice of such exercise specifying the number of Shares as to which the Option is so exercised.  Such notice shall be accompanied by an amount equal to the Exercise Price multiplied by the number of Shares exercised, in the form of any one or combination of the following&#58;&#160;&#160;cash or a certified check, bank draft, postal or express money order payable to the order of the Corporation in lawful money of the United States.  Unless otherwise determined by the Administrator in its sole discretion, the Participant may pay the Exercise Price, in whole or in part, by tendering to the Corporation or its authorized representative Shares, which have been owned by the Participant for at least six months prior to said tender, and having a fair market value, as determined by the Corporation, equal to the Exercise Price, or in lieu of the delivery of actual Shares in such tender, the Corporation may accept an attestation by the Participant, in a form prescribed by the Corporation or its authorized representative, that the Participant owns sufficient Shares of record or in an account in street name to satisfy the Exercise Price, and such attestation will be deemed a tender of Shares for purposes of this method of exercise.  The Corporation or its authorized representative may accept payment of the amount due upon the exercise of the Option in the form of a Participant&#8217;s personal check.  Payment may also be made by delivery (including by FAX transmission)&#160;to the Corporation or its authorized representative of an executed irrevocable Option exercise form together with irrevocable instructions to an approved registered investment broker to sell Shares in an amount sufficient to pay the Exercise Price plus any applicable Tax-Related Items (as defined in Section VIII.6) and to transfer the proceeds of such sale to the Corporation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">If required by the Corporation, by giving satisfactory assurance in writing, signed by the Participant, the Participant shall give the Participant's assurance that the Shares subject to the Option are being purchased for investment and not with a view to the distribution thereof&#59; provided that such assurance shall be deemed inapplicable to (i)&#160;any sale of the Shares by such Participant made in accordance with the terms of a registration statement covering such sale, which has heretofore been (or may hereafter be)&#160;filed and become effective under the U.S. Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;)&#160;and with respect to which no stop order suspending the effectiveness thereof has been issued, and (ii)&#160;any other sale of the Shares with respect to which, in the opinion of counsel for the Corporation, such assurance is not required to be given in order to comply with the provisions of the Securities Act.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(C)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">As soon as practicable after receipt of the notice and the assurance described in Sections&#160;II.6(A)&#160;and (B), the Corporation shall, without transfer or issue tax (except for withholding tax arrangements contemplated in Section&#160;VIII.6)&#160;and without other incidental expense to the Participant, credit the purchased Shares to the Participant&#8217;s brokerage account of record.  If the Participant does not have a brokerage account of record, then the Corporation shall cause an appropriate book entry to be entered in the records of the Corporation&#8217;s transfer agent recording the Participant&#8217;s unrestricted interest in the purchased Shares&#59; provided, however, that the time of such delivery may be postponed by the Corporation for such period as may be required for it with reasonable diligence to comply with applicable registration requirements under the Securities Act, the Exchange Act, any applicable listing requirements of any national securities exchange and requirements under any other law or regulation applicable to the issuance or transfer of the Shares.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Limitations on Transfer</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  An Option shall, during a Participant&#8217;s lifetime, be exercisable only by the Participant.  No Option or any right granted thereunder shall be transferable by the Participant by operation of law or otherwise, other than by will or the laws of descent and distribution.  Notwithstanding the foregoing&#58; (A)&#160;unless otherwise determined by the Administrator in its sole discretion, a Participant may designate a beneficiary to succeed, after the Participant&#8217;s death, to all of the Participant&#8217;s Options outstanding on the date of death&#59; (B)&#160;a Nonstatutory Stock Option may be transferable pursuant to a qualified domestic relations order as defined in the Code or Title I of the U.S. Employee Retirement Income Security Act&#59; and (C)&#160;any Participant, who is a senior executive officer recommended by the Chief Executive Officer of the Corporation and approved by the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Administrator may voluntarily transfer any Nonstatutory Stock Option to a Family Member as a gift or through a transfer to an entity in which more than 50% of the voting interests are owned by Family Members (or the Participant)&#160;in exchange for an interest in that entity.  In the event of any attempt by a Participant to alienate, assign, pledge, hypothecate, or otherwise dispose of an Option or of any right thereunder, except as provided herein, or in the event of the levy of any attachment, execution, or similar process upon the rights or interest hereby conferred, the Corporation at its election may terminate the affected Option by notice to the Participant and the Option shall thereupon become null and void.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">No Stockholder Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Neither a Participant nor any person entitled to exercise a Participant&#8217;s rights in the event of the Participant&#8217;s death shall have any of the rights of a stockholder with respect to the Shares subject to an Option except to the extent that a book entry has been entered in the records of the Corporation&#8217;s transfer agent with respect to such Shares upon the exercise of an Option.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">III.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:21.83pt">RESTRICTED STOCK</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Restricted Stock Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  A Restricted Stock Award granted under the Plan shall be evidenced by a Restricted Stock Agreement to be executed by the Participant and the Corporation setting forth the terms and conditions of the Restricted Stock Award.  Each Restricted Stock Grant Notice shall incorporate by reference and be subject to this Statement of Terms and Conditions, including the special terms and conditions in the Appendix for the Participant&#8217;s country (if any) which forms part of this Statement of Terms and Conditions, and together both documents shall constitute the Restricted Stock Agreement.  The Restricted Stock Award is also subject to the terms and conditions of the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Rights with Respect to Shares of Restricted Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Upon written acceptance of a Restricted Stock Award by a Participant, including the restrictions and other terms and conditions described in the Plan and the Restricted Stock Agreement, the Corporation shall cause an appropriate book entry to be entered in the records of the Corporation&#8217;s transfer agent recording the Participant&#8217;s interest in the Restricted Stock.  From and after the Grant Date, the Participant shall have the rights of Common Stock ownership, including the right to vote and to receive dividends on Shares of Restricted Stock, subject to the terms, conditions and restrictions described in the Plan and the Restricted Stock Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Special Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Each Restricted Stock Award made under the Plan shall be subject to the following terms, conditions and restrictions and such additional terms, conditions and restrictions as may be determined by the Administrator&#59; provided, however, that no Restricted Stock grant shall be subject to additional terms, conditions and restrictions which are more favorable to a Participant than the terms, conditions and restrictions set forth elsewhere in the Plan or the Restricted Stock Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt;text-decoration:underline">Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Until the restrictions imposed on any Restricted Stock grant shall lapse (the &#8220;Restriction Period&#8221;), Shares of Restricted Stock granted to a Participant&#160;(i)&#160;shall not be sold, assigned, transferred, pledged, hypothecated, or otherwise disposed of, other than pursuant to a qualified domestic relations order as defined in the Code or Title I of the U.S. Employee Retirement Income Security Act and (ii)&#160;shall, if the Participant&#8217;s continuous employment with the Corporation or any of its Affiliates shall terminate for any reason (except as otherwise provided in the Plan, or in Section&#160;III.3(B) or Section III.3(C))&#160;be returned to the Corporation forthwith, and all the rights of the Participant to such Shares shall immediately terminate.  If a Participant is absent from work with the Corporation or an Affiliate because of the Participant's Short-Term Disability or because the Participant is on an approved leave of absence, the Participant shall not be deemed during the period of any such absence, by virtue of such absence alone, to have terminated employment with the Corporation or an Affiliate except as the Administrator may otherwise expressly determine.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt;text-decoration:underline">Termination of Employment by Reason of Death, Long-Term Disability or Normal Retirement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Notwithstanding any provision to the contrary contained in the Restricted Stock Grant Notice, if a Participant who has been in the continuous employment of the Corporation or any of its Affiliates since the Grant Date of a Restricted Stock Award ceases to be a bona fide employee of the Corporation or an Affiliate as a result of&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.57pt">Death or Long-Term Disability, then the restrictions imposed on any Restricted Stock Award shall lapse as to all Shares granted to such Participant pursuant to such Restricted Stock Award on the date of such termination&#59; or </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.8pt">Normal Retirement on or after the first anniversary of the Grant Date of any time-vesting Restricted Stock Award, the restrictions applicable to such Restricted Stock Award shall continue to lapse at such time(s) as are set forth in the applicable Grant Notice, as though the Participant had continued to be employed by the Corporation or one of its Affiliates during such restricted period&#59; provided, that notwithstanding any other provision of the Plan or this Statement of Terms and Conditions, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">this Section III.3(B)(ii) shall not apply to any Restricted Stock Award the vesting of which is based, in whole or in part, on attainment of performance objectives.  The procedures set forth in Section VIII.6 will be applied for any taxes due upon the lapse of restrictions imposed on a Restricted Stock Award due to a Participant&#8217;s Normal Retirement eligibility.</font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(C)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt;text-decoration:underline">Termination of Employment by Reason of Severance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Notwithstanding any provision to the contrary contained in the Restricted Stock Grant Notice, if a Participant who has been in the continuous employment of the Corporation or any of its Affiliates since the Grant Date of a Restricted Stock Award ceases to be a bona fide employee of the Corporation or an Affiliate as a result of Severance, and&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.57pt">The Participant either (a) has attained the requirements for Normal Retirement on or prior to the Participant&#8217;s termination date or (b)&#160;would have attained the requirements for Normal Retirement within six months after the Participant&#8217;s termination date, then any time-vesting Restricted Stock Award shall be subject to the Normal Retirement provisions of Section&#160;III.3(B)(ii)&#59; or</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.8pt">The Participant has not attained the requirements for Normal Retirement on or prior to the Participant&#8217;s termination date, and would not have attained the requirements for Normal Retirement within six months after the Participant&#8217;s termination date, then the restrictions applicable to any time-vesting Restricted Stock Award shall lapse upon the Participant&#8217;s termination date, as to such Shares of Restricted Stock that would have vested at such time(s) as are set forth in the applicable Grant Notice as if the Participant had continued to be employed by the Corporation or one of its Affiliates during the six-month period after the Participant&#8217;s termination date.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, this Section III.3(C) shall not apply to any Restricted Stock Award the vesting of which is based, in whole or in part, on attainment of performance objectives. The procedures set forth in Section VIII.6 will be applied for any taxes due upon the lapse of restrictions imposed on a Restricted Stock Award due to a Participant&#8217;s Normal Retirement eligibility.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Dividends</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Cash dividends paid with respect to Restricted Stock during the Restriction Period shall be credited on behalf of the Participant to a deferred cash account (in a manner designed to comply with Code Section 409A) and the restrictions on such cash dividends shall lapse at the same time that the restrictions lapse on the associated Restricted Stock Award.  Stock dividends paid with respect to Restricted Stock during the Restriction Period shall be treated as Restricted Stock which shall be subject to the same restrictions as the original award for the duration of the Restriction Period.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Election to Recognize Gross Income in the Year of Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  If any Participant who is a U.S. taxpayer validly elects within 30 days of the Grant Date, to include in gross income for federal income tax purposes an amount equal to the fair market value of the Shares of Restricted Stock granted on the Grant Date, such Participant shall (at the same time or prior to the date that the Participant files the Participant's election with the Internal Revenue Service) (A) pay to the Corporation, or make arrangements satisfactory to the Administrator to pay to the Corporation in the year of such grant, any federal, state or local taxes required to be withheld with respect to such Shares in accordance with Section&#160;VIII.6, and (B) provide the Administrator with a copy of the election filed with the Internal Revenue Service.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Restrictive Legend</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Each book entry in the records of the Corporation&#8217;s transfer agent evidencing Shares granted pursuant to a Restricted Stock grant may bear an appropriate legend referring to the terms, conditions and restrictions described in the Plan and&#47;or the Restricted Stock Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Expiration of Restriction Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  If and when the Restriction Period applicable to the Restricted Stock expires without a prior forfeiture, Shares shall be credited to the Participant&#8217;s brokerage account of record.  If the Participant does not have a brokerage account of record, then an appropriate book entry recording the Participant&#8217;s interest in the unrestricted Shares shall be entered on the records of the Corporation&#8217;s transfer agent.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">IV.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.39pt">RESTRICTED STOCK UNITS </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Restricted Stock Unit Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Restricted Stock Units granted under the Plan shall be evidenced by a Restricted Stock Unit Agreement to be executed by the Participant and the Corporation setting forth the terms and conditions of the Restricted Stock Units.  Each Restricted Stock Unit Grant Notice shall incorporate by reference and be subject to this Statement of Terms and Conditions, including the special terms and conditions in the Appendix for the Participant&#8217;s country (if any) which forms part of this Statement of Terms and Conditions, and together both documents shall constitute the Restricted Stock Unit Agreement.  The Restricted Stock Units are also subject to the terms and conditions of the Plan.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Special Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Restricted Stock Units granted under the Plan shall be subject to the following terms, conditions and restrictions and such additional terms, conditions and restrictions as may be determined by the Administrator, consistent with the terms of the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt;text-decoration:underline">Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  If a Participant ceases to be a bona fide employee of the Corporation or any Affiliate (except as otherwise provided in the Plan, or in Section IV.2(B) or Section IV.2(C)) prior to the lapse of the restrictions imposed on the Award, the unvested Restricted Stock Units shall be canceled, and all the rights of the Participant to such Awards shall immediately terminate.  If a Participant is absent from work with the Corporation or an Affiliate because of the Participant's Short-Term Disability or because the Participant is on an approved leave of absence, the Participant shall not be deemed during the period of any such absence, by virtue of such absence alone, to have terminated employment with the Corporation or an Affiliate except as the Administrator may otherwise expressly determine.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt;text-decoration:underline">Termination of Employment by Reason of Death, Long-Term Disability or Normal Retirement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Notwithstanding any provision contained to the contrary in the Restricted Stock Unit Grant Notice, if a Participant who has been in the continuous employment of the Corporation or any of its Affiliates since the Grant Date of such Award ceases to be a bona fide employee of the Corporation or an Affiliate as a result of&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.57pt">Death or Long-Term Disability, then the restrictions imposed on any Award of Restricted Stock Units shall lapse on the date of such termination&#59; or</font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.8pt">Normal Retirement on or after the first anniversary of the Grant Date of any time-vesting Restricted Stock Units, the restrictions applicable to such Restricted Stock Units shall continue to lapse at such time(s) as are set forth in the applicable Grant Notice, as though the Participant had continued to be employed by the Corporation or one of its Affiliates during such restricted period.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(C)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt;text-decoration:underline">Termination of Employment by Reason of Severance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Notwithstanding any provision to the contrary contained in the Restricted Stock Unit Grant Notice, if a Participant who has been in the continuous employment of the Corporation or any of its Affiliates since the Grant Date of a Restricted Stock Unit Award ceases to be a bona fide employee of the Corporation or an Affiliate as a result of Severance, and&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.57pt">The Participant either (a) has attained the requirements for Normal Retirement on or prior to the Participant&#8217;s termination date or (b)&#160;would have attained the requirements for Normal Retirement within six months after the Participant&#8217;s termination date, then any time-vesting Restricted Stock Unit Award shall be subject to the Normal Retirement provisions of Section IV.2(B)(ii)&#59; or</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.8pt">The Participant has not attained the requirements for Normal Retirement on or prior to the Participant&#8217;s termination date, and would not have attained the requirements for Normal Retirement within six months after the Participant&#8217;s termination date, then the restrictions applicable to any time-vesting Restricted Stock Unit Award shall lapse upon the termination date, as to such Restricted Stock Units that would have vested at such time(s) as are set forth in the applicable Grant Notice as if the Participant had continued to be employed by the Corporation or one of its Affiliates during the six-month period after the termination date.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Dividend Equivalents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Subject to the discretion of the Compensation Committee, dividend equivalents shall be credited in respect of Restricted Stock Units.  Cash dividends shall be credited on behalf of the Participant to a deferred cash account (in a manner designed to comply with Code Section 409A) and the restrictions on such cash dividends shall lapse at the same time that the restrictions lapse on the associated Award of Restricted Stock Units, and cash dividends shall be paid in a lump sum at the same time that the Shares underlying the Restricted Stock Unit Award, and to which the cash dividends relate, are distributed.  Stock dividends shall be converted into additional Restricted Stock Units, which will be subject to all of the terms and conditions of the underlying Restricted Stock Units, including the same vesting restrictions as the underlying Award. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Assignability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  A Participant shall not be permitted to sell, transfer, pledge, assign or encumber Restricted Stock Units, other than pursuant to a qualified domestic relations order as defined in the Code or Title I of the U.S. Employee Retirement Income Security Act.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">No Stockholder Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Neither a Participant nor any person entitled to exercise a Participant&#8217;s rights in the event of the Participant&#8217;s death shall have any of the rights of a stockholder with respect to an Award of Restricted Stock Units except to the extent that a book entry has been entered in the records of the Corporation&#8217;s transfer agent with respect to the Shares paid upon the settlement of any vested Restricted Stock Units.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Time of Payment of Restricted Stock Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Upon the lapse of the restriction imposed on Restricted Stock Units, all Restricted Stock Units that were not forfeited pursuant to Section&#160;IV.2(A), Section IV.2(B)(i), Section IV.2(C)(i),&#160;or Section VI shall be paid to the Participant as soon as reasonably practicable after the restrictions lapse.  Payment shall be made in Shares to the Participant&#8217;s brokerage account of record.  If the Participant does not have a brokerage account of record, then in the form of an appropriate book entry entered in the records of the Corporation&#8217;s transfer agent recording the Participant&#8217;s unrestricted interest in the number of Shares subject to the Restricted Stock Units.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, if a Participant becomes eligible for Normal Retirement, or is eligible for additional vesting under Section IV.2(C)(ii), prior to the date of the lapse of restrictions imposed on Restricted Stock Units and the vesting provisions of Section IV.2(B)(ii) or Section IV.2(C)(ii) apply, then such Restricted Stock Units shall be paid to the Participant&#8217;s brokerage account of record as soon as reasonably practicable after the earlier of the Participant&#8217;s Separation from Service or the originally scheduled vesting date (in any event before the end of the calendar year in which such date occurs), subject to the delay of payment (if applicable) provided in Section VIII.14.  The procedures set forth in Section VIII.6 will be applied for any taxes due upon the lapse of restrictions imposed on a Restricted Stock Unit Award due to a Participant&#8217;s Normal Retirement eligibility or additional vesting as provided in Section IV.2(C)(ii).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">V.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:26.28pt">PERFORMANCE STOCK UNITS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Award Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Performance Stock Unit Awards shall be evidenced by a Performance Stock Unit Agreement to be executed by the Participant and the Corporation setting forth the terms and conditions of the Performance Stock Unit Award.  Performance Stock Unit Awards are &#8220;Performance Awards&#8221; as provided under Section 10 of the Plan.  Each Performance Stock Unit Agreement shall incorporate by reference and be subject to this Statement of Terms and Conditions, including the special terms and conditions in the Appendix for the Participant&#8217;s country (if any) which forms part of this Statement of Terms and Conditions, and together both documents shall constitute the Performance Stock Unit Agreement.  Performance Stock Unit Awards are also subject to the terms and conditions of the Plan.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Number of Shares Granted Based on Performance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The performance period of a Performance Stock Unit Award shall be greater than one year, and performance shall be based on such criteria as the Compensation Committee shall determine in its discretion at the beginning of the performance period.  Following the end of the performance period, the Compensation Committee shall determine the extent to which the criteria have been achieved, and shall authorize the grant and issuance of Shares in respect of the Performance Stock Unit Award.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Special Conditions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Performance Stock Unit Awards shall be subject to the following terms, conditions and restrictions and such additional terms, conditions and restrictions as may be determined by the Compensation Committee, consistent with the terms of the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt;text-decoration:underline">Forfeiture</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  If a Participant ceases to be a bona fide employee of the Corporation or any Affiliate (except as otherwise provided in the Plan or in Section V.3(B) or Section V.3(C)) prior to the end of the performance period, any then-outstanding Performance Stock Units shall be canceled, and all the rights of the Participant to such Award shall immediately terminate.  If a Participant is absent from work with the Corporation or an Affiliate because of the Participant's Short-Term Disability or because the Participant is on an approved leave of absence, the Participant shall not be deemed during the period of any such absence, by virtue of such absence alone, to have terminated employment with the Corporation or an Affiliate except as the Compensation Committee may otherwise expressly determine.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt;text-decoration:underline">Termination of Employment by Reason of Death, Long-Term Disability or Normal Retirement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Notwithstanding any provision contained herein or in the Plan or the Award Agreement to the contrary, if a Participant who has been in the continuous employment of the Corporation or any of its Affiliates since the Grant Date of such Award ceases to be a bona fide employee of the Corporation or an Affiliate as a result of&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.57pt">Death or Long-Term Disability, the Participant shall be eligible to receive, following completion of the applicable performance period, a prorated portion of each such Performance Stock Unit Award, equal to (1)&#160;the target number of Performance Stock Units subject to such Award, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">multiplied by</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (2)&#160;the performance criteria determined by the Compensation Committee to apply to such Award, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">multiplied by</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (3)&#160;a fraction, the numerator of which is the number of whole calendar months, rounded down to the nearest whole month, during which the Participant provided Service to the Corporation or an Affiliate during the performance period applicable to such Award, and the denominator of which is the number of calendar months in such performance period&#59; provided, that for purposes of this clause&#160;(3), &#8220;whole calendar months&#8221; shall be calculated commencing on the applicable Grant Date&#59; </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">provided, however, that in no event shall such amount exceed any applicable cap or limitation set forth in the Performance Stock Unit Grant Notice&#59; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.8pt">Normal Retirement on or after the first anniversary of the Grant Date, the Participant shall be eligible to vest in such Performance Stock Unit Award following completion of the applicable performance period, as though the Participant had continued to be employed by the Corporation or one of its Affiliates through the date on which the Compensation Committee determines performance against the applicable performance goals.  </font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts, if any, to be paid under this Section V.3(B) shall be paid in accordance with Section&#160;V.7 and, if applicable, Section&#160;VIII.14.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(C)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt;text-decoration:underline">Termination of Employment by Reason of Severance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. Notwithstanding any provision to the contrary, if the Participant has been in the continuous employment of the Corporation or any of its Affiliates since the Grant Date and ceases to be a bona fide employee of the Corporation or an Affiliate as a result of Severance, and&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.57pt">The Participant either (a) has attained the requirements for Normal Retirement on or prior to the Participant&#8217;s termination date or (b)&#160;would have attained the requirements for Normal Retirement within six months after the Participant&#8217;s termination date, then any Performance Stock Unit Award shall be subject to the Normal Retirement provisions of Section V.3(B)(ii)&#59; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:108pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.8pt">The Participant has not attained the requirements for Normal Retirement on or prior to the Participant&#8217;s termination date, and would not have attained the requirements for Normal Retirement within six months after the Participant&#8217;s termination date, then if such Participant&#8217;s termination date is no greater than six months prior to the date on which the Compensation Committee determines performance against the applicable performance goals, such Participant shall be eligible to vest in such Performance Stock Unit Award following completion of the applicable performance period, as though the Participant had continued to be employed by the Corporation or one of its Affiliates through such performance determination date.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts, if any, to be paid under this Section V.3(C) shall be paid in accordance with Section&#160;V.7 and, if applicable, Section&#160;VIII.14.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Dividend Equivalents</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Unless otherwise determined by the Compensation Committee in its sole discretion, Dividend Equivalents shall not be accrued with respect to Performance Stock Unit Awards during the performance period. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Assignability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  A Participant shall not be permitted to sell, transfer, pledge, assign or encumber all or any portion of a Performance Stock Unit Award.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">No Stockholder Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Neither a Participant nor any person entitled to exercise a Participant&#8217;s rights in the event of the Participant&#8217;s death shall have any of the rights of a stockholder with respect to a Performance Stock Unit Award, except to the extent that a book entry has been entered in the records of the Corporation&#8217;s transfer agent with respect to the Shares paid upon the settlement of any Performance Stock Unit Award.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Time of Payment of Performance Stock Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Compensation Committee shall determine the extent to which Shares are payable pursuant to a Performance Stock Unit Award as soon as practicable following the end of the performance period, and such Shares shall be paid as soon as practicable thereafter and in any event no later than the end of the period under which payment would be deemed to be a &#8220;short-term deferral&#8221; as defined in the regulations under Code Section 409A.  Payment shall be made in the form of Shares to the Participant&#8217;s brokerage account of record.  If the Participant does not have a brokerage account of record, then in the form of an appropriate book entry entered in the records of the Corporation&#8217;s transfer agent recording the Participant&#8217;s unrestricted interest in the number of Shares earned pursuant to the Performance Stock Unit Award.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">VI.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.39pt">SPECIAL FORFEITURE AND REPAYMENT RULES</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Any other provision of this Statement of Terms and Conditions to the contrary notwithstanding, if the Administrator determines that a Participant has engaged in any of the actions described in 3 below, the consequences set forth in 1 and 2 below shall result&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt">Any outstanding Option shall immediately and automatically terminate, be forfeited and shall cease to be exercisable, without limitation.  In addition, any Award of Restricted Stock or Restricted Stock Units as to which the restrictions have not lapsed shall immediately and automatically be forfeited, Performance Stock Unit Awards shall immediately and automatically be forfeited and any such Shares of Restricted Stock shall be returned to the Corporation and all of the rights of the Participant to such Awards and the underlying Shares shall immediately terminate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt">If the Participant exercised an Option within 12 months prior to the date upon which the Corporation discovered that the Participant engaged in any actions described in 3 below, the Participant, upon written notice from the Corporation, shall immediately pay to the Corporation the economic value realized or obtained by the exercise of such Option measured at the date of exercise.  In addition, if the restrictions imposed on any Award of Restricted Stock or Restricted Stock Units (including any unpaid dividends or Dividend Equivalents) lapsed, or any Performance Stock Unit Award was settled, within 12 months prior to the date the Corporation discovered that the Participant engaged in any action described in 3 below, the Participant, upon written notice from the Corporation, shall immediately pay to the Corporation the economic value realized or obtained with respect to such Award, measured at the date such Award vested. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt">The consequences described in 1 and 2 above shall apply if the Participant, either before or after termination of employment with the Corporation or its Affiliates&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">Discloses to others, or takes or uses for the Participant&#8217;s own purpose or the purpose of others, any trade secrets, confidential information, knowledge, data or know-how or any other proprietary information or intellectual property belonging to the Corporation or its Affiliates and obtained by the Participant during the term of the Participant&#8217;s employment, whether or not they are the Participant&#8217;s work product.  Examples of such confidential information or trade secrets include, without limitation, customer lists, supplier lists, pricing and cost data, computer programs, delivery routes, advertising plans, wage and salary data, financial information, research and development plans, processes, equipment, product information and all other types and categories of information as to which the Participant knows or has reason to know that the Corporation or its Affiliates intends or expects secrecy to be maintained&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">Fails to promptly return all documents and other tangible items belonging to the Corporation or its Affiliates in the Participant&#8217;s possession or control, including all complete or partial copies, recordings, abstracts, notes or reproductions of any kind made from or about such documents or information contained therein, upon termination of employment, whether pursuant to retirement or otherwise&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(C)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">Fails to provide the Corporation with at least 30&#160;days&#8217; written notice prior to directly or indirectly engaging in, becoming employed by, or rendering services, advice or assistance to any business in competition with the Corporation or its Affiliates.  As used herein, &#8220;business in competition&#8221; means any person, organization or enterprise which is engaged in or is about to become engaged in any line of business engaged in by the Corporation or its Affiliates at the time of the termination of the Participant&#8217;s employment with the Corporation or its Affiliates&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(D)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">Fails to inform any new employer, before accepting employment, of the terms of this paragraph and of the Participant&#8217;s continuing obligation to maintain the confidentiality of the trade secrets and other confidential information belonging to the Corporation or its Affiliates and obtained by the Participant during the term of the Participant&#8217;s employment with the Corporation or any of its Affiliates&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(E)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.24pt">Induces or attempts to induce, directly or indirectly, any of the customers of the Corporation or its Affiliates, employees, representatives or consultants to terminate, discontinue or cease working with or for the Corporation or its Affiliates, or to breach any contract with the Corporation or any of its Affiliates, in order to work with or for, or enter into a contract with, the Participant or any third party&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(F)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">Engages in conduct which is not in good faith and which disrupts, damages, impairs or interferes with the business, reputation or employees of the Corporation or its Affiliates&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(G)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">Fails to meet the Participant&#8217;s continuing obligations with respect to non-disclosure, non-competition and&#47;or non-solicitation under the Participant&#8217;s agreement with the Corporation or any Affiliate.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Administrator shall determine in its sole discretion whether the Participant has engaged in any of the acts set forth in (A) through (G) above, and its determination shall be conclusive and binding on all interested persons.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Any provision of this Section&#160;VI which is determined by a court of competent jurisdiction to be invalid or unenforceable should be construed or limited in a manner that is valid and enforceable and that comes closest to the business objectives intended by such invalid or unenforceable provision, without invalidating or rendering unenforceable the remaining provisions of this Section&#160;VI.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">VII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:18.5pt">CHANGE IN CONTROL  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If as a result of a Change in Control, the Common Stock ceases to be listed for trading on a national securities exchange (an &#8220;Exchange&#8221;), any Option, Restricted Stock Award, Restricted Stock Unit Award or Performance Stock Unit Award that is unvested on the effective date of the Change in Control shall continue to vest according to the terms and conditions of such Award, provided that such Award is replaced with an award for voting securities of the resulting corporation or the acquiring corporation, as the case may be, (including without limitation, the voting securities of any corporation which as a result of the Change in Control owns the Corporation or all or substantially all of the Corporation&#8217;s assets either directly or through one or more subsidiaries) (the &#8220;Surviving Company&#8221;) which are traded on an Exchange (a &#8220;Replacement Award&#8221;), which Replacement Award, (i) in the case of an Option, shall consist of an option with the number of underlying shares and exercise price determined in a manner consistent with Code Section 424(a) with vesting and any other terms continuing in the same manner as the replaced Option&#59; (ii) in the case of a Performance Stock Unit Award, shall consist of restricted stock or restricted stock units with a value (determined using the Surviving Company&#8217;s stock price as of the effective date of the Change in Control) equal to the value of the Performance Stock Unit Award (determined using the Corporation&#8217;s stock price and assuming attainment of target performance or actual performance achieved, if greater, as of the effective date of the Change in Control), with any restrictions on such Replacement Award lapsing at the end of the measuring period over which performance for the replaced Performance Stock Unit Award was to be measured prior to the granting of the Replacement Award&#59; and (iii) in the case of a Restricted Stock Award or Restricted Stock Unit Award, shall consist of restricted stock or restricted stock units with a value (determined using the Surviving Company&#8217;s stock price as of the effective date of the Change in Control) equal to the value of the Restricted Stock Award or Restricted Stock Unit Award (determined using the Corporation&#8217;s stock price as of the effective date of the Change in Control), with any restrictions on such restricted stock or restricted stock units lapsing at the same time and manner as the replaced Award&#59; provided, however, that in the event of the Participant&#8217;s involuntary Separation from Service by the Corporation without Cause or Separation from Service by the Participant for Good Reason during the vesting period of any Replacement Award, the Replacement Award shall immediately vest and be paid as soon as practicable following such Separation from Service (subject to Section VIII.14), based on the fair market value of the underlying shares on the vesting date, or in the case of options, based on the excess of the fair market value of the underlying shares over the option exercise price on the vesting date. If any Option, Restricted Stock Award, Restricted Stock Unit Award or Performance Stock Unit Award that is unvested at the effective time of the Change in Control is not replaced with a Replacement Award, such Award shall immediately vest and, in the case of a Performance Stock Unit Award, shall vest based upon deemed attainment of target performance or actual performance achieved, if greater.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If as a result of a Change in Control, the Common Stock continues to be listed for trading on an Exchange, any unvested Option, Restricted Stock Award, or Restricted Stock Unit Award shall continue to vest according to the terms and conditions of such Award and any Performance Stock Unit Award shall be replaced with a Restricted Stock Unit Award where the number of shares subject to such Restricted Stock Unit Award shall be equal to the number of Shares assuming attainment of target performance or actual performance achieved, if greater, as of the effective date of the Change in Control with any restrictions on such Restricted Stock Unit Award lapsing at the end of the measuring period over which performance for the replaced Performance Stock Unit Award was to be measured prior to the granting of the Replacement Award&#59; provided however, that, in the event of the Participant&#8217;s involuntary Separation from Service by the Corporation without Cause or Separation from Service by the Participant for Good Reason during the vesting period of an Award, such Award shall immediately vest and be paid as soon as practicable following such Separation from Service (subject to Section VIII.14).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">VIII.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:14.61pt">MISCELLANEOUS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">No Effect on Terms of Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Participation in the Plan shall not create a right to further employment with the Participant&#8217;s employer (the &#8220;Employer&#8221;) and shall not interfere with the ability of the Employer to terminate, with or without cause, or change the terms of employment of a Participant at any time.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Grants to Participants in Foreign Countries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  In making grants to Participants in foreign countries, the Administrator has the full discretion to deviate from this Statement of Terms and Conditions in order to adjust grants under the Plan to prevailing local conditions, including custom and legal and tax requirements.  Furthermore, the Corporation reserves the right to impose other requirements on the Participant&#8217;s participation in the Plan on the Award and on any Shares acquired under the Plan, to the extent the Corporation determines it is necessary or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">advisable in order to comply with local law or facilitate the administration of the Plan, and to require the Participant to sign any additional agreements or undertaking that may be necessary to accomplish the foregoing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Information Notification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Any information required to be given under the terms of an Award shall be addressed to the Corporation in care of its Corporate Secretary at McKesson Corporation, 6555 North State Highway 161, Irving, Texas 75039, and any notice to be given to a Participant shall be addressed to such Participant at the address indicated beneath the Participant's name on the Award Agreement or such other address as either party may designate in writing to the other.  Any such notice shall be deemed to have been duly given when enclosed in a properly sealed envelope or wrapper addressed as aforesaid, registered or certified and deposited (postage or registration or certification fee prepaid)&#160;in a post office or branch post office.  The parties may use email delivery, so long as the message is clearly marked, sent to the email address(es) set forth herein, and a delivery receipt and a read receipt are made part of the message.&#160; Email delivery will be deemed to occur when the sender receives confirmation that such message has been received and read by the recipient.  Emails to the Corporation shall be delivered to CorpSecretary&#64;McKesson.com.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Administrator Decisions Conclusive</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  All decisions of the Administrator administering the Plan upon any questions arising under the Plan or under an Award Agreement, shall be conclusive and binding on all interested persons.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">No Effect on Other Benefit Plans</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Nothing herein contained shall affect a Participant&#8217;s right to participate in and receive benefits from and in accordance with the then current provisions of any pensions, insurance or other employment welfare plan or program offered by the Corporation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  Regardless of any action the Corporation or the Employer takes with respect to any federal, state or local income tax, social insurance contributions, payroll tax, payment on account or other tax-related items related to the Participant&#8217;s participation in the Plan and legally applicable to the Participant (&#8220;Tax-Related Items&#8221;), the Participant acknowledges that the ultimate liability for all Tax-Related Items is and remains the Participant's responsibility and may exceed the amount actually withheld by the Corporation or the Employer.  The Participant further acknowledges that the Corporation and&#47;or the Employer (1) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of the Award, including the grant, vesting, settlement or exercise of the Award, as applicable, the subsequent sale of Shares acquired pursuant to the Plan and the receipt of any dividends and&#47;or dividend equivalents&#59; and (2) do not commit and are under no obligation to structure the terms of the grant or any aspect of the Award to reduce or eliminate the Participant&#8217;s liability for Tax-Related Items or achieve any particular tax result.  Further, if the Participant has become subject to tax in more than one jurisdiction between the Grant Date and the date of any relevant taxable event, the Participant acknowledges that the Corporation and&#47;or the Employer (or former employer, as applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior to any relevant taxable or tax withholding event, as applicable, the Participant will pay or make adequate arrangements satisfactory to the Corporation and&#47;or the Employer, or their respective agents, at their discretion, to satisfy the obligations with regard to all Tax-Related Items by one or a combination of the following&#58; (1) withholding from the Participant&#8217;s wages or other cash compensation paid to the Participant by the Corporation and&#47;or the Employer&#59; (2)&#160;withholding from proceeds of the sale of Shares acquired under the Plan either through a voluntary sale or through a mandatory sale arranged by the Corporation (on the Participant&#8217;s behalf pursuant to this authorization and any other authorization the Corporation and&#47;or the broker designated by the Corporation may require the Participant to sign in connection with the sale of Shares)&#59; (3) withholding Shares to be issued upon grant, vesting&#47;settlement or exercise, as applicable&#59; or (4) any other method of withholding determined by the Corporation and to the extent required by applicable law or the Plan, approved by the Compensation Committee. Calculation of the number of Shares to be withheld shall be made based on the closing price of the Common Stock on the New York Stock Exchange on the date that the amount of tax to be withheld is determined.  In no event, however, shall the Corporation be required to issue fractional Shares.  With respect to an Award other than an Option, if adequate arrangements to satisfy the obligations with regard to all Tax-Related Items are not made by the Participant with the Corporation and&#47;or the Employer prior to the relevant taxable event, the Corporation will satisfy such obligations as provided above in clause (3) of this paragraph.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Corporation or the Employer may withhold or account for Tax-Related Items by considering applicable minimum statutory withholding amounts or other applicable withholding rates, including maximum applicable rates in the Participant&#8217;s jurisdiction(s). If the obligation for Tax-Related Items is satisfied by withholding in Shares, for tax purposes, the Participant will be deemed to have been issued the full number of Shares subject to the Award, notwithstanding that a number of the Shares are held back solely for the purpose of paying the Tax-Related Items due as a result of any aspect of the Participant&#8217;s participation in the Plan. In the event any excess amounts are withheld to satisfy the obligation for Tax-Related Items, the Participant may be entitled to receive a refund of any over-withheld amount (with no entitlement to the Share equivalent), or if not refunded by the Corporation or the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employer, the Participant must seek a refund from the local tax authorities to the extent the Participant wishes to recover the over-withheld amount in the form of a refund. In the event of under-withholding, the Participant may be required to pay any additional Tax-Related Items directly to the applicable tax authority or to the Corporation and&#47;or the Employer.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finally, the Participant shall pay to the Corporation or the Employer any amount of Tax-Related Items that the Corporation or the Employer may be required to withhold or account for as a result of the Participant&#8217;s participation in the Plan that cannot be satisfied by the means previously described.  The Corporation may refuse to issue or deliver the Shares or the proceeds of the sale of Shares if the Participant fails to comply with the Participant's obligations in connection with the Tax-Related Items.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Administrator shall be authorized to establish such rules, forms and procedures as it deems necessary to implement the foregoing.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Successors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Award Agreements shall be binding upon and inure to the benefit of any successor or successors of the Corporation.  &#8220;Participant&#8221; as used herein shall include the Participant&#8217;s Beneficiary.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Delaware Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The interpretation, performance, and enforcement of all Award Agreements shall be governed by the laws of the State of Delaware.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt;text-decoration:underline">Nature of Grant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  In accepting the grant, the Participant acknowledges that&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">the Plan is established voluntarily by the Corporation, it is discretionary in nature and it may be modified, amended, suspended or terminated by the Corporation at any time&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">the grant of the Award is exceptional, voluntary and occasional and does not create any contractual or other right to receive future Award grants, or benefits in lieu of Awards, even if Awards have been granted repeatedly in the past&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(C)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.68pt">all decisions with respect to future Awards, if any, will be at the sole discretion of the Corporation&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(D)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">the Participant is voluntarily participating in the Plan&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(E)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.24pt">the Award and the Shares subject to the Award, and the income from and value of same, are not part of normal or expected compensation for any purpose, including, but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, end of service payments, bonuses, long-service awards, pension or retirement benefits or similar payments&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(F)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.78pt">the Award will not be interpreted to form an employment contract or relationship with the Corporation&#59; and furthermore, the Award will not be interpreted to form an employment contract with any subsidiary or Affiliate of the Corporation&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(G)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">the future value of the underlying Shares is unknown, indeterminable and cannot be predicted with certainty&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(H)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">if the underlying Shares do not increase in value, the Options will have no value&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:26.01pt">in consideration of the grant of the Award, no claim or entitlement to compensation or damages shall arise from forfeiture of the Award which results from termination of the Participant&#8217;s employment with the Employer or the Corporation or one of its Affiliates (for any reason whatsoever, and whether or not such forfeiture is later found to be invalid or in breach of employment laws in the jurisdiction where the Participant is employed or the terms of the Participant&#8217;s employment agreement, if any) and the Participant irrevocably releases the Corporation or its Affiliates from any such claim that may arise&#59; provided that, notwithstanding the foregoing, in the event any such claim is found by a court of competent jurisdiction to have arisen, then, by accepting the Award, the Participant shall be deemed irrevocably to have waived the Participant's entitlement to pursue such claim&#59;  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(J)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:25.45pt">for purposes of an Award, the Participant&#8217;s employment relationship will be considered terminated as of the date the Participant is no longer a bona fide employee of the Corporation, the Employer or one of the Corporation&#8217;s other Affiliates (regardless of the reason for such termination and whether or not later found to be invalid or in breach of the employment laws in the jurisdiction where the Participant is employed or the terms of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">the Participant&#8217;s employment agreement, if any), and unless otherwise expressly provided in this Award Agreement or determined by the Corporation in its sole discretion, the Participant&#8217;s right to receive Awards and vest in Awards under the Plan, if any, will terminate effective as of such date and will not be extended by any notice period mandated under local law (for example, the Participant&#8217;s period of service would not include any contractual notice period or any period of &#8220;garden leave&#8221; or similar period mandated under employment laws in the jurisdiction where the Participant is employed or the terms of the Participant&#8217;s employment agreement, if any)&#59; similarly, any right to exercise Options under the Plan after termination of employment will be measured as of the date the Participant is no longer a bona fide employee of the Corporation, the Employer or one of the Corporation&#8217;s other Affiliates and will not be extended by any notice period mandated under local law&#59; the Administrator shall have the sole discretion to determine when the Participant is no longer a bona fide employee for purposes of an Award (including whether the Participant may still be considered to be providing services while on a leave of absence)&#59; </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(K)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:22.12pt">the Corporation is not providing any tax, legal or financial advice, nor is the Corporation making any recommendations regarding participation in the Plan or the Participant&#8217;s acquisition or sale of Shares&#59; and</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(L)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.24pt">the Participant is hereby advised to consult with the Participant's own personal tax, legal and financial advisors regarding Participant&#8217;s participation in the Plan before taking any action related to the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:23.5pt;text-decoration:underline">Data Privacy Information and Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(A)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:22.12pt">Data Collection and Usage.  The Corporation and the Employer may collect, process and use certain personal information about the Participant, including, but not limited to, the Participant&#8217;s name, home address and telephone number, email address, date of birth, social insurance number, passport or other identification number, salary, nationality, job title, any Shares or directorships held in the Corporation, details of all Options, Restricted Stock, Restricted Stock Units, Performance Stock Units, Other Share-Based Awards, or any other entitlement to Shares awarded, canceled, exercised, vested, unvested or outstanding in the Employee&#8217;s favor (&#8220;Data&#8221;), for the purposes of implementing, administering and managing the Plan. The legal basis, where required, for the processing of Data is the Participant&#8217;s consent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(B)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:22.68pt">Stock Plan Administration Service Providers.  The Corporation transfers Data to Fidelity Stock Plan Services LLC and its affiliated companies, an independent service provider based in the United States, which is assisting the Corporation with the implementation, administration and management of the Plan. The Corporation may select a different service provider or additional service providers and share Data with such other provider serving in a similar manner. The Participant may be asked to agree on separate terms and data processing practices with the service provider, with such agreement being a condition to the ability to participate in the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(C)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:22.68pt">International Data Transfers.  The Corporation and its service providers are based in the United States.  The Participant&#8217;s country or jurisdiction may have different data privacy laws and protections than the United States. The Corporation&#8217;s legal basis, where required, for the transfer of Data is</font><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">the Participant&#8217;s consent.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(D)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:22.12pt">Data Retention.  The Corporation will hold and use the Data only as long as is necessary to implement, administer and manage the Participant&#8217;s participation in the Plan, or as required to comply with legal or regulatory obligations, including under tax and security laws.  In the latter case, the Participant understands and acknowledges that the Corporation&#8217;s legal basis for the processing of the Participant&#8217;s Data would be compliance with the relevant laws or regulations or the pursuit by the Corporation of respective legitimate interests not outweighed by the Participant&#8217;s interests, rights or freedoms.  When the Corporation no longer needs the Participant&#8217;s Data for any of the above purposes, the Participant understands the Corporation will remove it from its systems.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(E)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:23.24pt">Voluntariness and Consequences of Consent Denial or Withdrawal.  Participation in the Plan is voluntary and the Participant is providing the consents herein on a purely voluntary basis.  If the Participant does not consent, or if the Participant later seeks to revoke the Participant&#8217;s consent, the Participant&#8217;s salary from or employment with the Employer will not be affected&#59; the only consequence of refusing or withdrawing the Participant&#8217;s consent is that the Corporation would not be able to grant Awards to the Participant or administer or maintain such Awards.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(F)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;padding-left:23.78pt">Data Subject Rights.  The Participant may have a number of rights under data privacy laws in the Participant&#8217;s jurisdiction.  Depending on where the Participant is based, such rights may include the right to (i) inquire whether and what kind of Data the Corporation holds about the Participant and how it is processed, and to request access or copies of Data the Corporation processes, (ii) request the correction or </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">13</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">supplementation of Data about the Participant that is inaccurate, incomplete or out-of-date in light of the purposes underlying the processing, (iii) obtain the erasure of Data no longer necessary for the purposes underlying the processing, processed based on withdrawn consent, processed for legitimate interests that, in the context of the Participant&#8217;s objection, do not prove to be compelling, or processed in non-compliance with applicable legal requirements, (iv) request restrictions on processing of Data in certain situations where the Participant feels its processing is inappropriate, (v) request portability of the Participant&#8217;s Data that the Participant has actively or passively provided to the Corporation (which does not include data derived or inferred from the collected data), where the processing of such Data is based on consent or the Participant&#8217;s employment and is carried out by automated means, (vi) object, in certain circumstances, to the processing of Data for legitimate interests, (vii) lodge complaints with competent authorities in the Participant&#8217;s jurisdiction, and&#47;or (viii) receive a list with the names and addresses of any potential recipients of Data.  To receive clarification regarding these rights or to exercise these rights, the Participant can contact his or her local human resources representative.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">By accepting the Award and indicating consent via the Corporation&#8217;s acceptance procedure, the Participant is declaring that he or she agrees with the data processing practices described herein and consents to the collection, processing and use of Data by the Corporation and the transfer of Data to the recipients mentioned above, including recipients located in countries which do not adduce an adequate level of protection from a European (or other non-U.S.) data protection law perspective, for the purposes described above.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.5pt;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The provisions in this Statement of Terms and Conditions are severable and if any one or more provisions are determined to be illegal or otherwise unenforceable, in whole or in part, the remaining provisions shall nevertheless be binding and enforceable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.5pt;text-decoration:underline">Language</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Participant acknowledges that the Participant is proficient in the English language, or has consulted with an advisor who is sufficiently proficient in the English language, and, accordingly, understands the provisions of the Plan and this Statement of Terms and Conditions.  If the Participant has received this Statement of Terms and Conditions or any other document related to the Plan translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control unless otherwise required by local law.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.5pt;text-decoration:underline">Electronic Delivery</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  The Corporation may, in its sole discretion, decide to deliver any documents related to current or future participation in the Plan by electronic means.  The Participant hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by the Corporation or a third party designated by the Corporation.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:23.5pt;text-decoration:underline">Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.  If (A) the Participant is a Specified Employee at the time of the Participant&#8217;s Separation from Service, and (B) some or any portion of the amounts payable to the Participant, if any, when considered together with any other payments or benefits which may be considered deferred compensation under section 409A of the Internal Revenue Code of 1986, as amended (&#8220;Section 409A&#8221;) and subject to the plan aggregation rules under Treasury Regulation section 1.409A-1(c)(3)(viii) (together, the &#8220;Deferred Compensation Benefits&#8221;) would result in the imposition of additional tax under Section 409A if paid to the Participant on or within the six month period following the Separation from Service, then to the extent such portion of the Deferred Compensation Benefits resulting in the imposition of additional tax would otherwise have been payable on or within the first six months following the Separation from Service, it will instead become payable on the first payroll date that occurs in the seventh month following the Separation from Service (or such longer period as is required to avoid the imposition of additional tax under Section 409A). All subsequent Deferred Compensation Separation Benefits, if any, will be payable in accordance with the payment schedule applicable to each payment or benefit.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">IX.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:22.39pt">DEFINITIONS</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">When capitalized in this Statement of Terms and Conditions, the following terms shall have the meaning set forth below&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Award Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means an agreement between the Participant and the Corporation evidencing the grant of an Option, Restricted Stock Award, Restricted Stock Award, Performance Stock Unit Award or Other Share-Based Award, as applicable.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means termination of the Participant&#8217;s employment with the Corporation or an Affiliate upon the Participant&#8217;s negligent or willful engagement in misconduct which, in the sole determination of the Chief Executive Officer of the Corporation (or the Chief Executive Officer&#8217;s designee), is injurious to the Corporation, its employees, or its customers.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">14</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Early Retirement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means a termination of employment (other than due to death, Long-Term Disability or for Cause) which occurs prior to Normal Retirement but on or after the date on which the Participant&#8217;s age (expressed in terms of years and completed months) plus service with the Corporation or an Affiliate equals 65. For purposes of determining eligibility for Early Retirement, the term &#8220;service&#8221; shall include years and completed whole months of service.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:28.5pt">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Family Member</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any person identified as an &#8220;immediate family&#8221; member in Rule 16(a)-1(e) of the Exchange Act, as such Rule may be amended from time to time.  Notwithstanding the foregoing, the Administrator may designate any other person(s)&#160;or entity(ies) as a &#8220;family member.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means any of the following actions, if taken without the express written consent of the Participant&#58;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(A)&#160;&#160;&#160;&#160;Any material change by the Corporation in the Participant&#8217;s functions, duties, or responsibilities, which change would cause the Participant&#8217;s position with the Corporation to become of less dignity, responsibility, importance, or scope from the position and attributes that applied to the Participant immediately prior to the Change in Control&#59; provided, however, that, any such change attributable to the Corporation&#8217;s no longer being a company with publicly traded common stock shall not constitute Good Reason&#59; and provided, further, that a reduction in the Participant&#8217;s functions, duties or responsibilities solely by virtue of the Corporation being acquired and made part of a larger entity (for example, if following a Change in Control the Participant retains the Participant&#8217;s position, or has a comparable position, with respect to a division or subsidiary of the acquirer that contains the Corporation&#8217;s business) shall not constitute Good Reason&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(B)&#160;&#160;&#160;&#160;Any significant reduction in the Participant&#8217;s aggregate base annual salary and target incentive opportunity, as in effect immediately prior to the Change in Control&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(C)&#160;&#160;&#160;&#160;Any material failure by the Corporation to comply with any of the provisions of an Award subsequent to a Change in Control&#59; or</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(D)&#160;&#160;&#160;&#160;The Corporation&#8217;s requiring the Participant to be based at any location which would increase the Participant&#8217;s regular one-way commute by more than 25 miles from that in effect immediately preceding the Change in Control, except for travel reasonably required in the performance of the Participant&#8217;s responsibilities&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provided that the Participant gives notice to the Corporation of the existence of the Good Reason condition within 30 days of the initial existence of the Good Reason condition and the Corporation is provided 30 days after receipt of the Participant&#8217;s notice to remedy the Good Reason condition&#59; provided further that the Participant&#8217;s Separation from Service must occur within six months from the initial existence of the Good Reason condition if the Corporation does not remedy such condition for such separation to be considered to be for Good Reason. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Expiration Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the date that an Option expires as set forth in the Option Grant Notice as the &#8220;Expiration Date.&#8221;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Grant Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the date the Administrator grants the Award.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Grant Notice</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the notice of an Award granted to the Participant, which sets forth certain terms of such Award.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Long-Term Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means a physical or mental condition in respect of which the administrator of the Corporation&#8217;s long-term disability plan has determined that the Participant is eligible to receive income replacement benefits&#59; or, if the Participant is not then a participant in the Corporation&#8217;s long-term disability plan, a physical or mental condition that the administrator of the Corporation&#8217;s long-term disability plan determines would have rendered the Participant eligible to receive income replacement benefits, had the Participant been enrolled in such plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Normal Retirement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means termination of employment (other than due to death, Long-Term Disability or for Cause) at or after age 60 with at least 10 years of service with the Corporation or an Affiliate. For purposes of determining eligibility for Normal Retirement, &#8220;service&#8221; shall mean completed whole years of service (12 consecutive months).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">15</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Option Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means the period commencing on the Grant Date of an Option and, except at otherwise provided in Section&#160;II.5, ending on the Expiration Date.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Separation from Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means termination of employment with the Corporation or an affiliate. A Participant shall be deemed to have had a Separation from Service if the Participant&#8217;s service with the Corporation or an affiliate is reduced to an annual rate that is equal to or less than 20% of the services rendered, on average, during the immediately preceding three years of service with the Corporation or an affiliate (or, if providing service to the Corporation or an affiliate for less than three years, such lesser period).  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Severance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means termination of employment with the Corporation or an Affiliate, and qualified for participation in and entitlement to benefits under the McKesson Corporation Severance Pay Plan or the McKesson Corporation Severance Policy for Executive Employees, as applicable, in accordance with the terms and conditions of such plans. A Participant outside the United States who is not qualified for participation in and entitlement to the benefits under such plans will nonetheless be treated for the limited purposes of his or her Awards, and subject to the provisions of Section VIII.9 of this Statement of Terms and Conditions, as terminated by reason of Severance to the extent his or her employment with the Corporation or an Affiliate is terminated and he or she would satisfy the conditions for termination for reason of Severance but for the fact that such plan is only applicable to employees of the Corporation or an Affiliate in the United States who qualify for participation in that plan. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.&#160;&#160;&#160;&#160; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Short-Term Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means short-term disability as defined in the Corporation&#8217;s short-term disability plan. </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Specified Employee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8221; means those employees identified by the Corporation as &#34;Specified Employees&#34; for purposes of Code Section 409A.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">16</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OUTSIDE DIRECTOR</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MCKESSON CORPORATION 2022 STOCK PLAN </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RESTRICTED STOCK UNIT GRANT NOTICE</font></div><div style="text-align:center"><font><br></font></div><div style="padding-left:77.41pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.237%"><tr><td style="width:1.0%"></td><td style="width:54.698%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.102%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grantee Name&#58;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of RSUs Granted&#58;</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Date of Grant&#58;</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vesting Schedule</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#58;  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100% vested on grant date.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation (the &#8220;Company&#8221;) is pleased to grant you restricted stock units (&#8220;RSUs&#8221;) under the Company&#8217;s 2022 Stock Plan, as may be amended from time to time (the &#8220;Plan&#8221;) to receive shares of common stock of the Company (&#8220;Shares&#8221;). This Grant Notice (&#8220;Notice&#8221;), together with the Statement of Terms and Conditions, as provided as an attachment to this Notice (the &#8220;ST&#38;Cs&#8221;), constitute your Restricted Stock Unit Agreement, which along with the Plan set forth the terms of your grant.   </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Below is a list of documents that are made available to you in connection with this Notice.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PLEASE BE SURE TO READ THESE DOCUMENTS BECAUSE THEY CONTAIN IMPORTANT INFORMATION SPECIFIC TO THIS GRANT OF RSUs.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This grant, along with any other outstanding awards under the Plan, can be viewed on the Fidelity web site at </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">www.Netbenefits.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">. </font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">By signing below, I acknowledge that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#58;</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;I agree to receive copies of the stockholder information, including copies of any annual report, proxy and Form 10-K, from the Investors section of the McKesson website at www.mckesson.com&#59; and</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;I also acknowledge that copies of the Plan, Plan prospectus, Plan information and stockholder information are available upon written or telephonic request to the Corporate Secretary (1-855-466-2547)&#59; and </font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.&#160;&#160;&#160;&#160;I have access to the Company&#8217;s web site&#59; and</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.&#160;&#160;&#160;&#160;I consent to receiving electronically a copy of the documents set forth above and attachments to this Notice&#59; and</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.&#160;&#160;&#160;&#160;The Plan and ST&#38;Cs are incorporated by reference to this Notice&#59; and</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.&#160;&#160;&#160;&#160;The Company recommends that the Grantee consult with a tax advisor prior to accepting this grant of RSUs&#59; and</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.&#160;&#160;&#160;&#160;I accept ALL the terms and conditions as set forth in the Plan and the ST&#38;Cs applicable to this grant of RSUs.</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the Grantee has executed this Agreement, and the Company has caused these presents to be executed in its name and on its behalf, all as of the Grant Date.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;   </font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.246%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.170%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000000;padding:0 1pt"></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brian S. Tyler&#160;&#160;&#160;&#160;Grantee Signature                             Date</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ATTACHMENTS&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">* 2022 Stock Plan</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">* 2022 Stock Plan Prospectus for Non-Employee Directors</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">* ST&#38;Cs </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">* Hedging and Pledging Policy</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">* Appendix (Outside U.S. - country specific)</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 2022</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">17</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #4f81bd;padding:2px 3.77pt 2px 1pt;text-align:right;vertical-align:top"><font style="color:#17365d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Employee</font></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MCKESSON CORPORATION 2022 STOCK PLAN</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">RESTRICTED STOCK UNIT GRANT NOTICE</font></div><div style="text-align:center"><font><br></font></div><div style="padding-left:104.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:65.384%"><tr><td style="width:1.0%"></td><td style="width:44.488%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.312%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grantee Name&#58;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Number of RSUs Granted&#58;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Date of Grant&#58;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vesting Schedule&#58;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Please see Appendix</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation (the &#8220;Company&#8221;) is pleased to grant you restricted stock units (&#8220;RSUs&#8221;) under the Company&#8217;s 2022 Stock Plan (the &#8220;Plan&#8221;) which represent the contingent right to receive shares of common stock of the Company (&#8220;Shares&#8221;). This Grant Notice (&#8220;Notice&#8221;), together with the Statement of Terms and Conditions, as provided as an attachment to this Notice (the &#8220;ST&#38;Cs&#8221;), constitute your Restricted Stock Unit Agreement. Your Restricted Stock Unit Agreement and your RSUs are subject to the terms of the Plan, which incorporates by reference the Company&#8217;s Compensation Recoupment Policy (the &#8220;Recoupment Policy&#8221;) and the Company&#8217;s Stock Ownership Policy (the &#8220;Stock Ownership Policy&#8221;), as both are amended from time to time).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Below is a list of documents that are made available to you in connection with this Notice.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PLEASE BE SURE TO READ THESE DOCUMENTS BECAUSE THEY CONTAIN IMPORTANT INFORMATION SPECIFIC TO THIS GRANT OF RSUs.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This grant, along with any other outstanding awards under the Plan, can be viewed on the Fidelity web site at </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">www.Netbenefits.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">By signing below, I acknowledge that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#58;</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.5pt">I agree to receive copies of the Plan, the Plan prospectus and other Plan information, including information prepared to comply with the laws outside the United States, from the Company&#8217;s website and stockholder information, including copies of any annual report, proxy and Form 10-K, from the Investors section of the McKesson website at </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">www.mckesson.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#59; and</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.5pt">I also acknowledge that copies of the Plan, Plan prospectus, Plan information and stockholder information are available upon written or telephonic request to the Corporate Secretary (1-855-466-2547)&#59; and</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.5pt">I have access to the Company&#8217;s web site&#59; and</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.5pt">I consent to receiving electronically a copy of the documents set forth above and attachments to this Notice&#59; and</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.5pt">The Plan (including the Recoupment Policy and Stock Ownership Policy) and ST&#38;Cs are incorporated by reference to this Notice&#59; and</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.5pt">The Company recommends that the Grantee consult with a tax advisor prior to accepting this grant of RSUs&#59; and</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.5pt">I accept ALL the terms and conditions as set forth in the Plan and ST&#38;Cs applicable to this grant of RSUs.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the Grantee has executed this Agreement, and the Company has caused these presents to be executed in its name and on its behalf, all as of the Grant Date.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.924%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:0 1pt"></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brian S. Tyler&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Grantee Signature&#160;&#160;&#160;&#160;                 Date</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ATTACHMENTS&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">* 2022 Stock Plan</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">* 2022 Stock Plan Prospectus</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">* ST&#38;Cs Applicable to __________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">* Compensation Recoupment Policy</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">* Hedging and Pledging Policy (Section 16 only)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">* Stock Ownership Policy (EOT only)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">* Appendix (Outside U.S. &#8211; country-specific)</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 2022</font></div><div style="margin-bottom:12pt;text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">18</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #4f81bd;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MCKESSON CORPORATION 2022 STOCK PLAN</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PERFORMANCE STOCK UNIT GRANT NOTICE</font></div><div style="text-align:center"><font><br></font></div><div style="padding-left:80.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:76.121%"><tr><td style="width:1.0%"></td><td style="width:44.794%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.006%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Grantee Name&#58;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Target PSUs Granted&#58;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Date of Grant&#58;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Performance Period&#58;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FY&#160;20__ - FY&#160;20__</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation (the &#8220;Company&#8221;) is pleased to grant you target performance stock units (&#8220;PSUs&#8221;) under the Company&#8217;s 2022 Stock Plan (the &#8220;Plan&#8221;). This Grant Notice (&#8220;Notice&#8221;), together with the Statement of Terms and Conditions, as provided with this Notice (the &#8220;ST&#38;Cs&#8221;), constitute your Performance Stock Unit Agreement. Your Performance Stock Unit Agreement and your PSUs are subject to the terms of the Plan, which incorporates by reference the Company&#8217;s Compensation Recoupment Policy (the &#8220;Recoupment Policy&#8221;), and the Company&#8217;s Stock Ownership Policy (the &#8220;Stock Ownership Policy&#8221;), as both are amended from time to time.</font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Your PSUs will be earned subject to the Company&#8217;s attainment of performance goals that have been pre-established by the Compensation and Talent Committee (the &#8220;Committee&#8221;) of the Company&#8217;s Board of Directors. You may receive 0% - 200% of the target number of PSUs set forth above. PSUs, if earned, will be paid in the form of shares of the Company&#8217;s Common Stock (&#8220;Shares&#8221;) that are not subject to any further vesting restrictions. The Committee has the sole discretion to determine the Company&#8217;s performance against the pre-established goals after completion of the performance period, and to authorize the grant of Shares.  </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Below is a list of documents that are made available to you in connection with this Notice. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PLEASE BE SURE TO READ THESE DOCUMENTS BECAUSE THEY CONTAIN IMPORTANT INFORMATION SPECIFIC TO THIS GRANT OF PSUs. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This grant, along with any other outstanding awards under the Plan, can be viewed on the Fidelity web site at </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">www.Netbenefits.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-bottom:3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">By signing below, I acknowledge that</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#58;</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.5pt">I agree to receive copies of the Plan, the Plan prospectus and other Plan information, including information prepared to comply with the laws outside the United States, from the Company&#8217;s website and stockholder information, including copies of any annual report, proxy and Form 10-K, from the Investors section of the McKesson website at </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">www.mckesson.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#59; and</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.5pt">I also acknowledge that copies of the Plan, Plan prospectus, Plan information and stockholder information are available upon written or telephonic request to the Corporate Secretary (1-855-466-2547)&#59; and</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.5pt">I have access to the Company&#8217;s web site&#59; and</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.5pt">I consent to receiving electronically a copy of the documents set forth above and attachments to this Notice&#59; and</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.5pt">The Plan (including the Recoupment Policy and Stock Ownership Policy) and ST&#38;Cs are incorporated by reference to this Notice&#59; and</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.5pt">I should consult with a tax advisor prior to accepting this grant of PSUs or taking any other action with respect to this grant of PSUs&#59; and</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:10.5pt">I accept ALL the terms and conditions as set forth in the Plan and ST&#38;Cs applicable to this grant of PSUs.</font></div><div><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IN WITNESS WHEREOF, the Grantee has executed this Agreement, and the Company has caused these presents to be executed in its name and on its behalf, all as of the Grant Date.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.240%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.924%"></td><td style="width:0.1%"></td></tr><tr style="height:12pt"><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:0.75pt solid #000000;padding:0 1pt"></td></tr></table></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Brian S. Tyler&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Grantee Signature&#160;&#160;&#160;&#160;                 Date</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">McKesson Corporation</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Plan Documents and Related Policies</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">* 2022 Stock Plan</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">* 2022 Stock Plan Prospectus</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">* ST&#38;Cs Applicable to __________________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">* Compensation Recoupment Policy</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">* Hedging and Pledging Policy (Section 16 only)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">* Stock Ownership Policy (EOT only)</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">* Appendix (Outside U.S. - country specific)</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 2022</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">19</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>mck_ex102xmipstcsmay2023.htm
<DESCRIPTION>EX-10.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i8e90d423e8544b8ca79425c93206d8d0_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.2</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">FORM OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">McKESSON CORPORATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">STATEMENT OF TERMS AND CONDITIONS</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">APPLICABLE TO AWARDS</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PURSUANT TO THE MANAGEMENT INCENTIVE PLAN</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effective May 23, 2023</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following terms and conditions shall apply to awards made under the McKesson Corporation Management Incentive Plan (the &#8220;Plan&#8221;) to an executive, managerial or professional employee of the Company who is specifically designated as a participant in the Plan.  Capitalized terms used herein are defined in the Plan or in Section&#160;10.  In the event these terms and conditions conflict with the terms of the Plan document, the Plan document shall control.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:28.5pt;text-decoration:underline">Participant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Only an active employee of the Company who is employed in an executive, managerial or professional capacity may be designated as a Participant under the Plan&#59; provided, however, that designation as a Participant is contingent upon the execution and delivery to the Company of an agreement, within a period following presentment and in a form that is satisfactory to the Company, regarding confidentiality, intellectual property and&#47;or other restrictive covenants, as well as compliance with such agreement&#59; and provided, further, that the Committee shall determine in its sole discretion whether the Participant has complied with the provisions of any such agreement, which determination shall be conclusive and binding on all interested persons.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Committee shall review those employees who are eligible to participate in the Plan and recommended by management and determine which of those employees will become Plan Participants.  The Committee may add to or delete individuals from the list of designated Participants at any time and from time to time, at its sole discretion.  The Committee has delegated the authority to approve Plan Participants to the Chief Executive Officer of the Company.  </font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Participation in the Plan during the Performance Period does not guarantee payment of an Actual Award under the Plan for the Performance Period.  Participation in the Plan during one Performance Period does not guarantee participation during a subsequent Performance Period.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:28.5pt;text-decoration:underline">Individual Target Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Individual Target Award is the percentage of base annual salary specified at the beginning of the Performance Period (or beginning of participation, if later) for a Participant.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:26.28pt;text-decoration:underline">Newly Eligible Employees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A newly hired employee, or an employee who is promoted into or transferred from an ineligible position to an eligible position during a Performance Period, may be designated a Participant with an Individual Target Award for that Performance Period.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:26.84pt;text-decoration:underline">Transfers, Promotions and Demotions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A Participant who moves during the Performance Period from one eligible position to a new eligible position with a higher Individual Target Award will, in general, have the determination of his or her Actual Award prorated between the two Individual Target Awards.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A Participant who during the Performance Period is demoted to or transferred to a new eligible position with a lower Individual Target Award will have the determination of his or her Actual Award prorated in management&#8217;s discretion.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A Participant who during the Performance Period is demoted from or transferred from an eligible position to an ineligible position will have the determination of his or her Actual Award prorated in management&#8217;s discretion.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notwithstanding the foregoing, any proration must be based on the achievement of Performance Goals for the Performance Period.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:28.5pt;text-decoration:underline">Performance Measures and Goals</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Each Participant shall have one or more Individual Performance Measures.  Individual Performance Measures may be quantitative, qualitative or both.  The Performance Goals (defined in Article&#160;F of the Plan)&#160;established for each segment of the Company are referred to as the Business Scorecard.  A Participant&#8217;s Individual Performance Measures and the Performance Goals, taken as a whole, will determine the amount of the Participant&#8217;s Actual Award.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A Participant who changes jobs and &#47; or organizations during the Performance Period may have different Business Scorecards applicable to each job &#47; organization.  The Participant may, in management&#8217;s discretion, have the determination of his or her Actual Award prorated between the two Business Scorecards.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:28.5pt;text-decoration:underline">Individual Performance Modifier</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual Awards will be adjusted, in management&#8217;s discretion, to reflect the Participant&#8217;s individual contribution to Business Scorecard results and the Participant&#8217;s Individual Performance Measures.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:28.5pt;text-decoration:underline">Other Individual Requirements</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notwithstanding any provision of the Plan to the contrary, no amount shall be payable with respect to the Performance Period unless the Committee certifies that it is satisfied that the requirements (performance or otherwise) associated with such payment have been fully met.  Such requirements may include, but are not limited to&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">Completion of the Company&#8217;s Legal and Regulatory Compliance and Ethics Training Program.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:28.5pt;text-decoration:underline">Award Determination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Any payment to a Participant shall be based on Business Scorecard results during the Performance Period as modified by the Participant&#8217;s Individual Performance Modifier.  The Actual Award is determined by&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">Taking the Covered Compensation received during the Performance Period&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">Multiplying by the Individual Target Award&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">Multiplying that result by the Business Scorecard results (actual&#160;vs. target)&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:32.5pt">Adjusting the result determined above, up or down, by the Individual Performance Modifier.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management and the Committee shall review and approve, modify or disapprove the Actual Award, if any, to be paid to a Participant for the Performance Period.  Management and the Committee reserve the right to reduce or increase or eliminate the individual payments determined according to the above method.  No Personal Modifier shall exceed 150%.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:28.5pt;text-decoration:underline">Effect of a Termination of Employment, Prior to the End of the Performance Period, on Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:26.28pt;text-decoration:underline">Termination of Employment for Other Than Death, Retirement, Severance or Long-Term Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If the Participant ceases to be a bona fide employee of the Company prior to the payment of the Actual Award, for any reason other than death, Retirement, Severance or Long-Term Disability, the Participant&#8217;s interest in the Awards shall be forfeited and no amount shall be payable to the Participant with respect to service during the Performance Period.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:26.84pt;text-decoration:underline">Termination of Employment by Reason of Death or Long-Term Disability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If the Participant ceases to be a bona fide employee of the Company due to death or Long-Term Disability during the Performance Period, the Participant (or the Participant&#8217;s Beneficiary, if payment is made on account of the death of the Participant)&#160;shall be entitled to receive an Actual Award as calculated under Paragraph&#160;6 above.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:26.28pt;text-decoration:underline">Termination of Employment by Reason of Retirement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If the Participant ceases to be a bona fide employee of the Company due to Retirement prior to January 1 of the Performance Period, the Participant&#8217;s interest in the Awards shall be forfeited and no amount shall be payable to the Participant with respect to service during the Performance Period.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If the Participant ceases to be a bona fide employee of the Company due to Retirement on or after January 1 of the Performance Period, the Participant shall be entitled to receive an Actual Award as calculated under Paragraph&#160;6 above.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">D.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:26.28pt;text-decoration:underline">Termination of Employment by Reason of Severance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If the Participant ceases to be a bona fide employee of the Company due to Severance prior to January 1 of the Performance Period, the Participant&#8217;s interest in the Awards shall be forfeited and no amount shall be payable to the Participant with respect to service during the Performance Period.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">If the Participant ceases to be a bona fide employee of the Company due to Severance on or after January 1 of the Performance Period, the Participant shall be entitled to receive an Actual Award as calculated under Paragraph&#160;6 above.  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:28.5pt;text-decoration:underline">Data Privacy.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By accepting the Award, the Participant hereby explicitly and unambiguously consents to the collection, use and transfer, in electronic or other form, of his or her personal data as described in this document by and among, as applicable, the Participant&#8217;s employer (the &#8220;Employer&#8221;) and the Company for the exclusive purpose of implementing, administering and managing participation in the Plan.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Participant understands that the Company and the Employer hold certain personal information about the Participant, including but not limited to his or her name, home address and telephone number, date of birth, social insurance or other identification number, salary, nationality, job title, any shares of Company stock or directorships held in the Company, details of all compensation or any other entitlement to Company-sponsored benefits for the purpose of implementing, administering and managing the Plan (&#8220;Data&#8221;).  The Participant understands that Data may be transferred to any third parties assisting in the implementation, administration and management of the Plan, that these recipients may be located in the Participant&#8217;s country or elsewhere, such as in the United States of America, and that the recipient&#8217;s country may have different data privacy laws and protections than the Participant&#8217;s country.  The Participant understands that he or she may request a list with the names and addresses of any potential recipients of the Data by contacting the local human resources representative.  The Participant authorizes the recipients to receive, possess, use, retain and transfer the Data, in electronic or other form, for the purposes of implementing, administering and managing participation in the Plan.  The Participant understands that Data will be held only as long as is necessary to implement, administer and manage his or her participation in the Plan.  The Participant understands that he or she may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, without cost, by contacting in writing the local human resources representative.  The Participant understands, however, that refusing or withdrawing consent may affect his or her ability to participate in the Plan.  For more information on the consequences of refusal to consent or withdrawal of consent, the Participant understands that he or she may contact the local human resources representative.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:28.5pt;text-decoration:underline">GOVERNING LAW.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The law of the State of Delaware shall govern all question concerning the construction, validity and interpretation of the Plan and any Awards, without regard to the state&#8217;s conflict of laws rules.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;padding-left:23.5pt;text-decoration:underline">Definitions.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized terms shall have the same meaning as provided in the Plan.  Additional capitalized text that is not included in the Plan, but is used in this Statement of Terms and Conditions, shall have the meaning set forth below&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(a)&#160;&#160;&#160;&#160;&#8220;Actual Award&#8221; means the finally determined amount payable under the Plan for a Performance Period.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;&#8220;Awards&#8221; means, collectively, Individual Target Awards and Actual Awards.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(c)&#160;&#160;&#160;&#160;&#8220;Covered Compensation&#8221; means regular wages earned by and paid to the Participant during the Performance Period, including any Paid Time Off (PTO)&#160;pay.  Covered Compensation does not include any other compensation received during the Performance Period, including, but not limited to, earnings received during a paid leave, overtime or commission pay.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(d)&#160;&#160;&#160;&#160;&#8220;Long-Term Disability&#8221; means a physical or mental condition in respect of which the administrator of the Company&#8217;s long-term disability plan has determined that the Participant is eligible to receive income replacement benefits&#59; or, if the Participant is not then a participant in the Company&#8217;s long-term disability plan, a physical or mental condition that the administrator of the Company&#8217;s long-term disability plan determines would have rendered the Participant eligible to receive income replacement benefits, had the Participant been enrolled in such plan.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(e)&#160;&#160;&#160;&#160;&#8220;Retirement&#8221; means termination from the Company with age plus years of service equal to at least 65.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(f)&#160;&#160;&#160;&#160;&#8220;Severance&#8221; means termination of employment with the Company and qualified for participation in and entitlement to benefits under the McKesson Corporation Severance Pay Plan or the Amended and Restated McKesson Corporation Severance Policy for Executive Employees, as applicable, in accordance with the terms and conditions of such plans. A Participant outside the United States who is not qualified for participation in and entitlement to the benefits under such plans will nonetheless be treated for the limited purposes of his or her Awards as terminated by reason of Severance to the extent his or her employment with the Company is terminated and he or she would satisfy the conditions for termination for reason of Severance but for the fact that such plan is only applicable to employees of the Company in the United States who qualify for participation in that plan.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>mck_exhibit311x630202310-q.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i941c1586076643548886d8164fa40da1_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULE 13a-14(a) AND RULE 15d-14(a) OF THE SECURITIES EXCHANGE ACT, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Brian S. Tyler, certify that&#58; </font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this quarterly report on Form 10-Q of McKesson Corporation&#59;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and </font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="margin-bottom:7pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.049%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.834%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 2, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;Brian S. Tyler</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Brian S. Tyler</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>mck_exhibit312x630202310-q.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i4ee633cc6f7c4b16aa8243a4f81743e0_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:6.75pt;text-align:right;text-indent:-6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULE 13a-14(a) AND RULE 15d-14(a) OF THE SECURITIES EXCHANGE ACT, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Britt J. Vitalone, certify that&#58; </font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this quarterly report on Form 10-Q of McKesson Corporation&#59;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;  </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and </font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. </font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font><br></font></div><div style="margin-bottom:7pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:4.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.049%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.834%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 2, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;  Britt J. Vitalone</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Britt J. Vitalone</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>mck_exhibit32x630202310-q.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i117cb8936797484e94718d55cb25af5e_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:6.75pt;text-align:right;text-indent:-6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the quarterly report of McKesson Corporation (the &#8220;Company&#8221;) on Form 10-Q for the quarterly period ended June 30, 2023 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned, in the capacities and on the dates indicated below, each hereby certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that to the best of their knowledge&#58;</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="padding-left:18pt;text-align:justify"><font><br></font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:24pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:-6.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:49.119%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.753%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160; Brian S. Tyler</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Brian S. Tyler</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 2, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:36pt;padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:-6.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:49.119%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.753%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;  Britt J. Vitalone</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Britt J. Vitalone</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 2, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="padding-left:27pt;text-indent:-9pt"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This certification accompanies the Report pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, and shall not, except to the extent required by the Sarbanes-Oxley Act of 2002, be deemed filed by the Company for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section 906 has been provided to McKesson Corporation and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>mck-20230630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:65f23265-c924-40c8-9b40-7c0acd48a82a,g:b9e463ca-a0e1-4231-8e93-a7255a3f4103-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mck="http://mckesson123.com/20230630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://mckesson123.com/20230630">
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mck-20230630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mck-20230630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mck-20230630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mck-20230630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://mckesson123.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>0000002 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" roleURI="http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME">
        <link:definition>0000003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETS" roleURI="http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS">
        <link:definition>0000004 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>0000005 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT" roleURI="http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT">
        <link:definition>0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITParenthetical" roleURI="http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITParenthetical">
        <link:definition>0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>0000008 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPolicies" roleURI="http://mckesson123.com/role/SignificantAccountingPolicies">
        <link:definition>0000009 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessAcquisitionsandDivestitures" roleURI="http://mckesson123.com/role/BusinessAcquisitionsandDivestitures">
        <link:definition>0000010 - Disclosure - Business Acquisitions and Divestitures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringImpairmentandRelatedChargesNet" roleURI="http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNet">
        <link:definition>0000011 - Disclosure - Restructuring, Impairment, and Related Charges, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://mckesson123.com/role/IncomeTaxes">
        <link:definition>0000012 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerCommonShare" roleURI="http://mckesson123.com/role/EarningsPerCommonShare">
        <link:definition>0000013 - Disclosure - Earnings Per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNet" roleURI="http://mckesson123.com/role/GoodwillandIntangibleAssetsNet">
        <link:definition>0000014 - Disclosure - Goodwill and Intangible Assets, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtandFinancingActivities" roleURI="http://mckesson123.com/role/DebtandFinancingActivities">
        <link:definition>0000015 - Disclosure - Debt and Financing Activities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="HedgingActivities" roleURI="http://mckesson123.com/role/HedgingActivities">
        <link:definition>0000016 - Disclosure - Hedging Activities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://mckesson123.com/role/FairValueMeasurements">
        <link:definition>0000017 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingentLiabilities" roleURI="http://mckesson123.com/role/CommitmentsandContingentLiabilities">
        <link:definition>0000018 - Disclosure - Commitments and Contingent Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersDeficit" roleURI="http://mckesson123.com/role/StockholdersDeficit">
        <link:definition>0000019 - Disclosure - Stockholders' Deficit</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsofBusiness" roleURI="http://mckesson123.com/role/SegmentsofBusiness">
        <link:definition>0000020 - Disclosure - Segments of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesPolicies" roleURI="http://mckesson123.com/role/SignificantAccountingPoliciesPolicies">
        <link:definition>9954701 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessAcquisitionsandDivestituresTables" roleURI="http://mckesson123.com/role/BusinessAcquisitionsandDivestituresTables">
        <link:definition>9954702 - Disclosure - Business Acquisitions and Divestitures (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringImpairmentandRelatedChargesNetTables" roleURI="http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetTables">
        <link:definition>9954703 - Disclosure - Restructuring, Impairment, and Related Charges, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://mckesson123.com/role/IncomeTaxesTables">
        <link:definition>9954704 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerCommonShareTables" roleURI="http://mckesson123.com/role/EarningsPerCommonShareTables">
        <link:definition>9954705 - Disclosure - Earnings Per Common Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNetTables" roleURI="http://mckesson123.com/role/GoodwillandIntangibleAssetsNetTables">
        <link:definition>9954706 - Disclosure - Goodwill and Intangible Assets, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtandFinancingActivitiesTables" roleURI="http://mckesson123.com/role/DebtandFinancingActivitiesTables">
        <link:definition>9954707 - Disclosure - Debt and Financing Activities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="HedgingActivitiesTables" roleURI="http://mckesson123.com/role/HedgingActivitiesTables">
        <link:definition>9954708 - Disclosure - Hedging Activities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://mckesson123.com/role/FairValueMeasurementsTables">
        <link:definition>9954709 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingentLiabilitiesTables" roleURI="http://mckesson123.com/role/CommitmentsandContingentLiabilitiesTables">
        <link:definition>9954710 - Disclosure - Commitments and Contingent Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersDeficitTables" roleURI="http://mckesson123.com/role/StockholdersDeficitTables">
        <link:definition>9954711 - Disclosure - Stockholders' Deficit (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsofBusinessTables" roleURI="http://mckesson123.com/role/SegmentsofBusinessTables">
        <link:definition>9954712 - Disclosure - Segments of Business (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesNarrativeDetails" roleURI="http://mckesson123.com/role/SignificantAccountingPoliciesNarrativeDetails">
        <link:definition>9954713 - Disclosure - Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessAcquisitionsandDivestituresAcquisitionsDetails" roleURI="http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails">
        <link:definition>9954714 - Disclosure - Business Acquisitions and Divestitures - Acquisitions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedRxSavingsSolutionsDetails" roleURI="http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedRxSavingsSolutionsDetails">
        <link:definition>9954715 - Disclosure - Business Acquisitions and Divestitures - Identified Assets Acquired and Liabilities Assumed (Rx Savings Solutions) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails" roleURI="http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails">
        <link:definition>9954716 - Disclosure - Business Acquisitions and Divestitures - Identified Assets Acquired and Liabilities Assumed (SCRI Oncology, LLC) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessAcquisitionsandDivestituresDivestituresandOtherDetails" roleURI="http://mckesson123.com/role/BusinessAcquisitionsandDivestituresDivestituresandOtherDetails">
        <link:definition>9954717 - Disclosure - Business Acquisitions and Divestitures - Divestitures and Other (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringImpairmentandRelatedChargesNetNarrativeDetails" roleURI="http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetNarrativeDetails">
        <link:definition>9954718 - Disclosure - Restructuring, Impairment, and Related Charges, Net - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails" roleURI="http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails">
        <link:definition>9954719 - Disclosure - Restructuring, Impairment, and Related Charges, Net - Summary of Restructuring Charges (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails" roleURI="http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails">
        <link:definition>9954720 - Disclosure - Restructuring, Impairment, and Related Charges, Net - Summary of Restructuring Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofComponentsofIncomeTaxExpenseDetails" roleURI="http://mckesson123.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseDetails">
        <link:definition>9954721 - Disclosure - Income Taxes - Schedule of Components of Income Tax Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://mckesson123.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>9954722 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerCommonShareNarrativeDetails" roleURI="http://mckesson123.com/role/EarningsPerCommonShareNarrativeDetails">
        <link:definition>9954723 - Disclosure - Earnings Per Common Share - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails" roleURI="http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails">
        <link:definition>9954724 - Disclosure - Earnings Per Common Share - Schedule of Computations for Basic and Diluted Earnings per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNetScheduleofChangesintheCarryingAmountofGoodwillDetails" roleURI="http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofChangesintheCarryingAmountofGoodwillDetails">
        <link:definition>9954725 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Changes in the Carrying Amount of Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails" roleURI="http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails">
        <link:definition>9954726 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Information Regarding Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNetNarrativeDetails" roleURI="http://mckesson123.com/role/GoodwillandIntangibleAssetsNetNarrativeDetails">
        <link:definition>9954727 - Disclosure - Goodwill and Intangible Assets, Net - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtandFinancingActivitiesScheduleofLongTermDebtDetails" roleURI="http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails">
        <link:definition>9954728 - Disclosure - Debt and Financing Activities - Schedule of Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtandFinancingActivitiesLongTermDebtNarrativeDetails" roleURI="http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails">
        <link:definition>9954729 - Disclosure - Debt and Financing Activities - Long-Term Debt Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtandFinancingActivitiesRevolvingCreditFacilitiesNarrativeDetails" roleURI="http://mckesson123.com/role/DebtandFinancingActivitiesRevolvingCreditFacilitiesNarrativeDetails">
        <link:definition>9954730 - Disclosure - Debt and Financing Activities - Revolving Credit Facilities Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtandFinancingActivitiesCommercialPaperNarrativeDetails" roleURI="http://mckesson123.com/role/DebtandFinancingActivitiesCommercialPaperNarrativeDetails">
        <link:definition>9954731 - Disclosure - Debt and Financing Activities - Commercial Paper Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="HedgingActivitiesNarrativeDetails" roleURI="http://mckesson123.com/role/HedgingActivitiesNarrativeDetails">
        <link:definition>9954732 - Disclosure - Hedging Activities - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="HedgingActivitiesSummaryofForeignCurrencyGainsandLossesfromNonDerivativeInstrumentsDetails" roleURI="http://mckesson123.com/role/HedgingActivitiesSummaryofForeignCurrencyGainsandLossesfromNonDerivativeInstrumentsDetails">
        <link:definition>9954733 - Disclosure - Hedging Activities - Summary of Foreign Currency Gains and (Losses) from Non-Derivative Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails" roleURI="http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails">
        <link:definition>9954734 - Disclosure - Hedging Activities - Schedule of Notional Amounts of Outstanding Derivative Positions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="HedgingActivitiesSummaryofDerivativeInstrumentsGainLossDetails" roleURI="http://mckesson123.com/role/HedgingActivitiesSummaryofDerivativeInstrumentsGainLossDetails">
        <link:definition>9954735 - Disclosure - Hedging Activities - Summary of Derivative Instruments Gain (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="HedgingActivitiesScheduleofFairValueofDerivativesDetails" roleURI="http://mckesson123.com/role/HedgingActivitiesScheduleofFairValueofDerivativesDetails">
        <link:definition>9954736 - Disclosure - Hedging Activities - Schedule of Fair Value of Derivatives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://mckesson123.com/role/FairValueMeasurementsNarrativeDetails">
        <link:definition>9954737 - Disclosure - Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofLongTermDebtisRecordedatAmortizedCostDetails" roleURI="http://mckesson123.com/role/FairValueMeasurementsScheduleofLongTermDebtisRecordedatAmortizedCostDetails">
        <link:definition>9954738 - Disclosure - Fair Value Measurements - Schedule of Long-Term Debt is Recorded at Amortized Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingentLiabilitiesNarrativeDetails" roleURI="http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails">
        <link:definition>9954739 - Disclosure - Commitments and Contingent Liabilities - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingentLiabilitiesEstimatedAccrualLiabilityDetails" roleURI="http://mckesson123.com/role/CommitmentsandContingentLiabilitiesEstimatedAccrualLiabilityDetails">
        <link:definition>9954740 - Disclosure - Commitments and Contingent Liabilities - Estimated Accrual Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersDeficitNarrativeDetails" roleURI="http://mckesson123.com/role/StockholdersDeficitNarrativeDetails">
        <link:definition>9954741 - Disclosure - Stockholders' Deficit - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails" roleURI="http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails">
        <link:definition>9954742 - Disclosure - Stockholders' Deficit - Schedule of Changes in Accumulated Other Comprehensive Income (Loss) by Component (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsofBusinessNarrativeDetails" roleURI="http://mckesson123.com/role/SegmentsofBusinessNarrativeDetails">
        <link:definition>9954743 - Disclosure - Segments of Business - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsofBusinessReportableoperatingsegmentDetails" roleURI="http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails">
        <link:definition>9954744 - Disclosure - Segments of Business - Reportable operating segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="mck_InternationalSegmentMember" abstract="true" name="InternationalSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mck_LossContingencyNumberOfOtherDefendants" abstract="false" name="LossContingencyNumberOfOtherDefendants" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mck_ExciseTaxPayableCurrent" abstract="false" name="ExciseTaxPayableCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mck_SeniorUnsecuredCreditFacilitythe2020CreditFacilityCanadianDollarBritishPoundSterlingandEurosSublimitMember" abstract="true" name="SeniorUnsecuredCreditFacilitythe2020CreditFacilityCanadianDollarBritishPoundSterlingandEurosSublimitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mck_StateOfAlabamaAndSubdivisionsMember" abstract="true" name="StateOfAlabamaAndSubdivisionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mck_CommonStockVotingRightsNumberofVotesPerCommonShare" abstract="false" name="CommonStockVotingRightsNumberofVotesPerCommonShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mck_A488NotesDueMarch152044Member" abstract="true" name="A488NotesDueMarch152044Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mck_A3125NotesDue2029Member" abstract="true" name="A3125NotesDue2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mck_RestructuringImpairmentAndOtherRelatedCharges" abstract="false" name="RestructuringImpairmentAndOtherRelatedCharges" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mck_A380NotesDueMarch152024Member" abstract="true" name="A380NotesDueMarch152024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mck_IncomeTaxExaminationEstimateOfPossibleLiabilityAdjustment" abstract="false" name="IncomeTaxExaminationEstimateOfPossibleLiabilityAdjustment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mck_SarahCannonResearchInstituteMember" abstract="true" name="SarahCannonResearchInstituteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mck_A130NotesDueAugust152026Member" abstract="true" name="A130NotesDueAugust152026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mck_A163EuroNotesDueOctober302026Member" abstract="true" name="A163EuroNotesDueOctober302026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mck_AssetImpairmentChargesIncludingAcceleratedDepreciation" abstract="false" name="AssetImpairmentChargesIncludingAcceleratedDepreciation" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mck_USPharmaceuticalSegmentMember" abstract="true" name="USPharmaceuticalSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mck_FixedInterestRateSwapMember" abstract="true" name="FixedInterestRateSwapMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mck_RxTsSegmentMember" abstract="true" name="RxTsSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mck_EuroDenominatedNotesMember" abstract="true" name="EuroDenominatedNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mck_NationalPrescriptionOpiateLitigationMember" abstract="true" name="NationalPrescriptionOpiateLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mck_CorporateOperatingExpenseandOtherIncomeNet" abstract="false" name="CorporateOperatingExpenseandOtherIncomeNet" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mck_NoncontrollingInterestDecreaseFromReclassificationToLiability" abstract="false" name="NoncontrollingInterestDecreaseFromReclassificationToLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mck_EUBusinessesDisposalGroupMember" abstract="true" name="EUBusinessesDisposalGroupMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mck_A150EuroNotesDueNovember172025Member" abstract="true" name="A150EuroNotesDueNovember172025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mck_StrategicGrowthInitiativePlanOperationalEfficienciesAndCostOptimizationMember" abstract="true" name="StrategicGrowthInitiativePlanOperationalEfficienciesAndCostOptimizationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mck_NativeAmericanTribesOtherThanCherokeeNationMember" abstract="true" name="NativeAmericanTribesOtherThanCherokeeNationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mck_SeniorUnsecuredCreditFacilityThe2022CreditFacilityCanadianDollarBritishPoundSterlingAndEurosSublimitMember" abstract="true" name="SeniorUnsecuredCreditFacilityThe2022CreditFacilityCanadianDollarBritishPoundSterlingAndEurosSublimitMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mck_NetIncomeLossIncludingPortionAttributabletoNoncontrollingInterestExcludingRedeemableNoncontrollingInterest" abstract="false" name="NetIncomeLossIncludingPortionAttributabletoNoncontrollingInterestExcludingRedeemableNoncontrollingInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mck_LossContingencyClaimsSettledNumberOfJurisdictionsNotParticipatingInSettlement" abstract="false" name="LossContingencyClaimsSettledNumberOfJurisdictionsNotParticipatingInSettlement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mck_A525NotesDueFebruary152026Member" abstract="true" name="A525NotesDueFebruary152026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mck_A600NotesDueMarch12041Member" abstract="true" name="A600NotesDueMarch12041Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mck_StockIssuedDuringPeriodValueEmployeeStockPlansNetOfForfeitures" abstract="false" name="StockIssuedDuringPeriodValueEmployeeStockPlansNetOfForfeitures" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mck_SeniorUnsecuredCreditFacilityThe2022CreditFacilityMember" abstract="true" name="SeniorUnsecuredCreditFacilityThe2022CreditFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mck_LossContingencyNumberOfFormerOfficers" abstract="false" name="LossContingencyNumberOfFormerOfficers" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mck_AcceleratedShareRepurchaseInitialShareSettlementMember" abstract="true" name="AcceleratedShareRepurchaseInitialShareSettlementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mck_McKessonUSOncologyResearchMember" abstract="true" name="McKessonUSOncologyResearchMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mck_CherokeeNationMember" abstract="true" name="CherokeeNationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mck_DebtInstrumentRedemptionPeriod" abstract="false" name="DebtInstrumentRedemptionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mck_A490NotesDueJuly152028Member" abstract="true" name="A490NotesDueJuly152028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mck_OpenMarketShareRepurchaseTransactionsMember" abstract="true" name="OpenMarketShareRepurchaseTransactionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mck_AcceleratedShareRepurchaseMember" abstract="true" name="AcceleratedShareRepurchaseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mck_IndividualClaimantMember" abstract="true" name="IndividualClaimantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mck_CashCashEquivalentsRestrictedCashClassifiedWithinAssetsHeldForSalePeriodIncreaseDecrease" abstract="false" name="CashCashEquivalentsRestrictedCashClassifiedWithinAssetsHeldForSalePeriodIncreaseDecrease" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mck_A1625NotesDue2026Member" abstract="true" name="A1625NotesDue2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mck_ThreeLargestUSPharmaceuticalDistributorsMember" abstract="true" name="ThreeLargestUSPharmaceuticalDistributorsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mck_A765DebenturesDueMarch12027Member" abstract="true" name="A765DebenturesDueMarch12027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mck_LossContingencyNumberOfStatesFiledOnBehalfOf" abstract="false" name="LossContingencyNumberOfStatesFiledOnBehalfOf" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mck_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" abstract="false" name="FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mck_BusinessCombinationConsiderationTransferredOwnershipInterest" abstract="false" name="BusinessCombinationConsiderationTransferredOwnershipInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mck_A475NotesDueMay302029Member" abstract="true" name="A475NotesDueMay302029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mck_EffectiveIncomeTaxReconciliationTaxExpenseBenefitIntraEntityTransfersOfAssetsOtherThanInventoryAmount" abstract="false" name="EffectiveIncomeTaxReconciliationTaxExpenseBenefitIntraEntityTransfersOfAssetsOtherThanInventoryAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mck_DerivativeTerminationProceedsAmortizationPeriod" abstract="false" name="DerivativeTerminationProceedsAmortizationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="mck_RevenueDerivedFromServicesPercentage" abstract="false" name="RevenueDerivedFromServicesPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="mck_BritishPoundSterlingDenominatedNotesMember" abstract="true" name="BritishPoundSterlingDenominatedNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mck_LitigationSettlementAmountAwardedToOtherPartyPercentageOfTotalSettlementToBeUsedToRemediateDamages" abstract="false" name="LitigationSettlementAmountAwardedToOtherPartyPercentageOfTotalSettlementToBeUsedToRemediateDamages" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="mck_IncreaseDecreaseInLitigationReserve" abstract="false" name="IncreaseDecreaseInLitigationReserve" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mck_A1500NotesDue2025Member" abstract="true" name="A1500NotesDue2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mck_LitigationSettlementAwardAmountToBeUsedByStateAndLocalGovernment" abstract="false" name="LitigationSettlementAwardAmountToBeUsedByStateAndLocalGovernment" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="mck_EvanstonPolicePensionFundVMcKessonCorporationMember" abstract="true" name="EvanstonPolicePensionFundVMcKessonCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mck_A313SterlingNotesDueFebruary172029Member" abstract="true" name="A313SterlingNotesDueFebruary172029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mck_UnitedStatesExRelHartVMcKessonCorporationEtAl15CV00903RAMember" abstract="true" name="UnitedStatesExRelHartVMcKessonCorporationEtAl15CV00903RAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mck_AcceleratedShareRepurchaseCompletionOfProgramMember" abstract="true" name="AcceleratedShareRepurchaseCompletionOfProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="mck_RxSavingsSolutionsLLCMember" abstract="true" name="RxSavingsSolutionsLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mck_LossContingencyNumberofStates" abstract="false" name="LossContingencyNumberofStates" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mck_MedicalSurgicalSolutionsSegmentMember" abstract="true" name="MedicalSurgicalSolutionsSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mck_AureliusElephantLimitedMember" abstract="true" name="AureliusElephantLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mck_PaymentsForPurchaseOfGovernmentObligationsForSatisfactionAndDischargeOfLongTermDebt" abstract="false" name="PaymentsForPurchaseOfGovernmentObligationsForSatisfactionAndDischargeOfLongTermDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mck_A395NotesDueFebruary162028Member" abstract="true" name="A395NotesDueFebruary162028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermOperatingLeaseLiabilities" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermOperatingLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mck_StateOfWestVirginiaAndSubdivisionsMember" abstract="true" name="StateOfWestVirginiaAndSubdivisionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mck_SCRIOncologyLLCMember" abstract="true" name="SCRIOncologyLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mck_ThreeNationalPharmaceuticalDistributorsMember" abstract="true" name="ThreeNationalPharmaceuticalDistributorsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mck_OtherNonCurrentAssetsAndLiabilitiesMember" abstract="true" name="OtherNonCurrentAssetsAndLiabilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mck_AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember" abstract="true" name="AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mck_LossContingencyNumberOfCasesDismissed" abstract="false" name="LossContingencyNumberOfCasesDismissed" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="mck_StockIssuedDuringPeriodSharesEmployeeStockPlansNetOfForfeitures" abstract="false" name="StockIssuedDuringPeriodSharesEmployeeStockPlansNetOfForfeitures" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="mck_UKBusinessesDisposalGroupMember" abstract="true" name="UKBusinessesDisposalGroupMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mck_A510NotesDueJuly152033Member" abstract="true" name="A510NotesDueJuly152033Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mck_CurrentAssetLiabilityMember" abstract="true" name="CurrentAssetLiabilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mck_DerivativeNotionalAmountEnteredIntoDuringPeriod" abstract="false" name="DerivativeNotionalAmountEnteredIntoDuringPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mck_LeaseAndOtherObligationsMember" abstract="true" name="LeaseAndOtherObligationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mck_DisposalGroupIncludingDiscontinuedOperationConsiderationExpected" abstract="false" name="DisposalGroupIncludingDiscontinuedOperationConsiderationExpected" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdditionalPaidInCapital" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdditionalPaidInCapital" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="mck_EPSBasicAndDilutedAbstract" abstract="true" name="EPSBasicAndDilutedAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="mck_SeniorUnsecuredCreditFacilitythe2020CreditFacilityMember" abstract="true" name="SeniorUnsecuredCreditFacilitythe2020CreditFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mck_PrescriptionTechnologySolutionsMember" abstract="true" name="PrescriptionTechnologySolutionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="mck_A090NotesDueDecember32025Member" abstract="true" name="A090NotesDueDecember32025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>mck-20230630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:65f23265-c924-40c8-9b40-7c0acd48a82a,g:b9e463ca-a0e1-4231-8e93-a7255a3f4103-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="mck-20230630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_7b0be61c-65db-4c85-8d9e-930c93385d9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_32019c0c-9c35-4a17-ac40-49e051e30a35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_7b0be61c-65db-4c85-8d9e-930c93385d9a" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_32019c0c-9c35-4a17-ac40-49e051e30a35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_af5ed8e0-e69b-48f9-99ca-71a49f7412da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_7b0be61c-65db-4c85-8d9e-930c93385d9a" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_af5ed8e0-e69b-48f9-99ca-71a49f7412da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_RestructuringImpairmentAndOtherRelatedCharges_b29f0a31-3888-4a7a-b904-afbd911ae382" xlink:href="mck-20230630.xsd#mck_RestructuringImpairmentAndOtherRelatedCharges"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_7b0be61c-65db-4c85-8d9e-930c93385d9a" xlink:to="loc_mck_RestructuringImpairmentAndOtherRelatedCharges_b29f0a31-3888-4a7a-b904-afbd911ae382" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_15a312c1-a6df-41f3-a2a1-5bd764202033" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e7bcca9a-9f97-4f77-b1fb-3e6ee70d99fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_15a312c1-a6df-41f3-a2a1-5bd764202033" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_e7bcca9a-9f97-4f77-b1fb-3e6ee70d99fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_69a75d56-4edf-44e2-ab82-89c006419c8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_15a312c1-a6df-41f3-a2a1-5bd764202033" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_69a75d56-4edf-44e2-ab82-89c006419c8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_69a55d6c-98bc-4782-aeab-847527c08a7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_1eb53ee8-482f-4cdb-a10a-f4f32bf23bd6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_69a55d6c-98bc-4782-aeab-847527c08a7f" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_1eb53ee8-482f-4cdb-a10a-f4f32bf23bd6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_b635ae60-ba10-4ad4-9f96-3cda7db494ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_69a55d6c-98bc-4782-aeab-847527c08a7f" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_b635ae60-ba10-4ad4-9f96-3cda7db494ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_85918e6f-09f5-47bd-9cb4-35fc57347075" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_0ec4c585-fa49-46fc-a587-be6f6a21d95c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_85918e6f-09f5-47bd-9cb4-35fc57347075" xlink:to="loc_us-gaap_OperatingExpenses_0ec4c585-fa49-46fc-a587-be6f6a21d95c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_7d1bf6ad-492f-4ad0-8600-ef5d7f9531a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_85918e6f-09f5-47bd-9cb4-35fc57347075" xlink:to="loc_us-gaap_GrossProfit_7d1bf6ad-492f-4ad0-8600-ef5d7f9531a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_0ad78f1f-2256-4a0d-a61b-7f59c2046280" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_f2c22a9b-1993-47cb-a997-aec9117157ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_0ad78f1f-2256-4a0d-a61b-7f59c2046280" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_f2c22a9b-1993-47cb-a997-aec9117157ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_e15b59d3-1fa4-4abe-8482-2fe62aaa94a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_0ad78f1f-2256-4a0d-a61b-7f59c2046280" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_e15b59d3-1fa4-4abe-8482-2fe62aaa94a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_1f86e5c0-3b05-4e96-a2b0-ad605087bcfd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bf4c67cf-5db7-4914-b713-4602ad0f2233" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_1f86e5c0-3b05-4e96-a2b0-ad605087bcfd" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bf4c67cf-5db7-4914-b713-4602ad0f2233" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_dd3a7393-ae19-4776-8f77-d35f1709f540" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_1f86e5c0-3b05-4e96-a2b0-ad605087bcfd" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_dd3a7393-ae19-4776-8f77-d35f1709f540" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fa8dec68-0670-4df3-ab2a-f895cbd529e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_7f071e28-e0f1-4eda-929c-a924e5c4256b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fa8dec68-0670-4df3-ab2a-f895cbd529e6" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_7f071e28-e0f1-4eda-929c-a924e5c4256b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_b00854fc-ff20-4aba-bf59-796acf10ca4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fa8dec68-0670-4df3-ab2a-f895cbd529e6" xlink:to="loc_us-gaap_InterestExpense_b00854fc-ff20-4aba-bf59-796acf10ca4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_73d9748b-6cfb-49fa-a889-ae9979d6f208" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_fa8dec68-0670-4df3-ab2a-f895cbd529e6" xlink:to="loc_us-gaap_OperatingIncomeLoss_73d9748b-6cfb-49fa-a889-ae9979d6f208" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_008fe737-9b11-43d2-839d-e2a9137eb3ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_a8c64e04-8e37-4985-883c-ed24749a5f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_008fe737-9b11-43d2-839d-e2a9137eb3ab" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_a8c64e04-8e37-4985-883c-ed24749a5f6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_e55ec045-6424-41d5-b706-02accd9540c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_008fe737-9b11-43d2-839d-e2a9137eb3ab" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_e55ec045-6424-41d5-b706-02accd9540c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_549ead8e-15b1-4bfc-b81d-5697eb548e56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_541fe3b9-f9d6-40b7-9dae-1cda03d47e23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_549ead8e-15b1-4bfc-b81d-5697eb548e56" xlink:to="loc_us-gaap_ProfitLoss_541fe3b9-f9d6-40b7-9dae-1cda03d47e23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_7420587b-db7f-446c-94e5-7f5dbd28e7b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_549ead8e-15b1-4bfc-b81d-5697eb548e56" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_7420587b-db7f-446c-94e5-7f5dbd28e7b1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="simple" xlink:href="mck-20230630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"/>
  <link:calculationLink xlink:role="http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_044c8bc2-06f0-4c77-a85d-0a69dd8146fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_c76b0615-9aae-4d25-af8a-071e04baa1da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_044c8bc2-06f0-4c77-a85d-0a69dd8146fd" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_c76b0615-9aae-4d25-af8a-071e04baa1da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_201897a1-f0ab-483a-a41b-70e0e73f18b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_044c8bc2-06f0-4c77-a85d-0a69dd8146fd" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_201897a1-f0ab-483a-a41b-70e0e73f18b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_7590ea16-3bfd-482f-8bee-3ec7a3c49419" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c3313047-ee4b-4009-a996-4e797b92cf48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_7590ea16-3bfd-482f-8bee-3ec7a3c49419" xlink:to="loc_us-gaap_ProfitLoss_c3313047-ee4b-4009-a996-4e797b92cf48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_aeb15dbb-5f0b-43cb-b4b5-5fe8d7ed8c29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_7590ea16-3bfd-482f-8bee-3ec7a3c49419" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_aeb15dbb-5f0b-43cb-b4b5-5fe8d7ed8c29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_55ff8b0e-7dbe-4bd0-b626-dd45f220ce48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_dce66d8e-ac98-422c-ac77-14944873bc78" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_55ff8b0e-7dbe-4bd0-b626-dd45f220ce48" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_dce66d8e-ac98-422c-ac77-14944873bc78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_1520389d-dd9a-4067-b269-107050c158c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_55ff8b0e-7dbe-4bd0-b626-dd45f220ce48" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_1520389d-dd9a-4067-b269-107050c158c6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_308476e5-80fe-4fee-9de4-4ef3d900174a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_55ff8b0e-7dbe-4bd0-b626-dd45f220ce48" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_308476e5-80fe-4fee-9de4-4ef3d900174a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="mck-20230630.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_31882035-b469-47b9-8f3d-070659db82bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3adb1d84-bb4d-4252-936a-3a4cdeeae79b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_31882035-b469-47b9-8f3d-070659db82bf" xlink:to="loc_us-gaap_StockholdersEquity_3adb1d84-bb4d-4252-936a-3a4cdeeae79b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_ffa8f8f6-0f85-40fd-92c1-735c5a7d26d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_31882035-b469-47b9-8f3d-070659db82bf" xlink:to="loc_us-gaap_MinorityInterest_ffa8f8f6-0f85-40fd-92c1-735c5a7d26d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_9f31ec04-5986-4766-8297-ad30e1f4c8b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_0c6348cf-28c8-427d-b0c6-2847dcef2735" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9f31ec04-5986-4766-8297-ad30e1f4c8b0" xlink:to="loc_us-gaap_AssetsCurrent_0c6348cf-28c8-427d-b0c6-2847dcef2735" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_fe0b1c5a-f262-4d3c-8272-fcfefdfbf5bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9f31ec04-5986-4766-8297-ad30e1f4c8b0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_fe0b1c5a-f262-4d3c-8272-fcfefdfbf5bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_6ebd1dfa-b6ea-4ddc-83b3-ce1e8166a12b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9f31ec04-5986-4766-8297-ad30e1f4c8b0" xlink:to="loc_us-gaap_Goodwill_6ebd1dfa-b6ea-4ddc-83b3-ce1e8166a12b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2e806d2b-f904-41bc-80fa-e2ce0ddf9bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9f31ec04-5986-4766-8297-ad30e1f4c8b0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_2e806d2b-f904-41bc-80fa-e2ce0ddf9bd1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_8f9aa8cf-6e36-4e89-a9be-296de0c2caf7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9f31ec04-5986-4766-8297-ad30e1f4c8b0" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_8f9aa8cf-6e36-4e89-a9be-296de0c2caf7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_997ef4d4-4e3a-4f3f-8a5b-d76c41f9f9a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_9f31ec04-5986-4766-8297-ad30e1f4c8b0" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_997ef4d4-4e3a-4f3f-8a5b-d76c41f9f9a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_542983c9-6c6e-47da-848e-e9e275ce723d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_f53318b7-77a1-42ae-870b-021585c09b42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_542983c9-6c6e-47da-848e-e9e275ce723d" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_f53318b7-77a1-42ae-870b-021585c09b42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_b026c702-5dd2-44b7-a0aa-4a18805162a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_542983c9-6c6e-47da-848e-e9e275ce723d" xlink:to="loc_us-gaap_AccountsPayableCurrent_b026c702-5dd2-44b7-a0aa-4a18805162a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_9698c512-f786-4b79-96b4-b904fa30fcba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_542983c9-6c6e-47da-848e-e9e275ce723d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_9698c512-f786-4b79-96b4-b904fa30fcba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_525afd23-4d47-40f7-b426-83fdc3e6a972" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_542983c9-6c6e-47da-848e-e9e275ce723d" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_525afd23-4d47-40f7-b426-83fdc3e6a972" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_c9888991-e259-48ee-bd33-c813db237849" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_8537856f-aea2-45f7-99de-5fbab244322a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_c9888991-e259-48ee-bd33-c813db237849" xlink:to="loc_us-gaap_LiabilitiesCurrent_8537856f-aea2-45f7-99de-5fbab244322a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_f61b2bdb-af44-4354-ac85-a1929b680166" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_c9888991-e259-48ee-bd33-c813db237849" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_f61b2bdb-af44-4354-ac85-a1929b680166" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_3d479133-5428-4e89-87cb-0951dd9b7b6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_c9888991-e259-48ee-bd33-c813db237849" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_3d479133-5428-4e89-87cb-0951dd9b7b6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_85c68ece-7796-4c46-bab3-4a380e8add86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_c9888991-e259-48ee-bd33-c813db237849" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_85c68ece-7796-4c46-bab3-4a380e8add86" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveNoncurrent_85f4e392-f5d8-4d15-8c6c-d893914493c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationReserveNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_c9888991-e259-48ee-bd33-c813db237849" xlink:to="loc_us-gaap_LitigationReserveNoncurrent_85f4e392-f5d8-4d15-8c6c-d893914493c7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2ad0c1a7-0615-41b6-b6de-c270869a3868" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_c9888991-e259-48ee-bd33-c813db237849" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2ad0c1a7-0615-41b6-b6de-c270869a3868" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_780abdb2-36d3-472b-aea8-342012f88500" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_c9888991-e259-48ee-bd33-c813db237849" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_780abdb2-36d3-472b-aea8-342012f88500" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_208bd352-12ce-4b01-920e-9f5ed043b2e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_13583b55-6d87-4b3c-be2f-d12ead09bdc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_208bd352-12ce-4b01-920e-9f5ed043b2e5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_13583b55-6d87-4b3c-be2f-d12ead09bdc5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_30fa2cc8-6ab9-46b8-9200-633b60e8bbd5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_208bd352-12ce-4b01-920e-9f5ed043b2e5" xlink:to="loc_us-gaap_ReceivablesNetCurrent_30fa2cc8-6ab9-46b8-9200-633b60e8bbd5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_72fac33e-843d-4633-a534-6f933c941f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_208bd352-12ce-4b01-920e-9f5ed043b2e5" xlink:to="loc_us-gaap_InventoryNet_72fac33e-843d-4633-a534-6f933c941f0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8ab18f93-466f-427f-b802-8e37f555da53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_208bd352-12ce-4b01-920e-9f5ed043b2e5" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8ab18f93-466f-427f-b802-8e37f555da53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0028c0e4-df26-4532-a127-a24d4a662805" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_4ee6fa74-cf87-49a9-a2c0-ca2bd871d9b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0028c0e4-df26-4532-a127-a24d4a662805" xlink:to="loc_us-gaap_AdditionalPaidInCapital_4ee6fa74-cf87-49a9-a2c0-ca2bd871d9b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_180a0411-1f95-468e-bb34-986124eec595" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0028c0e4-df26-4532-a127-a24d4a662805" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_180a0411-1f95-468e-bb34-986124eec595" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_53ac2334-f8ed-4bf8-ac06-bf06d8252910" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0028c0e4-df26-4532-a127-a24d4a662805" xlink:to="loc_us-gaap_TreasuryStockCommonValue_53ac2334-f8ed-4bf8-ac06-bf06d8252910" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_f07b705a-8da0-49cb-9717-0fa47456ec68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0028c0e4-df26-4532-a127-a24d4a662805" xlink:to="loc_us-gaap_PreferredStockValue_f07b705a-8da0-49cb-9717-0fa47456ec68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_cffaebe6-bf37-4ca2-a60d-448d4a946fce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0028c0e4-df26-4532-a127-a24d4a662805" xlink:to="loc_us-gaap_CommonStockValue_cffaebe6-bf37-4ca2-a60d-448d4a946fce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_07c14543-27bf-452b-b36e-ad86b21dd474" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_0028c0e4-df26-4532-a127-a24d4a662805" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_07c14543-27bf-452b-b36e-ad86b21dd474" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="mck-20230630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a428a07d-7a43-431b-afb1-1f987f756257" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_05f283c3-0d12-4891-9247-59425ec80a15" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a428a07d-7a43-431b-afb1-1f987f756257" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_05f283c3-0d12-4891-9247-59425ec80a15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_d7579be0-a6dd-46c3-89bd-8afd942fdb10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a428a07d-7a43-431b-afb1-1f987f756257" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_d7579be0-a6dd-46c3-89bd-8afd942fdb10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_0582358a-6249-424b-81c2-8bcbeefa69da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a428a07d-7a43-431b-afb1-1f987f756257" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_0582358a-6249-424b-81c2-8bcbeefa69da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_8a4f2f67-a147-467b-a086-470424eb02ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a428a07d-7a43-431b-afb1-1f987f756257" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_8a4f2f67-a147-467b-a086-470424eb02ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_e1010c23-6a4d-45c6-9bb8-4922cc2fe28c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a428a07d-7a43-431b-afb1-1f987f756257" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_e1010c23-6a4d-45c6-9bb8-4922cc2fe28c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_1a98ef03-4a69-47e2-9f5c-88e478380e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a428a07d-7a43-431b-afb1-1f987f756257" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_1a98ef03-4a69-47e2-9f5c-88e478380e8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_27f24949-3f52-42a6-b8c6-e8be2a90eda3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a428a07d-7a43-431b-afb1-1f987f756257" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_27f24949-3f52-42a6-b8c6-e8be2a90eda3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_a7e39327-3196-4fa6-a457-b2f34bfd9663" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a428a07d-7a43-431b-afb1-1f987f756257" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_a7e39327-3196-4fa6-a457-b2f34bfd9663" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_PaymentsForPurchaseOfGovernmentObligationsForSatisfactionAndDischargeOfLongTermDebt_82dff707-5ed0-46e9-8855-687613eaf7c9" xlink:href="mck-20230630.xsd#mck_PaymentsForPurchaseOfGovernmentObligationsForSatisfactionAndDischargeOfLongTermDebt"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a428a07d-7a43-431b-afb1-1f987f756257" xlink:to="loc_mck_PaymentsForPurchaseOfGovernmentObligationsForSatisfactionAndDischargeOfLongTermDebt_82dff707-5ed0-46e9-8855-687613eaf7c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a259a68c-18b8-4dde-9ea0-8b04d75ac266" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_dd9ecd34-5acf-4a59-ab04-a1df6d26f33e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a259a68c-18b8-4dde-9ea0-8b04d75ac266" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_dd9ecd34-5acf-4a59-ab04-a1df6d26f33e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_d9eb8fbc-2995-4a9c-a8e4-01abe7c5a448" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a259a68c-18b8-4dde-9ea0-8b04d75ac266" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_d9eb8fbc-2995-4a9c-a8e4-01abe7c5a448" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherAssets_ba52ee72-7009-45e4-bf8a-0cc2f291c763" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfOtherAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a259a68c-18b8-4dde-9ea0-8b04d75ac266" xlink:to="loc_us-gaap_GainLossOnSaleOfOtherAssets_ba52ee72-7009-45e4-bf8a-0cc2f291c763" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_4134d9f3-c0cd-4a66-a981-22b2d1db1de5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a259a68c-18b8-4dde-9ea0-8b04d75ac266" xlink:to="loc_us-gaap_AdjustmentForAmortization_4134d9f3-c0cd-4a66-a981-22b2d1db1de5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_8c1a49fc-c3cc-4d78-8f3a-aa3efc3ee395" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a259a68c-18b8-4dde-9ea0-8b04d75ac266" xlink:to="loc_us-gaap_ProfitLoss_8c1a49fc-c3cc-4d78-8f3a-aa3efc3ee395" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedTaxesPayable_ce06a700-1d1c-49b9-b3ba-06939c15faaa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedTaxesPayable"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a259a68c-18b8-4dde-9ea0-8b04d75ac266" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedTaxesPayable_ce06a700-1d1c-49b9-b3ba-06939c15faaa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_16b5b02a-07b3-4ae2-b25d-e7cece995914" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a259a68c-18b8-4dde-9ea0-8b04d75ac266" xlink:to="loc_us-gaap_Depreciation_16b5b02a-07b3-4ae2-b25d-e7cece995914" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLIFOReservePeriodCharge_db75e35b-522c-4716-a43b-83e3ef4f9210" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryLIFOReservePeriodCharge"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a259a68c-18b8-4dde-9ea0-8b04d75ac266" xlink:to="loc_us-gaap_InventoryLIFOReservePeriodCharge_db75e35b-522c-4716-a43b-83e3ef4f9210" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables_92e96b90-0369-4306-936c-1f60b92a2c82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a259a68c-18b8-4dde-9ea0-8b04d75ac266" xlink:to="loc_us-gaap_IncreaseDecreaseInReceivables_92e96b90-0369-4306-936c-1f60b92a2c82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_9a665ef9-298f-44ba-b015-97030c90cf75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a259a68c-18b8-4dde-9ea0-8b04d75ac266" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_9a665ef9-298f-44ba-b015-97030c90cf75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ba81fb24-fa3f-4a83-8adf-b8914ec7abd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a259a68c-18b8-4dde-9ea0-8b04d75ac266" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_ba81fb24-fa3f-4a83-8adf-b8914ec7abd0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetImpairmentCharges_db2c528b-7fb0-4375-a503-bf9b89fdb521" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetImpairmentCharges"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a259a68c-18b8-4dde-9ea0-8b04d75ac266" xlink:to="loc_us-gaap_OtherAssetImpairmentCharges_db2c528b-7fb0-4375-a503-bf9b89fdb521" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_2c120d08-7524-4629-bfca-565f3cfb198c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a259a68c-18b8-4dde-9ea0-8b04d75ac266" xlink:to="loc_us-gaap_OperatingLeaseExpense_2c120d08-7524-4629-bfca-565f3cfb198c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_IncreaseDecreaseInLitigationReserve_824aad65-e0b5-4b51-9fd4-e1de8cb25465" xlink:href="mck-20230630.xsd#mck_IncreaseDecreaseInLitigationReserve"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a259a68c-18b8-4dde-9ea0-8b04d75ac266" xlink:to="loc_mck_IncreaseDecreaseInLitigationReserve_824aad65-e0b5-4b51-9fd4-e1de8cb25465" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_e1dd91b0-c09e-4b33-bb81-2891a8e87367" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a259a68c-18b8-4dde-9ea0-8b04d75ac266" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_e1dd91b0-c09e-4b33-bb81-2891a8e87367" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_d76a1cb3-5e44-4411-9900-4ecac0a08d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a259a68c-18b8-4dde-9ea0-8b04d75ac266" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_d76a1cb3-5e44-4411-9900-4ecac0a08d2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_dca87ae9-0c90-42c7-ace6-1174760e6d30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_a259a68c-18b8-4dde-9ea0-8b04d75ac266" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_dca87ae9-0c90-42c7-ace6-1174760e6d30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_dbdda3cf-a9b9-4cc0-96c6-32af5bb71d6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_8c019ed8-ff82-4956-9953-ae6e2f9da918" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_dbdda3cf-a9b9-4cc0-96c6-32af5bb71d6a" xlink:to="loc_us-gaap_RestrictedCashCurrent_8c019ed8-ff82-4956-9953-ae6e2f9da918" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_42a3407f-15d3-44ea-b160-f7eb61c04135" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_dbdda3cf-a9b9-4cc0-96c6-32af5bb71d6a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_42a3407f-15d3-44ea-b160-f7eb61c04135" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4014f9de-a59c-4cce-a554-691bc476a575" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d72ce51e-ca80-4a08-94c1-66681348cf6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4014f9de-a59c-4cce-a554-691bc476a575" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d72ce51e-ca80-4a08-94c1-66681348cf6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireSoftware_400bca6e-6cc3-40d3-aea2-b52b7035a3ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireSoftware"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4014f9de-a59c-4cce-a554-691bc476a575" xlink:to="loc_us-gaap_PaymentsToAcquireSoftware_400bca6e-6cc3-40d3-aea2-b52b7035a3ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_739364aa-26ef-4bd0-84b2-a1c4f8ab8a00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4014f9de-a59c-4cce-a554-691bc476a575" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_739364aa-26ef-4bd0-84b2-a1c4f8ab8a00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates_db6272f7-41ca-49b2-b657-7c7f4856c208" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4014f9de-a59c-4cce-a554-691bc476a575" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates_db6272f7-41ca-49b2-b657-7c7f4856c208" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_05d38675-5989-4c3d-a1b6-78bc7fb62f47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4014f9de-a59c-4cce-a554-691bc476a575" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_05d38675-5989-4c3d-a1b6-78bc7fb62f47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_99baa4aa-d58e-4422-af9a-0dc47004e5d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_CashCashEquivalentsRestrictedCashClassifiedWithinAssetsHeldForSalePeriodIncreaseDecrease_78eacaa7-ff18-44cc-8cae-961df8f2ae33" xlink:href="mck-20230630.xsd#mck_CashCashEquivalentsRestrictedCashClassifiedWithinAssetsHeldForSalePeriodIncreaseDecrease"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_99baa4aa-d58e-4422-af9a-0dc47004e5d2" xlink:to="loc_mck_CashCashEquivalentsRestrictedCashClassifiedWithinAssetsHeldForSalePeriodIncreaseDecrease_78eacaa7-ff18-44cc-8cae-961df8f2ae33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_edbae9d1-9e80-4a43-a7b9-4b403f639ae8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_99baa4aa-d58e-4422-af9a-0dc47004e5d2" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_edbae9d1-9e80-4a43-a7b9-4b403f639ae8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c3eaae25-8817-4042-ab2c-0c7dfb19650d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_99baa4aa-d58e-4422-af9a-0dc47004e5d2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c3eaae25-8817-4042-ab2c-0c7dfb19650d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c4442b67-d0f6-4d5b-93e9-a192efb21a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_99baa4aa-d58e-4422-af9a-0dc47004e5d2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_c4442b67-d0f6-4d5b-93e9-a192efb21a5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9eb213f3-2a2c-4866-972f-4b6894599df8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_99baa4aa-d58e-4422-af9a-0dc47004e5d2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9eb213f3-2a2c-4866-972f-4b6894599df8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails" xlink:type="simple" xlink:href="mck-20230630.xsd#BusinessAcquisitionsandDivestituresAcquisitionsDetails"/>
  <link:calculationLink xlink:role="http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_fb6929c5-2a20-4a75-84b3-7656ff2456dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_f5ddfa34-63a7-4560-9ba9-9ca5c3d1f4b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_fb6929c5-2a20-4a75-84b3-7656ff2456dd" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_f5ddfa34-63a7-4560-9ba9-9ca5c3d1f4b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_87cb6a9c-4f7f-4633-be50-763a8c306681" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_fb6929c5-2a20-4a75-84b3-7656ff2456dd" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_87cb6a9c-4f7f-4633-be50-763a8c306681" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails" xlink:type="simple" xlink:href="mck-20230630.xsd#BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails"/>
  <link:calculationLink xlink:role="http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest_8bc855c3-8676-4438-aa5a-ff2af237b389" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_73122c8d-1dde-4f2c-b18f-1ed10834767d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest_8bc855c3-8676-4438-aa5a-ff2af237b389" xlink:to="loc_us-gaap_Goodwill_73122c8d-1dde-4f2c-b18f-1ed10834767d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_c4768b77-6711-483d-8c93-0b7e2334ae83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest_8bc855c3-8676-4438-aa5a-ff2af237b389" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_c4768b77-6711-483d-8c93-0b7e2334ae83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdditionalPaidInCapital_fca734a5-bfc8-4b2d-ae3c-04f0be6cb137" xlink:href="mck-20230630.xsd#mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest_8bc855c3-8676-4438-aa5a-ff2af237b389" xlink:to="loc_mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdditionalPaidInCapital_fca734a5-bfc8-4b2d-ae3c-04f0be6cb137" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_a772b05c-8e89-480b-885b-36e0c66178c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest_8bc855c3-8676-4438-aa5a-ff2af237b389" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_a772b05c-8e89-480b-885b-36e0c66178c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_c9f533a7-2238-4882-a79a-0e6c91da9784" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_7f11a717-e85e-4d92-bf5a-54963997af05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_c9f533a7-2238-4882-a79a-0e6c91da9784" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_7f11a717-e85e-4d92-bf5a-54963997af05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_BusinessCombinationConsiderationTransferredOwnershipInterest_9e661ed9-be99-467d-bc44-6d99b3ce08b1" xlink:href="mck-20230630.xsd#mck_BusinessCombinationConsiderationTransferredOwnershipInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_c9f533a7-2238-4882-a79a-0e6c91da9784" xlink:to="loc_mck_BusinessCombinationConsiderationTransferredOwnershipInterest_9e661ed9-be99-467d-bc44-6d99b3ce08b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_7719f1c3-0747-4976-b2d4-e4193a157267" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermOperatingLeaseLiabilities_3373efb3-1320-49a6-9297-d31299750688" xlink:href="mck-20230630.xsd#mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermOperatingLeaseLiabilities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_7719f1c3-0747-4976-b2d4-e4193a157267" xlink:to="loc_mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermOperatingLeaseLiabilities_3373efb3-1320-49a6-9297-d31299750688" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_f3bb7040-1b92-4ade-bc16-7be47fb2f909" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_7719f1c3-0747-4976-b2d4-e4193a157267" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_f3bb7040-1b92-4ade-bc16-7be47fb2f909" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_4647ea97-fe6e-46e5-baef-931bca9fa68e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_7719f1c3-0747-4976-b2d4-e4193a157267" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_4647ea97-fe6e-46e5-baef-931bca9fa68e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_ba4e620c-eba0-4165-8b3a-cc90c9d27104" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_7719f1c3-0747-4976-b2d4-e4193a157267" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_ba4e620c-eba0-4165-8b3a-cc90c9d27104" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_3deb586e-c915-4157-aaca-ce9c961128f9" xlink:href="mck-20230630.xsd#mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_7719f1c3-0747-4976-b2d4-e4193a157267" xlink:to="loc_mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_3deb586e-c915-4157-aaca-ce9c961128f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_a252e1ca-4df8-42bf-bfc4-0b5108546062" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_7719f1c3-0747-4976-b2d4-e4193a157267" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_a252e1ca-4df8-42bf-bfc4-0b5108546062" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_70e1a3f2-e25e-4ff3-ae4d-546c05acf3fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_7719f1c3-0747-4976-b2d4-e4193a157267" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_70e1a3f2-e25e-4ff3-ae4d-546c05acf3fe" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails" xlink:type="simple" xlink:href="mck-20230630.xsd#RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails"/>
  <link:calculationLink xlink:role="http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_fd750b94-c163-4b91-9cea-8a0585935c5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_247ff695-63bf-415a-9ddb-6ebfa66a263e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringCharges_fd750b94-c163-4b91-9cea-8a0585935c5a" xlink:to="loc_us-gaap_SeveranceCosts1_247ff695-63bf-415a-9ddb-6ebfa66a263e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessExitCosts1_45e8232d-0188-45c8-b386-d145d3961a0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessExitCosts1"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringCharges_fd750b94-c163-4b91-9cea-8a0585935c5a" xlink:to="loc_us-gaap_BusinessExitCosts1_45e8232d-0188-45c8-b386-d145d3961a0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_AssetImpairmentChargesIncludingAcceleratedDepreciation_52fdfe91-f0c6-488c-a307-519a25547988" xlink:href="mck-20230630.xsd#mck_AssetImpairmentChargesIncludingAcceleratedDepreciation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringCharges_fd750b94-c163-4b91-9cea-8a0585935c5a" xlink:to="loc_mck_AssetImpairmentChargesIncludingAcceleratedDepreciation_52fdfe91-f0c6-488c-a307-519a25547988" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails" xlink:type="simple" xlink:href="mck-20230630.xsd#EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails"/>
  <link:calculationLink xlink:role="http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_8b2928bd-3b24-4843-972d-784ebd02fe7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_804fd328-41ef-4a66-a8f0-f0eb03b99af2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_8b2928bd-3b24-4843-972d-784ebd02fe7c" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_804fd328-41ef-4a66-a8f0-f0eb03b99af2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_f2673dcf-15b7-416e-8eb4-ae994701c95b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_8b2928bd-3b24-4843-972d-784ebd02fe7c" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_f2673dcf-15b7-416e-8eb4-ae994701c95b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c36afd7f-41b4-431c-8ea2-c5be0bde04dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_dadce9c1-750a-4320-b618-1181d9337675" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_c36afd7f-41b4-431c-8ea2-c5be0bde04dc" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_dadce9c1-750a-4320-b618-1181d9337675" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_3c8cd86b-a42b-49b4-b0c5-1b46aacb30bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_c36afd7f-41b4-431c-8ea2-c5be0bde04dc" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_3c8cd86b-a42b-49b4-b0c5-1b46aacb30bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_df0251cc-5f58-488d-b691-cf3583871a33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_37635627-55a2-4250-93b1-10e3d950ff01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_df0251cc-5f58-488d-b691-cf3583871a33" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_37635627-55a2-4250-93b1-10e3d950ff01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2e87de10-5d67-436a-84a2-1de731be7289" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_df0251cc-5f58-488d-b691-cf3583871a33" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2e87de10-5d67-436a-84a2-1de731be7289" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails" xlink:type="simple" xlink:href="mck-20230630.xsd#GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_fa685caf-27b9-4229-a251-a817a661b9bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_6925bde3-fc07-44fa-b5c0-97289e39d7ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_fa685caf-27b9-4229-a251-a817a661b9bd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_6925bde3-fc07-44fa-b5c0-97289e39d7ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ad091f6d-f1ad-49e3-9ff3-874567e0440a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_fa685caf-27b9-4229-a251-a817a661b9bd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ad091f6d-f1ad-49e3-9ff3-874567e0440a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails" xlink:type="simple" xlink:href="mck-20230630.xsd#DebtandFinancingActivitiesScheduleofLongTermDebtDetails"/>
  <link:calculationLink xlink:role="http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_0a8ab4ff-eee6-43a4-a52f-81e972bf4cb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_91b650ec-4270-4982-8862-5b5bcb0a5169" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_0a8ab4ff-eee6-43a4-a52f-81e972bf4cb0" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_91b650ec-4270-4982-8862-5b5bcb0a5169" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_f842ff90-e6a3-4faa-b938-d05d55ccf0cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_0a8ab4ff-eee6-43a4-a52f-81e972bf4cb0" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_f842ff90-e6a3-4faa-b938-d05d55ccf0cd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/CommitmentsandContingentLiabilitiesEstimatedAccrualLiabilityDetails" xlink:type="simple" xlink:href="mck-20230630.xsd#CommitmentsandContingentLiabilitiesEstimatedAccrualLiabilityDetails"/>
  <link:calculationLink xlink:role="http://mckesson123.com/role/CommitmentsandContingentLiabilitiesEstimatedAccrualLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_e2fdb16c-b771-47cb-a73f-75de985eed16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValueNoncurrent_b1ffd79f-a738-4e1b-9e6d-b574da50df47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualCarryingValueNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue_e2fdb16c-b771-47cb-a73f-75de985eed16" xlink:to="loc_us-gaap_LossContingencyAccrualCarryingValueNoncurrent_b1ffd79f-a738-4e1b-9e6d-b574da50df47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValueCurrent_b5cf5282-1997-42c9-a12f-1a087a9a7e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualCarryingValueCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue_e2fdb16c-b771-47cb-a73f-75de985eed16" xlink:to="loc_us-gaap_LossContingencyAccrualCarryingValueCurrent_b5cf5282-1997-42c9-a12f-1a087a9a7e9e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails" xlink:type="simple" xlink:href="mck-20230630.xsd#StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails"/>
  <link:calculationLink xlink:role="http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d6ad5546-80d8-4a36-abbb-5dd51f20b28c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_7b9c64bb-3449-4468-a451-76f878bc00a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d6ad5546-80d8-4a36-abbb-5dd51f20b28c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_7b9c64bb-3449-4468-a451-76f878bc00a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_9cab2be2-efed-46b1-9708-51acc8beac73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d6ad5546-80d8-4a36-abbb-5dd51f20b28c" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_9cab2be2-efed-46b1-9708-51acc8beac73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_b28cd5a4-ae90-4238-9a12-101b775339a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_40b6670b-4904-4f51-af6c-4587b5d6039c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_b28cd5a4-ae90-4238-9a12-101b775339a1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_40b6670b-4904-4f51-af6c-4587b5d6039c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_d83b823c-32b8-410c-88f2-5408b0fc558c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_b28cd5a4-ae90-4238-9a12-101b775339a1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_d83b823c-32b8-410c-88f2-5408b0fc558c" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>mck-20230630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:65f23265-c924-40c8-9b40-7c0acd48a82a,g:b9e463ca-a0e1-4231-8e93-a7255a3f4103-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://mckesson123.com/role/Cover" xlink:type="simple" xlink:href="mck-20230630.xsd#Cover"/>
  <link:definitionLink xlink:role="http://mckesson123.com/role/Cover" xlink:type="extended" id="i0f55cc9b7b89483592a21561ca66ec32_Cover">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_fe9b6671-3e12-4c42-9852-9149877588c5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_b8867d47-f9a4-467a-a253-be9c7f53b432" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_fe9b6671-3e12-4c42-9852-9149877588c5" xlink:to="loc_dei_DocumentType_b8867d47-f9a4-467a-a253-be9c7f53b432" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_5c779a27-d85c-4835-b63d-5ab98b28676a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_fe9b6671-3e12-4c42-9852-9149877588c5" xlink:to="loc_dei_DocumentQuarterlyReport_5c779a27-d85c-4835-b63d-5ab98b28676a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_7e8314a7-051a-4e1c-b308-824b19fb04d5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_fe9b6671-3e12-4c42-9852-9149877588c5" xlink:to="loc_dei_DocumentPeriodEndDate_7e8314a7-051a-4e1c-b308-824b19fb04d5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_0e227280-9120-4a70-9bab-de0d4aa953c4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_fe9b6671-3e12-4c42-9852-9149877588c5" xlink:to="loc_dei_DocumentTransitionReport_0e227280-9120-4a70-9bab-de0d4aa953c4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_c42a403d-ed41-41d0-8516-d6bcfe539302" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_fe9b6671-3e12-4c42-9852-9149877588c5" xlink:to="loc_dei_EntityFileNumber_c42a403d-ed41-41d0-8516-d6bcfe539302" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_92e93ae3-a8fe-4ae2-8da4-7f24de1da8da" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_fe9b6671-3e12-4c42-9852-9149877588c5" xlink:to="loc_dei_EntityRegistrantName_92e93ae3-a8fe-4ae2-8da4-7f24de1da8da" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_ee3bb635-a655-4fe9-8e35-4ee388bdca5d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_fe9b6671-3e12-4c42-9852-9149877588c5" xlink:to="loc_dei_EntityIncorporationStateCountryCode_ee3bb635-a655-4fe9-8e35-4ee388bdca5d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_92c1bc17-5074-435a-aef5-267c4af1f29b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_fe9b6671-3e12-4c42-9852-9149877588c5" xlink:to="loc_dei_EntityTaxIdentificationNumber_92c1bc17-5074-435a-aef5-267c4af1f29b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_5cd21940-c7f7-4830-91cc-22f4c9024c2b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_fe9b6671-3e12-4c42-9852-9149877588c5" xlink:to="loc_dei_EntityAddressAddressLine1_5cd21940-c7f7-4830-91cc-22f4c9024c2b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_394b743c-0f26-4f32-aa1b-b4ac5cb37f47" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_fe9b6671-3e12-4c42-9852-9149877588c5" xlink:to="loc_dei_EntityAddressCityOrTown_394b743c-0f26-4f32-aa1b-b4ac5cb37f47" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_eaaace15-e67a-4c97-9d05-d9ecd68c88bd" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_fe9b6671-3e12-4c42-9852-9149877588c5" xlink:to="loc_dei_EntityAddressStateOrProvince_eaaace15-e67a-4c97-9d05-d9ecd68c88bd" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_d751ad6b-34da-42d6-9dc2-24add92d3f4a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_fe9b6671-3e12-4c42-9852-9149877588c5" xlink:to="loc_dei_EntityAddressPostalZipCode_d751ad6b-34da-42d6-9dc2-24add92d3f4a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_dbd9760e-32e9-4ec4-9c1c-93805ee72f7c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_fe9b6671-3e12-4c42-9852-9149877588c5" xlink:to="loc_dei_CityAreaCode_dbd9760e-32e9-4ec4-9c1c-93805ee72f7c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_709507e4-79b0-4d73-9fc8-b9d041669f08" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_fe9b6671-3e12-4c42-9852-9149877588c5" xlink:to="loc_dei_LocalPhoneNumber_709507e4-79b0-4d73-9fc8-b9d041669f08" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_5b0fb9a0-ccde-4f6f-b6b5-60e30c2d54bb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_fe9b6671-3e12-4c42-9852-9149877588c5" xlink:to="loc_dei_Security12bTitle_5b0fb9a0-ccde-4f6f-b6b5-60e30c2d54bb" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_fba9437b-9443-4ddd-9638-5d9a13f1fcc5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_fe9b6671-3e12-4c42-9852-9149877588c5" xlink:to="loc_dei_TradingSymbol_fba9437b-9443-4ddd-9638-5d9a13f1fcc5" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_9384685d-21fc-4b31-aa9e-2e429117c8bf" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_fe9b6671-3e12-4c42-9852-9149877588c5" xlink:to="loc_dei_SecurityExchangeName_9384685d-21fc-4b31-aa9e-2e429117c8bf" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_9c84c18a-009e-41dd-b561-bd19adf9db09" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_fe9b6671-3e12-4c42-9852-9149877588c5" xlink:to="loc_dei_EntityCurrentReportingStatus_9c84c18a-009e-41dd-b561-bd19adf9db09" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_c29bfae9-02f9-42c1-96ac-6b39b2cb200a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_fe9b6671-3e12-4c42-9852-9149877588c5" xlink:to="loc_dei_EntityInteractiveDataCurrent_c29bfae9-02f9-42c1-96ac-6b39b2cb200a" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_a797fac2-8c1d-423f-97d0-c1f76eff8f66" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_fe9b6671-3e12-4c42-9852-9149877588c5" xlink:to="loc_dei_EntityFilerCategory_a797fac2-8c1d-423f-97d0-c1f76eff8f66" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_221a96cb-b256-46dc-8ad3-6a84d4864208" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_fe9b6671-3e12-4c42-9852-9149877588c5" xlink:to="loc_dei_EntitySmallBusiness_221a96cb-b256-46dc-8ad3-6a84d4864208" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_6de9f3c2-7e49-49d5-aa03-27d73f4ca818" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_fe9b6671-3e12-4c42-9852-9149877588c5" xlink:to="loc_dei_EntityEmergingGrowthCompany_6de9f3c2-7e49-49d5-aa03-27d73f4ca818" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_10799bef-a033-4437-9ac9-ca40bc341e53" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_fe9b6671-3e12-4c42-9852-9149877588c5" xlink:to="loc_dei_EntityShellCompany_10799bef-a033-4437-9ac9-ca40bc341e53" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_ce1fbfbf-4f24-4c83-a452-77c661cd3cf0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_fe9b6671-3e12-4c42-9852-9149877588c5" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_ce1fbfbf-4f24-4c83-a452-77c661cd3cf0" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_f5e2808e-6e44-4471-a694-4c154f59ca88" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_fe9b6671-3e12-4c42-9852-9149877588c5" xlink:to="loc_dei_EntityCentralIndexKey_f5e2808e-6e44-4471-a694-4c154f59ca88" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_2829c146-81b0-475f-a458-f4dac3e7347f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_fe9b6671-3e12-4c42-9852-9149877588c5" xlink:to="loc_dei_DocumentFiscalYearFocus_2829c146-81b0-475f-a458-f4dac3e7347f" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_09dd6a6e-0519-4840-9407-8e2bf2884141" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_fe9b6671-3e12-4c42-9852-9149877588c5" xlink:to="loc_dei_DocumentFiscalPeriodFocus_09dd6a6e-0519-4840-9407-8e2bf2884141" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_996ec339-68b0-44f6-8b7b-ef8ba8557c7b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_fe9b6671-3e12-4c42-9852-9149877588c5" xlink:to="loc_dei_AmendmentFlag_996ec339-68b0-44f6-8b7b-ef8ba8557c7b" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_9fd54e48-e9ed-4ea8-97a5-8aad63854423" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_fe9b6671-3e12-4c42-9852-9149877588c5" xlink:to="loc_dei_CurrentFiscalYearEndDate_9fd54e48-e9ed-4ea8-97a5-8aad63854423" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_cba14965-f0cd-4dde-a90f-a37ff4facbd4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityInformationLineItems_fe9b6671-3e12-4c42-9852-9149877588c5" xlink:to="loc_dei_EntitiesTable_cba14965-f0cd-4dde-a90f-a37ff4facbd4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3fdf2529-68fc-4045-ab9a-2d0332c7ca87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_cba14965-f0cd-4dde-a90f-a37ff4facbd4" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3fdf2529-68fc-4045-ab9a-2d0332c7ca87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_3fdf2529-68fc-4045-ab9a-2d0332c7ca87_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3fdf2529-68fc-4045-ab9a-2d0332c7ca87" xlink:to="loc_us-gaap_ClassOfStockDomain_3fdf2529-68fc-4045-ab9a-2d0332c7ca87_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d1784ff1-c70b-4e94-b4f5-6253819b140d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3fdf2529-68fc-4045-ab9a-2d0332c7ca87" xlink:to="loc_us-gaap_ClassOfStockDomain_d1784ff1-c70b-4e94-b4f5-6253819b140d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_48aed6c8-d805-4e3d-804f-b26f5df0768f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_d1784ff1-c70b-4e94-b4f5-6253819b140d" xlink:to="loc_us-gaap_CommonStockMember_48aed6c8-d805-4e3d-804f-b26f5df0768f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_A1500NotesDue2025Member_8c92d759-6a19-402c-a58b-4e2ea0149047" xlink:href="mck-20230630.xsd#mck_A1500NotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_d1784ff1-c70b-4e94-b4f5-6253819b140d" xlink:to="loc_mck_A1500NotesDue2025Member_8c92d759-6a19-402c-a58b-4e2ea0149047" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_A1625NotesDue2026Member_888e4d82-a0c6-4f48-8024-a3099605a11a" xlink:href="mck-20230630.xsd#mck_A1625NotesDue2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_d1784ff1-c70b-4e94-b4f5-6253819b140d" xlink:to="loc_mck_A1625NotesDue2026Member_888e4d82-a0c6-4f48-8024-a3099605a11a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_A3125NotesDue2029Member_9d97e41e-6a93-4a49-ac8c-c18bcd5796a5" xlink:href="mck-20230630.xsd#mck_A3125NotesDue2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_d1784ff1-c70b-4e94-b4f5-6253819b140d" xlink:to="loc_mck_A3125NotesDue2029Member_9d97e41e-6a93-4a49-ac8c-c18bcd5796a5" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT" xlink:type="simple" xlink:href="mck-20230630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT"/>
  <link:definitionLink xlink:role="http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT" xlink:type="extended" id="ib333923eed3f477589d2cd4e1166b239_CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3fe490e7-0a7d-4699-b55f-7849e16bdc3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3acb0b6b-c881-42fd-8ac1-0400503be981" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3fe490e7-0a7d-4699-b55f-7849e16bdc3f" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3acb0b6b-c881-42fd-8ac1-0400503be981" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_cacb413c-409c-4d9d-9df9-2dca84abe874" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3acb0b6b-c881-42fd-8ac1-0400503be981" xlink:to="loc_us-gaap_SharesOutstanding_cacb413c-409c-4d9d-9df9-2dca84abe874" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_cb92359f-b775-4df6-9ea0-06b431fc7de9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3acb0b6b-c881-42fd-8ac1-0400503be981" xlink:to="loc_us-gaap_TreasuryStockCommonShares_cb92359f-b775-4df6-9ea0-06b431fc7de9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_daacccc2-ff37-47e2-85ba-0f1416767713" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3acb0b6b-c881-42fd-8ac1-0400503be981" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_daacccc2-ff37-47e2-85ba-0f1416767713" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_StockIssuedDuringPeriodSharesEmployeeStockPlansNetOfForfeitures_6d7a6e0f-535e-4a00-9ab8-08bd9f6af220" xlink:href="mck-20230630.xsd#mck_StockIssuedDuringPeriodSharesEmployeeStockPlansNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3acb0b6b-c881-42fd-8ac1-0400503be981" xlink:to="loc_mck_StockIssuedDuringPeriodSharesEmployeeStockPlansNetOfForfeitures_6d7a6e0f-535e-4a00-9ab8-08bd9f6af220" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_StockIssuedDuringPeriodValueEmployeeStockPlansNetOfForfeitures_12ddc6ff-2763-4a5f-8649-57f6505c4409" xlink:href="mck-20230630.xsd#mck_StockIssuedDuringPeriodValueEmployeeStockPlansNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3acb0b6b-c881-42fd-8ac1-0400503be981" xlink:to="loc_mck_StockIssuedDuringPeriodValueEmployeeStockPlansNetOfForfeitures_12ddc6ff-2763-4a5f-8649-57f6505c4409" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_92d193ce-7200-4ffc-bf74-a52b2bba710a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3acb0b6b-c881-42fd-8ac1-0400503be981" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_92d193ce-7200-4ffc-bf74-a52b2bba710a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_b7477073-1fd6-44b1-a48a-8b3b09cde11f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3acb0b6b-c881-42fd-8ac1-0400503be981" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_b7477073-1fd6-44b1-a48a-8b3b09cde11f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_76fe4f8d-aed5-4e1b-9dc6-89ec54f9e1e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3acb0b6b-c881-42fd-8ac1-0400503be981" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_76fe4f8d-aed5-4e1b-9dc6-89ec54f9e1e9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_NetIncomeLossIncludingPortionAttributabletoNoncontrollingInterestExcludingRedeemableNoncontrollingInterest_d25a048f-6ee9-4528-a006-ae96cc61fedb" xlink:href="mck-20230630.xsd#mck_NetIncomeLossIncludingPortionAttributabletoNoncontrollingInterestExcludingRedeemableNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3acb0b6b-c881-42fd-8ac1-0400503be981" xlink:to="loc_mck_NetIncomeLossIncludingPortionAttributabletoNoncontrollingInterestExcludingRedeemableNoncontrollingInterest_d25a048f-6ee9-4528-a006-ae96cc61fedb" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_29691dc2-e3ef-477f-ae57-4a04834e4237" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3acb0b6b-c881-42fd-8ac1-0400503be981" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_29691dc2-e3ef-477f-ae57-4a04834e4237" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_7c8460db-fc4f-41c0-80ff-670322309381" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3acb0b6b-c881-42fd-8ac1-0400503be981" xlink:to="loc_us-gaap_DividendsCommonStockCash_7c8460db-fc4f-41c0-80ff-670322309381" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_d252173d-d7a6-4a6e-bc4a-970cedc21ffb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3acb0b6b-c881-42fd-8ac1-0400503be981" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_d252173d-d7a6-4a6e-bc4a-970cedc21ffb" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_NoncontrollingInterestDecreaseFromReclassificationToLiability_764750e2-72f0-480f-a888-1293fba4d09a" xlink:href="mck-20230630.xsd#mck_NoncontrollingInterestDecreaseFromReclassificationToLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3acb0b6b-c881-42fd-8ac1-0400503be981" xlink:to="loc_mck_NoncontrollingInterestDecreaseFromReclassificationToLiability_764750e2-72f0-480f-a888-1293fba4d09a" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_09e73fa8-c37f-4e69-8fd1-fcfe83cc602d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3acb0b6b-c881-42fd-8ac1-0400503be981" xlink:to="loc_us-gaap_StockholdersEquityOther_09e73fa8-c37f-4e69-8fd1-fcfe83cc602d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_a21e8cc8-2f92-4295-aff8-dda20826b6dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_de580325-5b77-4858-9c20-490ec361d6e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_050109c8-ff42-4de5-8044-893da9be6831" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_dfe6b338-ea36-4cad-b5a9-9f8f4104f3c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_3fe490e7-0a7d-4699-b55f-7849e16bdc3f" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_dfe6b338-ea36-4cad-b5a9-9f8f4104f3c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2ccdea01-7ab5-48cc-9e28-60b153bb8107" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_3fe490e7-0a7d-4699-b55f-7849e16bdc3f" xlink:to="loc_us-gaap_StatementTable_2ccdea01-7ab5-48cc-9e28-60b153bb8107" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1a1e7c92-e468-4273-abbd-b607d4d5fdc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2ccdea01-7ab5-48cc-9e28-60b153bb8107" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1a1e7c92-e468-4273-abbd-b607d4d5fdc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1a1e7c92-e468-4273-abbd-b607d4d5fdc5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1a1e7c92-e468-4273-abbd-b607d4d5fdc5" xlink:to="loc_us-gaap_EquityComponentDomain_1a1e7c92-e468-4273-abbd-b607d4d5fdc5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a1900edd-585d-4cea-8578-dce4ccabd4a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1a1e7c92-e468-4273-abbd-b607d4d5fdc5" xlink:to="loc_us-gaap_EquityComponentDomain_a1900edd-585d-4cea-8578-dce4ccabd4a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3eb7af76-524a-476e-a27d-b1eed9b02b20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a1900edd-585d-4cea-8578-dce4ccabd4a7" xlink:to="loc_us-gaap_CommonStockMember_3eb7af76-524a-476e-a27d-b1eed9b02b20" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_f6a64627-8237-4aaf-9d04-111e9a57b815" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a1900edd-585d-4cea-8578-dce4ccabd4a7" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_f6a64627-8237-4aaf-9d04-111e9a57b815" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_6c2415c0-ba41-434c-84ab-627e442d0d85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a1900edd-585d-4cea-8578-dce4ccabd4a7" xlink:to="loc_us-gaap_RetainedEarningsMember_6c2415c0-ba41-434c-84ab-627e442d0d85" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_124644f3-8aef-4fc3-ba3f-33f98482537e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a1900edd-585d-4cea-8578-dce4ccabd4a7" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_124644f3-8aef-4fc3-ba3f-33f98482537e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_5de723b0-1817-46ae-99d6-dc733c518298" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a1900edd-585d-4cea-8578-dce4ccabd4a7" xlink:to="loc_us-gaap_TreasuryStockCommonMember_5de723b0-1817-46ae-99d6-dc733c518298" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_0c37f20d-6a38-4263-8159-2e2ecfe0a184" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a1900edd-585d-4cea-8578-dce4ccabd4a7" xlink:to="loc_us-gaap_NoncontrollingInterestMember_0c37f20d-6a38-4263-8159-2e2ecfe0a184" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails" xlink:type="simple" xlink:href="mck-20230630.xsd#BusinessAcquisitionsandDivestituresAcquisitionsDetails"/>
  <link:definitionLink xlink:role="http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails" xlink:type="extended" id="if01cf71afb59415e97a7cf6ef3110cc1_BusinessAcquisitionsandDivestituresAcquisitionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_fcefa9bc-b952-46fd-8d85-a0dbabdfa9d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_aa8a000d-1e88-4c29-a682-888a4d84b0c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_fcefa9bc-b952-46fd-8d85-a0dbabdfa9d5" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_aa8a000d-1e88-4c29-a682-888a4d84b0c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_6bc6bcb4-d6f3-4f16-aae7-c5522715a1de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_fcefa9bc-b952-46fd-8d85-a0dbabdfa9d5" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_6bc6bcb4-d6f3-4f16-aae7-c5522715a1de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_8ba6a48c-614a-4c9e-900b-dabb83775a9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_fcefa9bc-b952-46fd-8d85-a0dbabdfa9d5" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_8ba6a48c-614a-4c9e-900b-dabb83775a9e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_a3625c45-8c16-42b6-85ce-b2fc6bc24534" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_fcefa9bc-b952-46fd-8d85-a0dbabdfa9d5" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_a3625c45-8c16-42b6-85ce-b2fc6bc24534" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_73de5426-46ec-4454-9ff5-d7d3a8e4c11f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_fcefa9bc-b952-46fd-8d85-a0dbabdfa9d5" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_73de5426-46ec-4454-9ff5-d7d3a8e4c11f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_99dc0478-c61b-40f3-b055-1f572fcd80e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_fcefa9bc-b952-46fd-8d85-a0dbabdfa9d5" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_99dc0478-c61b-40f3-b055-1f572fcd80e9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_6a6666f6-1488-4722-9ac2-0204615d81cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_fcefa9bc-b952-46fd-8d85-a0dbabdfa9d5" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_6a6666f6-1488-4722-9ac2-0204615d81cb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_a8480cac-bcab-43ed-bedf-933f3211d3af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_fcefa9bc-b952-46fd-8d85-a0dbabdfa9d5" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_a8480cac-bcab-43ed-bedf-933f3211d3af" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_8fff4a0c-ac8e-42ba-8335-6b4dc9f4d039" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_fcefa9bc-b952-46fd-8d85-a0dbabdfa9d5" xlink:to="loc_us-gaap_Goodwill_8fff4a0c-ac8e-42ba-8335-6b4dc9f4d039" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_e7603934-f73b-4863-943d-4345866866d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_fcefa9bc-b952-46fd-8d85-a0dbabdfa9d5" xlink:to="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_e7603934-f73b-4863-943d-4345866866d7" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_8cb1a8e8-119e-46af-9731-39aafde94d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_fcefa9bc-b952-46fd-8d85-a0dbabdfa9d5" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_8cb1a8e8-119e-46af-9731-39aafde94d2c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_103b68e4-1f05-4766-ae95-6b28cd333485" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_fcefa9bc-b952-46fd-8d85-a0dbabdfa9d5" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_103b68e4-1f05-4766-ae95-6b28cd333485" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7b5ad935-b38e-4b86-93ae-74d81a708e4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_103b68e4-1f05-4766-ae95-6b28cd333485" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7b5ad935-b38e-4b86-93ae-74d81a708e4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7b5ad935-b38e-4b86-93ae-74d81a708e4a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7b5ad935-b38e-4b86-93ae-74d81a708e4a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7b5ad935-b38e-4b86-93ae-74d81a708e4a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_95de2838-6e86-4992-863f-7ace3640b3ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7b5ad935-b38e-4b86-93ae-74d81a708e4a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_95de2838-6e86-4992-863f-7ace3640b3ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_RxSavingsSolutionsLLCMember_3a2e9ec9-c013-4aae-b44d-4fd90bb53f75" xlink:href="mck-20230630.xsd#mck_RxSavingsSolutionsLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_95de2838-6e86-4992-863f-7ace3640b3ba" xlink:to="loc_mck_RxSavingsSolutionsLLCMember_3a2e9ec9-c013-4aae-b44d-4fd90bb53f75" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_SCRIOncologyLLCMember_47e2335d-e0b2-4e89-8540-65757f0f3c2b" xlink:href="mck-20230630.xsd#mck_SCRIOncologyLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_95de2838-6e86-4992-863f-7ace3640b3ba" xlink:to="loc_mck_SCRIOncologyLLCMember_47e2335d-e0b2-4e89-8540-65757f0f3c2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_bfcf490c-0b48-4454-b0c4-dc8cc1405a1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_103b68e4-1f05-4766-ae95-6b28cd333485" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_bfcf490c-0b48-4454-b0c4-dc8cc1405a1a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_bfcf490c-0b48-4454-b0c4-dc8cc1405a1a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_bfcf490c-0b48-4454-b0c4-dc8cc1405a1a" xlink:to="loc_us-gaap_SegmentDomain_bfcf490c-0b48-4454-b0c4-dc8cc1405a1a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_e049e314-7d72-494e-93bb-3028692d746b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_bfcf490c-0b48-4454-b0c4-dc8cc1405a1a" xlink:to="loc_us-gaap_SegmentDomain_e049e314-7d72-494e-93bb-3028692d746b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_RxTsSegmentMember_5cb9b625-88c6-40fa-8e1c-23594b9d65f7" xlink:href="mck-20230630.xsd#mck_RxTsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_e049e314-7d72-494e-93bb-3028692d746b" xlink:to="loc_mck_RxTsSegmentMember_5cb9b625-88c6-40fa-8e1c-23594b9d65f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_USPharmaceuticalSegmentMember_8dc66aff-66fd-48f2-9547-5fce57f4213b" xlink:href="mck-20230630.xsd#mck_USPharmaceuticalSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_e049e314-7d72-494e-93bb-3028692d746b" xlink:to="loc_mck_USPharmaceuticalSegmentMember_8dc66aff-66fd-48f2-9547-5fce57f4213b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_9e989496-2688-4039-9cca-ed75bac65d7b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_103b68e4-1f05-4766-ae95-6b28cd333485" xlink:to="loc_srt_OwnershipAxis_9e989496-2688-4039-9cca-ed75bac65d7b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_9e989496-2688-4039-9cca-ed75bac65d7b_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_9e989496-2688-4039-9cca-ed75bac65d7b" xlink:to="loc_srt_OwnershipDomain_9e989496-2688-4039-9cca-ed75bac65d7b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_868807aa-18e7-42ef-811d-9503a1205f37" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_9e989496-2688-4039-9cca-ed75bac65d7b" xlink:to="loc_srt_OwnershipDomain_868807aa-18e7-42ef-811d-9503a1205f37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_SarahCannonResearchInstituteMember_3b4b29d4-e928-418e-ba32-bd5cdbe27ea0" xlink:href="mck-20230630.xsd#mck_SarahCannonResearchInstituteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_868807aa-18e7-42ef-811d-9503a1205f37" xlink:to="loc_mck_SarahCannonResearchInstituteMember_3b4b29d4-e928-418e-ba32-bd5cdbe27ea0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_McKessonUSOncologyResearchMember_f98eb6c5-fe65-4fe7-8228-f276c799ea13" xlink:href="mck-20230630.xsd#mck_McKessonUSOncologyResearchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_868807aa-18e7-42ef-811d-9503a1205f37" xlink:to="loc_mck_McKessonUSOncologyResearchMember_f98eb6c5-fe65-4fe7-8228-f276c799ea13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_97cd7e41-13bb-405d-97b7-7e88bc20f810" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_103b68e4-1f05-4766-ae95-6b28cd333485" xlink:to="loc_srt_RangeAxis_97cd7e41-13bb-405d-97b7-7e88bc20f810" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_97cd7e41-13bb-405d-97b7-7e88bc20f810_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_97cd7e41-13bb-405d-97b7-7e88bc20f810" xlink:to="loc_srt_RangeMember_97cd7e41-13bb-405d-97b7-7e88bc20f810_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4633d1b7-858e-459c-8d21-775d4374d611" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_97cd7e41-13bb-405d-97b7-7e88bc20f810" xlink:to="loc_srt_RangeMember_4633d1b7-858e-459c-8d21-775d4374d611" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a804b1b6-44ae-4dfd-a6ec-813ac96e59b3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4633d1b7-858e-459c-8d21-775d4374d611" xlink:to="loc_srt_MaximumMember_a804b1b6-44ae-4dfd-a6ec-813ac96e59b3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedRxSavingsSolutionsDetails" xlink:type="simple" xlink:href="mck-20230630.xsd#BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedRxSavingsSolutionsDetails"/>
  <link:definitionLink xlink:role="http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedRxSavingsSolutionsDetails" xlink:type="extended" id="ic0d0cff4548d4af3ba1ac2be45c8e621_BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedRxSavingsSolutionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_21cfd054-5e36-4a09-ba45-a2092cbea185" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_121f4444-2581-4c6e-8a91-114b0732f320" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_21cfd054-5e36-4a09-ba45-a2092cbea185" xlink:to="loc_us-gaap_BusinessCombinationsAbstract_121f4444-2581-4c6e-8a91-114b0732f320" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_2a4cbd58-5795-49d3-9480-75cae4002b20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_121f4444-2581-4c6e-8a91-114b0732f320" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_2a4cbd58-5795-49d3-9480-75cae4002b20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1ba0f4ff-d9ba-4fc8-be76-3d4cdf2f0fee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_121f4444-2581-4c6e-8a91-114b0732f320" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1ba0f4ff-d9ba-4fc8-be76-3d4cdf2f0fee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_d4905812-5666-4f96-93db-76809911b805" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_121f4444-2581-4c6e-8a91-114b0732f320" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_d4905812-5666-4f96-93db-76809911b805" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_5129408c-ff88-4b27-971e-0058c450fc30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_21cfd054-5e36-4a09-ba45-a2092cbea185" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_5129408c-ff88-4b27-971e-0058c450fc30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_0f303a4b-28ee-44a6-871f-593dec284ea4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_5129408c-ff88-4b27-971e-0058c450fc30" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_0f303a4b-28ee-44a6-871f-593dec284ea4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_e03bc6e5-9e62-4430-a118-46f78b4de649" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_5129408c-ff88-4b27-971e-0058c450fc30" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_e03bc6e5-9e62-4430-a118-46f78b4de649" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_9c701604-7d2e-4083-b9bb-13d3c4c809da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_5129408c-ff88-4b27-971e-0058c450fc30" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_9c701604-7d2e-4083-b9bb-13d3c4c809da" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_a5bc0bb9-bd8a-4fcb-86e2-76f1a05cebe4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_5129408c-ff88-4b27-971e-0058c450fc30" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_a5bc0bb9-bd8a-4fcb-86e2-76f1a05cebe4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_a0ee12eb-e2c1-4136-8fcd-4fb195d9e804" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_5129408c-ff88-4b27-971e-0058c450fc30" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_a0ee12eb-e2c1-4136-8fcd-4fb195d9e804" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_9075c994-4163-4a1b-9500-c7ec439937d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_5129408c-ff88-4b27-971e-0058c450fc30" xlink:to="loc_us-gaap_Goodwill_9075c994-4163-4a1b-9500-c7ec439937d4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest_891119a1-699e-4e2b-a4e2-9d87d84be5f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_5129408c-ff88-4b27-971e-0058c450fc30" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest_891119a1-699e-4e2b-a4e2-9d87d84be5f7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_07d778a6-14b4-4530-8cdd-95f23c6814de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_21cfd054-5e36-4a09-ba45-a2092cbea185" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_07d778a6-14b4-4530-8cdd-95f23c6814de" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_26abf937-234a-46b3-b2b8-5ee39d2cb4fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_07d778a6-14b4-4530-8cdd-95f23c6814de" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_26abf937-234a-46b3-b2b8-5ee39d2cb4fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_26abf937-234a-46b3-b2b8-5ee39d2cb4fb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_26abf937-234a-46b3-b2b8-5ee39d2cb4fb" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_26abf937-234a-46b3-b2b8-5ee39d2cb4fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e079001c-d26e-4f86-acbf-09e65c553acb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_26abf937-234a-46b3-b2b8-5ee39d2cb4fb" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e079001c-d26e-4f86-acbf-09e65c553acb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_RxSavingsSolutionsLLCMember_292ddc3a-cbb9-4278-964e-414f73a5cf63" xlink:href="mck-20230630.xsd#mck_RxSavingsSolutionsLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e079001c-d26e-4f86-acbf-09e65c553acb" xlink:to="loc_mck_RxSavingsSolutionsLLCMember_292ddc3a-cbb9-4278-964e-414f73a5cf63" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_a214ffab-fc34-4e39-9e92-1e2065c7a06a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_07d778a6-14b4-4530-8cdd-95f23c6814de" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_a214ffab-fc34-4e39-9e92-1e2065c7a06a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_a214ffab-fc34-4e39-9e92-1e2065c7a06a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_a214ffab-fc34-4e39-9e92-1e2065c7a06a" xlink:to="loc_us-gaap_SegmentDomain_a214ffab-fc34-4e39-9e92-1e2065c7a06a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_5f7a5dd6-7da5-48ed-a963-40c5caa0b1f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_a214ffab-fc34-4e39-9e92-1e2065c7a06a" xlink:to="loc_us-gaap_SegmentDomain_5f7a5dd6-7da5-48ed-a963-40c5caa0b1f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_RxTsSegmentMember_52133ced-91c7-4880-a0a4-662e0adc61d7" xlink:href="mck-20230630.xsd#mck_RxTsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_5f7a5dd6-7da5-48ed-a963-40c5caa0b1f9" xlink:to="loc_mck_RxTsSegmentMember_52133ced-91c7-4880-a0a4-662e0adc61d7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails" xlink:type="simple" xlink:href="mck-20230630.xsd#BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails"/>
  <link:definitionLink xlink:role="http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails" xlink:type="extended" id="i24846243173b4a1bab3b1cf6e059a83d_BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_b5b280e1-ee7c-4d82-8242-0e40c676675f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_fb1da884-e940-4733-9dc2-2c581a49d8c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_b5b280e1-ee7c-4d82-8242-0e40c676675f" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_fb1da884-e940-4733-9dc2-2c581a49d8c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_BusinessCombinationConsiderationTransferredOwnershipInterest_35abd795-c932-4a26-9103-6fa7d153ffbe" xlink:href="mck-20230630.xsd#mck_BusinessCombinationConsiderationTransferredOwnershipInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_b5b280e1-ee7c-4d82-8242-0e40c676675f" xlink:to="loc_mck_BusinessCombinationConsiderationTransferredOwnershipInterest_35abd795-c932-4a26-9103-6fa7d153ffbe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_79711c23-b35a-4ec0-8beb-428baf77d5aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_b5b280e1-ee7c-4d82-8242-0e40c676675f" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_79711c23-b35a-4ec0-8beb-428baf77d5aa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_55fd5900-fe5f-4068-872d-2f77cb020d55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_b5b280e1-ee7c-4d82-8242-0e40c676675f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_55fd5900-fe5f-4068-872d-2f77cb020d55" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_f4c45b11-3b2f-496e-b29a-37ce1c28e5b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_b5b280e1-ee7c-4d82-8242-0e40c676675f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_f4c45b11-3b2f-496e-b29a-37ce1c28e5b4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_2ad441a9-c312-4b0f-a3c7-72609ea74954" xlink:href="mck-20230630.xsd#mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_b5b280e1-ee7c-4d82-8242-0e40c676675f" xlink:to="loc_mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_2ad441a9-c312-4b0f-a3c7-72609ea74954" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_72291a86-82b8-4d22-8b56-eba793784160" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_b5b280e1-ee7c-4d82-8242-0e40c676675f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_72291a86-82b8-4d22-8b56-eba793784160" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_43299669-abfc-44be-824c-51e254b8b2fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_b5b280e1-ee7c-4d82-8242-0e40c676675f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_43299669-abfc-44be-824c-51e254b8b2fb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermOperatingLeaseLiabilities_2c10a7bc-afa2-4802-912f-c2292ccd36c5" xlink:href="mck-20230630.xsd#mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermOperatingLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_b5b280e1-ee7c-4d82-8242-0e40c676675f" xlink:to="loc_mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermOperatingLeaseLiabilities_2c10a7bc-afa2-4802-912f-c2292ccd36c5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_6e27897b-48ca-45cb-9ec6-a2a73888681a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_b5b280e1-ee7c-4d82-8242-0e40c676675f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_6e27897b-48ca-45cb-9ec6-a2a73888681a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_eee62102-ae8a-40ec-8a9f-7a00a1f8119e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_b5b280e1-ee7c-4d82-8242-0e40c676675f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_eee62102-ae8a-40ec-8a9f-7a00a1f8119e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_49bb5191-8729-4543-9753-fe50f84b7804" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_b5b280e1-ee7c-4d82-8242-0e40c676675f" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_49bb5191-8729-4543-9753-fe50f84b7804" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdditionalPaidInCapital_644b2592-843e-4036-b40a-efe1479ac497" xlink:href="mck-20230630.xsd#mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_b5b280e1-ee7c-4d82-8242-0e40c676675f" xlink:to="loc_mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdditionalPaidInCapital_644b2592-843e-4036-b40a-efe1479ac497" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_5b0ea3a3-0dd7-4845-814d-1ade13568206" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_b5b280e1-ee7c-4d82-8242-0e40c676675f" xlink:to="loc_us-gaap_Goodwill_5b0ea3a3-0dd7-4845-814d-1ade13568206" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest_82858071-b3eb-434e-9389-b2400ae4f6c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_b5b280e1-ee7c-4d82-8242-0e40c676675f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest_82858071-b3eb-434e-9389-b2400ae4f6c2" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_b8f3da9b-2538-4538-b2bd-9e4d3514aa4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_b5b280e1-ee7c-4d82-8242-0e40c676675f" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_b8f3da9b-2538-4538-b2bd-9e4d3514aa4d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_ee831d90-e2de-435e-8151-fad5bfd211ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_b8f3da9b-2538-4538-b2bd-9e4d3514aa4d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_ee831d90-e2de-435e-8151-fad5bfd211ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ee831d90-e2de-435e-8151-fad5bfd211ca_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ee831d90-e2de-435e-8151-fad5bfd211ca" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ee831d90-e2de-435e-8151-fad5bfd211ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7c6ea2bb-8eac-4af0-ad2f-c2beae9d52b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ee831d90-e2de-435e-8151-fad5bfd211ca" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7c6ea2bb-8eac-4af0-ad2f-c2beae9d52b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_SCRIOncologyLLCMember_784bc1fa-5fb3-48f0-ac0c-dfa2985e7732" xlink:href="mck-20230630.xsd#mck_SCRIOncologyLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7c6ea2bb-8eac-4af0-ad2f-c2beae9d52b7" xlink:to="loc_mck_SCRIOncologyLLCMember_784bc1fa-5fb3-48f0-ac0c-dfa2985e7732" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_886e7b1b-ca96-4e00-a37c-62c47a78a36c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_b8f3da9b-2538-4538-b2bd-9e4d3514aa4d" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_886e7b1b-ca96-4e00-a37c-62c47a78a36c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_886e7b1b-ca96-4e00-a37c-62c47a78a36c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_886e7b1b-ca96-4e00-a37c-62c47a78a36c" xlink:to="loc_us-gaap_SegmentDomain_886e7b1b-ca96-4e00-a37c-62c47a78a36c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_c10c4337-5ef0-4f92-88f2-83a2fe238341" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_886e7b1b-ca96-4e00-a37c-62c47a78a36c" xlink:to="loc_us-gaap_SegmentDomain_c10c4337-5ef0-4f92-88f2-83a2fe238341" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_USPharmaceuticalSegmentMember_8927a98d-e4a0-45ea-9217-6f32fe972c2a" xlink:href="mck-20230630.xsd#mck_USPharmaceuticalSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_c10c4337-5ef0-4f92-88f2-83a2fe238341" xlink:to="loc_mck_USPharmaceuticalSegmentMember_8927a98d-e4a0-45ea-9217-6f32fe972c2a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://mckesson123.com/role/BusinessAcquisitionsandDivestituresDivestituresandOtherDetails" xlink:type="simple" xlink:href="mck-20230630.xsd#BusinessAcquisitionsandDivestituresDivestituresandOtherDetails"/>
  <link:definitionLink xlink:role="http://mckesson123.com/role/BusinessAcquisitionsandDivestituresDivestituresandOtherDetails" xlink:type="extended" id="ic9e33b6d16334e4b94167ceb2fe59826_BusinessAcquisitionsandDivestituresDivestituresandOtherDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d6053d54-6421-4e65-8573-8df2298ff90d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_7f365ec1-3d63-4c32-b3ec-12c1ecd1c42c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d6053d54-6421-4e65-8573-8df2298ff90d" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_7f365ec1-3d63-4c32-b3ec-12c1ecd1c42c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_DisposalGroupIncludingDiscontinuedOperationConsiderationExpected_17757371-742c-4496-96f7-823f368de597" xlink:href="mck-20230630.xsd#mck_DisposalGroupIncludingDiscontinuedOperationConsiderationExpected"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d6053d54-6421-4e65-8573-8df2298ff90d" xlink:to="loc_mck_DisposalGroupIncludingDiscontinuedOperationConsiderationExpected_17757371-742c-4496-96f7-823f368de597" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_de029d4e-edcf-4ecd-9c7e-d9643c7ab493" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d6053d54-6421-4e65-8573-8df2298ff90d" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_de029d4e-edcf-4ecd-9c7e-d9643c7ab493" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_ecd94ff6-7a1d-48a9-a5fc-def109c31585" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationFromAociCurrentPeriodTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d6053d54-6421-4e65-8573-8df2298ff90d" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_ecd94ff6-7a1d-48a9-a5fc-def109c31585" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable_c94b6cfe-2f0d-44bb-905b-58268c5bd3e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromCollectionOfNotesReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d6053d54-6421-4e65-8573-8df2298ff90d" xlink:to="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable_c94b6cfe-2f0d-44bb-905b-58268c5bd3e8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_bf36249c-646a-47db-8ed2-f7929d9b3f95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d6053d54-6421-4e65-8573-8df2298ff90d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_bf36249c-646a-47db-8ed2-f7929d9b3f95" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_60823c04-2cb4-40e5-8a85-f9caa03c0608" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_bf36249c-646a-47db-8ed2-f7929d9b3f95" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_60823c04-2cb4-40e5-8a85-f9caa03c0608" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_60823c04-2cb4-40e5-8a85-f9caa03c0608_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_60823c04-2cb4-40e5-8a85-f9caa03c0608" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_60823c04-2cb4-40e5-8a85-f9caa03c0608_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8d4e9f60-3fa1-4040-a2d5-03d1a692a487" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_60823c04-2cb4-40e5-8a85-f9caa03c0608" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8d4e9f60-3fa1-4040-a2d5-03d1a692a487" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_EUBusinessesDisposalGroupMember_3ebdf056-980f-4781-bdaf-a8b12c3b32ec" xlink:href="mck-20230630.xsd#mck_EUBusinessesDisposalGroupMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8d4e9f60-3fa1-4040-a2d5-03d1a692a487" xlink:to="loc_mck_EUBusinessesDisposalGroupMember_3ebdf056-980f-4781-bdaf-a8b12c3b32ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_UKBusinessesDisposalGroupMember_e57a8f86-cff8-477e-925f-d9d030c75e2d" xlink:href="mck-20230630.xsd#mck_UKBusinessesDisposalGroupMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8d4e9f60-3fa1-4040-a2d5-03d1a692a487" xlink:to="loc_mck_UKBusinessesDisposalGroupMember_e57a8f86-cff8-477e-925f-d9d030c75e2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_InternationalSegmentMember_92db0f01-45c6-4aab-b259-951db9117d14" xlink:href="mck-20230630.xsd#mck_InternationalSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8d4e9f60-3fa1-4040-a2d5-03d1a692a487" xlink:to="loc_mck_InternationalSegmentMember_92db0f01-45c6-4aab-b259-951db9117d14" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_05e2523b-8d32-4db7-85f4-e75022378a70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_bf36249c-646a-47db-8ed2-f7929d9b3f95" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_05e2523b-8d32-4db7-85f4-e75022378a70" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_05e2523b-8d32-4db7-85f4-e75022378a70_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_05e2523b-8d32-4db7-85f4-e75022378a70" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_05e2523b-8d32-4db7-85f4-e75022378a70_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_ff68eb1f-2ceb-4269-989e-6bdeaadf95c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_05e2523b-8d32-4db7-85f4-e75022378a70" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_ff68eb1f-2ceb-4269-989e-6bdeaadf95c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_2a0b5fb5-c701-43a0-aeca-cba0d2d85451" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_ff68eb1f-2ceb-4269-989e-6bdeaadf95c2" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_2a0b5fb5-c701-43a0-aeca-cba0d2d85451" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_31d4b927-6189-42fb-83aa-6d757ab755a1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_bf36249c-646a-47db-8ed2-f7929d9b3f95" xlink:to="loc_dei_LegalEntityAxis_31d4b927-6189-42fb-83aa-6d757ab755a1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_31d4b927-6189-42fb-83aa-6d757ab755a1_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_31d4b927-6189-42fb-83aa-6d757ab755a1" xlink:to="loc_dei_EntityDomain_31d4b927-6189-42fb-83aa-6d757ab755a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_752241bb-ac55-45f6-b97a-76d8f6943b11" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_31d4b927-6189-42fb-83aa-6d757ab755a1" xlink:to="loc_dei_EntityDomain_752241bb-ac55-45f6-b97a-76d8f6943b11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_AureliusElephantLimitedMember_5677706a-5b3e-485a-a126-59115a821dab" xlink:href="mck-20230630.xsd#mck_AureliusElephantLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_752241bb-ac55-45f6-b97a-76d8f6943b11" xlink:to="loc_mck_AureliusElephantLimitedMember_5677706a-5b3e-485a-a126-59115a821dab" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetNarrativeDetails" xlink:type="simple" xlink:href="mck-20230630.xsd#RestructuringImpairmentandRelatedChargesNetNarrativeDetails"/>
  <link:definitionLink xlink:role="http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetNarrativeDetails" xlink:type="extended" id="ide3372d157fb47edb1b207f653046ad6_RestructuringImpairmentandRelatedChargesNetNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_1488a95d-b556-42c8-83d3-677b6305d29c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_RestructuringImpairmentAndOtherRelatedCharges_89170cc6-f9ab-4d5a-a4bc-af6e71a6f3ed" xlink:href="mck-20230630.xsd#mck_RestructuringImpairmentAndOtherRelatedCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1488a95d-b556-42c8-83d3-677b6305d29c" xlink:to="loc_mck_RestructuringImpairmentAndOtherRelatedCharges_89170cc6-f9ab-4d5a-a4bc-af6e71a6f3ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_2309d32e-096e-42ec-bbc8-bf78eb689cad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1488a95d-b556-42c8-83d3-677b6305d29c" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_2309d32e-096e-42ec-bbc8-bf78eb689cad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_676c207a-1b75-4a9f-8b06-7e0224c9dd76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1488a95d-b556-42c8-83d3-677b6305d29c" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_676c207a-1b75-4a9f-8b06-7e0224c9dd76" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_d75511ac-94e9-4c7e-b25c-2cd82f91b196" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1488a95d-b556-42c8-83d3-677b6305d29c" xlink:to="loc_us-gaap_RestructuringCharges_d75511ac-94e9-4c7e-b25c-2cd82f91b196" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_04dd805a-d66c-486c-a1e2-3d49f75da659" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1488a95d-b556-42c8-83d3-677b6305d29c" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_04dd805a-d66c-486c-a1e2-3d49f75da659" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_433cc071-908c-4e35-beb6-2bc9b6643a3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_04dd805a-d66c-486c-a1e2-3d49f75da659" xlink:to="loc_us-gaap_RestructuringPlanAxis_433cc071-908c-4e35-beb6-2bc9b6643a3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_433cc071-908c-4e35-beb6-2bc9b6643a3b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_433cc071-908c-4e35-beb6-2bc9b6643a3b" xlink:to="loc_us-gaap_RestructuringPlanDomain_433cc071-908c-4e35-beb6-2bc9b6643a3b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_8a499ad7-4ef9-443a-9f24-cbf4b0602c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_433cc071-908c-4e35-beb6-2bc9b6643a3b" xlink:to="loc_us-gaap_RestructuringPlanDomain_8a499ad7-4ef9-443a-9f24-cbf4b0602c4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_StrategicGrowthInitiativePlanOperationalEfficienciesAndCostOptimizationMember_ab4e632f-e5b9-43e1-81a4-3b5c6a36da1a" xlink:href="mck-20230630.xsd#mck_StrategicGrowthInitiativePlanOperationalEfficienciesAndCostOptimizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_8a499ad7-4ef9-443a-9f24-cbf4b0602c4d" xlink:to="loc_mck_StrategicGrowthInitiativePlanOperationalEfficienciesAndCostOptimizationMember_ab4e632f-e5b9-43e1-81a4-3b5c6a36da1a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails" xlink:type="simple" xlink:href="mck-20230630.xsd#RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails"/>
  <link:definitionLink xlink:role="http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails" xlink:type="extended" id="i86f211b9239d4811ab8fc0c35954a491_RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_9467560b-b01a-4b78-a7ed-ead97bfa0fa6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_08522e29-bf58-47e1-ad20-c341e9d79f3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_9467560b-b01a-4b78-a7ed-ead97bfa0fa6" xlink:to="loc_us-gaap_SeveranceCosts1_08522e29-bf58-47e1-ad20-c341e9d79f3f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessExitCosts1_00928050-00d5-4b06-a18f-7a34a916e2e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessExitCosts1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_9467560b-b01a-4b78-a7ed-ead97bfa0fa6" xlink:to="loc_us-gaap_BusinessExitCosts1_00928050-00d5-4b06-a18f-7a34a916e2e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_AssetImpairmentChargesIncludingAcceleratedDepreciation_d3e6b843-70f8-4a47-8c3f-c6ab2d0a5510" xlink:href="mck-20230630.xsd#mck_AssetImpairmentChargesIncludingAcceleratedDepreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_9467560b-b01a-4b78-a7ed-ead97bfa0fa6" xlink:to="loc_mck_AssetImpairmentChargesIncludingAcceleratedDepreciation_d3e6b843-70f8-4a47-8c3f-c6ab2d0a5510" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_4106f64d-eff9-4f23-bb90-8ff1847a5c60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_9467560b-b01a-4b78-a7ed-ead97bfa0fa6" xlink:to="loc_us-gaap_RestructuringCharges_4106f64d-eff9-4f23-bb90-8ff1847a5c60" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_56970f9a-c27e-47a2-a49a-73075385a34b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_9467560b-b01a-4b78-a7ed-ead97bfa0fa6" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_56970f9a-c27e-47a2-a49a-73075385a34b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_c2e9dda3-dd80-45a1-937a-d232a56bb1fe" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_56970f9a-c27e-47a2-a49a-73075385a34b" xlink:to="loc_srt_ConsolidationItemsAxis_c2e9dda3-dd80-45a1-937a-d232a56bb1fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_c2e9dda3-dd80-45a1-937a-d232a56bb1fe_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_c2e9dda3-dd80-45a1-937a-d232a56bb1fe" xlink:to="loc_srt_ConsolidationItemsDomain_c2e9dda3-dd80-45a1-937a-d232a56bb1fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_7a752aed-e146-491b-8b5e-07f0fe149f95" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_c2e9dda3-dd80-45a1-937a-d232a56bb1fe" xlink:to="loc_srt_ConsolidationItemsDomain_7a752aed-e146-491b-8b5e-07f0fe149f95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_7227f21d-e16f-46cf-adf7-33ccc0fde51b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_7a752aed-e146-491b-8b5e-07f0fe149f95" xlink:to="loc_us-gaap_OperatingSegmentsMember_7227f21d-e16f-46cf-adf7-33ccc0fde51b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_d04f2263-d4c4-4f3a-aae3-78827935242b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_7a752aed-e146-491b-8b5e-07f0fe149f95" xlink:to="loc_us-gaap_CorporateNonSegmentMember_d04f2263-d4c4-4f3a-aae3-78827935242b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_16b23d71-fdf3-4e32-be2e-63f7f3ea9b83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_56970f9a-c27e-47a2-a49a-73075385a34b" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_16b23d71-fdf3-4e32-be2e-63f7f3ea9b83" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_16b23d71-fdf3-4e32-be2e-63f7f3ea9b83_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_16b23d71-fdf3-4e32-be2e-63f7f3ea9b83" xlink:to="loc_us-gaap_SegmentDomain_16b23d71-fdf3-4e32-be2e-63f7f3ea9b83_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_187ce840-038c-42cc-81a9-976186a8fee2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_16b23d71-fdf3-4e32-be2e-63f7f3ea9b83" xlink:to="loc_us-gaap_SegmentDomain_187ce840-038c-42cc-81a9-976186a8fee2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_USPharmaceuticalSegmentMember_6099c9b9-7700-4f7b-a03d-0535be798984" xlink:href="mck-20230630.xsd#mck_USPharmaceuticalSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_187ce840-038c-42cc-81a9-976186a8fee2" xlink:to="loc_mck_USPharmaceuticalSegmentMember_6099c9b9-7700-4f7b-a03d-0535be798984" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_PrescriptionTechnologySolutionsMember_1e6aaabd-69c7-44ea-9b99-e19bff84d2d3" xlink:href="mck-20230630.xsd#mck_PrescriptionTechnologySolutionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_187ce840-038c-42cc-81a9-976186a8fee2" xlink:to="loc_mck_PrescriptionTechnologySolutionsMember_1e6aaabd-69c7-44ea-9b99-e19bff84d2d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_MedicalSurgicalSolutionsSegmentMember_3b521dce-6548-4d2e-86f0-06fdfcf6df41" xlink:href="mck-20230630.xsd#mck_MedicalSurgicalSolutionsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_187ce840-038c-42cc-81a9-976186a8fee2" xlink:to="loc_mck_MedicalSurgicalSolutionsSegmentMember_3b521dce-6548-4d2e-86f0-06fdfcf6df41" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_InternationalSegmentMember_7f93fb67-15d2-4910-a4a4-f8f5e4340ec3" xlink:href="mck-20230630.xsd#mck_InternationalSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_187ce840-038c-42cc-81a9-976186a8fee2" xlink:to="loc_mck_InternationalSegmentMember_7f93fb67-15d2-4910-a4a4-f8f5e4340ec3" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails" xlink:type="simple" xlink:href="mck-20230630.xsd#RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails"/>
  <link:definitionLink xlink:role="http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails" xlink:type="extended" id="i37a60908b061451081dc30506a65ab94_RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_c09fd113-54c3-4f33-8b2f-f7d5a4212101" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_88f1ea8c-a5ed-49aa-9672-c3833e6957f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c09fd113-54c3-4f33-8b2f-f7d5a4212101" xlink:to="loc_us-gaap_RestructuringReserveRollForward_88f1ea8c-a5ed-49aa-9672-c3833e6957f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_fad5f16f-f1cc-4cc2-945e-1f0404b6ff21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_88f1ea8c-a5ed-49aa-9672-c3833e6957f0" xlink:to="loc_us-gaap_RestructuringReserve_fad5f16f-f1cc-4cc2-945e-1f0404b6ff21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_8e3b29fc-47e9-4957-bbb4-a39c2cf3f3ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_88f1ea8c-a5ed-49aa-9672-c3833e6957f0" xlink:to="loc_us-gaap_RestructuringCharges_8e3b29fc-47e9-4957-bbb4-a39c2cf3f3ea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveSettledWithoutCash2_3ee6e299-9bc9-4e02-baa3-b03223edd7c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserveSettledWithoutCash2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_88f1ea8c-a5ed-49aa-9672-c3833e6957f0" xlink:to="loc_us-gaap_RestructuringReserveSettledWithoutCash2_3ee6e299-9bc9-4e02-baa3-b03223edd7c2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_a53d073c-68ca-436c-a03f-3318d5e6c7cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_88f1ea8c-a5ed-49aa-9672-c3833e6957f0" xlink:to="loc_us-gaap_PaymentsForRestructuring_a53d073c-68ca-436c-a03f-3318d5e6c7cb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveTranslationAndOtherAdjustment_db7d5bc1-2e0a-460a-9b1c-7eaadd7336e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserveTranslationAndOtherAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_88f1ea8c-a5ed-49aa-9672-c3833e6957f0" xlink:to="loc_us-gaap_RestructuringReserveTranslationAndOtherAdjustment_db7d5bc1-2e0a-460a-9b1c-7eaadd7336e7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_b26efea2-fba6-4be9-8d25-56aab17bd19d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserve"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_011a9071-74c7-4cbb-8d79-3b8e0be38695" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c09fd113-54c3-4f33-8b2f-f7d5a4212101" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_011a9071-74c7-4cbb-8d79-3b8e0be38695" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_e4f9a0d1-5d62-48d9-8903-7466a180004e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_011a9071-74c7-4cbb-8d79-3b8e0be38695" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_e4f9a0d1-5d62-48d9-8903-7466a180004e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_e4f9a0d1-5d62-48d9-8903-7466a180004e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_e4f9a0d1-5d62-48d9-8903-7466a180004e" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_e4f9a0d1-5d62-48d9-8903-7466a180004e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_a1dd99ee-ea72-4c0f-b534-348ba6166844" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_e4f9a0d1-5d62-48d9-8903-7466a180004e" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_a1dd99ee-ea72-4c0f-b534-348ba6166844" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_e94e6df2-6859-4ba7-aa84-979b33df3ff6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_a1dd99ee-ea72-4c0f-b534-348ba6166844" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_e94e6df2-6859-4ba7-aa84-979b33df3ff6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_54da3610-57d9-4780-9095-6aae62895673" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_a1dd99ee-ea72-4c0f-b534-348ba6166844" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_54da3610-57d9-4780-9095-6aae62895673" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_032f5ff5-3619-4a5c-9de8-48a634a6a8c8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_011a9071-74c7-4cbb-8d79-3b8e0be38695" xlink:to="loc_srt_ConsolidationItemsAxis_032f5ff5-3619-4a5c-9de8-48a634a6a8c8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_032f5ff5-3619-4a5c-9de8-48a634a6a8c8_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_032f5ff5-3619-4a5c-9de8-48a634a6a8c8" xlink:to="loc_srt_ConsolidationItemsDomain_032f5ff5-3619-4a5c-9de8-48a634a6a8c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_35be3ee6-fd2a-4149-8884-cba066afe21d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_032f5ff5-3619-4a5c-9de8-48a634a6a8c8" xlink:to="loc_srt_ConsolidationItemsDomain_35be3ee6-fd2a-4149-8884-cba066afe21d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_a7db2b57-2781-4353-bd53-da623c107367" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_35be3ee6-fd2a-4149-8884-cba066afe21d" xlink:to="loc_us-gaap_OperatingSegmentsMember_a7db2b57-2781-4353-bd53-da623c107367" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_86b0e3d6-7358-49d5-9524-7d98cdc6b4da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_35be3ee6-fd2a-4149-8884-cba066afe21d" xlink:to="loc_us-gaap_CorporateNonSegmentMember_86b0e3d6-7358-49d5-9524-7d98cdc6b4da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_791187bc-e467-48d5-a2bc-902b41340960" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_011a9071-74c7-4cbb-8d79-3b8e0be38695" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_791187bc-e467-48d5-a2bc-902b41340960" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_791187bc-e467-48d5-a2bc-902b41340960_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_791187bc-e467-48d5-a2bc-902b41340960" xlink:to="loc_us-gaap_SegmentDomain_791187bc-e467-48d5-a2bc-902b41340960_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_c7e8b19e-481b-49d4-95ac-8120764b2af7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_791187bc-e467-48d5-a2bc-902b41340960" xlink:to="loc_us-gaap_SegmentDomain_c7e8b19e-481b-49d4-95ac-8120764b2af7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_USPharmaceuticalSegmentMember_b190353d-0545-4991-8345-0f9a62644d4c" xlink:href="mck-20230630.xsd#mck_USPharmaceuticalSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_c7e8b19e-481b-49d4-95ac-8120764b2af7" xlink:to="loc_mck_USPharmaceuticalSegmentMember_b190353d-0545-4991-8345-0f9a62644d4c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_PrescriptionTechnologySolutionsMember_d32d6d55-8bbd-4c0c-bb39-5d76b78bf015" xlink:href="mck-20230630.xsd#mck_PrescriptionTechnologySolutionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_c7e8b19e-481b-49d4-95ac-8120764b2af7" xlink:to="loc_mck_PrescriptionTechnologySolutionsMember_d32d6d55-8bbd-4c0c-bb39-5d76b78bf015" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_MedicalSurgicalSolutionsSegmentMember_2e326c4c-4c41-4b57-9bc0-cfb1069001e4" xlink:href="mck-20230630.xsd#mck_MedicalSurgicalSolutionsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_c7e8b19e-481b-49d4-95ac-8120764b2af7" xlink:to="loc_mck_MedicalSurgicalSolutionsSegmentMember_2e326c4c-4c41-4b57-9bc0-cfb1069001e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_InternationalSegmentMember_c66fbc67-c68f-4665-a685-19b60737cb53" xlink:href="mck-20230630.xsd#mck_InternationalSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_c7e8b19e-481b-49d4-95ac-8120764b2af7" xlink:to="loc_mck_InternationalSegmentMember_c66fbc67-c68f-4665-a685-19b60737cb53" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://mckesson123.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="mck-20230630.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://mckesson123.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended" id="iff4be826293d4162a5c03b1c2e8b00bc_IncomeTaxesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_20a5a581-6c2d-4a16-a6d4-cf0172fdc7b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_EffectiveIncomeTaxReconciliationTaxExpenseBenefitIntraEntityTransfersOfAssetsOtherThanInventoryAmount_a5143e2a-9348-45f8-81f9-2dc11a2d16aa" xlink:href="mck-20230630.xsd#mck_EffectiveIncomeTaxReconciliationTaxExpenseBenefitIntraEntityTransfersOfAssetsOtherThanInventoryAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_20a5a581-6c2d-4a16-a6d4-cf0172fdc7b9" xlink:to="loc_mck_EffectiveIncomeTaxReconciliationTaxExpenseBenefitIntraEntityTransfersOfAssetsOtherThanInventoryAmount_a5143e2a-9348-45f8-81f9-2dc11a2d16aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_1f707c9a-0269-4221-8a10-33bb1e066668" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_20a5a581-6c2d-4a16-a6d4-cf0172fdc7b9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_1f707c9a-0269-4221-8a10-33bb1e066668" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_f5384703-5630-4972-af3d-2dd0d0b95046" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_20a5a581-6c2d-4a16-a6d4-cf0172fdc7b9" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_f5384703-5630-4972-af3d-2dd0d0b95046" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_03c5651f-27d9-4465-9934-7c047eaadbe8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_20a5a581-6c2d-4a16-a6d4-cf0172fdc7b9" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_03c5651f-27d9-4465-9934-7c047eaadbe8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_IncomeTaxExaminationEstimateOfPossibleLiabilityAdjustment_e232b292-bdf0-4fa8-8624-e1e73157c38e" xlink:href="mck-20230630.xsd#mck_IncomeTaxExaminationEstimateOfPossibleLiabilityAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_20a5a581-6c2d-4a16-a6d4-cf0172fdc7b9" xlink:to="loc_mck_IncomeTaxExaminationEstimateOfPossibleLiabilityAdjustment_e232b292-bdf0-4fa8-8624-e1e73157c38e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_aee16633-8979-423a-bd48-0527dff1f762" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_20a5a581-6c2d-4a16-a6d4-cf0172fdc7b9" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_aee16633-8979-423a-bd48-0527dff1f762" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_56c5a18e-50af-4213-b4ea-b2c0487869d3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_aee16633-8979-423a-bd48-0527dff1f762" xlink:to="loc_srt_RangeAxis_56c5a18e-50af-4213-b4ea-b2c0487869d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_56c5a18e-50af-4213-b4ea-b2c0487869d3_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_56c5a18e-50af-4213-b4ea-b2c0487869d3" xlink:to="loc_srt_RangeMember_56c5a18e-50af-4213-b4ea-b2c0487869d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b2741d82-1b09-4664-bf53-8a91766cd9ef" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_56c5a18e-50af-4213-b4ea-b2c0487869d3" xlink:to="loc_srt_RangeMember_b2741d82-1b09-4664-bf53-8a91766cd9ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_328e059a-a934-4de2-891f-3f339249af57" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b2741d82-1b09-4664-bf53-8a91766cd9ef" xlink:to="loc_srt_MinimumMember_328e059a-a934-4de2-891f-3f339249af57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_37ccaa59-1697-45dc-8fff-372b01816851" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b2741d82-1b09-4664-bf53-8a91766cd9ef" xlink:to="loc_srt_MaximumMember_37ccaa59-1697-45dc-8fff-372b01816851" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails" xlink:type="simple" xlink:href="mck-20230630.xsd#EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails"/>
  <link:definitionLink xlink:role="http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails" xlink:type="extended" id="i1311c85321484b1992c1170f11d2ff11_EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedLineItems_84634293-4233-426b-8b73-a2ef030d9657" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDilutedLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_ec303fbf-d599-43e2-a3f7-3a4bbf3d0f89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_84634293-4233-426b-8b73-a2ef030d9657" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_ec303fbf-d599-43e2-a3f7-3a4bbf3d0f89" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_a214f70a-3054-482a-87e4-027b73c5aa16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_84634293-4233-426b-8b73-a2ef030d9657" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_a214f70a-3054-482a-87e4-027b73c5aa16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_d4df8806-85b8-4333-bf84-f0f0f20719ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_84634293-4233-426b-8b73-a2ef030d9657" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_d4df8806-85b8-4333-bf84-f0f0f20719ee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_4147a68a-be59-494c-bdca-f9191fc4dc0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_84634293-4233-426b-8b73-a2ef030d9657" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_4147a68a-be59-494c-bdca-f9191fc4dc0e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7d8821aa-70ee-4fb2-866f-19d797b93324" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_84634293-4233-426b-8b73-a2ef030d9657" xlink:to="loc_us-gaap_NetIncomeLoss_7d8821aa-70ee-4fb2-866f-19d797b93324" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_ba02c390-5caf-430c-8720-e78c4d51f2e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_84634293-4233-426b-8b73-a2ef030d9657" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_ba02c390-5caf-430c-8720-e78c4d51f2e0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e9ea03a8-2a28-48b2-8880-19adc281496d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_ba02c390-5caf-430c-8720-e78c4d51f2e0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e9ea03a8-2a28-48b2-8880-19adc281496d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_777750f6-100d-4283-9ec4-6780392d3e5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_84634293-4233-426b-8b73-a2ef030d9657" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_777750f6-100d-4283-9ec4-6780392d3e5f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c3c16817-1fee-4798-8630-eaa2ab0985bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_84634293-4233-426b-8b73-a2ef030d9657" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c3c16817-1fee-4798-8630-eaa2ab0985bf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_EPSBasicAndDilutedAbstract_ddcf3f16-f3e2-4e18-a62b-41552ebe53b6" xlink:href="mck-20230630.xsd#mck_EPSBasicAndDilutedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_84634293-4233-426b-8b73-a2ef030d9657" xlink:to="loc_mck_EPSBasicAndDilutedAbstract_ddcf3f16-f3e2-4e18-a62b-41552ebe53b6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_4cbcd44a-4d44-4a11-a2d7-edfca37f2a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mck_EPSBasicAndDilutedAbstract_ddcf3f16-f3e2-4e18-a62b-41552ebe53b6" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_4cbcd44a-4d44-4a11-a2d7-edfca37f2a0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_0413cf15-775c-4376-8d1b-d69b58d8b50f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_4cbcd44a-4d44-4a11-a2d7-edfca37f2a0e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_0413cf15-775c-4376-8d1b-d69b58d8b50f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_3934c1d9-b549-4ff4-9bd8-e8409daef66c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_4cbcd44a-4d44-4a11-a2d7-edfca37f2a0e" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_3934c1d9-b549-4ff4-9bd8-e8409daef66c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_4f8bd0eb-54d7-4826-9856-48bb8f5af9ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_4cbcd44a-4d44-4a11-a2d7-edfca37f2a0e" xlink:to="loc_us-gaap_EarningsPerShareDiluted_4f8bd0eb-54d7-4826-9856-48bb8f5af9ce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_421e521a-28cf-406b-8761-7af236a03b32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mck_EPSBasicAndDilutedAbstract_ddcf3f16-f3e2-4e18-a62b-41552ebe53b6" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_421e521a-28cf-406b-8761-7af236a03b32" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_9d5a40e2-8355-440c-a15b-41b72c83796f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_421e521a-28cf-406b-8761-7af236a03b32" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_9d5a40e2-8355-440c-a15b-41b72c83796f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_b5f8cb3e-fb8a-4dc5-bd64-85653cbfc82c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_421e521a-28cf-406b-8761-7af236a03b32" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_b5f8cb3e-fb8a-4dc5-bd64-85653cbfc82c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_7dadff44-9360-468c-bd21-b64465dfd04c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_421e521a-28cf-406b-8761-7af236a03b32" xlink:to="loc_us-gaap_EarningsPerShareBasic_7dadff44-9360-468c-bd21-b64465dfd04c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_54ec1154-c8b3-4a75-9c07-437dd34b3a89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_84634293-4233-426b-8b73-a2ef030d9657" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_54ec1154-c8b3-4a75-9c07-437dd34b3a89" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_29a499b9-b799-4e9e-9e96-1cfd1c283198" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_54ec1154-c8b3-4a75-9c07-437dd34b3a89" xlink:to="loc_us-gaap_AwardTypeAxis_29a499b9-b799-4e9e-9e96-1cfd1c283198" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_29a499b9-b799-4e9e-9e96-1cfd1c283198_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_29a499b9-b799-4e9e-9e96-1cfd1c283198" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_29a499b9-b799-4e9e-9e96-1cfd1c283198_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0afbcab0-56b7-4f84-ba11-1674f9120002" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_29a499b9-b799-4e9e-9e96-1cfd1c283198" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0afbcab0-56b7-4f84-ba11-1674f9120002" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_70969eb8-cb9b-4a38-8ab0-7a7b627ea3e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0afbcab0-56b7-4f84-ba11-1674f9120002" xlink:to="loc_us-gaap_EmployeeStockOptionMember_70969eb8-cb9b-4a38-8ab0-7a7b627ea3e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_ee8b5f1a-b4d1-48b7-8a1c-9582855c96d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0afbcab0-56b7-4f84-ba11-1674f9120002" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_ee8b5f1a-b4d1-48b7-8a1c-9582855c96d6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofChangesintheCarryingAmountofGoodwillDetails" xlink:type="simple" xlink:href="mck-20230630.xsd#GoodwillandIntangibleAssetsNetScheduleofChangesintheCarryingAmountofGoodwillDetails"/>
  <link:definitionLink xlink:role="http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofChangesintheCarryingAmountofGoodwillDetails" xlink:type="extended" id="i2357f1e56999486d826906c60c5d9e97_GoodwillandIntangibleAssetsNetScheduleofChangesintheCarryingAmountofGoodwillDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_ecb4cbb5-027d-493e-b853-2b03e1cf45f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_5d985d2c-d0f1-4be5-840a-70898379e2cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_ecb4cbb5-027d-493e-b853-2b03e1cf45f0" xlink:to="loc_us-gaap_GoodwillRollForward_5d985d2c-d0f1-4be5-840a-70898379e2cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_1d3943d9-5f36-4b4b-b5cc-5961a5e0c599" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_5d985d2c-d0f1-4be5-840a-70898379e2cb" xlink:to="loc_us-gaap_Goodwill_1d3943d9-5f36-4b4b-b5cc-5961a5e0c599" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_7a8c39a1-74af-4f3a-8c06-220a99391b55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_5d985d2c-d0f1-4be5-840a-70898379e2cb" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_7a8c39a1-74af-4f3a-8c06-220a99391b55" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_7a255608-5a2b-4d35-9b3d-fd3832ddaf1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_5d985d2c-d0f1-4be5-840a-70898379e2cb" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_7a255608-5a2b-4d35-9b3d-fd3832ddaf1e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_20339c05-cf9a-4f9c-8d53-850a9fa9ecd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_36720e67-b1a4-4c7e-bf0b-a891ae1c32a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_ecb4cbb5-027d-493e-b853-2b03e1cf45f0" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_36720e67-b1a4-4c7e-bf0b-a891ae1c32a9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_42ab96e5-6fbc-4ee5-9b46-ece50b5aa3d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_36720e67-b1a4-4c7e-bf0b-a891ae1c32a9" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_42ab96e5-6fbc-4ee5-9b46-ece50b5aa3d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_42ab96e5-6fbc-4ee5-9b46-ece50b5aa3d5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_42ab96e5-6fbc-4ee5-9b46-ece50b5aa3d5" xlink:to="loc_us-gaap_SegmentDomain_42ab96e5-6fbc-4ee5-9b46-ece50b5aa3d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_13f38024-4875-4631-9d65-a0f84ba0d5a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_42ab96e5-6fbc-4ee5-9b46-ece50b5aa3d5" xlink:to="loc_us-gaap_SegmentDomain_13f38024-4875-4631-9d65-a0f84ba0d5a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_USPharmaceuticalSegmentMember_07cd3a04-0860-4f38-8ba2-9f2acc568f30" xlink:href="mck-20230630.xsd#mck_USPharmaceuticalSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_13f38024-4875-4631-9d65-a0f84ba0d5a8" xlink:to="loc_mck_USPharmaceuticalSegmentMember_07cd3a04-0860-4f38-8ba2-9f2acc568f30" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_PrescriptionTechnologySolutionsMember_15352e9e-2a7a-472f-9c10-70262e525c00" xlink:href="mck-20230630.xsd#mck_PrescriptionTechnologySolutionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_13f38024-4875-4631-9d65-a0f84ba0d5a8" xlink:to="loc_mck_PrescriptionTechnologySolutionsMember_15352e9e-2a7a-472f-9c10-70262e525c00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_MedicalSurgicalSolutionsSegmentMember_a03d11be-b452-4cd0-9ea5-bdd7c842eede" xlink:href="mck-20230630.xsd#mck_MedicalSurgicalSolutionsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_13f38024-4875-4631-9d65-a0f84ba0d5a8" xlink:to="loc_mck_MedicalSurgicalSolutionsSegmentMember_a03d11be-b452-4cd0-9ea5-bdd7c842eede" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_InternationalSegmentMember_9c60f1f9-de21-4695-9941-f18b231d0388" xlink:href="mck-20230630.xsd#mck_InternationalSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_13f38024-4875-4631-9d65-a0f84ba0d5a8" xlink:to="loc_mck_InternationalSegmentMember_9c60f1f9-de21-4695-9941-f18b231d0388" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails" xlink:type="simple" xlink:href="mck-20230630.xsd#GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails" xlink:type="extended" id="ice9ec334f94e4df28689e0f9b39d268f_GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f1f1b55b-8b28-4e6f-b3ff-4ed55baed6a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_83e64adc-04fb-461b-a001-18dd0f9b1d30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f1f1b55b-8b28-4e6f-b3ff-4ed55baed6a9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_83e64adc-04fb-461b-a001-18dd0f9b1d30" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_6f3564ed-666b-4dde-9897-06a4bfe26ea8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f1f1b55b-8b28-4e6f-b3ff-4ed55baed6a9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_6f3564ed-666b-4dde-9897-06a4bfe26ea8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_bb81489d-1aa6-4a06-8d23-9daa532a2879" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f1f1b55b-8b28-4e6f-b3ff-4ed55baed6a9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_bb81489d-1aa6-4a06-8d23-9daa532a2879" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d7507f6d-9cfe-42b9-9c2e-348259b1d9b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f1f1b55b-8b28-4e6f-b3ff-4ed55baed6a9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d7507f6d-9cfe-42b9-9c2e-348259b1d9b4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_961a59dc-a039-47b4-9624-b371e4b6140f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f1f1b55b-8b28-4e6f-b3ff-4ed55baed6a9" xlink:to="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_961a59dc-a039-47b4-9624-b371e4b6140f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a3395dc0-fa0f-464f-9b98-14ac0bb885a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_961a59dc-a039-47b4-9624-b371e4b6140f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a3395dc0-fa0f-464f-9b98-14ac0bb885a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a3395dc0-fa0f-464f-9b98-14ac0bb885a7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a3395dc0-fa0f-464f-9b98-14ac0bb885a7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_a3395dc0-fa0f-464f-9b98-14ac0bb885a7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_76776c5c-aa7e-4f0a-990b-933360d7593d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a3395dc0-fa0f-464f-9b98-14ac0bb885a7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_76776c5c-aa7e-4f0a-990b-933360d7593d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_0b1e18f5-11fe-4436-9c46-5bf60a525308" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_76776c5c-aa7e-4f0a-990b-933360d7593d" xlink:to="loc_us-gaap_CustomerRelationshipsMember_0b1e18f5-11fe-4436-9c46-5bf60a525308" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceAgreementsMember_93ae6bbf-c6cb-49a0-a44c-384e32b788be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServiceAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_76776c5c-aa7e-4f0a-990b-933360d7593d" xlink:to="loc_us-gaap_ServiceAgreementsMember_93ae6bbf-c6cb-49a0-a44c-384e32b788be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_2ca5a1f1-5f6e-4102-a63d-1f63409cd6e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_76776c5c-aa7e-4f0a-990b-933360d7593d" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_2ca5a1f1-5f6e-4102-a63d-1f63409cd6e9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_87b2cbad-80e1-4be9-9419-16973e065062" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_76776c5c-aa7e-4f0a-990b-933360d7593d" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_87b2cbad-80e1-4be9-9419-16973e065062" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_ae10fd4c-68f8-43ca-8392-5510425c3c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_76776c5c-aa7e-4f0a-990b-933360d7593d" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_ae10fd4c-68f8-43ca-8392-5510425c3c3f" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails" xlink:type="simple" xlink:href="mck-20230630.xsd#DebtandFinancingActivitiesScheduleofLongTermDebtDetails"/>
  <link:definitionLink xlink:role="http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails" xlink:type="extended" id="i9c8a16e9cca64d799d964f7eae754a34_DebtandFinancingActivitiesScheduleofLongTermDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_c4e16622-c480-43ea-900e-ee55c3fff2fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_6ae0e79c-fc82-4599-9aa8-12b06af983ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c4e16622-c480-43ea-900e-ee55c3fff2fc" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_6ae0e79c-fc82-4599-9aa8-12b06af983ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_84b330c4-4667-49b6-8622-29385e923d66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c4e16622-c480-43ea-900e-ee55c3fff2fc" xlink:to="loc_us-gaap_LongTermDebt_84b330c4-4667-49b6-8622-29385e923d66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_db08a058-f9bc-4301-ad7c-eaeb752ddc85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c4e16622-c480-43ea-900e-ee55c3fff2fc" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_db08a058-f9bc-4301-ad7c-eaeb752ddc85" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_fb46fb95-3550-4bfd-8abd-8db310fad653" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c4e16622-c480-43ea-900e-ee55c3fff2fc" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_fb46fb95-3550-4bfd-8abd-8db310fad653" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_b3d9a3b1-2dff-4885-905a-d0eaaff304ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c4e16622-c480-43ea-900e-ee55c3fff2fc" xlink:to="loc_us-gaap_DebtInstrumentTable_b3d9a3b1-2dff-4885-905a-d0eaaff304ac" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_af7d9ee1-6598-46dd-8dd0-581097351d84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b3d9a3b1-2dff-4885-905a-d0eaaff304ac" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_af7d9ee1-6598-46dd-8dd0-581097351d84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_af7d9ee1-6598-46dd-8dd0-581097351d84_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_af7d9ee1-6598-46dd-8dd0-581097351d84" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_af7d9ee1-6598-46dd-8dd0-581097351d84_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_08367e60-db54-4f53-8355-30dcdb9bd214" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_af7d9ee1-6598-46dd-8dd0-581097351d84" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_08367e60-db54-4f53-8355-30dcdb9bd214" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_b5c9252f-929d-40df-b053-c7e5e6edd03c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_08367e60-db54-4f53-8355-30dcdb9bd214" xlink:to="loc_us-gaap_LoansPayableMember_b5c9252f-929d-40df-b053-c7e5e6edd03c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_LeaseAndOtherObligationsMember_065eb69d-611d-46de-b67c-d076a1150ebe" xlink:href="mck-20230630.xsd#mck_LeaseAndOtherObligationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_08367e60-db54-4f53-8355-30dcdb9bd214" xlink:to="loc_mck_LeaseAndOtherObligationsMember_065eb69d-611d-46de-b67c-d076a1150ebe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_bdd27057-8f05-4990-ad5c-c0b977823598" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b3d9a3b1-2dff-4885-905a-d0eaaff304ac" xlink:to="loc_us-gaap_DebtInstrumentAxis_bdd27057-8f05-4990-ad5c-c0b977823598" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_bdd27057-8f05-4990-ad5c-c0b977823598_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_bdd27057-8f05-4990-ad5c-c0b977823598" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_bdd27057-8f05-4990-ad5c-c0b977823598_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_77d4a144-2440-4f94-9fa6-2a270c5f9a47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_bdd27057-8f05-4990-ad5c-c0b977823598" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_77d4a144-2440-4f94-9fa6-2a270c5f9a47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_A380NotesDueMarch152024Member_cb768762-e02c-4c0f-a120-016d4b7ce3de" xlink:href="mck-20230630.xsd#mck_A380NotesDueMarch152024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_77d4a144-2440-4f94-9fa6-2a270c5f9a47" xlink:to="loc_mck_A380NotesDueMarch152024Member_cb768762-e02c-4c0f-a120-016d4b7ce3de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_A090NotesDueDecember32025Member_830fd946-680e-4c55-861d-c1761fec4f96" xlink:href="mck-20230630.xsd#mck_A090NotesDueDecember32025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_77d4a144-2440-4f94-9fa6-2a270c5f9a47" xlink:to="loc_mck_A090NotesDueDecember32025Member_830fd946-680e-4c55-861d-c1761fec4f96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_A525NotesDueFebruary152026Member_a56b522f-7c2b-41d5-9136-c58e69765e44" xlink:href="mck-20230630.xsd#mck_A525NotesDueFebruary152026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_77d4a144-2440-4f94-9fa6-2a270c5f9a47" xlink:to="loc_mck_A525NotesDueFebruary152026Member_a56b522f-7c2b-41d5-9136-c58e69765e44" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_A130NotesDueAugust152026Member_7a58abb2-1ceb-48e6-bfb4-b9be841f1c7e" xlink:href="mck-20230630.xsd#mck_A130NotesDueAugust152026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_77d4a144-2440-4f94-9fa6-2a270c5f9a47" xlink:to="loc_mck_A130NotesDueAugust152026Member_7a58abb2-1ceb-48e6-bfb4-b9be841f1c7e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_A765DebenturesDueMarch12027Member_201d906d-6165-4619-aa04-e8754252783d" xlink:href="mck-20230630.xsd#mck_A765DebenturesDueMarch12027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_77d4a144-2440-4f94-9fa6-2a270c5f9a47" xlink:to="loc_mck_A765DebenturesDueMarch12027Member_201d906d-6165-4619-aa04-e8754252783d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_A395NotesDueFebruary162028Member_a540129a-6fcf-447a-8bfb-7296cf06dd9e" xlink:href="mck-20230630.xsd#mck_A395NotesDueFebruary162028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_77d4a144-2440-4f94-9fa6-2a270c5f9a47" xlink:to="loc_mck_A395NotesDueFebruary162028Member_a540129a-6fcf-447a-8bfb-7296cf06dd9e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_A490NotesDueJuly152028Member_ad7081fa-93d7-4378-b990-11a17d8ab6f9" xlink:href="mck-20230630.xsd#mck_A490NotesDueJuly152028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_77d4a144-2440-4f94-9fa6-2a270c5f9a47" xlink:to="loc_mck_A490NotesDueJuly152028Member_ad7081fa-93d7-4378-b990-11a17d8ab6f9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_A475NotesDueMay302029Member_0acb9b88-0860-42d6-8fe0-395d91185472" xlink:href="mck-20230630.xsd#mck_A475NotesDueMay302029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_77d4a144-2440-4f94-9fa6-2a270c5f9a47" xlink:to="loc_mck_A475NotesDueMay302029Member_0acb9b88-0860-42d6-8fe0-395d91185472" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_A510NotesDueJuly152033Member_635276a6-d9e2-4cc7-a678-e378a3fb14f3" xlink:href="mck-20230630.xsd#mck_A510NotesDueJuly152033Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_77d4a144-2440-4f94-9fa6-2a270c5f9a47" xlink:to="loc_mck_A510NotesDueJuly152033Member_635276a6-d9e2-4cc7-a678-e378a3fb14f3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_A600NotesDueMarch12041Member_5299b9fd-a6d3-4da6-97d9-97a755a7698e" xlink:href="mck-20230630.xsd#mck_A600NotesDueMarch12041Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_77d4a144-2440-4f94-9fa6-2a270c5f9a47" xlink:to="loc_mck_A600NotesDueMarch12041Member_5299b9fd-a6d3-4da6-97d9-97a755a7698e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_A488NotesDueMarch152044Member_8327b0c1-0286-489d-998c-602adbdafbca" xlink:href="mck-20230630.xsd#mck_A488NotesDueMarch152044Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_77d4a144-2440-4f94-9fa6-2a270c5f9a47" xlink:to="loc_mck_A488NotesDueMarch152044Member_8327b0c1-0286-489d-998c-602adbdafbca" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_A150EuroNotesDueNovember172025Member_cc8aa3d7-42eb-41c1-aa99-0b3634bc3280" xlink:href="mck-20230630.xsd#mck_A150EuroNotesDueNovember172025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_77d4a144-2440-4f94-9fa6-2a270c5f9a47" xlink:to="loc_mck_A150EuroNotesDueNovember172025Member_cc8aa3d7-42eb-41c1-aa99-0b3634bc3280" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_A163EuroNotesDueOctober302026Member_bd8bcd21-547c-4928-9757-96f92762768e" xlink:href="mck-20230630.xsd#mck_A163EuroNotesDueOctober302026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_77d4a144-2440-4f94-9fa6-2a270c5f9a47" xlink:to="loc_mck_A163EuroNotesDueOctober302026Member_bd8bcd21-547c-4928-9757-96f92762768e" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_A313SterlingNotesDueFebruary172029Member_a72a0a05-6e99-4714-bef2-51543e3b7ab5" xlink:href="mck-20230630.xsd#mck_A313SterlingNotesDueFebruary172029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_77d4a144-2440-4f94-9fa6-2a270c5f9a47" xlink:to="loc_mck_A313SterlingNotesDueFebruary172029Member_a72a0a05-6e99-4714-bef2-51543e3b7ab5" xlink:type="arc" order="13"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails" xlink:type="simple" xlink:href="mck-20230630.xsd#DebtandFinancingActivitiesLongTermDebtNarrativeDetails"/>
  <link:definitionLink xlink:role="http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails" xlink:type="extended" id="icc318110f7014d7e9daee163584823d4_DebtandFinancingActivitiesLongTermDebtNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_76fd2f97-b7a9-4ec3-8512-a138320547b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtAndCapitalLeaseObligations_293beec4-2639-4f9f-a24e-e3e410e3bd53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtAndCapitalLeaseObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_76fd2f97-b7a9-4ec3-8512-a138320547b2" xlink:to="loc_us-gaap_DebtAndCapitalLeaseObligations_293beec4-2639-4f9f-a24e-e3e410e3bd53" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_8f1c3cc0-2439-4820-8ac1-f8c0d3d7b89f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_76fd2f97-b7a9-4ec3-8512-a138320547b2" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_8f1c3cc0-2439-4820-8ac1-f8c0d3d7b89f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8e6fbb93-d055-4def-9064-53ec0800eb17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_76fd2f97-b7a9-4ec3-8512-a138320547b2" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8e6fbb93-d055-4def-9064-53ec0800eb17" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_51801195-c4a2-4dc3-b496-4dbbfe5a08f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_76fd2f97-b7a9-4ec3-8512-a138320547b2" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_51801195-c4a2-4dc3-b496-4dbbfe5a08f3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_b30d951f-e1e0-495d-b8bb-d8838a2d214e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_76fd2f97-b7a9-4ec3-8512-a138320547b2" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_b30d951f-e1e0-495d-b8bb-d8838a2d214e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_DebtInstrumentRedemptionPeriod_59056adc-4b60-44ef-abcd-527bef052ec1" xlink:href="mck-20230630.xsd#mck_DebtInstrumentRedemptionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_76fd2f97-b7a9-4ec3-8512-a138320547b2" xlink:to="loc_mck_DebtInstrumentRedemptionPeriod_59056adc-4b60-44ef-abcd-527bef052ec1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_3e2bcd71-d8a6-4b59-96d3-0b81b24d8606" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_76fd2f97-b7a9-4ec3-8512-a138320547b2" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_3e2bcd71-d8a6-4b59-96d3-0b81b24d8606" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_b0ad7cce-6487-433f-a2a0-21c6e34f0c4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_76fd2f97-b7a9-4ec3-8512-a138320547b2" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_b0ad7cce-6487-433f-a2a0-21c6e34f0c4f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_e1578435-fe2e-4479-ac02-c565184df563" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_76fd2f97-b7a9-4ec3-8512-a138320547b2" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_e1578435-fe2e-4479-ac02-c565184df563" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_PaymentsForPurchaseOfGovernmentObligationsForSatisfactionAndDischargeOfLongTermDebt_fe91a94a-723b-4355-9c6e-15ef589b6c6c" xlink:href="mck-20230630.xsd#mck_PaymentsForPurchaseOfGovernmentObligationsForSatisfactionAndDischargeOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_76fd2f97-b7a9-4ec3-8512-a138320547b2" xlink:to="loc_mck_PaymentsForPurchaseOfGovernmentObligationsForSatisfactionAndDischargeOfLongTermDebt_fe91a94a-723b-4355-9c6e-15ef589b6c6c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_de08210e-5800-400e-840f-f307c7aa1e52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_76fd2f97-b7a9-4ec3-8512-a138320547b2" xlink:to="loc_us-gaap_LongTermDebt_de08210e-5800-400e-840f-f307c7aa1e52" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a8726251-efc3-4218-a6ee-db090d32cd1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_76fd2f97-b7a9-4ec3-8512-a138320547b2" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a8726251-efc3-4218-a6ee-db090d32cd1f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_8e99d4e2-1040-4a7c-8bd2-38bff952d2af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_76fd2f97-b7a9-4ec3-8512-a138320547b2" xlink:to="loc_us-gaap_DebtInstrumentTable_8e99d4e2-1040-4a7c-8bd2-38bff952d2af" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_3566750a-7dae-4c39-bd13-72171ad59504" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8e99d4e2-1040-4a7c-8bd2-38bff952d2af" xlink:to="loc_us-gaap_DebtInstrumentAxis_3566750a-7dae-4c39-bd13-72171ad59504" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3566750a-7dae-4c39-bd13-72171ad59504_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_3566750a-7dae-4c39-bd13-72171ad59504" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3566750a-7dae-4c39-bd13-72171ad59504_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e8f93b0f-17cb-463d-9795-3848903ba1ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_3566750a-7dae-4c39-bd13-72171ad59504" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e8f93b0f-17cb-463d-9795-3848903ba1ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_A490NotesDueJuly152028Member_144dafa6-cb6d-4acd-85ed-653c94fbfc00" xlink:href="mck-20230630.xsd#mck_A490NotesDueJuly152028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8f93b0f-17cb-463d-9795-3848903ba1ef" xlink:to="loc_mck_A490NotesDueJuly152028Member_144dafa6-cb6d-4acd-85ed-653c94fbfc00" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_A510NotesDueJuly152033Member_2b95a02d-941c-4737-b0fb-e339f65bc3ec" xlink:href="mck-20230630.xsd#mck_A510NotesDueJuly152033Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8f93b0f-17cb-463d-9795-3848903ba1ef" xlink:to="loc_mck_A510NotesDueJuly152033Member_2b95a02d-941c-4737-b0fb-e339f65bc3ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_A380NotesDueMarch152024Member_dda1f53c-ecba-42ba-9a34-a592eedef59b" xlink:href="mck-20230630.xsd#mck_A380NotesDueMarch152024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8f93b0f-17cb-463d-9795-3848903ba1ef" xlink:to="loc_mck_A380NotesDueMarch152024Member_dda1f53c-ecba-42ba-9a34-a592eedef59b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_7ec4b8e0-577f-43dc-bd89-bb05691a12f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8e99d4e2-1040-4a7c-8bd2-38bff952d2af" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_7ec4b8e0-577f-43dc-bd89-bb05691a12f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7ec4b8e0-577f-43dc-bd89-bb05691a12f7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7ec4b8e0-577f-43dc-bd89-bb05691a12f7" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7ec4b8e0-577f-43dc-bd89-bb05691a12f7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_35c56b40-8f64-47b8-ac76-a8e9fed0914f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7ec4b8e0-577f-43dc-bd89-bb05691a12f7" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_35c56b40-8f64-47b8-ac76-a8e9fed0914f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_fc630b49-fd89-4ccf-89ac-8f3d89081819" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_35c56b40-8f64-47b8-ac76-a8e9fed0914f" xlink:to="loc_us-gaap_LoansPayableMember_fc630b49-fd89-4ccf-89ac-8f3d89081819" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6ecb0d3e-507a-488b-84a3-e2bd2f516ef4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8e99d4e2-1040-4a7c-8bd2-38bff952d2af" xlink:to="loc_srt_RangeAxis_6ecb0d3e-507a-488b-84a3-e2bd2f516ef4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6ecb0d3e-507a-488b-84a3-e2bd2f516ef4_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_6ecb0d3e-507a-488b-84a3-e2bd2f516ef4" xlink:to="loc_srt_RangeMember_6ecb0d3e-507a-488b-84a3-e2bd2f516ef4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_863922e8-5a0e-42c2-8daf-67267d41572a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_6ecb0d3e-507a-488b-84a3-e2bd2f516ef4" xlink:to="loc_srt_RangeMember_863922e8-5a0e-42c2-8daf-67267d41572a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b4daf777-ab58-41f9-b1e8-6e8cd49c72e5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_863922e8-5a0e-42c2-8daf-67267d41572a" xlink:to="loc_srt_MinimumMember_b4daf777-ab58-41f9-b1e8-6e8cd49c72e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7ed1c94f-bb9e-492b-9275-dcd46f00adbc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_863922e8-5a0e-42c2-8daf-67267d41572a" xlink:to="loc_srt_MaximumMember_7ed1c94f-bb9e-492b-9275-dcd46f00adbc" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://mckesson123.com/role/DebtandFinancingActivitiesRevolvingCreditFacilitiesNarrativeDetails" xlink:type="simple" xlink:href="mck-20230630.xsd#DebtandFinancingActivitiesRevolvingCreditFacilitiesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://mckesson123.com/role/DebtandFinancingActivitiesRevolvingCreditFacilitiesNarrativeDetails" xlink:type="extended" id="i8f9278aef9a8437aa76be825e03ad9e0_DebtandFinancingActivitiesRevolvingCreditFacilitiesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_3a74a39b-78bd-4ad3-8101-c370f3feda36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_bc108798-70a8-4079-8380-6a55da5cd1a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_3a74a39b-78bd-4ad3-8101-c370f3feda36" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_bc108798-70a8-4079-8380-6a55da5cd1a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_e64be29c-7571-494c-9b6d-b5ca9d88e73a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_3a74a39b-78bd-4ad3-8101-c370f3feda36" xlink:to="loc_us-gaap_DebtInstrumentTerm_e64be29c-7571-494c-9b6d-b5ca9d88e73a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_bc10543e-358b-4a59-a7db-b648b984d793" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_3a74a39b-78bd-4ad3-8101-c370f3feda36" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_bc10543e-358b-4a59-a7db-b648b984d793" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_8a81b365-ebee-4427-8cb6-40f7682ef6be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_3a74a39b-78bd-4ad3-8101-c370f3feda36" xlink:to="loc_us-gaap_LineOfCredit_8a81b365-ebee-4427-8cb6-40f7682ef6be" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_89ab3b53-34ea-4a09-a214-0a5ad69c7a46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_3a74a39b-78bd-4ad3-8101-c370f3feda36" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_89ab3b53-34ea-4a09-a214-0a5ad69c7a46" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ef568a48-1ab2-41df-9f85-3363691eb53a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_89ab3b53-34ea-4a09-a214-0a5ad69c7a46" xlink:to="loc_us-gaap_DebtInstrumentAxis_ef568a48-1ab2-41df-9f85-3363691eb53a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_ef568a48-1ab2-41df-9f85-3363691eb53a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_ef568a48-1ab2-41df-9f85-3363691eb53a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_ef568a48-1ab2-41df-9f85-3363691eb53a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_bc5ad2a0-42fb-4d5c-8156-9262e1457f71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_ef568a48-1ab2-41df-9f85-3363691eb53a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_bc5ad2a0-42fb-4d5c-8156-9262e1457f71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_SeniorUnsecuredCreditFacilityThe2022CreditFacilityMember_5ddedb44-cf0d-48a1-a194-1767ba25185f" xlink:href="mck-20230630.xsd#mck_SeniorUnsecuredCreditFacilityThe2022CreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bc5ad2a0-42fb-4d5c-8156-9262e1457f71" xlink:to="loc_mck_SeniorUnsecuredCreditFacilityThe2022CreditFacilityMember_5ddedb44-cf0d-48a1-a194-1767ba25185f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_SeniorUnsecuredCreditFacilityThe2022CreditFacilityCanadianDollarBritishPoundSterlingAndEurosSublimitMember_bbd30e37-0250-4d81-a6c1-40ab4e1c5f8d" xlink:href="mck-20230630.xsd#mck_SeniorUnsecuredCreditFacilityThe2022CreditFacilityCanadianDollarBritishPoundSterlingAndEurosSublimitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bc5ad2a0-42fb-4d5c-8156-9262e1457f71" xlink:to="loc_mck_SeniorUnsecuredCreditFacilityThe2022CreditFacilityCanadianDollarBritishPoundSterlingAndEurosSublimitMember_bbd30e37-0250-4d81-a6c1-40ab4e1c5f8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_SeniorUnsecuredCreditFacilitythe2020CreditFacilityMember_5d6b7c2a-c4d0-4905-ae2c-e322b36131ea" xlink:href="mck-20230630.xsd#mck_SeniorUnsecuredCreditFacilitythe2020CreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bc5ad2a0-42fb-4d5c-8156-9262e1457f71" xlink:to="loc_mck_SeniorUnsecuredCreditFacilitythe2020CreditFacilityMember_5d6b7c2a-c4d0-4905-ae2c-e322b36131ea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_SeniorUnsecuredCreditFacilitythe2020CreditFacilityCanadianDollarBritishPoundSterlingandEurosSublimitMember_24e5339d-68b6-48c0-ba95-be27f9fdd2e7" xlink:href="mck-20230630.xsd#mck_SeniorUnsecuredCreditFacilitythe2020CreditFacilityCanadianDollarBritishPoundSterlingandEurosSublimitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bc5ad2a0-42fb-4d5c-8156-9262e1457f71" xlink:to="loc_mck_SeniorUnsecuredCreditFacilitythe2020CreditFacilityCanadianDollarBritishPoundSterlingandEurosSublimitMember_24e5339d-68b6-48c0-ba95-be27f9fdd2e7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_6876ccb6-1df1-4d44-a413-bf7de0887c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_89ab3b53-34ea-4a09-a214-0a5ad69c7a46" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_6876ccb6-1df1-4d44-a413-bf7de0887c0f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6876ccb6-1df1-4d44-a413-bf7de0887c0f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6876ccb6-1df1-4d44-a413-bf7de0887c0f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6876ccb6-1df1-4d44-a413-bf7de0887c0f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_73bd0cad-3ab2-42c4-8c79-ab1ed7b3d146" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6876ccb6-1df1-4d44-a413-bf7de0887c0f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_73bd0cad-3ab2-42c4-8c79-ab1ed7b3d146" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_a6eb7107-fccc-444e-bb89-b17535c44c7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_73bd0cad-3ab2-42c4-8c79-ab1ed7b3d146" xlink:to="loc_us-gaap_UnsecuredDebtMember_a6eb7107-fccc-444e-bb89-b17535c44c7e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_51dec11c-7586-4656-a81a-6f590157620d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_89ab3b53-34ea-4a09-a214-0a5ad69c7a46" xlink:to="loc_us-gaap_CreditFacilityAxis_51dec11c-7586-4656-a81a-6f590157620d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_51dec11c-7586-4656-a81a-6f590157620d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_51dec11c-7586-4656-a81a-6f590157620d" xlink:to="loc_us-gaap_CreditFacilityDomain_51dec11c-7586-4656-a81a-6f590157620d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_7023f173-a22d-4ef1-bd97-93adcabaf15b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_51dec11c-7586-4656-a81a-6f590157620d" xlink:to="loc_us-gaap_CreditFacilityDomain_7023f173-a22d-4ef1-bd97-93adcabaf15b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_cba6945f-10d1-4e2b-99d5-cf69d41a6b4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_7023f173-a22d-4ef1-bd97-93adcabaf15b" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_cba6945f-10d1-4e2b-99d5-cf69d41a6b4c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://mckesson123.com/role/DebtandFinancingActivitiesCommercialPaperNarrativeDetails" xlink:type="simple" xlink:href="mck-20230630.xsd#DebtandFinancingActivitiesCommercialPaperNarrativeDetails"/>
  <link:definitionLink xlink:role="http://mckesson123.com/role/DebtandFinancingActivitiesCommercialPaperNarrativeDetails" xlink:type="extended" id="i795013e272ad4036b971ff59a1b5eda8_DebtandFinancingActivitiesCommercialPaperNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_abc06096-d1bc-4b5f-b373-6dcbf5e9b258" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_506c0ba3-dd04-4b95-9cab-7dc1ec64ce3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_abc06096-d1bc-4b5f-b373-6dcbf5e9b258" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_506c0ba3-dd04-4b95-9cab-7dc1ec64ce3a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommercialPaper_5c8edfb5-8018-44fe-86b6-0a1200aa385e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommercialPaper"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_abc06096-d1bc-4b5f-b373-6dcbf5e9b258" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommercialPaper_5c8edfb5-8018-44fe-86b6-0a1200aa385e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfCommercialPaper_f7f229c4-4a95-47e3-a536-dd8e080ed92c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfCommercialPaper"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_abc06096-d1bc-4b5f-b373-6dcbf5e9b258" xlink:to="loc_us-gaap_RepaymentsOfCommercialPaper_f7f229c4-4a95-47e3-a536-dd8e080ed92c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermCommercialPaperCurrent_281336f1-c959-4e4c-bb05-e278c612f587" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermCommercialPaperCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_abc06096-d1bc-4b5f-b373-6dcbf5e9b258" xlink:to="loc_us-gaap_LongTermCommercialPaperCurrent_281336f1-c959-4e4c-bb05-e278c612f587" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_ebb52a0a-59d0-4443-909e-3fb26d53bca8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_abc06096-d1bc-4b5f-b373-6dcbf5e9b258" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_ebb52a0a-59d0-4443-909e-3fb26d53bca8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_695e0e3d-d742-437f-bf3e-c5c9b1af36bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_ebb52a0a-59d0-4443-909e-3fb26d53bca8" xlink:to="loc_us-gaap_CreditFacilityAxis_695e0e3d-d742-437f-bf3e-c5c9b1af36bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_695e0e3d-d742-437f-bf3e-c5c9b1af36bb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_695e0e3d-d742-437f-bf3e-c5c9b1af36bb" xlink:to="loc_us-gaap_CreditFacilityDomain_695e0e3d-d742-437f-bf3e-c5c9b1af36bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_2b937294-e028-4b1f-9e0f-6af7ca6d4429" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_695e0e3d-d742-437f-bf3e-c5c9b1af36bb" xlink:to="loc_us-gaap_CreditFacilityDomain_2b937294-e028-4b1f-9e0f-6af7ca6d4429" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_c95777b9-48ae-46e3-a639-eb5fdde35dc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_2b937294-e028-4b1f-9e0f-6af7ca6d4429" xlink:to="loc_us-gaap_CommercialPaperMember_c95777b9-48ae-46e3-a639-eb5fdde35dc6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://mckesson123.com/role/HedgingActivitiesNarrativeDetails" xlink:type="simple" xlink:href="mck-20230630.xsd#HedgingActivitiesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://mckesson123.com/role/HedgingActivitiesNarrativeDetails" xlink:type="extended" id="i1e65d252a50543c59e659820b0d9c684_HedgingActivitiesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_0b5cac34-9465-489d-a683-3072d0d50227" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_DerivativeNotionalAmountEnteredIntoDuringPeriod_d5b72402-4212-4b17-954b-9c70001930ca" xlink:href="mck-20230630.xsd#mck_DerivativeNotionalAmountEnteredIntoDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_0b5cac34-9465-489d-a683-3072d0d50227" xlink:to="loc_mck_DerivativeNotionalAmountEnteredIntoDuringPeriod_d5b72402-4212-4b17-954b-9c70001930ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_c1523918-d535-47cf-bd13-ce6edef2fc3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_0b5cac34-9465-489d-a683-3072d0d50227" xlink:to="loc_us-gaap_DerivativeNotionalAmount_c1523918-d535-47cf-bd13-ce6edef2fc3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_b981eba5-9d50-4bb7-af93-4d0ebb81b488" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_0b5cac34-9465-489d-a683-3072d0d50227" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_b981eba5-9d50-4bb7-af93-4d0ebb81b488" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_056d3824-807a-4cd5-b1a8-2f6c6ec68d00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_0b5cac34-9465-489d-a683-3072d0d50227" xlink:to="loc_us-gaap_LongTermDebt_056d3824-807a-4cd5-b1a8-2f6c6ec68d00" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_DerivativeTerminationProceedsAmortizationPeriod_a31f9be6-702c-421c-a289-d042333a52dc" xlink:href="mck-20230630.xsd#mck_DerivativeTerminationProceedsAmortizationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_0b5cac34-9465-489d-a683-3072d0d50227" xlink:to="loc_mck_DerivativeTerminationProceedsAmortizationPeriod_a31f9be6-702c-421c-a289-d042333a52dc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_396474bc-833a-44ab-8ec6-e2d1031c31ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_0b5cac34-9465-489d-a683-3072d0d50227" xlink:to="loc_us-gaap_DerivativeTable_396474bc-833a-44ab-8ec6-e2d1031c31ca" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c303441e-cd92-4ff3-9085-05c74e551a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_396474bc-833a-44ab-8ec6-e2d1031c31ca" xlink:to="loc_us-gaap_DebtInstrumentAxis_c303441e-cd92-4ff3-9085-05c74e551a8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c303441e-cd92-4ff3-9085-05c74e551a8e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_c303441e-cd92-4ff3-9085-05c74e551a8e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c303441e-cd92-4ff3-9085-05c74e551a8e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b09a1f3f-9f32-45d5-99ff-47d9d0fa7443" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_c303441e-cd92-4ff3-9085-05c74e551a8e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b09a1f3f-9f32-45d5-99ff-47d9d0fa7443" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_49dd0ab1-19f6-4ac0-b988-476ba9e45976" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrencySwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b09a1f3f-9f32-45d5-99ff-47d9d0fa7443" xlink:to="loc_us-gaap_CurrencySwapMember_49dd0ab1-19f6-4ac0-b988-476ba9e45976" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_BritishPoundSterlingDenominatedNotesMember_0d42bdbb-cc57-4476-a70a-61d4981955f7" xlink:href="mck-20230630.xsd#mck_BritishPoundSterlingDenominatedNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b09a1f3f-9f32-45d5-99ff-47d9d0fa7443" xlink:to="loc_mck_BritishPoundSterlingDenominatedNotesMember_0d42bdbb-cc57-4476-a70a-61d4981955f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_a870964d-6a25-48d2-8764-be0c1b31a99e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_396474bc-833a-44ab-8ec6-e2d1031c31ca" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_a870964d-6a25-48d2-8764-be0c1b31a99e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_a870964d-6a25-48d2-8764-be0c1b31a99e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a870964d-6a25-48d2-8764-be0c1b31a99e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_a870964d-6a25-48d2-8764-be0c1b31a99e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_13de538f-779d-447c-8901-cf020b9c3070" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a870964d-6a25-48d2-8764-be0c1b31a99e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_13de538f-779d-447c-8901-cf020b9c3070" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_9f80994f-5333-4c07-bd73-570fd1cbd007" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_13de538f-779d-447c-8901-cf020b9c3070" xlink:to="loc_us-gaap_LoansPayableMember_9f80994f-5333-4c07-bd73-570fd1cbd007" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_4331d30b-61d0-40b1-9b1c-f0fccf54fed6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_396474bc-833a-44ab-8ec6-e2d1031c31ca" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_4331d30b-61d0-40b1-9b1c-f0fccf54fed6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_4331d30b-61d0-40b1-9b1c-f0fccf54fed6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_4331d30b-61d0-40b1-9b1c-f0fccf54fed6" xlink:to="loc_us-gaap_HedgingRelationshipDomain_4331d30b-61d0-40b1-9b1c-f0fccf54fed6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_f1a680ee-5b93-4634-a5bd-c0f5203cce40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_4331d30b-61d0-40b1-9b1c-f0fccf54fed6" xlink:to="loc_us-gaap_HedgingRelationshipDomain_f1a680ee-5b93-4634-a5bd-c0f5203cce40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_b4ed7516-5083-4f68-874c-b094d4500854" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_f1a680ee-5b93-4634-a5bd-c0f5203cce40" xlink:to="loc_us-gaap_FairValueHedgingMember_b4ed7516-5083-4f68-874c-b094d4500854" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_6c0558c4-2c9d-4f95-80ad-c899bfcc8027" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_f1a680ee-5b93-4634-a5bd-c0f5203cce40" xlink:to="loc_us-gaap_CashFlowHedgingMember_6c0558c4-2c9d-4f95-80ad-c899bfcc8027" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_e8435ca3-8f20-43ef-96e4-09f4df6130cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_396474bc-833a-44ab-8ec6-e2d1031c31ca" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_e8435ca3-8f20-43ef-96e4-09f4df6130cc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_e8435ca3-8f20-43ef-96e4-09f4df6130cc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_e8435ca3-8f20-43ef-96e4-09f4df6130cc" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_e8435ca3-8f20-43ef-96e4-09f4df6130cc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_0eed28b1-08c7-4e1b-9809-b80dbad15d06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_e8435ca3-8f20-43ef-96e4-09f4df6130cc" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_0eed28b1-08c7-4e1b-9809-b80dbad15d06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_051b9724-3853-4101-bd67-88dce1493969" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_0eed28b1-08c7-4e1b-9809-b80dbad15d06" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_051b9724-3853-4101-bd67-88dce1493969" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_566dfc7f-713b-4e08-80b9-b05c697339c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_396474bc-833a-44ab-8ec6-e2d1031c31ca" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_566dfc7f-713b-4e08-80b9-b05c697339c7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_566dfc7f-713b-4e08-80b9-b05c697339c7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_566dfc7f-713b-4e08-80b9-b05c697339c7" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_566dfc7f-713b-4e08-80b9-b05c697339c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0965cad8-94eb-4be7-85c7-66736e4b6a20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_566dfc7f-713b-4e08-80b9-b05c697339c7" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0965cad8-94eb-4be7-85c7-66736e4b6a20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_UKBusinessesDisposalGroupMember_3ce4d957-926c-43a5-9859-c06dc324ec3c" xlink:href="mck-20230630.xsd#mck_UKBusinessesDisposalGroupMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0965cad8-94eb-4be7-85c7-66736e4b6a20" xlink:to="loc_mck_UKBusinessesDisposalGroupMember_3ce4d957-926c-43a5-9859-c06dc324ec3c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_fd50dc08-d967-47e5-8650-80fc546fec6c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_396474bc-833a-44ab-8ec6-e2d1031c31ca" xlink:to="loc_srt_CurrencyAxis_fd50dc08-d967-47e5-8650-80fc546fec6c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_fd50dc08-d967-47e5-8650-80fc546fec6c_default" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_fd50dc08-d967-47e5-8650-80fc546fec6c" xlink:to="loc_currency_AllCurrenciesDomain_fd50dc08-d967-47e5-8650-80fc546fec6c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_151c4816-c51b-4b72-a3ec-c95f305b0ddc" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_fd50dc08-d967-47e5-8650-80fc546fec6c" xlink:to="loc_currency_AllCurrenciesDomain_151c4816-c51b-4b72-a3ec-c95f305b0ddc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_52b79367-b64c-460f-b174-867d32214e99" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_EUR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_151c4816-c51b-4b72-a3ec-c95f305b0ddc" xlink:to="loc_currency_EUR_52b79367-b64c-460f-b174-867d32214e99" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_22800719-c4da-4036-b207-fcef2c026e7e" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_USD"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_151c4816-c51b-4b72-a3ec-c95f305b0ddc" xlink:to="loc_currency_USD_22800719-c4da-4036-b207-fcef2c026e7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_79be6b1b-f82a-477e-8bc8-146df16034eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_396474bc-833a-44ab-8ec6-e2d1031c31ca" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_79be6b1b-f82a-477e-8bc8-146df16034eb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_79be6b1b-f82a-477e-8bc8-146df16034eb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_79be6b1b-f82a-477e-8bc8-146df16034eb" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_79be6b1b-f82a-477e-8bc8-146df16034eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_4e80a270-fe67-47fb-a664-6ca8ddcb0f8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_79be6b1b-f82a-477e-8bc8-146df16034eb" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_4e80a270-fe67-47fb-a664-6ca8ddcb0f8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_FixedInterestRateSwapMember_cf23d721-a5fc-415a-89cf-2a162d3255e1" xlink:href="mck-20230630.xsd#mck_FixedInterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4e80a270-fe67-47fb-a664-6ca8ddcb0f8d" xlink:to="loc_mck_FixedInterestRateSwapMember_cf23d721-a5fc-415a-89cf-2a162d3255e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_184c10ec-e740-4c4d-8847-8c3fd674919b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4e80a270-fe67-47fb-a664-6ca8ddcb0f8d" xlink:to="loc_us-gaap_InterestRateSwapMember_184c10ec-e740-4c4d-8847-8c3fd674919b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_9e79438b-7d31-483f-b70b-da262a66ee67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_396474bc-833a-44ab-8ec6-e2d1031c31ca" xlink:to="loc_us-gaap_HedgingDesignationAxis_9e79438b-7d31-483f-b70b-da262a66ee67" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_9e79438b-7d31-483f-b70b-da262a66ee67_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_9e79438b-7d31-483f-b70b-da262a66ee67" xlink:to="loc_us-gaap_HedgingDesignationDomain_9e79438b-7d31-483f-b70b-da262a66ee67_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_9e06ef6a-e8b5-430f-98aa-b318fe4bdc29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_9e79438b-7d31-483f-b70b-da262a66ee67" xlink:to="loc_us-gaap_HedgingDesignationDomain_9e06ef6a-e8b5-430f-98aa-b318fe4bdc29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_a6b2e7e5-ae6d-44a4-a3a9-237afc13297c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_9e06ef6a-e8b5-430f-98aa-b318fe4bdc29" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_a6b2e7e5-ae6d-44a4-a3a9-237afc13297c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://mckesson123.com/role/HedgingActivitiesSummaryofForeignCurrencyGainsandLossesfromNonDerivativeInstrumentsDetails" xlink:type="simple" xlink:href="mck-20230630.xsd#HedgingActivitiesSummaryofForeignCurrencyGainsandLossesfromNonDerivativeInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://mckesson123.com/role/HedgingActivitiesSummaryofForeignCurrencyGainsandLossesfromNonDerivativeInstrumentsDetails" xlink:type="extended" id="id26b39b328a241c8b580e32fef627932_HedgingActivitiesSummaryofForeignCurrencyGainsandLossesfromNonDerivativeInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_4f22f8ac-2b45-4185-abc6-b4311aa5483d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_082b320e-05c8-429c-b150-c16ab902e825" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_4f22f8ac-2b45-4185-abc6-b4311aa5483d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_082b320e-05c8-429c-b150-c16ab902e825" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_2993e626-5b6e-4297-9643-a7b386eedc7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_4f22f8ac-2b45-4185-abc6-b4311aa5483d" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_2993e626-5b6e-4297-9643-a7b386eedc7f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_b72f2399-c01b-48d9-91c2-34a946babe08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_2993e626-5b6e-4297-9643-a7b386eedc7f" xlink:to="loc_us-gaap_HedgingDesignationAxis_b72f2399-c01b-48d9-91c2-34a946babe08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_b72f2399-c01b-48d9-91c2-34a946babe08_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_b72f2399-c01b-48d9-91c2-34a946babe08" xlink:to="loc_us-gaap_HedgingDesignationDomain_b72f2399-c01b-48d9-91c2-34a946babe08_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_03ed769e-a9b2-478e-8bd7-8a01a5e4fd00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_b72f2399-c01b-48d9-91c2-34a946babe08" xlink:to="loc_us-gaap_HedgingDesignationDomain_03ed769e-a9b2-478e-8bd7-8a01a5e4fd00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_4d8e3239-e732-4b1f-bf9e-697641c18cbd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_03ed769e-a9b2-478e-8bd7-8a01a5e4fd00" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_4d8e3239-e732-4b1f-bf9e-697641c18cbd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_d2f35f33-62d7-4d38-b621-25c3d3e160f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_2993e626-5b6e-4297-9643-a7b386eedc7f" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_d2f35f33-62d7-4d38-b621-25c3d3e160f0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_d2f35f33-62d7-4d38-b621-25c3d3e160f0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_d2f35f33-62d7-4d38-b621-25c3d3e160f0" xlink:to="loc_us-gaap_HedgingRelationshipDomain_d2f35f33-62d7-4d38-b621-25c3d3e160f0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_77e06278-daf8-4c7c-bfe4-2db80f59e7e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_d2f35f33-62d7-4d38-b621-25c3d3e160f0" xlink:to="loc_us-gaap_HedgingRelationshipDomain_77e06278-daf8-4c7c-bfe4-2db80f59e7e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_b6ef70cf-be01-4be9-8f83-d737d0cbaafc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_77e06278-daf8-4c7c-bfe4-2db80f59e7e4" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_b6ef70cf-be01-4be9-8f83-d737d0cbaafc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d75eff91-9ed2-4ebd-858d-fe20f931db38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_2993e626-5b6e-4297-9643-a7b386eedc7f" xlink:to="loc_us-gaap_DebtInstrumentAxis_d75eff91-9ed2-4ebd-858d-fe20f931db38" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d75eff91-9ed2-4ebd-858d-fe20f931db38_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_d75eff91-9ed2-4ebd-858d-fe20f931db38" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d75eff91-9ed2-4ebd-858d-fe20f931db38_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0bdc4492-2a8c-4def-93b3-793a683aba69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_d75eff91-9ed2-4ebd-858d-fe20f931db38" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0bdc4492-2a8c-4def-93b3-793a683aba69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_EuroDenominatedNotesMember_4319c46b-1204-478a-ad94-e7b342d3cd08" xlink:href="mck-20230630.xsd#mck_EuroDenominatedNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0bdc4492-2a8c-4def-93b3-793a683aba69" xlink:to="loc_mck_EuroDenominatedNotesMember_4319c46b-1204-478a-ad94-e7b342d3cd08" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails" xlink:type="simple" xlink:href="mck-20230630.xsd#HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails"/>
  <link:definitionLink xlink:role="http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails" xlink:type="extended" id="i2f709c42421f412cad5d2a6783ec5256_HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_7dd4fe13-87dd-4238-94bb-62da7a2233cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_83a2461f-0132-48b0-bc5b-d4e360ea3567" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_7dd4fe13-87dd-4238-94bb-62da7a2233cf" xlink:to="loc_us-gaap_DerivativeNotionalAmount_83a2461f-0132-48b0-bc5b-d4e360ea3567" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_2c3561c2-5cbd-473b-aa6c-a991ff33dc25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_7dd4fe13-87dd-4238-94bb-62da7a2233cf" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_2c3561c2-5cbd-473b-aa6c-a991ff33dc25" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_07dd9ad4-4221-41ea-995a-4520b203283a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_2c3561c2-5cbd-473b-aa6c-a991ff33dc25" xlink:to="loc_us-gaap_HedgingDesignationAxis_07dd9ad4-4221-41ea-995a-4520b203283a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_07dd9ad4-4221-41ea-995a-4520b203283a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_07dd9ad4-4221-41ea-995a-4520b203283a" xlink:to="loc_us-gaap_HedgingDesignationDomain_07dd9ad4-4221-41ea-995a-4520b203283a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_d9b6781a-6a86-4574-bc9c-381e8bc79e08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_07dd9ad4-4221-41ea-995a-4520b203283a" xlink:to="loc_us-gaap_HedgingDesignationDomain_d9b6781a-6a86-4574-bc9c-381e8bc79e08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_1e030369-1e81-4b4e-802a-2c38e66ba6a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_d9b6781a-6a86-4574-bc9c-381e8bc79e08" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_1e030369-1e81-4b4e-802a-2c38e66ba6a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_ccc32cbc-379e-4d6a-bef3-e36814cd65df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_2c3561c2-5cbd-473b-aa6c-a991ff33dc25" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_ccc32cbc-379e-4d6a-bef3-e36814cd65df" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_ccc32cbc-379e-4d6a-bef3-e36814cd65df_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_ccc32cbc-379e-4d6a-bef3-e36814cd65df" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_ccc32cbc-379e-4d6a-bef3-e36814cd65df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_0b1b3b43-bf75-4600-9cf3-967afb625e90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_ccc32cbc-379e-4d6a-bef3-e36814cd65df" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_0b1b3b43-bf75-4600-9cf3-967afb625e90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_e026e59e-b529-4f0f-8b4c-d2a8d1b47c73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrencySwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0b1b3b43-bf75-4600-9cf3-967afb625e90" xlink:to="loc_us-gaap_CurrencySwapMember_e026e59e-b529-4f0f-8b4c-d2a8d1b47c73" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_fbd11106-c0ce-4408-8922-9a663540fd27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0b1b3b43-bf75-4600-9cf3-967afb625e90" xlink:to="loc_us-gaap_InterestRateSwapMember_fbd11106-c0ce-4408-8922-9a663540fd27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_FixedInterestRateSwapMember_06c4fac8-508c-49f8-9c89-9b2dfdcdd3db" xlink:href="mck-20230630.xsd#mck_FixedInterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0b1b3b43-bf75-4600-9cf3-967afb625e90" xlink:to="loc_mck_FixedInterestRateSwapMember_06c4fac8-508c-49f8-9c89-9b2dfdcdd3db" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_78b1895d-ba59-4b85-ab0b-3a95a214a1e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_2c3561c2-5cbd-473b-aa6c-a991ff33dc25" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_78b1895d-ba59-4b85-ab0b-3a95a214a1e8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_78b1895d-ba59-4b85-ab0b-3a95a214a1e8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_78b1895d-ba59-4b85-ab0b-3a95a214a1e8" xlink:to="loc_us-gaap_HedgingRelationshipDomain_78b1895d-ba59-4b85-ab0b-3a95a214a1e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_39f36f51-60a4-47b3-a8c7-60fae2cdcf7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_78b1895d-ba59-4b85-ab0b-3a95a214a1e8" xlink:to="loc_us-gaap_HedgingRelationshipDomain_39f36f51-60a4-47b3-a8c7-60fae2cdcf7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_66c826d8-e817-4895-b6bb-46233ea7c732" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_39f36f51-60a4-47b3-a8c7-60fae2cdcf7e" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_66c826d8-e817-4895-b6bb-46233ea7c732" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_9a57377a-1741-4266-a5ca-8e2516bb38e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_39f36f51-60a4-47b3-a8c7-60fae2cdcf7e" xlink:to="loc_us-gaap_FairValueHedgingMember_9a57377a-1741-4266-a5ca-8e2516bb38e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_0db9d0c9-881b-47d9-8c7d-e9df7316ebdc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_39f36f51-60a4-47b3-a8c7-60fae2cdcf7e" xlink:to="loc_us-gaap_CashFlowHedgingMember_0db9d0c9-881b-47d9-8c7d-e9df7316ebdc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_5d846f84-6fb8-4229-9d5e-b919077314d2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_2c3561c2-5cbd-473b-aa6c-a991ff33dc25" xlink:to="loc_srt_CurrencyAxis_5d846f84-6fb8-4229-9d5e-b919077314d2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_5d846f84-6fb8-4229-9d5e-b919077314d2_default" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_5d846f84-6fb8-4229-9d5e-b919077314d2" xlink:to="loc_currency_AllCurrenciesDomain_5d846f84-6fb8-4229-9d5e-b919077314d2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_29b741ca-4cbd-4eaf-9466-0b464f914135" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_5d846f84-6fb8-4229-9d5e-b919077314d2" xlink:to="loc_currency_AllCurrenciesDomain_29b741ca-4cbd-4eaf-9466-0b464f914135" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CAD_05cb71cd-1454-4761-962b-739bbc0b7b29" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_CAD"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_29b741ca-4cbd-4eaf-9466-0b464f914135" xlink:to="loc_currency_CAD_05cb71cd-1454-4761-962b-739bbc0b7b29" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_GBP_fcd8fda4-0189-4307-8668-e25073610e8e" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_GBP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_29b741ca-4cbd-4eaf-9466-0b464f914135" xlink:to="loc_currency_GBP_fcd8fda4-0189-4307-8668-e25073610e8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_732c3832-3534-4491-823f-f0aec9a3887b" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_EUR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_29b741ca-4cbd-4eaf-9466-0b464f914135" xlink:to="loc_currency_EUR_732c3832-3534-4491-823f-f0aec9a3887b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_acd9c943-2b29-400b-851c-c38fb265126a" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_USD"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_29b741ca-4cbd-4eaf-9466-0b464f914135" xlink:to="loc_currency_USD_acd9c943-2b29-400b-851c-c38fb265126a" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://mckesson123.com/role/HedgingActivitiesSummaryofDerivativeInstrumentsGainLossDetails" xlink:type="simple" xlink:href="mck-20230630.xsd#HedgingActivitiesSummaryofDerivativeInstrumentsGainLossDetails"/>
  <link:definitionLink xlink:role="http://mckesson123.com/role/HedgingActivitiesSummaryofDerivativeInstrumentsGainLossDetails" xlink:type="extended" id="i44e575507f0c49739b3f895db5f4d7f5_HedgingActivitiesSummaryofDerivativeInstrumentsGainLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_6135cf7b-ba51-4b9c-a711-fefc980f59c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_1ece5e75-fd47-4e79-9d55-3f8a9b261e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_6135cf7b-ba51-4b9c-a711-fefc980f59c0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_1ece5e75-fd47-4e79-9d55-3f8a9b261e1d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_8d6ae25c-1ef7-4c64-b2d6-684511aabbbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_6135cf7b-ba51-4b9c-a711-fefc980f59c0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_8d6ae25c-1ef7-4c64-b2d6-684511aabbbe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_772acca8-f652-43e6-9831-f591861c3a55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_6135cf7b-ba51-4b9c-a711-fefc980f59c0" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_772acca8-f652-43e6-9831-f591861c3a55" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_ba83a274-f65f-4e89-865b-613bc4ac3c66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_772acca8-f652-43e6-9831-f591861c3a55" xlink:to="loc_us-gaap_HedgingDesignationAxis_ba83a274-f65f-4e89-865b-613bc4ac3c66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_ba83a274-f65f-4e89-865b-613bc4ac3c66_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_ba83a274-f65f-4e89-865b-613bc4ac3c66" xlink:to="loc_us-gaap_HedgingDesignationDomain_ba83a274-f65f-4e89-865b-613bc4ac3c66_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_4b38a29d-1b03-451c-907a-4b191f50d896" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_ba83a274-f65f-4e89-865b-613bc4ac3c66" xlink:to="loc_us-gaap_HedgingDesignationDomain_4b38a29d-1b03-451c-907a-4b191f50d896" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_2689efd2-bac1-4ae7-b5f8-c60ea2e5e0b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_4b38a29d-1b03-451c-907a-4b191f50d896" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_2689efd2-bac1-4ae7-b5f8-c60ea2e5e0b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_1fca947b-bfdd-4393-8c49-1c42a34f8fbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_772acca8-f652-43e6-9831-f591861c3a55" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_1fca947b-bfdd-4393-8c49-1c42a34f8fbe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_1fca947b-bfdd-4393-8c49-1c42a34f8fbe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_1fca947b-bfdd-4393-8c49-1c42a34f8fbe" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_1fca947b-bfdd-4393-8c49-1c42a34f8fbe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_c42fb77a-a67a-40f0-bc4f-199fce9ca145" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_1fca947b-bfdd-4393-8c49-1c42a34f8fbe" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_c42fb77a-a67a-40f0-bc4f-199fce9ca145" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_a3a03a86-92b5-4f7b-a82d-9151bad2f7a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrencySwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c42fb77a-a67a-40f0-bc4f-199fce9ca145" xlink:to="loc_us-gaap_CurrencySwapMember_a3a03a86-92b5-4f7b-a82d-9151bad2f7a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_FixedInterestRateSwapMember_37f0d97a-5182-4f2a-91bb-f65338cf34c6" xlink:href="mck-20230630.xsd#mck_FixedInterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c42fb77a-a67a-40f0-bc4f-199fce9ca145" xlink:to="loc_mck_FixedInterestRateSwapMember_37f0d97a-5182-4f2a-91bb-f65338cf34c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_258a87a4-7d5f-4e5b-965a-fb6e24604343" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_772acca8-f652-43e6-9831-f591861c3a55" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_258a87a4-7d5f-4e5b-965a-fb6e24604343" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_258a87a4-7d5f-4e5b-965a-fb6e24604343_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_258a87a4-7d5f-4e5b-965a-fb6e24604343" xlink:to="loc_us-gaap_HedgingRelationshipDomain_258a87a4-7d5f-4e5b-965a-fb6e24604343_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_af38c3fa-a193-4207-a9fa-b88d06e5709c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_258a87a4-7d5f-4e5b-965a-fb6e24604343" xlink:to="loc_us-gaap_HedgingRelationshipDomain_af38c3fa-a193-4207-a9fa-b88d06e5709c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_c37759b6-95b0-4545-9fc5-e0c803d04606" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_af38c3fa-a193-4207-a9fa-b88d06e5709c" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_c37759b6-95b0-4545-9fc5-e0c803d04606" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_3168858d-a901-4c34-99b8-7d089a344608" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_af38c3fa-a193-4207-a9fa-b88d06e5709c" xlink:to="loc_us-gaap_CashFlowHedgingMember_3168858d-a901-4c34-99b8-7d089a344608" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://mckesson123.com/role/HedgingActivitiesScheduleofFairValueofDerivativesDetails" xlink:type="simple" xlink:href="mck-20230630.xsd#HedgingActivitiesScheduleofFairValueofDerivativesDetails"/>
  <link:definitionLink xlink:role="http://mckesson123.com/role/HedgingActivitiesScheduleofFairValueofDerivativesDetails" xlink:type="extended" id="i64df5aa266744eac883ef08f0766dd24_HedgingActivitiesScheduleofFairValueofDerivativesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_257f796b-0fe3-41a4-b760-cec7f23f15e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_3fc34220-29f0-4f61-9d96-fc72d0e32459" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_257f796b-0fe3-41a4-b760-cec7f23f15e4" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_3fc34220-29f0-4f61-9d96-fc72d0e32459" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_83c740c8-77f8-4dc7-b74c-af71bd8e3028" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_257f796b-0fe3-41a4-b760-cec7f23f15e4" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_83c740c8-77f8-4dc7-b74c-af71bd8e3028" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotionalAmount_d82acad0-1dc5-46fe-97ed-f93b3093d6fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssetNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_257f796b-0fe3-41a4-b760-cec7f23f15e4" xlink:to="loc_us-gaap_DerivativeAssetNotionalAmount_d82acad0-1dc5-46fe-97ed-f93b3093d6fb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount_0076d011-49c6-4446-b036-b5fcfc46ef0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_257f796b-0fe3-41a4-b760-cec7f23f15e4" xlink:to="loc_us-gaap_DerivativeLiabilityNotionalAmount_0076d011-49c6-4446-b036-b5fcfc46ef0b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_2d9cb661-88ea-4ad7-b4e7-fe3279f4cb47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_257f796b-0fe3-41a4-b760-cec7f23f15e4" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_2d9cb661-88ea-4ad7-b4e7-fe3279f4cb47" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_11e96eb3-3d7d-4afb-adda-2820524c8cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_2d9cb661-88ea-4ad7-b4e7-fe3279f4cb47" xlink:to="loc_us-gaap_HedgingDesignationAxis_11e96eb3-3d7d-4afb-adda-2820524c8cd4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_11e96eb3-3d7d-4afb-adda-2820524c8cd4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_11e96eb3-3d7d-4afb-adda-2820524c8cd4" xlink:to="loc_us-gaap_HedgingDesignationDomain_11e96eb3-3d7d-4afb-adda-2820524c8cd4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_7aaf84a3-7922-4690-acbc-3c539bae5e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_11e96eb3-3d7d-4afb-adda-2820524c8cd4" xlink:to="loc_us-gaap_HedgingDesignationDomain_7aaf84a3-7922-4690-acbc-3c539bae5e4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_e2b5f91d-4aba-449c-a03e-2510f4e1be86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_7aaf84a3-7922-4690-acbc-3c539bae5e4e" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_e2b5f91d-4aba-449c-a03e-2510f4e1be86" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_fbb543fd-bd11-4173-9982-a8005d1d3c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_2d9cb661-88ea-4ad7-b4e7-fe3279f4cb47" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_fbb543fd-bd11-4173-9982-a8005d1d3c5f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_fbb543fd-bd11-4173-9982-a8005d1d3c5f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_fbb543fd-bd11-4173-9982-a8005d1d3c5f" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_fbb543fd-bd11-4173-9982-a8005d1d3c5f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_a169fd4f-6352-42a5-a1c9-f3692f36f71b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_fbb543fd-bd11-4173-9982-a8005d1d3c5f" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_a169fd4f-6352-42a5-a1c9-f3692f36f71b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_1396b44d-33c2-4367-bebd-23c75d27300b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrencySwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a169fd4f-6352-42a5-a1c9-f3692f36f71b" xlink:to="loc_us-gaap_CurrencySwapMember_1396b44d-33c2-4367-bebd-23c75d27300b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_5f8986ec-bba3-4b09-9f16-e827d536caf7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a169fd4f-6352-42a5-a1c9-f3692f36f71b" xlink:to="loc_us-gaap_InterestRateSwapMember_5f8986ec-bba3-4b09-9f16-e827d536caf7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_a7a916d4-a5bc-4a73-8148-f691a27530d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_2d9cb661-88ea-4ad7-b4e7-fe3279f4cb47" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_a7a916d4-a5bc-4a73-8148-f691a27530d1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_a7a916d4-a5bc-4a73-8148-f691a27530d1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_a7a916d4-a5bc-4a73-8148-f691a27530d1" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_a7a916d4-a5bc-4a73-8148-f691a27530d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_05e56937-9e66-4c25-a411-bfd5683f7fef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_a7a916d4-a5bc-4a73-8148-f691a27530d1" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_05e56937-9e66-4c25-a411-bfd5683f7fef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_CurrentAssetLiabilityMember_d4466767-97d5-4f13-8526-fe87df7cad47" xlink:href="mck-20230630.xsd#mck_CurrentAssetLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_05e56937-9e66-4c25-a411-bfd5683f7fef" xlink:to="loc_mck_CurrentAssetLiabilityMember_d4466767-97d5-4f13-8526-fe87df7cad47" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_OtherNonCurrentAssetsAndLiabilitiesMember_c540bbbe-58ea-4305-be54-12e35d0c3aba" xlink:href="mck-20230630.xsd#mck_OtherNonCurrentAssetsAndLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_05e56937-9e66-4c25-a411-bfd5683f7fef" xlink:to="loc_mck_OtherNonCurrentAssetsAndLiabilitiesMember_c540bbbe-58ea-4305-be54-12e35d0c3aba" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://mckesson123.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="mck-20230630.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://mckesson123.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended" id="i6bb94fa8ccce4996878df8715cb32250_FairValueMeasurementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4884b158-e3a9-42e2-901b-39f13da509a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsAtCarryingValue_94813740-4883-4ad3-b035-904c95190549" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4884b158-e3a9-42e2-901b-39f13da509a4" xlink:to="loc_us-gaap_MoneyMarketFundsAtCarryingValue_94813740-4883-4ad3-b035-904c95190549" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_3c3794e4-dee2-4b15-891f-9878203b3561" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4884b158-e3a9-42e2-901b-39f13da509a4" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_3c3794e4-dee2-4b15-891f-9878203b3561" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b4eba24b-9895-4756-86e4-61ead69af756" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4884b158-e3a9-42e2-901b-39f13da509a4" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b4eba24b-9895-4756-86e4-61ead69af756" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_37824473-8221-4c87-b10c-adfaa37e973d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b4eba24b-9895-4756-86e4-61ead69af756" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_37824473-8221-4c87-b10c-adfaa37e973d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_37824473-8221-4c87-b10c-adfaa37e973d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_37824473-8221-4c87-b10c-adfaa37e973d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_37824473-8221-4c87-b10c-adfaa37e973d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7a344130-380c-4a20-af29-6e4c9b6ea9bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_37824473-8221-4c87-b10c-adfaa37e973d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7a344130-380c-4a20-af29-6e4c9b6ea9bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_8d38e70c-7b5b-4942-b99d-dc0176239af2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7a344130-380c-4a20-af29-6e4c9b6ea9bb" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_8d38e70c-7b5b-4942-b99d-dc0176239af2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_edab4d79-e258-4cdf-825d-70e8f16f640b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b4eba24b-9895-4756-86e4-61ead69af756" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_edab4d79-e258-4cdf-825d-70e8f16f640b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_edab4d79-e258-4cdf-825d-70e8f16f640b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_edab4d79-e258-4cdf-825d-70e8f16f640b" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_edab4d79-e258-4cdf-825d-70e8f16f640b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c8f98892-66b5-4cb6-bd49-d2c2491d2a08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_edab4d79-e258-4cdf-825d-70e8f16f640b" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c8f98892-66b5-4cb6-bd49-d2c2491d2a08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_84693f1a-bd9a-48c1-93b1-d905288b52e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_c8f98892-66b5-4cb6-bd49-d2c2491d2a08" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_84693f1a-bd9a-48c1-93b1-d905288b52e9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://mckesson123.com/role/FairValueMeasurementsScheduleofLongTermDebtisRecordedatAmortizedCostDetails" xlink:type="simple" xlink:href="mck-20230630.xsd#FairValueMeasurementsScheduleofLongTermDebtisRecordedatAmortizedCostDetails"/>
  <link:definitionLink xlink:role="http://mckesson123.com/role/FairValueMeasurementsScheduleofLongTermDebtisRecordedatAmortizedCostDetails" xlink:type="extended" id="iee1706b53a6241aeb908ad3fade42cf7_FairValueMeasurementsScheduleofLongTermDebtisRecordedatAmortizedCostDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_180d81c7-f9e8-444d-8db9-d8a0e025660f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_f872d1ae-4eb5-4a7c-bd65-e6cbaeb7f870" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_180d81c7-f9e8-444d-8db9-d8a0e025660f" xlink:to="loc_us-gaap_LongTermDebt_f872d1ae-4eb5-4a7c-bd65-e6cbaeb7f870" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_23c02c83-8c36-422b-a1a6-fb0712624c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_180d81c7-f9e8-444d-8db9-d8a0e025660f" xlink:to="loc_us-gaap_DebtInstrumentFairValue_23c02c83-8c36-422b-a1a6-fb0712624c1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e39e6d13-50cc-472d-bdce-b48b8c910f6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_180d81c7-f9e8-444d-8db9-d8a0e025660f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e39e6d13-50cc-472d-bdce-b48b8c910f6f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0725d644-b6ec-40a4-b5f3-bb8596f4011a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e39e6d13-50cc-472d-bdce-b48b8c910f6f" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0725d644-b6ec-40a4-b5f3-bb8596f4011a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_0725d644-b6ec-40a4-b5f3-bb8596f4011a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0725d644-b6ec-40a4-b5f3-bb8596f4011a" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_0725d644-b6ec-40a4-b5f3-bb8596f4011a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_9d9782da-89d0-4736-8d11-0988004d8f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0725d644-b6ec-40a4-b5f3-bb8596f4011a" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_9d9782da-89d0-4736-8d11-0988004d8f6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_f38c616b-9b95-4449-afc5-e2cbc451290f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_9d9782da-89d0-4736-8d11-0988004d8f6e" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_f38c616b-9b95-4449-afc5-e2cbc451290f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cb49853f-a153-4c85-99a8-466d67cf9032" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e39e6d13-50cc-472d-bdce-b48b8c910f6f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cb49853f-a153-4c85-99a8-466d67cf9032" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cb49853f-a153-4c85-99a8-466d67cf9032_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cb49853f-a153-4c85-99a8-466d67cf9032" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cb49853f-a153-4c85-99a8-466d67cf9032_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5d003734-0e9e-41a3-b199-25c8fae7ac7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cb49853f-a153-4c85-99a8-466d67cf9032" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5d003734-0e9e-41a3-b199-25c8fae7ac7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_af2b31ad-4a5d-4d2f-9b78-7e2c3d7bdfdd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5d003734-0e9e-41a3-b199-25c8fae7ac7a" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_af2b31ad-4a5d-4d2f-9b78-7e2c3d7bdfdd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails" xlink:type="simple" xlink:href="mck-20230630.xsd#CommitmentsandContingentLiabilitiesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails" xlink:type="extended" id="if15f4eaad4194d578d845fc8f900d2ff_CommitmentsandContingentLiabilitiesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_991edb6b-0961-4668-ab33-c600a9fadfa4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_LossContingencyNumberOfOtherDefendants_193cecbc-4acd-466b-a2ee-fc86d5b0a4f9" xlink:href="mck-20230630.xsd#mck_LossContingencyNumberOfOtherDefendants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_991edb6b-0961-4668-ab33-c600a9fadfa4" xlink:to="loc_mck_LossContingencyNumberOfOtherDefendants_193cecbc-4acd-466b-a2ee-fc86d5b0a4f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_LossContingencyNumberofStates_d043ad8b-c208-4243-b08c-3ae2992b0732" xlink:href="mck-20230630.xsd#mck_LossContingencyNumberofStates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_991edb6b-0961-4668-ab33-c600a9fadfa4" xlink:to="loc_mck_LossContingencyNumberofStates_d043ad8b-c208-4243-b08c-3ae2992b0732" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_LossContingencyNumberOfCasesDismissed_4ece62cf-0f09-40eb-9773-2c7595ae0047" xlink:href="mck-20230630.xsd#mck_LossContingencyNumberOfCasesDismissed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_991edb6b-0961-4668-ab33-c600a9fadfa4" xlink:to="loc_mck_LossContingencyNumberOfCasesDismissed_4ece62cf-0f09-40eb-9773-2c7595ae0047" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_03137444-8faf-4fa9-813f-95331c52b10c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_991edb6b-0961-4668-ab33-c600a9fadfa4" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_03137444-8faf-4fa9-813f-95331c52b10c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_a98a9fbd-3d27-4546-bac6-91cc5fd52d0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_991edb6b-0961-4668-ab33-c600a9fadfa4" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_a98a9fbd-3d27-4546-bac6-91cc5fd52d0c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_LitigationSettlementAwardAmountToBeUsedByStateAndLocalGovernment_a5188fcb-e890-4ac2-b045-23c1805fade5" xlink:href="mck-20230630.xsd#mck_LitigationSettlementAwardAmountToBeUsedByStateAndLocalGovernment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_991edb6b-0961-4668-ab33-c600a9fadfa4" xlink:to="loc_mck_LitigationSettlementAwardAmountToBeUsedByStateAndLocalGovernment_a5188fcb-e890-4ac2-b045-23c1805fade5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_LossContingencyClaimsSettledNumberOfJurisdictionsNotParticipatingInSettlement_fae65a6f-162b-4016-8466-2574a708399d" xlink:href="mck-20230630.xsd#mck_LossContingencyClaimsSettledNumberOfJurisdictionsNotParticipatingInSettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_991edb6b-0961-4668-ab33-c600a9fadfa4" xlink:to="loc_mck_LossContingencyClaimsSettledNumberOfJurisdictionsNotParticipatingInSettlement_fae65a6f-162b-4016-8466-2574a708399d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_LitigationSettlementAmountAwardedToOtherPartyPercentageOfTotalSettlementToBeUsedToRemediateDamages_9bab7eb8-cd6f-4fa3-af26-09c106eadb27" xlink:href="mck-20230630.xsd#mck_LitigationSettlementAmountAwardedToOtherPartyPercentageOfTotalSettlementToBeUsedToRemediateDamages"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_991edb6b-0961-4668-ab33-c600a9fadfa4" xlink:to="loc_mck_LitigationSettlementAmountAwardedToOtherPartyPercentageOfTotalSettlementToBeUsedToRemediateDamages_9bab7eb8-cd6f-4fa3-af26-09c106eadb27" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_2f391dba-2f7b-4b89-a679-f8cd9434e135" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_991edb6b-0961-4668-ab33-c600a9fadfa4" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_2f391dba-2f7b-4b89-a679-f8cd9434e135" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_LossContingencyNumberOfFormerOfficers_f706d433-d003-4052-a3bb-e8622e7ce67b" xlink:href="mck-20230630.xsd#mck_LossContingencyNumberOfFormerOfficers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_991edb6b-0961-4668-ab33-c600a9fadfa4" xlink:to="loc_mck_LossContingencyNumberOfFormerOfficers_f706d433-d003-4052-a3bb-e8622e7ce67b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_da728a5a-ce9c-44e0-ad91-060b22091d3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_991edb6b-0961-4668-ab33-c600a9fadfa4" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_da728a5a-ce9c-44e0-ad91-060b22091d3a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimatedInsuranceRecoveries_5e7380e9-9fd6-4dc2-887a-109a5f894aea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EstimatedInsuranceRecoveries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_991edb6b-0961-4668-ab33-c600a9fadfa4" xlink:to="loc_us-gaap_EstimatedInsuranceRecoveries_5e7380e9-9fd6-4dc2-887a-109a5f894aea" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_LossContingencyNumberOfStatesFiledOnBehalfOf_6067ffa8-92c9-4907-b330-c2bd2dc5257c" xlink:href="mck-20230630.xsd#mck_LossContingencyNumberOfStatesFiledOnBehalfOf"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_991edb6b-0961-4668-ab33-c600a9fadfa4" xlink:to="loc_mck_LossContingencyNumberOfStatesFiledOnBehalfOf_6067ffa8-92c9-4907-b330-c2bd2dc5257c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_a33f83c2-689d-4d66-884f-5244ce9176fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_991edb6b-0961-4668-ab33-c600a9fadfa4" xlink:to="loc_us-gaap_LossContingenciesTable_a33f83c2-689d-4d66-884f-5244ce9176fb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_3348f3a2-351d-44d7-8843-055f98c7f993" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_a33f83c2-689d-4d66-884f-5244ce9176fb" xlink:to="loc_srt_LitigationCaseAxis_3348f3a2-351d-44d7-8843-055f98c7f993" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_3348f3a2-351d-44d7-8843-055f98c7f993_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_3348f3a2-351d-44d7-8843-055f98c7f993" xlink:to="loc_srt_LitigationCaseTypeDomain_3348f3a2-351d-44d7-8843-055f98c7f993_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_68df0dbc-d94e-4180-b137-caf8950223b5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_3348f3a2-351d-44d7-8843-055f98c7f993" xlink:to="loc_srt_LitigationCaseTypeDomain_68df0dbc-d94e-4180-b137-caf8950223b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_NationalPrescriptionOpiateLitigationMember_034b3ff7-2f27-47b6-8311-91e2ec84122d" xlink:href="mck-20230630.xsd#mck_NationalPrescriptionOpiateLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_68df0dbc-d94e-4180-b137-caf8950223b5" xlink:to="loc_mck_NationalPrescriptionOpiateLitigationMember_034b3ff7-2f27-47b6-8311-91e2ec84122d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_EvanstonPolicePensionFundVMcKessonCorporationMember_1b54e41a-c937-4c95-bcf2-2062231c823b" xlink:href="mck-20230630.xsd#mck_EvanstonPolicePensionFundVMcKessonCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_68df0dbc-d94e-4180-b137-caf8950223b5" xlink:to="loc_mck_EvanstonPolicePensionFundVMcKessonCorporationMember_1b54e41a-c937-4c95-bcf2-2062231c823b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_UnitedStatesExRelHartVMcKessonCorporationEtAl15CV00903RAMember_d60354cc-73f6-49c3-8c4a-9b19a86f7671" xlink:href="mck-20230630.xsd#mck_UnitedStatesExRelHartVMcKessonCorporationEtAl15CV00903RAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_68df0dbc-d94e-4180-b137-caf8950223b5" xlink:to="loc_mck_UnitedStatesExRelHartVMcKessonCorporationEtAl15CV00903RAMember_d60354cc-73f6-49c3-8c4a-9b19a86f7671" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_8f3b1b7a-0652-4f07-9bc6-c21155fe135c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_a33f83c2-689d-4d66-884f-5244ce9176fb" xlink:to="loc_us-gaap_LitigationStatusAxis_8f3b1b7a-0652-4f07-9bc6-c21155fe135c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_8f3b1b7a-0652-4f07-9bc6-c21155fe135c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_8f3b1b7a-0652-4f07-9bc6-c21155fe135c" xlink:to="loc_us-gaap_LitigationStatusDomain_8f3b1b7a-0652-4f07-9bc6-c21155fe135c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_24fc43ff-4a29-49bc-a93a-9fcdbede8517" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_8f3b1b7a-0652-4f07-9bc6-c21155fe135c" xlink:to="loc_us-gaap_LitigationStatusDomain_24fc43ff-4a29-49bc-a93a-9fcdbede8517" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_431cda4e-8761-4abc-a894-d9f6333bb2d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SettledLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_24fc43ff-4a29-49bc-a93a-9fcdbede8517" xlink:to="loc_us-gaap_SettledLitigationMember_431cda4e-8761-4abc-a894-d9f6333bb2d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_50b786de-08c3-4985-805b-f9eae4c5c13f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_a33f83c2-689d-4d66-884f-5244ce9176fb" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_50b786de-08c3-4985-805b-f9eae4c5c13f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_50b786de-08c3-4985-805b-f9eae4c5c13f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_50b786de-08c3-4985-805b-f9eae4c5c13f" xlink:to="loc_us-gaap_LossContingencyNatureDomain_50b786de-08c3-4985-805b-f9eae4c5c13f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_13aefa4f-58fd-4fe7-a7ab-e2cb5f897457" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_50b786de-08c3-4985-805b-f9eae4c5c13f" xlink:to="loc_us-gaap_LossContingencyNatureDomain_13aefa4f-58fd-4fe7-a7ab-e2cb5f897457" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_NationalPrescriptionOpiateLitigationMember_1419e56d-5030-47dc-8080-8fe07769561a" xlink:href="mck-20230630.xsd#mck_NationalPrescriptionOpiateLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_13aefa4f-58fd-4fe7-a7ab-e2cb5f897457" xlink:to="loc_mck_NationalPrescriptionOpiateLitigationMember_1419e56d-5030-47dc-8080-8fe07769561a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_6f519cbb-2447-4b43-a5ad-d880088c0784" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_a33f83c2-689d-4d66-884f-5244ce9176fb" xlink:to="loc_dei_LegalEntityAxis_6f519cbb-2447-4b43-a5ad-d880088c0784" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_6f519cbb-2447-4b43-a5ad-d880088c0784_default" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_6f519cbb-2447-4b43-a5ad-d880088c0784" xlink:to="loc_dei_EntityDomain_6f519cbb-2447-4b43-a5ad-d880088c0784_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_76272841-7c7d-410f-9ca0-71b495f42996" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_6f519cbb-2447-4b43-a5ad-d880088c0784" xlink:to="loc_dei_EntityDomain_76272841-7c7d-410f-9ca0-71b495f42996" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_ThreeLargestUSPharmaceuticalDistributorsMember_236a40bc-f33c-4f9b-8c7f-71d18fc2116c" xlink:href="mck-20230630.xsd#mck_ThreeLargestUSPharmaceuticalDistributorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_76272841-7c7d-410f-9ca0-71b495f42996" xlink:to="loc_mck_ThreeLargestUSPharmaceuticalDistributorsMember_236a40bc-f33c-4f9b-8c7f-71d18fc2116c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_ThreeNationalPharmaceuticalDistributorsMember_5de5b434-843a-43b0-a228-9ce5e729ef0c" xlink:href="mck-20230630.xsd#mck_ThreeNationalPharmaceuticalDistributorsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_76272841-7c7d-410f-9ca0-71b495f42996" xlink:to="loc_mck_ThreeNationalPharmaceuticalDistributorsMember_5de5b434-843a-43b0-a228-9ce5e729ef0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_68306fed-a653-42a5-90e5-b89824d61395" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_a33f83c2-689d-4d66-884f-5244ce9176fb" xlink:to="loc_srt_CounterpartyNameAxis_68306fed-a653-42a5-90e5-b89824d61395" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_68306fed-a653-42a5-90e5-b89824d61395_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_68306fed-a653-42a5-90e5-b89824d61395" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_68306fed-a653-42a5-90e5-b89824d61395_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6e4804be-f8e1-4eca-9f82-be4897e61a6f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_68306fed-a653-42a5-90e5-b89824d61395" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6e4804be-f8e1-4eca-9f82-be4897e61a6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_StateOfAlabamaAndSubdivisionsMember_133ba27f-e18e-4bb8-a221-9d86bcb10365" xlink:href="mck-20230630.xsd#mck_StateOfAlabamaAndSubdivisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6e4804be-f8e1-4eca-9f82-be4897e61a6f" xlink:to="loc_mck_StateOfAlabamaAndSubdivisionsMember_133ba27f-e18e-4bb8-a221-9d86bcb10365" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_StateOfWestVirginiaAndSubdivisionsMember_fe83032b-3797-4cb4-85c8-dc3fab7b052e" xlink:href="mck-20230630.xsd#mck_StateOfWestVirginiaAndSubdivisionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6e4804be-f8e1-4eca-9f82-be4897e61a6f" xlink:to="loc_mck_StateOfWestVirginiaAndSubdivisionsMember_fe83032b-3797-4cb4-85c8-dc3fab7b052e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_CherokeeNationMember_612ff305-d6dc-4dbe-b686-f8c095b66369" xlink:href="mck-20230630.xsd#mck_CherokeeNationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6e4804be-f8e1-4eca-9f82-be4897e61a6f" xlink:to="loc_mck_CherokeeNationMember_612ff305-d6dc-4dbe-b686-f8c095b66369" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_NativeAmericanTribesOtherThanCherokeeNationMember_bd661fcc-9cbc-49fc-adef-e08c14f9be5e" xlink:href="mck-20230630.xsd#mck_NativeAmericanTribesOtherThanCherokeeNationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6e4804be-f8e1-4eca-9f82-be4897e61a6f" xlink:to="loc_mck_NativeAmericanTribesOtherThanCherokeeNationMember_bd661fcc-9cbc-49fc-adef-e08c14f9be5e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_IndividualClaimantMember_078cd4aa-559c-4949-83b0-e90eec5a56c9" xlink:href="mck-20230630.xsd#mck_IndividualClaimantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6e4804be-f8e1-4eca-9f82-be4897e61a6f" xlink:to="loc_mck_IndividualClaimantMember_078cd4aa-559c-4949-83b0-e90eec5a56c9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_d6b2ba9d-5e9e-41ab-87af-605d4c541100" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_a33f83c2-689d-4d66-884f-5244ce9176fb" xlink:to="loc_srt_StatementGeographicalAxis_d6b2ba9d-5e9e-41ab-87af-605d4c541100" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_d6b2ba9d-5e9e-41ab-87af-605d4c541100_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_d6b2ba9d-5e9e-41ab-87af-605d4c541100" xlink:to="loc_srt_SegmentGeographicalDomain_d6b2ba9d-5e9e-41ab-87af-605d4c541100_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_668398ce-6cc2-4062-8ed9-135a86824fd1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_d6b2ba9d-5e9e-41ab-87af-605d4c541100" xlink:to="loc_srt_SegmentGeographicalDomain_668398ce-6cc2-4062-8ed9-135a86824fd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_66871984-ec2e-423a-9fa9-a9bc7fc0cec7" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_668398ce-6cc2-4062-8ed9-135a86824fd1" xlink:to="loc_country_US_66871984-ec2e-423a-9fa9-a9bc7fc0cec7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_c26a3b7a-ddf5-4609-8d73-6efe3e62f825" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_668398ce-6cc2-4062-8ed9-135a86824fd1" xlink:to="loc_country_CA_c26a3b7a-ddf5-4609-8d73-6efe3e62f825" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_817d1bd4-bea6-4700-b198-9c5306ec7b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_a33f83c2-689d-4d66-884f-5244ce9176fb" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_817d1bd4-bea6-4700-b198-9c5306ec7b2d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_817d1bd4-bea6-4700-b198-9c5306ec7b2d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_817d1bd4-bea6-4700-b198-9c5306ec7b2d" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_817d1bd4-bea6-4700-b198-9c5306ec7b2d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_d3e28a2f-fb76-41de-91a7-1a011e8a272c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_817d1bd4-bea6-4700-b198-9c5306ec7b2d" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_d3e28a2f-fb76-41de-91a7-1a011e8a272c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_d0532860-478c-44cb-994b-e07530f1f832" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_d3e28a2f-fb76-41de-91a7-1a011e8a272c" xlink:to="loc_us-gaap_SubsequentEventMember_d0532860-478c-44cb-994b-e07530f1f832" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://mckesson123.com/role/CommitmentsandContingentLiabilitiesEstimatedAccrualLiabilityDetails" xlink:type="simple" xlink:href="mck-20230630.xsd#CommitmentsandContingentLiabilitiesEstimatedAccrualLiabilityDetails"/>
  <link:definitionLink xlink:role="http://mckesson123.com/role/CommitmentsandContingentLiabilitiesEstimatedAccrualLiabilityDetails" xlink:type="extended" id="i038e97ce2adb418a926b43b879ce5fd4_CommitmentsandContingentLiabilitiesEstimatedAccrualLiabilityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_8569ce76-2f56-4017-a527-695cf7a94265" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValueCurrent_2f2fea30-8141-4944-9405-2aa375db2cb3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualCarryingValueCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_8569ce76-2f56-4017-a527-695cf7a94265" xlink:to="loc_us-gaap_LossContingencyAccrualCarryingValueCurrent_2f2fea30-8141-4944-9405-2aa375db2cb3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValueNoncurrent_78cf0d21-52e4-4a2f-b26b-2af81891be7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualCarryingValueNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_8569ce76-2f56-4017-a527-695cf7a94265" xlink:to="loc_us-gaap_LossContingencyAccrualCarryingValueNoncurrent_78cf0d21-52e4-4a2f-b26b-2af81891be7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_22bb74af-4318-481a-9c44-7bc59c0f0e52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_8569ce76-2f56-4017-a527-695cf7a94265" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_22bb74af-4318-481a-9c44-7bc59c0f0e52" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_fec3f692-5ab2-45ec-b642-452ace52c953" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_8569ce76-2f56-4017-a527-695cf7a94265" xlink:to="loc_us-gaap_LossContingenciesTable_fec3f692-5ab2-45ec-b642-452ace52c953" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_e848dd37-4988-4e42-883f-2f2ff81d7e16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_fec3f692-5ab2-45ec-b642-452ace52c953" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_e848dd37-4988-4e42-883f-2f2ff81d7e16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_e848dd37-4988-4e42-883f-2f2ff81d7e16_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_e848dd37-4988-4e42-883f-2f2ff81d7e16" xlink:to="loc_us-gaap_LossContingencyNatureDomain_e848dd37-4988-4e42-883f-2f2ff81d7e16_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_b33742a5-6cf4-4e94-82cd-6a734827eadf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_e848dd37-4988-4e42-883f-2f2ff81d7e16" xlink:to="loc_us-gaap_LossContingencyNatureDomain_b33742a5-6cf4-4e94-82cd-6a734827eadf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_NationalPrescriptionOpiateLitigationMember_db4a78f0-b327-4ae6-8de8-9c6646f684d3" xlink:href="mck-20230630.xsd#mck_NationalPrescriptionOpiateLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_b33742a5-6cf4-4e94-82cd-6a734827eadf" xlink:to="loc_mck_NationalPrescriptionOpiateLitigationMember_db4a78f0-b327-4ae6-8de8-9c6646f684d3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://mckesson123.com/role/StockholdersDeficitNarrativeDetails" xlink:type="simple" xlink:href="mck-20230630.xsd#StockholdersDeficitNarrativeDetails"/>
  <link:definitionLink xlink:role="http://mckesson123.com/role/StockholdersDeficitNarrativeDetails" xlink:type="extended" id="i83ee091f8f27490a9eb831f0f7eb1df2_StockholdersDeficitNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesLineItems_ef44a0c3-08ea-46a0-86e1-93735a31e572" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcceleratedShareRepurchasesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_CommonStockVotingRightsNumberofVotesPerCommonShare_56110609-df88-4988-9841-eb28214c5faa" xlink:href="mck-20230630.xsd#mck_CommonStockVotingRightsNumberofVotesPerCommonShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesLineItems_ef44a0c3-08ea-46a0-86e1-93735a31e572" xlink:to="loc_mck_CommonStockVotingRightsNumberofVotesPerCommonShare_56110609-df88-4988-9841-eb28214c5faa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_53795286-9560-4608-81f3-b27e6a58d815" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesLineItems_ef44a0c3-08ea-46a0-86e1-93735a31e572" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_53795286-9560-4608-81f3-b27e6a58d815" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_b94cf247-7e04-4581-94ab-38ffe8e9e5ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesLineItems_ef44a0c3-08ea-46a0-86e1-93735a31e572" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_b94cf247-7e04-4581-94ab-38ffe8e9e5ab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_b423f669-0572-4734-bfef-611948f34a39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesLineItems_ef44a0c3-08ea-46a0-86e1-93735a31e572" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_b423f669-0572-4734-bfef-611948f34a39" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_c9e229ed-4bd0-4f7b-967b-3529e48c50ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesLineItems_ef44a0c3-08ea-46a0-86e1-93735a31e572" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_c9e229ed-4bd0-4f7b-967b-3529e48c50ee" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_4807c376-2c43-4f42-a15c-786336f63e4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesLineItems_ef44a0c3-08ea-46a0-86e1-93735a31e572" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_4807c376-2c43-4f42-a15c-786336f63e4f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredParValueMethod_a6ddcd2b-ede4-4654-8476-4506a7697920" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAcquiredParValueMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesLineItems_ef44a0c3-08ea-46a0-86e1-93735a31e572" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredParValueMethod_a6ddcd2b-ede4-4654-8476-4506a7697920" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_ExciseTaxPayableCurrent_a643df8f-850a-4c26-b31b-2989876578fe" xlink:href="mck-20230630.xsd#mck_ExciseTaxPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesLineItems_ef44a0c3-08ea-46a0-86e1-93735a31e572" xlink:to="loc_mck_ExciseTaxPayableCurrent_a643df8f-850a-4c26-b31b-2989876578fe" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_e39e8dd9-3576-4969-a610-59e8a179f5d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesLineItems_ef44a0c3-08ea-46a0-86e1-93735a31e572" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_e39e8dd9-3576-4969-a610-59e8a179f5d5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_8378b781-1828-463a-9591-0039b7b4e6e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesLineItems_ef44a0c3-08ea-46a0-86e1-93735a31e572" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_8378b781-1828-463a-9591-0039b7b4e6e5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_a8c1bcdd-c496-4fa4-be1b-292a546edf5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesLineItems_ef44a0c3-08ea-46a0-86e1-93735a31e572" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_a8c1bcdd-c496-4fa4-be1b-292a546edf5f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesTable_7974957c-75c1-4993-947a-e5e0f3e55d70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcceleratedShareRepurchasesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesLineItems_ef44a0c3-08ea-46a0-86e1-93735a31e572" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesTable_7974957c-75c1-4993-947a-e5e0f3e55d70" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_9f788e08-078b-4f40-90de-408547a807ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesTable_7974957c-75c1-4993-947a-e5e0f3e55d70" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_9f788e08-078b-4f40-90de-408547a807ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_9f788e08-078b-4f40-90de-408547a807ee_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_9f788e08-078b-4f40-90de-408547a807ee" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_9f788e08-078b-4f40-90de-408547a807ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_c2c0b895-2c07-4541-8015-d04d76e84a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_9f788e08-078b-4f40-90de-408547a807ee" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_c2c0b895-2c07-4541-8015-d04d76e84a3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_AcceleratedShareRepurchaseMember_a98154d2-cc74-4d10-a813-eb406bd31b30" xlink:href="mck-20230630.xsd#mck_AcceleratedShareRepurchaseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_c2c0b895-2c07-4541-8015-d04d76e84a3a" xlink:to="loc_mck_AcceleratedShareRepurchaseMember_a98154d2-cc74-4d10-a813-eb406bd31b30" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_AcceleratedShareRepurchaseInitialShareSettlementMember_8c60fce1-ef74-4f1d-a4cf-f65daf7d8ded" xlink:href="mck-20230630.xsd#mck_AcceleratedShareRepurchaseInitialShareSettlementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mck_AcceleratedShareRepurchaseMember_a98154d2-cc74-4d10-a813-eb406bd31b30" xlink:to="loc_mck_AcceleratedShareRepurchaseInitialShareSettlementMember_8c60fce1-ef74-4f1d-a4cf-f65daf7d8ded" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_AcceleratedShareRepurchaseCompletionOfProgramMember_5f87a23b-f1be-4e06-9bba-787ecd422172" xlink:href="mck-20230630.xsd#mck_AcceleratedShareRepurchaseCompletionOfProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mck_AcceleratedShareRepurchaseMember_a98154d2-cc74-4d10-a813-eb406bd31b30" xlink:to="loc_mck_AcceleratedShareRepurchaseCompletionOfProgramMember_5f87a23b-f1be-4e06-9bba-787ecd422172" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_OpenMarketShareRepurchaseTransactionsMember_33375127-0d04-48d6-bf70-062abfddd105" xlink:href="mck-20230630.xsd#mck_OpenMarketShareRepurchaseTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_c2c0b895-2c07-4541-8015-d04d76e84a3a" xlink:to="loc_mck_OpenMarketShareRepurchaseTransactionsMember_33375127-0d04-48d6-bf70-062abfddd105" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_339fbab1-a1b2-49b5-9fe8-efd42042616e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesTable_7974957c-75c1-4993-947a-e5e0f3e55d70" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_339fbab1-a1b2-49b5-9fe8-efd42042616e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_339fbab1-a1b2-49b5-9fe8-efd42042616e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_339fbab1-a1b2-49b5-9fe8-efd42042616e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_339fbab1-a1b2-49b5-9fe8-efd42042616e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_e3ade680-4b5b-4070-acea-80cbfafda5b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_339fbab1-a1b2-49b5-9fe8-efd42042616e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_e3ade680-4b5b-4070-acea-80cbfafda5b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_e9482d96-27f0-474a-92ca-5022a18df201" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_e3ade680-4b5b-4070-acea-80cbfafda5b1" xlink:to="loc_us-gaap_SubsequentEventMember_e9482d96-27f0-474a-92ca-5022a18df201" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails" xlink:type="simple" xlink:href="mck-20230630.xsd#StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails"/>
  <link:definitionLink xlink:role="http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails" xlink:type="extended" id="id11e3a9986364a0cbe0772fd62c1f451_StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_64e83798-22b7-4b4d-8820-4281ba63b248" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_6607ab71-da1d-4c22-abba-fa698a79853a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_64e83798-22b7-4b4d-8820-4281ba63b248" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_6607ab71-da1d-4c22-abba-fa698a79853a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0bc9e3b4-b69d-4d42-bc7d-b04435a8b11f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_6607ab71-da1d-4c22-abba-fa698a79853a" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0bc9e3b4-b69d-4d42-bc7d-b04435a8b11f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_bd240e14-83f6-41e3-87c9-630dc32eb6ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_6607ab71-da1d-4c22-abba-fa698a79853a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_bd240e14-83f6-41e3-87c9-630dc32eb6ab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_1c2ab531-a20a-4991-a54e-89afed069105" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_6607ab71-da1d-4c22-abba-fa698a79853a" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_1c2ab531-a20a-4991-a54e-89afed069105" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_dac6a117-f646-48c6-80f8-4f4f97dc3e80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_6607ab71-da1d-4c22-abba-fa698a79853a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_dac6a117-f646-48c6-80f8-4f4f97dc3e80" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_6185e5ab-e498-43c1-a13a-cc556db6e472" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_6607ab71-da1d-4c22-abba-fa698a79853a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_6185e5ab-e498-43c1-a13a-cc556db6e472" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_f6c251b0-23ff-4337-b812-8f317632a868" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_6607ab71-da1d-4c22-abba-fa698a79853a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_f6c251b0-23ff-4337-b812-8f317632a868" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_34df82c5-920c-44c8-93e6-c3005b024f26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_dab29118-9653-4693-a27d-c33ea19a841f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_64e83798-22b7-4b4d-8820-4281ba63b248" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_dab29118-9653-4693-a27d-c33ea19a841f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_e381a575-b761-4726-b070-12ad360d2399" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_64e83798-22b7-4b4d-8820-4281ba63b248" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_e381a575-b761-4726-b070-12ad360d2399" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_0c0363c4-4cc1-4847-b065-e6647656ff26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_64e83798-22b7-4b4d-8820-4281ba63b248" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_0c0363c4-4cc1-4847-b065-e6647656ff26" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_572f3fd3-55d5-4895-b0ca-2c6f4521d782" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_64e83798-22b7-4b4d-8820-4281ba63b248" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_572f3fd3-55d5-4895-b0ca-2c6f4521d782" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e7e43669-c2be-45d0-be0e-55e3bdc26a02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_572f3fd3-55d5-4895-b0ca-2c6f4521d782" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e7e43669-c2be-45d0-be0e-55e3bdc26a02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e7e43669-c2be-45d0-be0e-55e3bdc26a02_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e7e43669-c2be-45d0-be0e-55e3bdc26a02" xlink:to="loc_us-gaap_EquityComponentDomain_e7e43669-c2be-45d0-be0e-55e3bdc26a02_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4e9092b4-71d8-4b22-8e3f-24a4513c4184" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e7e43669-c2be-45d0-be0e-55e3bdc26a02" xlink:to="loc_us-gaap_EquityComponentDomain_4e9092b4-71d8-4b22-8e3f-24a4513c4184" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_01385bd6-7137-4346-864e-c5159c2c80e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4e9092b4-71d8-4b22-8e3f-24a4513c4184" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_01385bd6-7137-4346-864e-c5159c2c80e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_d42a94b8-2578-4aa5-b504-83674f5ca011" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_01385bd6-7137-4346-864e-c5159c2c80e0" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_d42a94b8-2578-4aa5-b504-83674f5ca011" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember_ff892499-5f7d-4338-9216-899f404a5cb9" xlink:href="mck-20230630.xsd#mck_AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_01385bd6-7137-4346-864e-c5159c2c80e0" xlink:to="loc_mck_AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember_ff892499-5f7d-4338-9216-899f404a5cb9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_c147bb1e-47d3-418f-b3e7-b96756dc59dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_01385bd6-7137-4346-864e-c5159c2c80e0" xlink:to="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_c147bb1e-47d3-418f-b3e7-b96756dc59dd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember_ec586865-364d-45aa-b9f4-b35f009a591f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_01385bd6-7137-4346-864e-c5159c2c80e0" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember_ec586865-364d-45aa-b9f4-b35f009a591f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_bc8a9094-009c-46e3-9299-a6dd372ef818" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_572f3fd3-55d5-4895-b0ca-2c6f4521d782" xlink:to="loc_us-gaap_HedgingDesignationAxis_bc8a9094-009c-46e3-9299-a6dd372ef818" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_bc8a9094-009c-46e3-9299-a6dd372ef818_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_bc8a9094-009c-46e3-9299-a6dd372ef818" xlink:to="loc_us-gaap_HedgingDesignationDomain_bc8a9094-009c-46e3-9299-a6dd372ef818_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_18037112-7baa-46b8-9564-2e342a224cb6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_bc8a9094-009c-46e3-9299-a6dd372ef818" xlink:to="loc_us-gaap_HedgingDesignationDomain_18037112-7baa-46b8-9564-2e342a224cb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_84270410-a6f0-453d-aeb6-fc178d5dc2d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_18037112-7baa-46b8-9564-2e342a224cb6" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_84270410-a6f0-453d-aeb6-fc178d5dc2d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_0f041ccd-ebc0-4dab-8faa-16db6a204f4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_572f3fd3-55d5-4895-b0ca-2c6f4521d782" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_0f041ccd-ebc0-4dab-8faa-16db6a204f4b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_0f041ccd-ebc0-4dab-8faa-16db6a204f4b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_0f041ccd-ebc0-4dab-8faa-16db6a204f4b" xlink:to="loc_us-gaap_HedgingRelationshipDomain_0f041ccd-ebc0-4dab-8faa-16db6a204f4b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_0e2dbae0-6b93-49b6-9b4b-666e5a66e01a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_0f041ccd-ebc0-4dab-8faa-16db6a204f4b" xlink:to="loc_us-gaap_HedgingRelationshipDomain_0e2dbae0-6b93-49b6-9b4b-666e5a66e01a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_ee1c300e-4e90-4f5d-a32e-2da8d469b498" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_0e2dbae0-6b93-49b6-9b4b-666e5a66e01a" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_ee1c300e-4e90-4f5d-a32e-2da8d469b498" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_4ad63a22-f1fb-44e7-b254-817b11023e2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrencySwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_0e2dbae0-6b93-49b6-9b4b-666e5a66e01a" xlink:to="loc_us-gaap_CurrencySwapMember_4ad63a22-f1fb-44e7-b254-817b11023e2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_24f84a13-dff8-4b94-9158-923a2edc4baf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_572f3fd3-55d5-4895-b0ca-2c6f4521d782" xlink:to="loc_us-gaap_DebtInstrumentAxis_24f84a13-dff8-4b94-9158-923a2edc4baf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_24f84a13-dff8-4b94-9158-923a2edc4baf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_24f84a13-dff8-4b94-9158-923a2edc4baf" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_24f84a13-dff8-4b94-9158-923a2edc4baf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3b880099-2f2b-4a2a-a0e8-2df004062f44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_24f84a13-dff8-4b94-9158-923a2edc4baf" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3b880099-2f2b-4a2a-a0e8-2df004062f44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_EuroDenominatedNotesMember_3824df0d-97af-426e-aa1a-5eb7959ebe21" xlink:href="mck-20230630.xsd#mck_EuroDenominatedNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3b880099-2f2b-4a2a-a0e8-2df004062f44" xlink:to="loc_mck_EuroDenominatedNotesMember_3824df0d-97af-426e-aa1a-5eb7959ebe21" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" xlink:type="simple" xlink:href="mck-20230630.xsd#SegmentsofBusinessReportableoperatingsegmentDetails"/>
  <link:definitionLink xlink:role="http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" xlink:type="extended" id="id729564685454e33b70e645af97f920b_SegmentsofBusinessReportableoperatingsegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_a3c4a703-c72f-4599-9e0c-d00b95a68c2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationProfitLossAbstract_429aaae8-11e4-421e-a760-7722f8200814" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationProfitLossAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a3c4a703-c72f-4599-9e0c-d00b95a68c2e" xlink:to="loc_us-gaap_SegmentReportingInformationProfitLossAbstract_429aaae8-11e4-421e-a760-7722f8200814" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_9aef18de-47bd-4e87-aa2e-3257c51080ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationProfitLossAbstract_429aaae8-11e4-421e-a760-7722f8200814" xlink:to="loc_us-gaap_RevenuesAbstract_9aef18de-47bd-4e87-aa2e-3257c51080ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fdd5bcb7-ef00-45e5-92bb-6e7d525eca1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_9aef18de-47bd-4e87-aa2e-3257c51080ea" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fdd5bcb7-ef00-45e5-92bb-6e7d525eca1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLossAbstract_d67bd302-b6c3-45ff-b808-eb674d1f11a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLossAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationProfitLossAbstract_429aaae8-11e4-421e-a760-7722f8200814" xlink:to="loc_us-gaap_OperatingIncomeLossAbstract_d67bd302-b6c3-45ff-b808-eb674d1f11a3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_61df08e3-9fd2-4df4-895b-22f05ee4d53b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingIncomeLossAbstract_d67bd302-b6c3-45ff-b808-eb674d1f11a3" xlink:to="loc_us-gaap_OperatingIncomeLoss_61df08e3-9fd2-4df4-895b-22f05ee4d53b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_CorporateOperatingExpenseandOtherIncomeNet_8d552c5d-7b9a-425d-a4c9-28c7c9dfa7b5" xlink:href="mck-20230630.xsd#mck_CorporateOperatingExpenseandOtherIncomeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationProfitLossAbstract_429aaae8-11e4-421e-a760-7722f8200814" xlink:to="loc_mck_CorporateOperatingExpenseandOtherIncomeNet_8d552c5d-7b9a-425d-a4c9-28c7c9dfa7b5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_fd9243e1-2796-408c-bf2e-d9ae9f04a662" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationProfitLossAbstract_429aaae8-11e4-421e-a760-7722f8200814" xlink:to="loc_us-gaap_InterestExpense_fd9243e1-2796-408c-bf2e-d9ae9f04a662" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4bb70132-91b5-45cf-8cb6-b96346402290" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationProfitLossAbstract_429aaae8-11e4-421e-a760-7722f8200814" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4bb70132-91b5-45cf-8cb6-b96346402290" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_RevenueDerivedFromServicesPercentage_6f21ec16-920e-4a70-9ec2-600d10c8d781" xlink:href="mck-20230630.xsd#mck_RevenueDerivedFromServicesPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a3c4a703-c72f-4599-9e0c-d00b95a68c2e" xlink:to="loc_mck_RevenueDerivedFromServicesPercentage_6f21ec16-920e-4a70-9ec2-600d10c8d781" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_70d01c22-6b4a-42c3-b4b8-7f042a52d055" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a3c4a703-c72f-4599-9e0c-d00b95a68c2e" xlink:to="loc_us-gaap_NumberOfReportableSegments_70d01c22-6b4a-42c3-b4b8-7f042a52d055" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLegalSettlements_8f5d971f-384c-411d-b233-88abaaf1b8e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLegalSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a3c4a703-c72f-4599-9e0c-d00b95a68c2e" xlink:to="loc_us-gaap_ProceedsFromLegalSettlements_8f5d971f-384c-411d-b233-88abaaf1b8e1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLIFOReservePeriodCharge_06dd4e25-b5c3-4789-ace4-dad0628cd987" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryLIFOReservePeriodCharge"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a3c4a703-c72f-4599-9e0c-d00b95a68c2e" xlink:to="loc_us-gaap_InventoryLIFOReservePeriodCharge_06dd4e25-b5c3-4789-ace4-dad0628cd987" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_39d788fd-8865-4fc9-9cbb-08aaca3dca35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a3c4a703-c72f-4599-9e0c-d00b95a68c2e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_39d788fd-8865-4fc9-9cbb-08aaca3dca35" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_1c571ba8-e52e-4831-9cd6-7b21b98f1c0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a3c4a703-c72f-4599-9e0c-d00b95a68c2e" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_1c571ba8-e52e-4831-9cd6-7b21b98f1c0a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_3d80c7e8-cc01-407b-88a3-7917b302e113" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a3c4a703-c72f-4599-9e0c-d00b95a68c2e" xlink:to="loc_us-gaap_RestructuringCharges_3d80c7e8-cc01-407b-88a3-7917b302e113" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1ed8ff2b-4c22-427f-a087-f8c978075c7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a3c4a703-c72f-4599-9e0c-d00b95a68c2e" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1ed8ff2b-4c22-427f-a087-f8c978075c7d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_d01c2068-c617-484f-a472-20fe404a7dde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1ed8ff2b-4c22-427f-a087-f8c978075c7d" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_d01c2068-c617-484f-a472-20fe404a7dde" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d01c2068-c617-484f-a472-20fe404a7dde_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d01c2068-c617-484f-a472-20fe404a7dde" xlink:to="loc_us-gaap_SegmentDomain_d01c2068-c617-484f-a472-20fe404a7dde_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_bb8827b7-9937-4b2f-a6c8-8680cfa8e319" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d01c2068-c617-484f-a472-20fe404a7dde" xlink:to="loc_us-gaap_SegmentDomain_bb8827b7-9937-4b2f-a6c8-8680cfa8e319" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_USPharmaceuticalSegmentMember_063a3a35-e9d5-4a19-be6a-4e50a10a670a" xlink:href="mck-20230630.xsd#mck_USPharmaceuticalSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_bb8827b7-9937-4b2f-a6c8-8680cfa8e319" xlink:to="loc_mck_USPharmaceuticalSegmentMember_063a3a35-e9d5-4a19-be6a-4e50a10a670a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_PrescriptionTechnologySolutionsMember_a46797ae-a1ef-43e3-84f5-bbc266b598a9" xlink:href="mck-20230630.xsd#mck_PrescriptionTechnologySolutionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_bb8827b7-9937-4b2f-a6c8-8680cfa8e319" xlink:to="loc_mck_PrescriptionTechnologySolutionsMember_a46797ae-a1ef-43e3-84f5-bbc266b598a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_MedicalSurgicalSolutionsSegmentMember_81cf7ce2-30f8-4c45-95ad-736c8dcb5856" xlink:href="mck-20230630.xsd#mck_MedicalSurgicalSolutionsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_bb8827b7-9937-4b2f-a6c8-8680cfa8e319" xlink:to="loc_mck_MedicalSurgicalSolutionsSegmentMember_81cf7ce2-30f8-4c45-95ad-736c8dcb5856" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_InternationalSegmentMember_7fcf8a43-a7d3-4294-b173-34dbb02be644" xlink:href="mck-20230630.xsd#mck_InternationalSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_bb8827b7-9937-4b2f-a6c8-8680cfa8e319" xlink:to="loc_mck_InternationalSegmentMember_7fcf8a43-a7d3-4294-b173-34dbb02be644" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_07074a48-716f-4815-aa00-0d65d40e6209" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1ed8ff2b-4c22-427f-a087-f8c978075c7d" xlink:to="loc_srt_ConsolidationItemsAxis_07074a48-716f-4815-aa00-0d65d40e6209" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_07074a48-716f-4815-aa00-0d65d40e6209_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_07074a48-716f-4815-aa00-0d65d40e6209" xlink:to="loc_srt_ConsolidationItemsDomain_07074a48-716f-4815-aa00-0d65d40e6209_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_ad455ce0-5f62-4624-986a-8333d6a6f00a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_07074a48-716f-4815-aa00-0d65d40e6209" xlink:to="loc_srt_ConsolidationItemsDomain_ad455ce0-5f62-4624-986a-8333d6a6f00a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_abb0cd4b-9b7a-4cba-95d8-17593261c32c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_ad455ce0-5f62-4624-986a-8333d6a6f00a" xlink:to="loc_us-gaap_OperatingSegmentsMember_abb0cd4b-9b7a-4cba-95d8-17593261c32c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_bb5be096-8559-4fc0-a017-41bddef44dca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_ad455ce0-5f62-4624-986a-8333d6a6f00a" xlink:to="loc_us-gaap_CorporateNonSegmentMember_bb5be096-8559-4fc0-a017-41bddef44dca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_b7a282a4-63a8-4992-907a-d4e862825c83" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1ed8ff2b-4c22-427f-a087-f8c978075c7d" xlink:to="loc_srt_LitigationCaseAxis_b7a282a4-63a8-4992-907a-d4e862825c83" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_b7a282a4-63a8-4992-907a-d4e862825c83_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_b7a282a4-63a8-4992-907a-d4e862825c83" xlink:to="loc_srt_LitigationCaseTypeDomain_b7a282a4-63a8-4992-907a-d4e862825c83_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_98190105-fe92-4b64-9d50-a6c5a295a6f7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_b7a282a4-63a8-4992-907a-d4e862825c83" xlink:to="loc_srt_LitigationCaseTypeDomain_98190105-fe92-4b64-9d50-a6c5a295a6f7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_NationalPrescriptionOpiateLitigationMember_e207f65a-9be2-4c94-91a1-8cc349d12b1e" xlink:href="mck-20230630.xsd#mck_NationalPrescriptionOpiateLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_98190105-fe92-4b64-9d50-a6c5a295a6f7" xlink:to="loc_mck_NationalPrescriptionOpiateLitigationMember_e207f65a-9be2-4c94-91a1-8cc349d12b1e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_24e7968e-6e4c-4503-b77e-0af5955c9910" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1ed8ff2b-4c22-427f-a087-f8c978075c7d" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_24e7968e-6e4c-4503-b77e-0af5955c9910" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_24e7968e-6e4c-4503-b77e-0af5955c9910_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_24e7968e-6e4c-4503-b77e-0af5955c9910" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_24e7968e-6e4c-4503-b77e-0af5955c9910_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_a1ca6757-3ce8-4988-8d29-1c59930ff2ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_24e7968e-6e4c-4503-b77e-0af5955c9910" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_a1ca6757-3ce8-4988-8d29-1c59930ff2ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_ffbe3d21-0067-4fd0-9830-bed7e68e4413" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_a1ca6757-3ce8-4988-8d29-1c59930ff2ce" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_ffbe3d21-0067-4fd0-9830-bed7e68e4413" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_b339a082-b82d-4f31-94b9-70907f53b7b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1ed8ff2b-4c22-427f-a087-f8c978075c7d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_b339a082-b82d-4f31-94b9-70907f53b7b1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b339a082-b82d-4f31-94b9-70907f53b7b1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_b339a082-b82d-4f31-94b9-70907f53b7b1" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_b339a082-b82d-4f31-94b9-70907f53b7b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_99446870-106d-47eb-b0dd-2f6106d3d42b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_b339a082-b82d-4f31-94b9-70907f53b7b1" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_99446870-106d-47eb-b0dd-2f6106d3d42b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_EUBusinessesDisposalGroupMember_e3af16c7-75e0-482c-ae7b-822e7f829001" xlink:href="mck-20230630.xsd#mck_EUBusinessesDisposalGroupMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_99446870-106d-47eb-b0dd-2f6106d3d42b" xlink:to="loc_mck_EUBusinessesDisposalGroupMember_e3af16c7-75e0-482c-ae7b-822e7f829001" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_f839d5bb-04ef-4a19-8849-20e08eff5205" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1ed8ff2b-4c22-427f-a087-f8c978075c7d" xlink:to="loc_srt_StatementGeographicalAxis_f839d5bb-04ef-4a19-8849-20e08eff5205" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_f839d5bb-04ef-4a19-8849-20e08eff5205_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_f839d5bb-04ef-4a19-8849-20e08eff5205" xlink:to="loc_srt_SegmentGeographicalDomain_f839d5bb-04ef-4a19-8849-20e08eff5205_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e91e850b-b86c-4910-8b63-b5e1386d9b76" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_f839d5bb-04ef-4a19-8849-20e08eff5205" xlink:to="loc_srt_SegmentGeographicalDomain_e91e850b-b86c-4910-8b63-b5e1386d9b76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_0e6dad5d-171b-4a90-ae8e-81e4db8dec10" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e91e850b-b86c-4910-8b63-b5e1386d9b76" xlink:to="loc_country_US_0e6dad5d-171b-4a90-ae8e-81e4db8dec10" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTypeOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="4"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>mck-20230630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:65f23265-c924-40c8-9b40-7c0acd48a82a,g:b9e463ca-a0e1-4231-8e93-a7255a3f4103-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_mck_StockIssuedDuringPeriodSharesEmployeeStockPlansNetOfForfeitures_9a31fc4c-64fa-4fa2-9f0c-a73688fbe353_terseLabel_en-US" xlink:label="lab_mck_StockIssuedDuringPeriodSharesEmployeeStockPlansNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of shares under employee plans, net of forfeitures (in shares)</link:label>
    <link:label id="lab_mck_StockIssuedDuringPeriodSharesEmployeeStockPlansNetOfForfeitures_label_en-US" xlink:label="lab_mck_StockIssuedDuringPeriodSharesEmployeeStockPlansNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Plans Net of Forfeitures</link:label>
    <link:label id="lab_mck_StockIssuedDuringPeriodSharesEmployeeStockPlansNetOfForfeitures_documentation_en-US" xlink:label="lab_mck_StockIssuedDuringPeriodSharesEmployeeStockPlansNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Plans Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_StockIssuedDuringPeriodSharesEmployeeStockPlansNetOfForfeitures" xlink:href="mck-20230630.xsd#mck_StockIssuedDuringPeriodSharesEmployeeStockPlansNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_StockIssuedDuringPeriodSharesEmployeeStockPlansNetOfForfeitures" xlink:to="lab_mck_StockIssuedDuringPeriodSharesEmployeeStockPlansNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_03e53ef0-5e5c-49b7-88b0-2c8e7624eec9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_f2aff3e1-a88e-42cd-85e5-52900e40a59d_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_62430697-4878-4b7d-b69c-9a14e18ba25c_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Non-Current Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_d155adc8-04c7-4229-93bd-beb9c5a58832_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations (in usd per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_e567394e-b593-4c81-b15f-895da5f017f3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations (in usd per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_8b13a6d8-f5fb-4ef9-9161-d46b0143ca89_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotionalAmount_fd5fad2b-c2c8-427b-a475-f414b7404506_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Dollar, notional amount, liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityNotionalAmount" xlink:to="lab_us-gaap_DerivativeLiabilityNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_021e00ed-89f5-499a-a391-2e9055b4bb1c_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit facility, maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_0c58b8ce-e60d-422c-b76c-6527bab38a1e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives designated as net investment hedges:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_2e1a0f46-cb8b-4a6f-9cc2-de348169f5c7_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net investment hedge, gain (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c5f1d0cc-7b09-402d-9178-1b65b70b612a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_419eca86-99c7-4b1a-b970-c213dc415f62_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of short-term borrowings</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Short-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:to="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_87fd5e17-f4cc-4a4a-8f86-e7c8cc92eb61_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt and Financing Activities</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationReserveNoncurrent_6b63dbd8-2706-48e8-9638-2172bae5caae_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserveNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term litigation liabilities</link:label>
    <link:label id="lab_us-gaap_LitigationReserveNoncurrent_label_en-US" xlink:label="lab_us-gaap_LitigationReserveNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationReserveNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserveNoncurrent" xlink:to="lab_us-gaap_LitigationReserveNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_efa46efa-95e9-4085-b25c-d2df23e6eacd_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_28f821a3-1594-40ae-a021-0350c82d0b7d_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payments to acquire business</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_d1c895d5-1a21-4bb8-abc7-1fdb8bd212c1_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_2132fec6-6263-4011-9b2d-87a1766046ac_netLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_925f8954-1cc8-49ad-b639-210ac6c667e8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identified Assets Acquired and Liabilities Assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_969bed9f-d7f8-45f3-ad4b-8566318830dd_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_94df53ea-641d-41a3-bbc1-6825699f17d4_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_0566d129-f916-44fa-903a-9dde18e3703c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_FixedInterestRateSwapMember_7754f3da-6d2c-49db-a853-cab901cc73f8_terseLabel_en-US" xlink:label="lab_mck_FixedInterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed interest rate swaps</link:label>
    <link:label id="lab_mck_FixedInterestRateSwapMember_label_en-US" xlink:label="lab_mck_FixedInterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed Interest Rate Swap [Member]</link:label>
    <link:label id="lab_mck_FixedInterestRateSwapMember_documentation_en-US" xlink:label="lab_mck_FixedInterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed Interest Rate Swap</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_FixedInterestRateSwapMember" xlink:href="mck-20230630.xsd#mck_FixedInterestRateSwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_FixedInterestRateSwapMember" xlink:to="lab_mck_FixedInterestRateSwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedLineItems_7d66e4c1-91f9-4e9a-b220-70a0b99d16ce_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedLineItems_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDilutedLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems" xlink:to="lab_us-gaap_EarningsPerShareDilutedLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_501b1ede-82dd-4614-9a90-70e2a5f08115_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_18dc4466-e598-4d05-8512-a75aa65c0131_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Drafts and accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedTaxesPayable_1eff6fd8-8f6b-4d32-bb30-9289d36c7d5c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedTaxesPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Taxes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedTaxesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedTaxesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_bfae694e-4ad3-45b1-8c9c-9562704ce8de_verboseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European businesses held for sale</link:label>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_8cdb1e63-2549-424a-9618-096b1a58ff2d_netLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European businesses, disposal group, losses (gains)</link:label>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_f25c7bc5-3f38-4e8b-8833-76568bf86ba8_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss (gain) to remeasure disposal group to fair value</link:label>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_label_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:to="lab_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_9db900f2-bdd8-4939-bc5e-3fdd5d9df4bc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Foreign Currency Gains and (Losses) from Non-Derivative Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives Not Designated as Hedging Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_ef8abc8e-2d77-40db-a8fb-d9d413ea2a73_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Complaints filed against the entity</link:label>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Pending Claims, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:to="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetImpairmentCharges_6ab09b3a-ac14-49f1-8d16-62fd4a698b41_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-lived asset impairment charges</link:label>
    <link:label id="lab_us-gaap_OtherAssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_OtherAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetImpairmentCharges" xlink:to="lab_us-gaap_OtherAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_0f343aa7-f350-4bc2-a5a8-a134426226c7_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Deficit</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_641f5b16-6691-4603-8631-a153d8d4babb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_f6b7b129-1b95-4cd9-a067-337faf3825eb_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_c7dd4e94-65d1-4d8d-850e-dd54ccba20f0_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:to="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_0d3b3b56-b087-4d21-9beb-aaa31cd38609_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_d2041cbb-4c93-45b9-a7df-65d8832ac7f3_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_CAD_16e41268-beed-4079-ba1c-1145473da9c6_terseLabel_en-US" xlink:label="lab_currency_CAD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CAD</link:label>
    <link:label id="lab_currency_CAD_label_en-US" xlink:label="lab_currency_CAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canada, Dollars</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CAD" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_CAD"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_CAD" xlink:to="lab_currency_CAD" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember_3b8a768a-0c56-4110-85d9-648f7889dab4_terseLabel_en-US" xlink:label="lab_mck_AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Losses on Net Investment Hedges, Net of Tax</link:label>
    <link:label id="lab_mck_AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember_label_en-US" xlink:label="lab_mck_AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Net Investment Hedges, Including Noncontrolling Interest [Member]</link:label>
    <link:label id="lab_mck_AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember_documentation_en-US" xlink:label="lab_mck_AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Net Investment Hedges, Including Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember" xlink:href="mck-20230630.xsd#mck_AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember" xlink:to="lab_mck_AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_a43c6fab-ff0f-428e-a365-e1e839fccbdd_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant, and equipment</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_34d9e347-63ad-43ba-b703-80a4abd38824_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_A510NotesDueJuly152033Member_c603e73d-f5e0-4e03-98f2-cb29a225050c_terseLabel_en-US" xlink:label="lab_mck_A510NotesDueJuly152033Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.10% Notes due July 15, 2033</link:label>
    <link:label id="lab_mck_A510NotesDueJuly152033Member_label_en-US" xlink:label="lab_mck_A510NotesDueJuly152033Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.10% Notes Due July 15, 2033 [Member]</link:label>
    <link:label id="lab_mck_A510NotesDueJuly152033Member_documentation_en-US" xlink:label="lab_mck_A510NotesDueJuly152033Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.10% Notes Due July 15, 2033</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_A510NotesDueJuly152033Member" xlink:href="mck-20230630.xsd#mck_A510NotesDueJuly152033Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_A510NotesDueJuly152033Member" xlink:to="lab_mck_A510NotesDueJuly152033Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_2df87714-2405-4c83-98c7-460143bb2ff1_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_263a128d-f39a-4ebf-b674-bbb7d14e46af_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.01 par value, 100 shares authorized, no shares issued or outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_b0fab06e-60e7-4d46-ba28-1003a266dd1a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3d3bda05-1ec0-4e8d-a61a-dce2117da268_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_92720bcb-0ac7-4787-8b2d-4167a89ff89a_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends paid</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDividendsCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Ordinary Dividends, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDividendsCommonStock" xlink:to="lab_us-gaap_PaymentsOfDividendsCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_5a6ee35d-1c93-485f-af6b-6c9fe534a890_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_ade82a35-7bbc-483f-8d85-d69f78f25e16_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of derivative, liability</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Subject to Master Netting Arrangement, before Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_baf231d9-b66a-439d-81e2-46050be2cbf6_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptionsAbstract_a69e641f-5d89-4dfc-9343-93ae3d9001f4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock transactions:</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptionsAbstract_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptionsAbstract" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_UnitedStatesExRelHartVMcKessonCorporationEtAl15CV00903RAMember_4ae031d6-90d1-44c5-9a40-86eab1d7cdfd_terseLabel_en-US" xlink:label="lab_mck_UnitedStatesExRelHartVMcKessonCorporationEtAl15CV00903RAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States Ex Rel. Hart V. McKesson Corporation, Et Al 15-CV-00903-RA</link:label>
    <link:label id="lab_mck_UnitedStatesExRelHartVMcKessonCorporationEtAl15CV00903RAMember_label_en-US" xlink:label="lab_mck_UnitedStatesExRelHartVMcKessonCorporationEtAl15CV00903RAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States Ex Rel. Hart V. McKesson Corporation, Et Al 15-CV-00903-RA [Member]</link:label>
    <link:label id="lab_mck_UnitedStatesExRelHartVMcKessonCorporationEtAl15CV00903RAMember_documentation_en-US" xlink:label="lab_mck_UnitedStatesExRelHartVMcKessonCorporationEtAl15CV00903RAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States Ex Rel. Hart V. McKesson Corporation, Et Al 15-CV-00903-RA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_UnitedStatesExRelHartVMcKessonCorporationEtAl15CV00903RAMember" xlink:href="mck-20230630.xsd#mck_UnitedStatesExRelHartVMcKessonCorporationEtAl15CV00903RAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_UnitedStatesExRelHartVMcKessonCorporationEtAl15CV00903RAMember" xlink:to="lab_mck_UnitedStatesExRelHartVMcKessonCorporationEtAl15CV00903RAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_51a0c9c0-810f-43b9-b4d3-6c74a62fdef3_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_080fe082-f4eb-4775-9200-9f04c60dd29d_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury shares (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_d68ecbe9-d26e-4e5c-98ea-bda0dfbdf1fe_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_9fc46f98-4361-4e98-881c-417007fd36e0_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_A380NotesDueMarch152024Member_2f3a6ee0-75b8-4634-a242-53afba651c28_terseLabel_en-US" xlink:label="lab_mck_A380NotesDueMarch152024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.80% Notes due March 15, 2024</link:label>
    <link:label id="lab_mck_A380NotesDueMarch152024Member_label_en-US" xlink:label="lab_mck_A380NotesDueMarch152024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.80% Notes Due March 15, 2024 [Member]</link:label>
    <link:label id="lab_mck_A380NotesDueMarch152024Member_documentation_en-US" xlink:label="lab_mck_A380NotesDueMarch152024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.80% Notes Due March 15, 2024</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_A380NotesDueMarch152024Member" xlink:href="mck-20230630.xsd#mck_A380NotesDueMarch152024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_A380NotesDueMarch152024Member" xlink:to="lab_mck_A380NotesDueMarch152024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_a7db7e65-467e-4217-b9e3-bff5a0bbd096_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_86724d12-9fe9-4bce-8d20-f1f1870d3388_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_747945a4-d30d-45c1-927b-1fc3094637c5_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanDomain" xlink:to="lab_us-gaap_RestructuringPlanDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_00092ef2-f395-498b-a83c-57dd7b980dc0_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to McKesson Corporation</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_a8515812-38ed-4b99-b3f0-a2002394cf2f_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_c0af6503-23f1-4ed1-bd2f-275395cc4b79_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_389343d2-40fc-456c-88b5-edecf5c41fb6_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_5a3524e8-5f7f-4e67-83d8-85625301d85c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Notional Amounts of Outstanding Derivative Positions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_43d98a2d-afc7-4ab4-a57d-492bf5467651_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_CommonStockVotingRightsNumberofVotesPerCommonShare_0bb5c6af-130c-4342-a963-302b4276043b_terseLabel_en-US" xlink:label="lab_mck_CommonStockVotingRightsNumberofVotesPerCommonShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of votes per share of common stock permitted on proposals presented to stockholders (vote)</link:label>
    <link:label id="lab_mck_CommonStockVotingRightsNumberofVotesPerCommonShare_label_en-US" xlink:label="lab_mck_CommonStockVotingRightsNumberofVotesPerCommonShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Voting Rights, Number of Votes Per Common Share</link:label>
    <link:label id="lab_mck_CommonStockVotingRightsNumberofVotesPerCommonShare_documentation_en-US" xlink:label="lab_mck_CommonStockVotingRightsNumberofVotesPerCommonShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Voting Rights, Number of Votes Per Common Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_CommonStockVotingRightsNumberofVotesPerCommonShare" xlink:href="mck-20230630.xsd#mck_CommonStockVotingRightsNumberofVotesPerCommonShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_CommonStockVotingRightsNumberofVotesPerCommonShare" xlink:to="lab_mck_CommonStockVotingRightsNumberofVotesPerCommonShare" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_AllCurrenciesDomain_0e5c6c10-11be-4b2d-bed6-7239aad7e4ff_terseLabel_en-US" xlink:label="lab_currency_AllCurrenciesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:label id="lab_currency_AllCurrenciesDomain_label_en-US" xlink:label="lab_currency_AllCurrenciesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_AllCurrenciesDomain" xlink:to="lab_currency_AllCurrenciesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtAndCapitalLeaseObligations_45b75111-ff63-44ef-8467-b65e5036a2b8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_DebtAndCapitalLeaseObligations_label_en-US" xlink:label="lab_us-gaap_DebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt and Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtAndCapitalLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtAndCapitalLeaseObligations" xlink:to="lab_us-gaap_DebtAndCapitalLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4e6d97c4-876b-4369-ab71-3cfb4dbf8cf3_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND DEFICIT</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_77ddf6ce-b93e-4990-8ede-f27ceae8ecca_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_65902a43-5c91-4fb1-a63d-626befaa83de_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_adbf1ffa-6d64-4464-82c1-aff37a276010_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares repurchased</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_587bc197-41f1-4630-9b79-b26d991f2c9c_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson Corporation stockholders&#8217; deficit</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_A475NotesDueMay302029Member_176cbf4e-b377-4d7a-b4fb-195dfbc31737_terseLabel_en-US" xlink:label="lab_mck_A475NotesDueMay302029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.75% Notes due May 30, 2029</link:label>
    <link:label id="lab_mck_A475NotesDueMay302029Member_label_en-US" xlink:label="lab_mck_A475NotesDueMay302029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.75% Notes Due May 30, 2029 [Member]</link:label>
    <link:label id="lab_mck_A475NotesDueMay302029Member_documentation_en-US" xlink:label="lab_mck_A475NotesDueMay302029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.75% Notes Due May 30, 2029</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_A475NotesDueMay302029Member" xlink:href="mck-20230630.xsd#mck_A475NotesDueMay302029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_A475NotesDueMay302029Member" xlink:to="lab_mck_A475NotesDueMay302029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInReceivables_321c816c-147b-4ad6-a208-b8083acf972b_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_d5ad4df2-9528-48f2-8dcd-0121397e03e6_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsMember" xlink:to="lab_us-gaap_OtherIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_06f6ce13-80d5-4016-8ff6-a71112a7ec5b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of computations for basic and diluted earnings per common share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_4fe4a85f-5e22-4110-99e7-bf2a4427531a_negatedLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_be2bf8cb-5916-474d-b0c0-707437f6c7bc_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable" xlink:to="lab_us-gaap_IncomeTaxContingencyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusDomain_5ac56b01-6cf6-45be-8dd0-6746f7412aa9_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusDomain_label_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusDomain" xlink:to="lab_us-gaap_LitigationStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_cb573f89-35eb-4d04-acb8-e358b3a80235_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average life of intangibles</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_SeniorUnsecuredCreditFacilityThe2022CreditFacilityMember_1888a9ba-ecb1-4fc2-9c07-00b958cf4396_terseLabel_en-US" xlink:label="lab_mck_SeniorUnsecuredCreditFacilityThe2022CreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Credit Facility (the 2022 Credit Facility)</link:label>
    <link:label id="lab_mck_SeniorUnsecuredCreditFacilityThe2022CreditFacilityMember_label_en-US" xlink:label="lab_mck_SeniorUnsecuredCreditFacilityThe2022CreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Credit Facility (the 2022 Credit Facility) [Member]</link:label>
    <link:label id="lab_mck_SeniorUnsecuredCreditFacilityThe2022CreditFacilityMember_documentation_en-US" xlink:label="lab_mck_SeniorUnsecuredCreditFacilityThe2022CreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Credit Facility (the 2022 Credit Facility)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_SeniorUnsecuredCreditFacilityThe2022CreditFacilityMember" xlink:href="mck-20230630.xsd#mck_SeniorUnsecuredCreditFacilityThe2022CreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_SeniorUnsecuredCreditFacilityThe2022CreditFacilityMember" xlink:to="lab_mck_SeniorUnsecuredCreditFacilityThe2022CreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_098afa05-e603-4bd3-9a11-0dfc5bbb5fa8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, inputs, level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveTranslationAndOtherAdjustment_f26bcdad-7eed-4c13-b667-084b44de5117_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveTranslationAndOtherAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveTranslationAndOtherAdjustment_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveTranslationAndOtherAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve, Translation and Other Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveTranslationAndOtherAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserveTranslationAndOtherAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveTranslationAndOtherAdjustment" xlink:to="lab_us-gaap_RestructuringReserveTranslationAndOtherAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_IndividualClaimantMember_00ea2903-14ac-4743-8e96-4c726903b629_terseLabel_en-US" xlink:label="lab_mck_IndividualClaimantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">An individual</link:label>
    <link:label id="lab_mck_IndividualClaimantMember_label_en-US" xlink:label="lab_mck_IndividualClaimantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Individual Claimant [Member]</link:label>
    <link:label id="lab_mck_IndividualClaimantMember_documentation_en-US" xlink:label="lab_mck_IndividualClaimantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Individual Claimant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_IndividualClaimantMember" xlink:href="mck-20230630.xsd#mck_IndividualClaimantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_IndividualClaimantMember" xlink:to="lab_mck_IndividualClaimantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_GBP_6a45b925-c0cd-44bf-971e-ce8c834c9d36_terseLabel_en-US" xlink:label="lab_currency_GBP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GBP</link:label>
    <link:label id="lab_currency_GBP_label_en-US" xlink:label="lab_currency_GBP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Kingdom, Pounds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_GBP" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_GBP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_GBP" xlink:to="lab_currency_GBP" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_bea97513-afa1-4be9-b59f-28fa06feea48_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_d8a643b0-24f1-40e3-a458-0d863ee511f1_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_61067490-88ea-498e-82d3-4a1a45179c21_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_10666dee-3591-405d-a5f3-fbac78d48a44_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_81b19e94-0f14-4d3b-af5d-bcb7a0eeb189_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_LitigationSettlementAwardAmountToBeUsedByStateAndLocalGovernment_04b57093-cc88-442c-b19d-caf9c82f0b75_terseLabel_en-US" xlink:label="lab_mck_LitigationSettlementAwardAmountToBeUsedByStateAndLocalGovernment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion of settlement award to be used by state and local government for remediation (percent)</link:label>
    <link:label id="lab_mck_LitigationSettlementAwardAmountToBeUsedByStateAndLocalGovernment_label_en-US" xlink:label="lab_mck_LitigationSettlementAwardAmountToBeUsedByStateAndLocalGovernment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Award Amount To Be Used by State and Local Government</link:label>
    <link:label id="lab_mck_LitigationSettlementAwardAmountToBeUsedByStateAndLocalGovernment_documentation_en-US" xlink:label="lab_mck_LitigationSettlementAwardAmountToBeUsedByStateAndLocalGovernment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Award Amount To Be Used by State and Local Government</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_LitigationSettlementAwardAmountToBeUsedByStateAndLocalGovernment" xlink:href="mck-20230630.xsd#mck_LitigationSettlementAwardAmountToBeUsedByStateAndLocalGovernment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_LitigationSettlementAwardAmountToBeUsedByStateAndLocalGovernment" xlink:to="lab_mck_LitigationSettlementAwardAmountToBeUsedByStateAndLocalGovernment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_9d046c21-9077-4451-b6d4-b6dffaab87a3_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_LeaseAndOtherObligationsMember_5fabb710-99b8-410b-af58-50d1d9754f7b_terseLabel_en-US" xlink:label="lab_mck_LeaseAndOtherObligationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease and other obligations</link:label>
    <link:label id="lab_mck_LeaseAndOtherObligationsMember_label_en-US" xlink:label="lab_mck_LeaseAndOtherObligationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease and Other Obligations [Member]</link:label>
    <link:label id="lab_mck_LeaseAndOtherObligationsMember_documentation_en-US" xlink:label="lab_mck_LeaseAndOtherObligationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease and Other Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_LeaseAndOtherObligationsMember" xlink:href="mck-20230630.xsd#mck_LeaseAndOtherObligationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_LeaseAndOtherObligationsMember" xlink:to="lab_mck_LeaseAndOtherObligationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_dff05006-4080-4665-9d1e-88089976841f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated annual amortization expense, 2028</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_de39ab89-7208-4b89-b28c-16ba9a9ba386_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and related cost, incurred cost to date</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Incurred Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:to="lab_us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_731f5b86-263e-4971-8e5f-f7fe092dd7f2_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_ec6f4c99-e6a1-41b1-a266-eaa3e8f384f7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_713f0723-bc45-41d3-9ee7-a3be52245f0f_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_1fb9aa78-cf6e-4831-a697-53060d14ac51_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notional</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_012eaffa-c231-48c1-b989-2c077d6684a6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends declared per common share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfCommercialPaper_77408c56-43bf-49f8-86c0-58a28fa00c83_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfCommercialPaper" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of commercial paper</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfCommercialPaper_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfCommercialPaper" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Commercial Paper</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfCommercialPaper" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfCommercialPaper"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfCommercialPaper" xlink:to="lab_us-gaap_RepaymentsOfCommercialPaper" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_76d193b7-527b-408f-8968-d02afdf6c0d1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_2dcff286-13f0-4513-aab1-a7fe37ffc650_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_bce2f5aa-f97d-43d9-b7f6-06e86411c81a_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification of gains from AOCI</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from AOCI, Current Period, before Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:to="lab_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_c69bf638-caf1-49a5-b28b-dc77384d619b_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_0453cd78-99e1-41a7-868d-d3b1f8319271_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit facility term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_d1242347-b10d-4e88-8995-6123feeb5092_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesMember" xlink:to="lab_us-gaap_AccruedLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_03b6ce57-7fa3-4b9c-b500-757c9eb80a02_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_e6246630-c172-4af7-b626-e5f196efc95e_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates_17eb2b44-26f0-419c-8a1e-fa6d6ef9c069_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales of businesses and investments, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Businesses and Interests in Affiliates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_c990d99a-4b15-4b0e-90bc-225110b38b69_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable" xlink:to="lab_us-gaap_LineOfCreditFacilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_b3adfa84-bc0b-4d45-a713-ef0a802096ed_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_56587428-5830-4437-9e87-033027bbbab9_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_ThreeLargestUSPharmaceuticalDistributorsMember_970de44e-826d-4a68-8921-8e7f8e868175_terseLabel_en-US" xlink:label="lab_mck_ThreeLargestUSPharmaceuticalDistributorsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Largest U.S. Pharmaceutical Distributors</link:label>
    <link:label id="lab_mck_ThreeLargestUSPharmaceuticalDistributorsMember_label_en-US" xlink:label="lab_mck_ThreeLargestUSPharmaceuticalDistributorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Largest U.S. Pharmaceutical Distributors [Member]</link:label>
    <link:label id="lab_mck_ThreeLargestUSPharmaceuticalDistributorsMember_documentation_en-US" xlink:label="lab_mck_ThreeLargestUSPharmaceuticalDistributorsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Largest U.S. Pharmaceutical Distributors</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_ThreeLargestUSPharmaceuticalDistributorsMember" xlink:href="mck-20230630.xsd#mck_ThreeLargestUSPharmaceuticalDistributorsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_ThreeLargestUSPharmaceuticalDistributorsMember" xlink:to="lab_mck_ThreeLargestUSPharmaceuticalDistributorsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_dcc8c9b9-c133-4d57-95c3-89152b7c2bd5_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in assets and liabilities, net of acquisitions:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_94200b2f-4e00-4396-ae1f-e67d09054b41_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Derivatives</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLossAbstract_8d1e679c-ddb9-4527-9388-5a2fc0a5f68a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment operating profit (loss)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLossAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLossAbstract" xlink:to="lab_us-gaap_OperatingIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_44b0e84b-27a2-4ea8-bacc-086867e6c6e8_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from debt issuance</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Debt, Net of Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_81302a98-1660-43e1-9712-80e598cc9590_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_LossContingencyNumberOfCasesDismissed_eca0e94e-08e3-4af6-ada7-176757aad5be_terseLabel_en-US" xlink:label="lab_mck_LossContingencyNumberOfCasesDismissed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, number of cases dismissed</link:label>
    <link:label id="lab_mck_LossContingencyNumberOfCasesDismissed_label_en-US" xlink:label="lab_mck_LossContingencyNumberOfCasesDismissed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Cases Dismissed</link:label>
    <link:label id="lab_mck_LossContingencyNumberOfCasesDismissed_documentation_en-US" xlink:label="lab_mck_LossContingencyNumberOfCasesDismissed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number Of Cases Dismissed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_LossContingencyNumberOfCasesDismissed" xlink:href="mck-20230630.xsd#mck_LossContingencyNumberOfCasesDismissed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_LossContingencyNumberOfCasesDismissed" xlink:to="lab_mck_LossContingencyNumberOfCasesDismissed" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_A130NotesDueAugust152026Member_4e5ef619-6038-4094-a7fb-b6b36560b758_terseLabel_en-US" xlink:label="lab_mck_A130NotesDueAugust152026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.30% Notes due August 15, 2026</link:label>
    <link:label id="lab_mck_A130NotesDueAugust152026Member_label_en-US" xlink:label="lab_mck_A130NotesDueAugust152026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.30% Notes Due August 15, 2026 [Member]</link:label>
    <link:label id="lab_mck_A130NotesDueAugust152026Member_documentation_en-US" xlink:label="lab_mck_A130NotesDueAugust152026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.30% Notes Due August 15, 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_A130NotesDueAugust152026Member" xlink:href="mck-20230630.xsd#mck_A130NotesDueAugust152026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_A130NotesDueAugust152026Member" xlink:to="lab_mck_A130NotesDueAugust152026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ed836181-55cc-4fa6-afe6-a676c1010814_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVESTING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusAxis_2e78f929-9b4a-4552-a7a6-f21ce44ee342_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusAxis_label_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusAxis" xlink:to="lab_us-gaap_LitigationStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_1ed640a8-1854-47bd-a640-4ccf1863d84f_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_ae3ca3d0-1212-455b-ab20-916b79f5bdd8_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_SeniorUnsecuredCreditFacilitythe2020CreditFacilityMember_3de12852-200c-4104-8010-acfef3aa2f4b_terseLabel_en-US" xlink:label="lab_mck_SeniorUnsecuredCreditFacilitythe2020CreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Credit Facility (the 2020 Credit Facility)</link:label>
    <link:label id="lab_mck_SeniorUnsecuredCreditFacilitythe2020CreditFacilityMember_label_en-US" xlink:label="lab_mck_SeniorUnsecuredCreditFacilitythe2020CreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Credit Facility (the 2020 Credit Facility) [Member]</link:label>
    <link:label id="lab_mck_SeniorUnsecuredCreditFacilitythe2020CreditFacilityMember_documentation_en-US" xlink:label="lab_mck_SeniorUnsecuredCreditFacilitythe2020CreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Credit Facility (the 2020 Credit Facility) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_SeniorUnsecuredCreditFacilitythe2020CreditFacilityMember" xlink:href="mck-20230630.xsd#mck_SeniorUnsecuredCreditFacilitythe2020CreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_SeniorUnsecuredCreditFacilitythe2020CreditFacilityMember" xlink:to="lab_mck_SeniorUnsecuredCreditFacilitythe2020CreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_793d05e1-2418-491a-a589-c2802bb490cd_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_59d0ae43-4f68-4033-85b9-726029e0e221_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potentially dilutive securities excluded from diluted earnings per share (less than)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_b9164c4d-b3b3-470c-a738-42c7116a6519_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_91bfa0dd-2b66-4301-899e-e4944f06a8b1_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_bd2403f8-890b-4e5d-be40-02a4781c1cf8_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e6f12c01-4b51-4bdb-bdd9-8bc9af3421b8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_389c6fb3-080b-40c5-a0fa-cd4a7a303431_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on debt extinguishment</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_dba0aa33-3ca0-4ea8-b4c9-8f0f64b90132_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_eafd6c16-bb6a-4aeb-8749-29bb40aca9f6_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_d9c23d17-6bfe-4d02-96cc-c5cf72a1d812_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated annual amortization expense, remainder of 2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_55b17ee9-a082-41e9-881e-3fa9a9bc465a_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_3bc5732f-1f5e-48c0-9ed0-79db55b1f819_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesFairValueLineItems" xlink:to="lab_us-gaap_DerivativesFairValueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_DerivativeTerminationProceedsAmortizationPeriod_4c411cbe-2f0d-4da2-bb2b-fbc2ec2de886_terseLabel_en-US" xlink:label="lab_mck_DerivativeTerminationProceedsAmortizationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative termination proceeds, amortization period (in years)</link:label>
    <link:label id="lab_mck_DerivativeTerminationProceedsAmortizationPeriod_label_en-US" xlink:label="lab_mck_DerivativeTerminationProceedsAmortizationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Termination Proceeds, Amortization Period</link:label>
    <link:label id="lab_mck_DerivativeTerminationProceedsAmortizationPeriod_documentation_en-US" xlink:label="lab_mck_DerivativeTerminationProceedsAmortizationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Termination Proceeds, Amortization Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_DerivativeTerminationProceedsAmortizationPeriod" xlink:href="mck-20230630.xsd#mck_DerivativeTerminationProceedsAmortizationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_DerivativeTerminationProceedsAmortizationPeriod" xlink:to="lab_mck_DerivativeTerminationProceedsAmortizationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_88c4bd16-db4a-4bed-87ce-9907fc86c7b9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveSettledWithoutCash2_a576d735-9c10-411f-b269-30fe6c7a9a3c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash charges</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveSettledWithoutCash2_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve, Settled without Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserveSettledWithoutCash2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:to="lab_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_2badb611-774a-4f9f-ae80-dcefb8dc4701_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_349d42d0-b74c-4d8e-86f9-4401309ab437_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_b96eef59-9797-4c48-9fd3-c38b0fa5505e_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_PrescriptionTechnologySolutionsMember_a712c97b-b6cb-428c-a18a-1ad4902cca73_terseLabel_en-US" xlink:label="lab_mck_PrescriptionTechnologySolutionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prescription Technology Solutions</link:label>
    <link:label id="lab_mck_PrescriptionTechnologySolutionsMember_label_en-US" xlink:label="lab_mck_PrescriptionTechnologySolutionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prescription Technology Solutions [Member]</link:label>
    <link:label id="lab_mck_PrescriptionTechnologySolutionsMember_documentation_en-US" xlink:label="lab_mck_PrescriptionTechnologySolutionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_PrescriptionTechnologySolutionsMember" xlink:href="mck-20230630.xsd#mck_PrescriptionTechnologySolutionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_PrescriptionTechnologySolutionsMember" xlink:to="lab_mck_PrescriptionTechnologySolutionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_b2255cfa-e11d-4d38-b69e-4bb060245e9b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_AcceleratedShareRepurchaseCompletionOfProgramMember_cd06e03e-ae8d-4af3-b373-9b695b487bda_terseLabel_en-US" xlink:label="lab_mck_AcceleratedShareRepurchaseCompletionOfProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchase, Completion Of Program</link:label>
    <link:label id="lab_mck_AcceleratedShareRepurchaseCompletionOfProgramMember_label_en-US" xlink:label="lab_mck_AcceleratedShareRepurchaseCompletionOfProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchase, Completion Of Program [Member]</link:label>
    <link:label id="lab_mck_AcceleratedShareRepurchaseCompletionOfProgramMember_documentation_en-US" xlink:label="lab_mck_AcceleratedShareRepurchaseCompletionOfProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchase, Completion Of Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_AcceleratedShareRepurchaseCompletionOfProgramMember" xlink:href="mck-20230630.xsd#mck_AcceleratedShareRepurchaseCompletionOfProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_AcceleratedShareRepurchaseCompletionOfProgramMember" xlink:to="lab_mck_AcceleratedShareRepurchaseCompletionOfProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComparabilityOfPriorYearFinancialData_992d7523-78fe-42e5-92df-18b9210afb6d_terseLabel_en-US" xlink:label="lab_us-gaap_ComparabilityOfPriorYearFinancialData" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Results of Operations</link:label>
    <link:label id="lab_us-gaap_ComparabilityOfPriorYearFinancialData_label_en-US" xlink:label="lab_us-gaap_ComparabilityOfPriorYearFinancialData" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comparability of Prior Year Financial Data, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComparabilityOfPriorYearFinancialData" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComparabilityOfPriorYearFinancialData"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComparabilityOfPriorYearFinancialData" xlink:to="lab_us-gaap_ComparabilityOfPriorYearFinancialData" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_04f2c647-2788-495f-9b15-dee4bd4e6ed8_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_860a181d-0156-4b5d-a505-aa8b0db1d15d_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_69e5d7dd-6369-4340-9c5c-1ecf5b5d5b88_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_4cb67fea-2bc3-404a-8d98-c5212b860ed9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_352d8a30-8348-4829-b750-4260e5318222_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_5ababa0b-cfc0-465b-b1f7-fc6e31fe0546_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_8db88a87-848c-4237-bcd8-0f24f6359e14_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_8d93b974-ea43-4d01-9497-aef421b47504_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_1bb0df61-46e7-4e97-be6c-8a2af88bc361_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average price of shares repurchased (in usd per share)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_label_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Acquired, Average Cost Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:to="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_a4d53f23-0a07-40dc-a9c0-9a43aa7f15e2_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetNotionalAmount_6d9fa8d3-80cf-4598-ba80-d1845b847931_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Dollar notional amount, asset</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssetNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetNotionalAmount" xlink:to="lab_us-gaap_DerivativeAssetNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_0db2138f-2266-4deb-bcdc-1a0c3edbb460_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2db14b9e-4d9c-443f-8647-5ef21265a6d3_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f2ee2c5b-cb29-46f6-948b-007925e594c6_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_947d33f6-d28c-4d5d-a252-18eb9f842bcd_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_LossContingencyClaimsSettledNumberOfJurisdictionsNotParticipatingInSettlement_48e292fb-c843-4227-99e0-907817b2585b_terseLabel_en-US" xlink:label="lab_mck_LossContingencyClaimsSettledNumberOfJurisdictionsNotParticipatingInSettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, claims settled, number of jurisdictions not participating in settlement</link:label>
    <link:label id="lab_mck_LossContingencyClaimsSettledNumberOfJurisdictionsNotParticipatingInSettlement_label_en-US" xlink:label="lab_mck_LossContingencyClaimsSettledNumberOfJurisdictionsNotParticipatingInSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Settled, Number Of Jurisdictions Not Participating In Settlement</link:label>
    <link:label id="lab_mck_LossContingencyClaimsSettledNumberOfJurisdictionsNotParticipatingInSettlement_documentation_en-US" xlink:label="lab_mck_LossContingencyClaimsSettledNumberOfJurisdictionsNotParticipatingInSettlement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Settled, Number Of Jurisdictions Not Participating In Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_LossContingencyClaimsSettledNumberOfJurisdictionsNotParticipatingInSettlement" xlink:href="mck-20230630.xsd#mck_LossContingencyClaimsSettledNumberOfJurisdictionsNotParticipatingInSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_LossContingencyClaimsSettledNumberOfJurisdictionsNotParticipatingInSettlement" xlink:to="lab_mck_LossContingencyClaimsSettledNumberOfJurisdictionsNotParticipatingInSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_1090840a-c93b-4b2f-86c6-f4a043171c99_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansPayableMember_db45537d-9bb5-4038-82b8-aa237f85cc53_verboseLabel_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans payable</link:label>
    <link:label id="lab_us-gaap_LoansPayableMember_06530d25-8d68-4758-aae5-235701d7ccfc_terseLabel_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan</link:label>
    <link:label id="lab_us-gaap_LoansPayableMember_label_en-US" xlink:label="lab_us-gaap_LoansPayableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans Payable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansPayableMember" xlink:to="lab_us-gaap_LoansPayableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_da68ecca-3d92-4c7a-9b82-c27a9d7acec2_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_ba5b5f21-f938-40a1-967d-dfcb41b6f674_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total purchase consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_845bc78e-c3d3-4ae8-a32d-6836af9fe9eb_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total purchase consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_26fc6c12-3b58-4d41-9af3-99f0cbf6641a_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_BritishPoundSterlingDenominatedNotesMember_56e7ecea-8d5e-4a61-a2e9-a7494403719b_terseLabel_en-US" xlink:label="lab_mck_BritishPoundSterlingDenominatedNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">British Pound Sterling Denominated Notes</link:label>
    <link:label id="lab_mck_BritishPoundSterlingDenominatedNotesMember_label_en-US" xlink:label="lab_mck_BritishPoundSterlingDenominatedNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">British Pound Sterling Denominated Notes [Member]</link:label>
    <link:label id="lab_mck_BritishPoundSterlingDenominatedNotesMember_documentation_en-US" xlink:label="lab_mck_BritishPoundSterlingDenominatedNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">British Pound Sterling Denominated Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_BritishPoundSterlingDenominatedNotesMember" xlink:href="mck-20230630.xsd#mck_BritishPoundSterlingDenominatedNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_BritishPoundSterlingDenominatedNotesMember" xlink:to="lab_mck_BritishPoundSterlingDenominatedNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeveranceCosts1_6d5ba7ce-824b-42a4-a1aa-029033b85e28_terseLabel_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance and employee-related costs, net</link:label>
    <link:label id="lab_us-gaap_SeveranceCosts1_label_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1" xlink:to="lab_us-gaap_SeveranceCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_4e66b476-85bd-47d1-8c03-e264e334b601_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_eacb34a1-472c-4b15-9236-2c246a9d07d6_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt and Lease Obligation, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_bc276e59-83db-4c1c-a403-656505dadd87_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury shares, at cost, 143 and 141 shares at June 30, 2023 and March 31, 2023, respectively</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonValue" xlink:to="lab_us-gaap_TreasuryStockCommonValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_efd5c4cc-4d9e-4670-9227-c0470f20e3d8_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_b1234fad-93eb-4368-aec6-42fe9a46fad0_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_a30c2688-1cd2-4f79-90e7-1118922670d8_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt outstanding</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_49284a49-9cb8-4abe-94b4-691bbbf88adb_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Value</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_c8a98c31-5e33-4214-b411-24a82e563072_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, distribution, general, and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_49dcd4b8-ef66-4fd1-8908-317f72ccf251_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_e9f7423f-574c-4515-a449-75c98f092461_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss) before reclassifications</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_e02ed1d7-36db-4412-a195-4fbf99854c19_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_d51d8760-de24-41d9-a4e5-362cdf94033b_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Activities</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_A090NotesDueDecember32025Member_b35c9754-3664-4385-955d-d7671d434118_terseLabel_en-US" xlink:label="lab_mck_A090NotesDueDecember32025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.90% Notes due December 3, 2025</link:label>
    <link:label id="lab_mck_A090NotesDueDecember32025Member_label_en-US" xlink:label="lab_mck_A090NotesDueDecember32025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.90% Notes Due December 3, 2025 [Member]</link:label>
    <link:label id="lab_mck_A090NotesDueDecember32025Member_documentation_en-US" xlink:label="lab_mck_A090NotesDueDecember32025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.90% Notes Due December 3, 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_A090NotesDueDecember32025Member" xlink:href="mck-20230630.xsd#mck_A090NotesDueDecember32025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_A090NotesDueDecember32025Member" xlink:to="lab_mck_A090NotesDueDecember32025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_bcc6d5ee-ab89-40a5-ab17-613640ca9beb_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount_414632bf-c741-43d0-82c1-957dcaca51bd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt principal redeemed</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Repurchased Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_d1df04e0-a944-4de8-b0b7-1ac6a92641ca_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_c3615d24-d3a8-46b7-91e4-3bf8ccfb02c6_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income attributable to McKesson Corporation</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_c2eba548-93c8-4639-b13b-ed99505cf0ed_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:to="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_d0a66f2d-163b-40ec-bc9f-e23409c48a02_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, Impairment, and Related Costs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_a7fc2b2d-f1d4-4db9-8bee-bbcf77cd978e_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrencySwapMember_9dad4cc6-7ccb-4c9a-a526-b5dddfd9a3c0_terseLabel_en-US" xlink:label="lab_us-gaap_CurrencySwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives designated as net investment hedges</link:label>
    <link:label id="lab_us-gaap_CurrencySwapMember_7b839280-6a96-40a3-b09c-100666aa94e8_netLabel_en-US" xlink:label="lab_us-gaap_CurrencySwapMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross-currency swaps</link:label>
    <link:label id="lab_us-gaap_CurrencySwapMember_09c5776b-a970-44bc-98a0-38428eeb90bc_verboseLabel_en-US" xlink:label="lab_us-gaap_CurrencySwapMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedges</link:label>
    <link:label id="lab_us-gaap_CurrencySwapMember_label_en-US" xlink:label="lab_us-gaap_CurrencySwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrencySwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrencySwapMember" xlink:to="lab_us-gaap_CurrencySwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_d8c956fd-0c97-46b9-b284-de02d14bcb7a_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations (in usd per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_750eaba9-3d3b-4306-8d56-c708def2a912_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discontinued operations (in usd per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_1d426cdb-45fe-473f-bdf7-5a550413ce5d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_OtherNonCurrentAssetsAndLiabilitiesMember_916a859d-ca8d-4452-bf89-5dbd60de232a_terseLabel_en-US" xlink:label="lab_mck_OtherNonCurrentAssetsAndLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets/liabilities</link:label>
    <link:label id="lab_mck_OtherNonCurrentAssetsAndLiabilitiesMember_label_en-US" xlink:label="lab_mck_OtherNonCurrentAssetsAndLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Non-Current Assets and Liabilities [Member]</link:label>
    <link:label id="lab_mck_OtherNonCurrentAssetsAndLiabilitiesMember_documentation_en-US" xlink:label="lab_mck_OtherNonCurrentAssetsAndLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Non-Current Assets and Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_OtherNonCurrentAssetsAndLiabilitiesMember" xlink:href="mck-20230630.xsd#mck_OtherNonCurrentAssetsAndLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_OtherNonCurrentAssetsAndLiabilitiesMember" xlink:to="lab_mck_OtherNonCurrentAssetsAndLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_00f419d4-31d0-4ac1-b4c6-efb2cff08e75_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-cash items</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_EvanstonPolicePensionFundVMcKessonCorporationMember_43faad90-4fb3-4a41-9fdd-d0c8e89132c6_terseLabel_en-US" xlink:label="lab_mck_EvanstonPolicePensionFundVMcKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evanston Police Pension Fund v. McKesson Corporation</link:label>
    <link:label id="lab_mck_EvanstonPolicePensionFundVMcKessonCorporationMember_label_en-US" xlink:label="lab_mck_EvanstonPolicePensionFundVMcKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evanston Police Pension Fund v. McKesson Corporation [Member]</link:label>
    <link:label id="lab_mck_EvanstonPolicePensionFundVMcKessonCorporationMember_documentation_en-US" xlink:label="lab_mck_EvanstonPolicePensionFundVMcKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evanston Police Pension Fund v. McKesson Corporation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_EvanstonPolicePensionFundVMcKessonCorporationMember" xlink:href="mck-20230630.xsd#mck_EvanstonPolicePensionFundVMcKessonCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_EvanstonPolicePensionFundVMcKessonCorporationMember" xlink:to="lab_mck_EvanstonPolicePensionFundVMcKessonCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_6ef940a1-507f-44f1-9458-a293a0b471d7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermOperatingLeaseLiabilities_dbaa3a27-8ff1-42b4-a0c1-25c9983cce9b_negatedTerseLabel_en-US" xlink:label="lab_mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermOperatingLeaseLiabilities_label_en-US" xlink:label="lab_mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Long-Term Operating Lease Liabilities</link:label>
    <link:label id="lab_mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Long-Term Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermOperatingLeaseLiabilities" xlink:href="mck-20230630.xsd#mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermOperatingLeaseLiabilities" xlink:to="lab_mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_ExciseTaxPayableCurrent_d1d63b71-7b4c-4830-8dd6-916bbe75858e_terseLabel_en-US" xlink:label="lab_mck_ExciseTaxPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excise taxes</link:label>
    <link:label id="lab_mck_ExciseTaxPayableCurrent_label_en-US" xlink:label="lab_mck_ExciseTaxPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excise Tax Payable, Current</link:label>
    <link:label id="lab_mck_ExciseTaxPayableCurrent_documentation_en-US" xlink:label="lab_mck_ExciseTaxPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excise Tax Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_ExciseTaxPayableCurrent" xlink:href="mck-20230630.xsd#mck_ExciseTaxPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_ExciseTaxPayableCurrent" xlink:to="lab_mck_ExciseTaxPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_1c7017cb-72c6-402d-a740-3bf00f2c587e_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks and trade names</link:label>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks and Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksAndTradeNamesMember" xlink:to="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_e88bef1b-7ef4-490e-8465-2a708f675bb5_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_411d6ba6-ca5d-4a75-854d-45c1d7dcf345_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_StateOfWestVirginiaAndSubdivisionsMember_a70ffab8-58b2-496c-aaab-c1ec89a4c526_terseLabel_en-US" xlink:label="lab_mck_StateOfWestVirginiaAndSubdivisionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State of West Virginia and Subdivisions</link:label>
    <link:label id="lab_mck_StateOfWestVirginiaAndSubdivisionsMember_label_en-US" xlink:label="lab_mck_StateOfWestVirginiaAndSubdivisionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State of West Virginia and Subdivisions [Member]</link:label>
    <link:label id="lab_mck_StateOfWestVirginiaAndSubdivisionsMember_documentation_en-US" xlink:label="lab_mck_StateOfWestVirginiaAndSubdivisionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State of West Virginia and Subdivisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_StateOfWestVirginiaAndSubdivisionsMember" xlink:href="mck-20230630.xsd#mck_StateOfWestVirginiaAndSubdivisionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_StateOfWestVirginiaAndSubdivisionsMember" xlink:to="lab_mck_StateOfWestVirginiaAndSubdivisionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_756299e7-b0d9-437c-a6bc-5d829f62af9d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of information regarding intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_dcfad2c9-aa1f-4f7e-b4a1-3f82e1edb3ed_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_6147c873-b46b-4d2d-af4a-e44d1a0c635c_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_f3789791-3ddb-443b-b8f4-81139963a37c_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_b53c2a26-cbc1-4a86-8881-810b5f5b844c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_AcceleratedShareRepurchaseMember_12bc053e-fcf8-4702-aa3c-3ddf31e1a331_terseLabel_en-US" xlink:label="lab_mck_AcceleratedShareRepurchaseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchase</link:label>
    <link:label id="lab_mck_AcceleratedShareRepurchaseMember_label_en-US" xlink:label="lab_mck_AcceleratedShareRepurchaseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchase [Member]</link:label>
    <link:label id="lab_mck_AcceleratedShareRepurchaseMember_documentation_en-US" xlink:label="lab_mck_AcceleratedShareRepurchaseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchase [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_AcceleratedShareRepurchaseMember" xlink:href="mck-20230630.xsd#mck_AcceleratedShareRepurchaseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_AcceleratedShareRepurchaseMember" xlink:to="lab_mck_AcceleratedShareRepurchaseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_43a93db3-a014-4aa4-a423-af2f10a136b6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Asset Impairment Charges</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_c561fad9-dbe1-4a26-98e7-dfd0ec37cdd5_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_03cc603a-381f-4b76-bc2d-36d572ab35ed_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss) before Reclassifications, Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss) before Reclassifications, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_ffae2d23-d054-46cd-84bc-6832945c0447_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: amounts attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcceleratedShareRepurchasesTable_7c33cd69-c67c-4299-9f8d-b8615c4c1d67_terseLabel_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchasesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchases [Table]</link:label>
    <link:label id="lab_us-gaap_AcceleratedShareRepurchasesTable_label_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchasesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchases [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcceleratedShareRepurchasesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesTable" xlink:to="lab_us-gaap_AcceleratedShareRepurchasesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_3b694c55-f376-473f-8db5-72f33dd03193_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_c6c1d01c-48c9-4852-83ff-6085f32304ce_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_e6b41eae-3ed0-46eb-b8fc-053a2acc26fd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_EffectiveIncomeTaxReconciliationTaxExpenseBenefitIntraEntityTransfersOfAssetsOtherThanInventoryAmount_eb897bdd-a8e0-4cd9-a055-63a8d78e2aa0_terseLabel_en-US" xlink:label="lab_mck_EffectiveIncomeTaxReconciliationTaxExpenseBenefitIntraEntityTransfersOfAssetsOtherThanInventoryAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax expense (benefit), intra-entity transfers of assets other than inventory, amount</link:label>
    <link:label id="lab_mck_EffectiveIncomeTaxReconciliationTaxExpenseBenefitIntraEntityTransfersOfAssetsOtherThanInventoryAmount_label_en-US" xlink:label="lab_mck_EffectiveIncomeTaxReconciliationTaxExpenseBenefitIntraEntityTransfersOfAssetsOtherThanInventoryAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Reconciliation, Tax Expense (Benefit), Intra-Entity Transfers Of Assets Other Than Inventory, Amount</link:label>
    <link:label id="lab_mck_EffectiveIncomeTaxReconciliationTaxExpenseBenefitIntraEntityTransfersOfAssetsOtherThanInventoryAmount_documentation_en-US" xlink:label="lab_mck_EffectiveIncomeTaxReconciliationTaxExpenseBenefitIntraEntityTransfersOfAssetsOtherThanInventoryAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Reconciliation, Tax Expense (Benefit), Intra-Entity Transfers Of Assets Other Than Inventory, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_EffectiveIncomeTaxReconciliationTaxExpenseBenefitIntraEntityTransfersOfAssetsOtherThanInventoryAmount" xlink:href="mck-20230630.xsd#mck_EffectiveIncomeTaxReconciliationTaxExpenseBenefitIntraEntityTransfersOfAssetsOtherThanInventoryAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_EffectiveIncomeTaxReconciliationTaxExpenseBenefitIntraEntityTransfersOfAssetsOtherThanInventoryAmount" xlink:to="lab_mck_EffectiveIncomeTaxReconciliationTaxExpenseBenefitIntraEntityTransfersOfAssetsOtherThanInventoryAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_914f138e-b0ed-437c-8f48-20a96ef886a1_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_351e3b7f-3b46-4a62-bf98-80520e35874a_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_a9487913-296f-43e1-b899-f15958ccd3ef_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments, net</link:label>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_30715f2f-db18-4d3c-821d-9331538f8031_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_EPSBasicAndDilutedAbstract_0b8819a2-6d05-45a0-8f06-f14c52eeed13_terseLabel_en-US" xlink:label="lab_mck_EPSBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings (loss) per common share attributable to McKesson:</link:label>
    <link:label id="lab_mck_EPSBasicAndDilutedAbstract_label_en-US" xlink:label="lab_mck_EPSBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EPS, Basic and Diluted [Abstract]</link:label>
    <link:label id="lab_mck_EPSBasicAndDilutedAbstract_documentation_en-US" xlink:label="lab_mck_EPSBasicAndDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_EPSBasicAndDilutedAbstract" xlink:href="mck-20230630.xsd#mck_EPSBasicAndDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_EPSBasicAndDilutedAbstract" xlink:to="lab_mck_EPSBasicAndDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_27d9b024-46b6-477b-a243-ac274a57eb0f_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_cce6c79d-caf7-4ec8-8471-9a2018fc94f2_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_2caf87a6-849d-494a-b8e1-4c8e9799ebd1_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest_a05fd16a-032b-4e8a-8e7f-cc676eb5e77a_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net assets acquired</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Less Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_2f0545be-f21a-47d0-877d-4b346b1d8d9c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_d18d9287-0982-45fb-88e5-926323d4c7fc_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share repurchases</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_62d45d45-cebc-4a47-a7b2-66b90862eb60_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_SCRIOncologyLLCMember_91459f7a-69d7-4ae2-a10d-f86fa3ea4c47_terseLabel_en-US" xlink:label="lab_mck_SCRIOncologyLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SCRI Oncology, LLC</link:label>
    <link:label id="lab_mck_SCRIOncologyLLCMember_label_en-US" xlink:label="lab_mck_SCRIOncologyLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SCRI Oncology, LLC [Member]</link:label>
    <link:label id="lab_mck_SCRIOncologyLLCMember_documentation_en-US" xlink:label="lab_mck_SCRIOncologyLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SCRI Oncology, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_SCRIOncologyLLCMember" xlink:href="mck-20230630.xsd#mck_SCRIOncologyLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_SCRIOncologyLLCMember" xlink:to="lab_mck_SCRIOncologyLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_67bb36ba-6c37-4288-9f4c-4cb4e17df1c1_terseLabel_en-US" xlink:label="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisitions and Divestitures</link:label>
    <link:label id="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mergers, Acquisitions and Dispositions Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:to="lab_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_a68a2b71-2d45-4764-b176-137c953e50fd_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_ce62fa28-7a50-4f07-825f-07d6b85f8062_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_06a1c861-81f4-49b2-9dda-3ed37d0ed912_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_e6d96f9c-5854-4563-9f8a-369d8d359b62_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e8a09007-29e6-4e1c-a12c-7f5050b4a6e9_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_a44a5557-2a25-46bc-895a-4df6d618d702_verboseLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Claims and litigation charges, net</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_label_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) Related to Litigation Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossRelatedToLitigationSettlement" xlink:to="lab_us-gaap_GainLossRelatedToLitigationSettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_4303ab42-cd82-4556-afb4-465a5c63bacf_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt principal amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_c9ca8c20-3938-4445-b8fd-1b2bfe6d822d_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_5e2a9dad-837d-4929-b944-277786034684_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_3e9eefb5-0297-4dd2-acf5-b0ce144f9189_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_8173964b-48f6-45ca-bb2b-58ca65d2c04c_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Divested net assets</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_fd77ac57-2bca-4eb3-81d5-c894d438ab07_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_4943860e-5c84-4e6c-9bf4-6e774784d5aa_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_bd863bc4-ea65-4f6e-bbbc-715a05cf32f0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c8ca88c7-3393-46ee-b891-909797af1eae_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPERATING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_7ffe382a-fafa-44af-af5e-f3f2ac577388_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Continuing operations (in usd per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_5d79de08-b03a-4079-b847-8c213a77be22_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Continuing operations (in usd per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_944cda0c-3bed-4f8d-ad73-c499fc86ed18_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated annual amortization expense, 2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_53f1422b-3fac-40e9-8c97-ce2c09ff1778_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_b923c50f-0bf5-43cd-bdf5-e06a1cc65192_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_a6950d1a-427b-41f7-8b64-82421b12f7c2_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, estimate of possible loss</link:label>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_label_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:to="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityOther_119984f5-04ab-4b6d-a102-40ce7569eb09_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOther_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOther" xlink:to="lab_us-gaap_StockholdersEquityOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_3e6d59a0-c631-4c27-82e7-8ab1344a2ee5_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from short-term borrowings</link:label>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Short-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromShortTermDebt" xlink:to="lab_us-gaap_ProceedsFromShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_47296ec8-cb79-4674-bcb6-4c9ee5019b42_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_9be151f3-56ed-42e5-8e4f-e022fbd8b07d_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_aaf06067-a805-4cfc-9587-6db0621f512d_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_d00b1fa3-67bf-49b4-bdc9-9a0ec8f62136_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_03f5f305-12b4-4448-870b-c20c7ce01181_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredParValueMethod_a018b62f-0be7-4c6f-a7f3-aa3039292306_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredParValueMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares repurchased</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredParValueMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredParValueMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Par Value Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredParValueMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAcquiredParValueMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredParValueMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredParValueMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_ca67cd8b-1b68-41a8-b0ed-8c678f0c95b5_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of derivative, asset</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Subject to Master Netting Arrangement, before Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock_8ec69e87-6f40-4072-9aaa-b77c7ba4ee13_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Estimated Accrual Liability</link:label>
    <link:label id="lab_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Loss Contingencies by Contingency [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock" xlink:to="lab_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_3abbb403-8e98-48cc-a06a-48bcc452c4f4_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_c2286a7e-1eff-4c88-bbfe-f7de5cd24866_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_8606471c-cc1e-4116-ac51-ec6a9b023709_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_9f8be32e-8d72-4fc2-9eff-618fbb6fd241_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_RxSavingsSolutionsLLCMember_1438cf5b-1000-4176-94d9-2a526322cfec_terseLabel_en-US" xlink:label="lab_mck_RxSavingsSolutionsLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rx Savings Solutions, LLC</link:label>
    <link:label id="lab_mck_RxSavingsSolutionsLLCMember_label_en-US" xlink:label="lab_mck_RxSavingsSolutionsLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rx Savings Solutions, LLC [Member]</link:label>
    <link:label id="lab_mck_RxSavingsSolutionsLLCMember_documentation_en-US" xlink:label="lab_mck_RxSavingsSolutionsLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rx Savings Solutions, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_RxSavingsSolutionsLLCMember" xlink:href="mck-20230630.xsd#mck_RxSavingsSolutionsLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_RxSavingsSolutionsLLCMember" xlink:to="lab_mck_RxSavingsSolutionsLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_f76644c4-160e-42d2-8c82-65a0f0ba6908_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives designated as cash flow and other hedges:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_6ebd0857-dc4d-4eaf-8d4c-805be59593db_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_A600NotesDueMarch12041Member_9c2c4569-4efb-417f-8934-11a13faefcf9_terseLabel_en-US" xlink:label="lab_mck_A600NotesDueMarch12041Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.00% Notes due March 1, 2041</link:label>
    <link:label id="lab_mck_A600NotesDueMarch12041Member_label_en-US" xlink:label="lab_mck_A600NotesDueMarch12041Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.00% Notes Due March 1, 2041 [Member]</link:label>
    <link:label id="lab_mck_A600NotesDueMarch12041Member_documentation_en-US" xlink:label="lab_mck_A600NotesDueMarch12041Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.00% Notes Due March 1, 2041</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_A600NotesDueMarch12041Member" xlink:href="mck-20230630.xsd#mck_A600NotesDueMarch12041Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_A600NotesDueMarch12041Member" xlink:to="lab_mck_A600NotesDueMarch12041Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateSwapMember_30effbbc-e6b9-4de3-ad44-a6150d3d99e0_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Floating interest rate swaps</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestRateSwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_1fbad4b4-46cd-41a5-a502-81a9b0784574_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_137f1189-0ce4-4e90-a3fc-e0a142e89a40_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from continuing operations attributable to McKesson Corporation</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_6e1f9d89-9f78-4b15-9036-fa22e9c34b4c_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reported income tax expense (benefit) rates (percent)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_0128b6b0-78d7-4635-b08c-cb07d49352b2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_SeniorUnsecuredCreditFacilityThe2022CreditFacilityCanadianDollarBritishPoundSterlingAndEurosSublimitMember_e508d972-33ff-425b-a8b2-0d2d76e73bdd_terseLabel_en-US" xlink:label="lab_mck_SeniorUnsecuredCreditFacilityThe2022CreditFacilityCanadianDollarBritishPoundSterlingAndEurosSublimitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Credit Facility (the 2022 Credit Facility), Canadian Dollar, British Pound Sterling, and Euros Sublimit</link:label>
    <link:label id="lab_mck_SeniorUnsecuredCreditFacilityThe2022CreditFacilityCanadianDollarBritishPoundSterlingAndEurosSublimitMember_label_en-US" xlink:label="lab_mck_SeniorUnsecuredCreditFacilityThe2022CreditFacilityCanadianDollarBritishPoundSterlingAndEurosSublimitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Credit Facility (the 2022 Credit Facility), Canadian Dollar, British Pound Sterling, and Euros Sublimit [Member]</link:label>
    <link:label id="lab_mck_SeniorUnsecuredCreditFacilityThe2022CreditFacilityCanadianDollarBritishPoundSterlingAndEurosSublimitMember_documentation_en-US" xlink:label="lab_mck_SeniorUnsecuredCreditFacilityThe2022CreditFacilityCanadianDollarBritishPoundSterlingAndEurosSublimitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Credit Facility (the 2022 Credit Facility), Canadian Dollar, British Pound Sterling, and Euros Sublimit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_SeniorUnsecuredCreditFacilityThe2022CreditFacilityCanadianDollarBritishPoundSterlingAndEurosSublimitMember" xlink:href="mck-20230630.xsd#mck_SeniorUnsecuredCreditFacilityThe2022CreditFacilityCanadianDollarBritishPoundSterlingAndEurosSublimitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_SeniorUnsecuredCreditFacilityThe2022CreditFacilityCanadianDollarBritishPoundSterlingAndEurosSublimitMember" xlink:to="lab_mck_SeniorUnsecuredCreditFacilityThe2022CreditFacilityCanadianDollarBritishPoundSterlingAndEurosSublimitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_e8892b8d-8a95-41f7-811a-3a87e33bbfd6_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_5a59f47f-55c9-4bae-ac82-3c33c6776bcb_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_8a106bf3-7e18-4895-9436-1c9a83112e1e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SettledLitigationMember_55e55a76-3c1b-4ae0-ac9d-b283686da2db_terseLabel_en-US" xlink:label="lab_us-gaap_SettledLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settled Litigation</link:label>
    <link:label id="lab_us-gaap_SettledLitigationMember_label_en-US" xlink:label="lab_us-gaap_SettledLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settled Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SettledLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SettledLitigationMember" xlink:to="lab_us-gaap_SettledLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_fb323363-dd28-4eff-b437-6e0fc41fee3c_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_0de391c3-fd94-43ab-a6b9-dd2576484df8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_8f30cb9e-4c3e-4cbb-bd83-bf6de91e5166_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CA_4c58ec19-b583-4896-8304-5839b0e7b4ec_terseLabel_en-US" xlink:label="lab_country_CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canada</link:label>
    <link:label id="lab_country_CA_label_en-US" xlink:label="lab_country_CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CANADA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CA" xlink:to="lab_country_CA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_25ed7c6f-ed98-46c7-9c99-c6cf6b569539_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposed of by sale</link:label>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:to="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_34d1543b-486e-495a-9551-a9c7e4f111ee_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_2fdd5a1c-5549-48ca-8963-7bdf134bfead_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per common share attributable to McKesson Corporation</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_8af70c66-82dd-4146-b356-c8876191ed07_terseLabel_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_label_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:to="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_fe24a194-dc12-45e0-888b-38348da0b75f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.01 par value, 800 shares authorized, 278 and 277 shares issued at June 30, 2023 and March 31, 2023, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_ebeb4ec1-4c3c-4477-a17c-8f688d20c905_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption price percentage of principal (percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualCarryingValueCurrent_6cd317cb-8f21-43d6-a730-cf961662fe89_verboseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualCarryingValueCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current litigation liabilities</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualCarryingValueCurrent_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualCarryingValueCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Accrual, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualCarryingValueCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualCarryingValueCurrent" xlink:to="lab_us-gaap_LossContingencyAccrualCarryingValueCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_USD_ce347917-aa0a-4c6b-b9b6-bc4b17f28c28_terseLabel_en-US" xlink:label="lab_currency_USD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">USD</link:label>
    <link:label id="lab_currency_USD_label_en-US" xlink:label="lab_currency_USD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States of America, Dollars</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_USD"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_USD" xlink:to="lab_currency_USD" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_RxTsSegmentMember_e0bcda70-3fd9-43d3-a554-f543b7afeed1_terseLabel_en-US" xlink:label="lab_mck_RxTsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RxTs Segment</link:label>
    <link:label id="lab_mck_RxTsSegmentMember_label_en-US" xlink:label="lab_mck_RxTsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RxTs Segment [Member]</link:label>
    <link:label id="lab_mck_RxTsSegmentMember_documentation_en-US" xlink:label="lab_mck_RxTsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RxTs Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_RxTsSegmentMember" xlink:href="mck-20230630.xsd#mck_RxTsSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_RxTsSegmentMember" xlink:to="lab_mck_RxTsSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_A1500NotesDue2025Member_722b00cb-ec18-4f0d-95e5-ba9b96fa05c6_terseLabel_en-US" xlink:label="lab_mck_A1500NotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.500% Notes Due 2025</link:label>
    <link:label id="lab_mck_A1500NotesDue2025Member_label_en-US" xlink:label="lab_mck_A1500NotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.500% Notes Due 2025 [Member]</link:label>
    <link:label id="lab_mck_A1500NotesDue2025Member_documentation_en-US" xlink:label="lab_mck_A1500NotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.500% Notes Due 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_A1500NotesDue2025Member" xlink:href="mck-20230630.xsd#mck_A1500NotesDue2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_A1500NotesDue2025Member" xlink:to="lab_mck_A1500NotesDue2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_790dc850-2662-4ad2-bef4-9abb809c6fc2_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_SarahCannonResearchInstituteMember_32803b69-f3ab-4d35-85f3-70471e5b59e5_terseLabel_en-US" xlink:label="lab_mck_SarahCannonResearchInstituteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SCRI</link:label>
    <link:label id="lab_mck_SarahCannonResearchInstituteMember_label_en-US" xlink:label="lab_mck_SarahCannonResearchInstituteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sarah Cannon Research Institute [Member]</link:label>
    <link:label id="lab_mck_SarahCannonResearchInstituteMember_documentation_en-US" xlink:label="lab_mck_SarahCannonResearchInstituteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sarah Cannon Research Institute</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_SarahCannonResearchInstituteMember" xlink:href="mck-20230630.xsd#mck_SarahCannonResearchInstituteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_SarahCannonResearchInstituteMember" xlink:to="lab_mck_SarahCannonResearchInstituteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_b35c8c79-a071-4d74-8547-68a67fc5c90f_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_f374ba0d-fd3c-4220-846e-b2651fbc2b93_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_3d06cbce-c817-47e1-bf7e-d2b479b8514a_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_7a0ea124-d868-4022-96d0-23d609bcd66e_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_label_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentForAmortization" xlink:to="lab_us-gaap_AdjustmentForAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_b9f13fae-bbc6-4296-aef9-051dd71fa9de_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_3963cb6f-9746-4e62-aaf2-1e434e161d7a_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_ccbbf310-a507-4054-ba60-0001d6306c32_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_7ec0112a-4298-49e7-aba4-2387b29bad93_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_14c02941-fa39-4780-a9e2-fb8bd089f74d_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_74fbed8f-51a3-4dae-a5b1-f49972073803_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-for-sale</link:label>
    <link:label id="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_label_en-US" xlink:label="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Held-for-Sale, Not Discontinued Operations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:to="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_57f9892e-e588-43b4-abc8-eccc0f5032e2_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authorized repurchase amount (up to)</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_aa125d6f-35f2-42a2-9331-80be2e9a78ee_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_e58d7e15-9d7e-4d3d-a036-7d49685c1bba_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_3e001ed7-a085-4dc3-a467-e82ec826d8c8_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share repurchases (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_fabc30ac-167f-4f91-9eac-d9bcc99689d9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_8100be31-9bb7-4358-8a2a-1b5306ebb44e_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_1d5dd23b-5faa-4712-9916-5457aca9e98c_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax expense (benefit), share-based payment arrangement</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_343307b4-3f89-42fe-9ff5-826523e68a6c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of information regarding changes in accumulated other comprehensive income (loss), net of tax, by component</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_3d21bc7a-9a1f-4582-acba-92b5a2c7649f_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_CorporateOperatingExpenseandOtherIncomeNet_43495afd-ed2b-40c1-b143-eed3a9c4651d_negatedTerseLabel_en-US" xlink:label="lab_mck_CorporateOperatingExpenseandOtherIncomeNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate income (expenses), net</link:label>
    <link:label id="lab_mck_CorporateOperatingExpenseandOtherIncomeNet_label_en-US" xlink:label="lab_mck_CorporateOperatingExpenseandOtherIncomeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Operating Expense and Other Income, Net</link:label>
    <link:label id="lab_mck_CorporateOperatingExpenseandOtherIncomeNet_documentation_en-US" xlink:label="lab_mck_CorporateOperatingExpenseandOtherIncomeNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Operating Expense and Other Income, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_CorporateOperatingExpenseandOtherIncomeNet" xlink:href="mck-20230630.xsd#mck_CorporateOperatingExpenseandOtherIncomeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_CorporateOperatingExpenseandOtherIncomeNet" xlink:to="lab_mck_CorporateOperatingExpenseandOtherIncomeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_2db2182e-7bc4-423d-8215-b370a7daf4bb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Restricted cash at end of period included in Prepaid expenses and other</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_AcceleratedShareRepurchaseInitialShareSettlementMember_dfee8080-1d41-4ebd-ae23-5c06afd5a1dd_terseLabel_en-US" xlink:label="lab_mck_AcceleratedShareRepurchaseInitialShareSettlementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchase, Initial Share Settlement</link:label>
    <link:label id="lab_mck_AcceleratedShareRepurchaseInitialShareSettlementMember_label_en-US" xlink:label="lab_mck_AcceleratedShareRepurchaseInitialShareSettlementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchase, Initial Share Settlement [Member]</link:label>
    <link:label id="lab_mck_AcceleratedShareRepurchaseInitialShareSettlementMember_documentation_en-US" xlink:label="lab_mck_AcceleratedShareRepurchaseInitialShareSettlementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchase, Initial Share Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_AcceleratedShareRepurchaseInitialShareSettlementMember" xlink:href="mck-20230630.xsd#mck_AcceleratedShareRepurchaseInitialShareSettlementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_AcceleratedShareRepurchaseInitialShareSettlementMember" xlink:to="lab_mck_AcceleratedShareRepurchaseInitialShareSettlementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_5b288e19-9682-4fe6-895a-afce5e3f09cf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of changes in the carrying amount of goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_084893f5-f638-4072-af08-f57fcae8303a_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcceleratedShareRepurchasesLineItems_a8d35422-8dbd-44f4-8da0-34e7074ee90b_terseLabel_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchasesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchases [Line Items]</link:label>
    <link:label id="lab_us-gaap_AcceleratedShareRepurchasesLineItems_label_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchasesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Share Repurchases [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcceleratedShareRepurchasesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesLineItems" xlink:to="lab_us-gaap_AcceleratedShareRepurchasesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_64cc3643-02d1-4f80-aa62-49b47f9abf02_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_MedicalSurgicalSolutionsSegmentMember_f935e778-a787-402f-abb5-f698c7a51fe4_terseLabel_en-US" xlink:label="lab_mck_MedicalSurgicalSolutionsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical-Surgical Solutions</link:label>
    <link:label id="lab_mck_MedicalSurgicalSolutionsSegmentMember_label_en-US" xlink:label="lab_mck_MedicalSurgicalSolutionsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical-Surgical Solutions Segment [Member]</link:label>
    <link:label id="lab_mck_MedicalSurgicalSolutionsSegmentMember_documentation_en-US" xlink:label="lab_mck_MedicalSurgicalSolutionsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical-Surgical Solutions Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_MedicalSurgicalSolutionsSegmentMember" xlink:href="mck-20230630.xsd#mck_MedicalSurgicalSolutionsSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_MedicalSurgicalSolutionsSegmentMember" xlink:to="lab_mck_MedicalSurgicalSolutionsSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_9d746e2c-7f15-4159-b559-88ec965e163a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_28499fbf-f47a-4b24-a412-dd13db9324e7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitiesTable_9f0f4942-62a7-4ca8-aa8d-82d01c45d849_terseLabel_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:label id="lab_dei_EntitiesTable_label_en-US" xlink:label="lab_dei_EntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitiesTable" xlink:to="lab_dei_EntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_StateOfAlabamaAndSubdivisionsMember_91f25763-aacc-483d-8aba-674dc55b5ee5_terseLabel_en-US" xlink:label="lab_mck_StateOfAlabamaAndSubdivisionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State of Alabama and Subdivisions</link:label>
    <link:label id="lab_mck_StateOfAlabamaAndSubdivisionsMember_label_en-US" xlink:label="lab_mck_StateOfAlabamaAndSubdivisionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State of Alabama and Subdivisions [Member]</link:label>
    <link:label id="lab_mck_StateOfAlabamaAndSubdivisionsMember_documentation_en-US" xlink:label="lab_mck_StateOfAlabamaAndSubdivisionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State of Alabama and Subdivisions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_StateOfAlabamaAndSubdivisionsMember" xlink:href="mck-20230630.xsd#mck_StateOfAlabamaAndSubdivisionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_StateOfAlabamaAndSubdivisionsMember" xlink:to="lab_mck_StateOfAlabamaAndSubdivisionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_b70826cb-f004-48c6-816d-2d4d991e2f32_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_5aaae84a-f561-4f84-a0a1-f162d0d74088_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_33f6817e-dfd2-4301-bde2-7d022f8b6eeb_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award payable under proposed framework</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="lab_us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfOtherAssets_8199694e-1bbd-4fd9-8566-3b613e4e4dc9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain from sales of businesses and investments</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfOtherAssets_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfOtherAssets" xlink:to="lab_us-gaap_GainLossOnSaleOfOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_A765DebenturesDueMarch12027Member_32e0bc24-c8f4-4531-b000-a5cdfa82901c_terseLabel_en-US" xlink:label="lab_mck_A765DebenturesDueMarch12027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7.65% Debentures due March 1, 2027</link:label>
    <link:label id="lab_mck_A765DebenturesDueMarch12027Member_label_en-US" xlink:label="lab_mck_A765DebenturesDueMarch12027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7.65% Debentures Due March 1, 2027 [Member]</link:label>
    <link:label id="lab_mck_A765DebenturesDueMarch12027Member_documentation_en-US" xlink:label="lab_mck_A765DebenturesDueMarch12027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">7.65% Debentures Due March 1, 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_A765DebenturesDueMarch12027Member" xlink:href="mck-20230630.xsd#mck_A765DebenturesDueMarch12027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_A765DebenturesDueMarch12027Member" xlink:to="lab_mck_A765DebenturesDueMarch12027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_LossContingencyNumberofStates_3734a880-79c5-4bd1-a120-b9dc34e82d52_terseLabel_en-US" xlink:label="lab_mck_LossContingencyNumberofStates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of states in which court cases are pending</link:label>
    <link:label id="lab_mck_LossContingencyNumberofStates_label_en-US" xlink:label="lab_mck_LossContingencyNumberofStates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of States</link:label>
    <link:label id="lab_mck_LossContingencyNumberofStates_documentation_en-US" xlink:label="lab_mck_LossContingencyNumberofStates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of States</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_LossContingencyNumberofStates" xlink:href="mck-20230630.xsd#mck_LossContingencyNumberofStates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_LossContingencyNumberofStates" xlink:to="lab_mck_LossContingencyNumberofStates" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_CherokeeNationMember_343e72eb-4a0e-4231-929b-5e15171f828a_terseLabel_en-US" xlink:label="lab_mck_CherokeeNationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cherokee Nation</link:label>
    <link:label id="lab_mck_CherokeeNationMember_label_en-US" xlink:label="lab_mck_CherokeeNationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cherokee Nation [Member]</link:label>
    <link:label id="lab_mck_CherokeeNationMember_documentation_en-US" xlink:label="lab_mck_CherokeeNationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cherokee Nation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_CherokeeNationMember" xlink:href="mck-20230630.xsd#mck_CherokeeNationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_CherokeeNationMember" xlink:to="lab_mck_CherokeeNationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_EUR_40a3dc13-0d04-48ed-a312-a9eda097b37a_terseLabel_en-US" xlink:label="lab_currency_EUR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EUR</link:label>
    <link:label id="lab_currency_EUR_label_en-US" xlink:label="lab_currency_EUR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euro Member Countries, Euro</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_EUR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_EUR" xlink:to="lab_currency_EUR" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_42a137a0-0dfc-4e5f-81b4-7a141fb44671_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate on debt instrument (percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_LossContingencyNumberOfStatesFiledOnBehalfOf_ea7483c9-9cf6-452c-8eb0-8ea9cb40d1cb_terseLabel_en-US" xlink:label="lab_mck_LossContingencyNumberOfStatesFiledOnBehalfOf" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of states filed on behalf of</link:label>
    <link:label id="lab_mck_LossContingencyNumberOfStatesFiledOnBehalfOf_label_en-US" xlink:label="lab_mck_LossContingencyNumberOfStatesFiledOnBehalfOf" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of States Filed On Behalf Of</link:label>
    <link:label id="lab_mck_LossContingencyNumberOfStatesFiledOnBehalfOf_documentation_en-US" xlink:label="lab_mck_LossContingencyNumberOfStatesFiledOnBehalfOf" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of States Filed On Behalf Of</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_LossContingencyNumberOfStatesFiledOnBehalfOf" xlink:href="mck-20230630.xsd#mck_LossContingencyNumberOfStatesFiledOnBehalfOf"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_LossContingencyNumberOfStatesFiledOnBehalfOf" xlink:to="lab_mck_LossContingencyNumberOfStatesFiledOnBehalfOf" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_f2d39d2f-c1af-46b3-9552-4d8c3315668a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInformationLineItems_7971da9c-f3f2-4e1b-b3d4-58fb6cebc636_terseLabel_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_EntityInformationLineItems_label_en-US" xlink:label="lab_dei_EntityInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationLineItems" xlink:to="lab_dei_EntityInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_b9028103-966b-4918-9979-4bc9a498b6e8_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total McKesson Corporation stockholders&#8217; deficit</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_b1dbbc81-9c43-4cdd-8c04-5d3962c62d11_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_4e849de1-33c5-4268-916a-ba4d747fd6b1_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_2b1c0b82-af04-43de-9ea1-3c23ec8b8451_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits that would impact effective tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_DisposalGroupIncludingDiscontinuedOperationConsiderationExpected_140acdbe-47e5-4fd4-af2a-c18faa0b2d36_terseLabel_en-US" xlink:label="lab_mck_DisposalGroupIncludingDiscontinuedOperationConsiderationExpected" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross purchase price</link:label>
    <link:label id="lab_mck_DisposalGroupIncludingDiscontinuedOperationConsiderationExpected_label_en-US" xlink:label="lab_mck_DisposalGroupIncludingDiscontinuedOperationConsiderationExpected" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration, Expected</link:label>
    <link:label id="lab_mck_DisposalGroupIncludingDiscontinuedOperationConsiderationExpected_documentation_en-US" xlink:label="lab_mck_DisposalGroupIncludingDiscontinuedOperationConsiderationExpected" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration, Expected</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_DisposalGroupIncludingDiscontinuedOperationConsiderationExpected" xlink:href="mck-20230630.xsd#mck_DisposalGroupIncludingDiscontinuedOperationConsiderationExpected"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_DisposalGroupIncludingDiscontinuedOperationConsiderationExpected" xlink:to="lab_mck_DisposalGroupIncludingDiscontinuedOperationConsiderationExpected" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_84c68b2b-1587-4572-b725-d0cfdd62be4a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_f3cfcb18-ecff-491b-818f-630fc95b704b_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_cdc5f9c8-c5af-4d67-9353-cb7fbf7354d2_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_f1eab919-cb62-46a1-a82d-30f1d20eb014_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations_label_en-US" xlink:label="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt and Lease Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:to="lab_us-gaap_LongTermDebtAndCapitalLeaseObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3759fea9-bc9c-4813-8884-a597c4e0c52c_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from continuing operations before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_2f97a17b-56ea-43d7-b679-1e038cc6930e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from continuing operations before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_NationalPrescriptionOpiateLitigationMember_d3ac0d95-d19b-44ee-8517-4849d9a38e55_terseLabel_en-US" xlink:label="lab_mck_NationalPrescriptionOpiateLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">National Prescription Opioid Litigation</link:label>
    <link:label id="lab_mck_NationalPrescriptionOpiateLitigationMember_label_en-US" xlink:label="lab_mck_NationalPrescriptionOpiateLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">National Prescription Opiate Litigation [Member]</link:label>
    <link:label id="lab_mck_NationalPrescriptionOpiateLitigationMember_documentation_en-US" xlink:label="lab_mck_NationalPrescriptionOpiateLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In re: National Prescription Opiate Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_NationalPrescriptionOpiateLitigationMember" xlink:href="mck-20230630.xsd#mck_NationalPrescriptionOpiateLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_NationalPrescriptionOpiateLitigationMember" xlink:to="lab_mck_NationalPrescriptionOpiateLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_345d695c-535b-4170-bd76-f410b8e8dd26_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, Impairment, and Related Charges, Net</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_SeniorUnsecuredCreditFacilitythe2020CreditFacilityCanadianDollarBritishPoundSterlingandEurosSublimitMember_68107c43-5384-4a72-b075-66181ece99cd_terseLabel_en-US" xlink:label="lab_mck_SeniorUnsecuredCreditFacilitythe2020CreditFacilityCanadianDollarBritishPoundSterlingandEurosSublimitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Credit Facility (the 2020 Credit Facility), Canadian Dollar, British Pound Sterling, and Euros Sublimit</link:label>
    <link:label id="lab_mck_SeniorUnsecuredCreditFacilitythe2020CreditFacilityCanadianDollarBritishPoundSterlingandEurosSublimitMember_label_en-US" xlink:label="lab_mck_SeniorUnsecuredCreditFacilitythe2020CreditFacilityCanadianDollarBritishPoundSterlingandEurosSublimitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Credit Facility (the 2020 Credit Facility), Canadian Dollar, British Pound Sterling, and Euros Sublimit [Member]</link:label>
    <link:label id="lab_mck_SeniorUnsecuredCreditFacilitythe2020CreditFacilityCanadianDollarBritishPoundSterlingandEurosSublimitMember_documentation_en-US" xlink:label="lab_mck_SeniorUnsecuredCreditFacilitythe2020CreditFacilityCanadianDollarBritishPoundSterlingandEurosSublimitMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Credit Facility (the 2020 Credit Facility), Canadian Dollar, British Pound Sterling, and Euros Sublimit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_SeniorUnsecuredCreditFacilitythe2020CreditFacilityCanadianDollarBritishPoundSterlingandEurosSublimitMember" xlink:href="mck-20230630.xsd#mck_SeniorUnsecuredCreditFacilitythe2020CreditFacilityCanadianDollarBritishPoundSterlingandEurosSublimitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_SeniorUnsecuredCreditFacilitythe2020CreditFacilityCanadianDollarBritishPoundSterlingandEurosSublimitMember" xlink:to="lab_mck_SeniorUnsecuredCreditFacilitythe2020CreditFacilityCanadianDollarBritishPoundSterlingandEurosSublimitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_bd5fbfa4-0c4a-4c97-a37f-535b2b385d0e_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_b7f4939e-be46-4740-a911-c4c4c8957c8b_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_8db3b408-ffd7-40e5-98bc-b8dc57008ae4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, inputs, level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_5bd7e8cb-31b1-47e6-bb16-a78f52c33fbe_verboseLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedges</link:label>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_7bd0fad8-cfdd-4d99-b082-97be46f3f93b_terseLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging</link:label>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_label_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetInvestmentHedgingMember" xlink:to="lab_us-gaap_NetInvestmentHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_9097b76d-2647-4a57-9466-8c0abb45c7b0_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_BusinessCombinationConsiderationTransferredOwnershipInterest_3ee1ae96-973b-43ae-83fa-6b9b8d7d55a4_terseLabel_en-US" xlink:label="lab_mck_BusinessCombinationConsiderationTransferredOwnershipInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contribution of USOR</link:label>
    <link:label id="lab_mck_BusinessCombinationConsiderationTransferredOwnershipInterest_label_en-US" xlink:label="lab_mck_BusinessCombinationConsiderationTransferredOwnershipInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Ownership Interest</link:label>
    <link:label id="lab_mck_BusinessCombinationConsiderationTransferredOwnershipInterest_documentation_en-US" xlink:label="lab_mck_BusinessCombinationConsiderationTransferredOwnershipInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Ownership Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_BusinessCombinationConsiderationTransferredOwnershipInterest" xlink:href="mck-20230630.xsd#mck_BusinessCombinationConsiderationTransferredOwnershipInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_BusinessCombinationConsiderationTransferredOwnershipInterest" xlink:to="lab_mck_BusinessCombinationConsiderationTransferredOwnershipInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_CashCashEquivalentsRestrictedCashClassifiedWithinAssetsHeldForSalePeriodIncreaseDecrease_dce6860f-d86d-49c1-b501-72bad1a835ef_terseLabel_en-US" xlink:label="lab_mck_CashCashEquivalentsRestrictedCashClassifiedWithinAssetsHeldForSalePeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in cash, cash equivalents, and restricted cash classified as Assets held for sale</link:label>
    <link:label id="lab_mck_CashCashEquivalentsRestrictedCashClassifiedWithinAssetsHeldForSalePeriodIncreaseDecrease_label_en-US" xlink:label="lab_mck_CashCashEquivalentsRestrictedCashClassifiedWithinAssetsHeldForSalePeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash Classified within Assets Held for Sale, Period Increase (Decrease)</link:label>
    <link:label id="lab_mck_CashCashEquivalentsRestrictedCashClassifiedWithinAssetsHeldForSalePeriodIncreaseDecrease_documentation_en-US" xlink:label="lab_mck_CashCashEquivalentsRestrictedCashClassifiedWithinAssetsHeldForSalePeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash Classified within Assets Held for Sale, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_CashCashEquivalentsRestrictedCashClassifiedWithinAssetsHeldForSalePeriodIncreaseDecrease" xlink:href="mck-20230630.xsd#mck_CashCashEquivalentsRestrictedCashClassifiedWithinAssetsHeldForSalePeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_CashCashEquivalentsRestrictedCashClassifiedWithinAssetsHeldForSalePeriodIncreaseDecrease" xlink:to="lab_mck_CashCashEquivalentsRestrictedCashClassifiedWithinAssetsHeldForSalePeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_9d3aa368-144c-4c32-b634-ccadfed6cd52_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_e60f40c5-f8e0-493f-ac84-d0cf2b1e2b63_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_7f3c6986-81cb-48c9-9ded-66b159b7ae87_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total identifiable net assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_078992de-8b51-4e12-ac81-6db2c7ea411a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_A3125NotesDue2029Member_ae8d7c86-0ef8-4931-b53f-f81168c88a9d_terseLabel_en-US" xlink:label="lab_mck_A3125NotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.125% Notes Due 2029</link:label>
    <link:label id="lab_mck_A3125NotesDue2029Member_label_en-US" xlink:label="lab_mck_A3125NotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.125% Notes Due 2029 [Member]</link:label>
    <link:label id="lab_mck_A3125NotesDue2029Member_documentation_en-US" xlink:label="lab_mck_A3125NotesDue2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.125% Notes Due 2029</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_A3125NotesDue2029Member" xlink:href="mck-20230630.xsd#mck_A3125NotesDue2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_A3125NotesDue2029Member" xlink:to="lab_mck_A3125NotesDue2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_c8957ac0-e2bc-4d81-81f3-47c0fc616360_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired identifiable intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_fe8d2684-3d0e-4dd6-9655-cd6ab5df1c66_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_2ae412d0-5147-4fee-9222-c0e4803e9c3f_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember_784f1de3-d510-431a-b706-d07e250e548a_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Losses and Other Components of Benefit Plans, Net of Tax</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_5ba5097e-4594-4c00-814b-c96448b787e4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash operating lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_EUBusinessesDisposalGroupMember_86bc8f8b-986d-4cab-8146-51afdda3a81c_terseLabel_en-US" xlink:label="lab_mck_EUBusinessesDisposalGroupMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">E.U. Businesses (Disposal Group)</link:label>
    <link:label id="lab_mck_EUBusinessesDisposalGroupMember_label_en-US" xlink:label="lab_mck_EUBusinessesDisposalGroupMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">E.U. Businesses (Disposal Group) [Member]</link:label>
    <link:label id="lab_mck_EUBusinessesDisposalGroupMember_documentation_en-US" xlink:label="lab_mck_EUBusinessesDisposalGroupMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">E.U. Businesses (Disposal Group)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_EUBusinessesDisposalGroupMember" xlink:href="mck-20230630.xsd#mck_EUBusinessesDisposalGroupMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_EUBusinessesDisposalGroupMember" xlink:to="lab_mck_EUBusinessesDisposalGroupMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_95ae4236-999c-468e-be6e-dbb8a786a150_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_6863b55f-0459-416a-bb5d-60bcecb762c9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in retirement-related benefit plans</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_1f8f0090-b66b-4179-8f8d-ca3b4b761f1a_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_fd31c04c-e82c-4d9d-a0ed-be4e0405f2c5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_3c9112b5-91fc-462e-847f-dbedec20b12c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Common Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_79c45a72-9034-48c8-8817-4cda6ab9747e_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_c200962f-43a0-4b8e-a5ce-94c8b396702d_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_A163EuroNotesDueOctober302026Member_229f9402-47c7-42a8-9270-b9f2dec935e7_terseLabel_en-US" xlink:label="lab_mck_A163EuroNotesDueOctober302026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.63% Euro Notes due October 30, 2026</link:label>
    <link:label id="lab_mck_A163EuroNotesDueOctober302026Member_label_en-US" xlink:label="lab_mck_A163EuroNotesDueOctober302026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.63% Euro Notes Due October 30, 2026 [Member]</link:label>
    <link:label id="lab_mck_A163EuroNotesDueOctober302026Member_documentation_en-US" xlink:label="lab_mck_A163EuroNotesDueOctober302026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.63% Euro Notes Due October 30, 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_A163EuroNotesDueOctober302026Member" xlink:href="mck-20230630.xsd#mck_A163EuroNotesDueOctober302026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_A163EuroNotesDueOctober302026Member" xlink:to="lab_mck_A163EuroNotesDueOctober302026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_f18d93da-906a-442d-85a0-253cacd44bc6_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deficit</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e52b3c58-bebe-4e00-a379-27136be8b074_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_a29e5757-a98c-4197-bef0-640556cded8a_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_d3cd4a8a-0d6e-4ee5-aa5e-c970ed964baf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_710ee7c1-f191-4e07-9e4f-30a5cb893855_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_PaymentsForPurchaseOfGovernmentObligationsForSatisfactionAndDischargeOfLongTermDebt_7f4c1775-792e-4b68-a390-668fba193f7c_negatedTerseLabel_en-US" xlink:label="lab_mck_PaymentsForPurchaseOfGovernmentObligationsForSatisfactionAndDischargeOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of U.S. government obligations for the satisfaction and discharge of long-term debt</link:label>
    <link:label id="lab_mck_PaymentsForPurchaseOfGovernmentObligationsForSatisfactionAndDischargeOfLongTermDebt_349719eb-d347-4f08-9d48-038a046eb093_terseLabel_en-US" xlink:label="lab_mck_PaymentsForPurchaseOfGovernmentObligationsForSatisfactionAndDischargeOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of U.S. government obligations for the satisfaction and discharge of long-term debt</link:label>
    <link:label id="lab_mck_PaymentsForPurchaseOfGovernmentObligationsForSatisfactionAndDischargeOfLongTermDebt_label_en-US" xlink:label="lab_mck_PaymentsForPurchaseOfGovernmentObligationsForSatisfactionAndDischargeOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Purchase Of Government Obligations For Satisfaction And Discharge Of Long-Term Debt</link:label>
    <link:label id="lab_mck_PaymentsForPurchaseOfGovernmentObligationsForSatisfactionAndDischargeOfLongTermDebt_documentation_en-US" xlink:label="lab_mck_PaymentsForPurchaseOfGovernmentObligationsForSatisfactionAndDischargeOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments For Purchase Of Government Obligations For Satisfaction And Discharge Of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_PaymentsForPurchaseOfGovernmentObligationsForSatisfactionAndDischargeOfLongTermDebt" xlink:href="mck-20230630.xsd#mck_PaymentsForPurchaseOfGovernmentObligationsForSatisfactionAndDischargeOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_PaymentsForPurchaseOfGovernmentObligationsForSatisfactionAndDischargeOfLongTermDebt" xlink:to="lab_mck_PaymentsForPurchaseOfGovernmentObligationsForSatisfactionAndDischargeOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLegalSettlements_7d6b5adf-16aa-4718-b96b-dfcae18bd6e4_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from legal settlements</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLegalSettlements_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Legal Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLegalSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLegalSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLegalSettlements" xlink:to="lab_us-gaap_ProceedsFromLegalSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_dd3f4890-a558-428a-9cc7-4a410d016b52_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant, and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_5c55052b-54da-467f-b351-1df6891f727a_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_6c1dec82-9f8d-4d27-a817-eaa724cd6b0a_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_9ab065c8-1ab3-4f9c-8f93-1c8815ba44b7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdditionalPaidInCapital_6e192254-bd63-43a8-86d4-83a0c3a9b9be_negatedTerseLabel_en-US" xlink:label="lab_mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdditionalPaidInCapital_label_en-US" xlink:label="lab_mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Additional-Paid-In Capital</link:label>
    <link:label id="lab_mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdditionalPaidInCapital_documentation_en-US" xlink:label="lab_mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Additional-Paid-In Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdditionalPaidInCapital" xlink:href="mck-20230630.xsd#mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdditionalPaidInCapital" xlink:to="lab_mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_f375c2ab-466b-4dfe-810f-159a978dfe7f_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, net</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent" xlink:to="lab_us-gaap_ReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_2171297d-239c-46b8-9ffa-a35531c3c497_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimatedInsuranceRecoveries_03d112fb-a2b5-4d82-8a8f-37936db22dde_terseLabel_en-US" xlink:label="lab_us-gaap_EstimatedInsuranceRecoveries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probable loss recovery</link:label>
    <link:label id="lab_us-gaap_EstimatedInsuranceRecoveries_label_en-US" xlink:label="lab_us-gaap_EstimatedInsuranceRecoveries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Insurance Recoveries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimatedInsuranceRecoveries" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EstimatedInsuranceRecoveries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimatedInsuranceRecoveries" xlink:to="lab_us-gaap_EstimatedInsuranceRecoveries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7c6c4b6e-6e5a-487d-91c9-e9077b22ae08_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_9f50b89f-81d6-46f3-8ad7-ae97c2b9845e_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_b90b7c27-6ede-4e73-964e-2df740d68126_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_249fea12-b8d1-43ef-9024-932a02cca10e_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation Adjustments, Net of Tax</link:label>
    <link:label id="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_A488NotesDueMarch152044Member_c7b5e202-e636-4ebd-99cf-cd2d499b6159_terseLabel_en-US" xlink:label="lab_mck_A488NotesDueMarch152044Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.88% Notes due March 15, 2044</link:label>
    <link:label id="lab_mck_A488NotesDueMarch152044Member_label_en-US" xlink:label="lab_mck_A488NotesDueMarch152044Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.88% Notes Due March 15, 2044 [Member]</link:label>
    <link:label id="lab_mck_A488NotesDueMarch152044Member_documentation_en-US" xlink:label="lab_mck_A488NotesDueMarch152044Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.88% Notes Due March 15, 2044</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_A488NotesDueMarch152044Member" xlink:href="mck-20230630.xsd#mck_A488NotesDueMarch152044Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_A488NotesDueMarch152044Member" xlink:to="lab_mck_A488NotesDueMarch152044Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_b2aa201f-abbc-4e76-a6cc-6a6914f51702_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividends declared</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Common Stock, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStockCash" xlink:to="lab_us-gaap_DividendsCommonStockCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_919807f4-5ad3-48c0-8e96-19e366ce1994_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c1c9210c-3035-4293-acc8-423348dd73ce_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_eb78dc52-5824-4561-974e-9cfe4afb12d4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuances of long-term debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_8dea9ac5-fc7f-43a5-872b-06e7e5279832_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_A395NotesDueFebruary162028Member_cb206528-599b-48c2-bf2c-449c839c7f91_terseLabel_en-US" xlink:label="lab_mck_A395NotesDueFebruary162028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.95% Notes due February 16, 2028</link:label>
    <link:label id="lab_mck_A395NotesDueFebruary162028Member_label_en-US" xlink:label="lab_mck_A395NotesDueFebruary162028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.95% Notes Due February 16, 2028 [Member]</link:label>
    <link:label id="lab_mck_A395NotesDueFebruary162028Member_documentation_en-US" xlink:label="lab_mck_A395NotesDueFebruary162028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.95% Notes Due February 16, 2028</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_A395NotesDueFebruary162028Member" xlink:href="mck-20230630.xsd#mck_A395NotesDueFebruary162028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_A395NotesDueFebruary162028Member" xlink:to="lab_mck_A395NotesDueFebruary162028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiscalPeriod_060b566c-3226-4dd1-908e-e9aa4a01c17e_terseLabel_en-US" xlink:label="lab_us-gaap_FiscalPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fiscal Period</link:label>
    <link:label id="lab_us-gaap_FiscalPeriod_label_en-US" xlink:label="lab_us-gaap_FiscalPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fiscal Period, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiscalPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiscalPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiscalPeriod" xlink:to="lab_us-gaap_FiscalPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_6a8dda33-c421-4264-8c13-1c92f0dec367_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_7b8522d0-b793-4cea-9af4-80c77547f061_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_b4eccee3-2f0d-4d26-9e89-b57990a3f653_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_0e64675c-b826-417a-9743-f62bbb403289_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from discontinued operations, net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_dbd79c8a-9394-4a07-b183-8ae08bf4eb92_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from discontinued operations, net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_9926cbee-ccd9-4e94-9cca-533ad601bc49_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identifiable assets acquired and liabilities assumed:</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_a1301879-094f-434d-9bed-5290358e3c9e_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_aff4ed0d-3bc0-4a49-ad33-9dfb041cb16f_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingent Liabilities</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_d6f1716e-5465-4a40-be28-d09e0197d1fc_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Continuing operations (in usd per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_d2aa0360-b451-4901-b86c-be7b05e0c0a1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Continuing operations (in usd per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_fe7d029a-b58d-430a-bb9a-784ef73adc52_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_621dde18-de96-4098-a9af-22344f92dec0_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business acquisition, percentage of controlling interest in combined business</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_01bd978c-4276-47db-9b0f-00212d62752f_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_301550eb-50ac-4722-9153-c69f54b70e99_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, expected tax deductible amount</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Goodwill, Expected Tax Deductible Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:to="lab_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_A150EuroNotesDueNovember172025Member_dd632956-3644-4c82-b1c3-f4e57011d79d_terseLabel_en-US" xlink:label="lab_mck_A150EuroNotesDueNovember172025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.50% Euro Notes due November 17, 2025</link:label>
    <link:label id="lab_mck_A150EuroNotesDueNovember172025Member_label_en-US" xlink:label="lab_mck_A150EuroNotesDueNovember172025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.50% Euro Notes Due November 17, 2025 [Member]</link:label>
    <link:label id="lab_mck_A150EuroNotesDueNovember172025Member_documentation_en-US" xlink:label="lab_mck_A150EuroNotesDueNovember172025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.50% Euro Notes Due November 17, 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_A150EuroNotesDueNovember172025Member" xlink:href="mck-20230630.xsd#mck_A150EuroNotesDueNovember172025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_A150EuroNotesDueNovember172025Member" xlink:to="lab_mck_A150EuroNotesDueNovember172025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_f9671773-d8ea-42f1-9832-ed6f4465a423_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and deficit</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_1b53a1bf-7bce-4ba9-8e56-254acceba28d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_fd280d98-2f1b-4e6e-9d32-5a4f46d8b054_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_9d54bea2-6787-4aa1-95a0-59f0c1da1367_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Remaining Amortization Period (Years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Remaining Amortization Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessExitCosts1_27567fb2-2775-4d03-9093-9666843dbcf9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessExitCosts1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exit and other-related costs</link:label>
    <link:label id="lab_us-gaap_BusinessExitCosts1_label_en-US" xlink:label="lab_us-gaap_BusinessExitCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Exit Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessExitCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessExitCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessExitCosts1" xlink:to="lab_us-gaap_BusinessExitCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_238a0407-35b6-493e-a11f-b431db185d1c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_c6b56387-69e5-4592-ae55-2241aed623da_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains on cash flow and other hedges</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_b7c05bd8-e08f-492e-9127-86e67a1bdfcb_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_a36f0f82-820a-4e99-8951-2c37c71d8712_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_DerivativeNotionalAmountEnteredIntoDuringPeriod_5d60f10e-5c84-4dcb-8130-bab3080b2fa2_terseLabel_en-US" xlink:label="lab_mck_DerivativeNotionalAmountEnteredIntoDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, notional amount, entered into during period</link:label>
    <link:label id="lab_mck_DerivativeNotionalAmountEnteredIntoDuringPeriod_label_en-US" xlink:label="lab_mck_DerivativeNotionalAmountEnteredIntoDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount, Entered Into During Period</link:label>
    <link:label id="lab_mck_DerivativeNotionalAmountEnteredIntoDuringPeriod_documentation_en-US" xlink:label="lab_mck_DerivativeNotionalAmountEnteredIntoDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount, Entered Into During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_DerivativeNotionalAmountEnteredIntoDuringPeriod" xlink:href="mck-20230630.xsd#mck_DerivativeNotionalAmountEnteredIntoDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_DerivativeNotionalAmountEnteredIntoDuringPeriod" xlink:to="lab_mck_DerivativeNotionalAmountEnteredIntoDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_99514e0d-4433-4a19-9bc7-988c4f42f524_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceAgreementsMember_60f1d276-9993-4e00-a4e4-b3f2672d2625_terseLabel_en-US" xlink:label="lab_us-gaap_ServiceAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service agreements</link:label>
    <link:label id="lab_us-gaap_ServiceAgreementsMember_label_en-US" xlink:label="lab_us-gaap_ServiceAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServiceAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceAgreementsMember" xlink:to="lab_us-gaap_ServiceAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CurrencyAxis_3dc590a6-e79d-4499-983b-9b68f3b6fc01_terseLabel_en-US" xlink:label="lab_srt_CurrencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency [Axis]</link:label>
    <link:label id="lab_srt_CurrencyAxis_label_en-US" xlink:label="lab_srt_CurrencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CurrencyAxis" xlink:to="lab_srt_CurrencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_0ae6a022-543f-4b6b-b09c-a11fd004dcf6_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected total pre-tax charges</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Expected Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_f0a5e879-25b1-4dd1-991c-212c76beb27e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_eccc0b5e-7a41-4d19-9dc6-5ab78683ffc8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of financial information relating to reportable operating segments and reconciliations to the condensed consolidated totals</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_b638b2b3-7650-45f1-a96c-f587863919ba_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_2754156a-6cbd-4209-824b-5834695b22c6_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring costs, anticipated total charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_b849f028-5026-4bff-9870-869345023e70_totalLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_0c91295a-ec57-45bd-b537-a7d4f3563eb3_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, impairment, and related charges, net</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_a054ce51-1dde-457f-b527-d01448089ad9_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_ac2f3ff0-872d-4927-b5a3-5626d4a1cd6c_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other adjustments</link:label>
    <link:label id="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_label_en-US" xlink:label="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Purchase Accounting Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:to="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnsecuredDebtMember_e9f0d9ca-2b7b-4a0c-95ef-a5c2faba63b6_terseLabel_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unsecured Debt</link:label>
    <link:label id="lab_us-gaap_UnsecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unsecured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnsecuredDebtMember" xlink:to="lab_us-gaap_UnsecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_feeb4f02-e087-4ba0-8f8e-16bd3c617eae_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase consideration:</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_a911ff98-38b2-4fb4-b553-87377d6779a3_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authorized amount available for future repurchases</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TechnologyBasedIntangibleAssetsMember_39b6e33e-6eea-4d66-8d54-96a3bda2636f_terseLabel_en-US" xlink:label="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology</link:label>
    <link:label id="lab_us-gaap_TechnologyBasedIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology-Based Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:to="lab_us-gaap_TechnologyBasedIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_UKBusinessesDisposalGroupMember_180bc820-08c4-4b3d-9ad7-d0af7f08400e_terseLabel_en-US" xlink:label="lab_mck_UKBusinessesDisposalGroupMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.K. Disposal Group (Disposal Group)</link:label>
    <link:label id="lab_mck_UKBusinessesDisposalGroupMember_label_en-US" xlink:label="lab_mck_UKBusinessesDisposalGroupMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.K. Businesses (Disposal Group) [Member]</link:label>
    <link:label id="lab_mck_UKBusinessesDisposalGroupMember_documentation_en-US" xlink:label="lab_mck_UKBusinessesDisposalGroupMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.K. Businesses (Disposal Group)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_UKBusinessesDisposalGroupMember" xlink:href="mck-20230630.xsd#mck_UKBusinessesDisposalGroupMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_UKBusinessesDisposalGroupMember" xlink:to="lab_mck_UKBusinessesDisposalGroupMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_bc0c0774-566d-42da-b339-54a5719f0c00_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Drafts and accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_fdb6b6c4-fb5f-4543-bb34-a65fe8f64e42_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromCollectionOfNotesReceivable_14092e28-25d9-4692-b4dc-f6ba898df411_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromCollectionOfNotesReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from collection of notes receivable</link:label>
    <link:label id="lab_us-gaap_ProceedsFromCollectionOfNotesReceivable_label_en-US" xlink:label="lab_us-gaap_ProceedsFromCollectionOfNotesReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Collection of Notes Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromCollectionOfNotesReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable" xlink:to="lab_us-gaap_ProceedsFromCollectionOfNotesReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_NetIncomeLossIncludingPortionAttributabletoNoncontrollingInterestExcludingRedeemableNoncontrollingInterest_67a8d09f-6104-43b5-89ff-351f9b2bc59f_terseLabel_en-US" xlink:label="lab_mck_NetIncomeLossIncludingPortionAttributabletoNoncontrollingInterestExcludingRedeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_mck_NetIncomeLossIncludingPortionAttributabletoNoncontrollingInterestExcludingRedeemableNoncontrollingInterest_label_en-US" xlink:label="lab_mck_NetIncomeLossIncludingPortionAttributabletoNoncontrollingInterestExcludingRedeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Excluding Redeemable Noncontrolling Interest</link:label>
    <link:label id="lab_mck_NetIncomeLossIncludingPortionAttributabletoNoncontrollingInterestExcludingRedeemableNoncontrollingInterest_documentation_en-US" xlink:label="lab_mck_NetIncomeLossIncludingPortionAttributabletoNoncontrollingInterestExcludingRedeemableNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Excluding Redeemable Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_NetIncomeLossIncludingPortionAttributabletoNoncontrollingInterestExcludingRedeemableNoncontrollingInterest" xlink:href="mck-20230630.xsd#mck_NetIncomeLossIncludingPortionAttributabletoNoncontrollingInterestExcludingRedeemableNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_NetIncomeLossIncludingPortionAttributabletoNoncontrollingInterestExcludingRedeemableNoncontrollingInterest" xlink:to="lab_mck_NetIncomeLossIncludingPortionAttributabletoNoncontrollingInterestExcludingRedeemableNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_6091ea34-596a-443b-a17f-80d9ec79ae84_terseLabel_en-US" xlink:label="lab_mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_label_en-US" xlink:label="lab_mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Right-Of-Use Assets</link:label>
    <link:label id="lab_mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_documentation_en-US" xlink:label="lab_mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Right-Of-Use Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:href="mck-20230630.xsd#mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:to="lab_mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_LossContingencyNumberOfOtherDefendants_88893ede-966c-4b6b-b440-4d37b038a75b_terseLabel_en-US" xlink:label="lab_mck_LossContingencyNumberOfOtherDefendants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of other national distributors named in suit</link:label>
    <link:label id="lab_mck_LossContingencyNumberOfOtherDefendants_label_en-US" xlink:label="lab_mck_LossContingencyNumberOfOtherDefendants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Other Defendants</link:label>
    <link:label id="lab_mck_LossContingencyNumberOfOtherDefendants_documentation_en-US" xlink:label="lab_mck_LossContingencyNumberOfOtherDefendants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Other Defendants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_LossContingencyNumberOfOtherDefendants" xlink:href="mck-20230630.xsd#mck_LossContingencyNumberOfOtherDefendants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_LossContingencyNumberOfOtherDefendants" xlink:to="lab_mck_LossContingencyNumberOfOtherDefendants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5b0160ea-36ce-4b71-b252-19d02fffea74_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_c3a2ce7e-8682-4890-ab75-a0e0efbfbd96_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_fd580a30-e52c-4fc5-8deb-b7628333a08c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, by Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f1da912f-559b-48fe-99bf-8c91fe79ac6d_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_IncomeTaxExaminationEstimateOfPossibleLiabilityAdjustment_c9536284-4b5a-43df-9c2b-ba9acd524c8c_terseLabel_en-US" xlink:label="lab_mck_IncomeTaxExaminationEstimateOfPossibleLiabilityAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax liability increase due to proposed adjustment to taxable income</link:label>
    <link:label id="lab_mck_IncomeTaxExaminationEstimateOfPossibleLiabilityAdjustment_label_en-US" xlink:label="lab_mck_IncomeTaxExaminationEstimateOfPossibleLiabilityAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination, Estimate Of Possible Liability Adjustment</link:label>
    <link:label id="lab_mck_IncomeTaxExaminationEstimateOfPossibleLiabilityAdjustment_documentation_en-US" xlink:label="lab_mck_IncomeTaxExaminationEstimateOfPossibleLiabilityAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination, Estimate Of Possible Liability Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_IncomeTaxExaminationEstimateOfPossibleLiabilityAdjustment" xlink:href="mck-20230630.xsd#mck_IncomeTaxExaminationEstimateOfPossibleLiabilityAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_IncomeTaxExaminationEstimateOfPossibleLiabilityAdjustment" xlink:to="lab_mck_IncomeTaxExaminationEstimateOfPossibleLiabilityAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_bda4369c-f10c-440a-8473-6e6fbff1dea7_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_b01d91f1-cc89-4568-a70b-5df9d132ef28_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveRollForward" xlink:to="lab_us-gaap_RestructuringReserveRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax_8f95b1ef-eca6-495e-a459-cbefce6f91aa_verboseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss adjustment</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from AOCI, Current Period, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationFromAociCurrentPeriodTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:to="lab_us-gaap_ReclassificationFromAociCurrentPeriodTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_AssetImpairmentChargesIncludingAcceleratedDepreciation_bef98dd4-d169-485c-b685-7ff7d345a24a_terseLabel_en-US" xlink:label="lab_mck_AssetImpairmentChargesIncludingAcceleratedDepreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairments and accelerated depreciation</link:label>
    <link:label id="lab_mck_AssetImpairmentChargesIncludingAcceleratedDepreciation_label_en-US" xlink:label="lab_mck_AssetImpairmentChargesIncludingAcceleratedDepreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges, Including Accelerated Depreciation</link:label>
    <link:label id="lab_mck_AssetImpairmentChargesIncludingAcceleratedDepreciation_documentation_en-US" xlink:label="lab_mck_AssetImpairmentChargesIncludingAcceleratedDepreciation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges, Including Accelerated Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_AssetImpairmentChargesIncludingAcceleratedDepreciation" xlink:href="mck-20230630.xsd#mck_AssetImpairmentChargesIncludingAcceleratedDepreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_AssetImpairmentChargesIncludingAcceleratedDepreciation" xlink:to="lab_mck_AssetImpairmentChargesIncludingAcceleratedDepreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_ThreeNationalPharmaceuticalDistributorsMember_c86b0c81-d5cd-4cbb-83ee-7b6eaaad8748_terseLabel_en-US" xlink:label="lab_mck_ThreeNationalPharmaceuticalDistributorsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three National Pharmaceutical Distributors</link:label>
    <link:label id="lab_mck_ThreeNationalPharmaceuticalDistributorsMember_label_en-US" xlink:label="lab_mck_ThreeNationalPharmaceuticalDistributorsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three National Pharmaceutical Distributors [Member]</link:label>
    <link:label id="lab_mck_ThreeNationalPharmaceuticalDistributorsMember_documentation_en-US" xlink:label="lab_mck_ThreeNationalPharmaceuticalDistributorsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three National Pharmaceutical Distributors</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_ThreeNationalPharmaceuticalDistributorsMember" xlink:href="mck-20230630.xsd#mck_ThreeNationalPharmaceuticalDistributorsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_ThreeNationalPharmaceuticalDistributorsMember" xlink:to="lab_mck_ThreeNationalPharmaceuticalDistributorsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_CurrentAssetLiabilityMember_22ff31ff-3f3a-4432-b9fc-b51e07dd48df_terseLabel_en-US" xlink:label="lab_mck_CurrentAssetLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other/Other accrued liabilities</link:label>
    <link:label id="lab_mck_CurrentAssetLiabilityMember_label_en-US" xlink:label="lab_mck_CurrentAssetLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Asset / Liability [Member]</link:label>
    <link:label id="lab_mck_CurrentAssetLiabilityMember_documentation_en-US" xlink:label="lab_mck_CurrentAssetLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Asset / Liability [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_CurrentAssetLiabilityMember" xlink:href="mck-20230630.xsd#mck_CurrentAssetLiabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_CurrentAssetLiabilityMember" xlink:to="lab_mck_CurrentAssetLiabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_450d7894-03b7-412b-bb65-70860d1902ee_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualCarryingValueNoncurrent_f7e383e8-6ff4-49d2-88ad-267172f1de33_verboseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualCarryingValueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term litigation liabilities</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualCarryingValueNoncurrent_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualCarryingValueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Accrual, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValueNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualCarryingValueNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualCarryingValueNoncurrent" xlink:to="lab_us-gaap_LossContingencyAccrualCarryingValueNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_RevenueDerivedFromServicesPercentage_18c51f79-0c19-4160-8b7d-cffafca67a17_terseLabel_en-US" xlink:label="lab_mck_RevenueDerivedFromServicesPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue derived from services, percentage (approximately or less than)</link:label>
    <link:label id="lab_mck_RevenueDerivedFromServicesPercentage_label_en-US" xlink:label="lab_mck_RevenueDerivedFromServicesPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Derived From Services, Percentage</link:label>
    <link:label id="lab_mck_RevenueDerivedFromServicesPercentage_documentation_en-US" xlink:label="lab_mck_RevenueDerivedFromServicesPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Derived From Services, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_RevenueDerivedFromServicesPercentage" xlink:href="mck-20230630.xsd#mck_RevenueDerivedFromServicesPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_RevenueDerivedFromServicesPercentage" xlink:to="lab_mck_RevenueDerivedFromServicesPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_d1715ef8-c061-4db2-a51c-58db425a39d7_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_DebtInstrumentRedemptionPeriod_fcebefdf-e734-4c57-837b-e7e786cfa791_terseLabel_en-US" xlink:label="lab_mck_DebtInstrumentRedemptionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, redemption period (in days)</link:label>
    <link:label id="lab_mck_DebtInstrumentRedemptionPeriod_label_en-US" xlink:label="lab_mck_DebtInstrumentRedemptionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Period</link:label>
    <link:label id="lab_mck_DebtInstrumentRedemptionPeriod_documentation_en-US" xlink:label="lab_mck_DebtInstrumentRedemptionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_DebtInstrumentRedemptionPeriod" xlink:href="mck-20230630.xsd#mck_DebtInstrumentRedemptionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_DebtInstrumentRedemptionPeriod" xlink:to="lab_mck_DebtInstrumentRedemptionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_8f4908f1-f442-426f-bacc-b59173eb92e4_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_3d010c5c-a372-49d7-9989-a6d0885c4fb9_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanAxis" xlink:to="lab_us-gaap_RestructuringPlanAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9917db50-a2a2-428c-96d9-24629f0f6e41_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryLIFOReservePeriodCharge_5488ddd6-c40d-45a9-9818-b18058ea861a_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLIFOReservePeriodCharge" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credits associated with last-in, first-out inventory method</link:label>
    <link:label id="lab_us-gaap_InventoryLIFOReservePeriodCharge_4d47d1a7-d3de-4dbb-bdec-b8a54d3ec814_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InventoryLIFOReservePeriodCharge" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-tax credits related to LIFO accounting</link:label>
    <link:label id="lab_us-gaap_InventoryLIFOReservePeriodCharge_label_en-US" xlink:label="lab_us-gaap_InventoryLIFOReservePeriodCharge" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, LIFO Reserve, Period Charge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLIFOReservePeriodCharge" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryLIFOReservePeriodCharge"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLIFOReservePeriodCharge" xlink:to="lab_us-gaap_InventoryLIFOReservePeriodCharge" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ae8368fb-28b1-441c-9744-9998c61f3fa1_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_bb4b8049-684b-498c-a871-748e20669016_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated annual amortization expense, 2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_08452df2-26f0-40dc-872b-550ff6487280_terseLabel_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_label_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:to="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_A1625NotesDue2026Member_56a82c9f-4668-4563-a7b1-f59221a0e1e6_terseLabel_en-US" xlink:label="lab_mck_A1625NotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625% Notes Due 2026</link:label>
    <link:label id="lab_mck_A1625NotesDue2026Member_label_en-US" xlink:label="lab_mck_A1625NotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625% Notes Due 2026 [Member]</link:label>
    <link:label id="lab_mck_A1625NotesDue2026Member_documentation_en-US" xlink:label="lab_mck_A1625NotesDue2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.625% Notes Due 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_A1625NotesDue2026Member" xlink:href="mck-20230630.xsd#mck_A1625NotesDue2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_A1625NotesDue2026Member" xlink:to="lab_mck_A1625NotesDue2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_StockIssuedDuringPeriodValueEmployeeStockPlansNetOfForfeitures_d4b254a5-9709-468c-a3d6-52ac1c9e45f8_terseLabel_en-US" xlink:label="lab_mck_StockIssuedDuringPeriodValueEmployeeStockPlansNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of shares under employee plans, net of forfeitures</link:label>
    <link:label id="lab_mck_StockIssuedDuringPeriodValueEmployeeStockPlansNetOfForfeitures_label_en-US" xlink:label="lab_mck_StockIssuedDuringPeriodValueEmployeeStockPlansNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Plans Net of Forfeitures</link:label>
    <link:label id="lab_mck_StockIssuedDuringPeriodValueEmployeeStockPlansNetOfForfeitures_documentation_en-US" xlink:label="lab_mck_StockIssuedDuringPeriodValueEmployeeStockPlansNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Plans Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_StockIssuedDuringPeriodValueEmployeeStockPlansNetOfForfeitures" xlink:href="mck-20230630.xsd#mck_StockIssuedDuringPeriodValueEmployeeStockPlansNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_StockIssuedDuringPeriodValueEmployeeStockPlansNetOfForfeitures" xlink:to="lab_mck_StockIssuedDuringPeriodValueEmployeeStockPlansNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_111987f6-08b3-447f-b5ac-eb20184f7532_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_NoncontrollingInterestDecreaseFromReclassificationToLiability_dce7d378-a00b-4994-b999-b6cce651328e_negatedTerseLabel_en-US" xlink:label="lab_mck_NoncontrollingInterestDecreaseFromReclassificationToLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification of recurring compensation to other accrued liabilities</link:label>
    <link:label id="lab_mck_NoncontrollingInterestDecreaseFromReclassificationToLiability_label_en-US" xlink:label="lab_mck_NoncontrollingInterestDecreaseFromReclassificationToLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Reclassification to Liability</link:label>
    <link:label id="lab_mck_NoncontrollingInterestDecreaseFromReclassificationToLiability_documentation_en-US" xlink:label="lab_mck_NoncontrollingInterestDecreaseFromReclassificationToLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Reclassification to Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_NoncontrollingInterestDecreaseFromReclassificationToLiability" xlink:href="mck-20230630.xsd#mck_NoncontrollingInterestDecreaseFromReclassificationToLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_NoncontrollingInterestDecreaseFromReclassificationToLiability" xlink:to="lab_mck_NoncontrollingInterestDecreaseFromReclassificationToLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_aab0a9f4-9402-4336-821b-47f225398819_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_a95959a6-6d26-4dec-a685-df86bf4a44e6_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_OpenMarketShareRepurchaseTransactionsMember_ef8829b8-9353-48c6-8bd2-c7028398a5cd_terseLabel_en-US" xlink:label="lab_mck_OpenMarketShareRepurchaseTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Market Share Repurchase Transactions</link:label>
    <link:label id="lab_mck_OpenMarketShareRepurchaseTransactionsMember_label_en-US" xlink:label="lab_mck_OpenMarketShareRepurchaseTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Market Share Repurchase Transactions [Member]</link:label>
    <link:label id="lab_mck_OpenMarketShareRepurchaseTransactionsMember_documentation_en-US" xlink:label="lab_mck_OpenMarketShareRepurchaseTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Open Market Share Repurchase Transactions [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_OpenMarketShareRepurchaseTransactionsMember" xlink:href="mck-20230630.xsd#mck_OpenMarketShareRepurchaseTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_OpenMarketShareRepurchaseTransactionsMember" xlink:to="lab_mck_OpenMarketShareRepurchaseTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_d3bb6561-78eb-4563-a168-2c4a59a886d7_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated annual amortization expense, 2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireSoftware_5e7184cc-98f1-41c1-a5b1-b25272621af2_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireSoftware" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized software expenditures</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireSoftware_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireSoftware" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Software</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireSoftware" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireSoftware"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireSoftware" xlink:to="lab_us-gaap_PaymentsToAcquireSoftware" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_b7ab7c98-0d9c-4a1d-a26c-083c85467a42_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value adjustment gain</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_803ce549-5da1-4213-bd10-d945c2c23f49_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_de1d93af-9e0c-4dda-a10c-5b73179b07ca_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payments</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_29d35668-ceb3-432a-9bac-3d38462d0e22_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_c54905ea-3e06-4b33-87ba-234f32420b22_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings under facility</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_6b99da20-26bb-4837-af5e-96ef5b3e9992_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_NativeAmericanTribesOtherThanCherokeeNationMember_d3e298e5-c937-45a6-8f17-8e9a77b8ce38_terseLabel_en-US" xlink:label="lab_mck_NativeAmericanTribesOtherThanCherokeeNationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Native American Tribes Other Than Cherokee Nation</link:label>
    <link:label id="lab_mck_NativeAmericanTribesOtherThanCherokeeNationMember_label_en-US" xlink:label="lab_mck_NativeAmericanTribesOtherThanCherokeeNationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Native American Tribes Other Than Cherokee Nation [Member]</link:label>
    <link:label id="lab_mck_NativeAmericanTribesOtherThanCherokeeNationMember_documentation_en-US" xlink:label="lab_mck_NativeAmericanTribesOtherThanCherokeeNationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Native American Tribes Other Than Cherokee Nation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_NativeAmericanTribesOtherThanCherokeeNationMember" xlink:href="mck-20230630.xsd#mck_NativeAmericanTribesOtherThanCherokeeNationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_NativeAmericanTribesOtherThanCherokeeNationMember" xlink:to="lab_mck_NativeAmericanTribesOtherThanCherokeeNationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_c7fee495-9182-4397-9fe7-442509442b7d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_b6ffcd87-2567-4344-8650-eff0beea7d9f_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_6ea9d2dd-f74f-41ca-8294-5b71b8b7cdb0_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonMember" xlink:to="lab_us-gaap_TreasuryStockCommonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_0fa4020c-41a2-422b-aedb-14b16abf26aa_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_db9445e4-ee52-4efb-bb79-14ac58603716_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_b006146a-ec28-4666-b722-76a6f191af32_totalLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total litigation liabilities</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_LitigationSettlementAmountAwardedToOtherPartyPercentageOfTotalSettlementToBeUsedToRemediateDamages_c8e5760f-b478-423c-9b6b-a5c84a2e27e2_terseLabel_en-US" xlink:label="lab_mck_LitigationSettlementAmountAwardedToOtherPartyPercentageOfTotalSettlementToBeUsedToRemediateDamages" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlement, amount awarded to other party, percentage of total settlement to be used to remediate damages</link:label>
    <link:label id="lab_mck_LitigationSettlementAmountAwardedToOtherPartyPercentageOfTotalSettlementToBeUsedToRemediateDamages_label_en-US" xlink:label="lab_mck_LitigationSettlementAmountAwardedToOtherPartyPercentageOfTotalSettlementToBeUsedToRemediateDamages" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party, Percentage of Total Settlement to Be Used to Remediate Damages</link:label>
    <link:label id="lab_mck_LitigationSettlementAmountAwardedToOtherPartyPercentageOfTotalSettlementToBeUsedToRemediateDamages_documentation_en-US" xlink:label="lab_mck_LitigationSettlementAmountAwardedToOtherPartyPercentageOfTotalSettlementToBeUsedToRemediateDamages" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Amount Awarded to Other Party, Percentage of Total Settlement to Be Used to Remediate Damages</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_LitigationSettlementAmountAwardedToOtherPartyPercentageOfTotalSettlementToBeUsedToRemediateDamages" xlink:href="mck-20230630.xsd#mck_LitigationSettlementAmountAwardedToOtherPartyPercentageOfTotalSettlementToBeUsedToRemediateDamages"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_LitigationSettlementAmountAwardedToOtherPartyPercentageOfTotalSettlementToBeUsedToRemediateDamages" xlink:to="lab_mck_LitigationSettlementAmountAwardedToOtherPartyPercentageOfTotalSettlementToBeUsedToRemediateDamages" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_13b8489d-b541-4cfb-b4cc-66c1881de09a_verboseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_4c809e0f-81a3-46f9-ae12-ba8605b83490_terseLabel_en-US" xlink:label="lab_mck_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated annual amortization expense, thereafter</link:label>
    <link:label id="lab_mck_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_label_en-US" xlink:label="lab_mck_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Four</link:label>
    <link:label id="lab_mck_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_documentation_en-US" xlink:label="lab_mck_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:href="mck-20230630.xsd#mck_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:to="lab_mck_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_28c81326-90e5-468d-ae07-35e1b57b77a9_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_b6fa8ab3-9496-4850-b3e9-6d55036554d3_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_7391f9da-aa20-4b89-9367-f9a2fa15d98c_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_ec36839e-dfa7-43db-ba89-1c5bf0d97b9d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense (benefit) related to continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_2a5bc0b7-dec7-4ca9-8e94-3e905cb6e73a_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives designated for hedge accounting</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_A490NotesDueJuly152028Member_4a964001-30b8-4964-881e-88a2c0d595a8_terseLabel_en-US" xlink:label="lab_mck_A490NotesDueJuly152028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.90% Notes due July 15, 2028</link:label>
    <link:label id="lab_mck_A490NotesDueJuly152028Member_label_en-US" xlink:label="lab_mck_A490NotesDueJuly152028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.90% Notes Due July 15, 2028 [Member]</link:label>
    <link:label id="lab_mck_A490NotesDueJuly152028Member_documentation_en-US" xlink:label="lab_mck_A490NotesDueJuly152028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.90% Notes Due July 15, 2028</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_A490NotesDueJuly152028Member" xlink:href="mck-20230630.xsd#mck_A490NotesDueJuly152028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_A490NotesDueJuly152028Member" xlink:to="lab_mck_A490NotesDueJuly152028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_527da4dc-1630-4cb7-9c45-fe479bba4f07_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_ecd0cc9f-fbb8-4cf3-a091-ee8cce6a91f2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_7b623585-ce7a-472e-b91a-f49448584705_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gains (Losses) on Cash Flow and Other Hedges, Net of Tax</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_AureliusElephantLimitedMember_6a546e75-6015-4aaa-a325-699d89913ef8_terseLabel_en-US" xlink:label="lab_mck_AureliusElephantLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aurelius Elephant Limited</link:label>
    <link:label id="lab_mck_AureliusElephantLimitedMember_label_en-US" xlink:label="lab_mck_AureliusElephantLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aurelius Elephant Limited [Member]</link:label>
    <link:label id="lab_mck_AureliusElephantLimitedMember_documentation_en-US" xlink:label="lab_mck_AureliusElephantLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aurelius Elephant Limited</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_AureliusElephantLimitedMember" xlink:href="mck-20230630.xsd#mck_AureliusElephantLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_AureliusElephantLimitedMember" xlink:to="lab_mck_AureliusElephantLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_657bae22-92a1-4cf0-8248-f349ce00114a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts reclassified to earnings and other</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_c0df47c1-5212-4b88-9628-a321ae2a930a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_18e60d82-cfa2-4de0-85de-ef7487170e32_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss) attributable to McKesson</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_dcd5ea73-f299-408a-a830-685ae9443877_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement payment</link:label>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_label_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Legal Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLegalSettlements" xlink:to="lab_us-gaap_PaymentsForLegalSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_0276ff52-aeb9-4a1d-912c-176aad14cde9_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c73c4e4b-9839-46db-b25b-d4f37d67a2f4_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cc0b5cbe-478b-4835-953c-1e6fb965e796_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_f97b33a8-5f25-4fbf-9292-fb96440c65e7_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_A525NotesDueFebruary152026Member_c285c1f6-d0d5-45c0-9ebe-1e9ca864ae78_terseLabel_en-US" xlink:label="lab_mck_A525NotesDueFebruary152026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.25% Notes due February 15, 2026</link:label>
    <link:label id="lab_mck_A525NotesDueFebruary152026Member_label_en-US" xlink:label="lab_mck_A525NotesDueFebruary152026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.25% Notes Due February 15, 2026 [Member]</link:label>
    <link:label id="lab_mck_A525NotesDueFebruary152026Member_documentation_en-US" xlink:label="lab_mck_A525NotesDueFebruary152026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.25% Notes Due February 15, 2026</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_A525NotesDueFebruary152026Member" xlink:href="mck-20230630.xsd#mck_A525NotesDueFebruary152026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_A525NotesDueFebruary152026Member" xlink:to="lab_mck_A525NotesDueFebruary152026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_fb7bdf1b-8230-415e-8f5e-44191fffada0_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_ea4d14c6-df59-40b4-a074-5a346c70aafd_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_9100d355-07a1-49f5-8c8c-31f31be609f5_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueHedgingMember_23aa25bb-f08b-4812-b6c2-431adb714842_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedges</link:label>
    <link:label id="lab_us-gaap_FairValueHedgingMember_label_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueHedgingMember" xlink:to="lab_us-gaap_FairValueHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_daced62c-0923-4642-ba85-e8cb24ab2e5e_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_bfaf6a45-ffce-446b-b2d5-e296588fb9d6_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_8ae6af4a-e357-4f50-8f52-cbce4546f1e7_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_408c5aa6-15ae-4e22-8767-42b75bc36f2e_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions, net of cash, cash equivalents, and restricted cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_5728ecb3-82de-420e-b8e1-f344bd89e105_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_e968c23b-5e20-48fd-88ec-38cade1902d5_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_InternationalSegmentMember_fe384a49-aed6-4e60-af2c-e07560f930e1_verboseLabel_en-US" xlink:label="lab_mck_InternationalSegmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International Segment</link:label>
    <link:label id="lab_mck_InternationalSegmentMember_7f473576-e5b4-411d-88ae-b4678c9e03f2_terseLabel_en-US" xlink:label="lab_mck_InternationalSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International</link:label>
    <link:label id="lab_mck_InternationalSegmentMember_label_en-US" xlink:label="lab_mck_InternationalSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International Segment [Member]</link:label>
    <link:label id="lab_mck_InternationalSegmentMember_documentation_en-US" xlink:label="lab_mck_InternationalSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_InternationalSegmentMember" xlink:href="mck-20230630.xsd#mck_InternationalSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_InternationalSegmentMember" xlink:to="lab_mck_InternationalSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_64677ffb-8133-49dc-b0f0-e708fc2e27ff_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock repurchased (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermCommercialPaperCurrent_9ad7c9f7-af93-4496-bb21-e9ea279d7f92_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermCommercialPaperCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_LongTermCommercialPaperCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermCommercialPaperCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Commercial Paper, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermCommercialPaperCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermCommercialPaperCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermCommercialPaperCurrent" xlink:to="lab_us-gaap_LongTermCommercialPaperCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8ee95537-0f32-4712-ad62-a69f122ecaf7_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3be3b698-b93c-4ced-a2ce-f861e6663568_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_USPharmaceuticalSegmentMember_af1207af-8e7c-493e-85d0-8883f627607c_terseLabel_en-US" xlink:label="lab_mck_USPharmaceuticalSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Pharmaceutical</link:label>
    <link:label id="lab_mck_USPharmaceuticalSegmentMember_label_en-US" xlink:label="lab_mck_USPharmaceuticalSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Pharmaceutical Segment [Member]</link:label>
    <link:label id="lab_mck_USPharmaceuticalSegmentMember_documentation_en-US" xlink:label="lab_mck_USPharmaceuticalSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Pharmaceutical Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_USPharmaceuticalSegmentMember" xlink:href="mck-20230630.xsd#mck_USPharmaceuticalSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_USPharmaceuticalSegmentMember" xlink:to="lab_mck_USPharmaceuticalSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_A313SterlingNotesDueFebruary172029Member_bc2c23b5-abec-47c7-9a3b-8bd8f0dfeb2f_terseLabel_en-US" xlink:label="lab_mck_A313SterlingNotesDueFebruary172029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.13% Sterling Notes due February 17, 2029</link:label>
    <link:label id="lab_mck_A313SterlingNotesDueFebruary172029Member_label_en-US" xlink:label="lab_mck_A313SterlingNotesDueFebruary172029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.13% Sterling Notes Due February 17, 2029 [Member]</link:label>
    <link:label id="lab_mck_A313SterlingNotesDueFebruary172029Member_documentation_en-US" xlink:label="lab_mck_A313SterlingNotesDueFebruary172029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.13% Sterling Notes Due February 17, 2029</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_A313SterlingNotesDueFebruary172029Member" xlink:href="mck-20230630.xsd#mck_A313SterlingNotesDueFebruary172029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_A313SterlingNotesDueFebruary172029Member" xlink:to="lab_mck_A313SterlingNotesDueFebruary172029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsAtCarryingValue_fa0940a0-a9d3-45b8-8eb7-e0cbd3ad13f4_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds at carrying value</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsAtCarryingValue" xlink:to="lab_us-gaap_MoneyMarketFundsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_01a809f8-2d32-4fb2-99c1-07d2860fc17e_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for property, plant, and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_bc29bf21-f627-4aaf-964c-c080b42f89d8_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_a4743e7b-3520-4b09-80ef-39d658716319_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_4a0fc981-110c-4b8a-9d06-1f66e24db8bc_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_4f0027f5-4718-4070-b2cb-db736c62ec13_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_ffe4ee4b-fe96-4a0e-906f-d403b1829e6d_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_96c5bab2-7b23-4f01-8d79-c55538b1252a_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommercialPaper_f91e7161-5916-4d48-97ce-f14433fa0cdb_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommercialPaper" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of commercial paper</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommercialPaper_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommercialPaper" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Commercial Paper</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommercialPaper" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommercialPaper"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommercialPaper" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommercialPaper" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_74e82cdf-b788-4e17-a250-a7d7f19d20ec_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_5a54f08f-17fa-4aef-a7c3-8b69b624e988_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_68105ab0-c78b-4a22-af9c-bc3a88adf1e5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_4ac35437-d6cf-4aab-8d3f-c5a88c5a8485_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_681c6bf5-f856-4043-a476-611ccaf12521_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_d97619ff-ba94-47fc-bd56-07fc9485e0f5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_6b3dd3cf-75ed-4177-94d1-c4b3374840b8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_44068cc0-93c3-4616-8c45-d42c9370ea84_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedges</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_b6aca738-5aaa-428a-930d-7f7c87c5fcf7_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_6410e557-f537-44b0-88df-b0efcbe41ef5_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments of Business</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_27bbc770-3b56-4008-b931-97878ce4870a_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net decrease in cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_40befbc6-b5c7-447b-bef4-1fcbfd79da9c_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FINANCING ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_e67334c0-48ed-47e4-aa5e-6a7111a7c612_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_980ae59e-d8d8-454b-87f2-792a4fa2c787_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_08481bf9-fded-46ef-8e94-7379dba27e7f_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_39ff0261-6ffa-4462-9b4c-16ed11646cac_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_8ca6ac23-8fcf-4962-8ce0-6b471ed58774_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_291d0495-4781-4681-b5d9-c437e08057cc_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating profit (loss)</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_5856a9d3-a14d-4a30-8ecc-683a27dbdace_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_6f0fd35a-c485-496b-804f-3b502ff064cb_terseLabel_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_2c9124a4-261f-4b37-8ae7-10c2e13daf12_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment revenues</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_IncreaseDecreaseInLitigationReserve_1aadd036-dd56-41c2-8028-f92ee29c4507_terseLabel_en-US" xlink:label="lab_mck_IncreaseDecreaseInLitigationReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation liabilities</link:label>
    <link:label id="lab_mck_IncreaseDecreaseInLitigationReserve_label_en-US" xlink:label="lab_mck_IncreaseDecreaseInLitigationReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Litigation Reserve</link:label>
    <link:label id="lab_mck_IncreaseDecreaseInLitigationReserve_documentation_en-US" xlink:label="lab_mck_IncreaseDecreaseInLitigationReserve" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Litigation Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_IncreaseDecreaseInLitigationReserve" xlink:href="mck-20230630.xsd#mck_IncreaseDecreaseInLitigationReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_IncreaseDecreaseInLitigationReserve" xlink:to="lab_mck_IncreaseDecreaseInLitigationReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_RestructuringImpairmentAndOtherRelatedCharges_1cfec84c-87ff-47d8-8cf2-d23c548b6f3c_negatedTerseLabel_en-US" xlink:label="lab_mck_RestructuringImpairmentAndOtherRelatedCharges" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, impairment, and related charges, net</link:label>
    <link:label id="lab_mck_RestructuringImpairmentAndOtherRelatedCharges_4e844c89-59aa-4ecd-a8ac-a0d38943678f_terseLabel_en-US" xlink:label="lab_mck_RestructuringImpairmentAndOtherRelatedCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, impairment, and related charges, net</link:label>
    <link:label id="lab_mck_RestructuringImpairmentAndOtherRelatedCharges_label_en-US" xlink:label="lab_mck_RestructuringImpairmentAndOtherRelatedCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, Impairment and Other Related Charges</link:label>
    <link:label id="lab_mck_RestructuringImpairmentAndOtherRelatedCharges_documentation_en-US" xlink:label="lab_mck_RestructuringImpairmentAndOtherRelatedCharges" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, Impairment and Other Related Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_RestructuringImpairmentAndOtherRelatedCharges" xlink:href="mck-20230630.xsd#mck_RestructuringImpairmentAndOtherRelatedCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_RestructuringImpairmentAndOtherRelatedCharges" xlink:to="lab_mck_RestructuringImpairmentAndOtherRelatedCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_a2e13725-92e4-46fb-8828-ad9442f28ac6_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income, net of tax</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_79e00816-42bd-4dec-a365-6b801cd2db52_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuances</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_eb3a1e23-2f90-4c44-b817-fff241c0da1f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_ae18e75c-2f50-45a7-94ee-b1eac64fbf9f_verboseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_080bd239-0333-4650-844d-d9e99691d7b1_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_McKessonUSOncologyResearchMember_9e3a2e8d-5e7a-4d82-9129-45670c61587e_terseLabel_en-US" xlink:label="lab_mck_McKessonUSOncologyResearchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">USOR</link:label>
    <link:label id="lab_mck_McKessonUSOncologyResearchMember_label_en-US" xlink:label="lab_mck_McKessonUSOncologyResearchMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson U.S. Oncology Research [Member]</link:label>
    <link:label id="lab_mck_McKessonUSOncologyResearchMember_documentation_en-US" xlink:label="lab_mck_McKessonUSOncologyResearchMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">McKesson U.S. Oncology Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_McKessonUSOncologyResearchMember" xlink:href="mck-20230630.xsd#mck_McKessonUSOncologyResearchMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_McKessonUSOncologyResearchMember" xlink:to="lab_mck_McKessonUSOncologyResearchMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationProfitLossAbstract_614b2056-d742-489a-b8b1-e40da09387da_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationProfitLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information, Profit (Loss) [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationProfitLossAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationProfitLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information, Profit (Loss) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationProfitLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationProfitLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationProfitLossAbstract" xlink:to="lab_us-gaap_SegmentReportingInformationProfitLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_619d4dbc-2bfd-4703-86b0-56061c0d464c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCredit_159c4d32-7c35-4961-96e1-33cf0aafe0c3_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts outstanding under facility</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_label_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Line of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_2f8b929d-4ce0-49ad-8568-fb3abed1aec9_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer relationships</link:label>
    <link:label id="lab_us-gaap_CustomerRelationshipsMember_label_en-US" xlink:label="lab_us-gaap_CustomerRelationshipsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Relationships [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRelationshipsMember" xlink:to="lab_us-gaap_CustomerRelationshipsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_EuroDenominatedNotesMember_f5417c5b-8d63-4b84-a674-17d1f82d0357_terseLabel_en-US" xlink:label="lab_mck_EuroDenominatedNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euro Denominated Notes</link:label>
    <link:label id="lab_mck_EuroDenominatedNotesMember_label_en-US" xlink:label="lab_mck_EuroDenominatedNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euro Denominated Notes [Member]</link:label>
    <link:label id="lab_mck_EuroDenominatedNotesMember_documentation_en-US" xlink:label="lab_mck_EuroDenominatedNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euro Denominated Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_EuroDenominatedNotesMember" xlink:href="mck-20230630.xsd#mck_EuroDenominatedNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_EuroDenominatedNotesMember" xlink:to="lab_mck_EuroDenominatedNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_StrategicGrowthInitiativePlanOperationalEfficienciesAndCostOptimizationMember_3d31bc23-7b18-47a6-9c5f-a7db7c1c742d_terseLabel_en-US" xlink:label="lab_mck_StrategicGrowthInitiativePlanOperationalEfficienciesAndCostOptimizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Growth Initiative Plan - Operational Efficiencies and Cost Optimization</link:label>
    <link:label id="lab_mck_StrategicGrowthInitiativePlanOperationalEfficienciesAndCostOptimizationMember_label_en-US" xlink:label="lab_mck_StrategicGrowthInitiativePlanOperationalEfficienciesAndCostOptimizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Growth Initiative Plan - Operational Efficiencies and Cost Optimization [Member]</link:label>
    <link:label id="lab_mck_StrategicGrowthInitiativePlanOperationalEfficienciesAndCostOptimizationMember_documentation_en-US" xlink:label="lab_mck_StrategicGrowthInitiativePlanOperationalEfficienciesAndCostOptimizationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Growth Initiative Plan - Operational Efficiencies and Cost Optimization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_StrategicGrowthInitiativePlanOperationalEfficienciesAndCostOptimizationMember" xlink:href="mck-20230630.xsd#mck_StrategicGrowthInitiativePlanOperationalEfficienciesAndCostOptimizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_StrategicGrowthInitiativePlanOperationalEfficienciesAndCostOptimizationMember" xlink:to="lab_mck_StrategicGrowthInitiativePlanOperationalEfficienciesAndCostOptimizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_mck_LossContingencyNumberOfFormerOfficers_8a1943c7-6d36-40b2-b7fc-e500166a4c66_terseLabel_en-US" xlink:label="lab_mck_LossContingencyNumberOfFormerOfficers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of former officers</link:label>
    <link:label id="lab_mck_LossContingencyNumberOfFormerOfficers_label_en-US" xlink:label="lab_mck_LossContingencyNumberOfFormerOfficers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Former Officers</link:label>
    <link:label id="lab_mck_LossContingencyNumberOfFormerOfficers_documentation_en-US" xlink:label="lab_mck_LossContingencyNumberOfFormerOfficers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Former Officers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_mck_LossContingencyNumberOfFormerOfficers" xlink:href="mck-20230630.xsd#mck_LossContingencyNumberOfFormerOfficers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mck_LossContingencyNumberOfFormerOfficers" xlink:to="lab_mck_LossContingencyNumberOfFormerOfficers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_a4c1ba74-a194-49fc-a942-40161baac362_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interests</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>mck-20230630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:65f23265-c924-40c8-9b40-7c0acd48a82a,g:b9e463ca-a0e1-4231-8e93-a7255a3f4103-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://mckesson123.com/role/Cover" xlink:type="simple" xlink:href="mck-20230630.xsd#Cover"/>
  <link:presentationLink xlink:role="http://mckesson123.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_9e3dbe18-eca1-4008-aaf3-2f5e02eaa97e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitiesTable_cba14965-f0cd-4dde-a90f-a37ff4facbd4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9e3dbe18-eca1-4008-aaf3-2f5e02eaa97e" xlink:to="loc_dei_EntitiesTable_cba14965-f0cd-4dde-a90f-a37ff4facbd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3fdf2529-68fc-4045-ab9a-2d0332c7ca87" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_cba14965-f0cd-4dde-a90f-a37ff4facbd4" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3fdf2529-68fc-4045-ab9a-2d0332c7ca87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_d1784ff1-c70b-4e94-b4f5-6253819b140d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3fdf2529-68fc-4045-ab9a-2d0332c7ca87" xlink:to="loc_us-gaap_ClassOfStockDomain_d1784ff1-c70b-4e94-b4f5-6253819b140d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_48aed6c8-d805-4e3d-804f-b26f5df0768f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_d1784ff1-c70b-4e94-b4f5-6253819b140d" xlink:to="loc_us-gaap_CommonStockMember_48aed6c8-d805-4e3d-804f-b26f5df0768f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_A1500NotesDue2025Member_8c92d759-6a19-402c-a58b-4e2ea0149047" xlink:href="mck-20230630.xsd#mck_A1500NotesDue2025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_d1784ff1-c70b-4e94-b4f5-6253819b140d" xlink:to="loc_mck_A1500NotesDue2025Member_8c92d759-6a19-402c-a58b-4e2ea0149047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_A1625NotesDue2026Member_888e4d82-a0c6-4f48-8024-a3099605a11a" xlink:href="mck-20230630.xsd#mck_A1625NotesDue2026Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_d1784ff1-c70b-4e94-b4f5-6253819b140d" xlink:to="loc_mck_A1625NotesDue2026Member_888e4d82-a0c6-4f48-8024-a3099605a11a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_A3125NotesDue2029Member_9d97e41e-6a93-4a49-ac8c-c18bcd5796a5" xlink:href="mck-20230630.xsd#mck_A3125NotesDue2029Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_d1784ff1-c70b-4e94-b4f5-6253819b140d" xlink:to="loc_mck_A3125NotesDue2029Member_9d97e41e-6a93-4a49-ac8c-c18bcd5796a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInformationLineItems_fe9b6671-3e12-4c42-9852-9149877588c5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_cba14965-f0cd-4dde-a90f-a37ff4facbd4" xlink:to="loc_dei_EntityInformationLineItems_fe9b6671-3e12-4c42-9852-9149877588c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_b8867d47-f9a4-467a-a253-be9c7f53b432" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_fe9b6671-3e12-4c42-9852-9149877588c5" xlink:to="loc_dei_DocumentType_b8867d47-f9a4-467a-a253-be9c7f53b432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_5c779a27-d85c-4835-b63d-5ab98b28676a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_fe9b6671-3e12-4c42-9852-9149877588c5" xlink:to="loc_dei_DocumentQuarterlyReport_5c779a27-d85c-4835-b63d-5ab98b28676a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_7e8314a7-051a-4e1c-b308-824b19fb04d5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_fe9b6671-3e12-4c42-9852-9149877588c5" xlink:to="loc_dei_DocumentPeriodEndDate_7e8314a7-051a-4e1c-b308-824b19fb04d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_0e227280-9120-4a70-9bab-de0d4aa953c4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_fe9b6671-3e12-4c42-9852-9149877588c5" xlink:to="loc_dei_DocumentTransitionReport_0e227280-9120-4a70-9bab-de0d4aa953c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_c42a403d-ed41-41d0-8516-d6bcfe539302" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_fe9b6671-3e12-4c42-9852-9149877588c5" xlink:to="loc_dei_EntityFileNumber_c42a403d-ed41-41d0-8516-d6bcfe539302" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_92e93ae3-a8fe-4ae2-8da4-7f24de1da8da" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_fe9b6671-3e12-4c42-9852-9149877588c5" xlink:to="loc_dei_EntityRegistrantName_92e93ae3-a8fe-4ae2-8da4-7f24de1da8da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_ee3bb635-a655-4fe9-8e35-4ee388bdca5d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_fe9b6671-3e12-4c42-9852-9149877588c5" xlink:to="loc_dei_EntityIncorporationStateCountryCode_ee3bb635-a655-4fe9-8e35-4ee388bdca5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_92c1bc17-5074-435a-aef5-267c4af1f29b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_fe9b6671-3e12-4c42-9852-9149877588c5" xlink:to="loc_dei_EntityTaxIdentificationNumber_92c1bc17-5074-435a-aef5-267c4af1f29b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_5cd21940-c7f7-4830-91cc-22f4c9024c2b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_fe9b6671-3e12-4c42-9852-9149877588c5" xlink:to="loc_dei_EntityAddressAddressLine1_5cd21940-c7f7-4830-91cc-22f4c9024c2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_394b743c-0f26-4f32-aa1b-b4ac5cb37f47" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_fe9b6671-3e12-4c42-9852-9149877588c5" xlink:to="loc_dei_EntityAddressCityOrTown_394b743c-0f26-4f32-aa1b-b4ac5cb37f47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_eaaace15-e67a-4c97-9d05-d9ecd68c88bd" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_fe9b6671-3e12-4c42-9852-9149877588c5" xlink:to="loc_dei_EntityAddressStateOrProvince_eaaace15-e67a-4c97-9d05-d9ecd68c88bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_d751ad6b-34da-42d6-9dc2-24add92d3f4a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_fe9b6671-3e12-4c42-9852-9149877588c5" xlink:to="loc_dei_EntityAddressPostalZipCode_d751ad6b-34da-42d6-9dc2-24add92d3f4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_dbd9760e-32e9-4ec4-9c1c-93805ee72f7c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_fe9b6671-3e12-4c42-9852-9149877588c5" xlink:to="loc_dei_CityAreaCode_dbd9760e-32e9-4ec4-9c1c-93805ee72f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_709507e4-79b0-4d73-9fc8-b9d041669f08" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_fe9b6671-3e12-4c42-9852-9149877588c5" xlink:to="loc_dei_LocalPhoneNumber_709507e4-79b0-4d73-9fc8-b9d041669f08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_5b0fb9a0-ccde-4f6f-b6b5-60e30c2d54bb" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_fe9b6671-3e12-4c42-9852-9149877588c5" xlink:to="loc_dei_Security12bTitle_5b0fb9a0-ccde-4f6f-b6b5-60e30c2d54bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_fba9437b-9443-4ddd-9638-5d9a13f1fcc5" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_fe9b6671-3e12-4c42-9852-9149877588c5" xlink:to="loc_dei_TradingSymbol_fba9437b-9443-4ddd-9638-5d9a13f1fcc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_9384685d-21fc-4b31-aa9e-2e429117c8bf" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_fe9b6671-3e12-4c42-9852-9149877588c5" xlink:to="loc_dei_SecurityExchangeName_9384685d-21fc-4b31-aa9e-2e429117c8bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_9c84c18a-009e-41dd-b561-bd19adf9db09" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_fe9b6671-3e12-4c42-9852-9149877588c5" xlink:to="loc_dei_EntityCurrentReportingStatus_9c84c18a-009e-41dd-b561-bd19adf9db09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_c29bfae9-02f9-42c1-96ac-6b39b2cb200a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_fe9b6671-3e12-4c42-9852-9149877588c5" xlink:to="loc_dei_EntityInteractiveDataCurrent_c29bfae9-02f9-42c1-96ac-6b39b2cb200a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_a797fac2-8c1d-423f-97d0-c1f76eff8f66" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_fe9b6671-3e12-4c42-9852-9149877588c5" xlink:to="loc_dei_EntityFilerCategory_a797fac2-8c1d-423f-97d0-c1f76eff8f66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_221a96cb-b256-46dc-8ad3-6a84d4864208" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_fe9b6671-3e12-4c42-9852-9149877588c5" xlink:to="loc_dei_EntitySmallBusiness_221a96cb-b256-46dc-8ad3-6a84d4864208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_6de9f3c2-7e49-49d5-aa03-27d73f4ca818" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_fe9b6671-3e12-4c42-9852-9149877588c5" xlink:to="loc_dei_EntityEmergingGrowthCompany_6de9f3c2-7e49-49d5-aa03-27d73f4ca818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_10799bef-a033-4437-9ac9-ca40bc341e53" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_fe9b6671-3e12-4c42-9852-9149877588c5" xlink:to="loc_dei_EntityShellCompany_10799bef-a033-4437-9ac9-ca40bc341e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_ce1fbfbf-4f24-4c83-a452-77c661cd3cf0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_fe9b6671-3e12-4c42-9852-9149877588c5" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_ce1fbfbf-4f24-4c83-a452-77c661cd3cf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_f5e2808e-6e44-4471-a694-4c154f59ca88" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_fe9b6671-3e12-4c42-9852-9149877588c5" xlink:to="loc_dei_EntityCentralIndexKey_f5e2808e-6e44-4471-a694-4c154f59ca88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_2829c146-81b0-475f-a458-f4dac3e7347f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_fe9b6671-3e12-4c42-9852-9149877588c5" xlink:to="loc_dei_DocumentFiscalYearFocus_2829c146-81b0-475f-a458-f4dac3e7347f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_09dd6a6e-0519-4840-9407-8e2bf2884141" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_fe9b6671-3e12-4c42-9852-9149877588c5" xlink:to="loc_dei_DocumentFiscalPeriodFocus_09dd6a6e-0519-4840-9407-8e2bf2884141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_996ec339-68b0-44f6-8b7b-ef8ba8557c7b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_fe9b6671-3e12-4c42-9852-9149877588c5" xlink:to="loc_dei_AmendmentFlag_996ec339-68b0-44f6-8b7b-ef8ba8557c7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_9fd54e48-e9ed-4ea8-97a5-8aad63854423" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_fe9b6671-3e12-4c42-9852-9149877588c5" xlink:to="loc_dei_CurrentFiscalYearEndDate_9fd54e48-e9ed-4ea8-97a5-8aad63854423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="mck-20230630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_bb031f76-8542-4429-b7e9-5c6d27b658e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_19716837-9fb7-44c9-9d6f-303816fa428e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_bb031f76-8542-4429-b7e9-5c6d27b658e8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_19716837-9fb7-44c9-9d6f-303816fa428e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_932c35b1-ef39-4491-9b4f-17577e15f112" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_bb031f76-8542-4429-b7e9-5c6d27b658e8" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_932c35b1-ef39-4491-9b4f-17577e15f112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_f2258a04-befd-4271-9eee-2e2a44482e50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_bb031f76-8542-4429-b7e9-5c6d27b658e8" xlink:to="loc_us-gaap_GrossProfit_f2258a04-befd-4271-9eee-2e2a44482e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_5f37542f-b386-477f-b6d8-665702f25da8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_bb031f76-8542-4429-b7e9-5c6d27b658e8" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_5f37542f-b386-477f-b6d8-665702f25da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_738de9e8-0623-4919-9126-ebb70c356435" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossRelatedToLitigationSettlement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_bb031f76-8542-4429-b7e9-5c6d27b658e8" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_738de9e8-0623-4919-9126-ebb70c356435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_RestructuringImpairmentAndOtherRelatedCharges_79729ae3-23ba-4d03-817e-37545389fd6e" xlink:href="mck-20230630.xsd#mck_RestructuringImpairmentAndOtherRelatedCharges"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_bb031f76-8542-4429-b7e9-5c6d27b658e8" xlink:to="loc_mck_RestructuringImpairmentAndOtherRelatedCharges_79729ae3-23ba-4d03-817e-37545389fd6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_cdb19947-33e5-49bb-85ed-ef3a38f23a73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_bb031f76-8542-4429-b7e9-5c6d27b658e8" xlink:to="loc_us-gaap_OperatingExpenses_cdb19947-33e5-49bb-85ed-ef3a38f23a73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_1e0619e2-26af-4f06-83ac-5b96dbe44bdd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_bb031f76-8542-4429-b7e9-5c6d27b658e8" xlink:to="loc_us-gaap_OperatingIncomeLoss_1e0619e2-26af-4f06-83ac-5b96dbe44bdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_5cef92da-ee03-498d-b109-3d3def78eea3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_bb031f76-8542-4429-b7e9-5c6d27b658e8" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_5cef92da-ee03-498d-b109-3d3def78eea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_2198a8e1-6d44-42ee-a1b2-1a4f86834203" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_bb031f76-8542-4429-b7e9-5c6d27b658e8" xlink:to="loc_us-gaap_InterestExpense_2198a8e1-6d44-42ee-a1b2-1a4f86834203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_40179ffc-5351-48ed-94e4-a9d8d509f57d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_bb031f76-8542-4429-b7e9-5c6d27b658e8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_40179ffc-5351-48ed-94e4-a9d8d509f57d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_079b36e6-0f9c-49ed-9813-b4aff1a24624" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_bb031f76-8542-4429-b7e9-5c6d27b658e8" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_079b36e6-0f9c-49ed-9813-b4aff1a24624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_6b3dd726-3f34-4f0e-a14b-2e18008863e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_bb031f76-8542-4429-b7e9-5c6d27b658e8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_6b3dd726-3f34-4f0e-a14b-2e18008863e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_bb357ca0-a700-4bbb-bc85-e780421ebe92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_bb031f76-8542-4429-b7e9-5c6d27b658e8" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_bb357ca0-a700-4bbb-bc85-e780421ebe92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_e8ef0941-bb94-424e-b100-923c240f95ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_bb031f76-8542-4429-b7e9-5c6d27b658e8" xlink:to="loc_us-gaap_ProfitLoss_e8ef0941-bb94-424e-b100-923c240f95ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_b9a4907b-afee-44ec-a82b-205e4ad6cd8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_bb031f76-8542-4429-b7e9-5c6d27b658e8" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_b9a4907b-afee-44ec-a82b-205e4ad6cd8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a17516f8-5315-4315-81b3-04c9d470ef99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_bb031f76-8542-4429-b7e9-5c6d27b658e8" xlink:to="loc_us-gaap_NetIncomeLoss_a17516f8-5315-4315-81b3-04c9d470ef99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_ac71f5c8-400e-48ec-9e3e-4f5089bdeea5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_bb031f76-8542-4429-b7e9-5c6d27b658e8" xlink:to="loc_us-gaap_EarningsPerShareAbstract_ac71f5c8-400e-48ec-9e3e-4f5089bdeea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_2ca9a62f-0e13-4f85-b7d0-bd83133a709b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ac71f5c8-400e-48ec-9e3e-4f5089bdeea5" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_2ca9a62f-0e13-4f85-b7d0-bd83133a709b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_090552b4-2e65-4bc8-8790-cd9af9ed6d04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_2ca9a62f-0e13-4f85-b7d0-bd83133a709b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_090552b4-2e65-4bc8-8790-cd9af9ed6d04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_65312471-6f8d-426b-8555-5b86ec4645fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_2ca9a62f-0e13-4f85-b7d0-bd83133a709b" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_65312471-6f8d-426b-8555-5b86ec4645fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_50cb9b4d-3bf9-449f-93a8-12c5b9ed5aa2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_2ca9a62f-0e13-4f85-b7d0-bd83133a709b" xlink:to="loc_us-gaap_EarningsPerShareDiluted_50cb9b4d-3bf9-449f-93a8-12c5b9ed5aa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_4e4a4d1d-d7e4-4716-b986-38a773d553dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ac71f5c8-400e-48ec-9e3e-4f5089bdeea5" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_4e4a4d1d-d7e4-4716-b986-38a773d553dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_c3451362-fdea-41bb-b775-835880a5efa4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_4e4a4d1d-d7e4-4716-b986-38a773d553dc" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_c3451362-fdea-41bb-b775-835880a5efa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_147aa598-ff43-46c0-9c6a-a6f4d3fa97b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_4e4a4d1d-d7e4-4716-b986-38a773d553dc" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_147aa598-ff43-46c0-9c6a-a6f4d3fa97b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_a0f308a6-766d-44b6-810d-770f51a2634e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_4e4a4d1d-d7e4-4716-b986-38a773d553dc" xlink:to="loc_us-gaap_EarningsPerShareBasic_a0f308a6-766d-44b6-810d-770f51a2634e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_2d73e077-9465-403e-b06f-574339893a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_bb031f76-8542-4429-b7e9-5c6d27b658e8" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_2d73e077-9465-403e-b06f-574339893a8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b0caba26-a896-4c15-b95c-101620852227" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_2d73e077-9465-403e-b06f-574339893a8d" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b0caba26-a896-4c15-b95c-101620852227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_772dcbe6-c71c-47ce-98ab-8563e8d840d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_2d73e077-9465-403e-b06f-574339893a8d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_772dcbe6-c71c-47ce-98ab-8563e8d840d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="simple" xlink:href="mck-20230630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"/>
  <link:presentationLink xlink:role="http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a20c019a-e5d2-4262-a33f-d8d7cde31af2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c2732b00-d2f6-4539-93eb-6254b0bb31dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a20c019a-e5d2-4262-a33f-d8d7cde31af2" xlink:to="loc_us-gaap_ProfitLoss_c2732b00-d2f6-4539-93eb-6254b0bb31dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_a0b81d32-ef6e-4f31-b6cd-37c7a6ae582b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a20c019a-e5d2-4262-a33f-d8d7cde31af2" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_a0b81d32-ef6e-4f31-b6cd-37c7a6ae582b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_6f879f9b-c0d4-4b97-bc00-5fe83ffb63a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_a0b81d32-ef6e-4f31-b6cd-37c7a6ae582b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_6f879f9b-c0d4-4b97-bc00-5fe83ffb63a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_cc50bd14-29fd-423b-b589-518e40b37407" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_a0b81d32-ef6e-4f31-b6cd-37c7a6ae582b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_cc50bd14-29fd-423b-b589-518e40b37407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_005bfa33-eeb1-41ef-9031-414f9d810703" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_a0b81d32-ef6e-4f31-b6cd-37c7a6ae582b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_005bfa33-eeb1-41ef-9031-414f9d810703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_b7cc8303-952b-4c7e-a01f-348c5474d761" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_a0b81d32-ef6e-4f31-b6cd-37c7a6ae582b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_b7cc8303-952b-4c7e-a01f-348c5474d761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_0870c783-2bd1-48c5-b0de-8eb7dc95f467" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a20c019a-e5d2-4262-a33f-d8d7cde31af2" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_0870c783-2bd1-48c5-b0de-8eb7dc95f467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_ff2868b2-8e00-4771-a254-296b6cb85ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a20c019a-e5d2-4262-a33f-d8d7cde31af2" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_ff2868b2-8e00-4771-a254-296b6cb85ad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_10d5190e-16e6-439c-a2c3-295203128699" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_a20c019a-e5d2-4262-a33f-d8d7cde31af2" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_10d5190e-16e6-439c-a2c3-295203128699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="mck-20230630.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_db263e66-b718-4c92-ba77-34940fada725" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_24d8c56a-3746-41eb-b2da-dbf40f8eb6df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_db263e66-b718-4c92-ba77-34940fada725" xlink:to="loc_us-gaap_AssetsAbstract_24d8c56a-3746-41eb-b2da-dbf40f8eb6df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_adc8d2ff-578a-4e7c-9b29-27c0f8bfa4de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_24d8c56a-3746-41eb-b2da-dbf40f8eb6df" xlink:to="loc_us-gaap_AssetsCurrentAbstract_adc8d2ff-578a-4e7c-9b29-27c0f8bfa4de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_462bba7c-2ecb-458e-82c4-388ae4e24ef2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_adc8d2ff-578a-4e7c-9b29-27c0f8bfa4de" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_462bba7c-2ecb-458e-82c4-388ae4e24ef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_34704b6f-c7fd-47aa-b225-d09db272afe1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_adc8d2ff-578a-4e7c-9b29-27c0f8bfa4de" xlink:to="loc_us-gaap_ReceivablesNetCurrent_34704b6f-c7fd-47aa-b225-d09db272afe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_bcbd4358-3081-4e75-bbee-5070ce6b0446" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_adc8d2ff-578a-4e7c-9b29-27c0f8bfa4de" xlink:to="loc_us-gaap_InventoryNet_bcbd4358-3081-4e75-bbee-5070ce6b0446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_42649d1a-6480-4e92-b74a-47092fa42c59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_adc8d2ff-578a-4e7c-9b29-27c0f8bfa4de" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_42649d1a-6480-4e92-b74a-47092fa42c59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_6a0ee79b-1336-4109-8e50-99b49732a46d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_adc8d2ff-578a-4e7c-9b29-27c0f8bfa4de" xlink:to="loc_us-gaap_AssetsCurrent_6a0ee79b-1336-4109-8e50-99b49732a46d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_038290ea-4211-4f89-9c2b-49aa8712db4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_24d8c56a-3746-41eb-b2da-dbf40f8eb6df" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_038290ea-4211-4f89-9c2b-49aa8712db4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_b1277ccb-406b-469e-b910-5c72d5fb763a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_24d8c56a-3746-41eb-b2da-dbf40f8eb6df" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_b1277ccb-406b-469e-b910-5c72d5fb763a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_05611451-feda-4045-b0c1-b2e6706c82d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_24d8c56a-3746-41eb-b2da-dbf40f8eb6df" xlink:to="loc_us-gaap_Goodwill_05611451-feda-4045-b0c1-b2e6706c82d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5f6a25e0-a173-4b1d-9107-c0d44b11b1ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_24d8c56a-3746-41eb-b2da-dbf40f8eb6df" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_5f6a25e0-a173-4b1d-9107-c0d44b11b1ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_777f9d61-5fdf-46f7-aea3-0e0e66f2cac5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_24d8c56a-3746-41eb-b2da-dbf40f8eb6df" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_777f9d61-5fdf-46f7-aea3-0e0e66f2cac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_0cdde05f-f9c6-4546-a479-f3709eade0e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_24d8c56a-3746-41eb-b2da-dbf40f8eb6df" xlink:to="loc_us-gaap_Assets_0cdde05f-f9c6-4546-a479-f3709eade0e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f94a8fde-1e6b-4844-9fff-d1fd0cc26614" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_db263e66-b718-4c92-ba77-34940fada725" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f94a8fde-1e6b-4844-9fff-d1fd0cc26614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_a36f1281-622f-42a3-87ae-de730352c829" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f94a8fde-1e6b-4844-9fff-d1fd0cc26614" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_a36f1281-622f-42a3-87ae-de730352c829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_55425a2e-3554-41d8-acca-e4c49a188dad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a36f1281-622f-42a3-87ae-de730352c829" xlink:to="loc_us-gaap_AccountsPayableCurrent_55425a2e-3554-41d8-acca-e4c49a188dad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_962dfde1-3b64-4dce-85db-cddd24818f11" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a36f1281-622f-42a3-87ae-de730352c829" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_962dfde1-3b64-4dce-85db-cddd24818f11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_9062c5cd-9854-4d5a-b4e5-94bfbad5a876" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a36f1281-622f-42a3-87ae-de730352c829" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_9062c5cd-9854-4d5a-b4e5-94bfbad5a876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_fa95f0c5-0417-46db-bfb8-b733c5b66e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a36f1281-622f-42a3-87ae-de730352c829" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_fa95f0c5-0417-46db-bfb8-b733c5b66e8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_b2b10208-a65e-455d-be0b-d86f8be446ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a36f1281-622f-42a3-87ae-de730352c829" xlink:to="loc_us-gaap_LiabilitiesCurrent_b2b10208-a65e-455d-be0b-d86f8be446ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_5c9ec3b9-39d3-4398-9d2e-8a10bb43b509" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f94a8fde-1e6b-4844-9fff-d1fd0cc26614" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_5c9ec3b9-39d3-4398-9d2e-8a10bb43b509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_5e09662d-498a-4cd0-bd64-7d18ab3a5a89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f94a8fde-1e6b-4844-9fff-d1fd0cc26614" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_5e09662d-498a-4cd0-bd64-7d18ab3a5a89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a02c9881-31b7-472d-acc8-08e71a65b1be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f94a8fde-1e6b-4844-9fff-d1fd0cc26614" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_a02c9881-31b7-472d-acc8-08e71a65b1be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserveNoncurrent_a4014738-2cc0-4ca8-b808-e75b4010bb3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationReserveNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f94a8fde-1e6b-4844-9fff-d1fd0cc26614" xlink:to="loc_us-gaap_LitigationReserveNoncurrent_a4014738-2cc0-4ca8-b808-e75b4010bb3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_8c52ecde-603e-4ed5-82bb-e30ae0cde04d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f94a8fde-1e6b-4844-9fff-d1fd0cc26614" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_8c52ecde-603e-4ed5-82bb-e30ae0cde04d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_0bb82c01-6ec9-47a7-b65d-31ee9a347592" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f94a8fde-1e6b-4844-9fff-d1fd0cc26614" xlink:to="loc_us-gaap_StockholdersEquityAbstract_0bb82c01-6ec9-47a7-b65d-31ee9a347592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_33ffe7b6-c32a-4852-a058-ecebbaa90830" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0bb82c01-6ec9-47a7-b65d-31ee9a347592" xlink:to="loc_us-gaap_PreferredStockValue_33ffe7b6-c32a-4852-a058-ecebbaa90830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_b3226597-eb83-4f73-8a19-c2c5d2a0e7d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0bb82c01-6ec9-47a7-b65d-31ee9a347592" xlink:to="loc_us-gaap_CommonStockValue_b3226597-eb83-4f73-8a19-c2c5d2a0e7d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_1f4155f3-cc5f-48b9-b81a-4cb1c72d2ba8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0bb82c01-6ec9-47a7-b65d-31ee9a347592" xlink:to="loc_us-gaap_AdditionalPaidInCapital_1f4155f3-cc5f-48b9-b81a-4cb1c72d2ba8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7ff2f1ba-10c0-4d2b-8f92-eff41e480951" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0bb82c01-6ec9-47a7-b65d-31ee9a347592" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_7ff2f1ba-10c0-4d2b-8f92-eff41e480951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0f73bc81-0374-43f8-82cb-b8a61bbc2298" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0bb82c01-6ec9-47a7-b65d-31ee9a347592" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0f73bc81-0374-43f8-82cb-b8a61bbc2298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_e434f7f7-f04a-451b-95cc-61fc9f1be72a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0bb82c01-6ec9-47a7-b65d-31ee9a347592" xlink:to="loc_us-gaap_TreasuryStockCommonValue_e434f7f7-f04a-451b-95cc-61fc9f1be72a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8badbcab-7d8d-4b45-9e61-f4ee91d9db5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0bb82c01-6ec9-47a7-b65d-31ee9a347592" xlink:to="loc_us-gaap_StockholdersEquity_8badbcab-7d8d-4b45-9e61-f4ee91d9db5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_3b06800d-e684-4c6e-9136-03cfc7406900" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0bb82c01-6ec9-47a7-b65d-31ee9a347592" xlink:to="loc_us-gaap_MinorityInterest_3b06800d-e684-4c6e-9136-03cfc7406900" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_bc14af6a-9fcd-436e-8383-93c3016101d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0bb82c01-6ec9-47a7-b65d-31ee9a347592" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_bc14af6a-9fcd-436e-8383-93c3016101d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_439b32dc-d4ca-4ffc-850a-d49754ea993c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_f94a8fde-1e6b-4844-9fff-d1fd0cc26614" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_439b32dc-d4ca-4ffc-850a-d49754ea993c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="mck-20230630.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_85823f23-1b84-42e7-9e84-d34bdb4d62b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_0e76d75b-de39-4390-b702-f39c85f530bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_85823f23-1b84-42e7-9e84-d34bdb4d62b9" xlink:to="loc_us-gaap_StockholdersEquityAbstract_0e76d75b-de39-4390-b702-f39c85f530bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_94c43967-b039-4964-ab89-5b552598ad39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0e76d75b-de39-4390-b702-f39c85f530bf" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_94c43967-b039-4964-ab89-5b552598ad39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_bd99f81d-c976-462b-b71e-a28622fd6dba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0e76d75b-de39-4390-b702-f39c85f530bf" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_bd99f81d-c976-462b-b71e-a28622fd6dba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_46b21863-f6b6-479a-9fb5-11c47123cb01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0e76d75b-de39-4390-b702-f39c85f530bf" xlink:to="loc_us-gaap_PreferredStockSharesIssued_46b21863-f6b6-479a-9fb5-11c47123cb01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_bfb7fe0e-0ab8-432f-9b91-a1c164e2dcd3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0e76d75b-de39-4390-b702-f39c85f530bf" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_bfb7fe0e-0ab8-432f-9b91-a1c164e2dcd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_958f177b-5d2c-4d64-aef1-a6dd89783e4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0e76d75b-de39-4390-b702-f39c85f530bf" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_958f177b-5d2c-4d64-aef1-a6dd89783e4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_30708f74-759e-4910-96f7-fdb4f2f81337" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0e76d75b-de39-4390-b702-f39c85f530bf" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_30708f74-759e-4910-96f7-fdb4f2f81337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_18be89ae-d8fa-4b3e-a65b-fdc50d1d06ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0e76d75b-de39-4390-b702-f39c85f530bf" xlink:to="loc_us-gaap_CommonStockSharesIssued_18be89ae-d8fa-4b3e-a65b-fdc50d1d06ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_204a021e-7dff-48ac-88a4-6d767e9aedc8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0e76d75b-de39-4390-b702-f39c85f530bf" xlink:to="loc_us-gaap_TreasuryStockCommonShares_204a021e-7dff-48ac-88a4-6d767e9aedc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT" xlink:type="simple" xlink:href="mck-20230630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT"/>
  <link:presentationLink xlink:role="http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_914ea767-a56d-4505-ac76-b02f043fd964" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2ccdea01-7ab5-48cc-9e28-60b153bb8107" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_914ea767-a56d-4505-ac76-b02f043fd964" xlink:to="loc_us-gaap_StatementTable_2ccdea01-7ab5-48cc-9e28-60b153bb8107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1a1e7c92-e468-4273-abbd-b607d4d5fdc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2ccdea01-7ab5-48cc-9e28-60b153bb8107" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1a1e7c92-e468-4273-abbd-b607d4d5fdc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a1900edd-585d-4cea-8578-dce4ccabd4a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1a1e7c92-e468-4273-abbd-b607d4d5fdc5" xlink:to="loc_us-gaap_EquityComponentDomain_a1900edd-585d-4cea-8578-dce4ccabd4a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3eb7af76-524a-476e-a27d-b1eed9b02b20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a1900edd-585d-4cea-8578-dce4ccabd4a7" xlink:to="loc_us-gaap_CommonStockMember_3eb7af76-524a-476e-a27d-b1eed9b02b20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_f6a64627-8237-4aaf-9d04-111e9a57b815" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a1900edd-585d-4cea-8578-dce4ccabd4a7" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_f6a64627-8237-4aaf-9d04-111e9a57b815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_6c2415c0-ba41-434c-84ab-627e442d0d85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a1900edd-585d-4cea-8578-dce4ccabd4a7" xlink:to="loc_us-gaap_RetainedEarningsMember_6c2415c0-ba41-434c-84ab-627e442d0d85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_124644f3-8aef-4fc3-ba3f-33f98482537e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a1900edd-585d-4cea-8578-dce4ccabd4a7" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_124644f3-8aef-4fc3-ba3f-33f98482537e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_5de723b0-1817-46ae-99d6-dc733c518298" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a1900edd-585d-4cea-8578-dce4ccabd4a7" xlink:to="loc_us-gaap_TreasuryStockCommonMember_5de723b0-1817-46ae-99d6-dc733c518298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_0c37f20d-6a38-4263-8159-2e2ecfe0a184" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a1900edd-585d-4cea-8578-dce4ccabd4a7" xlink:to="loc_us-gaap_NoncontrollingInterestMember_0c37f20d-6a38-4263-8159-2e2ecfe0a184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_3fe490e7-0a7d-4699-b55f-7849e16bdc3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2ccdea01-7ab5-48cc-9e28-60b153bb8107" xlink:to="loc_us-gaap_StatementLineItems_3fe490e7-0a7d-4699-b55f-7849e16bdc3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3acb0b6b-c881-42fd-8ac1-0400503be981" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3fe490e7-0a7d-4699-b55f-7849e16bdc3f" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3acb0b6b-c881-42fd-8ac1-0400503be981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_cacb413c-409c-4d9d-9df9-2dca84abe874" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3acb0b6b-c881-42fd-8ac1-0400503be981" xlink:to="loc_us-gaap_SharesOutstanding_cacb413c-409c-4d9d-9df9-2dca84abe874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_cb92359f-b775-4df6-9ea0-06b431fc7de9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3acb0b6b-c881-42fd-8ac1-0400503be981" xlink:to="loc_us-gaap_TreasuryStockCommonShares_cb92359f-b775-4df6-9ea0-06b431fc7de9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_daacccc2-ff37-47e2-85ba-0f1416767713" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3acb0b6b-c881-42fd-8ac1-0400503be981" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_daacccc2-ff37-47e2-85ba-0f1416767713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_StockIssuedDuringPeriodSharesEmployeeStockPlansNetOfForfeitures_6d7a6e0f-535e-4a00-9ab8-08bd9f6af220" xlink:href="mck-20230630.xsd#mck_StockIssuedDuringPeriodSharesEmployeeStockPlansNetOfForfeitures"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3acb0b6b-c881-42fd-8ac1-0400503be981" xlink:to="loc_mck_StockIssuedDuringPeriodSharesEmployeeStockPlansNetOfForfeitures_6d7a6e0f-535e-4a00-9ab8-08bd9f6af220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_StockIssuedDuringPeriodValueEmployeeStockPlansNetOfForfeitures_12ddc6ff-2763-4a5f-8649-57f6505c4409" xlink:href="mck-20230630.xsd#mck_StockIssuedDuringPeriodValueEmployeeStockPlansNetOfForfeitures"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3acb0b6b-c881-42fd-8ac1-0400503be981" xlink:to="loc_mck_StockIssuedDuringPeriodValueEmployeeStockPlansNetOfForfeitures_12ddc6ff-2763-4a5f-8649-57f6505c4409" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_92d193ce-7200-4ffc-bf74-a52b2bba710a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3acb0b6b-c881-42fd-8ac1-0400503be981" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_92d193ce-7200-4ffc-bf74-a52b2bba710a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_b7477073-1fd6-44b1-a48a-8b3b09cde11f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3acb0b6b-c881-42fd-8ac1-0400503be981" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_b7477073-1fd6-44b1-a48a-8b3b09cde11f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_76fe4f8d-aed5-4e1b-9dc6-89ec54f9e1e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3acb0b6b-c881-42fd-8ac1-0400503be981" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_76fe4f8d-aed5-4e1b-9dc6-89ec54f9e1e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_NetIncomeLossIncludingPortionAttributabletoNoncontrollingInterestExcludingRedeemableNoncontrollingInterest_d25a048f-6ee9-4528-a006-ae96cc61fedb" xlink:href="mck-20230630.xsd#mck_NetIncomeLossIncludingPortionAttributabletoNoncontrollingInterestExcludingRedeemableNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3acb0b6b-c881-42fd-8ac1-0400503be981" xlink:to="loc_mck_NetIncomeLossIncludingPortionAttributabletoNoncontrollingInterestExcludingRedeemableNoncontrollingInterest_d25a048f-6ee9-4528-a006-ae96cc61fedb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_29691dc2-e3ef-477f-ae57-4a04834e4237" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3acb0b6b-c881-42fd-8ac1-0400503be981" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_29691dc2-e3ef-477f-ae57-4a04834e4237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_7c8460db-fc4f-41c0-80ff-670322309381" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3acb0b6b-c881-42fd-8ac1-0400503be981" xlink:to="loc_us-gaap_DividendsCommonStockCash_7c8460db-fc4f-41c0-80ff-670322309381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_d252173d-d7a6-4a6e-bc4a-970cedc21ffb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3acb0b6b-c881-42fd-8ac1-0400503be981" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_d252173d-d7a6-4a6e-bc4a-970cedc21ffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_NoncontrollingInterestDecreaseFromReclassificationToLiability_764750e2-72f0-480f-a888-1293fba4d09a" xlink:href="mck-20230630.xsd#mck_NoncontrollingInterestDecreaseFromReclassificationToLiability"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3acb0b6b-c881-42fd-8ac1-0400503be981" xlink:to="loc_mck_NoncontrollingInterestDecreaseFromReclassificationToLiability_764750e2-72f0-480f-a888-1293fba4d09a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_09e73fa8-c37f-4e69-8fd1-fcfe83cc602d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityOther"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3acb0b6b-c881-42fd-8ac1-0400503be981" xlink:to="loc_us-gaap_StockholdersEquityOther_09e73fa8-c37f-4e69-8fd1-fcfe83cc602d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_a21e8cc8-2f92-4295-aff8-dda20826b6dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3acb0b6b-c881-42fd-8ac1-0400503be981" xlink:to="loc_us-gaap_SharesOutstanding_a21e8cc8-2f92-4295-aff8-dda20826b6dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_de580325-5b77-4858-9c20-490ec361d6e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3acb0b6b-c881-42fd-8ac1-0400503be981" xlink:to="loc_us-gaap_TreasuryStockCommonShares_de580325-5b77-4858-9c20-490ec361d6e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_050109c8-ff42-4de5-8044-893da9be6831" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3acb0b6b-c881-42fd-8ac1-0400503be981" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_050109c8-ff42-4de5-8044-893da9be6831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_dfe6b338-ea36-4cad-b5a9-9f8f4104f3c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_3fe490e7-0a7d-4699-b55f-7849e16bdc3f" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_dfe6b338-ea36-4cad-b5a9-9f8f4104f3c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITParenthetical" xlink:type="simple" xlink:href="mck-20230630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITParenthetical"/>
  <link:presentationLink xlink:role="http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_554e03f3-8700-41d7-9190-d0272878ba9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_f2a01e6e-2dff-4772-8967-5a7408e49ada" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_554e03f3-8700-41d7-9190-d0272878ba9d" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_f2a01e6e-2dff-4772-8967-5a7408e49ada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="mck-20230630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_5bbb6d43-0f9e-47c3-9f2f-bcc024ca3239" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c94b85e9-4206-4df2-a171-b57778aef5c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5bbb6d43-0f9e-47c3-9f2f-bcc024ca3239" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c94b85e9-4206-4df2-a171-b57778aef5c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_f76bb0b5-6bbd-4c76-a685-0ebe4b16070b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c94b85e9-4206-4df2-a171-b57778aef5c7" xlink:to="loc_us-gaap_ProfitLoss_f76bb0b5-6bbd-4c76-a685-0ebe4b16070b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7fa397a2-b5c5-46cc-8b7f-9edeac8da97d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c94b85e9-4206-4df2-a171-b57778aef5c7" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7fa397a2-b5c5-46cc-8b7f-9edeac8da97d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_6f72ab7a-2396-4e6e-8c85-d3984b858081" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7fa397a2-b5c5-46cc-8b7f-9edeac8da97d" xlink:to="loc_us-gaap_Depreciation_6f72ab7a-2396-4e6e-8c85-d3984b858081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_46578281-e233-4dca-a0b8-825c96ce9ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7fa397a2-b5c5-46cc-8b7f-9edeac8da97d" xlink:to="loc_us-gaap_AdjustmentForAmortization_46578281-e233-4dca-a0b8-825c96ce9ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetImpairmentCharges_bd0e08f2-d19c-4007-9d19-78edccf249ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetImpairmentCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7fa397a2-b5c5-46cc-8b7f-9edeac8da97d" xlink:to="loc_us-gaap_OtherAssetImpairmentCharges_bd0e08f2-d19c-4007-9d19-78edccf249ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_7f39ab19-d2af-4839-b8df-c209e18c53fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7fa397a2-b5c5-46cc-8b7f-9edeac8da97d" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_7f39ab19-d2af-4839-b8df-c209e18c53fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLIFOReservePeriodCharge_f8ff6066-ed00-4822-b953-7c7224fd329b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryLIFOReservePeriodCharge"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7fa397a2-b5c5-46cc-8b7f-9edeac8da97d" xlink:to="loc_us-gaap_InventoryLIFOReservePeriodCharge_f8ff6066-ed00-4822-b953-7c7224fd329b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_0bdb0dda-f604-4305-8f59-8d5911964797" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7fa397a2-b5c5-46cc-8b7f-9edeac8da97d" xlink:to="loc_us-gaap_OperatingLeaseExpense_0bdb0dda-f604-4305-8f59-8d5911964797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherAssets_509cc358-d458-4f15-a9fd-c175e4529375" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnSaleOfOtherAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7fa397a2-b5c5-46cc-8b7f-9edeac8da97d" xlink:to="loc_us-gaap_GainLossOnSaleOfOtherAssets_509cc358-d458-4f15-a9fd-c175e4529375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_61637350-1f52-4452-93ea-89b0555058cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7fa397a2-b5c5-46cc-8b7f-9edeac8da97d" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_61637350-1f52-4452-93ea-89b0555058cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_63beec7c-0346-4fec-8594-56d8d0d977a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7fa397a2-b5c5-46cc-8b7f-9edeac8da97d" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_63beec7c-0346-4fec-8594-56d8d0d977a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_49112724-3d83-4f80-b709-bd8e47308f0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7fa397a2-b5c5-46cc-8b7f-9edeac8da97d" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_49112724-3d83-4f80-b709-bd8e47308f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables_38baa459-b878-4f9a-b68f-5e7d2268b34d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_49112724-3d83-4f80-b709-bd8e47308f0e" xlink:to="loc_us-gaap_IncreaseDecreaseInReceivables_38baa459-b878-4f9a-b68f-5e7d2268b34d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_c20e1eba-180c-434c-9207-1175f87feb64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_49112724-3d83-4f80-b709-bd8e47308f0e" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_c20e1eba-180c-434c-9207-1175f87feb64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_5cee34c7-3ed9-4153-b650-87c6e19581bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_49112724-3d83-4f80-b709-bd8e47308f0e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_5cee34c7-3ed9-4153-b650-87c6e19581bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_fea2b86b-6706-41c9-b2f4-c9223533c466" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_49112724-3d83-4f80-b709-bd8e47308f0e" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_fea2b86b-6706-41c9-b2f4-c9223533c466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedTaxesPayable_3ad69b16-3000-4daf-8270-08ae37f34751" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedTaxesPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_49112724-3d83-4f80-b709-bd8e47308f0e" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedTaxesPayable_3ad69b16-3000-4daf-8270-08ae37f34751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_IncreaseDecreaseInLitigationReserve_f1719573-b861-4b30-be34-4a64b72b3f0d" xlink:href="mck-20230630.xsd#mck_IncreaseDecreaseInLitigationReserve"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_49112724-3d83-4f80-b709-bd8e47308f0e" xlink:to="loc_mck_IncreaseDecreaseInLitigationReserve_f1719573-b861-4b30-be34-4a64b72b3f0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_760df027-6896-4f88-8525-955beb69f210" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_49112724-3d83-4f80-b709-bd8e47308f0e" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_760df027-6896-4f88-8525-955beb69f210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e096fca6-ecc6-452e-a369-ec8cb18a665a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_c94b85e9-4206-4df2-a171-b57778aef5c7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_e096fca6-ecc6-452e-a369-ec8cb18a665a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8f2e4ae8-5c9a-48e4-9359-dd83db2fd277" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5bbb6d43-0f9e-47c3-9f2f-bcc024ca3239" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8f2e4ae8-5c9a-48e4-9359-dd83db2fd277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_770e311a-3d29-4440-b1cb-a3cff276bcb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8f2e4ae8-5c9a-48e4-9359-dd83db2fd277" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_770e311a-3d29-4440-b1cb-a3cff276bcb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireSoftware_e84e876d-fcc7-4f03-9d40-f8e3a7ef2a18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireSoftware"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8f2e4ae8-5c9a-48e4-9359-dd83db2fd277" xlink:to="loc_us-gaap_PaymentsToAcquireSoftware_e84e876d-fcc7-4f03-9d40-f8e3a7ef2a18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_78c620a5-a5e8-471c-b2d3-a9c1c0218f85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8f2e4ae8-5c9a-48e4-9359-dd83db2fd277" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_78c620a5-a5e8-471c-b2d3-a9c1c0218f85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates_b988b269-7fba-4d0d-9f53-cba511af2303" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8f2e4ae8-5c9a-48e4-9359-dd83db2fd277" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates_b988b269-7fba-4d0d-9f53-cba511af2303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_aab152de-807f-4247-bab5-0c3818eb2791" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8f2e4ae8-5c9a-48e4-9359-dd83db2fd277" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_aab152de-807f-4247-bab5-0c3818eb2791" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c477d710-87bd-4f76-9292-5fa36ddeeb25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8f2e4ae8-5c9a-48e4-9359-dd83db2fd277" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c477d710-87bd-4f76-9292-5fa36ddeeb25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c6876ad5-403b-4151-b2ad-454549c07eb7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5bbb6d43-0f9e-47c3-9f2f-bcc024ca3239" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c6876ad5-403b-4151-b2ad-454549c07eb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_6a7de9e3-7b72-49fd-b8ef-649b22fb69eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c6876ad5-403b-4151-b2ad-454549c07eb7" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_6a7de9e3-7b72-49fd-b8ef-649b22fb69eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_694001c5-e42d-457b-b4ec-66b99e4b5d45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c6876ad5-403b-4151-b2ad-454549c07eb7" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_694001c5-e42d-457b-b4ec-66b99e4b5d45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_57dc97ca-1557-4e73-a40d-ac875381b586" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c6876ad5-403b-4151-b2ad-454549c07eb7" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_57dc97ca-1557-4e73-a40d-ac875381b586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_bd2cfbbb-d1de-49c5-b7db-e0d290d66e3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c6876ad5-403b-4151-b2ad-454549c07eb7" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_bd2cfbbb-d1de-49c5-b7db-e0d290d66e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_PaymentsForPurchaseOfGovernmentObligationsForSatisfactionAndDischargeOfLongTermDebt_6e295f1e-2b50-4a2f-87b5-f1703dfc66ff" xlink:href="mck-20230630.xsd#mck_PaymentsForPurchaseOfGovernmentObligationsForSatisfactionAndDischargeOfLongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c6876ad5-403b-4151-b2ad-454549c07eb7" xlink:to="loc_mck_PaymentsForPurchaseOfGovernmentObligationsForSatisfactionAndDischargeOfLongTermDebt_6e295f1e-2b50-4a2f-87b5-f1703dfc66ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptionsAbstract_96ae6f15-7875-4b42-be31-15ec81b20dac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptionsAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c6876ad5-403b-4151-b2ad-454549c07eb7" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptionsAbstract_96ae6f15-7875-4b42-be31-15ec81b20dac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_fe779647-d79d-4752-9b3b-590ba6e635f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptionsAbstract_96ae6f15-7875-4b42-be31-15ec81b20dac" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_fe779647-d79d-4752-9b3b-590ba6e635f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_46235eec-ac16-4af4-ac87-38dd62578d93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptionsAbstract_96ae6f15-7875-4b42-be31-15ec81b20dac" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_46235eec-ac16-4af4-ac87-38dd62578d93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDividendsCommonStock_a6110057-a1b7-4cdd-a851-39fd54dc5c84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsOfDividendsCommonStock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c6876ad5-403b-4151-b2ad-454549c07eb7" xlink:to="loc_us-gaap_PaymentsOfDividendsCommonStock_a6110057-a1b7-4cdd-a851-39fd54dc5c84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_58783d8d-1e8f-41e5-9f8a-3c547ff2b77f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c6876ad5-403b-4151-b2ad-454549c07eb7" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_58783d8d-1e8f-41e5-9f8a-3c547ff2b77f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a7671799-2727-44e3-8d9f-80c4f28b2f01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c6876ad5-403b-4151-b2ad-454549c07eb7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a7671799-2727-44e3-8d9f-80c4f28b2f01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_dd2d51ed-c99c-469c-9dcc-44acaa916572" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5bbb6d43-0f9e-47c3-9f2f-bcc024ca3239" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_dd2d51ed-c99c-469c-9dcc-44acaa916572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_CashCashEquivalentsRestrictedCashClassifiedWithinAssetsHeldForSalePeriodIncreaseDecrease_0853fa80-1975-480c-8a96-365c171d5f1d" xlink:href="mck-20230630.xsd#mck_CashCashEquivalentsRestrictedCashClassifiedWithinAssetsHeldForSalePeriodIncreaseDecrease"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5bbb6d43-0f9e-47c3-9f2f-bcc024ca3239" xlink:to="loc_mck_CashCashEquivalentsRestrictedCashClassifiedWithinAssetsHeldForSalePeriodIncreaseDecrease_0853fa80-1975-480c-8a96-365c171d5f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9b2bac69-1aa5-43a9-b0a9-78f699890da1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5bbb6d43-0f9e-47c3-9f2f-bcc024ca3239" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9b2bac69-1aa5-43a9-b0a9-78f699890da1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_422a3d75-afd7-45ef-828a-c768fe591b79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5bbb6d43-0f9e-47c3-9f2f-bcc024ca3239" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_422a3d75-afd7-45ef-828a-c768fe591b79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f8bd9c2d-c64b-4343-a8ca-32cf0b42d2ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5bbb6d43-0f9e-47c3-9f2f-bcc024ca3239" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f8bd9c2d-c64b-4343-a8ca-32cf0b42d2ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_90f3a1af-dc36-4f10-8548-ef738565ac97" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5bbb6d43-0f9e-47c3-9f2f-bcc024ca3239" xlink:to="loc_us-gaap_RestrictedCashCurrent_90f3a1af-dc36-4f10-8548-ef738565ac97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6f2a2b8e-39fc-43ac-87fe-723193772361" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_5bbb6d43-0f9e-47c3-9f2f-bcc024ca3239" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6f2a2b8e-39fc-43ac-87fe-723193772361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/SignificantAccountingPolicies" xlink:type="simple" xlink:href="mck-20230630.xsd#SignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://mckesson123.com/role/SignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c5c04f8f-aa87-4d96-8163-40a939503a88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_4e01095e-db42-4345-8910-28e2ef9debb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c5c04f8f-aa87-4d96-8163-40a939503a88" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_4e01095e-db42-4345-8910-28e2ef9debb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/BusinessAcquisitionsandDivestitures" xlink:type="simple" xlink:href="mck-20230630.xsd#BusinessAcquisitionsandDivestitures"/>
  <link:presentationLink xlink:role="http://mckesson123.com/role/BusinessAcquisitionsandDivestitures" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_7b17a427-2855-4d62-b0db-93b8613a4164" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_f5e54551-db71-448f-9e85-8caf4064bbb2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_7b17a427-2855-4d62-b0db-93b8613a4164" xlink:to="loc_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock_f5e54551-db71-448f-9e85-8caf4064bbb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNet" xlink:type="simple" xlink:href="mck-20230630.xsd#RestructuringImpairmentandRelatedChargesNet"/>
  <link:presentationLink xlink:role="http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_29939df3-a500-4d0b-a105-164f46a352a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_1758adc0-15d9-48dd-a305-601a0cd6d7dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_29939df3-a500-4d0b-a105-164f46a352a2" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_1758adc0-15d9-48dd-a305-601a0cd6d7dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/IncomeTaxes" xlink:type="simple" xlink:href="mck-20230630.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://mckesson123.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_126e7beb-9c15-45ab-8134-5a510c7151a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_c684caab-9787-4b57-ae64-4cfaa9e70626" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_126e7beb-9c15-45ab-8134-5a510c7151a6" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_c684caab-9787-4b57-ae64-4cfaa9e70626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/EarningsPerCommonShare" xlink:type="simple" xlink:href="mck-20230630.xsd#EarningsPerCommonShare"/>
  <link:presentationLink xlink:role="http://mckesson123.com/role/EarningsPerCommonShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0630a2a6-e0b9-4bfd-b31a-16e3fd8ea9c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_db41a61a-d250-4a60-9a17-27eb5d436359" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0630a2a6-e0b9-4bfd-b31a-16e3fd8ea9c3" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_db41a61a-d250-4a60-9a17-27eb5d436359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/GoodwillandIntangibleAssetsNet" xlink:type="simple" xlink:href="mck-20230630.xsd#GoodwillandIntangibleAssetsNet"/>
  <link:presentationLink xlink:role="http://mckesson123.com/role/GoodwillandIntangibleAssetsNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5e613e09-4298-4ed8-8c4d-e465ba5bedad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_c6a24600-41cf-499d-9393-33ac7763a0be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5e613e09-4298-4ed8-8c4d-e465ba5bedad" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_c6a24600-41cf-499d-9393-33ac7763a0be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/DebtandFinancingActivities" xlink:type="simple" xlink:href="mck-20230630.xsd#DebtandFinancingActivities"/>
  <link:presentationLink xlink:role="http://mckesson123.com/role/DebtandFinancingActivities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_2b491278-6593-4053-9250-f2ff370e4bc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_a819272a-9647-49b8-90db-56eb65c1fa4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_2b491278-6593-4053-9250-f2ff370e4bc0" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_a819272a-9647-49b8-90db-56eb65c1fa4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/HedgingActivities" xlink:type="simple" xlink:href="mck-20230630.xsd#HedgingActivities"/>
  <link:presentationLink xlink:role="http://mckesson123.com/role/HedgingActivities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_5cf2c7c7-5f31-4036-89f7-5459c3938887" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_56968b41-fe03-446d-b295-c89b130bc7de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_5cf2c7c7-5f31-4036-89f7-5459c3938887" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_56968b41-fe03-446d-b295-c89b130bc7de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="mck-20230630.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://mckesson123.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e53baa51-c679-46db-a781-37cee709686c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_50e7cd54-aa75-45c3-8f7b-ad998b62542d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e53baa51-c679-46db-a781-37cee709686c" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_50e7cd54-aa75-45c3-8f7b-ad998b62542d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/CommitmentsandContingentLiabilities" xlink:type="simple" xlink:href="mck-20230630.xsd#CommitmentsandContingentLiabilities"/>
  <link:presentationLink xlink:role="http://mckesson123.com/role/CommitmentsandContingentLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_392be959-44ce-4468-9008-c6706bc5a3de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0eb7217d-abe9-49f8-ab45-5a8103db13c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_392be959-44ce-4468-9008-c6706bc5a3de" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_0eb7217d-abe9-49f8-ab45-5a8103db13c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/StockholdersDeficit" xlink:type="simple" xlink:href="mck-20230630.xsd#StockholdersDeficit"/>
  <link:presentationLink xlink:role="http://mckesson123.com/role/StockholdersDeficit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_d7f508f3-e16d-427d-b45d-9f5ee4cb9d9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_df010a6a-2047-4994-91aa-03d515a50d29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d7f508f3-e16d-427d-b45d-9f5ee4cb9d9c" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_df010a6a-2047-4994-91aa-03d515a50d29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/SegmentsofBusiness" xlink:type="simple" xlink:href="mck-20230630.xsd#SegmentsofBusiness"/>
  <link:presentationLink xlink:role="http://mckesson123.com/role/SegmentsofBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_fc80883b-8ec4-4333-a2b6-0068c009e118" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_db2f94cf-ad7f-4b48-a54b-55c4955a8b55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_fc80883b-8ec4-4333-a2b6-0068c009e118" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_db2f94cf-ad7f-4b48-a54b-55c4955a8b55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/SignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="mck-20230630.xsd#SignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://mckesson123.com/role/SignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_187d0870-9942-4e12-8f12-e3d2f490d901" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_17473c92-7361-453a-9f5f-3ab1b947785c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_187d0870-9942-4e12-8f12-e3d2f490d901" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_17473c92-7361-453a-9f5f-3ab1b947785c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiscalPeriod_680326b4-18ec-4ff1-b03c-40088ee747db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiscalPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_187d0870-9942-4e12-8f12-e3d2f490d901" xlink:to="loc_us-gaap_FiscalPeriod_680326b4-18ec-4ff1-b03c-40088ee747db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_9365d147-d753-4dc6-be71-e8a802d1ec36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_187d0870-9942-4e12-8f12-e3d2f490d901" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_9365d147-d753-4dc6-be71-e8a802d1ec36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_516673af-ea37-4b7d-897e-2231cf99779c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_187d0870-9942-4e12-8f12-e3d2f490d901" xlink:to="loc_us-gaap_UseOfEstimates_516673af-ea37-4b7d-897e-2231cf99779c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComparabilityOfPriorYearFinancialData_0f8ca0e5-2769-4fce-8482-72f3caa1f2ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComparabilityOfPriorYearFinancialData"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_187d0870-9942-4e12-8f12-e3d2f490d901" xlink:to="loc_us-gaap_ComparabilityOfPriorYearFinancialData_0f8ca0e5-2769-4fce-8482-72f3caa1f2ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_bea59461-cea7-46fa-b6e9-91ba5b210de8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_187d0870-9942-4e12-8f12-e3d2f490d901" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_bea59461-cea7-46fa-b6e9-91ba5b210de8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_4900d32f-1734-4738-bf24-8a49c10f0e22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_187d0870-9942-4e12-8f12-e3d2f490d901" xlink:to="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_4900d32f-1734-4738-bf24-8a49c10f0e22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/BusinessAcquisitionsandDivestituresTables" xlink:type="simple" xlink:href="mck-20230630.xsd#BusinessAcquisitionsandDivestituresTables"/>
  <link:presentationLink xlink:role="http://mckesson123.com/role/BusinessAcquisitionsandDivestituresTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_a5ef3c56-ac6f-415e-aff2-c87aa6a02154" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_65445b13-8607-4df7-988d-dca07be82e93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_a5ef3c56-ac6f-415e-aff2-c87aa6a02154" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_65445b13-8607-4df7-988d-dca07be82e93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetTables" xlink:type="simple" xlink:href="mck-20230630.xsd#RestructuringImpairmentandRelatedChargesNetTables"/>
  <link:presentationLink xlink:role="http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_60f4b58b-dd05-4ddf-9c38-2f9f82f04b30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_7d9838a8-2378-4a06-910d-f7902d0944d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_60f4b58b-dd05-4ddf-9c38-2f9f82f04b30" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_7d9838a8-2378-4a06-910d-f7902d0944d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_3d01b5a3-86ae-44ab-9ee4-e399dd05ee21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_60f4b58b-dd05-4ddf-9c38-2f9f82f04b30" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_3d01b5a3-86ae-44ab-9ee4-e399dd05ee21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="mck-20230630.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://mckesson123.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2c39ff9d-35e7-42be-9ff6-f1e38fb461c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_ee27bdd8-7189-4bcd-be8c-9914d33f5bb3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2c39ff9d-35e7-42be-9ff6-f1e38fb461c3" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_ee27bdd8-7189-4bcd-be8c-9914d33f5bb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/EarningsPerCommonShareTables" xlink:type="simple" xlink:href="mck-20230630.xsd#EarningsPerCommonShareTables"/>
  <link:presentationLink xlink:role="http://mckesson123.com/role/EarningsPerCommonShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_48343c20-41bc-49ba-8889-dac9d5515aeb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_092e6691-7f72-456f-afbd-98ed458d7c31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_48343c20-41bc-49ba-8889-dac9d5515aeb" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_092e6691-7f72-456f-afbd-98ed458d7c31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/GoodwillandIntangibleAssetsNetTables" xlink:type="simple" xlink:href="mck-20230630.xsd#GoodwillandIntangibleAssetsNetTables"/>
  <link:presentationLink xlink:role="http://mckesson123.com/role/GoodwillandIntangibleAssetsNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_be94ba82-ecf0-4fbc-ab36-afdea63a65d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_f352dd01-a1f7-4c9b-b680-9b9ccaa25b22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_be94ba82-ecf0-4fbc-ab36-afdea63a65d9" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_f352dd01-a1f7-4c9b-b680-9b9ccaa25b22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_58c633f1-fe73-465a-a58c-6940c1016255" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_be94ba82-ecf0-4fbc-ab36-afdea63a65d9" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_58c633f1-fe73-465a-a58c-6940c1016255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/DebtandFinancingActivitiesTables" xlink:type="simple" xlink:href="mck-20230630.xsd#DebtandFinancingActivitiesTables"/>
  <link:presentationLink xlink:role="http://mckesson123.com/role/DebtandFinancingActivitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_7bc3f929-82bf-456e-aa8e-f1085a5ca356" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_386c32a1-010f-4763-9a17-70c09a59eec4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7bc3f929-82bf-456e-aa8e-f1085a5ca356" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_386c32a1-010f-4763-9a17-70c09a59eec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/HedgingActivitiesTables" xlink:type="simple" xlink:href="mck-20230630.xsd#HedgingActivitiesTables"/>
  <link:presentationLink xlink:role="http://mckesson123.com/role/HedgingActivitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_60d39d4f-2fd5-4ecf-95e8-640c78a352e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_5a605dbc-7704-4c98-96b5-3c1f8824774e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_60d39d4f-2fd5-4ecf-95e8-640c78a352e2" xlink:to="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_5a605dbc-7704-4c98-96b5-3c1f8824774e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_b830a1b0-309b-4dc8-9081-19b5b65cc2b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_60d39d4f-2fd5-4ecf-95e8-640c78a352e2" xlink:to="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_b830a1b0-309b-4dc8-9081-19b5b65cc2b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_8bc0a5fc-1c5b-4686-b56d-dc5344f1760d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_60d39d4f-2fd5-4ecf-95e8-640c78a352e2" xlink:to="loc_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_8bc0a5fc-1c5b-4686-b56d-dc5344f1760d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_18c0728c-4d81-400e-b977-9fb8da9107da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_60d39d4f-2fd5-4ecf-95e8-640c78a352e2" xlink:to="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_18c0728c-4d81-400e-b977-9fb8da9107da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_924e368f-5429-450e-98e7-50aa8a85c549" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_60d39d4f-2fd5-4ecf-95e8-640c78a352e2" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTextBlock_924e368f-5429-450e-98e7-50aa8a85c549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="mck-20230630.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://mckesson123.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1f3d9533-d6fd-441d-99d7-6690eec2eff2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_ef5b1c4a-eaad-44a8-b8a9-5c69a39b5e39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1f3d9533-d6fd-441d-99d7-6690eec2eff2" xlink:to="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_ef5b1c4a-eaad-44a8-b8a9-5c69a39b5e39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/CommitmentsandContingentLiabilitiesTables" xlink:type="simple" xlink:href="mck-20230630.xsd#CommitmentsandContingentLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://mckesson123.com/role/CommitmentsandContingentLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8d1ca359-5ec5-40d0-9c03-dfd5240826e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock_8a9e09b2-f6c5-4440-96d9-9bef7b916117" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8d1ca359-5ec5-40d0-9c03-dfd5240826e8" xlink:to="loc_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock_8a9e09b2-f6c5-4440-96d9-9bef7b916117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/StockholdersDeficitTables" xlink:type="simple" xlink:href="mck-20230630.xsd#StockholdersDeficitTables"/>
  <link:presentationLink xlink:role="http://mckesson123.com/role/StockholdersDeficitTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_1e659848-814b-478f-887e-95ab123effa4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_2189c89d-91a1-4ac8-9f7a-e9d0fbfff96b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_1e659848-814b-478f-887e-95ab123effa4" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_2189c89d-91a1-4ac8-9f7a-e9d0fbfff96b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/SegmentsofBusinessTables" xlink:type="simple" xlink:href="mck-20230630.xsd#SegmentsofBusinessTables"/>
  <link:presentationLink xlink:role="http://mckesson123.com/role/SegmentsofBusinessTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_b9551a69-b6f7-4290-a332-b72063772a62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_32a38ccc-f66e-4643-8539-b553dbe540d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_b9551a69-b6f7-4290-a332-b72063772a62" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_32a38ccc-f66e-4643-8539-b553dbe540d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="mck-20230630.xsd#SignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://mckesson123.com/role/SignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c5f5c7be-3b08-4624-94fd-93fa1206c7e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_0741e92e-0e91-4f4e-8185-4ace60270e93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c5f5c7be-3b08-4624-94fd-93fa1206c7e2" xlink:to="loc_us-gaap_NumberOfReportableSegments_0741e92e-0e91-4f4e-8185-4ace60270e93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails" xlink:type="simple" xlink:href="mck-20230630.xsd#BusinessAcquisitionsandDivestituresAcquisitionsDetails"/>
  <link:presentationLink xlink:role="http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_a383c791-d4a0-457d-9d02-7c88cba4e1a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_103b68e4-1f05-4766-ae95-6b28cd333485" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_a383c791-d4a0-457d-9d02-7c88cba4e1a1" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_103b68e4-1f05-4766-ae95-6b28cd333485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7b5ad935-b38e-4b86-93ae-74d81a708e4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_103b68e4-1f05-4766-ae95-6b28cd333485" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7b5ad935-b38e-4b86-93ae-74d81a708e4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_95de2838-6e86-4992-863f-7ace3640b3ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7b5ad935-b38e-4b86-93ae-74d81a708e4a" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_95de2838-6e86-4992-863f-7ace3640b3ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_RxSavingsSolutionsLLCMember_3a2e9ec9-c013-4aae-b44d-4fd90bb53f75" xlink:href="mck-20230630.xsd#mck_RxSavingsSolutionsLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_95de2838-6e86-4992-863f-7ace3640b3ba" xlink:to="loc_mck_RxSavingsSolutionsLLCMember_3a2e9ec9-c013-4aae-b44d-4fd90bb53f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_SCRIOncologyLLCMember_47e2335d-e0b2-4e89-8540-65757f0f3c2b" xlink:href="mck-20230630.xsd#mck_SCRIOncologyLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_95de2838-6e86-4992-863f-7ace3640b3ba" xlink:to="loc_mck_SCRIOncologyLLCMember_47e2335d-e0b2-4e89-8540-65757f0f3c2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_bfcf490c-0b48-4454-b0c4-dc8cc1405a1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_103b68e4-1f05-4766-ae95-6b28cd333485" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_bfcf490c-0b48-4454-b0c4-dc8cc1405a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_e049e314-7d72-494e-93bb-3028692d746b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_bfcf490c-0b48-4454-b0c4-dc8cc1405a1a" xlink:to="loc_us-gaap_SegmentDomain_e049e314-7d72-494e-93bb-3028692d746b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_RxTsSegmentMember_5cb9b625-88c6-40fa-8e1c-23594b9d65f7" xlink:href="mck-20230630.xsd#mck_RxTsSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_e049e314-7d72-494e-93bb-3028692d746b" xlink:to="loc_mck_RxTsSegmentMember_5cb9b625-88c6-40fa-8e1c-23594b9d65f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_USPharmaceuticalSegmentMember_8dc66aff-66fd-48f2-9547-5fce57f4213b" xlink:href="mck-20230630.xsd#mck_USPharmaceuticalSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_e049e314-7d72-494e-93bb-3028692d746b" xlink:to="loc_mck_USPharmaceuticalSegmentMember_8dc66aff-66fd-48f2-9547-5fce57f4213b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_9e989496-2688-4039-9cca-ed75bac65d7b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_103b68e4-1f05-4766-ae95-6b28cd333485" xlink:to="loc_srt_OwnershipAxis_9e989496-2688-4039-9cca-ed75bac65d7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_868807aa-18e7-42ef-811d-9503a1205f37" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_9e989496-2688-4039-9cca-ed75bac65d7b" xlink:to="loc_srt_OwnershipDomain_868807aa-18e7-42ef-811d-9503a1205f37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_SarahCannonResearchInstituteMember_3b4b29d4-e928-418e-ba32-bd5cdbe27ea0" xlink:href="mck-20230630.xsd#mck_SarahCannonResearchInstituteMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_868807aa-18e7-42ef-811d-9503a1205f37" xlink:to="loc_mck_SarahCannonResearchInstituteMember_3b4b29d4-e928-418e-ba32-bd5cdbe27ea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_McKessonUSOncologyResearchMember_f98eb6c5-fe65-4fe7-8228-f276c799ea13" xlink:href="mck-20230630.xsd#mck_McKessonUSOncologyResearchMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_868807aa-18e7-42ef-811d-9503a1205f37" xlink:to="loc_mck_McKessonUSOncologyResearchMember_f98eb6c5-fe65-4fe7-8228-f276c799ea13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_97cd7e41-13bb-405d-97b7-7e88bc20f810" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_103b68e4-1f05-4766-ae95-6b28cd333485" xlink:to="loc_srt_RangeAxis_97cd7e41-13bb-405d-97b7-7e88bc20f810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4633d1b7-858e-459c-8d21-775d4374d611" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_97cd7e41-13bb-405d-97b7-7e88bc20f810" xlink:to="loc_srt_RangeMember_4633d1b7-858e-459c-8d21-775d4374d611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a804b1b6-44ae-4dfd-a6ec-813ac96e59b3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4633d1b7-858e-459c-8d21-775d4374d611" xlink:to="loc_srt_MaximumMember_a804b1b6-44ae-4dfd-a6ec-813ac96e59b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_fcefa9bc-b952-46fd-8d85-a0dbabdfa9d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_103b68e4-1f05-4766-ae95-6b28cd333485" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_fcefa9bc-b952-46fd-8d85-a0dbabdfa9d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_aa8a000d-1e88-4c29-a682-888a4d84b0c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_fcefa9bc-b952-46fd-8d85-a0dbabdfa9d5" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_aa8a000d-1e88-4c29-a682-888a4d84b0c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_6bc6bcb4-d6f3-4f16-aae7-c5522715a1de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_fcefa9bc-b952-46fd-8d85-a0dbabdfa9d5" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_6bc6bcb4-d6f3-4f16-aae7-c5522715a1de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_8ba6a48c-614a-4c9e-900b-dabb83775a9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_fcefa9bc-b952-46fd-8d85-a0dbabdfa9d5" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_8ba6a48c-614a-4c9e-900b-dabb83775a9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_a3625c45-8c16-42b6-85ce-b2fc6bc24534" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_fcefa9bc-b952-46fd-8d85-a0dbabdfa9d5" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_a3625c45-8c16-42b6-85ce-b2fc6bc24534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_73de5426-46ec-4454-9ff5-d7d3a8e4c11f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_fcefa9bc-b952-46fd-8d85-a0dbabdfa9d5" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_73de5426-46ec-4454-9ff5-d7d3a8e4c11f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_99dc0478-c61b-40f3-b055-1f572fcd80e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_fcefa9bc-b952-46fd-8d85-a0dbabdfa9d5" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_99dc0478-c61b-40f3-b055-1f572fcd80e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_6a6666f6-1488-4722-9ac2-0204615d81cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_fcefa9bc-b952-46fd-8d85-a0dbabdfa9d5" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_6a6666f6-1488-4722-9ac2-0204615d81cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_a8480cac-bcab-43ed-bedf-933f3211d3af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_fcefa9bc-b952-46fd-8d85-a0dbabdfa9d5" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_a8480cac-bcab-43ed-bedf-933f3211d3af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_8fff4a0c-ac8e-42ba-8335-6b4dc9f4d039" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_fcefa9bc-b952-46fd-8d85-a0dbabdfa9d5" xlink:to="loc_us-gaap_Goodwill_8fff4a0c-ac8e-42ba-8335-6b4dc9f4d039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_e7603934-f73b-4863-943d-4345866866d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_fcefa9bc-b952-46fd-8d85-a0dbabdfa9d5" xlink:to="loc_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount_e7603934-f73b-4863-943d-4345866866d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_8cb1a8e8-119e-46af-9731-39aafde94d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_fcefa9bc-b952-46fd-8d85-a0dbabdfa9d5" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_8cb1a8e8-119e-46af-9731-39aafde94d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedRxSavingsSolutionsDetails" xlink:type="simple" xlink:href="mck-20230630.xsd#BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedRxSavingsSolutionsDetails"/>
  <link:presentationLink xlink:role="http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedRxSavingsSolutionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_7bf5efa9-6d3e-494f-b84f-a0b209919990" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_07d778a6-14b4-4530-8cdd-95f23c6814de" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_7bf5efa9-6d3e-494f-b84f-a0b209919990" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_07d778a6-14b4-4530-8cdd-95f23c6814de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_26abf937-234a-46b3-b2b8-5ee39d2cb4fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_07d778a6-14b4-4530-8cdd-95f23c6814de" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_26abf937-234a-46b3-b2b8-5ee39d2cb4fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e079001c-d26e-4f86-acbf-09e65c553acb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_26abf937-234a-46b3-b2b8-5ee39d2cb4fb" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e079001c-d26e-4f86-acbf-09e65c553acb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_RxSavingsSolutionsLLCMember_292ddc3a-cbb9-4278-964e-414f73a5cf63" xlink:href="mck-20230630.xsd#mck_RxSavingsSolutionsLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e079001c-d26e-4f86-acbf-09e65c553acb" xlink:to="loc_mck_RxSavingsSolutionsLLCMember_292ddc3a-cbb9-4278-964e-414f73a5cf63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_a214ffab-fc34-4e39-9e92-1e2065c7a06a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_07d778a6-14b4-4530-8cdd-95f23c6814de" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_a214ffab-fc34-4e39-9e92-1e2065c7a06a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_5f7a5dd6-7da5-48ed-a963-40c5caa0b1f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_a214ffab-fc34-4e39-9e92-1e2065c7a06a" xlink:to="loc_us-gaap_SegmentDomain_5f7a5dd6-7da5-48ed-a963-40c5caa0b1f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_RxTsSegmentMember_52133ced-91c7-4880-a0a4-662e0adc61d7" xlink:href="mck-20230630.xsd#mck_RxTsSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_5f7a5dd6-7da5-48ed-a963-40c5caa0b1f9" xlink:to="loc_mck_RxTsSegmentMember_52133ced-91c7-4880-a0a4-662e0adc61d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_21cfd054-5e36-4a09-ba45-a2092cbea185" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_07d778a6-14b4-4530-8cdd-95f23c6814de" xlink:to="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_21cfd054-5e36-4a09-ba45-a2092cbea185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_121f4444-2581-4c6e-8a91-114b0732f320" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_21cfd054-5e36-4a09-ba45-a2092cbea185" xlink:to="loc_us-gaap_BusinessCombinationsAbstract_121f4444-2581-4c6e-8a91-114b0732f320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_2a4cbd58-5795-49d3-9480-75cae4002b20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_121f4444-2581-4c6e-8a91-114b0732f320" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_2a4cbd58-5795-49d3-9480-75cae4002b20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1ba0f4ff-d9ba-4fc8-be76-3d4cdf2f0fee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_121f4444-2581-4c6e-8a91-114b0732f320" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1ba0f4ff-d9ba-4fc8-be76-3d4cdf2f0fee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_d4905812-5666-4f96-93db-76809911b805" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_121f4444-2581-4c6e-8a91-114b0732f320" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_d4905812-5666-4f96-93db-76809911b805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_5129408c-ff88-4b27-971e-0058c450fc30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_21cfd054-5e36-4a09-ba45-a2092cbea185" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_5129408c-ff88-4b27-971e-0058c450fc30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_0f303a4b-28ee-44a6-871f-593dec284ea4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_5129408c-ff88-4b27-971e-0058c450fc30" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets_0f303a4b-28ee-44a6-871f-593dec284ea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_e03bc6e5-9e62-4430-a118-46f78b4de649" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_5129408c-ff88-4b27-971e-0058c450fc30" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_e03bc6e5-9e62-4430-a118-46f78b4de649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_9c701604-7d2e-4083-b9bb-13d3c4c809da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_5129408c-ff88-4b27-971e-0058c450fc30" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_9c701604-7d2e-4083-b9bb-13d3c4c809da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_a5bc0bb9-bd8a-4fcb-86e2-76f1a05cebe4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_5129408c-ff88-4b27-971e-0058c450fc30" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_a5bc0bb9-bd8a-4fcb-86e2-76f1a05cebe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_a0ee12eb-e2c1-4136-8fcd-4fb195d9e804" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_5129408c-ff88-4b27-971e-0058c450fc30" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_a0ee12eb-e2c1-4136-8fcd-4fb195d9e804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_9075c994-4163-4a1b-9500-c7ec439937d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_5129408c-ff88-4b27-971e-0058c450fc30" xlink:to="loc_us-gaap_Goodwill_9075c994-4163-4a1b-9500-c7ec439937d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest_891119a1-699e-4e2b-a4e2-9d87d84be5f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract_5129408c-ff88-4b27-971e-0058c450fc30" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest_891119a1-699e-4e2b-a4e2-9d87d84be5f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails" xlink:type="simple" xlink:href="mck-20230630.xsd#BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails"/>
  <link:presentationLink xlink:role="http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_7cb90796-6f4d-465e-8df1-d65d9325ef3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_b8f3da9b-2538-4538-b2bd-9e4d3514aa4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_7cb90796-6f4d-465e-8df1-d65d9325ef3a" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_b8f3da9b-2538-4538-b2bd-9e4d3514aa4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_ee831d90-e2de-435e-8151-fad5bfd211ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_b8f3da9b-2538-4538-b2bd-9e4d3514aa4d" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_ee831d90-e2de-435e-8151-fad5bfd211ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7c6ea2bb-8eac-4af0-ad2f-c2beae9d52b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_ee831d90-e2de-435e-8151-fad5bfd211ca" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7c6ea2bb-8eac-4af0-ad2f-c2beae9d52b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_SCRIOncologyLLCMember_784bc1fa-5fb3-48f0-ac0c-dfa2985e7732" xlink:href="mck-20230630.xsd#mck_SCRIOncologyLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7c6ea2bb-8eac-4af0-ad2f-c2beae9d52b7" xlink:to="loc_mck_SCRIOncologyLLCMember_784bc1fa-5fb3-48f0-ac0c-dfa2985e7732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_886e7b1b-ca96-4e00-a37c-62c47a78a36c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_b8f3da9b-2538-4538-b2bd-9e4d3514aa4d" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_886e7b1b-ca96-4e00-a37c-62c47a78a36c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_c10c4337-5ef0-4f92-88f2-83a2fe238341" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_886e7b1b-ca96-4e00-a37c-62c47a78a36c" xlink:to="loc_us-gaap_SegmentDomain_c10c4337-5ef0-4f92-88f2-83a2fe238341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_USPharmaceuticalSegmentMember_8927a98d-e4a0-45ea-9217-6f32fe972c2a" xlink:href="mck-20230630.xsd#mck_USPharmaceuticalSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_c10c4337-5ef0-4f92-88f2-83a2fe238341" xlink:to="loc_mck_USPharmaceuticalSegmentMember_8927a98d-e4a0-45ea-9217-6f32fe972c2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_b5b280e1-ee7c-4d82-8242-0e40c676675f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_b8f3da9b-2538-4538-b2bd-9e4d3514aa4d" xlink:to="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_b5b280e1-ee7c-4d82-8242-0e40c676675f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_fb1da884-e940-4733-9dc2-2c581a49d8c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_b5b280e1-ee7c-4d82-8242-0e40c676675f" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_fb1da884-e940-4733-9dc2-2c581a49d8c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_BusinessCombinationConsiderationTransferredOwnershipInterest_35abd795-c932-4a26-9103-6fa7d153ffbe" xlink:href="mck-20230630.xsd#mck_BusinessCombinationConsiderationTransferredOwnershipInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_b5b280e1-ee7c-4d82-8242-0e40c676675f" xlink:to="loc_mck_BusinessCombinationConsiderationTransferredOwnershipInterest_35abd795-c932-4a26-9103-6fa7d153ffbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_79711c23-b35a-4ec0-8beb-428baf77d5aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_b5b280e1-ee7c-4d82-8242-0e40c676675f" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_79711c23-b35a-4ec0-8beb-428baf77d5aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_55fd5900-fe5f-4068-872d-2f77cb020d55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_b5b280e1-ee7c-4d82-8242-0e40c676675f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables_55fd5900-fe5f-4068-872d-2f77cb020d55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_f4c45b11-3b2f-496e-b29a-37ce1c28e5b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_b5b280e1-ee7c-4d82-8242-0e40c676675f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_f4c45b11-3b2f-496e-b29a-37ce1c28e5b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_2ad441a9-c312-4b0f-a3c7-72609ea74954" xlink:href="mck-20230630.xsd#mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_b5b280e1-ee7c-4d82-8242-0e40c676675f" xlink:to="loc_mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets_2ad441a9-c312-4b0f-a3c7-72609ea74954" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_72291a86-82b8-4d22-8b56-eba793784160" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_b5b280e1-ee7c-4d82-8242-0e40c676675f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_72291a86-82b8-4d22-8b56-eba793784160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_43299669-abfc-44be-824c-51e254b8b2fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_b5b280e1-ee7c-4d82-8242-0e40c676675f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_43299669-abfc-44be-824c-51e254b8b2fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermOperatingLeaseLiabilities_2c10a7bc-afa2-4802-912f-c2292ccd36c5" xlink:href="mck-20230630.xsd#mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermOperatingLeaseLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_b5b280e1-ee7c-4d82-8242-0e40c676675f" xlink:to="loc_mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermOperatingLeaseLiabilities_2c10a7bc-afa2-4802-912f-c2292ccd36c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_6e27897b-48ca-45cb-9ec6-a2a73888681a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_b5b280e1-ee7c-4d82-8242-0e40c676675f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_6e27897b-48ca-45cb-9ec6-a2a73888681a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_eee62102-ae8a-40ec-8a9f-7a00a1f8119e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_b5b280e1-ee7c-4d82-8242-0e40c676675f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_eee62102-ae8a-40ec-8a9f-7a00a1f8119e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_49bb5191-8729-4543-9753-fe50f84b7804" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_b5b280e1-ee7c-4d82-8242-0e40c676675f" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue_49bb5191-8729-4543-9753-fe50f84b7804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdditionalPaidInCapital_644b2592-843e-4036-b40a-efe1479ac497" xlink:href="mck-20230630.xsd#mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdditionalPaidInCapital"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_b5b280e1-ee7c-4d82-8242-0e40c676675f" xlink:to="loc_mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdditionalPaidInCapital_644b2592-843e-4036-b40a-efe1479ac497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_5b0ea3a3-0dd7-4845-814d-1ade13568206" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_b5b280e1-ee7c-4d82-8242-0e40c676675f" xlink:to="loc_us-gaap_Goodwill_5b0ea3a3-0dd7-4845-814d-1ade13568206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest_82858071-b3eb-434e-9389-b2400ae4f6c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_b5b280e1-ee7c-4d82-8242-0e40c676675f" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest_82858071-b3eb-434e-9389-b2400ae4f6c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/BusinessAcquisitionsandDivestituresDivestituresandOtherDetails" xlink:type="simple" xlink:href="mck-20230630.xsd#BusinessAcquisitionsandDivestituresDivestituresandOtherDetails"/>
  <link:presentationLink xlink:role="http://mckesson123.com/role/BusinessAcquisitionsandDivestituresDivestituresandOtherDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_9d777f22-8751-45f4-b650-a01ce9406fae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_bf36249c-646a-47db-8ed2-f7929d9b3f95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_9d777f22-8751-45f4-b650-a01ce9406fae" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_bf36249c-646a-47db-8ed2-f7929d9b3f95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_60823c04-2cb4-40e5-8a85-f9caa03c0608" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_bf36249c-646a-47db-8ed2-f7929d9b3f95" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_60823c04-2cb4-40e5-8a85-f9caa03c0608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8d4e9f60-3fa1-4040-a2d5-03d1a692a487" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_60823c04-2cb4-40e5-8a85-f9caa03c0608" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8d4e9f60-3fa1-4040-a2d5-03d1a692a487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_EUBusinessesDisposalGroupMember_3ebdf056-980f-4781-bdaf-a8b12c3b32ec" xlink:href="mck-20230630.xsd#mck_EUBusinessesDisposalGroupMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8d4e9f60-3fa1-4040-a2d5-03d1a692a487" xlink:to="loc_mck_EUBusinessesDisposalGroupMember_3ebdf056-980f-4781-bdaf-a8b12c3b32ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_UKBusinessesDisposalGroupMember_e57a8f86-cff8-477e-925f-d9d030c75e2d" xlink:href="mck-20230630.xsd#mck_UKBusinessesDisposalGroupMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8d4e9f60-3fa1-4040-a2d5-03d1a692a487" xlink:to="loc_mck_UKBusinessesDisposalGroupMember_e57a8f86-cff8-477e-925f-d9d030c75e2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_InternationalSegmentMember_92db0f01-45c6-4aab-b259-951db9117d14" xlink:href="mck-20230630.xsd#mck_InternationalSegmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_8d4e9f60-3fa1-4040-a2d5-03d1a692a487" xlink:to="loc_mck_InternationalSegmentMember_92db0f01-45c6-4aab-b259-951db9117d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_05e2523b-8d32-4db7-85f4-e75022378a70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_bf36249c-646a-47db-8ed2-f7929d9b3f95" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_05e2523b-8d32-4db7-85f4-e75022378a70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_ff68eb1f-2ceb-4269-989e-6bdeaadf95c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_05e2523b-8d32-4db7-85f4-e75022378a70" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_ff68eb1f-2ceb-4269-989e-6bdeaadf95c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_2a0b5fb5-c701-43a0-aeca-cba0d2d85451" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_ff68eb1f-2ceb-4269-989e-6bdeaadf95c2" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_2a0b5fb5-c701-43a0-aeca-cba0d2d85451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_31d4b927-6189-42fb-83aa-6d757ab755a1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_bf36249c-646a-47db-8ed2-f7929d9b3f95" xlink:to="loc_dei_LegalEntityAxis_31d4b927-6189-42fb-83aa-6d757ab755a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_752241bb-ac55-45f6-b97a-76d8f6943b11" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_31d4b927-6189-42fb-83aa-6d757ab755a1" xlink:to="loc_dei_EntityDomain_752241bb-ac55-45f6-b97a-76d8f6943b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_AureliusElephantLimitedMember_5677706a-5b3e-485a-a126-59115a821dab" xlink:href="mck-20230630.xsd#mck_AureliusElephantLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_752241bb-ac55-45f6-b97a-76d8f6943b11" xlink:to="loc_mck_AureliusElephantLimitedMember_5677706a-5b3e-485a-a126-59115a821dab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d6053d54-6421-4e65-8573-8df2298ff90d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_bf36249c-646a-47db-8ed2-f7929d9b3f95" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d6053d54-6421-4e65-8573-8df2298ff90d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_7f365ec1-3d63-4c32-b3ec-12c1ecd1c42c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d6053d54-6421-4e65-8573-8df2298ff90d" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_7f365ec1-3d63-4c32-b3ec-12c1ecd1c42c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_DisposalGroupIncludingDiscontinuedOperationConsiderationExpected_17757371-742c-4496-96f7-823f368de597" xlink:href="mck-20230630.xsd#mck_DisposalGroupIncludingDiscontinuedOperationConsiderationExpected"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d6053d54-6421-4e65-8573-8df2298ff90d" xlink:to="loc_mck_DisposalGroupIncludingDiscontinuedOperationConsiderationExpected_17757371-742c-4496-96f7-823f368de597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_de029d4e-edcf-4ecd-9c7e-d9643c7ab493" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d6053d54-6421-4e65-8573-8df2298ff90d" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_de029d4e-edcf-4ecd-9c7e-d9643c7ab493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_ecd94ff6-7a1d-48a9-a5fc-def109c31585" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationFromAociCurrentPeriodTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d6053d54-6421-4e65-8573-8df2298ff90d" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodTax_ecd94ff6-7a1d-48a9-a5fc-def109c31585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable_c94b6cfe-2f0d-44bb-905b-58268c5bd3e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromCollectionOfNotesReceivable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d6053d54-6421-4e65-8573-8df2298ff90d" xlink:to="loc_us-gaap_ProceedsFromCollectionOfNotesReceivable_c94b6cfe-2f0d-44bb-905b-58268c5bd3e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetNarrativeDetails" xlink:type="simple" xlink:href="mck-20230630.xsd#RestructuringImpairmentandRelatedChargesNetNarrativeDetails"/>
  <link:presentationLink xlink:role="http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_7b8f9c45-d91d-4bb7-8227-e79a26f485a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_04dd805a-d66c-486c-a1e2-3d49f75da659" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_7b8f9c45-d91d-4bb7-8227-e79a26f485a7" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_04dd805a-d66c-486c-a1e2-3d49f75da659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_433cc071-908c-4e35-beb6-2bc9b6643a3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_04dd805a-d66c-486c-a1e2-3d49f75da659" xlink:to="loc_us-gaap_RestructuringPlanAxis_433cc071-908c-4e35-beb6-2bc9b6643a3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_8a499ad7-4ef9-443a-9f24-cbf4b0602c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_433cc071-908c-4e35-beb6-2bc9b6643a3b" xlink:to="loc_us-gaap_RestructuringPlanDomain_8a499ad7-4ef9-443a-9f24-cbf4b0602c4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_StrategicGrowthInitiativePlanOperationalEfficienciesAndCostOptimizationMember_ab4e632f-e5b9-43e1-81a4-3b5c6a36da1a" xlink:href="mck-20230630.xsd#mck_StrategicGrowthInitiativePlanOperationalEfficienciesAndCostOptimizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_8a499ad7-4ef9-443a-9f24-cbf4b0602c4d" xlink:to="loc_mck_StrategicGrowthInitiativePlanOperationalEfficienciesAndCostOptimizationMember_ab4e632f-e5b9-43e1-81a4-3b5c6a36da1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_1488a95d-b556-42c8-83d3-677b6305d29c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_04dd805a-d66c-486c-a1e2-3d49f75da659" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_1488a95d-b556-42c8-83d3-677b6305d29c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_RestructuringImpairmentAndOtherRelatedCharges_89170cc6-f9ab-4d5a-a4bc-af6e71a6f3ed" xlink:href="mck-20230630.xsd#mck_RestructuringImpairmentAndOtherRelatedCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1488a95d-b556-42c8-83d3-677b6305d29c" xlink:to="loc_mck_RestructuringImpairmentAndOtherRelatedCharges_89170cc6-f9ab-4d5a-a4bc-af6e71a6f3ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_2309d32e-096e-42ec-bbc8-bf78eb689cad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1488a95d-b556-42c8-83d3-677b6305d29c" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_2309d32e-096e-42ec-bbc8-bf78eb689cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_676c207a-1b75-4a9f-8b06-7e0224c9dd76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1488a95d-b556-42c8-83d3-677b6305d29c" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_676c207a-1b75-4a9f-8b06-7e0224c9dd76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_d75511ac-94e9-4c7e-b25c-2cd82f91b196" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_1488a95d-b556-42c8-83d3-677b6305d29c" xlink:to="loc_us-gaap_RestructuringCharges_d75511ac-94e9-4c7e-b25c-2cd82f91b196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails" xlink:type="simple" xlink:href="mck-20230630.xsd#RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails"/>
  <link:presentationLink xlink:role="http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_6faf8ff5-9de1-4622-b7bb-a7b1566e8cc8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_56970f9a-c27e-47a2-a49a-73075385a34b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_6faf8ff5-9de1-4622-b7bb-a7b1566e8cc8" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_56970f9a-c27e-47a2-a49a-73075385a34b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_c2e9dda3-dd80-45a1-937a-d232a56bb1fe" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_56970f9a-c27e-47a2-a49a-73075385a34b" xlink:to="loc_srt_ConsolidationItemsAxis_c2e9dda3-dd80-45a1-937a-d232a56bb1fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_7a752aed-e146-491b-8b5e-07f0fe149f95" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_c2e9dda3-dd80-45a1-937a-d232a56bb1fe" xlink:to="loc_srt_ConsolidationItemsDomain_7a752aed-e146-491b-8b5e-07f0fe149f95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_7227f21d-e16f-46cf-adf7-33ccc0fde51b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_7a752aed-e146-491b-8b5e-07f0fe149f95" xlink:to="loc_us-gaap_OperatingSegmentsMember_7227f21d-e16f-46cf-adf7-33ccc0fde51b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_d04f2263-d4c4-4f3a-aae3-78827935242b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_7a752aed-e146-491b-8b5e-07f0fe149f95" xlink:to="loc_us-gaap_CorporateNonSegmentMember_d04f2263-d4c4-4f3a-aae3-78827935242b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_16b23d71-fdf3-4e32-be2e-63f7f3ea9b83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_56970f9a-c27e-47a2-a49a-73075385a34b" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_16b23d71-fdf3-4e32-be2e-63f7f3ea9b83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_187ce840-038c-42cc-81a9-976186a8fee2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_16b23d71-fdf3-4e32-be2e-63f7f3ea9b83" xlink:to="loc_us-gaap_SegmentDomain_187ce840-038c-42cc-81a9-976186a8fee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_USPharmaceuticalSegmentMember_6099c9b9-7700-4f7b-a03d-0535be798984" xlink:href="mck-20230630.xsd#mck_USPharmaceuticalSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_187ce840-038c-42cc-81a9-976186a8fee2" xlink:to="loc_mck_USPharmaceuticalSegmentMember_6099c9b9-7700-4f7b-a03d-0535be798984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_PrescriptionTechnologySolutionsMember_1e6aaabd-69c7-44ea-9b99-e19bff84d2d3" xlink:href="mck-20230630.xsd#mck_PrescriptionTechnologySolutionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_187ce840-038c-42cc-81a9-976186a8fee2" xlink:to="loc_mck_PrescriptionTechnologySolutionsMember_1e6aaabd-69c7-44ea-9b99-e19bff84d2d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_MedicalSurgicalSolutionsSegmentMember_3b521dce-6548-4d2e-86f0-06fdfcf6df41" xlink:href="mck-20230630.xsd#mck_MedicalSurgicalSolutionsSegmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_187ce840-038c-42cc-81a9-976186a8fee2" xlink:to="loc_mck_MedicalSurgicalSolutionsSegmentMember_3b521dce-6548-4d2e-86f0-06fdfcf6df41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_InternationalSegmentMember_7f93fb67-15d2-4910-a4a4-f8f5e4340ec3" xlink:href="mck-20230630.xsd#mck_InternationalSegmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_187ce840-038c-42cc-81a9-976186a8fee2" xlink:to="loc_mck_InternationalSegmentMember_7f93fb67-15d2-4910-a4a4-f8f5e4340ec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_9467560b-b01a-4b78-a7ed-ead97bfa0fa6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_56970f9a-c27e-47a2-a49a-73075385a34b" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_9467560b-b01a-4b78-a7ed-ead97bfa0fa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_08522e29-bf58-47e1-ad20-c341e9d79f3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_9467560b-b01a-4b78-a7ed-ead97bfa0fa6" xlink:to="loc_us-gaap_SeveranceCosts1_08522e29-bf58-47e1-ad20-c341e9d79f3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessExitCosts1_00928050-00d5-4b06-a18f-7a34a916e2e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessExitCosts1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_9467560b-b01a-4b78-a7ed-ead97bfa0fa6" xlink:to="loc_us-gaap_BusinessExitCosts1_00928050-00d5-4b06-a18f-7a34a916e2e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_AssetImpairmentChargesIncludingAcceleratedDepreciation_d3e6b843-70f8-4a47-8c3f-c6ab2d0a5510" xlink:href="mck-20230630.xsd#mck_AssetImpairmentChargesIncludingAcceleratedDepreciation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_9467560b-b01a-4b78-a7ed-ead97bfa0fa6" xlink:to="loc_mck_AssetImpairmentChargesIncludingAcceleratedDepreciation_d3e6b843-70f8-4a47-8c3f-c6ab2d0a5510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_4106f64d-eff9-4f23-bb90-8ff1847a5c60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_9467560b-b01a-4b78-a7ed-ead97bfa0fa6" xlink:to="loc_us-gaap_RestructuringCharges_4106f64d-eff9-4f23-bb90-8ff1847a5c60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails" xlink:type="simple" xlink:href="mck-20230630.xsd#RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails"/>
  <link:presentationLink xlink:role="http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_491b6cc8-f7d3-43ac-82ed-799d485efa0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_011a9071-74c7-4cbb-8d79-3b8e0be38695" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_491b6cc8-f7d3-43ac-82ed-799d485efa0b" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_011a9071-74c7-4cbb-8d79-3b8e0be38695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_e4f9a0d1-5d62-48d9-8903-7466a180004e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_011a9071-74c7-4cbb-8d79-3b8e0be38695" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_e4f9a0d1-5d62-48d9-8903-7466a180004e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_a1dd99ee-ea72-4c0f-b534-348ba6166844" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_e4f9a0d1-5d62-48d9-8903-7466a180004e" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_a1dd99ee-ea72-4c0f-b534-348ba6166844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_e94e6df2-6859-4ba7-aa84-979b33df3ff6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_a1dd99ee-ea72-4c0f-b534-348ba6166844" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_e94e6df2-6859-4ba7-aa84-979b33df3ff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_54da3610-57d9-4780-9095-6aae62895673" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_a1dd99ee-ea72-4c0f-b534-348ba6166844" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_54da3610-57d9-4780-9095-6aae62895673" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_032f5ff5-3619-4a5c-9de8-48a634a6a8c8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_011a9071-74c7-4cbb-8d79-3b8e0be38695" xlink:to="loc_srt_ConsolidationItemsAxis_032f5ff5-3619-4a5c-9de8-48a634a6a8c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_35be3ee6-fd2a-4149-8884-cba066afe21d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_032f5ff5-3619-4a5c-9de8-48a634a6a8c8" xlink:to="loc_srt_ConsolidationItemsDomain_35be3ee6-fd2a-4149-8884-cba066afe21d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_a7db2b57-2781-4353-bd53-da623c107367" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_35be3ee6-fd2a-4149-8884-cba066afe21d" xlink:to="loc_us-gaap_OperatingSegmentsMember_a7db2b57-2781-4353-bd53-da623c107367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_86b0e3d6-7358-49d5-9524-7d98cdc6b4da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_35be3ee6-fd2a-4149-8884-cba066afe21d" xlink:to="loc_us-gaap_CorporateNonSegmentMember_86b0e3d6-7358-49d5-9524-7d98cdc6b4da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_791187bc-e467-48d5-a2bc-902b41340960" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_011a9071-74c7-4cbb-8d79-3b8e0be38695" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_791187bc-e467-48d5-a2bc-902b41340960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_c7e8b19e-481b-49d4-95ac-8120764b2af7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_791187bc-e467-48d5-a2bc-902b41340960" xlink:to="loc_us-gaap_SegmentDomain_c7e8b19e-481b-49d4-95ac-8120764b2af7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_USPharmaceuticalSegmentMember_b190353d-0545-4991-8345-0f9a62644d4c" xlink:href="mck-20230630.xsd#mck_USPharmaceuticalSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_c7e8b19e-481b-49d4-95ac-8120764b2af7" xlink:to="loc_mck_USPharmaceuticalSegmentMember_b190353d-0545-4991-8345-0f9a62644d4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_PrescriptionTechnologySolutionsMember_d32d6d55-8bbd-4c0c-bb39-5d76b78bf015" xlink:href="mck-20230630.xsd#mck_PrescriptionTechnologySolutionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_c7e8b19e-481b-49d4-95ac-8120764b2af7" xlink:to="loc_mck_PrescriptionTechnologySolutionsMember_d32d6d55-8bbd-4c0c-bb39-5d76b78bf015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_MedicalSurgicalSolutionsSegmentMember_2e326c4c-4c41-4b57-9bc0-cfb1069001e4" xlink:href="mck-20230630.xsd#mck_MedicalSurgicalSolutionsSegmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_c7e8b19e-481b-49d4-95ac-8120764b2af7" xlink:to="loc_mck_MedicalSurgicalSolutionsSegmentMember_2e326c4c-4c41-4b57-9bc0-cfb1069001e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_InternationalSegmentMember_c66fbc67-c68f-4665-a685-19b60737cb53" xlink:href="mck-20230630.xsd#mck_InternationalSegmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_c7e8b19e-481b-49d4-95ac-8120764b2af7" xlink:to="loc_mck_InternationalSegmentMember_c66fbc67-c68f-4665-a685-19b60737cb53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_c09fd113-54c3-4f33-8b2f-f7d5a4212101" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_011a9071-74c7-4cbb-8d79-3b8e0be38695" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_c09fd113-54c3-4f33-8b2f-f7d5a4212101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_88f1ea8c-a5ed-49aa-9672-c3833e6957f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_c09fd113-54c3-4f33-8b2f-f7d5a4212101" xlink:to="loc_us-gaap_RestructuringReserveRollForward_88f1ea8c-a5ed-49aa-9672-c3833e6957f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_fad5f16f-f1cc-4cc2-945e-1f0404b6ff21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_88f1ea8c-a5ed-49aa-9672-c3833e6957f0" xlink:to="loc_us-gaap_RestructuringReserve_fad5f16f-f1cc-4cc2-945e-1f0404b6ff21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_8e3b29fc-47e9-4957-bbb4-a39c2cf3f3ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_88f1ea8c-a5ed-49aa-9672-c3833e6957f0" xlink:to="loc_us-gaap_RestructuringCharges_8e3b29fc-47e9-4957-bbb4-a39c2cf3f3ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveSettledWithoutCash2_3ee6e299-9bc9-4e02-baa3-b03223edd7c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserveSettledWithoutCash2"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_88f1ea8c-a5ed-49aa-9672-c3833e6957f0" xlink:to="loc_us-gaap_RestructuringReserveSettledWithoutCash2_3ee6e299-9bc9-4e02-baa3-b03223edd7c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_a53d073c-68ca-436c-a03f-3318d5e6c7cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_88f1ea8c-a5ed-49aa-9672-c3833e6957f0" xlink:to="loc_us-gaap_PaymentsForRestructuring_a53d073c-68ca-436c-a03f-3318d5e6c7cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveTranslationAndOtherAdjustment_db7d5bc1-2e0a-460a-9b1c-7eaadd7336e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserveTranslationAndOtherAdjustment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_88f1ea8c-a5ed-49aa-9672-c3833e6957f0" xlink:to="loc_us-gaap_RestructuringReserveTranslationAndOtherAdjustment_db7d5bc1-2e0a-460a-9b1c-7eaadd7336e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_b26efea2-fba6-4be9-8d25-56aab17bd19d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_88f1ea8c-a5ed-49aa-9672-c3833e6957f0" xlink:to="loc_us-gaap_RestructuringReserve_b26efea2-fba6-4be9-8d25-56aab17bd19d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseDetails" xlink:type="simple" xlink:href="mck-20230630.xsd#IncomeTaxesScheduleofComponentsofIncomeTaxExpenseDetails"/>
  <link:presentationLink xlink:role="http://mckesson123.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_c1e15e5f-0557-4ad8-8af9-9ffdcfcab2ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a589c7d3-5aa9-44fe-9bf3-a5cb7978dd84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c1e15e5f-0557-4ad8-8af9-9ffdcfcab2ee" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_a589c7d3-5aa9-44fe-9bf3-a5cb7978dd84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_3019f25b-4183-4fef-8548-052a2d286441" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c1e15e5f-0557-4ad8-8af9-9ffdcfcab2ee" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_3019f25b-4183-4fef-8548-052a2d286441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="mck-20230630.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://mckesson123.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1ab0b9a2-d536-4b9d-8d70-84bf3c1f3de1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_aee16633-8979-423a-bd48-0527dff1f762" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1ab0b9a2-d536-4b9d-8d70-84bf3c1f3de1" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_aee16633-8979-423a-bd48-0527dff1f762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_56c5a18e-50af-4213-b4ea-b2c0487869d3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_aee16633-8979-423a-bd48-0527dff1f762" xlink:to="loc_srt_RangeAxis_56c5a18e-50af-4213-b4ea-b2c0487869d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b2741d82-1b09-4664-bf53-8a91766cd9ef" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_56c5a18e-50af-4213-b4ea-b2c0487869d3" xlink:to="loc_srt_RangeMember_b2741d82-1b09-4664-bf53-8a91766cd9ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_328e059a-a934-4de2-891f-3f339249af57" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b2741d82-1b09-4664-bf53-8a91766cd9ef" xlink:to="loc_srt_MinimumMember_328e059a-a934-4de2-891f-3f339249af57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_37ccaa59-1697-45dc-8fff-372b01816851" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b2741d82-1b09-4664-bf53-8a91766cd9ef" xlink:to="loc_srt_MaximumMember_37ccaa59-1697-45dc-8fff-372b01816851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_20a5a581-6c2d-4a16-a6d4-cf0172fdc7b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_aee16633-8979-423a-bd48-0527dff1f762" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_20a5a581-6c2d-4a16-a6d4-cf0172fdc7b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_EffectiveIncomeTaxReconciliationTaxExpenseBenefitIntraEntityTransfersOfAssetsOtherThanInventoryAmount_a5143e2a-9348-45f8-81f9-2dc11a2d16aa" xlink:href="mck-20230630.xsd#mck_EffectiveIncomeTaxReconciliationTaxExpenseBenefitIntraEntityTransfersOfAssetsOtherThanInventoryAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_20a5a581-6c2d-4a16-a6d4-cf0172fdc7b9" xlink:to="loc_mck_EffectiveIncomeTaxReconciliationTaxExpenseBenefitIntraEntityTransfersOfAssetsOtherThanInventoryAmount_a5143e2a-9348-45f8-81f9-2dc11a2d16aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_1f707c9a-0269-4221-8a10-33bb1e066668" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_20a5a581-6c2d-4a16-a6d4-cf0172fdc7b9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_1f707c9a-0269-4221-8a10-33bb1e066668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_f5384703-5630-4972-af3d-2dd0d0b95046" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_20a5a581-6c2d-4a16-a6d4-cf0172fdc7b9" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_f5384703-5630-4972-af3d-2dd0d0b95046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_03c5651f-27d9-4465-9934-7c047eaadbe8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_20a5a581-6c2d-4a16-a6d4-cf0172fdc7b9" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_03c5651f-27d9-4465-9934-7c047eaadbe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_IncomeTaxExaminationEstimateOfPossibleLiabilityAdjustment_e232b292-bdf0-4fa8-8624-e1e73157c38e" xlink:href="mck-20230630.xsd#mck_IncomeTaxExaminationEstimateOfPossibleLiabilityAdjustment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_20a5a581-6c2d-4a16-a6d4-cf0172fdc7b9" xlink:to="loc_mck_IncomeTaxExaminationEstimateOfPossibleLiabilityAdjustment_e232b292-bdf0-4fa8-8624-e1e73157c38e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/EarningsPerCommonShareNarrativeDetails" xlink:type="simple" xlink:href="mck-20230630.xsd#EarningsPerCommonShareNarrativeDetails"/>
  <link:presentationLink xlink:role="http://mckesson123.com/role/EarningsPerCommonShareNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_9d2274f1-5999-4add-b463-e4c98688f000" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7b731ffb-b41d-4470-971d-583f8510a3ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9d2274f1-5999-4add-b463-e4c98688f000" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7b731ffb-b41d-4470-971d-583f8510a3ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails" xlink:type="simple" xlink:href="mck-20230630.xsd#EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails"/>
  <link:presentationLink xlink:role="http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_bb9d615f-7c92-453a-a3b0-ce82486d78fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_54ec1154-c8b3-4a75-9c07-437dd34b3a89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_bb9d615f-7c92-453a-a3b0-ce82486d78fa" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_54ec1154-c8b3-4a75-9c07-437dd34b3a89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_29a499b9-b799-4e9e-9e96-1cfd1c283198" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_54ec1154-c8b3-4a75-9c07-437dd34b3a89" xlink:to="loc_us-gaap_AwardTypeAxis_29a499b9-b799-4e9e-9e96-1cfd1c283198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0afbcab0-56b7-4f84-ba11-1674f9120002" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_29a499b9-b799-4e9e-9e96-1cfd1c283198" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0afbcab0-56b7-4f84-ba11-1674f9120002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_70969eb8-cb9b-4a38-8ab0-7a7b627ea3e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0afbcab0-56b7-4f84-ba11-1674f9120002" xlink:to="loc_us-gaap_EmployeeStockOptionMember_70969eb8-cb9b-4a38-8ab0-7a7b627ea3e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_ee8b5f1a-b4d1-48b7-8a1c-9582855c96d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0afbcab0-56b7-4f84-ba11-1674f9120002" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_ee8b5f1a-b4d1-48b7-8a1c-9582855c96d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedLineItems_84634293-4233-426b-8b73-a2ef030d9657" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDilutedLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable_54ec1154-c8b3-4a75-9c07-437dd34b3a89" xlink:to="loc_us-gaap_EarningsPerShareDilutedLineItems_84634293-4233-426b-8b73-a2ef030d9657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_ec303fbf-d599-43e2-a3f7-3a4bbf3d0f89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_84634293-4233-426b-8b73-a2ef030d9657" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_ec303fbf-d599-43e2-a3f7-3a4bbf3d0f89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_a214f70a-3054-482a-87e4-027b73c5aa16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_84634293-4233-426b-8b73-a2ef030d9657" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_a214f70a-3054-482a-87e4-027b73c5aa16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_d4df8806-85b8-4333-bf84-f0f0f20719ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_84634293-4233-426b-8b73-a2ef030d9657" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_d4df8806-85b8-4333-bf84-f0f0f20719ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_4147a68a-be59-494c-bdca-f9191fc4dc0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_84634293-4233-426b-8b73-a2ef030d9657" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_4147a68a-be59-494c-bdca-f9191fc4dc0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7d8821aa-70ee-4fb2-866f-19d797b93324" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_84634293-4233-426b-8b73-a2ef030d9657" xlink:to="loc_us-gaap_NetIncomeLoss_7d8821aa-70ee-4fb2-866f-19d797b93324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_ba02c390-5caf-430c-8720-e78c4d51f2e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_84634293-4233-426b-8b73-a2ef030d9657" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_ba02c390-5caf-430c-8720-e78c4d51f2e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e9ea03a8-2a28-48b2-8880-19adc281496d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_ba02c390-5caf-430c-8720-e78c4d51f2e0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e9ea03a8-2a28-48b2-8880-19adc281496d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_777750f6-100d-4283-9ec4-6780392d3e5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_84634293-4233-426b-8b73-a2ef030d9657" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_777750f6-100d-4283-9ec4-6780392d3e5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c3c16817-1fee-4798-8630-eaa2ab0985bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_84634293-4233-426b-8b73-a2ef030d9657" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c3c16817-1fee-4798-8630-eaa2ab0985bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_EPSBasicAndDilutedAbstract_ddcf3f16-f3e2-4e18-a62b-41552ebe53b6" xlink:href="mck-20230630.xsd#mck_EPSBasicAndDilutedAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedLineItems_84634293-4233-426b-8b73-a2ef030d9657" xlink:to="loc_mck_EPSBasicAndDilutedAbstract_ddcf3f16-f3e2-4e18-a62b-41552ebe53b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_4cbcd44a-4d44-4a11-a2d7-edfca37f2a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mck_EPSBasicAndDilutedAbstract_ddcf3f16-f3e2-4e18-a62b-41552ebe53b6" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_4cbcd44a-4d44-4a11-a2d7-edfca37f2a0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_0413cf15-775c-4376-8d1b-d69b58d8b50f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_4cbcd44a-4d44-4a11-a2d7-edfca37f2a0e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_0413cf15-775c-4376-8d1b-d69b58d8b50f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_3934c1d9-b549-4ff4-9bd8-e8409daef66c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_4cbcd44a-4d44-4a11-a2d7-edfca37f2a0e" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_3934c1d9-b549-4ff4-9bd8-e8409daef66c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_4f8bd0eb-54d7-4826-9856-48bb8f5af9ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_4cbcd44a-4d44-4a11-a2d7-edfca37f2a0e" xlink:to="loc_us-gaap_EarningsPerShareDiluted_4f8bd0eb-54d7-4826-9856-48bb8f5af9ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_421e521a-28cf-406b-8761-7af236a03b32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasicAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mck_EPSBasicAndDilutedAbstract_ddcf3f16-f3e2-4e18-a62b-41552ebe53b6" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_421e521a-28cf-406b-8761-7af236a03b32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_9d5a40e2-8355-440c-a15b-41b72c83796f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_421e521a-28cf-406b-8761-7af236a03b32" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_9d5a40e2-8355-440c-a15b-41b72c83796f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_b5f8cb3e-fb8a-4dc5-bd64-85653cbfc82c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_421e521a-28cf-406b-8761-7af236a03b32" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_b5f8cb3e-fb8a-4dc5-bd64-85653cbfc82c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_7dadff44-9360-468c-bd21-b64465dfd04c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_421e521a-28cf-406b-8761-7af236a03b32" xlink:to="loc_us-gaap_EarningsPerShareBasic_7dadff44-9360-468c-bd21-b64465dfd04c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofChangesintheCarryingAmountofGoodwillDetails" xlink:type="simple" xlink:href="mck-20230630.xsd#GoodwillandIntangibleAssetsNetScheduleofChangesintheCarryingAmountofGoodwillDetails"/>
  <link:presentationLink xlink:role="http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofChangesintheCarryingAmountofGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_826f52d5-9e25-4d1c-b1a6-b227a1ba656e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_36720e67-b1a4-4c7e-bf0b-a891ae1c32a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_826f52d5-9e25-4d1c-b1a6-b227a1ba656e" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_36720e67-b1a4-4c7e-bf0b-a891ae1c32a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_42ab96e5-6fbc-4ee5-9b46-ece50b5aa3d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_36720e67-b1a4-4c7e-bf0b-a891ae1c32a9" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_42ab96e5-6fbc-4ee5-9b46-ece50b5aa3d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_13f38024-4875-4631-9d65-a0f84ba0d5a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_42ab96e5-6fbc-4ee5-9b46-ece50b5aa3d5" xlink:to="loc_us-gaap_SegmentDomain_13f38024-4875-4631-9d65-a0f84ba0d5a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_USPharmaceuticalSegmentMember_07cd3a04-0860-4f38-8ba2-9f2acc568f30" xlink:href="mck-20230630.xsd#mck_USPharmaceuticalSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_13f38024-4875-4631-9d65-a0f84ba0d5a8" xlink:to="loc_mck_USPharmaceuticalSegmentMember_07cd3a04-0860-4f38-8ba2-9f2acc568f30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_PrescriptionTechnologySolutionsMember_15352e9e-2a7a-472f-9c10-70262e525c00" xlink:href="mck-20230630.xsd#mck_PrescriptionTechnologySolutionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_13f38024-4875-4631-9d65-a0f84ba0d5a8" xlink:to="loc_mck_PrescriptionTechnologySolutionsMember_15352e9e-2a7a-472f-9c10-70262e525c00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_MedicalSurgicalSolutionsSegmentMember_a03d11be-b452-4cd0-9ea5-bdd7c842eede" xlink:href="mck-20230630.xsd#mck_MedicalSurgicalSolutionsSegmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_13f38024-4875-4631-9d65-a0f84ba0d5a8" xlink:to="loc_mck_MedicalSurgicalSolutionsSegmentMember_a03d11be-b452-4cd0-9ea5-bdd7c842eede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_InternationalSegmentMember_9c60f1f9-de21-4695-9941-f18b231d0388" xlink:href="mck-20230630.xsd#mck_InternationalSegmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_13f38024-4875-4631-9d65-a0f84ba0d5a8" xlink:to="loc_mck_InternationalSegmentMember_9c60f1f9-de21-4695-9941-f18b231d0388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_ecb4cbb5-027d-493e-b853-2b03e1cf45f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_36720e67-b1a4-4c7e-bf0b-a891ae1c32a9" xlink:to="loc_us-gaap_GoodwillLineItems_ecb4cbb5-027d-493e-b853-2b03e1cf45f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_5d985d2c-d0f1-4be5-840a-70898379e2cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_ecb4cbb5-027d-493e-b853-2b03e1cf45f0" xlink:to="loc_us-gaap_GoodwillRollForward_5d985d2c-d0f1-4be5-840a-70898379e2cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_1d3943d9-5f36-4b4b-b5cc-5961a5e0c599" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_5d985d2c-d0f1-4be5-840a-70898379e2cb" xlink:to="loc_us-gaap_Goodwill_1d3943d9-5f36-4b4b-b5cc-5961a5e0c599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_7a8c39a1-74af-4f3a-8c06-220a99391b55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_5d985d2c-d0f1-4be5-840a-70898379e2cb" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_7a8c39a1-74af-4f3a-8c06-220a99391b55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_7a255608-5a2b-4d35-9b3d-fd3832ddaf1e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_5d985d2c-d0f1-4be5-840a-70898379e2cb" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_7a255608-5a2b-4d35-9b3d-fd3832ddaf1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_20339c05-cf9a-4f9c-8d53-850a9fa9ecd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_5d985d2c-d0f1-4be5-840a-70898379e2cb" xlink:to="loc_us-gaap_Goodwill_20339c05-cf9a-4f9c-8d53-850a9fa9ecd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails" xlink:type="simple" xlink:href="mck-20230630.xsd#GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_35de168e-9bf8-4b72-a091-6a78b04d5938" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_961a59dc-a039-47b4-9624-b371e4b6140f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_35de168e-9bf8-4b72-a091-6a78b04d5938" xlink:to="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_961a59dc-a039-47b4-9624-b371e4b6140f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a3395dc0-fa0f-464f-9b98-14ac0bb885a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_961a59dc-a039-47b4-9624-b371e4b6140f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a3395dc0-fa0f-464f-9b98-14ac0bb885a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_76776c5c-aa7e-4f0a-990b-933360d7593d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a3395dc0-fa0f-464f-9b98-14ac0bb885a7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_76776c5c-aa7e-4f0a-990b-933360d7593d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRelationshipsMember_0b1e18f5-11fe-4436-9c46-5bf60a525308" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CustomerRelationshipsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_76776c5c-aa7e-4f0a-990b-933360d7593d" xlink:to="loc_us-gaap_CustomerRelationshipsMember_0b1e18f5-11fe-4436-9c46-5bf60a525308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceAgreementsMember_93ae6bbf-c6cb-49a0-a44c-384e32b788be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ServiceAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_76776c5c-aa7e-4f0a-990b-933360d7593d" xlink:to="loc_us-gaap_ServiceAgreementsMember_93ae6bbf-c6cb-49a0-a44c-384e32b788be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_2ca5a1f1-5f6e-4102-a63d-1f63409cd6e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_76776c5c-aa7e-4f0a-990b-933360d7593d" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_2ca5a1f1-5f6e-4102-a63d-1f63409cd6e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_87b2cbad-80e1-4be9-9419-16973e065062" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TechnologyBasedIntangibleAssetsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_76776c5c-aa7e-4f0a-990b-933360d7593d" xlink:to="loc_us-gaap_TechnologyBasedIntangibleAssetsMember_87b2cbad-80e1-4be9-9419-16973e065062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_ae10fd4c-68f8-43ca-8392-5510425c3c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_76776c5c-aa7e-4f0a-990b-933360d7593d" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_ae10fd4c-68f8-43ca-8392-5510425c3c3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f1f1b55b-8b28-4e6f-b3ff-4ed55baed6a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable_961a59dc-a039-47b4-9624-b371e4b6140f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f1f1b55b-8b28-4e6f-b3ff-4ed55baed6a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_83e64adc-04fb-461b-a001-18dd0f9b1d30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f1f1b55b-8b28-4e6f-b3ff-4ed55baed6a9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_83e64adc-04fb-461b-a001-18dd0f9b1d30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_6f3564ed-666b-4dde-9897-06a4bfe26ea8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f1f1b55b-8b28-4e6f-b3ff-4ed55baed6a9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_6f3564ed-666b-4dde-9897-06a4bfe26ea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_bb81489d-1aa6-4a06-8d23-9daa532a2879" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f1f1b55b-8b28-4e6f-b3ff-4ed55baed6a9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_bb81489d-1aa6-4a06-8d23-9daa532a2879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d7507f6d-9cfe-42b9-9c2e-348259b1d9b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_f1f1b55b-8b28-4e6f-b3ff-4ed55baed6a9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_d7507f6d-9cfe-42b9-9c2e-348259b1d9b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/GoodwillandIntangibleAssetsNetNarrativeDetails" xlink:type="simple" xlink:href="mck-20230630.xsd#GoodwillandIntangibleAssetsNetNarrativeDetails"/>
  <link:presentationLink xlink:role="http://mckesson123.com/role/GoodwillandIntangibleAssetsNetNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9fa9a6cc-7561-4297-8c50-bdcd07da9e92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_d49bf6db-b32e-4745-9336-a99957192881" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9fa9a6cc-7561-4297-8c50-bdcd07da9e92" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_d49bf6db-b32e-4745-9336-a99957192881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_bb2f50e9-c0f2-47ab-a556-d241e70ec685" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_9fa9a6cc-7561-4297-8c50-bdcd07da9e92" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_bb2f50e9-c0f2-47ab-a556-d241e70ec685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_0e98d41f-b9d8-470b-86d5-e01beae9d6a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_bb2f50e9-c0f2-47ab-a556-d241e70ec685" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_0e98d41f-b9d8-470b-86d5-e01beae9d6a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_49ecb3ee-c86f-43fe-9588-c6ce029722f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_bb2f50e9-c0f2-47ab-a556-d241e70ec685" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_49ecb3ee-c86f-43fe-9588-c6ce029722f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_725eaca2-0fac-49c9-905b-3ebd1639f737" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_bb2f50e9-c0f2-47ab-a556-d241e70ec685" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_725eaca2-0fac-49c9-905b-3ebd1639f737" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_ef4c22d0-0aab-4247-b203-9fec62a7ed8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_bb2f50e9-c0f2-47ab-a556-d241e70ec685" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_ef4c22d0-0aab-4247-b203-9fec62a7ed8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_fc5ad568-b966-441c-8598-bbcc59ae6026" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_bb2f50e9-c0f2-47ab-a556-d241e70ec685" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_fc5ad568-b966-441c-8598-bbcc59ae6026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_b70352fd-3eb0-4161-8849-d602f33de40f" xlink:href="mck-20230630.xsd#mck_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract_bb2f50e9-c0f2-47ab-a556-d241e70ec685" xlink:to="loc_mck_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_b70352fd-3eb0-4161-8849-d602f33de40f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails" xlink:type="simple" xlink:href="mck-20230630.xsd#DebtandFinancingActivitiesScheduleofLongTermDebtDetails"/>
  <link:presentationLink xlink:role="http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_cd911843-6ff5-4e59-895d-5edf2f707894" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_b3d9a3b1-2dff-4885-905a-d0eaaff304ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_cd911843-6ff5-4e59-895d-5edf2f707894" xlink:to="loc_us-gaap_DebtInstrumentTable_b3d9a3b1-2dff-4885-905a-d0eaaff304ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_af7d9ee1-6598-46dd-8dd0-581097351d84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b3d9a3b1-2dff-4885-905a-d0eaaff304ac" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_af7d9ee1-6598-46dd-8dd0-581097351d84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_08367e60-db54-4f53-8355-30dcdb9bd214" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_af7d9ee1-6598-46dd-8dd0-581097351d84" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_08367e60-db54-4f53-8355-30dcdb9bd214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_b5c9252f-929d-40df-b053-c7e5e6edd03c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_08367e60-db54-4f53-8355-30dcdb9bd214" xlink:to="loc_us-gaap_LoansPayableMember_b5c9252f-929d-40df-b053-c7e5e6edd03c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_LeaseAndOtherObligationsMember_065eb69d-611d-46de-b67c-d076a1150ebe" xlink:href="mck-20230630.xsd#mck_LeaseAndOtherObligationsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_08367e60-db54-4f53-8355-30dcdb9bd214" xlink:to="loc_mck_LeaseAndOtherObligationsMember_065eb69d-611d-46de-b67c-d076a1150ebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_bdd27057-8f05-4990-ad5c-c0b977823598" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b3d9a3b1-2dff-4885-905a-d0eaaff304ac" xlink:to="loc_us-gaap_DebtInstrumentAxis_bdd27057-8f05-4990-ad5c-c0b977823598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_77d4a144-2440-4f94-9fa6-2a270c5f9a47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_bdd27057-8f05-4990-ad5c-c0b977823598" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_77d4a144-2440-4f94-9fa6-2a270c5f9a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_A380NotesDueMarch152024Member_cb768762-e02c-4c0f-a120-016d4b7ce3de" xlink:href="mck-20230630.xsd#mck_A380NotesDueMarch152024Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_77d4a144-2440-4f94-9fa6-2a270c5f9a47" xlink:to="loc_mck_A380NotesDueMarch152024Member_cb768762-e02c-4c0f-a120-016d4b7ce3de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_A090NotesDueDecember32025Member_830fd946-680e-4c55-861d-c1761fec4f96" xlink:href="mck-20230630.xsd#mck_A090NotesDueDecember32025Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_77d4a144-2440-4f94-9fa6-2a270c5f9a47" xlink:to="loc_mck_A090NotesDueDecember32025Member_830fd946-680e-4c55-861d-c1761fec4f96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_A525NotesDueFebruary152026Member_a56b522f-7c2b-41d5-9136-c58e69765e44" xlink:href="mck-20230630.xsd#mck_A525NotesDueFebruary152026Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_77d4a144-2440-4f94-9fa6-2a270c5f9a47" xlink:to="loc_mck_A525NotesDueFebruary152026Member_a56b522f-7c2b-41d5-9136-c58e69765e44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_A130NotesDueAugust152026Member_7a58abb2-1ceb-48e6-bfb4-b9be841f1c7e" xlink:href="mck-20230630.xsd#mck_A130NotesDueAugust152026Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_77d4a144-2440-4f94-9fa6-2a270c5f9a47" xlink:to="loc_mck_A130NotesDueAugust152026Member_7a58abb2-1ceb-48e6-bfb4-b9be841f1c7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_A765DebenturesDueMarch12027Member_201d906d-6165-4619-aa04-e8754252783d" xlink:href="mck-20230630.xsd#mck_A765DebenturesDueMarch12027Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_77d4a144-2440-4f94-9fa6-2a270c5f9a47" xlink:to="loc_mck_A765DebenturesDueMarch12027Member_201d906d-6165-4619-aa04-e8754252783d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_A395NotesDueFebruary162028Member_a540129a-6fcf-447a-8bfb-7296cf06dd9e" xlink:href="mck-20230630.xsd#mck_A395NotesDueFebruary162028Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_77d4a144-2440-4f94-9fa6-2a270c5f9a47" xlink:to="loc_mck_A395NotesDueFebruary162028Member_a540129a-6fcf-447a-8bfb-7296cf06dd9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_A490NotesDueJuly152028Member_ad7081fa-93d7-4378-b990-11a17d8ab6f9" xlink:href="mck-20230630.xsd#mck_A490NotesDueJuly152028Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_77d4a144-2440-4f94-9fa6-2a270c5f9a47" xlink:to="loc_mck_A490NotesDueJuly152028Member_ad7081fa-93d7-4378-b990-11a17d8ab6f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_A475NotesDueMay302029Member_0acb9b88-0860-42d6-8fe0-395d91185472" xlink:href="mck-20230630.xsd#mck_A475NotesDueMay302029Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_77d4a144-2440-4f94-9fa6-2a270c5f9a47" xlink:to="loc_mck_A475NotesDueMay302029Member_0acb9b88-0860-42d6-8fe0-395d91185472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_A510NotesDueJuly152033Member_635276a6-d9e2-4cc7-a678-e378a3fb14f3" xlink:href="mck-20230630.xsd#mck_A510NotesDueJuly152033Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_77d4a144-2440-4f94-9fa6-2a270c5f9a47" xlink:to="loc_mck_A510NotesDueJuly152033Member_635276a6-d9e2-4cc7-a678-e378a3fb14f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_A600NotesDueMarch12041Member_5299b9fd-a6d3-4da6-97d9-97a755a7698e" xlink:href="mck-20230630.xsd#mck_A600NotesDueMarch12041Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_77d4a144-2440-4f94-9fa6-2a270c5f9a47" xlink:to="loc_mck_A600NotesDueMarch12041Member_5299b9fd-a6d3-4da6-97d9-97a755a7698e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_A488NotesDueMarch152044Member_8327b0c1-0286-489d-998c-602adbdafbca" xlink:href="mck-20230630.xsd#mck_A488NotesDueMarch152044Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_77d4a144-2440-4f94-9fa6-2a270c5f9a47" xlink:to="loc_mck_A488NotesDueMarch152044Member_8327b0c1-0286-489d-998c-602adbdafbca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_A150EuroNotesDueNovember172025Member_cc8aa3d7-42eb-41c1-aa99-0b3634bc3280" xlink:href="mck-20230630.xsd#mck_A150EuroNotesDueNovember172025Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_77d4a144-2440-4f94-9fa6-2a270c5f9a47" xlink:to="loc_mck_A150EuroNotesDueNovember172025Member_cc8aa3d7-42eb-41c1-aa99-0b3634bc3280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_A163EuroNotesDueOctober302026Member_bd8bcd21-547c-4928-9757-96f92762768e" xlink:href="mck-20230630.xsd#mck_A163EuroNotesDueOctober302026Member"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_77d4a144-2440-4f94-9fa6-2a270c5f9a47" xlink:to="loc_mck_A163EuroNotesDueOctober302026Member_bd8bcd21-547c-4928-9757-96f92762768e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_A313SterlingNotesDueFebruary172029Member_a72a0a05-6e99-4714-bef2-51543e3b7ab5" xlink:href="mck-20230630.xsd#mck_A313SterlingNotesDueFebruary172029Member"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_77d4a144-2440-4f94-9fa6-2a270c5f9a47" xlink:to="loc_mck_A313SterlingNotesDueFebruary172029Member_a72a0a05-6e99-4714-bef2-51543e3b7ab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_c4e16622-c480-43ea-900e-ee55c3fff2fc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b3d9a3b1-2dff-4885-905a-d0eaaff304ac" xlink:to="loc_us-gaap_DebtInstrumentLineItems_c4e16622-c480-43ea-900e-ee55c3fff2fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_6ae0e79c-fc82-4599-9aa8-12b06af983ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c4e16622-c480-43ea-900e-ee55c3fff2fc" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_6ae0e79c-fc82-4599-9aa8-12b06af983ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_84b330c4-4667-49b6-8622-29385e923d66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c4e16622-c480-43ea-900e-ee55c3fff2fc" xlink:to="loc_us-gaap_LongTermDebt_84b330c4-4667-49b6-8622-29385e923d66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_db08a058-f9bc-4301-ad7c-eaeb752ddc85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c4e16622-c480-43ea-900e-ee55c3fff2fc" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_db08a058-f9bc-4301-ad7c-eaeb752ddc85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_fb46fb95-3550-4bfd-8abd-8db310fad653" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_c4e16622-c480-43ea-900e-ee55c3fff2fc" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligations_fb46fb95-3550-4bfd-8abd-8db310fad653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails" xlink:type="simple" xlink:href="mck-20230630.xsd#DebtandFinancingActivitiesLongTermDebtNarrativeDetails"/>
  <link:presentationLink xlink:role="http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_d6fe2049-4b1d-47d6-9611-8e4ef6fc5725" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_8e99d4e2-1040-4a7c-8bd2-38bff952d2af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d6fe2049-4b1d-47d6-9611-8e4ef6fc5725" xlink:to="loc_us-gaap_DebtInstrumentTable_8e99d4e2-1040-4a7c-8bd2-38bff952d2af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_3566750a-7dae-4c39-bd13-72171ad59504" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8e99d4e2-1040-4a7c-8bd2-38bff952d2af" xlink:to="loc_us-gaap_DebtInstrumentAxis_3566750a-7dae-4c39-bd13-72171ad59504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e8f93b0f-17cb-463d-9795-3848903ba1ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_3566750a-7dae-4c39-bd13-72171ad59504" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e8f93b0f-17cb-463d-9795-3848903ba1ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_A490NotesDueJuly152028Member_144dafa6-cb6d-4acd-85ed-653c94fbfc00" xlink:href="mck-20230630.xsd#mck_A490NotesDueJuly152028Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8f93b0f-17cb-463d-9795-3848903ba1ef" xlink:to="loc_mck_A490NotesDueJuly152028Member_144dafa6-cb6d-4acd-85ed-653c94fbfc00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_A510NotesDueJuly152033Member_2b95a02d-941c-4737-b0fb-e339f65bc3ec" xlink:href="mck-20230630.xsd#mck_A510NotesDueJuly152033Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8f93b0f-17cb-463d-9795-3848903ba1ef" xlink:to="loc_mck_A510NotesDueJuly152033Member_2b95a02d-941c-4737-b0fb-e339f65bc3ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_A380NotesDueMarch152024Member_dda1f53c-ecba-42ba-9a34-a592eedef59b" xlink:href="mck-20230630.xsd#mck_A380NotesDueMarch152024Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8f93b0f-17cb-463d-9795-3848903ba1ef" xlink:to="loc_mck_A380NotesDueMarch152024Member_dda1f53c-ecba-42ba-9a34-a592eedef59b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_7ec4b8e0-577f-43dc-bd89-bb05691a12f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8e99d4e2-1040-4a7c-8bd2-38bff952d2af" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_7ec4b8e0-577f-43dc-bd89-bb05691a12f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_35c56b40-8f64-47b8-ac76-a8e9fed0914f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7ec4b8e0-577f-43dc-bd89-bb05691a12f7" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_35c56b40-8f64-47b8-ac76-a8e9fed0914f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_fc630b49-fd89-4ccf-89ac-8f3d89081819" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_35c56b40-8f64-47b8-ac76-a8e9fed0914f" xlink:to="loc_us-gaap_LoansPayableMember_fc630b49-fd89-4ccf-89ac-8f3d89081819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6ecb0d3e-507a-488b-84a3-e2bd2f516ef4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8e99d4e2-1040-4a7c-8bd2-38bff952d2af" xlink:to="loc_srt_RangeAxis_6ecb0d3e-507a-488b-84a3-e2bd2f516ef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_863922e8-5a0e-42c2-8daf-67267d41572a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_6ecb0d3e-507a-488b-84a3-e2bd2f516ef4" xlink:to="loc_srt_RangeMember_863922e8-5a0e-42c2-8daf-67267d41572a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b4daf777-ab58-41f9-b1e8-6e8cd49c72e5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_863922e8-5a0e-42c2-8daf-67267d41572a" xlink:to="loc_srt_MinimumMember_b4daf777-ab58-41f9-b1e8-6e8cd49c72e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7ed1c94f-bb9e-492b-9275-dcd46f00adbc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_863922e8-5a0e-42c2-8daf-67267d41572a" xlink:to="loc_srt_MaximumMember_7ed1c94f-bb9e-492b-9275-dcd46f00adbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_76fd2f97-b7a9-4ec3-8512-a138320547b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8e99d4e2-1040-4a7c-8bd2-38bff952d2af" xlink:to="loc_us-gaap_DebtInstrumentLineItems_76fd2f97-b7a9-4ec3-8512-a138320547b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtAndCapitalLeaseObligations_293beec4-2639-4f9f-a24e-e3e410e3bd53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtAndCapitalLeaseObligations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_76fd2f97-b7a9-4ec3-8512-a138320547b2" xlink:to="loc_us-gaap_DebtAndCapitalLeaseObligations_293beec4-2639-4f9f-a24e-e3e410e3bd53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_8f1c3cc0-2439-4820-8ac1-f8c0d3d7b89f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_76fd2f97-b7a9-4ec3-8512-a138320547b2" xlink:to="loc_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent_8f1c3cc0-2439-4820-8ac1-f8c0d3d7b89f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8e6fbb93-d055-4def-9064-53ec0800eb17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_76fd2f97-b7a9-4ec3-8512-a138320547b2" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8e6fbb93-d055-4def-9064-53ec0800eb17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_51801195-c4a2-4dc3-b496-4dbbfe5a08f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_76fd2f97-b7a9-4ec3-8512-a138320547b2" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_51801195-c4a2-4dc3-b496-4dbbfe5a08f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_b30d951f-e1e0-495d-b8bb-d8838a2d214e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_76fd2f97-b7a9-4ec3-8512-a138320547b2" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_b30d951f-e1e0-495d-b8bb-d8838a2d214e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_DebtInstrumentRedemptionPeriod_59056adc-4b60-44ef-abcd-527bef052ec1" xlink:href="mck-20230630.xsd#mck_DebtInstrumentRedemptionPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_76fd2f97-b7a9-4ec3-8512-a138320547b2" xlink:to="loc_mck_DebtInstrumentRedemptionPeriod_59056adc-4b60-44ef-abcd-527bef052ec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_3e2bcd71-d8a6-4b59-96d3-0b81b24d8606" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_76fd2f97-b7a9-4ec3-8512-a138320547b2" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_3e2bcd71-d8a6-4b59-96d3-0b81b24d8606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_b0ad7cce-6487-433f-a2a0-21c6e34f0c4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_76fd2f97-b7a9-4ec3-8512-a138320547b2" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_b0ad7cce-6487-433f-a2a0-21c6e34f0c4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_e1578435-fe2e-4479-ac02-c565184df563" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_76fd2f97-b7a9-4ec3-8512-a138320547b2" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_e1578435-fe2e-4479-ac02-c565184df563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_PaymentsForPurchaseOfGovernmentObligationsForSatisfactionAndDischargeOfLongTermDebt_fe91a94a-723b-4355-9c6e-15ef589b6c6c" xlink:href="mck-20230630.xsd#mck_PaymentsForPurchaseOfGovernmentObligationsForSatisfactionAndDischargeOfLongTermDebt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_76fd2f97-b7a9-4ec3-8512-a138320547b2" xlink:to="loc_mck_PaymentsForPurchaseOfGovernmentObligationsForSatisfactionAndDischargeOfLongTermDebt_fe91a94a-723b-4355-9c6e-15ef589b6c6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_de08210e-5800-400e-840f-f307c7aa1e52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_76fd2f97-b7a9-4ec3-8512-a138320547b2" xlink:to="loc_us-gaap_LongTermDebt_de08210e-5800-400e-840f-f307c7aa1e52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a8726251-efc3-4218-a6ee-db090d32cd1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_76fd2f97-b7a9-4ec3-8512-a138320547b2" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_a8726251-efc3-4218-a6ee-db090d32cd1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/DebtandFinancingActivitiesRevolvingCreditFacilitiesNarrativeDetails" xlink:type="simple" xlink:href="mck-20230630.xsd#DebtandFinancingActivitiesRevolvingCreditFacilitiesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://mckesson123.com/role/DebtandFinancingActivitiesRevolvingCreditFacilitiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_94774f1c-0634-4857-92e3-06ac6f55cfae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_89ab3b53-34ea-4a09-a214-0a5ad69c7a46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_94774f1c-0634-4857-92e3-06ac6f55cfae" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_89ab3b53-34ea-4a09-a214-0a5ad69c7a46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_ef568a48-1ab2-41df-9f85-3363691eb53a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_89ab3b53-34ea-4a09-a214-0a5ad69c7a46" xlink:to="loc_us-gaap_DebtInstrumentAxis_ef568a48-1ab2-41df-9f85-3363691eb53a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_bc5ad2a0-42fb-4d5c-8156-9262e1457f71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_ef568a48-1ab2-41df-9f85-3363691eb53a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_bc5ad2a0-42fb-4d5c-8156-9262e1457f71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_SeniorUnsecuredCreditFacilityThe2022CreditFacilityMember_5ddedb44-cf0d-48a1-a194-1767ba25185f" xlink:href="mck-20230630.xsd#mck_SeniorUnsecuredCreditFacilityThe2022CreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bc5ad2a0-42fb-4d5c-8156-9262e1457f71" xlink:to="loc_mck_SeniorUnsecuredCreditFacilityThe2022CreditFacilityMember_5ddedb44-cf0d-48a1-a194-1767ba25185f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_SeniorUnsecuredCreditFacilityThe2022CreditFacilityCanadianDollarBritishPoundSterlingAndEurosSublimitMember_bbd30e37-0250-4d81-a6c1-40ab4e1c5f8d" xlink:href="mck-20230630.xsd#mck_SeniorUnsecuredCreditFacilityThe2022CreditFacilityCanadianDollarBritishPoundSterlingAndEurosSublimitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bc5ad2a0-42fb-4d5c-8156-9262e1457f71" xlink:to="loc_mck_SeniorUnsecuredCreditFacilityThe2022CreditFacilityCanadianDollarBritishPoundSterlingAndEurosSublimitMember_bbd30e37-0250-4d81-a6c1-40ab4e1c5f8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_SeniorUnsecuredCreditFacilitythe2020CreditFacilityMember_5d6b7c2a-c4d0-4905-ae2c-e322b36131ea" xlink:href="mck-20230630.xsd#mck_SeniorUnsecuredCreditFacilitythe2020CreditFacilityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bc5ad2a0-42fb-4d5c-8156-9262e1457f71" xlink:to="loc_mck_SeniorUnsecuredCreditFacilitythe2020CreditFacilityMember_5d6b7c2a-c4d0-4905-ae2c-e322b36131ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_SeniorUnsecuredCreditFacilitythe2020CreditFacilityCanadianDollarBritishPoundSterlingandEurosSublimitMember_24e5339d-68b6-48c0-ba95-be27f9fdd2e7" xlink:href="mck-20230630.xsd#mck_SeniorUnsecuredCreditFacilitythe2020CreditFacilityCanadianDollarBritishPoundSterlingandEurosSublimitMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bc5ad2a0-42fb-4d5c-8156-9262e1457f71" xlink:to="loc_mck_SeniorUnsecuredCreditFacilitythe2020CreditFacilityCanadianDollarBritishPoundSterlingandEurosSublimitMember_24e5339d-68b6-48c0-ba95-be27f9fdd2e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_6876ccb6-1df1-4d44-a413-bf7de0887c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_89ab3b53-34ea-4a09-a214-0a5ad69c7a46" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_6876ccb6-1df1-4d44-a413-bf7de0887c0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_73bd0cad-3ab2-42c4-8c79-ab1ed7b3d146" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_6876ccb6-1df1-4d44-a413-bf7de0887c0f" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_73bd0cad-3ab2-42c4-8c79-ab1ed7b3d146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnsecuredDebtMember_a6eb7107-fccc-444e-bb89-b17535c44c7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnsecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_73bd0cad-3ab2-42c4-8c79-ab1ed7b3d146" xlink:to="loc_us-gaap_UnsecuredDebtMember_a6eb7107-fccc-444e-bb89-b17535c44c7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_51dec11c-7586-4656-a81a-6f590157620d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_89ab3b53-34ea-4a09-a214-0a5ad69c7a46" xlink:to="loc_us-gaap_CreditFacilityAxis_51dec11c-7586-4656-a81a-6f590157620d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_7023f173-a22d-4ef1-bd97-93adcabaf15b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_51dec11c-7586-4656-a81a-6f590157620d" xlink:to="loc_us-gaap_CreditFacilityDomain_7023f173-a22d-4ef1-bd97-93adcabaf15b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_cba6945f-10d1-4e2b-99d5-cf69d41a6b4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_7023f173-a22d-4ef1-bd97-93adcabaf15b" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_cba6945f-10d1-4e2b-99d5-cf69d41a6b4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_3a74a39b-78bd-4ad3-8101-c370f3feda36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_89ab3b53-34ea-4a09-a214-0a5ad69c7a46" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_3a74a39b-78bd-4ad3-8101-c370f3feda36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_bc108798-70a8-4079-8380-6a55da5cd1a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_3a74a39b-78bd-4ad3-8101-c370f3feda36" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_bc108798-70a8-4079-8380-6a55da5cd1a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_e64be29c-7571-494c-9b6d-b5ca9d88e73a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_3a74a39b-78bd-4ad3-8101-c370f3feda36" xlink:to="loc_us-gaap_DebtInstrumentTerm_e64be29c-7571-494c-9b6d-b5ca9d88e73a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_bc10543e-358b-4a59-a7db-b648b984d793" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_3a74a39b-78bd-4ad3-8101-c370f3feda36" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_bc10543e-358b-4a59-a7db-b648b984d793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_8a81b365-ebee-4427-8cb6-40f7682ef6be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_3a74a39b-78bd-4ad3-8101-c370f3feda36" xlink:to="loc_us-gaap_LineOfCredit_8a81b365-ebee-4427-8cb6-40f7682ef6be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/DebtandFinancingActivitiesCommercialPaperNarrativeDetails" xlink:type="simple" xlink:href="mck-20230630.xsd#DebtandFinancingActivitiesCommercialPaperNarrativeDetails"/>
  <link:presentationLink xlink:role="http://mckesson123.com/role/DebtandFinancingActivitiesCommercialPaperNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_9a4d41ab-3db2-40f2-856e-103993c32aee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_ebb52a0a-59d0-4443-909e-3fb26d53bca8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_9a4d41ab-3db2-40f2-856e-103993c32aee" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_ebb52a0a-59d0-4443-909e-3fb26d53bca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_695e0e3d-d742-437f-bf3e-c5c9b1af36bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_ebb52a0a-59d0-4443-909e-3fb26d53bca8" xlink:to="loc_us-gaap_CreditFacilityAxis_695e0e3d-d742-437f-bf3e-c5c9b1af36bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_2b937294-e028-4b1f-9e0f-6af7ca6d4429" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_695e0e3d-d742-437f-bf3e-c5c9b1af36bb" xlink:to="loc_us-gaap_CreditFacilityDomain_2b937294-e028-4b1f-9e0f-6af7ca6d4429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_c95777b9-48ae-46e3-a639-eb5fdde35dc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_2b937294-e028-4b1f-9e0f-6af7ca6d4429" xlink:to="loc_us-gaap_CommercialPaperMember_c95777b9-48ae-46e3-a639-eb5fdde35dc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_abc06096-d1bc-4b5f-b373-6dcbf5e9b258" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_ebb52a0a-59d0-4443-909e-3fb26d53bca8" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_abc06096-d1bc-4b5f-b373-6dcbf5e9b258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_506c0ba3-dd04-4b95-9cab-7dc1ec64ce3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_abc06096-d1bc-4b5f-b373-6dcbf5e9b258" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_506c0ba3-dd04-4b95-9cab-7dc1ec64ce3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommercialPaper_5c8edfb5-8018-44fe-86b6-0a1200aa385e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommercialPaper"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_abc06096-d1bc-4b5f-b373-6dcbf5e9b258" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommercialPaper_5c8edfb5-8018-44fe-86b6-0a1200aa385e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfCommercialPaper_f7f229c4-4a95-47e3-a536-dd8e080ed92c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RepaymentsOfCommercialPaper"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_abc06096-d1bc-4b5f-b373-6dcbf5e9b258" xlink:to="loc_us-gaap_RepaymentsOfCommercialPaper_f7f229c4-4a95-47e3-a536-dd8e080ed92c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermCommercialPaperCurrent_281336f1-c959-4e4c-bb05-e278c612f587" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermCommercialPaperCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_abc06096-d1bc-4b5f-b373-6dcbf5e9b258" xlink:to="loc_us-gaap_LongTermCommercialPaperCurrent_281336f1-c959-4e4c-bb05-e278c612f587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/HedgingActivitiesNarrativeDetails" xlink:type="simple" xlink:href="mck-20230630.xsd#HedgingActivitiesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://mckesson123.com/role/HedgingActivitiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_7d4df9cd-43bc-45ec-8518-5b4aa19d2c45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_396474bc-833a-44ab-8ec6-e2d1031c31ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_7d4df9cd-43bc-45ec-8518-5b4aa19d2c45" xlink:to="loc_us-gaap_DerivativeTable_396474bc-833a-44ab-8ec6-e2d1031c31ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c303441e-cd92-4ff3-9085-05c74e551a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_396474bc-833a-44ab-8ec6-e2d1031c31ca" xlink:to="loc_us-gaap_DebtInstrumentAxis_c303441e-cd92-4ff3-9085-05c74e551a8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b09a1f3f-9f32-45d5-99ff-47d9d0fa7443" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_c303441e-cd92-4ff3-9085-05c74e551a8e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b09a1f3f-9f32-45d5-99ff-47d9d0fa7443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_49dd0ab1-19f6-4ac0-b988-476ba9e45976" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrencySwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b09a1f3f-9f32-45d5-99ff-47d9d0fa7443" xlink:to="loc_us-gaap_CurrencySwapMember_49dd0ab1-19f6-4ac0-b988-476ba9e45976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_BritishPoundSterlingDenominatedNotesMember_0d42bdbb-cc57-4476-a70a-61d4981955f7" xlink:href="mck-20230630.xsd#mck_BritishPoundSterlingDenominatedNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b09a1f3f-9f32-45d5-99ff-47d9d0fa7443" xlink:to="loc_mck_BritishPoundSterlingDenominatedNotesMember_0d42bdbb-cc57-4476-a70a-61d4981955f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_a870964d-6a25-48d2-8764-be0c1b31a99e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_396474bc-833a-44ab-8ec6-e2d1031c31ca" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_a870964d-6a25-48d2-8764-be0c1b31a99e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_13de538f-779d-447c-8901-cf020b9c3070" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_a870964d-6a25-48d2-8764-be0c1b31a99e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_13de538f-779d-447c-8901-cf020b9c3070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansPayableMember_9f80994f-5333-4c07-bd73-570fd1cbd007" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LoansPayableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_13de538f-779d-447c-8901-cf020b9c3070" xlink:to="loc_us-gaap_LoansPayableMember_9f80994f-5333-4c07-bd73-570fd1cbd007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_4331d30b-61d0-40b1-9b1c-f0fccf54fed6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_396474bc-833a-44ab-8ec6-e2d1031c31ca" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_4331d30b-61d0-40b1-9b1c-f0fccf54fed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_f1a680ee-5b93-4634-a5bd-c0f5203cce40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_4331d30b-61d0-40b1-9b1c-f0fccf54fed6" xlink:to="loc_us-gaap_HedgingRelationshipDomain_f1a680ee-5b93-4634-a5bd-c0f5203cce40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_b4ed7516-5083-4f68-874c-b094d4500854" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_f1a680ee-5b93-4634-a5bd-c0f5203cce40" xlink:to="loc_us-gaap_FairValueHedgingMember_b4ed7516-5083-4f68-874c-b094d4500854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_6c0558c4-2c9d-4f95-80ad-c899bfcc8027" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_f1a680ee-5b93-4634-a5bd-c0f5203cce40" xlink:to="loc_us-gaap_CashFlowHedgingMember_6c0558c4-2c9d-4f95-80ad-c899bfcc8027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_e8435ca3-8f20-43ef-96e4-09f4df6130cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_396474bc-833a-44ab-8ec6-e2d1031c31ca" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_e8435ca3-8f20-43ef-96e4-09f4df6130cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_0eed28b1-08c7-4e1b-9809-b80dbad15d06" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_e8435ca3-8f20-43ef-96e4-09f4df6130cc" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_0eed28b1-08c7-4e1b-9809-b80dbad15d06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_051b9724-3853-4101-bd67-88dce1493969" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_0eed28b1-08c7-4e1b-9809-b80dbad15d06" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_051b9724-3853-4101-bd67-88dce1493969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_566dfc7f-713b-4e08-80b9-b05c697339c7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_396474bc-833a-44ab-8ec6-e2d1031c31ca" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_566dfc7f-713b-4e08-80b9-b05c697339c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0965cad8-94eb-4be7-85c7-66736e4b6a20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_566dfc7f-713b-4e08-80b9-b05c697339c7" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0965cad8-94eb-4be7-85c7-66736e4b6a20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_UKBusinessesDisposalGroupMember_3ce4d957-926c-43a5-9859-c06dc324ec3c" xlink:href="mck-20230630.xsd#mck_UKBusinessesDisposalGroupMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0965cad8-94eb-4be7-85c7-66736e4b6a20" xlink:to="loc_mck_UKBusinessesDisposalGroupMember_3ce4d957-926c-43a5-9859-c06dc324ec3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_fd50dc08-d967-47e5-8650-80fc546fec6c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_396474bc-833a-44ab-8ec6-e2d1031c31ca" xlink:to="loc_srt_CurrencyAxis_fd50dc08-d967-47e5-8650-80fc546fec6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_151c4816-c51b-4b72-a3ec-c95f305b0ddc" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_fd50dc08-d967-47e5-8650-80fc546fec6c" xlink:to="loc_currency_AllCurrenciesDomain_151c4816-c51b-4b72-a3ec-c95f305b0ddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_52b79367-b64c-460f-b174-867d32214e99" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_EUR"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_151c4816-c51b-4b72-a3ec-c95f305b0ddc" xlink:to="loc_currency_EUR_52b79367-b64c-460f-b174-867d32214e99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_22800719-c4da-4036-b207-fcef2c026e7e" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_USD"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_151c4816-c51b-4b72-a3ec-c95f305b0ddc" xlink:to="loc_currency_USD_22800719-c4da-4036-b207-fcef2c026e7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_79be6b1b-f82a-477e-8bc8-146df16034eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_396474bc-833a-44ab-8ec6-e2d1031c31ca" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_79be6b1b-f82a-477e-8bc8-146df16034eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_4e80a270-fe67-47fb-a664-6ca8ddcb0f8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_79be6b1b-f82a-477e-8bc8-146df16034eb" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_4e80a270-fe67-47fb-a664-6ca8ddcb0f8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_FixedInterestRateSwapMember_cf23d721-a5fc-415a-89cf-2a162d3255e1" xlink:href="mck-20230630.xsd#mck_FixedInterestRateSwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4e80a270-fe67-47fb-a664-6ca8ddcb0f8d" xlink:to="loc_mck_FixedInterestRateSwapMember_cf23d721-a5fc-415a-89cf-2a162d3255e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_184c10ec-e740-4c4d-8847-8c3fd674919b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_4e80a270-fe67-47fb-a664-6ca8ddcb0f8d" xlink:to="loc_us-gaap_InterestRateSwapMember_184c10ec-e740-4c4d-8847-8c3fd674919b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_9e79438b-7d31-483f-b70b-da262a66ee67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_396474bc-833a-44ab-8ec6-e2d1031c31ca" xlink:to="loc_us-gaap_HedgingDesignationAxis_9e79438b-7d31-483f-b70b-da262a66ee67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_9e06ef6a-e8b5-430f-98aa-b318fe4bdc29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_9e79438b-7d31-483f-b70b-da262a66ee67" xlink:to="loc_us-gaap_HedgingDesignationDomain_9e06ef6a-e8b5-430f-98aa-b318fe4bdc29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_a6b2e7e5-ae6d-44a4-a3a9-237afc13297c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_9e06ef6a-e8b5-430f-98aa-b318fe4bdc29" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_a6b2e7e5-ae6d-44a4-a3a9-237afc13297c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_0b5cac34-9465-489d-a683-3072d0d50227" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_396474bc-833a-44ab-8ec6-e2d1031c31ca" xlink:to="loc_us-gaap_DerivativeLineItems_0b5cac34-9465-489d-a683-3072d0d50227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_DerivativeNotionalAmountEnteredIntoDuringPeriod_d5b72402-4212-4b17-954b-9c70001930ca" xlink:href="mck-20230630.xsd#mck_DerivativeNotionalAmountEnteredIntoDuringPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_0b5cac34-9465-489d-a683-3072d0d50227" xlink:to="loc_mck_DerivativeNotionalAmountEnteredIntoDuringPeriod_d5b72402-4212-4b17-954b-9c70001930ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_c1523918-d535-47cf-bd13-ce6edef2fc3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_0b5cac34-9465-489d-a683-3072d0d50227" xlink:to="loc_us-gaap_DerivativeNotionalAmount_c1523918-d535-47cf-bd13-ce6edef2fc3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_b981eba5-9d50-4bb7-af93-4d0ebb81b488" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_0b5cac34-9465-489d-a683-3072d0d50227" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent_b981eba5-9d50-4bb7-af93-4d0ebb81b488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_056d3824-807a-4cd5-b1a8-2f6c6ec68d00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_0b5cac34-9465-489d-a683-3072d0d50227" xlink:to="loc_us-gaap_LongTermDebt_056d3824-807a-4cd5-b1a8-2f6c6ec68d00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_DerivativeTerminationProceedsAmortizationPeriod_a31f9be6-702c-421c-a289-d042333a52dc" xlink:href="mck-20230630.xsd#mck_DerivativeTerminationProceedsAmortizationPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_0b5cac34-9465-489d-a683-3072d0d50227" xlink:to="loc_mck_DerivativeTerminationProceedsAmortizationPeriod_a31f9be6-702c-421c-a289-d042333a52dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/HedgingActivitiesSummaryofForeignCurrencyGainsandLossesfromNonDerivativeInstrumentsDetails" xlink:type="simple" xlink:href="mck-20230630.xsd#HedgingActivitiesSummaryofForeignCurrencyGainsandLossesfromNonDerivativeInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://mckesson123.com/role/HedgingActivitiesSummaryofForeignCurrencyGainsandLossesfromNonDerivativeInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_733e232a-6bad-4bea-8c42-06440186233f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_2993e626-5b6e-4297-9643-a7b386eedc7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_733e232a-6bad-4bea-8c42-06440186233f" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_2993e626-5b6e-4297-9643-a7b386eedc7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_b72f2399-c01b-48d9-91c2-34a946babe08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_2993e626-5b6e-4297-9643-a7b386eedc7f" xlink:to="loc_us-gaap_HedgingDesignationAxis_b72f2399-c01b-48d9-91c2-34a946babe08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_03ed769e-a9b2-478e-8bd7-8a01a5e4fd00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_b72f2399-c01b-48d9-91c2-34a946babe08" xlink:to="loc_us-gaap_HedgingDesignationDomain_03ed769e-a9b2-478e-8bd7-8a01a5e4fd00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_4d8e3239-e732-4b1f-bf9e-697641c18cbd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_03ed769e-a9b2-478e-8bd7-8a01a5e4fd00" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_4d8e3239-e732-4b1f-bf9e-697641c18cbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_d2f35f33-62d7-4d38-b621-25c3d3e160f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_2993e626-5b6e-4297-9643-a7b386eedc7f" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_d2f35f33-62d7-4d38-b621-25c3d3e160f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_77e06278-daf8-4c7c-bfe4-2db80f59e7e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_d2f35f33-62d7-4d38-b621-25c3d3e160f0" xlink:to="loc_us-gaap_HedgingRelationshipDomain_77e06278-daf8-4c7c-bfe4-2db80f59e7e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_b6ef70cf-be01-4be9-8f83-d737d0cbaafc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_77e06278-daf8-4c7c-bfe4-2db80f59e7e4" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_b6ef70cf-be01-4be9-8f83-d737d0cbaafc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_d75eff91-9ed2-4ebd-858d-fe20f931db38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_2993e626-5b6e-4297-9643-a7b386eedc7f" xlink:to="loc_us-gaap_DebtInstrumentAxis_d75eff91-9ed2-4ebd-858d-fe20f931db38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_0bdc4492-2a8c-4def-93b3-793a683aba69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_d75eff91-9ed2-4ebd-858d-fe20f931db38" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_0bdc4492-2a8c-4def-93b3-793a683aba69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_EuroDenominatedNotesMember_4319c46b-1204-478a-ad94-e7b342d3cd08" xlink:href="mck-20230630.xsd#mck_EuroDenominatedNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_0bdc4492-2a8c-4def-93b3-793a683aba69" xlink:to="loc_mck_EuroDenominatedNotesMember_4319c46b-1204-478a-ad94-e7b342d3cd08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_4f22f8ac-2b45-4185-abc6-b4311aa5483d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_2993e626-5b6e-4297-9643-a7b386eedc7f" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_4f22f8ac-2b45-4185-abc6-b4311aa5483d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_082b320e-05c8-429c-b150-c16ab902e825" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_4f22f8ac-2b45-4185-abc6-b4311aa5483d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_082b320e-05c8-429c-b150-c16ab902e825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails" xlink:type="simple" xlink:href="mck-20230630.xsd#HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails"/>
  <link:presentationLink xlink:role="http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_2673487b-8888-4a2a-bfb1-27ec22b7eea1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_2c3561c2-5cbd-473b-aa6c-a991ff33dc25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_2673487b-8888-4a2a-bfb1-27ec22b7eea1" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_2c3561c2-5cbd-473b-aa6c-a991ff33dc25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_07dd9ad4-4221-41ea-995a-4520b203283a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_2c3561c2-5cbd-473b-aa6c-a991ff33dc25" xlink:to="loc_us-gaap_HedgingDesignationAxis_07dd9ad4-4221-41ea-995a-4520b203283a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_d9b6781a-6a86-4574-bc9c-381e8bc79e08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_07dd9ad4-4221-41ea-995a-4520b203283a" xlink:to="loc_us-gaap_HedgingDesignationDomain_d9b6781a-6a86-4574-bc9c-381e8bc79e08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_1e030369-1e81-4b4e-802a-2c38e66ba6a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_d9b6781a-6a86-4574-bc9c-381e8bc79e08" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_1e030369-1e81-4b4e-802a-2c38e66ba6a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_ccc32cbc-379e-4d6a-bef3-e36814cd65df" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_2c3561c2-5cbd-473b-aa6c-a991ff33dc25" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_ccc32cbc-379e-4d6a-bef3-e36814cd65df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_0b1b3b43-bf75-4600-9cf3-967afb625e90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_ccc32cbc-379e-4d6a-bef3-e36814cd65df" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_0b1b3b43-bf75-4600-9cf3-967afb625e90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_e026e59e-b529-4f0f-8b4c-d2a8d1b47c73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrencySwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0b1b3b43-bf75-4600-9cf3-967afb625e90" xlink:to="loc_us-gaap_CurrencySwapMember_e026e59e-b529-4f0f-8b4c-d2a8d1b47c73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_fbd11106-c0ce-4408-8922-9a663540fd27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0b1b3b43-bf75-4600-9cf3-967afb625e90" xlink:to="loc_us-gaap_InterestRateSwapMember_fbd11106-c0ce-4408-8922-9a663540fd27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_FixedInterestRateSwapMember_06c4fac8-508c-49f8-9c89-9b2dfdcdd3db" xlink:href="mck-20230630.xsd#mck_FixedInterestRateSwapMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0b1b3b43-bf75-4600-9cf3-967afb625e90" xlink:to="loc_mck_FixedInterestRateSwapMember_06c4fac8-508c-49f8-9c89-9b2dfdcdd3db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_78b1895d-ba59-4b85-ab0b-3a95a214a1e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_2c3561c2-5cbd-473b-aa6c-a991ff33dc25" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_78b1895d-ba59-4b85-ab0b-3a95a214a1e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_39f36f51-60a4-47b3-a8c7-60fae2cdcf7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_78b1895d-ba59-4b85-ab0b-3a95a214a1e8" xlink:to="loc_us-gaap_HedgingRelationshipDomain_39f36f51-60a4-47b3-a8c7-60fae2cdcf7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_66c826d8-e817-4895-b6bb-46233ea7c732" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_39f36f51-60a4-47b3-a8c7-60fae2cdcf7e" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_66c826d8-e817-4895-b6bb-46233ea7c732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_9a57377a-1741-4266-a5ca-8e2516bb38e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueHedgingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_39f36f51-60a4-47b3-a8c7-60fae2cdcf7e" xlink:to="loc_us-gaap_FairValueHedgingMember_9a57377a-1741-4266-a5ca-8e2516bb38e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_0db9d0c9-881b-47d9-8c7d-e9df7316ebdc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_39f36f51-60a4-47b3-a8c7-60fae2cdcf7e" xlink:to="loc_us-gaap_CashFlowHedgingMember_0db9d0c9-881b-47d9-8c7d-e9df7316ebdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_5d846f84-6fb8-4229-9d5e-b919077314d2" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_2c3561c2-5cbd-473b-aa6c-a991ff33dc25" xlink:to="loc_srt_CurrencyAxis_5d846f84-6fb8-4229-9d5e-b919077314d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_29b741ca-4cbd-4eaf-9466-0b464f914135" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_5d846f84-6fb8-4229-9d5e-b919077314d2" xlink:to="loc_currency_AllCurrenciesDomain_29b741ca-4cbd-4eaf-9466-0b464f914135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CAD_05cb71cd-1454-4761-962b-739bbc0b7b29" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_CAD"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_29b741ca-4cbd-4eaf-9466-0b464f914135" xlink:to="loc_currency_CAD_05cb71cd-1454-4761-962b-739bbc0b7b29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_GBP_fcd8fda4-0189-4307-8668-e25073610e8e" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_GBP"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_29b741ca-4cbd-4eaf-9466-0b464f914135" xlink:to="loc_currency_GBP_fcd8fda4-0189-4307-8668-e25073610e8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_732c3832-3534-4491-823f-f0aec9a3887b" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_EUR"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_29b741ca-4cbd-4eaf-9466-0b464f914135" xlink:to="loc_currency_EUR_732c3832-3534-4491-823f-f0aec9a3887b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_USD_acd9c943-2b29-400b-851c-c38fb265126a" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_USD"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_29b741ca-4cbd-4eaf-9466-0b464f914135" xlink:to="loc_currency_USD_acd9c943-2b29-400b-851c-c38fb265126a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_7dd4fe13-87dd-4238-94bb-62da7a2233cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_2c3561c2-5cbd-473b-aa6c-a991ff33dc25" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_7dd4fe13-87dd-4238-94bb-62da7a2233cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_83a2461f-0132-48b0-bc5b-d4e360ea3567" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_7dd4fe13-87dd-4238-94bb-62da7a2233cf" xlink:to="loc_us-gaap_DerivativeNotionalAmount_83a2461f-0132-48b0-bc5b-d4e360ea3567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/HedgingActivitiesSummaryofDerivativeInstrumentsGainLossDetails" xlink:type="simple" xlink:href="mck-20230630.xsd#HedgingActivitiesSummaryofDerivativeInstrumentsGainLossDetails"/>
  <link:presentationLink xlink:role="http://mckesson123.com/role/HedgingActivitiesSummaryofDerivativeInstrumentsGainLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_eae57609-a4bb-487b-be45-b801eabaeb03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_772acca8-f652-43e6-9831-f591861c3a55" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_eae57609-a4bb-487b-be45-b801eabaeb03" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_772acca8-f652-43e6-9831-f591861c3a55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_ba83a274-f65f-4e89-865b-613bc4ac3c66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_772acca8-f652-43e6-9831-f591861c3a55" xlink:to="loc_us-gaap_HedgingDesignationAxis_ba83a274-f65f-4e89-865b-613bc4ac3c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_4b38a29d-1b03-451c-907a-4b191f50d896" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_ba83a274-f65f-4e89-865b-613bc4ac3c66" xlink:to="loc_us-gaap_HedgingDesignationDomain_4b38a29d-1b03-451c-907a-4b191f50d896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_2689efd2-bac1-4ae7-b5f8-c60ea2e5e0b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_4b38a29d-1b03-451c-907a-4b191f50d896" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_2689efd2-bac1-4ae7-b5f8-c60ea2e5e0b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_1fca947b-bfdd-4393-8c49-1c42a34f8fbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_772acca8-f652-43e6-9831-f591861c3a55" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_1fca947b-bfdd-4393-8c49-1c42a34f8fbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_c42fb77a-a67a-40f0-bc4f-199fce9ca145" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_1fca947b-bfdd-4393-8c49-1c42a34f8fbe" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_c42fb77a-a67a-40f0-bc4f-199fce9ca145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_a3a03a86-92b5-4f7b-a82d-9151bad2f7a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrencySwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c42fb77a-a67a-40f0-bc4f-199fce9ca145" xlink:to="loc_us-gaap_CurrencySwapMember_a3a03a86-92b5-4f7b-a82d-9151bad2f7a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_FixedInterestRateSwapMember_37f0d97a-5182-4f2a-91bb-f65338cf34c6" xlink:href="mck-20230630.xsd#mck_FixedInterestRateSwapMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c42fb77a-a67a-40f0-bc4f-199fce9ca145" xlink:to="loc_mck_FixedInterestRateSwapMember_37f0d97a-5182-4f2a-91bb-f65338cf34c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_258a87a4-7d5f-4e5b-965a-fb6e24604343" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_772acca8-f652-43e6-9831-f591861c3a55" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_258a87a4-7d5f-4e5b-965a-fb6e24604343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_af38c3fa-a193-4207-a9fa-b88d06e5709c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_258a87a4-7d5f-4e5b-965a-fb6e24604343" xlink:to="loc_us-gaap_HedgingRelationshipDomain_af38c3fa-a193-4207-a9fa-b88d06e5709c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_c37759b6-95b0-4545-9fc5-e0c803d04606" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_af38c3fa-a193-4207-a9fa-b88d06e5709c" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_c37759b6-95b0-4545-9fc5-e0c803d04606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_3168858d-a901-4c34-99b8-7d089a344608" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_af38c3fa-a193-4207-a9fa-b88d06e5709c" xlink:to="loc_us-gaap_CashFlowHedgingMember_3168858d-a901-4c34-99b8-7d089a344608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_6135cf7b-ba51-4b9c-a711-fefc980f59c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_772acca8-f652-43e6-9831-f591861c3a55" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_6135cf7b-ba51-4b9c-a711-fefc980f59c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_1ece5e75-fd47-4e79-9d55-3f8a9b261e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_6135cf7b-ba51-4b9c-a711-fefc980f59c0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_1ece5e75-fd47-4e79-9d55-3f8a9b261e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_8d6ae25c-1ef7-4c64-b2d6-684511aabbbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_6135cf7b-ba51-4b9c-a711-fefc980f59c0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_8d6ae25c-1ef7-4c64-b2d6-684511aabbbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/HedgingActivitiesScheduleofFairValueofDerivativesDetails" xlink:type="simple" xlink:href="mck-20230630.xsd#HedgingActivitiesScheduleofFairValueofDerivativesDetails"/>
  <link:presentationLink xlink:role="http://mckesson123.com/role/HedgingActivitiesScheduleofFairValueofDerivativesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_bcf88a02-8e93-4e05-b200-45d7d00ac253" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_2d9cb661-88ea-4ad7-b4e7-fe3279f4cb47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_bcf88a02-8e93-4e05-b200-45d7d00ac253" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_2d9cb661-88ea-4ad7-b4e7-fe3279f4cb47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_11e96eb3-3d7d-4afb-adda-2820524c8cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_2d9cb661-88ea-4ad7-b4e7-fe3279f4cb47" xlink:to="loc_us-gaap_HedgingDesignationAxis_11e96eb3-3d7d-4afb-adda-2820524c8cd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_7aaf84a3-7922-4690-acbc-3c539bae5e4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_11e96eb3-3d7d-4afb-adda-2820524c8cd4" xlink:to="loc_us-gaap_HedgingDesignationDomain_7aaf84a3-7922-4690-acbc-3c539bae5e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_e2b5f91d-4aba-449c-a03e-2510f4e1be86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_7aaf84a3-7922-4690-acbc-3c539bae5e4e" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_e2b5f91d-4aba-449c-a03e-2510f4e1be86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_fbb543fd-bd11-4173-9982-a8005d1d3c5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_2d9cb661-88ea-4ad7-b4e7-fe3279f4cb47" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_fbb543fd-bd11-4173-9982-a8005d1d3c5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_a169fd4f-6352-42a5-a1c9-f3692f36f71b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_fbb543fd-bd11-4173-9982-a8005d1d3c5f" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_a169fd4f-6352-42a5-a1c9-f3692f36f71b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_1396b44d-33c2-4367-bebd-23c75d27300b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrencySwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a169fd4f-6352-42a5-a1c9-f3692f36f71b" xlink:to="loc_us-gaap_CurrencySwapMember_1396b44d-33c2-4367-bebd-23c75d27300b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_5f8986ec-bba3-4b09-9f16-e827d536caf7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a169fd4f-6352-42a5-a1c9-f3692f36f71b" xlink:to="loc_us-gaap_InterestRateSwapMember_5f8986ec-bba3-4b09-9f16-e827d536caf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_a7a916d4-a5bc-4a73-8148-f691a27530d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_2d9cb661-88ea-4ad7-b4e7-fe3279f4cb47" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_a7a916d4-a5bc-4a73-8148-f691a27530d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_05e56937-9e66-4c25-a411-bfd5683f7fef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_a7a916d4-a5bc-4a73-8148-f691a27530d1" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_05e56937-9e66-4c25-a411-bfd5683f7fef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_CurrentAssetLiabilityMember_d4466767-97d5-4f13-8526-fe87df7cad47" xlink:href="mck-20230630.xsd#mck_CurrentAssetLiabilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_05e56937-9e66-4c25-a411-bfd5683f7fef" xlink:to="loc_mck_CurrentAssetLiabilityMember_d4466767-97d5-4f13-8526-fe87df7cad47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_OtherNonCurrentAssetsAndLiabilitiesMember_c540bbbe-58ea-4305-be54-12e35d0c3aba" xlink:href="mck-20230630.xsd#mck_OtherNonCurrentAssetsAndLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_05e56937-9e66-4c25-a411-bfd5683f7fef" xlink:to="loc_mck_OtherNonCurrentAssetsAndLiabilitiesMember_c540bbbe-58ea-4305-be54-12e35d0c3aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_257f796b-0fe3-41a4-b760-cec7f23f15e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_2d9cb661-88ea-4ad7-b4e7-fe3279f4cb47" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_257f796b-0fe3-41a4-b760-cec7f23f15e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_3fc34220-29f0-4f61-9d96-fc72d0e32459" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_257f796b-0fe3-41a4-b760-cec7f23f15e4" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_3fc34220-29f0-4f61-9d96-fc72d0e32459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_83c740c8-77f8-4dc7-b74c-af71bd8e3028" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_257f796b-0fe3-41a4-b760-cec7f23f15e4" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_83c740c8-77f8-4dc7-b74c-af71bd8e3028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetNotionalAmount_d82acad0-1dc5-46fe-97ed-f93b3093d6fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeAssetNotionalAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_257f796b-0fe3-41a4-b760-cec7f23f15e4" xlink:to="loc_us-gaap_DerivativeAssetNotionalAmount_d82acad0-1dc5-46fe-97ed-f93b3093d6fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityNotionalAmount_0076d011-49c6-4446-b036-b5fcfc46ef0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeLiabilityNotionalAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_257f796b-0fe3-41a4-b760-cec7f23f15e4" xlink:to="loc_us-gaap_DerivativeLiabilityNotionalAmount_0076d011-49c6-4446-b036-b5fcfc46ef0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="mck-20230630.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://mckesson123.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9a81b151-dee8-4225-95cd-8afaef2237d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b4eba24b-9895-4756-86e4-61ead69af756" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9a81b151-dee8-4225-95cd-8afaef2237d6" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b4eba24b-9895-4756-86e4-61ead69af756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_37824473-8221-4c87-b10c-adfaa37e973d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b4eba24b-9895-4756-86e4-61ead69af756" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_37824473-8221-4c87-b10c-adfaa37e973d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7a344130-380c-4a20-af29-6e4c9b6ea9bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_37824473-8221-4c87-b10c-adfaa37e973d" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7a344130-380c-4a20-af29-6e4c9b6ea9bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_8d38e70c-7b5b-4942-b99d-dc0176239af2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_7a344130-380c-4a20-af29-6e4c9b6ea9bb" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_8d38e70c-7b5b-4942-b99d-dc0176239af2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_edab4d79-e258-4cdf-825d-70e8f16f640b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b4eba24b-9895-4756-86e4-61ead69af756" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_edab4d79-e258-4cdf-825d-70e8f16f640b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c8f98892-66b5-4cb6-bd49-d2c2491d2a08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_edab4d79-e258-4cdf-825d-70e8f16f640b" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c8f98892-66b5-4cb6-bd49-d2c2491d2a08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_84693f1a-bd9a-48c1-93b1-d905288b52e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_c8f98892-66b5-4cb6-bd49-d2c2491d2a08" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_84693f1a-bd9a-48c1-93b1-d905288b52e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4884b158-e3a9-42e2-901b-39f13da509a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b4eba24b-9895-4756-86e4-61ead69af756" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4884b158-e3a9-42e2-901b-39f13da509a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsAtCarryingValue_94813740-4883-4ad3-b035-904c95190549" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4884b158-e3a9-42e2-901b-39f13da509a4" xlink:to="loc_us-gaap_MoneyMarketFundsAtCarryingValue_94813740-4883-4ad3-b035-904c95190549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_3c3794e4-dee2-4b15-891f-9878203b3561" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4884b158-e3a9-42e2-901b-39f13da509a4" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_3c3794e4-dee2-4b15-891f-9878203b3561" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/FairValueMeasurementsScheduleofLongTermDebtisRecordedatAmortizedCostDetails" xlink:type="simple" xlink:href="mck-20230630.xsd#FairValueMeasurementsScheduleofLongTermDebtisRecordedatAmortizedCostDetails"/>
  <link:presentationLink xlink:role="http://mckesson123.com/role/FairValueMeasurementsScheduleofLongTermDebtisRecordedatAmortizedCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2a39ab21-8e76-406d-9791-0cc6730482e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e39e6d13-50cc-472d-bdce-b48b8c910f6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2a39ab21-8e76-406d-9791-0cc6730482e6" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e39e6d13-50cc-472d-bdce-b48b8c910f6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0725d644-b6ec-40a4-b5f3-bb8596f4011a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e39e6d13-50cc-472d-bdce-b48b8c910f6f" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0725d644-b6ec-40a4-b5f3-bb8596f4011a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_9d9782da-89d0-4736-8d11-0988004d8f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_0725d644-b6ec-40a4-b5f3-bb8596f4011a" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_9d9782da-89d0-4736-8d11-0988004d8f6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_f38c616b-9b95-4449-afc5-e2cbc451290f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_9d9782da-89d0-4736-8d11-0988004d8f6e" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_f38c616b-9b95-4449-afc5-e2cbc451290f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cb49853f-a153-4c85-99a8-466d67cf9032" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e39e6d13-50cc-472d-bdce-b48b8c910f6f" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cb49853f-a153-4c85-99a8-466d67cf9032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5d003734-0e9e-41a3-b199-25c8fae7ac7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_cb49853f-a153-4c85-99a8-466d67cf9032" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5d003734-0e9e-41a3-b199-25c8fae7ac7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_af2b31ad-4a5d-4d2f-9b78-7e2c3d7bdfdd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5d003734-0e9e-41a3-b199-25c8fae7ac7a" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_af2b31ad-4a5d-4d2f-9b78-7e2c3d7bdfdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_180d81c7-f9e8-444d-8db9-d8a0e025660f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_e39e6d13-50cc-472d-bdce-b48b8c910f6f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_180d81c7-f9e8-444d-8db9-d8a0e025660f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_f872d1ae-4eb5-4a7c-bd65-e6cbaeb7f870" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_180d81c7-f9e8-444d-8db9-d8a0e025660f" xlink:to="loc_us-gaap_LongTermDebt_f872d1ae-4eb5-4a7c-bd65-e6cbaeb7f870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_23c02c83-8c36-422b-a1a6-fb0712624c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_180d81c7-f9e8-444d-8db9-d8a0e025660f" xlink:to="loc_us-gaap_DebtInstrumentFairValue_23c02c83-8c36-422b-a1a6-fb0712624c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails" xlink:type="simple" xlink:href="mck-20230630.xsd#CommitmentsandContingentLiabilitiesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_68675b3b-e4b2-41f9-8905-65e8f81bf702" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_a33f83c2-689d-4d66-884f-5244ce9176fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_68675b3b-e4b2-41f9-8905-65e8f81bf702" xlink:to="loc_us-gaap_LossContingenciesTable_a33f83c2-689d-4d66-884f-5244ce9176fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_3348f3a2-351d-44d7-8843-055f98c7f993" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_a33f83c2-689d-4d66-884f-5244ce9176fb" xlink:to="loc_srt_LitigationCaseAxis_3348f3a2-351d-44d7-8843-055f98c7f993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_68df0dbc-d94e-4180-b137-caf8950223b5" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_3348f3a2-351d-44d7-8843-055f98c7f993" xlink:to="loc_srt_LitigationCaseTypeDomain_68df0dbc-d94e-4180-b137-caf8950223b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_NationalPrescriptionOpiateLitigationMember_034b3ff7-2f27-47b6-8311-91e2ec84122d" xlink:href="mck-20230630.xsd#mck_NationalPrescriptionOpiateLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_68df0dbc-d94e-4180-b137-caf8950223b5" xlink:to="loc_mck_NationalPrescriptionOpiateLitigationMember_034b3ff7-2f27-47b6-8311-91e2ec84122d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_EvanstonPolicePensionFundVMcKessonCorporationMember_1b54e41a-c937-4c95-bcf2-2062231c823b" xlink:href="mck-20230630.xsd#mck_EvanstonPolicePensionFundVMcKessonCorporationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_68df0dbc-d94e-4180-b137-caf8950223b5" xlink:to="loc_mck_EvanstonPolicePensionFundVMcKessonCorporationMember_1b54e41a-c937-4c95-bcf2-2062231c823b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_UnitedStatesExRelHartVMcKessonCorporationEtAl15CV00903RAMember_d60354cc-73f6-49c3-8c4a-9b19a86f7671" xlink:href="mck-20230630.xsd#mck_UnitedStatesExRelHartVMcKessonCorporationEtAl15CV00903RAMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_68df0dbc-d94e-4180-b137-caf8950223b5" xlink:to="loc_mck_UnitedStatesExRelHartVMcKessonCorporationEtAl15CV00903RAMember_d60354cc-73f6-49c3-8c4a-9b19a86f7671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_8f3b1b7a-0652-4f07-9bc6-c21155fe135c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_a33f83c2-689d-4d66-884f-5244ce9176fb" xlink:to="loc_us-gaap_LitigationStatusAxis_8f3b1b7a-0652-4f07-9bc6-c21155fe135c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_24fc43ff-4a29-49bc-a93a-9fcdbede8517" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_8f3b1b7a-0652-4f07-9bc6-c21155fe135c" xlink:to="loc_us-gaap_LitigationStatusDomain_24fc43ff-4a29-49bc-a93a-9fcdbede8517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_431cda4e-8761-4abc-a894-d9f6333bb2d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SettledLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_24fc43ff-4a29-49bc-a93a-9fcdbede8517" xlink:to="loc_us-gaap_SettledLitigationMember_431cda4e-8761-4abc-a894-d9f6333bb2d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_50b786de-08c3-4985-805b-f9eae4c5c13f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_a33f83c2-689d-4d66-884f-5244ce9176fb" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_50b786de-08c3-4985-805b-f9eae4c5c13f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_13aefa4f-58fd-4fe7-a7ab-e2cb5f897457" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_50b786de-08c3-4985-805b-f9eae4c5c13f" xlink:to="loc_us-gaap_LossContingencyNatureDomain_13aefa4f-58fd-4fe7-a7ab-e2cb5f897457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_NationalPrescriptionOpiateLitigationMember_1419e56d-5030-47dc-8080-8fe07769561a" xlink:href="mck-20230630.xsd#mck_NationalPrescriptionOpiateLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_13aefa4f-58fd-4fe7-a7ab-e2cb5f897457" xlink:to="loc_mck_NationalPrescriptionOpiateLitigationMember_1419e56d-5030-47dc-8080-8fe07769561a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_6f519cbb-2447-4b43-a5ad-d880088c0784" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_a33f83c2-689d-4d66-884f-5244ce9176fb" xlink:to="loc_dei_LegalEntityAxis_6f519cbb-2447-4b43-a5ad-d880088c0784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_76272841-7c7d-410f-9ca0-71b495f42996" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_6f519cbb-2447-4b43-a5ad-d880088c0784" xlink:to="loc_dei_EntityDomain_76272841-7c7d-410f-9ca0-71b495f42996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_ThreeLargestUSPharmaceuticalDistributorsMember_236a40bc-f33c-4f9b-8c7f-71d18fc2116c" xlink:href="mck-20230630.xsd#mck_ThreeLargestUSPharmaceuticalDistributorsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_76272841-7c7d-410f-9ca0-71b495f42996" xlink:to="loc_mck_ThreeLargestUSPharmaceuticalDistributorsMember_236a40bc-f33c-4f9b-8c7f-71d18fc2116c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_ThreeNationalPharmaceuticalDistributorsMember_5de5b434-843a-43b0-a228-9ce5e729ef0c" xlink:href="mck-20230630.xsd#mck_ThreeNationalPharmaceuticalDistributorsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_76272841-7c7d-410f-9ca0-71b495f42996" xlink:to="loc_mck_ThreeNationalPharmaceuticalDistributorsMember_5de5b434-843a-43b0-a228-9ce5e729ef0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_68306fed-a653-42a5-90e5-b89824d61395" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_a33f83c2-689d-4d66-884f-5244ce9176fb" xlink:to="loc_srt_CounterpartyNameAxis_68306fed-a653-42a5-90e5-b89824d61395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6e4804be-f8e1-4eca-9f82-be4897e61a6f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_68306fed-a653-42a5-90e5-b89824d61395" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6e4804be-f8e1-4eca-9f82-be4897e61a6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_StateOfAlabamaAndSubdivisionsMember_133ba27f-e18e-4bb8-a221-9d86bcb10365" xlink:href="mck-20230630.xsd#mck_StateOfAlabamaAndSubdivisionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6e4804be-f8e1-4eca-9f82-be4897e61a6f" xlink:to="loc_mck_StateOfAlabamaAndSubdivisionsMember_133ba27f-e18e-4bb8-a221-9d86bcb10365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_StateOfWestVirginiaAndSubdivisionsMember_fe83032b-3797-4cb4-85c8-dc3fab7b052e" xlink:href="mck-20230630.xsd#mck_StateOfWestVirginiaAndSubdivisionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6e4804be-f8e1-4eca-9f82-be4897e61a6f" xlink:to="loc_mck_StateOfWestVirginiaAndSubdivisionsMember_fe83032b-3797-4cb4-85c8-dc3fab7b052e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_CherokeeNationMember_612ff305-d6dc-4dbe-b686-f8c095b66369" xlink:href="mck-20230630.xsd#mck_CherokeeNationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6e4804be-f8e1-4eca-9f82-be4897e61a6f" xlink:to="loc_mck_CherokeeNationMember_612ff305-d6dc-4dbe-b686-f8c095b66369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_NativeAmericanTribesOtherThanCherokeeNationMember_bd661fcc-9cbc-49fc-adef-e08c14f9be5e" xlink:href="mck-20230630.xsd#mck_NativeAmericanTribesOtherThanCherokeeNationMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6e4804be-f8e1-4eca-9f82-be4897e61a6f" xlink:to="loc_mck_NativeAmericanTribesOtherThanCherokeeNationMember_bd661fcc-9cbc-49fc-adef-e08c14f9be5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_IndividualClaimantMember_078cd4aa-559c-4949-83b0-e90eec5a56c9" xlink:href="mck-20230630.xsd#mck_IndividualClaimantMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6e4804be-f8e1-4eca-9f82-be4897e61a6f" xlink:to="loc_mck_IndividualClaimantMember_078cd4aa-559c-4949-83b0-e90eec5a56c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_d6b2ba9d-5e9e-41ab-87af-605d4c541100" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_a33f83c2-689d-4d66-884f-5244ce9176fb" xlink:to="loc_srt_StatementGeographicalAxis_d6b2ba9d-5e9e-41ab-87af-605d4c541100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_668398ce-6cc2-4062-8ed9-135a86824fd1" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_d6b2ba9d-5e9e-41ab-87af-605d4c541100" xlink:to="loc_srt_SegmentGeographicalDomain_668398ce-6cc2-4062-8ed9-135a86824fd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_66871984-ec2e-423a-9fa9-a9bc7fc0cec7" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_668398ce-6cc2-4062-8ed9-135a86824fd1" xlink:to="loc_country_US_66871984-ec2e-423a-9fa9-a9bc7fc0cec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_c26a3b7a-ddf5-4609-8d73-6efe3e62f825" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_CA"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_668398ce-6cc2-4062-8ed9-135a86824fd1" xlink:to="loc_country_CA_c26a3b7a-ddf5-4609-8d73-6efe3e62f825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_817d1bd4-bea6-4700-b198-9c5306ec7b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_a33f83c2-689d-4d66-884f-5244ce9176fb" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_817d1bd4-bea6-4700-b198-9c5306ec7b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_d3e28a2f-fb76-41de-91a7-1a011e8a272c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_817d1bd4-bea6-4700-b198-9c5306ec7b2d" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_d3e28a2f-fb76-41de-91a7-1a011e8a272c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_d0532860-478c-44cb-994b-e07530f1f832" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_d3e28a2f-fb76-41de-91a7-1a011e8a272c" xlink:to="loc_us-gaap_SubsequentEventMember_d0532860-478c-44cb-994b-e07530f1f832" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_991edb6b-0961-4668-ab33-c600a9fadfa4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_a33f83c2-689d-4d66-884f-5244ce9176fb" xlink:to="loc_us-gaap_LossContingenciesLineItems_991edb6b-0961-4668-ab33-c600a9fadfa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_LossContingencyNumberOfOtherDefendants_193cecbc-4acd-466b-a2ee-fc86d5b0a4f9" xlink:href="mck-20230630.xsd#mck_LossContingencyNumberOfOtherDefendants"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_991edb6b-0961-4668-ab33-c600a9fadfa4" xlink:to="loc_mck_LossContingencyNumberOfOtherDefendants_193cecbc-4acd-466b-a2ee-fc86d5b0a4f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_LossContingencyNumberofStates_d043ad8b-c208-4243-b08c-3ae2992b0732" xlink:href="mck-20230630.xsd#mck_LossContingencyNumberofStates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_991edb6b-0961-4668-ab33-c600a9fadfa4" xlink:to="loc_mck_LossContingencyNumberofStates_d043ad8b-c208-4243-b08c-3ae2992b0732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_LossContingencyNumberOfCasesDismissed_4ece62cf-0f09-40eb-9773-2c7595ae0047" xlink:href="mck-20230630.xsd#mck_LossContingencyNumberOfCasesDismissed"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_991edb6b-0961-4668-ab33-c600a9fadfa4" xlink:to="loc_mck_LossContingencyNumberOfCasesDismissed_4ece62cf-0f09-40eb-9773-2c7595ae0047" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_03137444-8faf-4fa9-813f-95331c52b10c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_991edb6b-0961-4668-ab33-c600a9fadfa4" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_03137444-8faf-4fa9-813f-95331c52b10c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_a98a9fbd-3d27-4546-bac6-91cc5fd52d0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_991edb6b-0961-4668-ab33-c600a9fadfa4" xlink:to="loc_us-gaap_LitigationSettlementAmountAwardedToOtherParty_a98a9fbd-3d27-4546-bac6-91cc5fd52d0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_LitigationSettlementAwardAmountToBeUsedByStateAndLocalGovernment_a5188fcb-e890-4ac2-b045-23c1805fade5" xlink:href="mck-20230630.xsd#mck_LitigationSettlementAwardAmountToBeUsedByStateAndLocalGovernment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_991edb6b-0961-4668-ab33-c600a9fadfa4" xlink:to="loc_mck_LitigationSettlementAwardAmountToBeUsedByStateAndLocalGovernment_a5188fcb-e890-4ac2-b045-23c1805fade5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_LossContingencyClaimsSettledNumberOfJurisdictionsNotParticipatingInSettlement_fae65a6f-162b-4016-8466-2574a708399d" xlink:href="mck-20230630.xsd#mck_LossContingencyClaimsSettledNumberOfJurisdictionsNotParticipatingInSettlement"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_991edb6b-0961-4668-ab33-c600a9fadfa4" xlink:to="loc_mck_LossContingencyClaimsSettledNumberOfJurisdictionsNotParticipatingInSettlement_fae65a6f-162b-4016-8466-2574a708399d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_LitigationSettlementAmountAwardedToOtherPartyPercentageOfTotalSettlementToBeUsedToRemediateDamages_9bab7eb8-cd6f-4fa3-af26-09c106eadb27" xlink:href="mck-20230630.xsd#mck_LitigationSettlementAmountAwardedToOtherPartyPercentageOfTotalSettlementToBeUsedToRemediateDamages"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_991edb6b-0961-4668-ab33-c600a9fadfa4" xlink:to="loc_mck_LitigationSettlementAmountAwardedToOtherPartyPercentageOfTotalSettlementToBeUsedToRemediateDamages_9bab7eb8-cd6f-4fa3-af26-09c106eadb27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_2f391dba-2f7b-4b89-a679-f8cd9434e135" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_991edb6b-0961-4668-ab33-c600a9fadfa4" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_2f391dba-2f7b-4b89-a679-f8cd9434e135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_LossContingencyNumberOfFormerOfficers_f706d433-d003-4052-a3bb-e8622e7ce67b" xlink:href="mck-20230630.xsd#mck_LossContingencyNumberOfFormerOfficers"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_991edb6b-0961-4668-ab33-c600a9fadfa4" xlink:to="loc_mck_LossContingencyNumberOfFormerOfficers_f706d433-d003-4052-a3bb-e8622e7ce67b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_da728a5a-ce9c-44e0-ad91-060b22091d3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_991edb6b-0961-4668-ab33-c600a9fadfa4" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_da728a5a-ce9c-44e0-ad91-060b22091d3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimatedInsuranceRecoveries_5e7380e9-9fd6-4dc2-887a-109a5f894aea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EstimatedInsuranceRecoveries"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_991edb6b-0961-4668-ab33-c600a9fadfa4" xlink:to="loc_us-gaap_EstimatedInsuranceRecoveries_5e7380e9-9fd6-4dc2-887a-109a5f894aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_LossContingencyNumberOfStatesFiledOnBehalfOf_6067ffa8-92c9-4907-b330-c2bd2dc5257c" xlink:href="mck-20230630.xsd#mck_LossContingencyNumberOfStatesFiledOnBehalfOf"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_991edb6b-0961-4668-ab33-c600a9fadfa4" xlink:to="loc_mck_LossContingencyNumberOfStatesFiledOnBehalfOf_6067ffa8-92c9-4907-b330-c2bd2dc5257c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/CommitmentsandContingentLiabilitiesEstimatedAccrualLiabilityDetails" xlink:type="simple" xlink:href="mck-20230630.xsd#CommitmentsandContingentLiabilitiesEstimatedAccrualLiabilityDetails"/>
  <link:presentationLink xlink:role="http://mckesson123.com/role/CommitmentsandContingentLiabilitiesEstimatedAccrualLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7a1755c6-77e1-4115-aaf5-8d375edcd2b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_fec3f692-5ab2-45ec-b642-452ace52c953" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7a1755c6-77e1-4115-aaf5-8d375edcd2b1" xlink:to="loc_us-gaap_LossContingenciesTable_fec3f692-5ab2-45ec-b642-452ace52c953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_e848dd37-4988-4e42-883f-2f2ff81d7e16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_fec3f692-5ab2-45ec-b642-452ace52c953" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_e848dd37-4988-4e42-883f-2f2ff81d7e16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_b33742a5-6cf4-4e94-82cd-6a734827eadf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_e848dd37-4988-4e42-883f-2f2ff81d7e16" xlink:to="loc_us-gaap_LossContingencyNatureDomain_b33742a5-6cf4-4e94-82cd-6a734827eadf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_NationalPrescriptionOpiateLitigationMember_db4a78f0-b327-4ae6-8de8-9c6646f684d3" xlink:href="mck-20230630.xsd#mck_NationalPrescriptionOpiateLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_b33742a5-6cf4-4e94-82cd-6a734827eadf" xlink:to="loc_mck_NationalPrescriptionOpiateLitigationMember_db4a78f0-b327-4ae6-8de8-9c6646f684d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_8569ce76-2f56-4017-a527-695cf7a94265" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_fec3f692-5ab2-45ec-b642-452ace52c953" xlink:to="loc_us-gaap_LossContingenciesLineItems_8569ce76-2f56-4017-a527-695cf7a94265" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValueCurrent_2f2fea30-8141-4944-9405-2aa375db2cb3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualCarryingValueCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_8569ce76-2f56-4017-a527-695cf7a94265" xlink:to="loc_us-gaap_LossContingencyAccrualCarryingValueCurrent_2f2fea30-8141-4944-9405-2aa375db2cb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValueNoncurrent_78cf0d21-52e4-4a2f-b26b-2af81891be7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualCarryingValueNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_8569ce76-2f56-4017-a527-695cf7a94265" xlink:to="loc_us-gaap_LossContingencyAccrualCarryingValueNoncurrent_78cf0d21-52e4-4a2f-b26b-2af81891be7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_22bb74af-4318-481a-9c44-7bc59c0f0e52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_8569ce76-2f56-4017-a527-695cf7a94265" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_22bb74af-4318-481a-9c44-7bc59c0f0e52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/StockholdersDeficitNarrativeDetails" xlink:type="simple" xlink:href="mck-20230630.xsd#StockholdersDeficitNarrativeDetails"/>
  <link:presentationLink xlink:role="http://mckesson123.com/role/StockholdersDeficitNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_b35a13e3-de42-41a5-9d5f-fd05f41ea091" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesTable_7974957c-75c1-4993-947a-e5e0f3e55d70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcceleratedShareRepurchasesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_b35a13e3-de42-41a5-9d5f-fd05f41ea091" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesTable_7974957c-75c1-4993-947a-e5e0f3e55d70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_9f788e08-078b-4f40-90de-408547a807ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesTable_7974957c-75c1-4993-947a-e5e0f3e55d70" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_9f788e08-078b-4f40-90de-408547a807ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_c2c0b895-2c07-4541-8015-d04d76e84a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_9f788e08-078b-4f40-90de-408547a807ee" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_c2c0b895-2c07-4541-8015-d04d76e84a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_AcceleratedShareRepurchaseMember_a98154d2-cc74-4d10-a813-eb406bd31b30" xlink:href="mck-20230630.xsd#mck_AcceleratedShareRepurchaseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_c2c0b895-2c07-4541-8015-d04d76e84a3a" xlink:to="loc_mck_AcceleratedShareRepurchaseMember_a98154d2-cc74-4d10-a813-eb406bd31b30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_AcceleratedShareRepurchaseInitialShareSettlementMember_8c60fce1-ef74-4f1d-a4cf-f65daf7d8ded" xlink:href="mck-20230630.xsd#mck_AcceleratedShareRepurchaseInitialShareSettlementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mck_AcceleratedShareRepurchaseMember_a98154d2-cc74-4d10-a813-eb406bd31b30" xlink:to="loc_mck_AcceleratedShareRepurchaseInitialShareSettlementMember_8c60fce1-ef74-4f1d-a4cf-f65daf7d8ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_AcceleratedShareRepurchaseCompletionOfProgramMember_5f87a23b-f1be-4e06-9bba-787ecd422172" xlink:href="mck-20230630.xsd#mck_AcceleratedShareRepurchaseCompletionOfProgramMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mck_AcceleratedShareRepurchaseMember_a98154d2-cc74-4d10-a813-eb406bd31b30" xlink:to="loc_mck_AcceleratedShareRepurchaseCompletionOfProgramMember_5f87a23b-f1be-4e06-9bba-787ecd422172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_OpenMarketShareRepurchaseTransactionsMember_33375127-0d04-48d6-bf70-062abfddd105" xlink:href="mck-20230630.xsd#mck_OpenMarketShareRepurchaseTransactionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_c2c0b895-2c07-4541-8015-d04d76e84a3a" xlink:to="loc_mck_OpenMarketShareRepurchaseTransactionsMember_33375127-0d04-48d6-bf70-062abfddd105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_339fbab1-a1b2-49b5-9fe8-efd42042616e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesTable_7974957c-75c1-4993-947a-e5e0f3e55d70" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_339fbab1-a1b2-49b5-9fe8-efd42042616e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_e3ade680-4b5b-4070-acea-80cbfafda5b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_339fbab1-a1b2-49b5-9fe8-efd42042616e" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_e3ade680-4b5b-4070-acea-80cbfafda5b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_e9482d96-27f0-474a-92ca-5022a18df201" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_e3ade680-4b5b-4070-acea-80cbfafda5b1" xlink:to="loc_us-gaap_SubsequentEventMember_e9482d96-27f0-474a-92ca-5022a18df201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesLineItems_ef44a0c3-08ea-46a0-86e1-93735a31e572" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AcceleratedShareRepurchasesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesTable_7974957c-75c1-4993-947a-e5e0f3e55d70" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesLineItems_ef44a0c3-08ea-46a0-86e1-93735a31e572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_CommonStockVotingRightsNumberofVotesPerCommonShare_56110609-df88-4988-9841-eb28214c5faa" xlink:href="mck-20230630.xsd#mck_CommonStockVotingRightsNumberofVotesPerCommonShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesLineItems_ef44a0c3-08ea-46a0-86e1-93735a31e572" xlink:to="loc_mck_CommonStockVotingRightsNumberofVotesPerCommonShare_56110609-df88-4988-9841-eb28214c5faa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_53795286-9560-4608-81f3-b27e6a58d815" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesLineItems_ef44a0c3-08ea-46a0-86e1-93735a31e572" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_53795286-9560-4608-81f3-b27e6a58d815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_b94cf247-7e04-4581-94ab-38ffe8e9e5ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesLineItems_ef44a0c3-08ea-46a0-86e1-93735a31e572" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_b94cf247-7e04-4581-94ab-38ffe8e9e5ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_b423f669-0572-4734-bfef-611948f34a39" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesLineItems_ef44a0c3-08ea-46a0-86e1-93735a31e572" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_b423f669-0572-4734-bfef-611948f34a39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_c9e229ed-4bd0-4f7b-967b-3529e48c50ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesLineItems_ef44a0c3-08ea-46a0-86e1-93735a31e572" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_c9e229ed-4bd0-4f7b-967b-3529e48c50ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_4807c376-2c43-4f42-a15c-786336f63e4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesLineItems_ef44a0c3-08ea-46a0-86e1-93735a31e572" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_4807c376-2c43-4f42-a15c-786336f63e4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredParValueMethod_a6ddcd2b-ede4-4654-8476-4506a7697920" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TreasuryStockValueAcquiredParValueMethod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesLineItems_ef44a0c3-08ea-46a0-86e1-93735a31e572" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredParValueMethod_a6ddcd2b-ede4-4654-8476-4506a7697920" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_ExciseTaxPayableCurrent_a643df8f-850a-4c26-b31b-2989876578fe" xlink:href="mck-20230630.xsd#mck_ExciseTaxPayableCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesLineItems_ef44a0c3-08ea-46a0-86e1-93735a31e572" xlink:to="loc_mck_ExciseTaxPayableCurrent_a643df8f-850a-4c26-b31b-2989876578fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_e39e8dd9-3576-4969-a610-59e8a179f5d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesLineItems_ef44a0c3-08ea-46a0-86e1-93735a31e572" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_e39e8dd9-3576-4969-a610-59e8a179f5d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_8378b781-1828-463a-9591-0039b7b4e6e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesLineItems_ef44a0c3-08ea-46a0-86e1-93735a31e572" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_8378b781-1828-463a-9591-0039b7b4e6e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_a8c1bcdd-c496-4fa4-be1b-292a546edf5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesLineItems_ef44a0c3-08ea-46a0-86e1-93735a31e572" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_a8c1bcdd-c496-4fa4-be1b-292a546edf5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails" xlink:type="simple" xlink:href="mck-20230630.xsd#StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails"/>
  <link:presentationLink xlink:role="http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_f487dcd5-eab9-4250-9a77-3868b69ab3e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_572f3fd3-55d5-4895-b0ca-2c6f4521d782" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f487dcd5-eab9-4250-9a77-3868b69ab3e8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_572f3fd3-55d5-4895-b0ca-2c6f4521d782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_e7e43669-c2be-45d0-be0e-55e3bdc26a02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_572f3fd3-55d5-4895-b0ca-2c6f4521d782" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_e7e43669-c2be-45d0-be0e-55e3bdc26a02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4e9092b4-71d8-4b22-8e3f-24a4513c4184" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_e7e43669-c2be-45d0-be0e-55e3bdc26a02" xlink:to="loc_us-gaap_EquityComponentDomain_4e9092b4-71d8-4b22-8e3f-24a4513c4184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_01385bd6-7137-4346-864e-c5159c2c80e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4e9092b4-71d8-4b22-8e3f-24a4513c4184" xlink:to="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_01385bd6-7137-4346-864e-c5159c2c80e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_d42a94b8-2578-4aa5-b504-83674f5ca011" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_01385bd6-7137-4346-864e-c5159c2c80e0" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_d42a94b8-2578-4aa5-b504-83674f5ca011" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember_ff892499-5f7d-4338-9216-899f404a5cb9" xlink:href="mck-20230630.xsd#mck_AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_01385bd6-7137-4346-864e-c5159c2c80e0" xlink:to="loc_mck_AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember_ff892499-5f7d-4338-9216-899f404a5cb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_c147bb1e-47d3-418f-b3e7-b96756dc59dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_01385bd6-7137-4346-864e-c5159c2c80e0" xlink:to="loc_us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember_c147bb1e-47d3-418f-b3e7-b96756dc59dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember_ec586865-364d-45aa-b9f4-b35f009a591f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember_01385bd6-7137-4346-864e-c5159c2c80e0" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember_ec586865-364d-45aa-b9f4-b35f009a591f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_bc8a9094-009c-46e3-9299-a6dd372ef818" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_572f3fd3-55d5-4895-b0ca-2c6f4521d782" xlink:to="loc_us-gaap_HedgingDesignationAxis_bc8a9094-009c-46e3-9299-a6dd372ef818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_18037112-7baa-46b8-9564-2e342a224cb6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_bc8a9094-009c-46e3-9299-a6dd372ef818" xlink:to="loc_us-gaap_HedgingDesignationDomain_18037112-7baa-46b8-9564-2e342a224cb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_84270410-a6f0-453d-aeb6-fc178d5dc2d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_18037112-7baa-46b8-9564-2e342a224cb6" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_84270410-a6f0-453d-aeb6-fc178d5dc2d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_0f041ccd-ebc0-4dab-8faa-16db6a204f4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_572f3fd3-55d5-4895-b0ca-2c6f4521d782" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_0f041ccd-ebc0-4dab-8faa-16db6a204f4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_0e2dbae0-6b93-49b6-9b4b-666e5a66e01a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_0f041ccd-ebc0-4dab-8faa-16db6a204f4b" xlink:to="loc_us-gaap_HedgingRelationshipDomain_0e2dbae0-6b93-49b6-9b4b-666e5a66e01a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_ee1c300e-4e90-4f5d-a32e-2da8d469b498" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_0e2dbae0-6b93-49b6-9b4b-666e5a66e01a" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_ee1c300e-4e90-4f5d-a32e-2da8d469b498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrencySwapMember_4ad63a22-f1fb-44e7-b254-817b11023e2b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrencySwapMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_0e2dbae0-6b93-49b6-9b4b-666e5a66e01a" xlink:to="loc_us-gaap_CurrencySwapMember_4ad63a22-f1fb-44e7-b254-817b11023e2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_24f84a13-dff8-4b94-9158-923a2edc4baf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_572f3fd3-55d5-4895-b0ca-2c6f4521d782" xlink:to="loc_us-gaap_DebtInstrumentAxis_24f84a13-dff8-4b94-9158-923a2edc4baf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3b880099-2f2b-4a2a-a0e8-2df004062f44" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_24f84a13-dff8-4b94-9158-923a2edc4baf" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3b880099-2f2b-4a2a-a0e8-2df004062f44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_EuroDenominatedNotesMember_3824df0d-97af-426e-aa1a-5eb7959ebe21" xlink:href="mck-20230630.xsd#mck_EuroDenominatedNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3b880099-2f2b-4a2a-a0e8-2df004062f44" xlink:to="loc_mck_EuroDenominatedNotesMember_3824df0d-97af-426e-aa1a-5eb7959ebe21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_64e83798-22b7-4b4d-8820-4281ba63b248" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_572f3fd3-55d5-4895-b0ca-2c6f4521d782" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_64e83798-22b7-4b4d-8820-4281ba63b248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_6607ab71-da1d-4c22-abba-fa698a79853a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_64e83798-22b7-4b4d-8820-4281ba63b248" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_6607ab71-da1d-4c22-abba-fa698a79853a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0bc9e3b4-b69d-4d42-bc7d-b04435a8b11f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_6607ab71-da1d-4c22-abba-fa698a79853a" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0bc9e3b4-b69d-4d42-bc7d-b04435a8b11f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_bd240e14-83f6-41e3-87c9-630dc32eb6ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_6607ab71-da1d-4c22-abba-fa698a79853a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_bd240e14-83f6-41e3-87c9-630dc32eb6ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_1c2ab531-a20a-4991-a54e-89afed069105" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_6607ab71-da1d-4c22-abba-fa698a79853a" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_1c2ab531-a20a-4991-a54e-89afed069105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_dac6a117-f646-48c6-80f8-4f4f97dc3e80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_6607ab71-da1d-4c22-abba-fa698a79853a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_dac6a117-f646-48c6-80f8-4f4f97dc3e80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_6185e5ab-e498-43c1-a13a-cc556db6e472" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_6607ab71-da1d-4c22-abba-fa698a79853a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest_6185e5ab-e498-43c1-a13a-cc556db6e472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_f6c251b0-23ff-4337-b812-8f317632a868" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_6607ab71-da1d-4c22-abba-fa698a79853a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_f6c251b0-23ff-4337-b812-8f317632a868" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_34df82c5-920c-44c8-93e6-c3005b024f26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_6607ab71-da1d-4c22-abba-fa698a79853a" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_34df82c5-920c-44c8-93e6-c3005b024f26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_dab29118-9653-4693-a27d-c33ea19a841f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_64e83798-22b7-4b4d-8820-4281ba63b248" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_dab29118-9653-4693-a27d-c33ea19a841f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_e381a575-b761-4726-b070-12ad360d2399" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_64e83798-22b7-4b4d-8820-4281ba63b248" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_e381a575-b761-4726-b070-12ad360d2399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_0c0363c4-4cc1-4847-b065-e6647656ff26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_64e83798-22b7-4b4d-8820-4281ba63b248" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax_0c0363c4-4cc1-4847-b065-e6647656ff26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/SegmentsofBusinessNarrativeDetails" xlink:type="simple" xlink:href="mck-20230630.xsd#SegmentsofBusinessNarrativeDetails"/>
  <link:presentationLink xlink:role="http://mckesson123.com/role/SegmentsofBusinessNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_8c4004c8-0339-44cf-957f-7a7cfb59aaba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_b818df40-07b8-496f-8985-dbec6f9b5762" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_8c4004c8-0339-44cf-957f-7a7cfb59aaba" xlink:to="loc_us-gaap_NumberOfReportableSegments_b818df40-07b8-496f-8985-dbec6f9b5762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" xlink:type="simple" xlink:href="mck-20230630.xsd#SegmentsofBusinessReportableoperatingsegmentDetails"/>
  <link:presentationLink xlink:role="http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_20113cd9-8afe-4708-93a0-61e380c4d145" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1ed8ff2b-4c22-427f-a087-f8c978075c7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_20113cd9-8afe-4708-93a0-61e380c4d145" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1ed8ff2b-4c22-427f-a087-f8c978075c7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_d01c2068-c617-484f-a472-20fe404a7dde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1ed8ff2b-4c22-427f-a087-f8c978075c7d" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_d01c2068-c617-484f-a472-20fe404a7dde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_bb8827b7-9937-4b2f-a6c8-8680cfa8e319" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d01c2068-c617-484f-a472-20fe404a7dde" xlink:to="loc_us-gaap_SegmentDomain_bb8827b7-9937-4b2f-a6c8-8680cfa8e319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_USPharmaceuticalSegmentMember_063a3a35-e9d5-4a19-be6a-4e50a10a670a" xlink:href="mck-20230630.xsd#mck_USPharmaceuticalSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_bb8827b7-9937-4b2f-a6c8-8680cfa8e319" xlink:to="loc_mck_USPharmaceuticalSegmentMember_063a3a35-e9d5-4a19-be6a-4e50a10a670a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_PrescriptionTechnologySolutionsMember_a46797ae-a1ef-43e3-84f5-bbc266b598a9" xlink:href="mck-20230630.xsd#mck_PrescriptionTechnologySolutionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_bb8827b7-9937-4b2f-a6c8-8680cfa8e319" xlink:to="loc_mck_PrescriptionTechnologySolutionsMember_a46797ae-a1ef-43e3-84f5-bbc266b598a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_MedicalSurgicalSolutionsSegmentMember_81cf7ce2-30f8-4c45-95ad-736c8dcb5856" xlink:href="mck-20230630.xsd#mck_MedicalSurgicalSolutionsSegmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_bb8827b7-9937-4b2f-a6c8-8680cfa8e319" xlink:to="loc_mck_MedicalSurgicalSolutionsSegmentMember_81cf7ce2-30f8-4c45-95ad-736c8dcb5856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_InternationalSegmentMember_7fcf8a43-a7d3-4294-b173-34dbb02be644" xlink:href="mck-20230630.xsd#mck_InternationalSegmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_bb8827b7-9937-4b2f-a6c8-8680cfa8e319" xlink:to="loc_mck_InternationalSegmentMember_7fcf8a43-a7d3-4294-b173-34dbb02be644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_07074a48-716f-4815-aa00-0d65d40e6209" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1ed8ff2b-4c22-427f-a087-f8c978075c7d" xlink:to="loc_srt_ConsolidationItemsAxis_07074a48-716f-4815-aa00-0d65d40e6209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_ad455ce0-5f62-4624-986a-8333d6a6f00a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_07074a48-716f-4815-aa00-0d65d40e6209" xlink:to="loc_srt_ConsolidationItemsDomain_ad455ce0-5f62-4624-986a-8333d6a6f00a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_abb0cd4b-9b7a-4cba-95d8-17593261c32c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_ad455ce0-5f62-4624-986a-8333d6a6f00a" xlink:to="loc_us-gaap_OperatingSegmentsMember_abb0cd4b-9b7a-4cba-95d8-17593261c32c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_bb5be096-8559-4fc0-a017-41bddef44dca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_ad455ce0-5f62-4624-986a-8333d6a6f00a" xlink:to="loc_us-gaap_CorporateNonSegmentMember_bb5be096-8559-4fc0-a017-41bddef44dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_b7a282a4-63a8-4992-907a-d4e862825c83" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1ed8ff2b-4c22-427f-a087-f8c978075c7d" xlink:to="loc_srt_LitigationCaseAxis_b7a282a4-63a8-4992-907a-d4e862825c83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_98190105-fe92-4b64-9d50-a6c5a295a6f7" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_b7a282a4-63a8-4992-907a-d4e862825c83" xlink:to="loc_srt_LitigationCaseTypeDomain_98190105-fe92-4b64-9d50-a6c5a295a6f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_NationalPrescriptionOpiateLitigationMember_e207f65a-9be2-4c94-91a1-8cc349d12b1e" xlink:href="mck-20230630.xsd#mck_NationalPrescriptionOpiateLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_98190105-fe92-4b64-9d50-a6c5a295a6f7" xlink:to="loc_mck_NationalPrescriptionOpiateLitigationMember_e207f65a-9be2-4c94-91a1-8cc349d12b1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_24e7968e-6e4c-4503-b77e-0af5955c9910" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1ed8ff2b-4c22-427f-a087-f8c978075c7d" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_24e7968e-6e4c-4503-b77e-0af5955c9910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_a1ca6757-3ce8-4988-8d29-1c59930ff2ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupClassificationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_24e7968e-6e4c-4503-b77e-0af5955c9910" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_a1ca6757-3ce8-4988-8d29-1c59930ff2ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_ffbe3d21-0067-4fd0-9830-bed7e68e4413" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_a1ca6757-3ce8-4988-8d29-1c59930ff2ce" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_ffbe3d21-0067-4fd0-9830-bed7e68e4413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_b339a082-b82d-4f31-94b9-70907f53b7b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1ed8ff2b-4c22-427f-a087-f8c978075c7d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_b339a082-b82d-4f31-94b9-70907f53b7b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_99446870-106d-47eb-b0dd-2f6106d3d42b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_b339a082-b82d-4f31-94b9-70907f53b7b1" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_99446870-106d-47eb-b0dd-2f6106d3d42b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_EUBusinessesDisposalGroupMember_e3af16c7-75e0-482c-ae7b-822e7f829001" xlink:href="mck-20230630.xsd#mck_EUBusinessesDisposalGroupMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_99446870-106d-47eb-b0dd-2f6106d3d42b" xlink:to="loc_mck_EUBusinessesDisposalGroupMember_e3af16c7-75e0-482c-ae7b-822e7f829001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_f839d5bb-04ef-4a19-8849-20e08eff5205" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1ed8ff2b-4c22-427f-a087-f8c978075c7d" xlink:to="loc_srt_StatementGeographicalAxis_f839d5bb-04ef-4a19-8849-20e08eff5205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e91e850b-b86c-4910-8b63-b5e1386d9b76" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_f839d5bb-04ef-4a19-8849-20e08eff5205" xlink:to="loc_srt_SegmentGeographicalDomain_e91e850b-b86c-4910-8b63-b5e1386d9b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_0e6dad5d-171b-4a90-ae8e-81e4db8dec10" xlink:href="https://xbrl.sec.gov/country/2023/country-2023.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e91e850b-b86c-4910-8b63-b5e1386d9b76" xlink:to="loc_country_US_0e6dad5d-171b-4a90-ae8e-81e4db8dec10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_a3c4a703-c72f-4599-9e0c-d00b95a68c2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1ed8ff2b-4c22-427f-a087-f8c978075c7d" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_a3c4a703-c72f-4599-9e0c-d00b95a68c2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationProfitLossAbstract_429aaae8-11e4-421e-a760-7722f8200814" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SegmentReportingInformationProfitLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a3c4a703-c72f-4599-9e0c-d00b95a68c2e" xlink:to="loc_us-gaap_SegmentReportingInformationProfitLossAbstract_429aaae8-11e4-421e-a760-7722f8200814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_9aef18de-47bd-4e87-aa2e-3257c51080ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationProfitLossAbstract_429aaae8-11e4-421e-a760-7722f8200814" xlink:to="loc_us-gaap_RevenuesAbstract_9aef18de-47bd-4e87-aa2e-3257c51080ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fdd5bcb7-ef00-45e5-92bb-6e7d525eca1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_9aef18de-47bd-4e87-aa2e-3257c51080ea" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fdd5bcb7-ef00-45e5-92bb-6e7d525eca1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLossAbstract_d67bd302-b6c3-45ff-b808-eb674d1f11a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLossAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationProfitLossAbstract_429aaae8-11e4-421e-a760-7722f8200814" xlink:to="loc_us-gaap_OperatingIncomeLossAbstract_d67bd302-b6c3-45ff-b808-eb674d1f11a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_61df08e3-9fd2-4df4-895b-22f05ee4d53b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingIncomeLossAbstract_d67bd302-b6c3-45ff-b808-eb674d1f11a3" xlink:to="loc_us-gaap_OperatingIncomeLoss_61df08e3-9fd2-4df4-895b-22f05ee4d53b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_CorporateOperatingExpenseandOtherIncomeNet_8d552c5d-7b9a-425d-a4c9-28c7c9dfa7b5" xlink:href="mck-20230630.xsd#mck_CorporateOperatingExpenseandOtherIncomeNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationProfitLossAbstract_429aaae8-11e4-421e-a760-7722f8200814" xlink:to="loc_mck_CorporateOperatingExpenseandOtherIncomeNet_8d552c5d-7b9a-425d-a4c9-28c7c9dfa7b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_fd9243e1-2796-408c-bf2e-d9ae9f04a662" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationProfitLossAbstract_429aaae8-11e4-421e-a760-7722f8200814" xlink:to="loc_us-gaap_InterestExpense_fd9243e1-2796-408c-bf2e-d9ae9f04a662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4bb70132-91b5-45cf-8cb6-b96346402290" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationProfitLossAbstract_429aaae8-11e4-421e-a760-7722f8200814" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4bb70132-91b5-45cf-8cb6-b96346402290" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_mck_RevenueDerivedFromServicesPercentage_6f21ec16-920e-4a70-9ec2-600d10c8d781" xlink:href="mck-20230630.xsd#mck_RevenueDerivedFromServicesPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a3c4a703-c72f-4599-9e0c-d00b95a68c2e" xlink:to="loc_mck_RevenueDerivedFromServicesPercentage_6f21ec16-920e-4a70-9ec2-600d10c8d781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_70d01c22-6b4a-42c3-b4b8-7f042a52d055" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a3c4a703-c72f-4599-9e0c-d00b95a68c2e" xlink:to="loc_us-gaap_NumberOfReportableSegments_70d01c22-6b4a-42c3-b4b8-7f042a52d055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLegalSettlements_8f5d971f-384c-411d-b233-88abaaf1b8e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromLegalSettlements"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a3c4a703-c72f-4599-9e0c-d00b95a68c2e" xlink:to="loc_us-gaap_ProceedsFromLegalSettlements_8f5d971f-384c-411d-b233-88abaaf1b8e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLIFOReservePeriodCharge_06dd4e25-b5c3-4789-ace4-dad0628cd987" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InventoryLIFOReservePeriodCharge"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a3c4a703-c72f-4599-9e0c-d00b95a68c2e" xlink:to="loc_us-gaap_InventoryLIFOReservePeriodCharge_06dd4e25-b5c3-4789-ace4-dad0628cd987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_39d788fd-8865-4fc9-9cbb-08aaca3dca35" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a3c4a703-c72f-4599-9e0c-d00b95a68c2e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_39d788fd-8865-4fc9-9cbb-08aaca3dca35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_1c571ba8-e52e-4831-9cd6-7b21b98f1c0a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a3c4a703-c72f-4599-9e0c-d00b95a68c2e" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown_1c571ba8-e52e-4831-9cd6-7b21b98f1c0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_3d80c7e8-cc01-407b-88a3-7917b302e113" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_a3c4a703-c72f-4599-9e0c-d00b95a68c2e" xlink:to="loc_us-gaap_RestructuringCharges_3d80c7e8-cc01-407b-88a3-7917b302e113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>mck-20230630_g1.jpg
<TEXT>
begin 644 mck-20230630_g1.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  ^ 9@# 2(  A$! Q$!_\0
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M?$#XA>(?$4S;FU&]DG'7A2QV@>V,5CE& CC:DO:?"C;/,RGE].*I?$S]#O\
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MOK:UCTK71)/(L2EH(P,DX!^_ZFOJ^&430I(O1E##Z&OPG\+C_BIM(_Z^XO\
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MD5^IL,R7$*2QL'C<!E93D$'H:^+QV"G@JG)+;H?H&6YC3S"ESQW6Z/&/CO\
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M6=^U=\!E^/OPRETJV=(=;L9/M>G3/]WS ""C'L&!(]N#VKP\'..$QL7/9/\
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M1_>4?F,USYKE\<935:C\7YG5DV:2P%7V%;X7^!^P'\J^0?\ @I?_ ,D;T?\
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M/!(K8XW*\B,,^N%4_P# A7=?\$P/"%Q)KGC+Q2T96TB@BTV.0YP[LPD=0?\
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M)?LB,Z_1F!(KNU4*-H  [ "N;$<0RE&U&%KG5A>%XQES8B=_)''?"/X6Z/\
M!WP-I_AG1(MEM:KEY6'SS2'EG;W)_D!VKJ[RTAU"TFMKB))[>9#')'(,JRD8
M(([@C-3B@U\C*4IRYF]6?;PIQA!4XK1'YI_M.?L(:[X/U:]\0?#^QFUOP],Q
ME?2[=2]S:9Y(5>KKGICD>_6OD*ZM9K&9X;B*2"9#M>.5"K @X((/?ZU^]-<K
MXJ^%?@_QM(9->\-:7JLV,>;<VJ.^/3=C/ZU]1@\^J48J%:/,OQ/CL;PW3K3=
M2A+E\NA^'5;'ACP?KGC75(=-T#2;S5[Z4X2&SA:1NO4X' 'J>!U-?L!#^RK\
M)K>19$\"Z2&7UC)_0FO0/#_A+1/"5N;?1=)LM*@[QV=ND0/UV@9KNJ<11M^Z
MAKYGGT^%ZG-^]J:>1\J?L@_L5GX7WEOXP\:QPW'B=5S:6*D/'99'+$]&DQD<
M<#MZC[#H/2CTKY#$8FIBJCJ5'=GW.$PE+!TE2I+0_.7_ (*>1NWQ$\(%59A_
M9C]!G_EJ:^2/!$$G_"::!^[;_D(V_P#"?^>JU^X.H:#INK,KWMA:WCJ,*UQ"
MKD>PR*JKX/T&-E9=%T]64Y#+:H"/<<5[N&SGZOAE0Y+^9\UB\@>)Q3Q'M+7>
MUC7C^XOTK&\9>$]/\<^%]3T'5(5GL-0@:"5",\,,9'N.H^E;GI17S2DXNZ/K
MW!2CRRV/Q&^,'PMU/X0_$;6?"U_%(SV<W[F;:<30L,QN#[J1]"#Z5QOD2?W'
M_P"^37[LW_A[2]5G$UYIUK=S8VAYX5=L ],D=.3^=5AX+T#_ * FG?\ @+'_
M (5]A3XA<8*,H7:\SX2KPNI3<H5+)^1Y)^P^I7]E_P $ @@^5<<'_KZEHKVZ
HTLX+"W2"UACMH%^['$H51WX Z45\G5G[6<I]V?:T:?L*4:6]E8__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140642630395760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2023 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-13252<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">McKESSON CORPORATION<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">94-3207296<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">6555 State Hwy 161<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Irving<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">TX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">75039<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">972<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">446-4800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="nump">134,902,380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000927653<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--03-31<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.01 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MCK<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mck_A1500NotesDue2025Member', window );">1.500% Notes Due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.500% Notes due 2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MCK25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mck_A1625NotesDue2026Member', window );">1.625% Notes Due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.625% Notes due 2026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MCK26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mck_A3125NotesDue2029Member', window );">3.125% Notes Due 2029</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">3.125% Notes due 2029<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MCK29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mck_A1500NotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mck_A1500NotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mck_A1625NotesDue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mck_A1625NotesDue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mck_A3125NotesDue2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mck_A3125NotesDue2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140642627963088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 74,483<span></span>
</td>
<td class="nump">$ 67,154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="num">(71,461)<span></span>
</td>
<td class="num">(64,131)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">3,022<span></span>
</td>
<td class="nump">3,023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, distribution, general, and administrative expenses</a></td>
<td class="num">(1,870)<span></span>
</td>
<td class="num">(1,959)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Claims and litigation charges, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mck_RestructuringImpairmentAndOtherRelatedCharges', window );">Restructuring, impairment, and related charges, net</a></td>
<td class="num">(52)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="num">(1,922)<span></span>
</td>
<td class="num">(1,987)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">1,100<span></span>
</td>
<td class="nump">1,036<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(47)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income from continuing operations before income taxes</a></td>
<td class="nump">1,091<span></span>
</td>
<td class="nump">1,006<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(94)<span></span>
</td>
<td class="num">(199)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Income from continuing operations</a></td>
<td class="nump">997<span></span>
</td>
<td class="nump">807<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Income from discontinued operations, net of tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">997<span></span>
</td>
<td class="nump">809<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income attributable to noncontrolling interests</a></td>
<td class="num">(39)<span></span>
</td>
<td class="num">(41)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to McKesson Corporation</a></td>
<td class="nump">$ 958<span></span>
</td>
<td class="nump">$ 768<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Diluted</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Continuing operations (in usd per share)</a></td>
<td class="nump">$ 7.02<span></span>
</td>
<td class="nump">$ 5.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Discontinued operations (in usd per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0.01<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Total (in dollars per share)</a></td>
<td class="nump">7.02<span></span>
</td>
<td class="nump">5.26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Continuing operations (in usd per share)</a></td>
<td class="nump">7.07<span></span>
</td>
<td class="nump">5.31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Discontinued operations (in usd per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0.01<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Total (in dollars per share)</a></td>
<td class="nump">$ 7.07<span></span>
</td>
<td class="nump">$ 5.32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average common shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in usd per share)</a></td>
<td class="nump">136.6<span></span>
</td>
<td class="nump">145.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">135.5<span></span>
</td>
<td class="nump">144.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mck_RestructuringImpairmentAndOtherRelatedCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring, Impairment and Other Related Charges</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mck_RestructuringImpairmentAndOtherRelatedCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mck_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482551/740-270-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-4<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479836/810-10-S99-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140642631056720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 997<span></span>
</td>
<td class="nump">$ 809<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Other comprehensive income, net of tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">582<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Unrealized gains on cash flow and other hedges</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Changes in retirement-related benefit plans</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income, net of tax</a></td>
<td class="nump">57<span></span>
</td>
<td class="nump">636<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income</a></td>
<td class="nump">1,054<span></span>
</td>
<td class="nump">1,445<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive income attributable to noncontrolling interests</a></td>
<td class="num">(39)<span></span>
</td>
<td class="num">(91)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income attributable to McKesson Corporation</a></td>
<td class="nump">$ 1,015<span></span>
</td>
<td class="nump">$ 1,354<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140642628054528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 2,636<span></span>
</td>
<td class="nump">$ 4,678<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables, net</a></td>
<td class="nump">21,860<span></span>
</td>
<td class="nump">19,410<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">20,510<span></span>
</td>
<td class="nump">19,691<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other</a></td>
<td class="nump">533<span></span>
</td>
<td class="nump">513<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">45,539<span></span>
</td>
<td class="nump">44,292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant, and equipment, net</a></td>
<td class="nump">2,172<span></span>
</td>
<td class="nump">2,177<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">1,693<span></span>
</td>
<td class="nump">1,635<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">9,971<span></span>
</td>
<td class="nump">9,947<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">2,221<span></span>
</td>
<td class="nump">2,277<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">2,500<span></span>
</td>
<td class="nump">1,992<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">64,096<span></span>
</td>
<td class="nump">62,320<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Drafts and accounts payable</a></td>
<td class="nump">43,982<span></span>
</td>
<td class="nump">42,490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Current portion of long-term debt</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">968<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liabilities</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">4,090<span></span>
</td>
<td class="nump">4,200<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">48,422<span></span>
</td>
<td class="nump">47,957<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Long-term debt</a></td>
<td class="nump">5,611<span></span>
</td>
<td class="nump">4,626<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Long-term deferred tax liabilities</a></td>
<td class="nump">1,139<span></span>
</td>
<td class="nump">1,387<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">1,462<span></span>
</td>
<td class="nump">1,402<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationReserveNoncurrent', window );">Long-term litigation liabilities</a></td>
<td class="nump">6,628<span></span>
</td>
<td class="nump">6,625<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">2,074<span></span>
</td>
<td class="nump">1,813<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>McKesson Corporation stockholders&#8217; deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.01 par value, 100 shares authorized, no shares issued or outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value, 800 shares authorized, 278 and 277 shares issued at June 30, 2023 and March 31, 2023, respectively</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">7,824<span></span>
</td>
<td class="nump">7,747<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">13,182<span></span>
</td>
<td class="nump">12,295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(848)<span></span>
</td>
<td class="num">(905)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonValue', window );">Treasury shares, at cost, 143 and 141 shares at June 30, 2023 and March 31, 2023, respectively</a></td>
<td class="num">(21,763)<span></span>
</td>
<td class="num">(20,997)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total McKesson Corporation stockholders&#8217; deficit</a></td>
<td class="num">(1,602)<span></span>
</td>
<td class="num">(1,857)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="nump">362<span></span>
</td>
<td class="nump">367<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total deficit</a></td>
<td class="num">(1,240)<span></span>
</td>
<td class="num">(1,490)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and deficit</a></td>
<td class="nump">$ 64,096<span></span>
</td>
<td class="nump">$ 62,320<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserveNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserveNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481520/505-30-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.30)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140642630859856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>McKesson Corporation stockholders&#8217; deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">800,000,000<span></span>
</td>
<td class="nump">800,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">278,000,000<span></span>
</td>
<td class="nump">277,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury shares (in shares)</a></td>
<td class="nump">143,000,000<span></span>
</td>
<td class="nump">141,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140642625734096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Treasury</div></th>
<th class="th"><div>Noncontrolling Interests</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Beginning balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(130)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Mar. 31, 2022</a></td>
<td class="num">$ (1,792)<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 7,275<span></span>
</td>
<td class="nump">$ 9,030<span></span>
</td>
<td class="num">$ (1,534)<span></span>
</td>
<td class="num">$ (17,045)<span></span>
</td>
<td class="nump">$ 480<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mck_StockIssuedDuringPeriodSharesEmployeeStockPlansNetOfForfeitures', window );">Issuance of shares under employee plans, net of forfeitures (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mck_StockIssuedDuringPeriodValueEmployeeStockPlansNetOfForfeitures', window );">Issuance of shares under employee plans, net of forfeitures</a></td>
<td class="num">(60)<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(152)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common stock</a></td>
<td class="num">(1,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (944)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(56)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mck_NetIncomeLossIncludingPortionAttributabletoNoncontrollingInterestExcludingRedeemableNoncontrollingInterest', window );">Net income (loss)</a></td>
<td class="nump">809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="nump">636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Cash dividends declared</a></td>
<td class="num">(67)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(67)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Payments to noncontrolling interests</a></td>
<td class="num">(36)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mck_NoncontrollingInterestDecreaseFromReclassificationToLiability', window );">Reclassification of recurring compensation to other accrued liabilities</a></td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(133)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="num">$ (1,472)<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 7,350<span></span>
</td>
<td class="nump">9,732<span></span>
</td>
<td class="num">(948)<span></span>
</td>
<td class="num">$ (18,141)<span></span>
</td>
<td class="nump">532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Dividends declared per common share (in dollars per share)</a></td>
<td class="nump">$ 0.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Beginning balance (in shares) at Mar. 31, 2023</a></td>
<td class="num">(141)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(141)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Mar. 31, 2023</a></td>
<td class="num">$ (1,490)<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">7,747<span></span>
</td>
<td class="nump">12,295<span></span>
</td>
<td class="num">(905)<span></span>
</td>
<td class="num">$ (20,997)<span></span>
</td>
<td class="nump">367<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mck_StockIssuedDuringPeriodSharesEmployeeStockPlansNetOfForfeitures', window );">Issuance of shares under employee plans, net of forfeitures (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mck_StockIssuedDuringPeriodValueEmployeeStockPlansNetOfForfeitures', window );">Issuance of shares under employee plans, net of forfeitures</a></td>
<td class="num">(66)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(93)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchase of common stock</a></td>
<td class="num">(673)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (673)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchase of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mck_NetIncomeLossIncludingPortionAttributabletoNoncontrollingInterestExcludingRedeemableNoncontrollingInterest', window );">Net income (loss)</a></td>
<td class="nump">997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="nump">57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Cash dividends declared</a></td>
<td class="num">(73)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(73)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Payments to noncontrolling interests</a></td>
<td class="num">(39)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">278<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Ending balance (in shares) at Jun. 30, 2023</a></td>
<td class="num">(143)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(143)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Jun. 30, 2023</a></td>
<td class="num">$ (1,240)<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 7,824<span></span>
</td>
<td class="nump">$ 13,182<span></span>
</td>
<td class="num">$ (848)<span></span>
</td>
<td class="num">$ (21,763)<span></span>
</td>
<td class="nump">$ 362<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Dividends declared per common share (in dollars per share)</a></td>
<td class="nump">$ 0.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mck_NetIncomeLossIncludingPortionAttributabletoNoncontrollingInterestExcludingRedeemableNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Excluding Redeemable Noncontrolling Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mck_NetIncomeLossIncludingPortionAttributabletoNoncontrollingInterestExcludingRedeemableNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mck_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mck_NoncontrollingInterestDecreaseFromReclassificationToLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest, Decrease from Reclassification to Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mck_NoncontrollingInterestDecreaseFromReclassificationToLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mck_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mck_StockIssuedDuringPeriodSharesEmployeeStockPlansNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Employee Stock Plans Net of Forfeitures</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mck_StockIssuedDuringPeriodSharesEmployeeStockPlansNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mck_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mck_StockIssuedDuringPeriodValueEmployeeStockPlansNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Employee Stock Plans Net of Forfeitures</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mck_StockIssuedDuringPeriodValueEmployeeStockPlansNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mck_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140642630361360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Dividends declared per common share (in dollars per share)</a></td>
<td class="nump">$ 0.54<span></span>
</td>
<td class="nump">$ 0.47<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140642631151088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>OPERATING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 997<span></span>
</td>
<td class="nump">$ 809<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">64<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="nump">95<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetImpairmentCharges', window );">Long-lived asset impairment charges</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Deferred taxes</a></td>
<td class="num">(235)<span></span>
</td>
<td class="nump">109<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLIFOReservePeriodCharge', window );">Credits associated with last-in, first-out inventory method</a></td>
<td class="nump">32<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Non-cash operating lease expense</a></td>
<td class="nump">58<span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfOtherAssets', window );">Gain from sales of businesses and investments</a></td>
<td class="num">(19)<span></span>
</td>
<td class="num">(33)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown', window );">European businesses held for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other non-cash items</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract', window );"><strong>Changes in assets and liabilities, net of acquisitions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Receivables</a></td>
<td class="num">(2,380)<span></span>
</td>
<td class="num">(1,584)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(826)<span></span>
</td>
<td class="num">(955)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Drafts and accounts payable</a></td>
<td class="nump">1,473<span></span>
</td>
<td class="nump">1,006<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(80)<span></span>
</td>
<td class="num">(94)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedTaxesPayable', window );">Taxes</a></td>
<td class="nump">236<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mck_IncreaseDecreaseInLitigationReserve', window );">Litigation liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(370)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other</a></td>
<td class="num">(536)<span></span>
</td>
<td class="num">(186)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(1,052)<span></span>
</td>
<td class="num">(941)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>INVESTING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Payments for property, plant, and equipment</a></td>
<td class="num">(78)<span></span>
</td>
<td class="num">(71)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireSoftware', window );">Capitalized software expenditures</a></td>
<td class="num">(46)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisitions, net of cash, cash equivalents, and restricted cash acquired</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates', window );">Proceeds from sales of businesses and investments, net</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other</a></td>
<td class="num">(64)<span></span>
</td>
<td class="num">(100)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="num">(149)<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>FINANCING ACTIVITIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from short-term borrowings</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Repayments of short-term borrowings</a></td>
<td class="num">(65)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuances of long-term debt</a></td>
<td class="nump">991<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="num">(268)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mck_PaymentsForPurchaseOfGovernmentObligationsForSatisfactionAndDischargeOfLongTermDebt', window );">Purchase of U.S. government obligations for the satisfaction and discharge of long-term debt</a></td>
<td class="num">(647)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptionsAbstract', window );"><strong>Common stock transactions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Issuances</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Share repurchases</a></td>
<td class="num">(696)<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsCommonStock', window );">Dividends paid</a></td>
<td class="num">(74)<span></span>
</td>
<td class="num">(71)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="num">(176)<span></span>
</td>
<td class="num">(199)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(843)<span></span>
</td>
<td class="num">(1,181)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash, cash equivalents, and restricted cash</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mck_CashCashEquivalentsRestrictedCashClassifiedWithinAssetsHeldForSalePeriodIncreaseDecrease', window );">Change in cash, cash equivalents, and restricted cash classified as Assets held for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">470<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash, cash equivalents, and restricted cash</a></td>
<td class="num">(2,042)<span></span>
</td>
<td class="num">(1,595)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at beginning of period</a></td>
<td class="nump">4,679<span></span>
</td>
<td class="nump">3,935<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at end of period</a></td>
<td class="nump">2,637<span></span>
</td>
<td class="nump">2,340<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Less: Restricted cash at end of period included in Prepaid expenses and other</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(107)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">$ 2,636<span></span>
</td>
<td class="nump">$ 2,233<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mck_CashCashEquivalentsRestrictedCashClassifiedWithinAssetsHeldForSalePeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash Classified within Assets Held for Sale, Period Increase (Decrease)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mck_CashCashEquivalentsRestrictedCashClassifiedWithinAssetsHeldForSalePeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mck_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mck_IncreaseDecreaseInLitigationReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Litigation Reserve</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mck_IncreaseDecreaseInLitigationReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mck_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mck_PaymentsForPurchaseOfGovernmentObligationsForSatisfactionAndDischargeOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments For Purchase Of Government Obligations For Satisfaction And Discharge Of Long-Term Debt</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mck_PaymentsForPurchaseOfGovernmentObligationsForSatisfactionAndDischargeOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mck_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period of all taxes owed but not paid, including income, property and other taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLIFOReservePeriodCharge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The change in the inventory reserve representing the cumulative difference in cost between the first in, first out and the last in, first out inventory valuation methods, which change has been reflected in the statement of income during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLIFOReservePeriodCharge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividendsCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividendsCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireSoftware">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition from vendors of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireSoftware</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a business segment or subsidiary or sale of an entity that is related to it but not strictly controlled during the period (for example, an unconsolidated subsidiary, affiliate, joint venture or equity method investment).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140642633668336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text">Significant Accounting Policies<div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nature of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: McKesson Corporation (&#8220;McKesson,&#8221; or the &#8220;Company,&#8221;) is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. McKesson partners with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products, and services to help make quality care more accessible and affordable. The Company reports its financial results in four reportable segments: U.S. Pharmaceutical, Prescription Technology Solutions (&#8220;RxTS&#8221;), Medical-Surgical Solutions, and International. Refer to Financial Note 12, &#8220;Segments of Business,&#8221; for additional information.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements and accompanying notes are prepared in accordance with United States (&#8220;U.S.&#8221;) generally accepted accounting principles (&#8220;GAAP&#8221;) for interim financial reporting and the rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) and therefore do not include all information and disclosures normally included in the annual consolidated financial statements.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements of McKesson include the financial statements of all wholly-owned subsidiaries and majority-owned or controlled companies. For those consolidated subsidiaries where the Company&#8217;s ownership is less than 100%, the portion of the net income or loss allocable to the noncontrolling interests is reported as &#8220;Net income attributable to noncontrolling interests&#8221; in the Condensed Consolidated Statements of Operations. All significant intercompany balances and transactions have been eliminated in consolidation, including the intercompany portion of transactions with equity method investees. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income attributable to noncontrolling interests includes third-party equity interests in the Company&#8217;s consolidated entities, including ClarusONE Sourcing Services LLP, Vantage Oncology Holdings, LLC, and SCRI Oncology, LLC. Net income attributable to noncontrolling interests also included recurring compensation that the Company was obligated to pay to the noncontrolling shareholders of McKesson Europe AG (&#8220;McKesson Europe&#8221;). The Company&#8217;s noncontrolling interest in McKesson Europe was included in the divestiture of certain of the Company&#8217;s businesses in the European Union (&#8220;E.U.&#8221;) in October 2022, which is discussed further in Financial Note 2, &#8220;Business Acquisitions and Divestitures.&#8221; </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers itself to control an entity if it is the majority owner of or has voting control over such entity. The Company also assesses control through means other than voting rights and determines which business entity is the primary beneficiary of the variable interest entity (&#8220;VIE&#8221;). The Company consolidates VIEs when it is determined that it is the primary beneficiary of the VIE. Investments in business entities in which the Company does not have control, but instead has the ability to exercise significant influence over operating and financial policies, are accounted for using the equity method. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fiscal Period:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company&#8217;s fiscal year begins on April 1 and ends on March 31. Unless otherwise noted, all references to a particular year shall mean the Company&#8217;s fiscal year.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reclassifications:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Certain prior period amounts have been reclassified to conform to the current year presentation.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of these financial statements and income and expenses during the reporting period. Actual amounts could differ from those estimated amounts. In the opinion of management, the unaudited condensed consolidated financial statements include all normal recurring adjustments necessary for a fair presentation of the results of operations, financial position, and cash flows of McKesson for the interim periods presented.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations for the three months ended June 30, 2023 are not necessarily indicative of the results that may be anticipated for the entire year. These interim financial statements should be read in conjunction with the annual audited financial statements, accounting policies, and financial notes included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended March 31, 2023, previously filed with the SEC on May&#160;9, 2023 (the &#8220;2023 Annual Report&#8221;).</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 16, 2022, the U.S. government enacted the Inflation Reduction Act of 2022 (the &#8220;IRA&#8221;). Among other provisions, the IRA includes a 15% corporate minimum tax, a 1% excise tax on certain repurchases of an entity&#8217;s own common stock after December 31, 2022, and various drug pricing reforms. The Company does not anticipate that this guidance will have a material impact on its consolidated financial statements or related disclosures. The Company will continue to evaluate the full impact of these legislative changes as they are announced and implemented. Refer to Financial Note 11, &#8220;Stockholders' Deficit,&#8221; for further details regarding excise taxes incurred on the Company&#8217;s share repurchases during the three months ended June 30, 2023.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Pronouncements </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no accounting standards adopted by the Company during the three months ended June 30, 2023.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Issued Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Financial Accounting Standards Board issued Accounting Standards Update (&#8220;ASU&#8221;) 2022-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which clarifies the guidance when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of such equity security, and requires additional disclosure requirements. ASU 2022-03 is effective for the Company on a prospective basis for fiscal years beginning after December 15, 2023, with early adoption permitted. The Company does not anticipate that this guidance will have a material impact on its consolidated financial statements or related disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140642635602592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Acquisitions and Divestitures<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock', window );">Business Acquisitions and Divestitures</a></td>
<td class="text">Business Acquisitions and Divestitures<div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisitions </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rx Savings Solutions, LLC</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 1, 2022, the Company completed its acquisition of 100% of the shares of Rx Savings Solutions, LLC (&#8220;RxSS&#8221;), a privately-owned company headquartered in Overland Park, Kansas, to further connect biopharma and payer services to patients. RxSS is a prescription price transparency and benefit insight company that offers affordability and adherence solutions to health plans and employers. The purchase consideration included a payment of $600&#160;million in cash made upon closing and a maximum of $275&#160;million of contingent consideration based on RxSS&#8217; operational and financial performance through calendar year 2025. The payment made upon closing was funded from cash on hand. The financial results of RxSS are included in the Company&#8217;s RxTS segment as of the acquisition date. The transaction was accounted for as a business combination.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded a liability for the contingent consideration at its fair value of $92&#160;million as of the acquisition date. The fair value of the contingent consideration liability was estimated using a Monte Carlo simulation model, utilizing internal cash flow projections which are Level 3 inputs under Accounting Standards Codification (&#8220;ASC&#8221;) Topic 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The contingent liability will be remeasured to fair value at each reporting date until the liability is settled with changes in fair value being recognized within &#8220;Selling, distribution, general, and administrative expenses&#8221; in the Company&#8217;s Condensed Consolidated Statements of Operations. During the three months ended June 30, 2023, the Company recognized a fair value adjustment gain of $28&#160;million, which reduced its contingent consideration liability, based on the estimated amount and timing of projected operational and financial information and the probability of achievement of certain performance milestones. As of June 30, 2023 and March 31, 2023, the current portion of $45&#160;million and $83&#160;million, respectively, is included within &#8220;Other accrued liabilities&#8221; and the long-term portion of $19&#160;million and $9&#160;million, respectively, is included within &#8220;Other non-current liabilities&#8221; in the Company&#8217;s Condensed Consolidated Balance Sheets. Recognition of the initial fair value of this contingent consideration was a non-cash investing activity. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price allocation included acquired identifiable intangible assets of $229&#160;million, primarily representing customer relationships and technology with a weighted average amortization period of 12 years, and goodwill of $463&#160;million. Goodwill has been allocated to the Company&#8217;s RxTS segment, which reflects the expected future benefits from certain synergies and intangible assets that do not qualify for separate recognition. Goodwill attributable to the acquisition is deductible for tax purposes.</span></div><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the preliminary purchase price allocation for this acquisition:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.368%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts Recognized as of Acquisition Date (As Adjusted)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchase consideration:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total purchase consideration</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">692&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identifiable assets acquired and liabilities assumed:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total identifiable net assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net assets acquired</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">692&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SCRI Oncology, LLC</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 31, 2022, the Company completed a transaction with HCA Healthcare, Inc. (&#8220;HCA&#8221;) to form SCRI Oncology, LLC (&#8220;SCRI Oncology&#8221;), an oncology research business combining McKesson&#8217;s U.S. Oncology Research (&#8220;USOR&#8221;) and HCA&#8217;s Sarah Cannon Research Institute (&#8220;SCRI&#8221;) based in Nashville, Tennessee, to advance cancer care and increase access to oncology clinical research. Upon consummation of the transaction, McKesson owns a 51% controlling interest in the combined business, and the financial results are consolidated by the Company and reported within its U.S. Pharmaceutical segment as of the acquisition date. Transaction consideration included the transfer of full ownership interest in USOR to the combined business and $166&#160;million of net cash paid to HCA, which was funded from cash on hand. The transaction was accounted for as a business combination.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price allocation included acquired identifiable intangible assets of $177&#160;million, primarily representing customer relationships as well as trademarks and trade names with a weighted average amortization period of 17 years, and goodwill of $113&#160;million. Goodwill has been allocated to the Company&#8217;s U.S. Pharmaceutical segment, which reflects the expected future benefits from certain synergies and intangible assets that do not qualify for separate recognition. Goodwill attributable to the acquisition of $46&#160;million is deductible for tax purposes. The Company recorded noncontrolling interest of $222&#160;million as a component of equity, which includes HCA&#8217;s proportionate interest in the identifiable net assets of SCRI at fair value of $202&#160;million and its proportionate interest in the contributed net assets of USOR at carrying value of $20&#160;million. The difference between the fair value of the Company&#8217;s acquired interest in SCRI net assets and the $166&#160;million of net cash paid to HCA was recognized as additional paid in capital, as well as the Company&#8217;s reduction in ownership interest in USOR net assets. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the preliminary purchase price allocation for this acquisition:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.368%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts Recognized as of Acquisition Date (As Adjusted)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchase consideration:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contribution of USOR</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total purchase consideration</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identifiable assets acquired and liabilities assumed:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant, and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total identifiable net assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(222)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net assets acquired</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the acquired identifiable intangible assets from the acquisitions discussed above were determined by applying the income approach, using a discounted cash flow model in which cash flows anticipated over several periods are discounted to their present value using an appropriate rate that is commensurate with the risk inherent with the transaction. These inputs are considered Level 3 inputs under the fair value measurements and disclosure guidance. The amounts presented above are subject to change as the Company&#8217;s fair value assessments are finalized. There have been no material changes to the purchase price allocation of these acquisitions since the acquisition date. Pro forma financial information has not been provided as these acquisitions did not have a material impact, individually, or in the aggregate, to the Company&#8217;s consolidated results of operations.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Divestitures</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">European Divestiture Activities</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, the Company announced its intention to exit its businesses in Europe. On October 31, 2022, the Company completed its previously announced transaction to sell certain of its businesses in the European Union (&#8220;E.U.&#8221;) located in France, Italy, Ireland, Portugal, Belgium, and Slovenia, along with its German headquarters and wound-care business, part of a shared services center in Lithuania, and its ownership stake in a joint venture in the Netherlands (&#8220;E.U. disposal group&#8221;) to the PHOENIX Group. During the three months ended June 30, 2022, the Company recorded a gain of $12&#160;million to remeasure the E.U. disposal group to fair value less costs to sell which was recorded within &#8220;Selling, distribution, general, and administrative expenses&#8221; in the Condensed Consolidated Statement of Operations. The Company&#8217;s measurement of the fair value of the E.U. disposal group was based on the total consideration expected to be received by the Company as outlined in the transaction agreement. Certain components of the total consideration included fair value measurements that fall within Level 3 of the fair value hierarchy.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 6, 2022, the Company completed the previously announced sale of its retail and distribution businesses in the United Kingdom (&#8220;U.K. disposal group&#8221;) to Aurelius Elephant Limited for a purchase price of &#163;110&#160;million (or, approximately $144&#160;million), including certain adjustments. As part of the transaction, the Company divested net assets of $615&#160;million and released $731&#160;million of accumulated other comprehensive loss, within the International segment, and the buyer assumed and repaid a note payable to the Company of $118&#160;million.</span></div>At June 30, 2023 and March 31, 2023, the Company had no assets or liabilities related to these European divestiture activities that met the criteria for classification as held for sale. Subsequent to the divestiture activities discussed above, the Company&#8217;s European operations primarily consist of its retail and distribution businesses in Norway.<div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the periods presented, the Company also completed de minimis acquisitions and divestitures within its operating segments. Financial results for the Company&#8217;s business acquisitions have been included in its consolidated financial statements as of their respective acquisition dates. Purchase prices for business acquisitions have been allocated based on estimated fair values at the respective acquisition dates.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//805/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140642635660992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring, Impairment, and Related Charges, Net<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring, Impairment, and Related Charges, Net</a></td>
<td class="text">Restructuring, Impairment, and Related Charges, Net<div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded restructuring, impairment, and related charges, net of $52 million and $23 million for the three months ended June 30, 2023 and 2022, respectively. These charges were included in &#8220;Restructuring, impairment, and related charges, net&#8221; in the Condensed Consolidated Statements of Operations. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring Initiatives</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of fiscal 2023, the Company approved a broad set of initiatives to drive operational efficiencies and increase cost optimization efforts, with the intent of simplifying its infrastructure and realizing long-term sustainable growth. These initiatives include headcount reductions and the exit or downsizing of certain facilities. The Company anticipates total charges of approximately $125 million across its RxTS and U.S. Pharmaceutical segments as well as Corporate, consisting primarily of employee severance and other employee-related costs, facility and other exit-related costs, as well as long-lived asset impairments. Of this amount, $96 million of charges were recorded to date. For the three months ended June 30, 2023, the Company recorded charges of $36 million related to this program, which primarily includes real estate and other related asset impairments and facility costs within Corporate. This restructuring program is anticipated to be substantially complete by the end of fiscal 2024. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring, impairment, and related charges, net for the three months ended June 30, 2023 and 2022 consisted of the following: </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:20.861%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.102%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.173%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.784%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. Pharmaceutical</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Prescription Technology Solutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical-Surgical Solutions</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">International</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance and employee-related costs, net </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exit and other-related costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairments and accelerated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company&#8217;s technology solutions. </span></div><div style="margin-bottom:12pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred. </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:21.008%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.102%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.173%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.784%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.737%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. Pharmaceutical</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Prescription Technology Solutions</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical-Surgical Solutions</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance and employee-related costs, net </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exit and other-related costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairments and accelerated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to the liabilities associated with the Company&#8217;s restructuring initiatives for the three months ended June 30, 2023:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.946%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.263%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Prescription Technology Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical-Surgical Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, March 31, 2023 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, impairment, and related charges, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, June 30, 2023 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">As of March 31, 2023, the total reserve balance was $92 million, of which $66 million was recorded in &#8220;Other accrued liabilities&#8221; and $26 million was recorded in &#8220;Other non-current liabilities&#8221; in the Company&#8217;s Condensed Consolidated Balance Sheet.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Other primarily includes cumulative translation adjustments and transfers to certain other liabilities. </span></div><div style="margin-bottom:12pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">As of June 30, 2023, the total reserve balance was $74 million, of which $44 million was recorded in &#8220;Other accrued liabilities&#8221; and $30 million was recorded in &#8220;Other non-current liabilities&#8221; in the Company&#8217;s Condensed Consolidated Balance Sheet.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//420/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140642635658992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes <div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense related to continuing operations was as follows:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.574%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(Dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported income tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fluctuations in the Company&#8217;s reported income tax rates were primarily due to changes in the mix of earnings between various taxing jurisdictions and discrete items recognized in the quarters.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June 30, 2023, the Company repatriated certain intellectual property between McKesson wholly-owned legal entities that are based in different tax jurisdictions. The transferor entity of the intellectual property was not subject to income tax on this transaction. The recipient entity of the intellectual property is entitled to amortize the fair value of the assets for tax purposes. As a result of this repatriation, and in accordance with ASU 2016-16, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intra-Entity Transfers of Assets Other Than Inventory</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a net discrete tax benefit of $147&#160;million was recognized in the first quarter of fiscal 2024. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June 30, 2022, the Company recognized a net discrete tax benefit of $45&#160;million primarily related to the tax impact of share-based compensation.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June 30, 2023, the Company had $1.4 billion of unrecognized tax benefits, of which $1.3 billion would reduce income tax expense and the effective tax rate if recognized. During the next twelve months, the Company does not anticipate any material reduction in its unrecognized tax benefits based on the information currently available. However, this may change as the Company continues to have ongoing discussions with various taxing authorities throughout the year. &#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company files income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions, and various foreign jurisdictions. The Company is generally subject to audit by taxing authorities in various U.S. states and in foreign jurisdictions for fiscal years 2016 through the current fiscal year. </span></div>During the fourth quarter of fiscal 2023, the Internal Revenue Service (&#8220;IRS&#8221;) communicated proposed adjustments to taxable income reported in the Company&#8217;s fiscal 2018 and fiscal 2019 U.S. Federal Corporate Income Tax returns. The adjustments would increase the Company&#8217;s federal income tax liability in the range of $600&#160;million to $700&#160;million. The Company disagrees with the proposed adjustments and intends to pursue resolution through the administrative process with the IRS Independent Office of Appeals and, if necessary, through judicial remedies. During the first quarter of fiscal 2024, the Company filed a formal protest with the IRS. The Company does not anticipate a final resolution of these matters until fiscal 2026 or after. Although the final resolution of these matters is uncertain, the Company believes in the merits of its tax positions and believes that it has adequately reserved for any adjustments to the provision of income taxes that may ultimately result. However, if the IRS prevails in these matters, the assessed tax and interest could have a material adverse effect on the Company&#8217;s financial position, results of operations, and cash flows in future periods.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140642635660992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Common Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Common Share</a></td>
<td class="text">Earnings Per Common ShareBasic earnings per common share is computed by dividing net income by the weighted-average number of common shares outstanding during the reporting period. The computation of diluted earnings per common share is similar to that of basic earnings per common share, except that the former reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock. Potentially dilutive securities include outstanding stock options, restricted stock units, and performance-based restricted stock units. Less than 1.0 million of potentially dilutive securities for the three months ended June 30, 2023 and 2022 were excluded from the computation of diluted earnings per common share as they were anti-dilutive.<div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The computations for basic and diluted earnings per common share were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.574%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions, except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">997&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">807&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations attributable to McKesson Corporation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">958&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">766&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to McKesson Corporation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">958&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">768&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per common share attributable to McKesson Corporation: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.02&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.02&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.26&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.07&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.07&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.32&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes dilutive effect from restricted stock units and performance-based stock units.</span></div><div style="margin-bottom:12pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Certain computations may reflect rounding adjustments.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140642635657760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets, Net</a></td>
<td class="text">Goodwill and Intangible Assets, Net <div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates goodwill for impairment on an annual basis in the first fiscal quarter, and more frequently if indicators for potential impairment exist. Goodwill impairment testing is conducted at the reporting unit level, which is generally defined as an operating segment or one level below an operating segment (also known as a component), for which discrete financial information is available and segment management regularly reviews the operating results of that reporting unit. The annual impairment testing performed in fiscal 2024 and fiscal 2023 did not indicate any impairment of goodwill. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the carrying amount of goodwill were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:26.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.652%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. Pharmaceutical </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Prescription Technology Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical-Surgical Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">International</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, March 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,050&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,005&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,453&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,439&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,947&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other adjustments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, June 30, 2023</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,045&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,005&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,453&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,468&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,971&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The goodwill balance allocated to the U.S. Pharmaceutical segment related to McKesson Europe&#8217;s Celesio AG acquisition no longer reflects foreign currency translation adjustments as its functional currency was changed from Euros to U.S. dollars with the completion of the sale of the E.U. disposal group.</span></div><div style="margin-bottom:12pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes purchase price allocation adjustments related to the formation of SCRI Oncology, which is discussed in Financial Note 2, &#8220;Business Acquisitions and Divestitures.&#8221;</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangible Assets</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding intangible assets was as follows: </span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:23.716%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.032%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.032%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.156%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(Dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Amortization<br/>Period<br/>(Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,984&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,801)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,183&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,971&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,765)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,206&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service agreements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(641)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(623)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks and trade names</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(446)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">833&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(430)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(133)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(174)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(174)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,416&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,195)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,221&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,398&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,121)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,277&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>All intangible assets were subject to amortization as of June 30, 2023 and March 31, 2023. Amortization expense of intangible assets was $62 million and $56 million for the three months ended June 30, 2023 and 2022, respectively. Estimated amortization expense of the assets listed in the table above is as follows: $185 million, $240 million, $208 million, $202 million, and $198 million for the remainder of fiscal 2024 and each of the succeeding years through fiscal 2028, respectively, and $1.2 billion thereafter.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140642633668336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt and Financing Activities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt and Financing Activities</a></td>
<td class="text">Debt and Financing Activities<div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.636%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">U.S. Dollar notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1) (2)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.80% Notes due March 15, 2024</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">918&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.90% Notes due December 3, 2025</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.25% Notes due February 15, 2026</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.30% Notes due August 15, 2026</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.65% Debentures due March 1, 2027</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.95% Notes due February 16, 2028</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.90% Notes due July 15, 2028</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.75% Notes due May 30, 2029</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.10% Notes due July 15, 2033</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">596&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.00% Notes due March 1, 2041</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.88% Notes due March 15, 2044</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Foreign currency notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1) (3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.50% Euro Notes due November 17, 2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">653&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">649&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.63% Euro Notes due October 30, 2026 </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.13% Sterling Notes due February 17, 2029</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">571&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">555&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease and other obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,661&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,594&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">968&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,611&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,626&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">These notes are unsecured and unsubordinated obligations of the Company.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Interest on these U.S. dollar notes is payable semi-annually.</span></div><div style="margin-bottom:12pt;margin-top:3pt;padding-left:18pt;padding-right:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Interest on these foreign currency notes is payable annually.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-Term Debt</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s long-term debt includes both U.S. dollar and foreign currency-denominated borrowings. At June 30, 2023 and March 31, 2023, $5.7 billion and $5.6 billion, respectively, of total debt was outstanding, of which $50 million and $968 million, respectively, was included under the caption &#8220;Current portion of long-term debt&#8221; in the Company&#8217;s Condensed Consolidated Balance Sheets. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Notes Offerings</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 15, 2023, the Company completed a public offering of 4.90% Notes due July 15, 2028 in a principal amount of $400 million (the &#8220;2028 Notes&#8221;) and a public offering of 5.10% Notes due July 15, 2033 in a principal amount of $600 million (the &#8220;2033 Notes&#8221; and, together with the 2028 Notes, the &#8220;Notes&#8221;). Interest on the Notes is payable semi-annually on January 15th and July 15th of each year, commencing on January 15, 2024. Proceeds received from the issuance of the Notes, net of discounts and offering expenses, were $397 million for the 2028 Notes and $592 million for the 2033 Notes. The Company utilized a portion of the net proceeds from the offerings of the Notes to fund the purchase price payable with respect to the  portion of the Company&#8217;s then outstanding 3.80% Notes due March 15, 2024 (the &#8220;2024 Notes&#8221;) that was validly tendered and accepted for purchase pursuant to the Concurrent Tender Offer (as defined below) and to effect the satisfaction and discharge of the remaining portion of the 2024 Notes, all of which is described further below. The remaining net proceeds from the offerings of the Notes is available for general corporate purposes.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each series of the Notes is an unsecured and unsubordinated obligation of the Company and ranks equally with all of the Company&#8217;s existing, and future unsecured and unsubordinated indebtedness that may be outstanding from time-to-time. The Notes are governed by an indenture and officers&#8217; certificate that are materially similar to those of other series of notes issued by the Company. Upon at least 10 days&#8217; and not more than 60 days&#8217; notice to holders of the applicable series of the Notes, the Company may redeem either series of the Notes for cash in whole, at any time, or in part, from time to time, at redemption prices that include accrued and unpaid interest and a make-whole premium before a specified date, and at par plus accrued and unpaid interest thereafter until maturity, each as specified in the indenture and the officers&#8217; certificate. If there were to occur both (1) a change of control of the Company and (2) a downgrade of the applicable series of the Notes below an investment grade rating by each of the Ratings Agencies (as defined in the officers&#8217; certificate) within a specified period, then the Company would be required to make an offer to purchase those Notes at a price equal to 101% of the then outstanding principal amount of such Notes, plus accrued and unpaid interest to, but not including, the date of repurchase. The indenture and the related officers&#8217; certificate for the Notes, subject to the exceptions and in compliance with the conditions as applicable, specify that the Company may not consolidate, merge or sell all or substantially all of its assets, incur liens, or enter into sale-leaseback transactions exceeding specific terms, without the lenders&#8217; consent. The indenture also contains customary events of default provisions.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concurrent Tender Offer </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 16, 2023, the Company completed a cash tender offer for any and all of its then outstanding 2024 Notes, which was made concurrently with the offerings of the Notes (the &#8220;Concurrent Tender Offer&#8221;). The Company paid an aggregate consideration of $268 million in the Concurrent Tender Offer to repurchase $271 million principal amount of the 2024 Notes at a repurchase price equal to 98.75% of the principal amount plus accrued and unpaid interest. The repurchase of the 2024 Notes accepted for purchase in the Concurrent Tender Offer was accounted for as a debt extinguishment. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Satisfaction and Discharge of the 2024 Notes</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 16, 2023, after completing the Concurrent Tender Offer, the Company irrevocably deposited with the trustee under the indenture governing the 2024 Notes (the &#8220;2024 Notes Indenture&#8221;) U.S. government obligations in an amount sufficient to fund the payment of accrued and unpaid interest of the remaining $647&#160;million principal amount of the 2024 Notes as it becomes due, and of the principal amount of those 2024 Notes on their March 15, 2024 maturity date. The U.S. government obligations were purchased using a portion of the net proceeds from the offerings of the Notes. After the deposit of such funds with the trustee, the Company&#8217;s obligations under the 2024 Notes Indenture with respect to the 2024 Notes were satisfied and discharged and the transaction was accounted for as a debt extinguishment. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total gain recognized on the debt extinguishments described above for the three months ended June 30, 2023 was $9 million and included within &#8220;Interest expense&#8221; in the Company&#8217;s Condensed Consolidated Statement of Operations.  </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revolving Credit Facilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 7, 2022, the Company entered into a Credit Agreement (the &#8220;2022 Credit Facility&#8221;), that provides a syndicated $4.0 billion five-year senior unsecured credit facility with a $3.6 billion aggregate sublimit of availability in Canadian dollars, British pound sterling, and Euro. The 2022 Credit Facility is scheduled to mature in November 2027. The 2022 Credit Facility replaced the Company&#8217;s previous syndicated $4.0 billion five-year senior unsecured credit facility, dated as of September 25, 2019, as amended (the &#8220;2020 Credit Facility&#8221;), which was scheduled to mature in September 2024. The 2020 Credit Facility was terminated in connection with the execution of the 2022 Credit Facility. There were no borrowings under the 2020 Credit Facility during the three months ended June 30, 2022, and no amounts outstanding at the time of its termination. There were no borrowings under the 2022 Credit Facility during the three months ended June 30, 2023 and no amounts outstanding at June 30, 2023. At June 30, 2023, the Company was in compliance with all covenants under the 2022 Credit Facility. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commercial Paper</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a commercial paper program to support its working capital requirements and for other general corporate purposes. Under the program, the Company can issue up to $4.0 billion in outstanding commercial paper notes. During the three months ended June 30, 2023, the Company borrowed and repaid $65 million under the program. During the three months ended June 30, 2022, there were no material borrowings under the program. At June 30, 2023 and March 31, 2023, there were no commercial paper notes outstanding.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//470/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140642635777760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Hedging Activities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Hedging Activities</a></td>
<td class="text">Hedging Activities <div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company is exposed to interest rate and foreign currency exchange rate fluctuations. At times, the Company limits these risks through the use of derivatives as described below. In accordance with the Company&#8217;s policy, derivatives are only used for hedging purposes. It does not use derivatives for trading or speculative purposes. The Company uses different counterparties for its derivative contracts to minimize the exposure to credit risk but does not anticipate non-performance by these parties.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Exchange Risk</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company conducts its business worldwide in U.S. dollars and the functional currencies of its foreign subsidiaries, including Canadian dollars, Euro, and British pounds sterling. Changes in foreign currency exchange rates could have a material adverse impact on the Company&#8217;s financial results that are reported in U.S. dollars. The Company is also exposed to foreign currency exchange rate risk related to its foreign subsidiaries, including intercompany loans denominated in non-functional currencies. The Company has certain foreign currency exchange rate risk programs that use cross-currency swaps. These forward contracts and cross-currency swaps are generally used to offset the potential income statement effects from intercompany loans and other obligations denominated in non-functional currencies. These programs reduce but do not entirely eliminate foreign currency exchange rate risk. </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Derivative Instruments Designated as Hedges</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the divestiture of the E.U. disposal group, the Company had &#8364;1.1 billion of Euro-denominated notes designated as non-derivative net investment hedges. These hedges were utilized to hedge portions of the Company&#8217;s net investments in non-U.S. subsidiaries against the effect of exchange rate fluctuations on the translation of foreign currency balances to the U.S. dollar. For all notes that were designated as net investment hedges and met effectiveness requirements, the changes in carrying value of the notes attributable to the change in spot rates were recorded as foreign currency translation adjustments in &#8220;Accumulated other comprehensive loss&#8221; where they offset foreign currency translation gains and losses recorded on the Company&#8217;s net investments.&#160;To the extent foreign currency denominated notes designated as net investment hedges were ineffective, changes in carrying value attributable to the change in spot rates were recorded in earnings. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In connection with the divestiture of the E.U. disposal group in October 2022, the Euro-denominated notes described above were de-designated as net investment hedges.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the sale of the U.K. disposal group in April 2022, the Company reclassified $26&#160;million of gains from accumulated other comprehensive loss to &#8220;Selling, distribution, general, and administrative expenses&#8221; in the Condensed Consolidated Statement of Operations for the three months ended June 30, 2022. This amount related to the Company&#8217;s &#163;450 million of British pound sterling-denominated notes, which were previously accounted for as net investment hedges until de-designated in fiscal 2020, and was included in the fiscal 2022 calculation of charges to remeasure the assets and liabilities of the disposal group to fair value less costs to sell.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency gains (losses) from non-derivative instruments included in other comprehensive income in the Condensed Consolidated Statements of Comprehensive Income were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.531%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.574%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-derivatives designated as net investment hedges: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Euro-denominated notes </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">There was no ineffectiveness in these hedges for the three months ended June 30, 2022.</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Instruments</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June 30, 2023 and March 31, 2023, the notional amounts of the Company&#8217;s outstanding derivatives were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:42.640%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.178%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.658%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.480%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.336%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Currency</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity Date</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notional</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as net investment hedges: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swaps </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CAD</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-24 to Mar-25</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as fair value hedges: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swaps </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GBP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-28</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#163;</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#163;</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swaps </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EUR</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aug-25 to Jul-26</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8364;</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8364;</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Floating interest rate swaps </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">USD</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Feb-26 to Sep-29</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as cash flow hedges: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swaps </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CAD</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jan-24</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed interest rate swaps </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">USD</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jun-23</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The maturity date reflected is for outstanding derivatives as of June 30, 2023.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">There was no ineffectiveness in these hedges for the three months ended June 30, 2023 and 2022.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The Company agreed with third parties to exchange fixed interest payments in one currency for fixed interest payments in another currency at specified intervals and to exchange principal in one currency for principal in another currency, calculated by reference to agreed-upon notional amounts.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Represents cross-currency fixed-to-fixed interest rate swaps to mitigate the foreign currency exchange fluctuations on its foreign currency-denominated notes. </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Represents fixed-to-floating interest rate swaps to hedge the changes in fair value caused by fluctuations in the benchmark interest rates. </span></div><div style="margin-bottom:12pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The Company entered into agreements with financial institutions to lock into the fixed benchmark interest rates for future bond issuance, which were terminated during the first quarter of fiscal 2024 as discussed further below.</span></div><div style="margin-bottom:6pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Investment Hedges</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses cross-currency swaps to hedge portions of the Company&#8217;s net investments denominated in Canadian dollars against the effect of exchange rate fluctuations on the translation of foreign currency balances to the U.S. dollar. The changes in the fair value of these derivatives attributable to the changes in spot currency exchange rates and differences between spot and forward interest rates are recorded in accumulated other comprehensive loss and offset foreign currency translation gains and losses recorded on the Company&#8217;s net investments denominated in Canadian dollars. To the extent cross-currency swaps designated as hedges are ineffective, changes in carrying value attributable to the change in spot rates are recorded in earnings.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Hedges</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses cross-currency swaps to hedge the changes in the fair value of its foreign currency notes resulting from changes in benchmark interest rates and foreign currency exchange rates. The changes in the fair value of these derivatives and the offsetting changes in the fair value of the hedged notes are recorded in earnings. Gains from the changes in the Company&#8217;s fair value hedges recorded in earnings were largely offset by the losses recorded in earnings on the hedged item. For components excluded from the assessment of hedge effectiveness, the initial value of the excluded component is recognized in accumulated other comprehensive loss and then released into earnings over the life of the hedging instrument. The difference between the change in the fair value of the excluded component and the amount amortized into earnings during the period is recorded in other comprehensive income (loss).</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash Flow Hedges</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company enters into cross-currency swaps to hedge intercompany loans denominated in non-functional currencies to reduce the income statement effects arising from fluctuations in foreign currency rates and also enters into forward contracts to hedge the variability of future benchmark interest rates on planned bond issuances. The effective portion of changes in the fair value&#160;of these hedges is recorded in accumulated other comprehensive loss and reclassified into earnings in the same period in which the hedged transaction affects earnings. Changes in fair values representing hedge ineffectiveness are recognized in current earnings. Gains or losses reclassified from accumulated other comprehensive loss and recorded in &#8220;Selling, distribution, general, and administrative expenses&#8221; in the Condensed Consolidated Statements of Operations were not material for the three months ended June 30, 2023 and 2022.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company entered into forward-starting fixed interest rate swaps designated as cash flow hedges in fiscal 2023 with a notional amount of $450&#160;million, and in the first quarter of fiscal 2024 with a notional amount of $50&#160;million, to hedge the variability of future benchmark interest rates on a planned bond issuance. On June 15, 2023, the Company completed a public offering of the 2033 Notes, at which point the $500&#160;million cash flow hedges were terminated and the proceeds are amortized to interest expense over the life of the 2033 Notes, or 10 years. Refer to Financial Note 7, &#8220;Debt and Financing Activities,&#8221; for additional information on the public offering of the 2033 Notes.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivatives Not Designated as Hedges</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derivative instruments not designated as hedges are marked-to-market at the end of each accounting period with the change in fair value included in earnings. Changes in the fair values for contracts not designated as hedges are recorded directly into earnings in &#8220;Selling, distribution, general, and administrative expenses&#8221; in the Condensed Consolidated Statements of Operations. The Company did not have any outstanding derivative instruments not designated as hedges during the periods presented. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Information on Derivative Instruments</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains (losses) from derivatives included in other comprehensive income in the Condensed Consolidated Statements of Comprehensive Income were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.531%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.574%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as net investment hedges:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swaps</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as cash flow and other hedges:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swaps </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed interest rate swaps</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes other comprehensive income (loss) related to the excluded component of certain fair value hedges.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding the fair value of derivatives on a gross basis were as follows:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.263%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet <br/>Caption</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value of <br/>Derivative</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. Dollar Notional</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value of <br/>Derivative</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. Dollar Notional</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Asset</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liability</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Asset</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liability</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="39" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated for hedge accounting:</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swaps (current)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other/Other accrued liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swaps (non-current)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets/liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps (non-current)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets/liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Financial Note 9, "Fair Value Measurements," for more information on these recurring fair value measurements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-5C<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 815<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//815/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140642635776944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements <div style="margin-bottom:12pt;text-align:justify;text-indent:15.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures certain assets and liabilities at fair value in accordance with ASC Topic 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The fair value hierarchy consists of three levels of inputs that may be used to measure fair value as follows:</span></div><div style="margin-bottom:6pt;padding-left:58.5pt;text-align:justify;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 - quoted prices in active markets for identical assets or liabilities.</span></div><div style="margin-bottom:6pt;padding-left:58.5pt;text-align:justify;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2 - significant other observable market-based inputs.</span></div><div style="margin-bottom:12pt;padding-left:58.5pt;text-align:justify;text-indent:-40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 - significant unobservable inputs for which little or no market data exists and requires considerable assumptions that are significant to the fair value measurement.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents at June 30, 2023 and March 31, 2023 included investments in money market funds of $806 million and $1.4 billion, respectively, which are reported at fair value. The fair value of money market funds was determined using quoted prices for identical investments in active markets, which are considered to be Level 1 inputs under the fair value measurements and disclosure guidance. The carrying value of all other cash equivalents approximates their fair value due to their relatively short-term nature.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair values of the Company&#8217;s interest rate swaps and cross-currency swaps were determined using observable inputs from available market information, including quoted interest rates, foreign currency exchange rates, and other observable inputs from available market information.&#160;These inputs are considered Level 2 under the fair value measurements and disclosure guidance, and may not be representative of actual values that could have been realized or that will be realized in the future. Refer to Financial Note 8, &#8220;Hedging Activities,&#8221; for fair values and other information on the Company&#8217;s derivatives.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company holds investments in equity securities of U.S. growth stage companies that address both current and emerging business challenges in the healthcare industry and which had a carrying value of $237&#160;million at June 30, 2023 and March 31, 2023. These investments primarily consist of equity securities without readily determinable fair values and are included in &#8220;Other non-current assets&#8221; in the Condensed Consolidated Balance Sheets. The carrying value of publicly-traded investments, which was not material for the periods presented, was determined using quoted prices for identical investments in active markets and are considered to be Level 1 inputs. The net realized and unrealized gains as well as impairment charges related to these investments are included within &#8220;Other income, net&#8221; in the Condensed Consolidated Statements of Operations and were not material for the three months ended June 30, 2023 and 2022.  </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to assets and liabilities that are measured at fair value on a recurring basis, the Company&#8217;s assets and liabilities are also subject to nonrecurring fair value measurements. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges or as a result of charges to remeasure assets classified as held for sale to fair value less costs to sell.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June 30, 2023 and  March 31, 2023, the contingent consideration liability related to the Company&#8217;s acquisition of RxSS in November 2022 was measured at fair value on a nonrecurring basis. Refer to Financial Note 2, &#8220;Business Acquisitions and Divestitures," for more information on this transaction. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aforementioned investments in equity securities of U.S. growth stage companies include the carrying value of investments without readily determinable fair values, which were determined using a measurement alternative and are recorded at cost less impairment, plus or minus any changes in observable price from orderly transactions of the same or similar security of the same issuer. These inputs related to changes in observable price are considered Level 2 under the fair value measurements and disclosure guidance and may not be representative of actual values that could have been realized or that will be realized in the future. Inputs related to impairments of investments are generally considered Level 3 fair value measurements due to their inherently unobservable nature based on significant assumptions by management and use of company-specific information.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no other material assets or liabilities measured at fair value on a nonrecurring basis at June 30, 2023 and March 31, 2023.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Fair Value Disclosures</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June 30, 2023 and March 31, 2023, the carrying amounts of cash, certain cash equivalents, restricted cash, receivables, drafts and accounts payable, short-term borrowings, and other current assets and liabilities approximated their estimated fair values because of the short-term maturity of these financial instruments.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the fair value of commercial paper using quoted prices in active markets for identical instruments, which are considered Level 1 inputs under the fair value measurements and disclosure guidance.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s long-term debt is recorded at amortized cost. The carrying value and fair value of the Company&#8217;s long-term debt was as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.698%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, including current maturities</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,661&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,335&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,594&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,386&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the Company&#8217;s long-term debt was determined using quoted market prices in a less active market and other observable inputs from available market information, which are considered to be Level 2 inputs, and may not be representative of actual values that could have been realized or that will be realized in the future.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value assessments of the reporting unit and the reporting unit's net assets, which are performed for goodwill impairment tests, are considered a Level 3 measurement due to the significance of unobservable inputs developed using company-specific information. The Company considered a market approach as well as an income approach using a discounted cash flow (&#8220;DCF&#8221;) model to determine the fair value of each reporting unit.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-lived Assets</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes multiple approaches, including the DCF model and market approaches, for estimating the fair value of intangible assets. The future cash flows used in the analysis are based on internal cash flow projections from its long-range plans and include significant assumptions by management. Accordingly, the fair value assessment of long-lived assets is considered a Level 3 fair value measurement.</span></div>The Company measures certain long-lived and intangible assets at fair value on a nonrecurring basis when events occur that indicate an asset group may not be recoverable. If the carrying amount of an asset group is not recoverable, an impairment charge is recorded to reduce the carrying amount by the excess over its fair value.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140642635598800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingent Liabilities<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingent Liabilities</a></td>
<td class="text">Commitments and Contingent Liabilities<div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to commitments and obligations incurred in the ordinary course of business, the Company is subject to a variety of claims and legal proceedings, including claims from customers and vendors, pending and potential legal actions for damages, governmental investigations, and other matters. The Company and its affiliates are parties to the legal claims and proceedings described below and in </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/927653/000092765323000038/mck-20230331.htm#i04335d018da94076b0acf21e81ac886b_172" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Financial Note 1</a><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/927653/000092765323000038/mck-20230331.htm#i04335d018da94076b0acf21e81ac886b_172" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">7</a><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/927653/000092765323000038/mck-20230331.htm#i04335d018da94076b0acf21e81ac886b_172" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"> to the Company&#8217;s 202</a><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/927653/000092765323000038/mck-20230331.htm#i04335d018da94076b0acf21e81ac886b_172" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">3</a><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/927653/000092765323000038/mck-20230331.htm#i04335d018da94076b0acf21e81ac886b_172" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"> Annual Report</a></span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which disclosure is incorporated in this footnote by this reference. The Company is vigorously defending itself against those claims and in those proceedings. Significant developments in those matters are described below. If the Company is unsuccessful in defending, or if it determines to settle, any of these matters, it may be required to pay substantial sums, be subject to injunction and/or be forced to change how it operates its business, which could have a material adverse impact on its financial position or results of operations.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise stated, the Company is unable to reasonably estimate the loss or a range of possible loss for the matters described below. Often, the Company is unable to determine that a loss is probable, or to reasonably estimate the amount of loss or a range of loss, for a claim because of the limited information available and the potential effects of future events and decisions by third parties, such as courts and regulators, that will determine the ultimate resolution of the claim. Many of the matters described are at preliminary stages, raise novel theories of liability, or seek an indeterminate amount of damages. It is not uncommon for claims to remain unresolved over many years. The Company reviews loss contingencies at least quarterly to determine whether the likelihood of loss has changed and whether it can make a reasonable estimate of the loss or range of loss. When the Company determines that a loss from a claim is probable and reasonably estimable, it records a liability for an estimated amount. The Company also provides disclosure when it is reasonably possible that a loss may be incurred or when it is reasonably possible that the amount of a loss will exceed its recorded liability. Amounts included within &#8220;Claims and litigation charges, net&#8221; in the Condensed Consolidated Statements of Operations consist of estimated loss contingencies related to opioid-related litigation matters.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">I. Litigation and Claims Involving Distribution of Controlled Substances</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its affiliates have been sued as defendants in many cases asserting claims related to distribution of controlled substances. They have been named as defendants along with other pharmaceutical wholesale distributors, pharmaceutical manufacturers, and retail pharmacies. The plaintiffs in these actions have included state attorneys general, county and municipal governments, school districts, tribal nations, hospitals, health and welfare funds, third-party payors, and individuals. These actions have been filed in state and federal courts throughout the U.S., and in Puerto Rico and Canada. They have sought monetary damages and other forms of relief based on a variety of causes of action, including negligence, public nuisance, unjust enrichment, and civil conspiracy, as well as alleging violations of the Racketeer Influenced and Corrupt Organizations Act (&#8220;RICO&#8221;), state and federal controlled substances laws, and other statutes. Because of the many uncertainties associated with opioid-related litigation matters, the Company is not able to conclude that a liability is probable or provide a reasonable estimate for the range of ultimate possible loss for opioid-related litigation matters other than those for which an accrual is described below. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">State and Local Government Claims</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and two other national pharmaceutical distributors (collectively &#8220;Distributors&#8221;) entered into a settlement agreement (the &#8220;Settlement&#8221;) and consent judgment with 48 states and their participating subdivisions, as well as the District of Columbia and all eligible territories (the &#8220;Settling Governmental Entities&#8221;). Approximately 2,300 cases have been dismissed. The Distributors did not admit liability or wrongdoing and do not waive any defenses pursuant to the Settlement. Under the Settlement, the Company has paid the Settling Governmental Entities approximately $1.0&#160;billion as of June 30, 2023, and additionally will pay the Settling Governmental Entities up to approximately $6.8&#160;billion through 2038. A minimum of 85% of the Settlement payments must be used by state and local governmental entities to remediate the opioid epidemic, while the remainder relates to plaintiffs&#8217; attorneys&#8217; fees and costs and will be paid out through 2030. Under the Settlement, the Distributors will establish a clearinghouse to consolidate their controlled-substance distribution data, which will be available to the settling U.S. states to use as part of their anti-diversion efforts. Alabama and West Virginia did not participate in the Settlement. Under a separate settlement agreement with Alabama and its subdivisions, the Company has paid approximately $42&#160;million as of June 30, 2023, and additionally will pay approximately $132&#160;million through 2031. The Company previously settled with the state of West Virginia in 2018, so West Virginia and its subdivisions were not eligible to participate in the Settlement. Under a separate settlement agreement, the Company has paid certain West Virginia subdivisions approximately $38&#160;million as of June 30, 2023, and additionally will pay approximately $114&#160;million through 2033. That agreement does not include school districts or the claims of Cabell County and the City of Huntington. After a trial, the claims of Cabell County and the City of Huntington, were decided in the Company&#8217;s favor on July 4, 2022. Those subdivisions appealed that decision. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some other state and local governmental subdivisions did not participate in the Settlement, including certain municipal governments, government hospitals, school districts, and government-affiliated third-party payors. The Company contends that those subdivisions&#8217; claims are foreclosed by the Settlement or other dispositive defenses, but the subdivisions contend that their claims are not foreclosed. The City of Baltimore, Maryland, is one such subdivision, and a trial of its claims is scheduled to begin September 26, 2024. An accrual for the remaining governmental subdivision claims is reflected in the total estimated liability for opioid-related claims in a manner consistent with how Settlement amounts were allocated to Settling Governmental Entities.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Native American Tribe Claims</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also entered into settlement agreements for opioid-related claims of federally recognized Native American tribes. Under those agreements, the Company has paid the settling Native American tribes approximately $56&#160;million as of June 30, 2023, and additionally will pay approximately $140&#160;million through 2027. A minimum of 85% of the total settlement payments must be used by the settling Native American tribes to remediate the opioid epidemic.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s estimated accrued liability for the opioid-related claims of U.S. governmental entities, including Native American tribes, was as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:68.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.564%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current litigation liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term litigation liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,628&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,625&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total litigation liabilities</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,173&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,173&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">These amounts, recorded in &#8220;Other accrued liabilities&#8221; in the Condensed Consolidated Balance Sheets, are the amounts estimated to be paid within the next twelve months following each respective period end date.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June 30, 2023, the Company made no payments associated with the Settlement and the separate settlement agreements for opioid-related claims discussed above. In July 2023, the Company made payments totaling $529&#160;million associated with the Settlement and separate settlement agreements.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Non-Governmental Plaintiff Claims</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also a defendant in approximately 400 opioid-related cases brought in the U.S. by private plaintiffs, such as hospitals, health and welfare funds, third-party payors, and individuals. These claims, and those of private entities generally, are not included in the settlement agreements described above or in the charges recorded by the Company. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Canadian Plaintiff Claims</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and its Canadian affiliate are also defendants in four opioid-related cases pending in Canada. These cases involve the claims of the provincial governments, a group representing indigenous people, as well as one case brought by an individual.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Defense of Opioids Claims</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes it has valid legal defenses in all opioid-related matters, including claims not covered by settlement agreements, and it intends to mount a vigorous defense in such matters. Other than the settlement agreements and the U.S. governmental subdivision claims described above, the Company has not concluded a loss is probable in any of the matters; nor is any possible loss or range of loss reasonably estimable. An adverse judgment or negotiated resolution in any of these matters could have a material adverse impact on the Company&#8217;s financial position, cash flows or liquidity, or results of operations.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">II. Other Litigation and Claims</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 12, 2018, the Company received a purported class action complaint in the United States District Court for the Northern District of California, alleging that McKesson and two of its former officers, CEO John Hammergren and CFO James Beer, violated the Securities Exchange Act of 1934 by reporting profits and revenues from 2013 until early 2017 that were false and misleading, due to an alleged undisclosed conspiracy to fix the prices of generic drugs. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Evanston Police Pension Fund v. McKesson Corporation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, No. 3:18-06525. In October 2022, the parties reached an agreement in principle to settle this class action lawsuit for an amount covered in full by the Company&#8217;s insurance policy. This settlement does not include any admission of liability, and defendants expressly deny wrongdoing. The Company&#8217;s estimated probable loss, entirely offset by probable loss recovery from the Company&#8217;s insurers, was $141&#160;million, both of which were recognized in the Condensed Consolidated Balance Sheet as of September 30, 2022 within &#8220;Other accrued liabilities&#8221; and &#8220;Prepaid expenses and other.&#8221; In February 2023, the insurance carriers funded the settlement, and the probable loss and loss recovery of $141&#160;million have been reversed in the Consolidated Balance Sheet as of March 31, 2023. On July 14, 2023, the court granted the motion for final approval of the settlement. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, the Company was served with a first amended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> complaint filed in the United States District Court for the Southern District of New York by a relator on behalf of the U.S., 27 states and the District of Columbia against McKesson Corporation, McKesson Specialty Distribution LLC, and McKesson Specialty Care Distribution Corporation, alleging that defendants violated the Anti-Kickback Statute, federal False Claims Act, and various state false claims statutes by providing certain business analytical tools to oncology practice customers, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United States ex rel. Hart v. McKesson Corporation, et al.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 15-cv-00903-RA. The U.S. and the named states have declined to intervene in the case. The complaint seeks relief including damages, treble damages, civil penalties, attorney fees, and costs of suit, all in unspecified amounts. On May 5, 2022, the district court granted the Company&#8217;s motion to dismiss the complaint, but granted the plaintiff leave to amend the complaint. The relator filed the second amended complaint on June 7, 2022, which was dismissed on March 28, 2023. On April 26, 2023, the relator filed a notice of appeal to the United States Court of Appeals for the Second Circuit.  </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">III.&#160;Government Subpoenas and Investigations</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company receives subpoenas or requests for information from various government agencies. The Company generally responds to such subpoenas and requests in a cooperative, thorough, and timely manner. These responses sometimes require time and effort and can result in considerable costs being incurred by the Company. Such subpoenas and requests can lead to the assertion of claims or the commencement of civil or criminal legal proceedings against the Company and other members of the health care industry, as well as to settlements of claims against the Company. The Company responds to these requests in the ordinary course of business.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140642635602592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Deficit<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Deficit</a></td>
<td class="text">Stockholders' Deficit <div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each share of the Company&#8217;s outstanding common stock is permitted one vote on proposals presented to stockholders and is entitled to participate equally in any dividends declared by the Company&#8217;s Board of Directors (the &#8220;Board&#8221;). </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2023, the quarterly dividend was raised from $0.54 to $0.62 per share of common stock for dividends declared on or after such date by the Board. The Company anticipates that it will continue to pay quarterly cash dividends in the future.&#160;However, the payment and amount of future dividends remain within the discretion of the Board and will depend upon the Company's future earnings, financial condition, capital requirements, legal requirements, and other factors. </span></div><div style="margin-bottom:6pt;margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share Repurchase Plans </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board has authorized the repurchase of McKesson&#8217;s common stock. The Company may effect stock repurchases from time-to-time through open market transactions, privately negotiated transactions, accelerated share repurchase (&#8220;ASR&#8221;) programs, or by combinations of such methods, any of which may use pre-arranged trading plans that are designed to meet the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. The timing of any repurchases and the actual number of shares repurchased will depend on a variety of factors, including the Company&#8217;s stock price, corporate and regulatory requirements, tax implications, restrictions under the Company&#8217;s debt obligations, other uses for capital, impacts on the value of remaining shares, and market and economic conditions. The ASR programs discussed below were designed to comply with Rule 10b5-1(c).</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective January 1, 2023, the Company&#8217;s repurchase of McKesson&#8217;s common stock, adjusted for allowable items, are subject to a 1% excise tax as a result of the IRA. Excise taxes incurred on share repurchases of an entity&#8217;s own common stock are direct and incremental costs to purchase treasury stock, and accordingly are included in the total cost basis of the common stock acquired and reflected as a reduction of stockholders&#8217; equity within &#8220;Treasury shares&#8221; in the Company&#8217;s Condensed Consolidated Balance Sheets and Condensed Consolidated Statements of Stockholders&#8217; Deficit. Excise taxes are not reflected in the Company&#8217;s remaining authorization for the repurchase of McKesson&#8217;s common stock.  </span></div><div style="margin-bottom:12pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, the Company entered into an ASR program with a third-party financial institution to repurchase $1.0&#160;billion of the Company&#8217;s common stock. The total number of shares repurchased under this ASR program was 3.1 million shares at an average price per share of $321.05. The Company received 2.6 million shares as the initial share settlement, and in August 2022, the Company received an additional 0.5 million shares upon the completion of this ASR program.</span></div><div style="margin-bottom:12pt;margin-top:3pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, the Company entered into an ASR program with a third-party financial institution to repurchase $1.5 billion of the Company&#8217;s common stock. The total number of shares repurchased under this ASR program was 5.1 million shares at an average price per share of $295.16. The Company received 4.8 million shares as the initial share settlement in the fourth quarter of fiscal 2022, and in May 2022, the Company received an additional 0.3 million shares upon the completion of this ASR program.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June 30, 2023, the Company repurchased 1.8&#160;million of the Company&#8217;s shares of common stock for $673&#160;million through open market transactions at an average price per share of $379.14. Of the total dollar value, $4 million was accrued within &#8220;Other non-current liabilities&#8221; in the Company&#8217;s Condensed Consolidated Balance Sheet for excise taxes incurred during the three months ended June 30, 2023. As of March 31, 2023, the Company had $27&#160;million accrued within &#8220;Other accrued liabilities&#8221; for share repurchases that were executed in late March 2023, which settled in early April 2023. There were no open market share repurchases during the three months ended June 30, 2022.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total remaining authorization outstanding for repurchases of the Company&#8217;s common stock at June 30, 2023 was $2.9 billion. In July 2023, the Board approved an increase of $6.0 billion in the authorization for repurchase of McKesson&#8217;s common stock. </span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accumulated Other Comprehensive Loss </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding changes in accumulated other comprehensive loss, including noncontrolling interests, by components for the three months ended June 30, 2023 and 2022 were as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.657%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.228%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.657%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.333%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustments, Net of Tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Losses on Net Investment Hedges, <br/>Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized  Gains (Losses) on Cash Flow and Other Hedges, <br/>Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Losses and Other Components of Benefit Plans, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Accumulated Other Comprehensive Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, March 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(847)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(905)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8317;&#178;&#8318;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified to earnings and other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: amounts attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) attributable to McKesson</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, June 30, 2023</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(780)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(848)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Primarily results from the conversion of non-U.S. dollar financial statements of the Company&#8217;s operations in Canada and Europe into the Company&#8217;s reporting currency, U.S. dollars.</span></div><div style="margin-bottom:12pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Amounts recorded for the three months ended June 30, 2023 includ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e l</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">osses of $20 million related to net investment hedges from cross-currency swaps, which are net of income tax benefit of $5 million.</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.711%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.025%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.655%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.025%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.025%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.798%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.025%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.798%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.313%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustments, Net of Tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Net Investment Hedges, <br/>Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Gains on Cash Flow and Other  Hedges, <br/>Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) and Other Components of Benefit Plans, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Accumulated Other Comprehensive Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, March 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,504)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,534)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(176)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8317;&#178;&#8318;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified to earnings and other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">730&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">737&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">554&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: amounts attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income attributable to McKesson</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">507&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">586&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, June 30, 2022</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(997)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(948)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Primarily results from the conversion of non-U.S. dollar financial statements of the Company&#8217;s operations in Canada and Europe into the Company&#8217;s reporting currency, U.S. dollars.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Amounts recorded for the three months ended June 30, 2022 include gains of $64 million related to net investment hedges from Euro-denominated notes and gains of $12 million related to net investment hedges from cross-currency swaps. These amounts are net of income tax expense of $31 million.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Primarily included adjustments for amounts related to the sale of the U.K. disposal group, as discussed in more detail in Financial Note 2, &#8220;Business Acquisitions and Divestitures.&#8221; These amounts were included in the fiscal 2022 calculation of charges to remeasure the assets and liabilities held for sale to fair value less costs to sell recorded within &#8220;Selling, distribution, general, and administrative expenses&#8221; in the Consolidated Statements of Operations.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140642635632128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments of Business<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segments of Business</a></td>
<td class="text">Segments of Business<div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reports its financial results in four reportable segments: U.S. Pharmaceutical, RxTS, Medical-Surgical Solutions, and International. The organizational structure also includes Corporate, which consists of income and expenses associated with administrative functions and projects, and the results of certain investments. The factors for determining the reportable segments include the manner in which management evaluates the performance of the Company combined with the nature of the individual business activities. The Company evaluates the performance of its operating segments on a number of measures, including revenues and operating profit (loss) before interest expense and income taxes. Assets by operating segment are not reviewed by management for the purpose of assessing performance or allocating resources.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products in the U.S. This segment provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices. In addition, the segment sells financial, operational, and clinical solutions to pharmacies (retail, hospital, alternate sites) and provides consulting, outsourcing, technological, and other services.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The RxTS segment helps solve medication access, affordability, and adherence challenges for patients by working across healthcare to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies. RxTS serves our biopharma and life sciences partners, delivering innovative solutions that help people get the medicine they need to live healthier lives. RxTS also offers prescription price transparency, benefit insight, dispensing support services, third-party logistics, and wholesale distribution support across various therapeutic categories and temperature ranges to biopharma customers throughout the product lifecycle.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home health care agencies. This segment offers national brand medical-surgical products as well as McKesson&#8217;s own line of high-quality products through a network of distribution centers in the U.S.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The International segment includes the Company&#8217;s operations in Canada and Europe, bringing together non-U.S.-based drug distribution services, specialty pharmacy, retail, and infusion care services. The Company&#8217;s Canadian operations deliver medicines, supplies, and information technology solutions throughout Canada and includes Rexall Health retail pharmacies. The Company completed the divestitures of the U.K. disposal group in April 2022 and the E.U. disposal group in October 2022, as discussed in Financial Note 2, &#8220;Business Acquisitions and Divestitures.&#8221; The Company&#8217;s remaining operations in Europe provide distribution and services to wholesale, institutional, and retail customers in Norway where it owns, partners, or franchises with retail pharmacies. </span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial information relating to the Company&#8217;s reportable operating segments and reconciliations to the condensed consolidated totals was as follows: </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.531%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.574%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment revenues </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Pharmaceutical</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,947&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prescription Technology Solutions</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,066&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical-Surgical Solutions</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,611&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,468&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,549&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,483&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,154&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment operating profit (loss) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Pharmaceutical </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3) </span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prescription Technology Solutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical-Surgical Solutions</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5) </span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,342&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,090&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate expenses, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6) </span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(204)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations before income taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,006&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Revenues from services on a disaggregated basis represent approximately 1% of the U.S. Pharmaceutical segment&#8217;s total revenues, less than 37% of the RxTS segment&#8217;s total revenues, less than 1% of the Medical-Surgical Solutions segment&#8217;s total revenues, and less than 1% of the International segment&#8217;s total revenues. The International segment reflects foreign revenues. Revenues for the remaining three reportable segments are derived in the U.S.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Segment operating profit (loss) includes gross profit, net of total operating expenses, as well as other income, net, for the Company&#8217;s reportable segments.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The Company&#8217;s U.S. Pharmaceutical segment&#8217;s operating profit includes the following:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">cash receipts for the Company&#8217;s share of antitrust legal settlements of $118 million for the three months ended June 30, 2023; and</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">a charge of $32 million and a credit of $13 million related to the last-in, first-out (&#8220;LIFO&#8221;) method of accounting for inventories for the three months ended June 30, 2023 and 2022, respectively.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The Company&#8217;s RxTS segment&#8217;s operating profit for the three months ended June 30, 2023 includes a fair value adjustment gain of $28&#160;million, which reduced the Company&#8217;s contingent consideration liability related to the RxSS acquisition, as discussed in more detail in Financial Note 2, &#8220;Business Acquisitions and Divestitures.&#8221;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The Company&#8217;s International segment&#8217;s operating loss for the three months ended June 30, 2022 includes charges of $94 million to remeasure the assets and liabilities of the E.U. disposal group to fair value less costs to sell, as discussed in more detail in Financial Note 2, &#8220;Business Acquisitions and Divestitures.&#8221;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Corporate expenses, net includes the following:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">restructuring charges of $40 million for the three months ended June 30, 2023 for restructuring initiatives as discussed in more detail in Financial Note 3, &#8220;Restructuring, Impairment, and Related Charges, Net;&#8221; and</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">a gain of $106 million for the three months ended June 30, 2022 primarily related to the effect of accumulated other comprehensive loss components from the E.U. disposal group, as discussed in more detail in Financial Note 2, &#8220;Business Acquisitions and Divestitures.&#8221;</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//280/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-26<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-34<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-21<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140642630232768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss) Attributable to Parent</a></td>
<td class="nump">$ 958<span></span>
</td>
<td class="nump">$ 768<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140642633425408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140642628015440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements and accompanying notes are prepared in accordance with United States (&#8220;U.S.&#8221;) generally accepted accounting principles (&#8220;GAAP&#8221;) for interim financial reporting and the rules and regulations of the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) and therefore do not include all information and disclosures normally included in the annual consolidated financial statements.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements of McKesson include the financial statements of all wholly-owned subsidiaries and majority-owned or controlled companies. For those consolidated subsidiaries where the Company&#8217;s ownership is less than 100%, the portion of the net income or loss allocable to the noncontrolling interests is reported as &#8220;Net income attributable to noncontrolling interests&#8221; in the Condensed Consolidated Statements of Operations. All significant intercompany balances and transactions have been eliminated in consolidation, including the intercompany portion of transactions with equity method investees. </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income attributable to noncontrolling interests includes third-party equity interests in the Company&#8217;s consolidated entities, including ClarusONE Sourcing Services LLP, Vantage Oncology Holdings, LLC, and SCRI Oncology, LLC. Net income attributable to noncontrolling interests also included recurring compensation that the Company was obligated to pay to the noncontrolling shareholders of McKesson Europe AG (&#8220;McKesson Europe&#8221;). The Company&#8217;s noncontrolling interest in McKesson Europe was included in the divestiture of certain of the Company&#8217;s businesses in the European Union (&#8220;E.U.&#8221;) in October 2022, which is discussed further in Financial Note 2, &#8220;Business Acquisitions and Divestitures.&#8221; </span></div>The Company considers itself to control an entity if it is the majority owner of or has voting control over such entity. The Company also assesses control through means other than voting rights and determines which business entity is the primary beneficiary of the variable interest entity (&#8220;VIE&#8221;). The Company consolidates VIEs when it is determined that it is the primary beneficiary of the VIE. Investments in business entities in which the Company does not have control, but instead has the ability to exercise significant influence over operating and financial policies, are accounted for using the equity method.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiscalPeriod', window );">Fiscal Period</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fiscal Period:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company&#8217;s fiscal year begins on April 1 and ends on March 31. Unless otherwise noted, all references to a particular year shall mean the Company&#8217;s fiscal year.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassification</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reclassifications:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Certain prior period amounts have been reclassified to conform to the current year presentation.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of these financial statements and income and expenses during the reporting period. Actual amounts could differ from those estimated amounts. In the opinion of management, the unaudited condensed consolidated financial statements include all normal recurring adjustments necessary for a fair presentation of the results of operations, financial position, and cash flows of McKesson for the interim periods presented.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComparabilityOfPriorYearFinancialData', window );">Results of Operations</a></td>
<td class="text">The results of operations for the three months ended June 30, 2023 are not necessarily indicative of the results that may be anticipated for the entire year. These interim financial statements should be read in conjunction with the annual audited financial statements, accounting policies, and financial notes included in the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended March 31, 2023, previously filed with the SEC on May&#160;9, 2023 (the &#8220;2023 Annual Report&#8221;).<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Pronouncements </span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no accounting standards adopted by the Company during the three months ended June 30, 2023.</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Issued Accounting Pronouncements Not Yet Adopted</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, the Financial Accounting Standards Board issued Accounting Standards Update (&#8220;ASU&#8221;) 2022-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions</span>, which clarifies the guidance when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of such equity security, and requires additional disclosure requirements. ASU 2022-03 is effective for the Company on a prospective basis for fiscal years beginning after December 15, 2023, with early adoption permitted. The Company does not anticipate that this guidance will have a material impact on its consolidated financial statements or related disclosures<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to commitments and obligations incurred in the ordinary course of business, the Company is subject to a variety of claims and legal proceedings, including claims from customers and vendors, pending and potential legal actions for damages, governmental investigations, and other matters. The Company and its affiliates are parties to the legal claims and proceedings described below and in </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/927653/000092765323000038/mck-20230331.htm#i04335d018da94076b0acf21e81ac886b_172" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Financial Note 1</a><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/927653/000092765323000038/mck-20230331.htm#i04335d018da94076b0acf21e81ac886b_172" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">7</a><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/927653/000092765323000038/mck-20230331.htm#i04335d018da94076b0acf21e81ac886b_172" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"> to the Company&#8217;s 202</a><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/927653/000092765323000038/mck-20230331.htm#i04335d018da94076b0acf21e81ac886b_172" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">3</a><a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/927653/000092765323000038/mck-20230331.htm#i04335d018da94076b0acf21e81ac886b_172" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"> Annual Report</a></span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which disclosure is incorporated in this footnote by this reference. The Company is vigorously defending itself against those claims and in those proceedings. Significant developments in those matters are described below. If the Company is unsuccessful in defending, or if it determines to settle, any of these matters, it may be required to pay substantial sums, be subject to injunction and/or be forced to change how it operates its business, which could have a material adverse impact on its financial position or results of operations.</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless otherwise stated, the Company is unable to reasonably estimate the loss or a range of possible loss for the matters described below. Often, the Company is unable to determine that a loss is probable, or to reasonably estimate the amount of loss or a range of loss, for a claim because of the limited information available and the potential effects of future events and decisions by third parties, such as courts and regulators, that will determine the ultimate resolution of the claim. Many of the matters described are at preliminary stages, raise novel theories of liability, or seek an indeterminate amount of damages. It is not uncommon for claims to remain unresolved over many years. The Company reviews loss contingencies at least quarterly to determine whether the likelihood of loss has changed and whether it can make a reasonable estimate of the loss or range of loss. When the Company determines that a loss from a claim is probable and reasonably estimable, it records a liability for an estimated amount. The Company also provides disclosure when it is reasonably possible that a loss may be incurred or when it is reasonably possible that the amount of a loss will exceed its recorded liability. Amounts included within &#8220;Claims and litigation charges, net&#8221; in the Condensed Consolidated Statements of Operations consist of estimated loss contingencies related to opioid-related litigation matters.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 450<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480598/954-450-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComparabilityOfPriorYearFinancialData">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reporting any exceptions to the comparability of prior year financial data with data shown for the most recent accounting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483478/205-10-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComparabilityOfPriorYearFinancialData</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiscalPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining an entity's fiscal year or other fiscal period. This disclosure may include identification of the fiscal period end-date, the length of the fiscal period, any reporting period lag between the entity and its subsidiaries, or equity investees. If a reporting lag exists, the closing date of the entity having a different period end is generally noted, along with an explanation of the necessity for using different closing dates. Any intervening events that materially affect the entity's financial position or results of operations are generally also disclosed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiscalPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483504/205-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140642635694304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Acquisitions and Divestitures (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Identified Assets Acquired and Liabilities Assumed</a></td>
<td class="text"><div style="margin-bottom:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the preliminary purchase price allocation for this acquisition:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.368%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts Recognized as of Acquisition Date (As Adjusted)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchase consideration:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total purchase consideration</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">692&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identifiable assets acquired and liabilities assumed:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total identifiable net assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net assets acquired</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">692&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the preliminary purchase price allocation for this acquisition:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.368%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts Recognized as of Acquisition Date (As Adjusted)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Purchase consideration:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contribution of USOR</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total purchase consideration</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identifiable assets acquired and liabilities assumed:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Receivables</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant, and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total identifiable net assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">340&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(222)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net assets acquired</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Paragraph 1<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140642635596336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring, Impairment, and Related Charges, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Restructuring, Impairment, and Related Costs</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restructuring, impairment, and related charges, net for the three months ended June 30, 2023 and 2022 consisted of the following: </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:20.861%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.102%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.173%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.784%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. Pharmaceutical</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Prescription Technology Solutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical-Surgical Solutions</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">International</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance and employee-related costs, net </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exit and other-related costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairments and accelerated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company&#8217;s technology solutions. </span></div><div style="margin-bottom:12pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred. </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:21.008%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.102%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.173%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.784%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.737%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. Pharmaceutical</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Prescription Technology Solutions</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical-Surgical Solutions</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance and employee-related costs, net </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exit and other-related costs </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asset impairments and accelerated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Schedule of Restructuring and Asset Impairment Charges</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to the liabilities associated with the Company&#8217;s restructuring initiatives for the three months ended June 30, 2023:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.946%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.373%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.263%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Prescription Technology Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical-Surgical Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">International</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Corporate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, March 31, 2023 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring, impairment, and related charges, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash charges</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, June 30, 2023 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">As of March 31, 2023, the total reserve balance was $92 million, of which $66 million was recorded in &#8220;Other accrued liabilities&#8221; and $26 million was recorded in &#8220;Other non-current liabilities&#8221; in the Company&#8217;s Condensed Consolidated Balance Sheet.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Other primarily includes cumulative translation adjustments and transfers to certain other liabilities. </span></div><div style="margin-bottom:12pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">As of June 30, 2023, the total reserve balance was $74 million, of which $44 million was recorded in &#8220;Other accrued liabilities&#8221; and $30 million was recorded in &#8220;Other non-current liabilities&#8221; in the Company&#8217;s Condensed Consolidated Balance Sheet.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140642635660992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Income Tax Expense (Benefit)</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense related to continuing operations was as follows:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.574%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(Dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reported income tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 9<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140642635782752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Common Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of computations for basic and diluted earnings per common share</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The computations for basic and diluted earnings per common share were as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.531%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.574%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions, except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">997&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">807&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations attributable to McKesson Corporation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">958&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">766&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from discontinued operations, net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income attributable to McKesson Corporation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">958&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">768&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings per common share attributable to McKesson Corporation: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.02&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.02&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.26&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Continuing operations</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.07&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discontinued operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.07&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.32&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes dilutive effect from restricted stock units and performance-based stock units.</span></div><div style="margin-bottom:12pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Certain computations may reflect rounding adjustments.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140642635679456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of changes in the carrying amount of goodwill</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the carrying amount of goodwill were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:26.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.052%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.652%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. Pharmaceutical </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Prescription Technology Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Medical-Surgical Solutions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">International</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, March 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,050&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,005&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,453&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,439&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,947&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation adjustments, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other adjustments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, June 30, 2023</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,045&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,005&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,453&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,468&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,971&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The goodwill balance allocated to the U.S. Pharmaceutical segment related to McKesson Europe&#8217;s Celesio AG acquisition no longer reflects foreign currency translation adjustments as its functional currency was changed from Euros to U.S. dollars with the completion of the sale of the E.U. disposal group.</span></div><div style="margin-bottom:12pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes purchase price allocation adjustments related to the formation of SCRI Oncology, which is discussed in Financial Note 2, &#8220;Business Acquisitions and Divestitures.&#8221;</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of information regarding intangible assets</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding intangible assets was as follows: </span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:23.716%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.032%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.151%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.032%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.121%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.156%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(Dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Amortization<br/>Period<br/>(Years)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net<br/>Carrying<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,984&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,801)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,183&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,971&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,765)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,206&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service agreements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(641)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,137&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(623)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">514&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks and trade names</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(446)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">833&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(430)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Technology</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(133)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(174)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(174)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,416&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,195)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,221&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,398&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,121)</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,277&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140642630880960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt and Financing Activities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of Long-Term Debt</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.636%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.522%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">U.S. Dollar notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1) (2)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.80% Notes due March 15, 2024</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">918&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.90% Notes due December 3, 2025</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.25% Notes due February 15, 2026</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.30% Notes due August 15, 2026</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.65% Debentures due March 1, 2027</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.95% Notes due February 16, 2028</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.90% Notes due July 15, 2028</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">399&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.75% Notes due May 30, 2029</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.10% Notes due July 15, 2033</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">596&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.00% Notes due March 1, 2041</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.88% Notes due March 15, 2044</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline">Foreign currency notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1) (3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.50% Euro Notes due November 17, 2025</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">653&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">649&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.63% Euro Notes due October 30, 2026 </span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.13% Sterling Notes due February 17, 2029</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">571&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">555&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lease and other obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,661&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,594&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">968&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,611&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,626&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">These notes are unsecured and unsubordinated obligations of the Company.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Interest on these U.S. dollar notes is payable semi-annually.</span></div><div style="margin-bottom:12pt;margin-top:3pt;padding-left:18pt;padding-right:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Interest on these foreign currency notes is payable annually.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140642634125312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Hedging Activities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Summary of Foreign Currency Gains and (Losses) from Non-Derivative Instruments</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency gains (losses) from non-derivative instruments included in other comprehensive income in the Condensed Consolidated Statements of Comprehensive Income were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.531%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.574%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-derivatives designated as net investment hedges: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Euro-denominated notes </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">There was no ineffectiveness in these hedges for the three months ended June 30, 2022.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock', window );">Schedule of Notional Amounts of Outstanding Derivative Positions</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At June 30, 2023 and March 31, 2023, the notional amounts of the Company&#8217;s outstanding derivatives were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:42.640%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.178%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.658%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.480%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.336%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Currency</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maturity Date</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Notional</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as net investment hedges: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swaps </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CAD</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-24 to Mar-25</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as fair value hedges: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swaps </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GBP</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-28</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#163;</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#163;</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swaps </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EUR</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Aug-25 to Jul-26</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8364;</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8364;</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Floating interest rate swaps </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">USD</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Feb-26 to Sep-29</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as cash flow hedges: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swaps </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CAD</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jan-24</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed interest rate swaps </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">USD</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jun-23</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The maturity date reflected is for outstanding derivatives as of June 30, 2023.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">There was no ineffectiveness in these hedges for the three months ended June 30, 2023 and 2022.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The Company agreed with third parties to exchange fixed interest payments in one currency for fixed interest payments in another currency at specified intervals and to exchange principal in one currency for principal in another currency, calculated by reference to agreed-upon notional amounts.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Represents cross-currency fixed-to-fixed interest rate swaps to mitigate the foreign currency exchange fluctuations on its foreign currency-denominated notes. </span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Represents fixed-to-floating interest rate swaps to hedge the changes in fair value caused by fluctuations in the benchmark interest rates. </span></div><div style="margin-bottom:12pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The Company entered into agreements with financial institutions to lock into the fixed benchmark interest rates for future bond issuance, which were terminated during the first quarter of fiscal 2024 as discussed further below.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains (losses) from derivatives included in other comprehensive income in the Condensed Consolidated Statements of Comprehensive Income were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.531%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.574%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as net investment hedges:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swaps</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as cash flow and other hedges:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swaps </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed interest rate swaps</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes other comprehensive income (loss) related to the excluded component of certain fair value hedges.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains (losses) from derivatives included in other comprehensive income in the Condensed Consolidated Statements of Comprehensive Income were as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.531%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.574%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as net investment hedges:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swaps</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as cash flow and other hedges:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swaps </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fixed interest rate swaps</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Includes other comprehensive income (loss) related to the excluded component of certain fair value hedges.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Schedule of Fair Value of Derivatives</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding the fair value of derivatives on a gross basis were as follows:</span></div><div style="margin-bottom:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.263%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance Sheet <br/>Caption</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value of <br/>Derivative</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. Dollar Notional</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value of <br/>Derivative</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. Dollar Notional</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Asset</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liability</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Asset</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liability</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="39" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated for hedge accounting:</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swaps (current)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other/Other accrued liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">301&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross-currency swaps (non-current)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets/liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps (non-current)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non-current assets/liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of gain (loss) on derivative and nonderivative instruments designated and qualifying as cash flow hedge recorded in accumulated other comprehensive income (AOCI) and reclassified into earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4CCC<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4CCC<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the notional amounts of outstanding derivative positions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4C<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4CC<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4CC<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140642635767456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s long-term debt is recorded at amortized cost. The carrying value and fair value of the Company&#8217;s long-term debt was as follows:</span></div><div style="margin-bottom:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.677%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.698%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt, including current maturities</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,661&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,335&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,594&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,386&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140642633754320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingent Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock', window );">Schedule of Estimated Accrual Liability</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s estimated accrued liability for the opioid-related claims of U.S. governmental entities, including Native American tribes, was as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:68.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.562%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.564%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current litigation liabilities </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">545&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term litigation liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,628&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,625&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total litigation liabilities</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,173&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,173&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">These amounts, recorded in &#8220;Other accrued liabilities&#8221; in the Condensed Consolidated Balance Sheets, are the amounts estimated to be paid within the next twelve months following each respective period end date.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the loss contingencies that were reported in the period or disclosed as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140642633730016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Deficit (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of information regarding changes in accumulated other comprehensive income (loss), net of tax, by component</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information regarding changes in accumulated other comprehensive loss, including noncontrolling interests, by components for the three months ended June 30, 2023 and 2022 were as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.657%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.228%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.657%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.042%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.800%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.333%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustments, Net of Tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Losses on Net Investment Hedges, <br/>Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized  Gains (Losses) on Cash Flow and Other Hedges, <br/>Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Losses and Other Components of Benefit Plans, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Accumulated Other Comprehensive Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, March 31, 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(847)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(905)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8317;&#178;&#8318;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified to earnings and other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: amounts attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) attributable to McKesson</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, June 30, 2023</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(780)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(848)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Primarily results from the conversion of non-U.S. dollar financial statements of the Company&#8217;s operations in Canada and Europe into the Company&#8217;s reporting currency, U.S. dollars.</span></div><div style="margin-bottom:12pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Amounts recorded for the three months ended June 30, 2023 includ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e l</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">osses of $20 million related to net investment hedges from cross-currency swaps, which are net of income tax benefit of $5 million.</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.711%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.025%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.655%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.025%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.225%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.025%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.798%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.025%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.798%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.313%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustments, Net of Tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Net Investment Hedges, <br/>Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Gains on Cash Flow and Other  Hedges, <br/>Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) and Other Components of Benefit Plans, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Accumulated Other Comprehensive Loss</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, March 31, 2022</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,504)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,534)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(176)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#8317;&#178;&#8318;</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified to earnings and other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">730&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">737&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">554&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">636&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: amounts attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income attributable to McKesson</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">507&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">586&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance, June 30, 2022</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(997)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(948)</span></td><td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Primarily results from the conversion of non-U.S. dollar financial statements of the Company&#8217;s operations in Canada and Europe into the Company&#8217;s reporting currency, U.S. dollars.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Amounts recorded for the three months ended June 30, 2022 include gains of $64 million related to net investment hedges from Euro-denominated notes and gains of $12 million related to net investment hedges from cross-currency swaps. These amounts are net of income tax expense of $31 million.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Primarily included adjustments for amounts related to the sale of the U.K. disposal group, as discussed in more detail in Financial Note 2, &#8220;Business Acquisitions and Divestitures.&#8221; These amounts were included in the fiscal 2022 calculation of charges to remeasure the assets and liabilities held for sale to fair value less costs to sell recorded within &#8220;Selling, distribution, general, and administrative expenses&#8221; in the Consolidated Statements of Operations.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140642633742304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments of Business (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of financial information relating to reportable operating segments and reconciliations to the condensed consolidated totals</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial information relating to the Company&#8217;s reportable operating segments and reconciliations to the condensed consolidated totals was as follows: </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.531%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.574%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended June 30, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment revenues </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Pharmaceutical</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,947&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prescription Technology Solutions</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,066&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical-Surgical Solutions</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,611&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,468&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,549&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,483&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,154&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment operating profit (loss) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Pharmaceutical </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3) </span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">827&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prescription Technology Solutions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Medical-Surgical Solutions</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">227&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5) </span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,342&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,090&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate expenses, net </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6) </span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(204)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(47)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from continuing operations before income taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,091&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,006&#160;</span></td><td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Revenues from services on a disaggregated basis represent approximately 1% of the U.S. Pharmaceutical segment&#8217;s total revenues, less than 37% of the RxTS segment&#8217;s total revenues, less than 1% of the Medical-Surgical Solutions segment&#8217;s total revenues, and less than 1% of the International segment&#8217;s total revenues. The International segment reflects foreign revenues. Revenues for the remaining three reportable segments are derived in the U.S.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Segment operating profit (loss) includes gross profit, net of total operating expenses, as well as other income, net, for the Company&#8217;s reportable segments.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The Company&#8217;s U.S. Pharmaceutical segment&#8217;s operating profit includes the following:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">cash receipts for the Company&#8217;s share of antitrust legal settlements of $118 million for the three months ended June 30, 2023; and</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">a charge of $32 million and a credit of $13 million related to the last-in, first-out (&#8220;LIFO&#8221;) method of accounting for inventories for the three months ended June 30, 2023 and 2022, respectively.</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The Company&#8217;s RxTS segment&#8217;s operating profit for the three months ended June 30, 2023 includes a fair value adjustment gain of $28&#160;million, which reduced the Company&#8217;s contingent consideration liability related to the RxSS acquisition, as discussed in more detail in Financial Note 2, &#8220;Business Acquisitions and Divestitures.&#8221;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">The Company&#8217;s International segment&#8217;s operating loss for the three months ended June 30, 2022 includes charges of $94 million to remeasure the assets and liabilities of the E.U. disposal group to fair value less costs to sell, as discussed in more detail in Financial Note 2, &#8220;Business Acquisitions and Divestitures.&#8221;</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt">Corporate expenses, net includes the following:</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">restructuring charges of $40 million for the three months ended June 30, 2023 for restructuring initiatives as discussed in more detail in Financial Note 3, &#8220;Restructuring, Impairment, and Related Charges, Net;&#8221; and</span></div><div style="margin-bottom:3pt;margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt">a gain of $106 million for the three months ended June 30, 2022 primarily related to the effect of accumulated other comprehensive loss components from the E.U. disposal group, as discussed in more detail in Financial Note 2, &#8220;Business Acquisitions and Divestitures.&#8221;</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-25<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140642630361712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2023 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140642631253680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Acquisitions and Divestitures - Acquisitions (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 01, 2022</div></th>
<th class="th"><div>Oct. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Fair value adjustment gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,971<span></span>
</td>
<td class="nump">$ 9,947<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mck_USPharmaceuticalSegmentMember', window );">U.S. Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,045<span></span>
</td>
<td class="nump">4,050<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mck_RxSavingsSolutionsLLCMember', window );">Rx Savings Solutions, LLC | RxTs Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Business acquisition, percentage of controlling interest in combined business</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash payments to acquire business</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Other non-current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Acquired identifiable intangible assets</a></td>
<td class="nump">$ 229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted average life of intangibles</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mck_RxSavingsSolutionsLLCMember', window );">Rx Savings Solutions, LLC | RxTs Segment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">$ 275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mck_SCRIOncologyLLCMember', window );">SCRI Oncology, LLC | U.S. Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Business acquisition, percentage of controlling interest in combined business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash payments to acquire business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Acquired identifiable intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted average life of intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">17 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount', window );">Goodwill, expected tax deductible amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue', window );">Noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mck_SCRIOncologyLLCMember', window );">SCRI Oncology, LLC | U.S. Pharmaceutical | SCRI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue', window );">Noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mck_SCRIOncologyLLCMember', window );">SCRI Oncology, LLC | U.S. Pharmaceutical | USOR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue', window );">Noncontrolling interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the fair value of the noncontrolling interest in the acquiree at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479668/805-30-25-6<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479613/805-30-35-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479668/805-30-25-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479613/805-30-35-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479668/805-30-25-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479613/805-30-35-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mck_USPharmaceuticalSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mck_USPharmaceuticalSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mck_RxSavingsSolutionsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mck_RxSavingsSolutionsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mck_RxTsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mck_RxTsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mck_SCRIOncologyLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mck_SCRIOncologyLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=mck_SarahCannonResearchInstituteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=mck_SarahCannonResearchInstituteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=mck_McKessonUSOncologyResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=mck_McKessonUSOncologyResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140642628039248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business Acquisitions and Divestitures - Identified Assets Acquired and Liabilities Assumed (Rx Savings Solutions) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Nov. 01, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Identifiable assets acquired and liabilities assumed:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,971<span></span>
</td>
<td class="nump">$ 9,947<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mck_RxSavingsSolutionsLLCMember', window );">Rx Savings Solutions, LLC | RxTs Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Purchase consideration:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total purchase consideration</a></td>
<td class="nump">692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract', window );"><strong>Identifiable assets acquired and liabilities assumed:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets', window );">Current assets</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets</a></td>
<td class="nump">229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities', window );">Current liabilities</a></td>
<td class="num">(8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total identifiable net assets</a></td>
<td class="nump">229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest', window );">Net assets acquired</a></td>
<td class="nump">$ 692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479668/805-30-25-6<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479613/805-30-35-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the assets, including goodwill, in excess of (less than) the aggregate liabilities assumed, less the noncontrolling interest in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mck_RxSavingsSolutionsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mck_RxSavingsSolutionsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mck_RxTsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mck_RxTsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140642625413040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business Acquisitions and Divestitures - Identified Assets Acquired and Liabilities Assumed (SCRI Oncology, LLC) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Oct. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,971<span></span>
</td>
<td class="nump">$ 9,947<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mck_USPharmaceuticalSegmentMember', window );">U.S. Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,045<span></span>
</td>
<td class="nump">$ 4,050<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mck_SCRIOncologyLLCMember', window );">SCRI Oncology, LLC | U.S. Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Cash</a></td>
<td class="nump">$ 166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mck_BusinessCombinationConsiderationTransferredOwnershipInterest', window );">Contribution of USOR</a></td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total purchase consideration</a></td>
<td class="nump">206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables', window );">Receivables</a></td>
<td class="nump">224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property, plant, and equipment</a></td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets', window );">Operating lease right-of-use assets</a></td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets</a></td>
<td class="nump">177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities', window );">Current liabilities</a></td>
<td class="num">(42)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermOperatingLeaseLiabilities', window );">Long-term operating lease liabilities</a></td>
<td class="num">(29)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther', window );">Other non-current liabilities</a></td>
<td class="num">(43)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total identifiable net assets</a></td>
<td class="nump">340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue', window );">Noncontrolling interest</a></td>
<td class="num">(222)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="num">(25)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest', window );">Net assets acquired</a></td>
<td class="nump">$ 206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mck_BusinessCombinationConsiderationTransferredOwnershipInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Ownership Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mck_BusinessCombinationConsiderationTransferredOwnershipInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mck_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Additional-Paid-In Capital</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mck_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Long-Term Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mck_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Right-Of-Use Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mck_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionContingentConsiderationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the fair value of the noncontrolling interest in the acquiree at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 8<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 7<br> -SubTopic 30<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479637/805-30-30-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479303/805-10-55-37<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the assets, including goodwill, in excess of (less than) the aggregate liabilities assumed, less the noncontrolling interest in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mck_USPharmaceuticalSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mck_USPharmaceuticalSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mck_SCRIOncologyLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mck_SCRIOncologyLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140642630162016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Acquisitions and Divestitures - Divestitures and Other (Details)<br> &#163; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 06, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 06, 2022 </div>
<div>GBP (&#163;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown', window );">European businesses, disposal group, losses (gains)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mck_EUBusinessesDisposalGroupMember', window );">E.U. Businesses (Disposal Group) | Disposed of by sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown', window );">European businesses, disposal group, losses (gains)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mck_UKBusinessesDisposalGroupMember', window );">U.K. Disposal Group (Disposal Group) | Disposed of by sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mck_DisposalGroupIncludingDiscontinuedOperationConsiderationExpected', window );">Gross purchase price</a></td>
<td class="nump">$ 144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollectionOfNotesReceivable', window );">Proceeds from collection of notes receivable</a></td>
<td class="nump">118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mck_InternationalSegmentMember', window );">International Segment | Disposed of by sale | Aurelius Elephant Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation', window );">Divested net assets</a></td>
<td class="nump">615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodTax', window );">Accumulated other comprehensive loss adjustment</a></td>
<td class="nump">$ 731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mck_DisposalGroupIncludingDiscontinuedOperationConsiderationExpected">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Consideration, Expected</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mck_DisposalGroupIncludingDiscontinuedOperationConsiderationExpected</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mck_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -SubTopic 20<br> -Topic 205<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5B<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollectionOfNotesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with principal collections from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollectionOfNotesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAociCurrentPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-17A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAociCurrentPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mck_EUBusinessesDisposalGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mck_EUBusinessesDisposalGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mck_UKBusinessesDisposalGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mck_UKBusinessesDisposalGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mck_InternationalSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mck_InternationalSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mck_AureliusElephantLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mck_AureliusElephantLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140642631753152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring, Impairment, and Related Charges, Net - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mck_RestructuringImpairmentAndOtherRelatedCharges', window );">Restructuring, impairment, and related charges, net</a></td>
<td class="nump">$ 52<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring costs, anticipated total charges</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=mck_StrategicGrowthInitiativePlanOperationalEfficienciesAndCostOptimizationMember', window );">Strategic Growth Initiative Plan - Operational Efficiencies and Cost Optimization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Expected total pre-tax charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Restructuring and related cost, incurred cost to date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring costs, anticipated total charges</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mck_RestructuringImpairmentAndOtherRelatedCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring, Impairment and Other Related Charges</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mck_RestructuringImpairmentAndOtherRelatedCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mck_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount expected to be recognized in earnings for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostIncurredCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostIncurredCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=mck_StrategicGrowthInitiativePlanOperationalEfficienciesAndCostOptimizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=mck_StrategicGrowthInitiativePlanOperationalEfficienciesAndCostOptimizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140642626903104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring, Impairment, and Related Charges, Net - Summary of Restructuring Charges (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance and employee-related costs, net</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessExitCosts1', window );">Exit and other-related costs</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mck_AssetImpairmentChargesIncludingAcceleratedDepreciation', window );">Asset impairments and accelerated depreciation</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Total</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | U.S. Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance and employee-related costs, net</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessExitCosts1', window );">Exit and other-related costs</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mck_AssetImpairmentChargesIncludingAcceleratedDepreciation', window );">Asset impairments and accelerated depreciation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Total</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Prescription Technology Solutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance and employee-related costs, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessExitCosts1', window );">Exit and other-related costs</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mck_AssetImpairmentChargesIncludingAcceleratedDepreciation', window );">Asset impairments and accelerated depreciation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Total</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Medical-Surgical Solutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance and employee-related costs, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessExitCosts1', window );">Exit and other-related costs</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mck_AssetImpairmentChargesIncludingAcceleratedDepreciation', window );">Asset impairments and accelerated depreciation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Total</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance and employee-related costs, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessExitCosts1', window );">Exit and other-related costs</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mck_AssetImpairmentChargesIncludingAcceleratedDepreciation', window );">Asset impairments and accelerated depreciation</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Total</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance and employee-related costs, net</a></td>
<td class="nump">1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessExitCosts1', window );">Exit and other-related costs</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mck_AssetImpairmentChargesIncludingAcceleratedDepreciation', window );">Asset impairments and accelerated depreciation</a></td>
<td class="nump">27<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Total</a></td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mck_AssetImpairmentChargesIncludingAcceleratedDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Asset Impairment Charges, Including Accelerated Depreciation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mck_AssetImpairmentChargesIncludingAcceleratedDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mck_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessExitCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessExitCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mck_USPharmaceuticalSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mck_USPharmaceuticalSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mck_PrescriptionTechnologySolutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mck_PrescriptionTechnologySolutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mck_MedicalSurgicalSolutionsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mck_MedicalSurgicalSolutionsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mck_InternationalSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mck_InternationalSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140642631552816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring, Impairment, and Related Charges, Net - Summary of Restructuring Activity (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="nump">$ 92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring, impairment, and related charges, net</a></td>
<td class="nump">52<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveSettledWithoutCash2', window );">Non-cash charges</a></td>
<td class="num">(28)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments</a></td>
<td class="num">(37)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveTranslationAndOtherAdjustment', window );">Other</a></td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="nump">74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | U.S. Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring, impairment, and related charges, net</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveSettledWithoutCash2', window );">Non-cash charges</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments</a></td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveTranslationAndOtherAdjustment', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Prescription Technology Solutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring, impairment, and related charges, net</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveSettledWithoutCash2', window );">Non-cash charges</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments</a></td>
<td class="num">(13)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveTranslationAndOtherAdjustment', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Medical-Surgical Solutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring, impairment, and related charges, net</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveSettledWithoutCash2', window );">Non-cash charges</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments</a></td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveTranslationAndOtherAdjustment', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring, impairment, and related charges, net</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveSettledWithoutCash2', window );">Non-cash charges</a></td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments</a></td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveTranslationAndOtherAdjustment', window );">Other</a></td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring, impairment, and related charges, net</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveSettledWithoutCash2', window );">Non-cash charges</a></td>
<td class="num">(27)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments</a></td>
<td class="num">(15)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveTranslationAndOtherAdjustment', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="nump">66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Non-Current Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="nump">$ 30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveSettledWithoutCash2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in the reserve for full or partial settlement through consideration other than cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveSettledWithoutCash2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveTranslationAndOtherAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the restructuring reserve related to foreign currency translation (gain) loss and other increases (decreases).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveTranslationAndOtherAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mck_USPharmaceuticalSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mck_USPharmaceuticalSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mck_PrescriptionTechnologySolutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mck_PrescriptionTechnologySolutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mck_MedicalSurgicalSolutionsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mck_MedicalSurgicalSolutionsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mck_InternationalSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mck_InternationalSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140642633845504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Components of Income Tax Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit) related to continuing operations</a></td>
<td class="nump">$ 94<span></span>
</td>
<td class="nump">$ 199<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Reported income tax expense (benefit) rates (percent)</a></td>
<td class="nump">8.60%<span></span>
</td>
<td class="nump">19.80%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140642630429776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mck_EffectiveIncomeTaxReconciliationTaxExpenseBenefitIntraEntityTransfersOfAssetsOtherThanInventoryAmount', window );">Tax expense (benefit), intra-entity transfers of assets other than inventory, amount</a></td>
<td class="num">$ (147)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount', window );">Tax expense (benefit), share-based payment arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (45)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would impact effective tax rate</a></td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mck_IncomeTaxExaminationEstimateOfPossibleLiabilityAdjustment', window );">Tax liability increase due to proposed adjustment to taxable income</a></td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mck_IncomeTaxExaminationEstimateOfPossibleLiabilityAdjustment', window );">Tax liability increase due to proposed adjustment to taxable income</a></td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mck_EffectiveIncomeTaxReconciliationTaxExpenseBenefitIntraEntityTransfersOfAssetsOtherThanInventoryAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Reconciliation, Tax Expense (Benefit), Intra-Entity Transfers Of Assets Other Than Inventory, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mck_EffectiveIncomeTaxReconciliationTaxExpenseBenefitIntraEntityTransfersOfAssetsOtherThanInventoryAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mck_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mck_IncomeTaxExaminationEstimateOfPossibleLiabilityAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Tax Examination, Estimate Of Possible Liability Adjustment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mck_IncomeTaxExaminationEstimateOfPossibleLiabilityAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mck_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -SubTopic 740<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480887/718-740-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140642636659312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Common Share - Narrative (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from diluted earnings per share (less than)</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140642631209472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Common Share - Schedule of Computations for Basic and Diluted Earnings per Common Share (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedLineItems', window );"><strong>Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Income from continuing operations</a></td>
<td class="nump">$ 997<span></span>
</td>
<td class="nump">$ 807<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net income attributable to noncontrolling interests</a></td>
<td class="num">(39)<span></span>
</td>
<td class="num">(41)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Income from continuing operations attributable to McKesson Corporation</a></td>
<td class="nump">958<span></span>
</td>
<td class="nump">766<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Income from discontinued operations, net of tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to McKesson Corporation</a></td>
<td class="nump">$ 958<span></span>
</td>
<td class="nump">$ 768<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">135.5<span></span>
</td>
<td class="nump">144.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">136.6<span></span>
</td>
<td class="nump">145.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Diluted</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Continuing operations (in usd per share)</a></td>
<td class="nump">$ 7.02<span></span>
</td>
<td class="nump">$ 5.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Discontinued operations (in usd per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0.01<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Total (in dollars per share)</a></td>
<td class="nump">7.02<span></span>
</td>
<td class="nump">5.26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Basic</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Continuing operations (in usd per share)</a></td>
<td class="nump">7.07<span></span>
</td>
<td class="nump">5.31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Discontinued operations (in usd per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0.01<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Total (in dollars per share)</a></td>
<td class="nump">$ 7.07<span></span>
</td>
<td class="nump">$ 5.32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Effect of dilutive securities (in shares)</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Effect of dilutive securities (in shares)</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-18<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482551/740-270-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3A<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-5C<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-4<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483475/205-20-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479836/810-10-S99-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480454/718-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-28A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140642630290048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net - Schedule of Changes in the Carrying Amount of Goodwill (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">$ 9,947<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation adjustments, net</a></td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Other adjustments</a></td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">9,971<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mck_USPharmaceuticalSegmentMember', window );">U.S. Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">4,050<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation adjustments, net</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Other adjustments</a></td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">4,045<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mck_PrescriptionTechnologySolutionsMember', window );">Prescription Technology Solutions</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">2,005<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation adjustments, net</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Other adjustments</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">2,005<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mck_MedicalSurgicalSolutionsSegmentMember', window );">Medical-Surgical Solutions</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">2,453<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation adjustments, net</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Other adjustments</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">2,453<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mck_InternationalSegmentMember', window );">International</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">1,439<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation adjustments, net</a></td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Other adjustments</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">$ 1,468<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482598/350-20-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPurchaseAccountingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 16<br> -SubTopic 10<br> -Topic 805<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479405/805-10-25-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPurchaseAccountingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mck_USPharmaceuticalSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mck_USPharmaceuticalSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mck_PrescriptionTechnologySolutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mck_PrescriptionTechnologySolutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mck_MedicalSurgicalSolutionsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mck_MedicalSurgicalSolutionsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mck_InternationalSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mck_InternationalSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140642631159488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net - Schedule of Information Regarding Intangible Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 5,416<span></span>
</td>
<td class="nump">$ 5,398<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(3,195)<span></span>
</td>
<td class="num">(3,121)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 2,221<span></span>
</td>
<td class="nump">2,277<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember', window );">Customer relationships</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted- Average Remaining Amortization Period (Years)</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 2,984<span></span>
</td>
<td class="nump">2,971<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(1,801)<span></span>
</td>
<td class="num">(1,765)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 1,183<span></span>
</td>
<td class="nump">1,206<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ServiceAgreementsMember', window );">Service agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted- Average Remaining Amortization Period (Years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 1,141<span></span>
</td>
<td class="nump">1,137<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(641)<span></span>
</td>
<td class="num">(623)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">514<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember', window );">Trademarks and trade names</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted- Average Remaining Amortization Period (Years)</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 843<span></span>
</td>
<td class="nump">833<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(446)<span></span>
</td>
<td class="num">(430)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 397<span></span>
</td>
<td class="nump">403<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember', window );">Technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted- Average Remaining Amortization Period (Years)</a></td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 264<span></span>
</td>
<td class="nump">264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(133)<span></span>
</td>
<td class="num">(129)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 131<span></span>
</td>
<td class="nump">135<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Weighted- Average Remaining Amortization Period (Years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 184<span></span>
</td>
<td class="nump">193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(174)<span></span>
</td>
<td class="num">(174)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ServiceAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ServiceAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TechnologyBasedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140642628010416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense of intangible assets</a></td>
<td class="nump">$ 62<span></span>
</td>
<td class="nump">$ 56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract', window );"><strong>Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Estimated annual amortization expense, remainder of 2024</a></td>
<td class="nump">185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Estimated annual amortization expense, 2025</a></td>
<td class="nump">240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Estimated annual amortization expense, 2026</a></td>
<td class="nump">208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Estimated annual amortization expense, 2027</a></td>
<td class="nump">202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Estimated annual amortization expense, 2028</a></td>
<td class="nump">198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mck_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour', window );">Estimated annual amortization expense, thereafter</a></td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mck_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Asset, Expected Amortization, after Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mck_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mck_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140642631644768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt and Financing Activities - Schedule of Long-Term Debt (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 15, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 5,661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,594<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Less: Current portion</a></td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">968<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligations', window );">Total long-term debt</a></td>
<td class="nump">$ 5,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,626<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Loans payable | 3.80% Notes due March 15, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on debt instrument (percent)</a></td>
<td class="nump">3.80%<span></span>
</td>
<td class="nump">3.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">918<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Loans payable | 0.90% Notes due December 3, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on debt instrument (percent)</a></td>
<td class="nump">0.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Loans payable | 5.25% Notes due February 15, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on debt instrument (percent)</a></td>
<td class="nump">5.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">499<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Loans payable | 1.30% Notes due August 15, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on debt instrument (percent)</a></td>
<td class="nump">1.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">498<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Loans payable | 7.65% Debentures due March 1, 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on debt instrument (percent)</a></td>
<td class="nump">7.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Loans payable | 3.95% Notes due February 16, 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on debt instrument (percent)</a></td>
<td class="nump">3.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">343<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Loans payable | 4.90% Notes due July 15, 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on debt instrument (percent)</a></td>
<td class="nump">4.90%<span></span>
</td>
<td class="nump">4.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Loans payable | 4.75% Notes due May 30, 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on debt instrument (percent)</a></td>
<td class="nump">4.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 196<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">196<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Loans payable | 5.10% Notes due July 15, 2033</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on debt instrument (percent)</a></td>
<td class="nump">5.10%<span></span>
</td>
<td class="nump">5.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Loans payable | 6.00% Notes due March 1, 2041</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on debt instrument (percent)</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">218<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Loans payable | 4.88% Notes due March 15, 2044</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on debt instrument (percent)</a></td>
<td class="nump">4.88%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 255<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">255<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Loans payable | 1.50% Euro Notes due November 17, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on debt instrument (percent)</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">649<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Loans payable | 1.63% Euro Notes due October 30, 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on debt instrument (percent)</a></td>
<td class="nump">1.63%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">542<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Loans payable | 3.13% Sterling Notes due February 17, 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on debt instrument (percent)</a></td>
<td class="nump">3.13%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">555<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=mck_LeaseAndOtherObligationsMember', window );">Lease and other obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 271<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mck_A380NotesDueMarch152024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mck_A380NotesDueMarch152024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mck_A090NotesDueDecember32025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mck_A090NotesDueDecember32025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mck_A525NotesDueFebruary152026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mck_A525NotesDueFebruary152026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mck_A130NotesDueAugust152026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mck_A130NotesDueAugust152026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mck_A765DebenturesDueMarch12027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mck_A765DebenturesDueMarch12027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mck_A395NotesDueFebruary162028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mck_A395NotesDueFebruary162028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mck_A490NotesDueJuly152028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mck_A490NotesDueJuly152028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mck_A475NotesDueMay302029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mck_A475NotesDueMay302029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mck_A510NotesDueJuly152033Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mck_A510NotesDueJuly152033Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mck_A600NotesDueMarch12041Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mck_A600NotesDueMarch12041Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mck_A488NotesDueMarch152044Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mck_A488NotesDueMarch152044Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mck_A150EuroNotesDueNovember172025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mck_A150EuroNotesDueNovember172025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mck_A163EuroNotesDueOctober302026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mck_A163EuroNotesDueOctober302026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mck_A313SterlingNotesDueFebruary172029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mck_A313SterlingNotesDueFebruary172029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=mck_LeaseAndOtherObligationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=mck_LeaseAndOtherObligationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140642631300144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt and Financing Activities - Long-Term Debt Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 16, 2023</div></th>
<th class="th"><div>Jun. 15, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtAndCapitalLeaseObligations', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent', window );">Current portion of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">968<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">268<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mck_PaymentsForPurchaseOfGovernmentObligationsForSatisfactionAndDischargeOfLongTermDebt', window );">Purchase of U.S. government obligations for the satisfaction and discharge of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">647<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Debt outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,594<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain on debt extinguishment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price percentage of principal (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Term Loan | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mck_DebtInstrumentRedemptionPeriod', window );">Debt instrument, redemption period (in days)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember', window );">Term Loan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mck_DebtInstrumentRedemptionPeriod', window );">Debt instrument, redemption period (in days)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mck_A490NotesDueJuly152028Member', window );">4.90% Notes due July 15, 2028 | Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on debt instrument (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.90%<span></span>
</td>
<td class="nump">4.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Proceeds from debt issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Debt outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mck_A510NotesDueJuly152033Member', window );">5.10% Notes due July 15, 2033 | Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on debt instrument (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.10%<span></span>
</td>
<td class="nump">5.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Proceeds from debt issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 592<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Debt outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mck_A380NotesDueMarch152024Member', window );">3.80% Notes due March 15, 2024 | Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate on debt instrument (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.80%<span></span>
</td>
<td class="nump">3.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Redemption price percentage of principal (percent)</a></td>
<td class="nump">98.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="nump">$ 268<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Debt principal redeemed</a></td>
<td class="nump">271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mck_PaymentsForPurchaseOfGovernmentObligationsForSatisfactionAndDischargeOfLongTermDebt', window );">Purchase of U.S. government obligations for the satisfaction and discharge of long-term debt</a></td>
<td class="nump">$ 647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Debt outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 918<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mck_DebtInstrumentRedemptionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mck_DebtInstrumentRedemptionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mck_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mck_PaymentsForPurchaseOfGovernmentObligationsForSatisfactionAndDischargeOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments For Purchase Of Government Obligations For Satisfaction And Discharge Of Long-Term Debt</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mck_PaymentsForPurchaseOfGovernmentObligationsForSatisfactionAndDischargeOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mck_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtAndCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term and long-term debt and lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.13,16)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtAndCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482949/835-30-55-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482900/835-30-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -SubTopic 470<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480848/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchasedFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of the original debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchasedFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mck_A490NotesDueJuly152028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mck_A490NotesDueJuly152028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mck_A510NotesDueJuly152033Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mck_A510NotesDueJuly152033Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mck_A380NotesDueMarch152024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mck_A380NotesDueMarch152024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140642631643392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt and Financing Activities - Revolving Credit Facilities Narrative (Details) - Unsecured Debt - Revolving Credit Facility - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 07, 2022</div></th>
<th class="th"><div>Sep. 25, 2019</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mck_SeniorUnsecuredCreditFacilityThe2022CreditFacilityMember', window );">Senior Unsecured Credit Facility (the 2022 Credit Facility)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility, maximum borrowing capacity</a></td>
<td class="nump">$ 4,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Credit facility term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mck_SeniorUnsecuredCreditFacilityThe2022CreditFacilityCanadianDollarBritishPoundSterlingAndEurosSublimitMember', window );">Senior Unsecured Credit Facility (the 2022 Credit Facility), Canadian Dollar, British Pound Sterling, and Euros Sublimit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility, maximum borrowing capacity</a></td>
<td class="nump">$ 3,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Borrowings under facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Amounts outstanding under facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mck_SeniorUnsecuredCreditFacilitythe2020CreditFacilityMember', window );">Senior Unsecured Credit Facility (the 2020 Credit Facility)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Credit facility term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mck_SeniorUnsecuredCreditFacilitythe2020CreditFacilityCanadianDollarBritishPoundSterlingandEurosSublimitMember', window );">Senior Unsecured Credit Facility (the 2020 Credit Facility), Canadian Dollar, British Pound Sterling, and Euros Sublimit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Borrowings under facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Amounts outstanding under facility</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mck_SeniorUnsecuredCreditFacilityThe2022CreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mck_SeniorUnsecuredCreditFacilityThe2022CreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mck_SeniorUnsecuredCreditFacilityThe2022CreditFacilityCanadianDollarBritishPoundSterlingAndEurosSublimitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mck_SeniorUnsecuredCreditFacilityThe2022CreditFacilityCanadianDollarBritishPoundSterlingAndEurosSublimitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mck_SeniorUnsecuredCreditFacilitythe2020CreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mck_SeniorUnsecuredCreditFacilitythe2020CreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mck_SeniorUnsecuredCreditFacilitythe2020CreditFacilityCanadianDollarBritishPoundSterlingandEurosSublimitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mck_SeniorUnsecuredCreditFacilitythe2020CreditFacilityCanadianDollarBritishPoundSterlingandEurosSublimitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140642626929488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt and Financing Activities - Commercial Paper Narrative (Details) - Commercial Paper - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Credit facility, maximum borrowing capacity</a></td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommercialPaper', window );">Proceeds from issuance of commercial paper</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfCommercialPaper', window );">Repayments of commercial paper</a></td>
<td class="nump">65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermCommercialPaperCurrent', window );">Commercial paper</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermCommercialPaperCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the current portion of long-term unsecured obligations issued by corporations and other borrowers to investors (with maturities initially due after one year or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermCommercialPaperCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommercialPaper">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from borrowing by issuing commercial paper.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommercialPaper</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfCommercialPaper">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow due to repaying amounts borrowed by issuing commercial paper.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfCommercialPaper</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140642625766496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Hedging Activities - Narrative (Details)<br> &#163; in Millions, $ in Millions, &#8364; in Billions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 15, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Debt outstanding</a></td>
<td class="nump">$ 5,661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposed of by sale | U.K. Disposal Group (Disposal Group)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent', window );">Reclassification of gains from AOCI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember', window );">Fair Value Hedges | USD | Floating interest rate swaps | Derivatives designated for hedge accounting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedges | Floating interest rate swaps | Derivatives designated for hedge accounting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mck_DerivativeNotionalAmountEnteredIntoDuringPeriod', window );">Derivative, notional amount, entered into during period</a></td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mck_DerivativeTerminationProceedsAmortizationPeriod', window );">Derivative termination proceeds, amortization period (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedges | USD | Fixed interest rate swaps | Derivatives designated for hedge accounting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=us-gaap_CurrencySwapMember', window );">Derivatives designated as net investment hedges | Fair Value Hedges | EUR | Derivatives designated for hedge accounting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mck_BritishPoundSterlingDenominatedNotesMember', window );">British Pound Sterling Denominated Notes | Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Debt outstanding | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mck_DerivativeNotionalAmountEnteredIntoDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative, Notional Amount, Entered Into During Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mck_DerivativeNotionalAmountEnteredIntoDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mck_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mck_DerivativeTerminationProceedsAmortizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative, Termination Proceeds, Amortization Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mck_DerivativeTerminationProceedsAmortizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mck_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mck_UKBusinessesDisposalGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mck_UKBusinessesDisposalGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=mck_FixedInterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=mck_FixedInterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_CurrencySwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_CurrencySwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mck_BritishPoundSterlingDenominatedNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mck_BritishPoundSterlingDenominatedNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LoansPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140642630232640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Hedging Activities - Summary of Foreign Currency Gains and (Losses) from Non-Derivative Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated for hedge accounting | Net Investment Hedges | Euro Denominated Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax', window );">Derivatives designated as net investment hedges:</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 64<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from derivative designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4CCC<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mck_EuroDenominatedNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mck_EuroDenominatedNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140642630801632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Hedging Activities - Schedule of Notional Amounts of Outstanding Derivative Positions (Details) - Derivatives designated for hedge accounting<br> &#8364; in Millions, &#163; in Millions, $ in Millions, $ in Millions</strong></div></th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 15, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>CAD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Cross-currency swaps | Net Investment Hedges | CAD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Cross-currency swaps | Fair Value Hedges | GBP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Cross-currency swaps | Fair Value Hedges | EUR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional | &#8364;</a></td>
<td class="nump">&#8364; 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Cross-currency swaps | Cash Flow Hedges | CAD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Floating interest rate swaps | Fair Value Hedges | USD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Floating interest rate swaps | Cash Flow Hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Fixed interest rate swaps | Cash Flow Hedges | USD</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1B<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CAD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CAD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_GBP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_GBP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_USD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_USD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=mck_FixedInterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=mck_FixedInterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140642636504528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Hedging Activities - Summary of Derivative Instruments Gain (Loss) (Details) - Derivatives designated for hedge accounting - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Cross-currency swaps | Net Investment Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Derivatives designated as cash flow and other hedges:</a></td>
<td class="num">$ (20)<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Cross-currency swaps | Cash Flow Hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Derivatives designated as cash flow and other hedges:</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Fixed interest rate swaps | Cash Flow Hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Derivatives designated as cash flow and other hedges:</a></td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=mck_FixedInterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=mck_FixedInterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140642630318784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Hedging Activities - Schedule of Fair Value of Derivatives (Details) - Derivatives designated for hedge accounting - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Fair value of derivative, asset</a></td>
<td class="nump">$ 84<span></span>
</td>
<td class="nump">$ 80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Fair value of derivative, liability</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Net Investment Hedges | Prepaid expenses and other/Other accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Fair value of derivative, asset</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Fair value of derivative, liability</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">U.S. Dollar notional amount, asset</a></td>
<td class="nump">301<span></span>
</td>
<td class="nump">301<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Net Investment Hedges | Other non-current assets/liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Fair value of derivative, asset</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">74<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Fair value of derivative, liability</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetNotionalAmount', window );">U.S. Dollar notional amount, asset</a></td>
<td class="nump">2,760<span></span>
</td>
<td class="nump">2,760<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Floating interest rate swaps | Other non-current assets/liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Fair value of derivative, asset</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Fair value of derivative, liability</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityNotionalAmount', window );">U.S. Dollar, notional amount, liability</a></td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payments on the derivative asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column A)(Footnote 3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1B<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-7<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4B<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -SubTopic 20<br> -Topic 860<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481326/860-20-50-4D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483466/210-20-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483444/210-20-55-7<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4B<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -SubTopic 20<br> -Topic 860<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481326/860-20-50-4D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payments on the derivative liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5C<br> -Subparagraph (SX 210.12-13C(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5C<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SX 210.12-13(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5B<br> -Subparagraph (SX 210.12-13B(Column A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-5B<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1B<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CurrencySwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=mck_CurrentAssetLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=mck_CurrentAssetLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=mck_OtherNonCurrentAssetsAndLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=mck_OtherNonCurrentAssetsAndLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140642726313552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Investments in equity securities</a></td>
<td class="nump">$ 237<span></span>
</td>
<td class="nump">$ 237<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair value, inputs, level 1 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Money market funds at carrying value</a></td>
<td class="nump">$ 806<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482736/825-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MoneyMarketFundsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MoneyMarketFundsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140642625448096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Long-Term Debt is Recorded at Amortized Cost (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Carrying Value</a></td>
<td class="nump">$ 5,661<span></span>
</td>
<td class="nump">$ 5,594<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Recurring | Fair value, inputs, level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Carrying Value</a></td>
<td class="nump">5,661<span></span>
</td>
<td class="nump">5,594<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair Value</a></td>
<td class="nump">$ 5,335<span></span>
</td>
<td class="nump">$ 5,386<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481568/470-20-55-69C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-1D<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140642625971744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingent Liabilities - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>distributor </div>
<div>case </div>
<div>state </div>
<div>jurisdiction</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>state</div>
</th>
<th class="th">
<div>Dec. 12, 2018 </div>
<div>officer</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mck_LossContingencyNumberOfFormerOfficers', window );">Number of former officers | officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=mck_NationalPrescriptionOpiateLitigationMember', window );">National Prescription Opioid Litigation | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Complaints filed against the entity | case</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=mck_NationalPrescriptionOpiateLitigationMember', window );">National Prescription Opioid Litigation | Canada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Complaints filed against the entity | case</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=mck_NationalPrescriptionOpiateLitigationMember', window );">National Prescription Opioid Litigation | An individual | Canada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Complaints filed against the entity | case</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember', window );">Settled Litigation | National Prescription Opioid Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Settlement payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember', window );">Settled Litigation | National Prescription Opioid Litigation | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Settlement payment</a></td>
<td class="nump">$ 529<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mck_NationalPrescriptionOpiateLitigationMember', window );">National Prescription Opioid Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mck_LossContingencyNumberOfOtherDefendants', window );">Number of other national distributors named in suit | distributor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mck_LossContingencyNumberofStates', window );">Number of states in which court cases are pending | state</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mck_LossContingencyNumberOfCasesDismissed', window );">Loss contingency, number of cases dismissed | case</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mck_LitigationSettlementAwardAmountToBeUsedByStateAndLocalGovernment', window );">Portion of settlement award to be used by state and local government for remediation (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mck_LossContingencyClaimsSettledNumberOfJurisdictionsNotParticipatingInSettlement', window );">Loss contingency, claims settled, number of jurisdictions not participating in settlement | jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mck_NationalPrescriptionOpiateLitigationMember', window );">National Prescription Opioid Litigation | State of Alabama and Subdivisions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Settlement payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Award payable under proposed framework</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 132<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mck_NationalPrescriptionOpiateLitigationMember', window );">National Prescription Opioid Litigation | Native American Tribes Other Than Cherokee Nation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mck_LitigationSettlementAmountAwardedToOtherPartyPercentageOfTotalSettlementToBeUsedToRemediateDamages', window );">Litigation settlement, amount awarded to other party, percentage of total settlement to be used to remediate damages</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mck_NationalPrescriptionOpiateLitigationMember', window );">National Prescription Opioid Litigation | Three Largest U.S. Pharmaceutical Distributors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Settlement payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Award payable under proposed framework</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mck_NationalPrescriptionOpiateLitigationMember', window );">National Prescription Opioid Litigation | Three National Pharmaceutical Distributors | State of West Virginia and Subdivisions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Settlement payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Award payable under proposed framework</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mck_NationalPrescriptionOpiateLitigationMember', window );">National Prescription Opioid Litigation | Three National Pharmaceutical Distributors | Cherokee Nation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Settlement payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mck_NationalPrescriptionOpiateLitigationMember', window );">National Prescription Opioid Litigation | Three National Pharmaceutical Distributors | Native American Tribes Other Than Cherokee Nation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Award payable under proposed framework</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mck_EvanstonPolicePensionFundVMcKessonCorporationMember', window );">Evanston Police Pension Fund v. McKesson Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Loss contingency, estimate of possible loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 141<span></span>
</td>
<td class="nump">$ 141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EstimatedInsuranceRecoveries', window );">Probable loss recovery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 141<span></span>
</td>
<td class="nump">$ 141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=mck_UnitedStatesExRelHartVMcKessonCorporationEtAl15CV00903RAMember', window );">United States Ex Rel. Hart V. McKesson Corporation, Et Al 15-CV-00903-RA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mck_LossContingencyNumberOfStatesFiledOnBehalfOf', window );">Number of states filed on behalf of | state</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mck_LitigationSettlementAmountAwardedToOtherPartyPercentageOfTotalSettlementToBeUsedToRemediateDamages">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Litigation Settlement, Amount Awarded to Other Party, Percentage of Total Settlement to Be Used to Remediate Damages</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mck_LitigationSettlementAmountAwardedToOtherPartyPercentageOfTotalSettlementToBeUsedToRemediateDamages</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mck_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mck_LitigationSettlementAwardAmountToBeUsedByStateAndLocalGovernment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Litigation Settlement, Award Amount To Be Used by State and Local Government</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mck_LitigationSettlementAwardAmountToBeUsedByStateAndLocalGovernment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mck_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mck_LossContingencyClaimsSettledNumberOfJurisdictionsNotParticipatingInSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Claims Settled, Number Of Jurisdictions Not Participating In Settlement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mck_LossContingencyClaimsSettledNumberOfJurisdictionsNotParticipatingInSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mck_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mck_LossContingencyNumberOfCasesDismissed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Cases Dismissed</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mck_LossContingencyNumberOfCasesDismissed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mck_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mck_LossContingencyNumberOfFormerOfficers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number of Former Officers</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mck_LossContingencyNumberOfFormerOfficers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mck_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mck_LossContingencyNumberOfOtherDefendants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number of Other Defendants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mck_LossContingencyNumberOfOtherDefendants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mck_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mck_LossContingencyNumberOfStatesFiledOnBehalfOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number of States Filed On Behalf Of</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mck_LossContingencyNumberOfStatesFiledOnBehalfOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mck_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mck_LossContingencyNumberofStates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number of States</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mck_LossContingencyNumberofStates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mck_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EstimatedInsuranceRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts expected to be recovered under the terms of insurance contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EstimatedInsuranceRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=mck_NationalPrescriptionOpiateLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=mck_NationalPrescriptionOpiateLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mck_IndividualClaimantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mck_IndividualClaimantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mck_NationalPrescriptionOpiateLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mck_NationalPrescriptionOpiateLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mck_StateOfAlabamaAndSubdivisionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mck_StateOfAlabamaAndSubdivisionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mck_NativeAmericanTribesOtherThanCherokeeNationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mck_NativeAmericanTribesOtherThanCherokeeNationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mck_ThreeLargestUSPharmaceuticalDistributorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mck_ThreeLargestUSPharmaceuticalDistributorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=mck_ThreeNationalPharmaceuticalDistributorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=mck_ThreeNationalPharmaceuticalDistributorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mck_StateOfWestVirginiaAndSubdivisionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mck_StateOfWestVirginiaAndSubdivisionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=mck_CherokeeNationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=mck_CherokeeNationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mck_EvanstonPolicePensionFundVMcKessonCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mck_EvanstonPolicePensionFundVMcKessonCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=mck_UnitedStatesExRelHartVMcKessonCorporationEtAl15CV00903RAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=mck_UnitedStatesExRelHartVMcKessonCorporationEtAl15CV00903RAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140642636593728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingent Liabilities - Estimated Accrual Liability (Details) - National Prescription Opioid Litigation - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualCarryingValueCurrent', window );">Current litigation liabilities</a></td>
<td class="nump">$ 545<span></span>
</td>
<td class="nump">$ 548<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualCarryingValueNoncurrent', window );">Long-term litigation liabilities</a></td>
<td class="nump">6,628<span></span>
</td>
<td class="nump">6,625<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Total litigation liabilities</a></td>
<td class="nump">$ 7,173<span></span>
</td>
<td class="nump">$ 7,173<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482425/460-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualCarryingValueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability expected to be resolved within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualCarryingValueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualCarryingValueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability expected to be resolved after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualCarryingValueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=mck_NationalPrescriptionOpiateLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=mck_NationalPrescriptionOpiateLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140642625913888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Deficit - Narrative (Details)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">4 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 28, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesLineItems', window );"><strong>Accelerated Share Repurchases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mck_CommonStockVotingRightsNumberofVotesPerCommonShare', window );">Number of votes per share of common stock permitted on proposals presented to stockholders (vote) | vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Dividends declared per common share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.54<span></span>
</td>
<td class="nump">$ 0.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Shares repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 673<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mck_ExciseTaxPayableCurrent', window );">Excise taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Authorized amount available for future repurchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesLineItems', window );"><strong>Accelerated Share Repurchases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Dividends declared per common share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Authorized repurchase amount (up to)</a></td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=mck_AcceleratedShareRepurchaseMember', window );">Accelerated Share Repurchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesLineItems', window );"><strong>Accelerated Share Repurchases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Shares repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Share repurchases (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.1<span></span>
</td>
<td class="nump">5.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Average price of shares repurchased (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 321.05<span></span>
</td>
<td class="nump">$ 295.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=mck_AcceleratedShareRepurchaseInitialShareSettlementMember', window );">Accelerated Share Repurchase, Initial Share Settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesLineItems', window );"><strong>Accelerated Share Repurchases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Common stock repurchased (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=mck_AcceleratedShareRepurchaseCompletionOfProgramMember', window );">Accelerated Share Repurchase, Completion Of Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesLineItems', window );"><strong>Accelerated Share Repurchases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Common stock repurchased (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=mck_OpenMarketShareRepurchaseTransactionsMember', window );">Open Market Share Repurchase Transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesLineItems', window );"><strong>Accelerated Share Repurchases [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Average price of shares repurchased (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 379.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Common stock repurchased (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredParValueMethod', window );">Shares repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mck_CommonStockVotingRightsNumberofVotesPerCommonShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Voting Rights, Number of Votes Per Common Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mck_CommonStockVotingRightsNumberofVotesPerCommonShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mck_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mck_ExciseTaxPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Excise Tax Payable, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mck_ExciseTaxPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mck_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcceleratedShareRepurchasesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcceleratedShareRepurchasesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total cost of shares repurchased divided by the total number of shares repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockAcquiredAverageCostPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredParValueMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the par value method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredParValueMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=mck_AcceleratedShareRepurchaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=mck_AcceleratedShareRepurchaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=mck_AcceleratedShareRepurchaseInitialShareSettlementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=mck_AcceleratedShareRepurchaseInitialShareSettlementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=mck_AcceleratedShareRepurchaseCompletionOfProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=mck_AcceleratedShareRepurchaseCompletionOfProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=mck_OpenMarketShareRepurchaseTransactionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=mck_OpenMarketShareRepurchaseTransactionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140642626843696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Deficit - Schedule of Changes in Accumulated Other Comprehensive Income (Loss) by Component (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">$ (1,490)<span></span>
</td>
<td class="num">$ (1,792)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income, net of tax</a></td>
<td class="nump">57<span></span>
</td>
<td class="nump">636<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss) attributable to McKesson</a></td>
<td class="nump">57<span></span>
</td>
<td class="nump">636<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">(1,240)<span></span>
</td>
<td class="num">(1,472)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated for hedge accounting | Net Investment Hedging | Euro Denominated Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax', window );">Other comprehensive income (loss), net investment hedge, gain (loss)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Derivatives designated for hedge accounting | Cross-currency swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax', window );">Other comprehensive income (loss), net investment hedge, gain (loss)</a></td>
<td class="num">(20)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember', window );">Total Accumulated Other Comprehensive Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">(905)<span></span>
</td>
<td class="num">(1,534)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="nump">57<span></span>
</td>
<td class="num">(101)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified to earnings and other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">737<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income, net of tax</a></td>
<td class="nump">57<span></span>
</td>
<td class="nump">636<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest', window );">Less: amounts attributable to noncontrolling interests</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss) attributable to McKesson</a></td>
<td class="nump">57<span></span>
</td>
<td class="nump">586<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">(848)<span></span>
</td>
<td class="num">(948)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Foreign Currency Translation Adjustments, Net of Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">(847)<span></span>
</td>
<td class="num">(1,504)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="nump">67<span></span>
</td>
<td class="num">(176)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified to earnings and other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">730<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income, net of tax</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">554<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest', window );">Less: amounts attributable to noncontrolling interests</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss) attributable to McKesson</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">507<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">(780)<span></span>
</td>
<td class="num">(997)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=mck_AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember', window );">Unrealized Losses on Net Investment Hedges, Net of Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">(14)<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="num">(15)<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified to earnings and other</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(17)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income, net of tax</a></td>
<td class="num">(15)<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest', window );">Less: amounts attributable to noncontrolling interests</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss) attributable to McKesson</a></td>
<td class="num">(15)<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">(29)<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax', window );">Other Comprehensive Income (Loss) before Reclassifications, Tax</a></td>
<td class="nump">5<span></span>
</td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember', window );">Unrealized Gains (Losses) on Cash Flow and Other Hedges, Net of Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">(36)<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified to earnings and other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income, net of tax</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest', window );">Less: amounts attributable to noncontrolling interests</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss) attributable to McKesson</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">(29)<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember', window );">Unrealized Losses and Other Components of Benefit Plans, Net of Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(67)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified to earnings and other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income, net of tax</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest', window );">Less: amounts attributable to noncontrolling interests</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss) attributable to McKesson</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance</a></td>
<td class="num">$ (10)<span></span>
</td>
<td class="num">$ (34)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AOCIAttributableToParentNetOfTaxRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss) before reclassification adjustment from accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 815<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from derivative designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480434/815-10-50-4CCC<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482739/220-10-55-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mck_EuroDenominatedNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mck_EuroDenominatedNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CurrencySwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CurrencySwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=mck_AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=mck_AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140642633710272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments of Business - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2023 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm140642626667488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments of Business - Reportable operating segment (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Segment revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 74,483<span></span>
</td>
<td class="nump">$ 67,154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLossAbstract', window );"><strong>Segment operating profit (loss)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating profit (loss)</a></td>
<td class="nump">1,100<span></span>
</td>
<td class="nump">1,036<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mck_CorporateOperatingExpenseandOtherIncomeNet', window );">Corporate income (expenses), net</a></td>
<td class="num">(204)<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(47)<span></span>
</td>
<td class="num">(45)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income from continuing operations before income taxes</a></td>
<td class="nump">$ 1,091<span></span>
</td>
<td class="nump">1,006<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLegalSettlements', window );">Proceeds from legal settlements</a></td>
<td class="nump">$ 118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLIFOReservePeriodCharge', window );">Pre-tax credits related to LIFO accounting</a></td>
<td class="num">(32)<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Fair value adjustment gain</a></td>
<td class="nump">28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown', window );">Loss (gain) to remeasure disposal group to fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring costs, anticipated total charges</a></td>
<td class="nump">$ 52<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLossAbstract', window );"><strong>Segment operating profit (loss)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLossAbstract', window );"><strong>Segment operating profit (loss)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating profit (loss)</a></td>
<td class="nump">$ 1,342<span></span>
</td>
<td class="nump">1,090<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLossAbstract', window );"><strong>Segment operating profit (loss)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring costs, anticipated total charges</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate | Held-for-sale | E.U. Businesses (Disposal Group)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLossAbstract', window );"><strong>Segment operating profit (loss)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown', window );">Loss (gain) to remeasure disposal group to fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(106)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mck_USPharmaceuticalSegmentMember', window );">U.S. Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Segment revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">67,160<span></span>
</td>
<td class="nump">56,947<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mck_USPharmaceuticalSegmentMember', window );">U.S. Pharmaceutical | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLossAbstract', window );"><strong>Segment operating profit (loss)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating profit (loss)</a></td>
<td class="nump">$ 827<span></span>
</td>
<td class="nump">696<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mck_RevenueDerivedFromServicesPercentage', window );">Revenue derived from services, percentage (approximately or less than)</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLIFOReservePeriodCharge', window );">Pre-tax credits related to LIFO accounting</a></td>
<td class="num">$ (32)<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring costs, anticipated total charges</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mck_PrescriptionTechnologySolutionsMember', window );">Prescription Technology Solutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Segment revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">1,244<span></span>
</td>
<td class="nump">1,066<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mck_PrescriptionTechnologySolutionsMember', window );">Prescription Technology Solutions | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLossAbstract', window );"><strong>Segment operating profit (loss)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating profit (loss)</a></td>
<td class="nump">$ 231<span></span>
</td>
<td class="nump">144<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mck_RevenueDerivedFromServicesPercentage', window );">Revenue derived from services, percentage (approximately or less than)</a></td>
<td class="nump">37.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring costs, anticipated total charges</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mck_MedicalSurgicalSolutionsSegmentMember', window );">Medical-Surgical Solutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Segment revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">2,611<span></span>
</td>
<td class="nump">2,592<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mck_MedicalSurgicalSolutionsSegmentMember', window );">Medical-Surgical Solutions | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLossAbstract', window );"><strong>Segment operating profit (loss)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating profit (loss)</a></td>
<td class="nump">$ 227<span></span>
</td>
<td class="nump">256<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mck_RevenueDerivedFromServicesPercentage', window );">Revenue derived from services, percentage (approximately or less than)</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring costs, anticipated total charges</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mck_InternationalSegmentMember', window );">International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Segment revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">3,468<span></span>
</td>
<td class="nump">6,549<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mck_InternationalSegmentMember', window );">International | Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLossAbstract', window );"><strong>Segment operating profit (loss)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Total operating profit (loss)</a></td>
<td class="nump">$ 57<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_mck_RevenueDerivedFromServicesPercentage', window );">Revenue derived from services, percentage (approximately or less than)</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring costs, anticipated total charges</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=mck_InternationalSegmentMember', window );">International | Operating Segments | Held-for-sale | E.U. Businesses (Disposal Group)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLossAbstract', window );"><strong>Segment operating profit (loss)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown', window );">Loss (gain) to remeasure disposal group to fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mck_CorporateOperatingExpenseandOtherIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Corporate Operating Expense and Other Income, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mck_CorporateOperatingExpenseandOtherIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mck_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mck_RevenueDerivedFromServicesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue Derived From Services, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mck_RevenueDerivedFromServicesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mck_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482130/360-10-45-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLIFOReservePeriodCharge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The change in the inventory reserve representing the cumulative difference in cost between the first in, first out and the last in, first out inventory valuation methods, which change has been reflected in the statement of income during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480581/330-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLIFOReservePeriodCharge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received for the settlement of litigation during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mck_EUBusinessesDisposalGroupMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mck_EUBusinessesDisposalGroupMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mck_USPharmaceuticalSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mck_USPharmaceuticalSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mck_PrescriptionTechnologySolutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mck_PrescriptionTechnologySolutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mck_MedicalSurgicalSolutionsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mck_MedicalSurgicalSolutionsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=mck_InternationalSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=mck_InternationalSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>mck-20230630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2023"
  xmlns:currency="http://xbrl.sec.gov/currency/2023"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:mck="http://mckesson123.com/20230630"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="mck-20230630.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mck:A1500NotesDue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mck:A1625NotesDue2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mck:A3125NotesDue2029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mck:RxSavingsSolutionsLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:RxTsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-01</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mck:RxSavingsSolutionsLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:RxTsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-01</endDate>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mck:RxSavingsSolutionsLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:RxTsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-01</instant>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mck:RxSavingsSolutionsLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:RxTsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mck:RxSavingsSolutionsLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:RxTsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mck:SCRIOncologyLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:USPharmaceuticalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mck:SCRIOncologyLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:USPharmaceuticalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-31</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">mck:SarahCannonResearchInstituteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mck:SCRIOncologyLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:USPharmaceuticalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">mck:McKessonUSOncologyResearchMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mck:SCRIOncologyLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:USPharmaceuticalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-10-31</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mck:EUBusinessesDisposalGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mck:UKBusinessesDisposalGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-06</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mck:InternationalSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mck:AureliusElephantLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-06</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mck:InternationalSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mck:AureliusElephantLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-06</startDate>
            <endDate>2022-04-06</endDate>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mck:UKBusinessesDisposalGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-06</startDate>
            <endDate>2022-04-06</endDate>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">mck:StrategicGrowthInitiativePlanOperationalEfficienciesAndCostOptimizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">mck:StrategicGrowthInitiativePlanOperationalEfficienciesAndCostOptimizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">mck:StrategicGrowthInitiativePlanOperationalEfficienciesAndCostOptimizationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:USPharmaceuticalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:PrescriptionTechnologySolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:MedicalSurgicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:InternationalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:USPharmaceuticalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:PrescriptionTechnologySolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:MedicalSurgicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:InternationalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:USPharmaceuticalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:PrescriptionTechnologySolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:MedicalSurgicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:InternationalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:USPharmaceuticalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:PrescriptionTechnologySolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:MedicalSurgicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:InternationalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:USPharmaceuticalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:PrescriptionTechnologySolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:MedicalSurgicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:InternationalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:USPharmaceuticalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:PrescriptionTechnologySolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:MedicalSurgicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:InternationalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:USPharmaceuticalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:PrescriptionTechnologySolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:MedicalSurgicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:InternationalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:CustomerRelationshipsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ServiceAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ServiceAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TechnologyBasedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:A380NotesDueMarch152024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:A380NotesDueMarch152024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:A090NotesDueDecember32025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:A090NotesDueDecember32025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:A525NotesDueFebruary152026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:A525NotesDueFebruary152026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:A130NotesDueAugust152026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:A130NotesDueAugust152026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:A765DebenturesDueMarch12027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:A765DebenturesDueMarch12027Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:A395NotesDueFebruary162028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:A395NotesDueFebruary162028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:A490NotesDueJuly152028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:A490NotesDueJuly152028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:A475NotesDueMay302029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:A475NotesDueMay302029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:A510NotesDueJuly152033Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:A510NotesDueJuly152033Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:A600NotesDueMarch12041Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:A600NotesDueMarch12041Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:A488NotesDueMarch152044Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:A488NotesDueMarch152044Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:A150EuroNotesDueNovember172025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:A150EuroNotesDueNovember172025Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:A163EuroNotesDueOctober302026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:A163EuroNotesDueOctober302026Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:A313SterlingNotesDueFebruary172029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:A313SterlingNotesDueFebruary172029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mck:LeaseAndOtherObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">mck:LeaseAndOtherObligationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:A490NotesDueJuly152028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-15</instant>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:A510NotesDueJuly152033Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-15</instant>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:A490NotesDueJuly152028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-15</startDate>
            <endDate>2023-06-15</endDate>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:A510NotesDueJuly152033Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-15</startDate>
            <endDate>2023-06-15</endDate>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:A380NotesDueMarch152024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-15</instant>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:A380NotesDueMarch152024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-16</startDate>
            <endDate>2023-06-16</endDate>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:A380NotesDueMarch152024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-16</instant>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:SeniorUnsecuredCreditFacilityThe2022CreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-07</instant>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:SeniorUnsecuredCreditFacilityThe2022CreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-07</startDate>
            <endDate>2022-11-07</endDate>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:SeniorUnsecuredCreditFacilityThe2022CreditFacilityCanadianDollarBritishPoundSterlingAndEurosSublimitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-07</instant>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:SeniorUnsecuredCreditFacilitythe2020CreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-25</instant>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:SeniorUnsecuredCreditFacilitythe2020CreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-25</startDate>
            <endDate>2019-09-25</endDate>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:SeniorUnsecuredCreditFacilitythe2020CreditFacilityCanadianDollarBritishPoundSterlingandEurosSublimitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:SeniorUnsecuredCreditFacilitythe2020CreditFacilityCanadianDollarBritishPoundSterlingandEurosSublimitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-07</instant>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:SeniorUnsecuredCreditFacilityThe2022CreditFacilityCanadianDollarBritishPoundSterlingAndEurosSublimitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:SeniorUnsecuredCreditFacilityThe2022CreditFacilityCanadianDollarBritishPoundSterlingAndEurosSublimitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mck:UKBusinessesDisposalGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:BritishPoundSterlingDenominatedNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LoansPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:EuroDenominatedNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mck:EuroDenominatedNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mck:FixedInterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:USD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mck:FixedInterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-15</instant>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mck:FixedInterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">mck:FixedInterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mck:CurrentAssetLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mck:CurrentAssetLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mck:OtherNonCurrentAssetsAndLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mck:OtherNonCurrentAssetsAndLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mck:OtherNonCurrentAssetsAndLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">mck:OtherNonCurrentAssetsAndLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mck:NationalPrescriptionOpiateLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mck:NationalPrescriptionOpiateLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mck:ThreeLargestUSPharmaceuticalDistributorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mck:StateOfAlabamaAndSubdivisionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mck:NationalPrescriptionOpiateLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mck:StateOfWestVirginiaAndSubdivisionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mck:NationalPrescriptionOpiateLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mck:ThreeNationalPharmaceuticalDistributorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mck:CherokeeNationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mck:NationalPrescriptionOpiateLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mck:ThreeNationalPharmaceuticalDistributorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mck:NativeAmericanTribesOtherThanCherokeeNationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mck:NationalPrescriptionOpiateLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">mck:ThreeNationalPharmaceuticalDistributorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mck:NativeAmericanTribesOtherThanCherokeeNationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mck:NationalPrescriptionOpiateLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mck:NationalPrescriptionOpiateLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mck:NationalPrescriptionOpiateLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mck:NationalPrescriptionOpiateLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mck:NationalPrescriptionOpiateLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-07-31</endDate>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mck:NationalPrescriptionOpiateLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mck:NationalPrescriptionOpiateLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">mck:IndividualClaimantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">mck:NationalPrescriptionOpiateLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
        </entity>
        <period>
            <instant>2018-12-12</instant>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mck:EvanstonPolicePensionFundVMcKessonCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mck:EvanstonPolicePensionFundVMcKessonCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">mck:UnitedStatesExRelHartVMcKessonCorporationEtAl15CV00903RAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-07-31</endDate>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">mck:AcceleratedShareRepurchaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">mck:AcceleratedShareRepurchaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">mck:AcceleratedShareRepurchaseInitialShareSettlementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">mck:AcceleratedShareRepurchaseCompletionOfProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="c-230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">mck:AcceleratedShareRepurchaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-02-28</endDate>
        </period>
    </context>
    <context id="c-231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">mck:AcceleratedShareRepurchaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-02-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">mck:AcceleratedShareRepurchaseInitialShareSettlementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="c-233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">mck:AcceleratedShareRepurchaseCompletionOfProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-05-01</startDate>
            <endDate>2022-05-31</endDate>
        </period>
    </context>
    <context id="c-234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">mck:OpenMarketShareRepurchaseTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">mck:OpenMarketShareRepurchaseTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">mck:OpenMarketShareRepurchaseTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-31</instant>
        </period>
    </context>
    <context id="c-238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mck:AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mck:AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mck:AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mck:AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mck:AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">mck:AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AociIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="c-269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CurrencySwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:USPharmaceuticalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:PrescriptionTechnologySolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:MedicalSurgicalSolutionsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:InternationalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mck:EUBusinessesDisposalGroupMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">mck:InternationalSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000927653</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">mck:EUBusinessesDisposalGroupMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>mck:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="gbp">
        <measure>iso4217:GBP</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="cad">
        <measure>iso4217:CAD</measure>
    </unit>
    <unit id="distributor">
        <measure>mck:distributor</measure>
    </unit>
    <unit id="state">
        <measure>mck:state</measure>
    </unit>
    <unit id="case">
        <measure>mck:case</measure>
    </unit>
    <unit id="jurisdiction">
        <measure>mck:jurisdiction</measure>
    </unit>
    <unit id="officer">
        <measure>mck:officer</measure>
    </unit>
    <unit id="vote">
        <measure>mck:vote</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-34">0000927653</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-35">--03-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-36">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-37">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag contextRef="c-1" id="f-38">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c-1" id="f-2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2023-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">1-13252</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-6">McKESSON CORPORATION</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-8">94-3207296</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-9">6555 State Hwy 161</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-10">Irving</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-11">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-12">75039</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-13">972</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-14">446-4800</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-2" id="f-15">Common stock, $0.01 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-2" id="f-16">MCK</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-2" id="f-17">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-3" id="f-18">1.500% Notes due 2025</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-3" id="f-19">MCK25</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-3" id="f-20">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-4" id="f-21">1.625% Notes due 2026</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-4" id="f-22">MCK26</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-4" id="f-23">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle contextRef="c-5" id="f-24">3.125% Notes due 2029</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-5" id="f-25">MCK29</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-5" id="f-26">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-27">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-28">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-29">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-30">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-31">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="c-1" id="f-32">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-6" decimals="INF" id="f-33" unitRef="shares">134902380</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-6" id="f-39" unitRef="usd">74483000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-7" decimals="-6" id="f-40" unitRef="usd">67154000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-1" decimals="-6" id="f-41" unitRef="usd">71461000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-7" decimals="-6" id="f-42" unitRef="usd">64131000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit contextRef="c-1" decimals="-6" id="f-43" unitRef="usd">3022000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-7" decimals="-6" id="f-44" unitRef="usd">3023000000</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-1" decimals="-6" id="f-45" unitRef="usd">1870000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-7" decimals="-6" id="f-46" unitRef="usd">1959000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:GainLossRelatedToLitigationSettlement contextRef="c-1" decimals="-6" id="f-47" unitRef="usd">0</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement contextRef="c-7" decimals="-6" id="f-48" unitRef="usd">-5000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <mck:RestructuringImpairmentAndOtherRelatedCharges contextRef="c-1" decimals="-6" id="f-49" unitRef="usd">52000000</mck:RestructuringImpairmentAndOtherRelatedCharges>
    <mck:RestructuringImpairmentAndOtherRelatedCharges contextRef="c-7" decimals="-6" id="f-50" unitRef="usd">23000000</mck:RestructuringImpairmentAndOtherRelatedCharges>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-6" id="f-51" unitRef="usd">1922000000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-7" decimals="-6" id="f-52" unitRef="usd">1987000000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-6" id="f-53" unitRef="usd">1100000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-7" decimals="-6" id="f-54" unitRef="usd">1036000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-6" id="f-55" unitRef="usd">38000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-7" decimals="-6" id="f-56" unitRef="usd">15000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InterestExpense contextRef="c-1" decimals="-6" id="f-57" unitRef="usd">47000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-7" decimals="-6" id="f-58" unitRef="usd">45000000</us-gaap:InterestExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-6" id="f-59" unitRef="usd">1091000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-7" decimals="-6" id="f-60" unitRef="usd">1006000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-6" id="f-61" unitRef="usd">94000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-7" decimals="-6" id="f-62" unitRef="usd">199000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest contextRef="c-1" decimals="-6" id="f-63" unitRef="usd">997000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest contextRef="c-7" decimals="-6" id="f-64" unitRef="usd">807000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax contextRef="c-1" decimals="-6" id="f-65" unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax contextRef="c-7" decimals="-6" id="f-66" unitRef="usd">2000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-6" id="f-67" unitRef="usd">997000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-7" decimals="-6" id="f-68" unitRef="usd">809000000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-1" decimals="-6" id="f-69" unitRef="usd">39000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-7" decimals="-6" id="f-70" unitRef="usd">41000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-6" id="f-71" unitRef="usd">958000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-6" id="f-72" unitRef="usd">768000000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="c-1"
      decimals="2"
      id="f-73"
      unitRef="usdPerShare">7.02</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="c-7"
      decimals="2"
      id="f-74"
      unitRef="usdPerShare">5.25</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="c-1"
      decimals="2"
      id="f-75"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="c-7"
      decimals="2"
      id="f-76"
      unitRef="usdPerShare">0.01</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-77"
      unitRef="usdPerShare">7.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-7"
      decimals="2"
      id="f-78"
      unitRef="usdPerShare">5.26</us-gaap:EarningsPerShareDiluted>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="c-1"
      decimals="2"
      id="f-79"
      unitRef="usdPerShare">7.07</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="c-7"
      decimals="2"
      id="f-80"
      unitRef="usdPerShare">5.31</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="c-1"
      decimals="2"
      id="f-81"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="c-7"
      decimals="2"
      id="f-82"
      unitRef="usdPerShare">0.01</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-83"
      unitRef="usdPerShare">7.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-7"
      decimals="2"
      id="f-84"
      unitRef="usdPerShare">5.32</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-5" id="f-85" unitRef="shares">136600000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-7" decimals="-5" id="f-86" unitRef="shares">145900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-5" id="f-87" unitRef="shares">135500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-7" decimals="-5" id="f-88" unitRef="shares">144200000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-6" id="f-89" unitRef="usd">997000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-7" decimals="-6" id="f-90" unitRef="usd">809000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-1" decimals="-6" id="f-91" unitRef="usd">52000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-7" decimals="-6" id="f-92" unitRef="usd">582000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax contextRef="c-1" decimals="-6" id="f-93" unitRef="usd">7000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax contextRef="c-7" decimals="-6" id="f-94" unitRef="usd">18000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax contextRef="c-1" decimals="-6" id="f-95" unitRef="usd">2000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax contextRef="c-7" decimals="-6" id="f-96" unitRef="usd">-36000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-1" decimals="-6" id="f-97" unitRef="usd">57000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-7" decimals="-6" id="f-98" unitRef="usd">636000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-1" decimals="-6" id="f-99" unitRef="usd">1054000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-7" decimals="-6" id="f-100" unitRef="usd">1445000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="c-1" decimals="-6" id="f-101" unitRef="usd">39000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest contextRef="c-7" decimals="-6" id="f-102" unitRef="usd">91000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-6" id="f-103" unitRef="usd">1015000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-7" decimals="-6" id="f-104" unitRef="usd">1354000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-6" decimals="-6" id="f-105" unitRef="usd">2636000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-8" decimals="-6" id="f-106" unitRef="usd">4678000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ReceivablesNetCurrent contextRef="c-6" decimals="-6" id="f-107" unitRef="usd">21860000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent contextRef="c-8" decimals="-6" id="f-108" unitRef="usd">19410000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:InventoryNet contextRef="c-6" decimals="-6" id="f-109" unitRef="usd">20510000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-8" decimals="-6" id="f-110" unitRef="usd">19691000000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-6" decimals="-6" id="f-111" unitRef="usd">533000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-8" decimals="-6" id="f-112" unitRef="usd">513000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-6" decimals="-6" id="f-113" unitRef="usd">45539000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-8" decimals="-6" id="f-114" unitRef="usd">44292000000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-6" decimals="-6" id="f-115" unitRef="usd">2172000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-8" decimals="-6" id="f-116" unitRef="usd">2177000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-6" decimals="-6" id="f-117" unitRef="usd">1693000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-8" decimals="-6" id="f-118" unitRef="usd">1635000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill contextRef="c-6" decimals="-6" id="f-119" unitRef="usd">9971000000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-8" decimals="-6" id="f-120" unitRef="usd">9947000000</us-gaap:Goodwill>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-6" decimals="-6" id="f-121" unitRef="usd">2221000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-8" decimals="-6" id="f-122" unitRef="usd">2277000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-6" decimals="-6" id="f-123" unitRef="usd">2500000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-8" decimals="-6" id="f-124" unitRef="usd">1992000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-6" decimals="-6" id="f-125" unitRef="usd">64096000000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-8" decimals="-6" id="f-126" unitRef="usd">62320000000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-6" decimals="-6" id="f-127" unitRef="usd">43982000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-8" decimals="-6" id="f-128" unitRef="usd">42490000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent contextRef="c-6" decimals="-6" id="f-129" unitRef="usd">50000000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent contextRef="c-8" decimals="-6" id="f-130" unitRef="usd">968000000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-6" decimals="-6" id="f-131" unitRef="usd">300000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-8" decimals="-6" id="f-132" unitRef="usd">299000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-6" decimals="-6" id="f-133" unitRef="usd">4090000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-8" decimals="-6" id="f-134" unitRef="usd">4200000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-6" decimals="-6" id="f-135" unitRef="usd">48422000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-8" decimals="-6" id="f-136" unitRef="usd">47957000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations contextRef="c-6" decimals="-6" id="f-137" unitRef="usd">5611000000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations contextRef="c-8" decimals="-6" id="f-138" unitRef="usd">4626000000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-6" decimals="-6" id="f-139" unitRef="usd">1139000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-8" decimals="-6" id="f-140" unitRef="usd">1387000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-6" decimals="-6" id="f-141" unitRef="usd">1462000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-8" decimals="-6" id="f-142" unitRef="usd">1402000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LitigationReserveNoncurrent contextRef="c-6" decimals="-6" id="f-143" unitRef="usd">6628000000</us-gaap:LitigationReserveNoncurrent>
    <us-gaap:LitigationReserveNoncurrent contextRef="c-8" decimals="-6" id="f-144" unitRef="usd">6625000000</us-gaap:LitigationReserveNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-6" decimals="-6" id="f-145" unitRef="usd">2074000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-8" decimals="-6" id="f-146" unitRef="usd">1813000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-8"
      decimals="INF"
      id="f-147"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-6"
      decimals="INF"
      id="f-148"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-6" decimals="-6" id="f-149" unitRef="shares">100000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-8" decimals="-6" id="f-150" unitRef="shares">100000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="c-6" decimals="INF" id="f-151" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="c-8" decimals="INF" id="f-152" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-8" decimals="INF" id="f-153" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-6" decimals="INF" id="f-154" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue contextRef="c-6" decimals="-6" id="f-155" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-8" decimals="-6" id="f-156" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-8"
      decimals="INF"
      id="f-157"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-6"
      decimals="INF"
      id="f-158"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-6" decimals="-6" id="f-159" unitRef="shares">800000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-8" decimals="-6" id="f-160" unitRef="shares">800000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-6" decimals="-6" id="f-161" unitRef="shares">278000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="c-8" decimals="-6" id="f-162" unitRef="shares">277000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue contextRef="c-6" decimals="-6" id="f-163" unitRef="usd">3000000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-8" decimals="-6" id="f-164" unitRef="usd">3000000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-6" decimals="-6" id="f-165" unitRef="usd">7824000000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-8" decimals="-6" id="f-166" unitRef="usd">7747000000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-6" decimals="-6" id="f-167" unitRef="usd">13182000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-8" decimals="-6" id="f-168" unitRef="usd">12295000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-6" decimals="-6" id="f-169" unitRef="usd">-848000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-8" decimals="-6" id="f-170" unitRef="usd">-905000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:TreasuryStockCommonShares contextRef="c-6" decimals="-6" id="f-171" unitRef="shares">143000000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares contextRef="c-8" decimals="-6" id="f-172" unitRef="shares">141000000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonValue contextRef="c-6" decimals="-6" id="f-173" unitRef="usd">21763000000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:TreasuryStockCommonValue contextRef="c-8" decimals="-6" id="f-174" unitRef="usd">20997000000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:StockholdersEquity contextRef="c-6" decimals="-6" id="f-175" unitRef="usd">-1602000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-8" decimals="-6" id="f-176" unitRef="usd">-1857000000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest contextRef="c-6" decimals="-6" id="f-177" unitRef="usd">362000000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest contextRef="c-8" decimals="-6" id="f-178" unitRef="usd">367000000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-6" decimals="-6" id="f-179" unitRef="usd">-1240000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-8" decimals="-6" id="f-180" unitRef="usd">-1490000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-6" decimals="-6" id="f-181" unitRef="usd">64096000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-8" decimals="-6" id="f-182" unitRef="usd">62320000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:SharesOutstanding contextRef="c-9" decimals="-6" id="f-183" unitRef="shares">277000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-9" decimals="-6" id="f-184" unitRef="usd">3000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-10" decimals="-6" id="f-185" unitRef="usd">7747000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-11" decimals="-6" id="f-186" unitRef="usd">12295000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-12" decimals="-6" id="f-187" unitRef="usd">-905000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares contextRef="c-13" decimals="-6" id="f-188" unitRef="shares">141000000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-13" decimals="-6" id="f-189" unitRef="usd">-20997000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-14" decimals="-6" id="f-190" unitRef="usd">367000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-8" decimals="-6" id="f-191" unitRef="usd">-1490000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <mck:StockIssuedDuringPeriodSharesEmployeeStockPlansNetOfForfeitures contextRef="c-15" decimals="-6" id="f-192" unitRef="shares">1000000</mck:StockIssuedDuringPeriodSharesEmployeeStockPlansNetOfForfeitures>
    <mck:StockIssuedDuringPeriodValueEmployeeStockPlansNetOfForfeitures contextRef="c-16" decimals="-6" id="f-193" unitRef="usd">27000000</mck:StockIssuedDuringPeriodValueEmployeeStockPlansNetOfForfeitures>
    <mck:StockIssuedDuringPeriodValueEmployeeStockPlansNetOfForfeitures contextRef="c-17" decimals="-6" id="f-194" unitRef="usd">-93000000</mck:StockIssuedDuringPeriodValueEmployeeStockPlansNetOfForfeitures>
    <mck:StockIssuedDuringPeriodValueEmployeeStockPlansNetOfForfeitures contextRef="c-1" decimals="-6" id="f-195" unitRef="usd">-66000000</mck:StockIssuedDuringPeriodValueEmployeeStockPlansNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-16" decimals="-6" id="f-196" unitRef="usd">43000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-6" id="f-197" unitRef="usd">43000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockRepurchasedDuringPeriodShares contextRef="c-17" decimals="-6" id="f-198" unitRef="shares">2000000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue contextRef="c-17" decimals="-6" id="f-199" unitRef="usd">673000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue contextRef="c-1" decimals="-6" id="f-200" unitRef="usd">673000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <mck:NetIncomeLossIncludingPortionAttributabletoNoncontrollingInterestExcludingRedeemableNoncontrollingInterest contextRef="c-18" decimals="-6" id="f-201" unitRef="usd">958000000</mck:NetIncomeLossIncludingPortionAttributabletoNoncontrollingInterestExcludingRedeemableNoncontrollingInterest>
    <mck:NetIncomeLossIncludingPortionAttributabletoNoncontrollingInterestExcludingRedeemableNoncontrollingInterest contextRef="c-19" decimals="-6" id="f-202" unitRef="usd">39000000</mck:NetIncomeLossIncludingPortionAttributabletoNoncontrollingInterestExcludingRedeemableNoncontrollingInterest>
    <mck:NetIncomeLossIncludingPortionAttributabletoNoncontrollingInterestExcludingRedeemableNoncontrollingInterest contextRef="c-1" decimals="-6" id="f-203" unitRef="usd">997000000</mck:NetIncomeLossIncludingPortionAttributabletoNoncontrollingInterestExcludingRedeemableNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-20" decimals="-6" id="f-204" unitRef="usd">57000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-6" id="f-205" unitRef="usd">57000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="c-1"
      decimals="2"
      id="f-206"
      unitRef="usdPerShare">0.54</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash contextRef="c-18" decimals="-6" id="f-207" unitRef="usd">73000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash contextRef="c-1" decimals="-6" id="f-208" unitRef="usd">73000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders contextRef="c-19" decimals="-6" id="f-209" unitRef="usd">39000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders contextRef="c-1" decimals="-6" id="f-210" unitRef="usd">39000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:StockholdersEquityOther contextRef="c-16" decimals="-6" id="f-211" unitRef="usd">-7000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther contextRef="c-18" decimals="-6" id="f-212" unitRef="usd">-2000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther contextRef="c-19" decimals="-6" id="f-213" unitRef="usd">5000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther contextRef="c-1" decimals="-6" id="f-214" unitRef="usd">-4000000</us-gaap:StockholdersEquityOther>
    <us-gaap:SharesOutstanding contextRef="c-21" decimals="-6" id="f-215" unitRef="shares">278000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-21" decimals="-6" id="f-216" unitRef="usd">3000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-22" decimals="-6" id="f-217" unitRef="usd">7824000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-23" decimals="-6" id="f-218" unitRef="usd">13182000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-24" decimals="-6" id="f-219" unitRef="usd">-848000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares contextRef="c-25" decimals="-6" id="f-220" unitRef="shares">143000000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-25" decimals="-6" id="f-221" unitRef="usd">-21763000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-26" decimals="-6" id="f-222" unitRef="usd">362000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-6" decimals="-6" id="f-223" unitRef="usd">-1240000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding contextRef="c-27" decimals="-6" id="f-224" unitRef="shares">275000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-27" decimals="-6" id="f-225" unitRef="usd">2000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-28" decimals="-6" id="f-226" unitRef="usd">7275000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-29" decimals="-6" id="f-227" unitRef="usd">9030000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-30" decimals="-6" id="f-228" unitRef="usd">-1534000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares contextRef="c-31" decimals="-6" id="f-229" unitRef="shares">130000000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-31" decimals="-6" id="f-230" unitRef="usd">-17045000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-32" decimals="-6" id="f-231" unitRef="usd">480000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-33" decimals="-6" id="f-232" unitRef="usd">-1792000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <mck:StockIssuedDuringPeriodSharesEmployeeStockPlansNetOfForfeitures contextRef="c-34" decimals="-6" id="f-233" unitRef="shares">2000000</mck:StockIssuedDuringPeriodSharesEmployeeStockPlansNetOfForfeitures>
    <mck:StockIssuedDuringPeriodValueEmployeeStockPlansNetOfForfeitures contextRef="c-34" decimals="-6" id="f-234" unitRef="usd">1000000</mck:StockIssuedDuringPeriodValueEmployeeStockPlansNetOfForfeitures>
    <mck:StockIssuedDuringPeriodValueEmployeeStockPlansNetOfForfeitures contextRef="c-35" decimals="-6" id="f-235" unitRef="usd">91000000</mck:StockIssuedDuringPeriodValueEmployeeStockPlansNetOfForfeitures>
    <mck:StockIssuedDuringPeriodValueEmployeeStockPlansNetOfForfeitures contextRef="c-36" decimals="-6" id="f-236" unitRef="usd">-152000000</mck:StockIssuedDuringPeriodValueEmployeeStockPlansNetOfForfeitures>
    <mck:StockIssuedDuringPeriodValueEmployeeStockPlansNetOfForfeitures contextRef="c-7" decimals="-6" id="f-237" unitRef="usd">-60000000</mck:StockIssuedDuringPeriodValueEmployeeStockPlansNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-35" decimals="-6" id="f-238" unitRef="usd">40000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-7" decimals="-6" id="f-239" unitRef="usd">40000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockRepurchasedDuringPeriodShares contextRef="c-35" decimals="-6" id="f-240" unitRef="shares">56000000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodShares contextRef="c-36" decimals="-6" id="f-241" unitRef="shares">3000000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue contextRef="c-36" decimals="-6" id="f-242" unitRef="usd">944000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue contextRef="c-7" decimals="-6" id="f-243" unitRef="usd">1000000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <mck:NetIncomeLossIncludingPortionAttributabletoNoncontrollingInterestExcludingRedeemableNoncontrollingInterest contextRef="c-37" decimals="-6" id="f-244" unitRef="usd">768000000</mck:NetIncomeLossIncludingPortionAttributabletoNoncontrollingInterestExcludingRedeemableNoncontrollingInterest>
    <mck:NetIncomeLossIncludingPortionAttributabletoNoncontrollingInterestExcludingRedeemableNoncontrollingInterest contextRef="c-38" decimals="-6" id="f-245" unitRef="usd">41000000</mck:NetIncomeLossIncludingPortionAttributabletoNoncontrollingInterestExcludingRedeemableNoncontrollingInterest>
    <mck:NetIncomeLossIncludingPortionAttributabletoNoncontrollingInterestExcludingRedeemableNoncontrollingInterest contextRef="c-7" decimals="-6" id="f-246" unitRef="usd">809000000</mck:NetIncomeLossIncludingPortionAttributabletoNoncontrollingInterestExcludingRedeemableNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-39" decimals="-6" id="f-247" unitRef="usd">586000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-38" decimals="-6" id="f-248" unitRef="usd">50000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-7" decimals="-6" id="f-249" unitRef="usd">636000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="c-7"
      decimals="2"
      id="f-250"
      unitRef="usdPerShare">0.47</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DividendsCommonStockCash contextRef="c-37" decimals="-6" id="f-251" unitRef="usd">67000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash contextRef="c-7" decimals="-6" id="f-252" unitRef="usd">67000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders contextRef="c-38" decimals="-6" id="f-253" unitRef="usd">36000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders contextRef="c-7" decimals="-6" id="f-254" unitRef="usd">36000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <mck:NoncontrollingInterestDecreaseFromReclassificationToLiability contextRef="c-38" decimals="-6" id="f-255" unitRef="usd">2000000</mck:NoncontrollingInterestDecreaseFromReclassificationToLiability>
    <mck:NoncontrollingInterestDecreaseFromReclassificationToLiability contextRef="c-7" decimals="-6" id="f-256" unitRef="usd">2000000</mck:NoncontrollingInterestDecreaseFromReclassificationToLiability>
    <us-gaap:StockholdersEquityOther contextRef="c-37" decimals="-6" id="f-257" unitRef="usd">-1000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther contextRef="c-38" decimals="-6" id="f-258" unitRef="usd">1000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther contextRef="c-7" decimals="-6" id="f-259" unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:SharesOutstanding contextRef="c-40" decimals="-6" id="f-260" unitRef="shares">277000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-40" decimals="-6" id="f-261" unitRef="usd">3000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-41" decimals="-6" id="f-262" unitRef="usd">7350000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-42" decimals="-6" id="f-263" unitRef="usd">9732000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-43" decimals="-6" id="f-264" unitRef="usd">-948000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares contextRef="c-44" decimals="-6" id="f-265" unitRef="shares">133000000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-44" decimals="-6" id="f-266" unitRef="usd">-18141000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-45" decimals="-6" id="f-267" unitRef="usd">532000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-46" decimals="-6" id="f-268" unitRef="usd">-1472000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-6" id="f-269" unitRef="usd">997000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-7" decimals="-6" id="f-270" unitRef="usd">809000000</us-gaap:ProfitLoss>
    <us-gaap:Depreciation contextRef="c-1" decimals="-6" id="f-271" unitRef="usd">64000000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-7" decimals="-6" id="f-272" unitRef="usd">61000000</us-gaap:Depreciation>
    <us-gaap:AdjustmentForAmortization contextRef="c-1" decimals="-6" id="f-273" unitRef="usd">95000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization contextRef="c-7" decimals="-6" id="f-274" unitRef="usd">87000000</us-gaap:AdjustmentForAmortization>
    <us-gaap:OtherAssetImpairmentCharges contextRef="c-1" decimals="-6" id="f-275" unitRef="usd">28000000</us-gaap:OtherAssetImpairmentCharges>
    <us-gaap:OtherAssetImpairmentCharges contextRef="c-7" decimals="-6" id="f-276" unitRef="usd">0</us-gaap:OtherAssetImpairmentCharges>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes contextRef="c-1" decimals="-6" id="f-277" unitRef="usd">235000000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes contextRef="c-7" decimals="-6" id="f-278" unitRef="usd">-109000000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:InventoryLIFOReservePeriodCharge contextRef="c-1" decimals="-6" id="f-279" unitRef="usd">32000000</us-gaap:InventoryLIFOReservePeriodCharge>
    <us-gaap:InventoryLIFOReservePeriodCharge contextRef="c-7" decimals="-6" id="f-280" unitRef="usd">-13000000</us-gaap:InventoryLIFOReservePeriodCharge>
    <us-gaap:OperatingLeaseExpense contextRef="c-1" decimals="-6" id="f-281" unitRef="usd">58000000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense contextRef="c-7" decimals="-6" id="f-282" unitRef="usd">63000000</us-gaap:OperatingLeaseExpense>
    <us-gaap:GainLossOnSaleOfOtherAssets contextRef="c-1" decimals="-6" id="f-283" unitRef="usd">19000000</us-gaap:GainLossOnSaleOfOtherAssets>
    <us-gaap:GainLossOnSaleOfOtherAssets contextRef="c-7" decimals="-6" id="f-284" unitRef="usd">33000000</us-gaap:GainLossOnSaleOfOtherAssets>
    <us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown contextRef="c-1" decimals="-6" id="f-285" unitRef="usd">0</us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown>
    <us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown contextRef="c-7" decimals="-6" id="f-286" unitRef="usd">20000000</us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-1" decimals="-6" id="f-287" unitRef="usd">-41000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-7" decimals="-6" id="f-288" unitRef="usd">-102000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInReceivables contextRef="c-1" decimals="-6" id="f-289" unitRef="usd">2380000000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInReceivables contextRef="c-7" decimals="-6" id="f-290" unitRef="usd">1584000000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-1" decimals="-6" id="f-291" unitRef="usd">826000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-7" decimals="-6" id="f-292" unitRef="usd">955000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-6" id="f-293" unitRef="usd">1473000000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-7" decimals="-6" id="f-294" unitRef="usd">1006000000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-1" decimals="-6" id="f-295" unitRef="usd">-80000000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-7" decimals="-6" id="f-296" unitRef="usd">-94000000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInAccruedTaxesPayable contextRef="c-1" decimals="-6" id="f-297" unitRef="usd">236000000</us-gaap:IncreaseDecreaseInAccruedTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedTaxesPayable contextRef="c-7" decimals="-6" id="f-298" unitRef="usd">37000000</us-gaap:IncreaseDecreaseInAccruedTaxesPayable>
    <mck:IncreaseDecreaseInLitigationReserve contextRef="c-1" decimals="-6" id="f-299" unitRef="usd">0</mck:IncreaseDecreaseInLitigationReserve>
    <mck:IncreaseDecreaseInLitigationReserve contextRef="c-7" decimals="-6" id="f-300" unitRef="usd">-370000000</mck:IncreaseDecreaseInLitigationReserve>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="c-1" decimals="-6" id="f-301" unitRef="usd">536000000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="c-7" decimals="-6" id="f-302" unitRef="usd">186000000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-6" id="f-303" unitRef="usd">-1052000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-7" decimals="-6" id="f-304" unitRef="usd">-941000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-6" id="f-305" unitRef="usd">78000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-7" decimals="-6" id="f-306" unitRef="usd">71000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireSoftware contextRef="c-1" decimals="-6" id="f-307" unitRef="usd">46000000</us-gaap:PaymentsToAcquireSoftware>
    <us-gaap:PaymentsToAcquireSoftware contextRef="c-7" decimals="-6" id="f-308" unitRef="usd">29000000</us-gaap:PaymentsToAcquireSoftware>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-1" decimals="-6" id="f-309" unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-7" decimals="-6" id="f-310" unitRef="usd">1000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates contextRef="c-1" decimals="-6" id="f-311" unitRef="usd">39000000</us-gaap:ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates>
    <us-gaap:ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates contextRef="c-7" decimals="-6" id="f-312" unitRef="usd">240000000</us-gaap:ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="c-1" decimals="-6" id="f-313" unitRef="usd">64000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="c-7" decimals="-6" id="f-314" unitRef="usd">100000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-6" id="f-315" unitRef="usd">-149000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-7" decimals="-6" id="f-316" unitRef="usd">39000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromShortTermDebt contextRef="c-1" decimals="-6" id="f-317" unitRef="usd">65000000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt contextRef="c-7" decimals="-6" id="f-318" unitRef="usd">0</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt contextRef="c-1" decimals="-6" id="f-319" unitRef="usd">65000000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt contextRef="c-7" decimals="-6" id="f-320" unitRef="usd">0</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-1" decimals="-6" id="f-321" unitRef="usd">991000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-7" decimals="-6" id="f-322" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-1" decimals="-6" id="f-323" unitRef="usd">268000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-7" decimals="-6" id="f-324" unitRef="usd">2000000</us-gaap:RepaymentsOfLongTermDebt>
    <mck:PaymentsForPurchaseOfGovernmentObligationsForSatisfactionAndDischargeOfLongTermDebt contextRef="c-1" decimals="-6" id="f-325" unitRef="usd">647000000</mck:PaymentsForPurchaseOfGovernmentObligationsForSatisfactionAndDischargeOfLongTermDebt>
    <mck:PaymentsForPurchaseOfGovernmentObligationsForSatisfactionAndDischargeOfLongTermDebt contextRef="c-7" decimals="-6" id="f-326" unitRef="usd">0</mck:PaymentsForPurchaseOfGovernmentObligationsForSatisfactionAndDischargeOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c-1" decimals="-6" id="f-327" unitRef="usd">27000000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c-7" decimals="-6" id="f-328" unitRef="usd">91000000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-1" decimals="-6" id="f-329" unitRef="usd">696000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-7" decimals="-6" id="f-330" unitRef="usd">1000000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock contextRef="c-1" decimals="-6" id="f-331" unitRef="usd">74000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:PaymentsOfDividendsCommonStock contextRef="c-7" decimals="-6" id="f-332" unitRef="usd">71000000</us-gaap:PaymentsOfDividendsCommonStock>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="c-1" decimals="-6" id="f-333" unitRef="usd">-176000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="c-7" decimals="-6" id="f-334" unitRef="usd">-199000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-6" id="f-335" unitRef="usd">-843000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-7" decimals="-6" id="f-336" unitRef="usd">-1181000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-1" decimals="-6" id="f-337" unitRef="usd">2000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-7" decimals="-6" id="f-338" unitRef="usd">18000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <mck:CashCashEquivalentsRestrictedCashClassifiedWithinAssetsHeldForSalePeriodIncreaseDecrease contextRef="c-1" decimals="-6" id="f-339" unitRef="usd">0</mck:CashCashEquivalentsRestrictedCashClassifiedWithinAssetsHeldForSalePeriodIncreaseDecrease>
    <mck:CashCashEquivalentsRestrictedCashClassifiedWithinAssetsHeldForSalePeriodIncreaseDecrease contextRef="c-7" decimals="-6" id="f-340" unitRef="usd">470000000</mck:CashCashEquivalentsRestrictedCashClassifiedWithinAssetsHeldForSalePeriodIncreaseDecrease>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-6" id="f-341" unitRef="usd">-2042000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-7" decimals="-6" id="f-342" unitRef="usd">-1595000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-8" decimals="-6" id="f-343" unitRef="usd">4679000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-33" decimals="-6" id="f-344" unitRef="usd">3935000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-6" decimals="-6" id="f-345" unitRef="usd">2637000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-46" decimals="-6" id="f-346" unitRef="usd">2340000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RestrictedCashCurrent contextRef="c-6" decimals="-6" id="f-347" unitRef="usd">1000000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent contextRef="c-46" decimals="-6" id="f-348" unitRef="usd">107000000</us-gaap:RestrictedCashCurrent>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-6" decimals="-6" id="f-349" unitRef="usd">2636000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-46" decimals="-6" id="f-350" unitRef="usd">2233000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-351">Significant Accounting Policies&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Nature of Operations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: McKesson Corporation (&#x201c;McKesson,&#x201d; or the &#x201c;Company,&#x201d;) is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. McKesson partners with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products, and services to help make quality care more accessible and affordable. The Company reports its financial results in four reportable segments: U.S. Pharmaceutical, Prescription Technology Solutions (&#x201c;RxTS&#x201d;), Medical-Surgical Solutions, and International. Refer to Financial Note 12, &#x201c;Segments of Business,&#x201d; for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basis of Presentation: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The condensed consolidated financial statements and accompanying notes are prepared in accordance with United States (&#x201c;U.S.&#x201d;) generally accepted accounting principles (&#x201c;GAAP&#x201d;) for interim financial reporting and the rules and regulations of the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) and therefore do not include all information and disclosures normally included in the annual consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The condensed consolidated financial statements of McKesson include the financial statements of all wholly-owned subsidiaries and majority-owned or controlled companies. For those consolidated subsidiaries where the Company&#x2019;s ownership is less than 100%, the portion of the net income or loss allocable to the noncontrolling interests is reported as &#x201c;Net income attributable to noncontrolling interests&#x201d; in the Condensed Consolidated Statements of Operations. All significant intercompany balances and transactions have been eliminated in consolidation, including the intercompany portion of transactions with equity method investees. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income attributable to noncontrolling interests includes third-party equity interests in the Company&#x2019;s consolidated entities, including ClarusONE Sourcing Services LLP, Vantage Oncology Holdings, LLC, and SCRI Oncology, LLC. Net income attributable to noncontrolling interests also included recurring compensation that the Company was obligated to pay to the noncontrolling shareholders of McKesson Europe AG (&#x201c;McKesson Europe&#x201d;). The Company&#x2019;s noncontrolling interest in McKesson Europe was included in the divestiture of certain of the Company&#x2019;s businesses in the European Union (&#x201c;E.U.&#x201d;) in October 2022, which is discussed further in Financial Note 2, &#x201c;Business Acquisitions and Divestitures.&#x201d; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers itself to control an entity if it is the majority owner of or has voting control over such entity. The Company also assesses control through means other than voting rights and determines which business entity is the primary beneficiary of the variable interest entity (&#x201c;VIE&#x201d;). The Company consolidates VIEs when it is determined that it is the primary beneficiary of the VIE. Investments in business entities in which the Company does not have control, but instead has the ability to exercise significant influence over operating and financial policies, are accounted for using the equity method. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fiscal Period:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company&#x2019;s fiscal year begins on April 1 and ends on March 31. Unless otherwise noted, all references to a particular year shall mean the Company&#x2019;s fiscal year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reclassifications:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Certain prior period amounts have been reclassified to conform to the current year presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of Estimates:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of these financial statements and income and expenses during the reporting period. Actual amounts could differ from those estimated amounts. In the opinion of management, the unaudited condensed consolidated financial statements include all normal recurring adjustments necessary for a fair presentation of the results of operations, financial position, and cash flows of McKesson for the interim periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The results of operations for the three months ended June 30, 2023 are not necessarily indicative of the results that may be anticipated for the entire year. These interim financial statements should be read in conjunction with the annual audited financial statements, accounting policies, and financial notes included in the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended March 31, 2023, previously filed with the SEC on May&#160;9, 2023 (the &#x201c;2023 Annual Report&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 16, 2022, the U.S. government enacted the Inflation Reduction Act of 2022 (the &#x201c;IRA&#x201d;). Among other provisions, the IRA includes a 15% corporate minimum tax, a 1% excise tax on certain repurchases of an entity&#x2019;s own common stock after December 31, 2022, and various drug pricing reforms. The Company does not anticipate that this guidance will have a material impact on its consolidated financial statements or related disclosures. The Company will continue to evaluate the full impact of these legislative changes as they are announced and implemented. Refer to Financial Note 11, &#x201c;Stockholders' Deficit,&#x201d; for further details regarding excise taxes incurred on the Company&#x2019;s share repurchases during the three months ended June 30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Adopted Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no accounting standards adopted by the Company during the three months ended June 30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Issued Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2022, the Financial Accounting Standards Board issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2022-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which clarifies the guidance when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of such equity security, and requires additional disclosure requirements. ASU 2022-03 is effective for the Company on a prospective basis for fiscal years beginning after December 15, 2023, with early adoption permitted. The Company does not anticipate that this guidance will have a material impact on its consolidated financial statements or related disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-352"
      unitRef="segment">4</us-gaap:NumberOfReportableSegments>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c-1" id="f-353">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Basis of Presentation: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The condensed consolidated financial statements and accompanying notes are prepared in accordance with United States (&#x201c;U.S.&#x201d;) generally accepted accounting principles (&#x201c;GAAP&#x201d;) for interim financial reporting and the rules and regulations of the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) and therefore do not include all information and disclosures normally included in the annual consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The condensed consolidated financial statements of McKesson include the financial statements of all wholly-owned subsidiaries and majority-owned or controlled companies. For those consolidated subsidiaries where the Company&#x2019;s ownership is less than 100%, the portion of the net income or loss allocable to the noncontrolling interests is reported as &#x201c;Net income attributable to noncontrolling interests&#x201d; in the Condensed Consolidated Statements of Operations. All significant intercompany balances and transactions have been eliminated in consolidation, including the intercompany portion of transactions with equity method investees. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income attributable to noncontrolling interests includes third-party equity interests in the Company&#x2019;s consolidated entities, including ClarusONE Sourcing Services LLP, Vantage Oncology Holdings, LLC, and SCRI Oncology, LLC. Net income attributable to noncontrolling interests also included recurring compensation that the Company was obligated to pay to the noncontrolling shareholders of McKesson Europe AG (&#x201c;McKesson Europe&#x201d;). The Company&#x2019;s noncontrolling interest in McKesson Europe was included in the divestiture of certain of the Company&#x2019;s businesses in the European Union (&#x201c;E.U.&#x201d;) in October 2022, which is discussed further in Financial Note 2, &#x201c;Business Acquisitions and Divestitures.&#x201d; &lt;/span&gt;&lt;/div&gt;The Company considers itself to control an entity if it is the majority owner of or has voting control over such entity. The Company also assesses control through means other than voting rights and determines which business entity is the primary beneficiary of the variable interest entity (&#x201c;VIE&#x201d;). The Company consolidates VIEs when it is determined that it is the primary beneficiary of the VIE. Investments in business entities in which the Company does not have control, but instead has the ability to exercise significant influence over operating and financial policies, are accounted for using the equity method.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:FiscalPeriod contextRef="c-1" id="f-354">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fiscal Period:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company&#x2019;s fiscal year begins on April 1 and ends on March 31. Unless otherwise noted, all references to a particular year shall mean the Company&#x2019;s fiscal year.&lt;/span&gt;</us-gaap:FiscalPeriod>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="c-1" id="f-355">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reclassifications:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Certain prior period amounts have been reclassified to conform to the current year presentation.&lt;/span&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-356">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of Estimates:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The preparation of financial statements in conformity with U.S. GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of these financial statements and income and expenses during the reporting period. Actual amounts could differ from those estimated amounts. In the opinion of management, the unaudited condensed consolidated financial statements include all normal recurring adjustments necessary for a fair presentation of the results of operations, financial position, and cash flows of McKesson for the interim periods presented.&lt;/span&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ComparabilityOfPriorYearFinancialData contextRef="c-1" id="f-357">The results of operations for the three months ended June 30, 2023 are not necessarily indicative of the results that may be anticipated for the entire year. These interim financial statements should be read in conjunction with the annual audited financial statements, accounting policies, and financial notes included in the Company&#x2019;s Annual Report on Form 10-K for the fiscal year ended March 31, 2023, previously filed with the SEC on May&#160;9, 2023 (the &#x201c;2023 Annual Report&#x201d;).</us-gaap:ComparabilityOfPriorYearFinancialData>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-358">&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Adopted Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no accounting standards adopted by the Company during the three months ended June 30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Issued Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2022, the Financial Accounting Standards Board issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2022-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions&lt;/span&gt;, which clarifies the guidance when measuring the fair value of an equity security subject to contractual restrictions that prohibit the sale of such equity security, and requires additional disclosure requirements. ASU 2022-03 is effective for the Company on a prospective basis for fiscal years beginning after December 15, 2023, with early adoption permitted. The Company does not anticipate that this guidance will have a material impact on its consolidated financial statements or related disclosures</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock contextRef="c-1" id="f-359">Business Acquisitions and Divestitures&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Acquisitions &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Rx Savings Solutions, LLC&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 1, 2022, the Company completed its acquisition of 100% of the shares of Rx Savings Solutions, LLC (&#x201c;RxSS&#x201d;), a privately-owned company headquartered in Overland Park, Kansas, to further connect biopharma and payer services to patients. RxSS is a prescription price transparency and benefit insight company that offers affordability and adherence solutions to health plans and employers. The purchase consideration included a payment of $600&#160;million in cash made upon closing and a maximum of $275&#160;million of contingent consideration based on RxSS&#x2019; operational and financial performance through calendar year 2025. The payment made upon closing was funded from cash on hand. The financial results of RxSS are included in the Company&#x2019;s RxTS segment as of the acquisition date. The transaction was accounted for as a business combination.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded a liability for the contingent consideration at its fair value of $92&#160;million as of the acquisition date. The fair value of the contingent consideration liability was estimated using a Monte Carlo simulation model, utilizing internal cash flow projections which are Level 3 inputs under Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements and Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The contingent liability will be remeasured to fair value at each reporting date until the liability is settled with changes in fair value being recognized within &#x201c;Selling, distribution, general, and administrative expenses&#x201d; in the Company&#x2019;s Condensed Consolidated Statements of Operations. During the three months ended June 30, 2023, the Company recognized a fair value adjustment gain of $28&#160;million, which reduced its contingent consideration liability, based on the estimated amount and timing of projected operational and financial information and the probability of achievement of certain performance milestones. As of June 30, 2023 and March 31, 2023, the current portion of $45&#160;million and $83&#160;million, respectively, is included within &#x201c;Other accrued liabilities&#x201d; and the long-term portion of $19&#160;million and $9&#160;million, respectively, is included within &#x201c;Other non-current liabilities&#x201d; in the Company&#x2019;s Condensed Consolidated Balance Sheets. Recognition of the initial fair value of this contingent consideration was a non-cash investing activity. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The purchase price allocation included acquired identifiable intangible assets of $229&#160;million, primarily representing customer relationships and technology with a weighted average amortization period of 12 years, and goodwill of $463&#160;million. Goodwill has been allocated to the Company&#x2019;s RxTS segment, which reflects the expected future benefits from certain synergies and intangible assets that do not qualify for separate recognition. Goodwill attributable to the acquisition is deductible for tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the preliminary purchase price allocation for this acquisition:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.432%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.368%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amounts Recognized as of Acquisition Date (As Adjusted)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Purchase consideration:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total purchase consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Identifiable assets acquired and liabilities assumed:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total identifiable net assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;SCRI Oncology, LLC&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 31, 2022, the Company completed a transaction with HCA Healthcare, Inc. (&#x201c;HCA&#x201d;) to form SCRI Oncology, LLC (&#x201c;SCRI Oncology&#x201d;), an oncology research business combining McKesson&#x2019;s U.S. Oncology Research (&#x201c;USOR&#x201d;) and HCA&#x2019;s Sarah Cannon Research Institute (&#x201c;SCRI&#x201d;) based in Nashville, Tennessee, to advance cancer care and increase access to oncology clinical research. Upon consummation of the transaction, McKesson owns a 51% controlling interest in the combined business, and the financial results are consolidated by the Company and reported within its U.S. Pharmaceutical segment as of the acquisition date. Transaction consideration included the transfer of full ownership interest in USOR to the combined business and $166&#160;million of net cash paid to HCA, which was funded from cash on hand. The transaction was accounted for as a business combination.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The purchase price allocation included acquired identifiable intangible assets of $177&#160;million, primarily representing customer relationships as well as trademarks and trade names with a weighted average amortization period of 17 years, and goodwill of $113&#160;million. Goodwill has been allocated to the Company&#x2019;s U.S. Pharmaceutical segment, which reflects the expected future benefits from certain synergies and intangible assets that do not qualify for separate recognition. Goodwill attributable to the acquisition of $46&#160;million is deductible for tax purposes. The Company recorded noncontrolling interest of $222&#160;million as a component of equity, which includes HCA&#x2019;s proportionate interest in the identifiable net assets of SCRI at fair value of $202&#160;million and its proportionate interest in the contributed net assets of USOR at carrying value of $20&#160;million. The difference between the fair value of the Company&#x2019;s acquired interest in SCRI net assets and the $166&#160;million of net cash paid to HCA was recognized as additional paid in capital, as well as the Company&#x2019;s reduction in ownership interest in USOR net assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the preliminary purchase price allocation for this acquisition:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.432%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.368%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amounts Recognized as of Acquisition Date (As Adjusted)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Purchase consideration:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contribution of USOR&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total purchase consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Identifiable assets acquired and liabilities assumed:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant, and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total identifiable net assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(222)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Additional paid-in capital&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the acquired identifiable intangible assets from the acquisitions discussed above were determined by applying the income approach, using a discounted cash flow model in which cash flows anticipated over several periods are discounted to their present value using an appropriate rate that is commensurate with the risk inherent with the transaction. These inputs are considered Level 3 inputs under the fair value measurements and disclosure guidance. The amounts presented above are subject to change as the Company&#x2019;s fair value assessments are finalized. There have been no material changes to the purchase price allocation of these acquisitions since the acquisition date. Pro forma financial information has not been provided as these acquisitions did not have a material impact, individually, or in the aggregate, to the Company&#x2019;s consolidated results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Divestitures&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;European Divestiture Activities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2021, the Company announced its intention to exit its businesses in Europe. On October 31, 2022, the Company completed its previously announced transaction to sell certain of its businesses in the European Union (&#x201c;E.U.&#x201d;) located in France, Italy, Ireland, Portugal, Belgium, and Slovenia, along with its German headquarters and wound-care business, part of a shared services center in Lithuania, and its ownership stake in a joint venture in the Netherlands (&#x201c;E.U. disposal group&#x201d;) to the PHOENIX Group. During the three months ended June 30, 2022, the Company recorded a gain of $12&#160;million to remeasure the E.U. disposal group to fair value less costs to sell which was recorded within &#x201c;Selling, distribution, general, and administrative expenses&#x201d; in the Condensed Consolidated Statement of Operations. The Company&#x2019;s measurement of the fair value of the E.U. disposal group was based on the total consideration expected to be received by the Company as outlined in the transaction agreement. Certain components of the total consideration included fair value measurements that fall within Level 3 of the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 6, 2022, the Company completed the previously announced sale of its retail and distribution businesses in the United Kingdom (&#x201c;U.K. disposal group&#x201d;) to Aurelius Elephant Limited for a purchase price of &#xa3;110&#160;million (or, approximately $144&#160;million), including certain adjustments. As part of the transaction, the Company divested net assets of $615&#160;million and released $731&#160;million of accumulated other comprehensive loss, within the International segment, and the buyer assumed and repaid a note payable to the Company of $118&#160;million.&lt;/span&gt;&lt;/div&gt;At June 30, 2023 and March 31, 2023, the Company had no assets or liabilities related to these European divestiture activities that met the criteria for classification as held for sale. Subsequent to the divestiture activities discussed above, the Company&#x2019;s European operations primarily consist of its retail and distribution businesses in Norway.&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the periods presented, the Company also completed de minimis acquisitions and divestitures within its operating segments. Financial results for the Company&#x2019;s business acquisitions have been included in its consolidated financial statements as of their respective acquisition dates. Purchase prices for business acquisitions have been allocated based on estimated fair values at the respective acquisition dates.&lt;/span&gt;&lt;/div&gt;</us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired contextRef="c-47" decimals="2" id="f-360" unitRef="number">1</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-48" decimals="-6" id="f-361" unitRef="usd">600000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-49" decimals="-6" id="f-362" unitRef="usd">275000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-47" decimals="-6" id="f-363" unitRef="usd">92000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-1" decimals="-6" id="f-364" unitRef="usd">-28000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="c-50" decimals="-6" id="f-365" unitRef="usd">45000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="c-51" decimals="-6" id="f-366" unitRef="usd">83000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="c-50" decimals="-6" id="f-367" unitRef="usd">19000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="c-51" decimals="-6" id="f-368" unitRef="usd">9000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-47" decimals="-6" id="f-369" unitRef="usd">229000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife contextRef="c-48" id="f-370">P12Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:Goodwill contextRef="c-47" decimals="-6" id="f-371" unitRef="usd">463000000</us-gaap:Goodwill>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="c-1" id="f-372">&lt;div style="margin-bottom:6pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the preliminary purchase price allocation for this acquisition:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.432%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.368%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amounts Recognized as of Acquisition Date (As Adjusted)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Purchase consideration:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total purchase consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Identifiable assets acquired and liabilities assumed:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total identifiable net assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the preliminary purchase price allocation for this acquisition:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.432%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.368%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amounts Recognized as of Acquisition Date (As Adjusted)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Purchase consideration:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contribution of USOR&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total purchase consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Identifiable assets acquired and liabilities assumed:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant, and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(43)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total identifiable net assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Noncontrolling interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(222)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Additional paid-in capital&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net assets acquired&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-48" decimals="-6" id="f-373" unitRef="usd">600000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-47" decimals="-6" id="f-374" unitRef="usd">92000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="c-48" decimals="-6" id="f-375" unitRef="usd">692000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets contextRef="c-47" decimals="-6" id="f-376" unitRef="usd">5000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-47" decimals="-6" id="f-377" unitRef="usd">229000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets contextRef="c-47" decimals="-6" id="f-378" unitRef="usd">3000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities contextRef="c-47" decimals="-6" id="f-379" unitRef="usd">8000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="c-47" decimals="-6" id="f-380" unitRef="usd">229000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:Goodwill contextRef="c-47" decimals="-6" id="f-381" unitRef="usd">463000000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest contextRef="c-47" decimals="-6" id="f-382" unitRef="usd">692000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired contextRef="c-52" decimals="2" id="f-383" unitRef="number">0.51</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-53" decimals="-6" id="f-384" unitRef="usd">166000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-52" decimals="-6" id="f-385" unitRef="usd">177000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife contextRef="c-53" id="f-386">P17Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:Goodwill contextRef="c-52" decimals="-6" id="f-387" unitRef="usd">113000000</us-gaap:Goodwill>
    <us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount contextRef="c-52" decimals="-6" id="f-388" unitRef="usd">46000000</us-gaap:BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount>
    <us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue contextRef="c-52" decimals="-6" id="f-389" unitRef="usd">222000000</us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue>
    <us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue contextRef="c-54" decimals="-6" id="f-390" unitRef="usd">202000000</us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue>
    <us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue contextRef="c-55" decimals="-6" id="f-391" unitRef="usd">20000000</us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-53" decimals="-6" id="f-392" unitRef="usd">166000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-53" decimals="-6" id="f-393" unitRef="usd">166000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <mck:BusinessCombinationConsiderationTransferredOwnershipInterest contextRef="c-53" decimals="-6" id="f-394" unitRef="usd">40000000</mck:BusinessCombinationConsiderationTransferredOwnershipInterest>
    <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="c-53" decimals="-6" id="f-395" unitRef="usd">206000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables contextRef="c-52" decimals="-6" id="f-396" unitRef="usd">224000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment contextRef="c-52" decimals="-6" id="f-397" unitRef="usd">22000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <mck:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets contextRef="c-52" decimals="-6" id="f-398" unitRef="usd">31000000</mck:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-52" decimals="-6" id="f-399" unitRef="usd">177000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities contextRef="c-52" decimals="-6" id="f-400" unitRef="usd">42000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities>
    <mck:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermOperatingLeaseLiabilities contextRef="c-52" decimals="-6" id="f-401" unitRef="usd">29000000</mck:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermOperatingLeaseLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther contextRef="c-52" decimals="-6" id="f-402" unitRef="usd">43000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="c-52" decimals="-6" id="f-403" unitRef="usd">340000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue contextRef="c-52" decimals="-6" id="f-404" unitRef="usd">222000000</us-gaap:BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue>
    <mck:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdditionalPaidInCapital contextRef="c-52" decimals="-6" id="f-405" unitRef="usd">25000000</mck:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdditionalPaidInCapital>
    <us-gaap:Goodwill contextRef="c-52" decimals="-6" id="f-406" unitRef="usd">113000000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest contextRef="c-52" decimals="-6" id="f-407" unitRef="usd">206000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest>
    <us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown contextRef="c-56" decimals="-6" id="f-408" unitRef="usd">-12000000</us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown>
    <mck:DisposalGroupIncludingDiscontinuedOperationConsiderationExpected contextRef="c-57" decimals="-6" id="f-409" unitRef="gbp">110000000</mck:DisposalGroupIncludingDiscontinuedOperationConsiderationExpected>
    <mck:DisposalGroupIncludingDiscontinuedOperationConsiderationExpected contextRef="c-57" decimals="-6" id="f-410" unitRef="usd">144000000</mck:DisposalGroupIncludingDiscontinuedOperationConsiderationExpected>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation contextRef="c-58" decimals="-6" id="f-411" unitRef="usd">615000000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:ReclassificationFromAociCurrentPeriodTax contextRef="c-59" decimals="-6" id="f-412" unitRef="usd">731000000</us-gaap:ReclassificationFromAociCurrentPeriodTax>
    <us-gaap:ProceedsFromCollectionOfNotesReceivable contextRef="c-60" decimals="-6" id="f-413" unitRef="usd">118000000</us-gaap:ProceedsFromCollectionOfNotesReceivable>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock contextRef="c-1" id="f-414">Restructuring, Impairment, and Related Charges, Net&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded restructuring, impairment, and related charges, net of $52 million and $23 million for the three months ended June 30, 2023 and 2022, respectively. These charges were included in &#x201c;Restructuring, impairment, and related charges, net&#x201d; in the Condensed Consolidated Statements of Operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restructuring Initiatives&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the fourth quarter of fiscal 2023, the Company approved a broad set of initiatives to drive operational efficiencies and increase cost optimization efforts, with the intent of simplifying its infrastructure and realizing long-term sustainable growth. These initiatives include headcount reductions and the exit or downsizing of certain facilities. The Company anticipates total charges of approximately $125 million across its RxTS and U.S. Pharmaceutical segments as well as Corporate, consisting primarily of employee severance and other employee-related costs, facility and other exit-related costs, as well as long-lived asset impairments. Of this amount, $96 million of charges were recorded to date. For the three months ended June 30, 2023, the Company recorded charges of $36 million related to this program, which primarily includes real estate and other related asset impairments and facility costs within Corporate. This restructuring program is anticipated to be substantially complete by the end of fiscal 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restructuring, impairment, and related charges, net for the three months ended June 30, 2023 and 2022 consisted of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.861%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.102%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.173%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.784%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.613%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.884%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;U.S. Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Prescription Technology Solutions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Medical-Surgical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;International&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Severance and employee-related costs, net &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exit and other-related costs &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset impairments and accelerated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company&#x2019;s technology solutions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.008%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.102%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.173%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.784%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.613%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.737%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;U.S. Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Prescription Technology Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Medical-Surgical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Severance and employee-related costs, net &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exit and other-related costs &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset impairments and accelerated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity related to the liabilities associated with the Company&#x2019;s restructuring initiatives for the three months ended June 30, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.946%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.373%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.180%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.263%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;U.S. Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Prescription Technology Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Medical-Surgical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance, March 31, 2023 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring, impairment, and related charges, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance, June 30, 2023 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;As of March 31, 2023, the total reserve balance was $92 million, of which $66 million was recorded in &#x201c;Other accrued liabilities&#x201d; and $26 million was recorded in &#x201c;Other non-current liabilities&#x201d; in the Company&#x2019;s Condensed Consolidated Balance Sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Other primarily includes cumulative translation adjustments and transfers to certain other liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;As of June 30, 2023, the total reserve balance was $74 million, of which $44 million was recorded in &#x201c;Other accrued liabilities&#x201d; and $30 million was recorded in &#x201c;Other non-current liabilities&#x201d; in the Company&#x2019;s Condensed Consolidated Balance Sheet.&lt;/span&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <mck:RestructuringImpairmentAndOtherRelatedCharges contextRef="c-1" decimals="-6" id="f-415" unitRef="usd">52000000</mck:RestructuringImpairmentAndOtherRelatedCharges>
    <mck:RestructuringImpairmentAndOtherRelatedCharges contextRef="c-7" decimals="-6" id="f-416" unitRef="usd">23000000</mck:RestructuringImpairmentAndOtherRelatedCharges>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1 contextRef="c-61" decimals="-6" id="f-417" unitRef="usd">125000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:RestructuringAndRelatedCostIncurredCost contextRef="c-62" decimals="-6" id="f-418" unitRef="usd">96000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringCharges contextRef="c-63" decimals="-6" id="f-419" unitRef="usd">36000000</us-gaap:RestructuringCharges>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock contextRef="c-1" id="f-420">&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restructuring, impairment, and related charges, net for the three months ended June 30, 2023 and 2022 consisted of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.861%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.102%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.173%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.784%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.613%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.884%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;U.S. Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Prescription Technology Solutions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Medical-Surgical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;International&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Severance and employee-related costs, net &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exit and other-related costs &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset impairments and accelerated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company&#x2019;s technology solutions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.008%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.102%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.223%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.173%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.784%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.613%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.737%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;U.S. Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Prescription Technology Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Medical-Surgical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Severance and employee-related costs, net &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exit and other-related costs &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asset impairments and accelerated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:SeveranceCosts1 contextRef="c-64" decimals="-6" id="f-421" unitRef="usd">1000000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1 contextRef="c-65" decimals="-6" id="f-422" unitRef="usd">0</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1 contextRef="c-66" decimals="-6" id="f-423" unitRef="usd">0</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1 contextRef="c-67" decimals="-6" id="f-424" unitRef="usd">0</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1 contextRef="c-68" decimals="-6" id="f-425" unitRef="usd">1000000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1 contextRef="c-1" decimals="-6" id="f-426" unitRef="usd">2000000</us-gaap:SeveranceCosts1>
    <us-gaap:BusinessExitCosts1 contextRef="c-64" decimals="-6" id="f-427" unitRef="usd">1000000</us-gaap:BusinessExitCosts1>
    <us-gaap:BusinessExitCosts1 contextRef="c-65" decimals="-6" id="f-428" unitRef="usd">2000000</us-gaap:BusinessExitCosts1>
    <us-gaap:BusinessExitCosts1 contextRef="c-66" decimals="-6" id="f-429" unitRef="usd">2000000</us-gaap:BusinessExitCosts1>
    <us-gaap:BusinessExitCosts1 contextRef="c-67" decimals="-6" id="f-430" unitRef="usd">5000000</us-gaap:BusinessExitCosts1>
    <us-gaap:BusinessExitCosts1 contextRef="c-68" decimals="-6" id="f-431" unitRef="usd">12000000</us-gaap:BusinessExitCosts1>
    <us-gaap:BusinessExitCosts1 contextRef="c-1" decimals="-6" id="f-432" unitRef="usd">22000000</us-gaap:BusinessExitCosts1>
    <mck:AssetImpairmentChargesIncludingAcceleratedDepreciation contextRef="c-64" decimals="-6" id="f-433" unitRef="usd">0</mck:AssetImpairmentChargesIncludingAcceleratedDepreciation>
    <mck:AssetImpairmentChargesIncludingAcceleratedDepreciation contextRef="c-65" decimals="-6" id="f-434" unitRef="usd">0</mck:AssetImpairmentChargesIncludingAcceleratedDepreciation>
    <mck:AssetImpairmentChargesIncludingAcceleratedDepreciation contextRef="c-66" decimals="-6" id="f-435" unitRef="usd">0</mck:AssetImpairmentChargesIncludingAcceleratedDepreciation>
    <mck:AssetImpairmentChargesIncludingAcceleratedDepreciation contextRef="c-67" decimals="-6" id="f-436" unitRef="usd">1000000</mck:AssetImpairmentChargesIncludingAcceleratedDepreciation>
    <mck:AssetImpairmentChargesIncludingAcceleratedDepreciation contextRef="c-68" decimals="-6" id="f-437" unitRef="usd">27000000</mck:AssetImpairmentChargesIncludingAcceleratedDepreciation>
    <mck:AssetImpairmentChargesIncludingAcceleratedDepreciation contextRef="c-1" decimals="-6" id="f-438" unitRef="usd">28000000</mck:AssetImpairmentChargesIncludingAcceleratedDepreciation>
    <us-gaap:RestructuringCharges contextRef="c-64" decimals="-6" id="f-439" unitRef="usd">2000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-65" decimals="-6" id="f-440" unitRef="usd">2000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-66" decimals="-6" id="f-441" unitRef="usd">2000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-67" decimals="-6" id="f-442" unitRef="usd">6000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-68" decimals="-6" id="f-443" unitRef="usd">40000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-1" decimals="-6" id="f-444" unitRef="usd">52000000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-69" decimals="-6" id="f-445" unitRef="usd">3000000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1 contextRef="c-70" decimals="-6" id="f-446" unitRef="usd">0</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1 contextRef="c-71" decimals="-6" id="f-447" unitRef="usd">0</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1 contextRef="c-72" decimals="-6" id="f-448" unitRef="usd">0</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1 contextRef="c-73" decimals="-6" id="f-449" unitRef="usd">-1000000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1 contextRef="c-7" decimals="-6" id="f-450" unitRef="usd">2000000</us-gaap:SeveranceCosts1>
    <us-gaap:BusinessExitCosts1 contextRef="c-69" decimals="-6" id="f-451" unitRef="usd">1000000</us-gaap:BusinessExitCosts1>
    <us-gaap:BusinessExitCosts1 contextRef="c-70" decimals="-6" id="f-452" unitRef="usd">2000000</us-gaap:BusinessExitCosts1>
    <us-gaap:BusinessExitCosts1 contextRef="c-71" decimals="-6" id="f-453" unitRef="usd">1000000</us-gaap:BusinessExitCosts1>
    <us-gaap:BusinessExitCosts1 contextRef="c-72" decimals="-6" id="f-454" unitRef="usd">2000000</us-gaap:BusinessExitCosts1>
    <us-gaap:BusinessExitCosts1 contextRef="c-73" decimals="-6" id="f-455" unitRef="usd">15000000</us-gaap:BusinessExitCosts1>
    <us-gaap:BusinessExitCosts1 contextRef="c-7" decimals="-6" id="f-456" unitRef="usd">21000000</us-gaap:BusinessExitCosts1>
    <mck:AssetImpairmentChargesIncludingAcceleratedDepreciation contextRef="c-69" decimals="-6" id="f-457" unitRef="usd">0</mck:AssetImpairmentChargesIncludingAcceleratedDepreciation>
    <mck:AssetImpairmentChargesIncludingAcceleratedDepreciation contextRef="c-70" decimals="-6" id="f-458" unitRef="usd">5000000</mck:AssetImpairmentChargesIncludingAcceleratedDepreciation>
    <mck:AssetImpairmentChargesIncludingAcceleratedDepreciation contextRef="c-71" decimals="-6" id="f-459" unitRef="usd">0</mck:AssetImpairmentChargesIncludingAcceleratedDepreciation>
    <mck:AssetImpairmentChargesIncludingAcceleratedDepreciation contextRef="c-72" decimals="-6" id="f-460" unitRef="usd">0</mck:AssetImpairmentChargesIncludingAcceleratedDepreciation>
    <mck:AssetImpairmentChargesIncludingAcceleratedDepreciation contextRef="c-73" decimals="-6" id="f-461" unitRef="usd">-5000000</mck:AssetImpairmentChargesIncludingAcceleratedDepreciation>
    <mck:AssetImpairmentChargesIncludingAcceleratedDepreciation contextRef="c-7" decimals="-6" id="f-462" unitRef="usd">0</mck:AssetImpairmentChargesIncludingAcceleratedDepreciation>
    <us-gaap:RestructuringCharges contextRef="c-69" decimals="-6" id="f-463" unitRef="usd">4000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-70" decimals="-6" id="f-464" unitRef="usd">7000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-71" decimals="-6" id="f-465" unitRef="usd">1000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-72" decimals="-6" id="f-466" unitRef="usd">2000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-73" decimals="-6" id="f-467" unitRef="usd">9000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-7" decimals="-6" id="f-468" unitRef="usd">23000000</us-gaap:RestructuringCharges>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock contextRef="c-1" id="f-469">&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity related to the liabilities associated with the Company&#x2019;s restructuring initiatives for the three months ended June 30, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.946%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.373%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.180%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.263%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;U.S. Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Prescription Technology Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Medical-Surgical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance, March 31, 2023 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring, impairment, and related charges, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-cash charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance, June 30, 2023 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;As of March 31, 2023, the total reserve balance was $92 million, of which $66 million was recorded in &#x201c;Other accrued liabilities&#x201d; and $26 million was recorded in &#x201c;Other non-current liabilities&#x201d; in the Company&#x2019;s Condensed Consolidated Balance Sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Other primarily includes cumulative translation adjustments and transfers to certain other liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;As of June 30, 2023, the total reserve balance was $74 million, of which $44 million was recorded in &#x201c;Other accrued liabilities&#x201d; and $30 million was recorded in &#x201c;Other non-current liabilities&#x201d; in the Company&#x2019;s Condensed Consolidated Balance Sheet.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:RestructuringReserve contextRef="c-74" decimals="-6" id="f-470" unitRef="usd">15000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-75" decimals="-6" id="f-471" unitRef="usd">26000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-76" decimals="-6" id="f-472" unitRef="usd">3000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-77" decimals="-6" id="f-473" unitRef="usd">13000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-78" decimals="-6" id="f-474" unitRef="usd">35000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-8" decimals="-6" id="f-475" unitRef="usd">92000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges contextRef="c-64" decimals="-6" id="f-476" unitRef="usd">2000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-65" decimals="-6" id="f-477" unitRef="usd">2000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-66" decimals="-6" id="f-478" unitRef="usd">2000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-67" decimals="-6" id="f-479" unitRef="usd">6000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-68" decimals="-6" id="f-480" unitRef="usd">40000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-1" decimals="-6" id="f-481" unitRef="usd">52000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringReserveSettledWithoutCash2 contextRef="c-64" decimals="-6" id="f-482" unitRef="usd">0</us-gaap:RestructuringReserveSettledWithoutCash2>
    <us-gaap:RestructuringReserveSettledWithoutCash2 contextRef="c-65" decimals="-6" id="f-483" unitRef="usd">0</us-gaap:RestructuringReserveSettledWithoutCash2>
    <us-gaap:RestructuringReserveSettledWithoutCash2 contextRef="c-66" decimals="-6" id="f-484" unitRef="usd">0</us-gaap:RestructuringReserveSettledWithoutCash2>
    <us-gaap:RestructuringReserveSettledWithoutCash2 contextRef="c-67" decimals="-6" id="f-485" unitRef="usd">1000000</us-gaap:RestructuringReserveSettledWithoutCash2>
    <us-gaap:RestructuringReserveSettledWithoutCash2 contextRef="c-68" decimals="-6" id="f-486" unitRef="usd">27000000</us-gaap:RestructuringReserveSettledWithoutCash2>
    <us-gaap:RestructuringReserveSettledWithoutCash2 contextRef="c-1" decimals="-6" id="f-487" unitRef="usd">28000000</us-gaap:RestructuringReserveSettledWithoutCash2>
    <us-gaap:PaymentsForRestructuring contextRef="c-64" decimals="-6" id="f-488" unitRef="usd">5000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-65" decimals="-6" id="f-489" unitRef="usd">13000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-66" decimals="-6" id="f-490" unitRef="usd">2000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-67" decimals="-6" id="f-491" unitRef="usd">2000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-68" decimals="-6" id="f-492" unitRef="usd">15000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-1" decimals="-6" id="f-493" unitRef="usd">37000000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserveTranslationAndOtherAdjustment contextRef="c-64" decimals="-6" id="f-494" unitRef="usd">0</us-gaap:RestructuringReserveTranslationAndOtherAdjustment>
    <us-gaap:RestructuringReserveTranslationAndOtherAdjustment contextRef="c-65" decimals="-6" id="f-495" unitRef="usd">0</us-gaap:RestructuringReserveTranslationAndOtherAdjustment>
    <us-gaap:RestructuringReserveTranslationAndOtherAdjustment contextRef="c-66" decimals="-6" id="f-496" unitRef="usd">0</us-gaap:RestructuringReserveTranslationAndOtherAdjustment>
    <us-gaap:RestructuringReserveTranslationAndOtherAdjustment contextRef="c-67" decimals="-6" id="f-497" unitRef="usd">-5000000</us-gaap:RestructuringReserveTranslationAndOtherAdjustment>
    <us-gaap:RestructuringReserveTranslationAndOtherAdjustment contextRef="c-68" decimals="-6" id="f-498" unitRef="usd">0</us-gaap:RestructuringReserveTranslationAndOtherAdjustment>
    <us-gaap:RestructuringReserveTranslationAndOtherAdjustment contextRef="c-1" decimals="-6" id="f-499" unitRef="usd">-5000000</us-gaap:RestructuringReserveTranslationAndOtherAdjustment>
    <us-gaap:RestructuringReserve contextRef="c-79" decimals="-6" id="f-500" unitRef="usd">12000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-80" decimals="-6" id="f-501" unitRef="usd">15000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-81" decimals="-6" id="f-502" unitRef="usd">3000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-82" decimals="-6" id="f-503" unitRef="usd">11000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-83" decimals="-6" id="f-504" unitRef="usd">33000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-6" decimals="-6" id="f-505" unitRef="usd">74000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-8" decimals="-6" id="f-506" unitRef="usd">92000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-84" decimals="-6" id="f-507" unitRef="usd">66000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-85" decimals="-6" id="f-508" unitRef="usd">26000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-6" decimals="-6" id="f-509" unitRef="usd">74000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-86" decimals="-6" id="f-510" unitRef="usd">44000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-87" decimals="-6" id="f-511" unitRef="usd">30000000</us-gaap:RestructuringReserve>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-512">Income Taxes &lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax expense related to continuing operations was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.531%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.574%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30, &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reported income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fluctuations in the Company&#x2019;s reported income tax rates were primarily due to changes in the mix of earnings between various taxing jurisdictions and discrete items recognized in the quarters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended June 30, 2023, the Company repatriated certain intellectual property between McKesson wholly-owned legal entities that are based in different tax jurisdictions. The transferor entity of the intellectual property was not subject to income tax on this transaction. The recipient entity of the intellectual property is entitled to amortize the fair value of the assets for tax purposes. As a result of this repatriation, and in accordance with ASU 2016-16, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intra-Entity Transfers of Assets Other Than Inventory&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, a net discrete tax benefit of $147&#160;million was recognized in the first quarter of fiscal 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended June 30, 2022, the Company recognized a net discrete tax benefit of $45&#160;million primarily related to the tax impact of share-based compensation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June 30, 2023, the Company had $1.4 billion of unrecognized tax benefits, of which $1.3 billion would reduce income tax expense and the effective tax rate if recognized. During the next twelve months, the Company does not anticipate any material reduction in its unrecognized tax benefits based on the information currently available. However, this may change as the Company continues to have ongoing discussions with various taxing authorities throughout the year. &#160;&#160;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company files income tax returns in the U.S. federal jurisdiction, various U.S. state jurisdictions, and various foreign jurisdictions. The Company is generally subject to audit by taxing authorities in various U.S. states and in foreign jurisdictions for fiscal years 2016 through the current fiscal year. &lt;/span&gt;&lt;/div&gt;During the fourth quarter of fiscal 2023, the Internal Revenue Service (&#x201c;IRS&#x201d;) communicated proposed adjustments to taxable income reported in the Company&#x2019;s fiscal 2018 and fiscal 2019 U.S. Federal Corporate Income Tax returns. The adjustments would increase the Company&#x2019;s federal income tax liability in the range of $600&#160;million to $700&#160;million. The Company disagrees with the proposed adjustments and intends to pursue resolution through the administrative process with the IRS Independent Office of Appeals and, if necessary, through judicial remedies. During the first quarter of fiscal 2024, the Company filed a formal protest with the IRS. The Company does not anticipate a final resolution of these matters until fiscal 2026 or after. Although the final resolution of these matters is uncertain, the Company believes in the merits of its tax positions and believes that it has adequately reserved for any adjustments to the provision of income taxes that may ultimately result. However, if the IRS prevails in these matters, the assessed tax and interest could have a material adverse effect on the Company&#x2019;s financial position, results of operations, and cash flows in future periods.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c-1" id="f-513">&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax expense related to continuing operations was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.531%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.574%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30, &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reported income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-6" id="f-514" unitRef="usd">94000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-7" decimals="-6" id="f-515" unitRef="usd">199000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-1" decimals="3" id="f-516" unitRef="number">0.086</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-7" decimals="3" id="f-517" unitRef="number">0.198</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <mck:EffectiveIncomeTaxReconciliationTaxExpenseBenefitIntraEntityTransfersOfAssetsOtherThanInventoryAmount contextRef="c-1" decimals="-6" id="f-518" unitRef="usd">-147000000</mck:EffectiveIncomeTaxReconciliationTaxExpenseBenefitIntraEntityTransfersOfAssetsOtherThanInventoryAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount contextRef="c-7" decimals="-6" id="f-519" unitRef="usd">-45000000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-6" decimals="-8" id="f-520" unitRef="usd">1400000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate contextRef="c-6" decimals="-8" id="f-521" unitRef="usd">1300000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <mck:IncomeTaxExaminationEstimateOfPossibleLiabilityAdjustment contextRef="c-88" decimals="-6" id="f-522" unitRef="usd">600000000</mck:IncomeTaxExaminationEstimateOfPossibleLiabilityAdjustment>
    <mck:IncomeTaxExaminationEstimateOfPossibleLiabilityAdjustment contextRef="c-89" decimals="-6" id="f-523" unitRef="usd">700000000</mck:IncomeTaxExaminationEstimateOfPossibleLiabilityAdjustment>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-524">Earnings Per Common ShareBasic earnings per common share is computed by dividing net income by the weighted-average number of common shares outstanding during the reporting period. The computation of diluted earnings per common share is similar to that of basic earnings per common share, except that the former reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock. Potentially dilutive securities include outstanding stock options, restricted stock units, and performance-based restricted stock units. Less than 1.0 million of potentially dilutive securities for the three months ended June 30, 2023 and 2022 were excluded from the computation of diluted earnings per common share as they were anti-dilutive.&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The computations for basic and diluted earnings per common share were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.531%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.574%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30, &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from continuing operations attributable to McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from discontinued operations, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings per common share attributable to McKesson Corporation: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Includes dilutive effect from restricted stock units and performance-based stock units.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Certain computations may reflect rounding adjustments.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="-3" id="f-525" unitRef="shares">1000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-7" decimals="-3" id="f-526" unitRef="shares">1000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-527">&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The computations for basic and diluted earnings per common share were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.531%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.574%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30, &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions, except per share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from continuing operations attributable to McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from discontinued operations, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income attributable to McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;768&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings per common share attributable to McKesson Corporation: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Continuing operations&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discontinued operations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Includes dilutive effect from restricted stock units and performance-based stock units.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Certain computations may reflect rounding adjustments.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest contextRef="c-1" decimals="-6" id="f-528" unitRef="usd">997000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest contextRef="c-7" decimals="-6" id="f-529" unitRef="usd">807000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-1" decimals="-6" id="f-530" unitRef="usd">39000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-7" decimals="-6" id="f-531" unitRef="usd">41000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperations contextRef="c-1" decimals="-6" id="f-532" unitRef="usd">958000000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations contextRef="c-7" decimals="-6" id="f-533" unitRef="usd">766000000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax contextRef="c-1" decimals="-6" id="f-534" unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax contextRef="c-7" decimals="-6" id="f-535" unitRef="usd">2000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-6" id="f-536" unitRef="usd">958000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-6" id="f-537" unitRef="usd">768000000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-5" id="f-538" unitRef="shares">135500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-7" decimals="-5" id="f-539" unitRef="shares">144200000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-90" decimals="-5" id="f-540" unitRef="shares">200000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-91" decimals="-5" id="f-541" unitRef="shares">300000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-92" decimals="-5" id="f-542" unitRef="shares">900000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="c-93" decimals="-5" id="f-543" unitRef="shares">1400000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-5" id="f-544" unitRef="shares">136600000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-7" decimals="-5" id="f-545" unitRef="shares">145900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="c-1"
      decimals="2"
      id="f-546"
      unitRef="usdPerShare">7.02</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="c-7"
      decimals="2"
      id="f-547"
      unitRef="usdPerShare">5.25</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="c-1"
      decimals="2"
      id="f-548"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="c-7"
      decimals="2"
      id="f-549"
      unitRef="usdPerShare">0.01</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-550"
      unitRef="usdPerShare">7.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-7"
      decimals="2"
      id="f-551"
      unitRef="usdPerShare">5.26</us-gaap:EarningsPerShareDiluted>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="c-1"
      decimals="2"
      id="f-552"
      unitRef="usdPerShare">7.07</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="c-7"
      decimals="2"
      id="f-553"
      unitRef="usdPerShare">5.31</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="c-1"
      decimals="2"
      id="f-554"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="c-7"
      decimals="2"
      id="f-555"
      unitRef="usdPerShare">0.01</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-556"
      unitRef="usdPerShare">7.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-7"
      decimals="2"
      id="f-557"
      unitRef="usdPerShare">5.32</us-gaap:EarningsPerShareBasic>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="c-1" id="f-558">Goodwill and Intangible Assets, Net &lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates goodwill for impairment on an annual basis in the first fiscal quarter, and more frequently if indicators for potential impairment exist. Goodwill impairment testing is conducted at the reporting unit level, which is generally defined as an operating segment or one level below an operating segment (also known as a component), for which discrete financial information is available and segment management regularly reviews the operating results of that reporting unit. The annual impairment testing performed in fiscal 2024 and fiscal 2023 did not indicate any impairment of goodwill. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the carrying amount of goodwill were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.653%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.052%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.556%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.647%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.556%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.652%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;U.S. Pharmaceutical &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Prescription Technology Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Medical-Surgical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;International&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance, March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other adjustments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance, June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;The goodwill balance allocated to the U.S. Pharmaceutical segment related to McKesson Europe&#x2019;s Celesio AG acquisition no longer reflects foreign currency translation adjustments as its functional currency was changed from Euros to U.S. dollars with the completion of the sale of the E.U. disposal group.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Includes purchase price allocation adjustments related to the formation of SCRI Oncology, which is discussed in Financial Note 2, &#x201c;Business Acquisitions and Divestitures.&#x201d;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information regarding intangible assets was as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.716%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.885%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.032%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.032%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.156%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Amortization&lt;br/&gt;Period&lt;br/&gt;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,801)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,765)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(641)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(623)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks and trade names&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(446)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(430)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(133)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(129)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(174)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(174)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,195)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;All intangible assets were subject to amortization as of June 30, 2023 and March 31, 2023. Amortization expense of intangible assets was $62 million and $56 million for the three months ended June 30, 2023 and 2022, respectively. Estimated amortization expense of the assets listed in the table above is as follows: $185 million, $240 million, $208 million, $202 million, and $198 million for the remainder of fiscal 2024 and each of the succeeding years through fiscal 2028, respectively, and $1.2 billion thereafter.</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock contextRef="c-1" id="f-559">&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the carrying amount of goodwill were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.653%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.052%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.556%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.647%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.556%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.652%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;U.S. Pharmaceutical &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Prescription Technology Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Medical-Surgical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;International&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance, March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustments, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other adjustments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance, June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,005&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;The goodwill balance allocated to the U.S. Pharmaceutical segment related to McKesson Europe&#x2019;s Celesio AG acquisition no longer reflects foreign currency translation adjustments as its functional currency was changed from Euros to U.S. dollars with the completion of the sale of the E.U. disposal group.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Includes purchase price allocation adjustments related to the formation of SCRI Oncology, which is discussed in Financial Note 2, &#x201c;Business Acquisitions and Divestitures.&#x201d;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill contextRef="c-94" decimals="-6" id="f-560" unitRef="usd">4050000000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-95" decimals="-6" id="f-561" unitRef="usd">2005000000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-96" decimals="-6" id="f-562" unitRef="usd">2453000000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-97" decimals="-6" id="f-563" unitRef="usd">1439000000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-8" decimals="-6" id="f-564" unitRef="usd">9947000000</us-gaap:Goodwill>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss contextRef="c-98" decimals="-6" id="f-565" unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss contextRef="c-99" decimals="-6" id="f-566" unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss contextRef="c-100" decimals="-6" id="f-567" unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss contextRef="c-101" decimals="-6" id="f-568" unitRef="usd">29000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss contextRef="c-1" decimals="-6" id="f-569" unitRef="usd">29000000</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:GoodwillPurchaseAccountingAdjustments contextRef="c-98" decimals="-6" id="f-570" unitRef="usd">-5000000</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:GoodwillPurchaseAccountingAdjustments contextRef="c-99" decimals="-6" id="f-571" unitRef="usd">0</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:GoodwillPurchaseAccountingAdjustments contextRef="c-100" decimals="-6" id="f-572" unitRef="usd">0</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:GoodwillPurchaseAccountingAdjustments contextRef="c-101" decimals="-6" id="f-573" unitRef="usd">0</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:GoodwillPurchaseAccountingAdjustments contextRef="c-1" decimals="-6" id="f-574" unitRef="usd">-5000000</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:Goodwill contextRef="c-102" decimals="-6" id="f-575" unitRef="usd">4045000000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-103" decimals="-6" id="f-576" unitRef="usd">2005000000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-104" decimals="-6" id="f-577" unitRef="usd">2453000000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-105" decimals="-6" id="f-578" unitRef="usd">1468000000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-6" decimals="-6" id="f-579" unitRef="usd">9971000000</us-gaap:Goodwill>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="c-1" id="f-580">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information regarding intangible assets was as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.716%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.885%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.032%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.151%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.032%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.121%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.156%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(Dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Amortization&lt;br/&gt;Period&lt;br/&gt;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;br/&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,801)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,765)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(641)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(623)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks and trade names&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(446)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(430)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(133)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(129)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(174)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(174)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,195)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="c-106" id="f-581">P12Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-106" decimals="-6" id="f-582" unitRef="usd">2984000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-106" decimals="-6" id="f-583" unitRef="usd">1801000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-106" decimals="-6" id="f-584" unitRef="usd">1183000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-107" decimals="-6" id="f-585" unitRef="usd">2971000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-107" decimals="-6" id="f-586" unitRef="usd">1765000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-107" decimals="-6" id="f-587" unitRef="usd">1206000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="c-108" id="f-588">P10Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-108" decimals="-6" id="f-589" unitRef="usd">1141000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-108" decimals="-6" id="f-590" unitRef="usd">641000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-108" decimals="-6" id="f-591" unitRef="usd">500000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-109" decimals="-6" id="f-592" unitRef="usd">1137000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-109" decimals="-6" id="f-593" unitRef="usd">623000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-109" decimals="-6" id="f-594" unitRef="usd">514000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="c-110" id="f-595">P12Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-110" decimals="-6" id="f-596" unitRef="usd">843000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-110" decimals="-6" id="f-597" unitRef="usd">446000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-110" decimals="-6" id="f-598" unitRef="usd">397000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-111" decimals="-6" id="f-599" unitRef="usd">833000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-111" decimals="-6" id="f-600" unitRef="usd">430000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-111" decimals="-6" id="f-601" unitRef="usd">403000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="c-112" id="f-602">P11Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-112" decimals="-6" id="f-603" unitRef="usd">264000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-112" decimals="-6" id="f-604" unitRef="usd">133000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-112" decimals="-6" id="f-605" unitRef="usd">131000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-113" decimals="-6" id="f-606" unitRef="usd">264000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-113" decimals="-6" id="f-607" unitRef="usd">129000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-113" decimals="-6" id="f-608" unitRef="usd">135000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="c-114" id="f-609">P6Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-114" decimals="-6" id="f-610" unitRef="usd">184000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-114" decimals="-6" id="f-611" unitRef="usd">174000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-114" decimals="-6" id="f-612" unitRef="usd">10000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-115" decimals="-6" id="f-613" unitRef="usd">193000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-115" decimals="-6" id="f-614" unitRef="usd">174000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-115" decimals="-6" id="f-615" unitRef="usd">19000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-6" decimals="-6" id="f-616" unitRef="usd">5416000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-6" decimals="-6" id="f-617" unitRef="usd">3195000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-6" decimals="-6" id="f-618" unitRef="usd">2221000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-8" decimals="-6" id="f-619" unitRef="usd">5398000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-8" decimals="-6" id="f-620" unitRef="usd">3121000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-8" decimals="-6" id="f-621" unitRef="usd">2277000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="-6" id="f-622" unitRef="usd">62000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-7" decimals="-6" id="f-623" unitRef="usd">56000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear contextRef="c-6" decimals="-6" id="f-624" unitRef="usd">185000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="c-6" decimals="-6" id="f-625" unitRef="usd">240000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c-6" decimals="-6" id="f-626" unitRef="usd">208000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="c-6" decimals="-6" id="f-627" unitRef="usd">202000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="c-6" decimals="-6" id="f-628" unitRef="usd">198000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <mck:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour contextRef="c-6" decimals="-8" id="f-629" unitRef="usd">1200000000</mck:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour>
    <us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-630">Debt and Financing Activities&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term debt consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.636%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.522%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;U.S. Dollar notes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.80% Notes due March 15, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.90% Notes due December 3, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.25% Notes due February 15, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.30% Notes due August 15, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.65% Debentures due March 1, 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.95% Notes due February 16, 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.90% Notes due July 15, 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.75% Notes due May 30, 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.10% Notes due July 15, 2033&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.00% Notes due March 1, 2041&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.88% Notes due March 15, 2044&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;Foreign currency notes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) (3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.50% Euro Notes due November 17, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.63% Euro Notes due October 30, 2026 &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.13% Sterling Notes due February 17, 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease and other obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;These notes are unsecured and unsubordinated obligations of the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Interest on these U.S. dollar notes is payable semi-annually.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:3pt;padding-left:18pt;padding-right:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Interest on these foreign currency notes is payable annually.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Long-Term Debt&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s long-term debt includes both U.S. dollar and foreign currency-denominated borrowings. At June 30, 2023 and March 31, 2023, $5.7 billion and $5.6 billion, respectively, of total debt was outstanding, of which $50 million and $968 million, respectively, was included under the caption &#x201c;Current portion of long-term debt&#x201d; in the Company&#x2019;s Condensed Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Notes Offerings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 15, 2023, the Company completed a public offering of 4.90% Notes due July 15, 2028 in a principal amount of $400 million (the &#x201c;2028 Notes&#x201d;) and a public offering of 5.10% Notes due July 15, 2033 in a principal amount of $600 million (the &#x201c;2033 Notes&#x201d; and, together with the 2028 Notes, the &#x201c;Notes&#x201d;). Interest on the Notes is payable semi-annually on January 15th and July 15th of each year, commencing on January 15, 2024. Proceeds received from the issuance of the Notes, net of discounts and offering expenses, were $397 million for the 2028 Notes and $592 million for the 2033 Notes. The Company utilized a portion of the net proceeds from the offerings of the Notes to fund the purchase price payable with respect to the  portion of the Company&#x2019;s then outstanding 3.80% Notes due March 15, 2024 (the &#x201c;2024 Notes&#x201d;) that was validly tendered and accepted for purchase pursuant to the Concurrent Tender Offer (as defined below) and to effect the satisfaction and discharge of the remaining portion of the 2024 Notes, all of which is described further below. The remaining net proceeds from the offerings of the Notes is available for general corporate purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each series of the Notes is an unsecured and unsubordinated obligation of the Company and ranks equally with all of the Company&#x2019;s existing, and future unsecured and unsubordinated indebtedness that may be outstanding from time-to-time. The Notes are governed by an indenture and officers&#x2019; certificate that are materially similar to those of other series of notes issued by the Company. Upon at least 10 days&#x2019; and not more than 60 days&#x2019; notice to holders of the applicable series of the Notes, the Company may redeem either series of the Notes for cash in whole, at any time, or in part, from time to time, at redemption prices that include accrued and unpaid interest and a make-whole premium before a specified date, and at par plus accrued and unpaid interest thereafter until maturity, each as specified in the indenture and the officers&#x2019; certificate. If there were to occur both (1) a change of control of the Company and (2) a downgrade of the applicable series of the Notes below an investment grade rating by each of the Ratings Agencies (as defined in the officers&#x2019; certificate) within a specified period, then the Company would be required to make an offer to purchase those Notes at a price equal to 101% of the then outstanding principal amount of such Notes, plus accrued and unpaid interest to, but not including, the date of repurchase. The indenture and the related officers&#x2019; certificate for the Notes, subject to the exceptions and in compliance with the conditions as applicable, specify that the Company may not consolidate, merge or sell all or substantially all of its assets, incur liens, or enter into sale-leaseback transactions exceeding specific terms, without the lenders&#x2019; consent. The indenture also contains customary events of default provisions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Concurrent Tender Offer &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 16, 2023, the Company completed a cash tender offer for any and all of its then outstanding 2024 Notes, which was made concurrently with the offerings of the Notes (the &#x201c;Concurrent Tender Offer&#x201d;). The Company paid an aggregate consideration of $268 million in the Concurrent Tender Offer to repurchase $271 million principal amount of the 2024 Notes at a repurchase price equal to 98.75% of the principal amount plus accrued and unpaid interest. The repurchase of the 2024 Notes accepted for purchase in the Concurrent Tender Offer was accounted for as a debt extinguishment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Satisfaction and Discharge of the 2024 Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 16, 2023, after completing the Concurrent Tender Offer, the Company irrevocably deposited with the trustee under the indenture governing the 2024 Notes (the &#x201c;2024 Notes Indenture&#x201d;) U.S. government obligations in an amount sufficient to fund the payment of accrued and unpaid interest of the remaining $647&#160;million principal amount of the 2024 Notes as it becomes due, and of the principal amount of those 2024 Notes on their March 15, 2024 maturity date. The U.S. government obligations were purchased using a portion of the net proceeds from the offerings of the Notes. After the deposit of such funds with the trustee, the Company&#x2019;s obligations under the 2024 Notes Indenture with respect to the 2024 Notes were satisfied and discharged and the transaction was accounted for as a debt extinguishment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total gain recognized on the debt extinguishments described above for the three months ended June 30, 2023 was $9 million and included within &#x201c;Interest expense&#x201d; in the Company&#x2019;s Condensed Consolidated Statement of Operations.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revolving Credit Facilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 7, 2022, the Company entered into a Credit Agreement (the &#x201c;2022 Credit Facility&#x201d;), that provides a syndicated $4.0 billion five-year senior unsecured credit facility with a $3.6 billion aggregate sublimit of availability in Canadian dollars, British pound sterling, and Euro. The 2022 Credit Facility is scheduled to mature in November 2027. The 2022 Credit Facility replaced the Company&#x2019;s previous syndicated $4.0 billion five-year senior unsecured credit facility, dated as of September 25, 2019, as amended (the &#x201c;2020 Credit Facility&#x201d;), which was scheduled to mature in September 2024. The 2020 Credit Facility was terminated in connection with the execution of the 2022 Credit Facility. There were no borrowings under the 2020 Credit Facility during the three months ended June 30, 2022, and no amounts outstanding at the time of its termination. There were no borrowings under the 2022 Credit Facility during the three months ended June 30, 2023 and no amounts outstanding at June 30, 2023. At June 30, 2023, the Company was in compliance with all covenants under the 2022 Credit Facility. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Commercial Paper&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains a commercial paper program to support its working capital requirements and for other general corporate purposes. Under the program, the Company can issue up to $4.0 billion in outstanding commercial paper notes. During the three months ended June 30, 2023, the Company borrowed and repaid $65 million under the program. During the three months ended June 30, 2022, there were no material borrowings under the program. At June 30, 2023 and March 31, 2023, there were no commercial paper notes outstanding.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock contextRef="c-1" id="f-631">&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term debt consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.636%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.519%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.522%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;U.S. Dollar notes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) (2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.80% Notes due March 15, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.90% Notes due December 3, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.25% Notes due February 15, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.30% Notes due August 15, 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.65% Debentures due March 1, 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.95% Notes due February 16, 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.90% Notes due July 15, 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.75% Notes due May 30, 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.10% Notes due July 15, 2033&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.00% Notes due March 1, 2041&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.88% Notes due March 15, 2044&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%;text-decoration:underline"&gt;Foreign currency notes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) (3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.50% Euro Notes due November 17, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.63% Euro Notes due October 30, 2026 &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.13% Sterling Notes due February 17, 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lease and other obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;These notes are unsecured and unsubordinated obligations of the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Interest on these U.S. dollar notes is payable semi-annually.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:3pt;padding-left:18pt;padding-right:72pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Interest on these foreign currency notes is payable annually.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-116" decimals="4" id="f-632" unitRef="number">0.0380</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt contextRef="c-116" decimals="-6" id="f-633" unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-117" decimals="-6" id="f-634" unitRef="usd">918000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-118" decimals="4" id="f-635" unitRef="number">0.0090</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt contextRef="c-118" decimals="-6" id="f-636" unitRef="usd">500000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-119" decimals="-6" id="f-637" unitRef="usd">500000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-120" decimals="4" id="f-638" unitRef="number">0.0525</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt contextRef="c-120" decimals="-6" id="f-639" unitRef="usd">499000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-121" decimals="-6" id="f-640" unitRef="usd">499000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-122" decimals="4" id="f-641" unitRef="number">0.0130</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt contextRef="c-122" decimals="-6" id="f-642" unitRef="usd">499000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-123" decimals="-6" id="f-643" unitRef="usd">498000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-124" decimals="4" id="f-644" unitRef="number">0.0765</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt contextRef="c-124" decimals="-6" id="f-645" unitRef="usd">150000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-125" decimals="-6" id="f-646" unitRef="usd">150000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-126" decimals="4" id="f-647" unitRef="number">0.0395</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt contextRef="c-126" decimals="-6" id="f-648" unitRef="usd">343000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-127" decimals="-6" id="f-649" unitRef="usd">343000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-128" decimals="4" id="f-650" unitRef="number">0.0490</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt contextRef="c-128" decimals="-6" id="f-651" unitRef="usd">399000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-129" decimals="-6" id="f-652" unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-130" decimals="4" id="f-653" unitRef="number">0.0475</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt contextRef="c-130" decimals="-6" id="f-654" unitRef="usd">196000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-131" decimals="-6" id="f-655" unitRef="usd">196000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-132" decimals="4" id="f-656" unitRef="number">0.0510</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt contextRef="c-132" decimals="-6" id="f-657" unitRef="usd">596000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-133" decimals="-6" id="f-658" unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-134" decimals="4" id="f-659" unitRef="number">0.0600</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt contextRef="c-134" decimals="-6" id="f-660" unitRef="usd">218000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-135" decimals="-6" id="f-661" unitRef="usd">218000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-136" decimals="4" id="f-662" unitRef="number">0.0488</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt contextRef="c-136" decimals="-6" id="f-663" unitRef="usd">255000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-137" decimals="-6" id="f-664" unitRef="usd">255000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-138" decimals="4" id="f-665" unitRef="number">0.0150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt contextRef="c-138" decimals="-6" id="f-666" unitRef="usd">653000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-139" decimals="-6" id="f-667" unitRef="usd">649000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-140" decimals="4" id="f-668" unitRef="number">0.0163</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt contextRef="c-140" decimals="-6" id="f-669" unitRef="usd">545000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-141" decimals="-6" id="f-670" unitRef="usd">542000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-142" decimals="4" id="f-671" unitRef="number">0.0313</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt contextRef="c-142" decimals="-6" id="f-672" unitRef="usd">571000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-143" decimals="-6" id="f-673" unitRef="usd">555000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-144" decimals="-6" id="f-674" unitRef="usd">237000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-145" decimals="-6" id="f-675" unitRef="usd">271000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-6" decimals="-6" id="f-676" unitRef="usd">5661000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-8" decimals="-6" id="f-677" unitRef="usd">5594000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent contextRef="c-6" decimals="-6" id="f-678" unitRef="usd">50000000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent contextRef="c-8" decimals="-6" id="f-679" unitRef="usd">968000000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations contextRef="c-6" decimals="-6" id="f-680" unitRef="usd">5611000000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligations contextRef="c-8" decimals="-6" id="f-681" unitRef="usd">4626000000</us-gaap:LongTermDebtAndCapitalLeaseObligations>
    <us-gaap:DebtAndCapitalLeaseObligations contextRef="c-6" decimals="-8" id="f-682" unitRef="usd">5700000000</us-gaap:DebtAndCapitalLeaseObligations>
    <us-gaap:DebtAndCapitalLeaseObligations contextRef="c-8" decimals="-8" id="f-683" unitRef="usd">5600000000</us-gaap:DebtAndCapitalLeaseObligations>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent contextRef="c-6" decimals="-6" id="f-684" unitRef="usd">50000000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent contextRef="c-8" decimals="-6" id="f-685" unitRef="usd">968000000</us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-146" decimals="4" id="f-686" unitRef="number">0.0490</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-146" decimals="-6" id="f-687" unitRef="usd">400000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-147" decimals="4" id="f-688" unitRef="number">0.0510</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-147" decimals="-6" id="f-689" unitRef="usd">600000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="c-148" decimals="-6" id="f-690" unitRef="usd">397000000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts contextRef="c-149" decimals="-6" id="f-691" unitRef="usd">592000000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-150" decimals="4" id="f-692" unitRef="number">0.0380</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <mck:DebtInstrumentRedemptionPeriod contextRef="c-151" id="f-693">P10D</mck:DebtInstrumentRedemptionPeriod>
    <mck:DebtInstrumentRedemptionPeriod contextRef="c-152" id="f-694">P60D</mck:DebtInstrumentRedemptionPeriod>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="c-153"
      decimals="INF"
      id="f-695"
      unitRef="number">1.01</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-154" decimals="-6" id="f-696" unitRef="usd">268000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount contextRef="c-155" decimals="-6" id="f-697" unitRef="usd">271000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentRedemptionPricePercentage contextRef="c-154" decimals="4" id="f-698" unitRef="number">0.9875</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <mck:PaymentsForPurchaseOfGovernmentObligationsForSatisfactionAndDischargeOfLongTermDebt contextRef="c-154" decimals="-6" id="f-699" unitRef="usd">647000000</mck:PaymentsForPurchaseOfGovernmentObligationsForSatisfactionAndDischargeOfLongTermDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-1" decimals="-6" id="f-700" unitRef="usd">9000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-156" decimals="-8" id="f-701" unitRef="usd">4000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentTerm contextRef="c-157" id="f-702">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-158" decimals="-8" id="f-703" unitRef="usd">3600000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-159" decimals="-8" id="f-704" unitRef="usd">4000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentTerm contextRef="c-160" id="f-705">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:ProceedsFromLinesOfCredit contextRef="c-161" decimals="INF" id="f-706" unitRef="usd">0</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:LineOfCredit contextRef="c-162" decimals="INF" id="f-707" unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit contextRef="c-163" decimals="INF" id="f-708" unitRef="usd">0</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:LineOfCredit contextRef="c-164" decimals="INF" id="f-709" unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-165" decimals="-8" id="f-710" unitRef="usd">4000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:RepaymentsOfCommercialPaper contextRef="c-166" decimals="-6" id="f-711" unitRef="usd">65000000</us-gaap:RepaymentsOfCommercialPaper>
    <us-gaap:ProceedsFromIssuanceOfCommercialPaper contextRef="c-166" decimals="-6" id="f-712" unitRef="usd">65000000</us-gaap:ProceedsFromIssuanceOfCommercialPaper>
    <us-gaap:ProceedsFromIssuanceOfCommercialPaper contextRef="c-167" decimals="-6" id="f-713" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommercialPaper>
    <us-gaap:LongTermCommercialPaperCurrent contextRef="c-168" decimals="-6" id="f-714" unitRef="usd">0</us-gaap:LongTermCommercialPaperCurrent>
    <us-gaap:LongTermCommercialPaperCurrent contextRef="c-165" decimals="-6" id="f-715" unitRef="usd">0</us-gaap:LongTermCommercialPaperCurrent>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock contextRef="c-1" id="f-716">Hedging Activities &lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, the Company is exposed to interest rate and foreign currency exchange rate fluctuations. At times, the Company limits these risks through the use of derivatives as described below. In accordance with the Company&#x2019;s policy, derivatives are only used for hedging purposes. It does not use derivatives for trading or speculative purposes. The Company uses different counterparties for its derivative contracts to minimize the exposure to credit risk but does not anticipate non-performance by these parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Exchange Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company conducts its business worldwide in U.S. dollars and the functional currencies of its foreign subsidiaries, including Canadian dollars, Euro, and British pounds sterling. Changes in foreign currency exchange rates could have a material adverse impact on the Company&#x2019;s financial results that are reported in U.S. dollars. The Company is also exposed to foreign currency exchange rate risk related to its foreign subsidiaries, including intercompany loans denominated in non-functional currencies. The Company has certain foreign currency exchange rate risk programs that use cross-currency swaps. These forward contracts and cross-currency swaps are generally used to offset the potential income statement effects from intercompany loans and other obligations denominated in non-functional currencies. These programs reduce but do not entirely eliminate foreign currency exchange rate risk. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Non-Derivative Instruments Designated as Hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the divestiture of the E.U. disposal group, the Company had &#x20ac;1.1 billion of Euro-denominated notes designated as non-derivative net investment hedges. These hedges were utilized to hedge portions of the Company&#x2019;s net investments in non-U.S. subsidiaries against the effect of exchange rate fluctuations on the translation of foreign currency balances to the U.S. dollar. For all notes that were designated as net investment hedges and met effectiveness requirements, the changes in carrying value of the notes attributable to the change in spot rates were recorded as foreign currency translation adjustments in &#x201c;Accumulated other comprehensive loss&#x201d; where they offset foreign currency translation gains and losses recorded on the Company&#x2019;s net investments.&#160;To the extent foreign currency denominated notes designated as net investment hedges were ineffective, changes in carrying value attributable to the change in spot rates were recorded in earnings. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;In connection with the divestiture of the E.U. disposal group in October 2022, the Euro-denominated notes described above were de-designated as net investment hedges.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the sale of the U.K. disposal group in April 2022, the Company reclassified $26&#160;million of gains from accumulated other comprehensive loss to &#x201c;Selling, distribution, general, and administrative expenses&#x201d; in the Condensed Consolidated Statement of Operations for the three months ended June 30, 2022. This amount related to the Company&#x2019;s &#xa3;450 million of British pound sterling-denominated notes, which were previously accounted for as net investment hedges until de-designated in fiscal 2020, and was included in the fiscal 2022 calculation of charges to remeasure the assets and liabilities of the disposal group to fair value less costs to sell.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign currency gains (losses) from non-derivative instruments included in other comprehensive income in the Condensed Consolidated Statements of Comprehensive Income were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.531%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.574%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Non-derivatives designated as net investment hedges: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Euro-denominated notes &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;There was no ineffectiveness in these hedges for the three months ended June 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:3pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Derivative Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At June 30, 2023 and March 31, 2023, the notional amounts of the Company&#x2019;s outstanding derivatives were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.640%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.178%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.658%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.480%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.336%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Currency&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Maturity Date&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Notional&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivatives designated as net investment hedges: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swaps &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CAD&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nov-24 to Mar-25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;C$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;C$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivatives designated as fair value hedges: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swaps &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;GBP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nov-28&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#xa3;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#xa3;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swaps &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;EUR&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Aug-25 to Jul-26&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x20ac;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x20ac;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Floating interest rate swaps &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;USD&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Feb-26 to Sep-29&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivatives designated as cash flow hedges: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swaps &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CAD&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Jan-24&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;C$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;C$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed interest rate swaps &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;USD&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Jun-23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;The maturity date reflected is for outstanding derivatives as of June 30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;There was no ineffectiveness in these hedges for the three months ended June 30, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;The Company agreed with third parties to exchange fixed interest payments in one currency for fixed interest payments in another currency at specified intervals and to exchange principal in one currency for principal in another currency, calculated by reference to agreed-upon notional amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Represents cross-currency fixed-to-fixed interest rate swaps to mitigate the foreign currency exchange fluctuations on its foreign currency-denominated notes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Represents fixed-to-floating interest rate swaps to hedge the changes in fair value caused by fluctuations in the benchmark interest rates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(6)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;The Company entered into agreements with financial institutions to lock into the fixed benchmark interest rates for future bond issuance, which were terminated during the first quarter of fiscal 2024 as discussed further below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:3pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net Investment Hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses cross-currency swaps to hedge portions of the Company&#x2019;s net investments denominated in Canadian dollars against the effect of exchange rate fluctuations on the translation of foreign currency balances to the U.S. dollar. The changes in the fair value of these derivatives attributable to the changes in spot currency exchange rates and differences between spot and forward interest rates are recorded in accumulated other comprehensive loss and offset foreign currency translation gains and losses recorded on the Company&#x2019;s net investments denominated in Canadian dollars. To the extent cross-currency swaps designated as hedges are ineffective, changes in carrying value attributable to the change in spot rates are recorded in earnings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses cross-currency swaps to hedge the changes in the fair value of its foreign currency notes resulting from changes in benchmark interest rates and foreign currency exchange rates. The changes in the fair value of these derivatives and the offsetting changes in the fair value of the hedged notes are recorded in earnings. Gains from the changes in the Company&#x2019;s fair value hedges recorded in earnings were largely offset by the losses recorded in earnings on the hedged item. For components excluded from the assessment of hedge effectiveness, the initial value of the excluded component is recognized in accumulated other comprehensive loss and then released into earnings over the life of the hedging instrument. The difference between the change in the fair value of the excluded component and the amount amortized into earnings during the period is recorded in other comprehensive income (loss).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash Flow Hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company enters into cross-currency swaps to hedge intercompany loans denominated in non-functional currencies to reduce the income statement effects arising from fluctuations in foreign currency rates and also enters into forward contracts to hedge the variability of future benchmark interest rates on planned bond issuances. The effective portion of changes in the fair value&#160;of these hedges is recorded in accumulated other comprehensive loss and reclassified into earnings in the same period in which the hedged transaction affects earnings. Changes in fair values representing hedge ineffectiveness are recognized in current earnings. Gains or losses reclassified from accumulated other comprehensive loss and recorded in &#x201c;Selling, distribution, general, and administrative expenses&#x201d; in the Condensed Consolidated Statements of Operations were not material for the three months ended June 30, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company entered into forward-starting fixed interest rate swaps designated as cash flow hedges in fiscal 2023 with a notional amount of $450&#160;million, and in the first quarter of fiscal 2024 with a notional amount of $50&#160;million, to hedge the variability of future benchmark interest rates on a planned bond issuance. On June 15, 2023, the Company completed a public offering of the 2033 Notes, at which point the $500&#160;million cash flow hedges were terminated and the proceeds are amortized to interest expense over the life of the 2033 Notes, or 10 years. Refer to Financial Note 7, &#x201c;Debt and Financing Activities,&#x201d; for additional information on the public offering of the 2033 Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivatives Not Designated as Hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Derivative instruments not designated as hedges are marked-to-market at the end of each accounting period with the change in fair value included in earnings. Changes in the fair values for contracts not designated as hedges are recorded directly into earnings in &#x201c;Selling, distribution, general, and administrative expenses&#x201d; in the Condensed Consolidated Statements of Operations. The Company did not have any outstanding derivative instruments not designated as hedges during the periods presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Information on Derivative Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gains (losses) from derivatives included in other comprehensive income in the Condensed Consolidated Statements of Comprehensive Income were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.531%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.574%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivatives designated as net investment hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivatives designated as cash flow and other hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swaps &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed interest rate swaps&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Includes other comprehensive income (loss) related to the excluded component of certain fair value hedges.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information regarding the fair value of derivatives on a gross basis were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.999%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.256%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.256%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.256%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.256%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.256%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.263%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance Sheet &lt;br/&gt;Caption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value of &lt;br/&gt;Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;U.S. Dollar Notional&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value of &lt;br/&gt;Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;U.S. Dollar Notional&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="39" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivatives designated for hedge accounting:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swaps (current)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other/Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swaps (non-current)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-current assets/liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swaps (non-current)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-current assets/liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to Financial Note 9, "Fair Value Measurements," for more information on these recurring fair value measurements.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:DerivativeNotionalAmount contextRef="c-169" decimals="-8" id="f-717" unitRef="eur">1100000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent contextRef="c-170" decimals="-6" id="f-718" unitRef="usd">26000000</us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent>
    <us-gaap:LongTermDebt contextRef="c-171" decimals="-6" id="f-719" unitRef="gbp">450000000</us-gaap:LongTermDebt>
    <us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock contextRef="c-1" id="f-720">&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign currency gains (losses) from non-derivative instruments included in other comprehensive income in the Condensed Consolidated Statements of Comprehensive Income were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.531%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.574%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Non-derivatives designated as net investment hedges: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Euro-denominated notes &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;There was no ineffectiveness in these hedges for the three months ended June 30, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax contextRef="c-172" decimals="-6" id="f-721" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax contextRef="c-173" decimals="-6" id="f-722" unitRef="usd">64000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock contextRef="c-1" id="f-723">&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At June 30, 2023 and March 31, 2023, the notional amounts of the Company&#x2019;s outstanding derivatives were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.640%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.178%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.658%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.480%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.336%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Currency&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Maturity Date&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Notional&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivatives designated as net investment hedges: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swaps &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CAD&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nov-24 to Mar-25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;C$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;C$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivatives designated as fair value hedges: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swaps &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;GBP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nov-28&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#xa3;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#xa3;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swaps &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;EUR&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Aug-25 to Jul-26&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x20ac;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x20ac;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Floating interest rate swaps &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;USD&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Feb-26 to Sep-29&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivatives designated as cash flow hedges: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swaps &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CAD&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Jan-24&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;C$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;C$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed interest rate swaps &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;USD&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Jun-23&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;The maturity date reflected is for outstanding derivatives as of June 30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;There was no ineffectiveness in these hedges for the three months ended June 30, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;The Company agreed with third parties to exchange fixed interest payments in one currency for fixed interest payments in another currency at specified intervals and to exchange principal in one currency for principal in another currency, calculated by reference to agreed-upon notional amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Represents cross-currency fixed-to-fixed interest rate swaps to mitigate the foreign currency exchange fluctuations on its foreign currency-denominated notes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Represents fixed-to-floating interest rate swaps to hedge the changes in fair value caused by fluctuations in the benchmark interest rates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(6)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;The Company entered into agreements with financial institutions to lock into the fixed benchmark interest rates for future bond issuance, which were terminated during the first quarter of fiscal 2024 as discussed further below.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock>
    <us-gaap:DerivativeNotionalAmount contextRef="c-174" decimals="-6" id="f-724" unitRef="cad">1500000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-175" decimals="-6" id="f-725" unitRef="cad">1500000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-176" decimals="-6" id="f-726" unitRef="gbp">450000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-177" decimals="-6" id="f-727" unitRef="gbp">450000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-178" decimals="-6" id="f-728" unitRef="eur">1100000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-179" decimals="-6" id="f-729" unitRef="eur">1100000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-180" decimals="-6" id="f-730" unitRef="usd">1250000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-181" decimals="-6" id="f-731" unitRef="usd">1250000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-182" decimals="-6" id="f-732" unitRef="cad">400000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-183" decimals="-6" id="f-733" unitRef="cad">400000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-184" decimals="-6" id="f-734" unitRef="usd">0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-185" decimals="-6" id="f-735" unitRef="usd">450000000</us-gaap:DerivativeNotionalAmount>
    <mck:DerivativeNotionalAmountEnteredIntoDuringPeriod contextRef="c-186" decimals="-6" id="f-736" unitRef="usd">450000000</mck:DerivativeNotionalAmountEnteredIntoDuringPeriod>
    <mck:DerivativeNotionalAmountEnteredIntoDuringPeriod contextRef="c-187" decimals="-6" id="f-737" unitRef="usd">50000000</mck:DerivativeNotionalAmountEnteredIntoDuringPeriod>
    <us-gaap:DerivativeNotionalAmount contextRef="c-188" decimals="-6" id="f-738" unitRef="usd">500000000</us-gaap:DerivativeNotionalAmount>
    <mck:DerivativeTerminationProceedsAmortizationPeriod contextRef="c-187" id="f-739">P10Y</mck:DerivativeTerminationProceedsAmortizationPeriod>
    <us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock contextRef="c-1" id="f-740">&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gains (losses) from derivatives included in other comprehensive income in the Condensed Consolidated Statements of Comprehensive Income were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.531%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.574%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivatives designated as net investment hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivatives designated as cash flow and other hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swaps &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed interest rate swaps&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Includes other comprehensive income (loss) related to the excluded component of certain fair value hedges.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock contextRef="c-1" id="f-741">&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gains (losses) from derivatives included in other comprehensive income in the Condensed Consolidated Statements of Comprehensive Income were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.531%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.574%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivatives designated as net investment hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivatives designated as cash flow and other hedges:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swaps &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fixed interest rate swaps&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Includes other comprehensive income (loss) related to the excluded component of certain fair value hedges.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax contextRef="c-189" decimals="-6" id="f-742" unitRef="usd">-20000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax contextRef="c-190" decimals="-6" id="f-743" unitRef="usd">12000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax contextRef="c-191" decimals="-6" id="f-744" unitRef="usd">-6000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax contextRef="c-192" decimals="-6" id="f-745" unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax contextRef="c-193" decimals="-6" id="f-746" unitRef="usd">16000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax contextRef="c-194" decimals="-6" id="f-747" unitRef="usd">27000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock contextRef="c-1" id="f-748">&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information regarding the fair value of derivatives on a gross basis were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.999%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.256%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.256%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.256%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.256%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.256%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.263%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance Sheet &lt;br/&gt;Caption&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value of &lt;br/&gt;Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;U.S. Dollar Notional&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value of &lt;br/&gt;Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;U.S. Dollar Notional&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="39" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivatives designated for hedge accounting:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swaps (current)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other/Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross-currency swaps (non-current)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-current assets/liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swaps (non-current)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non-current assets/liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="c-195" decimals="-6" id="f-749" unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="c-195" decimals="-6" id="f-750" unitRef="usd">2000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeAssetNotionalAmount contextRef="c-195" decimals="-6" id="f-751" unitRef="usd">301000000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="c-196" decimals="-6" id="f-752" unitRef="usd">5000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="c-196" decimals="-6" id="f-753" unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeAssetNotionalAmount contextRef="c-196" decimals="-6" id="f-754" unitRef="usd">301000000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="c-197" decimals="-6" id="f-755" unitRef="usd">84000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="c-197" decimals="-6" id="f-756" unitRef="usd">12000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeAssetNotionalAmount contextRef="c-197" decimals="-6" id="f-757" unitRef="usd">2760000000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="c-198" decimals="-6" id="f-758" unitRef="usd">74000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="c-198" decimals="-6" id="f-759" unitRef="usd">2000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeAssetNotionalAmount contextRef="c-198" decimals="-6" id="f-760" unitRef="usd">2760000000</us-gaap:DerivativeAssetNotionalAmount>
    <us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="c-199" decimals="-6" id="f-761" unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="c-199" decimals="-6" id="f-762" unitRef="usd">39000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeLiabilityNotionalAmount contextRef="c-199" decimals="-6" id="f-763" unitRef="usd">1250000000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="c-200" decimals="-6" id="f-764" unitRef="usd">1000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="c-200" decimals="-6" id="f-765" unitRef="usd">15000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeLiabilityNotionalAmount contextRef="c-200" decimals="-6" id="f-766" unitRef="usd">1700000000</us-gaap:DerivativeLiabilityNotionalAmount>
    <us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="c-201" decimals="-6" id="f-767" unitRef="usd">84000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="c-201" decimals="-6" id="f-768" unitRef="usd">53000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="c-202" decimals="-6" id="f-769" unitRef="usd">80000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="c-202" decimals="-6" id="f-770" unitRef="usd">17000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-771">Fair Value Measurements &lt;div style="margin-bottom:12pt;text-align:justify;text-indent:15.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures certain assets and liabilities at fair value in accordance with ASC Topic 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements and Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The fair value hierarchy consists of three levels of inputs that may be used to measure fair value as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:58.5pt;text-align:justify;text-indent:-40.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 - quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:58.5pt;text-align:justify;text-indent:-40.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2 - significant other observable market-based inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:58.5pt;text-align:justify;text-indent:-40.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 - significant unobservable inputs for which little or no market data exists and requires considerable assumptions that are significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Assets and Liabilities Measured at Fair Value on a Recurring Basis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents at June 30, 2023 and March 31, 2023 included investments in money market funds of $806 million and $1.4 billion, respectively, which are reported at fair value. The fair value of money market funds was determined using quoted prices for identical investments in active markets, which are considered to be Level 1 inputs under the fair value measurements and disclosure guidance. The carrying value of all other cash equivalents approximates their fair value due to their relatively short-term nature.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair values of the Company&#x2019;s interest rate swaps and cross-currency swaps were determined using observable inputs from available market information, including quoted interest rates, foreign currency exchange rates, and other observable inputs from available market information.&#160;These inputs are considered Level 2 under the fair value measurements and disclosure guidance, and may not be representative of actual values that could have been realized or that will be realized in the future. Refer to Financial Note 8, &#x201c;Hedging Activities,&#x201d; for fair values and other information on the Company&#x2019;s derivatives.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company holds investments in equity securities of U.S. growth stage companies that address both current and emerging business challenges in the healthcare industry and which had a carrying value of $237&#160;million at June 30, 2023 and March 31, 2023. These investments primarily consist of equity securities without readily determinable fair values and are included in &#x201c;Other non-current assets&#x201d; in the Condensed Consolidated Balance Sheets. The carrying value of publicly-traded investments, which was not material for the periods presented, was determined using quoted prices for identical investments in active markets and are considered to be Level 1 inputs. The net realized and unrealized gains as well as impairment charges related to these investments are included within &#x201c;Other income, net&#x201d; in the Condensed Consolidated Statements of Operations and were not material for the three months ended June 30, 2023 and 2022.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to assets and liabilities that are measured at fair value on a recurring basis, the Company&#x2019;s assets and liabilities are also subject to nonrecurring fair value measurements. Generally, assets are recorded at fair value on a nonrecurring basis as a result of impairment charges or as a result of charges to remeasure assets classified as held for sale to fair value less costs to sell.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At June 30, 2023 and  March 31, 2023, the contingent consideration liability related to the Company&#x2019;s acquisition of RxSS in November 2022 was measured at fair value on a nonrecurring basis. Refer to Financial Note 2, &#x201c;Business Acquisitions and Divestitures," for more information on this transaction. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aforementioned investments in equity securities of U.S. growth stage companies include the carrying value of investments without readily determinable fair values, which were determined using a measurement alternative and are recorded at cost less impairment, plus or minus any changes in observable price from orderly transactions of the same or similar security of the same issuer. These inputs related to changes in observable price are considered Level 2 under the fair value measurements and disclosure guidance and may not be representative of actual values that could have been realized or that will be realized in the future. Inputs related to impairments of investments are generally considered Level 3 fair value measurements due to their inherently unobservable nature based on significant assumptions by management and use of company-specific information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no other material assets or liabilities measured at fair value on a nonrecurring basis at June 30, 2023 and March 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Fair Value Disclosures&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At June 30, 2023 and March 31, 2023, the carrying amounts of cash, certain cash equivalents, restricted cash, receivables, drafts and accounts payable, short-term borrowings, and other current assets and liabilities approximated their estimated fair values because of the short-term maturity of these financial instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines the fair value of commercial paper using quoted prices in active markets for identical instruments, which are considered Level 1 inputs under the fair value measurements and disclosure guidance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s long-term debt is recorded at amortized cost. The carrying value and fair value of the Company&#x2019;s long-term debt was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.794%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.677%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.698%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, including current maturities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of the Company&#x2019;s long-term debt was determined using quoted market prices in a less active market and other observable inputs from available market information, which are considered to be Level 2 inputs, and may not be representative of actual values that could have been realized or that will be realized in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value assessments of the reporting unit and the reporting unit's net assets, which are performed for goodwill impairment tests, are considered a Level 3 measurement due to the significance of unobservable inputs developed using company-specific information. The Company considered a market approach as well as an income approach using a discounted cash flow (&#x201c;DCF&#x201d;) model to determine the fair value of each reporting unit.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Long-lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company utilizes multiple approaches, including the DCF model and market approaches, for estimating the fair value of intangible assets. The future cash flows used in the analysis are based on internal cash flow projections from its long-range plans and include significant assumptions by management. Accordingly, the fair value assessment of long-lived assets is considered a Level 3 fair value measurement.&lt;/span&gt;&lt;/div&gt;The Company measures certain long-lived and intangible assets at fair value on a nonrecurring basis when events occur that indicate an asset group may not be recoverable. If the carrying amount of an asset group is not recoverable, an impairment charge is recorded to reduce the carrying amount by the excess over its fair value.</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:MoneyMarketFundsAtCarryingValue contextRef="c-203" decimals="-6" id="f-772" unitRef="usd">806000000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:MoneyMarketFundsAtCarryingValue contextRef="c-204" decimals="-8" id="f-773" unitRef="usd">1400000000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-6" decimals="-6" id="f-774" unitRef="usd">237000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-8" decimals="-6" id="f-775" unitRef="usd">237000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock contextRef="c-1" id="f-776">&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s long-term debt is recorded at amortized cost. The carrying value and fair value of the Company&#x2019;s long-term debt was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:56.794%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.677%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.698%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term debt, including current maturities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock>
    <us-gaap:LongTermDebt contextRef="c-205" decimals="-6" id="f-777" unitRef="usd">5661000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentFairValue contextRef="c-205" decimals="-6" id="f-778" unitRef="usd">5335000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:LongTermDebt contextRef="c-206" decimals="-6" id="f-779" unitRef="usd">5594000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentFairValue contextRef="c-206" decimals="-6" id="f-780" unitRef="usd">5386000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-781">Commitments and Contingent Liabilities&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to commitments and obligations incurred in the ordinary course of business, the Company is subject to a variety of claims and legal proceedings, including claims from customers and vendors, pending and potential legal actions for damages, governmental investigations, and other matters. The Company and its affiliates are parties to the legal claims and proceedings described below and in &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/927653/000092765323000038/mck-20230331.htm#i04335d018da94076b0acf21e81ac886b_172" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Financial Note 1&lt;/a&gt;&lt;a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/927653/000092765323000038/mck-20230331.htm#i04335d018da94076b0acf21e81ac886b_172" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;7&lt;/a&gt;&lt;a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/927653/000092765323000038/mck-20230331.htm#i04335d018da94076b0acf21e81ac886b_172" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt; to the Company&#x2019;s 202&lt;/a&gt;&lt;a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/927653/000092765323000038/mck-20230331.htm#i04335d018da94076b0acf21e81ac886b_172" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;3&lt;/a&gt;&lt;a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/927653/000092765323000038/mck-20230331.htm#i04335d018da94076b0acf21e81ac886b_172" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt; Annual Report&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which disclosure is incorporated in this footnote by this reference. The Company is vigorously defending itself against those claims and in those proceedings. Significant developments in those matters are described below. If the Company is unsuccessful in defending, or if it determines to settle, any of these matters, it may be required to pay substantial sums, be subject to injunction and/or be forced to change how it operates its business, which could have a material adverse impact on its financial position or results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless otherwise stated, the Company is unable to reasonably estimate the loss or a range of possible loss for the matters described below. Often, the Company is unable to determine that a loss is probable, or to reasonably estimate the amount of loss or a range of loss, for a claim because of the limited information available and the potential effects of future events and decisions by third parties, such as courts and regulators, that will determine the ultimate resolution of the claim. Many of the matters described are at preliminary stages, raise novel theories of liability, or seek an indeterminate amount of damages. It is not uncommon for claims to remain unresolved over many years. The Company reviews loss contingencies at least quarterly to determine whether the likelihood of loss has changed and whether it can make a reasonable estimate of the loss or range of loss. When the Company determines that a loss from a claim is probable and reasonably estimable, it records a liability for an estimated amount. The Company also provides disclosure when it is reasonably possible that a loss may be incurred or when it is reasonably possible that the amount of a loss will exceed its recorded liability. Amounts included within &#x201c;Claims and litigation charges, net&#x201d; in the Condensed Consolidated Statements of Operations consist of estimated loss contingencies related to opioid-related litigation matters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;I. Litigation and Claims Involving Distribution of Controlled Substances&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and its affiliates have been sued as defendants in many cases asserting claims related to distribution of controlled substances. They have been named as defendants along with other pharmaceutical wholesale distributors, pharmaceutical manufacturers, and retail pharmacies. The plaintiffs in these actions have included state attorneys general, county and municipal governments, school districts, tribal nations, hospitals, health and welfare funds, third-party payors, and individuals. These actions have been filed in state and federal courts throughout the U.S., and in Puerto Rico and Canada. They have sought monetary damages and other forms of relief based on a variety of causes of action, including negligence, public nuisance, unjust enrichment, and civil conspiracy, as well as alleging violations of the Racketeer Influenced and Corrupt Organizations Act (&#x201c;RICO&#x201d;), state and federal controlled substances laws, and other statutes. Because of the many uncertainties associated with opioid-related litigation matters, the Company is not able to conclude that a liability is probable or provide a reasonable estimate for the range of ultimate possible loss for opioid-related litigation matters other than those for which an accrual is described below. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;State and Local Government Claims&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and two other national pharmaceutical distributors (collectively &#x201c;Distributors&#x201d;) entered into a settlement agreement (the &#x201c;Settlement&#x201d;) and consent judgment with 48 states and their participating subdivisions, as well as the District of Columbia and all eligible territories (the &#x201c;Settling Governmental Entities&#x201d;). Approximately 2,300 cases have been dismissed. The Distributors did not admit liability or wrongdoing and do not waive any defenses pursuant to the Settlement. Under the Settlement, the Company has paid the Settling Governmental Entities approximately $1.0&#160;billion as of June 30, 2023, and additionally will pay the Settling Governmental Entities up to approximately $6.8&#160;billion through 2038. A minimum of 85% of the Settlement payments must be used by state and local governmental entities to remediate the opioid epidemic, while the remainder relates to plaintiffs&#x2019; attorneys&#x2019; fees and costs and will be paid out through 2030. Under the Settlement, the Distributors will establish a clearinghouse to consolidate their controlled-substance distribution data, which will be available to the settling U.S. states to use as part of their anti-diversion efforts. Alabama and West Virginia did not participate in the Settlement. Under a separate settlement agreement with Alabama and its subdivisions, the Company has paid approximately $42&#160;million as of June 30, 2023, and additionally will pay approximately $132&#160;million through 2031. The Company previously settled with the state of West Virginia in 2018, so West Virginia and its subdivisions were not eligible to participate in the Settlement. Under a separate settlement agreement, the Company has paid certain West Virginia subdivisions approximately $38&#160;million as of June 30, 2023, and additionally will pay approximately $114&#160;million through 2033. That agreement does not include school districts or the claims of Cabell County and the City of Huntington. After a trial, the claims of Cabell County and the City of Huntington, were decided in the Company&#x2019;s favor on July 4, 2022. Those subdivisions appealed that decision. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Some other state and local governmental subdivisions did not participate in the Settlement, including certain municipal governments, government hospitals, school districts, and government-affiliated third-party payors. The Company contends that those subdivisions&#x2019; claims are foreclosed by the Settlement or other dispositive defenses, but the subdivisions contend that their claims are not foreclosed. The City of Baltimore, Maryland, is one such subdivision, and a trial of its claims is scheduled to begin September 26, 2024. An accrual for the remaining governmental subdivision claims is reflected in the total estimated liability for opioid-related claims in a manner consistent with how Settlement amounts were allocated to Settling Governmental Entities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Native American Tribe Claims&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also entered into settlement agreements for opioid-related claims of federally recognized Native American tribes. Under those agreements, the Company has paid the settling Native American tribes approximately $56&#160;million as of June 30, 2023, and additionally will pay approximately $140&#160;million through 2027. A minimum of 85% of the total settlement payments must be used by the settling Native American tribes to remediate the opioid epidemic.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s estimated accrued liability for the opioid-related claims of U.S. governmental entities, including Native American tribes, was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.548%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.562%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.826%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.564%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current litigation liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term litigation liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total litigation liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;These amounts, recorded in &#x201c;Other accrued liabilities&#x201d; in the Condensed Consolidated Balance Sheets, are the amounts estimated to be paid within the next twelve months following each respective period end date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended June 30, 2023, the Company made no payments associated with the Settlement and the separate settlement agreements for opioid-related claims discussed above. In July 2023, the Company made payments totaling $529&#160;million associated with the Settlement and separate settlement agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Non-Governmental Plaintiff Claims&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is also a defendant in approximately 400 opioid-related cases brought in the U.S. by private plaintiffs, such as hospitals, health and welfare funds, third-party payors, and individuals. These claims, and those of private entities generally, are not included in the settlement agreements described above or in the charges recorded by the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Canadian Plaintiff Claims&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and its Canadian affiliate are also defendants in four opioid-related cases pending in Canada. These cases involve the claims of the provincial governments, a group representing indigenous people, as well as one case brought by an individual.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Defense of Opioids Claims&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company believes it has valid legal defenses in all opioid-related matters, including claims not covered by settlement agreements, and it intends to mount a vigorous defense in such matters. Other than the settlement agreements and the U.S. governmental subdivision claims described above, the Company has not concluded a loss is probable in any of the matters; nor is any possible loss or range of loss reasonably estimable. An adverse judgment or negotiated resolution in any of these matters could have a material adverse impact on the Company&#x2019;s financial position, cash flows or liquidity, or results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;II. Other Litigation and Claims&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 12, 2018, the Company received a purported class action complaint in the United States District Court for the Northern District of California, alleging that McKesson and two of its former officers, CEO John Hammergren and CFO James Beer, violated the Securities Exchange Act of 1934 by reporting profits and revenues from 2013 until early 2017 that were false and misleading, due to an alleged undisclosed conspiracy to fix the prices of generic drugs. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Evanston Police Pension Fund v. McKesson Corporation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, No. 3:18-06525. In October 2022, the parties reached an agreement in principle to settle this class action lawsuit for an amount covered in full by the Company&#x2019;s insurance policy. This settlement does not include any admission of liability, and defendants expressly deny wrongdoing. The Company&#x2019;s estimated probable loss, entirely offset by probable loss recovery from the Company&#x2019;s insurers, was $141&#160;million, both of which were recognized in the Condensed Consolidated Balance Sheet as of September 30, 2022 within &#x201c;Other accrued liabilities&#x201d; and &#x201c;Prepaid expenses and other.&#x201d; In February 2023, the insurance carriers funded the settlement, and the probable loss and loss recovery of $141&#160;million have been reversed in the Consolidated Balance Sheet as of March 31, 2023. On July 14, 2023, the court granted the motion for final approval of the settlement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2020, the Company was served with a first amended &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; complaint filed in the United States District Court for the Southern District of New York by a relator on behalf of the U.S., 27 states and the District of Columbia against McKesson Corporation, McKesson Specialty Distribution LLC, and McKesson Specialty Care Distribution Corporation, alleging that defendants violated the Anti-Kickback Statute, federal False Claims Act, and various state false claims statutes by providing certain business analytical tools to oncology practice customers, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;United States ex rel. Hart v. McKesson Corporation, et al.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, 15-cv-00903-RA. The U.S. and the named states have declined to intervene in the case. The complaint seeks relief including damages, treble damages, civil penalties, attorney fees, and costs of suit, all in unspecified amounts. On May 5, 2022, the district court granted the Company&#x2019;s motion to dismiss the complaint, but granted the plaintiff leave to amend the complaint. The relator filed the second amended complaint on June 7, 2022, which was dismissed on March 28, 2023. On April 26, 2023, the relator filed a notice of appeal to the United States Court of Appeals for the Second Circuit.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;III.&#160;Government Subpoenas and Investigations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company receives subpoenas or requests for information from various government agencies. The Company generally responds to such subpoenas and requests in a cooperative, thorough, and timely manner. These responses sometimes require time and effort and can result in considerable costs being incurred by the Company. Such subpoenas and requests can lead to the assertion of claims or the commencement of civil or criminal legal proceedings against the Company and other members of the health care industry, as well as to settlements of claims against the Company. The Company responds to these requests in the ordinary course of business.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock contextRef="c-1" id="f-782">&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to commitments and obligations incurred in the ordinary course of business, the Company is subject to a variety of claims and legal proceedings, including claims from customers and vendors, pending and potential legal actions for damages, governmental investigations, and other matters. The Company and its affiliates are parties to the legal claims and proceedings described below and in &lt;/span&gt;&lt;span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;&lt;a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/927653/000092765323000038/mck-20230331.htm#i04335d018da94076b0acf21e81ac886b_172" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Financial Note 1&lt;/a&gt;&lt;a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/927653/000092765323000038/mck-20230331.htm#i04335d018da94076b0acf21e81ac886b_172" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;7&lt;/a&gt;&lt;a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/927653/000092765323000038/mck-20230331.htm#i04335d018da94076b0acf21e81ac886b_172" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt; to the Company&#x2019;s 202&lt;/a&gt;&lt;a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/927653/000092765323000038/mck-20230331.htm#i04335d018da94076b0acf21e81ac886b_172" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;3&lt;/a&gt;&lt;a href="https://www.sec.gov/ix?doc=/Archives/edgar/data/927653/000092765323000038/mck-20230331.htm#i04335d018da94076b0acf21e81ac886b_172" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt; Annual Report&lt;/a&gt;&lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which disclosure is incorporated in this footnote by this reference. The Company is vigorously defending itself against those claims and in those proceedings. Significant developments in those matters are described below. If the Company is unsuccessful in defending, or if it determines to settle, any of these matters, it may be required to pay substantial sums, be subject to injunction and/or be forced to change how it operates its business, which could have a material adverse impact on its financial position or results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unless otherwise stated, the Company is unable to reasonably estimate the loss or a range of possible loss for the matters described below. Often, the Company is unable to determine that a loss is probable, or to reasonably estimate the amount of loss or a range of loss, for a claim because of the limited information available and the potential effects of future events and decisions by third parties, such as courts and regulators, that will determine the ultimate resolution of the claim. Many of the matters described are at preliminary stages, raise novel theories of liability, or seek an indeterminate amount of damages. It is not uncommon for claims to remain unresolved over many years. The Company reviews loss contingencies at least quarterly to determine whether the likelihood of loss has changed and whether it can make a reasonable estimate of the loss or range of loss. When the Company determines that a loss from a claim is probable and reasonably estimable, it records a liability for an estimated amount. The Company also provides disclosure when it is reasonably possible that a loss may be incurred or when it is reasonably possible that the amount of a loss will exceed its recorded liability. Amounts included within &#x201c;Claims and litigation charges, net&#x201d; in the Condensed Consolidated Statements of Operations consist of estimated loss contingencies related to opioid-related litigation matters.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <mck:LossContingencyNumberOfOtherDefendants
      contextRef="c-207"
      decimals="INF"
      id="f-783"
      unitRef="distributor">2</mck:LossContingencyNumberOfOtherDefendants>
    <mck:LossContingencyNumberofStates
      contextRef="c-207"
      decimals="INF"
      id="f-784"
      unitRef="state">48</mck:LossContingencyNumberofStates>
    <mck:LossContingencyNumberOfCasesDismissed contextRef="c-207" decimals="INF" id="f-785" unitRef="case">2300</mck:LossContingencyNumberOfCasesDismissed>
    <us-gaap:PaymentsForLegalSettlements contextRef="c-208" decimals="-8" id="f-786" unitRef="usd">1000000000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty contextRef="c-208" decimals="-8" id="f-787" unitRef="usd">6800000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <mck:LitigationSettlementAwardAmountToBeUsedByStateAndLocalGovernment contextRef="c-207" decimals="2" id="f-788" unitRef="number">0.85</mck:LitigationSettlementAwardAmountToBeUsedByStateAndLocalGovernment>
    <us-gaap:PaymentsForLegalSettlements contextRef="c-209" decimals="-6" id="f-789" unitRef="usd">42000000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty contextRef="c-209" decimals="-6" id="f-790" unitRef="usd">132000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:PaymentsForLegalSettlements contextRef="c-210" decimals="-6" id="f-791" unitRef="usd">38000000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty contextRef="c-210" decimals="-6" id="f-792" unitRef="usd">114000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <mck:LossContingencyClaimsSettledNumberOfJurisdictionsNotParticipatingInSettlement
      contextRef="c-207"
      decimals="INF"
      id="f-793"
      unitRef="jurisdiction">1</mck:LossContingencyClaimsSettledNumberOfJurisdictionsNotParticipatingInSettlement>
    <us-gaap:PaymentsForLegalSettlements contextRef="c-211" decimals="-6" id="f-794" unitRef="usd">56000000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty contextRef="c-212" decimals="-6" id="f-795" unitRef="usd">140000000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <mck:LitigationSettlementAmountAwardedToOtherPartyPercentageOfTotalSettlementToBeUsedToRemediateDamages contextRef="c-213" decimals="2" id="f-796" unitRef="number">0.85</mck:LitigationSettlementAmountAwardedToOtherPartyPercentageOfTotalSettlementToBeUsedToRemediateDamages>
    <us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock contextRef="c-1" id="f-797">&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s estimated accrued liability for the opioid-related claims of U.S. governmental entities, including Native American tribes, was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:68.548%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.562%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.826%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.564%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current litigation liabilities &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term litigation liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total litigation liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;These amounts, recorded in &#x201c;Other accrued liabilities&#x201d; in the Condensed Consolidated Balance Sheets, are the amounts estimated to be paid within the next twelve months following each respective period end date.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock>
    <us-gaap:LossContingencyAccrualCarryingValueCurrent contextRef="c-214" decimals="-6" id="f-798" unitRef="usd">545000000</us-gaap:LossContingencyAccrualCarryingValueCurrent>
    <us-gaap:LossContingencyAccrualCarryingValueCurrent contextRef="c-215" decimals="-6" id="f-799" unitRef="usd">548000000</us-gaap:LossContingencyAccrualCarryingValueCurrent>
    <us-gaap:LossContingencyAccrualCarryingValueNoncurrent contextRef="c-214" decimals="-6" id="f-800" unitRef="usd">6628000000</us-gaap:LossContingencyAccrualCarryingValueNoncurrent>
    <us-gaap:LossContingencyAccrualCarryingValueNoncurrent contextRef="c-215" decimals="-6" id="f-801" unitRef="usd">6625000000</us-gaap:LossContingencyAccrualCarryingValueNoncurrent>
    <us-gaap:LossContingencyAccrualAtCarryingValue contextRef="c-214" decimals="-6" id="f-802" unitRef="usd">7173000000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue contextRef="c-215" decimals="-6" id="f-803" unitRef="usd">7173000000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:PaymentsForLegalSettlements contextRef="c-216" decimals="-6" id="f-804" unitRef="usd">0</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:PaymentsForLegalSettlements contextRef="c-217" decimals="-6" id="f-805" unitRef="usd">529000000</us-gaap:PaymentsForLegalSettlements>
    <us-gaap:LossContingencyPendingClaimsNumber contextRef="c-218" decimals="INF" id="f-806" unitRef="case">400</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber contextRef="c-219" decimals="INF" id="f-807" unitRef="case">4</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyPendingClaimsNumber contextRef="c-220" decimals="INF" id="f-808" unitRef="case">1</us-gaap:LossContingencyPendingClaimsNumber>
    <mck:LossContingencyNumberOfFormerOfficers
      contextRef="c-221"
      decimals="0"
      id="f-809"
      unitRef="officer">2</mck:LossContingencyNumberOfFormerOfficers>
    <us-gaap:LossContingencyEstimateOfPossibleLoss contextRef="c-222" decimals="-6" id="f-810" unitRef="usd">141000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:EstimatedInsuranceRecoveries contextRef="c-222" decimals="-6" id="f-811" unitRef="usd">141000000</us-gaap:EstimatedInsuranceRecoveries>
    <us-gaap:LossContingencyEstimateOfPossibleLoss contextRef="c-223" decimals="-6" id="f-812" unitRef="usd">141000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:EstimatedInsuranceRecoveries contextRef="c-223" decimals="-6" id="f-813" unitRef="usd">141000000</us-gaap:EstimatedInsuranceRecoveries>
    <mck:LossContingencyNumberOfStatesFiledOnBehalfOf contextRef="c-224" decimals="0" id="f-814" unitRef="state">27</mck:LossContingencyNumberOfStatesFiledOnBehalfOf>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-815">Stockholders' Deficit &lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each share of the Company&#x2019;s outstanding common stock is permitted one vote on proposals presented to stockholders and is entitled to participate equally in any dividends declared by the Company&#x2019;s Board of Directors (the &#x201c;Board&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2023, the quarterly dividend was raised from $0.54 to $0.62 per share of common stock for dividends declared on or after such date by the Board. The Company anticipates that it will continue to pay quarterly cash dividends in the future.&#160;However, the payment and amount of future dividends remain within the discretion of the Board and will depend upon the Company's future earnings, financial condition, capital requirements, legal requirements, and other factors. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Share Repurchase Plans &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Board has authorized the repurchase of McKesson&#x2019;s common stock. The Company may effect stock repurchases from time-to-time through open market transactions, privately negotiated transactions, accelerated share repurchase (&#x201c;ASR&#x201d;) programs, or by combinations of such methods, any of which may use pre-arranged trading plans that are designed to meet the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. The timing of any repurchases and the actual number of shares repurchased will depend on a variety of factors, including the Company&#x2019;s stock price, corporate and regulatory requirements, tax implications, restrictions under the Company&#x2019;s debt obligations, other uses for capital, impacts on the value of remaining shares, and market and economic conditions. The ASR programs discussed below were designed to comply with Rule 10b5-1(c).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Effective January 1, 2023, the Company&#x2019;s repurchase of McKesson&#x2019;s common stock, adjusted for allowable items, are subject to a 1% excise tax as a result of the IRA. Excise taxes incurred on share repurchases of an entity&#x2019;s own common stock are direct and incremental costs to purchase treasury stock, and accordingly are included in the total cost basis of the common stock acquired and reflected as a reduction of stockholders&#x2019; equity within &#x201c;Treasury shares&#x201d; in the Company&#x2019;s Condensed Consolidated Balance Sheets and Condensed Consolidated Statements of Stockholders&#x2019; Deficit. Excise taxes are not reflected in the Company&#x2019;s remaining authorization for the repurchase of McKesson&#x2019;s common stock.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:3pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2022, the Company entered into an ASR program with a third-party financial institution to repurchase $1.0&#160;billion of the Company&#x2019;s common stock. The total number of shares repurchased under this ASR program was 3.1 million shares at an average price per share of $321.05. The Company received 2.6 million shares as the initial share settlement, and in August 2022, the Company received an additional 0.5 million shares upon the completion of this ASR program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:3pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2022, the Company entered into an ASR program with a third-party financial institution to repurchase $1.5 billion of the Company&#x2019;s common stock. The total number of shares repurchased under this ASR program was 5.1 million shares at an average price per share of $295.16. The Company received 4.8 million shares as the initial share settlement in the fourth quarter of fiscal 2022, and in May 2022, the Company received an additional 0.3 million shares upon the completion of this ASR program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended June 30, 2023, the Company repurchased 1.8&#160;million of the Company&#x2019;s shares of common stock for $673&#160;million through open market transactions at an average price per share of $379.14. Of the total dollar value, $4 million was accrued within &#x201c;Other non-current liabilities&#x201d; in the Company&#x2019;s Condensed Consolidated Balance Sheet for excise taxes incurred during the three months ended June 30, 2023. As of March 31, 2023, the Company had $27&#160;million accrued within &#x201c;Other accrued liabilities&#x201d; for share repurchases that were executed in late March 2023, which settled in early April 2023. There were no open market share repurchases during the three months ended June 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total remaining authorization outstanding for repurchases of the Company&#x2019;s common stock at June 30, 2023 was $2.9 billion. In July 2023, the Board approved an increase of $6.0 billion in the authorization for repurchase of McKesson&#x2019;s common stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accumulated Other Comprehensive Loss &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information regarding changes in accumulated other comprehensive loss, including noncontrolling interests, by components for the three months ended June 30, 2023 and 2022 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.757%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.042%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.657%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.042%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.228%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.042%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.657%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.042%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.800%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Adjustments, Net of Tax&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized Losses on Net Investment Hedges, &lt;br/&gt;Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized  Gains (Losses) on Cash Flow and Other Hedges, &lt;br/&gt;Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized Losses and Other Components of Benefit Plans, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Accumulated Other Comprehensive Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance, March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(847)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(905)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;&#x207d;&#xb2;&#x207e;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts reclassified to earnings and other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: amounts attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) attributable to McKesson&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance, June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(780)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(848)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Primarily results from the conversion of non-U.S. dollar financial statements of the Company&#x2019;s operations in Canada and Europe into the Company&#x2019;s reporting currency, U.S. dollars.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Amounts recorded for the three months ended June 30, 2023 includ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;e l&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;osses of $20 million related to net investment hedges from cross-currency swaps, which are net of income tax benefit of $5 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.711%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.025%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.655%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.025%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.225%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.025%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.798%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.025%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.798%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.313%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Adjustments, Net of Tax&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Net Investment Hedges, &lt;br/&gt;Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized Gains on Cash Flow and Other  Hedges, &lt;br/&gt;Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) and Other Components of Benefit Plans, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Accumulated Other Comprehensive Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance, March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,504)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(67)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,534)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(176)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;&#x207d;&#xb2;&#x207e;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts reclassified to earnings and other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: amounts attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income attributable to McKesson&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance, June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(997)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(948)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Primarily results from the conversion of non-U.S. dollar financial statements of the Company&#x2019;s operations in Canada and Europe into the Company&#x2019;s reporting currency, U.S. dollars.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Amounts recorded for the three months ended June 30, 2022 include gains of $64 million related to net investment hedges from Euro-denominated notes and gains of $12 million related to net investment hedges from cross-currency swaps. These amounts are net of income tax expense of $31 million.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Primarily included adjustments for amounts related to the sale of the U.K. disposal group, as discussed in more detail in Financial Note 2, &#x201c;Business Acquisitions and Divestitures.&#x201d; These amounts were included in the fiscal 2022 calculation of charges to remeasure the assets and liabilities held for sale to fair value less costs to sell recorded within &#x201c;Selling, distribution, general, and administrative expenses&#x201d; in the Consolidated Statements of Operations.&lt;/span&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <mck:CommonStockVotingRightsNumberofVotesPerCommonShare contextRef="c-6" decimals="INF" id="f-816" unitRef="vote">1</mck:CommonStockVotingRightsNumberofVotesPerCommonShare>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="c-1"
      decimals="INF"
      id="f-817"
      unitRef="usdPerShare">0.54</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="c-225"
      decimals="INF"
      id="f-818"
      unitRef="usdPerShare">0.62</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:StockRepurchasedDuringPeriodValue contextRef="c-226" decimals="-8" id="f-819" unitRef="usd">1000000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="c-227"
      decimals="-5"
      id="f-820"
      unitRef="shares">3100000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="c-227"
      decimals="2"
      id="f-821"
      unitRef="usdPerShare">321.05</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-228"
      decimals="-5"
      id="f-822"
      unitRef="shares">2600000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-229"
      decimals="-5"
      id="f-823"
      unitRef="shares">500000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:StockRepurchasedDuringPeriodValue contextRef="c-230" decimals="-8" id="f-824" unitRef="usd">1500000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="c-231"
      decimals="-5"
      id="f-825"
      unitRef="shares">5100000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="c-231"
      decimals="2"
      id="f-826"
      unitRef="usdPerShare">295.16</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-232"
      decimals="-5"
      id="f-827"
      unitRef="shares">4800000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-233"
      decimals="-5"
      id="f-828"
      unitRef="shares">300000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-234"
      decimals="-5"
      id="f-829"
      unitRef="shares">1800000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredParValueMethod contextRef="c-234" decimals="-6" id="f-830" unitRef="usd">673000000</us-gaap:TreasuryStockValueAcquiredParValueMethod>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="c-234"
      decimals="2"
      id="f-831"
      unitRef="usdPerShare">379.14</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <mck:ExciseTaxPayableCurrent contextRef="c-6" decimals="-6" id="f-832" unitRef="usd">4000000</mck:ExciseTaxPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-235" decimals="-6" id="f-833" unitRef="usd">27000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="c-236"
      decimals="-5"
      id="f-834"
      unitRef="shares">0</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1 contextRef="c-6" decimals="-8" id="f-835" unitRef="usd">2900000000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1 contextRef="c-237" decimals="-8" id="f-836" unitRef="usd">6000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock contextRef="c-1" id="f-837">&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Information regarding changes in accumulated other comprehensive loss, including noncontrolling interests, by components for the three months ended June 30, 2023 and 2022 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.757%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.042%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.657%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.042%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.228%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.042%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.657%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.042%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.800%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.333%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Adjustments, Net of Tax&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized Losses on Net Investment Hedges, &lt;br/&gt;Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized  Gains (Losses) on Cash Flow and Other Hedges, &lt;br/&gt;Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized Losses and Other Components of Benefit Plans, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Accumulated Other Comprehensive Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance, March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(847)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(905)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;&#x207d;&#xb2;&#x207e;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts reclassified to earnings and other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: amounts attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) attributable to McKesson&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance, June 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(780)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(848)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Primarily results from the conversion of non-U.S. dollar financial statements of the Company&#x2019;s operations in Canada and Europe into the Company&#x2019;s reporting currency, U.S. dollars.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Amounts recorded for the three months ended June 30, 2023 includ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;e l&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;osses of $20 million related to net investment hedges from cross-currency swaps, which are net of income tax benefit of $5 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.711%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.025%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.655%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.025%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.225%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.025%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.798%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.025%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.798%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.313%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Foreign Currency Translation Adjustments, Net of Tax&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Net Investment Hedges, &lt;br/&gt;Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized Gains on Cash Flow and Other  Hedges, &lt;br/&gt;Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) and Other Components of Benefit Plans, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Accumulated Other Comprehensive Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance, March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,504)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(67)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,534)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(176)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;&#x207d;&#xb2;&#x207e;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts reclassified to earnings and other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: amounts attributable to noncontrolling interests&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income attributable to McKesson&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance, June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(997)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(948)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Primarily results from the conversion of non-U.S. dollar financial statements of the Company&#x2019;s operations in Canada and Europe into the Company&#x2019;s reporting currency, U.S. dollars.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Amounts recorded for the three months ended June 30, 2022 include gains of $64 million related to net investment hedges from Euro-denominated notes and gains of $12 million related to net investment hedges from cross-currency swaps. These amounts are net of income tax expense of $31 million.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Primarily included adjustments for amounts related to the sale of the U.K. disposal group, as discussed in more detail in Financial Note 2, &#x201c;Business Acquisitions and Divestitures.&#x201d; These amounts were included in the fiscal 2022 calculation of charges to remeasure the assets and liabilities held for sale to fair value less costs to sell recorded within &#x201c;Selling, distribution, general, and administrative expenses&#x201d; in the Consolidated Statements of Operations.&lt;/span&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-238" decimals="-6" id="f-838" unitRef="usd">-847000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-239" decimals="-6" id="f-839" unitRef="usd">-14000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-240" decimals="-6" id="f-840" unitRef="usd">-36000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-241" decimals="-6" id="f-841" unitRef="usd">-8000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-242" decimals="-6" id="f-842" unitRef="usd">-905000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-243" decimals="-6" id="f-843" unitRef="usd">67000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-244" decimals="-6" id="f-844" unitRef="usd">-15000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-245" decimals="-6" id="f-845" unitRef="usd">7000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-246" decimals="-6" id="f-846" unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-247" decimals="-6" id="f-847" unitRef="usd">57000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-243" decimals="-6" id="f-848" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-244" decimals="-6" id="f-849" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-245" decimals="-6" id="f-850" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-246" decimals="-6" id="f-851" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-247" decimals="-6" id="f-852" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-243" decimals="-6" id="f-853" unitRef="usd">67000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-244" decimals="-6" id="f-854" unitRef="usd">-15000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-245" decimals="-6" id="f-855" unitRef="usd">7000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-246" decimals="-6" id="f-856" unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-247" decimals="-6" id="f-857" unitRef="usd">57000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest contextRef="c-243" decimals="-6" id="f-858" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest contextRef="c-244" decimals="-6" id="f-859" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest contextRef="c-245" decimals="-6" id="f-860" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest contextRef="c-246" decimals="-6" id="f-861" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest contextRef="c-247" decimals="-6" id="f-862" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-243" decimals="-6" id="f-863" unitRef="usd">67000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-244" decimals="-6" id="f-864" unitRef="usd">-15000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-245" decimals="-6" id="f-865" unitRef="usd">7000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-246" decimals="-6" id="f-866" unitRef="usd">-2000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-247" decimals="-6" id="f-867" unitRef="usd">57000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-248" decimals="-6" id="f-868" unitRef="usd">-780000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-249" decimals="-6" id="f-869" unitRef="usd">-29000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-250" decimals="-6" id="f-870" unitRef="usd">-29000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-251" decimals="-6" id="f-871" unitRef="usd">-10000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-252" decimals="-6" id="f-872" unitRef="usd">-848000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax contextRef="c-253" decimals="-6" id="f-873" unitRef="usd">-20000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-244" decimals="-6" id="f-874" unitRef="usd">-5000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-254" decimals="-6" id="f-875" unitRef="usd">-1504000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-255" decimals="-6" id="f-876" unitRef="usd">10000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-256" decimals="-6" id="f-877" unitRef="usd">27000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-257" decimals="-6" id="f-878" unitRef="usd">-67000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-258" decimals="-6" id="f-879" unitRef="usd">-1534000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-259" decimals="-6" id="f-880" unitRef="usd">-176000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-260" decimals="-6" id="f-881" unitRef="usd">45000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-261" decimals="-6" id="f-882" unitRef="usd">18000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-262" decimals="-6" id="f-883" unitRef="usd">12000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax contextRef="c-263" decimals="-6" id="f-884" unitRef="usd">-101000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-259" decimals="-6" id="f-885" unitRef="usd">-730000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-260" decimals="-6" id="f-886" unitRef="usd">17000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-261" decimals="-6" id="f-887" unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-262" decimals="-6" id="f-888" unitRef="usd">-24000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax contextRef="c-263" decimals="-6" id="f-889" unitRef="usd">-737000000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-259" decimals="-6" id="f-890" unitRef="usd">554000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-260" decimals="-6" id="f-891" unitRef="usd">28000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-261" decimals="-6" id="f-892" unitRef="usd">18000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-262" decimals="-6" id="f-893" unitRef="usd">36000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-263" decimals="-6" id="f-894" unitRef="usd">636000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest contextRef="c-259" decimals="-6" id="f-895" unitRef="usd">47000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest contextRef="c-260" decimals="-6" id="f-896" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest contextRef="c-261" decimals="-6" id="f-897" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest contextRef="c-262" decimals="-6" id="f-898" unitRef="usd">3000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest contextRef="c-263" decimals="-6" id="f-899" unitRef="usd">50000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-259" decimals="-6" id="f-900" unitRef="usd">507000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-260" decimals="-6" id="f-901" unitRef="usd">28000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-261" decimals="-6" id="f-902" unitRef="usd">18000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-262" decimals="-6" id="f-903" unitRef="usd">33000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-263" decimals="-6" id="f-904" unitRef="usd">586000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-264" decimals="-6" id="f-905" unitRef="usd">-997000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-265" decimals="-6" id="f-906" unitRef="usd">38000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-266" decimals="-6" id="f-907" unitRef="usd">45000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-267" decimals="-6" id="f-908" unitRef="usd">-34000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-268" decimals="-6" id="f-909" unitRef="usd">-948000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax contextRef="c-173" decimals="-6" id="f-910" unitRef="usd">64000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax contextRef="c-269" decimals="-6" id="f-911" unitRef="usd">12000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax contextRef="c-260" decimals="-6" id="f-912" unitRef="usd">31000000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsTax>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c-1" id="f-913">Segments of Business&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reports its financial results in four reportable segments: U.S. Pharmaceutical, RxTS, Medical-Surgical Solutions, and International. The organizational structure also includes Corporate, which consists of income and expenses associated with administrative functions and projects, and the results of certain investments. The factors for determining the reportable segments include the manner in which management evaluates the performance of the Company combined with the nature of the individual business activities. The Company evaluates the performance of its operating segments on a number of measures, including revenues and operating profit (loss) before interest expense and income taxes. Assets by operating segment are not reviewed by management for the purpose of assessing performance or allocating resources.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products in the U.S. This segment provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices. In addition, the segment sells financial, operational, and clinical solutions to pharmacies (retail, hospital, alternate sites) and provides consulting, outsourcing, technological, and other services.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The RxTS segment helps solve medication access, affordability, and adherence challenges for patients by working across healthcare to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies. RxTS serves our biopharma and life sciences partners, delivering innovative solutions that help people get the medicine they need to live healthier lives. RxTS also offers prescription price transparency, benefit insight, dispensing support services, third-party logistics, and wholesale distribution support across various therapeutic categories and temperature ranges to biopharma customers throughout the product lifecycle.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home health care agencies. This segment offers national brand medical-surgical products as well as McKesson&#x2019;s own line of high-quality products through a network of distribution centers in the U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The International segment includes the Company&#x2019;s operations in Canada and Europe, bringing together non-U.S.-based drug distribution services, specialty pharmacy, retail, and infusion care services. The Company&#x2019;s Canadian operations deliver medicines, supplies, and information technology solutions throughout Canada and includes Rexall Health retail pharmacies. The Company completed the divestitures of the U.K. disposal group in April 2022 and the E.U. disposal group in October 2022, as discussed in Financial Note 2, &#x201c;Business Acquisitions and Divestitures.&#x201d; The Company&#x2019;s remaining operations in Europe provide distribution and services to wholesale, institutional, and retail customers in Norway where it owns, partners, or franchises with retail pharmacies. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial information relating to the Company&#x2019;s reportable operating segments and reconciliations to the condensed consolidated totals was as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.531%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.574%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Segment revenues &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prescription Technology Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical-Surgical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Segment operating profit (loss) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Pharmaceutical &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prescription Technology Solutions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical-Surgical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate expenses, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(6) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(204)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from continuing operations before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Revenues from services on a disaggregated basis represent approximately 1% of the U.S. Pharmaceutical segment&#x2019;s total revenues, less than 37% of the RxTS segment&#x2019;s total revenues, less than 1% of the Medical-Surgical Solutions segment&#x2019;s total revenues, and less than 1% of the International segment&#x2019;s total revenues. The International segment reflects foreign revenues. Revenues for the remaining three reportable segments are derived in the U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Segment operating profit (loss) includes gross profit, net of total operating expenses, as well as other income, net, for the Company&#x2019;s reportable segments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;The Company&#x2019;s U.S. Pharmaceutical segment&#x2019;s operating profit includes the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt"&gt;cash receipts for the Company&#x2019;s share of antitrust legal settlements of $118 million for the three months ended June 30, 2023; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt"&gt;a charge of $32 million and a credit of $13 million related to the last-in, first-out (&#x201c;LIFO&#x201d;) method of accounting for inventories for the three months ended June 30, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;The Company&#x2019;s RxTS segment&#x2019;s operating profit for the three months ended June 30, 2023 includes a fair value adjustment gain of $28&#160;million, which reduced the Company&#x2019;s contingent consideration liability related to the RxSS acquisition, as discussed in more detail in Financial Note 2, &#x201c;Business Acquisitions and Divestitures.&#x201d;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;The Company&#x2019;s International segment&#x2019;s operating loss for the three months ended June 30, 2022 includes charges of $94 million to remeasure the assets and liabilities of the E.U. disposal group to fair value less costs to sell, as discussed in more detail in Financial Note 2, &#x201c;Business Acquisitions and Divestitures.&#x201d;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(6)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Corporate expenses, net includes the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt"&gt;restructuring charges of $40 million for the three months ended June 30, 2023 for restructuring initiatives as discussed in more detail in Financial Note 3, &#x201c;Restructuring, Impairment, and Related Charges, Net;&#x201d; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt"&gt;a gain of $106 million for the three months ended June 30, 2022 primarily related to the effect of accumulated other comprehensive loss components from the E.U. disposal group, as discussed in more detail in Financial Note 2, &#x201c;Business Acquisitions and Divestitures.&#x201d;&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-914"
      unitRef="segment">4</us-gaap:NumberOfReportableSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="c-1" id="f-915">&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial information relating to the Company&#x2019;s reportable operating segments and reconciliations to the condensed consolidated totals was as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.531%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.572%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.574%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended June 30, &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Segment revenues &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prescription Technology Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical-Surgical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,549&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,483&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Segment operating profit (loss) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Pharmaceutical &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prescription Technology Solutions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Medical-Surgical Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate expenses, net &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(6) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(204)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income from continuing operations before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:2pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:2pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Revenues from services on a disaggregated basis represent approximately 1% of the U.S. Pharmaceutical segment&#x2019;s total revenues, less than 37% of the RxTS segment&#x2019;s total revenues, less than 1% of the Medical-Surgical Solutions segment&#x2019;s total revenues, and less than 1% of the International segment&#x2019;s total revenues. The International segment reflects foreign revenues. Revenues for the remaining three reportable segments are derived in the U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Segment operating profit (loss) includes gross profit, net of total operating expenses, as well as other income, net, for the Company&#x2019;s reportable segments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;The Company&#x2019;s U.S. Pharmaceutical segment&#x2019;s operating profit includes the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt"&gt;cash receipts for the Company&#x2019;s share of antitrust legal settlements of $118 million for the three months ended June 30, 2023; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt"&gt;a charge of $32 million and a credit of $13 million related to the last-in, first-out (&#x201c;LIFO&#x201d;) method of accounting for inventories for the three months ended June 30, 2023 and 2022, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;The Company&#x2019;s RxTS segment&#x2019;s operating profit for the three months ended June 30, 2023 includes a fair value adjustment gain of $28&#160;million, which reduced the Company&#x2019;s contingent consideration liability related to the RxSS acquisition, as discussed in more detail in Financial Note 2, &#x201c;Business Acquisitions and Divestitures.&#x201d;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;The Company&#x2019;s International segment&#x2019;s operating loss for the three months ended June 30, 2022 includes charges of $94 million to remeasure the assets and liabilities of the E.U. disposal group to fair value less costs to sell, as discussed in more detail in Financial Note 2, &#x201c;Business Acquisitions and Divestitures.&#x201d;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(6)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.52pt"&gt;Corporate expenses, net includes the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt"&gt;restructuring charges of $40 million for the three months ended June 30, 2023 for restructuring initiatives as discussed in more detail in Financial Note 3, &#x201c;Restructuring, Impairment, and Related Charges, Net;&#x201d; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:14.85pt"&gt;a gain of $106 million for the three months ended June 30, 2022 primarily related to the effect of accumulated other comprehensive loss components from the E.U. disposal group, as discussed in more detail in Financial Note 2, &#x201c;Business Acquisitions and Divestitures.&#x201d;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-98" decimals="-6" id="f-916" unitRef="usd">67160000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-270" decimals="-6" id="f-917" unitRef="usd">56947000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-99" decimals="-6" id="f-918" unitRef="usd">1244000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-271" decimals="-6" id="f-919" unitRef="usd">1066000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-100" decimals="-6" id="f-920" unitRef="usd">2611000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-272" decimals="-6" id="f-921" unitRef="usd">2592000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-101" decimals="-6" id="f-922" unitRef="usd">3468000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-273" decimals="-6" id="f-923" unitRef="usd">6549000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-6" id="f-924" unitRef="usd">74483000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-7" decimals="-6" id="f-925" unitRef="usd">67154000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingIncomeLoss contextRef="c-64" decimals="-6" id="f-926" unitRef="usd">827000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-69" decimals="-6" id="f-927" unitRef="usd">696000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-65" decimals="-6" id="f-928" unitRef="usd">231000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-70" decimals="-6" id="f-929" unitRef="usd">144000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-66" decimals="-6" id="f-930" unitRef="usd">227000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-71" decimals="-6" id="f-931" unitRef="usd">256000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-67" decimals="-6" id="f-932" unitRef="usd">57000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-72" decimals="-6" id="f-933" unitRef="usd">-6000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-274" decimals="-6" id="f-934" unitRef="usd">1342000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-275" decimals="-6" id="f-935" unitRef="usd">1090000000</us-gaap:OperatingIncomeLoss>
    <mck:CorporateOperatingExpenseandOtherIncomeNet contextRef="c-1" decimals="-6" id="f-936" unitRef="usd">204000000</mck:CorporateOperatingExpenseandOtherIncomeNet>
    <mck:CorporateOperatingExpenseandOtherIncomeNet contextRef="c-7" decimals="-6" id="f-937" unitRef="usd">39000000</mck:CorporateOperatingExpenseandOtherIncomeNet>
    <us-gaap:InterestExpense contextRef="c-1" decimals="-6" id="f-938" unitRef="usd">47000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-7" decimals="-6" id="f-939" unitRef="usd">45000000</us-gaap:InterestExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-6" id="f-940" unitRef="usd">1091000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-7" decimals="-6" id="f-941" unitRef="usd">1006000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <mck:RevenueDerivedFromServicesPercentage contextRef="c-64" decimals="2" id="f-942" unitRef="number">0.01</mck:RevenueDerivedFromServicesPercentage>
    <mck:RevenueDerivedFromServicesPercentage contextRef="c-65" decimals="2" id="f-943" unitRef="number">0.37</mck:RevenueDerivedFromServicesPercentage>
    <mck:RevenueDerivedFromServicesPercentage contextRef="c-66" decimals="2" id="f-944" unitRef="number">0.01</mck:RevenueDerivedFromServicesPercentage>
    <mck:RevenueDerivedFromServicesPercentage contextRef="c-67" decimals="2" id="f-945" unitRef="number">0.01</mck:RevenueDerivedFromServicesPercentage>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-276"
      decimals="INF"
      id="f-946"
      unitRef="segment">3</us-gaap:NumberOfReportableSegments>
    <us-gaap:ProceedsFromLegalSettlements contextRef="c-1" decimals="-6" id="f-947" unitRef="usd">118000000</us-gaap:ProceedsFromLegalSettlements>
    <us-gaap:InventoryLIFOReservePeriodCharge contextRef="c-64" decimals="-6" id="f-948" unitRef="usd">32000000</us-gaap:InventoryLIFOReservePeriodCharge>
    <us-gaap:InventoryLIFOReservePeriodCharge contextRef="c-69" decimals="-6" id="f-949" unitRef="usd">-13000000</us-gaap:InventoryLIFOReservePeriodCharge>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-1" decimals="-6" id="f-950" unitRef="usd">-28000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown contextRef="c-277" decimals="-6" id="f-951" unitRef="usd">94000000</us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown>
    <us-gaap:RestructuringCharges contextRef="c-68" decimals="-6" id="f-952" unitRef="usd">40000000</us-gaap:RestructuringCharges>
    <us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown contextRef="c-278" decimals="-6" id="f-953" unitRef="usd">-106000000</us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-1" id="f-954">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-1" id="f-955">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-1" id="f-956">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-1" id="f-957">false</ecd:Rule10b51ArrTrmntdFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>80
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( ,J+ E<'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " #*BP)7C'YBR^T    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M2L0P$(9?17)O)TU!)'1[6?&D(+B@> N3V=U@TX9DI-VWMXV[740?P&-F_GSS
M#4R#0>,0Z3D.@2([2C>3[_JD,6S$D3EH@(1'\B:5<Z*?F_LA>L/S,QX@&/PP
M!P(EY2UX8F,-&UB 15B)HFTL:HQD>(AGO,45'SYCEV$6@3KRU'."JJQ M,O$
M<)JZ!JZ !<84??HND%V)N?HG-G= G)-3<FMJ',=RK'-NWJ&"MZ?'E[QNX?K$
MID>:?R6G^11H(RZ37^OM_>Y!M$JJNI!WA50[5>E::EF]+ZX__*["?K!N[_ZQ
M\46P;>#77;1?4$L#!!0    ( ,J+ E>97)PC$ 8  )PG   3    >&PO=&AE
M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X?
MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@
MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?<D3$L/<@HL(2W@4R]9<
MX%L:+R/6ZK3;W5:$:6RA&$=D8'U>+&A T%116F]?(+3E'S/X%<M4C66C 1-7
M02:YB+3R^6S%_-K>/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1
MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP
M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?=
MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP
M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%,
M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I
MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88<G;CL3<CH<9T)\S_;VD:4E
M,L_O^0KK3CQG'U:6L%W/S^2>C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ
MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A
M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;S<HY=8%0&7&-\TJC4LQ=9XE<#QK9P\
M'1,2S90+!D&&ER0F$JDY?DU($_XKI=K^G-- \)0O)/I*D8]ILR.G=";-Z#,:
MP4:O&W6':-(\>OX%^9PU"AR1&QT"9QNS1B&$:;OP'J\DCIJMPA$K0CYB&38:
M<K46@;9QJ81@6A+&T7A.TK01_%FL-9,^8,CLS9%USM:1#A&27C="/F+.BY 1
MOQZ&.$J:[:)Q6 3]GE[#2<'H@LMF_;A^AM4S;"R.]T?4%TKD#R:G/^DR- >C
MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_
M+GW/I>^Y]#VATK<W(WUGP=.+6]Y&;EO$^ZXQVM<T+BAC5W+-R,=4KY,IV#F?
MP.S]:#Z>\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE"<M4TV4WBA*>
M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT
ML<QP3A[+##MG/)(=MG>@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3
M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.'
M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\
M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^
M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON<K2<15.+]%,[82EQB\X^;'
M<4Y3N!)VM@\",KF[.:EZ93%GIO+?+0P)+%N(61+B35WMU>>;G*YZ(G;ZEW?!
M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4<!A87,N10[I*0
M!A,!S93)1/ "@F2F'("8^@N]\@RY*17.K3XY?T4L@X9.7M(E$A2*L P%(1=R
MX^_ODVIWC-?Z+(%MA%0R9-47RD.)P3TS<D/85"7SKMHF"X7;XE3-NQJ^)F!+
MPWING2TG_]M>U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83
M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL'
M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M4L!+ GLGXICW?V'4C"FXN)1_2FTB,L5B\G>TW%\9.&*_ZW@#C)NQ!Q=7]2*
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M1:IOQ.-GOC6H(AB+5%5_T>,6ZPU07"@MLNU@8) E>?V?/6T=L3, ^ST#R'8
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M159=KCF#D"T!\/M2"/UR4W[P:3[PS?X'4$L#!!0    ( ,J+ E>4M Z_"P,
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M$43@"^4"R\<"/(@BY4GR^%TZU:J8"K@^7GG_DHN78IXP!X]&OT@@PH'6TU
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MKRAV,C6$4H&J\98QG3KBS,@TNO<A1W? 6P?7^IZINQ8T=Q=*<Z$T#TKSH;0
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M26)D>I]+GH'21V3TL&;FB?SJ+;11^*Y_'ZI>Q=X^S&Y[_5*7-(6NA\VL06W
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MKD"92FIU;#EC9I3MF)&%GJ00T(KLCFY+,>B4#NJB&].X"F@Q"HBDZ7.,X@T
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MI1?E@L<-'Q_7XW"-M3Q>I%F[RQ+"I@(_*O<-'C\3*$'AL<QXZBGR-4\TKO"
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M*CKJ>X*+D3](2KBF<Z9=A(RD)F)@I7@')B&SS"2K]9N0FJD-Q/< -CG)2";
MW4S33TF$UX5,&+:,BBG1I^F,DHFY:\#)T)3 C%8%3'9S703 \RJ9YR8SL[N
M/E+<<%=$4H!4H<FCE(!'_P@R(EBU29GD#;E:NP N,V-21D6.O),ZU [$S]43
M* T84WFE<@#-AXIOD]]3:@M=R-?;(N3CM"1:6[$O%[E 3"QW!_2;(4Q8PG7S
M,3=+#5SF!>ADIJ>AX#H%9D=P;9O :.DA?4!8=DK4H%U;$2,I@9'GM;B"RUMR
M>V&<B@QN:F"#&\9)GB8TV, ^%X%#980^Z+GOB9= #G2'?C\5CZ[RROAN3YPS
MGKDJQAE<.7#:W=)+4O81\.:<H5:E>^)Z(\5\BNJ.T-X5Q"DOMR4"V,=GXXGJ
M;>:I&(Y7KMJQ'3U2!SXYK)7G]+Q<J!3K1Q"( W;%L;A:<RSEQ#INQ(>C>H[V
M H].]Z+0G9S+E6]/6L< 1?B'YEDM=U!M?/GI"BU4PGE5-U0?$V^HGQH]T%#)
M+I^DK'QS>2[><%.0@!?UH')R4-,</*QI#K$0U))-$E2O=QZUNBU@7[Q)V*RX
MR*RP5HK7]\E;W#!YG:Q?#L8']7R(LSBT6N[+^..G6CQR:Q27QXZ19W/$5)Y3
M^U -O<JY7:68;,E<3Q(J-_+[ V)Q"6_ ()]53G(JQ4V?3)<,\ G]1>]'7#)
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MCR"1ZZXC"*RH*JBP"@IE58EK*.<ZA  Y:-:W")X4;*3>E#IX>U\"G9?$MDO
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M>[/@GU2^E:47\'QJ$'CQ@A:H/Z \^P]02P,$%     @ RHL"5YE:RWD!!P
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M6R:,+R?-1B+4@HZZ0Q^G$(8]"]MGHH ([HG"=/IUHA"/OWD4]IV!C#J'6KE
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ML\2_ ^38 ,\+:\/^@@.T_V#,_P%02P,$%     @ RHL"5]Q[^\26!   [ L
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MLH0PQ]18!$:O9YQBGEL@HO&MQ@P:DU9Q^WN#_I/SG7R9,8U3F7_EF5F.@T$
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M^W[NK:T)C'X="S=GVK\G5:X?QIK=9I2]\A/<J[B?@^^86G#BD>.<5*.PWPU
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M\+2MD[*?'M9)6H+#E-H8>*,41C)GZ%",)J/7?41AJV[0>-WX-52U$5!'^,9
M,U 4TRMG$AUSN-[)!"U>B3NB!0B9KXX/Z[6R%$/Q(?,A#!T'\6HI1_-/\T21
M'BGR$C",8)<7)0./]RX8"BFLC72.B,K4E/ /8J>S41.]%[1?B &+L;K@[$L.
M[L&]CS>ZI_=>/+DWQ-I[T]:(AMDH;A$[#:32^L9('ZL@WS%[V*^H8.A354BK
M?I-9&$_8B-P.'N$=[%82J'M4T@XH*:#"/+8[8GY@#L5':R*E8@<81@H81$%9
MD[(5VKF2X1#:2' C4QR;&%R(XN1\9ZR"K1YR A;6[>"2.)TN+^H(HE1[00DE
MMIP<6%-%>-CN$:(L=*+_ZS'6@)\DR*Z\\J9VPM3@;7N!3(DUJHN?Y"5Z +5X
M0 #>5C'G'(;BI/6\M+MEOZSP+&OW@.?H2@_.LQZ<BZWT;>5>HD*1WT)10PA]
M7T:1RJG:*&2-#Z6EK-46H[ZCT"P^L[0O9_$":G$( =E#EZ0CEJ\>2"E\3AY#
MV&&.N+4,YR!\3$G?2KNI,6$5'>#(U5YH&G<& J!MFJ&F?5UD]8I,+RW7"UO@
M$]UH_*Z$0JV\ESKAU%%$-BI3%M4<&0O3T-XH-+EQ!*B?J3[ NXG![FG)OG6^
M]E# BZW,OCJA_O*%RA *WA_"BWH 6>99P9.L)*)X?'>=47=7<09BX?&1@MBM
M5 =U/E8X I\5YHS^]Y']LR80&Y IRYDGJUDID]2JE%$&U@4K!5X7&H\HA+PC
M:<"Q%N%C)YU&[6(8,^ 07W+6$Z4FPA4?<*7?M,-*ON2$KD(DX%D@TB,1R\=Z
M=[((TB+%F*?M,['H+L"'5+78?6L2X+O.J,QSC('0/O=2W1U=%$1$7*E4*-VS
MO4$'P2J2;DL#8X?=U(#,)GD*,@:^I4]R:8M!DP.."W^,M;1'ZB<Y-YN0PS#P
MJ:1M62<^EYH2'D:#GVVI_*K.>&\HP% H4R2?*! ^HTZ%1$&>IKG'%)3#'I$G
MI3NJG7Q6<HUW^ @MEA)<6EV D? P0;=HU =2T85-J,VGH(,AM_:[^,& J)@(
M,/>DCEBN%&@MF6\M.$<6UO3KAO<A#BM! '?9QLI8?5NV?8/Q6+^'ORGU0R^/
MUD U U"RHT'J$S]UXGI#PY,.)ZU^&?P_XNU++GWF%4W8<MAEXH&?$FVW=J9,
MJ L#'G^5FBH?T:%,D\'<[^A!W>)]E85J+CQU005PTZ&%X]'XQ\J/O8ETB.:X
M$HZ'JG@>*68@5F7!1>EQRPV,-B/8D3ZK*EM]X]D'BE6);Z9'>DW%!()A:(/_
M:4UB]4#3CT\YI!2A9OJIF;#4] LXBG58Y5H8&82T//KZZ[<"\BUJB/% I(IG
M'K4%='/NZ'1!N:*P%KX-AC:OB1 Y!_H\H/  X(D&(>+FH"B&%$F#R9JH,VIX
M:B6CKZ+ W'!^SCIV37&R G8B0;R>*!7\0C+9WH2G>1,Y2$+_7L 39[B:,%-=
MN!<D JCN%5$WXG'^)I(F[;VF*U/,QZ=(0\W_%\_Q?VZ3GJX$!%,ZJQINQ6H/
MH&WBX!D#,:"42C6JS:IFZQ%"T.963_C3$/ VPV2XH_#D9F/5AI#(MUJ0JJ?^
MZ:0YP#5'K,,Q0[*;>H#DQ;B6/%2+7>[DZ[LEWROUY25?\P2Y/7W/%7/%N&KU
M!PPXR#*?\9DR!D&R(4C2 W],5@_464OMMBGC]:[/,6_['+-ES3X _<P*T"/\
M'+&K"U>-!?>&VL$C+ ,SU&1L#:O"HEB4:IW!FZKR_*G:K67?84*/\UV0K*D]
MWV)X-3R+VK<V-#:R*H6NI!:IE6?TS9E%/GJY]=%FO<?23Q>SB^_"'\PI,)H0
M8'^$&02.>!AP_)RF4TN%/]-JVS_\5 R#QX9'XK&H,&NH  A/';GSMPZ!0W'-
MX.'1Y0%03T,*M-L#0P= -8MO6]F@Y5#Z#YXI6PO91W_HTB&C]8DKKH=G:UA\
M5Z51A/U]U09HH ._V61\E@[7#@>DVH<UN4)FZK%<;"VJ(_7?VE"1Q;WK-3+M
M=-FY^*HOM@(["I527W^$RX/_[_+JKL!_55%\R$.[1I8_H<R3>X++#;@5DOQ>
M1CKQWU^@H=0WR_[>=]+M$CRSF?,A7;+2<(W1X/?J5?RDM\=C5?$#SS1XRM)=
M)HCA(P9>Q*:?SH:C^M9QK>_5&5W>@&QDVMC6@3#RNM=!=SA?BM-I<T?9&EN.
M[L%2#^IP-O9BB.N-S&0,LA1N4C%KWZ$6D704%/48%R[(?;G3Y;K'SR$7Z=1,
M7_K&95)15P:[;L66ON\XH@$C*)&1B@_F&P>=>VTPR?Y^Q ;"8T5R)[BCR>;-
MXZ8T7@ZX?%(/YUYJ1T^GMN$I3\2AM1/?NH5 [*ED'43VZN,^D8\L?!-=MR/U
M /=ZMRU[0>5=JN-69EIWX=TNM6]$7-IJMCU3Y9-!.*"' ="Y 1>!6?,IN*)[
MP3?8_JWV[:/EV^V;/F->9^W^5P3=5N"OYO?.&41F(^ \D[3!<=.)6J<X3$0X
M,XB/$DVJ0SUI2GNF+OW%K5^8\T*T#IQ84P*6*W.:>QQ1^O$">1/)7%-O#V=(
MW[S#%R3A/N;8E=B7VNZP3X_;T]&9KF]$F9,%G?K370:_9WGFI^WMMZ>MN[E'
M1IB :!5$<4X7\WJTE'W;OV<OW^];.*RNM@X#LM[AF[Y.ZFH^')AV[(:'OO\_
M;_U*@P^B]%L4'.8(T?X'&_73^N<NU_Y7'LUR_UL9V+<A>"5J#=$1#@\GPOK?
MG_@WA<GY-Q\K4^"DR"^W"F<O2POP^=K Y/"&-JA_!'3U/U!+ P04    " #*
MBP)7',.V6;<-   9+P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6S5
M6MMRW#82_164HDK95:/17'1Q+-M5LF0ERJX=EV5G'[;V 4-B9K#FD P 2E:^
M?D\WP.N0(]FI)+4/MC@DT&ATG[X"+^XR\]FNE7+BRR9)[<N]M7/Y\\-#&ZW5
M1MIQEJL47Y:9V4B'GV9U:'.C9,R3-LGA;#(Y.=Q(G>Z]>L'OWIM7+[+")3I5
M[XVPQ68CS?UKE61W+_>F>^6+#WJU=O3B\-6+7*[4C7*?\O<&OPXK*K'>J-3J
M+!5&+5_NG4^?OSZB\3S@5ZWN;.-9T$X66?:9?ES'+_<FQ)!*5.2(@L2?6W6A
MDH0(@8W? LV]:DF:V'PNJ5_QWK&7A;3J(DO^I6.W?KGW;$_$:BF+Q'W([GY2
M83_'1"_*$LO_BSL_]@2#H\*Z;!,F@X.-3OU?^27(H3'AV61@PBQ,F#'??B'F
M\E(Z^>J%R>Z$H=&@1@^\59X-YG1*2KEQ!E\UYKE7/ZEXI=.5."?I:*>5?7'H
M0)>^'D:!QFM/8S9 8R[>9JE;6_$FC57<GG\(?BJF9B53KV<["?Y<I&,QGXS$
M;#*;[Z WKS8Y9WKS 7J7RNA;2>H7UZEUI@"JG!4RC<7V_L6EME&2V<(H\>_S
M!88#.?_IDXI?]*A_4;*FYS:7D7JY!W.QRMRJO5???S<]F9SMV-)1M:6C7=0?
MJ;>OI0'Q"+=6(B7 )R+*"F.5R)9B45A,MG;$GR^R32[3>Z&M4%_RS*I8N$SH
MU"ELU DCG6+APF? *E+@V!B51O<8':UENE)^R#(I(E=(LDX[%N=..)A[9XE$
M;S14A5=@Q&C[F9Y-5JS6/*SP[,65@J%5BY\V,GH!MA;D=<:T+1E%F8EE&BE8
MF%LW%_G^NV>SZ>F9%7F6Z.A^U"8'&&1I<D]+\8[$.H@M+PSM':Q?.Q%G&)MF
MCCEJSJ<9@%!,,_!H<Q45B<=B3>!C8\<@@!WHY1+"3!WI@.2:2\,*(G(DD'H)
MC$@9HY:4 !<!B?VN>'^L',(Q/D1&Q=JQ"*'-!L,R=3K2.2DDS=*#7!EV]22H
MQ7T0?%A]+*Z"1B]*C;XI-?J!"#?W ;;B@K@B=DO\D(].8K@X!;B(3^.;,1A)
M$FF\-1+3RR)EATWX\ZO0OJ%DHE,BRA8+JV,MC2; Z#1*"I;PA4PA:IF65$?B
M36&R$1-_;8!QNX:6BS2VPD*JL(C56%SP#BQQM!NQEK21Q&(M(78)-PP2&GS*
M^%:1H6CL/'* 2R^ZECJ%5&D\K 1!@Y L'0/,J#PS#OCJ"*6-#)B;3&S6M+D'
M+(RU;13P%DST$2)D,XY*\\MD2F!+,P!+!@X))KU::K.[AB5&RCCYH%P]G[G)
M5D9N@EC(CB*367M0S;%W,O=KX!LHWDD3-]!/.NZ;P1)>J509F91V#%EDRZ5%
MTD.:RC,'4R/-0 S91@$;X(J"A%"P0R*^--FF3S2T: 8:1F2+1*^\,_LZ@9%]
ME5N'D19D>&R@;)[$&#0(B9$K3-EO/BS,L7B'-0?BWJ6RF,[,0444!8#L]T:3
MI\I8(#&Y+J<=^0Y8'KUZ,_X$6&H+Z&$+*[C@O.VIUS(6P/K\Y.AL.IZ*A4X2
M2KLPG4SPH"D2[$NQEVZP03)J.+44JM$I<<%J6#.3I;C\+W$'#RD*IQ/X.U8I
MOQ=D2JR%P'G7#MND;:D@MKNF40BY G2MAXC' 9$<CF&EX0./J4WX'4W84M="
M)N1>;2GMAL6SAX65)T%&; J\SXZT^L3#8-RH$K00([M<HWXK "'>K%=95#N\
M2!IS3V9_*Y.B4K9?7#J'*%HXN4A4R6O8.V8""2YX16;0* JPGKVM+3=%(N/_
M%@W9DUYFD[/S*"HVA?=4WJ#(T(Q:4P$ 0" CLSQT>B;NUK0@!MV75KQS058C
M"X>(*%NS.N"I.P@![+(03\E/;"_V(+9[M<520U0LE37:H9=O5 6^*6E2T+&<
M!,%9IJ$<JI*@Q]DZD?HE<MD"BD%6/O- &K;LD'_)10;=!0 ?/$(J@VR"DXJ_
M3^-_]/%WGAN=-+@K/1/$D4AK]5)CX?W9"9*DRC=Y;+!WEX] (,D^ /8&E20$
M.R)&O') <E0&&I]RR)CR,2HAV*DA<(.6JG"L2_BA;DHI+.')(@>-F8>;*@B!
MSU^0EP4OPQDEN9FU44IL?.FEJ/02*)Q463C-R%M2RK"A#+*9!?1!G@J3^=G1
M\:0IG%;&5"5,VPH?P2)UM/9ZAL1N=598A"S*N2E[]7GSH"%@"/36Q@?E#*C#
M).MSXJ5Y)VW(4_P SA:K03/83.)S:\\][,.LO)<E[R=])HPYP((*^4*B)0*5
MKWT"N#JXHB1+:A/L,"&'&F76)]L6$*ASXLH=>$P]\<[FJ0=7)[SI1CAN;JD/
M=R$G>218>!\7+0+7G@!KAYUS@J+(/@<\"$#-VKT&T!.884 "MD!UN)?QN]8^
M'N7HGHLGTZ=#KF*?S6DZ.\/3R1&/_,C>_8YS@J9_Y&#FI5#G (\WAH%D"&5G
M<^"<8?%6&L!Y/O6O1F5,].F;-ZC!]"(K'-+'E'/IIJ2VQ-]>MKUD1_Y5N?56
MPD]K=R\N*?D@:;TKV;K\:JW,0+@O7WXRQX?S2Y"^/9@=$=#!W,'L6%SLB^GH
M>#*I'X87;1C-PPL>/14_OG[O%WP6?)$@9]1X')SYYM,'<5ZLB$&P^G.1',#%
MATP4;$XGD\ZO*Z3NKBIUJHY%H'C\5'RZN117:D%T0/%&Y0>S'P1M>08^RK_#
M6X\D?.822GZ\J'^6*8D:<CWRXJ4_5_H+>X4>)D\\DX#0 <#2-"(25; B*E ]
M6F*N"]22>J%$TMO-$%(E8[L%SS%OX<^P3&]PWD1)&LT*4JXP-2YS (UJKVR#
MN*S.PY=M,>7ROLHM,ZQ329P8VC%6IL'YEN.1>5.WQJ<-/ 5P#GV*QO)(.E+J
MGR2]"[:^=I<852&+6E64J'#3)^(4SV_^H,BS=,OWC!GX'Q0W%HG_3MW+VSQP
MV<%R$$+<*W)4L?J@.%Q4=DN<9A.A'+WMV<=L20T6:YYVF5]5Q77JE(8[B227
M\)!7B[,0'Q=@9[V1YG.;//%STD:7XN\LG2!MCP6&6]VLH5"-[-@O@I%)%GWV
M<WS^\87;C/V+>LP5G%LO$+AA>;:@VJ^5,6%&*;H8]@K)>,H&9'XK@'CJ+BP;
MJ<X1-SGQL[#<E"P,PRHT.]_!W5_7[C[4]ULMQMY6R3<7T9V.1[</]_?4TA_;
M&&*IUCCR.^NT:X<++5M56D/-0?(,9>.66%HH=Z=4F!3ZX=RSZH!$=DJV1Q4B
MW'CZ"XK?AS3;+8Y[8=6.CV6WXD\H?[NBK*O?*U+\KTSMVRS"/02F/K\8LES?
M\*7]<#'0(#/H.1X^/['?!O#09O?889X>HN %4&;LPR+^L:ZE>X2UU0[O)HB]
M5+V'3*B22ZINCS^7V )T<UH =^!<HS;RK36R) 1I C:$Z>NNBF,J#*TM2VZO
M]E:2XRL!E/3<+&[)J*)6K4!I%O&V2KD_^36&C6]TY)V@:"T#5+VS6^43JT0O
M6QKR(;6L;#PX:G=4>:.V[?0KO&<S)6Y".P%_$"!^W^*N$<!RH"Z+2RF8ARM<
MKIB?CN%BD#]?4?X<+/6*%:0WWO;QM]W?X4!N/2.[;?@/G&WX-@)WYST&!@X*
MI-&V,O1N@K)ET+6M^Y.=QDZV#SA:KN@6"_G>Q3T'QI!D#+D3V$..2)E2LM),
M1((3J5!>!O[00'G(LP3+[>CXT3AO=>;:0 J+6KFID92&K*EAV1SJ9+CA$510
M>Z2+O@22> U9*2FJ1$:[FBF]7&V\7F=NR]_!J=2.J-[-XUN*01"5]/[R_J+M
M-!C9Y=+94W7 ^0VUW&"F'7!] -,Q/B0.UBB[R^IVCW#N\W;9K95H;_N-OJ87
M7-4]W)%C[Z#7)/<'K5+VV^58_))ZV4Z/FUVH^G1]DR>*)2/R8I'HB(*C8N<;
MG/AL,I]3>XCZLW2*Q*:39V"!/^]3_Z9L]F[)MEN8E.X_-UF$LM0;2!T$FM<_
M @K[ U63*8!J.A'WBK/(#U3[$IVKJO*B8>)T5!K$I5KX,!1&M&ZNC$K,<Z<Y
MCG50FD[]Q35V:5[I#XIKW.KMX%7_B>EE?SN7#&<PWR40^"J8GQPIA@,N9_/P
M+5!1Z)KS%1/O^*I#D#IN-YQQLW_<Z_K:SML7I754V<EOY9=BC4>'%&S+2__=
M[JKM:F+->6JXHH$7_4VNQVEL*YFQ(@0.%<- V:%?MP$VT&7^L>=(H)F5_U^=
M 7QUI[FW];DOGLPF3ZF=NHMB[9CJFQ8[R5+O<Y][/?O<LQQNHDY/Q.R4QU][
MZ=N'D]/N,5I/HDR)4WGKI5OBC%MP,6J%0%CU>UKI51,<'"56M%FZ@*I[CA)>
M^RZ(N.%[O#L/%AIU,);A=LDE5_+U2<(CAK2A<4X':N*?5>3K_AY0;WF93C5<
MWI!60_;U5+Q'\B9AY*7SJ'%QZ T2M$RAVD=[S0;Y#/_FDRG^/VZ]IW?]:U--
M4*WO%VF\"L>)A\WUGAT1JF>CTY.).#T2Y>-U7RO_ZZF7/,]_"$<14R0)>#Q%
M0/^8.:AGGSC !NEHX!D?69P.!M@?1F*OH?&W_J#4WQ;98QTARJN>0&HY/(!-
M3N)J]&X:%,9]5UT/&]>5-PJ5/5W*MOZFH[^Y7+VM[GV?^^O.]7!_:1S@7I%G
M3=024R?CT^,]8?Q%;/_#93E??EYDSF4;?EPK">NB <>T/\@@_* %JMOPK_X'
M4$L#!!0    ( ,J+ E<XFX\/UPD  +\>   9    >&PO=V]R:W-H965T<R]S
M:&5E=#$W+GAM;,59;6\;-Q+^*X0:]%I EFW)=GR)8\!V+VT.21K$;>_#X3Y0
MNY26#9?<D%S+NE]_SY#<-[W83BY /R36+LGA<.:99V:X%RMC/[E"",_N2Z7=
MJU'A??7B\-!EA2BYFYA*:(PLC"VYQZ-='KK*"IZ'1:4ZG!X=G1V67.K1Y45X
M]\%>7IC:*ZG%!\M<79;<KJ^%,JM7H^-1\^*C7!:>7AQ>7E1\*6Z%_[WZ8/%T
MV$K)92FTDT8S*Q:O1E?'+ZY/:'Z8\(<4*]?[S>@D<V,^T<.;_-7HB!022F2>
M)'#\N1,W0BD2!#4^)YFC=DM:V/_=2'\=SHZSS+D3-T;]2^:^>#4Z'[%<+'BM
M_$>S^D6D\YR2O,PH%_YGJSAW=C)B6>V\*=-B:%!*'?_R^V2'WH+SHST+IFG!
M-.@=-PI:_L0]O[RP9L4LS88T^A&.&E9#.:G)*;?>8E1BG;]\S:5E?W!5"_9.
M<%=; 8M[=W'H(9RF'&9)T'44--TC:,;>&>T+Q_ZA<Y$/UQ]"J5:S::/9]?1!
M@?^L]83-CL9L>C2=/2!OUIYT%N3-'C_I3])ERM!A'?OWU=QY"W#\9]>9H\B3
MW2(I8%ZXBF?BU0@1X82]$Z/+[[\[/CMZ^8#")ZW")P])_Q+7?)4@]ELAV(TI
M*Z[7K(P#CF7">L0RX\X)S.$Z9TKRN5322PQSSQ8D[BZ(HWE99FS.=2: 7%^P
MJ]L;]INI9,;.IW#>OKU);M\-DZ!-3W0AA>4V*]8L,Z  AS5FP7QAA6!*W D5
MGJ6N:HSX GJ5?,WF@M5.Y,R;YD1]F=RQA5'@(?>"O249[)@=L,^U\5A269E!
M$=DP!>393V0",!^3.;26&5>-7?"N9Y9)$C>%.">76BXP5WMF?"$L,W."!I^K
M1N8!\4B>E&_6SC;6UKJW+IV35%D5,BNPN?=XCV=MDE26@P"8N ^V(OM:\;F6
MP:=DP1SV)%$X0%U61(G);AQ&ZF\,V_FA+\K.<Q-VU0'C;0\8R;LY(:3G=")>
M]E%DM;52+]DUARO9#7=%$)#1#](2^T18>(:X%VW<AUGO" =L=IQ>29VI.@_V
MNQ/.1SS!;:718MW88E'K/"#DV?G1&8A3J9 #(.W9\>2$S>.+,6SD*A'\K=;C
M9%LRB!65L3X>I[/$%DJQP8YM5P!:+KRP(&R(J!T=?0BS(:@V3C($8%^MQI,1
MXD![ ^,$$&P/P.UW7_1;W@8>6]8R!&\\6<:M79.R[>FX4@G%V[ZJ*FON)3*C
M("0)[-?;-,>_B"2\LD+Q:&/F"MCU@&S#-/=081+A$E:E&&]IZ?OOSJ?'SU^2
M4; ")F(6NS&WXE4\26:-<P>$+J&S=1I88>JV_7=$DS4EXW=<JEYL8C"6.@$>
M$6L]]PT4@6LP%XE?LU8%<9\57"]%,X&TW**!IRH0O.+:^1L(:#CGJYT>M2/>
MU,83FH!ZRF/:!V\%_V>^!D"3=P)?9*96.2LX)LR%H-*,*_E?Z&-LG+!"<$5I
M:0"0#MK5T=\?Q8+T->RUU%!#0OY[&)>=CQDY?'KT\A>1+\GH5Q0(@5_&8>3X
M90B<10\PG7U[=B/:V04CV GPI;.YR2#]%4;E;C,,">P>H"+VBB0'@_P^N9VP
M)5(Y<IWSJ%MA#Y(A&_/P/(<-'9M#JP0+'[2$+VPXU9P 25. %(586L:T0PH7
M,)DO,G*TU#G*/[L.:R,#%!Q\M"-(GTUGSSN.>YQ".UAUYP4O 7]2M?F6!&];
M@'(\:GOR;4Z3FS + -[T2SQ&R]:-=W\-[M)&'[3F"3FE<;%LG =<:TJ4^.6,
M F8I J^Y"M7&+=6\;A]O5?5<R4RM#U#;;>2*AD^)I0GW1&"60+@P,8HJ/)J<
M3!)B0>3C;\SHK7$>H?-X."U\%TJTLM;MXQ*EFJ.Z9H6^AOY*8%%:VI?090E:
M@7SC#G[+[0,7D7,WW81!4X(IH,73_',+\DBT S_\"F/R6&P$'!,U[S1ZK.S*
MV$,(ZB%VP!@_IE]5@;PWL-FP"'FC*51EH N89D^]VU9(94]ZOP @Z9WH.8D>
M[^2>?04U9'/E#-KB^9^H1$@7W==V#Z=/V,]"P[:*ZI9&=BA<J![?K>= ;E"5
M($/Z.S2QH9[>A@_\LS&I&8&FI$PLLY,*F<(/5)*D@ .=(5.0AQUJ!IK?TT@%
M!C14K&( ?;J"9Q_GKFA<!(['(8*>37$;/-F8=KT!^VUW9. V%]V/,WV\O[TE
M8+\W=Z*< _<$M1#V#SE^VZ#[L]NTS6[7#?]?=3HT'1%%IJ0TZ<:C8+G2A C=
M2&WP'(A-.YZU90+C5(N0Z_!FNSK^XF266"&:>XM?^]*?FA-:XMU9G_$^O!$2
M&-:Q#&G8L@]M DZ$4 ?9,:M4'0 +N359=,UB,18LT*N_ F7'\HLD6BC=,V=;
MA3I>AA;+2217;AOCK0?C$OV4L!N56@]\#VGPK0NZOZ:>>[-UYLXG;A,L=.1E
MPUS;AY_M/?*@H9 :N0FO(6+0)\>6@L7^&I'2[VO[C>^<.C8-P)=-=5:[8)^(
M__4!=86T<*L:A_24Q%+9V6:RG3<#7T@?3ZO>8F;><Z'U= YM@IJ7IDZ>HB9O
MW-X!;;9\H5WV0"ZY.4Z%_D(&VV,TMWS15#=9%H56?$VCXW[C-S<6G(.M!_W1
ML!C<3I1=NYDG%!!7QN=^Y3D7&4_>#$':[5L2.KKXQ9Q%R]&HH[RM4VKMMP8M
M4;G-B(QP054?!%0<I<[.RO"Q*Z7>UGMZ_6_;Y6^F0F7T,AHH%W/TGV[ M$"'
M]2'LB7-WUMNTV] NNS+NQC:46_L7<D/0;MSY_(!J+34X[D=VTVP?T=\+A/TC
M;P>[]SO[!G<)'82U9^QT?'9V'/[.9J?A[^G?3^+S^5FPP2[P?<'1]W43Z1*@
M!YV8Y@8(^O]N%9YPH31-POZB&X*?C<G#G.YJ*-""<VU.H>GQDHZ,5VL9C;+]
M^F\N=%"15?I'1[B2242L4)?-EKT2V,/'9(*AG7B;JOH%2Y>>>DDG"Q;:=9.;
MDPA3M=Y_-.^T?#30I($#<2.G<W6=(->I=^M&FT*+F('8.;$X6R "V0^I.OWI
MYG5J]'Y$\9GCH#A6B]8='"A(]-#FDQAN"A#)FW:M?X;:2_([LB-:"EFI3D=*
M(UUHTF;0)^D1H3@X<+J":X*Q63-44 *M>BG3Y7=[:1#!UEG Q4\'"8JH#M0Z
M9.1^/1&N_S#2LQL4^5.DNC&$GO0IX&VX!ZP43]5]4U$_J2A!,Q2^K.!(U.%M
MG*H+!CJ@ZHR=DJ=TNQ&[YU)_U]>JP]Y'1;JY"I].22R $[\OMF_;K[-7\:-D
M-SU^V@69+^F>0HD%EAY-GI^.F(V?2^.#-U7X1#DWWILR_"S03 A+$TZI$0(W
MI@?:H/UF??D_4$L#!!0    ( ,J+ E=$?FYQ7A,  !8W   9    >&PO=V]R
M:W-H965T<R]S:&5E=#$X+GAM;*U;:W,;-[+]*RAM=BNIHBB*DFS%KRI9MC?*
MQK'+2C9UZ];] ,Z ).*9 0W,4.;^^CW=#<R+E.S=ZR\2.8-'O_MT WQVY_S'
ML#:F5I_+H@K/C]9UO7ER<A*RM2EUF+J-J?!FZ7RI:WSUJY.P\4;G/*DL3N:S
MV:.34MOJZ,4S?O;>OWCFFKJPE7GO56C*4OO=2U.XN^='IT?IP0>[6M?TX.3%
MLXU>F5M3_[YY[_'MI%TEMZ6I@G65\F;Y_.CJ],G+<QK/ _YIS5WH?5;$R<*Y
MC_3E)G]^-"."3&&RFE;0^+<UUZ8H:"&0\2FN>=1N21/[G]/J;YAW\++0P5R[
MX@^;U^OG1Y='*C=+W13U!W?WDXG\7-!ZF2L"_U5W,O9B?J2R)M2NC)-!06DK
M^:\_1SGT)ES.[IDPCQ/F3+=LQ%2^TK5^\<R[.^5I-%:C#\PJSP9QMB*EW-8>
M;RWFU2^N75G:&E*N@])5KJY=5=MJA>_J%ZL7MK"U->'928V]:,9)%M=]*>O.
M[UGW3+W%2NN@7E>YR8?S3T!C2^@\$?IR_N""/S?55)W-)FH^FY\]L-Y9R_@9
MKW?VGS*>@5_URH:L<*'Q1OWOU2+4'M;S?X>D()N<']Z$/.I)V.C,/#^"RP3C
MM^;HQ=_^<OIH]O0!%LY;%LX?6OW_H;MOL:ZZ@4_EN67GJIW*1K/<HK K36^#
MLE76>&]R?%#UVBCG<ULA!F!2XP.^+]6B"2 CA D/  D;7>V4#0@7BS_APK2%
M5EOMK:EW-"$KM"UEJ\*L=*$VWF7&8.$5%L&.14.?T[BE=V5T*.-EVM94N?,8
MC C'0^GAQM5@P6(]655GP@+BG\IUB4"%"2NW-;XB7C'"5EL3ZL3K1)@'$QY^
M6M?8;*I^Z[%$KRW):+F$)'4-26J8V49[EBK8) '(YCT>>]PAZH3,VP7DN:"H
M*DM6Z@UD"O/%O%_!A#I5C]-J<>^__>5R?OKX:2 ?4F?JJJH:#/Y@-L[7:J+N
MUC9;J[PS?<N:<Q[O06?4GB59N+JB+18[>8!(:CQ<QPQ9Q9NM73GOFE#L*%9&
M.8-]4RR57B%I!&AV[6 #/5YY'WK68WJJ;NVJLDN;:=AA;K;@?"/6U@Z/\F9Y
MCF0T53?+L64U56BR##:W;$B+'8$3&*BR2]")9UBQ),LD6093UX4A%;,)8KUN
MUPD-+_4.^T$>GQI+]HXY&SR"#8=:BUDA_6$L!O4,VU9_-E5,4U5^@MWQ'A:7
MR1+96L/]U!JJQAY(R)[-AJRH<QO1'ARJR-5:;PV\!9093WOJ'/8*4BUXQX[8
MAN8N6WO9N"!^C)T1IY#1 O$G.Y%53]7O58%MQ+#O+-8"0[")/7=M*KTH#%$-
MC! <?=LI\@\B1DS;T3H>]'EF"QMA_V!I&K\C5Z.!29U[JGRWA(\^L'.K- S1
M-3;B93$$]K2@0:S@!TC4I6M@9:#L +'T:,)$:C%:D)7I1L(8,V@1"-E=!#2Q
M6K?:%DP?&3B-Z@*-62YA!RSQ95.3X\&Z4QC-368#1R!Q-I^G4#&!!4'C.G 4
MC<.]636%KCFL,?-WMB@& C$*ZA56H6I7-*)X(9WYF:JWG8$?T *Y%U9&1B-.
M.8[#&#@P>DVF42$\%C39>0II)+.8-W8L^6#,1U + 27"B)I.Z#'.PF=KTAI"
M#91+^06$DMQCJ& %$O#$6V9E"^(H,H-FT+\S>AQ[O=D2K!.M9H.,#X8*6$.M
M/C40K_$PB8$EW:T-QW11\$>POG8N;TUD36I@-\U9#VDX_!4!"P1])(=L[<UT
M]I:,)AK:P,RFZH^UJ0:&W@](/>/F]);LL6?IT2A&9LXN -*\073/ RV2%"2&
M7;7TY5$OHR16!$=[;"W,HI\R[HA>RVKK[=KZ=Y_D&"M;;(!]OV;VT#_C6FSE
MYC,E"PYMPAB^M'Q-U15/"A$:X-V=A3]5BK+B?/;TNH<G;$KGI%//EEV9F@>>
M/DT@!K H1W5B&"#!^FS.XKJEN"B)"?2]:T,HV5NP@:GNA'O $N%6_ KFYS;6
MV?PX/>G1U4*+FRE 6?N8X9HP<E-MX1&4;@%F:WANZ^B$Y[PK"B)6$A.2X)<P
M"J>4A8%^0D-&$6*ZU#$#L\MEJ(\P*P#IUCWLU>,H']&2=;2$EA:VM5UORTJ7
M>WOJPF$'TF%$6QNHJ@36QMH9HNK=VB%C:9A-NZ> O>$PT-TLD11AO#Z"-V]J
M!.LTT$9ZU ;,0$_+940<E/L3.F126\/BU(B(@@TKLPL*FH45%!,*U%4MXBV;
MRF9V PHZ,$DA/4-8*2+)&3TATC&J2O 22&=C@3OIH]$%V.=X T!%<7G95#F'
M?B2*8TH4.P(@+K&&B&OALX!]PM28!98V="Y@+_*!>4N3$P<IT]1K8+K5&D4^
M>\+OT]MI6E^];Z!\IS[8S(DYZDKGNJ_20'.!E1Q\BI)'#/<]X$QYD]V'4HQ9
M<MV=$VP95@"4='F8\-!'_959H?P@2 J--RA%,E4U-FA^T !NP1%-!1&O2?!"
M? ;1%.RF&XN"#[D*%@?!%O1?PT97M/+6NB)Z= S='W3V$5$9=-]4RZ*A3?-8
M.'G?;&KUSJ]T9?\59UT!@7T?@\Z'F^MW,:S\,#DH[P/NH0I]-Z@S:%Y3DYV^
M'"(1=DJD3FB$;5><TV66W5%\YTLA9@]G43I.2 OTL<VW@;U-(_T<A,@><\4]
M.3 AOC;YM1!E'QE^D> H%%"4ZH(EIQ:"QYKZ0)FGLL<> ):WK0)^<10<_MZZ
M9HJJXRA9W[FXGSBH+L8!IA]]U/<9*9,[44ALT0A>]48D8X!Q@A=V0RY\I?)@
M2O3*&_GT/<DL+G+;#FB78)N&Q='0/YM\Q7-8Z>>78FLAH5'K!5521.+(#6NC
M2!%B2=OY 6WY*D8G229%4RZLYI4T96'XG61KX[VM!0+N44I[_+U?1;^&>9*!
M)NJ1KS<PFL]L!I#5?'(VF\4$TX4J"+>T2#>YA.B^)/$N%UO- <=[EDG&X)$[
M<I=J_MSQP#MMJ6RJ8JE*.VT:'QHJ.&,AW4F9*J(\XL'NZ=!9"!1NM,V[0?>R
MK?2 V^].IS,%>@M.ZAQI?FZ 0E,#3+P_M5\@]IU ("HVOV*S9L/ME.&6CZ:7
M[98QP&.OLTMH@CJ/MFQ*HN/RXJ\IO'1\T\:">4J*K(!U#47LQ:X7TPIVJ4'K
MQ"2"!,JCTD\5F'BY,AL$C=)F7-X6\DHP/\E>8@#/[I)S;')TZ3<]6)IH[YD+
ML5IBF2V,*$FR6<OW["$-#PQ-P"<819H):T;A*#T@?23(D,)D HC1V[K ?MP&
M]B$XPF"=JOI$9U=%1GL,2<^4@I-/XQWMR\;GZZ@L2ZB^ML?P:L1(V@!EIT,R
MAWJQ)%(P2^0/\*'^:3U2'7PZN5 7&TQ"O_N>0$$* VG,P6C%D:>_%R',89PY
MZ#PC,SV?PQK_*\<8N]A9MU)/[Z?#2F=#-:,TL(2KF#=9^G4LX(92@X3FL]-+
MY',W>G.(:T16;UC*7>1TWT3B]\@SHH$1:0.21I(ZN_Q6(C\]/R3R,Q*Y[MM*
M[HP C8BI]W"QBH@A5AB4B/2"4M1U![&9>RM8\:>&2ZS:5;#W9<W"JZDW-ODO
MEYF(WJ@]DW>-[7&C=:FW!%DJ2 S\G[/ YL0MP9*QR('FJ4@B2:2N#R")*TT/
MYMT;2@>+?97?#IKDT2;NJ4JZ+_WR8[]6(=JZL<=M^9@?*$B&;D;Q$)5=2#7^
M6#XIB*<NL6=49ZCM('EFE(](ZBPT4"?=S:UIT_I$+6+E,I!:I*%M,UC?WX[D
MV6T9J8]F\5(37L7+B7J+BJ: '"8$,%'A2).NMT]T%[$^FDP!(>Y#QQW9VN1-
M(=7R@DH.L+6I3;D ,_-';$'GL.$.R+;@F?,B:?,^P^AMX\V2<&AGN;7CA-PU
M)@8-H1'H3NM4W&2N4-VF[D8;Z*E9W=.'CLT7=AK$"!AP[ @\#%6FZE?-NKLJ
MC:?>O_J-$/M!.$X]J0%L/A04#Q81G?O'PJO8<0MIA:H-K\<D4)(VH<,'9*S=
M!@]@P#9='UYQ'"XO'GVKN'L^.Q!WYX_OAW9B#N$K -[7\/4E>#>(!6WP[+4@
MR=3WC+);Z( B&1 =!)O]N'>87L1VJOC)5&"I=^&)^OZF2@(,/PS50!X/#S\[
MC5^OJ9M9U?W"M.B=FGY_^H/Z3EV<7_#?2Q2:U>J86KKW37@T>32_Y+\7ZC?6
MRCT#OU./)Z>/S]K_M%-L\8CS3;JV:-?V?,=1<BS@KA#[0K<3D8^AZRW=0* ,
MX/LG*'T=<C@35XB-5QI7F<^(M2@NH852;@R(T$D[1D.PWH2-5,QJ RTY6 V5
M;%ASJEXU!+/%8-?PO[2$H4L'8V_I>V6I<XKHG56/VR*C=))PP(-XZZ'00BWR
MA@I5I1<PRBF=GC,FN(>VEC!V1&+RNXOYC[UP\$5R'R85<=55QX.0^SZ54(>"
MJPT27W77@N7P/X@SYZC0Q^QSP;[PTO*+2F??7!"VMEMN\K3%6W>F]:W;G**'
M2=2DDQY9(J"M0V.GMMA-VIS?=G4C\8<UWSL=(_WR ;*,CR<(G>_%F!DE.Y4&
MJ47P>5 !J71H1[?@2L[C2#G#COS2-?O6R.I(]QTPJ->=)2'Q:\LG!V8$C/G,
MDKIX<F0\P(=:K:#A#7CD:RZ,D5D)D"=J)VSH-GQNWO61"!K1=JUM+';Q2#!J
M#MXM<$V.48B-<$@P"VH1;_DXG)/M%NZ2KH2T?1PR5>P[DD9W<C^^+4**SXC#
MV,0XI/-H:F0A$;HZ)>=2NKWVD"C@;CI9=GMN\Z[?I+S/JE+8V4]F!U#=R 3W
M88@PE<QY_U2<I;1W\/L4\SS[?[4;M6/'QY4'#QH%J\8+"&T;$E,KLW*UQ+#>
M0?2 AMZ=CJ^]V'"P"MN[Z# AVUNK)65WHJ6PGQJ;I_/I>ZY W-PDM1T^<7M7
MP60S0>JG\TEL O2U@!A@[):%OVGH6DW,$!"='&'0+2J)AFVLK&Q[JABZSNLU
M'<2T*.A7K 2ZJF%G%HZ  2CN)]WI!=<V;[-_&"20JNM@2Q5"QRZ@W2&R9.P7
MUZ_?J9_=NE(_Z1)O8)B1X3=XKDL0]-(8/XEG(B8U.C.D90ZGKS_'JRM70M+I
MCV?GY$^>KQP1/;"]I6WO+FQ-U9AXF WIG2DJMX'<M.=,>?HXWFF@(F*)D"?5
M<&E#8;1<W,D;;I_H2E@&2<@4<CQM\M[9#@U:VL\QJME,SI$X_-M,Y;ZA&T>O
MM[H*J/75>^ =@)SW\3+JFX9NCTT[.5['.U+T<@)M3-79D]/+X]FCB_D%I_IW
M6>VX@$/Y+R:1[GMY CE\7M1K?T#W( HFNY%ND$0'N6LU,!<Z"6ILG0[MX[EX
MBER4!!KJ'.X.NH6M0N,9O6V(OQUE :I NU"TUX;A3)13RSV>W_8N=LAME38#
MF<^4"^3B%V9U+?<O@?TV',E%&\HFGM %S!*D"6[HC>#$"GYW8C;W,LH&3;@>
MU=!I E(3M7!T"+9,C5:RK%[E]Q^ WUBB=<5Z1)[ST3V#+P)NDF,<^QZ.0H 9
MLI0\UI[Y3=-H&-<;L_ -':1V6+)3;::]MQ1 "3*9?)1L)FV*&<I4FDQ]X8*U
MON!Z9S#DMCX,A/6PB(8%TY3B)D/AT_,^5.>C9N *&%,DNW1L\V3K%-$+09];
MZ:(,^1K@Z]DP"),-\%7<B)TU5O.!6A12-B 3J%J7O5#<'HA_=4"^=<U^0/[5
MW*G_<?XC0QTYO)#FX,*L=;%,7,AI^OSQZ(CNGE.W>(?R4"B:=$]O44(A_P$F
M#RZ#_/++M5C @8'7!"L'HP=+#S-*S^\'N>"*CAS^8;./"YU]9)DU-9!).MY^
MPS$\ID_D""&&CO@).TF_4^)\Q#CII#M& 2#%?O<R78;$*KK8R?%K[5S!T S
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M]D?\,CSAERG_/^V-#Z/033@ "";';$^P.,3(A3!3*B>9=$[/ZS%2G$P@%R(
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M87DVX0@;7IPN_+%QIAT>0OUPB:=^,$2 W^=:N_J%%#3_(XS_ U!+ P04
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M1P,/5#-AFXV1E9MJ&VEH1KIE3C\EJ*P ?=]*:0X;:Z#[S5G\ U!+ P04
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MQ2K+I=G'R6&M/SZK*6UZI?*2%P]OWQR'P?C4_$_:LS5'8<.62F+U,2?L-M,
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M"MZ0, @CHJ$VC8)7>*.Y'I'CC2[PGJO!STVN49G^^74N\9$O/L]G9VJM.UI
MZIFAT: .X&4O7RQO@@]7U,:SVO@:>_;0MSDH(BLS'YU42',.QV+H<V)'NI6C
ML_-ZR.+$/YPJ\$]ZJ055NXG1Q%5E;*OY=![*S=B+_]S'B;ZGJF9"$PZ5@0:+
M=R:N&J=D-%!VKC-SB:;/W;8Q#PLHZV#N*RGQ:-@ \U.5_0502P,$%     @
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MVF^M[-HWVV;C7#"8L.3C<UD$M=.@:*Z][Y7M:9/%%C]]@,3:3=MF.WU69-4
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M50-Y?,F8>-I0'51?EL[^ U!+ P04    " #*BP)73<5 NP@$  !&%0  &0
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M+:K+#8(R350-Y/T5I>)04"=C[=%I_"]02P,$%     @ RHL"5RQ\&?85!0
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M/"@I&XKGYB1@R97BF;G<$)P0H1^ ^RL.OS^JAAZ@/JZ:_0M02P,$%     @
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MH&_O?J"^]H=J]P"<I^EIL!Q W]@!03TM$,[^$9RDJ0B+ [1A%P1U&<"Y.+I
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MFTOZT*!V!30_5\IN.VZ!YM.5_ 902P,$%     @ RHL"5VOZ=@:F P  A@X
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M&3:*(,T&_)X*H9\F1D';>D;_ 5!+ P04    " #*BP)7/J4%FWD"  #X!0
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M6B=@NT[HD>5>&<GO)CF[YUMKL'-/T==%A2Y"H':&AW41 L,.$8)K$8+[NZK
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M +A<]+S0>QFX8].9L0-^W)W3*0S!W,]O%?;\0B5A*0C-I" *)CVO'YZ>A<[
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M6\#>,PDHFWS<;/6RH.0K-5:2&;8;&PFO]&9'UE;!VMH'*^(URO!:6WA1/=C
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M\9&6M;Y'0572M)SLM9P8M2QR"76;DTDEC$HYF]K?2.C:_DB8/SD>V#S/K@F
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MBP=UFJ TBJ+IXE5.DV.>?M/FD:@9T5DQJ+OD',^(<:='HR34-"IIAX]%3\S
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M-J .+93F0VD!E!:B:%41E3:MT^CNU0UY"].%?\W3R$\8]4(=7RC-@])\*"V
MTD(4K2J\TO=U3F&C7JC;"Z5Y4)H/I0506HBB5?52NL-.LSU\Z,#G[-EPX-G
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MF>]5R@^T6&9;91Z$UB+)OBX8C9BT-YCK,V'R6G%@"]CL&!O]!U!+ P04
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MX&U;[AV!-9085DH,'?I@AQ*U]CJ$2\85?&1ICO#YA@SAVF"FO[0),.Q2@([
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M3-4R/0U)!UILD@.%)Z&UB)++-1"CMPTPSY="Z/W GE'D9U+3_P%02P,$%
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MCJK&5[4QLG 38"P-SA.WG.'$!V4-\/U$2K/:V*'2_(=(?@-02P,$%     @
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MM>3)YQ7/%JP4WX%+=ILFJ01#<*W&RV*=,<!OP7Q%BR43("W >9*L\W5&)5N
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MJ5 I=AS7C=]L&X<]C2/PF>9BS<&/^8(LVO7'TI#&&KBSY@9:!?Y2Y)< >>\
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MGUA'N=FH;<-E1E3E>"Z];I;7KM];?:4H"MDIZKC4(M*307IJ$>G9H+[4(E*
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M@F;5QS6)Y-I9%I"_+RD5NX>R@>:UQ_G_4$L#!!0    ( ,N+ E=+P&(':0,
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M-AK.E2:(<9[;V@3HF,6]+76NE4>0'PG(C[R0GVJOC?(>"/^JX>'M"4*:0DS
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M^M])]7@^MUPO?UE^[9S<XQ><TVU%??X+4$L#!!0    ( ,N+ E>E?PYQ[@$
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M2P$"% ,4    " #*BP)7C'YBR^T    K @  $0              @ &O
M9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " #*BP)7F5R<(Q &  "<)P
M$P              @ '+ 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0
M   ( ,J+ E>*71'J,08  -@?   8              " @0P(  !X;"]W;W)K
M<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " #*BP)7S+K!FML%  #_&
M&               @(%S#@  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L!
M A0#%     @ RHL"5X:'VQVY P  RPL  !@              ("!A!0  'AL
M+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( ,J+ E<C\]ZZC 8
M .P;   8              " @7,8  !X;"]W;W)K<VAE971S+W-H965T-"YX
M;6Q02P$"% ,4    " #*BP)7E+0.OPL#  !8"@  &               @($U
M'P  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ RHL"5](K
MR2:["0  8UL  !@              ("!=B(  'AL+W=O<FMS:&5E=',O<VAE
M970V+GAM;%!+ 0(4 Q0    ( ,J+ E>_FJ?5FP(  /@%   8
M  " @6<L  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " #*
MBP)79X\MW(4(  "J)@  &               @($X+P  >&PO=V]R:W-H965T
M<R]S:&5E=#@N>&UL4$L! A0#%     @ RHL"5]DH;AF "P  Q1T  !@
M         ("!\S<  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0
M   ( ,J+ E<7:-$9] T  $PI   9              " @:E#  !X;"]W;W)K
M<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ RHL"5YE:RWD!!P  /Q4
M !D              ("!U%$  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q0
M2P$"% ,4    " #*BP)7%6PW]S8%  !L#   &0              @($,60
M>&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( ,J+ E?<>_O$
ME@0  .P+   9              " @7E>  !X;"]W;W)K<VAE971S+W-H965T
M,3,N>&UL4$L! A0#%     @ RHL"5V?BL$C5!0  "@T  !D
M ("!1F,  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " #*
MBP)7VCIGPE\,   0)   &0              @(%2:0  >&PO=V]R:W-H965T
M<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( ,J+ E<<P[99MPT  !DO   9
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M970R,"YX;6Q02P$"% ,4    " #*BP)7-'(6LU0"  "S!0  &0
M    @($HN   >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    (
M ,J+ E=8C2:51 (  (H&   9              " @;.Z  !X;"]W;W)K<VAE
M971S+W-H965T,C(N>&UL4$L! A0#%     @ RHL"5SS7O662"P  1B   !D
M             ("!+KT  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"
M% ,4    " #*BP)7]2'?H;H#  !S"0  &0              @('WR   >&PO
M=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( ,J+ E=S?4 0;P4
M %,0   9              " @>C,  !X;"]W;W)K<VAE971S+W-H965T,C4N
M>&UL4$L! A0#%     @ RHL"5RR63B.  @  ? 4  !D              ("!
MCM(  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " #*BP)7
M9R+(Q< #  #R"   &0              @(%%U0  >&PO=V]R:W-H965T<R]S
M:&5E=#(W+GAM;%!+ 0(4 Q0    ( ,J+ E>-^>6GZ 0  "\+   9
M      " @3S9  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%
M  @ RHL"5XZ*;JSV P  V0@  !D              ("!6]X  'AL+W=O<FMS
M:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " #*BP)7%VM?I@<'  #Q%@
M&0              @(&(X@  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+
M 0(4 Q0    ( ,J+ E?0]5/&IP(   $&   9              " @<;I  !X
M;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ RHL"5X@H _9-
M P  # <  !D              ("!I.P  'AL+W=O<FMS:&5E=',O<VAE970S
M,BYX;6Q02P$"% ,4    " #*BP)7K>M#JQ\&  "/$0  &0
M@($H\   >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( ,J+
M E=#PD9-1P8  $H1   9              " @7[V  !X;"]W;W)K<VAE971S
M+W-H965T,S0N>&UL4$L! A0#%     @ RHL"5_F*L\8L @  M@0  !D
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M=#,Y+GAM;%!+ 0(4 Q0    ( ,J+ E?V1&@YNP,  '41   9
M  " @2L5 0!X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @
MRHL"5Y5>0O!3!0  =A\  !D              ("!'1D! 'AL+W=O<FMS:&5E
M=',O<VAE970T,2YX;6Q02P$"% ,4    " #*BP)7NQT6R-H&  #K,0  &0
M            @(&G'@$ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4
M Q0    ( ,J+ E=[)IOML (  ,8&   9              " @;@E 0!X;"]W
M;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ RHL"5VOZ=@:F P
MA@X  !D              ("!GR@! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX
M;6Q02P$"% ,4    " #*BP)7/J4%FWD"  #X!0  &0              @(%\
M+ $ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( ,J+ E?H
M.?O '@4  "<7   9              " @2PO 0!X;"]W;W)K<VAE971S+W-H
M965T-#8N>&UL4$L! A0#%     @ RHL"5ZA%18LY!   O1,  !D
M     ("!@30! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,J+ E?25#29D00  #8@   9              "
M@:=2 0!X;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ RHL"
M5[4:"#,( P  + H  !D              ("!;U<! 'AL+W=O<FMS:&5E=',O
M<VAE970U,RYX;6Q02P$"% ,4    " #*BP)7&67Z0&4&   ]-@  &0
M        @(&N6@$ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0
M   ( ,J+ E=P6"^2T@(  $@'   9              " @4IA 0!X;"]W;W)K
M<VAE971S+W-H965T-34N>&UL4$L! A0#%     @ RHL"5_&B$D0[!@  Y$8
M !D              ("!4V0! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q0
M2P$"% ,4    " #*BP)7E^HY5U4#  #!#   &0              @('%:@$
M>&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( ,J+ E=O'4+$
M_0,  )\2   9              " @5%N 0!X;"]W;W)K<VAE971S+W-H965T
M-3@N>&UL4$L! A0#%     @ RHL"5W=I]<W# @  3P@  !D
M ("!A7(! 'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q02P$"% ,4    " #*
MBP)7<U*63M8"  #P"   &0              @(%_=0$ >&PO=V]R:W-H965T
M<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    ( ,J+ E?'._27]@H  "UY   9
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M970V-2YX;6Q02P$"% ,4    " #+BP)7W=5CO& (   ".0  &0
M    @(%DF@$ >&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4 Q0    (
M ,N+ E=+P&(':0,  ,85   -              "  ?NB 0!X;"]S='EL97,N
M>&UL4$L! A0#%     @ RXL"5Y>*NQS     $P(   L              ( !
MCZ8! %]R96QS+RYR96QS4$L! A0#%     @ RXL"5T%Y4Q'V!   'BP   \
M             ( !>*<! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( ,N+
M E<>WYE>' (  #TG   :              "  9NL 0!X;"]?<F5L<R]W;W)K
M8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( ,N+ E>E?PYQ[@$  ) F   3
M          "  >^N 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !* $H
*/10   ZQ 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>278</ContextCount>
  <ElementCount>309</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>106</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>14</UnitCount>
  <MyReports>
    <Report instance="mck-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mckesson123.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="mck-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="mck-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="mck-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="mck-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="mck-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="mck-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="mck-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="mck-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mckesson123.com/role/SignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="mck-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Business Acquisitions and Divestitures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mckesson123.com/role/BusinessAcquisitionsandDivestitures</Role>
      <ShortName>Business Acquisitions and Divestitures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="mck-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Restructuring, Impairment, and Related Charges, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNet</Role>
      <ShortName>Restructuring, Impairment, and Related Charges, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="mck-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mckesson123.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="mck-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Earnings Per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mckesson123.com/role/EarningsPerCommonShare</Role>
      <ShortName>Earnings Per Common Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="mck-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Goodwill and Intangible Assets, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mckesson123.com/role/GoodwillandIntangibleAssetsNet</Role>
      <ShortName>Goodwill and Intangible Assets, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="mck-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Debt and Financing Activities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mckesson123.com/role/DebtandFinancingActivities</Role>
      <ShortName>Debt and Financing Activities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="mck-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Hedging Activities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mckesson123.com/role/HedgingActivities</Role>
      <ShortName>Hedging Activities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="mck-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mckesson123.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="mck-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Commitments and Contingent Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mckesson123.com/role/CommitmentsandContingentLiabilities</Role>
      <ShortName>Commitments and Contingent Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="mck-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Stockholders' Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mckesson123.com/role/StockholdersDeficit</Role>
      <ShortName>Stockholders' Deficit</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="mck-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Segments of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mckesson123.com/role/SegmentsofBusiness</Role>
      <ShortName>Segments of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="mck-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="mck-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="mck-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9954701 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mckesson123.com/role/SignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://mckesson123.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="mck-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9954702 - Disclosure - Business Acquisitions and Divestitures (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mckesson123.com/role/BusinessAcquisitionsandDivestituresTables</Role>
      <ShortName>Business Acquisitions and Divestitures (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://mckesson123.com/role/BusinessAcquisitionsandDivestitures</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="mck-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9954703 - Disclosure - Restructuring, Impairment, and Related Charges, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetTables</Role>
      <ShortName>Restructuring, Impairment, and Related Charges, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNet</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="mck-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9954704 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mckesson123.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://mckesson123.com/role/IncomeTaxes</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="mck-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9954705 - Disclosure - Earnings Per Common Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mckesson123.com/role/EarningsPerCommonShareTables</Role>
      <ShortName>Earnings Per Common Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://mckesson123.com/role/EarningsPerCommonShare</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="mck-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9954706 - Disclosure - Goodwill and Intangible Assets, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mckesson123.com/role/GoodwillandIntangibleAssetsNetTables</Role>
      <ShortName>Goodwill and Intangible Assets, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://mckesson123.com/role/GoodwillandIntangibleAssetsNet</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="mck-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9954707 - Disclosure - Debt and Financing Activities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mckesson123.com/role/DebtandFinancingActivitiesTables</Role>
      <ShortName>Debt and Financing Activities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://mckesson123.com/role/DebtandFinancingActivities</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="mck-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9954708 - Disclosure - Hedging Activities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mckesson123.com/role/HedgingActivitiesTables</Role>
      <ShortName>Hedging Activities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://mckesson123.com/role/HedgingActivities</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="mck-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9954709 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mckesson123.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://mckesson123.com/role/FairValueMeasurements</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="mck-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9954710 - Disclosure - Commitments and Contingent Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mckesson123.com/role/CommitmentsandContingentLiabilitiesTables</Role>
      <ShortName>Commitments and Contingent Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://mckesson123.com/role/CommitmentsandContingentLiabilities</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="mck-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954711 - Disclosure - Stockholders' Deficit (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mckesson123.com/role/StockholdersDeficitTables</Role>
      <ShortName>Stockholders' Deficit (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://mckesson123.com/role/StockholdersDeficit</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="mck-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9954712 - Disclosure - Segments of Business (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mckesson123.com/role/SegmentsofBusinessTables</Role>
      <ShortName>Segments of Business (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://mckesson123.com/role/SegmentsofBusiness</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="mck-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9954713 - Disclosure - Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mckesson123.com/role/SignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="mck-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954714 - Disclosure - Business Acquisitions and Divestitures - Acquisitions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails</Role>
      <ShortName>Business Acquisitions and Divestitures - Acquisitions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="mck-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954715 - Disclosure - Business Acquisitions and Divestitures - Identified Assets Acquired and Liabilities Assumed (Rx Savings Solutions) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedRxSavingsSolutionsDetails</Role>
      <ShortName>Business Acquisitions and Divestitures - Identified Assets Acquired and Liabilities Assumed (Rx Savings Solutions) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="mck-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954716 - Disclosure - Business Acquisitions and Divestitures - Identified Assets Acquired and Liabilities Assumed (SCRI Oncology, LLC) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails</Role>
      <ShortName>Business Acquisitions and Divestitures - Identified Assets Acquired and Liabilities Assumed (SCRI Oncology, LLC) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="mck-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954717 - Disclosure - Business Acquisitions and Divestitures - Divestitures and Other (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mckesson123.com/role/BusinessAcquisitionsandDivestituresDivestituresandOtherDetails</Role>
      <ShortName>Business Acquisitions and Divestitures - Divestitures and Other (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="mck-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954718 - Disclosure - Restructuring, Impairment, and Related Charges, Net - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetNarrativeDetails</Role>
      <ShortName>Restructuring, Impairment, and Related Charges, Net - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="mck-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954719 - Disclosure - Restructuring, Impairment, and Related Charges, Net - Summary of Restructuring Charges (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails</Role>
      <ShortName>Restructuring, Impairment, and Related Charges, Net - Summary of Restructuring Charges (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="mck-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954720 - Disclosure - Restructuring, Impairment, and Related Charges, Net - Summary of Restructuring Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails</Role>
      <ShortName>Restructuring, Impairment, and Related Charges, Net - Summary of Restructuring Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="mck-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954721 - Disclosure - Income Taxes - Schedule of Components of Income Tax Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mckesson123.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseDetails</Role>
      <ShortName>Income Taxes - Schedule of Components of Income Tax Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="mck-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9954722 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mckesson123.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="mck-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9954723 - Disclosure - Earnings Per Common Share - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mckesson123.com/role/EarningsPerCommonShareNarrativeDetails</Role>
      <ShortName>Earnings Per Common Share - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="mck-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9954724 - Disclosure - Earnings Per Common Share - Schedule of Computations for Basic and Diluted Earnings per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails</Role>
      <ShortName>Earnings Per Common Share - Schedule of Computations for Basic and Diluted Earnings per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="mck-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9954725 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Changes in the Carrying Amount of Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofChangesintheCarryingAmountofGoodwillDetails</Role>
      <ShortName>Goodwill and Intangible Assets, Net - Schedule of Changes in the Carrying Amount of Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="mck-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9954726 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Information Regarding Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails</Role>
      <ShortName>Goodwill and Intangible Assets, Net - Schedule of Information Regarding Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="mck-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9954727 - Disclosure - Goodwill and Intangible Assets, Net - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mckesson123.com/role/GoodwillandIntangibleAssetsNetNarrativeDetails</Role>
      <ShortName>Goodwill and Intangible Assets, Net - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="mck-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9954728 - Disclosure - Debt and Financing Activities - Schedule of Long-Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails</Role>
      <ShortName>Debt and Financing Activities - Schedule of Long-Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="mck-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9954729 - Disclosure - Debt and Financing Activities - Long-Term Debt Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails</Role>
      <ShortName>Debt and Financing Activities - Long-Term Debt Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="mck-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9954730 - Disclosure - Debt and Financing Activities - Revolving Credit Facilities Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mckesson123.com/role/DebtandFinancingActivitiesRevolvingCreditFacilitiesNarrativeDetails</Role>
      <ShortName>Debt and Financing Activities - Revolving Credit Facilities Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="mck-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9954731 - Disclosure - Debt and Financing Activities - Commercial Paper Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mckesson123.com/role/DebtandFinancingActivitiesCommercialPaperNarrativeDetails</Role>
      <ShortName>Debt and Financing Activities - Commercial Paper Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="mck-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9954732 - Disclosure - Hedging Activities - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mckesson123.com/role/HedgingActivitiesNarrativeDetails</Role>
      <ShortName>Hedging Activities - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="mck-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9954733 - Disclosure - Hedging Activities - Summary of Foreign Currency Gains and (Losses) from Non-Derivative Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mckesson123.com/role/HedgingActivitiesSummaryofForeignCurrencyGainsandLossesfromNonDerivativeInstrumentsDetails</Role>
      <ShortName>Hedging Activities - Summary of Foreign Currency Gains and (Losses) from Non-Derivative Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="mck-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9954734 - Disclosure - Hedging Activities - Schedule of Notional Amounts of Outstanding Derivative Positions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails</Role>
      <ShortName>Hedging Activities - Schedule of Notional Amounts of Outstanding Derivative Positions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="mck-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9954735 - Disclosure - Hedging Activities - Summary of Derivative Instruments Gain (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mckesson123.com/role/HedgingActivitiesSummaryofDerivativeInstrumentsGainLossDetails</Role>
      <ShortName>Hedging Activities - Summary of Derivative Instruments Gain (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="mck-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9954736 - Disclosure - Hedging Activities - Schedule of Fair Value of Derivatives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mckesson123.com/role/HedgingActivitiesScheduleofFairValueofDerivativesDetails</Role>
      <ShortName>Hedging Activities - Schedule of Fair Value of Derivatives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="mck-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9954737 - Disclosure - Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mckesson123.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="mck-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9954738 - Disclosure - Fair Value Measurements - Schedule of Long-Term Debt is Recorded at Amortized Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mckesson123.com/role/FairValueMeasurementsScheduleofLongTermDebtisRecordedatAmortizedCostDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Long-Term Debt is Recorded at Amortized Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="mck-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9954739 - Disclosure - Commitments and Contingent Liabilities - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails</Role>
      <ShortName>Commitments and Contingent Liabilities - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="mck-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9954740 - Disclosure - Commitments and Contingent Liabilities - Estimated Accrual Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mckesson123.com/role/CommitmentsandContingentLiabilitiesEstimatedAccrualLiabilityDetails</Role>
      <ShortName>Commitments and Contingent Liabilities - Estimated Accrual Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="mck-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9954741 - Disclosure - Stockholders' Deficit - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mckesson123.com/role/StockholdersDeficitNarrativeDetails</Role>
      <ShortName>Stockholders' Deficit - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="mck-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9954742 - Disclosure - Stockholders' Deficit - Schedule of Changes in Accumulated Other Comprehensive Income (Loss) by Component (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails</Role>
      <ShortName>Stockholders' Deficit - Schedule of Changes in Accumulated Other Comprehensive Income (Loss) by Component (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="mck-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9954743 - Disclosure - Segments of Business - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mckesson123.com/role/SegmentsofBusinessNarrativeDetails</Role>
      <ShortName>Segments of Business - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="mck-20230630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9954744 - Disclosure - Segments of Business - Reportable operating segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails</Role>
      <ShortName>Segments of Business - Reportable operating segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="mck-20230630.htm">mck-20230630.htm</File>
    <File>mck-20230630.xsd</File>
    <File>mck-20230630_cal.xml</File>
    <File>mck-20230630_def.xml</File>
    <File>mck-20230630_lab.xml</File>
    <File>mck-20230630_pre.xml</File>
    <File>mck_ex101x2022stockplanstcs.htm</File>
    <File>mck_ex102xmipstcsmay2023.htm</File>
    <File>mck_exhibit311x630202310-q.htm</File>
    <File>mck_exhibit312x630202310-q.htm</File>
    <File>mck_exhibit32x630202310-q.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>mck-20230630_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="844">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>85
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "mck-20230630.htm": {
   "axisCustom": 0,
   "axisStandard": 30,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 844,
    "http://xbrl.sec.gov/dei/2023": 38,
    "http://xbrl.sec.gov/ecd/2023": 4
   },
   "contextCount": 278,
   "dts": {
    "calculationLink": {
     "local": [
      "mck-20230630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "mck-20230630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "mck-20230630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "mck-20230630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "mck-20230630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "mck-20230630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"
     ]
    }
   },
   "elementCount": 635,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2023": 5,
    "total": 5
   },
   "keyCustom": 32,
   "keyStandard": 277,
   "memberCustom": 55,
   "memberStandard": 46,
   "nsprefix": "mck",
   "nsuri": "http://mckesson123.com/20230630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://mckesson123.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Business Acquisitions and Divestitures",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://mckesson123.com/role/BusinessAcquisitionsandDivestitures",
     "shortName": "Business Acquisitions and Divestitures",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Restructuring, Impairment, and Related Charges, Net",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNet",
     "shortName": "Restructuring, Impairment, and Related Charges, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://mckesson123.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Earnings Per Common Share",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://mckesson123.com/role/EarningsPerCommonShare",
     "shortName": "Earnings Per Common Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Goodwill and Intangible Assets, Net",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://mckesson123.com/role/GoodwillandIntangibleAssetsNet",
     "shortName": "Goodwill and Intangible Assets, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Debt and Financing Activities",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://mckesson123.com/role/DebtandFinancingActivities",
     "shortName": "Debt and Financing Activities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Hedging Activities",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://mckesson123.com/role/HedgingActivities",
     "shortName": "Hedging Activities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Fair Value Measurements",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://mckesson123.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Commitments and Contingent Liabilities",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://mckesson123.com/role/CommitmentsandContingentLiabilities",
     "shortName": "Commitments and Contingent Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Stockholders' Deficit",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://mckesson123.com/role/StockholdersDeficit",
     "shortName": "Stockholders' Deficit",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Segments of Business",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://mckesson123.com/role/SegmentsofBusiness",
     "shortName": "Segments of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "shortName": "Pay vs Performance Disclosure",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ecd:NonRule10b51ArrTrmntdFlag",
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "shortName": "Insider Trading Arrangements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "ecd:NonRule10b51ArrTrmntdFlag",
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954701 - Disclosure - Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "23",
     "role": "http://mckesson123.com/role/SignificantAccountingPoliciesPolicies",
     "shortName": "Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954702 - Disclosure - Business Acquisitions and Divestitures (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresTables",
     "shortName": "Business Acquisitions and Divestitures (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954703 - Disclosure - Restructuring, Impairment, and Related Charges, Net (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetTables",
     "shortName": "Restructuring, Impairment, and Related Charges, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954704 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://mckesson123.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954705 - Disclosure - Earnings Per Common Share (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://mckesson123.com/role/EarningsPerCommonShareTables",
     "shortName": "Earnings Per Common Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954706 - Disclosure - Goodwill and Intangible Assets, Net (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetTables",
     "shortName": "Goodwill and Intangible Assets, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954707 - Disclosure - Debt and Financing Activities (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://mckesson123.com/role/DebtandFinancingActivitiesTables",
     "shortName": "Debt and Financing Activities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954708 - Disclosure - Hedging Activities (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://mckesson123.com/role/HedgingActivitiesTables",
     "shortName": "Hedging Activities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954709 - Disclosure - Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://mckesson123.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954710 - Disclosure - Commitments and Contingent Liabilities (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesTables",
     "shortName": "Commitments and Contingent Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954711 - Disclosure - Stockholders' Deficit (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://mckesson123.com/role/StockholdersDeficitTables",
     "shortName": "Stockholders' Deficit (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954712 - Disclosure - Segments of Business (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://mckesson123.com/role/SegmentsofBusinessTables",
     "shortName": "Segments of Business (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954713 - Disclosure - Significant Accounting Policies - Narrative (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://mckesson123.com/role/SignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Significant Accounting Policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954714 - Disclosure - Business Acquisitions and Divestitures - Acquisitions (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails",
     "shortName": "Business Acquisitions and Divestitures - Acquisitions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-47",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-6",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954715 - Disclosure - Business Acquisitions and Divestitures - Identified Assets Acquired and Liabilities Assumed (Rx Savings Solutions) (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedRxSavingsSolutionsDetails",
     "shortName": "Business Acquisitions and Divestitures - Identified Assets Acquired and Liabilities Assumed (Rx Savings Solutions) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-48",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-6",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954716 - Disclosure - Business Acquisitions and Divestitures - Identified Assets Acquired and Liabilities Assumed (SCRI Oncology, LLC) (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails",
     "shortName": "Business Acquisitions and Divestitures - Identified Assets Acquired and Liabilities Assumed (SCRI Oncology, LLC) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-53",
      "decimals": "-6",
      "lang": "en-US",
      "name": "mck:BusinessCombinationConsiderationTransferredOwnershipInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954717 - Disclosure - Business Acquisitions and Divestitures - Divestitures and Other (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresDivestituresandOtherDetails",
     "shortName": "Business Acquisitions and Divestitures - Divestitures and Other (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-56",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-6",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-6",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ReceivablesNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "mck:RestructuringImpairmentAndOtherRelatedCharges",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954718 - Disclosure - Restructuring, Impairment, and Related Charges, Net - Narrative (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetNarrativeDetails",
     "shortName": "Restructuring, Impairment, and Related Charges, Net - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-61",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostExpectedCost1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SeveranceCosts1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954719 - Disclosure - Restructuring, Impairment, and Related Charges, Net - Summary of Restructuring Charges (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails",
     "shortName": "Restructuring, Impairment, and Related Charges, Net - Summary of Restructuring Charges (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SeveranceCosts1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-8",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954720 - Disclosure - Restructuring, Impairment, and Related Charges, Net - Summary of Restructuring Activity (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails",
     "shortName": "Restructuring, Impairment, and Related Charges, Net - Summary of Restructuring Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-8",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954721 - Disclosure - Income Taxes - Schedule of Components of Income Tax Expense (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://mckesson123.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseDetails",
     "shortName": "Income Taxes - Schedule of Components of Income Tax Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": "3",
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "mck:EffectiveIncomeTaxReconciliationTaxExpenseBenefitIntraEntityTransfersOfAssetsOtherThanInventoryAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954722 - Disclosure - Income Taxes - Narrative (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://mckesson123.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "mck:EffectiveIncomeTaxReconciliationTaxExpenseBenefitIntraEntityTransfersOfAssetsOtherThanInventoryAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954723 - Disclosure - Earnings Per Common Share - Narrative (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://mckesson123.com/role/EarningsPerCommonShareNarrativeDetails",
     "shortName": "Earnings Per Common Share - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954724 - Disclosure - Earnings Per Common Share - Schedule of Computations for Basic and Diluted Earnings per Common Share (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails",
     "shortName": "Earnings Per Common Share - Schedule of Computations for Basic and Diluted Earnings per Common Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-8",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954725 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Changes in the Carrying Amount of Goodwill (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofChangesintheCarryingAmountofGoodwillDetails",
     "shortName": "Goodwill and Intangible Assets, Net - Schedule of Changes in the Carrying Amount of Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:GoodwillForeignCurrencyTranslationGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-6",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954726 - Disclosure - Goodwill and Intangible Assets, Net - Schedule of Information Regarding Intangible Assets (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails",
     "shortName": "Goodwill and Intangible Assets, Net - Schedule of Information Regarding Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-6",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954727 - Disclosure - Goodwill and Intangible Assets, Net - Narrative (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetNarrativeDetails",
     "shortName": "Goodwill and Intangible Assets, Net - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-6",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-6",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-6",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954728 - Disclosure - Debt and Financing Activities - Schedule of Long-Term Debt (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails",
     "shortName": "Debt and Financing Activities - Schedule of Long-Term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-118",
      "decimals": "4",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-6",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtAndCapitalLeaseObligations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954729 - Disclosure - Debt and Financing Activities - Long-Term Debt Narrative (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails",
     "shortName": "Debt and Financing Activities - Long-Term Debt Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-6",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtAndCapitalLeaseObligations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-156",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954730 - Disclosure - Debt and Financing Activities - Revolving Credit Facilities Narrative (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://mckesson123.com/role/DebtandFinancingActivitiesRevolvingCreditFacilitiesNarrativeDetails",
     "shortName": "Debt and Financing Activities - Revolving Credit Facilities Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-156",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-165",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954731 - Disclosure - Debt and Financing Activities - Commercial Paper Narrative (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://mckesson123.com/role/DebtandFinancingActivitiesCommercialPaperNarrativeDetails",
     "shortName": "Debt and Financing Activities - Commercial Paper Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-165",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-6",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954732 - Disclosure - Hedging Activities - Narrative (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails",
     "shortName": "Hedging Activities - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-170",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-172",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954733 - Disclosure - Hedging Activities - Summary of Foreign Currency Gains and (Losses) from Non-Derivative Instruments (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://mckesson123.com/role/HedgingActivitiesSummaryofForeignCurrencyGainsandLossesfromNonDerivativeInstrumentsDetails",
     "shortName": "Hedging Activities - Summary of Foreign Currency Gains and (Losses) from Non-Derivative Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-174",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954734 - Disclosure - Hedging Activities - Schedule of Notional Amounts of Outstanding Derivative Positions (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails",
     "shortName": "Hedging Activities - Schedule of Notional Amounts of Outstanding Derivative Positions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-174",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNotionalAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "cad",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-189",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954735 - Disclosure - Hedging Activities - Summary of Derivative Instruments Gain (Loss) (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://mckesson123.com/role/HedgingActivitiesSummaryofDerivativeInstrumentsGainLossDetails",
     "shortName": "Hedging Activities - Summary of Derivative Instruments Gain (Loss) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "us-gaap:ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-189",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-201",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954736 - Disclosure - Hedging Activities - Schedule of Fair Value of Derivatives (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://mckesson123.com/role/HedgingActivitiesScheduleofFairValueofDerivativesDetails",
     "shortName": "Hedging Activities - Schedule of Fair Value of Derivatives (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-201",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-6",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNi",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954737 - Disclosure - Fair Value Measurements - Narrative (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://mckesson123.com/role/FairValueMeasurementsNarrativeDetails",
     "shortName": "Fair Value Measurements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-6",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNi",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-27",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-27",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-6",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954738 - Disclosure - Fair Value Measurements - Schedule of Long-Term Debt is Recorded at Amortized Cost (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://mckesson123.com/role/FairValueMeasurementsScheduleofLongTermDebtisRecordedatAmortizedCostDetails",
     "shortName": "Fair Value Measurements - Schedule of Long-Term Debt is Recorded at Amortized Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-205",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-221",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "mck:LossContingencyNumberOfFormerOfficers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "officer",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954739 - Disclosure - Commitments and Contingent Liabilities - Narrative (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails",
     "shortName": "Commitments and Contingent Liabilities - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-221",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "mck:LossContingencyNumberOfFormerOfficers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "officer",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-214",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyAccrualCarryingValueCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954740 - Disclosure - Commitments and Contingent Liabilities - Estimated Accrual Liability (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesEstimatedAccrualLiabilityDetails",
     "shortName": "Commitments and Contingent Liabilities - Estimated Accrual Liability (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLossContingenciesByContingencyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-214",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyAccrualCarryingValueCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-6",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "mck:CommonStockVotingRightsNumberofVotesPerCommonShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "vote",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954741 - Disclosure - Stockholders' Deficit - Narrative (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://mckesson123.com/role/StockholdersDeficitNarrativeDetails",
     "shortName": "Stockholders' Deficit - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-6",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "mck:CommonStockVotingRightsNumberofVotesPerCommonShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "vote",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-8",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954742 - Disclosure - Stockholders' Deficit - Schedule of Changes in Accumulated Other Comprehensive Income (Loss) by Component (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails",
     "shortName": "Stockholders' Deficit - Schedule of Changes in Accumulated Other Comprehensive Income (Loss) by Component (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-253",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954743 - Disclosure - Segments of Business - Narrative (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://mckesson123.com/role/SegmentsofBusinessNarrativeDetails",
     "shortName": "Segments of Business - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "9954744 - Disclosure - Segments of Business - Reportable operating segment (Details)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails",
     "shortName": "Segments of Business - Reportable operating segment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": "-6",
      "lang": "en-US",
      "name": "mck:CorporateOperatingExpenseandOtherIncomeNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareDeclared",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (Parenthetical)",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITParenthetical",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000008 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "menuCat": "Statements",
     "order": "8",
     "role": "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://mckesson123.com/role/SignificantAccountingPolicies",
     "shortName": "Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "mck-20230630.htm",
      "contextRef": "c-1",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 106,
   "tag": {
    "country_CA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CANADA",
        "terseLabel": "Canada"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "presentation": [
      "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2023",
     "presentation": [
      "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails",
      "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_AllCurrenciesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Currencies [Domain]",
        "terseLabel": "All Currencies [Domain]"
       }
      }
     },
     "localname": "AllCurrenciesDomain",
     "nsuri": "http://xbrl.sec.gov/currency/2023",
     "presentation": [
      "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails",
      "http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_CAD": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Canada, Dollars",
        "terseLabel": "CAD"
       }
      }
     },
     "localname": "CAD",
     "nsuri": "http://xbrl.sec.gov/currency/2023",
     "presentation": [
      "http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_EUR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Euro Member Countries, Euro",
        "terseLabel": "EUR"
       }
      }
     },
     "localname": "EUR",
     "nsuri": "http://xbrl.sec.gov/currency/2023",
     "presentation": [
      "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails",
      "http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_GBP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "United Kingdom, Pounds",
        "terseLabel": "GBP"
       }
      }
     },
     "localname": "GBP",
     "nsuri": "http://xbrl.sec.gov/currency/2023",
     "presentation": [
      "http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_USD": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "United States of America, Dollars",
        "terseLabel": "USD"
       }
      }
     },
     "localname": "USD",
     "nsuri": "http://xbrl.sec.gov/currency/2023",
     "presentation": [
      "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails",
      "http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://mckesson123.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://mckesson123.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://mckesson123.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://mckesson123.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://mckesson123.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://mckesson123.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r774"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://mckesson123.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r807"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://mckesson123.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://mckesson123.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance",
        "label": "Entities [Table]",
        "terseLabel": "Entities [Table]"
       }
      }
     },
     "localname": "EntitiesTable",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://mckesson123.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://mckesson123.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://mckesson123.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://mckesson123.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://mckesson123.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r772"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://mckesson123.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://mckesson123.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://mckesson123.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresDivestituresandOtherDetails",
      "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r772"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://mckesson123.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://mckesson123.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r772"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://mckesson123.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://mckesson123.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Information [Line Items]",
        "terseLabel": "Entity Information [Line Items]"
       }
      }
     },
     "localname": "EntityInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://mckesson123.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r846"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://mckesson123.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r772"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://mckesson123.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r772"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://mckesson123.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r772"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://mckesson123.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r772"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://mckesson123.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresDivestituresandOtherDetails",
      "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://mckesson123.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r771"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://mckesson123.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r773"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://mckesson123.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "presentation": [
      "http://mckesson123.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "auth_ref": [
      "r808"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]",
        "terseLabel": "Additional 402(v) Disclosure"
       }
      }
     },
     "localname": "Additional402vDisclosureTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_AdjToCompAmt": {
     "auth_ref": [
      "r814"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount",
        "terseLabel": "Adjustment to Compensation, Amount"
       }
      }
     },
     "localname": "AdjToCompAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_AdjToCompAxis": {
     "auth_ref": [
      "r814"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]",
        "terseLabel": "Adjustment to Compensation:"
       }
      }
     },
     "localname": "AdjToCompAxis",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "auth_ref": [
      "r814"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]",
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote"
       }
      }
     },
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "auth_ref": [
      "r814"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]",
        "terseLabel": "Adjustment To PEO Compensation, Footnote"
       }
      }
     },
     "localname": "AdjToPeoCompFnTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_AggtErrCompAmt": {
     "auth_ref": [
      "r779",
      "r790",
      "r800",
      "r825"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount",
        "terseLabel": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "localname": "AggtErrCompAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "auth_ref": [
      "r782",
      "r793",
      "r803",
      "r828"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]",
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined"
       }
      }
     },
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_AllAdjToCompMember": {
     "auth_ref": [
      "r814"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]",
        "terseLabel": "All Adjustments to Compensation"
       }
      }
     },
     "localname": "AllAdjToCompMember",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "domainItemType"
    },
    "ecd_AllExecutiveCategoriesMember": {
     "auth_ref": [
      "r821"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]",
        "terseLabel": "All Executive Categories"
       }
      }
     },
     "localname": "AllExecutiveCategoriesMember",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "domainItemType"
    },
    "ecd_AllIndividualsMember": {
     "auth_ref": [
      "r786",
      "r794",
      "r804",
      "r821",
      "r829",
      "r833",
      "r841"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]",
        "terseLabel": "All Individuals"
       }
      }
     },
     "localname": "AllIndividualsMember",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "domainItemType"
    },
    "ecd_AllTradingArrangementsMember": {
     "auth_ref": [
      "r839"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]",
        "terseLabel": "All Trading Arrangements"
       }
      }
     },
     "localname": "AllTradingArrangementsMember",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "xbrltype": "domainItemType"
    },
    "ecd_AwardExrcPrice": {
     "auth_ref": [
      "r836"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Exercise Price",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "localname": "AwardExrcPrice",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "xbrltype": "perShareItemType"
    },
    "ecd_AwardGrantDateFairValue": {
     "auth_ref": [
      "r837"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Grant Date Fair Value",
        "terseLabel": "Fair Value as of Grant Date"
       }
      }
     },
     "localname": "AwardGrantDateFairValue",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_AwardTmgDiscLineItems": {
     "auth_ref": [
      "r832"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "localname": "AwardTmgDiscLineItems",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "xbrltype": "stringItemType"
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "auth_ref": [
      "r832"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing, How MNPI Considered [Text Block]",
        "terseLabel": "Award Timing, How MNPI Considered"
       }
      }
     },
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_AwardTmgMethodTextBlock": {
     "auth_ref": [
      "r832"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Method [Text Block]",
        "terseLabel": "Award Timing Method"
       }
      }
     },
     "localname": "AwardTmgMethodTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "auth_ref": [
      "r832"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Considered [Flag]",
        "terseLabel": "Award Timing MNPI Considered"
       }
      }
     },
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "xbrltype": "booleanItemType"
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "auth_ref": [
      "r832"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing MNPI Disclosure [Text Block]",
        "terseLabel": "Award Timing MNPI Disclosure"
       }
      }
     },
     "localname": "AwardTmgMnpiDiscTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "auth_ref": [
      "r832"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Predetermined [Flag]",
        "terseLabel": "Award Timing Predetermined"
       }
      }
     },
     "localname": "AwardTmgPredtrmndFlag",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "xbrltype": "booleanItemType"
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "auth_ref": [
      "r835"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Underlying Securities Amount",
        "terseLabel": "Underlying Securities"
       }
      }
     },
     "localname": "AwardUndrlygSecuritiesAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "xbrltype": "decimalItemType"
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "auth_ref": [
      "r834"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "localname": "AwardsCloseToMnpiDiscIndName",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "auth_ref": [
      "r833"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures"
       }
      }
     },
     "localname": "AwardsCloseToMnpiDiscTable",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "auth_ref": [
      "r833"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]",
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table"
       }
      }
     },
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "auth_ref": [
      "r812"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]",
        "terseLabel": "Changed Peer Group, Footnote"
       }
      }
     },
     "localname": "ChangedPeerGroupFnTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_CoSelectedMeasureAmt": {
     "auth_ref": [
      "r813"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount",
        "terseLabel": "Company Selected Measure Amount"
       }
      }
     },
     "localname": "CoSelectedMeasureAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "decimalItemType"
    },
    "ecd_CoSelectedMeasureName": {
     "auth_ref": [
      "r813"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name",
        "terseLabel": "Company Selected Measure Name"
       }
      }
     },
     "localname": "CoSelectedMeasureName",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "auth_ref": [
      "r818"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure"
       }
      }
     },
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "auth_ref": [
      "r817"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Net Income"
       }
      }
     },
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "auth_ref": [
      "r819"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Other Measure"
       }
      }
     },
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "auth_ref": [
      "r816"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]",
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return"
       }
      }
     },
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "auth_ref": [
      "r815"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]",
        "terseLabel": "Equity Valuation Assumption Difference, Footnote"
       }
      }
     },
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "auth_ref": [
      "r779",
      "r790",
      "r800",
      "r825"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]",
        "terseLabel": "Erroneous Compensation Analysis"
       }
      }
     },
     "localname": "ErrCompAnalysisTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_ErrCompRecoveryTable": {
     "auth_ref": [
      "r776",
      "r787",
      "r797",
      "r822"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]",
        "terseLabel": "Erroneously Awarded Compensation Recovery"
       }
      }
     },
     "localname": "ErrCompRecoveryTable",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_ExecutiveCategoryAxis": {
     "auth_ref": [
      "r821"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]",
        "terseLabel": "Executive Category:"
       }
      }
     },
     "localname": "ExecutiveCategoryAxis",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "auth_ref": [
      "r783",
      "r794",
      "r804",
      "r829"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "auth_ref": [
      "r783",
      "r794",
      "r804",
      "r829"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount",
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "auth_ref": [
      "r783",
      "r794",
      "r804",
      "r829"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "auth_ref": [
      "r783",
      "r794",
      "r804",
      "r829"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]",
        "terseLabel": "Forgone Recovery, Explanation of Impracticability"
       }
      }
     },
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_ForgoneRecoveryIndName": {
     "auth_ref": [
      "r783",
      "r794",
      "r804",
      "r829"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "localname": "ForgoneRecoveryIndName",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_IndividualAxis": {
     "auth_ref": [
      "r786",
      "r794",
      "r804",
      "r821",
      "r829",
      "r833",
      "r841"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]",
        "terseLabel": "Individual:"
       }
      }
     },
     "localname": "IndividualAxis",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_InsiderTradingArrLineItems": {
     "auth_ref": [
      "r839"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "localname": "InsiderTradingArrLineItems",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "xbrltype": "stringItemType"
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "auth_ref": [
      "r775",
      "r845"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "localname": "InsiderTradingPoliciesProcLineItems",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "xbrltype": "stringItemType"
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "auth_ref": [
      "r775",
      "r845"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Adopted [Flag]",
        "terseLabel": "Insider Trading Policies and Procedures Adopted"
       }
      }
     },
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "xbrltype": "booleanItemType"
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "auth_ref": [
      "r775",
      "r845"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]",
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted"
       }
      }
     },
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_MeasureAxis": {
     "auth_ref": [
      "r813"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]",
        "terseLabel": "Measure:"
       }
      }
     },
     "localname": "MeasureAxis",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_MeasureName": {
     "auth_ref": [
      "r813"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name",
        "terseLabel": "Name"
       }
      }
     },
     "localname": "MeasureName",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "auth_ref": [
      "r832"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]",
        "terseLabel": "MNPI Disclosure Timed for Compensation Value"
       }
      }
     },
     "localname": "MnpiDiscTimedForCompValFlag",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "xbrltype": "booleanItemType"
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "auth_ref": [
      "r840"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Material Terms of Trading Arrangement [Text Block]",
        "terseLabel": "Material Terms of Trading Arrangement"
       }
      }
     },
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "auth_ref": [
      "r814"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]",
        "terseLabel": "Named Executive Officers, Footnote"
       }
      }
     },
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "auth_ref": [
      "r813"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]",
        "terseLabel": "Non-GAAP Measure Description"
       }
      }
     },
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_NonNeosMember": {
     "auth_ref": [
      "r783",
      "r794",
      "r804",
      "r821",
      "r829"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]",
        "terseLabel": "Non-NEOs"
       }
      }
     },
     "localname": "NonNeosMember",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "domainItemType"
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "auth_ref": [
      "r811"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "auth_ref": [
      "r810"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount",
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_NonPeoNeoMember": {
     "auth_ref": [
      "r821"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]",
        "terseLabel": "Non-PEO NEO"
       }
      }
     },
     "localname": "NonPeoNeoMember",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "domainItemType"
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "auth_ref": [
      "r840"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "localname": "NonRule10b51ArrAdoptedFlag",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "xbrltype": "booleanItemType"
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "auth_ref": [
      "r840"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "localname": "NonRule10b51ArrTrmntdFlag",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "xbrltype": "booleanItemType"
    },
    "ecd_OtherPerfMeasureAmt": {
     "auth_ref": [
      "r813"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure, Amount",
        "terseLabel": "Other Performance Measure, Amount"
       }
      }
     },
     "localname": "OtherPerfMeasureAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "decimalItemType"
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "auth_ref": [
      "r781",
      "r792",
      "r802",
      "r827"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount",
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "localname": "OutstandingAggtErrCompAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "auth_ref": [
      "r784",
      "r795",
      "r805",
      "r830"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount",
        "terseLabel": "Compensation Amount"
       }
      }
     },
     "localname": "OutstandingRecoveryCompAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_OutstandingRecoveryIndName": {
     "auth_ref": [
      "r784",
      "r795",
      "r805",
      "r830"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "localname": "OutstandingRecoveryIndName",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "auth_ref": [
      "r809"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "localname": "PayVsPerformanceDisclosureLineItems",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "xbrltype": "stringItemType"
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "auth_ref": [
      "r812"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]",
        "terseLabel": "Peer Group Issuers, Footnote"
       }
      }
     },
     "localname": "PeerGroupIssuersFnTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "auth_ref": [
      "r812"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount",
        "terseLabel": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "auth_ref": [
      "r811"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount",
        "terseLabel": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "localname": "PeoActuallyPaidCompAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_PeoMember": {
     "auth_ref": [
      "r821"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]",
        "terseLabel": "PEO"
       }
      }
     },
     "localname": "PeoMember",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "domainItemType"
    },
    "ecd_PeoName": {
     "auth_ref": [
      "r814"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name",
        "terseLabel": "PEO Name"
       }
      }
     },
     "localname": "PeoName",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "ecd_PeoTotalCompAmt": {
     "auth_ref": [
      "r810"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount",
        "terseLabel": "PEO Total Compensation Amount"
       }
      }
     },
     "localname": "PeoTotalCompAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_PvpTable": {
     "auth_ref": [
      "r809"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]",
        "terseLabel": "Pay vs Performance Disclosure"
       }
      }
     },
     "localname": "PvpTable",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_PvpTableTextBlock": {
     "auth_ref": [
      "r809"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]",
        "terseLabel": "Pay vs Performance Disclosure, Table"
       }
      }
     },
     "localname": "PvpTableTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "auth_ref": [
      "r776",
      "r787",
      "r797",
      "r822"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "xbrltype": "stringItemType"
    },
    "ecd_RestatementDateAxis": {
     "auth_ref": [
      "r777",
      "r788",
      "r798",
      "r823"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]",
        "terseLabel": "Restatement Determination Date:"
       }
      }
     },
     "localname": "RestatementDateAxis",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_RestatementDeterminationDate": {
     "auth_ref": [
      "r778",
      "r789",
      "r799",
      "r824"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date",
        "terseLabel": "Restatement Determination Date"
       }
      }
     },
     "localname": "RestatementDeterminationDate",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "dateItemType"
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "auth_ref": [
      "r785",
      "r796",
      "r806",
      "r831"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]",
        "terseLabel": "Restatement does not require Recovery"
       }
      }
     },
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "auth_ref": [
      "r840"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Adopted"
       }
      }
     },
     "localname": "Rule10b51ArrAdoptedFlag",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "xbrltype": "booleanItemType"
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "auth_ref": [
      "r840"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]",
        "terseLabel": "Rule 10b5-1 Arrangement Terminated"
       }
      }
     },
     "localname": "Rule10b51ArrTrmntdFlag",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "xbrltype": "booleanItemType"
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "auth_ref": [
      "r780",
      "r791",
      "r801",
      "r826"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]",
        "terseLabel": "Stock Price or TSR Estimation Method"
       }
      }
     },
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_TabularListTableTextBlock": {
     "auth_ref": [
      "r820"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]",
        "terseLabel": "Tabular List, Table"
       }
      }
     },
     "localname": "TabularListTableTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_TotalShareholderRtnAmt": {
     "auth_ref": [
      "r812"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount",
        "terseLabel": "Total Shareholder Return Amount"
       }
      }
     },
     "localname": "TotalShareholderRtnAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "auth_ref": [
      "r819"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]",
        "terseLabel": "Total Shareholder Return Vs Peer Group"
       }
      }
     },
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_TradingArrAxis": {
     "auth_ref": [
      "r839"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]",
        "terseLabel": "Trading Arrangement:"
       }
      }
     },
     "localname": "TradingArrAxis",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_TradingArrByIndTable": {
     "auth_ref": [
      "r841"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]",
        "terseLabel": "Trading Arrangements, by Individual"
       }
      }
     },
     "localname": "TradingArrByIndTable",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_TrdArrAdoptionDate": {
     "auth_ref": [
      "r842"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Adoption Date",
        "terseLabel": "Adoption Date"
       }
      }
     },
     "localname": "TrdArrAdoptionDate",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_TrdArrDuration": {
     "auth_ref": [
      "r843"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Duration",
        "terseLabel": "Arrangement Duration"
       }
      }
     },
     "localname": "TrdArrDuration",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "xbrltype": "durationItemType"
    },
    "ecd_TrdArrIndName": {
     "auth_ref": [
      "r841"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Name",
        "terseLabel": "Name"
       }
      }
     },
     "localname": "TrdArrIndName",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_TrdArrIndTitle": {
     "auth_ref": [
      "r841"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Individual Title",
        "terseLabel": "Title"
       }
      }
     },
     "localname": "TrdArrIndTitle",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "auth_ref": [
      "r844"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement, Securities Aggregate Available Amount",
        "terseLabel": "Aggregate Available"
       }
      }
     },
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "xbrltype": "sharesItemType"
    },
    "ecd_TrdArrTerminationDate": {
     "auth_ref": [
      "r842"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement Termination Date",
        "terseLabel": "Termination Date"
       }
      }
     },
     "localname": "TrdArrTerminationDate",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "auth_ref": [
      "r838"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underlying Security Market Price Change, Percent",
        "terseLabel": "Underlying Security Market Price Change"
       }
      }
     },
     "localname": "UndrlygSecurityMktPriceChngPct",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "xbrltype": "pureItemType"
    },
    "mck_A090NotesDueDecember32025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.90% Notes Due December 3, 2025",
        "label": "0.90% Notes Due December 3, 2025 [Member]",
        "terseLabel": "0.90% Notes due December 3, 2025"
       }
      }
     },
     "localname": "A090NotesDueDecember32025Member",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mck_A130NotesDueAugust152026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.30% Notes Due August 15, 2026",
        "label": "1.30% Notes Due August 15, 2026 [Member]",
        "terseLabel": "1.30% Notes due August 15, 2026"
       }
      }
     },
     "localname": "A130NotesDueAugust152026Member",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mck_A1500NotesDue2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.500% Notes Due 2025",
        "label": "1.500% Notes Due 2025 [Member]",
        "terseLabel": "1.500% Notes Due 2025"
       }
      }
     },
     "localname": "A1500NotesDue2025Member",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "mck_A150EuroNotesDueNovember172025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.50% Euro Notes Due November 17, 2025",
        "label": "1.50% Euro Notes Due November 17, 2025 [Member]",
        "terseLabel": "1.50% Euro Notes due November 17, 2025"
       }
      }
     },
     "localname": "A150EuroNotesDueNovember172025Member",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mck_A1625NotesDue2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.625% Notes Due 2026",
        "label": "1.625% Notes Due 2026 [Member]",
        "terseLabel": "1.625% Notes Due 2026"
       }
      }
     },
     "localname": "A1625NotesDue2026Member",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "mck_A163EuroNotesDueOctober302026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.63% Euro Notes Due October 30, 2026",
        "label": "1.63% Euro Notes Due October 30, 2026 [Member]",
        "terseLabel": "1.63% Euro Notes due October 30, 2026"
       }
      }
     },
     "localname": "A163EuroNotesDueOctober302026Member",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mck_A3125NotesDue2029Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.125% Notes Due 2029",
        "label": "3.125% Notes Due 2029 [Member]",
        "terseLabel": "3.125% Notes Due 2029"
       }
      }
     },
     "localname": "A3125NotesDue2029Member",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "mck_A313SterlingNotesDueFebruary172029Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.13% Sterling Notes Due February 17, 2029",
        "label": "3.13% Sterling Notes Due February 17, 2029 [Member]",
        "terseLabel": "3.13% Sterling Notes due February 17, 2029"
       }
      }
     },
     "localname": "A313SterlingNotesDueFebruary172029Member",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mck_A380NotesDueMarch152024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.80% Notes Due March 15, 2024",
        "label": "3.80% Notes Due March 15, 2024 [Member]",
        "terseLabel": "3.80% Notes due March 15, 2024"
       }
      }
     },
     "localname": "A380NotesDueMarch152024Member",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails",
      "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mck_A395NotesDueFebruary162028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.95% Notes Due February 16, 2028",
        "label": "3.95% Notes Due February 16, 2028 [Member]",
        "terseLabel": "3.95% Notes due February 16, 2028"
       }
      }
     },
     "localname": "A395NotesDueFebruary162028Member",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mck_A475NotesDueMay302029Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.75% Notes Due May 30, 2029",
        "label": "4.75% Notes Due May 30, 2029 [Member]",
        "terseLabel": "4.75% Notes due May 30, 2029"
       }
      }
     },
     "localname": "A475NotesDueMay302029Member",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mck_A488NotesDueMarch152044Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.88% Notes Due March 15, 2044",
        "label": "4.88% Notes Due March 15, 2044 [Member]",
        "terseLabel": "4.88% Notes due March 15, 2044"
       }
      }
     },
     "localname": "A488NotesDueMarch152044Member",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mck_A490NotesDueJuly152028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.90% Notes Due July 15, 2028",
        "label": "4.90% Notes Due July 15, 2028 [Member]",
        "terseLabel": "4.90% Notes due July 15, 2028"
       }
      }
     },
     "localname": "A490NotesDueJuly152028Member",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails",
      "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mck_A510NotesDueJuly152033Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.10% Notes Due July 15, 2033",
        "label": "5.10% Notes Due July 15, 2033 [Member]",
        "terseLabel": "5.10% Notes due July 15, 2033"
       }
      }
     },
     "localname": "A510NotesDueJuly152033Member",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails",
      "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mck_A525NotesDueFebruary152026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.25% Notes Due February 15, 2026",
        "label": "5.25% Notes Due February 15, 2026 [Member]",
        "terseLabel": "5.25% Notes due February 15, 2026"
       }
      }
     },
     "localname": "A525NotesDueFebruary152026Member",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mck_A600NotesDueMarch12041Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "6.00% Notes Due March 1, 2041",
        "label": "6.00% Notes Due March 1, 2041 [Member]",
        "terseLabel": "6.00% Notes due March 1, 2041"
       }
      }
     },
     "localname": "A600NotesDueMarch12041Member",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mck_A765DebenturesDueMarch12027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "7.65% Debentures Due March 1, 2027",
        "label": "7.65% Debentures Due March 1, 2027 [Member]",
        "terseLabel": "7.65% Debentures due March 1, 2027"
       }
      }
     },
     "localname": "A765DebenturesDueMarch12027Member",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mck_AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AOCI, Accumulated Gain (Loss), Net Investment Hedges, Including Noncontrolling Interest",
        "label": "AOCI, Accumulated Gain (Loss), Net Investment Hedges, Including Noncontrolling Interest [Member]",
        "terseLabel": "Unrealized Losses on Net Investment Hedges, Net of Tax"
       }
      }
     },
     "localname": "AOCIAccumulatedGainLossNetInvestmentHedgesIncludingNoncontrollingInterestMember",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mck_AcceleratedShareRepurchaseCompletionOfProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accelerated Share Repurchase, Completion Of Program",
        "label": "Accelerated Share Repurchase, Completion Of Program [Member]",
        "terseLabel": "Accelerated Share Repurchase, Completion Of Program"
       }
      }
     },
     "localname": "AcceleratedShareRepurchaseCompletionOfProgramMember",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/StockholdersDeficitNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mck_AcceleratedShareRepurchaseInitialShareSettlementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accelerated Share Repurchase, Initial Share Settlement",
        "label": "Accelerated Share Repurchase, Initial Share Settlement [Member]",
        "terseLabel": "Accelerated Share Repurchase, Initial Share Settlement"
       }
      }
     },
     "localname": "AcceleratedShareRepurchaseInitialShareSettlementMember",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/StockholdersDeficitNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mck_AcceleratedShareRepurchaseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accelerated Share Repurchase [Member]",
        "label": "Accelerated Share Repurchase [Member]",
        "terseLabel": "Accelerated Share Repurchase"
       }
      }
     },
     "localname": "AcceleratedShareRepurchaseMember",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/StockholdersDeficitNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mck_AssetImpairmentChargesIncludingAcceleratedDepreciation": {
     "auth_ref": [],
     "calculation": {
      "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_RestructuringCharges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Impairment Charges, Including Accelerated Depreciation",
        "label": "Asset Impairment Charges, Including Accelerated Depreciation",
        "terseLabel": "Asset impairments and accelerated depreciation"
       }
      }
     },
     "localname": "AssetImpairmentChargesIncludingAcceleratedDepreciation",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mck_AureliusElephantLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aurelius Elephant Limited",
        "label": "Aurelius Elephant Limited [Member]",
        "terseLabel": "Aurelius Elephant Limited"
       }
      }
     },
     "localname": "AureliusElephantLimitedMember",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresDivestituresandOtherDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mck_BritishPoundSterlingDenominatedNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "British Pound Sterling Denominated Notes [Member]",
        "label": "British Pound Sterling Denominated Notes [Member]",
        "terseLabel": "British Pound Sterling Denominated Notes"
       }
      }
     },
     "localname": "BritishPoundSterlingDenominatedNotesMember",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mck_BusinessCombinationConsiderationTransferredOwnershipInterest": {
     "auth_ref": [],
     "calculation": {
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Consideration Transferred, Ownership Interest",
        "label": "Business Combination, Consideration Transferred, Ownership Interest",
        "terseLabel": "Contribution of USOR"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredOwnershipInterest",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdditionalPaidInCapital": {
     "auth_ref": [],
     "calculation": {
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Additional-Paid-In Capital",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Additional-Paid-In Capital",
        "negatedTerseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAdditionalPaidInCapital",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Long-Term Operating Lease Liabilities",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Long-Term Operating Lease Liabilities",
        "negatedTerseLabel": "Long-term operating lease liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLongTermOperatingLeaseLiabilities",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mck_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets": {
     "auth_ref": [],
     "calculation": {
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Right-Of-Use Assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Operating Lease Right-Of-Use Assets",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOperatingLeaseRightOfUseAssets",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mck_CashCashEquivalentsRestrictedCashClassifiedWithinAssetsHeldForSalePeriodIncreaseDecrease": {
     "auth_ref": [],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash Classified within Assets Held for Sale, Period Increase (Decrease)",
        "label": "Cash, Cash Equivalents, Restricted Cash Classified within Assets Held for Sale, Period Increase (Decrease)",
        "terseLabel": "Change in cash, cash equivalents, and restricted cash classified as Assets held for sale"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashClassifiedWithinAssetsHeldForSalePeriodIncreaseDecrease",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mck_CherokeeNationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cherokee Nation",
        "label": "Cherokee Nation [Member]",
        "terseLabel": "Cherokee Nation"
       }
      }
     },
     "localname": "CherokeeNationMember",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mck_CommonStockVotingRightsNumberofVotesPerCommonShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Voting Rights, Number of Votes Per Common Share",
        "label": "Common Stock, Voting Rights, Number of Votes Per Common Share",
        "terseLabel": "Number of votes per share of common stock permitted on proposals presented to stockholders (vote)"
       }
      }
     },
     "localname": "CommonStockVotingRightsNumberofVotesPerCommonShare",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/StockholdersDeficitNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mck_CorporateOperatingExpenseandOtherIncomeNet": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate Operating Expense and Other Income, Net",
        "label": "Corporate Operating Expense and Other Income, Net",
        "negatedTerseLabel": "Corporate income (expenses), net"
       }
      }
     },
     "localname": "CorporateOperatingExpenseandOtherIncomeNet",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mck_CurrentAssetLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current Asset / Liability [Member]",
        "label": "Current Asset / Liability [Member]",
        "terseLabel": "Prepaid expenses and other/Other accrued liabilities"
       }
      }
     },
     "localname": "CurrentAssetLiabilityMember",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/HedgingActivitiesScheduleofFairValueofDerivativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mck_DebtInstrumentRedemptionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Redemption Period",
        "label": "Debt Instrument, Redemption Period",
        "terseLabel": "Debt instrument, redemption period (in days)"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriod",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mck_DerivativeNotionalAmountEnteredIntoDuringPeriod": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative, Notional Amount, Entered Into During Period",
        "label": "Derivative, Notional Amount, Entered Into During Period",
        "terseLabel": "Derivative, notional amount, entered into during period"
       }
      }
     },
     "localname": "DerivativeNotionalAmountEnteredIntoDuringPeriod",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mck_DerivativeTerminationProceedsAmortizationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative, Termination Proceeds, Amortization Period",
        "label": "Derivative, Termination Proceeds, Amortization Period",
        "terseLabel": "Derivative termination proceeds, amortization period (in years)"
       }
      }
     },
     "localname": "DerivativeTerminationProceedsAmortizationPeriod",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "mck_DisposalGroupIncludingDiscontinuedOperationConsiderationExpected": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Consideration, Expected",
        "label": "Disposal Group, Including Discontinued Operation, Consideration, Expected",
        "terseLabel": "Gross purchase price"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationConsiderationExpected",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresDivestituresandOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mck_EPSBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnings Per Share, Basic and Diluted",
        "label": "EPS, Basic and Diluted [Abstract]",
        "terseLabel": "Earnings (loss) per common share attributable to McKesson:"
       }
      }
     },
     "localname": "EPSBasicAndDilutedAbstract",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "mck_EUBusinessesDisposalGroupMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "E.U. Businesses (Disposal Group)",
        "label": "E.U. Businesses (Disposal Group) [Member]",
        "terseLabel": "E.U. Businesses (Disposal Group)"
       }
      }
     },
     "localname": "EUBusinessesDisposalGroupMember",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresDivestituresandOtherDetails",
      "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mck_EffectiveIncomeTaxReconciliationTaxExpenseBenefitIntraEntityTransfersOfAssetsOtherThanInventoryAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Reconciliation, Tax Expense (Benefit), Intra-Entity Transfers Of Assets Other Than Inventory, Amount",
        "label": "Effective Income Tax Reconciliation, Tax Expense (Benefit), Intra-Entity Transfers Of Assets Other Than Inventory, Amount",
        "terseLabel": "Tax expense (benefit), intra-entity transfers of assets other than inventory, amount"
       }
      }
     },
     "localname": "EffectiveIncomeTaxReconciliationTaxExpenseBenefitIntraEntityTransfersOfAssetsOtherThanInventoryAmount",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mck_EuroDenominatedNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Euro Denominated Notes [Member]",
        "label": "Euro Denominated Notes [Member]",
        "terseLabel": "Euro Denominated Notes"
       }
      }
     },
     "localname": "EuroDenominatedNotesMember",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/HedgingActivitiesSummaryofForeignCurrencyGainsandLossesfromNonDerivativeInstrumentsDetails",
      "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mck_EvanstonPolicePensionFundVMcKessonCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Evanston Police Pension Fund v. McKesson Corporation",
        "label": "Evanston Police Pension Fund v. McKesson Corporation [Member]",
        "terseLabel": "Evanston Police Pension Fund v. McKesson Corporation"
       }
      }
     },
     "localname": "EvanstonPolicePensionFundVMcKessonCorporationMember",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mck_ExciseTaxPayableCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excise Tax Payable, Current",
        "label": "Excise Tax Payable, Current",
        "terseLabel": "Excise taxes"
       }
      }
     },
     "localname": "ExciseTaxPayableCurrent",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/StockholdersDeficitNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mck_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived Intangible Asset, Expected Amortization, after Year Four",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Four",
        "terseLabel": "Estimated annual amortization expense, thereafter"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mck_FixedInterestRateSwapMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed Interest Rate Swap",
        "label": "Fixed Interest Rate Swap [Member]",
        "terseLabel": "Fixed interest rate swaps"
       }
      }
     },
     "localname": "FixedInterestRateSwapMember",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails",
      "http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails",
      "http://mckesson123.com/role/HedgingActivitiesSummaryofDerivativeInstrumentsGainLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mck_IncomeTaxExaminationEstimateOfPossibleLiabilityAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Tax Examination, Estimate Of Possible Liability Adjustment",
        "label": "Income Tax Examination, Estimate Of Possible Liability Adjustment",
        "terseLabel": "Tax liability increase due to proposed adjustment to taxable income"
       }
      }
     },
     "localname": "IncomeTaxExaminationEstimateOfPossibleLiabilityAdjustment",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mck_IncreaseDecreaseInLitigationReserve": {
     "auth_ref": [],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in Litigation Reserve",
        "label": "Increase (Decrease) in Litigation Reserve",
        "terseLabel": "Litigation liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInLitigationReserve",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mck_IndividualClaimantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Individual Claimant",
        "label": "Individual Claimant [Member]",
        "terseLabel": "An individual"
       }
      }
     },
     "localname": "IndividualClaimantMember",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mck_InternationalSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "International Segment",
        "label": "International Segment [Member]",
        "terseLabel": "International",
        "verboseLabel": "International Segment"
       }
      }
     },
     "localname": "InternationalSegmentMember",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresDivestituresandOtherDetails",
      "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofChangesintheCarryingAmountofGoodwillDetails",
      "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails",
      "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails",
      "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mck_LeaseAndOtherObligationsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease and Other Obligations",
        "label": "Lease and Other Obligations [Member]",
        "terseLabel": "Lease and other obligations"
       }
      }
     },
     "localname": "LeaseAndOtherObligationsMember",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mck_LitigationSettlementAmountAwardedToOtherPartyPercentageOfTotalSettlementToBeUsedToRemediateDamages": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation Settlement, Amount Awarded to Other Party, Percentage of Total Settlement to Be Used to Remediate Damages",
        "label": "Litigation Settlement, Amount Awarded to Other Party, Percentage of Total Settlement to Be Used to Remediate Damages",
        "terseLabel": "Litigation settlement, amount awarded to other party, percentage of total settlement to be used to remediate damages"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedToOtherPartyPercentageOfTotalSettlementToBeUsedToRemediateDamages",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "mck_LitigationSettlementAwardAmountToBeUsedByStateAndLocalGovernment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation Settlement, Award Amount To Be Used by State and Local Government",
        "label": "Litigation Settlement, Award Amount To Be Used by State and Local Government",
        "terseLabel": "Portion of settlement award to be used by state and local government for remediation (percent)"
       }
      }
     },
     "localname": "LitigationSettlementAwardAmountToBeUsedByStateAndLocalGovernment",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mck_LossContingencyClaimsSettledNumberOfJurisdictionsNotParticipatingInSettlement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Claims Settled, Number Of Jurisdictions Not Participating In Settlement",
        "label": "Loss Contingency, Claims Settled, Number Of Jurisdictions Not Participating In Settlement",
        "terseLabel": "Loss contingency, claims settled, number of jurisdictions not participating in settlement"
       }
      }
     },
     "localname": "LossContingencyClaimsSettledNumberOfJurisdictionsNotParticipatingInSettlement",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mck_LossContingencyNumberOfCasesDismissed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number Of Cases Dismissed",
        "label": "Loss Contingency, Number Of Cases Dismissed",
        "terseLabel": "Loss contingency, number of cases dismissed"
       }
      }
     },
     "localname": "LossContingencyNumberOfCasesDismissed",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mck_LossContingencyNumberOfFormerOfficers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number of Former Officers",
        "label": "Loss Contingency, Number of Former Officers",
        "terseLabel": "Number of former officers"
       }
      }
     },
     "localname": "LossContingencyNumberOfFormerOfficers",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mck_LossContingencyNumberOfOtherDefendants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number of Other Defendants",
        "label": "Loss Contingency, Number of Other Defendants",
        "terseLabel": "Number of other national distributors named in suit"
       }
      }
     },
     "localname": "LossContingencyNumberOfOtherDefendants",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mck_LossContingencyNumberOfStatesFiledOnBehalfOf": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number of States Filed On Behalf Of",
        "label": "Loss Contingency, Number of States Filed On Behalf Of",
        "terseLabel": "Number of states filed on behalf of"
       }
      }
     },
     "localname": "LossContingencyNumberOfStatesFiledOnBehalfOf",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mck_LossContingencyNumberofStates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number of States",
        "label": "Loss Contingency, Number of States",
        "terseLabel": "Number of states in which court cases are pending"
       }
      }
     },
     "localname": "LossContingencyNumberofStates",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "mck_McKessonUSOncologyResearchMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "McKesson U.S. Oncology Research",
        "label": "McKesson U.S. Oncology Research [Member]",
        "terseLabel": "USOR"
       }
      }
     },
     "localname": "McKessonUSOncologyResearchMember",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mck_MedicalSurgicalSolutionsSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical-Surgical Solutions Segment [Member]",
        "label": "Medical-Surgical Solutions Segment [Member]",
        "terseLabel": "Medical-Surgical Solutions"
       }
      }
     },
     "localname": "MedicalSurgicalSolutionsSegmentMember",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofChangesintheCarryingAmountofGoodwillDetails",
      "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails",
      "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails",
      "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mck_NationalPrescriptionOpiateLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In re: National Prescription Opiate Litigation [Member]",
        "label": "National Prescription Opiate Litigation [Member]",
        "terseLabel": "National Prescription Opioid Litigation"
       }
      }
     },
     "localname": "NationalPrescriptionOpiateLitigationMember",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesEstimatedAccrualLiabilityDetails",
      "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails",
      "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mck_NativeAmericanTribesOtherThanCherokeeNationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Native American Tribes Other Than Cherokee Nation",
        "label": "Native American Tribes Other Than Cherokee Nation [Member]",
        "terseLabel": "Native American Tribes Other Than Cherokee Nation"
       }
      }
     },
     "localname": "NativeAmericanTribesOtherThanCherokeeNationMember",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mck_NetIncomeLossIncludingPortionAttributabletoNoncontrollingInterestExcludingRedeemableNoncontrollingInterest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Excluding Redeemable Noncontrolling Interest",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Excluding Redeemable Noncontrolling Interest",
        "terseLabel": "Net income (loss)"
       }
      }
     },
     "localname": "NetIncomeLossIncludingPortionAttributabletoNoncontrollingInterestExcludingRedeemableNoncontrollingInterest",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mck_NoncontrollingInterestDecreaseFromReclassificationToLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncontrolling Interest, Decrease from Reclassification to Liability",
        "label": "Noncontrolling Interest, Decrease from Reclassification to Liability",
        "negatedTerseLabel": "Reclassification of recurring compensation to other accrued liabilities"
       }
      }
     },
     "localname": "NoncontrollingInterestDecreaseFromReclassificationToLiability",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mck_OpenMarketShareRepurchaseTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Open Market Share Repurchase Transactions [Member]",
        "label": "Open Market Share Repurchase Transactions [Member]",
        "terseLabel": "Open Market Share Repurchase Transactions"
       }
      }
     },
     "localname": "OpenMarketShareRepurchaseTransactionsMember",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/StockholdersDeficitNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mck_OtherNonCurrentAssetsAndLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Non-Current Assets and Liabilities",
        "label": "Other Non-Current Assets and Liabilities [Member]",
        "terseLabel": "Other non-current assets/liabilities"
       }
      }
     },
     "localname": "OtherNonCurrentAssetsAndLiabilitiesMember",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/HedgingActivitiesScheduleofFairValueofDerivativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mck_PaymentsForPurchaseOfGovernmentObligationsForSatisfactionAndDischargeOfLongTermDebt": {
     "auth_ref": [],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments For Purchase Of Government Obligations For Satisfaction And Discharge Of Long-Term Debt",
        "label": "Payments For Purchase Of Government Obligations For Satisfaction And Discharge Of Long-Term Debt",
        "negatedTerseLabel": "Purchase of U.S. government obligations for the satisfaction and discharge of long-term debt",
        "terseLabel": "Purchase of U.S. government obligations for the satisfaction and discharge of long-term debt"
       }
      }
     },
     "localname": "PaymentsForPurchaseOfGovernmentObligationsForSatisfactionAndDischargeOfLongTermDebt",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mck_PrescriptionTechnologySolutionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "International Segment [Member]",
        "label": "Prescription Technology Solutions [Member]",
        "terseLabel": "Prescription Technology Solutions"
       }
      }
     },
     "localname": "PrescriptionTechnologySolutionsMember",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofChangesintheCarryingAmountofGoodwillDetails",
      "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails",
      "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails",
      "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mck_RestructuringImpairmentAndOtherRelatedCharges": {
     "auth_ref": [],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring, Impairment and Other Related Charges",
        "label": "Restructuring, Impairment and Other Related Charges",
        "negatedTerseLabel": "Restructuring, impairment, and related charges, net",
        "terseLabel": "Restructuring, impairment, and related charges, net"
       }
      }
     },
     "localname": "RestructuringImpairmentAndOtherRelatedCharges",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mck_RevenueDerivedFromServicesPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Derived From Services, Percentage",
        "label": "Revenue Derived From Services, Percentage",
        "terseLabel": "Revenue derived from services, percentage (approximately or less than)"
       }
      }
     },
     "localname": "RevenueDerivedFromServicesPercentage",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "mck_RxSavingsSolutionsLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rx Savings Solutions, LLC",
        "label": "Rx Savings Solutions, LLC [Member]",
        "terseLabel": "Rx Savings Solutions, LLC"
       }
      }
     },
     "localname": "RxSavingsSolutionsLLCMember",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails",
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedRxSavingsSolutionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mck_RxTsSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RxTs Segment",
        "label": "RxTs Segment [Member]",
        "terseLabel": "RxTs Segment"
       }
      }
     },
     "localname": "RxTsSegmentMember",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails",
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedRxSavingsSolutionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mck_SCRIOncologyLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SCRI Oncology, LLC",
        "label": "SCRI Oncology, LLC [Member]",
        "terseLabel": "SCRI Oncology, LLC"
       }
      }
     },
     "localname": "SCRIOncologyLLCMember",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails",
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mck_SarahCannonResearchInstituteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sarah Cannon Research Institute",
        "label": "Sarah Cannon Research Institute [Member]",
        "terseLabel": "SCRI"
       }
      }
     },
     "localname": "SarahCannonResearchInstituteMember",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mck_SeniorUnsecuredCreditFacilityThe2022CreditFacilityCanadianDollarBritishPoundSterlingAndEurosSublimitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Credit Facility (the 2022 Credit Facility), Canadian Dollar, British Pound Sterling, and Euros Sublimit",
        "label": "Senior Unsecured Credit Facility (the 2022 Credit Facility), Canadian Dollar, British Pound Sterling, and Euros Sublimit [Member]",
        "terseLabel": "Senior Unsecured Credit Facility (the 2022 Credit Facility), Canadian Dollar, British Pound Sterling, and Euros Sublimit"
       }
      }
     },
     "localname": "SeniorUnsecuredCreditFacilityThe2022CreditFacilityCanadianDollarBritishPoundSterlingAndEurosSublimitMember",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/DebtandFinancingActivitiesRevolvingCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mck_SeniorUnsecuredCreditFacilityThe2022CreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Credit Facility (the 2022 Credit Facility)",
        "label": "Senior Unsecured Credit Facility (the 2022 Credit Facility) [Member]",
        "terseLabel": "Senior Unsecured Credit Facility (the 2022 Credit Facility)"
       }
      }
     },
     "localname": "SeniorUnsecuredCreditFacilityThe2022CreditFacilityMember",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/DebtandFinancingActivitiesRevolvingCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mck_SeniorUnsecuredCreditFacilitythe2020CreditFacilityCanadianDollarBritishPoundSterlingandEurosSublimitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Credit Facility (the 2020 Credit Facility), Canadian Dollar, British Pound Sterling, and Euros Sublimit [Member]",
        "label": "Senior Unsecured Credit Facility (the 2020 Credit Facility), Canadian Dollar, British Pound Sterling, and Euros Sublimit [Member]",
        "terseLabel": "Senior Unsecured Credit Facility (the 2020 Credit Facility), Canadian Dollar, British Pound Sterling, and Euros Sublimit"
       }
      }
     },
     "localname": "SeniorUnsecuredCreditFacilitythe2020CreditFacilityCanadianDollarBritishPoundSterlingandEurosSublimitMember",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/DebtandFinancingActivitiesRevolvingCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mck_SeniorUnsecuredCreditFacilitythe2020CreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Credit Facility (the 2020 Credit Facility) [Member]",
        "label": "Senior Unsecured Credit Facility (the 2020 Credit Facility) [Member]",
        "terseLabel": "Senior Unsecured Credit Facility (the 2020 Credit Facility)"
       }
      }
     },
     "localname": "SeniorUnsecuredCreditFacilitythe2020CreditFacilityMember",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/DebtandFinancingActivitiesRevolvingCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mck_StateOfAlabamaAndSubdivisionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "State of Alabama and Subdivisions",
        "label": "State of Alabama and Subdivisions [Member]",
        "terseLabel": "State of Alabama and Subdivisions"
       }
      }
     },
     "localname": "StateOfAlabamaAndSubdivisionsMember",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mck_StateOfWestVirginiaAndSubdivisionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "State of West Virginia and Subdivisions",
        "label": "State of West Virginia and Subdivisions [Member]",
        "terseLabel": "State of West Virginia and Subdivisions"
       }
      }
     },
     "localname": "StateOfWestVirginiaAndSubdivisionsMember",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mck_StockIssuedDuringPeriodSharesEmployeeStockPlansNetOfForfeitures": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Employee Stock Plans Net of Forfeitures",
        "label": "Stock Issued During Period, Shares, Employee Stock Plans Net of Forfeitures",
        "terseLabel": "Issuance of shares under employee plans, net of forfeitures (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPlansNetOfForfeitures",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "mck_StockIssuedDuringPeriodValueEmployeeStockPlansNetOfForfeitures": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Employee Stock Plans Net of Forfeitures",
        "label": "Stock Issued During Period, Value, Employee Stock Plans Net of Forfeitures",
        "terseLabel": "Issuance of shares under employee plans, net of forfeitures"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPlansNetOfForfeitures",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "mck_StrategicGrowthInitiativePlanOperationalEfficienciesAndCostOptimizationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Strategic Growth Initiative Plan - Operational Efficiencies and Cost Optimization",
        "label": "Strategic Growth Initiative Plan - Operational Efficiencies and Cost Optimization [Member]",
        "terseLabel": "Strategic Growth Initiative Plan - Operational Efficiencies and Cost Optimization"
       }
      }
     },
     "localname": "StrategicGrowthInitiativePlanOperationalEfficienciesAndCostOptimizationMember",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mck_ThreeLargestUSPharmaceuticalDistributorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Largest U.S. Pharmaceutical Distributors",
        "label": "Three Largest U.S. Pharmaceutical Distributors [Member]",
        "terseLabel": "Three Largest U.S. Pharmaceutical Distributors"
       }
      }
     },
     "localname": "ThreeLargestUSPharmaceuticalDistributorsMember",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mck_ThreeNationalPharmaceuticalDistributorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three National Pharmaceutical Distributors",
        "label": "Three National Pharmaceutical Distributors [Member]",
        "terseLabel": "Three National Pharmaceutical Distributors"
       }
      }
     },
     "localname": "ThreeNationalPharmaceuticalDistributorsMember",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mck_UKBusinessesDisposalGroupMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "U.K. Businesses (Disposal Group)",
        "label": "U.K. Businesses (Disposal Group) [Member]",
        "terseLabel": "U.K. Disposal Group (Disposal Group)"
       }
      }
     },
     "localname": "UKBusinessesDisposalGroupMember",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresDivestituresandOtherDetails",
      "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mck_USPharmaceuticalSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "U.S. Pharmaceutical Segment [Member]",
        "label": "U.S. Pharmaceutical Segment [Member]",
        "terseLabel": "U.S. Pharmaceutical"
       }
      }
     },
     "localname": "USPharmaceuticalSegmentMember",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails",
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails",
      "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofChangesintheCarryingAmountofGoodwillDetails",
      "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails",
      "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails",
      "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "mck_UnitedStatesExRelHartVMcKessonCorporationEtAl15CV00903RAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "United States Ex Rel. Hart V. McKesson Corporation, Et Al 15-CV-00903-RA",
        "label": "United States Ex Rel. Hart V. McKesson Corporation, Et Al 15-CV-00903-RA [Member]",
        "terseLabel": "United States Ex Rel. Hart V. McKesson Corporation, Et Al 15-CV-00903-RA"
       }
      }
     },
     "localname": "UnitedStatesExRelHartVMcKessonCorporationEtAl15CV00903RAMember",
     "nsuri": "http://mckesson123.com/20230630",
     "presentation": [
      "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r279",
      "r318",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r335",
      "r339",
      "r388",
      "r389",
      "r390",
      "r391",
      "r393",
      "r394",
      "r396",
      "r398",
      "r399",
      "r901",
      "r902"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails",
      "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails",
      "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r279",
      "r318",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r335",
      "r339",
      "r388",
      "r389",
      "r390",
      "r391",
      "r393",
      "r394",
      "r396",
      "r398",
      "r399",
      "r901",
      "r902"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails",
      "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails",
      "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r277",
      "r278",
      "r405",
      "r432",
      "r555",
      "r733",
      "r735"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CurrencyAxis": {
     "auth_ref": [
      "r914"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency [Axis]",
        "terseLabel": "Currency [Axis]"
       }
      }
     },
     "localname": "CurrencyAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails",
      "http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails",
      "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails",
      "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r382",
      "r383",
      "r384",
      "r385",
      "r454",
      "r561",
      "r605",
      "r637",
      "r638",
      "r689",
      "r691",
      "r693",
      "r694",
      "r705",
      "r726",
      "r727",
      "r739",
      "r746",
      "r753",
      "r757",
      "r903",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails",
      "http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails",
      "http://mckesson123.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r382",
      "r383",
      "r384",
      "r385",
      "r454",
      "r561",
      "r605",
      "r637",
      "r638",
      "r689",
      "r691",
      "r693",
      "r694",
      "r705",
      "r726",
      "r727",
      "r739",
      "r746",
      "r753",
      "r757",
      "r903",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails",
      "http://mckesson123.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r382",
      "r383",
      "r384",
      "r385",
      "r447",
      "r454",
      "r479",
      "r480",
      "r481",
      "r560",
      "r561",
      "r605",
      "r637",
      "r638",
      "r689",
      "r691",
      "r693",
      "r694",
      "r705",
      "r726",
      "r727",
      "r739",
      "r746",
      "r753",
      "r757",
      "r760",
      "r891",
      "r903",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails",
      "http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails",
      "http://mckesson123.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r382",
      "r383",
      "r384",
      "r385",
      "r447",
      "r454",
      "r479",
      "r480",
      "r481",
      "r560",
      "r561",
      "r605",
      "r637",
      "r638",
      "r689",
      "r691",
      "r693",
      "r694",
      "r705",
      "r726",
      "r727",
      "r739",
      "r746",
      "r753",
      "r757",
      "r760",
      "r891",
      "r903",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails",
      "http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails",
      "http://mckesson123.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r277",
      "r278",
      "r405",
      "r432",
      "r555",
      "r734",
      "r735"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r343",
      "r344",
      "r633",
      "r634",
      "r635",
      "r690",
      "r692",
      "r695",
      "r706",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r729",
      "r747",
      "r760",
      "r904",
      "r927"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails",
      "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r343",
      "r344",
      "r633",
      "r634",
      "r635",
      "r690",
      "r692",
      "r695",
      "r706",
      "r714",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r729",
      "r747",
      "r760",
      "r904",
      "r927"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2023",
     "presentation": [
      "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails",
      "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]",
        "terseLabel": "AOCI Attributable to Parent, Net of Tax [Roll Forward]"
       }
      }
     },
     "localname": "AOCIAttributableToParentNetOfTaxRollForward",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AcceleratedShareRepurchasesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accelerated Share Repurchases [Line Items]",
        "terseLabel": "Accelerated Share Repurchases [Line Items]"
       }
      }
     },
     "localname": "AcceleratedShareRepurchasesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/StockholdersDeficitNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AcceleratedShareRepurchasesTable": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table reflecting activity in an accelerated share repurchase (ASR) program.",
        "label": "Accelerated Share Repurchases [Table]",
        "terseLabel": "Accelerated Share Repurchases [Table]"
       }
      }
     },
     "localname": "AcceleratedShareRepurchasesTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/StockholdersDeficitNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r39",
      "r756"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Drafts and accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Other accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://mckesson123.com/role/StockholdersDeficitNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesMember": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.",
        "label": "Accrued Liabilities [Member]",
        "terseLabel": "Accrued Liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r11",
      "r26",
      "r52",
      "r260",
      "r860",
      "r861"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) related to gain (loss) component of defined benefit plans including the portion attributable to the noncontrolling interest.",
        "label": "Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Unrealized Losses and Other Components of Benefit Plans, Net of Tax"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentNetGainLossIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r10",
      "r26",
      "r52",
      "r260",
      "r860",
      "r861"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, including the portion attributable to the noncontrolling interest.",
        "label": "Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Foreign Currency Translation Adjustments, Net of Tax"
       }
      }
     },
     "localname": "AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember": {
     "auth_ref": [
      "r252",
      "r260",
      "r514",
      "r860",
      "r861"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, including portion attributable to noncontrolling interest.",
        "label": "Accumulated Gain (Loss), Cash Flow Hedge, Including Noncontrolling Interest [Member]",
        "terseLabel": "Unrealized Gains (Losses) on Cash Flow and Other Hedges, Net of Tax"
       }
      }
     },
     "localname": "AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [
      "r260",
      "r261",
      "r542",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r51",
      "r52",
      "r169",
      "r246",
      "r578",
      "r610",
      "r611"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r260",
      "r261",
      "r542",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r8",
      "r26",
      "r52",
      "r521",
      "r524",
      "r554",
      "r606",
      "r607",
      "r859",
      "r860",
      "r861",
      "r871",
      "r872",
      "r873"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "verboseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Weighted average life of intangibles"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r163",
      "r756",
      "r929"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r483",
      "r484",
      "r485",
      "r621",
      "r871",
      "r872",
      "r873",
      "r910",
      "r931"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentForAmortization": {
     "auth_ref": [
      "r19",
      "r74"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.",
        "label": "Amortization",
        "terseLabel": "Amortization"
       }
      }
     },
     "localname": "AdjustmentForAmortization",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r90",
      "r91",
      "r455"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r19",
      "r71",
      "r74"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization expense of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Potentially dilutive securities excluded from diluted earnings per share (less than)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/EarningsPerCommonShareNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AociIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r8",
      "r26",
      "r52",
      "r859",
      "r860",
      "r861"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, including the portion attributable to the noncontrolling interest. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Total Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AociIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r211",
      "r241",
      "r275",
      "r316",
      "r331",
      "r337",
      "r346",
      "r388",
      "r389",
      "r391",
      "r392",
      "r393",
      "r395",
      "r397",
      "r399",
      "r400",
      "r510",
      "r515",
      "r540",
      "r573",
      "r657",
      "r756",
      "r770",
      "r901",
      "r902",
      "r916"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r235",
      "r248",
      "r275",
      "r346",
      "r388",
      "r389",
      "r391",
      "r392",
      "r393",
      "r395",
      "r397",
      "r399",
      "r400",
      "r510",
      "r515",
      "r540",
      "r756",
      "r901",
      "r902",
      "r916"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": {
     "auth_ref": [
      "r7",
      "r143",
      "r154",
      "r191",
      "r233",
      "r234"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Assets",
        "verboseLabel": "Divested net assets"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresDivestituresandOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/HedgingActivitiesScheduleofFairValueofDerivativesDetails",
      "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r121",
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/HedgingActivitiesScheduleofFairValueofDerivativesDetails",
      "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "verboseLabel": "Significant Accounting Policies"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/SignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r505",
      "r751",
      "r752"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails",
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedRxSavingsSolutionsDetails",
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r93",
      "r95",
      "r505",
      "r751",
      "r752"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails",
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedRxSavingsSolutionsDetails",
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionContingentConsiderationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition, Contingent Consideration [Line Items]",
        "terseLabel": "Business Acquisition, Contingent Consideration [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionContingentConsiderationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedRxSavingsSolutionsDetails",
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.",
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "terseLabel": "Business acquisition, percentage of controlling interest in combined business"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount": {
     "auth_ref": [
      "r103"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of goodwill arising from a business combination that is expected to be deductible for tax purposes.",
        "label": "Business Acquisition, Goodwill, Expected Tax Deductible Amount",
        "terseLabel": "Goodwill, expected tax deductible amount"
       }
      }
     },
     "localname": "BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the fair value of the noncontrolling interest in the acquiree at the acquisition date.",
        "label": "Business Combination, Acquisition of Less than 100 Percent, Noncontrolling Interest, Fair Value",
        "negatedTerseLabel": "Noncontrolling interest",
        "terseLabel": "Noncontrolling interest"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionOfLessThan100PercentNoncontrollingInterestFairValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails",
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r2",
      "r3",
      "r23"
     ],
     "calculation": {
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Total purchase consideration",
        "totalLabel": "Total purchase consideration"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedRxSavingsSolutionsDetails",
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r508",
      "r865"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "negatedLabel": "Fair value adjustment gain"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails",
      "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r4",
      "r102",
      "r507"
     ],
     "calculation": {
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "totalLabel": "Contingent consideration",
        "verboseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails",
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedRxSavingsSolutionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r5",
      "r102"
     ],
     "calculation": {
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationContingentConsiderationLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r5",
      "r102"
     ],
     "calculation": {
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationContingentConsiderationLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets": {
     "auth_ref": [
      "r97"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets",
        "terseLabel": "Current assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedRxSavingsSolutionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from customers or clients for goods or services, including trade receivables, that have been delivered or sold in the normal course of business, and amounts due from others, including related parties expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Receivables",
        "terseLabel": "Receivables"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities",
        "negatedTerseLabel": "Current liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedRxSavingsSolutionsDetails",
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r96",
      "r97"
     ],
     "calculation": {
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "terseLabel": "Acquired identifiable intangible assets",
        "verboseLabel": "Intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails",
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedRxSavingsSolutionsDetails",
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities [Abstract]",
        "terseLabel": "Identifiable assets acquired and liabilities assumed:"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedRxSavingsSolutionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r96",
      "r97"
     ],
     "calculation": {
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net",
        "totalLabel": "Total identifiable net assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedRxSavingsSolutionsDetails",
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other",
        "negatedTerseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": {
     "auth_ref": [
      "r97"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedRxSavingsSolutionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "auth_ref": [
      "r96",
      "r97"
     ],
     "calculation": {
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "terseLabel": "Property, plant, and equipment"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized as of the acquisition date for the assets, including goodwill, in excess of (less than) the aggregate liabilities assumed, less the noncontrolling interest in the acquiree.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Less Noncontrolling Interest",
        "totalLabel": "Net assets acquired"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedRxSavingsSolutionsDetails",
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]",
        "terseLabel": "Purchase consideration:"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedRxSavingsSolutionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessExitCosts1": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_RestructuringCharges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Business Exit Costs",
        "terseLabel": "Exit and other-related costs"
       }
      }
     },
     "localname": "BusinessExitCosts1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r61",
      "r237",
      "r730"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents at end of period"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r61",
      "r180",
      "r272"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of period",
        "totalLabel": "Cash, cash equivalents, and restricted cash at end of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r6",
      "r180"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowHedgingMember": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.",
        "label": "Cash Flow Hedging [Member]",
        "terseLabel": "Cash Flow Hedges"
       }
      }
     },
     "localname": "CashFlowHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails",
      "http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails",
      "http://mckesson123.com/role/HedgingActivitiesSummaryofDerivativeInstrumentsGainLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r229",
      "r243",
      "r244",
      "r245",
      "r275",
      "r296",
      "r300",
      "r302",
      "r304",
      "r310",
      "r311",
      "r346",
      "r388",
      "r391",
      "r392",
      "r393",
      "r399",
      "r400",
      "r430",
      "r431",
      "r434",
      "r437",
      "r443",
      "r540",
      "r613",
      "r614",
      "r615",
      "r616",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r645",
      "r666",
      "r684",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r847",
      "r868",
      "r874"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r195",
      "r762",
      "r763",
      "r764",
      "r767"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/DebtandFinancingActivitiesCommercialPaperNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r193",
      "r379",
      "r380",
      "r715",
      "r894"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingent Liabilities"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CommitmentsandContingentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "auth_ref": [
      "r82",
      "r716"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Dividends declared per common share (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT",
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICITParenthetical",
      "http://mckesson123.com/role/StockholdersDeficitNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r758",
      "r759",
      "r760",
      "r762",
      "r763",
      "r764",
      "r767",
      "r871",
      "r872",
      "r910",
      "r928",
      "r931"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT",
      "http://mckesson123.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r162",
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r162",
      "r577",
      "r756"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.01 par value, 800 shares authorized, 278 and 277 shares issued at June 30, 2023 and March 31, 2023, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComparabilityOfPriorYearFinancialData": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reporting any exceptions to the comparability of prior year financial data with data shown for the most recent accounting period.",
        "label": "Comparability of Prior Year Financial Data, Policy [Policy Text Block]",
        "terseLabel": "Results of Operations"
       }
      }
     },
     "localname": "ComparabilityOfPriorYearFinancialData",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r53",
      "r257",
      "r259",
      "r267",
      "r569",
      "r591"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income attributable to McKesson Corporation"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income, net of tax"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r16",
      "r108",
      "r112",
      "r257",
      "r259",
      "r266",
      "r568",
      "r590"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Comprehensive income attributable to noncontrolling interests"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r112",
      "r207",
      "r257",
      "r259",
      "r265",
      "r567",
      "r589"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r109",
      "r736"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CorporateNonSegmentMember": {
     "auth_ref": [
      "r32",
      "r330",
      "r331",
      "r332",
      "r333",
      "r339",
      "r877"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.",
        "label": "Corporate, Non-Segment [Member]",
        "terseLabel": "Corporate"
       }
      }
     },
     "localname": "CorporateNonSegmentMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails",
      "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails",
      "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r176",
      "r562"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "negatedLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/DebtandFinancingActivitiesCommercialPaperNarrativeDetails",
      "http://mckesson123.com/role/DebtandFinancingActivitiesRevolvingCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/DebtandFinancingActivitiesCommercialPaperNarrativeDetails",
      "http://mckesson123.com/role/DebtandFinancingActivitiesRevolvingCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrencySwapMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Swap involving the exchange of principal and interest in one currency for another currency.",
        "label": "Currency Swap [Member]",
        "netLabel": "Cross-currency swaps",
        "terseLabel": "Derivatives designated as net investment hedges",
        "verboseLabel": "Net Investment Hedges"
       }
      }
     },
     "localname": "CurrencySwapMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails",
      "http://mckesson123.com/role/HedgingActivitiesScheduleofFairValueofDerivativesDetails",
      "http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails",
      "http://mckesson123.com/role/HedgingActivitiesSummaryofDerivativeInstrumentsGainLossDetails",
      "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerRelationshipsMember": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships.",
        "label": "Customer Relationships [Member]",
        "terseLabel": "Customer relationships"
       }
      }
     },
     "localname": "CustomerRelationshipsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtAndCapitalLeaseObligations": {
     "auth_ref": [
      "r216"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term and long-term debt and lease obligation.",
        "label": "Debt and Lease Obligation",
        "terseLabel": "Long-term debt"
       }
      }
     },
     "localname": "DebtAndCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r194",
      "r273",
      "r401",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r417",
      "r424",
      "r425",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "verboseLabel": "Debt and Financing Activities"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/DebtandFinancingActivities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r36",
      "r159",
      "r160",
      "r212",
      "r213",
      "r279",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r408",
      "r413",
      "r414",
      "r415",
      "r416",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r551",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r869"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails",
      "http://mckesson123.com/role/DebtandFinancingActivitiesRevolvingCreditFacilitiesNarrativeDetails",
      "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails",
      "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails",
      "http://mckesson123.com/role/HedgingActivitiesSummaryofForeignCurrencyGainsandLossesfromNonDerivativeInstrumentsDetails",
      "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r138",
      "r140",
      "r402",
      "r551",
      "r742",
      "r743"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt principal amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r415",
      "r539",
      "r742",
      "r743"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/FairValueMeasurementsScheduleofLongTermDebtisRecordedatAmortizedCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r44",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate on debt instrument (percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails",
      "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [
      "r279",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r408",
      "r413",
      "r414",
      "r415",
      "r416",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r426",
      "r551",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r869"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails",
      "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r45",
      "r279",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r408",
      "r413",
      "r414",
      "r415",
      "r416",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r551",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r869"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails",
      "http://mckesson123.com/role/DebtandFinancingActivitiesRevolvingCreditFacilitiesNarrativeDetails",
      "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails",
      "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails",
      "http://mckesson123.com/role/HedgingActivitiesSummaryofForeignCurrencyGainsandLossesfromNonDerivativeInstrumentsDetails",
      "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.",
        "label": "Debt Instrument, Redemption Price, Percentage",
        "terseLabel": "Redemption price percentage of principal (percent)"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentRepurchasedFaceAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of the original debt instrument that was repurchased.",
        "label": "Debt Instrument, Repurchased Face Amount",
        "terseLabel": "Debt principal redeemed"
       }
      }
     },
     "localname": "DebtInstrumentRepurchasedFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r45",
      "r86",
      "r87",
      "r137",
      "r138",
      "r140",
      "r141",
      "r197",
      "r198",
      "r279",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r408",
      "r413",
      "r414",
      "r415",
      "r416",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r426",
      "r551",
      "r741",
      "r742",
      "r743",
      "r744",
      "r745",
      "r869"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails",
      "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Credit facility term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/DebtandFinancingActivitiesRevolvingCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r488",
      "r489",
      "r574"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Long-term deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r19",
      "r75"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetNotionalAmount": {
     "auth_ref": [
      "r696",
      "r699",
      "r701",
      "r703",
      "r906",
      "r907",
      "r908"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payments on the derivative asset.",
        "label": "Derivative Asset, Notional Amount",
        "terseLabel": "U.S. Dollar notional amount, asset"
       }
      }
     },
     "localname": "DerivativeAssetNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/HedgingActivitiesScheduleofFairValueofDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [
      "r636",
      "r638",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r658",
      "r659",
      "r660",
      "r661",
      "r672",
      "r673",
      "r674",
      "r675",
      "r678",
      "r679",
      "r680",
      "r681",
      "r696",
      "r698",
      "r702",
      "r704",
      "r758",
      "r760"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative, Name [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails",
      "http://mckesson123.com/role/HedgingActivitiesScheduleofFairValueofDerivativesDetails",
      "http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails",
      "http://mckesson123.com/role/HedgingActivitiesSummaryofDerivativeInstrumentsGainLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeAsset": {
     "auth_ref": [
      "r33",
      "r124",
      "r168",
      "r249",
      "r735"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.",
        "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset",
        "terseLabel": "Fair value of derivative, asset"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeAsset",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/HedgingActivitiesScheduleofFairValueofDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "auth_ref": [
      "r33",
      "r124",
      "r168",
      "r249",
      "r735"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
        "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset",
        "terseLabel": "Fair value of derivative, liability"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/HedgingActivitiesScheduleofFairValueofDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r122",
      "r125",
      "r127",
      "r130",
      "r636",
      "r638",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r658",
      "r659",
      "r660",
      "r661",
      "r672",
      "r673",
      "r674",
      "r675",
      "r678",
      "r679",
      "r680",
      "r681",
      "r696",
      "r698",
      "r702",
      "r704",
      "r735",
      "r758",
      "r760"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative, by Nature [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails",
      "http://mckesson123.com/role/HedgingActivitiesScheduleofFairValueofDerivativesDetails",
      "http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails",
      "http://mckesson123.com/role/HedgingActivitiesSummaryofDerivativeInstrumentsGainLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r210",
      "r519",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "terseLabel": "Hedging Activities"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/HedgingActivities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r28",
      "r122",
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails",
      "http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails",
      "http://mckesson123.com/role/HedgingActivitiesSummaryofDerivativeInstrumentsGainLossDetails",
      "http://mckesson123.com/role/HedgingActivitiesSummaryofForeignCurrencyGainsandLossesfromNonDerivativeInstrumentsDetails",
      "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeLiabilityNotionalAmount": {
     "auth_ref": [
      "r697",
      "r699",
      "r700",
      "r703",
      "r906",
      "r907",
      "r908"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payments on the derivative liability.",
        "label": "Derivative Liability, Notional Amount",
        "terseLabel": "U.S. Dollar, notional amount, liability"
       }
      }
     },
     "localname": "DerivativeLiabilityNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/HedgingActivitiesScheduleofFairValueofDerivativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative [Line Items]"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r907",
      "r908"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Notional",
        "verboseLabel": "Derivative, notional amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails",
      "http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r28",
      "r113",
      "r114",
      "r116",
      "r120",
      "r123",
      "r127",
      "r131",
      "r132",
      "r134",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativesFairValueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivatives, Fair Value [Line Items]",
        "terseLabel": "Derivatives, Fair Value [Line Items]"
       }
      }
     },
     "localname": "DerivativesFairValueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/HedgingActivitiesScheduleofFairValueofDerivativesDetails",
      "http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails",
      "http://mckesson123.com/role/HedgingActivitiesSummaryofDerivativeInstrumentsGainLossDetails",
      "http://mckesson123.com/role/HedgingActivitiesSummaryofForeignCurrencyGainsandLossesfromNonDerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Derivatives designated for hedge accounting"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails",
      "http://mckesson123.com/role/HedgingActivitiesScheduleofFairValueofDerivativesDetails",
      "http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails",
      "http://mckesson123.com/role/HedgingActivitiesSummaryofDerivativeInstrumentsGainLossDetails",
      "http://mckesson123.com/role/HedgingActivitiesSummaryofForeignCurrencyGainsandLossesfromNonDerivativeInstrumentsDetails",
      "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by disposal group classification.",
        "label": "Disposal Group Classification [Axis]",
        "terseLabel": "Disposal Group Classification [Axis]"
       }
      }
     },
     "localname": "DisposalGroupClassificationAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresDivestituresandOtherDetails",
      "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails",
      "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.",
        "label": "Disposal Group Classification [Domain]",
        "terseLabel": "Disposal Group Classification [Domain]"
       }
      }
     },
     "localname": "DisposalGroupClassificationDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresDivestituresandOtherDetails",
      "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails",
      "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": {
     "auth_ref": [
      "r20",
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations.",
        "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]",
        "terseLabel": "Disposed of by sale"
       }
      }
     },
     "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresDivestituresandOtherDetails",
      "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember": {
     "auth_ref": [
      "r14",
      "r30",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disposal group that is classified as held-for-sale. Excludes disposals classified as discontinued operations.",
        "label": "Disposal Group, Held-for-Sale, Not Discontinued Operations [Member]",
        "terseLabel": "Held-for-sale"
       }
      }
     },
     "localname": "DisposalGroupHeldforsaleNotDiscontinuedOperationsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown": {
     "auth_ref": [
      "r19",
      "r20",
      "r190"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a disposal group. Excludes discontinued operations.",
        "label": "Disposal Group, Not Discontinued Operation, Loss (Gain) on Write-down",
        "netLabel": "European businesses, disposal group, losses (gains)",
        "terseLabel": "Loss (gain) to remeasure disposal group to fair value",
        "verboseLabel": "European businesses held for sale"
       }
      }
     },
     "localname": "DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresDivestituresandOtherDetails",
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [
      "r751",
      "r752"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresDivestituresandOtherDetails",
      "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails",
      "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DividendsCommonStockCash": {
     "auth_ref": [
      "r199"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.",
        "label": "Dividends, Common Stock, Cash",
        "negatedTerseLabel": "Cash dividends declared"
       }
      }
     },
     "localname": "DividendsCommonStockCash",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings per common share attributable to McKesson Corporation"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r268",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r294",
      "r296",
      "r302",
      "r303",
      "r304",
      "r308",
      "r529",
      "r530",
      "r570",
      "r592",
      "r737"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "totalLabel": "Total (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Basic"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r268",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r296",
      "r302",
      "r303",
      "r304",
      "r308",
      "r529",
      "r530",
      "r570",
      "r592",
      "r737"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "totalLabel": "Total (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted [Abstract]",
        "terseLabel": "Diluted"
       }
      }
     },
     "localname": "EarningsPerShareDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDilutedLineItems": {
     "auth_ref": [
      "r296",
      "r300",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]",
        "terseLabel": "Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]"
       }
      }
     },
     "localname": "EarningsPerShareDilutedLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r293",
      "r305",
      "r306",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Earnings Per Common Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/EarningsPerCommonShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r541"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of exchange rate changes on cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Reported income tax expense (benefit) rates (percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": {
     "auth_ref": [
      "r849",
      "r905"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount",
        "terseLabel": "Tax expense (benefit), share-based payment arrangement"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r27",
      "r230",
      "r260",
      "r261",
      "r262",
      "r280",
      "r281",
      "r282",
      "r284",
      "r290",
      "r292",
      "r309",
      "r347",
      "r348",
      "r444",
      "r483",
      "r484",
      "r485",
      "r497",
      "r498",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r528",
      "r542",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r554",
      "r606",
      "r607",
      "r608",
      "r621",
      "r684"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT",
      "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r242",
      "r538",
      "r732"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.",
        "label": "Equity Securities, FV-NI, Current",
        "terseLabel": "Investments in equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EstimatedInsuranceRecoveries": {
     "auth_ref": [
      "r857"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of amounts expected to be recovered under the terms of insurance contracts.",
        "label": "Estimated Insurance Recoveries",
        "terseLabel": "Probable loss recovery"
       }
      }
     },
     "localname": "EstimatedInsuranceRecoveries",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [
      "r532",
      "r533",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/FairValueMeasurementsNarrativeDetails",
      "http://mckesson123.com/role/FairValueMeasurementsScheduleofLongTermDebtisRecordedatAmortizedCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r532",
      "r533",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/FairValueMeasurementsNarrativeDetails",
      "http://mckesson123.com/role/FairValueMeasurementsScheduleofLongTermDebtisRecordedatAmortizedCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
     "auth_ref": [
      "r135",
      "r136"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Derivatives"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/HedgingActivitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r415",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r533",
      "r557",
      "r558",
      "r559",
      "r742",
      "r743",
      "r748",
      "r749",
      "r750"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/FairValueMeasurementsNarrativeDetails",
      "http://mckesson123.com/role/FairValueMeasurementsScheduleofLongTermDebtisRecordedatAmortizedCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r532",
      "r533",
      "r534",
      "r535",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/FairValueMeasurementsNarrativeDetails",
      "http://mckesson123.com/role/FairValueMeasurementsScheduleofLongTermDebtisRecordedatAmortizedCostDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueHedgingMember": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk.",
        "label": "Fair Value Hedging [Member]",
        "terseLabel": "Fair Value Hedges"
       }
      }
     },
     "localname": "FairValueHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails",
      "http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r415",
      "r448",
      "r453",
      "r533",
      "r557",
      "r748",
      "r749",
      "r750"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Fair value, inputs, level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r415",
      "r448",
      "r453",
      "r533",
      "r558",
      "r742",
      "r743",
      "r748",
      "r749",
      "r750"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Fair value, inputs, level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/FairValueMeasurementsScheduleofLongTermDebtisRecordedatAmortizedCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/FairValueMeasurementsNarrativeDetails",
      "http://mckesson123.com/role/FairValueMeasurementsScheduleofLongTermDebtisRecordedatAmortizedCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r415",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r557",
      "r558",
      "r559",
      "r742",
      "r743",
      "r748",
      "r749",
      "r750"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/FairValueMeasurementsNarrativeDetails",
      "http://mckesson123.com/role/FairValueMeasurementsScheduleofLongTermDebtisRecordedatAmortizedCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r531",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/FairValueMeasurementsNarrativeDetails",
      "http://mckesson123.com/role/FairValueMeasurementsScheduleofLongTermDebtisRecordedatAmortizedCostDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": {
     "auth_ref": [
      "r121",
      "r123",
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]",
        "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]"
       }
      }
     },
     "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/HedgingActivitiesScheduleofFairValueofDerivativesDetails",
      "http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails",
      "http://mckesson123.com/role/HedgingActivitiesSummaryofDerivativeInstrumentsGainLossDetails",
      "http://mckesson123.com/role/HedgingActivitiesSummaryofForeignCurrencyGainsandLossesfromNonDerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r239",
      "r363"
     ],
     "calculation": {
      "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r189"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "Estimated annual amortization expense, 2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "Estimated annual amortization expense, remainder of 2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r189"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "Estimated annual amortization expense, 2028"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r189"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "Estimated annual amortization expense, 2027"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r189"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "Estimated annual amortization expense, 2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r361",
      "r362",
      "r363",
      "r364",
      "r563",
      "r564"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]",
        "terseLabel": "Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseCurrentAndFiveSucceedingFiscalYearsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r188",
      "r564"
     ],
     "calculation": {
      "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "verboseLabel": "Gross Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r72",
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r188",
      "r563"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Net Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Assets, Remaining Amortization Period",
        "terseLabel": "Weighted- Average Remaining Amortization Period (Years)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiscalPeriod": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining an entity's fiscal year or other fiscal period. This disclosure may include identification of the fiscal period end-date, the length of the fiscal period, any reporting period lag between the entity and its subsidiaries, or equity investees. If a reporting lag exists, the closing date of the entity having a different period end is generally noted, along with an explanation of the necessity for using different closing dates. Any intervening events that materially affect the entity's financial position or results of operations are generally also disclosed.",
        "label": "Fiscal Period, Policy [Policy Text Block]",
        "terseLabel": "Fiscal Period"
       }
      }
     },
     "localname": "FiscalPeriod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GainLossOnSaleOfOtherAssets": {
     "auth_ref": [
      "r866"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of other assets.",
        "label": "Gain (Loss) on Disposition of Other Assets",
        "negatedTerseLabel": "Gain from sales of businesses and investments"
       }
      }
     },
     "localname": "GainLossOnSaleOfOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossRelatedToLitigationSettlement": {
     "auth_ref": [
      "r895"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.",
        "label": "Gain (Loss) Related to Litigation Settlement",
        "verboseLabel": "Claims and litigation charges, net"
       }
      }
     },
     "localname": "GainLossRelatedToLitigationSettlement",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r19",
      "r84",
      "r85"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "terseLabel": "Gain on debt extinguishment"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r238",
      "r349",
      "r565",
      "r740",
      "r756",
      "r880",
      "r887"
     ],
     "calculation": {
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedLessNoncontrollingInterest",
       "weight": 1.0
      },
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails",
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedRxSavingsSolutionsDetails",
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails",
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofChangesintheCarryingAmountofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Goodwill and Intangible Assets, Net"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/GoodwillandIntangibleAssetsNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r356"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Foreign Currency Translation Gain (Loss)",
        "terseLabel": "Foreign currency translation adjustments, net"
       }
      }
     },
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofChangesintheCarryingAmountofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r740"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofChangesintheCarryingAmountofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillPurchaseAccountingAdjustments": {
     "auth_ref": [
      "r1",
      "r886"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Purchase Accounting Adjustments",
        "terseLabel": "Other adjustments"
       }
      }
     },
     "localname": "GoodwillPurchaseAccountingAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofChangesintheCarryingAmountofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofChangesintheCarryingAmountofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r174",
      "r275",
      "r316",
      "r330",
      "r336",
      "r339",
      "r346",
      "r388",
      "r389",
      "r391",
      "r392",
      "r393",
      "r395",
      "r397",
      "r399",
      "r400",
      "r540",
      "r738",
      "r901"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r28",
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails",
      "http://mckesson123.com/role/HedgingActivitiesScheduleofFairValueofDerivativesDetails",
      "http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails",
      "http://mckesson123.com/role/HedgingActivitiesSummaryofDerivativeInstrumentsGainLossDetails",
      "http://mckesson123.com/role/HedgingActivitiesSummaryofForeignCurrencyGainsandLossesfromNonDerivativeInstrumentsDetails",
      "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails",
      "http://mckesson123.com/role/HedgingActivitiesScheduleofFairValueofDerivativesDetails",
      "http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails",
      "http://mckesson123.com/role/HedgingActivitiesSummaryofDerivativeInstrumentsGainLossDetails",
      "http://mckesson123.com/role/HedgingActivitiesSummaryofForeignCurrencyGainsandLossesfromNonDerivativeInstrumentsDetails",
      "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails",
      "http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails",
      "http://mckesson123.com/role/HedgingActivitiesSummaryofDerivativeInstrumentsGainLossDetails",
      "http://mckesson123.com/role/HedgingActivitiesSummaryofForeignCurrencyGainsandLossesfromNonDerivativeInstrumentsDetails",
      "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperations": {
     "auth_ref": [
      "r107",
      "r175",
      "r182",
      "r285",
      "r286",
      "r287",
      "r288",
      "r301",
      "r304"
     ],
     "calculation": {
      "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent",
        "totalLabel": "Income from continuing operations attributable to McKesson Corporation"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r171",
      "r218",
      "r316",
      "r330",
      "r336",
      "r339",
      "r571",
      "r583",
      "r738"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "terseLabel": "Income from continuing operations before income taxes",
        "totalLabel": "Income from continuing operations before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r207",
      "r275",
      "r283",
      "r316",
      "r330",
      "r336",
      "r339",
      "r346",
      "r388",
      "r389",
      "r391",
      "r392",
      "r393",
      "r395",
      "r397",
      "r399",
      "r400",
      "r530",
      "r540",
      "r583",
      "r738",
      "r901"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      },
      "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Income from continuing operations",
        "totalLabel": "Income from continuing operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "auth_ref": [
      "r170",
      "r217",
      "r219",
      "r268",
      "r283",
      "r285",
      "r286",
      "r287",
      "r288",
      "r296",
      "r302",
      "r303",
      "r530",
      "r570",
      "r926"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "terseLabel": "Continuing operations (in usd per share)",
        "verboseLabel": "Continuing operations (in usd per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "auth_ref": [
      "r170",
      "r268",
      "r283",
      "r285",
      "r286",
      "r287",
      "r288",
      "r296",
      "r302",
      "r303",
      "r304",
      "r530",
      "r570",
      "r926"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "terseLabel": "Continuing operations (in usd per share)",
        "verboseLabel": "Continuing operations (in usd per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": {
     "auth_ref": [
      "r144",
      "r145",
      "r146",
      "r147",
      "r148",
      "r156",
      "r234",
      "r502",
      "r584"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      },
      "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Income from discontinued operations, net of tax",
        "verboseLabel": "Income from discontinued operations, net of tax"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": {
     "auth_ref": [
      "r172",
      "r268",
      "r300",
      "r302",
      "r303",
      "r924",
      "r926"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share",
        "terseLabel": "Discontinued operations (in usd per share)",
        "verboseLabel": "Discontinued operations (in usd per share)"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": {
     "auth_ref": [
      "r209",
      "r300",
      "r302",
      "r303"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share",
        "terseLabel": "Discontinued operations (in usd per share)",
        "verboseLabel": "Discontinued operations (in usd per share)"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [
      "r751",
      "r752"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresDivestituresandOtherDetails",
      "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails",
      "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails",
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresDivestituresandOtherDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r22",
      "r30",
      "r38",
      "r143",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r155",
      "r157",
      "r158",
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails",
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresDivestituresandOtherDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Contingency [Line Items]",
        "terseLabel": "Income Tax Contingency [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxContingencyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "auth_ref": [
      "r24",
      "r92",
      "r202",
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Income Tax Contingency [Table]",
        "terseLabel": "Income Tax Contingency [Table]"
       }
      }
     },
     "localname": "IncomeTaxContingencyTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r276",
      "r486",
      "r492",
      "r495",
      "r496",
      "r499",
      "r501",
      "r503",
      "r504",
      "r618"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r222",
      "r228",
      "r291",
      "r292",
      "r324",
      "r490",
      "r500",
      "r593"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax expense",
        "terseLabel": "Income tax expense (benefit) related to continuing operations"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://mckesson123.com/role/IncomeTaxesScheduleofComponentsofIncomeTaxExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Drafts and accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedTaxesPayable": {
     "auth_ref": [
      "r865"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period of all taxes owed but not paid, including income, property and other taxes.",
        "label": "Increase (Decrease) in Accrued Taxes Payable",
        "terseLabel": "Taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "negatedLabel": "Deferred taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Assets [Abstract]",
        "terseLabel": "Changes in assets and liabilities, net of acquisitions:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r852",
      "r865"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInReceivables": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Receivables",
        "negatedLabel": "Receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInReceivables",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r297",
      "r298",
      "r299",
      "r304",
      "r456"
     ],
     "calculation": {
      "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "terseLabel": "Effect of dilutive securities (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r139",
      "r221",
      "r263",
      "r320",
      "r550",
      "r669",
      "r768",
      "r930"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r728",
      "r765",
      "r766"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "terseLabel": "Floating interest rate swaps"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails",
      "http://mckesson123.com/role/HedgingActivitiesScheduleofFairValueofDerivativesDetails",
      "http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryLIFOReservePeriodCharge": {
     "auth_ref": [
      "r185"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The change in the inventory reserve representing the cumulative difference in cost between the first in, first out and the last in, first out inventory valuation methods, which change has been reflected in the statement of income during the period.",
        "label": "Inventory, LIFO Reserve, Period Charge",
        "negatedTerseLabel": "Pre-tax credits related to LIFO accounting",
        "terseLabel": "Credits associated with last-in, first-out inventory method"
       }
      }
     },
     "localname": "InventoryLIFOReservePeriodCharge",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r247",
      "r731",
      "r756"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories, net"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r167",
      "r215",
      "r581",
      "r756",
      "r870",
      "r878",
      "r911"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and deficit"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND DEFICIT"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r43",
      "r236",
      "r275",
      "r346",
      "r388",
      "r389",
      "r391",
      "r392",
      "r393",
      "r395",
      "r397",
      "r399",
      "r400",
      "r511",
      "r515",
      "r516",
      "r540",
      "r756",
      "r901",
      "r916",
      "r917"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCredit": {
     "auth_ref": [
      "r36",
      "r213",
      "r925"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-Term Line of Credit",
        "terseLabel": "Amounts outstanding under facility"
       }
      }
     },
     "localname": "LineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/DebtandFinancingActivitiesRevolvingCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "auth_ref": [
      "r869"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Line of Credit Facility [Line Items]",
        "terseLabel": "Line of Credit Facility [Line Items]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/DebtandFinancingActivitiesCommercialPaperNarrativeDetails",
      "http://mckesson123.com/role/DebtandFinancingActivitiesRevolvingCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r40"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Credit facility, maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/DebtandFinancingActivitiesCommercialPaperNarrativeDetails",
      "http://mckesson123.com/role/DebtandFinancingActivitiesRevolvingCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "auth_ref": [
      "r40",
      "r869"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Line of Credit Facility [Table]",
        "terseLabel": "Line of Credit Facility [Table]"
       }
      }
     },
     "localname": "LineOfCreditFacilityTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/DebtandFinancingActivitiesCommercialPaperNarrativeDetails",
      "http://mckesson123.com/role/DebtandFinancingActivitiesRevolvingCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationReserveNoncurrent": {
     "auth_ref": [
      "r47",
      "r895"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid after one year or beyond the normal operating cycle, if longer.",
        "label": "Estimated Litigation Liability, Noncurrent",
        "terseLabel": "Long-term litigation liabilities"
       }
      }
     },
     "localname": "LitigationReserveNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementAmountAwardedToOtherParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount awarded to other party in judgment or settlement of litigation.",
        "label": "Litigation Settlement, Amount Awarded to Other Party",
        "terseLabel": "Award payable under proposed framework"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedToOtherParty",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationStatusAxis": {
     "auth_ref": [
      "r895"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Axis]",
        "terseLabel": "Litigation Status [Axis]"
       }
      }
     },
     "localname": "LitigationStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationStatusDomain": {
     "auth_ref": [
      "r895"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Domain]",
        "terseLabel": "Litigation Status [Domain]"
       }
      }
     },
     "localname": "LitigationStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LoansPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing supported by a written promise to pay an obligation.",
        "label": "Loans Payable [Member]",
        "terseLabel": "Term Loan",
        "verboseLabel": "Loans payable"
       }
      }
     },
     "localname": "LoansPayableMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails",
      "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails",
      "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermCommercialPaperCurrent": {
     "auth_ref": [
      "r41"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the current portion of long-term unsecured obligations issued by corporations and other borrowers to investors (with maturities initially due after one year or beyond the operating cycle if longer).",
        "label": "Long-Term Commercial Paper, Current",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "LongTermCommercialPaperCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/DebtandFinancingActivitiesCommercialPaperNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r36",
      "r213",
      "r414",
      "r428",
      "r742",
      "r743",
      "r925"
     ],
     "calculation": {
      "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "terseLabel": "Debt outstanding",
        "totalLabel": "Total debt",
        "verboseLabel": "Carrying Value"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails",
      "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails",
      "http://mckesson123.com/role/FairValueMeasurementsScheduleofLongTermDebtisRecordedatAmortizedCostDetails",
      "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligations": {
     "auth_ref": [
      "r36",
      "r575"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      },
      "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as noncurrent.",
        "label": "Long-Term Debt and Lease Obligation",
        "terseLabel": "Total long-term debt",
        "verboseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtAndCapitalLeaseObligationsCurrent": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt and lease obligation, classified as current.",
        "label": "Long-Term Debt and Lease Obligation, Current",
        "terseLabel": "Less: Current portion",
        "verboseLabel": "Current portion of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtAndCapitalLeaseObligationsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails",
      "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails",
      "http://mckesson123.com/role/DebtandFinancingActivitiesRevolvingCreditFacilitiesNarrativeDetails",
      "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails",
      "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r45",
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails",
      "http://mckesson123.com/role/DebtandFinancingActivitiesRevolvingCreditFacilitiesNarrativeDetails",
      "http://mckesson123.com/role/DebtandFinancingActivitiesScheduleofLongTermDebtDetails",
      "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r381",
      "r382",
      "r383",
      "r387",
      "r896",
      "r898"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesEstimatedAccrualLiabilityDetails",
      "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [
      "r381",
      "r382",
      "r383",
      "r387",
      "r896",
      "r898"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesEstimatedAccrualLiabilityDetails",
      "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r381",
      "r382",
      "r383",
      "r387",
      "r896",
      "r898"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesEstimatedAccrualLiabilityDetails",
      "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "auth_ref": [
      "r381",
      "r848"
     ],
     "calculation": {
      "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesEstimatedAccrualLiabilityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability.",
        "label": "Loss Contingency Accrual",
        "totalLabel": "Total litigation liabilities"
       }
      }
     },
     "localname": "LossContingencyAccrualAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesEstimatedAccrualLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyAccrualCarryingValueCurrent": {
     "auth_ref": [
      "r381"
     ],
     "calculation": {
      "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesEstimatedAccrualLiabilityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LossContingencyAccrualAtCarryingValue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability expected to be resolved within one year or the normal operating cycle, if longer.",
        "label": "Loss Contingency, Accrual, Current",
        "verboseLabel": "Current litigation liabilities"
       }
      }
     },
     "localname": "LossContingencyAccrualCarryingValueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesEstimatedAccrualLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyAccrualCarryingValueNoncurrent": {
     "auth_ref": [
      "r381"
     ],
     "calculation": {
      "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesEstimatedAccrualLiabilityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LossContingencyAccrualAtCarryingValue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss contingency liability expected to be resolved after one year or beyond the normal operating cycle, if longer.",
        "label": "Loss Contingency, Accrual, Noncurrent",
        "verboseLabel": "Long-term litigation liabilities"
       }
      }
     },
     "localname": "LossContingencyAccrualCarryingValueNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesEstimatedAccrualLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyEstimateOfPossibleLoss": {
     "auth_ref": [
      "r382",
      "r383",
      "r386",
      "r387"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.",
        "label": "Loss Contingency, Estimate of Possible Loss",
        "terseLabel": "Loss contingency, estimate of possible loss"
       }
      }
     },
     "localname": "LossContingencyEstimateOfPossibleLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r381",
      "r382",
      "r383",
      "r387",
      "r896",
      "r898"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesEstimatedAccrualLiabilityDetails",
      "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyPendingClaimsNumber": {
     "auth_ref": [
      "r896",
      "r898"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of pending claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Pending Claims, Number",
        "terseLabel": "Complaints filed against the entity"
       }
      }
     },
     "localname": "LossContingencyPendingClaimsNumber",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": {
     "auth_ref": [
      "r142",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.",
        "label": "Mergers, Acquisitions and Dispositions Disclosures [Text Block]",
        "terseLabel": "Business Acquisitions and Divestitures"
       }
      }
     },
     "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestitures"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r50",
      "r214",
      "r275",
      "r346",
      "r388",
      "r391",
      "r392",
      "r393",
      "r399",
      "r400",
      "r540",
      "r580",
      "r647"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.",
        "label": "Equity, Attributable to Noncontrolling Interest",
        "terseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": {
     "auth_ref": [
      "r199"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders",
        "negatedTerseLabel": "Payments to noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsAtCarryingValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.",
        "label": "Money Market Funds, at Carrying Value",
        "terseLabel": "Money market funds at carrying value"
       }
      }
     },
     "localname": "MoneyMarketFundsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r271"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "FINANCING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r271"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "INVESTING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r180",
      "r181",
      "r182"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "OPERATING ACTIVITIES"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r173",
      "r182",
      "r220",
      "r234",
      "r255",
      "r258",
      "r262",
      "r275",
      "r283",
      "r285",
      "r286",
      "r287",
      "r288",
      "r291",
      "r292",
      "r301",
      "r316",
      "r330",
      "r336",
      "r339",
      "r346",
      "r388",
      "r389",
      "r391",
      "r392",
      "r393",
      "r395",
      "r397",
      "r399",
      "r400",
      "r530",
      "r540",
      "r587",
      "r665",
      "r682",
      "r683",
      "r738",
      "r768",
      "r901"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss)",
        "terseLabel": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net income attributable to McKesson Corporation"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r111",
      "r208",
      "r255",
      "r258",
      "r291",
      "r292",
      "r586",
      "r861"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "negatedTerseLabel": "Net income attributable to noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetInvestmentHedgingMember": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedges of a net investment in a foreign operation.",
        "label": "Net Investment Hedging [Member]",
        "terseLabel": "Net Investment Hedging",
        "verboseLabel": "Net Investment Hedges"
       }
      }
     },
     "localname": "NetInvestmentHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/HedgingActivitiesScheduleofNotionalAmountsofOutstandingDerivativePositionsDetails",
      "http://mckesson123.com/role/HedgingActivitiesSummaryofDerivativeInstrumentsGainLossDetails",
      "http://mckesson123.com/role/HedgingActivitiesSummaryofForeignCurrencyGainsandLossesfromNonDerivativeInstrumentsDetails",
      "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r105",
      "r444",
      "r871",
      "r872",
      "r873",
      "r931"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling Interests"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r876"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/SegmentsofBusinessNarrativeDetails",
      "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails",
      "http://mckesson123.com/role/SignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "negatedTotalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r316",
      "r330",
      "r336",
      "r339",
      "r738"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Total operating profit (loss)",
        "totalLabel": "Operating income"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss) [Abstract]",
        "terseLabel": "Segment operating profit (loss)"
       }
      }
     },
     "localname": "OperatingIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r915"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Non-cash operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r553"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r553"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r552"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segments"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails",
      "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails",
      "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherAssetImpairmentCharges": {
     "auth_ref": [
      "r866",
      "r890"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The charge against earnings resulting from the write down of long lived assets other than goodwill due to the difference between the carrying value and lower fair value.",
        "label": "Other Asset Impairment Charges",
        "terseLabel": "Long-lived asset impairment charges"
       }
      }
     },
     "localname": "OtherAssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r240"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": {
     "auth_ref": [
      "r35",
      "r52",
      "r261",
      "r542",
      "r545",
      "r548",
      "r859"
     ],
     "calculation": {
      "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax",
        "terseLabel": "Other comprehensive income (loss) before reclassifications"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsTax": {
     "auth_ref": [
      "r13",
      "r260",
      "r588"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) before reclassification adjustment from accumulated other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss) before Reclassifications, Tax",
        "negatedTerseLabel": "Other Comprehensive Income (Loss) before Reclassifications, Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": {
     "auth_ref": [
      "r250",
      "r251"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax",
        "terseLabel": "Unrealized gains on cash flow and other hedges"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": {
     "auth_ref": [
      "r227",
      "r251",
      "r253"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax",
        "terseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax",
        "verboseLabel": "Derivatives designated as cash flow and other hedges:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/HedgingActivitiesSummaryofDerivativeInstrumentsGainLossDetails",
      "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r9"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "verboseLabel": "Foreign currency translation adjustments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax": {
     "auth_ref": [
      "r517"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from derivative designated and qualifying as net investment hedge.",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax",
        "terseLabel": "Derivatives designated as net investment hedges:",
        "verboseLabel": "Other comprehensive income (loss), net investment hedge, gain (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/HedgingActivitiesSummaryofDerivativeInstrumentsGainLossDetails",
      "http://mckesson123.com/role/HedgingActivitiesSummaryofForeignCurrencyGainsandLossesfromNonDerivativeInstrumentsDetails",
      "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r27",
      "r35",
      "r256",
      "r259",
      "r264",
      "r542",
      "r543",
      "r548",
      "r566",
      "r588",
      "r859",
      "r860"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "totalLabel": "Other comprehensive income, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
      "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r16",
      "r25",
      "r207",
      "r256",
      "r259"
     ],
     "calculation": {
      "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to noncontrolling interests.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Less: amounts attributable to noncontrolling interests"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r16",
      "r25",
      "r207",
      "r256",
      "r259"
     ],
     "calculation": {
      "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other comprehensive income (loss)",
        "totalLabel": "Other comprehensive income (loss) attributable to McKesson"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT",
      "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": {
     "auth_ref": [
      "r12",
      "r169"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax",
        "negatedTerseLabel": "Changes in retirement-related benefit plans"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible assets classified as other.",
        "label": "Other Intangible Assets [Member]",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "OtherIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r182"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other non-cash items"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "verboseLabel": "Other Non-Current Liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r178"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForLegalSettlements": {
     "auth_ref": [
      "r17"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period.",
        "label": "Payments for Legal Settlements",
        "terseLabel": "Settlement payment"
       }
      }
     },
     "localname": "PaymentsForLegalSettlements",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r850",
      "r862"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Share repurchases"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRestructuring": {
     "auth_ref": [
      "r369",
      "r864"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.",
        "label": "Payments for Restructuring",
        "negatedLabel": "Cash payments"
       }
      }
     },
     "localname": "PaymentsForRestructuring",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDividendsCommonStock": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow in the form of ordinary dividends to common shareholders of the parent entity.",
        "label": "Payments of Ordinary Dividends, Common Stock",
        "negatedLabel": "Dividends paid"
       }
      }
     },
     "localname": "PaymentsOfDividendsCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r56",
      "r506"
     ],
     "calculation": {
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "netLabel": "Cash",
        "terseLabel": "Cash payments to acquire business",
        "verboseLabel": "Cash"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails",
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedRxSavingsSolutionsDetails",
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Acquisitions, net of cash, cash equivalents, and restricted cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r179"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Payments for property, plant, and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireSoftware": {
     "auth_ref": [
      "r179"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition from vendors of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization.",
        "label": "Payments to Acquire Software",
        "negatedLabel": "Capitalized software expenditures"
       }
      }
     },
     "localname": "PaymentsToAcquireSoftware",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r161",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r161",
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r161",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r161",
      "r645",
      "r663",
      "r931",
      "r932"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r161",
      "r576",
      "r756"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.01 par value, 100 shares authorized, no shares issued or outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r858"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r855"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Reclassification"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromCollectionOfNotesReceivable": {
     "auth_ref": [
      "r54"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with principal collections from a borrowing supported by a written promise to pay an obligation.",
        "label": "Proceeds from Collection of Notes Receivable",
        "terseLabel": "Proceeds from collection of notes receivable"
       }
      }
     },
     "localname": "ProceedsFromCollectionOfNotesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresDivestituresandOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": {
     "auth_ref": [
      "r269"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.",
        "label": "Proceeds from Debt, Net of Issuance Costs",
        "terseLabel": "Proceeds from debt issuance"
       }
      }
     },
     "localname": "ProceedsFromDebtNetOfIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the sale of a business segment or subsidiary or sale of an entity that is related to it but not strictly controlled during the period (for example, an unconsolidated subsidiary, affiliate, joint venture or equity method investment).",
        "label": "Proceeds from Divestiture of Businesses and Interests in Affiliates",
        "terseLabel": "Proceeds from sales of businesses and investments, net"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfBusinessesAndInterestsInAffiliates",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommercialPaper": {
     "auth_ref": [
      "r57"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from borrowing by issuing commercial paper.",
        "label": "Proceeds from Issuance of Commercial Paper",
        "terseLabel": "Proceeds from issuance of commercial paper"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommercialPaper",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/DebtandFinancingActivitiesCommercialPaperNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r57",
      "r613"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "terseLabel": "Proceeds from issuances of long-term debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r15",
      "r29"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised",
        "terseLabel": "Issuances"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised [Abstract]",
        "terseLabel": "Common stock transactions:"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ProceedsFromLegalSettlements": {
     "auth_ref": [
      "r60"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received for the settlement of litigation during the current period.",
        "label": "Proceeds from Legal Settlements",
        "verboseLabel": "Proceeds from legal settlements"
       }
      }
     },
     "localname": "ProceedsFromLegalSettlements",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "auth_ref": [
      "r57",
      "r869"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Proceeds from Lines of Credit",
        "terseLabel": "Borrowings under facility"
       }
      }
     },
     "localname": "ProceedsFromLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/DebtandFinancingActivitiesRevolvingCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r851",
      "r863"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromShortTermDebt": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Proceeds from Short-Term Debt",
        "terseLabel": "Proceeds from short-term borrowings"
       }
      }
     },
     "localname": "ProceedsFromShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r234",
      "r255",
      "r258",
      "r270",
      "r275",
      "r283",
      "r291",
      "r292",
      "r316",
      "r330",
      "r336",
      "r339",
      "r346",
      "r388",
      "r389",
      "r391",
      "r392",
      "r393",
      "r395",
      "r397",
      "r399",
      "r400",
      "r509",
      "r512",
      "r513",
      "r530",
      "r540",
      "r571",
      "r585",
      "r620",
      "r665",
      "r682",
      "r683",
      "r738",
      "r754",
      "r755",
      "r769",
      "r861",
      "r901"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income",
        "totalLabel": "Net income",
        "verboseLabel": "Net income"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME",
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r21",
      "r572",
      "r582",
      "r756"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, plant, and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r756"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "Receivables, Net, Current",
        "terseLabel": "Receivables, net"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": {
     "auth_ref": [
      "r35",
      "r52",
      "r261",
      "r542",
      "r547",
      "r548",
      "r859"
     ],
     "calculation": {
      "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax",
        "negatedTerseLabel": "Amounts reclassified to earnings and other"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent": {
     "auth_ref": [
      "r52"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.",
        "label": "Reclassification from AOCI, Current Period, before Tax, Attributable to Parent",
        "terseLabel": "Reclassification of gains from AOCI"
       }
      }
     },
     "localname": "ReclassificationFromAociCurrentPeriodBeforeTaxAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/HedgingActivitiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAociCurrentPeriodTax": {
     "auth_ref": [
      "r13",
      "r254",
      "r260",
      "r588"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income (loss).",
        "label": "Reclassification from AOCI, Current Period, Tax",
        "verboseLabel": "Accumulated other comprehensive loss adjustment"
       }
      }
     },
     "localname": "ReclassificationFromAociCurrentPeriodTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresDivestituresandOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfCommercialPaper": {
     "auth_ref": [
      "r59"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow due to repaying amounts borrowed by issuing commercial paper.",
        "label": "Repayments of Commercial Paper",
        "terseLabel": "Repayments of commercial paper"
       }
      }
     },
     "localname": "RepaymentsOfCommercialPaper",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/DebtandFinancingActivitiesCommercialPaperNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r59",
      "r616"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-Term Debt",
        "negatedTerseLabel": "Repayments of long-term debt",
        "terseLabel": "Repayments of long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://mckesson123.com/role/DebtandFinancingActivitiesLongTermDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfShortTermDebt": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Repayments of Short-Term Debt",
        "negatedTerseLabel": "Repayments of short-term borrowings"
       }
      }
     },
     "localname": "RepaymentsOfShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r856",
      "r867"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "negatedTerseLabel": "Less: Restricted cash at end of period included in Prepaid expenses and other"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]",
        "terseLabel": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r366",
      "r367",
      "r369",
      "r372",
      "r378"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring, Impairment, and Related Charges, Net"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringAndRelatedCostExpectedCost1": {
     "auth_ref": [
      "r368",
      "r371",
      "r375",
      "r377"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost.",
        "label": "Restructuring and Related Cost, Expected Cost",
        "terseLabel": "Expected total pre-tax charges"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostExpectedCost1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringAndRelatedCostIncurredCost": {
     "auth_ref": [
      "r368",
      "r371",
      "r375",
      "r377"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.",
        "label": "Restructuring and Related Cost, Incurred Cost",
        "terseLabel": "Restructuring and related cost, incurred cost to date"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostIncurredCost",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r19",
      "r373",
      "r375",
      "r892"
     ],
     "calculation": {
      "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Restructuring costs, anticipated total charges",
        "totalLabel": "Total",
        "verboseLabel": "Restructuring, impairment, and related charges, net"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetNarrativeDetails",
      "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails",
      "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails",
      "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [
      "r368",
      "r369",
      "r370",
      "r371",
      "r375",
      "r376",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetNarrativeDetails",
      "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails",
      "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringPlanAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by individual restructuring plan.",
        "label": "Restructuring Plan [Axis]",
        "terseLabel": "Restructuring Plan [Axis]"
       }
      }
     },
     "localname": "RestructuringPlanAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringPlanDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the individual restructuring plans.",
        "label": "Restructuring Plan [Domain]",
        "terseLabel": "Restructuring Plan [Domain]"
       }
      }
     },
     "localname": "RestructuringPlanDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r369",
      "r374"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Restructuring Reserve [Roll Forward]",
        "terseLabel": "Restructuring Reserve [Roll Forward]"
       }
      }
     },
     "localname": "RestructuringReserveRollForward",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringReserveSettledWithoutCash2": {
     "auth_ref": [
      "r369",
      "r376"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in the reserve for full or partial settlement through consideration other than cash.",
        "label": "Restructuring Reserve, Settled without Cash",
        "negatedTerseLabel": "Non-cash charges"
       }
      }
     },
     "localname": "RestructuringReserveSettledWithoutCash2",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveTranslationAndOtherAdjustment": {
     "auth_ref": [
      "r79",
      "r893"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the restructuring reserve related to foreign currency translation (gain) loss and other increases (decreases).",
        "label": "Restructuring Reserve, Translation and Other Adjustment",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "RestructuringReserveTranslationAndOtherAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r164",
      "r199",
      "r579",
      "r609",
      "r611",
      "r617",
      "r646",
      "r756"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated undistributed earnings (deficit).",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r230",
      "r280",
      "r281",
      "r282",
      "r284",
      "r290",
      "r292",
      "r347",
      "r348",
      "r483",
      "r484",
      "r485",
      "r497",
      "r498",
      "r520",
      "r522",
      "r523",
      "r525",
      "r528",
      "r606",
      "r608",
      "r621",
      "r931"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated undistributed earnings (deficit).",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r317",
      "r318",
      "r329",
      "r334",
      "r335",
      "r341",
      "r343",
      "r345",
      "r445",
      "r446",
      "r562"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total revenues",
        "verboseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Segment revenues"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Revolving Credit Facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/DebtandFinancingActivitiesRevolvingCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r52",
      "r912",
      "r913"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of information regarding changes in accumulated other comprehensive income (loss), net of tax, by component"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/StockholdersDeficitTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the major classes of acquired finite-lived intangible assets showing the amount, any significant residual value, weighted average amortization period, and other characteristics. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.",
        "label": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]",
        "terseLabel": "Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetByMajorClassTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information about a contingent payment arrangement including the terms that will result in payment and the accounting treatment that will be followed if such contingency occurs, including the potential impact on earnings per share if the contingency is to be settled in shares of common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.",
        "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]",
        "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedRxSavingsSolutionsDetails",
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.",
        "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of gain (loss) on derivative and nonderivative instruments designated and qualifying as cash flow hedge recorded in accumulated other comprehensive income (AOCI) and reclassified into earnings.",
        "label": "Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Cash Flow Hedges Included in Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ScheduleOfCashFlowHedgesIncludedInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/HedgingActivitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Components of Income Tax Expense (Benefit)"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Schedule of Long-Term Debt"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/DebtandFinancingActivitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r875"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of computations for basic and diluted earnings per common share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/EarningsPerCommonShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable": {
     "auth_ref": [
      "r62",
      "r63",
      "r296",
      "r300",
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Complete disclosure pertaining to an entity's diluted earnings per share.",
        "label": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]",
        "terseLabel": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table]"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareDilutedByCommonClassTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r72",
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of information regarding intangible assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r740"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Schedule of Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofChangesintheCarryingAmountofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r740",
      "r879",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of changes in the carrying amount of goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfLossContingenciesByContingencyTextBlock": {
     "auth_ref": [
      "r895",
      "r897",
      "r899",
      "r900"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the loss contingencies that were reported in the period or disclosed as of the balance sheet date.",
        "label": "Schedule of Loss Contingencies by Contingency [Table Text Block]",
        "terseLabel": "Schedule of Estimated Accrual Liability"
       }
      }
     },
     "localname": "ScheduleOfLossContingenciesByContingencyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r909"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period.",
        "label": "Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/HedgingActivitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the notional amounts of outstanding derivative positions.",
        "label": "Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]",
        "terseLabel": "Schedule of Notional Amounts of Outstanding Derivative Positions"
       }
      }
     },
     "localname": "ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/HedgingActivitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "auth_ref": [
      "r129",
      "r853"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument.",
        "label": "Derivatives Not Designated as Hedging Instruments [Table Text Block]",
        "terseLabel": "Summary of Foreign Currency Gains and (Losses) from Non-Derivative Instruments"
       }
      }
     },
     "localname": "ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/HedgingActivitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.",
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Identified Assets Acquired and Liabilities Assumed"
       }
      }
     },
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r368",
      "r369",
      "r370",
      "r371",
      "r375",
      "r376",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetNarrativeDetails",
      "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails",
      "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "auth_ref": [
      "r76",
      "r78",
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "terseLabel": "Restructuring, Impairment, and Related Costs"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "auth_ref": [
      "r77",
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.",
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "terseLabel": "Schedule of Restructuring and Asset Impairment Charges"
       }
      }
     },
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r67",
      "r68",
      "r69",
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r67",
      "r68",
      "r69",
      "r70"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of financial information relating to reportable operating segments and reconciliations to the condensed consolidated totals"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/SegmentsofBusinessTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r313",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r339",
      "r345",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r371",
      "r377",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r740",
      "r854",
      "r927"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails",
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedRxSavingsSolutionsDetails",
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails",
      "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofChangesintheCarryingAmountofGoodwillDetails",
      "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails",
      "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails",
      "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r328",
      "r333",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segments of Business"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/SegmentsofBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingInformationProfitLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information, Profit (Loss) [Abstract]",
        "terseLabel": "Segment Reporting Information, Profit (Loss) [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingInformationProfitLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r177"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "negatedTerseLabel": "Selling, distribution, general, and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ServiceAgreementsMember": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Limited duration contract between, for example, an electricity transmission customer and an electricity transmission provider for service.",
        "label": "Service Agreements [Member]",
        "terseLabel": "Service agreements"
       }
      }
     },
     "localname": "ServiceAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SettledLitigationMember": {
     "auth_ref": [
      "r895"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement reached between parties in a litigation that occurs without judicial intervention, supervision or approval.",
        "label": "Settled Litigation [Member]",
        "terseLabel": "Settled Litigation"
       }
      }
     },
     "localname": "SettledLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeveranceCosts1": {
     "auth_ref": [
      "r19"
     ],
     "calculation": {
      "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_RestructuringCharges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Severance Costs",
        "terseLabel": "Severance and employee-related costs, net"
       }
      }
     },
     "localname": "SeveranceCosts1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by share repurchase program.",
        "label": "Share Repurchase Program [Axis]",
        "terseLabel": "Share Repurchase Program [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/StockholdersDeficitNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the share repurchase program.",
        "label": "Share Repurchase Program [Domain]",
        "terseLabel": "Share Repurchase Program [Domain]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/StockholdersDeficitNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r232",
      "r313",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r339",
      "r345",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r365",
      "r371",
      "r377",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r740",
      "r854",
      "r927"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]",
        "verboseLabel": "Business Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresAcquisitionsDetails",
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedRxSavingsSolutionsDetails",
      "http://mckesson123.com/role/BusinessAcquisitionsandDivestituresIdentifiedAssetsAcquiredandLiabilitiesAssumedSCRIOncologyLLCDetails",
      "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofChangesintheCarryingAmountofGoodwillDetails",
      "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringActivityDetails",
      "http://mckesson123.com/role/RestructuringImpairmentandRelatedChargesNetSummaryofRestructuringChargesDetails",
      "http://mckesson123.com/role/SegmentsofBusinessReportableoperatingsegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r229",
      "r243",
      "r244",
      "r245",
      "r275",
      "r296",
      "r300",
      "r302",
      "r304",
      "r310",
      "r311",
      "r346",
      "r388",
      "r391",
      "r392",
      "r393",
      "r399",
      "r400",
      "r430",
      "r431",
      "r434",
      "r437",
      "r443",
      "r540",
      "r613",
      "r614",
      "r615",
      "r616",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r645",
      "r666",
      "r684",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r847",
      "r868",
      "r874"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r27",
      "r48",
      "r230",
      "r260",
      "r261",
      "r262",
      "r280",
      "r281",
      "r282",
      "r284",
      "r290",
      "r292",
      "r309",
      "r347",
      "r348",
      "r444",
      "r483",
      "r484",
      "r485",
      "r497",
      "r498",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r528",
      "r542",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r554",
      "r606",
      "r607",
      "r608",
      "r621",
      "r684"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT",
      "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [
      "r280",
      "r281",
      "r282",
      "r309",
      "r562",
      "r612",
      "r632",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r664",
      "r667",
      "r668",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r684",
      "r761"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r280",
      "r281",
      "r282",
      "r309",
      "r562",
      "r612",
      "r632",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r664",
      "r667",
      "r668",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r684",
      "r761"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period.",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "terseLabel": "Stock Appreciation Rights (SARs)"
       }
      }
     },
     "localname": "StockAppreciationRightsSARSMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Authorized repurchase amount (up to)"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/StockholdersDeficitNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "terseLabel": "Authorized amount available for future repurchases"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/StockholdersDeficitNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r27",
      "r161",
      "r162",
      "r199",
      "r616",
      "r684",
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Shares",
        "negatedTerseLabel": "Repurchase of common stock (in shares)",
        "terseLabel": "Share repurchases (in shares)"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT",
      "http://mckesson123.com/role/StockholdersDeficitNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r27",
      "r161",
      "r162",
      "r199",
      "r621",
      "r684",
      "r710",
      "r769"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Value",
        "negatedTerseLabel": "Repurchase of common stock",
        "terseLabel": "Shares repurchased"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT",
      "http://mckesson123.com/role/StockholdersDeficitNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r162",
      "r165",
      "r166",
      "r184",
      "r647",
      "r663",
      "r685",
      "r686",
      "r756",
      "r770",
      "r870",
      "r878",
      "r911",
      "r931"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.",
        "label": "Equity, Attributable to Parent",
        "totalLabel": "Total McKesson Corporation stockholders\u2019 deficit"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "McKesson Corporation stockholders\u2019 deficit"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r105",
      "r106",
      "r110",
      "r230",
      "r231",
      "r261",
      "r280",
      "r281",
      "r282",
      "r284",
      "r290",
      "r347",
      "r348",
      "r444",
      "r483",
      "r484",
      "r485",
      "r497",
      "r498",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r528",
      "r542",
      "r544",
      "r548",
      "r554",
      "r607",
      "r608",
      "r619",
      "r647",
      "r663",
      "r685",
      "r686",
      "r712",
      "r769",
      "r870",
      "r878",
      "r911",
      "r931"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total deficit"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT",
      "http://mckesson123.com/role/StockholdersDeficitScheduleofChangesinAccumulatedOtherComprehensiveIncomeLossbyComponentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r196",
      "r274",
      "r429",
      "r431",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r444",
      "r527",
      "r687",
      "r688",
      "r713"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for equity.",
        "label": "Equity [Text Block]",
        "verboseLabel": "Stockholders' Deficit"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/StockholdersDeficit"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.",
        "label": "Stockholders' Equity, Other",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "StockholdersEquityOther",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r549",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails",
      "http://mckesson123.com/role/StockholdersDeficitNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r549",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails",
      "http://mckesson123.com/role/StockholdersDeficitNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r549",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CommitmentsandContingentLiabilitiesNarrativeDetails",
      "http://mckesson123.com/role/StockholdersDeficitNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TechnologyBasedIntangibleAssetsMember": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Technology-based intangible assets, including, but not limited to, patented technology, unpatented technology, and developed technology rights.",
        "label": "Technology-Based Intangible Assets [Member]",
        "terseLabel": "Technology"
       }
      }
     },
     "localname": "TechnologyBasedIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TrademarksAndTradeNamesMember": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trademarks and Trade Names [Member]",
        "terseLabel": "Trademarks and trade names"
       }
      }
     },
     "localname": "TrademarksAndTradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/GoodwillandIntangibleAssetsNetScheduleofInformationRegardingIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockAcquiredAverageCostPerShare": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.",
        "label": "Shares Acquired, Average Cost Per Share",
        "terseLabel": "Average price of shares repurchased (in usd per share)"
       }
      }
     },
     "localname": "TreasuryStockAcquiredAverageCostPerShare",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/StockholdersDeficitNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TreasuryStockCommonMember": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common [Member]",
        "terseLabel": "Treasury"
       }
      }
     },
     "localname": "TreasuryStockCommonMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockCommonShares": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Shares",
        "negatedPeriodEndLabel": "Ending balance (in shares)",
        "negatedPeriodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Treasury shares (in shares)"
       }
      }
     },
     "localname": "TreasuryStockCommonShares",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSDEFICIT"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockCommonValue": {
     "auth_ref": [
      "r49",
      "r88",
      "r89"
     ],
     "calculation": {
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Value",
        "negatedLabel": "Treasury shares, at cost, 143 and 141 shares at June 30, 2023 and March 31, 2023, respectively"
       }
      }
     },
     "localname": "TreasuryStockCommonValue",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r27",
      "r162",
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "terseLabel": "Common stock repurchased (in shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/StockholdersDeficitNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredParValueMethod": {
     "auth_ref": [
      "r27",
      "r88",
      "r199"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the par value method.",
        "label": "Treasury Stock, Value, Acquired, Par Value Method",
        "terseLabel": "Shares repurchased"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredParValueMethod",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/StockholdersDeficitNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r487",
      "r493"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r494"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "terseLabel": "Unrecognized tax benefits that would impact effective tax rate"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnsecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets.",
        "label": "Unsecured Debt [Member]",
        "terseLabel": "Unsecured Debt"
       }
      }
     },
     "localname": "UnsecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/DebtandFinancingActivitiesRevolvingCreditFacilitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r64",
      "r65",
      "r66",
      "r223",
      "r224",
      "r225",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r295",
      "r304"
     ],
     "calculation": {
      "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in usd per share)",
        "totalLabel": "Diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Weighted-average common shares outstanding",
        "verboseLabel": "Weighted-average common shares outstanding:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r294",
      "r304"
     ],
     "calculation": {
      "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "presentation": [
      "http://mckesson123.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://mckesson123.com/role/EarningsPerCommonShareScheduleofComputationsforBasicandDilutedEarningsperCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 14
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479405/805-10-25-16",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-20",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-31",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-6",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-12",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-18",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-21",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(i)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(ii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(iii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i-k)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-12",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-5",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480401/815-10-55-182",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480238/815-25-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-14",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//205-20/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-11",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-3B",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-4B",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5B",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5D",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-7",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(13))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(14))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.13)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org//235/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.L)",
   "Topic": "330",
   "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "https://asc.fasb.org//350/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org//440/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org//470/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-12A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org//505/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-7",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-5",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481138/505-30-25-5",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "https://asc.fasb.org//805/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "c",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.E)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147479836/810-10-S99-5",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "https://asc.fasb.org//815/tableOfContent",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.13,16)",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(20))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-5C",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-17A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org//260/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-28A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "https://asc.fasb.org//280/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4D",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-13",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "https://asc.fasb.org//420/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483478/205-10-45-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480454/718-10-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org//740/tableOfContent",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482551/740-270-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4CCC",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4E",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-5C",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(iii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)(iv)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(i)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-1A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(17))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "27",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(e)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(f)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(g)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "205",
   "Subparagraph": "(h)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)(2)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(2)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(4)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(e)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(f)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(17))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(19))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(8))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-05(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-05(4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "220",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07(9))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13A(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483475/205-20-45-10",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13B(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13B(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13C(Column E))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(b)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(c)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "https://asc.fasb.org//1943274/2147480598/954-450-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(b)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Subparagraph": "(a)(1)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(d)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13C(Column A)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13C(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "830",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r771": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r772": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r773": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r774": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r775": {
   "Name": "Form 20-F",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "16",
   "Subsection": "J",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r776": {
   "Name": "Form 20-F",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "6",
   "Subsection": "F",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r777": {
   "Name": "Form 20-F",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "6",
   "Subparagraph": "i",
   "Subsection": "F",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r778": {
   "Name": "Form 20-F",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "6",
   "Sentence": "A",
   "Subparagraph": "i",
   "Subsection": "F",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r779": {
   "Name": "Form 20-F",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "6",
   "Sentence": "B",
   "Subparagraph": "i",
   "Subsection": "F",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r780": {
   "Name": "Form 20-F",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "6",
   "Sentence": "C",
   "Subparagraph": "i",
   "Subsection": "F",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r781": {
   "Name": "Form 20-F",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "6",
   "Sentence": "D",
   "Subparagraph": "i",
   "Subsection": "F",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r782": {
   "Name": "Form 20-F",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "6",
   "Sentence": "E",
   "Subparagraph": "i",
   "Subsection": "F",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r783": {
   "Name": "Form 20-F",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "6",
   "Subparagraph": "ii",
   "Subsection": "F",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r784": {
   "Name": "Form 20-F",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "6",
   "Subparagraph": "iii",
   "Subsection": "F",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r785": {
   "Name": "Form 20-F",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "6",
   "Subsection": "F",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r786": {
   "Name": "Form 20-F",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "6",
   "Subparagraph": "ii",
   "Subsection": "F",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r787": {
   "Name": "Form 40-F",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "19",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r788": {
   "Name": "Form 40-F",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "19",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r789": {
   "Name": "Form 40-F",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "19",
   "Sentence": "i",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r790": {
   "Name": "Form 40-F",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "19",
   "Sentence": "ii",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r791": {
   "Name": "Form 40-F",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "19",
   "Sentence": "iii",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r792": {
   "Name": "Form 40-F",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "19",
   "Sentence": "iv",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r793": {
   "Name": "Form 40-F",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "19",
   "Sentence": "v",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r794": {
   "Name": "Form 40-F",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "19",
   "Subparagraph": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r795": {
   "Name": "Form 40-F",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "19",
   "Subparagraph": "3",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r796": {
   "Name": "Form 40-F",
   "Paragraph": "b",
   "Publisher": "SEC",
   "Section": "19",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r797": {
   "Name": "Form N-CSR",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "18",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r798": {
   "Name": "Form N-CSR",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "18",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r799": {
   "Name": "Form N-CSR",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "18",
   "Sentence": "i",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r800": {
   "Name": "Form N-CSR",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "18",
   "Sentence": "ii",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r801": {
   "Name": "Form N-CSR",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "18",
   "Sentence": "iii",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r802": {
   "Name": "Form N-CSR",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "18",
   "Sentence": "iv",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r803": {
   "Name": "Form N-CSR",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "18",
   "Sentence": "v",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r804": {
   "Name": "Form N-CSR",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "18",
   "Subparagraph": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r805": {
   "Name": "Form N-CSR",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "18",
   "Subparagraph": "3",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r806": {
   "Name": "Form N-CSR",
   "Paragraph": "b",
   "Publisher": "SEC",
   "Section": "18",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r807": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r808": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Publisher": "SEC",
   "Section": "402",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r809": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "402",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r810": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "ii",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r811": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "iii",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r812": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "iv",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r813": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "vi",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r814": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "3",
   "Publisher": "SEC",
   "Section": "402",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r815": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "4",
   "Publisher": "SEC",
   "Section": "402",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r816": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "5",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "i",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r817": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "5",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "ii",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r818": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "5",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "iii",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r819": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "5",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "iv",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r820": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "6",
   "Publisher": "SEC",
   "Section": "402",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r821": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "6",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "i",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r822": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "402",
   "Subsection": "w",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r823": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "i",
   "Subsection": "w",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r824": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "402",
   "Sentence": "A",
   "Subparagraph": "i",
   "Subsection": "w",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r825": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "402",
   "Sentence": "B",
   "Subparagraph": "i",
   "Subsection": "w",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r826": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "402",
   "Sentence": "C",
   "Subparagraph": "i",
   "Subsection": "w",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r827": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "402",
   "Sentence": "D",
   "Subparagraph": "i",
   "Subsection": "w",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r828": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "402",
   "Sentence": "E",
   "Subparagraph": "i",
   "Subsection": "w",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r829": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "ii",
   "Subsection": "w",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r830": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "iii",
   "Subsection": "w",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r831": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "402",
   "Subsection": "w",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r832": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "402",
   "Subsection": "x",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r833": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "402",
   "Subsection": "x",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r834": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "402",
   "Sentence": "A",
   "Subparagraph": "ii",
   "Subsection": "x",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r835": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "402",
   "Sentence": "C",
   "Subparagraph": "ii",
   "Subsection": "x",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r836": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "402",
   "Sentence": "D",
   "Subparagraph": "ii",
   "Subsection": "x",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r837": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "402",
   "Sentence": "E",
   "Subparagraph": "ii",
   "Subsection": "x",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r838": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "402",
   "Sentence": "F",
   "Subparagraph": "ii",
   "Subsection": "x",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r839": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Publisher": "SEC",
   "Section": "408",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r840": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "408",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r841": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "408",
   "Subparagraph": "A",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r842": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "408",
   "Subparagraph": "B",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r843": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "408",
   "Subparagraph": "C",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r844": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "408",
   "Subparagraph": "D",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r845": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "408",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r846": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r847": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r848": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r849": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "740",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147480887/718-740-35-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r850": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r851": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r852": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r853": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4CC",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r854": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r855": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "https://asc.fasb.org//1943274/2147483504/205-10-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r856": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r857": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r858": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r859": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r860": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r861": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r862": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r863": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r864": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r865": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r866": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r867": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r868": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r869": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r870": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r871": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r872": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r873": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r874": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r875": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r876": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r877": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r878": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r879": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r880": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r881": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r882": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r883": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r884": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r885": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r886": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r887": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r888": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r889": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r890": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r891": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r892": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147482047/420-10-45-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r893": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r894": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org//450/tableOfContent",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r895": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r896": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r897": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r898": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r899": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r900": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r901": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r902": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r903": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r904": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r905": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r906": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r907": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r908": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r909": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4CCC",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r910": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r911": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r912": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r913": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r914": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org//1943274/2147479424/830-30-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r915": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r916": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r917": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r918": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r919": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-217",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r920": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r921": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r922": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r923": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r924": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r925": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r926": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r927": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r928": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "205",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r929": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-04(18))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r930": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "220",
   "Subparagraph": "(i)",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r931": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r932": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-09(7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479303/805-10-55-37",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-14",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>86
<FILENAME>0000927653-23-000062-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000927653-23-000062-xbrl.zip
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MX!Q@]BT=?OP!/RN<@81]4I/D2IM'_T\5FPU%^N5NXZTI/M(EW/0>#5<#YO]
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M#/GI#V]S]'DH"'"%BT>X97&0:&#6Q0/C,A@2&AAU\2"V\&XO#5PJ>D!^+=^
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MX8VN\6^(7HR^07Z^!]]M\OP7$\$K&H<@\O_["YY]38=:>'[&O6^A.>.[T)@
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M\7_ONH2G?>391M;)_'_&(C!=X2?$2KNI\))*D>-Y5'H#OS.<%G8Z%PXBF[$
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ML!3GN]'T"7Z&)H30]YF0-ZV@2Y6V5"49HL(ZBJFC-0:Y\TW-&9"3 \@5.4%
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MD-:B'VHEL$,'*HO$5HQ!VK8M5#E+WRT'HF'\&^K<%!B6RR&X:\"=<1/3?N>
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M"M&(;#T(_'HAW<E-SYCV ^@-)X\KNL?)FI3!ZMP!6!>@%U")$!6GZ]/#Z>_
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M"\(3A+>.\)IV"*Y/>&-!>(+P!.&M(SQE;X0W$80G".]-$=Z[1I0W7*4\'S8
M/VUAS^EE_5\*P0]!7X*^3IJ^&I'7KDX2K8V"YG,:.5'FQ!=3)^*%[7?J1.4L
M;-&QM\HM6JMEK];&'%[1V+G#:%+EXJN')HH8)W#F:-)& W!M*+C)F:-)A?ND
M'IJH@IN<.9H4;/UMT 2G2XKI)&>-)VV@"8Y*[)+4$5,GQ-2)?1EW!^G5KK4>
M0A3-D;N(9.M,PU:[(VN3%D:,"33J,AKMH<EV?5ZE"U[U)I!LC>%Y$"0;#022
MG2J2M1NC;E4TCN0RT=@XC"UPJ9,,ZYC\2NDBOQ)C*<18BA83/43/ORV"PC6;
M_HVP7>?I]_P3W3H%Y9X*Y5;%Z>M2KGIQM?-(,T&Y@G(%Y;:5.E&7<K7VDB<$
MY0K*%92[<S9+7<H=B8$R@G(%Y78HP:@NY8XOKG1!N8)R!>5V).6K+N'BS.6=
M6[H<GW*;3*58G4,@QE*\L3D$Q3$$^;$#N;D$Q6$P*P6!QIR:H4WO9SF2@U^H
M]TQ_?WU\7<(US+I\A+?\;KO&CY3Z] N) DTNX7WP*+W8@+6C:IS<!TK6'#OP
M.*=PJ+;MON"!1)V]PP5L 5[BLUDBR%J>K> U.[4$_VY;9&K95L"&E?B^BV&Z
M"!-*9Y!X63##H<*3K"".8Q4^$;"NM@N7=;6EA:ZVP_>->NL?MDTY"(+^@ N#
MQGW*M;ZNCO;1IWRXEV[:DRT;BE=TTQX,]]%->Q^+G?1'NK:79MKKO[D#8.7)
M=J\]/&#UOK*7M>X#L).^,JH'@>W[;Q].]S]4\^W3ZG6Z78OM!DUA3PL<;;3+
M/EO@[-3Z^FRATK2-]=D"HMAU^@T"X0"]HTL<$TWZG!P'+K\3&UO3]*0_B6?,
MI:',[9U#-2XI6U3;C4M:.]!S<Y(VWO\9N4+5!K[0R#%3X@L=#]JHD]Z"L1RU
M+=I6L0I!;&^7V+1VB$V^N%)&@M@$L0EBVT!LHW:(33G W 9!:X+63IK6FD34
M-] :]NX2Q":(31#;)F*;M$-L*@@V8;()8A/$MH'86J(U[>)*WWMCZ[9HK:7>
MUJ?8/"QWGKU,%S&>(Y5D9_&D0#8Y<*L.8F^CM=ZHB7-Q?:+EN,7:!M&#L9.(
MTL0QM@%1Q@)1SAQ1FCAU-B#*1"#*F2-*.SG^8_WB:F=/NT"4+B-*$PU_/:),
M!A=7ZD!@RAEC2CLE]A-LN-8EV=-2J^CN-KNZ<YU+@_CSV&H3+9_;,=@B=\<#
M#0*;FO_BU4<W &BE09NX22?;Q(E6A$>U\-K!K*' K#>!65O$^7?$+%5@UJEB
M5J-6O(V,R$VH542ATD9+HNWNF>#-%E&CFGB#KO!B;SV!..>!.$U,S&9X@Y[Q
M23?PYD"C<X]G<.(A2$ORRJ8/O;'P8#,^66%N?HU@^-GU<JA?AN"E(U[JX[?P
MO'4:42JLQR:(HI?F& I,.1-,J; &&V"*7CJ,7B#*F2!*A6W7!%%D@2AGC"@5
MQEP31%%*JR0%IIP'IE18;TT097AQ-=S%S#_5^. !RO_+#_J>=;\[4+%_V1*V
M+?97UA3[G[E;9=]1S4</%F>SIBG7CLFPX]K$QH%(P@UB!;J(%;P-'-LBOMD:
MCFD"Q]X$CFT1Z6P-QT8"QTX5QW:TBU?&C^Z ;46L&HOIHR>%2ON.@K;&KB:"
M79TJCNUF<^^36^F=X5;[F&-;4CY:9;0O+-.T:2?:]N6ZE)]BU[YATZY]-8_T
MS5:MMPZ?;K/-1BTDFHSH75O6K@VPZ]\AIHXU.J<#><3KLM(VAQ@)>A;T7-JE
MHLG@W@WT++?1Q5/0LZ!G0<^[T?,6B:!E]-Q&[T)!SH*<!3GO1LY-9OQN(&=L
MCWB(\=R"G@4]"WK>0,]-)O]NH&?LP"CDLZ!G0<]'CE2U0\[:Q=58/1=R;C(5
M>"B& K<[%/C:QY&_^4E$/3Z?%<<WX1Q71$)IRJ,?T@OQI?_>>UO3;/35"1>7
MIAM<1F\I(X=1:<_3>%1A#W?X,K=@A\U6OM7 FH9+'U]<C8IMO^*E,W![U$ 2
M-"7+D3#2K P^\!Q2-J@9_IZ9S<NNRQ]8"]%FF]UJ8$C#S4Y*IXG4VZR#O75P
M,K03E&T8;B\;0WSC(LWC:&GXB;$NUE4UBN5)#W-*@Y5)TW5YS_#4>(_2-=[#
M#W;I63B VG[%T=]V:,(GC7 1\H"F%*21<XDD(7.?(3B[-J,>FT]N@(@A@ 5\
MN'@&0_I2S?-=G3A_<@<\[-H!<^&2BY>W*ENVTJ8:\BR]5-7:6;8<8.DR-@I<
MO_0#RI:M9G8TW*P,%FZQ*V+'9$NTO+MP 31F\-\15I83,A;'N1-NR9JIYL0T
M!H/15!^IVF1(Y/&0:KJLZKHZEK7Q_ZG#B\8L35;:9T[5Z3.,.ZE];IX4__TM
M!Y1BUE4>66X=PUW01_+SH^4;MNN''GV$VW^W7>-'B@T*QT& *S6O$8F,L:'J
M$\,PA\9$508J4;29I@]D..'A6";P&0HXM80/ 2I2'&6+GY'@.P""XKEE#W7E
M#/GQ57\OO[[A; J7!U.J*ZHZ@X,V-#(C=*+HVL2<#FAB9M8$TX,QIV9HT_L9
MHJWKH-"\GR7 ^_1SB:C[.W7HS H>T?8J@>)P%2KK,6U4+1KW(1FK372%#R9F
MIQF0GQ+E.T\:[*/JP$\"F(_D+JG'3M%G' /^-W-MVWWQWS=1(HJ @'TS S>Q
MQKE1#?NWR=*G[^,?/IB6O[3)ZWO+8;M@#WW(?Z(DN8M]D%_^$ VS'PSZ ^Z>
MB)+WHB]7S[H?C_K:4%Y[.3OLOLEK];XV5K9ZZ^9K$V6XE[6J==]:XHN,3Q'H
ME7;CSHHTSLH$8/U4AU#//4JE/^&^N2]]<E#Z)_IHC>'<!P'Z4;V_B7;/7OC>
M L7<,NKD3G]$E@6V%VA'D9+E%Q*4R]STZ]R)FS*".XA8:,RTLMT:<]_/"&;*
MWHGN"(3<?(!2T_3WHP8XBMI3:X.DSCH.UFSSYQ/DJD@I6V.$E!GUZL65OG.<
MJRDM'G5J8/LC P6)G2&)57C4&I 8M@?6]1.FL3/0%FI$XD]*8?A&EZX7,$=K
MHCEX)"BH#;7*2YL"YT1J3]=2NQ,NIM3;*%.'J_3^:3:C!L;+$L+_!N"^2?Q:
M]XE;*V$!ETK* T875Y-^6\.GFF!Q4S9PC(/Z6QTK;R=@[-+I[(V3Q7B?9#%&
MT=@O]K(6=%&7+CHJF_/)9JO!G::^_:X$.3[;&$.-HA=K8I;>&LGL2R_4HYE<
M##.D+#0R)\X335ZWL'YBP)L2SP%L]:4I#5XH=:1G>,@-?7P=1E'^"CW+-RV#
M+P7CQ7 4AD<#*ED!7?!([),#>S/C-_\[)+ NSZ^;C-/QL_C(8MD\UX%YH!?<
M TWS'N@T(R(Z*#P@$G@6G_T<I;18P/%LF^+AVG!$&*,*7A/8_VG\D_H^AKCG
MKFV_7KHO#L;MZ1/<#%!@D6SX! DDXF&NA<^!;EK '%G$&W$@=V)]Z7%.D^P:
MU^.O><63QZ66+P?#98X+3"V<_@77$'DR..;B*5L^?REGH_PK@ G6TL)EU/F(
MY?/;;!ZX(PM 9C@5]L2,6!X@H@V(&[V#^#X-,(+GL34L0V_I^I@0= U(B=DG
MH1WP>RT_!3S+ZD"<!2 1 S,&>'**%<REZX?O<&;RZ%(>]?;3^2'%K_K^^"C$
M";"]_,2!^)AD1L'VKCD8>*K#(Q"T=.L\ QA=[W7/6]BX8  R#C5/60.>T90;
MJKCL1BDF5<U9%L:/,FT V)!C6#8_]8*YS$#*(9H ]'[&P<F@B<!,8'F] *$?
M-,Y;F8"2H18;L'(=8S5[)<\S9Y;G!S'G1)#-+'P_<A5U->NM/-,D.O+H7%2,
M+!=[BB0!Y;_E$P B3CQ('R%34&G"8/TCA?!$Q)ZO?IMZOUZM9?WK'CLTRLK#
M%:!F_IU[:5COB5Y./4I^7)(9+/8]L5_(JW_Q:UZ<@2R+7CY&6;8*LK4[G,WV
MEJ7#I:>):5(,2=Z#%DL]WC7F-]*9M4@@48'J_ZLZ1PHT>);;@L2!:C\?DT*Z
MA&GEV5(@U#\]/-S?23?WW[[>?[M^O+V_J]*,T.NFE<4 C[2'S[=WUW<WM]=?
MI+O[QT\/TKN;^[O'V[OOGS[^LJ62=]3MO/M^=_W]X^UC8?D;LL JL[I6LL#H
M:*Q,)E-E(M.AJLF$F+(Y,J>3P6@\-HFJ;LK .AN-6%G5B!.YUZ+"4+?W9+D+
M(:\X/,Q!L_X=%6M<,R@0[*^??AJ@E\,#D3:QI7Z@7URIZQJEQ.I!:K9ELMH8
MI %"%H#18 #R<9V7W (P,BL]$YMK;;9YC$ESTC!Q.9^D/5G%C>].BIOI.?OU
MCEA/CEC!WE;]DD3M:72\L*LP\ZDLWOO;)J!OMS50>(-_N:%MWC*D2H@C(HO&
M.\<N0/UB77*R\Q?\%B"U&1HT:T[&29RL"@1.F,8+21P:DC7+<(Z^E&$_#D!!
M MO9?HZ94!Y-3)=R4Y8 :P;K%-^&?X>- 6*RN@58#V?R\#\PK=:>3F1NNTYD
MTW+PX)-1NCF0+'DFEHU*2E_ZN_M"GZG7XQ;I@KQ&_A?,0\VN,!8:K/!E3F ?
MKO/DXOZ0-X:^SQ-8T6)=\<R0,)B[7NP3\-SP"6?YL9>_4N+UI;5)VF?!(AXS
M0)Q9-G-LI7XP&H1>ZCK[WG_H2S,*2B<<>=8_TDN RF[Q T20G .%^P_BN^#0
M80U.F8\E7@N<]A.@#'P)$"+C02&A";)M^EIV?)93L@X_]ER4?I2Y0B(C$8_;
M9\Z,&!'8KN,RB,Q=C4S)DT*'<J6M6@G+,).9&WI 9J5&>"1^;E%I=>!/WX"X
M@6JE!^H]6\#0WD5%*+??'J)2DU]0+B^ ;QM,BJ/?RT4&DJU\0]%.?C*K)D+>
MC%.WU.F;K$B>,/1(?]<YZGR.L/S&]98NXYYI^4-,%AQALPOAS!G6 *:N3\N_
M'+TX0V5Q?<UKO%J/<;BF^MMD35TQ.GHRV0^ -0[7Q@#QD('?S[ZZP!\!>E_B
MA:QK^URMG"G*Q=5H4*PZRFMG<&#-MK:F9>9AMS:\N!I7;2W/Q$#VD"?0["/)
M@V=;BL"<0X$M;C)D7H:>'R(2,]\1 UB&'Q$3MFGY@<?+0>&%J%6G7P#: 60U
MZ9(R;B+=SV9(6NCV7"XI0! _UT-MP*'X)/%>>\D'_@+V:G")OJ FJQ7-DO8&
M]UI>8T!1@M8) S%S5P,G#G*+7 %5F8H!KW%X560,".['!MJ"@\/@"*!-8-F9
M=8PD8.C,R=27KFV<RQN!K?I5%KXMBC#D=S.EM@6<*@WZ ',-F&Z-_V&>],CA
MQ\\RN9\%&4!>S;%RQJ0 N8 RFX15])E,^N '5KD91Y1GRX\6FG*+^*6H"H4V
M1W/^1O@MHR]9LP09EAY%A2I>?;KC7A(3\/U(38LQT</3,A@[8]H4274]8L('
M_%C#C#6Y(H=UB,,P*09-+UHD@UM:5<0U P/']LZPK(B)ZA 8+(  /NB:& !;
ME:\E!<PU2P3U[4H$.U+V7-,QH_6/&<:H4IB/ 9%FI8*?HFCN5^HQ3T:Q$%!1
M5QU5JCE31T,#_F>:ZFQ  .'&LQ$AQI2,M9$Q72T<C+\AP4>0>L#NDMC'-I=6
MGI=B60VTE9K0R72L*_I4'@ZI.M')5%6)8<PT?6;H5,?QPK\3'\XW"<<#"V$*
M)'R0^7J0R:.C)T3E<(H2^ME"NF9NM(C+HG$!'(UOAYJ7P/\\ @H9S[=![I5]
M(["S, !+PV&O,5-AR750_(WS,2[O^,=)+(%,RV9+V;A@WX(#(1Z7#(0YKJ:;
MM]F3Z$^#+@-^/]?*/4 G6-0,0\C<>%ZZZ/Y''LV6P14-$O-]UP#+!^4(OPA"
MP*?P%VYJ@=SB;27<*6!;E&&! 6X?-9=X*0&0#$^CH#^I9UC,\L>5.IBVP]1S
M5FR:WMV7OL:+PI2+DB]'+3%R4.<?<I>10$'A!92#'^!74+>,! U BNDD(.@C
MOU_YW7WI"VI5 0:'UZJJ' $V1UX+*5C7L+MX8P_)OC[]9-LR/WONXB;%D?O9
M*B_:SFFJ:!L2R<JW,>[B-D;H'BOJX.N[' "M+"LPBF5#U$A+8?B#WO@8I?E6
MI1GLE7L*FM(V=V*]\O>AXGL9KZ]$YUDK!T2LNF:L6A6QZ@ZL1<2J1:SZ1&+5
ME=KFMAU(5J4ATUJO'?,C%QEKNH\HXW/I/K*B"7,9S'5:GAM;)3FYQ-S0BT1T
M%Q'=18Z>52^ZBXCN(JUU%[E-NXHDYCWRQ<B48/:4Z#<B^HV(?B-GVV^$>1I*
M>[.)]B.B-\*.[4>^N+[/W7;%8M!;YG2%/WU%E[;K7 >!9TU#IBT_NG>N@]_S
M0*>&6VZC\&&9^VYR<:7KZTH[3J&U@FA?(DCT>.U+#D&B^L759'#*)'H&NDM4
M'W]*&LI=&C\E&<S#F*"3P[TDO:2@LS1I\G""?1S>M2BQ =HI1]B2TH>#BZMA
ML<U1P8)LB*6'F%_51IN0<\>@"H'2"@;)%U=J<29BAS#H#&1!)$G+8,309E4H
MY'+0]*+KNMMV;$%X)+T<XDQLN&LKP;&[5MT]AG!0&[", 2A@SVD[MP/JHCVW
MDXAYZ[BVLS%3AFN8?E\R&.QT<.T,A-$)&B99D8.U@'$^:2X%';,_L1Z _'QC
M1LG>),C'#*A3N@:M\W[V2'[F\_YFUD]J7OZ'>FX9W:N843Y19.5#2VWGA,'2
M1>QJ)#.JL*N(1=K%57$>9M?PYPPD1+FYTFD)L<%U5<?Z$'Y\X<??SG%7QJ=&
M;\ZB$O0CZ&<[MV49_8S12CQE^NFL#K!2;B)KC(K;5H3K=Q"/!A)+IANBM&Z<
MT=7])786%<Y:'?S7:MWGVFK/]W6R#[=V,';O'6> CR?HP&*U(<(M5;_B5EM5
M&F**ON8$?<?JN.]GK/+&OT_IF4&Z3*G CL1#K;^NZ6!W' C" ;43'HWWC$<Z
M%J&J?>&($II'&;9^BCKJE+9<$,K&L>]L2=G@G%/O."X^9%MJ".UCD]30!YO%
MQBWV \3>7L3F?7ZXP,@G7:4=D[^25[SYVF-M %E/L!)9H@XNK@8G($F$1K(;
M;E6HMOO!+1EQJ]B$N&NX=08B8D<M)5/^7VA0=R0$_U;:3FD_HX%&?:W&FDJ:
MXJ!C[G+8+ZGLQYY0O&7*.WFU4\06*6!O@$,IQ^!0"G*HMF;T=B@8)G KAUO#
M8^#6L'SX0-=PZPRDWPEZ8Z,./2W,;3[SM. V/;41T N.MC+J5=%7.VI[=O.1
M4RA:M)G>,O9MY]]M@GT:>GBUW363(V)?9^7*;@D(+7HQUT?W=\Y!Z.(J.XL0
M!U,TUIG9B1,W4V]WK-C!^B:S-7):WY^B?:Y4V><'2O8Y\#O.@!Q/,#97I?=W
M+X F@G G'X1+2R.W:?55-TC2N6W7SY(NV^*)6BRA;\;=@#<:S4KS:EIX;]:&
M2>R606JWC"ZNQOW!&883!76<.W6,]T\=8QRII'0__>\,Q/6F=B==%]<?R\O+
M=VE7<DX^N98DW.;:WP(U5Q2:9ZA\TEJAN8@KG@#.-9$;#7&NB%LZQJL'Q5Y9
M74.L,Y @&Z3L<-QQ"?+H!L3>3Y#@3)7;LR^0W4YDK@Z8B?A3"6O2!JV:?B<1
M+Q44)2BJJ4+0@*)D9BZ><@;"&:@!)QACV%SIN5/(MS/!!U$9+^(2PO-Z'@*S
MA;@$8WGKK&9-8:KISL,(1%1"T$:WE,D6:&.(2N9P9X^2B$F(F(3P#^\])I&E
MY=H1":V]UK<B(G$"&-=J1&*S]-!$/.+ AEYD^$8SI95J3\Y9!RO*P2#\KCM"
MYOQX8K,P1[[S4H;?C5JU)%LXJ@,9H+6XSI;A$4'#@H;W$%A92\,L"V_8<J"R
M.S3<457G5U8X%-?89"JA%L1[LIP8@$/ GN@O"+41_%KH2)(%TU^A'UBSUWSY
MU#[:ENA5:*VPT7IILX^#?ST/J'%?4Q *?)XK?"+I!4=Y>S@VR<8K[[)"'!,+
MP)B%Z1CT$JNE<G?T\R53:X]35O+G.3RU\U2Z=IXWP!&(Y6!MWC(,HFEW"_(*
M1SFS\5P9D\*0"C$1F*P]Q<IQ19SO+ES L@S^>V0%LA?R T5^:<U4<V(:@\%H
MJH]4;3(D\GA(-5U6=5T=R]KX_]"YWA0+V.]KT&"?9UZ03>/20Q_UN2@H_OM;
M#G!%%3,OD?YP7?/%LNUKQ[QU N(\6< !KWV?!CZ:W;;KAQY]A!?\;@-AI0)J
MP@4?L\FOT<$STTUYJ.LC0]>GZDP?3 Q%-2D=*+HJ3\TIN9 HB+DE?#KP0F"[
M\8<9':>?EOBW>Q).*BDBP2I!USM_>829/]%C*W@4O:)R]?G=CJ9D/(0[9'E&
M5:)0?3J%.T>C@3*;*H,!O=B ::,21*O@+OM%-/;&]Q98N)91@]_$)]>$O1YU
M?QMW\SBGT@WP*>*\2O29V( 5\/*G&#M!O$@67+4\9%(2X O!_P'RV!)(',N7
M@,\%\(Z9Y?D@L"S4Y:1_A\0+J-=CR+UP/9S)1O\=PAOL5\F:P3,F:$R!Z_GL
M TLW@$L6/)CY%/UI^4%?2N@D<PE6&"#WA*\#6IHADXTD8.OPZ!*'HL-5%(*2
M39^IW9->YI8QQ_N?J$,]8L,R3#H#8,!S*$IC=SD\YM,GOE4/=DOY"Z0IM=V7
M\OO>@:KK2C\<]\5A[V)<'YYT@E]Z;'?\VSB/SJ,! LH!><TVZW#W,*-">/*9
M6#:KW$:HQ:^' R:\@1%L[2FTB6>C''FVZ(O/-IRN"!2%T ;- *?;S4FP HJ^
MA$<='5T),"-= B ")QJ=HS)05+::]/<A[,24'#>(#Q'?^9K#D5F"/GVI*-2*
M0BS"^ @M5:P$+Y:)OUAF,(\-D\Q3$94-TD?(%'3X,%C_2(88#8HCCR/2N_IM
MZOU:PF0K'CLTQ<K:"E S_\Z3SAE+P)K+J4?)CTLR@\6^)_8+>?4O?LVS*N!3
MT<O'R*=60;9VA[/9WH0[YXQ@1<8-"T!7HAYO!/ ;Z<Q:I+F'.L5_58M?,&8?
M&5T#96#\%[6]WWXE7<*T<B7K3^.?GQX>[N^DF_MO7^^_73_>WM]523T4Z5I>
MXAUU#Y]O[Z[O;FZOOTAW]X^?'J1W-_=WC[=WWS]]_&5+ 7[4[;S[?G?]_>/M
M8V'Y&Y2[2F5M1;D;C^6AJJN:8NA#=3)3IH#?(U66S:%,=7DP3#Q#-77L!V-.
MS="F][-8F)<HU/JJ@KQ9@>RN0G4SQXZ#B5YD$,][9:;> HR^G'247BCV;$$=
MR ;U(M/V?0-#B'8+F^-=7A(QR+Q8L$F;+'WZ/O[A0^SLL1RV5/;0ASP\2UJO
ML _RRY%,T/6^-I)1+$0!L>C#D<3H,XFQXI#CUY11?Z0-UUX>].6UUS:]5M;Z
M TW9ZK6;/RDKVSZY8;%*7]-&I[+807^DCD]EL:<&V9HX6Q%[[D2NN][<@F::
MY;M;1X+OV.@7^Z5&$GP+O;PZ(+_9UK_W'_K2USD!N\^@(5OUH?IQE2UH;_VR
MBX=7(]5_PSGS0SM2>*S\*+^"O6UX%AN;(3U28^[ AY]>I0>T/C<FWKT!X/Q)
M3;:4AQ T#43RPT/EU%C#+7[;87H[L05Y%5..MDWFK1WAK<(>>,.1@/$[L3'(
MUY/^))XQEX9RC_GBQ'QR,5]Y_7QE7=T\8#FVQO-IRDZXN#1=YO3")TLZ'X\&
M%U=J;Z -3GCT\@Z+$4/-!=%M(#IM3T0G7UPIO<%@Y\YD@N@$T9T=T8WV1'0*
M$IVJ[3P?31"=(+JS([KQGH@.AS+UU&%;([\$T0FB.QNBF^R)YM2+*[VGJSM7
MS1R$YBH<0=W+KG_+=XK#.J$[Q6&=T)VM]J$:E*@&J_...B4U/[L>_.I(1NAY
MU#%>I<"#M]D\[RE35]&3'!J(J?;KU?B:*D4$[YL(W(\IM/\@EH.]"BK;763T
M#:VU=A?=Z_@DD"M%+OT8R#42R/46D N>. 9VC05VO0WLDMO#KB(632ZNE+9&
MQPH$ZB0"[1-]](ZASZ%[-I_ F-;[8$Z]K"5REH-7S[.EV[O=+"@?-@ _K2/Y
MKZ%GS '&UX:!-2$ F^L42TJH?3RXN"K&_0N9TPUI370$[(28J&LB52!-;?UU
M+(M.DV\!KVI;1ZTAEB(0ZVT@5DW-MC7$&@K$.E7$:J1(%?"J;3U*[8P>=8C6
MLB=0SO"/T*'2<-"PFD'TICP 9+K-5YH)+&4_63-CC15"J&U-B^Y<GTK1:U;0
M<Q?I>;@G>AZU5&,AZ%G0LZ#G^O2\IT+%\;BE\@U!SX*>!3W7I^<]U4".)ZPR
M9#01]"SH6=#SH>AY3\658YW5G(S;FFMX1&H6TQ,.\O7R;OO8UCAIJ3CEGD6)
MV+:+S8E-*7!9'\:RQEMQCV66$L%O_=/X)_5]((A/H><N*0L[C#_XT@VUJ6^Y
MTO4?$C'^'5H\F4)R7,EVG2?JQ:W]64/K6GGIV/@1YSC,0L?@/7_21U[@FL'Z
M2)I\!@2NQL?UL6V8V-S1\Z47*YCS)I/N8FE3]@76_)E*/N']9O'G3_WO?>P_
MO73AKQ+2SE+,ACCZK(]E%+R0EIZ5(NPJDF10DW593QJ&P]D^W'R[E>X=@[4=
MR_0XQU;CH>_S3MZ?DW;C=VY ):4G(4XK@P^_ASXLV/>EZQ2?^521C]8S]@0/
M0H_Z?7:W_&$E"ZC%X13R",VT3?UK*_O1KO2O5971:*A369M,=561B3Y3)H/!
MC-"9.= 'D\G%&0\G*$R2R!_<EGU[ 8FL@'X!O"A,R6"=K8O]?">#9OU\5R1B
M=]O[WF::]GOTB7ALCHN5@ITPL# 6GFGM*S5AN*?=[G?8'\O;-63=]-I)?S+1
M3J3-ZZ0O:]N]]?!KU?N#X:ET43XEN)[26D\-!^IQEU/HH#RI9:R7V\-IYI!\
MHBT^-V9_;#BRM3E4LG:BD-C0UO,4T'CK1N ?(TO6:M80?*TWIR(+ZI GOTK:
MY0?_+_8+-2_9[*%K6!EYHNSG;W1!+)R6RJ\L<)33?YC>R?[P%3[GFNS'=_]+
M 8:MP:U&)^'S@?\?GNO[#(HWT:".&-RAL[YK@(#H>HA>&T:X")G7HHBY J#-
M 7I'@QT0]$V"3%"UH.J. [0N51^]Z?U1PY0WH0\?9^$5'D'QY]:RS@B)=N%R
M5(MA8P!WC2MW4(C2;G#A)IIFEJBY?BGG@KJP5N.]&7JOH&^FGE[YXDI6UHXJ
MWLL1B1Z9HD?FIORCBHR%#;3 -(>FF0P3UB9:GZ@GT3U34*.@QH-6]>U CAFU
M,RN<&A,H:RD]&113C1H7_PG:%+39:=H\%&F" =.8#%4D0WDBQBD(6A2T6*#%
MBGD*K6NM&M-:=\^_%=0HJ/$4J+&AUKH].;:EM8Y07(Y'+;2L$+0I:+/3M'DH
MTMQ&:QTC&2J#T4G(R9:& G2:1!ZH]\QRYI\\2EF>_%;NYNJ=GY[??W(XOS\6
M8PY:\?N+GL+U65_%M(;6C02=F>QJ6T5ZHE5U1[7=[?%JK;9;0"9]<'$U*D&E
M^NJLP*(S94Y,+RLBC'QQI0UVGC,NL*;36%/1 +EMD:8K3*0-=YYU*-"JVR)M
M>[QJ(-*&(-*48D!#B+3.8M&AD&B-2,,>M/+.F2(M8HV8^2CN;/W.0\^#.08C
M>?2(21?$^\';)@3X*V,/.R6HGI,[2AX<S!VE:VVGH;[1CNV-Q*-<,6.B6G<O
M"LC1Q=5$;2M%1'3Z[Z9RO@/B-%#.QQ=7JEJ,VXC)29W%HD,AT1KE?')Q-=1W
M=@P(K.DTUE2,K]E&9ND@LX9"9IT:WC246=LC3FV9-1H,0&8-BRYO(;,ZBT6'
M0J)2F34:R( P@R[QGK>0@O)(C;G#&B^*U),(L95#V?JC 49P9)%Z<F#.53%%
MJ;G>-!H,+ZZ449><X0)O]J W;8\X#?0FK"TJ4<%%(*ZS6'0H)%JC-Z'#>"CR
MVLX;:RHFA6TCLT9"9ITBWC246=LC3@.9A94%BBYDUNE@T:&0:(W,PIS[85OC
M"8]BZY]@G/\^F%-/A/0CG%8/9^;K%U<C$=$_,,^JF,6XA<8D#X!KM=8<2?BU
M.ZHQ;8\X]34F&9O-C8NH)*(CG<6B0R%1N<8D*]DJ1<%ZSA)I*L:-;B.RL&&8
MWJ6@FL";/8BL[1&G@<A2A<@Z,2PZ%!*M$5GHF"XZA4XOGE]K:'%V8;+><4_
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MS0HK'*QGA:GK;PT"9;[$DDTC#"J\DKT#?=M)\!D!Z=!(?XTU;/H3MK>265;
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M9?L\40.HM'-1Q0"A]090T<89E3<J:FCAE!/@7AT @@;>-@U4C(EJ0@/CKM'
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M.RP!UBH+*+1$+7TK5SN !SQ1^S7F1:#$XAM7>4WVL8CO1"NW KKH2Y]=SN3
MJD:> \"T0WPN63'!]_E,*L/.^;'G'$%\5J;E@-D%ZDT.1LG;DB^@]P_7]N0
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M'P+V_3QG(UCL!V:_L)E_]CXM4D&>RI?W4)[.@VSA#D>CO<4:A 0'9NL*=/Q
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M7FN )YQ2>M$>@11[W&+P""?JU0M#[^JC2USX&_HN"H,-I'VWGN4=:;!)[P7
MJ]4'HL71#]8DG" L%V[5(9);0;5ZBF;S-HI;%+M]=#_R'T!1'V?$"*\<DT1Z
M?"S1]L[U>'_]L\M^MO_(WY2]'W\)#USXBR?HZAAR4= SG"6<##;I$*D4+JX0
M00[-,2T5O1)FM\:G8,5/+(/BFS:7Y7\8+T$J%48Y/1U[RV1.1NP/4W\8<<G.
MQ7@=<F/)$E(B9^%>BLZJL8P7I%B2<-S[6*1LX9AUS; YP_SHL8O.$>&W4,YU
M*4QB3\MYY&E)>RLQZR":1R+7&4?@5"FBHB^:DR)%%ES#[Q*;\@)Y6!9&1 +K
M'(06]U!J8<C.]; BZPI>R29"0/T+1RC_MX7:F\4B9AN+/JXB!UF>B4H!W$AS
MH/.T Y+TR6^ARS<M1G/9[%;L8;"\B']K'IHHY!^ 'J&O&O9:C(7N<^M[X(PQ
M, 8-$"BM5=!(4%LS'9N;8I13Y(T(7)+N0\+Y0(8<T[@*>*DWFOV:YKMS5_)P
M+9YL&JMC[D[P? $6JYJ+]-)22]KFM)N-5T/T0?/LLK5(Z!T T5=M?;^(K@.B
M-Q=U[<E!=!KFS))\T72Y\')'1:IS01E-NJME> MM"C9$:^,ZCN\0SLG!'O\(
M274/L++\"MV;@+(!)@+5-GQ-30W$,BPS3B:?SX$<L6?TESMPZG"&[9J<_OM(
M/O%Y1.?,IB$F+(BR0TYETMD#UN3'D9*%RD\*)&M)VE1ZO>0G"P)[\2_)"%XV
MW(=KB^\]CR*P9DY,+].G(.".Z:N,AOE35FJ72NSS*##",<E":(9S&B3B#@$-
MV\!0N.*91R9;31O*X%\*:G(-45*%Y24_A_",/RE7+Y'[(\.0#URLX62@F0UP
MJ&&,9B'G^3/T+-^TZ*];6=/"<R8V;BK3^K\2;_?OW.!;TM=PFV!<!7U$@];9
MI>OP'.\&IETE8"F9L^ 35+DOQE8B++$81$Z-D0U>@!CAZ*:!'*?8)5IO [>)
MXUU1C(VT=<381<B?^(S'1^B-BGE,X)*9$*>:I%)\YF)SZCT.Y3XZ#O=4ODJD
M?F(.90+GU-PG8F\@D5Q#)0XL-UQ/M?_%G6C(<T6I-["@1PQ7GJZO%Q/ 4G[-
M/'TN-PP<RU 9.K=GE*_UY% GHGDXHE6'\7)E4"*OC#^PQ+T4V7?Y;]Q.;VJ^
MGLK8/KOL+.IP=@B543^DRM@!E;&]R-F651GUWI9>HV:KF-=HT4:_<0_#>^R)
MWX\>D3''SRCWTJ/[7;EQ;D2:39Y?:=!=[E<27-]?P[NT#HVL\BWM9II:6LJ#
MC/@X2PC];$'JH'?*$],2F;>H#V0D=WP,.2Q5S/S-\Q,F%>#\TZZM')OVVK/1
M!H-ZK]';9#1:MU_OM-<>8+7V:YNM>J>K[V6&5W<_BUUO/%PU &FMS99PE,K.
M1X8=*R"6C S;<@;,#L>\+,M\VVO[WFLYT261@YD<C[N7CB#=>F>-M>6D9"+
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M1*1@E;L3;0V3+XCR/7"2Y[,PDR=<@C-Z3@!)\3O!3(7X!29F1A(HAB)UY01
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MUO#,M2]=<CY+"CT1OEF'9UQ4SW]Q(Y3.-"R]45G[!#\1$A'RGNX0=?DRBY\
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M)4=!/>;@W7F[?="P^]GIF9MV3MKF:%^WX=ER;K5AS[.*YBN:7T7S!^_[VQV
M"9.=$UR1?$7R%<GO@^0[!^\HW&M4)%^1?$7RKT?R!^]5W&N>738KQ;XB^8KD
M7XGD#]X&N:?CJ)W=-2@_!,V3#_(][?QRU63Z5GK8.L[MEDLX1_*B*=VK)GF?
M[V.4]V 5>HE9]O'LQU?_>AI0O7I'1RA\\P![/?B4!A@6VCCTVW,G-/4;,!#.
MS4<J<$=8 7+^H_Y0UTP<Q.UI(\MACF$Q&S;! CY1\^_P20Q],&=&:66]"_CS
ME'NBP1Q.*[]F#C,9=2S[%'IP#<M)W-P'/3Y%\L!IYW(H:$U++,*O+YPOGD:;
MII[&F]:QX8U>-KQ)-*1#YF"N/RM>C*'?RW96,WF")M?L@T'S[%*.+AUIOQ63
M-9D<M<T"X/&P5!KSB1-!\<I\YQ/1(#+3QL0))^>F&YS+E>1)I!;8G5DE5(T[
MUFA8KFA>Z/  L"&:W3JFL:."_Q@>K.E<$;WFO["I7]->QI8QUIC'Z5$ H4R*
M#-@O;2CG;A8&[#Y[7V\"O_;9938)2X%O,<-+,*]HBK-(#U6B7PAQ SGGU.<?
MU \7*BYH.82L]-!%FG_F3#2F[XG+%W(4?*-1;XA@NHPHRB^OGB+?:M1[S<W&
MVB\=3@\7]<Y&KUU^K=O9[*T'6*Q>US=\ZT$@VQOTW_AB6_56L[76:U<$[U?F
M^ R.=)KPNH/B]S-Q^6AO71-=#NJYB%0H>N$'*X"/&>O8[;>.$I%+>G8E/$H[
MGQ"]0A27F4[RII3O=+W=>F>-!5],7=_"M7T@'1'TJPL\G_-6/4?]&#*?XPO.
M+K6$42VTHJW.?0WJV@AY2LA'$T/MT0SPM7=BMOWO&N 'HD1L*VAD+ "F_'WH
MO;^LAMKG@L]%WX8_UC[;[@NY-T0=5P6[(J@7PPU-+==1?J6/TK[[9L-G\SC6
M6P3CHPL"4DMT*$V +BX=1-"FH+1EUN<.I>9!4SZ_,L\8:ZTF.:;T/8U]/.E(
MT)L*]JSK)]I5L*>@WZAS=MFL=1K5=/>*<$^=<(O1[8H:QOW%9KNYZ1B;-56H
M:+*BR1.BR14=>?9'D[VS2WWK.KJ*)BN:/ ::+*C@9JI:7SV;J9_;%:528"O"
M?-.$^=HU@P4MSP%9GJW26YY54['E3<6&E,22F#$JLUC>V*SP@L2Y;G'?;L?Q
M]AM =+UN-=SY>/"J$%IU,P5D>\6FYMEE.YMU=G1#Z,NN\?3^1LTV6\W>!<"V
MU[^@7_H9$%>4D*"$3%W57BE!![Z:K:<X.DJH>.L2C,J4[>P5HUJ 4=G^815&
ME1NCBFF!W5UDYV^ 6]BRL]$LAQ:XHW$YFV3<96IY#H0TB:H8>8:BTH$SSX'U
M^93=XI(A]DJ)=GGKW##1[EUK59Y=U>A]?7-PMZ.&LYP!^ZBV=A5]K*8*E%3L
MK+ 2]XUD&.'>@;^^0J]2\K)5EM>!IJ7W>V6<6%'AWRO8:0>2I?VS2ST;W:AP
M[91P;5T#;M^X-D"];5<9*B6*FI76)[L\-E8-U-F-%;23V<&#QMEEI[,U)ZX:
M\I\:OFT3+5N&;TT0_+L*!I0:W<B?(_:#16I;^'DJ7-PB7K4,%W<9F"HU+E;H
M]EK!K&7HUCJ[;&732RIT>^OHMH-1B7GHUCZ[[!X)ONTHSB608U!RR^@+]_T/
M&I-QK?FQHTXJ@13[^%$&Z689@V_$T[ +VVB[-/M!Y^RR72870^7/*J5%M)^!
MTX-NY;Y_&RBX T-H3RA819#>" KNP#C:4M;VP8ZJD.RDD6Q?T^/71[+!V66G
M3+D^5:75@DJK>0/JJ_%/,+!<IPHSE<J46C2'=]# "%3C. ;Q5GZQ4["W%J/B
MFPE.59A8"K-K,296H:D*$U_3^EJ,B1BUVMK<JC#QY#!Q7R;:8DS$,1[]DPAH
MJ?D@L V^''NK._=_YY:]>Y>/2BQ7KN:*]KW)L5*;=N^MACQ60QY7R8[7[ON;
ME26=L\O!8'=]T:K!KA7-OS6:+T;R!VH9/&ATP7[9VI*NJ+VB]HK:UZ?V S4C
M'C1ZN^BZ55%[1>UOF]H+ZO.';G,\:&!.R.ZZI58D7Y%\1?)+2?ZU&RAG27X
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M> &&39 9S\YQ.@<LT#'H+8G51AN/O@S8> OX#QJR4,5(PY7+1$TN(01J<21
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M=TNM^<52/ZGM")E%>MN2Y$G!$;(^2R&/X0@,L/M9Y'F1B9\F^AU-\J5$,;+
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M):?1?W$:/X(SDV"C/F@T@!=CSNQ@;."%:+"2+;0CDZ;;2,V&F<\H5P'!Q1,
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MU/+2N6MR;*^L,5U[1N:Z^5:5#E)T"?DZR.=U9Y<2&_/B5'<P;5V1XEJ+$SB
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M_$6TV_^MT^Y$H6]\-NE 5H7&A%(JH\6.^9YB>\K-(E--X@5CPRV9_)5HRN.
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M.T+H@:6,?%KDK^=?+L'@B,:^37)B66#DDD) ,7"\.YAY/W!$6%HLZ.U(\-V
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MA 4,PP3\6]6YS&(5@+73],N+("0QMJP .:IPP6./)C7A^I/3D.ZG][U./[?
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M@AKX>Y.);X/%B6\?A[[]"/\UCB;N+_\?4$L#!!0    ( ,N+ E<"1J*>WA0
M -;:   0    ;6-K+3(P,C,P-C,P+GAS9.U=ZY/:.+;_/G^%;G_93%5(\^AG
M:I(M!^@).YV& I+9^VE+V )T8RQ&MONQ?_T>R38V^"'932>^ZYZJ3 /6>4B_
MHR/IZ$C^[>^/&QO=$^Y2YGPXZ;QKGR#BF,RBSNK#R=?Y3>OJY.\??_GEM_]I
MM?[Y:7J+!LST-\3Q4)\3[!$+/5!OC;PU07\R_IW>8S2QL;=D?--J?91D?;9]
MXG2U]E"WW>U%Q:*G_/W%^;+;ZUZ<M\SK[EGKK&U>M:X79^W6I=G&IG5VA:^Z
M^.WJ_>*:G%WT3-S";=)IG75[G=85N>ZU\&7W_!SWEF>==D\R?73?N^::;#""
MJCGN^T?WP\G:\[;O3T\?'A[>/?3>,;XZ[;;;G=-_?KF=R:(G85F;.M_W2C\N
MN!V5[YV*QPOLDJCXQHQ+PV?BNLSI='OO3+8Y%95M7_3:45G!B1;PIH[K8<?<
M\;8\WO*>ML3M9!/!\U/Q7 AJM]J=5K>3(E53=EO0:CV@Q)['Z<+WR U -R!+
M[-O>AQ/?^<O'-EU28H%=V$0@OU<@\=C#?$6\.[PA[A:;1-TP'W]!2*!%-UO&
M/>2D*)?874B-7>Y)LA,4('O+3.Q)@Q4E72@J*Y<J?TILSQ7?6N+;NT?7.CG5
ME^J[K17&VU*2DS2!]/"7,AHDS+1S?7U]^BCL+EN#3%.2Y5OB8ZO3!71+B,VS
M27W9\*T5T1U#A[C/E=,AHGNF#IG=+,\65)3RN_M<-79]MK0:(64I-20CEYCO
M5NS^U&2^X_$GG2Z111)]*=,9]IGYG,/P5$Z!),WN6V45+$++2(^*BP^591+3
M*B,S*BX^9,C$CL,\22]^"7_;;JFS9,$/\)/H/>^C+C0ERV@02PV0&7Y*_GF/
MN<F9K7!JIUO.MH1[E+C)P54R6'.R_' "HT<K&C'^9>/%.U D*I'BO^\&Q.-3
M("'V;5R1B%9T@0\G+K2_38*FJ7&]MYR4K3>0N#!82YC_OU??Q';9Z@.)Z=O_
M%;6WR+)L[8&$.K1"Y07U')XC:GTXZ3-8%YP@\=O7Z2AW/B<E!F4C9A&[6(^/
M;?E?![7B%40+2:K?3@_+'G#Q76*-G8_R\Z%9A\1AD0+" X/0IMMORDRR\,>H
M[8I:='PW&-[-A@/X,!O?C@;&?#B8S>'_7X9W\]GX9CP93HWY")[JMGL)CDIT
MN@#)#-J61/!$S%&2.XK9H_$-B@6\ ADW>W_\93(=?H8RHV_#T1U\'1X+T2S6
M2FA[5:#=DX0"44T'^9-Q:]SUA[//P^'\69UTGY$2P#,] $.N*&#["E:BC2<8
M)O[>FG@4%#X:<OM<E3">5X$1O=F3\FO384UZP]E\W/_C\_AV,)S.!L.;47\T
M/Y:CS6*M!/BBBJ--2OH;"F6]HEP(Q=&Z<RDY2OPOCX;_:Z\OF ,9L\\WM^,_
MCS9-CADJ$;ZJ-)4"_D@*:!",,[IRZ!*,U_$,4X;^J+.:,)N:L/351*Z8AQ*L
M:['@I*YI,]?G1" 7\T,Q0Q1Q;! ZGWR7.M#@AOF73UW)U<6.-:#WQ/6H!\VE
MBY$.)Q52G?8A4A%7E&2+@"]*,FX08%.H-/=-J#98[&BSQ90+%P0M,B6VV(OM
MK\46G'M'/$W@RG!4 M@Y!'"/^UL4\W\K40Q%H%#&6P12&H3FR $8R!P_:G>S
M)(42C>XA&@$UDN0-:N8AY@Z8GSLAO,\V&^;,P-R(9HOG$"L;OW?8^!$C!)Q0
MP I)7@U"XG?&K =JV]#W1\+'K.C")H;K$J^$QU(P42)S=HA,Q%"ZI)@E"G@V
MS2D-R$)X_QOJ8,<$@S5,C]Y33W^Z5L! B<WY(3:"F<1EQP[%_!J$RF=BK:J
MD:938G!QB$'(HYD-?P,3EF_8]LD7@D5[B,F+;N-GTRH!N#P$0/!!DA%*<FH0
M"F*\I)ZL-3B#/I,K-OAV2_&"VF4ZA XG)4)7AP@EN$IO%?-%"<8- FSF,?/[
MFMD6X>X &)M4=WC/HE0"DE[C)[C\#85\FM3^9"6MD2VC-;1N\Z<)5:W?3:W;
M(R:(+7=K^"8U?E' ZIC!+YT@V/7U^=EE.[4R5P3!T)OH4Y."SAI1K#F&I<$1
MHV(A/R6 J<6\7FP,O0D$- G%$B&M4FB6YZM$-14EJ! P:R+$B3A8*0C3=$J(
M4N&"9!2MB6V?'1$K!4,A"R4BJ2!!;FBMB? 4A\=*P:3%2@E7*IZ@$6]K(G#Y
M<;-2H"G9* %+Q1\*@W!-A"H552N%4!ZU$IA4V"$=F6LB&IEAME*(%'%0HI**
M/>2$ZYH(C4:TK110^OQ4L*63#?1B>$U$,2,D5PJU?'HE2NFX159@KY&@I )U
MY3#)(U="DHI$9$7[&HE(4:CN#G,.^MV3 ?$PM8\2_DOQ5&*7BC>HPH MM!."
MWH1BFH2I1@0O^:@<N!69*U%.A2PT8X6M_>>O>&=",K*@>O+"BV#!*HMR8D&Q
MQ#P!GOD;8DT?9_A>Q"9FS/9?QD2.I(_2JE)A%VVKBC4,U_@HTE&63LZN0C71
MF^DC"C5%.U5_?37)(YC K#\=C1V3V6SU='O;_[GVF*.,TAA30:47-4:A)8K4
M?(M T5=3S$$_^1D>C;TUX4<WL2(A2M-)A;>T36?OJW@N!3?2$DKLA56<^3Y'
M@M(&4I&T*OMN39\;ET!HYF\VF#^QY1Y-^/S%[$)+JM)64O&]:K82*B,6R7L,
MHG*O)E0%S##R_?2#;>A0K,J(TBE21S:B2*%&6E%B5U_<Y6CY-F'+/MMLF1.$
MN'8%AH];XK@E1Z+*[)56D8IN[N46 -RA.(%W+%!\BPNB4&C3D:\XS2CBH,2O
M\(15X^<'V5D>%7'29*:$3/]<UBM^F4V^[P+]H'+NDO%/V!5Q9%BHV3X,71'U
M=H_Z&* ?1P.EI:2BJ$66<NBI(ZT0J(6D7N&"4FH6L]JF,I8::&C%>48)N-?P
MC,!B'9;=?>B:3V(FMA%[%FP9\2AG8"\A66E8J4"J3D+4@8D%^B#JR'NW(Y50
MH),HL>/Y:E#YL(X<<4NY5'9*5IB+*\\/"5[&H,I(5AI4I0R[?8-*Z(-V"J5)
M7ZTIA6G%^4Q)IDH;2$4U]6R@V3.<_%S)N*?>,F<U)^*^^X57#N*JW)58IZ*7
MQ0F:^SU=2&P)D0'5*^Q)8))P5.S8%9DK04^%(56@'P#]VM.S49F2>V:+C>8^
M)Q;U;K 9;O\='7]]22ICZ*7"B2ICV,E&@7 42W^UC!R\Q+J,<)-B>X)AG79T
M>U#Q5UI!*GRHLH)8(I(B&PY]*A&_(L1J/DHH4Y'$C-3^IL_64LV\VYNY89S0
ME=,/7^SQ.Z8R9>"6P5S777*VN6/.@'!Z+QMOY(B=$YFR^DR<CZ> TD!2<<M,
M TGL#X4JH4@G))62WN%-H->O2&B&0+56K!M**/=J9?N3]3LF9& [B+*X;#GV
M/?&6([%6CEMPPBHE@QY?KM*F4A'.;)M*+!XB3<) D]R*2BB#$G:T4^?5BO9<
M1:8;$'U3=,IC^2,M(4K[2 4J53XGQXT(P8'3:6;:7$'7WIT\2V)V/,]1S%YI
M !I7@1TXB,39MSU[:*87R#Q76'&2J<=+":GNY6*-GVUFMG=VX(["TMYDW"(6
M]F!@Y![]-['ZS"T9+SRF1*4=I&*(^790$#VD+HH40=A#.U60T*619J-Q0K6B
M ZC"66D&J:BBYBG8IGL'#3"&KD<W(HG/,$WN8SMZ5#)7\1B25&9P5O4P= OM
M9*-0^.YY,W,1,\XZ5SWZJ<%)":SF^>FF=^>,MLY(_@ +]S>^3,R5)S]$H@\G
M:^*X<J$E4O_$(F?QM,O5?#;B1]5":2WIH]TYUI*3BY)0+3P;LZ=<E!X9+@47
M3W%2:S.M+G4&OZJK4#-28I\^&IYUK+_QCB+5TE,B7M\L+CL0;W3%8I1T@T+/
MQ5#-60EJ*L*7 VHL"NUDH5#8?SO.OYWNO_PZ^+[W@FSQ>FQB!V][$E8  /YK
MY'B$.SB(AX;-^H5L%N)]N7CA>AR;WH<3C_OD1+[;6R2KYU,X(A5H(5[K&U"(
M-_K2]P %9990]<.)Y7-)>H)<?R%/(8IOOW/F;S^<!,6I1S8GR N*>[PE/KF=
M]Q;;8.J,X*'@%+\$_+!&PBOOYGGFTYTO5!LOP].52^)86-Y]'M=NB6UW5SU=
M<G55J2,"RIYF3<-?H'%7A*MK.7PTJ2L2_B?X2:@1[(]XN=7*+5^B'L&C!;:Q
M(][O;LHM^%+5V\ HZ6'^I*[?C#B4\:^.2TSH\M9>KL$38-%M=]O[/_:Q@RV*
MG0&#"O%/'/J0NYXPW[%F8+#08U:P ACZG+DS?V%36!<4V_F/U* ._4:^"6Z\
M-$ 1O,$&*.TO+'I/7;'[H6@J'=(ZU#%,H!?3P6],=/$I7:T]-^CD; F_D=3[
M=7(Z5!56/]EG&&=75W="KX%/OF!NKCOGW?;963&V"J(ZH&KT.MWS2$?HEM>*
M&N45KT-=<LYT&N'U /L'.W.-LR27,A4_& 0LLGBQ,<#H7;53IM=5V6LQ41TP
M3ARTQ!L:3*6B -1X.8$)B$AQW@6@#.O_?%<&L7+Q?@;'NH[_F.-U7\Q?'3!F
M(H 4>[%"#%$,1AJ4=; "H]/;&:KAKP 0::D7"O-64-6C9A<],<V)]!R;'@/E
M>FV=ZFF0UJ*.XOQ![%E#5PK]T/8MN8MM @477G9 8 UITE"?G Y<E5U-/??7
MV01JL,$F\>4KG[46E@JB.J!^0Q^))1? ,,!. 8[9 ]X6UZJ0I YUFC[.72U\
M,@K607_A+@;$87+<(Y;T',45*:*H0XWNPN#*!$S&Y'0KOHVWT.5A!/?H2CXM
MKF$9#G6H<9_Q+1/N;1R%[<+K(*)KL8()CGR[9NYZ3)]%3;WF'0,5'8\SVP[.
M44J?,2 PT<(NN>%L,R6FC6$R)ZXZ%:+G;#>GRVV89W*M:5L-OT9Q7W&/FKME
M+K8E<T775Y'5H3<8G?-V<A)TQ^ZE=IU+F 6=JR90.K1UJ.7,$[UU14U@^N#!
M'!T\4Y !#.83=F+APX9+L5U'''&1K^'(]* Q.+0-_;>&(SRRD#JTVYW4W]B
M4!,[<TX7Q)4.;K[&3A_^LN^$W&D.$B49U:'^A7'9N8S+=LO&98WC18:/K$$=
M6AS&S'A#?K<FF8@D.>88G@>6X\M=-X]E#S;#QY!F2BQ"-J)H=L'\0>P'JO",
M$>]%0R('.U-]&],-3,@]SX8Y;+A-]0^?4]>BIA#LPA@PP=!")MW*"='("4H7
MAI*.+.5GA[S/XU#O#5EP'UI:*\RBI*M#QS0NV@>QSF[[K*.H62%-'6HE]U1&
MKNL3:R #V!,I7B;U#C=;FST1(LN(,5Q<,S$6!]>6)+C1-M>PG\NVKFZA_&AT
M[-&M3L:3LWT/2&[$7YCE$5YZ\_^0^F<[M3@:*#<6IV3K0T>&U5PPO[6#^\5V
M7ECA$"IR>SFTM<'^8OXA,Y"^SJ);S:.(?W&5U71U,.4R<_GZ3M?% 8OX%)V8
M?6UD."KPOKD]445V]*H%OT1$.IOIU[MQ]!^^'<P.KE1[Z44T=4 +EL0.S J^
M$^_ %\PY#(HXF/$55[(4BSK4.=\!5G6<=:K=R!&9.):/;3F5Q^KTOKSR=:A-
M'[MK\6_XET_OL2UR0&6N ZQ%8*HB'H:13&+]2;TU=8)[PCX3VX)!? 84@0.!
M):0,?T9AT/RP\HL)K&E@U>A<[&7'J#=LLXO7P5KF:T[(K=Q*]0YW%P?4#:(&
MC"L<6EDN=:BY<7EQ#D,H_"1?-!(O];J7"CS5A'6H7\Y$728BNC?4%NG2G\@:
MV\OQLNQL/X?)3Y[TWXBL<')+[\GA38MBGTMXH_#8JFQY8^D1_K\PI;UA/L]M
M@&?QK)XX])+N*]K>Z;/-(DR$ HA=:H6A?CD)61(."]CQ@P.KN37=*J./SV-:
MU\"!<79Y'D>"GF2.C2IULHBD#GYAN%P2T]N=()OC1W&PVQ%QB@"IW=L-/A&'
M+"FL,:":0_ !WE.$HCM>!H/X;C-DY-R#$,:?@OMB\I/L?XSTFLX<XFLRQ,GZ
ML)],.#,)L=RD(U$N_4KR^>EKP2D!A'PB%2>6V%*?$7Y/39D!;HKC0ZO\&:8>
M\4MVKFT@1\.Y9FQ<E4N]*<.A#OXD3I>) V!!-S0>L+@O8LYD/Q4[($\Q7N/E
MG'DB@RVBF;-/Y*LKBD_ANR4R<09X@XMRN'^$Z)>9T\ RF&AE0>^MB$9.7&,1
MCN/W^7U&B[:F;E)D:+03*R:-A([,XK7M'L(Z T.-3._3DYQ3&^(J05@T_<[N
M"7>*=R&?S?C8IEW%7P[O84SW8*!B-OCSB3@^SIP;<'W?H@ATE+6F#/!68E6#
M$+W1Z_0B1Y_:4+W4.JRC25^'_O!5K*>L8 $YA,F?_1F<<Q9"0\^P.^?];^WV
M=;LW-12)T<_D6@<SR(V5BKL3;"(35)<PR5MQO*D:=BU@58,F2+^S^O:VK\JX
M+B"I@[UG+(S%BF?EB-NSHE<4X]TK(:)7%!M9[U#>Y>W>BA%=GJ8<+\')!Z1E
MUN8OID(]0QZ982P6AK'*!;]BJI\<[?H"$U5Q!,3G*_DWLG^M@PJ:Q'7H0 9,
ME6WJNT.;;&&I[]V*W#]B*3Q@,5$=ZC7!3_*"CAO&)Z%W'B_CZ=EX88?3.U?N
MDL":<!GL#!KBO6>N*<\_C?<N"\RUY!>15=N@7>\ZG9AVH;'UK*2K@]D<TYE'
M>.X[]42Y'S*D:&A1UQ.XP:4.?Q+7^T;!DSJTTJ40&O1UL+Q9?SJ*DH&4\[*<
MPG6HA]RLW!W_>LZ.ISZ3.M1;AL+N6/CN B_LF7L]4I&VHL^@#O4UQOU1XIZZ
MZ%)TF2=_3X+#_>*:Z\0AXNQ\=\6P<6PQ=6B[G'W?/@X.A6TH8)^_/:%)_9,G
MT#G9SG+%[!X_BUJ?[PMMUKA2 8T(S1^5S@TJR>I@U\9Y)Y5>V.NI#CH4T=2A
M5DF'O#N7JLB&+2*I0YWB+<[]EZ(,I;<4R1@LV;LTMDHU^=1T3T1.BJ/;B1(+
MMF*8552U0#KI+'9CI%AVRB'$WP6=#E)*H@2<?.B?S;B>T:QC+KX,RZ+A)!93
MZ U]O*4>MG_(PB]7=DV7>\/)3+[@W=B]>-X(&REW2ZJ XJ5&>4]>:/:\,U&9
M=S<>^R[(.OF@Y"T@<V*N';EPW85%BZNN25R'>AKM^'C%@)A2LY[&#KN*[,?6
M35[<ZYIKLL$??_D/4$L#!!0    ( ,N+ E>I&_K\/20  "UI 0 4    ;6-K
M+3(P,C,P-C,P7V-A;"YX;6SM?5MS6\F1YKM_A;;W==.J^\5A>X)-J=N*D)L*
M43T];XBZ9)%8@P 7 '7QK]\L *1("A1!H YPJ)F7;A$$S\FL_"IOE97YU__X
M?#%Z\1&GL^%D_+>?^)_93R]PG"9Y.#[[VT^_?_@%W$__\?<__>FO_PO@OWY^
M__;%JTFZNL#Q_,7Q%,,<\XM/P_GYB_DYOOAC,OW7\&-X\6X4YF4RO0#X^^+/
MCB>77Z;#L_/Y"\&$O/[:]6^G?S&Z""F,AN2% L62 Q\5 YM82%FYX$3X/V=_
MB1Z5D2E 8,A!"<G!H9<0K- ZR*(XDXN'CH;C?_VE_B>&&;X@]L:SQ8]_^^E\
M/K_\R\N7GSY]^O/G.!W]>3(]>RD8DR^OO_W3ZNN?O_G^)[GX-O?>OUS\]N:K
ML^&Z+])C^<O_^N?;TW2.%P&&X]D\C%-]P6SXE]GBP[>3%.:+57^4KA</?J/^
M!-=?@_H1< &2__GS+/_T]S^]>+%<CNEDA.^QO*C___W]FYM77J1_X6PV&7,A
M_YPF%R_K[U\>G_SVZO5OIZ]?T3].3]Z^>77TX?6KTP_TWW^^_NW#Z<DO)^]>
MOS_Z\(9^2_PLGC__<HE_^VDVO+@<X?5GYU,L?_N)W@!5[LQ(5HGZWT]Y^LNO
M'*0P2E>CQ8*]I9]7[ZCT=L0,?I[C..-R%:^I&$W2G2^-J@PGT^N_'(6(H\6G
M@ZL9G(5P.3BYQ"E1/3Y[_?D2QS.<#6QD$0U/8'2.H)+3X+)'\)(E+Z73V8>[
M:UCYFQ&#"]&7,(L+^:_>\+*N[DL<S6?7GRS6>['6#Q*Q7-GMN3K%$?WJ[%<<
MTX-'1^-\E"^&X^%L7E_S$5>O&4C!N$\L@4]2@PK<0DBTM95'ICE*%J1NS.IF
ME-WE_Q:VCJ;IQ62:<4JZ\*<7G[#JK95:7)(9IND.Z+[=DJMOO)Q=75PLG@G#
M.5Y<_WV93BY:(F0^Z5PR2U 06[NBYM<P'+^=S&;O<51-QX?)V^%\>+98HU.<
MST=8#<L@%(W9(0,TGKAWQ8/WI/<M#\H7J[C(K??'1H1M@AGQ%3/PC$#37C [
M8X:4^> ]$FROTOQJ2HR^N;@,PVDEA$!]0@['=$7M\7F8GM$"1.$+P9:#=,X1
MI&V Z)F"4&+VG >43CQBFY[\TDTP(9^5'NEVW=NIDBG!]=UT4H;S 2?WCXO$
M(9A<0/%"3J$(''3,UB@2,).RM<+X^OI=.7F/'W%\A;^0/(\G8U+3:?X'N=3'
M5[/YY *GKS^GT57UQH]F)-(9;<[P>8 VIA1\ %^\!56LA<A+!(D&T;+L?<F-
M.=Z"S#X9V6WQ<E]3=BVM9AOD>#*;GY1?)Y,\HWU[BM./PX2ST\DH#XP/5F=M
M0&'E7Z& $)T 1PX!,XK\ I<:H^=A:GIE55NAI-'B-P/#DJ5JX>O[M<Z&'#\7
M$RA+KPX8(CAEM:"0VP5;&@O_Z]MWY>/-F.(ZK$^ZWH##\17MMI7IFXQG](WE
M!GPWF2Y0-)]/A_%J'N((/TQ^F] #:-=.%C[RF_$<IV3J!ARCEHADO)P@F20R
MEH&S $45*6(1,F;3>$VZX:1/&G=+S-W?2CT0>;-M>)>75\-96K*#^2LWOR%I
MCFHUHI$ZH&$0B3!RJ[*J]L. 3#G8')6GCSH%Y??I>Z+>?GY0:RB>9@"Z<?&_
MDCIPVG.'I@#SA2)Y&S/%]%&!U"5I*Y5EMG6.90T9S3B["5X8)I4TA2R%HDM0
MIB0(VI'K1+R:('CVNK67\DB:[%%]NJ>0?TOAWX?[;DO>221G,X_TI@S*5ZT<
M,@-G& ,L.MOBM>3![2N2.ZQ*:RWL;5>YF9A?A^F8V)F]P^GI>9CBJ^'H:HYY
MP$*VKO "0E2G.+!,#C>/8(OV23!EA&.-1?X *=T[I_3"U;L6[QT4D80(/@+W
M7I) $SDAGD+$@,ES;KFVI;4O_F0B^^12ML#0T_W+7:1V$-?Q/L'(==0^2^"D
MUVEY(I([1(Z1*&A$"(%<%7M 3W(+P.U+"W</N.XDV1'TVD5@Q1G4B8&,C*P9
MDN\<1&00LF&:.1M3\QSF/H+N+M;W9RR3*2Z_1ZC V>O/\VF@O3 <A^F7-P3A
MV0.+'(M*QJ8".D=+]IXKB):3UC),D-TO0C1/C7?(3I]L40]VQ=--V7Z U%CS
M$*&K".5G'&-U8'.6P<I:^X.<XA1K#;B:5<_D"7-;O6/5VF=\@)1>9:]["\G=
M)+A'0[;]_BC!94S& 3.6@<KUM""* ,51S!RS%A[WGT)NI&BWR.;48V)Z].1N
M%'M=?&(+LQR% V2%UX.0 %[X1&ZT4(0T14Y5;)W:^2Y%S\NP[ >EWZ2+VLFT
MX8Y>,G9-1&3,:542E")J4C8&B.22@_4FI,)9"JIUSO >"<_,(!P&2KN(K=-<
MNI796^4BF%0B>3DE0'#.DY6B -]G0^2USC\^FDL_;%%17R&TJ_0ZRVO^'&;#
M-"! %[32@H^<M*', IST&5 $SZ7%*$-K"[>6D+WD-!=O6B8H@DM&(5/@4-8P
MH5:<.9D LU!6^:"+V7]0?X?$/IGZW;&S539S2WD=*I=YBUS4&A-3&HRJ5T5X
MUA2%,@,4@Z:4/04-R1\VD_DTH!TJC]D::%W)L!GDB)1;AD(KCR$[!*XC,1[)
M\XB.9]#&$]=:.=2M@[4[!#0LY]**%Y310R$#!XI%DF8.Q%G*@<FL+(K6";Z'
MRKD.JTNWE_!]:&^YNMU@=:,,C56":6<CY&AK36$M?Z&@JQY'Y)B%0QMYEWAN
M59JVM\"H'5BZ%=8]3/WUY?W%>TL_=W7+[_CDG^_>O_X'?>?-?[Y^\QO]^/HN
M76VN^ZU[S3[N_3W*7J,+@,>3B\LIGE.@._RX"I-NBLB84LG%)"@"*A0!)6LI
M8M$96# ^9\>5:7X&]AUR=B\Y?_#16R6>DS61&:[!!]*Y*@L-H;@ -='$5 R!
M-[\(UIB%/AG(5CC\MM;]<%)O>%OB028V(EHP[KP-' H+]6J<#!!4+0A@R,C%
M+MPUM\ [DMPK>WP ;#87ZSZPN-6&LMHS#-R C"4OZ]U=1 2)R0:9E%>\==#<
MJ1K=*5Y*4G+)E 5$11)ES-?BK7H;QWH;O4A%M<[P]C->.B3*OA-Q/44^[8X"
MZM'6F@6I%-WHH8"1DX<>01=&E,D4(:JHZ4=TV6)V2;3>1IO0U:<T4Y\PU5RF
M^T6;UJ6XR!!LCN0%Q<P@&F$@9Z6+$"QA<SWU=+2UY?V7R91 .CZ^FDYQG+Y\
MF(;Q+*0%6,9Y\=,*V/G_7LWF]4+ZS6KEA,;4"#XD[T )D>A?Y"AP@HAR5L9D
M][E:VW/2)PO1'*=/V:)[ L->-O5QF)W_,II\^@?F,[QNM7%4YK630AJ%V6Q8
MALM64)4WXH!KP:3SF5;1!S*"QD(4Q@-GEFF6N':I=7ZZ)?U],DD'!7&G@M\+
M=-_5#Q;D+;[U;C*;3W$^G"X:PJR*^=Z-:#>NV8>2.64-:G"LT*H6,MP^HR)7
MKLCL&>-6->]SU0TK3RS(Z/@:X"$1O2\\[#WQ_?/1VZ/?CE^?_N/UZP_-NMK=
M?6A72>WOD-XHA7TZGZ1_G4]&!/39Z_]W-9Q_V<J=E]PYTF^:?&Q3BWZC!T>B
M!U)N1OL<G8BMK[NUH7SG;GG?4#&0(4>>G8(8%84V0@OPT@200:6,&"C<;5T@
M]"T5??(V#X"Q;UKG[2:F9@;YG\/Q9+I8@.M"N1)<<<4 *TZ36T#!L*^=::S4
M20>;A<FM+_#=IZ%//ET/H+*3B)H!I3:9FL\&ODA>2VI >V>($6/ B7HA-4N&
MO-3T>>OK,,LWMZ%_&>/-!RP9J5PJ(%RJ<9O-$.DS^E%9BNF*L,V;A=XAH$_:
M< O)WH?H]HO;LNW4)4[G7ZI'6+L'ULUZN?()!P59Y+0WH @C0&69B#<KH*2"
M)9=8='-OX'OT]$G!-9!^LZ5OU^=C,LF?AJ/1P&#,/)= $0E2D)LSO5U&"0DY
M.FY,X**UZW/][CY5UC<0\E9+VDR@OPS'Q.%;B@\SF<$P/AN2M5UR54$FT#&3
M1812FX$J'E,-_ *@2,AR+IY(;BSF[U.TB?#5\Q%^P^5OFTI:T4!.U\KVN.)#
MJ+;'H*PG>?5*AH\(PIN,+(D42FOW=2TAFP! /Q\ [+[8[>]2O<4PP_=U_4[*
M[[,E' ?>6RPJUTR/).U49 $7=(1L35*\>**XLUM5ZPC:! ?F&>&@V>(WP\/;
M88C#T7 ^Q!L'5"OAG4P>3#)('.906Y<@H$=A=4(K9.M2QV^IV)FOR?CL TXO
M7F&L3M5QN!S.PVBQ[B=QM.J8?L-RT9)BS&C!UA(B)0*"LRP"$UP[G9B/2K1F
M^2D$]BG@V1$Q]_=$=X)J%[RG-+D:SV?OPI>:IKBF)3)ADF4"=,[DFRNB*K 0
MZH@&YYCF1H36H%E/29\"HL;H:+#T'9G.:T:_7-/DC7=)<XK-;#4,T7KP)JI%
MA_T2)"LI=C8L9BU%?0JA&L.BH2A::HGI%>9UG H=2A:2PCUE:\;1 JDI\AMD
MR4FB"=YVH"C6$].GT*J]KF@@@"X\J]I9_ML3B^2=<]YS"O2T!^(2(68I(3DN
M<Q32.M6Z3/$QFCKP)ITF1K0IM;DSJ6I-:^]]1M EABB4DD*T5HO;H?X _M/N
MN/C&F]I- &W3"[>(N17V%L.CB+6+>U$4ZTBM(-1Y-X%[X:-QC)M.2J;64M-3
MUZD],!H)I!E 7F%!>GV^Z49RFS8*ANN57<^).;((;ID<<;5_*_.:Y^RCC:9U
M?Z!'2.JI.]4>*BU%T\Z:;A0FDK)+QF%"B@_K582D#)"6(\,?I&/H0LZNM7+9
MC+*>^ET=6*#V@FKHDEW/RGN/,YQ^Q-O96%T42D\Q@\Z$ZLPUN&029.>EYTIY
MF5JGOK]#3I\2X!T[+&U$T@PCC4I6:JO5Q(.%Q059Q2/AVY#7E81ESGA"N6F=
M2>^B@NZP*?=.D7< 07>=BKJU=ZQC@7PZ =+DVOI>Q.K_.Y!*,"Z*<YJUKC1Z
ME*A-H&5_!&BU%4_C(K3KN% P1PQI 5RD6GC..'C!$'R='<N4C +W6,3U=&[J
ME8V%@S$[KR+[&$;TT-G1_#A,IU]H[?\SC*YPP*5V,FH-)CM+7,H$$46!S 72
MSO4QI]9<;D18GS(2V^/BFUO\S672#/SOR=DD@DB5UR#FFEG)2A I.3 AUCE*
MT55F&1@IHR$_-,;<&AYK">E3'J(=''9?\X:=##_2NR?3+S6"M:*$)&4=R2$S
M44!J/6BIP!0O9?**%X:-I7[[_7W*)+03]M8KW+"(%2_#,*]Z%5_??+K+H0N1
MNU*G 1E3:G5M@>B86'35+%KK3&0VKV5]E*P^90?:(:*U/#J,\0:,"9<8*LA%
M&%!:"@A<6 A"915,'1/4VA"T/WXYRGE8)1Q&[VC=WXQ7R9>!0C0E6 6I5(/K
M@R>^$H,41"03S&O2KK6KMYZ4/KD].Z+@F^/'!HO?\C#ZZJ(N+>:-;J%RBD>8
MXAQX\13%&D?13B1][9WA@CA(VC</!IY&8I\\I-;(Z5!8S1#U84JQ[-7TRX)W
MHO!B,EYZ\UJ&)"2]OCC,M2>G@Y"8@5@8^?=""\];9QH>HJ57M[\;@Z3)^K=T
MM9:'1 MREH049J-E.H#+@9&B2Q&\Y1;(W5=6:5,'"+1WK>Z3T2=7JC$$=EWT
MEGWO"'ZWJ$BE!(Q805>;TY-I@V 8H5$YXLK7^<2M ZK[-/3IQ*2QW'=:[H8)
ME'D8CC%?=ZB_9;5>81FFX7S ;.)**PG"1G+FM8@0I4$(V9DH>,X$R>;9E,>H
MZM.!1F-@-!;)87M8'YW^XY>W)W\T:^FQ_N%[Z5>]GI5&+3YJ)BW,SM]-)Q^'
M]+2?O_P^J[4:OPS'89P(!4=I/ORX.-@8!"5<8#:##80 )7FM\8D+O]'98K41
MNG7<MSEU#:XL)\2\F&KQ9C:[HN?C25E,KIC]3NL\)<\9Q_2VFGFXGJ6!N3K7
MY%DOQ+[H?W-SZK?8G">7R_H$IHMP,DE@F0M0SM>\A[*@O1(:$WG@O'5 U"E#
M?0J\.T+PFHO5/0%(RVOZ:UBZ77(SR%9;'Y&11Y!KYI4H=#YF<*%D(JWDV#P<
M>YRJ/@7O!T7?UJ)J!Z'PI387J&T;W^/EU32=U\JL<LO')&@[(;4+8(3RH(2*
MX'@2X&**B*5V\VY=LOTX5;V*[?>%H;:RZD0-G9Y/IO,;2+N@BBB&W%=>;UH8
M2]RRQ3U91K1A9"*T#@0?)*9/F8 #*)WM!=-<UYR45\/*]SC/;F,7.>,L"0DF
MU)9=.AGP,3I07HB41$&*C#K2,^LI>F(.X8?2,0UDU##5<'E#U1V+R8-W6%@M
M$UXT D-1#R(3.(?*ND7E<.M.1 _1\L2TP@^!E29RZ<0*W;*4BR.4=9P+6\A&
MDI6418MZ=]Q =(1G=+'.46280P<#^)Y"8I\*) ]@L5H+L1-]=->L!HO22V%!
M\GJ-@?PM"$K77M!%JDANO#&M,?4@,9N@Q_W &FE[R>P,E NRE+?0^^[&5?]U
M\A&GX_KYK<LO](U3^M>LW+3)KU-9S\/T['Z$Z$0NQ3(+M=B&O#;TI%)KX:2S
MADL,Q=Z?HOM-;K0CTC8!F_]!P-8'Z;:<6;INK6Y*UF^OE= ^&)> N^KQY8S@
M,3"*+9G*5H<DFM_4W9RZ!J.MZXDZOL+E_]^,KPL8*^LY>TQ9*B N"WDUVD,@
MKBEZRL5D88J4[2M$OT/0$].W!]ENNT)HS>#J1A)J>ZV]7N,@]I>%.:OBQ@%1
M$UV)"82O-3G!)PCD_ +C]!2;=%#=3 %:1TRO!@;N"2QM)-.NA>IJA,C)^#2,
M2._?JGP=Q* %HA5@Z\PTI8F6N!B;6>-IX7FRS7W&[Y#S'/*JK<'22CKMRC5O
M9G"0]W!T4:\?_GNQ7@/%I<J^2$@LY1I>DQOK'0<AHLB\MKQO?TOK(6*>04*U
M-5+:"*9ERN-Z_*)+/"A?$B29$G%E7>V)'R $B25)I.BG@P/J)XS'W%>QU9Z0
ML.72-[S =-\;6O6[^A ^XW5_O$%"9@)I+N"9$VD^>H@RDO8R7OK$=0FA]='=
M1H3UJ0CK8.[KK@)KV'SG<HIIN%1DW$1=CW^ V47_#100A<Y OA$F))_)\]9%
M>[??_PQRGJV1L?7RM[\-^?;-+R>KQAOO<#J<Y.-%HF*0H]4H=01=AS(JRVOV
M3$9P$DG'J>)%\RJ2QVAZ8GKS1P!*4S%U:(ENW?,=>('>1,^ R7H4))FI<YB(
M_6)8]"*(Y%HWN_PN0<\A4=F]Z=E60AV"YH$F&0/BVF@LGN)U5VIOWP"1<0W>
M,LF29ZG8UH[MQL1ME(9C/YH2ZD)RW?K%MWM&4T3O>(E"00FR9@J=!!=RO6=,
MIK7.)X^YO2U[A*B-@'3@>MR].,1;2ZJ#22AO+B[#<%J#_:5YG9%]%4D+%\&6
MR$A56@U!,PFQ>**IY*A%Z\DXWR%G(] <N(RVD[QN ^ETU'KK.LDL$A<L,P=6
M$WR5$13&E11 &UUD*I'[YJ5L:PG9""+[ZBVR+XCL+)$FY__?JK=O>AL.G% A
M9*,!6=2@HN9 .%6 /*-+%/<I<\^W67N>O\&K-@+"#Y*L[6+UNW1\JTJ[X7W5
M)J(VS<':/I>3*DO,UUXKDE19K"EE,G_!H;/2M+ZNM3EU&P'JT,6Q>_!]6PBO
M0W!]T[RYVDEK D]1@L;:X+MVCO">D<7$%!(+S&71VCAM1-A&D#IT#6WWD-I5
M9.W2PL/9Y6061K].)U>7OTWFM6YI,B;>KS"OEF&R.#>MYZ<GXS^FM*"O)I_&
M@YR"LP$]U"@/E$@60D(#G%ME#4.39>L(:UM:-\+<CY9OWH=<VS67H!6YUT"2
M#/A\.DQSS*L&DW<_N/5-B@ER#N3?U5&*'E1*#+Q)!J0(1<=H>3:M#\!V(GCW
MTN3;#[[IJI88]Y@=E.($**\-J0\M(:!!47P.GK>N1EI+2)]N'>\/5]\6*>\J
MHZ:;Z_$&K4H$J9@MP'7M3JPP0.2&0;$8#4],\>;SW9LUS=U7_N-P<&HOPZZ+
MB^LYUNR>05.,JU+G$ 7M4UV!^B^MP) 3G<BZ!-T\S;\Y=:TN/GZ8'"42T10?
M'/).GIY(J#D"V5JRL>3:@5>)@S'&<:E<*J;UC/7-J7L.9<>[@NNA"Y&-9=?\
M4NT-?:>3,O\4IK3E&8LI& 23$FUYEN5RYE?4(EHF=9"A]>#>!XEY#C7(G2-G
M*\ET!Y2?KV;#,<YFN&PEN; CR]_D@95>&A4""(,%5,P46JA8>U$E55R(+C2?
M%_$4^IY#E7+G<&HEOTYNX+X:+KB?7TWQI'REE/3E]:B4V9OQ42G#T3#,%X<W
M1EA1+"B>0BU\H]U@M 6;;%%.FR18^VZ16Y/[#$J?F\-O3\+MHK/-;=H7&=MU
MB\/(,7;&:M#>51]<9MHMT8!UD<@D#HIJG6Y_(HG/H1]%5UJO"RGV(T>UK.#[
M-@^\ZC+V^G,Z#^,S?$\[Z74IF.8#[V,(5;EG[9!B.4%ZO?@ +--J,J90Y]8U
M=?OE<)=SUT<I/1Z%V6Q8AIC_&,[/A^/E19]_X"@OKNJ.<#VY ^LPI! LE,(=
MK7I*X%) "M1Y+JZ(@/+>/:VUA[5=T??#Y-:ZW0^W#XE[ 95F2FBY&"?E]@*=
MC'?+2V&. 7WFX'$1T2H*5&S-4$7%9#'2!VSME77 Q@^3)]S/UN@+H [1XR!)
M# &%!N<XN:M,T7I%D8 EFVN1D-&L=<YDVQX'AQT4]8QPW)'XNX;GNG8E21'K
MT5C(K!A064?P$OUB-CN6*'C0K;/#VW9P/FQ0_/SAN:OX#W&(XY%HD$5"O34"
MRAD#GN)^TN[&>:6])^^G)X<XA[VD_/SAN:OXNQPN<)V16F1#9XLI7+-0^R[=
M9*WN_.I5'9LPFMVE;*-! UN^J,'0@18L-AI <$W*\>0BDLZJ[SM>E!.=U=I\
M>CG!9E53=',UJ$3CA4^Z(J6Z@5;7]+0$:[0I12AM<FLW:PLR=]6<6[SRUDSH
MHG,NH0[)E!1)TI(PH&WLP:>@D\R\D,]\^#5ZVCCO?24@NL;D?26Y/TDW,^M;
MD'Q3JF13-+5QDBJV+*>Y1M2,5DH&ET@]&M?Z&M3VU/8I^'\&L-Q&Q@>VY6]R
M'=M1LW3+_-SU(2A][9HM\D[H=U<7F$^/W[\Y&:?):'+VY>W;XTYM?PO"]N,K
M-%_"[GR+]Y@F9^/AO\D)71%=[XK>)?O7R21_&HY&1^O(?TO/J\J7-@(M#[WY
M[/K0<N!B<EK7N1O&4GREI(,0= #:9Z$(::-TOGO%UB&'._>Q6[UV8"47(KD,
MO):>JT+^?AW<#!PS9TXJ:VQK!^[ZW3WW,_J"SV^:W&TCNBZ]C4T6:NT"U>M5
M]=C816O!6,XIU)097/(26+18IY\&=*V;)C9FH>=^25]A?$@@-;D7W)*!AV:,
MEQ0LD:[K%6<'*HH, 64"I@J+:%+DTC[BWNR)U%X5\CV#;=!'!'5I)&[YK">E
MKN6'\S#FC+W#:1W6MWYE?PG#Z?+60[!61%8GCV"M!G(LUI;J$:1!EHSAUJ76
ME3+-F7CBL<I_^RW2#S1UG*?Y&KE_F(;Q;'ECF ^2+UK6))(0M%3*.0'!UD0_
M;5G/<_#6[2=GN)Z^#DO8?YW65JRV<![JO'-TFGS;[ 4I,,*+5MY([VTHK'D7
MW$=HZGFXT@9+3ZA5?[J@NG*['F+]Y-,8I[/SX>6-&O)(NQNSAXC>UVEY&6)2
M"DSV/LJ$S$6^G3^U,0T]#Q?:PFBO NMMC&LM]X77D<*VSFCT9 ')#U. BGL9
MN+:B>?^73F/<P\5)UV-VUG<JK$?74EJ))4K@LF;9?3#@A;>0)1>DCC0SSNTY
M8GJ4Z%[=QCPD^+L*CMK"II=ZAC1F&)\-%XU@BXS1,L6 1S+'*F0DI<D-V(C*
MEBB*9SW)?C_&2L^-Y=XW1I^0T\MM\/"=;F6417)2H*#!.I1-0PQ8P$L>4_ E
M&-=Z\M=>&.M3+?&/ND7:H*J7&V95)K#\YNUNXC$H-((EP!C((G*CP449(-6&
MSSX+R]D>,A#-^>I3;?./NEV:8*IW9S1WG<?W%1\GY??9ZD\',F/4CI0 !<.:
M>-,60DC$&_KD#>?"E4U&NNZ/XCZ54?=A)_08+WVV'+>CJ""TP$5G@%P<*!%+
M/792P*+FS&EEF-G#*4U#CIXXWNK'C\Q["*1>;HZO1<&W?K?H=3"P#'F010"*
MFC$OI?8,4AF(J\3JT%M9^AR(/,S9$R=^_<]F.2"PNJST7=QWNDKSJVD]?+V9
M[A#J32AZ.*Z&7-5F1Z=5FM,ODW+G;U:_W[ZDMS4%#6IW.UV41D6ZZ]XW*-EJ
M%KV"Q(T$%3T'GS" "TP[[:5.NG7CW75T[*K<3_$CN6/CA,>3V7S&!T+94HS7
M8"09%W*_ OB<(QB,%+2;($SS0?#W2.C3>?+.DK^O\G99[N8&_?7GX7Q%A]+H
MA!09&'?D6.CD($IG('.ELR2_.[#2D?']2D6?LMK-);_CHC<)^]?/%;JY6'N4
M$HYJ<(;YSLA.+4HN2,P6EDP]X4X0)+.@N2>'5"OK-SH[W.[M?<KC-@/%GH31
MI3?S.DS'1&:]K$W^V\5D?$H,X&DZQWPUPDFA#R^OYHNWS,ID^G.8#=/B4L[H
MBEBZ_NO+.W^]O6?3)34-O)R]+58CCV<YFJ..2*B]Z)97ZJZ(A)OI";.!B\(+
M%S/(.L!..27K7?@,UBF,F8F"MH,A*X]0U6"^S"-ON-F?[R;3A1::SZ?#2+*C
M,.7#Y*$J3Z9*EH)T/*_-2LFP0W"%T1;&R&3T/I0.9L1VP$F??+/&&%TSM^;0
M4&C9X>0K.QN162ALESG5;OJQ=C4U" ZCHL#9>V493[Z+/CQ/([)7+;<[1F.W
M$NP&:(,D32#OJ,8U]&(E>2TL#P*2CLAB1J9R:Q-QAX#NK<$@AUP/)CB0#QB(
M1<$@&NZ <\>SE]*:+H8W/\D*'E9+;X^(IROD)TFCY4RZ6W2MG36U[%_^(7P>
MR.12=B9"4"+61M$*(DL::#E,""E*6H5.\?)]^OH4@7>%G(82:H:A/Q8+BOFH
M9H?.\+>KBXC3D[+R_Q?N_NSD:CZK>5&"_" 7)C1/"731BYKS3$"GF# 5J9UT
MEH?[K7IWAM$326PRZ7&1"1[=BGGNF;[%9Q0L85[=QSB:3FMGL,75C %M=ZF-
MH-!8$U"4T R\C!PX0YF]9J6PUEU<=J>Z3[J[2U2N'1.Y/WEWO7._69Q%2#\0
MZ&Q&SD!G0TX9Z31PBHCE&:WD$:UHWG_C203V2?_O$WW=2;'+%-SUI=,POE6L
MO#PKK<=E-]FE-^,RF5ZLSE?/PC0OXX0[?[!]ZJT+*AJDW#I?G$:IME^&8]H'
M;X<?<1V=@UHIJU,H(!9=I(7P$ CF$!RWP1@>?7.'\?L4[:HPO_/TY<U)XX4F
MATY"28QVERH!HJ[S NNV0NFS#:VCQL=HZI-1;HB7^UJPJ6B:6=CO4'64TM7%
MU:),X.BB)N'^O3PC"9EY7DR&PD,F'YXH]K7LPUFEC:580;'69_-/I[)7Z:O#
MH*J%_+HTL*\P5L._IE/U5_MQ?8>N?G=[([KMFQH8RB9,-C*&M]\S8,&%J$H!
M1#3D9@4%08L"CB,IG%A4BJU']-U^_ZYZZ_:S%N-K%XUG%D7/)W$T/%OEK#R/
M1C-,M*MLO6'I!#AG!.BH(S$8-#>M0X+-*.N3T=L:%_>540=":6;H-J/MNG]I
M<4J4XAF@"1+(%),M]M)!9CIKG5)AJ;5C^"0"^Q1*[AD^VXBH2S-6$RK#^2))
M0HK^:X/<6Y6RKV?SX<7"#J<TO2*6KMOE;F_26KRU@7EKSGPS4U<+GU?4I"^K
M5]^?:HZBY,A-@F@M!V53A&!E :LS>J<1,S?-=_D&A.VNZ]:]Y,XK;O4/C[R4
M;'VIO#M0R"-X)/<P:JMRT"RWGUSY) +[92I;X^I;)=B5[!J:TD=)O%;2%, 6
M+<C <^\IIA6I3ILA<\ #<S;X8-&W+GC>G+I^&=$> &L;J75I6D_GD_2O\\F(
M)#%[A668AK=2B\>+,36SX?A6G+NXDE++_:9XCN,91<5?3R?CE_J+R9@8W-[L
M=DU1 Y.\UT5K9*Z_1\+-V7$V@1P[9<"Q3+HN2 ,AQ@@Z9\V+8%&XUJG+3>C:
M59M^[QT_8YE,:;^DU231=.\XW4:?C*(UD$IY4,HX"$ISL*:X.K*843"UQR5Y
MA-P^&?+FB+NO;O<EUF96_3XYM9IC RVQLAG+J6(W'/@4HH@H  MF4"9R\)8Y
MT#RDY"*&9%N74+2DOU?9X\ZA>C#)-\/N)DNTMH[X75@Z/+0Z68=%_28CAX=\
M:4\>#W#&R=/24M)/!S MWR%Y'RLV4"P:8UDMU&(*5*EG$H6\3Z6=C3H;)OWA
M+6[_[4@KY#W%Q&PEP\/OQP?*K;.3T0F90(I8B_M9 N>* *V8BZPDK0_B^C6^
MV]$KBW)(T'8%C0UCU=7G]3\QS/#O?_K_4$L#!!0    ( ,N+ E?6-=,#8X8
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MQF"28G#^B(IDB64T23>>.*IKV>1RF%&(.%I\=Y!Q.'@YG@_GWUZ-ZP82+B:
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MU3"@K;[V/3S%UY/9;)T[,[_'G7GY]>)WWF-&/*T?O<_O$3HPY0H8K(U=M'!
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M<;ZR:5\,9S6864'\^HV^^#R9A='?IY.SSU<)A/4SI,3#\1GM<)_Q_";MV56
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M(+'HK75"ZN;=_.^B.!93KJ-\>P@%W$1T[5!H$UP]F7+W87H<8ZXK9VM5H*/
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M(,= ;C,AKHAO= MB<<U>GDTG2W1O)E\6H+B]%H!)R=7>V&0'B.JX<8(:@O?
MHC12Q22%VZ3S\"9C'0/9K46Z@O-N02UNY'6 ;]-\4D-N[)JO'K.+*0L.9! D
M4%XX6FRT!4]V'^TR]-]FB_;#0QT%XVT%NH+P;N$MR>6'.4[I9Y_N.'3VFG48
MK @L, T&Z[7 EBN(6 1HKI5$&6V(>A/6-QSO&*CO0[0K^.^A?_']16;7,ZG?
MA.DTT ^PC^*]M0/U6;NW^0QO-QI.DCO.6;&,JVS1YX!(K[]VR@F9UY7NK1VS
MG\H]:TH6Q5L@]:K7?*=Z^Q47$'B]BHO14A1;%WSW6+FW)JE?>!D1$[V^IK;%
M*KY $ K)]T'%&;U>N7EIQ5,IJ=A&!U8=JC>2>L]5>0_7"+G"DTR)T0I?P3K!
MP 4RNXI++),E%IUO7<7^1.NVNFA,?YSTGINSM@#5H2DQ>@F9:4T>.!;PS"C0
M$A-SC&'D_6;K/(URX*Z+30]L])[D]UM(>'YI]T!SQSCW&I(*@G#1]*/RY-/G
M& OJP-SM*&9C+;G"<HPZL:.D>ZCB>S>=),0\^XVDL+#G</ZVO)K-SLCHP^>3
MV7PVB))EKWD!Y$@>A=<9HHL1LG/2!5$3FELW$'@8U7%H16/I-SZ!OCGC]YCQ
M]//5?0@#[9DV]3H$%>L)C**U*\2400M+#B'3 A/?P,=>/\K3YKFQ%!L>/:^>
M[35TTV'":QN51$&H+">]JWWGH_;@:PB?1<>C4-D9UKI7Q(;0GK:&],E#P^/L
M)<SW^#E\6_05?'NC;\\@LMJG("$8Y>HQNZP>5"![F">#4A665&NGY#XLQZ$0
M323=\.#[/D7]?'&%>KYFTR#7UBFIH:"H/4BMAY"8@*0-F3LJ%VWZM1Y7PCH.
MO6@M_\8'Z.\NE/:WR?3=!;)Z8_47G([K]Z^YSO2)#_2W60EIP<(XOQC.Z!>F
MG_"6QA?T/'@5P H92>/)4_*DZ\ U%NU\-,FD#0R-'J ];94Z!+X:'O*OBMP,
M,C(G.$/0Y$V#JFTXG&(%BF0VV1 XZM:!X^-1D,X2;7G(OP3S=Y+"[/5D-L/9
MV_'+K_/A^-/9<':RT-:R0!B<%49H#EAHEDIP!\$@0H[,LRQ%RKRU+?(@J.-0
MA+:R;YD.L*XPUZ'W6:$ SNJ1:+ )7,P"I(NE>$T^=&BM#P?8E:B=T;&]5 ^E
M*]&*4DVIC;&:T6:50ZW)DAYBYI+V+FYYR-IKUKH9R6&7L6_%Z\-E[-O(=Y]5
MRYO@^E[+V+?B;-/RY5T$OD^%0%>\C&3(<%MO2*@][[VMW?6<<I[)2(9-O[O$
MX96Q]Z('V\BY=1'LND(1KE0.-5,J19-IW4N9]L=ZBZN6R:L22V(;Y88^C5J;
MK5C8M-9F&Q&VKF%?5U @HM>!B5PO(DB@K"0CB)4(**4O1L<D<9, PA.IR=B9
MVE8BW&OSB9P#+Z1?@"F&>M]I !^D@J"]0"0BM(\;97H^C>83.Y/;3(@]M1V^
MTQ+/8E+1(0-M;0$E<Z+-Q]$.%)DVG@<N2NM$E4-O%MK%-.\LXSWPODQAW@#5
M]]HL="O&-FL4N8NX]]<L5.JD321U=\6H>D^L@Y"L@4 O0\',/&]^L'CHS4)[
MT(%MI+R?9J$ET?8<E8=2IZ92*N!\H 6O2/H&<]SQUG?"'7"ST*WX>;A9Z#;"
M;6BHSZ;SP?LP_G2NQH:,#98E@F8VU'Z)$9P*$E#0GE8T-U@VBKS14Z^Q2U]=
M,7MCP*>^D^\NO89Y@Y<@EK7:&\#89J_>A,SV[^;#FW('X=^FKX/D&BZ]M^$X
M([T0Z(#</"07( EPY,R#L<+8K+BV(CP% N_94-OSMXW &O/V.TGJ].QT69!9
M@R[66@A1.U"\D"7 "9=!E[+RR0K<Z!Z?!YB[,>C^-L9.8I^TD%GC#?#W\/4:
M$(N9U]@8&6\>:S5M!"^LADPP3&$LY+A13_2'R+L^Z!,D;V>9W?OF[:< ]3U^
MF8R^T+>>3S$/:][_<+3X0:_5J)N/VF=IZHYSOU6GZFI5N0M8?'!*VA"LB>B$
M1B9#]LC6U*EN#J"C]S(<X]MR8Y!OKR_/W66PM+7X")8L/#+UL@3'&8<D+2N2
MC/<@F]^RMPY09U]MQ<,OWL]?)]/IY,\J\/"9?C+_-HB),V>] \L"K;/,>G#2
M,3!!ZQQTRCPTO^IC"WR/X-\UTY4[;EY?O/10\'K+)2)_=X!&110^@=66TZ*N
M$OAZBA1U"CX[AU9N9'_NGJ1#*(Y)'SK*N(<HS_5JISK'V7+B"W6LW2- :C+%
M5= >@LT1HE$N>E>O%FZ=,'XOF&/2@382[R/R?VW* Q<<C])HP(@U75U8<"D:
M6I:*-4Y@,;<OB&FZ21P3X3O+M8?2TE6SO(A^^1!EU!*D0G*_ R/E$UP!"SID
M0]Y74/LPB?::EKG?C7][.1]PBB86;5Q0#GB(HO93+^"+TR"ED<9SI!GV:QH\
M9O2X$;L/)VIN(^6]YN5M@.M[3=3<BK.-$_1V$/@^%2(FTN]:\:A$(=.EWJOC
MN#;@A1'(E;;%\B>M"-LG:O:B!]O(N7'*UP<<#R?3/\8S3&>T\MU:_4Z0"!*W
M/-V+_K(Y8XY*02J,]E$7. 3N%7!K; Q"<Z=O90NLS ;;=?P#2A3;BKW)GD7?
M./ES>\S/PSCD81B_F(Q&8?KKE%B:G;R;G(WSL@?BLW&NG3!G'\[B:'@ZG"\/
M#F*6#*4%)NJEZ]G1+$TB9YJ%J) G7=PFMVOL#_%WJ9)[H7>?:]Y\,4MVSXMG
MHDTB0%*Y=HAA&@**!"B%(/>/2XZ;M*[>=?QC5[!6HF]\T]/VF!]^*<+JET(H
MU%+6NV==C1ZXQ" &KR&BL,67G 7:7A1L5\3?I4KNA=X^PD2K4ASK58BIQJK(
ME*75-Y-9$127$(NM]>?.)M9WUN?Q.?V=);V_%/!-4'VO*>!;,;99^N\NXMY?
M"KB5,;,4,LB%=RN2 I=J3YO(,=LH,V\?+C[P%/ >=& ;*?? _>565V$M6\T;
MC)8S"R6E!$HIA!AKHCNW6NJDU)WK*CL3OP+&P22!;\70I*UX>T@"N+F]+=1:
M\XR)\WI 72^0,;IFN/-Z+9_VC&MK!,N-";^+XK@V_8Y2[L'@NXGH0K<WP=33
MAK\*S^-L]UVY6DM]!T'WL-ROQ&:)FL*M).T6&132UA:SM^!ER"G$4+B.3Y;\
M![;Y?7"_C7Q[X'QU/N8REI)B,%[I IQE,FFP9O7ZK"$5X[/BP42U42;T%N2O
M!;3_;;\[9W=ZB+82^+W;_W[2J)]/3D]I(QV&T;M .VJOR=,/C=5GRO16\[R5
M*&V]9ERBL")DQ:2)WO)"*T7@46,.;DVB]$/#]ID>'6)BAGD#F<?:!)OT,4I2
M=Y-3+!I]%-H=;7JT9B:Q&"3DS!1-WM=.F2&"S8EC,BIA\\R6;? =6F;<-KK2
M*3UZ&UYZ\(RNIVTN;P,@[#??TH%.#G.)&ASCCMRW@N!,-.05<,%8"-+I/N]E
MN!?8,6E->R9ZL:NN6H7?AE9L$<(G4N(:TE<6R9#0DF21'3+','O1WJJZ%\XQ
MJ48KJ?<45*\)_[=@+2^K$HY+:<B03%[73J J+5I' -D.+ADNBG9]=-:Y']$Q
MJ45#V>\U)QMCU/5B3]"^'F4K)<$SCR!+%"9K&5/8AQUV0#G9K:V-[>5\*#G9
M*V(3QFMD*#-DJP0H:4DX12(DG7SDH9#_T6^HYC CM5NQ^W"D=ALI[RM(MPFF
M[S%2NQ57FT3K=A'TOI1 1"^M\ J0";)X(R_@D14PH=@43%9*M.[.=,B1VN;<
M;R/?/CB_:;PL X9>6VMCO=^TM@,VU:JM]^4B;8TYH]0YM3Z'7PGD0"*S6W%T
MF_3. MY+1/;?,7^Z$2EL$'E]^)G=(ZQ;XKX52>5H=!:TC^M:(INTIZ^]$RRR
M[)-Q:O#PX[N6ODR'7Q;/N[)&62W23E*!5X9<2N<SZ8:3()D5F67-A&A_;^\=
M&-VNDUP^[LVD,AI&Y]=5O5Q<D)M?C>>3%V=3DNO%S8A91RL4JYD.7-3WRX+7
M*H)/EC'&O61ID[SF+8=]C-S1;FS?O&RR/QGWT@=B-=Q!XEI(SQV0S5P#**F<
M=YY/:&H[8E&2;-^,?S66IZL03:7<2]PRC<)L-BS#M+ABK 99GTW2\")6<JZB
MOV*93/%C^/IL/I\.X]F\^ED?)^_"(IP2O>,8@P:?:[U&C!9"\1)49N2*.1Z5
M:QVUZ([ZZ6O4GIGK,42ZN+2*:9.E$PK<HAU@RAK(:G?P_[?W9<MM)$FV[_=?
M?#KVY>6:44O5U)TJ22:I>AYIL4JX31)J %05Y^O' PM7 ,P$(A(@))L>%1<)
M><*/9X2[AR\LJZ 2'OGQ\>B'%S\DKJX^["S-BB'.A\=?03.Z<HL1NHL['-ST
M)K/1_[A[PY<=I]GZI$ 3%LH9&, Q8R$2P3CG3K+893!$S\>^7+Y;R_BI.NP\
MP/SITA<1.FZ5T,(',/AL$,)Y,*B4D%BDA-. _ZO?3.(!A.$&P;4R(_I+\E@B
MV6MJYP,G7 B:($2+)G#.)61K)! 9M$A2XM95^QK]>+J+[,7I\SU%^LAVR!82
M77#]J#U%>G'6M9?$+@(?M*<(L8YF7MIF<,0GT6:Q-F?TB:*-)#LM1-N)Y<?7
M4Z2)'O21<XNX]MP_"3>?_G+?EC%786,DSE.@-JLRLXP NB8&$2GO;!+2ZNI!
M[2<HCJE@N0]#CZ/:^XFW<E>0=270;]+5>&ZSICB?AK5$2:)@/GH/(4B-QUZ9
MK*&) T6C0#_52OEXUM1:/Z#[$U\XX0W%.T!9Z7Q[<T83-'8B*,>*)1P9&*T$
M^$0"]9PZ:ZLWG3RB"O.:AM_>\AVNKKP+JA^UKKP78]UJBG<1]W!UY93')+G)
MH#7ZP;@MH?;;TG0S$T:\10-(MPC['7-=>0,=Z"/E)MP_F7YELR&VS(^0G',0
M@6CP47.0FN1(@X^$U,]_/=K18KWX>7ZT6!_A-KU1O#-VIK_B.G\?3Z>O;I8W
M]Q_3Q3Q$.?TZ^C;7>\$YC9SX8I(0$ 0-5NMI@$QR"%F*G&)M+V WI*=@+PS
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M5@R6E<FG)?K@#(M@J:3>19:UJWUY</25H+U8>KX2M(^(*QHBS]6P<9U)M+A
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M/J2KB%\N7L'%NW?.,K<T>@<L:WRAO+'@E+:038A6<)$HE[4-M&=1O7CU:D3
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M5"9$$,6RJ!\&&5(1GC4>A]&#/G*NG+/Q]GHR?I.NQI>C>43F79G8ONJ!:YA
M !&L=AD$4PF<HPYD\MI*FWQBC]*,UH_]V_B$X4_[.@R,JXMOF,: BWS\Z3B_
MNIZ.KE(I=?HVGLRO^,;?2D]=-(262?M[-/O;X2D5&OCMN[;'3?DT*_%,9:20
M(G'N-4E*2)>MSI81?[[+ _>L@UA\V.(Q\YAI'D\NW5)4RTH2QX-PFG (:+*
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M,.QETMTBL;,+F$8Y[0^ '+CGZ_Y$K4_XVD/*S:GWWABFO09K2P<=CYNL4\&
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MK?+7'T(9[IBOQ].FY/4]A-RB1<PJH?K=^.JA'>*]](E8!49*6^Y#"1YF)9Q
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M]*]%]>'GC.*R0KU7+G#R"?4;W#X&U4?0]:#O_O2]8'_YU_\&0 U'GJWX5RZ
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M6BD"<$L+4&9@?:"'?*I61--"&SYB>@0VS@!,0V@*]%IX\(,2_T=P\0K[0Q7
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M2[Q-P8#\I+[,,SPY/6?(>!!&?H(X)$'B0T1C%Q(W$#!. H8#X;B1T+J7G7C
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M!LR'$?Q1Z0A&.2\="7];.Q;+TDV[MQD'VC>[H)&Z&7JQ_"U;?5.!1X=A276
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MF2JC5E53>S5JZF]"Y9G[IG]]?/:8Z9D,4XS$R%;$KJSF+_4,D5J<**^Y /6
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MF>Z/V1-I$AZ\+>6JKM4TBKG>JI1'>?ER*Z=&*9]0M_;/2ITE1CX-!290"$=
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M :T-K"8Z@#V"F9V#U3X,.@Y.3[XZV<%HG_#M@\_>9P>FQ__EP^TRQ"@@B1=
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M3,BFM\>Y4<WG;/T 94=/(-N*#E:5>_"J$5X[?$P?=3W&L8KER'RSDQ54PB[
M3EQU,K,5V![S:&-CB7?Z^YN4=;35?\TY^B\.W1/)K551I"*EU6'[)RGZ14;3
MCW7KMU52Q ]<9#F_Q]\ORC)/R:94)_+WV2VN)@>AW!,!QE D$9/[)Y9 $HD0
M.B&/0^2Z-':QV=;I7)'FQEFO-5)[A@><K@N@OBG@XN;CM>DVZ^Q1T]V-33D6
MHV_:7@W##OT%:!0"M48+0"J=@%1J =IJ*=_16C&;FSQ;(%O;"YXMT,1;1EL
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MU(T\B+"09D+HA9 'PDU"+F@2:)6D/M;X_"A@+YOIA&]!ICO)AP$Q^L36P&#
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M7MT!PJ (ZF/M318DW:%,.PZZZS$++M6<E%]X>2.NBV*C!DZ5Z"N62+GWQ8A
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M.9Q2HYW&X>0S0U?G=AG/E!?5WF1)DI!S$20PB9(((HIBF CF0^K'Q!$X")Q
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MWJI@#[.1UX#.4@#RR_FEX\MI,[]_"Y7Q4_>KSN:2E;^EN$'"_?9;YFF!53X
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M<^/"FR/\ES:S4_'@CX!4"H'\M49F#'G.\.FQY42#,C)S:K!E,R!OM!F'1RW
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M"JXZV0_%Y5/M4K:,M9XGD)\Q!$.?>1!AZD.": RY( $5PDMY$IE5H;G8EUG
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M@[#>GF0<W!S/9UO(S*M6#*(Q5J6)RQU-6QUB4.&3B@[#;]@>MU0$&KA*=?F
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MXAN *V7,[.S8(ZEG@]]P?-[D2&6O'.AJU^[O6_UJ/L6]AJ!1L?_F_1@EK<=
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MWRE4Z4BI\X%*QX_:3>Y5N9Y]$\^ZP7^*Y7-)7K\7JMDFP3K3=P19+'4=MQ!
MB@0@*1, 0X9H@K,\C(VRN/3V,K4)WI70,G5]/YK]L]L;1@//;SMXC*>VD?I]
M*[MJH+.JJY]V4[R_[5$FN9%Z[30W>]@A65.4)1\VY;)-BO+ UDLJRB142&7-
MM7T<8XEA&.O$(VH=CPD".,Y#0+&,E:V/DU3DQHF;+O<WM<D?_98E_PBTT$WF
M';X102-WD(0W.@M/9I&PR #Q?EH8 ,>!">((POL3$+HD?S+ TB(1E%],1_(R
M,\+64Y(H<X#Z$D89M#)>\BASE?8225F\YECNXRB%ITL@STQ&B..$$[4;RPB
M,.8 I<IPB].$$<8AI"RS23OO1RPKBA\MVSP7LF"%8;U7S^,DTI@F+$6 "BH
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M7IJX'TQHF*4,@8C0!$")&4 2)R!B"$4I)1!2HY *D\ZFMO[4@< [88-&6LO
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MY1%'>6158.%$'U.SRKXQ96]MYKMZT.NV'G2PDWP5_%4);WAYU@>Q&0]<"=S
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MHFC+]^VM_J>2WY;E_::N7F1JZ^^_-34B4:*I'ZOSFZ"5T=RL/T#DLC'O#L;
M%/!4$EZ%7MK@866RGU;=R5 _:&HT\_RT"EVC_,P3=G.-BV+V8;%66_E;SDM=
MQUS]]:%\6OZ]F,F0I$)7!(]3&@'(>00PCAB(HYCE&14TSH7)S.SI8VI3M!8S
M:.2\";2D"L= RVHV5?L [9^SGF :>O_M@I#QY#7 H&<6J[?K6:S^LIO%?6V.
M,IT-E&KGM<FC#JFY_R8E?WIY_F/Q6MPM5KSD'^?DV3@G]\FWIS9S*RF#I^)%
MKRQ_?'G\I*M=K@HN^FH6F2)U>;&]'J2!YVT?/L%?6EA?*;5[D7#+I7VZR?&2
M:/>JM)<]N_])QZOZQL_W07X3S]I:^BI>=>8"7:9)+LN7:OW__:WYQ]UYKV",
MA305("=0K]_:Y8>S#*2$YBA#B90,65WEN\DQ-:;HNDW+8D$6K%#;^F*G0E"E
M+-#S9+U4?]<Z:J_>MF"Q^OVJ5K'.8EH*_0D5\Z(I9JQ>6G\7NK0=%XM5E?E@
ML5K."TZVAPBVS@6.'X#9(<((PSHPMW5'M!$SV"H1=+2X">C;]HG:+S[P>E_@
M"5-?G@Z.4HSK"7$=5$>>$E<VYT;1=]LIKG/):$^MM]TTI%F":$P3D&=I"& J
M(T!PQH!,D>+A!$>86D5G]W4V-;+5(5(K/2\?5:NM9[0=^_5B:T9QOA ;^GZD
M*^9-[7OY%OS5_'<0HC)!QA,;]78U*N68*'W(*T;O>+B1N:NO%73>*!BE&0$9
MHQS .,0 Q9""%"4PPRF-8^9^^])T,C6RV+\;J!)&W2@3:UVPXG5G/'FX>6E!
MI@AB&<8(I&&< 4BE!!CE(4 93J#Z72+RT";$^FJ0QXJP]H!=R' 4XY0 P=)<
MK6KJ*Z5ID@.2<RB3-$L$368_1$F78WVBW<Y&^DAO@N+EE12EMB5NFMU D^ZL
MEO\F6/1D[S%'V^$^T '!4>_^[BY,X^ON^ ZT'^(^K^WB_>[N#I3LO:<[?-;^
MGN"^B6Y[*LFB+C18V]8S$J:0B30"$>="44$N%17$.>!A!"$*$2;<*,=A7R=3
M6ZM:.8.=H,V>T_R>X"R@ER\*?, T\&QW0,CJGN 2!$X7!6<;'>VFX)):W:N"
MB\^ZWQ6H_1I?ER\+IZN"O9>G-G/W3L*UI$+GFM"%K^WO"?91,K\F< 9HS%N"
M/6P&N2,X"<-55P3[+8Y^0W!2H5,7!*<?=-L_MG5]V[*_NYC!78'5U8RP6"92
MJLU-'G.=3BI7BS1)0)K%&8<D8CRSRD]JU.O4YGZ=5H[L!+0SS<V0-K/5O>,W
M,#7LJI*W$@>=..%; TBM#7HKB#Q9^&9]CFKR6\%PN >P>]F-@/Y<*(+>*$;3
MN7":P%>!9<@Q(R"F.060A S@5$A 4L5#A)(LH5;G5R?ZF!JY;$6L<C#9,<LI
M",UXY$I@!F:-?4P&B!GN4=\3(YSJ8=3YWZ/BX6SO>_2ZD@9WRQ=:+.HK[FW.
M"RD$A3*,=8K*7)=Q5-:%1 )$&>4)RZ)<$",/09/.IC;;MZL@:_QH*G'_KUN%
M@Y/HFLU_7Y@-3 3;J@==.0?)*F("B.=B"">[>I>R"'U*GRN0T/N.H\N2+B/[
M5;PV<^2Q7#Z7Y&57>66S_KXL=0[NW3-U7J1H1G 428D1T)?F $H*U3XE3=2V
M)<ESGN4Y)HF5UY*S*%-CG)VH35J[@/P@Q;SR8I'+,I";M:)^[;'4Z&'K9N0^
M:&94-<Y0#$QDE1+!3L*@46.OJ-1NI#H/^JI>Z0].7WY&[H*,ZVIT-6!'WD;7
MM^A&L$^"?5\LY\OGM]]5FT<UKIH=1()I)I)$@$P( B#/,H!X"@'.2$(YB;,D
MDS9<:M3KU&AS)[0='9I!;,9\WH$;F.1V\H)*X.,:>@-LY:Q \D1=9GV.RE)6
M,!P2DMW+KG&93]6E0&4QWI.UT1;O[,O3HXNM>(&6SS9"\Q";RY="5\,R-!F<
MB-<T1LDA;O,,$E>$;QZV.'(4YQF%CH,YSSUHGT?\SW]O=W=B=5^L7I<K,J^J
M>C?+5H1"RE <@A Q""!-.,"$:Y<-(G,9(AB&1M/:H*^I3? _?_OWWX)6SJ;B
M_"_[/QN6&C$!NG_Z>X9OZ,-<C=Q.V"/4+ML$UO"9I_7V".-(:;POP>DG7[<A
M+CWYN2^U,%H^;D-5NOFW35]QVX5]6K!2EP:\%_5_/RV:Z[75(WFKZHQ0%K(P
MSR%(LTR[<7,":))@D$*2YI&NE!Z&-CNPBSU.C6WO2R*;0#G22!J\UJ+:;<<N
M8VVV%?.*X,"$V\JJJ*&1]M>@6+3W[JO@\0*0UELP8W \;;\N]S?JULM8_<-M
ME_F+KO%E+R_+177:5%6>6NU.EF:2TXQFRHJ3-)4 IC !E"80D"R5 LD,"FA5
M+:JGKZF12RUJL-*RWM15XA35[ Y?=1VY^K>6Q>/Z\#:C&4\H#DPP#8#?:@!K
M03NGUS[CS"["X2W,['Q/(T>9753Y.,CL\BMN!/)8+ID0?/51B7FWG,\%T[;M
M@_RR7(O55\%$\:-:0R,8XEC$",0IQP!F. 84<@9D1@G"B$L8&67BM.QW:L32
MBAWH80W85G =R:JS4J]TU'\CNQVSF Z$&<L, ._ C+./[-T>LI74P=?+R%K3
MCR5.GJC(M-=1:<D2BD.*LGW=_NCJBUCO*O&JO\TWO"I_4E9YQM?KLJ";*B''
M>OE%J;Q<K)7Z\RK 7]=4TCD(FW>^"B[$BW[T](.S+">(AUB"+ HA@ E- <)2
M@B2-)*8Q92DVNA\;5^RID:727.U*ZMK<<UU]V_SX9\2QOGP0-\T1')B/]> =
M%%;?JAXTN@==Y75^FWVM@E8MG;VU?74'P;FG)_F5F)\W3O-K&>GH<H)?C=6A
MZ/B#UW.^.J(PHQW5C@]P]]3W'7JWMW-.N%\J^VGYO-#;O4]<3>)"%F1[=7_+
M_F=3E(+?+OAG]>MB7JQU-3A==T7PAS8UV6=]^O2U>/Z^?I!_KII79UF((T$2
M"%*<$5T!D@(2Y1*@D&/!<DP$,BK^.*[84[-SMM(&\^I0MM3R@J4$&_4#J40V
M7]-&'/W+EL\TQW1@R^>41[IVXFSU#KJ*MUY/K>K5A49'^:#1_B;8?245 $&%
M 'B0X,]5V\HDOQ)SRV>:7\M(EL\$OQHKRV?\P>NQ?$849C3+9WR NY;/._1N
M;_EHJ^QN606AZJ(V7S;Z*OY!5L'9]T**!2<ZCAHAA!-E?P&<9:PI0 -A""!/
M<AHFB.0I-;5:S+J<FL51BZF/1I=5X'H]H&0>\&)5&['+<A7H%KB^%UYM"HM=
MM>$H7+8>_&,[\,JO!0XZ$M\$.Z#K# $[L;WC:;[.^L=UI#72"[Y6JYH=5#TK
MDF%#HZTF=HIU5P++-]VN%3^2HM0U0-OE9&\9^4,M&SH6^4$O09NR*1:D]M%E
M^V.5'?:S6K ^K<7+:I;2,,I"04"2,:$(/X\ C=,81)B'L912D-QHFSJ(=%-;
M&[1R51E=<=.:F8?69:MB4&7>:K2JGNJJ&=0Y>O_2F@:5JH;^F\-\!&87G^\V
MM ,O3>\RJM;7J8.@[^G2U:]LHU[-#@+KX07N,)U<6]FB.K'](>I\-/\F^+-8
M53YTFY=-E4^U6K9T#=I2?!>+5?%#[ YXJSS^NY3@+"$Q$[D *$,Q@ B'@- \
M!204H9!44HZM,L\,(>34%I-N!87Z;J=5,ZCU;-Q.6TT;,VY/U_T+(=<*%QX_
M!+.5Y+V'=^ %Q?_(CE0XP_]H>*^JX5'$=RJYX1_D\_4X!NC+;=6Y%V7Q0VV!
M=0<Z07)5):18_:LJKBUYBD*2A$"D,0-0LA0@+BB@>1:C)$E(B*S2)/9U-K55
M8"=K52CG"ZGRB=C4*C>"V(R7?0$W,+_NQ QV<GHK<&X#AB=ZZ^UJ5)HR4?J0
M;HS><:.-3K[$I^77INB7V',U>%K>D=7WQW+YH^""__[V9Q6"OSU'OV5*L/J$
M?9M!+>($1[$$:8JI,E:E !A3"1##D10Y)BSC-G0SA)!3HZF.CG6%MD9+_<-"
MF3A,J1=L5O69^*YH&]DJ9IFD;9"!-R/!]Q[.@<GS8"2W"@9'_F7ZG[6>0:NH
M7J!^^;,>Y%\[UZ<[?0=)+C?D@'@B\$%$')7XAP3Y<,$8M"^']/OS>9-NHY-M
MH\TU9)J%OZ>-R7'Y?!Z<R"]B>.UV$;%^EO4)UM!,>08GCVF83-%PR\_?U_!X
M:?H-U-O+UF_RO+W_0TTM3^3GAY^DS??R8;4N7M0V^$$^*LK1&9O:8]FW'47-
M&$X3M0_5&5M2 F#")< L5KM3HBQ%GL:0F>U.KY)B:ARB5 CFK9@Z$J6.F>>;
MRB)\+9>O2VTG[++^5R5ZR<_J%*L.7#&_Y7<?N\N.%*.,R,!$U5AM>DPZ6MP$
MK1[!@PQ:3;;76F^=^@%C#(6Y#\8H0S*26\9P0V/EJW$UI#WN&^YMC^;1<;7Z
M72>/ZQMS,E%5.\HH7KZ\6ANF!V].;2G19M;!IE0+*Q8KB\+%9T RLD6OP&<$
M"[0'&O^&Z!DH7,W/P^;&-#K/J')@:IY[ZMI;CNUM_8QR I,,,R"CD $(0P(0
MS!.0B4Q2*2,N2.YVN7'D$3"5&=TYGW?W<#J%I>TMAA-"XUU>#.,HU*.^]^N*
MS^_CM-.CXOG+B>-'/90.5S^(\H?XNIS//RY+76AN1L.(XTA&@#&$ 4PS!$@>
M4I!RB7F4Q$+&R+F*^'%_4YO\^P6'&WF#O[3$02.R)1-< MR,%3S".#!#7(7@
M=16<S^,R1#'G$[V]7UWG\ZKWEGCN><V57MB<J#V$+%AEY.FD+[=+5MQMRE(9
M@8^*SY9<[3YF2.*41D("P4@&($X%(##%@%$AF3(N<$2(;3%XLZYMYLHX!>*[
MSE1UV [;<Z;2*5(ZAU&V_&,X(J9$Y!_EP1EI7^0ZD=3MP]VGFZ 1.ZCEOM%'
M'3[)R0XK;RQEV.W(=&4'QC%O6;[O7LGZOE@Q4[/]['L3F@![-9JUD(I0-CIO
MHU\3_B(45]5IWF]Q]#K-)Q4Z5:?Y](/V5SZ5L_VGEU=2E)KT[[Z3LO)_;-*,
MJ#5#S/5]LJ[<J-8*5M1'TVKYQ(AS"'B4*?L=I0S0#*4@ES+G"4Q)#(GI?8^;
M"%,SZ2LM@F*KQC:U="M\P#O2FU\F. [0Y4N=X6$?FF\JQ'<:!(T*W91/'2V"
M^S'Q-[_)&7X<1KK&&60\K&YPKH.RY_K&L>'1[FZN4[Q[<7-E2_;6T,-FO5HK
MJJRVB6RIMD)O^JCY]F5M>GMSOH6IK1%[]Q(7JB[: '79=O2#T<"$WA$R:*4,
M;#"SLB$O0^)D2/8T.YHU>5FUKDEI\+2]7?FDP!-?FK0@CXI%7M28;]9J5S6_
M[^0(::X@&<IHR% $>*KPA(Q2@!(A0$XS00CA*(=&Q\'6/4^-(2KA@U;Z8%_\
MH"N_N05C-Q27#<?! !Z87LRQ=:@790>RN74X&-@C&84>/F@K$] )KQ[+SZZ]
MT0P^)S6[=IY; _;K0'-N5IF56W>?9A;$L91)I-.:RZ3*_AD#BB4#-(U$F',.
M$3?.<M[3S]0X_K$4RKSF@?BI#1M1'Q14!_+_IXYQ)HR5&[5!FN_R'Y@341_@
ME[G=$XP#,WE[G%[O./]/QR?0GKC[\#*G:4^XC43*5^!G1<8&J/10;]_;HQ&M
M@0I=6C5YW+G2UF$ ^A>Q?I!/Y&<W<?33F<31,YB&/$<8@C"A.8"1=LZG60KR
M$&4ACW 8"S%;B&>]M7^R*LIUC5A&DP/7D^-(N&$WZKN+T::&!#E(&[_83P1?
M-"H9<K6O<36[3QUCF$:K#'8N <A-%9ZYE/IZ]<8TR[_74F(^,/97;NPJ:<8N
M2>8#NA-ER[PTZ\;8!XD.;[551^9WI"S?U*^J5%>ZWWK%F,E<)"@1"&120@ Q
MCP%"A(,XRZ,\UBZP26+GJ6+5__3<53XO%\] #<1+H$W@Y_H T-HD=AL,,U(=
M#."!*?0X#6HC^DVPD]<?+SK!Y(D%[?H>E?.<8#ED.+=&[+?Q7\4/L=B(RE%8
M<.T4\TV4/PHF5H]"?95JQ_(L9A%B:21S#$(6865B9B% -.> 24DD(UE.(B,O
M?M,.I[:Q;V0.>"UT[0"V:L2^"5ZW@@>_D-?7<OFS"H>:OZE1".8Z=?_Z.UE8
M%"DS&I3+>W[?4 _,7BW*C;R!%CCXMD5Y)[-G(,T/ WP#.M*IP/7 6AT.V*#4
M<TI@U,QHQP4V2G7/#:S><TT3Q8OFN)<4_-/BCKP6:S*?\2B/4B$18&$6 <AI
M#$@:,9 B3F&<D@1SJ]BK,_U,C:QW8@;Z-!84BX#5DMHF83H-JYD)Z0&L@>FV
M@Y,64:>NNKN DT/RHEX4O.4?.MW+R"F$>E4]S@+4_[B])7<OZ+J3@DYP\?*J
M>Z@]FV>2"2HDET#DB=J&LC0'*,FI^E'D*&.2Y-BHSO;EKJ9&"%I:]76WXMX$
MY59@;;HIB8-?U,?/R9M-(=D+<%^VSOR!.#!15/A]ZN"WD[6)>_"&FKDIY@^]
MD8RP*U"TLK[,@.FQNRXT,)K%9:9(U]8R?,,Q<_R&KL3_;%3#'Y1%MWY2K52Y
M99&$.$0R A+"&, XDX 2IN^Z<90G@N)86)40.=//U$AU)V90R1EH09TR]YX#
MULS.\@#7P/3IA)1]&O-^''QE(C_3R[C)Q/M5/<H'?N%Q#W'PCVK JV\VX6$4
MLI0!DN2Q/NO/@?H\," 9#Q%*&904.T>_M[U,C0KV([:UE$X\<!I1,Q:X&J?!
MC[9L(;HNDOT0@B'BU[=]O%_4^J&:O;'J1P\[V@'*4*RR,C[(^N+Q=L%/7$=N
MTRYC909PFH: Q$3;!X@!G'$,8IC%6(8R$]!HW^78_]3(8BN^OLX_>>5OD$39
MR\ 8VA?#P3VTW>$#:7L[Q TO7_:)9>_CVBUNT!S9,X[-N-&=+J"R4$/^]OG3
MQX<FW4>]GZHCR&8I1(ASG@$&0PY@2C# *$* 1BA,D2 HBXP"ADT[G!JAW96"
M%SHH>+5:ZJ YP8._B_7W8$Y6:U L;@)9E.IORXT^@VI4"U[$^KOIL8GQ2$ .
M<QZ1'/"$"WW>3P'E0NU$$4DA3P1#$71P!/0R(.-[^CV6 JS)SX UXU.*.D'*
M>AEH1;0OM@XY4X:!YV$P6U=\?N8#+R1;46]JY!II;YICJR8:V-\28@J-IS7C
M8G>C+A*FRA^N"L;ON2T#36C#ASJR0:TX54!#7="Q<8V>$8&2#$D*8D0C &&D
M+-T<0K4#QHAED4PDL;)T#?J<VF)P/@+$CF1,X#;C&<\@#DPU+7Z-N!5\=>A,
M+?$VX9(_MK$ R!/AF/0X*N=80'!(.S:O.A;\+A;%6GS6WA.?%FOUL>C\TDTE
MV9=EN2[^M\Y!74OP7X*4503<C%)(40@QR!"D "H* @3E$<@A$G&893B,K(JR
M.LHQ-89J<W5S-;<6&S(/2$?XEK=N O71YI8UN1W'R8S&1D!_8&JK-0"5"L%.
MAYK8;BK&8WI8NNK<!%J3H%+%8RWMZ[#T537;48IQZV-?!]51)>PKF[-/PO)I
ML2K4D[N:,I\M\M*=?WE"\ZH1\DRMHL^^$]1=QL0IN4A/LZ,E%[FL6C>YB,'3
MCNZ,#W>?]H-X'HFV(]H GTZRV5F(8!IS&8,XDR& (6< Y3$%:1I*F4'U=Q1:
MN3B:]SVUA5V+?A0:5TO?#9^[*A>US="8K>L# 3XPYWC&VMZMTAXU7ZZ6%CV/
MZWYI#\F12Z9#$PYY.:,L3K\LUV)UOU$;D3AK4A*D&4$QPQ+ +$,Z<7X"2$XC
M(%,<QQ$)122,]BL]?4R-LJ+?E)C_""I! R6IWG5D%@D<SR#9SSR>\!F884Y"
MXY $XQQ&%EDLK\=J) ]+N\_)+O]D/PA]"2;/O#E>!LE^T?=21%YXU)[LOJV7
M[%^?5JN-X/>U$T9U)%V%+WYX>9TOWX2HGM'.&:N*:!7#2E&L=7[I&8<T3B%)
M <Y#K(A1G^$D/ -I3%C$L("I-,X>=YTH4Z-.K0A18Z\MC=5WHI-Q;Q9Z&R0:
M58)7K<9-59Y</2-WJIB3QY6C=YF'QQN3@>FZ$C*H-0GN&R^OIB1 I<U-T.H3
MU,]6&K6VXL=W&!WS%6"\41IIH1AAM*Q6%S\ ]RQ"5W8PVEKE!XCNDN:I14=7
M0?9=\,U</,AOXKD.27C5IWPZ$8DBY)?J,__]K?G')[WGF$51A%$N,Q BF@ (
M<PEH2A@0- XC!&6>)K&5NZ"]#%-;ZUH5]-QKY RV6@0=-6X"^K9]XJ]*%UL?
M0H<1,SOH&'@<AE[?!AD">^="=Q!].1@Z2#"NDZ$[1$>.AE<T9;]5.)VIZ5[4
MM=5UX/QA!9^GY381WXPSD?,D1X"$H;[MQ1!0C#&@&6,B2Z,D1C9)\*X6:*).
M<4>EK-1\+H7.(J/G,>MF9%\OFUIB5R4MO6Y4+^\@AA^D<0CV3 Z[FZ!5I<XY
M<S1^VINQ56>L43'?.8PV.B-M' 8=):LM@Q=D>W8,U[4_VH;!"PS=_8*?!NU6
M/RZ*V8?%6C7P53SK%-UDL?ZBOL(9(30D6$* 81@#F"090'&DEK=<QG&:8(0B
MHVC"<QU,S="O90QV0@9:2C-:.PMB_QKB YJ!EP9+5(QIY)+J/7X,ZM7:6%9_
MV=G(9QL<A0XNJ=/.\HO/V3O9_+$NY\IZ>UD]R*>2WY;ED_BY_ET)]2_32D?G
M6YC:'/U#F:IE0>9!)6YUT7WL>&->^Z@'NOZ)ZP^U@:>O$6!JJZQ$#RK9/3DJ
M70;'R5&II]G1')4NJ]9U5#)XVKW4ZQ]5()?U?#_S^M0F^U[AUS\L8M;Z(+H\
MKSV@,_"D/@', %/X @Y7E<,];'/T@KAGE#I5$O?<HZX1K<J8KS:+\[OER\MR
M\:VZ/]WW_*E^][LR^?DC>=,/=]U*9P2GZG\D QF/,P!UD"7117*Y1!F5D$!H
MYJOC3Z2I,<<'*06K;LMX,=^L==#Y2I\S5<='5;JU^M;:,.&:Q[$S.ZX?=T0&
M9JN.,D&M35"K<^3#>-\.UF[\JB=!I670J+GG8^TS[M,7YMXB0Z\6:.3845\
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M3F>[)J=&WW\JO-3<_[8F:]-:LAU\^EG53>N!>>_/+Y^>/MP'WYYNGSY\NY[
MCG7LV64V#]<,T_RP(Y=.4Z-,_V/1VPEZXE^N+.K>.(E6<UU-TTU9[LJ29R@*
M4T)#P')=XIW$L4ZMR !E"4&(<!D)JR(B)IU.;1KN:IK?!%M1'8N^]V%M9@;Y
M1G#@*7T2O"%KPAO XKM"?%^7[U,OW@"$L]7C3=YU8YRONHKDAJTWNL7;A;()
MYCKVZY:MBQ_*,A"K[9$I)"Q)89(#GC&I'<HI0#R1@*6*=?0?$%G1CG'/4^.>
M/<&K$*I&]& GN_41M?UXF%'3("@/S$^^ +8F+&NP/+&6>;^C4I<U'(?\9=^
M&XE56:T_%W4^&-6L+NC6I$A6QA++J$R!1&D&8 @30&">@2R*&--I_](XLF&M
M\UU-C:;J9.R+Y0(T @;SG=AVI-2#KQD+^4%M8-JI >M(>1/LY/1',I>Q\,0J
M/1V-2B.7%3[D#8,W[)UN52-?Q'+5&/:&7K9[+TUMABOAP)</#X:3^1B#_KE[
ME?H#3]56<X^;EK/J.GG![K<TFMOK206Z?JZG'W!;=>L2JT_DY\ZYY>WSUIF*
MXSR+L)2 $@P!S"4#E*LE.%1_PVJK($)IM5WH[6UJ,[,I=:RD[3AAO5WAM=:/
MM=DB[ W!@2?W->!9K\9&H'A:D/O[&G5--E+[<%DV>\DQ$'6S4BUI1[D76BR:
M2XOJ>N)_!?_$U=)?R$*7:ZZ#;]H:66I3T;$3U+]M7@1OBE)T_F&6T83SA$F0
MIX(#&.4YP)!'@$&:)#E$,*2H3;WS9!'5.JC41G-R/V?/TQ@^>-=N)P8>:S,V
MG,#0C12DVR@:=#2]"7:Z!EUE@UK;;3G ZO2EHU?0:+PMR-/]1X\1OZ,,CJ^X
MX6&%'3?Z>!3@CV*8Q^G5;66Z(ZOO'^?+O_]-\.?=Q1"$8888"P%.6 )@%F4
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M5S_@M5@N@++;DK7Z #8D*4>P^>:D#F):E7034O0C_F""B2NZZ>MJ6G8Q</J
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M/J]S^=>[-^TG\@<EC7CWYG]02P,$%     @ RXL"5XHP2(>OO   +[L( !0
M  !M8VLM,C R,S V,S!?<')E+GAM;.R]69<;27(N^*Y?4=/S.M;E^Z(CZ1X6
MEVX>L2HY)$M][[S@^&*>A!H)4 "21>K7CSF0^X+$XH&(9*NJFY4+&&'+Y^9F
MYF;F__*_OIU-?OJ*\\5X-OW7/_$_LS_]A-,TR^/IZ;_^Z?=/;\#]Z7_]VS_]
MT[_\7P#_^Y</[WYZ-4OG9SA=_O1RCF&)^:<_QLO//RT_XT]_F\W_/OX:?GH_
M"<LRFY\!_-OJK[V<??D^'Y]^7OXDF)"7'[O\[?R?C2Y""J,A>:% L>3 1\7
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M/G5_2?9=H['.X5W;NLL>+E^R5J@<H,<,"H,#;X.F>#UD(YU62AP6OSSVYNV
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MU1ER'Y#D<IZ6YW-:16_/OH3Q?"6N:3Y9?L;Y!:<O/X?Y*2Y&UEOA:_^^D#&
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M=E6X2=_QR%-K2[*9HB&X,4T TU#P X#1#6^]GN1>>&76VN*SX:!++F00BX6
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M]-;[_7JK1R5I?R\6"JL-GYI'\#HE,+PD3\L,K6A]^O<8+?WF"#K"51/!'SJ
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M\TI.[^HZ>_VMMNOBB,4<6<X!B!4%2C(-KF@/+FO/N3?*^N:M* \1TF]?]>#
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M+L;+WNU''#&GZ[W@#+BO+G\=4N*"-R"-3MSRK O?IM.X*_KZS5TW1_-@5#D
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M&FK3]MMI3=>M>@9I)[GW]H<VK51$LLF"+I+7WC #SA?Z5FERO+UTSK4N/#N
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M1\]+'H;GHVMZ %9\74][4G;@F]Q21ANG0L"<2AT@F,$GBY"]43)1 **\;&S
M]R#S1\\ M+'=7>M_$ =('S#=RN.](76]F*7QQ?",]S@?S_*G\&U$K'A5**JR
M@6>*A(*'H$N"C(4SGR37KG55Z;:T_>B^>ALX=Z+I06#X_7R6$/.B<O1R-IG0
M;K-JS21_"V\,J!PEKZ))!4$4ENOTEPB>Z0C:">.2CEEBZ[K.+4GK=YCB<T%P
M%WINYF>T;6'Y@(OE_#PMS^>U-^?_9^]-M]O*D371)XINS,-/I]-9G=V9:2_;
M><ZZO[0"D\T^$NDF*5?Y//T-4(,E6:+V)K&YH<RJJN629)D(1'Q #(CAX@LN
MUE4TN$SO\WFM9'S]&=>?\N:/O/T#UY7+7_/A]2O'K-:B>*79;AM5KMRCY]4M
M%:\(;U_O3RVVP14?E28%7^_*4!]BA;"0K4=A2@T8MLYP'4Q<NZ&H3RSY>K79
M7@>2F$K),8V0C"'3WM$?R+,@[U7Y8G5"HWUC/HP@;]Y8Q31H>GJN:5MI=>"(
MW=M0[9J[>^E14L98"Q5]G1JNLM00<C @0O3!D+F-LG6GOT<)Z65N:6.Q_V ]
M'BN#'H%TDTF(RGNLM>2Y>#(8)((O0D$,105FF(C-QS8_04I'-]5A0GX.-@=P
M?.[)HW0W;_.G121+]Y_;S[\NZ<[>62!U.[<F+IZ_*>19+?(RUAM]N3MW;[]L
M%Q>+_][]PO6#(@:R>:4HD'6@C<O,H<[? 1ET-"A-PH>-XQZ?6-J2J,Y =PA$
M5CW(J[<;KFYIIP@V>?TU?_?!N'+DU.L$06L#2D0'3B8)QMI (--)^-:O3$/H
MZF5*Z@D5:0L)S7P]/N&[O;IN,'#?@3MSGEL6HX'B,8!*-9]"[7J,FFPYFB+S
MD"*848MV=+TUD??J%,SO[2Z[?PYOGI3JU_R,P.&3%!E8G9BA1(X0 K$P%.O(
M4'$^XJ3FVQ[:YKW3)L/>I"+J&WJ_7C5YW7U]9JR)@ED$'JP&57M9.K)-P&8F
MA(H^)=NZ^== TN9]XIL3> <+J#?<W5S;R6K-.4;P*I,)6I\3@] 11$Q.%,\#
M]Y.";(P:G>R5[;2(.H3U+_\EX</EQ06NOZW*8[PXR>O"( I._.(PGBLG?X4P
M!8LK18-/Y)\J(P0$6U.A;>#:F.QB;/VPV>4KA#;>,C)N(0HZJ<JB( .7OK62
M62V=1JE:AX3_@J\08]!TS"O$&&G-J)LWZ^U9S6=;G2_23EH[7;.+C$:1R8)
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M^;86*?+,==8%F"8+7V%RX+"0 59*BB5B$+EU;<T><HZ]L!YR]:>\S&6Q)5/
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MP8DYR4).):*T16#S8,DS),UCX[64^K"WN(-$T &BGH\NTD;OWJMG3'$9"]=
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MDVX-JWT$]5*X?H3('\*H&?^[R(FZIOZZJH_+(AT3->/>TODRDH-/1@.RXE1
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MS JYC<5&-(GT=>O&WR\B<#U*MD,"UV,8W0-8[JO[FYBIU];:4!N[U4%/)DO
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MSR_S]8YNA[SG9#4WH)FC713CR&:HCSC,JZ0T8TZW+HE\G))YD=5(S*OF/.\
M.:]Q\_F7\]4_[V_"1*:UJ].98[4>BJ]9"DA\<=X'.E>.B=9VU:.$S.NU38.;
MXSG> 6Q^7FR^K#9X_H_UZO++ZW/<;!9E$:\DLVN07$<E193@BJ!;6=99MR8K
M8+ZH5 R7++;."'F&I+G[]S4TF1KROF\H79\V.FA).%+LS$4+*O, GMP1"(ZE
M@(GKU'Y6XW-$S6PKM83 <'@=((_> ';U34YORT_?/N!Y_F.U*]Q:+;>+Y27]
M^$M>7UWV-R%8S8.W0H%TFF[Z6EP:DK'@7(J9*T\'N77IR3'T=@O+0Z"S#YA3
MRK$#S/ZZC*N+JQ'RU0_Z"<]K$NF'SSEO7RW3JY06=7-X_CV7@ERD>PS:T$><
M7Z;ZN/ H7ZXZ7QF32K0%+*^#X3(C8Y4%$@?3T7@KI8^M[;S3[&SN,=[MM'V'
M2.C@?(S:X)U'.^8-Z<7DP*M,VPR9;@!--Y$Q5I*"# 9%ZW#+@:3.>Y/WB+I]
MZF B",S\*O_G__GI<E/[F&QV67/?MWNMU"3YF<GOAER92&8>:M*FVI,;:E*4
MHD[T&S*4]9EE.K(IIA+S:AJ>SPB?S7I[FY*R.VHE:98B';#DR>Q1-FMP1C,Z
M;R5J94K^88#OXS<???"=6X^^^W[C/5QS$'!,STKX*"[.*/UX3?/9J_/S:_IK
MXNWUTZ#F43EN())-3"?#"D"98TWR+Y+IP%+:AX1-CO_CT^KK_[Q9XPH--]]]
M1\,^&N:Y4HZ3YJHQ:WN QYL_WY]I$:R7M/]@%%UHAI7: EL1)VR20G"5_3X/
M=S0<:,UYQ-].<@^A,):-/8C^SP\_GPGA&+/<U]$T="4R:2"(74?T7$1DPN2]
MW>9'BY[6G">B/YWHQ[*Q!]_ID8?6]XO-?^VN1.M#-H'X4)R@O5B;P87H@"NR
MU+EADJRI$Z1 W- S""ZV9Q.B.=>[0M!KLL%K!<^=S".5'4-A&92\4ZHE !JC
MP$1T=)("^V&*7D,$_4A/?TD-ATG]23@=*8*97=Q?%O_*Z=<E?5C>;-_C-M_)
MGX]%R&0%!]2%5"K7",[' @*Y$:14M<X/)M ^ZM[N6:(7<!PKPU5[AG9PS3RQ
M"^Y4Y(P4=+:*@2*E"\ZIVK!3EF2L\MRW5E%'H.<$.>6-T-.0[1V YSJ]XN>\
M67Q:?G\9]=EZ)5WMZ"(Y*"?)3+<L0$)A!+$H$[^FR;=[0,D@\+B78-DTX'27
M>+D^2CXSDXM!R"YH4)(<.^\0(4CN2E8AQ>;-!Y^BI8LTNJ/D_"QT#F!Z!^"Y
MV4!.KS;7>_IN[]W.&PLBUQ 39E,S\E&1FXD>A+18(I?"V^8I4<^3U1ND#I'_
M#Z9Q6V%T@:^;Z_JWV[XOK(Y B%*!5Z86!/E$*MY)D,R*Q))FHGF.YB-D#,*/
M?PEJ[%@>S^Q(?2?_C]75V^RKB]7E<OMF9\U5CV#U\^6:SL([^L55.DLZ6*%8
MG:3(16T%:L%K%<!'RQCC7K*'[4H>=:Y&+MN+PW6@B%>GX7=7-\[][9U%KH7T
MW$'2LG8:(_<Q)"XA9I-3+J*0.S#9M7.?EE[\K^/ U)3C!R/G:UZ'5;-6@?%>
M[E_M@_AJ%1?7;<6N#L1/N:S6=&W_Z]5VNUZ$RVV]P#^NWNUX?Q:\XSG4MW5B
M&IV68 %+3;5/+(?@>%"N=2?>XZGNI2JO#1Y/+,4.[KR;;GBUE/:,:9.D$PH<
MLV1*Q*0A<'0@BHF&; J7V!2UZ#?K]U*NT 9+!W.V&Z.J4K^X<E%NVKO2];S>
M+O[[ZF=72AXE+S6H#Y:)6#5]!!3.0V)*2#))M7B86O&,435HV5Z275L:5>WY
M_5(:5'ZXO+C ];=5^85N5G)D;S)6:BGL!I>IEL/F397#'^0N/U8TV["S93MB
M)FF).1&O>NBE*6464B"8@*FF+R*XJ 0PHQ3CSA"\IS.S3]Y+\[:6=O.=B,W=
MI./?5E=&R$_?'G_VN*T/OQ-*N@H)".]E-L* #B;3%5'',ALE 6V0SM"]$FUK
M1DZWFU[<YVGQ_&2E];SHZ,!"?2($'ZPHY"+6).2:P>22!\^C *F0%'"@SV&M
MO:4C'K4FPV<O.!GV/C9&:%U"[R;17N9DC<^ O@ZYLZYFL20+#AE'G55I[RB]
MJ/>Q47(>^CXVAND=@&?(DXQ*+DM11T=9*:YF4X5".S3>&L4C=S&TSQM[J>]C
MH^1_P/O8&&%T@:^#>@<E4:0N4H(1Q#N5I(-@! >AHTPR<\-*\VK Z?I]31;I
M[E2OGD#H'4#[Z28TUF9FA'60L#A0T48ZHUF!2,&QHGVVN75WI[]6Z[!12!C<
M.FR,6#K UQ]Y^^N2SO.V,NU!*RN3BV7UN2DS7GTV#ZXX"<E*FU@,B*5UQLK3
MU'2AB(\5]VH2WG?QZ/=(!_YD=2[%<_ YD1&10P*G78*2!2M>\D1W?'/U>M <
MB\D>Y;I5G4<)JX-KZ\FV["RDJ)07(-!%NM1KZR,9)%@OZQ,$!FS?L.>EC,08
M)>.A(S'&,'SFY[PWE^O5$ZWVE>0^DCL.7-3!G]8A8*J#DNDT*9%D3 ]#:(^^
MW#V]0D]@.%1ZJ^:L[.(FN;V8;V_K[R^9J@A1'$8006E0W&G $ T$VB5'U,K)
MZ:K9'B%HWKR ;M59*Q%V@,>WV\]Y_7IU0>M_SLO-SJFIS7BJ+_.#P9AOO)R'
MV3JWB3EGS(D@!<MU\)&KC"4#E6L&D1L,GHGL1.NI?(VW,/?5V0Q<JWXD_6*R
M(>+GG"[/\ZK<SXK<K,K;R^UFB\M=-Z!;&;U;;7:MJ9HF01Q+PS2Y#TTYTT'*
M@S!6*F<#.%>'9*% \J0#!V%S%"+8G)%/IFK_4BD/46I3GYAT) M?61D T41
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MGBOYD+:PY(D=FCNZG8M HI]<<;JLI72Q2!4?F.F3U-#,4UIU""!:,K2#:^3
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M2F;6&J_-PU*2%QEZ:B[@PR)08[@](X927IS]EC_A^1OBU/;J6)FBN8\A0.V
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M7\WG]TXC\Y$<[""5B?SPS:[AW/;-5_JC9L=?9:1RFWA(BNPH-* LJ[GQOCY
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MK[3W6VG3YA&M9Z>G.J;RWMYH,F0?@W5[NQ+HH5VOSZZYMV_93S$"B[].'^M
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M3F/[YH\B \LB*A&+6MF8V;\:).R6G@YT%@4G*D]95V!L.2G!W\] ![X?!#3
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M: ['7K\?%?'@G")?0T6<89A+GZ\LG-=ZW_?H!+W!>R0<9'MX P\T7N[PJH)
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M(X7F&U1G_NK@&666WY]>OKFX?'=T?GSJ%IKOQDFP377FO+<VI:[\O<-"VU8
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MC.\K]%>E<Q,/L:"TX5CJ^D;8W6OB_O: B#+I,(&]@FN(01^$I66FR!S\Y2+
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M.\6QJ)P[W>M*33BE/=QI](D>ZUQ?+N.N=5V":J_:-\W,'.]QP+MP>XN/_"G
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MNG/IUUT4G=- 6(,S! ."B7!*,@@AFF "Q'*H])P$AB<3[.'F.=#U#2WE)YV
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M^N$S3=;*C>/3]/:J_;_^Y?#5TU\T(?5\+U6@8*B7L,R4YR<3.Y!Y[L9N?7G
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MR#5'"K!^N;A3H/?$VT;M"@R >JO8I>Y2!'WU.HTY>-H<H1R1 "W]XH/CP%C
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M##75-]+%[N(Y[@CXI=PPW(<[@-@#<@A!H6).Q=7MBCDEB*&AR@P(S0VFELM
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M":: #I<(N!80L/@KG T%!*[:[0*-3J[,3K6J0--?PQGZZB6;;-X:[*PCG+8
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M7G>YMW7C>6P[?HL%.)8MVS0+;%RR3&0I.Z+5VR,)0NIU"3(4XI5F/B@30?K
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MJ/X=*?,O:W&?5UXKA\HLJWH,,6<(5 ',4,/^?.CXJ*H@SL60"-/#E=<[4G4
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MK3S63RU)+='29A&6ETZC&/29K-&/M"B8Y1(X*ESE0BY+P]\ -Q>$"^OUF>0
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MK,$*R%S@U?E>7,A38<_#1F_:EQ26WBV(#-T,!NL!TR+1T#NX\=&94VY10K4
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M"M@3D',\]9H.H(.6LJ,/+M1Z4BP"=:.%055QT(%(S:?^2(V9F7$4"EPNH-V
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MER,^(!XZ'-&+]UA"+^$U[%$QKYH=A9*E@/!5 .7%\. ,_DMZ)!,B+(#_UUV
MQ=K5"Q6MXYFR+"5J+Z?1'9 6L ,'XJF9I)PZ0UP258*!4F/S+7*OO^C&)%^D
MNAVZ'\=1E58A>W.RWLAX#XDT]PK"HY(VV*;4R&-2IT]Y\0T::/ACZHL@8R3-
M:)R<V#SFL@',%XK3E)5'H8GOYM54?$9[*T3[8PK56HME8#SX2OI6GSZ=,D(5
MR(39026$2Y0CM3[@8<7.(405UDQB37@,3%/!H@]G$$\J%293+B/%CE]II:+*
M;F\H@N5(H9<MINVY*[E7D'Q;^-VBM2K)B-UQDB(]HF_H2&:JBBO=CRO914.<
M(UQ+'*I!'*V>@[^D\Q^I0 PUY&SRJC$0.*J^D7&)$1)L.D;M?LQ.<!-XK7%B
MN5F09.=#[]X9=6@,4P5?Q M1=^A.!*I>E$FZFDR7SV'T#AH<^A1G_PQRX?*F
M):F[E@>ZQ7K!>&M3=,NDXV3RH_P:'YIJ((+'B@Z"V&)(29\GEDXRQ#&LR#6&
MBX1;Z2&AAN?MSCPT:=PZ-YC4<,;]M6)GI].?:NX'?1*TAC,^U+O]V7'#3^::
M7&(^%DL<&R>:$#M0%2Y]#M@^_%F1 W-II7CST[;"7=-D-.[-AU>2D\E<657K
M5@L6&?(KDQN M *-B5&F;1*3<!@?* G@4DWB&ED)0&M01125S2T61![G8>/#
M)Z"I37IF)>>B3ZNTF,%M*T/7/B9N,%8-[5QL:F?%MT,E?VHI),DIF_95G7JI
M[JC_NB3_$P--F3%6\IM3N%4X&2AK.NGF[\[)OPDIGX(#F H38%+,@/Q(AOIW
M\"\5"7OU2\&_GD\U/_!*,H^ SC3ER!O1>18E,(G/+'%3M1,+F3JCZ7@(35LF
M,V2W6A!@!VVI9?74U!&#KMOXL5@OY0O^E-4TN8QS81P7R)5C"HEP7#?XD.0I
MW3G Y38IH_LHZ^R]:-3J+/T K\K(9L&';!=5DET $X]"QK"3JWH47B=P=34)
M373='SU)<AVYWR,@"7 7,=_07?&M_996#VO[ @7J2) +?T-)%>4TD\_4!R&9
MZ'0R6AJQW@&ZIJ8U79?4#A*67H6@VH=+P24/08Z&0\ 0F(F=L)8,^/"0Q5K=
M1XB6-\6F#D;_W<&<W&>O4_FQDTN5*ZB5K[C>ZA*MCJ9SJ9U'DX&-;12R#)N^
MY)J,=>)M'S XQ<UA6E$LZ USHV9^-0S+9 U1*)2]=%]\0,RX$L9 2# AR=]2
MJKJB^)HCUF"Z5_Y4 #[AMKCG>G&V0).)U9(0.T4C*PIVY"KF*>D_[\OD(\3-
MMY>*(<L'D!8K2\Y_(*YM;D;7U!/] \4#F\(61-#="EO!8M6<> :U?1"_>E%,
M7TPX5I3APO&EK"+91M6";7+C<,5XBS&>783)E8C740,SK0+IXS1"Y1TO4*NK
M:72EULJU*M7?@F=[S6_"Y?(H :TEM$.7RU#@4: D1Z&P$K(-'J)QLPR'2!U<
M^/W %U#D+UP7PR0B1B_&[.8)RWBG=[WD3 FY'KDWTI^K%)8PU6M)6>H],M,D
MR2JTB(P'D5   [(XJR@7>\8(()_D-!9NM>34I>!2^D?H"V48@8(D%?U#XZ2;
MA&U[%&96UZX\TJA3@'KS+F%LYC0IP8U5!(&<Z$LHTKH?&DMAKQYJ#9DL41(E
M[[@.)(H)A<N1/R".RA+(V.#@ 2"B%G<1QMR1E@T6%$_&?V,"TMBP."WC>@;&
M;(RF;M&6SFD397RT>'96")>9G%FX/3F6K''B)E?BFDHX-(D$X2VHC"1W9":N
M:VV#0&*3/7CN9*@;(148&$$QYZYW2OG!K:)AHK$P=72JTFH>4B6&]VLB"LW/
MFJY"''&'*'&/ ?15_/A6@>UN:W&?P@$KZA(,4K.;R=T6$?H\T$U[[RT'8(XO
M;,&)?8SY%-REC1O* &3!8U"O*0ZZYAX@ S1NK61LO<7;I@)7#W(91MZC/36B
MV RE 8^5C-*HYW,3*WA :#Y%!MWD66ICCO>%H14#LQ+=&87Y)(FR&0\SO@4B
MMJ K0'6T#J1*0X4F#@KT70'XJZ2CSA*A%I&45H7;N>8D&-70133*L;<(9:K@
M:OEZ<'6PKY9-_@80S8!FX!"4)Q^MEQ,GL3W"OH(8OC_T52L13U=($4 7:P^X
MTXP.=K)08'4#=4A($=6!+"Y.F4N8.I)@DQKCR?!]H]: "RTR%7+6]0MUSEQM
MU,4%&O7>%M2X Z Z0K^$?##!6R1=H5Y#6.D<!B:^@Y41!J6A000'#Q^*[!]M
MD>Q_BO*;.KK9=%]4UZ/U9Q^:<24@G,0P"$.#\AND9\UX5N@%@-7+8%A97X^J
M'I&M(,S(M%Y/^5ED#:]\L)#=D+M1BN6&0@LW&FIWHE01,[K@UCG4_O#7+6:,
MN)WQFMK!@F9-"F'HJEHS&X)+URXW!<RQG[B<LMG$02X'ZQGX-9C71KK'>(XX
M^Q5CVW5R6Z6NY:/X6Z'OCQ1/PUJ>(FM66)FM953UQE"4R:LM4B8CL/G*(D]C
M8./$EMX]T"L.="ELK:(#(K%)0@4\Q+^-C0/YN%C],66W6<@ $A-(!P1^&21Z
M8= -]6@\!O";AK3TQJC&3@W#?I[JG8XN'UGQ[6BC0/7:@L#["U@SZC>HGD?Y
M&8N@D7+<J6SOZV\C ,Y)*KP7>/&RNS/64(YFCSJCKV'CDD-R_/+=R:;Y6:?!
MWLF^[T*/@BOA*"&!IT+Y2I8^(.7LBGI=$;Q/.6H,P:3H[][[?7'<9XFJ^BQ*
MD^U!-OR81\N6IK5&/2PVFS;+ZFXH@*UXFAB]R-1>%J\DN9T,430>,DDX=&;1
M6U#HOC)V3@Z8<6Q9< E<!36<K@FNSN&[W]Y05S>B/U6H:'/_)3J:L"(VF1LV
MOXYN;B#F0\$?(+GGH5R76/:YA-['LO>:'-[A 3SZQ>%>O+_W:I^#5'MR=>A:
MEPAM.5NKMQNW-E==@#F%Q9T:6(>E,XF"P*"61I<"](4&:<X4=JVM,R*I+=@U
M?G:5?A=N4BYVD0M#5<-&_+A5P!8(_+"ZGJ#&=H2L>]8\3P/FWCE56AMM FDZ
M4BG#C>E-TQ):N<A)5NM.+^6JWS07%T,TD3UAC??HI\OFT[HM60$9#A7HK)!:
MXY:7>:T!8)@%UY,3%KPYA- RH5/179%.'B,E^P?!";3KT@V'_7MEC%!N6Y-4
M5*Y+2Z]ZV9&[BL7-6F>)TRL;J0U4UVZE.=IOS%\/4W0\8$R1=:F#:6/9.B]^
MBK'CCU6?_=^?9.RLA?9\]0Z3XZ./9^=GUV<7YU?#L"@10AA'<\P@_-L@"EGI
MX=/]:BA4_([#5"!=]"K!3DA"(XT3\?VGIKW?I$G>'XL<FR;\Y3_9Y-G@L#J<
M H=_9I-^@:1:H>99:(/JXAK=4-[%>[B.: )9[#RV.C\P@8;L.MJH>&1R)F\E
MI/S07PXINYN6;5613H/E@3B^/8IO;\,I.X6^KOTY6S_ =NB&?'*#A1C;4[4]
M+$]NA""S30N6\K3.@B2_D>6&XIZ;I154S]7 > Q>L@(%49@N\0S[]#9-IL'H
M>Q+7B.^_@!"^;C]J=XLONWZB!DIQJR39#PF+ RB,HJX\L)@08XB2L8?*G^$O
ML3BKPC_">K)A'/<>1:"WX;B/@'8+BI 81]:?DQ]U$'OM&=D=Z+6+0? (* X^
M <4]V)S!A[12\+,2D0RHVO8YK,6NONJ7?4[,_I<&!7XMPR[,,W;+M&$(+(5G
MM"D0R#_M,9,>V\62)6V91%Q++!&4$XYP[ ?SK-;5FVNI,<!_9%7PYO5!\-$A
MX9(Z"(R+1!S4E-<"%L+==++'X?LRZ,6CD#MB]]3SS8&R[!RKT41W [$A>A0[
MWP:E\A%?%WQ. -W=(XU"#(I [RGI38@34)PI7L]T-DLF>+1H//H!"%07)_D2
MPF"';_:B_1>'>T*;\/4]^AX+923._0D@-:.*@H#X95GCSS%NPIM"?@"N:?'_
MXNH][V;Z1;2=Q>H'SU19*S..C]/;J_;_]M?#-R__(1FIEWMI(A0,-A/FF=+\
M>&('/,]AG-;7!S1[W__V^-3\7A03H92!?K9?9X9%7,=KB!2-PLF+Z%M"<'I9
M/, 77W!?IHM%8@"C/>;[D%H8M@G=B5A" %^7@&5F+>%GRVVS)Z9U+E=\4B]2
MMM^A5AB2<GBQIYIAA5]!29<XDF7CWF)OF7CP6AL(L\/TB=@Z1+%,Q,HCY9/U
M;@ IS!#NCXV+( ,2%_-$(^O5:S#KOUB4J;"M)%0* PZ)-^FEM#&BG%*C:SU-
M42S9:8$P&YL_':BR[HFAGBHV-#LZ_5".P<R?^I#*NO!$<Z8 %PZ7O,_K<9;&
M0'->1A/*A\X@R8@A%P83<N6?4,)BRH%QQG4''CUL[L43\LI@IZ?XP=+A$PYT
M3*EEY5U:+FH?1:V<9,Q9*D)23!+5_0K@5>6-Y,M:.NS'0AD8*J*Y1XWMA8:[
M:=Y>Y"O%1N'B>/D)-:H_=1OI <T/8=FHVDDW(N($.DVPI%5&G+\<AD\(QE#J
M**1_?[TM'8@^>]^IS\#RP)(+W,8UA%0FZ8F(1HA6#B377*6*L5&0+"S7 >$"
M7M\YJ)2:]$V$25FB\WZH6AC(AIRN=\%,HS0#A)?GAG$(.XRKW09_*OYF(\>,
MQZI%[1;E0);X0^L27[?H!LKH>TJ?&:-.U6'<J1=K.U(5/: +6C5M:CLYQ"&"
MM.(O[I&/<C8#O2,V&&'R& 0Y>AV(!9&M1JADL^6\)'&B?(S&AH;<T98J/\H(
MZDJH(P+W/.&K0?:,-1(-'=%9]S(:T+'\8K9L:0C!C5!DE21P]Q0KRK80WZ&&
MW5A$XTXQ6-H8'O/J93")E@JF+;Q"K));\R&^/)1B/1#SD$^GF!>".N>=-:YZ
M=A!,FBS;W^TTN6%CQ[MRJX!RP4R( <7PY+*86"%I>#YP;=*F2:3J2'ER9$6J
M7Z@V(94>IRSN=;CLX:O&:P\&$F]_LYW.]NC[/.7]^B T8W\<;A5E)A= 9H+!
MJTZ1E+8R$!&LAODKOV/^^)S.8U29($9GNL.*][S=3A&D[>JM]+DA1^H\3Q^
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MK=6IP_"R([(>M2[H5:[J!(/KF-Y=YV)NOK/CJA[M[V[;GW_;^@0)@G,_39B
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M4L5E.C9)G$SS^H^A='AZLT6U9)\3X6QB]8 LMMXTF8%UA"Q30)=VH2#*/HP
M8LZR@*]TS3J3^ R"74773[K-WR^#F_1.NED6U['8*0A(1+40O1()W\H$*D.@
M7222+QD11])10E4PX7B(+,N+)#=:^^(=JJ2$*K,59TJC4);B.+ISIZ8+@H"#
M-#"%)%[!8W.3F(D<O&(F1#-5[%1D/&J>%[J(+0*969TMTGF6^JXT'I5Z<2C]
M6B!1DE4]&,8IH<'9V+C%Z%M,88CB;%*4QU%U2\Q54$!)M>K"HXV_A<$XRK\%
MDU)X,"'>$M2ND\MS(#*40!$3E*W-HZ4L%*"HU23Q]>N$,6?1O?!JY:_I*U8+
M#3!'<JQH-EG]U%7#*V,7$(GG@JA4T"=PDE; <"V-L(:>$&/U+#ZN)S4:I.>!
M@L#**&12+#V$W7P?=\LH[9ND'\>('[8'+>Z-R9A#M&YT(P*GC- J2B<\*/*5
MQ$.Q0"68 DW0C&B"[H F* SL7K%-@R+L$LB0ET)(9"VW:I)DD&K!K8OB1:T*
MO%6?4SDT=ZF0+SVF(K <(KO GD 5Y(U5H)8_)-NPG&P/^ VBS@U@\\M=9;'\
M8-A.P9<$\X[G("95POTWX9E'9-? P87I+4K@TLPCXI4W.]2X"T>->J"0SI@G
M-@+2Q7D1+Y5QO-V6":C29NKNE:>?2Z4?)(C&\HL3("G6,#%&F@EZB];2#U!J
MT@Y]NCK':TP+L['"RG]4(V*L7_A]BC%_#,.9(&N=DJ<]S3TG_OSQY/\&XFSG
MU2RM(.4KP7*/.(&$+TRPS138E&69W!46KY&:+,Y+<<NA]6!^/<V%!-1LUG(_
M.UF?628WP'M:HM4*H4'J$UP6WQ(ZM4EFGA1](1A"*+[F5T[!/*LKU/!&$O,Z
M^O[B,B%GZFR1".=ISVX.8_6">K//Q'FTK%.. HK1QTDRT6VSJDBK<6.9AQ+/
MZ&&AX=E4\V?X%/1864BD<(36A8QJ5%4U58[#Q44M)<( #"+OO=)6+WR3WC7*
MC_]>&4]7ZK.+K!()C<<)YI'K,KZ-)#.)<19 _,#;H_[#P5TJUI0?,H&+/!W7
MG" 3IZB8^E) I%'5T-S>EL+FL;IYJ2H=K'B.=(B>IR*C?;:%,$FZ^\VAWJ/C
MSBJH4J25&$=4J75XI;[Y*^27611(9($VP!Z7/L/?*3 _3GC$PK_GU !G I+I
M%([SG4D4\/7@Z@!.>0V[+^9S0MWF#]^]>F5U0]F#+W,K&OOKW'!%+=.DX3+1
MZ'.AP!;%G V[JJ[FW.(6[PHYM)QH:'#[<,(X2R2$D<""U-P2*J?U;(QW$,KB
M+>;"\B/3%JYFH5E5B,(Z.(ZT<'<_DZM&B [(/]YK-#7Q1^P[O=2[;N,B<936
M&@Y%-?:P"/8$3/H"6TW-D5"(CC:=%6COFLZ5%<,>F(S3Z7VWPDD-DJ4WPBG6
MTB_NAZ;ABFHF1($HZH6^/T&](=G1(OH>[#&_ 4@B?%-X$G1 Q&=1*7YRP\ %
MB/9!A"]:>-I'\U5M'T=X*1T582)A3RYA6PDO+,FKQ(.P" /A_DQ24MI:&TO^
MIW9$!ADKT"5>VKS*'":J#/<&F11)96 UNAY@Q!L;2QL0!X:TIH2C@X0:1?$-
M,CKE4H9%<VE><205GNMKU*@A)G*GQ)#R!?]":BW?"M2Y6")Q$\6T-_"^:B%?
MZ"YE=[S71!R@(E*&+O,-@4,MK&V_5Z.A5DS95,F?*?6%M^M"JDJ _1._72J4
M2\*].DU59ER-UN5EH6KTW6+KN)"-4K$ 0I#I+XXYFJ64#G>[#,#7*!8AI+;2
M3TWDPT#,/8/0%T06W0?(P7,#J0.T-JQK'H8&!Q%/.UP$ZH":E\I @L9OMRAH
MC 1D$6=R\N":]V73D6.;(%+U#_<[LUDZ3:B!G*^RNVEG6V1]'&O&K+VBLU^X
M-(/8#IB6!I_L"0J)/Q5S@ZZ-CX0*D(4F,Q6TF$LIT@W/$=^M*"]=Q=(.-PUN
M'+'-=<(^?G)3R(AAH*[)^JEB<U$C,J?BN7"7&(E^<)_K&/S4T "P^'9+$F%Q
MJ'\5(*>RDJ^^/#XI>6$6\)7<@6IE!6UMI9GDC(S&TA-AT@NU$@>$HL&1H/WI
M:^\Z0:UV#0VG@S,5,@7;7S;<--%N9SGZ"ZR_EV3EPR30OCDUS&_+9N#^UY%0
MT7E*I)#<EKN ^ 396\6,/0IY9=VFR=3HX'W!7_5$?K&KC R6\,]W@"-%:;X#
M'#V_[F]RCMT)Z1#6=)D";D(9B^)HM)]R/,@?<7C!YP2S,XAVOTFG"]*XE.6.
MC#@;1@JQ9?R2L@S@4FN2\=<O%6GK78$VE#0]*XRKJ%2!]=H*PP>.?N/3G>;:
MO)H29,"V9H6!2N-I:>0$4>O9'.\=6TVC9DV3G(!:%>CK,)AGR>1&_/MV.8=K
M(<8/S>L)]#[$M&WB3:INU1>DOAA#@RU.18#@TS27.0EKR'C-)7=+8_A1?$NX
M%%9DG%"LA$F2127%/<4UI@+>.(2*'LXK!2\4"R <-K&+I20LLI3: J^V).-(
M*\B4PM^0&XJQ$3%ZGK-X'CNJ34=L%3$71X+R&J#%XJMW13H9B%7[VQ99M<*\
M0XT 'KXXW<A"OUG*>6' )2G:?_9AS276 1,R=.(SBGQIL(37/.+3X#MGK6:7
MV4@-G;>I=; @:EH9Z^;&^/PA9JTM6"-XN)0B,U:@PHX_'"YP!XC^N&RXXLN3
MJ;$.IDM<C]K$'1[\AE5*;K/68>B_;>H7=ZE#9&09]:9S7- <6E<CSI9&<IZG
MJ(YR'(F4N62/IR[O<"O*^: ^=/Y)R'9PC4]WC>$>W1BN?:,98-$B3[N6<5NC
MJ\CXP*O\4E_E&NWC[O"&51CB\"5RD= Z%-6>>O422J/KH[F'5:8T4MEDET.%
M/FEUH-=&Q^+N\]*2-.M/9L=-YKA3$6O_$4#S&*92(49-(M &GU!M@[69>UK,
M9F(!:(7 =R^KVW3>V!5R>0MP^1,)S<&4)@!;4[R1)A@V;Q?61E<9W-/0W%!*
MKA@"\-@='HCRVJ;>@5=\RUX:^[=A_>0W04@/(7*FS<1R!-7IJ-XMLAI+.:'O
M2,MCQ<]4SG1%AJ([D9L7S0FC0>F=W,.&2-8.Q/@P&CB-[HI2$:[;<3?9"G2-
MI^JN4DE6)?<0/[(..]MC/^>L[\H=C'*'==RJ'ISRKZH*T9*K= 8QW EU)EEV
MGXHLFHN+WP2>&?/CPG4)/@L[KCB=-2W<4!4$NA7"SRHFJXIL(J/3&+9E:P%C
MN!2LGEC1ZHD_7 V8:RNSVH]TGH.DXRQVDQ[#\+*PP+"HJ_6ZMBQ]7" 4C%;!
M[:G,;1/CY)X.V.ME-!DRI/:1\7NGK>O9P:N]]_OPF:[U@[^=[O,L$?JRJ,N<
M9,$#F%G<PHS(#91]ZK15YIIO3D"/'>?9+)G ?,TZVEV;H &T"=JNBZMW*/6N
MB^O:KID>Z0T?PR4A"6D_$#3#UU8D\'$Y;3JCXFG_HPD(60.!8BT!H0+_$9EJ
MOC-,UVP1A/ +C9C.U=.;:KN-Q\"KM%-"\#?XMMML^">A4<!\N#B:=0:C?7#]
M['8QN?7GI$K^83QHL"FM'7SRA]MV)!ZF;4?UL9&N:C(LM495A6DXX8<M+W @
M6&XC*TD,.. ^$CT2**8A;F/X>P3+/W5+?B&9L_Q"$'JBEA;>MTN FBPK+*T+
M3:&R5V'G"7"[K0;,B-?0;[(U]D]FY31PZ'-VENP@!<<F5O>H,Q(0@2R27R.9
MLL/FR3-Y/&!LWCJZ<4.JT"%^(0<1*8RT!X,$B[([88M&0%@=*QPA[11R$X\>
M1Y)%H5GUC] N,.CD&1%G$'*2E(O!8)\0]HJSA(@E$X>WI:$[U]^JZF]4,5S
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MU+%^!2V^:U=!NZN@[9-JW%70;MR;[0:0:\"X"R5O Y WG,2-H\BU^ML5S@X
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M.P8=0;R[:OZH7/7Q,-K)$U4"6YNM%[_6?V9HOC0 GJ6&_ Q)Y'M7T6&+/#A
M#;%%(TWHL4SHMD7PZB6A]";1LF)A=;T*Y>A,Q';&<(A07M2_T(T!$09!03)P
M^(>!R@Q)/B$X@JVKJ4"9[A!FF@9 #$308M5><5Q7$/C&0P7G0@B3'O[*HP@8
MG0HL'<GVH2J$6YXKTW_"?T%2,(F:@+'?1'GZ;_4BC#F+-1'6D"IX-CPY8CFG
M8X;:'CL-.:X>["4<(348XW,_BM4U8^@>6G!F6YHKQNE<;;6L;ZX/YKQ^Z--Y
M)7-=G5?2P"@>N7@?GY\RE/Y7% , 1A\M)M4W^\;)?!00N@N[;4[&58<P,)0:
MJ]_'8L<X#E H"T4FBY0QBM0__$[+#M5W:*OMV@=3O8/:RE/#-239'_5']E\=
M'!UCI#87!@N9+Y&X<82%QB<!_ARVW#>AF>F4#HX/E= 4J5!5V*%!!5QD8E<P
M0UFQ60:)SBBG<1CI&0SE4=D!?A'3,N#$(2%'2A0^TJ=>,0:Z3"'QA][/DK/"
M\0-E,Z3;!I'\A<%K1P,)U57%_2GMMS2KOV6W@]NTG*#QN5S!>;%=TO^Q3]+_
M%BVU$=[Y;(CDZ-8J@P*"".+O-T4Q":816FQ0ZH0?"UDLZSD8_Y-H!D\((:(>
MI64EHR0E$)]76IRDF8%"7R^T*2-/PUJGYS$E=CV6B-_[(Q$-6V"6)(UT0?>E
M736B\GF1OYA0++ NDQ#_;1K26"9\_/8?&++*7U1%)E[$LB$+A/P#B!0Y7I?"
M4H(SD$3G=0.>TT(#[I2H*-^X6<O6@=]Q4#E[)_NJ9$U(+@7P"6^)S.-6T9K9
MHSC.Q-F_XQ8(*2$4"HI_2+A=,F%?9]=+4>_VNQVZ9P-G[,2B;5#P.KN<4-^2
M=O$8F#@UM<X@/0<:ZK^%DU!-N&D@15_3_$Y,'E.:=9Z ?R+,.8CY5;<2-8P-
M,[!H3#(D\1F5_=B)=:D*Z$EPN,P'$1Y$?(,:HU$Z1L%5E=-?8,T[&I\4,J9Y
M8'"N=9!J>73$G[\;H7-HA5KLGU(B'ER[9K,SWT(/I6G467^@LX><ICW]X^3\
M]U%P=AZ<7IQ?7UY\&DHE%_!OV\PD47!Z&^4W>#V>RK@W%WK.Q*$DV(7%B0+9
M*>[ !D$&>6<%=+]%&00=H'$WI':2[S$]?B_*98QOQ'_CH-X^N8R$8 F;D!*&
M+G2U;!,CZ82*2'U0Y]RL6,(IIE,ZXE:_PL:"Z#X]Y&+*0GNJOC8B)FT==DP(
MAF*"Q$$9V(L4$EKS+(HEA@.@_URK7P9WQ8*BLVII==M5X-_$0G[+RB-3!1@6
MG ]#20H>@YM,W11"$[/CRU7"][UC(!?9"&"C^G>DS+^LQ7U>>>U3*K:LZC$$
MG2%0!4A#C?SSU39$505Q+@9%F+$):9@ATP"03I9(:%*EDS2"].-^L </9>&\
MJLN[] ZF":4^8G)22N7$2@ZM,4 J&&D)E\^XI&U$&QSW5DLZ/:3Q!5C^?<5M
M%%$J7X'A0BV $(?GSPH-E'/J,0R@8\5%1W %2LP8I)6MTF[SZG1[9=C%-$?'
M0)F#'ZCNA@SQY P=G@##!^(Y5=$LD:]@Z5/"3I,D_Q7[=;KKL*+VL+$X1M%*
M)9%JC;_5B%2C@\9PJCUC3>I*1B^]$H$R1P^BY8S4@5Q3J>QK6F8\6SB"-=KS
MM(S2=R:L\<$V556-V1]B85&4640$;5:,P2%D)(?)5J+:$*53R8\2/F+FH=1O
M2QMY6*CVK,[Q0%P@#=RM,B-$&UI,W'#A3I>;&6.7T3\E=2NQA0P&D(@Y"U"(
M[9:,QE&>$P_2#(LN)-HGTOYKKA53.5Q9?]1"//80/+FH/F#Y'1E&C8@9P@A1
M %[5:,A2![DL3FA5%;AP0X1OGR-TJZVIL">Y*6V!4^JV4J[ZK1E"@3/W.\1(
MF9#02 FIGLY6EQ3/O>@]71[0+!EDU$FRJYQ5%\Q234++;/8,RC.G;[&0"=66
M#D8WC5)A543E-Z%#+<EN7L/\"[,_<V@TNI#:@6[VRGD/E-A72H ?\M8[#F^Q
MQ> 8 IY!'6"CGI]ME$OEKHZFF3]O6H\<AW=L9I\,=;8GDH(3/L[LP)_3/B$*
MARN:G_"&'4B ]M&N)WM=*[Q/;8B'7'/ 4K5*A%=<-$_G^BE+>3W.Q:9<MP_R
M'E TCA/ A]]MWK%ZKE#+9M[6C3KOGIB1*XW(]HENJ3FI0@>6!1 .R 1XD,;^
M"5?]<&*L/0JR'A^\.82E^'QV=3KZ].GD?'3Q=2 T!'VK?U[!E#5"30LJ\UHB
MU#23^*9;T$HM@@?2; 6G"=UBO#S J(#?P@&>UB7&H7R0LG;H&5!!&S' $?]1
MA?YTQ3<A/QC#H1^MVNZ1\I4/<&!*$@ D%2KVHD0+A$.(%E;0YC6WR26 ;0+@
M0&+-!V(>]JU0N>OD(&$\WNC&GB!2Z&-1)D => K4/A!<WG1;VUSXB(B"NVD=
M\Y3'',LQDQ%N@REN.3(QK0%3H=$3@#M/[I":B,M;UR)<,;%QT01$40[0P+;
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M#ZQ+LH0/TY#(P"=]Q!T!L62QM\EMK5!+*;H8. ;&52X/015Y?,E/63**XR'
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M6]O.LJ>24'0$;!!IG.'"R> $-E*D;X>S'A]XJ]WDGMINE 3WK_7Q3=WX5\[
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MJXVDN5G5!10GH8F<^-4O39#)S?T1@[[JVVP>&OJ>'0&R$H,962O2KH2N-Q&
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MNDU^ Y!F@#-P#,J3D+;=B2^Q/I/]";KA^I!N/0EYND%B ]I8:\#XYJCO2:4
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M_L\O(!)#88V;J[/3\T_GIW"O[B_G-QP@N/R$?N.;O:Y_'''IXG1MN;/<\OI
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MH_?C;=*?Z_\,I^/1W_\?4$L#!!0    ( ,N+ E?SF_7&ZQ(  %%^   <
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M#(&_:JZCB&DQ HS'AA"6)$H#L!"8%4%+5F09P%P)/ 0>0-<6IRKYZ8>]5X?
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M/C&A>*EU.&S<)M<*NC]F;E(2>).ZZI28VX\^+G<5**O:I:A<C@:O6Z(J8EH
M3530M<EB/PLT\0,R*!:+[WIA0LYG+"UAVM#K5:6.H3TM?)U9"B!WT.X+4_XI
M3)NAIN&)15@K J@S9*FP]BP!3M-B592M,%TS*F.^D#'X6'T)9\,((115,#;
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M.P%KG_9]H@/S'M/?4$L! A0#%     @ RXL"5Y$Q<PATD@$ 91X6 !
M         ( !     &UC:RTR,#(S,#8S,"YH=&U02P$"% ,4    " #+BP)7
M D:BGMX4  #6V@  $               @ &BD@$ ;6-K+3(P,C,P-C,P+GAS
M9%!+ 0(4 Q0    ( ,N+ E>I&_K\/20  "UI 0 4              "  :ZG
M 0!M8VLM,C R,S V,S!?8V%L+GAM;%!+ 0(4 Q0    ( ,N+ E?6-=,#8X8
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M,#(S,#8S,%]P<F4N>&UL4$L! A0#%     @ RXL"5Q_]M/\1'P$ U+(( !\
M             ( !;%T$ &UC:U]E>#$P,7@R,#(R<W1O8VMP;&%N<W1C<RYH
M=&U02P$"% ,4    " #+BP)7\YOUQNL2  !1?@  '               @ &Z
M? 4 ;6-K7V5X,3 R>&UI<'-T8W-M87DR,#(S+FAT;5!+ 0(4 Q0    ( ,N+
M E=:)8'=_P<  !XI   >              "  =^/!0!M8VM?97AH:6)I=#,Q
M,7@V,S R,#(S,3 M<2YH=&U02P$"% ,4    " #+BP)7?,:%(!((   R*0
M'@              @ $:F 4 ;6-K7V5X:&EB:70S,3)X-C,P,C R,S$P+7$N
M:'1M4$L! A0#%     @ RXL"5S"='0;J!0  SB0  !T              ( !
M:* % &UC:U]E>&AI8FET,S)X-C,P,C R,S$P+7$N:'1M4$L%!@     ,  P
*/P,  (VF!0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
